"Rank","NCT Number","Title","Recruitment","Study Results","Conditions","Interventions","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Types","Study Designs","Other IDs","First Received","Start Date","Completion Date","Last Updated","Last Verified","Results First Received","Acronym","Primary Completion Date","Outcome Measures","URL"
1,"NCT02139280","Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy","Active, not recruiting","No Results Available","Hematologic Malignancies","Drug: Cyclophosphamide","Dartmouth-Hitchcock Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","43","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D13179","March 3, 2014","December 2013","December 2016","November 2, 2016","November 2016","No Study Results Posted","null","December 2016","Cyclophosphamide Dose|Resource Utilization","https://ClinicalTrials.gov/show/NCT02139280"
2,"NCT00501995","High Dose Cyclophosphamide for Treatment of Scleroderma","Completed","Has Results","Scleroderma","Drug: IV Cyclophosphamide","Johns Hopkins University","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","00-11-17-02","July 13, 2007","February 2001","May 2010","August 29, 2016","August 2016","March 25, 2014","null","July 2008","The Primary Endpoint Will be an Improvement in the Modified Rodnan Skin Score.|Secondary Endpoint Was Changes in the Total Severity Score (Composite) and Measures of Severity in Each Specific Organ (Organ Specific Measures).","https://ClinicalTrials.gov/show/NCT00501995"
3,"NCT01836289","High-dose Cyclophosphamide for Severe Refractory Crohn Disease","Recruiting","No Results Available","Crohn's Disease|Crohn Disease","Drug: High-dose Cyclophosphamide","Johns Hopkins University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NA_00052668","April 17, 2013","March 2015","March 2018","March 1, 2015","March 2015","No Study Results Posted","null","March 2018","Evaluation of safety of the High-Dose Cyclophosphamide (HDC) protocol|HDC-Induced Steroid-free remission|HDC-Induced Mucosal Healing|Improvement in patient reported quality of life|Molecular Mechanisms of High-dose Cyclophosphamide (HiCy) Therapy","https://ClinicalTrials.gov/show/NCT01836289"
4,"NCT02389309","A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors","Recruiting","No Results Available","Solid Tumors","Drug: Dasatinib|Drug: Cyclophosphamide|Drug: Temsirolimus","M.D. Anderson Cancer Center","All","12 Months to 20 Years   (Child, Adult)","Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2014-0692|NCI-2015-00524","March 4, 2015","October 5, 2015","October 2018","March 7, 2017","March 2017","No Study Results Posted","null","October 2018","Maximum Tolerated Dose (MTD) of Dasatinib, Cyclophosphamide, and Temsirolimus in Participants With Advanced Solid Tumors|Tumor Response of Dasatinib, Cyclophosphamide, and Temsirolimus in Participants With Advanced Solid Tumors","https://ClinicalTrials.gov/show/NCT02389309"
5,"NCT01630538","Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney Transplants","Active, not recruiting","No Results Available","Antibody Mediated Rejection","Drug: Cyclophosphamide","University of Manitoba","All","18 Years and older   (Adult, Senior)","Phase 2","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","TMCT-01","June 25, 2012","June 2013","December 2018","April 10, 2017","April 2017","No Study Results Posted","null","April 2018","Microvascular inflammation|titre of donor specific antibody (DSA)|antibody-mediated tissue injury|Urine Albumin/Creatinine ratios|Creatinine Clearance and estimated GFR|Graft Survival|Patient Survival","https://ClinicalTrials.gov/show/NCT01630538"
6,"NCT01974518","Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus","Unknown status","No Results Available","Pemphigus","Drug: Rituximab and Cyclophosphamide IV","Uprety Shraddha|Postgraduate Institute of Medical Education and Research","All","18 Years and older   (Adult, Senior)","Phase 3","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider)|Primary Purpose: Treatment","9187-PG-2012","October 4, 2013","November 2013","June 2015","October 29, 2014","October 2014","No Study Results Posted","null","June 2015","Study the clinical efficacy of IV rituximab vs IV rituximab and IV cyclophosphamide combination for treatment of refractory pemphigus in terms of early and late end points as defined by the international pemphigus committee|Study the characteristics of B cell depletion and repopulation following IV rituximab and combination of IV cyclophosphamide with IV rituximab.","https://ClinicalTrials.gov/show/NCT01974518"
7,"NCT02444091","Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS)","Active, not recruiting","No Results Available","Chronic Fatigue Syndrome (CFS)|Myalgic Encephalomyelitis (ME)","Drug: Cyclophosphamide","Haukeland University Hospital|The Kavli Foundation|Oslo University Hospital","All","18 Years to 65 Years   (Adult)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KTS-7-2015|2014-004029-41","March 25, 2015","March 2015","January 2017","April 11, 2016","April 2016","No Study Results Posted","CycloME","January 2017","Fatigue score, selfreported|Overall response|Short Form-36 (SF-36)|Physical activity (Sensewear armband)|Cardiopulmonary exercise tests for two following days|Self-recorded Function level|Fatigue Severity Scale|Longest continuous response duration|Sustained clinical response at 12 months|Safety and tolerability","https://ClinicalTrials.gov/show/NCT02444091"
8,"NCT00412243","Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients","Completed","Has Results","Burkitt's Lymphoma|Lymphoblastic Lymphoma|Acute Lymphoblastic Leukemia","Drug: Clofarabine|Drug: Cyclophosphamide","M.D. Anderson Cancer Center|Genzyme, a Sanofi Company","All","21 Years and older   (Adult, Senior)","Phase 1|Phase 2","51","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0552","December 14, 2006","March 2006","April 2012","March 8, 2013","March 2013","January 25, 2013","null","April 2012","Maximum Tolerated Dose for Cyclophosphamide (MTD)","https://ClinicalTrials.gov/show/NCT00412243"
9,"NCT01740401","CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma","Terminated","Has Results","Melanoma","Drug: Cyclophosphamide","Icahn School of Medicine at Mount Sinai|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","GCO 14-0677|114660","November 29, 2012","October 2012","December 2014","March 15, 2017","March 2017","March 15, 2017","null","December 2013","The Primary Objective of This Study is: Evaluate the Anti-tumor Activity of the Combination of Low Dose Cyclophosphamide and CTLA-4 Blockade Using Objective Response Rate (ORR) by 12 Weeks Following mWHO RC.|Progression-free Survival|T Regulatory Cell Profile in Peripheral Blood","https://ClinicalTrials.gov/show/NCT01740401"
10,"NCT01995331","Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia","Unknown status","No Results Available","Aplastic Anemia","Drug: cyclophosphamide,cyclosporine A","Xiaofan Zhu|Chinese Academy of Medical Sciences","All","1 Year to 18 Years   (Child, Adult)","Phase 4","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","YL20102601","November 21, 2013","March 2012","March 2015","November 21, 2013","November 2013","No Study Results Posted","null","March 2015","The reponse of Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia|The side effect of Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia","https://ClinicalTrials.gov/show/NCT01995331"
11,"NCT00981708","Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)","Unknown status","No Results Available","Amyloidosis","Drug: Lenalidomide, Dexamethasone and Cyclophosphamide","University of Athens|Hellenic Cooperative Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RV-178","September 19, 2009","February 2008","February 2015","January 30, 2014","January 2014","No Study Results Posted","null","December 2011","To assess the maximum tolerated dose of lenalidomide and cyclophosphamide and assess the hematologic response rate of the combination of Cyclophosphamide/Dexamethasone plus lenalidomide in patients with AL amyloidosis.|To assess the toxicity of Cyclophosphamide/Dexamethasone plus lenalidomide combination in patients with AL amyloidosis and organ response rate","https://ClinicalTrials.gov/show/NCT00981708"
12,"NCT02013336","Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors","Recruiting","No Results Available","Recurrent or Refractory Solid Tumors|Ewing Sarcoma|Rhabdomyosarcoma|Neuroblastoma|Osteosarcoma","Drug: MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide","South Plains Oncology Consortium","All","12 Months to 20 Years   (Child, Adult)","Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SPOC-2012-001","December 11, 2013","December 2013","December 2017","February 2, 2017","February 2017","No Study Results Posted","null","December 2017","To determine the Maximum Tolerated Dose (MTD) of MM-398 in combination with intravenous cyclophosphamide by assessing the occurrence of dose limiting toxicities|Measurement of plasma levels of study drug to determine the pharmacokinetic properties of MM-398 in combination with cyclophosphamide","https://ClinicalTrials.gov/show/NCT02013336"
13,"NCT01207297","Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis","Completed","No Results Available","SLE|Lupus Nephritis|Renal Insufficiency|End-stage Renal Disease","Drug: Tacrolimus|Drug: cyclophosphamide","Zhejiang University","All","15 Years to 64 Years   (Child, Adult)","Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ChiCTR-TKMS-1000960|ChiCTR-TNRC-10000960","September 21, 2010","March 2003","June 2010","August 22, 2011","September 2010","No Study Results Posted","null","March 2010","Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis|Evaluating the effective and safety of TAC for severe lupus nephritis compared CYC protocol.","https://ClinicalTrials.gov/show/NCT01207297"
14,"NCT02794077","Cyclophosphamide for Nasopharyngeal Carcinoma","Active, not recruiting","No Results Available","Recurrent Nasopharyngeal Undifferentiated Carcinoma|Stage IV Nasopharyngeal Undifferentiated Carcinoma","Drug: Cyclophosphamide","The University of Hong Kong","All","15 Years to 80 Years   (Child, Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Cyclophosphamide","May 30, 2016","January 2008","June 2016","June 2, 2016","June 2016","No Study Results Posted","null","December 2015","Progression-free survival|Objective response rate|Disease control rate|Number of participants with treatment-related adverse events as assessed by CTCAE version 4.0|Overall survival","https://ClinicalTrials.gov/show/NCT02794077"
15,"NCT00890955","Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies","Completed","No Results Available","Lung Cancer","Drug: Amrubicin|Drug: Cyclophosphamide","Lawrence Einhorn|Celgene Corporation|Hoosier Cancer Research Network","All","18 Years and older   (Adult, Senior)","Phase 1","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HOG LUN07-130","April 29, 2009","March 2009","July 2010","December 21, 2015","December 2015","No Study Results Posted","null","July 2010","To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of the combination of amrubicin and cyclophosphamide in patients with advanced solid tumors.|To determine the toxicities of the combination of amrubicin and cyclophosphamide in patients with advanced solid tumors.|To assess response to the combination of amrubicin and cyclophosphamide","https://ClinicalTrials.gov/show/NCT00890955"
16,"NCT02441491","Treatment of Rapid Onset Obesity, Hypoventilation, Hypothalamic Dysfunction, and Autonomic Dysregulation (ROHHAD )","Recruiting","No Results Available","ROHHAD Syndrome","Drug: Cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center","All","12 Months to 22 Years   (Child, Adult)","","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J1520|IRB00060912","April 8, 2015","March 2015","March 2023","May 17, 2016","May 2016","No Study Results Posted","null","March 2022","Symptomatic improvement on the ROHHAD Symptoms Scale of children with ROHHAD syndrome after treatment with high-dose cyclophosphamide .|Safety and toxicity of high-dose cyclophosphamide used to treat children with ROHHAD of as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0.|To calculate Area Under Curve (AUC) of high dose cyclophosphamide in obese children.|Neuropsychological function of patients with ROHHAD before and after high-dose cyclophosphamide measured using complementary age appropriate evaluation tools including Wechsler Preschool and Primary Scale of Intelligence RAN objects, and AIM.","https://ClinicalTrials.gov/show/NCT02441491"
17,"NCT00176605","Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer","Completed","Has Results","Prostate Cancer","Drug: Etoposide|Drug: Cyclophosphamide","Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Bristol-Myers Squibb","Male","18 Years and older   (Adult, Senior)","Phase 2","15","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","080408|P30CA072720|0220044931|CDR0000443482","September 13, 2005","May 2005","October 2008","April 18, 2014","April 2014","September 17, 2013","null","October 2008","PSA Response Rate|Toxicities Related to Chronic Administration of Etoposide and Cyclophosphamide in Patients With Stage D0 Prostate Cancer.","https://ClinicalTrials.gov/show/NCT00176605"
18,"NCT00605566","Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors","Completed","No Results Available","Neuroendocrine Tumors","Drug: sorafenib and cyclophosphamide","University Health Network, Toronto","All","18 Years and older   (Adult, Senior)","Phase 2","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","SOR-NET-001","January 18, 2008","January 2008","February 2015","March 14, 2016","March 2016","No Study Results Posted","null","February 2015","To determine the efficacy of combination sorafenib plus metronomic cyclophosphamide in advanced, progressive NET, as measured by the objective response rate (ORR), and to assess the feasibility of the individual dose adjustment of sorafenib.|To assess the toxicity, time-to-progression (TTP), overall survival (OS), and 1 year survival rate.","https://ClinicalTrials.gov/show/NCT00605566"
19,"NCT02821507","Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma","Recruiting","No Results Available","Conventional Chondrosarcoma|Myxoid Liposarcoma|Mesenchymal Chondrosarcoma|Dedifferentiated Chondrosarcoma","Drug: sirolimus and cyclophosphamide","Leiden University Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","105","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","COSYMO","January 9, 2016","June 2014","June 2017","July 11, 2016","July 2016","No Study Results Posted","null","January 2017","Using the growth modulation index to evaluate time till disease progression with combination treatment of sirolimus and cyclophosphamide|Comparing pre-treatment tumor material and tumor material taken during treatment using immunohistochemistry to compare activation of the pS6, Bcl-2 and mTor pathway and DNA analysis for taqman analysis to search for hotspot mutations.|Register adverse events to evaluate the patient safety and tolerability of the sirolimus and cyclophosphamide combination in myxoid liposarcoma and chondrosarcoma|To evaluate the response according to response evaluation criteria in solid tumors (RECIST) 1.1|The median progression free survival after start of treatment|The overall survival after start of treatment till death","https://ClinicalTrials.gov/show/NCT02821507"
20,"NCT01554371","Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies","Recruiting","No Results Available","Malignant Solid Tumour|Breast Cancer Nos Metastatic Recurrent|Neuropathy","Drug: Eribulin in Combination w/ Cyclophosphamide","University of California, San Francisco|Eisai Inc.","All","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","58","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCSF Protocol Number11996","March 9, 2012","March 2012","December 2019","May 12, 2016","May 2016","No Study Results Posted","null","December 2017","Phase Ib: 1. Maximum tolerated dose (MTD) of eribulin in combination with cyclophosphamide in patients with any solid tumor|Phase II 1. Clinical benefit (complete response, partial response, and stable disease) of the combination of eribulin and cyclophosphamide in patients with advanced breast cancer|Phase Ib: 1. Safety of treatment|Phase Ib: 2. Dose Limiting Toxicity (DLT)|Phase Ib: 3. Pharmacokinetics (PK) and potential for drug-drug interaction|Phase Ib: 4. Quality of life|Phase Ib: 5. Pharmacodynamic, pharmacogenomic and response prediction biomarkers|Phase II 1. Efficacy of drug combination in patients with advanced breast cancer including response rate, duration of response and time to progression|Phase II 2. Safety of drug combination in expanded cohort - metastatic breast cancer|Phase II 3. Quality of life endpoints|Phase II 4. Pharmacodynamic, pharmacogenomic and response prediction biomarkers","https://ClinicalTrials.gov/show/NCT01554371"
21,"NCT00381173","A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing","Completed","No Results Available","Breast Cancer|Ovarian Cancer|Prostate Cancer|Colon Cancer|Renal Cancer","Drug: Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)","Eisai Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZYC3-002","September 26, 2006","November 2006","October 2008","May 13, 2013","July 2011","No Study Results Posted","null","October 2008","Determine the feasibility, safety and tolerability of administering ZYC300 intramuscularly every other wk for 6 doses (400 micrograms DNA/total dose) to the study pop. pre-dosed with 600 mg/m^2 cyclophosphamide intravenously 3 days prior to study drug.|Assess the effect of cyclophosphamide on T reg number and function. Assess the generation of CYP1B1-specific immun. as a result of vac. regimen. Assess the effect of vac. regimen on tumor response, if any, in pat. pop.","https://ClinicalTrials.gov/show/NCT00381173"
22,"NCT01910844","Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes","Terminated","No Results Available","Metastatic Breast Cancer","Drug: Cisplatin|Drug: Cyclophosphamide","Centre Jean Perrin","Female","18 Years and older   (Adult, Senior)","Phase 2","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CJP 4.2 - META2","May 28, 2013","July 2013","September 2016","October 10, 2016","July 2016","No Study Results Posted","META2","September 2016","Response rate of cisplatine - metronomic cyclophosphamide treatment|Disease free progression|Safety profile of cisplatin - metronomic cyclophosphamide association|Overall survival|Predictive factors to response and/or resistance treatment","https://ClinicalTrials.gov/show/NCT01910844"
23,"NCT00334646","Cyclophosphamide Drug Interaction Study In Cancer Patients","Terminated","No Results Available","Nausea and Vomiting, Chemotherapy-Induced|Cancer","Drug: Oral GW679769|Drug: IV Cyclophosphamide 500-700mg/m2","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 1","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","NKV103444","June 6, 2006","August 2005","September 2009","July 26, 2012","July 2012","No Study Results Posted","null","September 2009","Cmax and AUC of cyclophosphamide and 4-hydroxycyclophosphamideSafety and tolerability parameters including pharmacoeconomics, blood pressure, heart rate, ECG, laboratory tests, clinical observation and adverse event reporting.|Terminal t1/2, Vd, and Cl of cyclophosphamideTerminal t1/2 of 4-hydroxycyclophosphamideAUC ratio of 4-hydroxycyclophosphamide and cyclophosphamideANC nadir","https://ClinicalTrials.gov/show/NCT00334646"
24,"NCT00844506","p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer","Completed","No Results Available","Ovarian Cancer","Drug: P53-SLP vaccine|Drug: Cyclophosphamide","University Medical Center Groningen|ISA Pharmaceuticals B.V.|Dutch Cancer Society","Female","18 Years and older   (Adult, Senior)","Phase 2","19","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ISA-P53-CTX|EUDRACT 2007-007734-19|CCMO NL21308.000.07","February 13, 2009","October 2008","July 2009","February 24, 2011","February 2011","No Study Results Posted","ISA-P53-CTX","July 2009","Clinical responses to the p53 synthetic long peptide vaccine preceded by cyclophosphamide will be assessed by measurement of serum CA-125 levels and CT-scan.|Immunogenicity will be evaluated by assessing induction and frequency of p53-specific T cells by proliferation and IFN-γ ELISPOT.|Safety of the vaccine preceded by cyclophosphamide will be assessed by monitoring the incidence and severity of adverse events using Common Terminology Criteria for Adverse Events v3.0.","https://ClinicalTrials.gov/show/NCT00844506"
25,"NCT03132584","Cyclophosphamide and Alemtuzumab In Lymphoma","Not yet recruiting","No Results Available","Non Hodgkin Lymphoma|High-grade B-cell Lymphoma|CD52 Positive Non-Hodgkin Lymphoma|DLBCL or High-grade B-cell Lymphoma NOS","Drug: Cyclophosphamide|Drug: Alemtuzumab","Dana-Farber Cancer Institute|Genzyme, a Sanofi Company|Sanofi","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","43","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","17-034","April 24, 2017","May 30, 2017","May 1, 2023","April 26, 2017","April 2017","No Study Results Posted","null","September 1, 2020","MTD of Cyclophosphamide and Alemtuzumab|Overall Response Rate|Complete Response Rate|Progression Free Survival|Overall Survival|Response Rate","https://ClinicalTrials.gov/show/NCT03132584"
26,"NCT00743509","A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma","Completed","Has Results","Osteosarcoma","Drug: Cyclophosphamide and Sirolimus","University of Michigan Cancer Center","All","16 Years and older   (Child, Adult, Senior)","Phase 2","49","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCC 2008.049","August 27, 2008","August 2008","September 2012","August 31, 2015","August 2015","April 4, 2013","OCR","April 2010","Number of Patients Alive Without Disease Progression|Median Overall Survival Time","https://ClinicalTrials.gov/show/NCT00743509"
27,"NCT01540110","Study of Neoadjuvant Docetaxel and Cyclophosphamide in Locally Advanced or Node Positive Primary Breast Cancer With Companion Pharmacokinetic and Pharmacogenomic Analyses","Active, not recruiting","No Results Available","Breast Cancer","Drug: Neoadjuvant Docetaxel and Cyclophosphamide","National Cancer Centre, Singapore","All","21 Years and older   (Adult, Senior)","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCC0907","January 31, 2012","August 2010","August 2018","September 2, 2016","September 2016","No Study Results Posted","null","August 2018","To evaluate tumour pathological complete response rate after 6 cycles of neoadjuvant docetaxel and cyclophosphamide in Asian population","https://ClinicalTrials.gov/show/NCT01540110"
28,"NCT00667615","Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)","Completed","No Results Available","Hodgkin's Disease|Lymphoma","Drug: rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim","Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp.|Northwestern University|NorthShore University HealthSystem Research Institute|Weill Medical College of Cornell University","All","60 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","08-045","April 24, 2008","April 2008","February 2017","February 22, 2017","February 2017","No Study Results Posted","null","February 2017","To determine the maximum tolerated dose (MTD) of vorinostat given orally for 10 days in combination with cyclophosphamide, etoposide, prednisone and rituximab for elderly patients with relapsed diffuse large B-cell lymphoma|determine the complete response rate to rituximab and a combination of vorinostat with cyclophosphamide, etoposide, and prednisone in elderly pts with relapsed diffuse large B-cell lymphoma who aren't candidates for autologous stem cell transplantation.|To estimate the quality of life for these patients at baseline, during and at completion of treatment.","https://ClinicalTrials.gov/show/NCT00667615"
29,"NCT00954135","Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Breast Cancer Patients","Unknown status","No Results Available","Breast Cancer","Drug: letrozolo+cyclophosphamide|Drug: letrozolo+sorafenib+cyclophosphamide","University of Turin, Italy","Female","18 Years and older   (Adult, Senior)","Phase 2","190","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT 2007-006208-39","August 6, 2009","September 2007","December 2010","August 6, 2009","August 2009","No Study Results Posted","null","June 2010","Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00954135"
30,"NCT01570764","Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease","Recruiting","No Results Available","Systemic Sclerosis|Scleroderma|Interstitial Lung Disease|Lung Fibrosis","Drug: Cyclophosphamide|Drug: Placebo","Assistance Publique - Hôpitaux de Paris|Hôpital Claude-Huriez","All","18 Years and older   (Adult, Senior)","Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P081241|2011-004709-26","April 2, 2012","January 2013","October 2018","September 14, 2016","August 2016","No Study Results Posted","SCLEROCYC","April 2018","Forced vital capacity|Mortality|Progression free survival|Carbon monoxide diffusing capacity (DLCO)|Treatment failure|Walk test distance|Dyspnea|Health Assessment Questionnaire|Quality of life|Chest CT (computed tomography) scan","https://ClinicalTrials.gov/show/NCT01570764"
31,"NCT01351909","Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer","Active, not recruiting","No Results Available","HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer","Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Drug: Veliparib","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","35","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2011-02590|CDR0000700033|11-02-068|P8853_A18PAMDREVW01|8853|N01CM62204|P30CA013330","May 10, 2011","May 2, 2011","null","May 23, 2017","January 2017","No Study Results Posted","null","November 25, 2016","Recommended phase II dose of veliparib and cyclophosphamide|Clinical response (complete or partial response) according to RECIST version 1.1|MacroH2A1.1 expression levels|Overall survival|PARP1 expression status","https://ClinicalTrials.gov/show/NCT01351909"
32,"NCT00852709","Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias","Unknown status","No Results Available","Myelodysplastic Syndrome|Acute Myeloid Leukemia|Myeloproliferative Disorders|Acute Lymphocytic Leukemia|Acute Promyelocytic Leukemia|Acute Leukemia|Chronic Myelogenous Leukemia|Myelofibrosis|Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia","Drug: Clofarabine|Drug: Cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center|Genzyme, a Sanofi Company","All","1 Year to 21 Years   (Child, Adult)","Phase 1","35","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0715|POE07-01","February 26, 2009","September 2007","null","September 21, 2010","September 2010","No Study Results Posted","POE07-01","January 2010","To determine the feasibility, tolerability, toxicities, and MTD of clofarabine followed by fractionated cyclophosphamide in pediatric patients with relapsed or refractory acute leukemias.|To obtain preliminary descriptive data of the biologic and pharmacodynamic effects of clofarabine followed by fractionated cyclophosphamide on marrow and circulating leukemic blasts in pediatric patients with relapsed or refractory acute leukemias.","https://ClinicalTrials.gov/show/NCT00852709"
33,"NCT02298348","Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma","Recruiting","No Results Available","Neuroblastoma","Drug: Sorafenib|Drug: Cyclophosphamide|Drug: Topotecan","New Approaches to Neuroblastoma Therapy Consortium|University of California, San Francisco|Children's Hospital Los Angeles|Lucile Packard Children's Hospital|Children's Hospital Medical Center, Cincinnati|University of Michigan|Seattle Children's Hospital|Dana-Farber Cancer Institute|The Hospital for Sick Children|Children's Healthcare of Atlanta|University of Chicago|Cook Children's Health Care System|Memorial Sloan Kettering Cancer Center|Children's Hospital Colorado","All","up to 30 Years   (Child, Adult)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NANT 2013-02","August 26, 2014","April 2015","February 2018","March 21, 2017","March 2017","No Study Results Posted","N2013-02","October 2017","The maximum tolerated dose of sorafenib given twice each day when given in combination with cyclophosphamide/topotecan for 5 days|The number and types of toxicities of sorafenib when administered in combination with cyclophosphamide and topotecan.","https://ClinicalTrials.gov/show/NCT02298348"
34,"NCT00999986","Low Dose Cyclophosphamide Treats Genital Warts","Completed","No Results Available","Genital Wart","Drug: cyclophosphamide","Huazhong University of Science and Technology","All","18 Years to 60 Years   (Adult)","Phase 3","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","Sheng-Qi-An","October 21, 2009","January 2007","August 2009","November 24, 2009","November 2009","No Study Results Posted","null","June 2009","low-dose cyclophosphamide effectively prevents the recurrence of large genital warts after laser therapy","https://ClinicalTrials.gov/show/NCT00999986"
35,"NCT01238770","Phase I/II Study of Pazopanib and Cyclophosphamide in Patients With Platinum-resistant Recurrent Ovarian Cancer","Completed","No Results Available","Epithelial Ovarian Cancer","Drug: Pazopanib","Priv.-Doz. Dr. med. Joachim Rom|University Hospital Heidelberg","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","3107000","November 10, 2010","November 2010","October 2015","February 8, 2016","February 2016","No Study Results Posted","null","October 2014","Determination of the optimal doses for pazopanib (phase I)|Overall response rate according to RECIST criteria / clinical benefit (stable disease or partial response or complete response) (phase II)|Time to progression (TTP) according to RECIST criteria|Overall survival|Evaluation of CA125 tumour response|Number of patients with Adverse Events|Assessment of quality of life over time as defined by EORTC-QLQ C 30 and Ovar 28 questionnaire","https://ClinicalTrials.gov/show/NCT01238770"
36,"NCT01492673","Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma","Active, not recruiting","No Results Available","Neuroblastoma|Sarcoma","Drug: Cyclophosphamide, Topotecan, and Bevacizumab","Memorial Sloan Kettering Cancer Center|Genentech, Inc.|Children's Mercy Hospital Kansas City|Penn State University|University of Colorado, Denver|Sidney Kimmel Comprehensive Cancer Center|Phoenix Children's Hospital Center for Cancer & Blood Disorders|Alberta Children's Hospital|MD Anderson Cancer Center Orlando|M.D. Anderson Cancer Center","All","up to 21 Years   (Child, Adult)","Phase 2","9","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","11-183","December 12, 2011","December 2011","December 2018","April 25, 2017","April 2017","No Study Results Posted","null","December 2018","efficacy|safety","https://ClinicalTrials.gov/show/NCT01492673"
37,"NCT00258206","Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma","Completed","Has Results","Multiple Myeloma and Plasma Cell Neoplasm","Biological: rituximab|Drug: cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","21","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0478 CDR0000441169|P30CA006973|JHOC-J0478","November 22, 2005","December 2004","April 2015","June 10, 2015","June 2015","May 28, 2015","null","April 2015","Event-free Survival|Safety of Maintenance Rituximab Following High Dose Cyclophosphamide|Safety and Toxicity|Complete Response (CR) Rate and Partial Response (PR) Rate|Effect of Rituximab by Clonogenic Growth of Multiple Myeloma (MM) Progenitors and the Mechanisms by Which MM Stem Cells Are Inhibited|Overall Survival","https://ClinicalTrials.gov/show/NCT00258206"
38,"NCT01092962","Cyclophosphamide Versus Mycophenolate Mofetil for the Treatment of Steroid-dependent Nephrotic Syndrome in Children","Completed","No Results Available","Idiopathic Nephrotic Syndrome","Drug: Cyclophosphamide|Drug: Mycophenolate mofetil","Assistance Publique - Hôpitaux de Paris","All","2 Years to 16 Years   (Child)","Phase 3","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P071221","February 26, 2010","September 2010","February 2015","March 25, 2015","August 2013","No Study Results Posted","NEPHROMYCY","February 2015","Relapse of nephrotic syndrome (defined by occurrence of proteinuria ≥ 0,25 g/mmol of CREATININURIA (or ≥ 2g/g) with hypoalbuminemia ≤ 30g/L AND/OR dipsticks >2+ during 3 days and proteinuria/CREATININURIA ratio ≥ 0,25 g/mmol) during 2 years.|In case of relapse, steroid threshold dose to maintain a remission compare to those before inclusion in the study|Cumulative steroid dose received during the years before and under treatment|Comparison of growth data, during the year before and under treatment|Pharmacokinetics measurement of MPA and relation with efficacy in case of treatment with MMF","https://ClinicalTrials.gov/show/NCT01092962"
39,"NCT01861561","Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children","Recruiting","No Results Available","Renal Insufficiency|Infection","Drug: Low-dose intravenous cyclophosphamide|Drug: High-dose intravenous cyclophosphamide","Mahidol University","All","up to 15 Years   (Child)","Phase 4","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","125/2556(EC2)","May 19, 2013","May 2013","November 2018","April 1, 2017","April 2017","No Study Results Posted","Low/highIVCY","May 2018","renal response|infection","https://ClinicalTrials.gov/show/NCT01861561"
40,"NCT01543152","Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T","Active, not recruiting","No Results Available","HIV","Genetic: SB-728-T|Genetic: SB-728-T|Genetic: SB-728-T|Genetic: SB-728-T|Genetic: SB-728-T","Sangamo Therapeutics","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","26","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SB-728-1101","March 1, 2012","December 2011","September 2017","January 6, 2017","January 2017","No Study Results Posted","null","March 2017","Treatment related Adverse Events on subjects who received cyclophosphamide prior to SB-728-T infusion|Effect of escalating doses of cyclophosphamide on SB-728-T engraftment as measured by pentamer PCR|Effect of SB-728-T on plasma HIV-1 RNA levels following HAART interruption|Change in CD4+ T-cell counts in peripheral blood after treatment with SB-728-T","https://ClinicalTrials.gov/show/NCT01543152"
41,"NCT03088293","Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)","Not yet recruiting","No Results Available","Idiopathic Refractory Scleritis","Drug: Infliximab|Drug: Cyclophosphamide","Hospices Civils de Lyon","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","69HCL17_0028","March 17, 2017","September 2017","April 2020","March 17, 2017","March 2017","No Study Results Posted","CIRIS","April 2020","percentage of patients with resolution (score=0) of the scleral inflammation and with a prednisone dose lower than 0.1 mg/kg/day","https://ClinicalTrials.gov/show/NCT03088293"
42,"NCT01910870","Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes","Terminated","No Results Available","Metastatic Breast Cancer","Drug: Cisplatin|Drug: Metronomic Cyclophosphamide","Centre Jean Perrin","Female","18 Years and older   (Adult, Senior)","Phase 2","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","META1 - CJP4.1","May 28, 2013","July 2013","September 2016","October 10, 2016","July 2016","No Study Results Posted","null","September 2016","Response rate of cisplatin - metronomic cyclophosphamide treatment|Disease free progression|safety profile of cisplatin - metronomic cyclophosphamide association|Overall survival|Predictive factors to response and/or resistance treatment","https://ClinicalTrials.gov/show/NCT01910870"
43,"NCT01670175","Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors","Active, not recruiting","No Results Available","Malignant Solid Tumor|Childhood Solid Tumor","Drug: Sirolimus, Cyclophosphamide, Topotecan","University of California, San Francisco|Hyundai Hope On Wheels","All","up to 25 Years   (Child, Adult)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCSF CC# 12083|IRB # 12-09399","August 17, 2012","August 2012","November 2015","August 7, 2015","August 2015","No Study Results Posted","null","September 2015","Dose Limiting Toxicity|Antitumor Activity|Biologic efects of drug combination|Antiangiogenic properties of drug combination","https://ClinicalTrials.gov/show/NCT01670175"
44,"NCT01346787","Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE","Stichting Hemato-Oncologie voor Volwassenen Nederland|Fondazione Neoplasie Sangue Onlus","All","65 Years and older   (Adult, Senior)","Phase 2","53","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IST-CAR-506","April 19, 2011","July 2011","October 2019","May 9, 2016","May 2016","No Study Results Posted","CCD","October 2012","Toxicity: Assessment of adverse events will be performed at the end of third cycle according to the National Cancer Institute Common Terminology Criteria of Adverse Events (CTCAE version 4.0)|Efficacy will be assessed by considering partial response (PR) following the proposed regimen. Assessment of Partial Response rate will be performed at the end of third cycle according to the criteria of the International Myeloma Working Group.|Response rate|Duration of Progression Free Survival|Time to progression (TTP)|Duration of Response (DOR)|Duration of Overall Survival|Time to next therapy|Progressio Free Survival|β2-microglobulin as prognostic factors|peripheral neuropathy|Progression Free Survival|C reactive protein as prognostic factors|cytogenetics as prognostic factors|microRNA|gene expression profile|Overall Survival","https://ClinicalTrials.gov/show/NCT01346787"
45,"NCT02876679","Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT","Recruiting","No Results Available","Graft vs Host Disease","Drug: Cyclophosphamide|Drug: Anti-Thymocyte Globulin|Drug: Conditioning regimen","Assistance Publique - Hôpitaux de Paris","All","18 Years to 65 Years   (Adult)","Phase 2","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Prevention","P150955|2016-002129-12","August 12, 2016","March 2017","February 2020","March 21, 2017","March 2017","No Study Results Posted","ATG-CyGVHD","February 2020","Composite endpoint of GVHD-free, relapse-free survival (GRFS)|Cumulative incidence of grade 2-4 and grade 3-4 severe acute GVHD|Cumulative incidence of non-relapse mortality within the first 12 months after transplantation.|Disease-free survival|Overall survival.|Quality of Life (QoL) with EORTC QLQ-C30|Quality of Life (QoL) with FACT-BMT|Immune recovery measurement","https://ClinicalTrials.gov/show/NCT02876679"
46,"NCT03139851","Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide","Not yet recruiting","No Results Available","Metastatic Breast Cancer","Drug: Cyclophosphamide 50mg|Drug: Pembrolizumab 100 MG in 4 ML Injection","Centre Leon Berard|Merck Sharp & Dohme Corp.","Female","18 Years and older   (Adult, Senior)","Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ET16-073|2016-002736-33","April 10, 2017","May 30, 2017","February 2020","May 2, 2017","May 2017","No Study Results Posted","CHEMOIMMUNE","February 2020","Severe Toxicities (ST) in Run-In Phase Part|24-week Clinical Benefit Rate (CBR24w) in Phase II part|Overall response Rate (ORR) at 24 weeks|Duration of response (DoR)|Progression-Free Survival (PFS)|Overall Survival (OS)|Adverse events reporting","https://ClinicalTrials.gov/show/NCT03139851"
47,"NCT01758120","Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy","Active, not recruiting","No Results Available","IgA Nephropathy","Drug: prednisone plus cyclophosphamide|Drug: Prednisone alone","Guangdong General Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 4","135","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GGH2012-36","December 12, 2012","December 2012","December 2019","January 17, 2017","January 2017","No Study Results Posted","TOPplus-IgAN","December 2019","the changes of kidney function or death|the changes of proteinuria","https://ClinicalTrials.gov/show/NCT01758120"
48,"NCT00296205","Phase II High-Dose Cyclophosphamide for Multiple Sclerosis","Withdrawn","No Results Available","Multiple Sclerosis","Drug: Cyclophosphamide","Stony Brook University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20055203","February 23, 2006","October 2003","February 2006","July 21, 2009","October 2006","No Study Results Posted","null","null","The primary endpoint of this study is to evaluate the response rate of MS patients after high-dose cyclophosphamide therapy as determined by a sustained (greater than 6 months) decrease of greater than or equal to 1.0 in their EDSS score.|The secondary endpoint of this study is to evaluate time to EDSS score progression.","https://ClinicalTrials.gov/show/NCT00296205"
49,"NCT02755844","Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients","Not yet recruiting","No Results Available","Recurrent Endometrial Cancer","Drug: Olaparib|Drug: metformin|Drug: metronomic cyclophosphamide","Hospices Civils de Lyon","Female","18 Years to 81 Years   (Adult, Senior)","Phase 1|Phase 2","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","69HCL15_0321","April 14, 2016","April 2016","November 2019","April 26, 2016","April 2016","No Study Results Posted","ENDOLA","April 2018","Recommended phase 2 trial (RP2D) dose of olaparib combined to metronomic cyclophosphamide and metformin|Efficacy of olaparib combined to metronomic cyclophosphamide and metformin|Number of patients with adverse events relative to the study treatment olaparib combined to metronomic cyclophosphamide and metformin|Pharmacodynamic effects of the 3 drugs on circulating tumor DNA (ctDNA),|Pharmacodynamic effects of the 3 drugs on circulating Insulin Growth Factor (IGF-1)|Pharmacodynamic effects of the 3 drugs on circulating (Cancer Antigen) CA-125 values","https://ClinicalTrials.gov/show/NCT02755844"
50,"NCT01253460","Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)","Active, not recruiting","No Results Available","Leukemia","Drug: Cyclophosphamide|Drug: Rituximab|Drug: Sapacitabine","M.D. Anderson Cancer Center|Cyclacel Pharmaceuticals, Inc.|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","19","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-0516|NCI-2011-00119|5P01CA081534","December 1, 2010","July 2011","null","December 15, 2016","December 2016","No Study Results Posted","null","July 2019","Overall Response Rate (ORR)","https://ClinicalTrials.gov/show/NCT01253460"
51,"NCT01322776","Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma","Unknown status","No Results Available","Mantle Cell Lymphoma Recurrent","Drug: Combination of Bortezomib, Fludarabine and Cyclophosphamide","Sun Yat-sen University|Fudan University|Zhejiang University|West China Hospital|Ruijin Hospital|Tianjin Medical University Cancer Institute and Hospital|Beijing Cancer Hospital|Jiangsu Cancer Institute & Hospital","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Vel-FC-4003","March 24, 2011","March 2011","October 2013","March 24, 2011","March 2011","No Study Results Posted","null","October 2013","Clinical efficacy will be assessed according to the CT scan and bone marrow aspirate and biopsy|Maximum Tolerated Dose（MTD）of Cyclophosphamide","https://ClinicalTrials.gov/show/NCT01322776"
52,"NCT01537029","Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide","Recruiting","No Results Available","Breast Cancer|Obesity","Drug: Doxorubicin|Drug: Cyclophosphamide","Texas Tech University Health Sciences Center|University of Texas","Female","18 Years and older   (Adult, Senior)","Phase 4","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","A11-3691","February 16, 2012","February 2012","February 2019","November 9, 2016","November 2016","No Study Results Posted","null","February 2018","Area under the curve (AUC) for doxorubicin and cyclophosphamide","https://ClinicalTrials.gov/show/NCT01537029"
53,"NCT01236456","High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy","Withdrawn","No Results Available","Chronic Inflammatory Demyelinating Polyneuropathy","Drug: Cyclophosphamide","Stony Brook University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","65865","November 5, 2010","October 2003","November 2006","August 11, 2011","August 2011","No Study Results Posted","null","null","The primary endpoint of this study is to evaluate the response rate of CIDP patients as determined by functional score, change in Summated compound motor action potential and strength, after high-dose cyclophosphamide therapy.|The secondary endpoint of this study is to determine remission duration.","https://ClinicalTrials.gov/show/NCT01236456"
54,"NCT02996773","Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndromes|Chronic Myelogenous Leukemia|Juvenile Myelomonocytic Leukemia|Lymphoma,Non-Hodgkin|Lymphoma, Hodgkin|Lymphoma, Follicular|Marginal Zone Lymphoma|Large Cell Lymphoma|Mantle-Cell Lymphoma|Gray Zone Lymphoma|Burkitt Lymphoma","Drug: Bendamustine|Drug: Cyclophosphamide","University of Arizona","All","12 Years to 65 Years   (Child, Adult)","Phase 1|Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1609876907","December 1, 2016","November 2016","April 2018","December 14, 2016","December 2016","No Study Results Posted","null","April 2018","Safety in regards to engraftment, incidence and grade of acute and chronic graft versus host disease and toxicity/non-relapse mortality post-haploidentical bone marrow transplantation.|Incidence of regimen-related organ toxicities|Severity of regimen-related organ toxicities|Incidence of acute GvHD|Severity of acute GvHD|Incidence of chronic GvHD|Extent of chronic GvHD|Incidence of graft failure|Level of donor cell engraftment|Duration of neutropenia and thrombocytopenia|Severity of neutropenia and thrombocytopenia|Requirement for blood product support|Infection risk|Infection severity|Number of patients relapse free|Overall patient survival|Immune reconstitution following haploidentical BMT|Length of stay of the protocol|Cost effectiveness of the protocol|Reconstituting T-cell subsets change with escalation of PT- BEN and de-escalation of day +4 PT-CY during the phase I trial","https://ClinicalTrials.gov/show/NCT02996773"
55,"NCT00201708","Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Docetaxel|Drug: Doxorubicin|Drug: Cyclophosphamide (AC)","Ohio State University Comprehensive Cancer Center","Female","18 Years and older   (Adult, Senior)","Phase 2","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","OSU-0450","September 12, 2005","October 2004","February 2014","September 1, 2016","September 2016","No Study Results Posted","null","December 2006","Select one of two adjuvant chemotherapy regimens for evaluation in subsequent phase III trial.|Determine the toxicities of Docetaxel administered before or after doxorubicin/cyclophosphamide(AC).","https://ClinicalTrials.gov/show/NCT00201708"
56,"NCT00939549","High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis","Suspended","No Results Available","Relapsing Remitting Multiple Sclerosis","Drug: Cyclophosphamide/Glatiramer acetate","Sidney Kimmel Comprehensive Cancer Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0840|NA_00016884","July 14, 2009","March 2011","March 2014","November 8, 2010","November 2010","No Study Results Posted","HiCy","March 2014","Safety - Serious adverse events|Radiologic - reduction in the number of gadolinium enhancing lesions, T2 plaque burden, and change in brain parenchymal fraction.|Clinical/Neurological - Change in disability|Immunological - change in immune profile","https://ClinicalTrials.gov/show/NCT00939549"
57,"NCT02441270","Evaluation of the Immunological Effects of a Combined Treatment With Radiation and Cyclophosphamide in Metastasized Breast Cancer Patients","Unknown status","No Results Available","Radiotherapy|Immunology","Drug: Cyclophosphamide|Radiation: Stereotactic body radiotherapy","University Hospital, Ghent","Female","18 Years and older   (Adult, Senior)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EC 2015/0204","April 24, 2015","April 2015","null","May 7, 2015","May 2015","No Study Results Posted","null","October 2016","Identification of the immunological effects, in peripheral blood and tumor biopsies, of the combined treatment with radiation and cyclophosphamide|Evaluation of the clinical/radiographical response of irradiated metastases|Evaluation of the response of non-irradiated metastases (the so-called ""abscopal effect"").","https://ClinicalTrials.gov/show/NCT02441270"
58,"NCT01001780","Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease","Withdrawn","No Results Available","Active Chronic Graft Versus Host Disease","Drug: Pentostatin; Cyclophosphamide; Rituximab","University of Rochester","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","25260","October 26, 2009","August 2009","January 2011","October 14, 2013","October 2013","No Study Results Posted","null","January 2011","Determine whether complete response rate following use of PCR regimen exceeds 25% in selected (for poor prognosis) chronic GvHD patients.|Assess the ability to successfully wean patients from all immunosuppressive therapy following complete response.|Describe the incidence, frequency and type of all observed opportunistic infections.|Describe the pattern of immune recovery in these patients|Assess the incidence, frequency and type of hematologic dysfunction before and after therapy.|Assess the incidence of relapse (of the underlying malignant diagnosis for which the allogeneic hematopoietic stem cell transplant was performed), progression-free and overall survival.","https://ClinicalTrials.gov/show/NCT01001780"
59,"NCT03099356","Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer","Recruiting","No Results Available","Metastatic Thyroid Cancer","Drug: Cyclophosphamide|Drug: Sirolimus","University of Michigan Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","UMCC 2017.013|HUM00126559","March 28, 2017","April 27, 2017","May 12, 2023","May 23, 2017","May 2017","No Study Results Posted","null","May 12, 2022","Percentage of patients that respond to treatment|The number of patients that experience toxicity|Median overall survival time|Median progression free survival time","https://ClinicalTrials.gov/show/NCT03099356"
60,"NCT03149679","The p53 Colorectal Cancer Trial","Not yet recruiting","No Results Available","Colorectal Cancer Metastatic|Colorectal Cancer Stage IV|TP53 Gene Mutation","Drug: Cyclophosphamide","Haukeland University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2016/1637","March 14, 2017","May 2017","June 2025","May 9, 2017","May 2017","No Study Results Posted","null","June 2020","Objective response rate (ORR)|Possible molecular markers of therapy response/resistance and survival outcome beyond TP53 mutations will be examined.|Number of patients with treatment response among patients harboring TP53 mutations belonging to particular mutation subgroups|Clinical benefit rate (CBR)|Recurrence-free and overall survival, compared to historical data|Safety and tolerability of the study treatment including recording of number of participants with treatment-related adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT03149679"
61,"NCT02360111","GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant","Recruiting","No Results Available","Leukemia|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma","Drug: Cyclophosphamide","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Senior)","","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","14-273","February 5, 2015","February 2015","February 2020","April 26, 2017","April 2017","No Study Results Posted","null","February 2020","# GVHD (grade II-IV) Chronic GVHD will be diagnosed and graded according to the (NIH criteria)|Disease-free survival|Overall survival|# Renal insufficiency defined as a calculated eGFR <60 ml/min/1.73m2. Those with a eGFR < 30 ml/min/1.73m2 will be considered ineligible.|The occurrence of life-threatening opportunistic infections","https://ClinicalTrials.gov/show/NCT02360111"
62,"NCT00882323","Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)","Unknown status","No Results Available","Aplastic Anemia","Drug: Cyclophosphamide, Fludarabine, Thymoglobulin","The Korean Society of Pediatric Hematology Oncology","All","1 Year to 21 Years   (Child, Adult)","Phase 2","33","Other","Interventional","Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KSPHO-SCT 0802","April 15, 2009","November 2008","October 2012","March 23, 2012","March 2012","No Study Results Posted","null","October 2012","To evaluate engraftment potential of reduced toxicity fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia.|To evaluate toxicities of reduced toxicity fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for UBMT/PBSCT in SAA.|To evaluate overall and EFS rate after UBMT/PBSCT.|To evaluate GVHD and immunologic recovery after UBMT/PBSCT.","https://ClinicalTrials.gov/show/NCT00882323"
63,"NCT00976300","Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study","Completed","No Results Available","Systemic Lupus Erythematosus|Lupus Nephritis","Drug: Cyclosporine A|Drug: Cyclophosphamide","Institute of Rheumatology, Prague|Ministry of Health, Czech Republic|Charles University, Czech Republic|Palacky University|Department of Rheumatology, Hospital, Ceske Budejovice, Czech Republic|National Institute of Rheumatology, Piestany, Slovakia|St. Anna Hospital, Brno, Czech","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RU 8444-3|IGA MZ CR 8444-3|MZO 00023728","September 11, 2009","January 2002","April 2009","June 22, 2010","September 2009","No Study Results Posted","CYCLOFA-LUNE","May 2008","renal remission and renal response|incidence of adverse events and relapse free period","https://ClinicalTrials.gov/show/NCT00976300"
64,"NCT02406781","Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial","Recruiting","No Results Available","Sarcoma","Drug: Combination of MK3475 with Metronomic CP","Institut Bergonié|Merck Sharp & Dohme Corp.|Ministry of Health, France","All","18 Years and older   (Adult, Senior)","Phase 2","163","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IB 2014-04","March 12, 2015","March 2015","March 2018","November 8, 2016","November 2016","No Study Results Posted","PEMBROSARC","March 2017","Assessment of the efficacy of MK3476 associated with Metronomic Cyclophosphamide per RECIST v1.1 criteria|Efficacy of MK3475 and Metronomic CP in terms of Best overall response|Efficacy of MK3475 and Metronomic CP in terms of Progression-free Survival|Efficacy of MK3475 and Metronomic CP in terms of Immune_related Response|Efficacy of MK3475 and Metronomic CP in terms of Overall Survival.|Exploration of blood cytokines levels (TNFγ, TNFα, TGFβ, IL2, 4, 6, 10) (ELISA)|Exploration of blood VEGF, Svegfr2 and TPS-1 levels (ELISA)|Exploration of lymphocytes subpopulations monitoring, CD8+/Treg ratio (flow cytometry)|Exploration of Plasma levels of Kynurenine and Kynurenine to Tryptophan ratio (ELISA and LC/MS)","https://ClinicalTrials.gov/show/NCT02406781"
65,"NCT01229605","Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer","Withdrawn","No Results Available","Breast Cancer","Drug: Cyclophosphamide and docetaxel","Tufts Medical Center","Female","18 Years and older   (Adult, Senior)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Tufts BR01","October 18, 2010","October 2010","December 2011","December 8, 2011","December 2011","No Study Results Posted","null","December 2011","Complete Response Rate|Change in mean Tiam1 expression levels before and after therapy","https://ClinicalTrials.gov/show/NCT01229605"
66,"NCT02805725","Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide","Recruiting","No Results Available","Soft-tissue Sarcomas","Drug: Phase 1: Trabectedin|Drug: Phase 2: Trabectedin|Drug: Phase 1: Cyclophosphamide|Drug: Phase 2: Cyclophosphamide","Institut Bergonié|PharmaMar","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","71","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IB 2015-04","May 25, 2016","December 2015","December 2018","June 15, 2016","June 2016","No Study Results Posted","TARMIC","June 2018","Phase I: Maximum tolerated dose (MTD) evaluated on the first cycle (D1 to D28) of Trabectedin when administered in association with CP|Phase II: Assessment of the antitumor activity of the association of Trabectedin and metronomic cyclophosphamide based on 6 month non-progression (CR, PR or SD more than 24 weeks) following RECIST v1.1 criteria|Recommended phase II dose (RP2D) of Trabectedin when administered in association with CP|Dose Limiting Toxicities (DLT) of Trabectedin when administered in association with CP|Phase I: Antitumor activity of Trabectedin when administered in association with CP in terms of objective response rate (ORR) as per RECIST V1.1|Phase I: Antitumor activity of Trabectedin when administered in association with CP in terms of 6-month Non-progression rate (NPR) as per RECIST 1.1|Phase I: Antitumor activity of Trabectedin when administered in association with CP in terms of 1-year Progression-free survival (PFS) as per RECIST 1.1|Phase I: Antitumor activity of Trabectedin when administered in association with CP in terms of 1-year Overall Survival (OS)|Phase I: PK measurements expressed as Area Under Curve for CP|Phase I: PK measurements expressed as Area Under Curve for Trabectedin|Phase I: PK measurements expressed as half-life for CP|Phase I: PK measurements expressed as half-life for Trabectedin|Phase I: PK measurements expressed as concentration peak for CP|Phase I: PK measurements expressed as concentration peak for Trabectedin|Phase I: Predictive biomarkers analysis (cytokines levels)|Phase I: Predictive biomarkers analysis (VEGF and TPS-1 levels)|Phase I: Predictive biomarkers analysis (lymphocytes levels)|Phase I: Number of participants with exploratory markers available (markers analyzed for Hematoxylin and eosin staining (H&E))|Phase I: Number of participants with exploratory markers available (markers analyzed for Immunohistochemistry (IHC)|Phase II: Antitumor activity of Trabectedin when administered in association with CP in terms of objective response rate (ORR) as per RECIST V1.1|Phase II: Antitumor activity of Trabectedin when administered in association with CP in terms of 1-year Progression-free survival (PFS) as per RECIST V1.1|Phase II: Antitumor activity of Trabectedin when administered in association with CP in terms of 1-year Overall Survival (OS)|Phase II: Toxicity graded using the common toxicity criteria from the NCI v4.0|Phase II (optional): Predictive biomarkers analysis (cytokines levels)|Phase II (optional): Predictive biomarkers analysis (VEGF and TPS-1 levels)|Phase II (optional): Predictive biomarkers analysis (lymphocyte levels|27. Phase II (optional): Number of participants with exploratory markers available (markers analyzed for Hematoxylin and eosin staining (H&E))|28. Phase II (optional): Number of participants with exploratory markers available (markers analyzed for Immunohistochemistry (IHC)","https://ClinicalTrials.gov/show/NCT02805725"
67,"NCT01339988","Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)","Not yet recruiting","No Results Available","Acute Leukemias|Chronic Leukemias|Myelodysplastic Syndrome|Juvenile Myelomonocytic Leukemia","Drug: Busulfan/Cyclophosphamide","Tel-Aviv Sourasky Medical Center","Male","up to 21 Years   (Child, Adult)","Phase 4","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TASMC-11-MB-442-CTIL","April 20, 2011","June 2011","June 2019","April 20, 2011","April 2011","No Study Results Posted","null","June 2014","Overall survival|Disease free survival","https://ClinicalTrials.gov/show/NCT01339988"
68,"NCT02645565","Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis","Completed","No Results Available","Lupus Nephritis","Drug: Cyclophosphamide|Drug: Azathioprine|Drug: Methylprednisolone","Jawaharlal Institute of Postgraduate Medical Education & Research","All","16 Years and older   (Child, Adult, Senior)","Phase 4","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","JIP/IEC/SC/2013/5/435","December 30, 2015","December 2015","December 2016","March 2, 2017","March 2017","No Study Results Posted","null","December 2016","Assessment of Primary Renal Response|Proportion of patients with Renal and Non renal disease flares|Assessment of adverse events","https://ClinicalTrials.gov/show/NCT02645565"
69,"NCT01976182","Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia","Recruiting","No Results Available","Large Granular Lymphocytes Leukemia","Drug: Methotrexate|Drug: Cyclophosphamide","Rennes University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LGL","October 22, 2013","September 2013","March 2018","April 11, 2016","April 2016","No Study Results Posted","null","March 2018","Complete response (CR)|overall response rate (ORR)|Hematological partial response (PR)|Progressive disease|Time-to-relapse|Molecular remission|Adverse events rate|Compliance|relationship between the response to treatment and the phenotypic subtype","https://ClinicalTrials.gov/show/NCT01976182"
70,"NCT02512926","Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children","Recruiting","No Results Available","Relapsed Solid Tumors|Refractory Solid Tumors|Leukemias","Drug: Carfilzomib|Drug: Cyclophosphamide|Drug: Etoposide","Phoenix Children's Hospital|Amgen|Pediatric Oncology Experimental Therapeutics Investigators' Consortium","All","6 Months to 29 Years   (Child, Adult)","Phase 1","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","POE14-01","July 21, 2015","July 2015","December 2017","April 7, 2016","April 2016","No Study Results Posted","POE14-01","July 2017","To determine the DLTs and MTD of carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors|Collect information on all adverse events that occur with this regimen|Determine patient response rate (CR, PR, SD, PD) with this regimen|Circulating plasma proteasome (cProt) levels post treatment|Levels of proteasome activity|Inhibition of proteasome activity by carfilzomib|Proteasome inhibition in patient PBMCs before and during treatment by determination of the level of protein ubiquitination.|In vitro sensitivity of patient leukemias and solid tumors to carfilzomib alone and in combination with study chemotherapeutic agents|Alterations of proteasome activity in tumor samples|Expression of actionable mutations","https://ClinicalTrials.gov/show/NCT02512926"
71,"NCT01445522","ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer","Completed","No Results Available","Neoplasms|Lymphoma","Drug: ABT-888|Drug: Cyclophosphamide","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 110 Years   (Adult, Senior)","Phase 1","18","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","090048|09-C-0048","September 30, 2011","December 3, 2008","July 3, 2012","May 12, 2017","June 29, 2012","No Study Results Posted","null","July 3, 2012","Establish the safety and tolerability of the combination of ABT-888 with metronomic cyclophosphamide in patients with refractory solid tumors and lymphomas. Establish the MTD of the combination of ABT-888 with metronomic cyclophosphamide.|Evaluate the pharmacokinetics of ABT-888 when administered combination with cyclophosphamide. Evaluate for anti-tumor response.","https://ClinicalTrials.gov/show/NCT01445522"
72,"NCT01005979","A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)","Terminated","No Results Available","Leukemia, Lymphocytic, Chronic, B-Cell|Chronic Lymphocytic Leukemia|Lymphoma, Small Lymphocytic","Drug: Lenalidomide, Rituximab, and Cyclophosphamide","Emory University|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 1","6","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB00024085|WCI1642-09","September 30, 2009","July 2010","null","August 12, 2014","August 2014","No Study Results Posted","null","October 2012","The primary endpoint is to determine the maximum tolerated dose of lenalidomide in combination with cyclophosphamide and rituximab for the treatment of CLL or SLL.|Assess response criteria, including complete response rate, survival at 1 year, time to progression, duration of response, and eradication of minimal residual disease.","https://ClinicalTrials.gov/show/NCT01005979"
73,"NCT01093183","Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer","Unknown status","No Results Available","Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer","Drug: lenalidomide|Drug: cyclophosphamide|Other: laboratory biomarker analysis|Procedure: quality-of-life assessment|Other: questionnaire administration","University of Nebraska|National Cancer Institute (NCI)","Male","19 Years and older   (Adult, Senior)","Phase 1|Phase 2","53","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","479-09|NCI-2010-00363|P30CA036727","March 24, 2010","March 2010","null","April 3, 2014","April 2014","No Study Results Posted","null","February 2014","Maximum tolerated dose of lenalidomide administered in combination with oral cyclophosphamide (Phase I)|Proportion of patients achieving objective PSA response (50% decrease in PSA levels sustained for at least 4 weeks) as defined by PSA working group criteria|Anti-tumor activity as assessed by the sum of complete response (CR), partial response (PR), and stable disease (SD) measured by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1|Proportion of patients achieving CR|Proportion of patients achieving a CR or PR (overall response rate)|Event-free survival|Overall survival|Change in quality of life|Change in bone pain as assessed by the McGill Pain Questionnaire-Short Form (MPQ-SF) (Phase II)","https://ClinicalTrials.gov/show/NCT01093183"
74,"NCT02969980","Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS","Recruiting","No Results Available","Myelodysplastic Syndromes","Drug: Cyclophosphamide","Asan Medical Center","All","15 Years and older   (Child, Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MDS_PTCy_2016","November 17, 2016","November 2016","November 2020","November 17, 2016","November 2016","No Study Results Posted","null","November 2018","the incidence of acute and chronic graft-versus-host disease","https://ClinicalTrials.gov/show/NCT02969980"
75,"NCT01352338","Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)","Completed","No Results Available","Multiple Myeloma","Drug: Lenalidomide, endoxan, prednisone|Drug: lenalidomide, endoxan, prednisone","UMC Utrecht|Celgene Corporation","All","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","82","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RV-MM-PI-0630","April 13, 2011","August 2011","February 2016","February 25, 2016","February 2016","No Study Results Posted","REPEAT","November 2014","Phase 1 Revlimid, Endoxan, Prednisone Evaluation After prior revlimid Treatment (REPEAT)|phase 1 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT)|phase 2 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT)","https://ClinicalTrials.gov/show/NCT01352338"
76,"NCT01749111","Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis","Terminated","No Results Available","Acute Myelogenous Leukemia|Acute Lymphoid Leukemia|Myeloproliferative Disease|Myelodysplastic Syndrome|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia","Drug: ARM A Cyclophosphamide|Drug: ARM B Calcineurin inhibitor and methotrexate","Hospital Israelita Albert Einstein","All","18 Years to 60 Years   (Adult)","Phase 3","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Prevention","GEDECH-2012","December 11, 2012","December 2012","August 2016","March 2, 2017","March 2017","No Study Results Posted","CICLODECH","August 2016","The rate of patients alive, in remission and without immunosuppression, one year after bone marrow transplantation.|Cumulative incidence of chronic graft versus host disease, one year after bone marrow transplantation","https://ClinicalTrials.gov/show/NCT01749111"
77,"NCT00635050","Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin","Completed","Has Results","Invasive Breast Cancer","Drug: Doxil, Paclitaxel, Cyclophosphamide, Avastin","University of Alabama at Birmingham|Ortho Biotech, Inc.|Genentech, Inc.","Female","19 Years and older   (Adult, Senior)","Phase 2","32","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","F070824009|UAB 0493","March 6, 2008","March 2008","June 2015","June 15, 2016","June 2016","March 31, 2016","null","December 2014","Rate of Achievement of Pathological Complete Response (pCR)|Number of Participant With Clinical or Subclinical Cardiotoxicity|Calculate Progression Free Survival|Assess Toxicities of Regimen Including Hand Foot Syndrome","https://ClinicalTrials.gov/show/NCT00635050"
78,"NCT02790580","Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer","Drug: Dose-dense doxorubicin/cyclophosphamide + sunitinib|Drug: Dose-dense doxorubicin/cyclophosphamide","National University Hospital, Singapore","Female","18 Years to 99 Years   (Adult, Senior)","Phase 2","98","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BR01/01/16|2016/00327","May 30, 2016","May 2016","November 2020","May 30, 2016","May 2016","No Study Results Posted","null","May 2020","Clinical response rate|Pathological complete response rate|Progression-free survival","https://ClinicalTrials.gov/show/NCT02790580"
79,"NCT02768701","Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer","Recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Pembrolizumab|Drug: Cyclophosphamide","UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","LCCC 1525","May 5, 2016","October 2016","December 2022","May 19, 2017","May 2017","No Study Results Posted","null","December 2018","The Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT02768701"
80,"NCT02948101","Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer","Not yet recruiting","No Results Available","Malignant Neoplasm of Female Genital Organs","Biological: PD 0360324|Drug: Cyclophosphamide","M.D. Anderson Cancer Center|Pfizer","All","18 Years and older   (Adult, Senior)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2016-0053|NCI-2016-01928","October 25, 2016","December 2016","null","December 12, 2016","December 2016","No Study Results Posted","null","December 2018","Safety of PD 0360324 Followed by Cyclophosphamide in Participants with Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancers|Change in Density of Cluster of Differentiation 8 (CD8+) T cells in Tumor Biopsies Before and After PD 0360324|Progression Free Survival (PFS) Associated With Low Dose Oral Cyclophosphamide After PD 0360324 Treatment","https://ClinicalTrials.gov/show/NCT02948101"
81,"NCT00450814","Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma","Recruiting","No Results Available","Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma","Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Biological: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Other: Pharmacological Study","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","85","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","MC038C|NCI-2009-01194|P30CA015083|R01CA125614|R01CA168719","March 20, 2007","January 2007","December 2017","January 26, 2017","August 2016","No Study Results Posted","null","December 2017","MTD of oncolytic measles virus encoding thyroidal sodium iodide symporter when administered with or without cyclophosphamide (Phase I)|Proportion of confirmed response, defined as a partial response (PR) or better (Phase II)|Failure-free survival (Phase II)|Incidence of adverse events, graded according to the NCI CTCAE v3.0 (Phase II)|Incidence of toxicity incidents as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0) (Phase I)|Number of clinical responses (Phase I)|Overall survival (Phase II)|Progression-free rate (Phase II)|Time to progression (Phase II)|Time until any treatment related toxicity (Phase I)|Time until hematologic nadirs (white blood cells, ANC, platelets) (Phase I)|Time until treatment related grade 3+ toxicity (Phase I)","https://ClinicalTrials.gov/show/NCT00450814"
82,"NCT00562913","Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin","Completed","No Results Available","Cancer","Drug: Nexavar (Sorafenib, BAY43-9006)","Bayer","All","18 Years and older   (Adult, Senior)","Phase 1","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12347","November 21, 2007","December 2007","March 2010","November 24, 2013","November 2013","No Study Results Posted","null","June 2009","To determine the pharmacokinetics and safety of cyclophosphamide when co-administered with 400 mg BID sorafenib and doxorubicin administered|To evaluate the tumor response to the combination of cyclophosphamide, doxorubicin and sorafenib","https://ClinicalTrials.gov/show/NCT00562913"
83,"NCT01420965","Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer","Suspended","No Results Available","Prostatic Neoplasms","Drug: CT-011 (Anti-PD1 Antibody)|Other: Sipuleucel-T (Provenge)|Drug: Cyclophosphamide","Augusta University","Male","18 Years and older   (Adult, Senior)","Phase 2","57","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","11C0231|11-C-0231","August 19, 2011","September 2012","December 2018","June 28, 2016","June 2016","No Study Results Posted","null","December 2016","Determine feasibility of Provenge plus low-dose Cyclophosphamide as well as the immune efficacy of Provenge alone versus Provenge plus low-dose Cyclophosphamide and anti PD1 monoclonal antibodies (CT011) on the change in specific immune response...|Determine whether the combination of low dose-Cyclophosphamide and anti PD1 monoclonal antibodies (CT-011) with Provenge(tm) lead to improvement in increase progression free survival (PFS) and Overall Survival (OS) in patients with advanced, min...","https://ClinicalTrials.gov/show/NCT01420965"
84,"NCT00107276","S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer","Completed","Has Results","Breast Cancer","Drug: capecitabine|Drug: cyclophosphamide","Southwest Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","112","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000423180|S0430|U10CA032102","April 5, 2005","August 2005","August 2009","July 3, 2013","July 2013","November 15, 2012","null","March 2008","Response Rate (Complete and Partial, Confirmed and Unconfirmed)|Progression-free Survival and Overall Survival|Toxicity","https://ClinicalTrials.gov/show/NCT00107276"
85,"NCT01374620","Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel","Completed","No Results Available","Cancer","Drug: Paclitaxel dose escalation|Drug: Paclitaxel|Drug: Cyclophosphamide|Biological: Blood collection","Centre Oscar Lambret","All","18 Years to 65 Years   (Adult)","Phase 1","28","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PAL-ANGI2","June 14, 2011","June 2011","April 2013","July 28, 2016","July 2016","No Study Results Posted","PAL-ANGI2","February 2013","Determination of the iv paclitaxel maximum tolerated dose and recommended dose in association with a fixed dose of oral cyclophosphamide|Description of the nature of adverse events|Evaluation of objective response after 2 cycles|Estimation of the free-progression median time|Calculation of the Growth Modulation Index (GMI)|Evaluation of the correlation between clinical response and biological parameters|Description of the severity of adverse events","https://ClinicalTrials.gov/show/NCT01374620"
86,"NCT00885326","N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma","Active, not recruiting","No Results Available","Neuroblastoma","Drug: Bevacizumab|Drug: cyclophosphamide|Drug: zoledronic acid","New Approaches to Neuroblastoma Therapy Consortium|National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","Phase 1","36","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CDR0000638257|P01CA081403","April 18, 2009","December 2009","November 2017","March 23, 2017","March 2017","No Study Results Posted","null","April 2014","Determination of toxicities and feasibility of the combination of bolus plus metronomic cyclophosphamide and zoledronic acid with and without bevacizumab when given to children with refractory or recurrent high risk neuroblastoma.|Evaluation of response within the confines of a phase I study.|Analysis of Circulating Endothelial Cells, Circulating Factors, Gene expression and Bone Metabolism Studies.","https://ClinicalTrials.gov/show/NCT00885326"
87,"NCT02176213","Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma","Active, not recruiting","No Results Available","Multiple Myeloma in Relapse|Multiple Myeloma, Refractory","Drug: Pomalidomide|Drug: Cyclophosphamide|Drug: Dexamethasone","Ajai Chari|Celgene Corporation|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Senior)","Phase 2","35","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GCO 14-0825|PO-CL-MM-PI-002404","June 25, 2014","June 2014","June 2019","January 5, 2017","January 2017","No Study Results Posted","null","June 2019","Best overall response rate (ORR)|Stringent complete response (sCR)|Complete response (CR)|Very good partial response (VGPR)|Partial response (PR)|Time to progression (TTP)|Duration of response (DOR)|Clinical benefit response (CBR)|Progression free survival (PFS)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02176213"
88,"NCT01963481","Exemestane and Cyclophosphamide for Metastatic Breast Cancer","Active, not recruiting","No Results Available","Metastatic Beast Cancer","Drug: Exemestane|Drug: Cyclophosphamide","New York University School of Medicine","All","18 Years and older   (Adult, Senior)","Phase 2","23","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S13-00761","October 11, 2013","September 2013","September 2017","December 1, 2016","December 2016","No Study Results Posted","null","July 2017","Progression-free survival (PFS) rate at 3 months|Response rate (complete response and partial response)|Clinical benefit rate","https://ClinicalTrials.gov/show/NCT01963481"
89,"NCT01076556","Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Terminated","No Results Available","Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage I Small Lymphocytic Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma","Drug: Alvocidib Hydrochloride|Drug: Cyclophosphamide|Other: Diagnostic Laboratory Biomarker Analysis|Other: Pharmacological Study|Biological: Rituximab","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","9","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-01373|OSU 09089|CDR0000666448|OSU-09089|8267|P30CA016058|U01CA076576","February 25, 2010","April 2010","null","November 10, 2015","November 2015","No Study Results Posted","null","July 2010","Maximum-tolerated dose of combination therapy with Cyclophosphamide, Alvocidib, and Rituximab|Treatment related adverse events assessed using the CTEP Active Version of the CTCAE","https://ClinicalTrials.gov/show/NCT01076556"
90,"NCT00722098","Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients","Terminated","No Results Available","Malignant Melanoma Stage IV","Biological: DC Vaccine & Cyclophosphamide|Biological: DC Vaccine & Placebo","Baylor Research Institute","All","21 Years to 75 Years   (Adult, Senior)","Phase 2","9","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","Baylor IRB #006-123","July 23, 2008","June 2008","July 2012","July 5, 2013","July 2013","No Study Results Posted","null","April 2011","Induction of melanoma-specific CD8+T Cell Immunity.|Rate of objective clinical responses.","https://ClinicalTrials.gov/show/NCT00722098"
91,"NCT00206388","Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement","Completed","No Results Available","NEUROBLASTOMA","Drug: Zolendric acid|Drug: Cyclophosphamide","Baylor College of Medicine|New Approaches to Neuroblastoma Therapy Consortium","All","up to 30 Years   (Child, Adult)","Phase 1","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","16758|ZOMETA","September 14, 2005","April 2005","May 2013","August 1, 2013","August 2013","No Study Results Posted","null","April 2008","Toxicity|Maximum tolerated dose (MTD)|Anti tumor activity|Pharmacokinetics|Biologic activity","https://ClinicalTrials.gov/show/NCT00206388"
92,"NCT00901069","Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma","Completed","No Results Available","Lymphoma|Hodgkin Disease|Lymphoma, Non-Hodgkin","Drug: Azacitidine with rituximab, vincristine, and cyclophosphamide","Shams Shakil|Celgene|University of Kentucky","All","18 Years and older   (Adult, Senior)","Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-NHL-06-UK/CC","May 11, 2009","May 2009","November 2012","October 13, 2016","October 2016","No Study Results Posted","null","January 2012","Determine the maximal tolerated dose (MTD) of azacitidine in combination with rituximab, vincristine, and cyclophosphamide in patients with lymphoma","https://ClinicalTrials.gov/show/NCT00901069"
93,"NCT00667329","Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab","Active, not recruiting","No Results Available","Lymphoma","Drug: 2CdA|Drug: Cyclophosphamide|Drug: Rituximab","M.D. Anderson Cancer Center","All","Child, Adult, Senior","","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM99-070|NCI-2010-01457","April 24, 2008","July 1999","null","September 12, 2016","September 2016","No Study Results Posted","null","July 2018","Response Rate|After these drugs are given for 2 courses, a second goal is to see how long a remission lasts.|A third goal is to see how often repeat remissions can be achieved when the lymphoma returns later and the same drugs are restarted.","https://ClinicalTrials.gov/show/NCT00667329"
94,"NCT00665990","Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia","Completed","No Results Available","Refractory Solid Tumors|Leukemia","Drug: Bevacizumab|Drug: Sorafenib|Drug: Cyclophosphamide","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","Phase 1","49","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ANGIO1|NCI-2011-01146","April 22, 2008","November 2007","August 2013","January 8, 2015","January 2015","No Study Results Posted","null","August 2013","Determine the maximum tolerated dose and dose limiting toxicity of bevacizumab and sorafenib administered in combination with low dose cyclophosphamide to patients with refractory solid tumors.","https://ClinicalTrials.gov/show/NCT00665990"
95,"NCT02985333","Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma","Recruiting","No Results Available","Relapse/Refractory Multiple Myeloma","Drug: Paclitaxel|Drug: Cyclophosphamide|Drug: Dexamethasone","Sun Yat-sen University","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MM-2014","December 5, 2016","January 2014","June 2019","December 8, 2016","December 2016","No Study Results Posted","null","December 2018","Overall Response Rate (ORR)|Progression Free Survival (PFS)|Overall survival (OS)|Safety of combination therapy assessed using the National Cancer institute-Common Toxicology Criteria (NCI-CTC) grade scale for AEs and Lab assessments","https://ClinicalTrials.gov/show/NCT02985333"
96,"NCT00007475","Permeability Factor in Focal Segmental Glomerulosclerosis","Completed","Has Results","Focal Segmental Glomerulosclerosis","Procedure: Plasma exchange|Drug: Cyclophosphamide","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 1|Phase 2","15","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","010053|01-DK-0053","December 22, 2000","December 2000","June 2014","February 8, 2016","February 2016","June 19, 2015","null","June 2014","Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide.|Comparison of RNA Expression Profiles in PBMC From Patients With FPF, Without FPF and Control Subjects|Define the Kinetics of FPF in FSGS Patients Receiving Immunomodulatory Therapy or Plasma Exchange.|Correlate the Effect of Immunosuppressive Agents Which Reduce Proteinuria in Recurrent FSGS With the Effect on FPF Levels|Determine Whether Renal Transplantation in Patients Whose Elevated FPF Levels Have Been Reduced for a Sustained Period is Associated With a Reduced Prevalence of Recurrent FSGS.","https://ClinicalTrials.gov/show/NCT00007475"
97,"NCT01779882","Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT","Recruiting","No Results Available","Myeloid Leukemia|Precursor Myeloid Neoplasms|Lymphoid Neoplasms","Drug: Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation","University Hospital, Basel, Switzerland|University Hospital, Zürich|University Hospital, Geneva","All","18 Years to 65 Years   (Adult)","","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BuCyBu study","January 28, 2013","January 2013","December 2017","August 2, 2016","August 2016","No Study Results Posted","null","December 2017","Liver toxicity|VOD|Acute graft-versus-host disease (GvHD)|Toxicity|Efficacy|Cumulative liver values|Maximum liver values","https://ClinicalTrials.gov/show/NCT01779882"
98,"NCT00617370","Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility","Completed","No Results Available","Breast Cancer|Adenocarcinoma of the Breast","Drug: epirubicin, cyclophosphamide, Paclitaxel,","Memorial Sloan Kettering Cancer Center|Amgen|Pfizer","Female","18 Years and older   (Adult, Senior)","","38","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04-065","February 4, 2008","November 2004","June 2008","December 21, 2015","December 2015","No Study Results Posted","null","July 2005","To evaluate the feasibility and safety of this dose-dense regimen.","https://ClinicalTrials.gov/show/NCT00617370"
99,"NCT00615901","Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer","Completed","Has Results","Breast Cancer","Drug: cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim","Memorial Sloan Kettering Cancer Center|Amgen","Female","18 Years to 70 Years   (Adult, Senior)","","38","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-133","February 1, 2008","January 2008","June 2010","January 11, 2017","January 2017","December 23, 2015","null","June 2010","The Number of Patients Who Completed 8 Cycles.","https://ClinicalTrials.gov/show/NCT00615901"
100,"NCT00833560","A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy","Completed","Has Results","Multiple Myeloma","Drug: Cyclophosphamide|Drug: Bortezomib|Drug: Dexamethasone","Janssen-Cilag G.m.b.H","All","18 Years to 60 Years   (Adult)","Phase 2","401","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR005242|26866138MMY2031|2005-003902-27","January 23, 2009","March 2006","June 2009","November 11, 2014","November 2014","October 30, 2013","null","June 2009","Participants With Complete Response (CR) + Partial Response (PR) (Efficacy Set)|Participants With Complete Response (CR) + Partial Response (PR) (Per-protocol Analysis Set)|Percentage of Participants With Complete Response + Partial Response in Relation to Cytogenetic Subgroups (Efficacy Set)|Percentage of Participants With Complete Response + Partial Response in Relation to Cytogenetic Subgroups (Per-protocol Set)","https://ClinicalTrials.gov/show/NCT00833560"
101,"NCT00908869","Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b ("" Metronomic Chemotherapy "") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm","Completed","No Results Available","Advanced Neoplasm","Drug: Vinorelbine, Cyclophosphamide and Interferon alpha 2b","Institut Paoli-Calmettes","All","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","METRO1/IPC2005-001","May 25, 2009","May 2006","May 2011","January 26, 2012","January 2012","No Study Results Posted","METRO1","May 2010","Estimation of the toxicity of the combination of continuous low doses of Vinorelbine, Cyclophosphamide and Interferon alpha 2b.|Estimation of the antiangiogenic and/or antivascular effect (VEGF measurement) in radiography (DEC-MRI), biology and immunohistochemistry of the treatment.","https://ClinicalTrials.gov/show/NCT00908869"
102,"NCT01527487","Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer","Completed","Has Results","HER2 Negative Breast Cancer","Drug: Eribulin|Drug: Cyclophosphamide|Drug: Docetaxel","SCRI Development Innovations, LLC|Eisai Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","76","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI BRE 197","January 31, 2012","June 2012","July 2016","October 3, 2016","October 2016","March 18, 2016","null","September 2014","Pathologic Complete Response (pCR) Rate in Patients Treated With ErC for 6 Cycles Prior to Surgery|The Number of Adverse Events as a Measure of Safety and Tolerability.|Clinical Response Rate (cRR) of ErC as Neoadjuvant Therapy|Disease-Free Survival (DFS) at 2 Years","https://ClinicalTrials.gov/show/NCT01527487"
103,"NCT00315705","A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.","Completed","Has Results","Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Relapsed Leukemia","Drug: clofarabine|Drug: Etoposide|Drug: Cyclophosphamide","Genzyme, a Sanofi Company|Sanofi","All","1 Year to 21 Years   (Child, Adult)","Phase 1|Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLO21800205","April 18, 2006","March 2006","May 2010","March 17, 2014","March 2014","April 27, 2011","null","May 2010","Maximum Tolerated Dose (MTD) in Phase 1|Participants With Dose Limiting Toxicity in Phase 1|Percentage of Participants Achieving A Response Over the First Two Treatment Cycles in Phase 2|Summary of Participants With Adverse Events (AEs) in Phase 1|Percentage of Participants Achieving A Response Over the First Two Treatment Cycles in Phase 1|Time to Remission for Participants Who Had a Response in Phase 1|Kaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 1|Kaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 1|Number of Participants With 4-month Event Free Survival in Phase 1|Kaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 1|Summary of Participants With Adverse Events (AEs) in Phase 2|Time to Remission for Participants Who Had a Response in Phase 2|Kaplan Meier Estimate of Duration of Remission (DOR) for Participants Who Achieved Overall Remission (OR) in Phase 2|Kaplan Meier Estimates of Event-free Survival (EFS) for Participants in Phase 2|Number of Participants With 4-month Event Free Survival in Phase 2|Kaplan Meier Estimates of Overall Survival (OS) for Participants in Phase 2","https://ClinicalTrials.gov/show/NCT00315705"
104,"NCT01955434","SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma","Recruiting","No Results Available","Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma","Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Quality-of-Life Assessment|Drug: Smac Mimetic LCL161","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","27","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MC1381|NCI-2013-01276|CLCL161AUS01T|P30CA015083","September 27, 2013","November 2013","January 2018","March 21, 2017","August 2016","No Study Results Posted","null","January 2018","Proportion of confirmed overall responses (stringent complete response [sCR], complete response [CR], very good partial response [VGPR], or partial response [PR]) with single agent SMAC mimetic LCL161|Confirmed overall response rate with the addition of cyclophosphamide|Event-free survival|Incidence of adverse events graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Overall survival","https://ClinicalTrials.gov/show/NCT01955434"
105,"NCT01100944","A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies","Terminated","Has Results","Thymoma|Thymic Carcinoma","Drug: PXD101with cisplatin+doxorubicin+cyclophosphamide","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Senior)","Phase 1|Phase 2","26","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","100077|10-C-0077","March 18, 2010","March 2010","June 2017","November 14, 2016","November 2016","July 26, 2016","null","May 2016","Maximum Tolerated Dose (MTD) of Belinostat|Number of Participants With Grade 3 and 4 Dose Limiting Toxicity (DLT) at 2000mg/m(2) Belinostat|Objective Response Rate (Partial Response (PR) + Complete Response (CR) of Belinostat in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Patients With Advanced Thymic Malignancies|Number of Participants With Serious and Non-serious Adverse Events|Treatment-related Grade 3 and 4 Adverse Events (Highest Grade Per Event Per Patient)|Clinical Response|Disease Control Rate (DCR)|Time to Response|Duration of Response|Progression Free Survival (PFS)|Overall Survival (OS)|Time to Half Life (t1/2) of Belinostat|Total Clearance (CL) of Belinostat|Maximum Observed Plasma Concentration (Cmax) of Belinostat|Maximum Plasma Concentration (Cmax)/Dose|Time to Maximum Plasma Concentration (Tmax)|Area Under the Plasma Concentration vs. Time Curve Extrapolated to Infinity (AUC(INF))|Area Under the Plasma Concentration vs. Time Curve Extrapolated to Infinity (AUC(INF)/Dose|Relative Change Observed in Total Protein Hyperacetylation of Cluster of Differentiation 3 (CD3)+T Cells With Belinostat|Relative Changes in the Number of Tregs With Treatment|Relative Changes in T Cell Immunoglobulin Domain and Mucin Domain-3 (TIM3)-Expressing Cluster of Differentiation 8 (CD8)+Tcells","https://ClinicalTrials.gov/show/NCT01100944"
106,"NCT00912444","Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer","Terminated","No Results Available","Breast Cancer","Drug: Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide|Drug: Docetaxel, cyclophosphamide","Shanghai Jiao Tong University School of Medicine","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","102","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NATT","June 1, 2009","July 2009","October 2015","November 19, 2016","November 2016","No Study Results Posted","NATT","May 2012","pathological complete remission (pCR) rate|disease free survival (DFS) and overall survival (OS)|clinical response rate|safety profile|breast conservation therapy (BCT) rate","https://ClinicalTrials.gov/show/NCT00912444"
107,"NCT00800839","Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide","Completed","Has Results","Hematologic Diseases|Leukemia|Lymphoma|Myeloma","Drug: Busulfan|Drug: Fludarabine|Drug: Cyclophosphamide","M.D. Anderson Cancer Center","All","6 Months to 75 Years   (Child, Adult, Senior)","Phase 2","56","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-0261|NCI-2012-01660","December 1, 2008","September 2008","null","July 28, 2016","July 2016","July 28, 2016","null","July 2015","Cumulative Incidence of Grade II to IV Acute GVHD|Cumulative Incidence of Grade III to IV Acute GVHD|Day-100 Treatment-Related Mortality|Rate of Engraftment|2-year Progression-Free Survival|2-year Overall Survival","https://ClinicalTrials.gov/show/NCT00800839"
108,"NCT02629809","First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)","Recruiting","No Results Available","Leukemia|Chronic Lymphocytic Leukemia","Drug: Obinutuzumab|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Ibrutinib|Drug: Allopurinol|Drug: Valacyclovir","M.D. Anderson Cancer Center|Genentech, Inc.|Pharmacyclics LLC.","All","18 Years and older   (Adult, Senior)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2015-0281|NCI-2016-00016","December 10, 2015","March 2016","March 2022","April 26, 2017","April 2017","No Study Results Posted","null","March 2022","Number of Participants with Complete Remission (CR) or CR with Incomplete Marrow Recovery (CRi)|Number of Participants with Negative Bone Marrow Minimal Residual Disease (MRD)|Safety of Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients with Chronic Lymphocytic Leukemia (CLL) with Mutated IGHV gene and Non-del(17p)","https://ClinicalTrials.gov/show/NCT02629809"
109,"NCT00002501","Cyclophosphamide and Filgrastim in Treating Patients With Stage IV, Relapsed, or Refractory Low-Grade Follicular Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Drug: cyclophosphamide","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years to 55 Years   (Adult)","Phase 2","29","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-9150|CLB-9150|CDR0000077861","November 1, 1999","October 1992","January 2006","June 30, 2016","June 2016","No Study Results Posted","null","July 2001","Toxicity","https://ClinicalTrials.gov/show/NCT00002501"
110,"NCT01885013","Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients","Completed","No Results Available","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","Drug: Metformin + Myocet + Cyclophosphamide|Drug: Myocet + Cyclophosphamide","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IRST174.04|2009-014662-26","June 19, 2013","September 2010","May 2015","December 31, 2015","December 2015","No Study Results Posted","MYME","May 2015","progression-free survival (PFS)|Objective response rate|Overall survival|Progression free survival as function of Homa Index levels|objective response rate as function of Homa Index levels|overall survival as function of Homa Index levels|patient metabolic profile (metabolic syndrome)","https://ClinicalTrials.gov/show/NCT01885013"
111,"NCT03136146","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)","Not yet recruiting","No Results Available","Hematopoietic/Lymphoid Cancer|Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Burkitt Leukemia/Lymphoma","Drug: Clofarabine|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Liposomal Vincristine|Drug: Bortezomib|Drug: Ofatumumab|Drug: Rituximab|Drug: Pegfilgrastim","M.D. Anderson Cancer Center","All","Child, Adult, Senior","Phase 2","42","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2016-0211","April 27, 2017","June 2017","June 2025","April 27, 2017","April 2017","No Study Results Posted","null","June 2025","Dose Limiting Toxicity (DLT) of Addition of Liposomal VCR and Bortezomib to CEC (Clofarabine, Etoposide, Cyclophosphamide)|Overall Response Rate (ORR) of Addition of Liposomal VCR and Bortezomib to CEC (Clofarabine, Etoposide, Cyclophosphamide)","https://ClinicalTrials.gov/show/NCT03136146"
112,"NCT00390156","Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor","Biological: bevacizumab|Drug: cyclophosphamide|Drug: imatinib","University of California, San Francisco|National Cancer Institute (NCI)|Novartis","All","18 Years and older   (Adult, Senior)","Phase 1","35","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06991|P30CA082103|H9672-28868|CSTI571BUS245","October 18, 2006","August 2006","January 2011","October 9, 2013","October 2013","No Study Results Posted","null","January 2011","Maximum tolerated dose of imatinib when given together with bevacizumab and metronomic cyclophosphamide|Pharmacokinetics of imatinib|Safety of imatinib in combination with cyclophosphamide and bevacizumab","https://ClinicalTrials.gov/show/NCT00390156"
113,"NCT00628732","A Pharmacokinetic Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors","Completed","No Results Available","Solid Tumors","Drug: Cyclophosphamide and Topotecan","Children's Medical Center Dallas|Metabolic Solutions Inc.|Simmons Cancer Center","All","up to 21 Years   (Child, Adult)","Phase 2","36","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","012005004","February 25, 2008","January 2005","February 2007","January 27, 2009","January 2009","No Study Results Posted","null","February 2007","Radiographic imaging","https://ClinicalTrials.gov/show/NCT00628732"
114,"NCT02206503","Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)","Recruiting","No Results Available","Multiple Myeloma","Drug: Cyclophosphamide|Drug: Lenalidomide|Drug: Dexamethasone","Fondazione Neoplasie Sangue Onlus","All","Child, Adult, Senior","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRd","February 6, 2014","March 2013","April 2018","February 5, 2016","February 2016","No Study Results Posted","null","April 2015","Efficacy|Safety|The progression free survival (PFS)|The overall survival (OS)|Duration of time to progression (TTP)|Time to next therapy (TNT)|Identification of patient's subgroups according to specific prognostic factors","https://ClinicalTrials.gov/show/NCT02206503"
115,"NCT00430105","Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides","Completed","No Results Available","ANCA Associated Systemic Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis","Drug: cyclophosphamide","Cambridge University Hospitals NHS Foundation Trust","All","18 Years to 80 Years   (Adult, Senior)","Phase 2|Phase 3","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IC20-CT97-0019|BMH4-CT97-2328","January 31, 2007","February 1998","April 2004","January 31, 2007","January 2007","No Study Results Posted","null","null","Disease free period, time from remission to relapse or study end.|Adverse events|Vasculitis Damage Index|Cumulative exposure to cyclophosphamide","https://ClinicalTrials.gov/show/NCT00430105"
116,"NCT02046915","Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide","Active, not recruiting","No Results Available","Relapsed or Refractory Multiple Myeloma","Drug: Imnovid (pomalidomide)|Drug: Dexamethasone|Drug: Endoxan (Cyclophosphamide)","University Hospital Tuebingen","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013-003678-29","January 22, 2014","April 2014","September 2017","October 25, 2016","October 2016","No Study Results Posted","PERSPECTIVE","August 2016","response rate|progression free survival of Pomalidomide in combination with low-dose Dexamethasone and intravenous Cyclophosphamide","https://ClinicalTrials.gov/show/NCT02046915"
117,"NCT00445744","Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome","Completed","No Results Available","Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Childhood Acute Myeloid Leukemia in Remission|Childhood Myelodysplastic Syndromes|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Myelodysplastic Syndrome With Isolated Del(5q)|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Secondary Myelofibrosis|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies","Drug: cyclophosphamide|Drug: busulfan|Drug: tacrolimus|Drug: methotrexate|Genetic: cytogenetic analysis|Other: flow cytometry|Other: pharmacological study|Other: pharmacogenomic studies|Procedure: peripheral blood stem cell transplantation|Procedure: allogeneic hematopoietic stem cell transplantation","Fred Hutchinson Cancer Research Center|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","","52","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2130.00|NCI-2010-00270|P01HL036444","March 7, 2007","December 2006","June 2013","April 3, 2014","April 2014","No Study Results Posted","null","June 2011","Effectiveness of cyclophosphamide/busulfan regimen in reducing regimen-related toxicity|Non-relapse mortality (NRM) (patients with AML/MDS)","https://ClinicalTrials.gov/show/NCT00445744"
118,"NCT01306032","Phase II ABT-888 With Cyclophosphamide","Completed","Has Results","Ovarian Cancer|Primary Peritoneal Cancer|Serous Carcinoma Cancer|Triple-Negative Breast Cancer|Fallopian Tube Cancer","Drug: ABT-888|Drug: Cyclophosphamide","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","124","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: No masking|Primary Purpose: Treatment","110080|11-C-0080","February 26, 2011","January 12, 2011","December 15, 2016","March 16, 2017","March 2017","December 23, 2015","null","December 31, 2014","Percentage of Participants With an Overall Response Rate|Progression Free Survival|Number of Participants With Adverse Events|Change in Poly-ADP Ribose (PAR) Concentration Levels From Baseline|Change in ϓH2AX- Positive Circulating Tumor Cells (CTCs) in Whole Blood|Number of Participants With Deleterious Mutations in DNA Repair Genes","https://ClinicalTrials.gov/show/NCT01306032"
119,"NCT01283776","Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation","Completed","No Results Available","Multiple Myeloma|Non-Hodgkin-Lymphoma|Hodgkin's Disease","Drug: Cyclophosphamide","University of Cologne","All","18 Years and older   (Adult, Senior)","Phase 2","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","Uni-Koeln-1430","January 25, 2011","March 2011","June 2014","June 8, 2014","June 2014","No Study Results Posted","OCTET-CY","December 2013","Number of patients not requiring additional immunosuppression|Overall Survival|engraftment|chimerism|relapse incidence|acute GvHD|non-relapse mortality|immune reconstitution","https://ClinicalTrials.gov/show/NCT01283776"
120,"NCT00607581","Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis","Completed","No Results Available","Amyloidosis","Drug: cyclophosphamide|Drug: lenalidomide|Drug: dexamethasone","IRCCS Policlinico S. Matteo|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AC-003-IT|RV-AMYL-PI-303","January 22, 2008","February 2008","January 2012","February 9, 2012","February 2012","No Study Results Posted","null","December 2011","hematologic response rate|organ response rate|time to response|time to progression|survival|toxicity","https://ClinicalTrials.gov/show/NCT00607581"
121,"NCT02065154","Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis","Recruiting","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndrome|Myelofibrosis|Severe Aplastic Anemia|Allogeneic Transplant","Drug: Cyclophosphamide","University of Alabama at Birmingham","All","19 Years to 65 Years   (Adult)","Phase 2","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","UAB 1286","November 5, 2013","August 2013","June 2019","October 23, 2016","October 2016","No Study Results Posted","null","July 2018","Grade II-IV acute GVHD|Overall Survival|Disease-free Survival|Regimen Related Toxicity|Immune Reconstitution|Relapse Rate","https://ClinicalTrials.gov/show/NCT02065154"
122,"NCT02650635","TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors","Active, not recruiting","No Results Available","Colorectal Adenocarcinoma|Metastatic Pancreatic Adenocarcinoma|Recurrent Breast Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Melanoma of the Skin|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Renal Cell Carcinoma|Solid Neoplasm|Stage IV Breast Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Renal Cell Cancer|Stage IV Skin Melanoma|Stage IVA Colorectal Cancer|Stage IVA Pancreatic Cancer|Stage IVB Colorectal Cancer|Stage IVB Pancreatic Cancer","Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Biological: Pegfilgrastim|Other: Pharmacological Study|Drug: TLR8 Agonist VTX-2337","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","4","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC1245|NCI-2015-02150|P30CA015083","December 30, 2015","February 2016","null","October 17, 2016","June 2016","No Study Results Posted","null","May 2021","Change in pharmacodynamics after TLR8 agonist VTX-2337 alone vs TLR8 agonist VTX-2337+cyclophosphamide|Duration of response, assessed by irDOR, defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented|Incidence of adverse events of cyclophosphamide and TLR8 agonist VTX-2337, using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Overall response rate assessed by irBORR|Overall survival (OS)|PFS as measured by serial imaging studies and assessed by irRECIST","https://ClinicalTrials.gov/show/NCT02650635"
123,"NCT00866905","Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Ixabepilone|Drug: Cyclophosphamide","SCRI Development Innovations, LLC|Bristol-Myers Squibb","Female","18 Years and older   (Adult, Senior)","Phase 2","168","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI BRE 133","March 19, 2009","April 2009","October 2014","December 5, 2014","December 2014","November 21, 2014","null","July 2014","Pathologic Complete Response Rate (pCR)|Absence of Grade-4 Non-hematologic Toxicity Excluding, Alopecia, Nausea, Vomiting and Bone Pain|Overall Survival|Disease Free Survival","https://ClinicalTrials.gov/show/NCT00866905"
124,"NCT00759824","A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide","Completed","No Results Available","Small Cell Lung Carcinoma","Drug: Adriamycin, cyclophosphamide, vindesine, valproic acid","European Lung Cancer Working Party","All","18 Years and older   (Adult, Senior)","Phase 2","64","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01081","September 24, 2008","September 2008","June 2014","February 11, 2015","February 2015","No Study Results Posted","null","December 2013","Six-months progression-free survival|Survival|Response rate|Toxicity","https://ClinicalTrials.gov/show/NCT00759824"
125,"NCT01462253","Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults","Active, not recruiting","No Results Available","Acute Lymphoblastic Leukemia","Drug: Clofarabine, Cyclophosphamide","Gruppo Italiano Malattie EMatologiche dell'Adulto","All","18 Years to 60 Years   (Adult)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","LAL1610","October 21, 2011","October 2012","December 2017","February 16, 2017","February 2017","No Study Results Posted","LAL1610","December 2017","The primary end-point is the rate of patients in CR after induction therapy.|Number of participants with toxicity of grade 2 or greater (CTCAE version 4.0) events|Rate of ALL blast cells in apoptosis and DNA damage per patient induced by Clofarabine when used in combination with Cyclophosphamide.|Number of participants with minimal residual disease (MRD) response in remission.|Disease-free survival (DFS)|Overall Survival (OS).|Cumulative incidence of relapse (CIR).|Rate of Disease free survival (DFS) in very high risk and high risk patients|Rate of Overall Survival (OS) in very high risk and high risk patients|Rate of Cumulative Incidence of Relapse (CIR) in very high risk and high risk patients","https://ClinicalTrials.gov/show/NCT01462253"
126,"NCT01833767","Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma","Withdrawn","No Results Available","Metastatic Melanoma","Drug: Cyclophosphamide and Interleukin 2","Western Regional Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12-12","April 14, 2013","October 2012","December 2015","June 1, 2015","June 2015","No Study Results Posted","null","December 2015","Response Rate|Median Survival","https://ClinicalTrials.gov/show/NCT01833767"
127,"NCT02457221","A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis","Recruiting","No Results Available","Lupus Nephritis","Drug: Tacrolimus capsules|Drug: Cyclophosphamide injections|Drug: Prednisone","Astellas Pharma China, Inc.|Astellas Pharma Inc","All","18 Years to 60 Years   (Adult)","Phase 3","294","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","F506-CL-0912","May 22, 2015","March 10, 2015","June 30, 2018","April 27, 2017","April 2017","No Study Results Posted","null","June 30, 2018","Remission rate (complete remission + partial remission)|24-hour urine protein|Change of 24-hour urine protein from baseline|Serum albumin|Change of Serum albumin from baseline|Serum creatinine|Change of Serum creatinine from baseline|eGFR comparing with baseline|Percentage of patients converted to other immunosuppressive therapy|Percentage of patients with serum creatinine rising to two times of the baseline|Percentage of patients with dsDNA and ANA converting from positive to negative|SLE-DAI|Immune parameters assessed by ESR, C3, C4 and dsDNA|Change of SLE-DAI from baseline|Change of immune parameters from baseline|Renal biopsy AI (Active Index)|CI (Chronic Index)|Change of Renal biopsy AI (Active Index) from baseline|Change of CI (Chronic Index) from baseline","https://ClinicalTrials.gov/show/NCT02457221"
128,"NCT00399529","Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer","Completed","No Results Available","Breast Neoplasms","Biological: Allogeneic GM-CSF-secreting breast cancer vaccine|Drug: Trastuzumab|Drug: Cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center|American Cancer Society, Inc.|Avon Foundation|Cancer Treatment Research Foundation|The Commonwealth Fund|United States Department of Defense|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","22","Other|U.S. Fed|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J05118|RAC 0605-778","November 13, 2006","September 2006","February 2010","December 11, 2012","December 2012","No Study Results Posted","null","February 2010","Safety will be evaluated by assessing toxicity related to the vaccine, CY, Trastuzumab, cardiac dysfunction, and the potential induction of autoimmunity.|Clinical benefit will be assessed by re-evaluating disease status with tumor markers and RECIST criteria, or with full evaluation upon the development of new symptoms.|Immunological response","https://ClinicalTrials.gov/show/NCT00399529"
129,"NCT01980589","A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects","Completed","Has Results","Multiple Myeloma","Drug: Carfilzomib|Drug: Cyclophosphamide|Drug: Dexamethasone","Onyx Therapeutics, Inc.|Amgen","All","18 Years and older   (Adult, Senior)","Phase 1","22","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-003","October 28, 2013","August 2013","March 2016","September 7, 2016","September 2016","September 7, 2016","CHAMPION 2","March 2016","Number of Participants With Dose-limiting Toxicities (DLTs)|Overall Response Rate (ORR)|Time To Response (TTR)|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT01980589"
130,"NCT03018535","Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy","Recruiting","No Results Available","Glomerulonephritis, Membranous","Drug: Rituximab|Drug: Methylprednisolone|Drug: Cyclophosphamide","Azienda Ospedaliera Spedali Civili di Brescia|University of Bari|Azienda Ospedaliera Brotzu|University of Messina|University of Milan|Universita di Verona|University of Chieti|University of Bologna|Azienda Sanitaria Locale Roma E|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|Regione Piemonte|University of Modena and Reggio Emilia|University of Pisa|University of Milano Bicocca|Humanitas Hospital, Italy|Azienda Ospedaliera Universitaria Policlinico|Fondazione Salvatore Maugeri|University of Bern|University of Alberta|Istituto Giannina Gaslini","All","18 Years and older   (Adult, Senior)","Phase 3","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT 2011 006115-59","January 9, 2017","January 2012","December 2019","January 10, 2017","January 2017","No Study Results Posted","RI-CYCLO","December 2018","change in probability of complete remission (proteinuria < 0.3 g/day) Primary Outcome Measures The primary outcome measure is the change in probability of complete remission (proteinuria < 0.3 g/day) at one year (see Design and power considerations).|Change from baseline in proteinuria|CR (Complete Remission) or PR (Partial Remission: Reduction in UP of > 50% plus final UP ≤ 3.5 g but >0.3g )|Estimated Glomerular filtration rate (MDRD formula)|Serum creatinine level (mg/dl)|Frequency of and time to relapse of nephrotic syndrome|Frequency of auto-antibodies and its relation to therapy and proteinuria response in a subgroup of patients|serious side effects: Death, Life-threatening event, Hospitalization, Disability in the patient's body function/structure or physical activity or quality of life, Congenital anomaly, Intervention to prevent permanent impairment or damage)","https://ClinicalTrials.gov/show/NCT03018535"
131,"NCT00083161","Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide","Gundersen Lutheran Health System","All","18 Years and older   (Adult, Senior)","Phase 2","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000363799|GLO-03-06-06","May 14, 2004","June 2003","May 2010","September 1, 2012","September 2012","No Study Results Posted","null","May 2010","Safety|Effect of metronomic chemotherapy on circulating endothelial cells|Progression-free survival|Response rate|Overall survival","https://ClinicalTrials.gov/show/NCT00083161"
132,"NCT02059850","NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma","Withdrawn","No Results Available","Adult Synovial Sarcoma|Myxoid/Round Cell Liposarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma","Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 85 Years   (Adult, Senior)","Phase 1","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2720.00|NCI-2013-02464|K23CA175167|P30CA015704","February 7, 2014","July 2014","January 2016","February 1, 2016","February 2016","No Study Results Posted","null","January 2016","Incidence of grade III or greater toxicity graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0|Persistence of tetramer positive T cells","https://ClinicalTrials.gov/show/NCT02059850"
133,"NCT02399358","Factors Associated With Hyponatremia Induced by High-dose Cyclophosphamide","Not yet recruiting","No Results Available","Hyponatremia","","Diego Hernan Giunta, MD|Hospital Italiano de Buenos Aires","All","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2439","March 22, 2015","December 2015","November 2017","December 16, 2015","December 2015","No Study Results Posted","null","June 2017","Hyponatremia","https://ClinicalTrials.gov/show/NCT02399358"
134,"NCT01729338","Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Velcade|Drug: Cyclophosphamide|Drug: Revlimid","Duke University|Millennium Pharmaceuticals, Inc.|Duke Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 2","17","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00038924|Millennium","November 14, 2012","December 2012","December 2020","August 30, 2016","August 2016","No Study Results Posted","null","December 2015","Overall response rate (ORR) during induction therapy|Number of patients with any grade or severe adverse events, as a measure of tolerability and safety|Maximum depth of response during induction therapy|Maximum depth of response during maintenance therapy|Median time to response|Median duration of response|Median progression-free survival|Median overall survival|Quality of life|Functionality","https://ClinicalTrials.gov/show/NCT01729338"
135,"NCT01301040","Early Cardiac Toxicity of Adjuvant CT in Elderly BC.","Terminated","No Results Available","Breast Cancer","Drug: epirubicin, cyclophosphamide, docetaxel","Jules Bordet Institute|Sanofi","Female","65 Years and older   (Adult, Senior)","Phase 2","2","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","IJB 11-01|2011-000562-35","February 18, 2011","March 2011","March 2016","August 29, 2013","February 2011","No Study Results Posted","null","March 2013","The difference between cardiac strain rates measured at baseline and after 4 cycles of chemotherapy.","https://ClinicalTrials.gov/show/NCT01301040"
136,"NCT02838342","Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors","Recruiting","No Results Available","Neuroendocrine Tumors","Drug: Metronomic cyclophosphamide|Drug: Interferon-alpha","Centre Hospitalier Universitaire de Besancon","All","18 Years and older   (Adult, Senior)","Phase 2","29","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","API/2015/61","July 18, 2016","May 2015","November 2019","July 18, 2016","July 2016","No Study Results Posted","EPICentro","August 2018","rate of patients with an immune response defined as ""Tregs lymphocytes decrease ≥ 20% in blood by the flow cytometry technique""","https://ClinicalTrials.gov/show/NCT02838342"
137,"NCT01435499","Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma","Completed","No Results Available","Melanoma","Biological: melanoma GVAX|Drug: Cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center|The John P. Hussman Foundation","All","18 Years and older   (Adult, Senior)","Phase 1","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J1112","September 8, 2011","September 2011","March 2016","May 23, 2016","May 2016","No Study Results Posted","null","January 2013","Number of Participants with Adverse Events as a Measure of Safety and Tolerability of Administering Melanoma GVAX With and Without Cyclophosphamide|In vitro correlates of anti-melanoma immunization","https://ClinicalTrials.gov/show/NCT01435499"
138,"NCT01606241","Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","Active, not recruiting","No Results Available","Recurrent Breast Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IIA Breast Cancer|Stage IIA Fallopian Tube Cancer|Stage IIA Ovarian Cancer|Stage IIB Breast Cancer|Stage IIB Fallopian Tube Cancer|Stage IIB Ovarian Cancer|Stage IIC Fallopian Tube Cancer|Stage IIC Ovarian Cancer|Stage IIIA Breast Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Breast Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Breast Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer","Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Biological: Multi-epitope Folate Receptor Alpha Peptide Vaccine","Mayo Clinic|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC1015|NCI-2012-00586|P30CA015083","May 23, 2012","July 2012","null","October 10, 2016","October 2016","No Study Results Posted","null","June 2017","Proportion of patients who experience severe toxicities (grades 3-5 of the National Cancer Institute's Cancer Therapy Evaluation Program [CTEP] Common Terminology Criteria for Adverse Events, version 4.0)|Disease-free survival|FRa expression|Overall survival time|Percentage change in plasma concentration of cytokines and chemokines","https://ClinicalTrials.gov/show/NCT01606241"
139,"NCT00414128","Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis","Completed","No Results Available","Vasculitis","Drug: mycophenolate mofetil|Drug: cyclophosphamide","Cambridge University Hospitals NHS Foundation Trust|Aspreva Pharmaceuticals|Vifor Pharma","All","Child, Adult, Senior","Phase 2|Phase 3","140","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MYCYC|Eudract: 2006-001663-33","December 19, 2006","March 2007","February 2013","December 5, 2013","December 2013","No Study Results Posted","MYCYC","July 2011","Remission rates at 6 months","https://ClinicalTrials.gov/show/NCT00414128"
140,"NCT00541034","Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia","Completed","Has Results","Leukemia|Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: pentostatin","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Astex Pharmaceuticals","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","49","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05-051|P30CA008748|MSKCC-05051","October 5, 2007","May 2005","January 2016","January 9, 2017","January 2017","January 9, 2017","null","January 2016","Overall Objective Response","https://ClinicalTrials.gov/show/NCT00541034"
141,"NCT01271010","A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status","Completed","No Results Available","Lymphocytic Leukemia, Chronic","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Rituximab","Hoffmann-La Roche","All","18 Years to 70 Years   (Adult, Senior)","Phase 4","89","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML25136","January 4, 2011","June 2011","May 2016","November 1, 2016","November 2016","No Study Results Posted","null","May 2016","Percentage of Participants With Therapy Response (Complete Remission, Partial Remission, Stable Disease, and Disease Progression) as Assessed by the Investigator Based on Physical Examination, Hematology, ECOG PS, and Radiology|Duration of Response as Assessed by the Investigator Based on Physical Examination, Hematology, ECOG PS, and Radiology|Overall Survival|Progression-Free Survival as Assessed by the Investigator Based on Physical Examination, Hematology, ECOG PS, and Radiology|Event-Free Survival as Assessed by the Investigator Based on Physical Examination, Hematology, ECOG PS, and Radiology|Percentage of Participants with Primary Resistance to Therapy|Percentage of Participants Who Achieved Minimal Residual Disease (MRD) Negativity|Percentage of Participants with Adverse Events","https://ClinicalTrials.gov/show/NCT01271010"
142,"NCT00751517","Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides","Unknown status","No Results Available","Wegener's Granulomatosis|Churg-Strauss Syndrome|Microscopic Polyangiitis|Polyarteritis Nodosa","Drug: Methotrexate|Drug: Cyclophosphamide","University of Parma","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PCM 01","September 11, 2008","null","null","September 11, 2008","September 2008","No Study Results Posted","null","null","Time from remission to relapse|Recurrence rate|Therapy-related toxicity|Hospitalization rate|Mortality","https://ClinicalTrials.gov/show/NCT00751517"
143,"NCT01864018","Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma","Suspended","No Results Available","Plasma Cell Myeloma","Drug: Cyclophosphamide|Drug: Dexamethasone|Drug: Ixazomib Citrate|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","51","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC1382|NCI-2013-01042|X16009|P30CA015083","May 23, 2013","August 2013","null","December 20, 2016","June 2016","No Study Results Posted","null","October 2017","Maximum tolerated dose of ixazomib with cyclophosphamide and dexamethasone, defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least 1/3 of patients, as assessed by NCI CTCAE version 4.0 (Phase I)|Rate of complete response or VGPR (Phase II)|Incidence of adverse events as assessed by the NCI CTCAE version 4.0|Progression-free survival (PFS)|Survival time","https://ClinicalTrials.gov/show/NCT01864018"
144,"NCT00721747","Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: Docetaxel, Liposomal doxorubicine and Cyclophosphamide","Grupo Oncológico Gallego|Pivotal S.L.","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","83","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GOG/2007-01|2007-005173-56","July 23, 2008","January 2008","January 2015","March 15, 2012","March 2012","No Study Results Posted","null","January 2011","Determine proportion of Pathological complete responses|Determine proportion of clinical responses|Describe treatment safety|Determine proportion of conservative breast surgery|Evaluate disease free survival|Evaluate Overall survival|Evaluate gene patterns regarding prediction of treatment response","https://ClinicalTrials.gov/show/NCT00721747"
145,"NCT02630368","A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)","Recruiting","No Results Available","Solid Tumors|Soft-tissue Sarcoma|Breast Cancer","Drug: Cyclophosphamide and JX-594 dose escalation|Drug: Cyclophosphamide and JX-594|Drug: Cyclophosphamide","Institut Bergonié|National Cancer Institute, France|Fondation ARC","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","118","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IB 2014-02|2014-001078-33","November 19, 2015","September 2015","September 2020","December 10, 2015","December 2015","No Study Results Posted","METROmaJX","September 2018","Phase Ib : Maximum Tolerated Dose evaluated on the first cycle (D1 to D28) of the combination of JX-594 And metronomic cyclophosphamide|Phase II : Advanced soft-tissue sarcoma: Assessment of the antitumor activity of the association of JX-594 and metronomic cyclophosphamide based on 6 month non-progression (CR, PR or SD more than 24 weeks) following RECIST v1.1 criteria|Phase II : Advanced Breast cancer: Assessment of the antitumor activity of the association of JX-594 and metronomic cyclophosphamide Efficacy will be defined based on objective response under treatment (CR or PR) following RECIST v1.1 criteria|Phase Ib : Recommended Phase II dose (RP2D) of the association of JX-594 and metronomic cyclophosphamide|Phase Ib: Objective response under treatment as per RECIST V1.1|Phase Ib: Best overall response as per RECIST V1.1|Phase Ib: 6-months non-progression as per RECIST V1.1|Phase Ib: 1-year progression-free survival as per RECIST V1.1|Phase Ib: 2-year progression-free survival as per RECIST V1.1|Phase Ib : Pharmacokinetics (PK): PK measurements expressed as Area Under the curve forJX-594|Phase Ib : Pharmacokinetics (PK): PK measurements expressed as half-life forJX-594|Phase Ib : Pharmacokinetics (PK): PK measurements expressed as Concentration peak forJX-594|Phase Ib : Dose-Limiting toxicity of the association of JX-594 and metronomic cyclophosphamide|Phase Ib : Predictive biomarkers analysis (cytokines levels)|Phase Ib : Predictive biomarkers analysis (lymphocytes levels)|Phase II : Best overall response defined as per RECIST v1.1 criteria|Phase II : For sarcoma only: objective response following CHOI criteria|Phase II : For sarcoma only: best overall response following CHOI criteria|Phase II : For sarcoma only: 6- month non-progression following CHOI criteria|Phase II : 1-year Progression-Free Survival (PFS) defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause), whichever occurs first|Phase II : 2-year Progression-Free Survival (PFS) defined as the time from study treatment initiation to the first occurrence of disease progression or death (of any cause), whichever occurs first|Phase II : 1-year Overall Survial (OS) defined as the time from study treatment initiation to death (of any cause)|Phase II : 2-year Overall Survial (OS) defined as the time from study treatment initiation to death (of any cause)|Phase II : Toxicity graded using the common toxicity criteria from the NCI v4.0|Predictive biomarkers (cytokines level)|Predictive biomarkers (lymphocytes level)|Phase II : Relationship between levels of anti-JX-594 antibodies and efficacy of CP + JX-594 in terms of 6-month non progression for sarcoma (as per RECIST V1.1)|Phase II : Relationship between levels of anti-JX-594 antibodies and efficacy of CP + JX-594 in terms of objective response for breast cancer (as per RECIST V1.1)|Phase II : Relationship between activation of the pRB/E2F/TK pathway and efficacy of CP + JX-594 on available archived tumor tissue in terms of 6- month non progression for sarcoma (as per RECIST V1.1)|Phase II : Relationship between activation of the pRB/E2F/TK pathway and efficacy of CP + JX-594 on available archived tumor tissue in terms objective response for breast cancer (as per RECIST V1.1)","https://ClinicalTrials.gov/show/NCT02630368"
146,"NCT01374841","Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors","Recruiting","No Results Available","Hematologic Neoplasms","Drug: Cyclophosphamide|Other: Hematopoietic Stem Cell Transplantation,","European Institute of Oncology","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IEO S513/110|2009-018083-94","June 15, 2011","August 2010","December 2019","August 9, 2016","August 2016","No Study Results Posted","null","August 2019","Donor engraftment|Incidence and severity of graft versus host disease|Non-relapse-related mortality","https://ClinicalTrials.gov/show/NCT01374841"
147,"NCT01438177","Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma","Completed","Has Results","Multiple Myeloma","Drug: Velcade|Drug: Cyclophosphamide|Drug: Chloroquine","New York University School of Medicine|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NYU# 10-02008","September 8, 2011","October 2011","February 2014","June 16, 2016","June 2016","May 14, 2015","null","February 2014","Response Rate (CR + PR After 2 Cycles)|Number of Participants With Adverse Events of Grade 3 or Higher|Percentage of Subjects Who Have Complete Response or Partial Response and Have 2+ or Higher Autophagy|Median Duration of Response of This Regimen","https://ClinicalTrials.gov/show/NCT01438177"
148,"NCT02460588","Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis","Recruiting","No Results Available","Idiopathic Pulmonary Fibrosis","Drug: Cyclophosphamide|Drug: Placebo|Drug: Corticosteroid (prednisolone)","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Senior)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","P 140908|2015-000492-27","March 16, 2015","December 2015","December 2018","March 21, 2017","March 2017","No Study Results Posted","EXAFIP","December 2018","""Early"" survival|Overall Survival|Respiratory disease-specific mortality|Respiratory Morbidity|Chest HRCT features (HRCT images will be scored at 5 levels)|Prognosis factors of AE-IPF|Time to visit after clinical worsening|Laboratory evaluation (LDH, CRP) at AE diagnosis (composite)|Time to dispense treatment of AE-IPF|Hemorrhagic cystitis (occurence of hematuria on urine dipstick and pelvic pain and/or dysuria should lead to cystoscopy)|Number of Infectious disease|Diabetes mellitus (capillary blood glucose monitoring and fasting plasma glucose > 1.26 g/l)|Hypertension (Blood pressure > 160/100 mmHg)|Clinical laboratory evaluation (blood count, serum creatinin measurement composite) according to Common Terminology Criteria for Adverse Event (CTCAE).","https://ClinicalTrials.gov/show/NCT02460588"
149,"NCT01019174","Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Drug: Cyclophosphamide|Drug: Cyclophosphamide","Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","RV-MM-DSMM-0279|GMIHO-005/2008","November 24, 2009","November 2009","December 2013","February 17, 2017","July 2014","No Study Results Posted","MM_LEN_DEX_CY","December 2013","To determine the maximum tolerated dose (MTD) of CY (PO and IV) in combination with LEN/low-dose DEX|To investigate the best objective response (EBMT criteria) to both treatment regimens|To investigate safety and tolerability of both treatment regimens|To investigate other efficacy parameters of both treatment regimens","https://ClinicalTrials.gov/show/NCT01019174"
150,"NCT00241254","Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis","Completed","No Results Available","Multiple Sclerosis, Chronic Progressive","Drug: Cyclophosphamide (drug)|Drug: Methylprednisolone (drug)","University Hospital, Bordeaux|Ministry of Health, France","All","18 Years to 65 Years   (Adult)","Phase 3","138","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","9408-04|2004-005","October 17, 2005","December 2005","March 2012","March 14, 2012","March 2012","No Study Results Posted","PROMESS","March 2010","Delay to disability deterioration as assessed by the Expanded Disability Status Scale (EDSS: 0.5 or 1 point increase, depending on baseline score)|Proportion of patients with disability deterioration (EDSS: 0.5 or 1 point increase, depending on baseline score)|Multiple Sclerosis Functional Composite (MSFC) and the Z scores of MSFC three components|Number of MS relapses|Proportion of patients with adverse events and delay of occurrence of adverse events|Quality of life questionnaires|Disability self-assessment questionnaires","https://ClinicalTrials.gov/show/NCT00241254"
151,"NCT01060410","Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment","Completed","No Results Available","Lupus Erythematosus, Systemic|Adverse Effects","Genetic: Polymorphism Analysis|Drug: Cyclophosphamide|Other: Pharmacokinetic analysis","Sun Yat-sen University|First Affiliated Hospital, Sun Yat-Sen University","All","12 Years to 80 Years   (Child, Adult, Senior)","","222","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","30873124-CTX2008","February 1, 2010","May 2010","June 2012","June 18, 2012","June 2012","No Study Results Posted","null","June 2012","","https://ClinicalTrials.gov/show/NCT01060410"
152,"NCT00795899","Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)","Completed","No Results Available","Breast Cancer","Drug: Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab","German Breast Group|AGO Study Group","Female","18 Years to 65 Years   (Adult)","Phase 2","230","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TECHNO","November 20, 2008","January 2002","September 2008","August 15, 2011","August 2011","No Study Results Posted","null","December 2005","To estimate the rate of cardiac (serious) events NYHA III/IV-and pathological complete remission after study therapy.|To assess: the rate of breast conserving surgery, the clinical response rates, the histopathological lymph node status after preoperative therapy, the disease-free and overall survival.|To evaluate the quality of life.","https://ClinicalTrials.gov/show/NCT00795899"
153,"NCT02467010","Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance","Completed","No Results Available","Multiple Myeloma","Drug: Bortezomib|Drug: Cyclophosphamide|Drug: Dexamethasone","University Medical Center Groningen","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","73","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMCG REMM|2008-004822-17","February 17, 2014","September 2008","July 2013","June 8, 2015","June 2015","No Study Results Posted","REMM","July 2013","Toxicity of induction chemotherapy according to CTCAE version 3.0|Progression Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02467010"
154,"NCT01883323","Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma","Recruiting","No Results Available","Metastatic, Stage III or Stage IV, Melanoma","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Tumor-Infiltrating Lymphocytes|Biological: Low-Dose Interleukin","University Health Network, Toronto","All","18 Years and older   (Adult, Senior)","Phase 2","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TILs-002-MEL","June 11, 2013","June 2013","December 2023","June 21, 2016","June 2016","No Study Results Posted","null","June 2023","Clinical response to treatment|Number occurrences and severity of side effects|Number of patients with an immunity and no immunity to the study treatment","https://ClinicalTrials.gov/show/NCT01883323"
155,"NCT02444728","Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE","Recruiting","No Results Available","Thrombocytopenia","Drug: Hydroxychloroquine|Drug: Cyclophosphamide|Drug: Azathioprine|Drug: Methylprednisolone","Chinese SLE Treatment And Research Group|Peking Union Medical College Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CSTAR001","May 12, 2015","July 2015","December 2018","March 7, 2017","July 2015","No Study Results Posted","CHORUS","January 2018","complete remission rate|partial remission rate","https://ClinicalTrials.gov/show/NCT02444728"
156,"NCT01498588","Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer","Terminated","Has Results","Breast Neoplasms|Breast Cancer|Breast Tumors|Cancer of the Breast|Neoplasms, Breast|Tumors, Breast","Drug: Eribulin|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Pegfilgrastim","Emory University|Eisai Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB00050068|WCI1937-10","October 13, 2011","November 2011","June 2015","September 28, 2016","September 2016","June 21, 2016","null","June 2015","Pathologic Complete Response Rate at the Time of Surgery|Toxicity of Chemotherapy Regimen (Number of Participants With Any Adverse Events)","https://ClinicalTrials.gov/show/NCT01498588"
157,"NCT00958256","Study of Bortezomib in Combination With Cyclophosphamide and Rituximab","Completed","Has Results","Mantle Cell Lymphoma|Lymphoma","Drug: Bortezomib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Mesna|Drug: G-CSF","M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc.","All","18 Years to 85 Years   (Adult, Senior)","Phase 2","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-0057|X05290|NCI-2009-01577","August 11, 2009","August 2009","March 2014","March 31, 2015","March 2015","March 31, 2015","null","March 2014","Response Rate","https://ClinicalTrials.gov/show/NCT00958256"
158,"NCT00072566","Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer","Completed","Has Results","Primary Peritoneal Carcinoma|Recurrent Ovarian Carcinoma|Stage IV Ovarian Cancer","Biological: Bevacizumab|Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis","National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 2","70","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02562|NCI-5789|CHNMC-PHII-45|CDR0000340522|CCC-PHII-45|PHII-45|5789|N01CM17101|P30CA033572","November 4, 2003","December 2003","November 2008","May 8, 2015","December 2012","April 14, 2015","null","November 2008","Median Time to Progression|Response Rate Based on the RECIST|Median Overall Survival","https://ClinicalTrials.gov/show/NCT00072566"
159,"NCT00313235","Combined Modality Treatment for Patients With Stage IV Melanoma","Completed","No Results Available","Malignant Melanoma Stage IV","Biological: DC Vaccine and Cyclophosphamide","Baylor Research Institute","All","21 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Baylor IRB #006-025-01|IND 12919","April 10, 2006","March 2006","June 2012","June 12, 2013","June 2013","No Study Results Posted","null","June 2011","Safety and tolerability of the combination of DC vaccination and CPA therapy in human subjects|Feasibility of this combination therapy|Objective clinical responses|Immunogenicity of DC vaccinations in subjects|Effect of CPA at this dose and schedule on the regulatory/suppressor T cells","https://ClinicalTrials.gov/show/NCT00313235"
160,"NCT00813150","Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma","Completed","Has Results","Multiple Myeloma","Drug: Dexamethasone|Drug: Bortezomib|Drug: Cyclophosphamide","Janssen-Cilag G.m.b.H","All","18 Years and older   (Adult, Senior)","Phase 3","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CR015247|26866138MMY3022|2008-003213-27","December 18, 2008","January 2009","January 2013","July 31, 2014","July 2014","March 28, 2014","null","January 2013","Time to Progression of Disease|Progression-Free Survival (PFS)|Overall Survival (OS)|Overall Response Rate (ORR) - International Myeloma Working Group (IMWG) Response Criteria","https://ClinicalTrials.gov/show/NCT00813150"
161,"NCT01321775","Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet","Hospital Universitario Madrid Sanchinarro","Female","18 Years and older   (Adult, Senior)","Phase 2","44","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AVANTHER","March 23, 2011","August 2009","November 2013","March 23, 2011","June 2010","No Study Results Posted","null","February 2013","Pathologic response in breast and axilla|To evaluate tumor markers as potential predictors of the pathologic response","https://ClinicalTrials.gov/show/NCT01321775"
162,"NCT00774280","Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen","Completed","No Results Available","Leukemia|Myelodysplastic Syndrome","Drug: BuCy vs BuFlu","Cooperative Study Group A for Hematology","All","15 Years to 70 Years   (Child, Adult, Senior)","Phase 3","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","C-005","October 15, 2008","May 2002","December 2010","February 10, 2011","February 2011","No Study Results Posted","BuCyvsBUFlu","November 2009","related toxicities of two different conditioning regimens, intravenous once-daily busulfan plus cyclophosphamide (BuCy) vs. fludarabine (BuFlu) for allogeneic hematopoietic cell transplantation (HCT) in leukemia and myelodysplastic syndrome","https://ClinicalTrials.gov/show/NCT00774280"
163,"NCT01681563","Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia","Completed","No Results Available","Chronic Lymphocytic Leukemia","Drug: Pentostatin|Drug: Cyclophosphamide|Drug: Ofatumumab","Niguarda Hospital|Regione Lombardia|GlaxoSmithKline|Hospira, now a wholly owned subsidiary of Pfizer","All","65 Years and older   (Adult, Senior)","Phase 2","47","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PCO|2010-022332-37","June 18, 2012","September 2011","December 2016","December 27, 2016","December 2016","No Study Results Posted","null","November 2015","Overall Response Rate (ORR)|Adverse Events according to CTCAE, Version 3.0 NCI CTCAE|Complete Response Rate (CRR)|Minimal Residual Disease (MRD)|Progression-Free Survival|Overall Survival (OS)|Time To Progression (TTP)|Genetic analysis by Fish|Ofatumumab pharmacokinetics parameter|IgVH mutation status","https://ClinicalTrials.gov/show/NCT01681563"
164,"NCT00184002","Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas","Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone","University of Southern California|Ortho Biotech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","68","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","13NHL-02-3","September 12, 2005","January 10, 2003","May 7, 2013","April 8, 2017","April 2017","No Study Results Posted","null","December 19, 2012","To determine the percentage of patients with complete response to the combination chemotherapy|Number of patients with Adverse Events as a Measure of Safety and Tolerability","https://ClinicalTrials.gov/show/NCT00184002"
165,"NCT00002943","Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer","Completed","No Results Available","Extragonadal Germ Cell Tumor|Ovarian Cancer|Testicular Germ Cell Tumor|Unspecified Adult Solid Tumor, Protocol Specific","Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous bone marrow transplantation","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","11","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CDR0000065392|CCCWFU-95193|NCI-G97-1146","November 1, 1999","February 1993","August 2007","January 18, 2017","July 2012","No Study Results Posted","null","October 2003","To investigate the response rate High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Transplantation|evaluate toxicity of High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Transplantation","https://ClinicalTrials.gov/show/NCT00002943"
166,"NCT00306670","Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A","Terminated","Has Results","Hemophilia A","Drug: Rituxan|Drug: prednisone","Georgetown University|Genentech, Inc.","All","18 Years to 65 Years   (Adult)","Phase 2|Phase 3","2","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","U2688","March 23, 2006","April 2006","August 2011","December 20, 2016","December 2016","December 20, 2016","null","January 2011","To Evaluate the Total Number of Circulating Lymphocytes and Lymphocyte Phenotypes and to Correlate With the Effectiveness of Rituximab and Oral Cyclophosphamide to Achieve and Preserve Complete Eradication of the Refractory Autoantibody.","https://ClinicalTrials.gov/show/NCT00306670"
167,"NCT00276848","Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia","Completed","No Results Available","Chronic Lymphocytic Leukemia","Drug: Fludarabine plus Cyclophosphamide|Drug: Fludarabine","German CLL Study Group","All","18 Years to 65 Years   (Adult)","Phase 3","375","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CLL4|EU-20538|GCLLSG-153|ISRCTN75653261|MEDAC-GCLLSG-CLL4|CDR0000455094","January 12, 2006","July 1999","July 2007","September 23, 2016","September 2016","No Study Results Posted","null","July 2003","Progression-free survival|Overall survival|Duration of remission|Incidence of side effects|Quality of life","https://ClinicalTrials.gov/show/NCT00276848"
168,"NCT01670500","Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa","Recruiting","No Results Available","Breast Cancer","Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Doxorubicin","Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 2","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","12-258","August 16, 2012","October 2012","June 2018","February 4, 2017","February 2017","No Study Results Posted","null","June 2018","pCR to neoadjuvant cisplatin vs. pCR to AC|Residual Cancer Burden after neoadjuvant cisplatin or AC|Clinical response rate|Comparison of toxicities of cisplatin and AC|Collection of pre-chemotherapy biopsies","https://ClinicalTrials.gov/show/NCT01670500"
169,"NCT00750815","Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)","Completed","Has Results","Multiple Myeloma","Drug: Cyclophosphamide|Drug: Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)","H. Lee Moffitt Cancer Center and Research Institute|Millennium Pharmaceuticals, Inc.|Ortho Biotech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","58","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MCC-15399|106692|Millennium X05248|DOXILMMY2008","September 10, 2008","September 2008","May 2013","December 3, 2013","September 2013","September 23, 2013","null","December 2012","Phase I - Maximum Planned Dose (MPD) Level|Phase II: Overall Response Rate (ORR)|Phase II: Progression-Free Survival (PFS)|Phase II: Two Year Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00750815"
170,"NCT00038142","Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients","Terminated","No Results Available","Ewing's Sarcoma","Drug: Vincristine|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Dexrazoxane|Biological: ImmTher","M.D. Anderson Cancer Center","All","3 Years to 60 Years   (Child, Adult)","Phase 2","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ID97-198|NCI-2012-01285","May 29, 2002","November 1997","March 2016","March 3, 2016","March 2016","No Study Results Posted","null","March 2016","To see if treatment with the drugs, vincristine, doxorubicin, cyclophosphamide and dexrazoxane (VACdxr) given in high doses with or without ImmTher will help patients with Ewing's Sarcoma live longer.","https://ClinicalTrials.gov/show/NCT00038142"
171,"NCT01303705","Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer","Active, not recruiting","No Results Available","Metastatic Prostate Cancer|Cancer of the Prostate|Prostate Cancer","Drug: Anti-OX40|Radiation: Radiation|Drug: Cyclophosphamide","Providence Health & Services|MedImmune LLC","Male","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","10","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PH&S IRB 10-088","November 9, 2010","October 2010","October 2017","March 28, 2016","September 2015","No Study Results Posted","null","October 2016","Maximum tolerated dose|Immune and Clinical Responses","https://ClinicalTrials.gov/show/NCT01303705"
172,"NCT01039025","TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma","Completed","No Results Available","Myeloma","Drug: Topotecan|Drug: Cyclophosphamide|Drug: Melphalan|Other: Peripheral Blood Stem Cells","M.D. Anderson Cancer Center|SmithKline Beecham","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM01-331","December 23, 2009","February 2002","May 2006","July 31, 2012","July 2012","No Study Results Posted","null","May 2006","Response Rate","https://ClinicalTrials.gov/show/NCT01039025"
173,"NCT01808911","Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)","Recruiting","No Results Available","Acquired Haemophilia","Drug: Steroid + cyclophosphamide|Drug: Steroid + rituximab","University Hospital, Rouen","All","18 Years and older   (Adult, Senior)","Phase 3","164","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2011/090/HP","October 16, 2012","May 2012","November 2018","November 18, 2016","November 2016","No Study Results Posted","CREHA","November 2017","Primary objective|Primary efficacy outcome|Primary safety outcomes|Secondary objective|Other key safety outcome","https://ClinicalTrials.gov/show/NCT01808911"
174,"NCT00779129","A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948)","Completed","No Results Available","Breast Neoplasm","Drug: Pegylated Lyposomal Doxorubicin|Drug: Cyclophosphamide","Merck Sharp & Dohme Corp.|Princess Margaret Hospital, Canada","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","70","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P02948","October 23, 2008","March 2003","August 2007","September 29, 2015","September 2015","No Study Results Posted","null","August 2007","Time to response; Duration of response; Time to progression; Survival|Left ventricular ejection fraction (LVEF), (MUGA Scan); Radiological imaging; Examination of adverse events, laboratory data, vital signs","https://ClinicalTrials.gov/show/NCT00779129"
175,"NCT01453140","In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for Steroid-refractory Acute Graft-versus-host Disease","Completed","No Results Available","Graft Versus Host Disease","Drug: Cyclophospahmide and Sirolimus|Drug: Low dose IL-2, Cyclophosphamide and Sirolimus|Drug: Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus","Hackensack University Medical Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","3","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TREG - Pro2219","October 13, 2011","August 2011","July 2012","July 17, 2013","July 2013","No Study Results Posted","T-REG","March 2012","The primary objective of this study is to determine the response rate of patients treated steroid-refractory GVHD using cyclophospahmide and sirolimus combined with 3 variations of low-dose IL 2 and low-dose Vidaza.","https://ClinicalTrials.gov/show/NCT01453140"
176,"NCT02282904","Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide","Suspended","No Results Available","Chronic Granulomatous Disease","Drug: Pre-Transplant Conditioning Medications|Other: Haploidentical Cellular Infusion|Drug: Post-Trasnplant Medications|Radiation: Total Body Irradiation","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","2 Years to 65 Years   (Child, Adult)","Early Phase 1","10","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","150007|15-I-0007","November 4, 2014","October 22, 2014","January 1, 2030","May 12, 2017","April 7, 2017","No Study Results Posted","null","January 1, 2024","To use a subablative conditioning regimen followed by post-transplant cyclophosphamide to attain an engraftment rate of 100% with no occurrence of acute Grade 3 or higher GvHD (graft versus host disease).|Stable Chimerism as indicated by 30-50% myeloid engraftment and 50% lymphoid engraftment as assessed by 1 year post transplant|Immune reconstitution levels with DHR as a marker of normal neutrophil function by 1 year post transplant.","https://ClinicalTrials.gov/show/NCT02282904"
177,"NCT01716689","Clinical Study of Metronomic Oral Cyclophosphamide in Patients With Advanced Sarcomas","Completed","No Results Available","Sarcoma","Drug: oral cyclophosphamide","National Cancer Centre, Singapore","All","21 Years and older   (Adult, Senior)","Phase 2","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCC1201","May 13, 2012","June 2012","October 2016","March 27, 2017","March 2017","No Study Results Posted","null","October 2016","Clinical benefit as defined by the composite of complete response (CR), partial response (PR) and stable disease (SD) lasting > 12 weeks per RECIST 1.1 as a measure of disease control|Assessment of objective response rate (ORR)|Assessment of progression free survival|Assessment on duration of response to oral metronomic cyclophosphamide in patients who exhibit objective responses","https://ClinicalTrials.gov/show/NCT01716689"
178,"NCT00540644","Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma","Completed","Has Results","Multiple Myeloma","Drug: lenalidomide (Revlimid®)|Drug: Cyclophosphamide|Drug: Prednisone","Attaya Suvannasankha|Celgene|Indiana University","All","18 Years and older   (Adult, Senior)","Phase 2","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0704-06; IUCRO-0170","October 5, 2007","October 2007","August 2014","May 12, 2016","May 2016","April 5, 2016","null","December 2012","Response Rate (RR) After 6 Cycles of Therapy Using the Proposed International Myeloma Working Group Uniform Response Criteria|Treatment Related Adverse Events Grade 3 or Higher|Quality of Life Using the FACT-G Data","https://ClinicalTrials.gov/show/NCT00540644"
179,"NCT00538031","Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","Active, not recruiting","No Results Available","Fallopian Tube Cancer|Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer","Drug: cyclophosphamide|Drug: celecoxib","City of Hope Medical Center","Female","18 Years and older   (Adult, Senior)","Phase 2","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","03092|NCI-2009-01597|CDR0000567043","October 1, 2007","December 2003","July 2018","February 10, 2017","February 2017","No Study Results Posted","null","July 2018","Response rate|Time to disease progression|Toxicity as assessed by NCI CTC v2.0","https://ClinicalTrials.gov/show/NCT00538031"
180,"NCT01610869","Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer","Active, not recruiting","No Results Available","Ovarian Cancer|Fallopian Tube Cancer","Drug: BIBF 1120","University College, London|Boehringer Ingelheim","Female","18 Years and older   (Adult, Senior)","Phase 2","124","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Treatment","UCL/10/0470|2011-005814-12","November 25, 2011","August 2014","October 2017","May 3, 2017","December 2016","No Study Results Posted","METRO-BIBF","October 2017","Overall survival|Quality of life|Adverse events for all patients|Progression free survival","https://ClinicalTrials.gov/show/NCT01610869"
181,"NCT01595321","Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas","Active, not recruiting","No Results Available","Pancreatic Cancer","Drug: Cyclophosphamide|Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine|Radiation: Stereotactic Body Radiation (SBRT)|Drug: FOLFIRINOX","Sidney Kimmel Comprehensive Cancer Center","All","18 Years to 76 Years   (Adult, Senior)","","19","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J1179|NA_00050233","April 27, 2012","August 2012","August 2018","August 22, 2016","August 2016","No Study Results Posted","null","July 2017","Number of participants with adverse events as a measure of toxicity|Survival|Time to disease progression using immune correlates","https://ClinicalTrials.gov/show/NCT01595321"
182,"NCT03140553","TCH (Docetaxel/Carboplatin/Trastuzumab) Versus EC -TH(Epirubicin/Cyclophosphamide Followed by Docetaxe/Trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer","Recruiting","No Results Available","HER2-Positive Breast Cancer","Drug: TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)","Guangdong General Hospital","Female","18 Years and older   (Adult, Senior)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","20170308","May 2, 2017","September 1, 2016","September 1, 2019","May 3, 2017","May 2017","No Study Results Posted","null","September 1, 2018","pCR","https://ClinicalTrials.gov/show/NCT03140553"
183,"NCT02049580","Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas","Unknown status","No Results Available","Lymphoma","Drug: Thiotepa|Drug: Fludarabine|Drug: Cyclophosphamide","Istituto Clinico Humanitas","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","47","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ONC-2011-005","January 28, 2014","July 2013","November 2016","January 29, 2014","January 2014","No Study Results Posted","null","August 2016","Procedure activity|Neutrophils recovery|Platelets recovery|Incidence of graft failure|Cumulative incidence of acute and chronic GVHD|Incidence of infections|Cumulative incidence of relapse/progression|Treatment related mortality (TRM)|Immunological reconstitution","https://ClinicalTrials.gov/show/NCT02049580"
184,"NCT02597062","High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma","Recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Cyclophosphamide|Drug: Dexamethasone","Canadian Cancer Trials Group|Amgen|Myeloma Canada Research Network","All","18 Years and older   (Adult, Senior)","Phase 2","76","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MYX1|MCRN003","November 3, 2015","March 29, 2016","December 2022","May 8, 2017","March 2017","No Study Results Posted","null","February 2019","Overall response rate after 4 cycles|Number and severity of adverse events|Response rates assessed by current International Myeloma Working Group (IMWG) criteria.|Progression-free survival assessed by biochemistry, radiology and immunology tests|Overall survival","https://ClinicalTrials.gov/show/NCT02597062"
185,"NCT01660750","A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma","Completed","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Cyclophosphamide|Drug: Dexamethasone","Academic Myeloma Consortium|Amgen","All","18 Years and older   (Adult, Senior)","Phase 1","29","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMyC 11-MM-01|CAR-IST-520","August 7, 2012","January 2013","December 2015","July 12, 2016","July 2016","No Study Results Posted","11-MM-01","August 2015","Adverse Events as a measure of safety and tolerability|Overall Response after induction therapy|Overall Response post ASCT|Time to Progression|Progression Free Survival|Time to Next Therapy","https://ClinicalTrials.gov/show/NCT01660750"
186,"NCT00740805","Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma","Active, not recruiting","No Results Available","Solid Neoplasm|Stage III Non-Hodgkin Lymphoma|Stage IV Non-Hodgkin Lymphoma","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Veliparib","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","90","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2009-00262|050803|CDR0000600234|7998|P30CA072720|U01CA132194|U01CA099118|UM1CA186716","August 22, 2008","August 18, 2008","null","May 23, 2017","May 2017","No Study Results Posted","null","June 1, 2017","MTD, defined as the dose level that no more than 2/6 or 1/3 patients experience DLT and at least 2/3 or 3/6 patients treated with next higher dose level will have had DLT|Change in gammaH2AX levels (quantification of the time point of maximal DNA damage)|Change in pharmacokinetic parameters","https://ClinicalTrials.gov/show/NCT00740805"
187,"NCT01903330","ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme","Recruiting","No Results Available","Glioblastoma|Gliosarcoma","Drug: ERC1671|Drug: GM-CSF|Drug: Cyclophosphamide|Drug: Oral Control (Sucrose pill)|Drug: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))|Drug: Bevacizumab","Daniela A. Bota|University of California, Irvine|Epitopoietic Research Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","UCI 13-14 ERC1671-H02|UCI 13-14|2013-9863","June 26, 2013","March 2014","March 2019","December 28, 2016","December 2016","No Study Results Posted","null","March 2019","Safety|Efficacy|Immune Response","https://ClinicalTrials.gov/show/NCT01903330"
188,"NCT02390843","Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors","Recruiting","No Results Available","Retinoblastoma|Clear Cell Sarcoma|Renal Cell Carcinoma|Rhabdoid Tumor|Wilms Tumor|Hepatoblastoma|Neuroblastoma|Germ Cell Tumors|Ewings Sarcoma|Non-rhabdomyosarcoma Soft Tissue Sarcoma|Osteosarcoma|Rhabdomyosarcoma","Drug: Simvastatin|Drug: Cyclophosphamide|Drug: Topotecan|Drug: Myeloid growth factor","Emory University|Children's Healthcare of Atlanta","All","1 Year to 29 Years   (Child, Adult)","Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB00078790","February 24, 2015","February 2015","February 2021","October 13, 2016","October 2016","No Study Results Posted","AflacST1402","February 2019","Maximum Tolerated Dose (MTD) of Simvastatin|Number of Dose-Limiting Toxicities (DLTs)|Percentage of Participants With Overall Tumor Response (Response Rate)|Change in Total Cholesterol Level|Change in serum interleukin-6 (IL-6) level|Change in soluble interleukin 6 receptor (sIL-6R)|Change in signal transducer and activator of transcription 3 (STAT-3) expression|Change in phospho-STAT3 expression","https://ClinicalTrials.gov/show/NCT02390843"
189,"NCT01193283","Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia","Completed","Has Results","Aplastic Anemia|Neutropenia|Pancytopenia|Severe Aplastic Anemia","Drug: Cyclophosphamide|Drug: Cyclosporine","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","2 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","22","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","100176|10-H-0176","August 31, 2010","August 2010","September 2014","April 11, 2017","April 2017","October 13, 2015","null","September 2014","Blood Counts and Adverse Event Profile After 6 Months of Treatment.","https://ClinicalTrials.gov/show/NCT01193283"
190,"NCT00482911","Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma","Terminated","Has Results","Intraocular Melanoma|Malignant Conjunctival Neoplasm","Drug: cyclophosphamide|Drug: lenalidomide|Drug: sunitinib malate","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","12","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","070134|NCI-07-C-0134","June 4, 2007","April 2007","April 2009","February 6, 2017","February 2017","October 11, 2012","null","April 2009","Response Rate (Complete and Partial Response)|Toxicity|Overall Survival|Progression Free Survival|Changes in Gene Expression, Methylation and Protein Modification","https://ClinicalTrials.gov/show/NCT00482911"
191,"NCT02654119","Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery","Recruiting","No Results Available","HER2 Positive Breast Carcinoma|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer","Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Biological: Trastuzumab","University of Nebraska|National Cancer Institute (NCI)","Female","19 Years and older   (Adult, Senior)","Phase 2","75","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","318-15|NCI-2015-01879|P30CA036727","January 11, 2016","December 2015","null","June 15, 2016","June 2016","No Study Results Posted","null","November 2018","Incidence of grade 3/4 cardiotoxicity, graded according to the NCI CTCAE v4.03|Incidence of grade 3/4 nausea/vomiting, graded according to the NCI CTCAE v4.03|Incidence of inability to complete treatment, defined as a patient that requires a lower dose of therapy (defined as dose lowered by 50%), or a postponement of scheduled treatment of longer than 28 days, or discontinuation of treatment for any reason|Incidence of neutropenia, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.03|Incidence of paclitaxel-related neuropathy, graded according to the NCI CTCAE v4.03|Recurrence free survival (RFS)","https://ClinicalTrials.gov/show/NCT02654119"
192,"NCT01241682","Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma","Completed","No Results Available","Malignant (Pleural) Mesothelioma","Biological: DC + CTX","Erasmus Medical Center","All","Child, Adult, Senior","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NL24050.000.08","June 1, 2010","October 2009","October 2012","February 26, 2014","February 2014","No Study Results Posted","PMR-MM-002","October 2011","number of cytotoxic T cells and regulatory T cells in the blood of patients|safety and toxicity","https://ClinicalTrials.gov/show/NCT01241682"
193,"NCT00809341","R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma","Terminated","No Results Available","Non-Hodgkin's Lymphoma","Drug: R-CHOP, R-CHOEP, R-EPOCH|Drug: R-ICE, Cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","26","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J0802|NA_00013656","December 16, 2008","January 2009","April 2014","October 30, 2015","October 2015","No Study Results Posted","null","April 2014","Estimate survival in patient receiving early treatment intensification based on a positive mid-treatment PET scan compared to the historical event-free survival of mid-treatment PET positive patients not given early treatment intensification.|Estimate overall survival in patients whose treatment is determined on the basis of a mid-treatment [18F] FDG-PET scan result.","https://ClinicalTrials.gov/show/NCT00809341"
194,"NCT00352378","Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine","National Cancer Center, Korea","Female","18 Years and older   (Adult, Senior)","Phase 3","209","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCCTS-02-034","July 13, 2006","June 2002","January 2006","June 23, 2011","September 2007","No Study Results Posted","null","October 2005","pathologic complete remission","https://ClinicalTrials.gov/show/NCT00352378"
195,"NCT00478218","Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma","Completed","Has Results","Multiple Myeloma and Plasma Cell Neoplasm","Drug: cyclophosphamide|Drug: dexamethasone|Drug: lenalidomide","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","53","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000546657|P30CA015083|MC058E|06-002786|RV-MM-PI-0116","May 23, 2007","July 2006","April 2011","August 29, 2011","August 2011","June 30, 2011","null","September 2008","Number of Participants Who Achieved a Confirmed Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) During Treatment|Overall Survival (OS)|Progression-free Survival (PFS)|Duration of Response (DOR)","https://ClinicalTrials.gov/show/NCT00478218"
196,"NCT00794820","Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline","Completed","Has Results","Chronic Lymphocytic Leukemia","Drug: Fludarabine Phosphate|Drug: Cyclophosphamide|Drug: Rituximab","M.D. Anderson Cancer Center|Genentech, Inc.","All","16 Years and older   (Child, Adult, Senior)","Phase 2","66","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-0591|NCI-2010-01220","November 18, 2008","December 2003","December 2014","July 13, 2016","July 2016","July 13, 2016","null","December 2014","Complete Remission (CR) Rate of FCR3 in Treatment-naïve Participants With Chronic Lymphocytic Leukemia (CLL) at 6 Months|Remission Duration/Time to Progression (TTP)|Overall Survival (OS) Rate","https://ClinicalTrials.gov/show/NCT00794820"
197,"NCT01074060","Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma","Completed","No Results Available","Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma","Drug: plerixafor|Biological: filgrastim|Drug: cyclophosphamide|Procedure: autologous hematopoietic stem cell transplantation|Other: laboratory biomarker analysis","City of Hope Medical Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08186|NCI-2010-00160","February 19, 2010","April 2010","February 2013","February 13, 2013","February 2013","No Study Results Posted","null","February 2013","To assess the MTD ( maximum tolerated dose) of IV plerixafor when given post cyclophosphamide and GCSF for stem cell priming.Dose limiting toxicity will be defined as any grade 3 or 4 nonhematologic toxicity.|Tolerability and safety of PLERIXAFOR|Frequency of collecting 5 x 10^6 or more CD34+ cells/kg in 2 or less apheresis days|Percentage of plasma cells|Completion of 100 days post-transplant|Overall and disease-free survival|Time to engraftment","https://ClinicalTrials.gov/show/NCT01074060"
198,"NCT00824265","Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia","Active, not recruiting","Has Results","Leukaemia, Lymphocytic, Chronic","Drug: OFC Infusion|Drug: FC infusion","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 3","365","Industry","Interventional","Allocation: Randomized|Masking: No masking|Primary Purpose: Treatment","110913","January 15, 2009","March 2009","October 2017","January 31, 2017","January 2017","August 10, 2015","null","December 2014","Progression-free Survival (PFS), as Assessed by the Independent Review Committee (IRC)|Overall Survival (OS)|Time to Response, as Assessed by the IRC|Duration of Response (DOR), as Assessed by the IRC|Time to Progression, as Assessed by the IRC|Time to Next Therapy|Number of Participants With Improvement in Eastern Cooperative Oncology Group (ECOG) Performance Status|Number of Participants With no B-Symptoms or at Least One B-symptoms Over the Time|Percentage of Participants With the Best Overall Response (OR), as Assessed by the IRC|Percentage of Participants With the Best OR, as Assessed by the Investigator|Number of Participants Who Were Negative for Minimal Residual Disease (MRD) Assessed by IRC|Number of Participants Who Were Negative for MRD Assessed by Investigator|Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)|Number of Participants With a Human Anti-human Antibody (HAHA) Positive Result at Indicated Time Points|Number of Participants With Autoimmune Hemolytic Anaemia (AIHA)|Number of Participants With Drug Related AEs and SAEs of Maximum Severity of Grade 3 or Higher|Number of Participants With at Least One Grade 3/Grade 4 Myelosuppression (Anemia, Neutropenia, and Thrombocytopenia)|Number of Participants Who Received no Transfusion or at Least One Transfusion During the Study|Mean Level of Immunoglobulin (Ig) Antibodies IgA, IgG, and IgM|Change From Baseline in Cluster of Differentiation (CD) Cell Counts, CD5+ and CD19+|Change From Baseline in Cell Counts, CD5- CD19+|Prognostic and Biological Markers Correlating With Clinical Response|Changes in Patient Reported Outcome (PRO) Measures and Scores for European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Chronic Lymphocytic Leukaemia 16 Item Module (EORTC QLQ-CLL 16)|Change From Baseline in Patient Reported Outcome (PRO) as Assessed by EuroQoL Five-Dimension (EQ-5D) Score at Indicated Visit|Change From Baseline in the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score|Mean of Health Change Questionnaire (HCQ)|Mean Area Under the Time-concentration Curve (AUC) Curve Over the Dosing Interval (AUC[0-tau]) of Ofatumumab|Maximum Concentration (Cmax) and Observed Drug Concentration Prior to the Next Dose (Ctrough) of Ofatumumab|Time of Occurrence of Cmax (Tmax) of Ofatumumab","https://ClinicalTrials.gov/show/NCT00824265"
199,"NCT01723839","Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide","Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia (CLL)","Drug: Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide","Hackensack University Medical Center|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","54","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00002262 RV-CLL-PI-0530","November 6, 2012","September 2011","December 2015","August 21, 2015","August 2015","No Study Results Posted","FCR","December 2015","Complete Response|Overall Response Rate","https://ClinicalTrials.gov/show/NCT01723839"
200,"NCT02853318","Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","Recruiting","No Results Available","Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Serous Adenocarcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Undifferentiated Fallopian Tube Carcinoma|Undifferentiated Ovarian Carcinoma","Biological: Bevacizumab|Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","40","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","I 270715|NCI-2016-00534|P30CA016056","July 29, 2016","September 1, 2016","March 3, 2018","March 9, 2017","March 2017","No Study Results Posted","null","August 3, 2017","Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events|Progression-free survival (PFS)|Duration of overall survival|An anti-tumor immune response in circulation and tumor tissue|Objective tumor response assessed by modified RECIST version 1.1 criteria","https://ClinicalTrials.gov/show/NCT02853318"
201,"NCT00305760","Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer","Completed","Has Results","Pancreatic Cancer","Drug: Cetuximab|Biological: Pancreatic tumor vaccine|Drug: Cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0501|P30CA006973|BMS-CA225247","March 21, 2006","December 2005","null","June 18, 2015","June 2015","June 18, 2015","null","February 2009","Safety of Combining the Pancreatic Tumor Vaccine in Sequence With Cyclophosphamide and Erbitux. Safety is Defined as the Number of Treatment-related Grade 3 or 4 Adverse Events Observed in Greater Than 5% of the Patient Population","https://ClinicalTrials.gov/show/NCT00305760"
202,"NCT00785122","IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)","Completed","No Results Available","Colorectal Carcinoma","Drug: Endoxana, Leukine, IMA910|Drug: Endoxana, Leukine, IMA910, Aldara","immatics Biotechnologies GmbH","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","92","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT Nr. 2007-005666-12","November 4, 2008","June 2008","May 2013","May 15, 2013","May 2013","No Study Results Posted","IMA910-101","January 2011","Disease control rate|Safety assessment|Tumour response rates and SD rate|DCR|Duration of response|Progression free survival|Cellular immunomonitoring|Biomarkers|Analysis of tumor tissue|Overall Safety|Effect of imiquimod (2nd Cohort) on immune response|Overall survival|Non-Cellular immunomonitoring","https://ClinicalTrials.gov/show/NCT00785122"
203,"NCT00190229","Efficacy of Steroid Versus Steroid Plus Cyclophosphamide for Severe Henoch-Schoenlein Purpura","Completed","No Results Available","Henoch-Schoenlein Purpura","Drug: Cyclophosphamide","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Senior)","","200","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P011014","September 13, 2005","September 2002","January 2008","May 3, 2011","March 2007","No Study Results Posted","null","January 2008","Birmingham Vasculitis Activity Score (BVAS)|Chronic lesions (Vasculitis Damage Index)|Renal function at 12 months|Kidney survival at 12 months|Patient survival at 12 months|Blood pressure|Infections|Adverse events related to steroid or cyclophosphamide","https://ClinicalTrials.gov/show/NCT00190229"
204,"NCT01862926","Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD","Recruiting","No Results Available","Interstitial Lung Disease|Scleroderma|Idiopathic Inflammatory Myositis|Mixed Connective Tissue Disease","Drug: Rituximab|Drug: Cyclophosphamide","Royal Brompton & Harefield NHS Foundation Trust|Imperial College London|University of East Anglia|University College London Hospitals","All","18 Years to 80 Years   (Adult, Senior)","Phase 2|Phase 3","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RBHIPF004|2012-003633-42","May 22, 2013","November 2014","null","May 6, 2015","May 2015","No Study Results Posted","RECITAL","November 2017","Absolute change in FVC|• Change from baseline in diffusing capacity for carbon monoxide (DLco)|• Change from baseline in health related quality of life scores|• Change from baseline in global disease activity score|• Progression free survival|• Adverse and serious adverse events (as defined in GCP)","https://ClinicalTrials.gov/show/NCT01862926"
205,"NCT00066469","Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation","Active, not recruiting","Has Results","Lymphoproliferative Disorder","Biological: rituximab|Drug: cyclophosphamide|Drug: methylprednisolone|Drug: prednisone","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","Phase 2","55","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ANHL0221|CDR0000316241|COG-ANHL0221|NCI-2012-02544|U10CA098543","August 6, 2003","April 2004","null","September 14, 2016","September 2016","September 17, 2013","null","October 2009","Event-free Survival","https://ClinicalTrials.gov/show/NCT00066469"
206,"NCT00049114","Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer","Completed","No Results Available","Inflammatory Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer","Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Drug: tipifarnib|Biological: filgrastim|Procedure: therapeutic conventional surgery|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","62","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02500|02-05-125|AECM-0205125|NCI-5598|CDR0000257811|N01CM62204","November 12, 2002","February 2003","null","June 5, 2013","June 2013","No Study Results Posted","null","January 2007","Pathological complete response in the breast|Proportion of patients who have a clinical complete response|Grade 3 or 4 toxicities assessed using NCI CTCAE version 3.0|Median disease-free survival|Percentage of patients free of disease","https://ClinicalTrials.gov/show/NCT00049114"
207,"NCT01696877","A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer","Active, not recruiting","No Results Available","Prostate Cancer Adenocarcinoma in Situ","Drug: degarelix acetate|Drug: Cyclophosphamide|Drug: GVAX","Sidney Kimmel Comprehensive Cancer Center","Male","21 Years and older   (Adult, Senior)","Phase 1|Phase 2","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J1265|NA_00073453","September 14, 2012","September 2012","April 2018","December 28, 2016","December 2016","No Study Results Posted","null","April 2018","Intraprostatic CD8+ T cell infiltration|Number of participants with adverse events|Intraprostatic CD4+ T cell and Treg infiltration|Quantification of tissue androgen concentrations|Quantification of markers of apoptosis|Pathological complete responses|Serum antibodies to prostate-associated antigens|PSA response rate and time-to-PSA-recurrence","https://ClinicalTrials.gov/show/NCT01696877"
208,"NCT00564512","Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP","Completed","No Results Available","Leukemia","Biological: Campath|Biological: rituximab|Drug: cyclophosphamide|Drug: fludarabine","French Innovative Leukemia Organisation","All","18 Years to 65 Years   (Adult)","Phase 3","178","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000577580|CLL-2007-FMP","November 27, 2007","November 2007","July 2013","July 24, 2013","April 2009","No Study Results Posted","null","January 2009","Progression-free survival at 36 months|Disease-free survival|Event-free survival|Overall survival|Time to next treatment|Overall response rate (complete response [CR] and partial response [PR])|Duration of phenotypic, molecular, NCI complete and partial responses|Response rates and survival times in biological subgroups|Treatment-related adverse effects","https://ClinicalTrials.gov/show/NCT00564512"
209,"NCT02082405","Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma","Withdrawn","No Results Available","Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma","Drug: bortezomib|Drug: cyclophosphamide|Drug: dexamethasone|Other: laboratory biomarker analysis|Other: quality-of-life assessment","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","65 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE3A13|NCI-2014-00250|CASE 3A13|P30CA043703","March 6, 2014","April 2015","null","April 23, 2015","April 2015","No Study Results Posted","null","August 2016","Overall Response rate in accordance with the IMWG Uniform Response criteria|Incidence of toxicities according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4|Changes in quality of life as assessed by the Functional Assessment of Cancer Therapy-General|Changes in functional status|Overall Survival","https://ClinicalTrials.gov/show/NCT02082405"
210,"NCT02244125","A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial","Active, not recruiting","No Results Available","Multiple Myeloma|First Relapse","Drug: PCD|Procedure: Autologous transplantation (ASCT)","Institut Curie|Intergroupe Francophone du Myelome|Celgene Corporation","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","100","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IC 2013-05","September 8, 2014","April 2014","December 2020","May 9, 2017","May 2017","No Study Results Posted","PCD","January 2017","Response rate (Partial response (PR) or better)|Safety : incidence of Adverse Events and Serious Adverse Events and laboratory abnormalities","https://ClinicalTrials.gov/show/NCT02244125"
211,"NCT00589901","An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC)","Unknown status","No Results Available","Breast Cancer","Drug: capecitabine and cyclophosphamide","Fudan University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","200507CX","December 26, 2007","August 2006","December 2008","April 17, 2008","April 2008","No Study Results Posted","null","December 2008","TTP (first treatment of this regimen to disease progression)|side effects|pharmacogenetic analysis","https://ClinicalTrials.gov/show/NCT00589901"
212,"NCT00201721","Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia","Completed","No Results Available","B-Chronic Lymphocytic Leukemia","Drug: Pentostatin|Drug: Rituximab|Drug: Cyclophosphamide","Ohio State University Comprehensive Cancer Center|Astex Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","OSU-0143","September 12, 2005","July 2002","September 2006","February 6, 2017","February 2017","No Study Results Posted","null","July 2006","To assess the rate of complete and overall response using rituximab and pentostatin with and without cyclophosphamide.|To monitor and assess toxicity of this regimen.","https://ClinicalTrials.gov/show/NCT00201721"
213,"NCT02664103","Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer Metastatic","Drug: Fixed-dose combination of capecitabine and cyclophosphamide SAR439281","Sanofi","Female","18 Years to 65 Years   (Adult)","Phase 2","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CAPCYR07568|U1111-1166-1149","January 15, 2016","January 2016","June 2017","March 31, 2017","March 2017","No Study Results Posted","METRO-ABC","June 2017","Proportion of patients with adverse events|Assessment of PK parameter: maximum concentration (Cmax)|Assessment of PK parameter: time to reach Cmax (Tmax)|Disease Control Rate (DCR)|Objective Response Rate (ORR)|Time to Progression (TTP)|Proportion of patients compliant with treatment","https://ClinicalTrials.gov/show/NCT02664103"
214,"NCT02684071","Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors","Recruiting","No Results Available","Recurrent Childhood Medulloblastoma|Recurrent Childhood Ependymoma|Childhood Atypical Teratoid/Rhabdoid Tumor|Embryonal Tumor With Abundant Neuropil and True Rosettes|Metastatic Malignant Neoplasm to the Leptomeninges","Drug: Intra thecal methotrexate|Drug: topotecan|Drug: cyclophosphamide","Nicklaus Children's Hospital f/k/a Miami Children's Hospital","All","up to 22 Years   (Child, Adult)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCH-CNS-1601","February 11, 2016","February 2016","February 2020","January 12, 2017","January 2017","No Study Results Posted","null","February 2018","Tumor response|Toxicity of chemotherapy regimen (topotecan and cyclophosphamide)","https://ClinicalTrials.gov/show/NCT02684071"
215,"NCT02549677","Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer","Recruiting","No Results Available","Breast Neoplasms","Drug: Epirubicin|Drug: Docetaxel|Drug: cyclophosphamide","Ruijin Hospital","Female","18 Years to 70 Years   (Adult, Senior)","Phase 4","264","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","RJBC1506","September 6, 2015","October 2015","September 2019","April 10, 2017","April 2016","No Study Results Posted","ELEGANT","September 2017","number of participants with grade 3-4 neutropenia assessed by CTCAE v4.0|number of participants with grade 3-4 leukopenia assessed by CTCAE v4.0|number of participants with febrile neutropenia assessed by CTCAE v4.0|breast cancer relapse|all cause mortality","https://ClinicalTrials.gov/show/NCT02549677"
216,"NCT01120171","Myocet Plus Endoxan for Older Patients With Breast Cancer","Terminated","No Results Available","Breast Cancer","Drug: Cyclophosphamide|Drug: Liposomal-encapsulated doxorubicin","Hellenic Oncology Research Group","Female","18 Years and older   (Adult, Senior)","Phase 2","64","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/08.32","May 5, 2010","September 2009","May 2015","October 6, 2015","October 2015","No Study Results Posted","null","May 2015","Overall Response Rate|Toxicity profile|Time to Tumor Progression|Overall Survival","https://ClinicalTrials.gov/show/NCT01120171"
217,"NCT01614197","A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma","Recruiting","No Results Available","Lymphoblastic Leukemia, Acute, Childhood|Lymphoblastic Lymphoma|Peripheral T-cell Lymphoma","Drug: Temsirolimus|Drug: Etoposide|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Hydrocortisone|Drug: Cytarabine","Therapeutic Advances in Childhood Leukemia Consortium|Pfizer","All","1 Year to 21 Years   (Child, Adult)","Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","T2014-001","May 18, 2012","March 2015","December 2019","May 31, 2016","May 2016","No Study Results Posted","null","December 2018","The dose of temsirolimus that can be safely given with etoposide and cyclophosphamide.|The response rate after treatment.|Responsiveness of patient lymphoblasts to mTOR inhibition using in-vitro and in-vivo pharmacodynamic (PD) assessments.|Minimal residual disease (MRD) levels present at end of cycle 1 therapy in patients with bone marrow involvement.","https://ClinicalTrials.gov/show/NCT01614197"
218,"NCT02461888","Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.","Recruiting","No Results Available","Multiple Myeloma","Drug: Ixazomib|Drug: Cyclophosphamide|Drug: Dexamethasone","University of Leeds|Myeloma UK|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","250","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HM13/10993","June 1, 2015","December 2015","May 2019","November 16, 2016","May 2016","No Study Results Posted","MUKEight","May 2018","Progression free survival|Response to treatment|Maximum response|Time to progression|Time to maximum response|Response duration|Overall survival|Evaluate the safety and toxicity as measured by adverse reactions and serious adverse event reporting.|Treatment compliance measured by treatment delays and missed treatment doses.|Quality of life measured by the completion of EQ-5D and EORTC QLQ-C30 questionnaires|Cost effectiveness of treatment assessed by health economic evaluations.","https://ClinicalTrials.gov/show/NCT02461888"
219,"NCT01166113","Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Pomalidomide, Cyclophosphamide, Prednisone","Fondazione Neoplasie Sangue Onlus","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","67","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PO0023|2009−014850−13","July 16, 2010","July 2010","July 2018","February 5, 2016","February 2016","No Study Results Posted","PCP","June 2011","PCP safety and efficacy|Overall survival|Progression-free survival|Time-to-progression|Time to next therapy|Tumor response and survival in particular subgroups of patients","https://ClinicalTrials.gov/show/NCT01166113"
220,"NCT02903524","Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Doxorubicin Hydrochloride Liposome injection and cyclophosphamide|Drug: pirarubicin and cyclophosphamide","Hebei Medical University Fourth Hospital","Female","18 Years to 70 Years   (Adult, Senior)","Phase 4","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CSPC-DMS-BC-03","September 13, 2016","September 2016","December 2018","September 15, 2016","September 2016","No Study Results Posted","null","September 2018","pathological complete response","https://ClinicalTrials.gov/show/NCT02903524"
221,"NCT00676949","Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors","Completed","No Results Available","Metastatic Tumors","Biological: 5 peptide vaccines of KOC1, TTK, CO16, DEPDC1, MPHOSPH1","Kyushu University|Human Genome Center, Institute of Medical Science, University of Tokyo","All","20 Years to 80 Years   (Adult, Senior)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KU-CY5peptides|19-40","March 3, 2008","November 2007","March 2010","June 22, 2011","April 2011","No Study Results Posted","peptidevac","March 2010","safety of the cyclophosphamide combined tumor specific epitope peptide cocktail|immunological efficacies and clinical efficacies of the cyclophosphamide combined tumor specific epitope peptides cocktail","https://ClinicalTrials.gov/show/NCT00676949"
222,"NCT00331552","Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer","Completed","No Results Available","HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer","Drug: pegylated liposomal doxorubicin hydrochloride|Drug: cyclophosphamide|Biological: trastuzumab","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","6139|NCI-2010-00798","May 30, 2006","February 2006","null","May 7, 2013","May 2013","No Study Results Posted","null","February 2011","Maximum tolerated dose and optimal tolerated dose of pegylated liposomal doxorubicin hydrochloride (Doxil) when given in combination with cyclophosphamide (Phase I)|Efficacy as assessed by the overall clinical response rate (Phase II)|Safety as assessed by grade 1, 2, 3, 4, fatal toxicity, need for dose reduction, treatment interruption, or treatment discontinuation (Phase II)|Treatment-related toxicity (Phase I)|Time to progression (Phase II)|Progression-free survival (Phase II)|Overall survival (Phase II)|Comparison of response rate in 2 subgroups--heavily pre-treated (1 or more regimens for advanced disease) vs less heavily pre-treated (no regimens for advanced disease) (Phase II)","https://ClinicalTrials.gov/show/NCT00331552"
223,"NCT01581970","Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer","Completed","No Results Available","Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma","Drug: Cyclophosphamide|Drug: Cetuximab","Masonic Cancer Center, University of Minnesota","All","18 Years and older   (Adult, Senior)","Phase 2","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2012LS002","April 18, 2012","June 2012","July 2015","July 15, 2015","July 2015","No Study Results Posted","null","February 2015","Progression Free Survival|Ratio of Tregs to Effector Cells|Ratio of Tregs to Natural Killer (NK) Cells|Myeloid-derived suppressor cells in Tumor Tissue|Quality of Life Scores|Overall survival","https://ClinicalTrials.gov/show/NCT01581970"
224,"NCT02838992","ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia","Not yet recruiting","No Results Available","Aplastic Anemia","Drug: Rabbit ATG, (Genzyme)|Drug: Cy|Drug: CsA|Biological: Cord blood","Jinan Military General Hospital|Shandong University of Traditional Chinese Medicine|Jining Medical University|Affiliated Hospital of Weifang Medical University|Guangzhou First People's Hospital|Harbin Hematology and Oncology Institute|JINING No.1 People's Hospital|JIANGXI Provincal People's Hospital|Jinhua Central Hospital|Linyi People's Hospital|Shandong Cord Blood Bank|Qingdao Center Medical Group|Qingdao University|Taian City Central Hospital|Yantai Yuhuangding Hospital|Yishui Central Hospital of LINYI|Institute of Hematology & Blood Diseases Hospital|Shengjing Hospital","All","1 Year to 60 Years   (Child, Adult)","Phase 4","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","JinanMGH","July 6, 2016","February 2017","July 2019","January 31, 2017","January 2017","No Study Results Posted","null","December 2018","The total response rate|Neutrophil recovery time|Infection rates|Overall survival|Treatment related mortality","https://ClinicalTrials.gov/show/NCT02838992"
225,"NCT02215876","Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer","Withdrawn","No Results Available","Breast Cancer","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Eribulin","Sidney Kimmel Comprehensive Cancer Center","Female","21 Years to 100 Years   (Adult, Senior)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JS1405|2013/01251","August 6, 2014","September 2014","March 2020","April 13, 2016","April 2016","No Study Results Posted","null","August 2017","Pathologic Response Rate","https://ClinicalTrials.gov/show/NCT02215876"
226,"NCT01187017","A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia","Completed","Has Results","Aplastic Anemia|Neutropenia|Pancytopenia|Severe Aplastic Anemia","Drug: Cyclophosphamide|Drug: Fludarabine","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","2 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","1","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","100177|10-H-0177","August 20, 2010","August 2010","July 2012","February 3, 2016","February 2016","June 5, 2014","null","July 2012","Response Rate at 6 Months|Secondary Endpoints Will Evaluated for the Study to Include: (a) Hematologic Response at 3 and 12 Months and Yearly Thereafter; (b) Relapse (c) Clonal Evolution to Paroxysmal Nocturnal Hemoglobinuria (PNH), Myelodysplasia or Acute Leukemia; (e) Survival.","https://ClinicalTrials.gov/show/NCT01187017"
227,"NCT01222715","Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma","Completed","Has Results","Adult Rhabdomyosarcoma|Childhood Alveolar Rhabdomyosarcoma|Childhood Pleomorphic Rhabdomyosarcoma|Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Adult Soft Tissue Sarcoma|Recurrent Childhood Rhabdomyosarcoma","Biological: Bevacizumab|Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Drug: Temsirolimus|Drug: Vinorelbine Tartrate","National Cancer Institute (NCI)","All","up to 29 Years   (Child, Adult)","Phase 2","87","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2011-02607|COG-ARST0921|CDR0000687113|ARST0921|U10CA098543","October 15, 2010","October 2010","June 2015","March 24, 2017","March 2017","January 9, 2017","null","June 2015","Event Free Survival Probability|Rate of Dose-Limiting Toxicities|Response Rate (CR + PR)","https://ClinicalTrials.gov/show/NCT01222715"
228,"NCT02498912","Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors","Recruiting","No Results Available","Solid Tumors","Procedure: Production of Genetically-modified T cells|Drug: Cyclophosphamide|Device: IP Catheter Insertion|Genetic: Infusion of 4H11-28z/fIL-12/EFGRt+ Genetically-modified T cells","Memorial Sloan Kettering Cancer Center|Stanford University|Juno Therapeutics, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","15-014","July 10, 2015","August 2015","August 2018","April 24, 2017","April 2017","No Study Results Posted","null","August 2018","maximum tolerated dose (MTD)|evidence of anti-tumor activity","https://ClinicalTrials.gov/show/NCT02498912"
229,"NCT00477945","Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL","Completed","No Results Available","Non Hodgkin's Lymphoma","Drug: clofarabine","Indiana University School of Medicine|Genzyme, a Sanofi Company|Indiana University","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0704-29 IUCRO-0187","May 22, 2007","May 2007","November 2010","September 10, 2014","September 2014","No Study Results Posted","null","November 2010","Determine the maximum tolerated dose (MTD) of clofarabine in association with high-dose etoposide and cyclophosphamide followed by ASCT in patients with refractory lymphoma malignancies.|Assessment of the toxicity of the combination of clofarabine, and high-dose etoposide and cyclophosphamide-- Describe engraftment kinetics-- Describe the response rate-- Describe relapse rate and event-free survival-- Assess clofarabine p","https://ClinicalTrials.gov/show/NCT00477945"
230,"NCT02953340","Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Early- Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (RECOVER)","Not yet recruiting","No Results Available","Neutropenia|Breastcancer","Drug: SPI-2012|Drug: Pegfilgrastim|Drug: Docetaxel|Drug: Cyclophosphamide","Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Senior)","Phase 3","218","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SPI-GCF-302","October 27, 2016","February 2017","null","November 1, 2016","October 2016","No Study Results Posted","null","April 2019","Duration of severe neutropenia (DSN) in Cycle 1|Time to Absolute Neutrophil Count (ANC) Recovery in Cycle 1|Depth of ANC Nadir, defined as the patient's lowest ANC in Cycle 1|Incidence of Febrile Neutropenia (FN) in patients during Cycle 1","https://ClinicalTrials.gov/show/NCT02953340"
231,"NCT00816595","Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Active, not recruiting","Has Results","Leukemia|Lymphoma","Biological: bevacizumab|Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: pentostatin","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","68","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000630491|P30CA015083|RC0783|08-002080|AVF4491s|NCI-2009-01225","December 31, 2008","February 2009","May 2016","April 13, 2016","April 2016","April 9, 2014","null","July 2013","Complete and Overall Response Rate|Overall Survival|Progression-free Survival","https://ClinicalTrials.gov/show/NCT00816595"
232,"NCT02030964","N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan","Recruiting","No Results Available","Neuroblastoma","Drug: DFMO|Drug: Celecoxib|Drug: Cyclophosphamide|Drug: Topotecan","New Approaches to Neuroblastoma Therapy Consortium|National Cancer Institute (NCI)","All","2 Years to 30 Years   (Child, Adult)","Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","N2012-01|P01CA081403","January 2, 2014","December 2013","December 2017","March 21, 2017","March 2017","No Study Results Posted","DFMO","August 2017","Number of participants with adverse events as a measure of safety and tolerability.","https://ClinicalTrials.gov/show/NCT02030964"
233,"NCT00441220","Cyclophosphamide in Lupus Nephritis","Unknown status","No Results Available","Systemic Lupus Erythematosus","","University of Auckland, New Zealand|Auckland District Health Board|Counties Manukau Health|Auckland Medical Research Foundation|Arthritis New Zealand","All","18 Years to 80 Years   (Adult, Senior)","","60","Other","Observational","Observational Model: Case-Only","ADHB3557","February 27, 2007","October 2006","October 2010","March 4, 2009","February 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00441220"
234,"NCT02027220","Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma","Unknown status","No Results Available","Myeloma|Bortezomib|Cyclophosphamide|Dexamethasone|Granulocyte Colony-Stimulating Factor","Drug: G-CSF|Drug: Bortezomib|Drug: Cyclophosphamide|Drug: Dexamethasone","Second Affiliated Hospital of Soochow University","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GBCD-001","December 21, 2013","December 2013","December 2015","January 2, 2014","January 2014","No Study Results Posted","null","December 2015","Overall Response Rate (ORR)|Number of participants with treatment related adverse events.|Overall Survival (OS)|Progression Free Survival (PFS)|Duration of Response (DOR)","https://ClinicalTrials.gov/show/NCT02027220"
235,"NCT00918723","Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage I Small Lymphocytic Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma","Drug: Fludarabine Phosphate|Drug: Cyclophosphamide|Biological: Rituximab|Drug: Vorinostat","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","58","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","PSOC 2401|NCI-2010-00324|P30CA015704","June 9, 2009","June 2009","October 2019","February 21, 2017","February 2017","No Study Results Posted","null","October 2016","MTD of vorinostat that can be combined with fludarabine phosphate, cyclophosphamide and rituximab (Phase I)|Progression-free survival (Phase II)","https://ClinicalTrials.gov/show/NCT00918723"
236,"NCT00652041","Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Drug: Bortezomib|Drug: Thalidomide|Drug: Bortezomib","PETHEMA Foundation","All","18 Years and older   (Adult, Senior)","Phase 4","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TaCyDexVMP7","March 31, 2008","January 2007","June 2010","September 16, 2011","September 2011","No Study Results Posted","TaCyDexVMP7","January 2010","Efficacy of a sequential scheme treatment with Bortezomib, Melfalan,Prednisone (V-MP) or Bortezomib, Adriamycine, Melfalan,Prednisone (VAMP) followed by Thalidomide, Cyclophosphamide and Dexamethasone (TaCyDex) in relapsed or refractory MM patients|Evaluate the response type in function to different initial situation (primary resistance, relapse, progression)|To analyze the response duration","https://ClinicalTrials.gov/show/NCT00652041"
237,"NCT01210768","A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer","Drug: Epirubicin+Cyclophosphamide|Drug: liposomal-doxorubicin+Cyclophosphamide","TTY Biopharm","Female","20 Years to 70 Years   (Adult, Senior)","Phase 2","254","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","TTYLD0914","August 31, 2010","June 2010","August 2018","February 6, 2017","February 2017","No Study Results Posted","null","July 2018","Disease-free survival|Overall survival|Quality of life|Safety profiles|Survival correlation with biomarkers expression","https://ClinicalTrials.gov/show/NCT01210768"
238,"NCT00958854","Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma","Unknown status","No Results Available","Lymphoma","Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: thalidomide|Other: laboratory biomarker analysis","Cancer Research UK|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","37","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000644123|CRUK-UCL-AITL|EUDRACT-2005-003931-40|EU-20947","August 12, 2009","January 2006","null","August 23, 2013","August 2009","No Study Results Posted","null","March 2012","Response rate after chemotherapy with fludarabine and cyclophosphamide|Incremental response rate to thalidomide treatment|Toxicity according to the NCI CTCAE v.3.0|Progression-free and overall survival","https://ClinicalTrials.gov/show/NCT00958854"
239,"NCT00727441","Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery","Active, not recruiting","No Results Available","Pancreatic Cancer","Biological: GVAX pancreatic cancer vaccine|Drug: cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","","87","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JHOC-J0810, CDR0000600355|P30CA006973|JHOC-J0810|JHOC_NA_00015858","August 1, 2008","July 2008","March 2018","January 11, 2017","January 2017","No Study Results Posted","null","December 2017","Safety, as measured by local and systemic toxicity according to NCI CTCAE v3.0|Feasibility|Immune response|Overall survival|Progression-free survival","https://ClinicalTrials.gov/show/NCT00727441"
240,"NCT00165451","A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer","Completed","No Results Available","Neoplasms","Drug: Thalidomide|Drug: Celecoxib|Drug: Etoposide|Drug: Cyclophosphamide","Dana-Farber Cancer Institute","All","up to 21 Years   (Child, Adult)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","01-046","September 9, 2005","June 2001","October 2006","July 6, 2011","July 2011","No Study Results Posted","null","October 2006","To evaluate the feasibility of administering thalidomide, celecoxib, etoposide and cyclophosphamide for recurrent and poor prognosis tumors.|To obtain preliminary evidence of biologic activity of these four orally administered|to evaluate and document side effects from chronic administration of these four drugs at the doses prescribed in this protocol|to evaluate different radiographic techniques as markers of tumor response.","https://ClinicalTrials.gov/show/NCT00165451"
241,"NCT00719173","Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer","Completed","No Results Available","Breast Cancer|Nausea and Vomiting","Drug: aprepitant|Drug: cyclophosphamide|Other: placebo","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1","19","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","LCCC 0514|P30CA016086|CDR0000600836|UNC-05-2917|UNC-GCRC-2411-ORC","July 18, 2008","August 2005","October 2010","February 27, 2017","February 2017","No Study Results Posted","NRR","October 2010","Effect of aprepitant on cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics as measured by plasma AUC","https://ClinicalTrials.gov/show/NCT00719173"
242,"NCT01416974","Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab","Active, not recruiting","No Results Available","Leukemia","Drug: cyclophosphamide|Biological: modified T cells","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11-048","August 12, 2011","November 2011","August 2017","September 26, 2016","September 2016","No Study Results Posted","null","August 2017","toxicity|maximum tolerated dose (MTD)|disease response|change in cellular and cytokine tumor microenvironment|the impact of infused modified T cells","https://ClinicalTrials.gov/show/NCT01416974"
243,"NCT00525642","Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer","Unknown status","No Results Available","Breast Neoplasms|Adjuvant|Chemotherapy","Drug: Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Drug: Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide","Fudan University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","603","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TAX-619","September 4, 2007","June 2003","June 2015","September 4, 2007","August 2007","No Study Results Posted","null","null","Disease Free Survival|Grade III/IV Adverse Event,Severe Adverse Event|Overall Survival|Distant disease free Survival|Time to treatment failure","https://ClinicalTrials.gov/show/NCT00525642"
244,"NCT01176799","Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor","Recruiting","No Results Available","Breast Cancer","Drug: Arm A|Drug: Arm B","National University Hospital, Singapore","Female","18 Years and older   (Adult, Senior)","Phase 2","73","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BR01/09/10","August 5, 2010","August 2010","December 2017","June 21, 2016","June 2016","No Study Results Posted","null","December 2016","pathological complete response rate|clinical response rate","https://ClinicalTrials.gov/show/NCT01176799"
245,"NCT00483119","Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus","Terminated","Has Results","Pemphigus Vulgaris","Drug: intravenous immunoglobulin|Drug: cyclophosphamide","New York University School of Medicine","All","18 Years to 85 Years   (Adult, Senior)","Phase 2","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","3343","June 5, 2007","April 2007","February 2011","January 21, 2016","January 2016","October 5, 2015","null","February 2010","Clinical Outcome: Extent and Severity of Disease|Serum Levels of Pemphigus Antibodies|Toxicity of Treatment: Measured in Renal Toxicity, Myelosuppression or Hepatic Toxicity|Ability to be Weaned Off Steroids","https://ClinicalTrials.gov/show/NCT00483119"
246,"NCT00258180","Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy","Completed","No Results Available","Diarrhea|Gastrointestinal Complications|Unspecified Childhood Solid Tumor, Protocol Specific","Biological: filgrastim|Drug: cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 2","3","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","J0326, CDR0000441133|P30CA006973|JHOC-J0326|JHOC-03070804","November 22, 2005","June 2005","January 2009","June 13, 2012","June 2012","No Study Results Posted","null","January 2009","Treatment-free remission at 1 year after study completion|Toxicities during study treatment|Effect of treatment on anti-enterocyte antibody titers at 1 year after study completion","https://ClinicalTrials.gov/show/NCT00258180"
247,"NCT02412228","BrUOG 299 :Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.","Recruiting","No Results Available","Multiple Myeloma","Drug: Ixazomib|Drug: Cyclophosphamide|Drug: Dexamethasone","Ryan Stevenson|Rhode Island Hospital|The Miriam Hospital|Memorial Hospital of Rhode Island|Brown University","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","299","February 16, 2015","August 2015","September 2017","June 8, 2016","June 2016","No Study Results Posted","null","May 2017","Response rate of Ixazomib with metronomic cyclophosphamide and dexamethasone for first-line treatment of multiple myeloma","https://ClinicalTrials.gov/show/NCT02412228"
248,"NCT01947062","Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma","Unknown status","No Results Available","Lung Cancer|Squamous Cell Carcinoma of the Lung|Locally Advanced and Metastatic Squamous Cell Carcinoma of the Lung","Drug: Intravenous Cisplatin & etoposide|Drug: Intravenous Cisplatin & etoposide along with oral cyclophosphamide","Swami Rama Cancer Hospital and Research Institute","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MetroCyclo1","September 10, 2013","October 2013","October 2014","September 17, 2013","September 2013","No Study Results Posted","null","June 2014","Progression free survival|Response rate","https://ClinicalTrials.gov/show/NCT01947062"
249,"NCT00389506","Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma","Withdrawn","No Results Available","Lymphoma","Biological: LMB-2 immunotoxin|Drug: cyclophosphamide|Drug: fludarabine phosphate|Other: pharmacological study","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","0","NIH","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","060240|06-C-0240|NCI-P6761|NCI-7835|CDR0000508789","October 18, 2006","September 2006","May 2008","March 14, 2012","March 2012","No Study Results Posted","null","null","Feasibility of using fludarabine phosphate and cyclophosphamide to decrease neutralizing antibodies|Response rate|Response duration|Correlation of serum levels of LMB-2 immunotoxin with toxicity and response|Development of neutralizing antibodies and its effect on blood level of LMB-2 immunotoxin and toxicity|Correlation of soluble Tac-peptide with treatment response","https://ClinicalTrials.gov/show/NCT00389506"
250,"NCT00927797","Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)","Unknown status","No Results Available","Immunocytoma/Morbus Waldenström|B-Cell Non-Hodgkin's Lymphoma|B-Cell Chronic Lymphocytic Leukemia","Drug: Cyclophosphamide, Pentostatin, Rituximab","Heidelberg University|Diakonie Krankenhaus Schwäbisch Hall, Germany|Ludwig-Maximilians - University of Munich|Klinikum am Plattenwald, Bad Friedrichshall, Germany|Diakonieklinikum Stuttgart, Germany|Gemeinschaftspraxis Porowski & Koniczek, Heilbronn, Germany|Universitätsmedizin Mannheim","All","18 Years and older   (Adult, Senior)","Phase 2","185","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","L-278/2004|BfArM 4022892","June 23, 2009","February 2005","January 2012","June 24, 2009","June 2009","No Study Results Posted","PERLL","January 2009","Efficacy: overall response rate|Toxicity according to WHO-Grading|Efficacy: complete remission rate|Efficacy: partial remission rate|Efficacy: progression-free survival","https://ClinicalTrials.gov/show/NCT00927797"
251,"NCT00301600","Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy","Completed","No Results Available","IGA Nephropathy","Drug: Mycophenolate mofetil","Nanjing University School of Medicine","All","12 Years to 65 Years   (Child, Adult)","","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NJCT-0606","March 10, 2006","January 2003","January 2006","May 25, 2010","July 2008","No Study Results Posted","null","May 2005","To compare the efficacy and safety of Mycophenolate mofetil versus intravenous Cyclophosphamide pulses in the treatment of crescentic IgA nephropathy","https://ClinicalTrials.gov/show/NCT00301600"
252,"NCT01082939","Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","Completed","Has Results","Chronic Lymphocytic Leukemia","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Alemtuzumab|Drug: Rituximab","M.D. Anderson Cancer Center|Bayer","All","Child, Adult, Senior","Phase 2","80","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM02-593","March 5, 2010","December 2002","January 2011","February 17, 2012","February 2012","July 26, 2011","null","January 2011","Number of Participants With an Overall Response","https://ClinicalTrials.gov/show/NCT01082939"
253,"NCT00793377","Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer","Completed","No Results Available","Primary Breast Cancer","Drug: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen|Drug: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid","German Breast Group|German Adjuvant Breast Cancer Group","Female","18 Years and older   (Adult, Senior)","Phase 3","913","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","Gepar-Duo","November 17, 2008","null","September 2001","November 18, 2008","November 2008","No Study Results Posted","null","null","Pathological locoregional complete tumor response (pCR) between both arms|Survival Local tumor response by palpation (cRR=cCR+cPR) Local tumor response by best imaging method (iRR=iCR+iPR) Response of axillary lymphnodes (NR) Breast conservation therapy (BCT) Toxicity","https://ClinicalTrials.gov/show/NCT00793377"
254,"NCT01106898","Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery","Unknown status","No Results Available","Stage I Breast Cancer|Stage II Breast Cancer","Drug: cyclophosphamide|Drug: paclitaxel|Biological: trastuzumab","University of Nebraska|National Cancer Institute (NCI)","Female","19 Years and older   (Adult, Senior)","Phase 2","120","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","371-09|NCI-2010-00608|P30CA036727","April 13, 2010","March 2010","null","May 14, 2013","May 2013","No Study Results Posted","null","December 2014","Primary toxicity (i.e., neutropenia)|Secondary toxicities (i.e., paclitaxel-related neuropathy, grade 3/4 cardiotoxicity and grade 3/4 nausea and vomiting)|Recurrence-free survival","https://ClinicalTrials.gov/show/NCT01106898"
255,"NCT03029403","Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer","Not yet recruiting","No Results Available","Advanced Cancer|Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer","Drug: Pembrolizumab|Biological: DPX-Survivac|Drug: Cyclophosphamide","University Health Network, Toronto|Merck Sharp & Dohme Corp.|ImmunoVaccine Technologies, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","42","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","PESCO","January 20, 2017","March 13, 2017","September 13, 2022","January 20, 2017","January 2017","No Study Results Posted","null","March 13, 2022","Overall response rate (ORR)|Progression free survival (PFS) rate|Overall survival (OS) rate|Number of side effects","https://ClinicalTrials.gov/show/NCT03029403"
256,"NCT01427881","Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies","Completed","Has Results","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Myeloid Leukemia in Remission|Adult Erythroleukemia (M6a)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Adult Pure Erythroid Leukemia (M6b)|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Erythroleukemia (M6)|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Philadelphia Chromosome Negative Chronic Myelogenous Leukemia|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Multiple Myeloma|Testicular Lymphoma|Waldenström Macroglobulinemia","Drug: cyclophosphamide|Drug: cyclosporine|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation|Drug: fludarabine phosphate|Drug: busulfan|Procedure: allogeneic hematopoietic stem cell transplantation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","43","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2541.00|NCI-2011-02459|P30CA015704","August 31, 2011","September 2011","July 2015","May 17, 2017","May 2017","April 11, 2017","null","June 2014","Chronic GVHD Requiring Systemic Immunosuppressive Treatment|Donor Engraftment|Grades II-IV and III-IV Acute GVHD|Duration of Systemic Immunosuppressive Treatment|Persistent or Recurrent Malignancy After HCT|Non-relapse Mortality|Overall Survival|Disease-free Survival|Hematologic Recovery|Graft Failure","https://ClinicalTrials.gov/show/NCT01427881"
257,"NCT00281918","Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia","Completed","Has Results","Leukemia","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate","Hoffmann-La Roche|German CLL Study Group","All","18 Years and older   (Adult, Senior)","Phase 3","817","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000454560|GCLLSG-CLL-8|EU-20560|ML17102","January 24, 2006","July 2003","October 2011","September 9, 2013","September 2013","December 21, 2009","CLL-8","July 2007","Progression-free Survival (PFS)|Final Analysis: Time to Progression-free Survival Event|Event-free Survival (EFS)|Overall Survival (OS)|Disease-free Survival (DFS) of Patients With Confirmed Complete Response (CR).|Final Analysis: Time to Overall Survival Event|Final Analysis: Time to Event-free Survival Event|Final Analysis: Time to Disease-free Survival (DFS) Event in Participants With Complete Response (CR)|Final Analysis: Duration of Response|Final Analysis: Percentage of Participants With Complete Response (CR) and Partial Response|Final Analysis: Time to New Treatment for Chronic Lymphocytic Leukemia(CLL)","https://ClinicalTrials.gov/show/NCT00281918"
258,"NCT00531453","A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma","Completed","Has Results","Multiple Myeloma","Drug: bortezomib, dexamethasone, and thalidomide|Drug: bortezomib, dexamethasone, thalidomide, and cyclophosphamide","Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","98","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","26866138-MMY-2043","September 14, 2007","October 2007","May 2009","January 25, 2012","January 2012","April 9, 2010","null","April 2009","Percent of Particpants Achieving Overall Combined Complete Response (CR) Following Induction|Percent of Participants Achieving Overall Combined Complete Response (CR) Following High-dose Chemotherapy (HDT)/Stem Cell Transplantation (SCT)","https://ClinicalTrials.gov/show/NCT00531453"
259,"NCT00616122","Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer","Completed","Has Results","Breast Cancer","Drug: cyclophosphamide|Drug: methotrexate|Drug: sunitinib malate|Other: laboratory biomarker analysis","University of California, San Francisco|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","32","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000583268|UCSF-057519","February 14, 2008","March 2006","December 2012","November 1, 2013","November 2013","December 18, 2012","null","March 2011","Maximum Tolerated Dose (Phase I)|PFS Greater Than or Equal to 12 Weeks (Phase II)|Response|Duration of Response|Correlation of Outcome Measures With Possible Surrogate Markers Including Serial Measurements of Circulating Tumor Cells and Circulating Endothelial Cells","https://ClinicalTrials.gov/show/NCT00616122"
260,"NCT01881789","Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Oprozomib|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Cyclophosphamide","Amgen","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","134","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","OPZ003","June 13, 2013","August 2013","August 2017","April 28, 2017","April 2017","No Study Results Posted","null","May 2017","Maximum Tolerated Dose (MTD)|Adverse Events (AEs) and Serious Adverse Events (SAEs)|Overall Response Rate (ORR)|Complete Response Rate (CRR)|Population Pharmacokinetic (PK) Parameters - Apparent Clearance|Population Pharmacokinetic (PK) Parameters - Volume of Distribution|Duration of Response (DOR)|Progression-Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01881789"
261,"NCT00275054","Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia","Completed","No Results Available","Chronic Lymphocytic Leukemia","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Rituximab","German CLL Study Group","All","18 Years and older   (Adult, Senior)","Phase 3","825","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CLL7|EU-20559|ROCHE-GCLLSG-CLL7|2005-003018-14","January 10, 2006","October 2005","June 2015","September 30, 2016","September 2016","No Study Results Posted","null","July 2007","Event-free survival|Development of a new prognostic staging system|Progression free survival|Overall survival|Time to progression to Binet stages B and C|Time to treatment|Quality of life|Pharmacoeconomic analysis|Overall response (complete and partial) rate in patients in the early treatment arm|Percentage of patients achieving complete molecular remission in the early treatment arm|Duration of response in patients in the early treatment arm|Adverse events in patients in the early treatment arm","https://ClinicalTrials.gov/show/NCT00275054"
262,"NCT01072773","Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis","Completed","Has Results","Primary Systemic Amyloidosis","Drug: bortezomib|Drug: cyclophosphamide|Drug: dexamethasone","Mayo Clinic","All","18 Years and older   (Adult, Senior)","Phase 2","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC0985|NCI-2009-01564|09-005736|X05306","February 17, 2010","March 2010","June 2012","March 5, 2014","March 2014","November 7, 2012","null","March 2011","Number of Participants With a Confirmed Hematologic Response|Number of Participants With Treatment Related Adverse Events.|Number of Participants With an Organ Response.|Overall Survival|Time to Disease Progression|Duration of Response","https://ClinicalTrials.gov/show/NCT01072773"
263,"NCT01298193","Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients","Completed","No Results Available","Breast Cancer","Drug: Aprepitant","Spanish Breast Cancer Research Group|Merck Sharp & Dohme Corp.","Female","18 Years and older   (Adult, Senior)","Phase 4","212","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEICAM/2009-02|2010-022689-29","February 11, 2011","May 2011","April 2014","May 18, 2015","June 2013","No Study Results Posted","null","March 2013","To determine the incidence of complete response, defined as no vomiting and no use of rescue treatment within the first cycle of Docetaxel-Cyclophosphamide for the treatment of early-stage breast cancer patients|To evaluate in cycle 2 the efficacy of aprepitant (days 1, 2 and 3) as secondary prevention in patients without complete response in cycle 1|To evaluate the toxicity of study drug (cycle 2) in those patients.","https://ClinicalTrials.gov/show/NCT01298193"
264,"NCT01328249","Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer","Active, not recruiting","No Results Available","Her2normal","Drug: eribulin mesylate","Eisai Inc.","All","18 Years to 100 Years   (Adult, Senior)","Phase 2","81","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","E7389-A001-210","March 22, 2011","March 2, 2011","November 2017","March 10, 2017","March 2017","No Study Results Posted","null","October 27, 2014","To measure the feasibility of the regimen for each individual subject. The regimen is considered feasible if the subject is able to complete the eribulin portion of the regimen without dose delay or reduction|To evaluate the toxicities of 4 cycles of AC followed by 4 cycles of eribulin mesylate as measured by the monitoring and recording of all adverse events, clinical laboratory results, vital signs, physical examinations, ECGs, and LVEF.","https://ClinicalTrials.gov/show/NCT01328249"
265,"NCT01078441","Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant","Terminated","Has Results","Refractory Multiple Myeloma","Drug: liposomal doxorubicin|Drug: bortezomib|Drug: dexamethasone|Drug: cyclophosphamide","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","2","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-02002|E2A08|U10CA021115","February 27, 2010","September 2010","March 2014","January 5, 2015","July 2014","January 5, 2015","null","February 2014","One-year Survival in Patients Treated With This Regimen.","https://ClinicalTrials.gov/show/NCT01078441"
266,"NCT02225652","A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.","Completed","No Results Available","Women With Primary Breast Cancer","Drug: FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRST174.05|2010-020772-38","August 25, 2014","September 2010","July 2014","August 25, 2014","August 2014","No Study Results Posted","null","September 2013","Tolerability of the treatment|Toxicity|Progression-free survival (PFS)|Overall survival (OS)|Relapse-free survival|Kaplan-Meier curves","https://ClinicalTrials.gov/show/NCT02225652"
267,"NCT01191957","Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML","Completed","No Results Available","Acute Myeloid Leukemia (AML)","Drug: Busulphan plus Cyclophosphamide|Drug: Busulphan plus Fludarabine","Gruppo Italiano Trapianto di Midollo Osseo","All","40 Years to 65 Years   (Adult)","Phase 3","252","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GITMO AMLR2","June 10, 2010","January 2008","October 2014","September 2, 2015","September 2015","No Study Results Posted","GITMO-AMLR2","December 2012","transplant-related mortality (TRM)|Assessment in the two arms of the safety and efficacy profile","https://ClinicalTrials.gov/show/NCT01191957"
268,"NCT00971737","Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Biological: allogeneic GM-CSF-secreting breast cancer vaccine|Biological: trastuzumab|Drug: cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J0947 CDR0000653173|P30CA006973|JHOC-J0947|NA_00024527|GENENTECH-JHOC-J0947","September 3, 2009","July 2009","null","September 23, 2015","September 2015","No Study Results Posted","null","March 2016","Toxicity as assessed by NCI CTCAE v3.0|Progression-free survival at 6 months|HER-2/neu-specific immune responses|Pharmacodynamics of peripheral CD4+CD25+ regulatory T cells|Immune priming in in-vivo vaccine-site biopsies|Enumeration of CD8+ T cells specific for hTERT by ELISPOT|Characterization of the T-cell memory pool pre- and post-vaccination","https://ClinicalTrials.gov/show/NCT00971737"
269,"NCT01971658","Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)","Completed","No Results Available","Multiple Myeloma","Drug: Thalidomide®|Drug: Cyclophosphamide|Drug: Velcade®|Drug: Dexaméthasone","Nantes University Hospital","All","18 Years to 65 Years   (Adult)","Phase 3","358","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RC13_0284|2013-003174-27","September 30, 2013","October 2013","August 2015","October 6, 2015","October 2015","No Study Results Posted","IFM2013-04","August 2015","Response assessment according to the criteria IMWG|Number of Adverse Events|Number of collected stem cell|Number of death|Number of relapse according to the criteria IMWG","https://ClinicalTrials.gov/show/NCT01971658"
270,"NCT00801411","Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery","Unknown status","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride","National Cancer Centre, Singapore|National Cancer Institute (NCI)","Female","21 Years and older   (Adult, Senior)","Phase 2","318","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000624374|SINGAPORE-NCC0705|SANOFI-AVENTIS-NCC0705","December 2, 2008","October 2008","null","June 16, 2009","June 2009","No Study Results Posted","null","null","Pathological complete response rate|Clinical and pathological overall response rate|Toxicity as assessed by NCI CTCAE v3.0|Overall survival|Disease-free survival","https://ClinicalTrials.gov/show/NCT00801411"
271,"NCT00005778","High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide","Completed","No Results Available","Lupus Erythematosus, Systemic","Drug: High-dose immunoablative therapy","National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","100","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","N01 AR92243|NIAMS-046","June 3, 2000","January 2000","April 2006","November 5, 2008","November 2008","No Study Results Posted","null","April 2006","RIFLE","https://ClinicalTrials.gov/show/NCT00005778"
272,"NCT00004474","Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia","Completed","No Results Available","Aplastic Anemia","Drug: Anti-thymocyte globulin|Drug: Cyclophosphamide|Procedure: Bone marrow transplantation","Roswell Park Cancer Institute|Office of Rare Diseases (ORD)","All","up to 59 Years   (Child, Adult)","Phase 3","224","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","199/14004|RPCI-RP-9804|NCI-G98-1491|IBMTR-1","October 18, 1999","September 1998","August 2007","October 1, 2008","October 2008","No Study Results Posted","null","August 2007","Graft failure, graft versus host disease, and survival","https://ClinicalTrials.gov/show/NCT00004474"
273,"NCT01689350","A Prospective Study of Cyclophosphamide in Systemic Lupus Erythematosus Treatment","Completed","Has Results","Systemic Lupus Erythematosus","Genetic: Genotype Detection","Sun Yat-sen University|First Affiliated Hospital, Sun Yat-Sen University","All","12 Years to 60 Years   (Child, Adult)","","92","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","2012ZX09506001-004","September 17, 2012","October 2012","March 2014","August 27, 2014","August 2014","June 10, 2014","SLE","December 2013","Adverse Reaction (Leucopenia)|Adverse Reaction ( Infection )","https://ClinicalTrials.gov/show/NCT01689350"
274,"NCT00915408","A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Drug: Lenalidomide|Drug: Dexamethasone|Drug: Cyclophosphamide","King's College Hospital NHS Trust","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05CC15|REC - 06/Q1606/75|EudraCT - 2005-005145-19","June 5, 2009","September 2006","March 2014","September 1, 2015","April 2013","No Study Results Posted","CRD","March 2014","Dose limiting toxicity defined as: a) NCI Grade 4 haematological toxicity b) NCI Grade ¾ non-haematological toxicity|Safety (type, frequency, severity, and relationship of adverse events)|Time to progression|Paraprotein response|Bone marrow response|Duration of response|Overall survival","https://ClinicalTrials.gov/show/NCT00915408"
275,"NCT00293384","Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant","Completed","Has Results","Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Nausea and Vomiting|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor","Drug: Aprepitant|Drug: Cyclophosphamide|Drug: Dexamethasone|Drug: Granisetron hydrochloride","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","","40","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CDR0000456201|P30CA022453|WSU-D-2797|WSU-0504001728","February 16, 2006","October 2004","February 2012","February 12, 2016","February 2016","May 12, 2014","null","June 2009","Proportion of Participants With Controlled Acute Vomiting|Delayed Vomiting Controlled|Toxicity Grade 3, 4, or 5","https://ClinicalTrials.gov/show/NCT00293384"
276,"NCT03043105","TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial","Recruiting","No Results Available","Multicentric Castleman Disease","Drug: Thalidomide, cyclophosphamide and prednisone","Peking Union Medical College Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","55","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ZS-1159","January 31, 2017","January 1, 2017","January 1, 2021","February 3, 2017","February 2017","No Study Results Posted","null","January 1, 2020","Durable tumor and symptomatic response|Progression-free survival (PFS)|Overall survival (OS)|Change in SF-36 score|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 ( ≥1 grade)|Number of participants with treatment-related serious adverse events as assessed by CTCAE v4.0 ( ≥3 grade)","https://ClinicalTrials.gov/show/NCT03043105"
277,"NCT02623439","A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies","Suspended","No Results Available","Hematologic Malignancies","Drug: Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant","University of California, San Diego","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","120931","August 29, 2013","July 2012","July 2020","December 4, 2015","December 2015","No Study Results Posted","null","July 2020","The primary endpoint is overall survival at 180 days from the time of transplantation.|Incidence of Neutrophil Engraftment","https://ClinicalTrials.gov/show/NCT02623439"
278,"NCT02054104","Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum","Suspended","No Results Available","Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma","Biological: H1299 Lysate Vaccine|Drug: Cyclophosphamide|Drug: Celecoxib","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 1|Phase 2","21","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","140053|14-C-0053","February 1, 2014","January 27, 2014","November 5, 2018","May 12, 2017","September 26, 2016","No Study Results Posted","null","September 3, 2018","Comparison of immune response rates in patients taking vaccine alone versus those taking vaccine plus metronomic chemotherapy.|Determine whether oral metronomic cyclophosphamide andcelecoxib therapy diminishes the percentage and number of Tregulatory cells and diminishes activity of these cells in patientswith thoracic malignancies|Determine whether H1299 cell lysate/Iscomatrix vaccinationenhances immunologic response to autologous tumor orepigenetically modified autologous EBV-transformed lymphocytes(B cells)","https://ClinicalTrials.gov/show/NCT02054104"
279,"NCT00774527","Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT","Completed","No Results Available","Bone Marrow Failure Syndromes","Drug: Cyclophosphamide-fludarabine-anti thymocyte globulin","Cooperative Study Group A for Hematology","All","15 Years to 60 Years   (Child, Adult)","Phase 3","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","C-002","October 12, 2008","March 2003","January 2011","February 16, 2011","February 2011","No Study Results Posted","CyFluCyATG","February 2010","Occurrence of regimen related toxicities|Secondary end point will be the occurrence of engraftment failure (primary and secondary)","https://ClinicalTrials.gov/show/NCT00774527"
280,"NCT00002556","Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma","Completed","No Results Available","Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma","Drug: vincristine sulfate|Drug: carmustine|Drug: melphalan|Drug: cyclophosphamide|Drug: prednisone|Biological: recombinant interferon alfa-2b|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","312","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02445|E5A93|ECOG-E5A93|U10CA021115","November 1, 1999","July 1994","null","May 30, 2013","May 2013","No Study Results Posted","null","January 2006","Median survival|Objective response, evaluated using the following ECOG Myeloma Response Criteria","https://ClinicalTrials.gov/show/NCT00002556"
281,"NCT00586560","Karenitecin in Pediatric Patients With Refractory or Recurrent Solid Tumors N10010)","Completed","No Results Available","Solid Tumors","Drug: Kareniticin and cyclophosphamide","Baylor College of Medicine|Pediatric Brain Tumor Consortium","All","12 Months to 21 Years   (Child, Adult)","Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","H-20159|KTN10010|BMP1350","December 20, 2007","February 2007","January 2011","May 11, 2012","May 2012","No Study Results Posted","KTN10010","January 2011","To determine the maximum tolerated dose (MTD) levels and recommended Phase 2 dose levels of Karenitecin when administered intravenously for 5 consecutive days with a fixed dose of Cytoxan®|Secondary objectives include the assessment of toxicity associated with Karenitecin administered in combination with cyclophosphamide; and the assessment of antitumor activity of Karenitecin administered in combination with cyclophosphamide.","https://ClinicalTrials.gov/show/NCT00586560"
282,"NCT00784927","Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma","Completed","Has Results","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: dexamethasone|Drug: lenalidomide","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","36","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC0882|P30CA015083|RV-NHL-PI-0336|08-001485","November 1, 2008","November 2008","February 2016","August 25, 2016","August 2016","March 23, 2015","null","October 2013","Assessment of Tumor Response|Tumor Response to Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone in the Subgroup of Patients With Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia).|Survival Time|Progression-free Survival Time|Time to Treatment Failure","https://ClinicalTrials.gov/show/NCT00784927"
283,"NCT02999854","Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer","Not yet recruiting","No Results Available","Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome","Biological: ATIR101|Drug: Cyclophosphamide|Procedure: T-cell depleted HSCT from a related, haploidentical donor|Procedure: T-cell replete HSCT from a related, haploidentical donor","Kiadis Pharma","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","195","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Prevention","CR-AIR-009|2016-004672-21","December 19, 2016","May 2017","May 2020","April 24, 2017","April 2017","No Study Results Posted","HATCY","May 2020","Graft-versus-host disease-free, relapse-free survival (GRFS)|Overall survival (OS)|Progression-free survival (PFS)|Relapse-related mortality (RRM)|Transplant-related mortality (TRM)","https://ClinicalTrials.gov/show/NCT02999854"
284,"NCT00564889","Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis","Completed","Has Results","Multiple Myeloma and Plasma Cell Neoplasm","Drug: cyclophosphamide|Drug: dexamethasone|Drug: lenalidomide","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","35","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC0685|P30CA015083|NCI-2010-01954|06-005711","November 28, 2007","December 2007","June 2012","April 10, 2013","April 2013","July 19, 2011","null","February 2009","Number of Participants Who Achieved a Confirmed Response Defined as a Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR)|Number of Patients With Organ Response|Number of Participants With Severe Adverse Events|Progression Free Survival (PFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00564889"
285,"NCT00114530","Scleroderma: Cyclophosphamide or Transplantation (SCOT)","Completed","No Results Available","Scleroderma, Systemic|Sclerosis|Autoimmune Disease","Procedure: Autologous stem cell transplantation|Drug: Cyclophosphamide|Drug: Antithymocyte globulin, equine|Drug: Methylprednisolone|Drug: Growth colony stimulating factor (G-CSF)|Radiation: Total body irradiation (TBI)","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 69 Years   (Adult, Senior)","Phase 2|Phase 3","75","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","DAIT SCSSc-01|SCOT","June 15, 2005","June 2005","April 2016","April 3, 2017","April 2017","No Study Results Posted","null","April 2016","Global rank composite score (GRCS) at 54 months post- randomization.|Treatment-related mortality|Mortality due to any cause|Regimen-related toxicities defined as adverse events (AEs) Grade 3 or worse|Infectious complications|Engraftment (for the High-dose immunosuppressive therapy followed by stem cell transplantation arm only)|A decrease of more than in 0.4 on two successive Modified Scleroderma Health Assessment Questionnaires (SHAQ)taken within 3 months of each other|Quality of life as measured by the Short Form 36 (SF-36)|Pulmonary function measured by Diffusion in Liters of Carbon Monoxide (DLCO)|Pulmonary function measured by Forced Vital Capacity (FVC)|Skin condition as indicated by Modified Rodnan Skin Score (mRSS)|New or worsening arrhythmias, congestive heart failure (CHF), or pericardial effusion|New or worsening pulmonary hypertension|Occurrence of scleroderma renal crisis|Documented myositis, requiring more than 30 mg per day of prednisone for over 1 month|Increase in Modified Scleroderma Health Assessment Questionnaire (SHAQ) by more than 0.4 from baseline on 2 successive occasions within 3 months|Decrease in quality of life as measured by the Short Form 36 (SF-36)|Initiating use of disease-modifying antirheumatic drugs|Global rank composite score (GRCS) at 48 months post-randomization.|Event-free Survival (EFS) at 48 and 54 months after randomization.","https://ClinicalTrials.gov/show/NCT00114530"
286,"NCT00001155","Treatment of Wegener's Granulomatosis With Cyclophosphamide","Completed","No Results Available","Vasculitis|Wegener's Granulomatosis","Drug: cyclophosphamide","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","200","NIH","Interventional","Primary Purpose: Treatment","760042|76-I-0042","November 3, 1999","February 1976","February 2002","March 3, 2008","February 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001155"
287,"NCT02046070","Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Cyclophosphamide|Drug: Ixazomib (MLN9708)|Drug: Dexamethasone","Millennium Pharmaceuticals, Inc.|Takeda","All","18 Years and older   (Adult, Senior)","Phase 2","148","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","C16020|2013-003113-17|U1111-1158-2714","December 12, 2013","March 2014","July 2017","January 12, 2017","January 2017","No Study Results Posted","null","February 2017","Combined Response Rate during the Induction Phase in Newly Diagnosed Multiple Myeloma (NDMM) Participants|Overall Response Rate (ORR) in Relapsed and/or Refractory Multiple Myeloma (RRMM) Participants|Number of Participants with Adverse Events (AEs), Grade 3 or higher AEs, AEs resulting in discontinuation, AEs resulting in dose reduction and Serious Adverse Events (SAEs) in NDMM Participants|Overall response rate (ORR), CR, VGPR, PR and stable disease (SD), progressive disease(PD) during the Induction Phase and the ORR (CR + VGPR + PR), CR + VGPR, CR, VGPR, and PR through out the entire treatment period in NDMM Participants|Time to Response (TTR) in NDMM Participants|Duration of Response (DOR) in NDMM Participants|Time to Progression (TTP) in NDMM Participants|Progression Free Survival (PFS) in NDMM Participants|Number of participants with AEs, SAEs, AEs resulting in discontinuation and AEs resulting in dose reduction in NDMM Participants Remaining on Treatment after 13 Cycles|Change from Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) during the Induction Phase in NDMM Participants|ORR, CR, VGPR, and PR in NDMM Participants Remaining on Treatment after 13 Cycles|Cmax: Maximum Observed Plasma Concentration in NDMM Participants|Tmax: Time to reach the maximum plasma concentration (Cmax) in NDMM Participants|AUC: Area under the Plasma Concentration Versus Time Curve in NDMM Participants|Number of Participants with Adverse Events (AEs), Grade 3 or higher AEs, AEs resulting in discontinuation, AEs resulting in dose reduction, serious adverse events (SAEs) in RRMM Participants|Cmax: Maximum Observed Plasma Concentration in RRMM Participants|Tmax: Time to reach the maximum plasma concentration (Cmax) in RRMM Participants|AUC: Area under the Plasma Concentration Versus Time Curve in RRMM Participants|CR + VGPR , CR, VGPR, PR, SD and PD in RRMM Participants|Time to Response (TTR) in RRMM Participants|Duration of Response (DOR) in RRMM Participants|Time to Progression (TTP) in RRMM Participants|Progression Free Survival (PFS) in RRMM Participants|Change from Baseline in EORTC Quality of Life Questionnaire (QLQ-C30) in RRMM Participants","https://ClinicalTrials.gov/show/NCT02046070"
288,"NCT01046487","Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate","Completed","No Results Available","Cancer","Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 1 )|Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 2)|Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 3)|Procedure: Blood sampling","Centre Oscar Lambret","All","18 Years and older   (Adult, Senior)","Phase 1","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PALANGI-3 0804","January 11, 2010","January 2009","February 2012","June 6, 2012","June 2012","No Study Results Posted","PALANGI3","April 2011","For safety: NCI-CTCAE scale version 3.0|For anti tumoral efficiency : RECIST criteria","https://ClinicalTrials.gov/show/NCT01046487"
289,"NCT01677949","Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia","Withdrawn","No Results Available","Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia","Drug: Clofarabine|Drug: Etoposide|Drug: Cyclophosphamide|Biological: allogeneic hematopoietic cell transplantation","Masonic Cancer Center, University of Minnesota","All","up to 60 Years   (Child, Adult)","Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2011LS158|HM2012-05","August 28, 2012","December 2013","January 2016","April 21, 2016","April 2016","No Study Results Posted","null","January 2016","Number of Patients Unable to Proceed to Transplantation|Rate of Pre-Transplant Chemotherapy-Induced Aplasia|Rate of Infectious Complications|Treatment-Related Mortality After Transplant|Disease-Free Survival After Transplant|Rate of Leukemic Relapse After Transplant","https://ClinicalTrials.gov/show/NCT01677949"
290,"NCT00131963","A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: doxorubicin|Drug: paclitaxel","Duke University|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","","94","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00014267|DUMC-4522-04-1-R1|CDR0000438673","August 16, 2005","October 2003","October 2014","July 22, 2016","November 2015","No Study Results Posted","null","October 2014","Treatment-induced myelosuppression (e.g., neutropenia)|Incidence of peripheral neuropathy|Response (relapse in adjuvant setting) for 10 years after completion of study treatment","https://ClinicalTrials.gov/show/NCT00131963"
291,"NCT02414945","Tumor-Infiltrating Lymphocytes and Low-Dose Interleukin-2 Therapy Following Cyclophosphamide and Fludarabine in Patients With Pleural Mesothelioma","Recruiting","No Results Available","Pleural Mesothelioma","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Autologous tumor infiltrating lymphocytes (TILs)|Biological: Interleukin-2","University Health Network, Toronto","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TILs-003-Meso","April 8, 2015","June 2015","November 2025","May 31, 2016","May 2016","No Study Results Posted","null","June 2025","Total number of adverse events for each event reported and the severity and attribution to study therapy of each event|Percentage of patients with a clinical response to the study treatment","https://ClinicalTrials.gov/show/NCT02414945"
292,"NCT00629499","Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer","Completed","Has Results","Breast Cancer","Drug: nab paclitaxel|Drug: Cyclophosphamide|Drug: Trastuzumab","SCRI Development Innovations, LLC|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","63","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI BRE 116","February 26, 2008","April 2008","September 2010","August 29, 2013","August 2013","August 22, 2012","null","October 2008","Tolerability of Adjuvant Nab Paclitaxel Using Weekly Dosing Schedule Assessed by Patient Survival, Disease Recurrence, and Treatment-related Toxicity.|Disease-free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00629499"
293,"NCT00147901","Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)","Completed","No Results Available","B-cell Chronic Lymphocytic Leukemia","Drug: FCCam","German CLL Study Group|University of Cologne|MedacSchering Onkologie","All","18 Years and older   (Adult, Senior)","Phase 2","61","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLL-2L|2005-003017-32","September 2, 2005","January 2005","November 2011","September 30, 2016","September 2016","No Study Results Posted","null","November 2008","Overall response rate (complete and partial response rate)|Toxicity|MRD response rate|Response rate in biological defined risk groups|Duration of response|Treatment administration (dose intensity)|Overall survival","https://ClinicalTrials.gov/show/NCT00147901"
294,"NCT00003659","Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia","Completed","Has Results","Leukemia","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: fludarabine phosphate","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","39","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","98-080|MSKCC-98080|NCI-G98-1483","November 1, 1999","September 1998","May 2009","January 11, 2017","January 2017","November 28, 2012","null","May 2009","Overall Response Rate|Utilize Flow Cytometry and Polymerase Chain Reaction as Sensitive Measures of Minimal Residual Disease|Overall Survival Status","https://ClinicalTrials.gov/show/NCT00003659"
295,"NCT00293410","Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Myelodysplastic/Myeloproliferative Diseases","Drug: clofarabine|Drug: cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","2 Years and older   (Child, Adult, Senior)","Phase 1","70","Other|NIH","Interventional","Primary Purpose: Treatment","J0561 CDR0000456431|P30CA006973|JHOC-J0561|JHOC-00000845","February 16, 2006","November 2005","null","May 5, 2010","May 2010","No Study Results Posted","null","April 2010","","https://ClinicalTrials.gov/show/NCT00293410"
296,"NCT01526499","Docetaxel With or Without Metronomic Cyclophosphamide as First Line Chemotherapy in Metastatic Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: Docetaxel and Cyclophosphamide (TC)|Drug: Docetaxel (T)","Fudan University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TCvsT","January 29, 2012","December 2011","July 2013","February 5, 2012","February 2012","No Study Results Posted","null","July 2013","Progression Free Survival|Biomarker serum VEGF level|Biomarker immuno-marker|Efficacy Overall Response Rate|Efficacy Overall Survival|Safety|genetic polymorphisms","https://ClinicalTrials.gov/show/NCT01526499"
297,"NCT00981799","Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL","Terminated","No Results Available","Relapsed T-Cell Acute Lymphoblastic Leukemia|Relapsed T-Cell Lymphoblastic Lymphoma","Drug: Nelarabine|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Filgrastim","Therapeutic Advances in Childhood Leukemia Consortium|GlaxoSmithKline|Novartis","All","1 Year to 21 Years   (Child, Adult)","Phase 1|Phase 2","23","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","T2008-002","September 9, 2009","June 2010","null","November 20, 2015","November 2015","No Study Results Posted","null","November 2015","To determine the maximum tolerated doses and dose-limiting toxicities (DLTs) of nelarabine, etoposide and cyclophosphamide when given in combination to children with T-ALL and bone marrow relapse or T-LL.|To determine the complete remission rate after 1 and 2 courses of this therapy in children with T-ALL and bone marrow relapse or T-LL.|To determine the percent of children with T-ALL and 1st BM relapse that have a complete response after therapy on this study and proceed to stem cell transplantation in complete response within 20 weeks of beginning this regimen.|To determine minimal residual disease (MRD) levels at the end of each course of treatment.|To evaluate the vitamin B12 pathway and metabolites and the potential association of neurotoxicity following nelarabine therapy with alterations in this pathway.|To determine, in a preliminary manner, whether patients with relapsed T-ALL/LL have a distinct signaling signature that distinguishes malignant cells from normal thymocytes.|To evaluate, in a preliminary manner, whether phospho-flow cytometry can be used to predict clinical response to Nelarabine.","https://ClinicalTrials.gov/show/NCT00981799"
298,"NCT01194791","Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed","Completed","No Results Available","Primary Systemic Amyloidosis","Drug: Lenalidomide|Drug: Cyclophosphamide|Drug: Dexamethasone","PETHEMA Foundation","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","LENDEXAL|2009-017707-28","July 26, 2010","October 2010","December 2016","April 23, 2017","November 2015","No Study Results Posted","LENDEXAL","September 2012","Hematologic response rate to the association of Lenalidomide, Cyclophosphamide and Dexamethasone|Organ response rate|Predictors of response (cardiac biomarkers, serum free light chains)|Safety and tolerability|Duration of response|Time to progression|Overall survival","https://ClinicalTrials.gov/show/NCT01194791"
299,"NCT00518206","Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma","Completed","No Results Available","Melanoma","Biological: NY-ESO-1 ISCOMATRIX® vaccine|Drug: Cyclophosphamide","Ludwig Institute for Cancer Research","All","18 Years and older   (Adult, Senior)","Phase 2","46","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LUD2002-013|CTN Trial No.: 2007/123|CTN-Protocol# LUD2002-013AMEND","August 16, 2007","December 2003","November 2012","February 27, 2013","February 2013","No Study Results Posted","null","January 2010","Effect of adding cyclophosphamide in the additional cohort on ""Tumor Response"": Measured as objective tumor response (RECIST criteria). Measured at 11 weeks but a superior response observed at a later timepoint will be recorded as the best response.|Effect of adding cyclophosphamide in the additional cohort on ""Immunological Response"": Measured by DTH skin reactions, antibodies and T cell responses against NY-ESO-1.|Effect of adding cyclophosphamide in the additional cohort on ""Safety"": Measured as toxicity","https://ClinicalTrials.gov/show/NCT00518206"
300,"NCT01435447","Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult ALL","Recruiting","No Results Available","Acute Lymphocytic Leukemia","Drug: FLu-Bu-Cy","Shanghai Jiao Tong University School of Medicine","All","18 Years to 60 Years   (Adult)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RJH-ALL-2011","September 14, 2011","April 2011","June 2017","May 9, 2016","May 2016","No Study Results Posted","null","December 2016","overall survival|transplantation related mortality|relapse rate|overall -survival","https://ClinicalTrials.gov/show/NCT01435447"
301,"NCT00089726","A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC)","Completed","No Results Available","Lung Cancer|Carcinoma, Non-Small-Cell Lung","Biological: CG8123|Drug: Cyclophosphamide","Cell Genesys","All","18 Years and older   (Adult, Senior)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D-0031","August 11, 2004","March 2003","January 2006","December 18, 2007","December 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00089726"
302,"NCT01093196","Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Melphalan, Prednisone, Lenalidomide|Drug: Cyclophosphamide, Prednisone, Lenalidomide|Drug: Lenalidomide, dexamethasone","Fondazione Neoplasie Sangue Onlus","All","18 Years and older   (Adult, Senior)","Phase 3","660","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMN01","March 24, 2010","October 2009","November 2017","February 5, 2016","February 2016","No Study Results Posted","null","November 2012","Progression Free Survival|Overall Survival|Overall Response Rate|Time to progression|Time and duration of response|Time to next therapy|Grade 3-4 hematological and non-hematological adverse events (AEs)|Prognosis and cytogenetic abnormalities","https://ClinicalTrials.gov/show/NCT01093196"
303,"NCT00003340","Cyclophosphamide Plus Topotecan in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia","Completed","No Results Available","Leukemia","Drug: cyclophosphamide|Drug: topotecan hydrochloride","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","J9736 CDR0000066314|JHOC-97100102|J-9736|NCI-G98-1435","November 1, 1999","November 1997","February 2000","May 1, 2014","May 2014","No Study Results Posted","null","February 2000","","https://ClinicalTrials.gov/show/NCT00003340"
304,"NCT02225665","Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART","Active, not recruiting","No Results Available","Human Immunodeficiency Virus (HIV)","Genetic: SB-728mR-T|Genetic: SB-728mR-T|Drug: Cyclophosphamide","Sangamo Therapeutics","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SB-728mR-1401","August 22, 2014","August 2014","June 2018","January 6, 2017","January 2017","No Study Results Posted","null","June 2018","Primary Outcome Measure|Secondary Outcome Measure","https://ClinicalTrials.gov/show/NCT02225665"
305,"NCT01421017","Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases","Active, not recruiting","No Results Available","Breast Cancer|Metastatic Breast Cancer|Recurrent Breast Cancer","Radiation: Radiation|Drug: Imiquimod|Drug: Cyclophosphamide","New York University School of Medicine|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","55","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NYU 11-00598|1R01CA161891-01","August 17, 2011","August 2011","February 2019","February 16, 2017","February 2017","No Study Results Posted","null","February 2018","systemic tumor response rates (Complete Response+Partial Response)|Local tumor response rates (Clinical Complete Response+Partial Response)","https://ClinicalTrials.gov/show/NCT01421017"
306,"NCT02879526","Chidamide Combined With Cyclophosphamide、Prednisone、Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma","Recruiting","No Results Available","Relapse/Refratory Peripheral T Cell Lymphoma","Drug: C-CPT","The First Affiliated Hospital with Nanjing Medical University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JSPH-003","August 21, 2016","August 2016","August 2019","August 21, 2016","August 2016","No Study Results Posted","null","March 2018","Overall response rate (ORR)|Duration of response|Progress-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02879526"
307,"NCT01860170","Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis","Active, not recruiting","Has Results","Hematological Malignancy","Drug: Cohort 1-Bortezomib (Velcade ®)|Drug: Cohort 2-Bortezomib (Velcade ®)|Drug: Cohort 3-Bortezomib (Velcade ®)","Spectrum Health Hospitals|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","28","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Prevention","2013-083","May 14, 2013","April 2012","March 2018","April 7, 2017","April 2017","April 7, 2017","null","March 2016","Dose Limiting Toxicity|Engraftment","https://ClinicalTrials.gov/show/NCT01860170"
308,"NCT00093834","Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: allogeneic GM-CSF-secreting breast cancer vaccine|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1","60","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0085 CDR0000391826|R01CA093714|P30CA006973|JHOC-J0085|JHOC-RPN-01012502|JHOC-RAC-0304-578","October 6, 2004","January 2004","null","July 19, 2011","April 2011","No Study Results Posted","null","August 2008","Toxicity of vaccine w/ & w/o cyclophosphamide+doxorubicin by history and phys. exam. at 28-42 days after each vaccination, 56-84 days after third vaccination, 6 months after first vaccination, and annually after first vaccination|Toxicity of vaccine w/ & w/o cyclophosphamide+doxorubicin by CBC w/ differential at days 7, 14, 21, and 28-42 days after each vaccination, 56-84 days after third vaccination, 6 months after first vaccination, and annually after first vaccination|Toxicity of vaccine w/ & w/o cyclophosphamide+doxorubicin by comprehensive metabolic panel at day 7 and 28-42 days after each vaccination, 56-84 days after third vaccination, 6 months after first vaccination, and annually after first vaccination|Immune resp. of HER-2/neu by serum antibody titers, delayed hypersensitivity to HER-2/neu-derived peptides, and CD4+ T-cell resp. by ELISPOT at days 28-42 after each vaccination and days 56-84 after third vaccination|Immune responses by immunohistochemical analysis of vaccine site biopsies at days 3 and 7 after the first and third vaccinations|Time to disease progression by history and physical examination, computed tomography, bone scans, and tumor markers as appropriate at days 28-42 after third and fourth vaccinations and days 56-84 after third vaccination","https://ClinicalTrials.gov/show/NCT00093834"
309,"NCT01057225","Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma","Active, not recruiting","Has Results","Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma","Drug: carfilzomib|Drug: cyclophosphamide|Drug: thalidomide|Drug: dexamethasone","Mayo Clinic","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","64","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC0982|NCI-2009-01699|PT-171-502|09-004091","January 26, 2010","March 2010","null","September 26, 2016","January 2016","August 2, 2016","null","March 2014","Maximum Tolerated Dose (Phase I)|Percentage of Patients Who Have at Least a Confirmed Very Good Partial Response (Phase II)|Progression-free Survival (Phase II)|Time to Treatment Failure|Stem Cell Collection and Engraftment (Phase II)|Complete Response (Phase II)|Survival Time (Phase II)|Progression Free Survival (12 Month)|Progession Free Survival (24 Month)|Overall Survival (12 Month)|Overall Survival (24 Month)","https://ClinicalTrials.gov/show/NCT01057225"
310,"NCT00881933","Study of Fludarabine + Cyclophosphamide + TBI Conditioning Regimen for Double Units Cord Blood Transplantation(CBT)in Severe Aplastic Anemia(SAA)","Unknown status","No Results Available","Aplastic Anemia","Other: Cyclophosphosphamide, TBI","The Korean Society of Pediatric Hematology Oncology","All","1 Year to 21 Years   (Child, Adult)","Phase 1|Phase 2","5","Other","Interventional","Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KSPHO-SCT0804","April 14, 2009","November 2008","September 2012","March 23, 2012","March 2012","No Study Results Posted","null","September 2012","To evaluate the engraftment potential of fludarabine, busulfan plus thymoglobulin conditioning regimen for cord blood transplantation (CBT) in severe aplastic anemia.|To evaluate the incidence and severity of toxicity and treatment related mortality|To evaluate overall and event free survival rate|To evaluate acute and chronic GVHD|To evaluate immunologic recovery after CBT","https://ClinicalTrials.gov/show/NCT00881933"
311,"NCT00602836","Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Active, not recruiting","Has Results","Leukemia|Lymphoma","Biological: Rituximab|Drug: Cyclophosphamide|Drug: Lenalidomide|Drug: Pentostatin","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","45","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CDR0000582676|P30CA015083|MC0784|07-002156|RV-CLL-PI-146|NCI-2009-01281","January 12, 2008","February 2008","December 2017","March 21, 2017","April 2016","March 15, 2012","null","December 2010","Number of Participants With Complete Response (CR)|Number of Participants Who Convert From a Nodular Partial Response (nPR), Partial Response (PR), or Stable Disease (SD) After Pentostatin, Cyclophosphamide, and Rituximab (PCR) to a Complete Response (CR) After 6 Courses of Consolidation With Lenalidomide|Number of Participants Who Convert From a CR With Minimal Residual Disease (MRD) Positive Status After PCR to a CR With MRD-negative Status After 6 Courses of Consolidation With Lenalidomide|Number of Participants Who Convert From a CR With MRD or nPR, PR, or Stable Disease With Residual Disease After PCR to a CR With MRD-negative Status After 6 Courses of Consolidation With Lenalidomide|Number of Participants With a Response (CR, nPR, PR)|Overall Survival (OS)|Time to Disease Progression (TTP)|Number of Participants With IgVH Testing at Baseline Who Also Had a Clinical Response (CR, nPR, or PR).|Number of Participants With CD38 Testing at Baseline Who Also Had a Clinical Response (CR, nPR, or PR).|Number of Participants With ZAP-70 Testing at Baseline Who Also Had a Clinical Response (CR, nPR, or PR).|Number of Participants With FISH Testing at Baseline Who Also Had a Clinical Response (CR, nPR, or PR).","https://ClinicalTrials.gov/show/NCT00602836"
312,"NCT02048813","Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Active, not recruiting","No Results Available","Anemia|Chronic Lymphocytic Leukemia|Fatigue|Fever, Sweat, and Hot Flashes|Hepatomegaly|Lymphadenopathy|Lymphocytosis|Small Lymphocytic Lymphoma|Splenomegaly|Thrombocytopenia|Weight Change","Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Other: Pharmacogenomic Study|Other: Quality-of-Life Assessment|Biological: Rituximab","National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","519","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2014-00118|E1912|ECOG-E1912|U10CA180820|U10CA021115","January 27, 2014","February 20, 2014","null","May 23, 2017","May 2017","No Study Results Posted","null","March 2, 2020","Change in quality of life assessed using Functional Assessment of Cancer Therapy -Leukemia (FACT-Leu) Trial Outcome Index (TOI)|PFS|Adherence to prescription assessed by the Moriskey Adherence Scale (Arm A only)|Change in FACT-Leu TOI score|Impact of CLL on QOL|Incidence of toxicity, defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment, graded according to NCI Common Terminology for Adverse Events version 4.0|OS","https://ClinicalTrials.gov/show/NCT02048813"
313,"NCT00003754","Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers","Completed","No Results Available","Unspecified Childhood Solid Tumor, Protocol Specific","Drug: cyclophosphamide|Drug: thalidomide","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","98-088|CDR0000066878|MSKCC-98088A(4)|NCI-G99-1498","November 1, 1999","September 1998","July 2001","June 24, 2013","June 2013","No Study Results Posted","null","July 2001","","https://ClinicalTrials.gov/show/NCT00003754"
314,"NCT01985724","Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Docetaxel|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: 5-fluoruracil|Drug: Granulocyte-colony stimulating growth factor","Hellenic Oncology Research Group|University Hospital of Crete","Female","18 Years and older   (Adult, Senior)","Phase 3","650","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/07.17","November 9, 2013","October 2007","December 2013","May 13, 2014","May 2014","No Study Results Posted","null","December 2013","3-year disease-free survival|Overall survival|Recurrence rate","https://ClinicalTrials.gov/show/NCT01985724"
315,"NCT00590785","Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)","Completed","No Results Available","High Risk|Breast Cancer|Positive Nodes|Cyclophosphamide|Doxorubicin","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: G-CSF|Drug: tamoxifen|Drug: ciprofloxacin","Memorial Sloan Kettering Cancer Center|Cancer and Leukemia Group B","Female","Child, Adult, Senior","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","96-041|INT 0137|CALGB 9394","December 26, 2007","August 13, 1996","January 13, 2015","February 15, 2017","November 2016","No Study Results Posted","null","June 10, 1997","To compare disease-free survival (DFS), overall survival (s), and toxicity of high-isk primary breast cancer patients with negative axillary lymph nodes or with one to three positive nodes.|To obtain tumor tissue for biologic studies. The details of these biologic studies will be described in a companion protocol or protocols to be developed through the Intergroup mechanism.","https://ClinicalTrials.gov/show/NCT00590785"
316,"NCT02270307","MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis","Unknown status","No Results Available","Leukemia|Multiple Myeloma","Drug: Cyclophosphamide|Biological: Mesenchymal stromal cells","National Research Center for Hematology, Russia","All","18 Years to 65 Years   (Adult)","Phase 2|Phase 3","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","MSC-CY-Russia","April 7, 2014","January 2014","January 2016","October 17, 2014","October 2014","No Study Results Posted","MSC-CY","January 2016","Overall survival","https://ClinicalTrials.gov/show/NCT02270307"
317,"NCT00924170","Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia","Active, not recruiting","No Results Available","Adult T-Cell Leukemia (ATL)","Drug: LMB-2|Drug: Fludarabine|Drug: Cyclophosphamide","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Senior)","Phase 1|Phase 2","18","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","090025|09-C-0025","June 17, 2009","October 31, 2008","June 30, 2018","March 17, 2017","March 13, 2017","No Study Results Posted","null","January 2, 2016","Response Rate","https://ClinicalTrials.gov/show/NCT00924170"
318,"NCT00420563","Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer","Completed","No Results Available","Cancer","Drug: CYCLOPHOSPHAMIDE|Drug: MEGESTROL","Centre Oscar Lambret","All","18 Years and older   (Adult, Senior)","Phase 2","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PAL-ANGI 0601","January 9, 2007","September 2006","July 2009","July 20, 2012","July 2012","No Study Results Posted","PALANGI-0601","January 2009","Progression free survival rate at 2 months|Progression free survival rate and objective response (RECIST) at 2, 4 and 6 months|Toxicity according to NCI scale v3.0|Biological markers|Overall survival|Median time between the beginning of treatment and hospitalization due to progression or toxicity","https://ClinicalTrials.gov/show/NCT00420563"
319,"NCT00003605","Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma","Withdrawn","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide","Hoag Memorial Hospital Presbyterian|Cancer Biotherapy Research Group","All","Child, Adult, Senior","Phase 2","0","Other","Interventional","Primary Purpose: Treatment","CDR0000066680|CBRG-9801|GENENTECH-CBRG-9801|NBSG-9801|NCI-V98-1483","November 1, 1999","May 1998","January 2000","August 17, 2015","August 2015","No Study Results Posted","null","January 2000","","https://ClinicalTrials.gov/show/NCT00003605"
320,"NCT01135329","Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers","Terminated","No Results Available","Lymphoma|Leukemia|Myelodysplastic Syndrome","Drug: Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus,","Sidney Kimmel Comprehensive Cancer Center","All","6 Months to 75 Years   (Child, Adult, Senior)","Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J1046|NA_00039363","June 1, 2010","August 2010","May 2012","April 16, 2014","April 2014","No Study Results Posted","null","May 2012","Estimate the proportion of patients achieving full donor chimerism|Graft-versus-host disease (GVHD)","https://ClinicalTrials.gov/show/NCT01135329"
321,"NCT02693210","A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis","Completed","No Results Available","Rheumatoid Arthritis","Drug: Cyclophosphamide|Drug: Methotrexate|Other: Placebo Cyclophosphamide|Other: Placebo Methotrexate|Other: Placebo Rituximab|Drug: Rituximab","Hoffmann-La Roche","All","21 Years and older   (Adult, Senior)","Phase 2","161","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WA16291","February 23, 2016","February 2001","August 2004","October 29, 2016","October 2016","No Study Results Posted","null","August 2002","Percentage of participants achieving American College of Rheumatology (ACR) 50 response at Week 24|Percentage of participants achieving ACR 20 and ACR 70 responses at Week 24|Area Under the Curve (AUC) of American College of Rheumatology Response (ACRn)|AUC of the mean Disease Activity Scores (DAS)|Change from Baseline in the Swollen Joint Count|Change from Baseline in the Tender Joint Count|Change from Baseline in participant's global assessment of disease activity using a Visual Analog Scale (VAS)|Change from Baseline in physician's global assessment of disease activity using VAS|Change from Baseline in the Health Assessment Questionnaire - Disease Index (HAQ-DI) scores|Change from Baseline in participant's pain measured by VAS|Change from Baseline in C-Reactive Protein (CRP) Levels|Change from Baseline in Erythrocyte Sedimentation Rate (ESR)|Mean change in Rheumatoid factor levels at 24 weeks|Percentage of participants who withdrew due to insufficient therapeutic response","https://ClinicalTrials.gov/show/NCT02693210"
322,"NCT00849251","Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma","Terminated","No Results Available","Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma","Drug: cyclophosphamide|Drug: pegylated liposomal doxorubicin hydrochloride|Drug: bortezomib|Drug: dexamethasone","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","31","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","6817|NCI-2009-01665","February 20, 2009","November 2008","June 2015","September 17, 2015","September 2015","No Study Results Posted","null","December 2011","Maximum tolerated dose of this combination of drugs as assessed by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (cohort 1)|Response rate (complete remission [CR] or near CR) (cohort II)","https://ClinicalTrials.gov/show/NCT00849251"
323,"NCT00551889","Cyclophosphamide and Celecoxib in Treating Patients With Advanced Cancer","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: celecoxib|Drug: cyclophosphamide|Other: laboratory biomarker analysis","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","57","Other|NIH","Interventional","Primary Purpose: Treatment","00191|P30CA033572|CHNMC-00191|CDR0000570416","October 30, 2007","September 2001","February 2012","November 8, 2012","November 2012","No Study Results Posted","null","February 2012","Toxicity|Maximum tolerated dose|Survival|Time to failure","https://ClinicalTrials.gov/show/NCT00551889"
324,"NCT02861417","Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation","Recruiting","No Results Available","Other Diseases of Blood and Blood-forming Organs|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Chronic Myeloid Leukemia|Chronic Lymphocytic Leukemia|Myelodysplastic Syndrome|Myeloproliferative Syndrome|Non-Hodgkins Lymphoma|Hodgkins Lymphoma|Multiple Myeloma","Drug: Busulfan|Drug: Thiotepa|Drug: Fludarabine monophosphate|Procedure: Stem Cell Infusion|Drug: Mesna|Drug: Cyclophosphamide|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Drug: G-CSF","M.D. Anderson Cancer Center","All","12 Years to 70 Years   (Child, Adult, Senior)","Phase 2","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2016-0137|NCI-2016-01285","August 5, 2016","August 2016","August 2021","May 11, 2017","May 2017","No Study Results Posted","null","August 2021","Non-Relapse Mortality (NRM) in Participants Undergoing Allogeneic Transplantation From Haploidentical Donor|Non-Relapse Mortality (NRM) in Participants Undergoing Allogeneic Transplantation From Matched Donor|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02861417"
325,"NCT00727415","Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy","Completed","No Results Available","Chronic Lymphocytic Leukemia","Drug: Cyclophosphamide|Drug: Fludarabine phosphate|Drug: Lenalidomide","Gruppo Italiano Malattie EMatologiche dell'Adulto","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","52","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LLC0606|2006-006185-42","August 1, 2008","February 2008","January 2016","August 16, 2016","August 2016","No Study Results Posted","LLC0606","January 2016","Maximum tolerated dose of lenalidomide (Phase I)|Overall complete response (CR) rate (Phase II)|CR rate (Phase I)|Toxicity as assessed by NCI CTCAE v3.0|Infection rate|Median number of delivered courses of treatment.|Overall response rate.|Progression-free survival.|Correlation between response and baseline biologic parameters (i.e., IgVH, FISH, ZAP-70, CD38).","https://ClinicalTrials.gov/show/NCT00727415"
326,"NCT00492921","High-Dose Cyclophosphamide in Treating Patients With Acute Graft-Versus-Host Disease That Did Not Respond to Steroid Therapy","Completed","No Results Available","Graft Versus Host Disease","Biological: filgrastim|Drug: cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","12","Other|NIH","Interventional","Primary Purpose: Supportive Care","J06116 CDR0000549900|P01CA015396|P30CA006973|JHOC-J06116|JHOC-NA_00003256","June 25, 2007","May 2007","January 2013","June 3, 2013","June 2013","No Study Results Posted","null","January 2013","Maximum tolerated dose of high-dose cyclophosphamide","https://ClinicalTrials.gov/show/NCT00492921"
327,"NCT00356928","Cyclophosphamide Plus Transplantation of Partially HLA-mismatched, CD8+ T Cell-depleted Peripheral Blood Cells for Patients With Myelodysplastic Syndrome , Refractory Acute Myeloid Leukemia, Refractory Lymphoma or Myeloproliferative Disorders","Terminated","No Results Available","Leukemia|Myelodysplastic Syndromes","Biological: donor lymphocytes|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","","9","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0551 CDR0000483771|R21CA121588|P30CA006973|JHOC-J0551|JHOC-NA_00000901","July 26, 2006","May 2006","December 2017","August 3, 2016","August 2016","No Study Results Posted","null","May 2011","Maximum tolerated dose of CD8-positive T-cell-depleted haploidentical donor lymphocytes","https://ClinicalTrials.gov/show/NCT00356928"
328,"NCT00759798","Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)","Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia|Leukemia","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab","M.D. Anderson Cancer Center","All","16 Years and older   (Child, Adult, Senior)","Phase 2","300","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-0431|NCI-2012-01663|246915","September 24, 2008","August 2008","null","September 30, 2016","September 2016","No Study Results Posted","null","August 2018","Complete Remission Rate (CRR)","https://ClinicalTrials.gov/show/NCT00759798"
329,"NCT00003764","Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Drug: cyclophosphamide|Drug: fludarabine phosphate","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Southwest Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 3","280","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066890|E2997|CALGB-10103|SWOG-E2997","November 1, 1999","December 1999","null","January 26, 2010","January 2010","No Study Results Posted","null","November 2005","","https://ClinicalTrials.gov/show/NCT00003764"
330,"NCT01873833","Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer","Recruiting","No Results Available","HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer","Drug: capecitabine|Drug: cyclophosphamide|Drug: lapatinib ditosylate|Biological: trastuzumab|Other: laboratory biomarker analysis","University of Southern California|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","40","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","1B-12-10|NCI-2013-01086|P30CA014089","June 6, 2013","July 29, 2013","July 27, 2019","March 22, 2017","March 2017","No Study Results Posted","null","July 27, 2018","PFS","https://ClinicalTrials.gov/show/NCT01873833"
331,"NCT02193880","Safety and Efficacy Trial for Alpha-Beta Depleted T-Cell Infusions Post Haplo Transplant","Recruiting","No Results Available","Hematologic Neoplasms|Graft-Versus-Host Disease","Device: Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.","Ayman Saad|University of Alabama at Birmingham","All","19 Years to 65 Years   (Adult)","Phase 1|Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UAB 1397","July 14, 2014","October 2014","October 2019","December 27, 2016","December 2016","No Study Results Posted","ABD","October 2017","One-year progression-free survival.|Incidence of acute graft-versus-host disease.|Incidence of chronic graft-versus-host disease.|Incidence of relapse.|Incidence of overall survival.","https://ClinicalTrials.gov/show/NCT02193880"
332,"NCT00148317","Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Drug: Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin, Cyclophosphamide","Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","38","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0504007841","September 2, 2005","June 2005","November 2012","November 20, 2012","November 2012","No Study Results Posted","null","February 2011","efficacy of drug combination as therapy for myeloma","https://ClinicalTrials.gov/show/NCT00148317"
333,"NCT01024010","Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Unknown status","No Results Available","Hematopoietic/Lymphoid Cancer|B-cell Chronic Lymphocytic Leukemia|Contiguous Stage II Small Lymphocytic Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Stage 0 Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage I Small Lymphocytic Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma","Drug: pentostatin|Drug: cyclophosphamide|Biological: ofatumumab|Procedure: laboratory biomarker analysis|Other: flow cytometry|Genetic: protein expression analysis","Mayo Clinic","All","18 Years and older   (Adult, Senior)","Phase 2","82","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC0983|NCI-2009-01437|OFT113301|09-003675","December 1, 2009","August 2010","null","October 30, 2014","October 2014","No Study Results Posted","null","May 2014","Arm A: Proportion of complete responses|Arm B: Treatment-free Survival at 18 months|Overall response rate|Complete response rate|Depth of response after ofatumumab consolidation|Progression-free survival|Treatment-free survival|Duration of response|Differences in the distributions of risk factors (VH gene mutation, CD38, CD49d, ZAP-70 and FISH status) by clinical outcome (responders vs nonresponders)|Adverse events","https://ClinicalTrials.gov/show/NCT01024010"
334,"NCT00551265","Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy","Withdrawn","No Results Available","Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma|Recurrent Ovarian Carcinoma|Stage III Ovarian Cancer|Stage IV Ovarian Cancer","Biological: Oregovomab|Drug: Cyclophosphamide|Procedure: Laboratory Biomarker Analysis","Gynecologic Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GOG-0243|NCI-2009-00607|CDR0000570624|U10CA027469","October 25, 2007","October 2007","null","May 7, 2015","May 2015","No Study Results Posted","null","January 2009","Serum human anti-murine antibodies (HAMA) as assessed by enzyme-linked immunosorbent assay (ELISA)|Frequency and severity of adverse events as assessed by NCI CTCAE v3.0|Serum HAMA and anti-idiotype antibodies as assessed by ELISA over the course of treatment|Frequency and magnitude of patients who have a delayed-type hypersensitivity (DTH) response to oregovomab, tetanus, mumps, and Candida as assessed by DTH skin testing|Duration of time from first response to first recurrence|Duration of time from second response to second recurrence","https://ClinicalTrials.gov/show/NCT00551265"
335,"NCT01462214","Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer","Completed","No Results Available","Metastatic Renal Cell Cancer","Drug: Everolimus","Hans J. van der Vliet, MD, PhD|Dutch Cancer Society|Novartis|VU University Medical Center","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","96","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","11/016","October 10, 2011","October 2011","January 2017","May 9, 2017","May 2017","No Study Results Posted","null","January 2017","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Number of patients progression-free at 4 months.|Depletion of circulating CD4+CD25+ regulatory T cells|Response rate|Frequency of tumor infiltrating CD4+CD25+FOXP3+ regulatory T cells.|Peripheral blood drug levels of everolimus and cyclophosphamide|Overall survival","https://ClinicalTrials.gov/show/NCT01462214"
336,"NCT02965950","The p53 Breast Cancer Trial","Recruiting","No Results Available","Locally Advanced Breast Cancer|Metastatic Breast Carcinoma","Drug: Cyclophosphamide","Haukeland University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","140","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2016/816|2016-003459-31","November 4, 2016","October 2016","May 2030","November 14, 2016","November 2016","No Study Results Posted","p53b","May 2020","Objective response rate (ORR) measured clinically (with calipers) or radiologically per RECIST guidelines.|Number of patients harboring the same molecular aberration or set of aberrations, and which are associated with either response to treatment or survival.|Number of patients harboring the same TP53 mutation subtype|Number of patients achieving pathological complete response (pCR)|Recurrence-free survival|Overall survival|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02965950"
337,"NCT00004067","Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2","Active, not recruiting","No Results Available","Breast Cancer","Biological: herceptin|Drug: adriamycin|Drug: cyclophosphamide|Drug: taxol","NSABP Foundation Inc|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","2130","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP B-31|CDR0000067269","December 10, 1999","February 2000","March 2020","March 22, 2016","March 2016","No Study Results Posted","null","March 2005","Disease Free Survival (DFS)|Cardiotoxicity|Survival|Long term effect of trastuzumab on cardiac function","https://ClinicalTrials.gov/show/NCT00004067"
338,"NCT02323230","A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Biological: DPX-Survivac|Drug: Cyclophosphamide","ImmunoVaccine Technologies, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ONC-DPX-Survivac-05","December 12, 2014","January 2015","February 2017","December 14, 2015","December 2015","No Study Results Posted","null","June 2016","Objective response rate|Immune response|Frequency of adverse events","https://ClinicalTrials.gov/show/NCT02323230"
339,"NCT01329627","Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer","Terminated","No Results Available","Locally Advanced HER2-negative Breast Cancer","Drug: Paclitaxel/doxorubicin/cyclophosphamide|Drug: Paclitaxel/doxorubicin/cyclophosphamide","Instituto do Cancer do Estado de São Paulo|Fundação Faculdade de Medicina","Female","18 Years and older   (Adult, Senior)","Phase 2","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NP 50/2010 - TAME","November 8, 2010","August 2010","August 2012","May 20, 2014","May 2014","No Study Results Posted","TAME-01","August 2011","Incidence of febrile neutropenia|Efficacy","https://ClinicalTrials.gov/show/NCT01329627"
340,"NCT00883129","Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)","Completed","Has Results","Scleroderma|Interstitial Lung Disease","Drug: Mycophenolate mofetil|Drug: Cyclophosphamide|Drug: Placebo","Michael Roth|National Heart, Lung, and Blood Institute (NHLBI)|Hoffmann-La Roche|University of California, Los Angeles","All","18 Years and older   (Adult, Senior)","Phase 2","142","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","632|R01HL089901|R01HL089758","April 16, 2009","September 2009","November 2015","February 6, 2017","February 2017","November 6, 2016","SLSII","January 2015","Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value|Total Lung Capacity (TLC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value|Single-breath Diffusing Capacity for Carbon Monoxide (DLCO), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value|Fibrosis Score, as Measured by Thoracic High Resolution Computerized Tomography (HRCT)|Transitional Dyspnea Index Score|Health-related Quality of Life as Measured by the Patient Responses to the Health Assessment Questionnaire Disability Index (HAQ-DI)|Skin Involvement, as Measured by the Modified Rodnam Skin Thickness Scores (mRSS)|Toxicity, as Measured by Adverse Events, Serious Adverse Events, and Death|Tolerability, as Assessed by the Time to Withdrawal From the Study Drug or Meeting Protocol-defined Criteria for Treatment Failure.","https://ClinicalTrials.gov/show/NCT00883129"
341,"NCT00689156","Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer","Completed","No Results Available","Breast Neoplasms","Drug: Epirubicin, cyclophosphamide and docetaxel|Drug: docetaxel, cyclophosphamide","Danish Breast Cancer Cooperative Group|Fonden Til Fremme af Klinisk- Eksperimentel Cancerforskning|Sanofi|Dako","Female","18 Years to 75 Years   (Adult, Senior)","Phase 3","2015","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DBCG 07-READ","May 29, 2008","June 2008","January 2013","January 3, 2013","January 2013","No Study Results Posted","READ","January 2013","IDFS; invasive disease-free survival|Overall survival|DDFS; distant disease-free survival|Serious adverse events","https://ClinicalTrials.gov/show/NCT00689156"
342,"NCT00595127","Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine","Completed","Has Results","Fanconi Anemia","Drug: Cyclophosphamide|Drug: Fludarabine|Radiation: Total body irradiation (TBI)","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Miltenyi Biotec, Inc.","All","Child, Adult, Senior","","21","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-062","January 7, 2008","June 2001","May 2013","June 29, 2016","June 2016","December 22, 2015","null","May 2013","Incidence & Quality of Engraftment & Hematopoietic Reconstitution","https://ClinicalTrials.gov/show/NCT00595127"
343,"NCT03012100","Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer","Active, not recruiting","No Results Available","Bilateral Breast Carcinoma|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma|Unilateral Breast Carcinoma","Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Biological: Multi-epitope Folate Receptor Alpha Peptide Vaccine|Other: Placebo|Biological: Sargramostim","Academic and Community Cancer Research United|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","280","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Treatment","RU011501I|NCI-2016-01878|P30CA015083","December 29, 2016","March 31, 2017","December 2021","April 17, 2017","December 2016","No Study Results Posted","null","July 2021","Disease-free survival|FRalpha levels|Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events 4.0|Overall survival|Vaccine induced FRalpha-specific T cell responses defined as the proportion of patients with at least a 2-fold increase in the number of cells/plasma concentration","https://ClinicalTrials.gov/show/NCT03012100"
344,"NCT01005537","Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma","No longer available","No Results Available","Melanoma (Skin)","Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","null","Other|NIH","Expanded Access","","2355.00|P30CA015704|FHCRC-2355.00|IR-6984|CDR0000648071","October 30, 2009","June 2009","null","August 4, 2010","August 2010","No Study Results Posted","null","October 2010","","https://ClinicalTrials.gov/show/NCT01005537"
345,"NCT00254163","Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients","Completed","Has Results","B-Cell Chronic Lymphocytic Leukemia","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab|Drug: Pentostatin","US Oncology Research|Astex Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 3","184","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","03017|NIP-03-007","November 9, 2005","December 2003","September 2011","September 15, 2016","September 2016","February 2, 2016","null","September 2011","Infection Rate|Infective Event Rate|Percentage of Patients Hospitalized|Hematologic Recovery|Mean Absolute Neutrophil Count (ANC) at Post-treatment|Complete Remission (CR)|Objective Remission Rate (ORR)|Progression-free Survival (PFS) Rate at 1-year|Progression-free Survival (PFS) Rate at 2-year","https://ClinicalTrials.gov/show/NCT00254163"
346,"NCT00121992","Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-Fluorouracil in Combination With Doxorubicin and Cyclophosphamide (5 FAC) as Adjuvant Treatment of Breast Cancer Patients","Completed","No Results Available","Breast Neoplasms","Drug: Docetaxel/Doxorubicin/cyclophosphamide (75/50/500) mg/m2 q3w","Spanish Breast Cancer Research Group|Sanofi","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","1054","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GEICAM 9805|TAX.ES1.301","July 18, 2005","June 1999","June 2005","August 8, 2005","August 2005","No Study Results Posted","null","null","10 year Disease-free survival (DFS)|10 year Overall survival (OS)|Toxicity|Quality of life|Biological markers","https://ClinicalTrials.gov/show/NCT00121992"
347,"NCT01592981","Randomised Trial in Waldenstrom's Macroglobulinaemia","Active, not recruiting","No Results Available","Waldenstrom's Macroglobulinaemia","Drug: Bortezomib|Drug: Cyclophosphamide|Biological: Rituximab|Drug: Fludarabine","University College, London","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UCL/11/0353","May 3, 2012","January 2013","July 2021","November 21, 2016","November 2016","No Study Results Posted","R2W","March 2017","Disease response|Toxicity|Progression free survival|Overall survival|Quality of life","https://ClinicalTrials.gov/show/NCT01592981"
348,"NCT00516295","Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma","Completed","Has Results","Ewing Sarcoma of Bone|Extraosseous Ewing Sarcoma|Peripheral Primitive Neuroectodermal Tumor|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","Drug: topotecan hydrochloride|Drug: vincristine sulfate|Drug: cyclophosphamide|Biological: bevacizumab","National Cancer Institute (NCI)","All","1 Year to 29 Years   (Child, Adult)","Phase 2","7","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00369|AEWS0521|U10CA098543","August 14, 2007","February 2008","January 2010","August 20, 2014","July 2014","December 18, 2013","null","August 2009","The Occurrence of Limiting Toxicity in an Eligible and Evaluable Patient.|Time to Disease Progression in Patients Receiving VTC With or Without Bevacizumab","https://ClinicalTrials.gov/show/NCT00516295"
349,"NCT00295932","Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma","Active, not recruiting","No Results Available","Leukemia|Lymphoma","Biological: rituximab|Drug: bortezomib|Drug: cyclophosphamide|Drug: prednisone","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey|Columbia University|Emory University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","117","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","05-103|MSKCC-05103","February 23, 2006","December 2005","September 2017","September 26, 2016","September 2016","No Study Results Posted","null","September 2017","Maximum tolerated dose|Progression-free survival|Duration of response (mean and median)|Event-free survival|Overall survival|Toxicity","https://ClinicalTrials.gov/show/NCT00295932"
350,"NCT00278161","Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma","Completed","No Results Available","Leukemia|Lymphoma","Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","82","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","J0260 CDR0000451458|P50CA096888|P30CA006973|JHOC-J0260|JHOC-03022409","January 16, 2006","January 2005","July 2011","April 16, 2014","April 2014","No Study Results Posted","null","December 2009","Achievement of count recovery within 30 days|Mortality|Pathologic complete response conversion|Duration of response","https://ClinicalTrials.gov/show/NCT00278161"
351,"NCT00254410","FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years","Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Mitoxantrone|Drug: Rituximab|Drug: Filgrastim","M.D. Anderson Cancer Center|OSI Pharmaceuticals|Genentech, Inc.","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2005-0106|NCI-2010-00437","November 14, 2005","March 2005","March 2018","February 20, 2017","February 2017","No Study Results Posted","null","March 2018","Clinical Response Rate (combined morphological [NCI WG criteria] + flow cytometry criteria) following treatment with FCM-R|Molecular response rate (PCR for IgH rearrangements) following treatment with FCM-R","https://ClinicalTrials.gov/show/NCT00254410"
352,"NCT00499122","NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Doxorubicin|Drug: NOV 002","University of Miami","Female","18 Years to 120 Years   (Adult, Senior)","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","20071167|MUSC-101072|MUSC-HR-17111","July 10, 2007","October 6, 2008","April 2011","April 3, 2017","April 2017","January 18, 2013","null","April 2011","Percentage of Participants Achieving Pathologic Complete Response|Definition of the Safety Profiles of Protocol Therapy|The Correlation of Serum Protein Glutathionylation With Clinical and Pathologic Responses","https://ClinicalTrials.gov/show/NCT00499122"
353,"NCT01493154","Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients","Terminated","No Results Available","Head and Neck Cancer","Biological: DNA Vaccine|Drug: Cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center|National Institute of Dental and Craniofacial Research (NIDCR)|Ichor Medical Systems Incorporated","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","2","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J11129|P50DE019032|NA_00023916","November 21, 2011","April 2012","October 2019","October 12, 2016","October 2016","No Study Results Posted","null","October 2015","Number of participants with adverse events after administration of pNGVL4a-CRT/E7 (detox) DNA vaccine using the intramuscular TriGridTM Delivery System (TDS-IM) in combination with cyclophosphamide|Number of participants with measurable HPV-specific immune responses after vaccination","https://ClinicalTrials.gov/show/NCT01493154"
354,"NCT02533401","A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)","Completed","Has Results","Lymphocytic Leukemia, Chronic","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Rituximab","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","34","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18429","August 24, 2015","February 2006","December 2014","March 30, 2016","March 2016","March 29, 2016","null","December 2014","Percentage of Participants With Death or Disease Progression|Progression-Free Survival (PFS)|Percentage of Participants Who Died|Overall Survival (OS)|Percentage of Participants With Complete Response (CR), Nodular Partial Response (nPR), or Partial Response (PR)","https://ClinicalTrials.gov/show/NCT02533401"
355,"NCT02488967","Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer","Recruiting","No Results Available","Breast Adenocarcinoma|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma","Drug: Carboplatin|Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel","NRG Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","990","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NRG-BR003|NCI-2015-00128|NRG-BR1428|U10CA180868","June 30, 2015","July 2015","null","October 4, 2016","October 2016","No Study Results Posted","null","April 2021","IDFS|BCFS|DRFI|Frequencies of adverse events categorized using the National Cancer Institute CTCAE v4.0|OS|RFI","https://ClinicalTrials.gov/show/NCT02488967"
356,"NCT00003829","Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Drug: cyclophosphamide|Drug: fludarabine phosphate","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","34","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-978151|CDR0000066985|NCI-2012-02296","November 1, 1999","August 1999","October 2008","December 5, 2016","December 2016","No Study Results Posted","null","May 2001","proportion of confirmed responses|overall survival|progression free survival|time to progression","https://ClinicalTrials.gov/show/NCT00003829"
357,"NCT01204437","Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast","Completed","No Results Available","Breast Cancer","Drug: Epirubicin, Cyclophosphamide|Drug: Cyclophosphamide, Methotrexate, 5 FU|Drug: Capecitabine, Nab-Paclitaxel","German Breast Group","All","65 Years and older   (Adult, Senior)","Phase 2|Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GBG 52|2008-003995-23","September 10, 2010","March 2009","January 2014","February 9, 2016","February 2016","No Study Results Posted","ICE-II","January 2014","To determine the compliance and safety of epirubicin plus cyclophosphamide or CMF (EC/CMF) and nab-paclitaxel in combination with capecitabine (PX).|To compare the disease-free survival (DFS) and distant disease free survival (DDFS) with epirubicin plus cyclophosphamide or CMF (EC/CMF) vs. nab-paclitaxel in combination with capecitabine (PX).|To compare the overall survival (OS) with epirubicin plus cyclophosphamide or CMF (EC/CMF) vs nab-paclitaxel in combination with capecitabine (PX).|To analyze the efficacy of treatments in subgroups according to clinical stratification factors.|To determine prognostic factors on tumor tissue collected from primary surgery and to correlate them with study treatment effect.|To compare the geriatric assessment scores (Charlson, VES-13, IADL, G8) at baseline and end of therapy","https://ClinicalTrials.gov/show/NCT01204437"
358,"NCT00003288","Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors","Completed","No Results Available","Unspecified Childhood Solid Tumor, Protocol Specific","Biological: filgrastim|Drug: cyclophosphamide|Drug: tirapazamine","National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 1","12","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01837|POG-9675|CDR0000066219","November 1, 1999","August 1998","null","February 4, 2013","April 2000","No Study Results Posted","null","June 2003","","https://ClinicalTrials.gov/show/NCT00003288"
359,"NCT01416038","Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer","Completed","No Results Available","Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer","Biological: DPX-Survivac|Drug: low dose cyclophosphamide (oral)","ImmunoVaccine Technologies, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 1","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ONC-DPX-Survivac-01","August 9, 2011","December 2011","May 2013","April 20, 2017","April 2017","No Study Results Posted","null","May 2013","Number of reported adverse events|Levels of cell mediated immunity targeting the survivin epitopes","https://ClinicalTrials.gov/show/NCT01416038"
360,"NCT01288131","Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment","Terminated","No Results Available","Anti-r-HuEpo Associated PRCA Subjects","Drug: Cyclosporine combine with mycophenolate mofetil|Drug: Cyclophosphamide + pred","Chulalongkorn University","All","18 Years to 60 Years   (Adult)","Phase 3","8","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2011/01_Medicine","February 1, 2011","January 2009","January 2012","January 27, 2014","January 2014","No Study Results Posted","null","January 2012","anti-r-HuEpo antibody|Absolute reticulocyte count","https://ClinicalTrials.gov/show/NCT01288131"
361,"NCT01907529","A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer","Not yet recruiting","No Results Available","Stage III Breast Cancer","Drug: docetaxel, epirubicin and cyclophosphamide|Drug: docetaxel, epirubicin and cyclophosphamide plus endostar","Hebei Medical University Fourth Hospital","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HBMUFH-101","July 22, 2013","August 2018","December 2021","August 29, 2016","August 2016","No Study Results Posted","TENDENCY","August 2020","Clinical/pathological response|PFS","https://ClinicalTrials.gov/show/NCT01907529"
362,"NCT01432600","Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide","Completed","Has Results","Myeloma","Drug: Pomalidomide|Drug: Dexamethasone|Drug: Cyclophosphamide","H. Lee Moffitt Cancer Center and Research Institute|Celgene","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-16705|PO-MM-PI-0039","September 9, 2011","November 2011","August 2016","April 18, 2017","February 2017","March 6, 2017","null","August 2016","Phase I - Maximum Tolerated Dose (MTD)|Phase II - Overall Response Rate (ORR)|Phase II - Median Progression Free Survival (PFS)|Phase II - Median Overall Survival (OS)|Phase II - Occurrence of Possibly Related Adverse Events (AEs)","https://ClinicalTrials.gov/show/NCT01432600"
363,"NCT01088724","Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)","Completed","No Results Available","Post-transplant Lymphoproliferative Disease (PTLD)|Non Burkitt","Drug: fludarabine, cyclophosphamide, doxorubicin, rituximab","A.O. Ospedale Papa Giovanni XXIII","All","6 Months to 18 Years   (Child, Adult)","Phase 4","4","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment","OORRPED 1","March 11, 2010","February 2002","March 2010","March 16, 2010","March 2010","No Study Results Posted","FCD-R","March 2010","Complete remission rate|graft rejection rate|Continuous complete remission rate","https://ClinicalTrials.gov/show/NCT01088724"
364,"NCT00499733","Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer","Unknown status","No Results Available","Cancer","Drug: cyclophosphamide|Other: laboratory biomarker analysis|Procedure: biopsy|Procedure: cryosurgery","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","23","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000554417|JHOC-J0685|NA_00003073","July 10, 2007","June 2007","null","February 24, 2011","July 2009","No Study Results Posted","null","July 2010","Safety, in terms of absences of severe adverse events (SAE) and unacceptable toxicity|Tumor response, according to RECIST criteria","https://ClinicalTrials.gov/show/NCT00499733"
365,"NCT00589238","Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery","Terminated","No Results Available","Breast Cancer","Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel","National Cancer Centre, Singapore","Female","18 Years and older   (Adult, Senior)","Phase 2","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000579522|SINGAPORE-NCC-0701","January 3, 2008","January 2008","null","June 18, 2013","June 2013","No Study Results Posted","null","July 2012","Pathological complete response rate|Clinical and pathological overall response rates|Overall and disease-free survival|Incidence of each toxicity item|Correlation between low BRCA1 expression (protein and mRNA), p53 mutation, positive CK5/6, positive CK14, basal like gene expression profile, and response to carboplatin based treatment","https://ClinicalTrials.gov/show/NCT00589238"
366,"NCT01689987","Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma","Active, not recruiting","No Results Available","Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma","Drug: Cyclophosphamide|Drug: Dexamethasone|Drug: Hydroxychloroquine|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sirolimus","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IRB00008296|NCI-2012-01754|CR00022154|MR00041096|P30CA069533","September 17, 2012","September 2012","null","May 23, 2017","May 2017","No Study Results Posted","null","April 2016","MTD of hydroxychloroquine defined as the highest dose at which 0/6 or 1/6 subjects experience a dose limiting toxicity (DLT) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0|Duration of overall response|Myeloma response (stringent complete response, complete response, very good partial response, partial response, stable disease, and progressive disease), as assessed by the International Myeloma Working Group|Progression-free survival|Time to response","https://ClinicalTrials.gov/show/NCT01689987"
367,"NCT00991133","A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)","Completed","No Results Available","Lymphoblastic Leukemia, Acute, Childhood","Drug: Clofarabine incorporated into a 5-drug regimen","Genzyme, a Sanofi Company|Sanofi","All","1 Year to 30 Years   (Child, Adult)","Phase 1","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLO08808","October 5, 2009","October 2009","April 2011","April 29, 2015","April 2015","No Study Results Posted","null","April 2011","The incidence of DLTs (Dose Limiting Toxicities) experienced with 1 cycle of this 5-drug regimen in this patient population (in all patients who receive any doses of study drugs)|Overall toxicity profile documented by incidence of AEs, SAEs, and/or DLTs|Efficacy as documented by complete remission (CR), time and duration of remission, event-free survival (EFS), 4-month EFS, disease-free survival (DFS), and overall survival","https://ClinicalTrials.gov/show/NCT00991133"
368,"NCT00004563","Scleroderma Lung Disease","Completed","Has Results","Lung Diseases|Pulmonary Fibrosis|Systemic Scleroderma|Scleroderma, Systemic","Drug: Cyclophosphamide|Drug: Placebo","The University of Texas Health Science Center, Houston|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Senior)","Phase 3","158","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Prevention","220|U01HL060839","February 9, 2000","August 1999","May 2013","March 5, 2015","March 2015","February 19, 2015","SLS","May 2013","Forced Vital Capacity|Total Lung Capacity|DLCO","https://ClinicalTrials.gov/show/NCT00004563"
369,"NCT01010217","Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide","Active, not recruiting","No Results Available","Blood Stem Cell Transplant Failure|Leukemia|Hematologic Malignancies","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Melphalan|Drug: Mesna|Drug: Rituximab|Procedure: Stem Cell Transplantation|Drug: Thiotepa|Drug: Tacrolimus|Drug: Mycofenolate mofetil|Drug: G-CSF","M.D. Anderson Cancer Center","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","177","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-0266|NCI-2011-03144","November 6, 2009","November 2009","null","December 14, 2016","December 2016","No Study Results Posted","null","November 2018","100-Day Non-relapse Mortality (NRM)","https://ClinicalTrials.gov/show/NCT01010217"
370,"NCT02315716","Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Multiple Myeloma","Recruiting","No Results Available","Multiple Myeloma","Procedure: Autologous Stem Cell Transplant (ASCT)|Drug: Consolidation with 4 cycles of CarCyDex","University College, London|Amgen","All","18 Years and older   (Adult, Senior)","Phase 2","280","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UCL/12/0500","December 3, 2014","May 2015","May 2026","November 7, 2016","November 2016","No Study Results Posted","Cardamon","May 2018","Response rate|PFS|Toxicity|Disease response rate|Overall survival|MRD conversion following treatment|MRD conversion following maintenance","https://ClinicalTrials.gov/show/NCT02315716"
371,"NCT00448019","FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)","Completed","Has Results","Chronic Lymphocytic Leukemia","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab|Drug: Bevacizumab","M.D. Anderson Cancer Center|Genentech, Inc.","All","Child, Adult, Senior","Phase 2","64","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MDACC-2005-0992|NCI-2010-00591","March 13, 2007","February 2007","October 2014","October 5, 2015","October 2015","July 13, 2015","null","October 2014","Progression Free Survival (PFS) Rate|Number of Participants With Complete or Partial Response to Fludarabine, Cyclophosphamide, Rituximab, and Bevacizumab Therapy in Previously Treated Chronic Lymphocytic Leukemia (CLL)|Overall Response Rate (ORR) to Fludarabine, Cyclophosphamide, Rituximab, and Bevacizumab Therapy in Previously Treated CLL","https://ClinicalTrials.gov/show/NCT00448019"
372,"NCT00041119","Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer","Completed","Has Results","Breast Cancer","Drug: AC regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","3871","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: No masking|Primary Purpose: Treatment","CALGB-40101|CDR0000069444|NCI-2009-00474|U10CA180821","July 8, 2002","May 2002","June 2014","April 12, 2017","April 2017","January 9, 2017","null","April 2012","Relapse Free Survival (RFS) 4 vs. 6 Cycles|Duration of Disease Free Survival (RFS)|Overall Survival (OS)|Adverse Events|Time to Distant Metastases|Local Control|Overall Survival (OS) for 4 vs. 6 Cycles","https://ClinicalTrials.gov/show/NCT00041119"
373,"NCT00438984","Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma","Completed","No Results Available","Recurrent Melanoma|Stage IV Melanoma","Drug: cyclophosphamide|Biological: therapeutic autologous lymphocytes|Biological: aldesleukin|Other: immunohistochemistry staining method|Procedure: biopsy|Other: laboratory biomarker analysis|Other: immunologic technique|Genetic: polymerase chain reaction","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium|National Cancer Institute (NCI)|Fred Hutchinson Cancer Research Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","11","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2140.00|NCI-2010-01280|R21CA128283","February 20, 2007","December 2006","February 2012","March 14, 2012","March 2012","No Study Results Posted","null","January 2011","The identification of a CY/IL-2 regimen that is considered to be safe|The identification of a CY/IL-2 regimen (among those considered safe) which yields the greatest effect on the duration of in vivo persistence of adoptively transferred CTL clones","https://ClinicalTrials.gov/show/NCT00438984"
374,"NCT00545714","A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)","Completed","No Results Available","Lymphocytic Leukemia, Chronic","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Rituximab","Hoffmann-La Roche","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","90","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML21135","October 16, 2007","November 2007","June 2016","November 1, 2016","November 2016","No Study Results Posted","null","June 2016","Percentage of Participants With Complete Response (CR) Based on Protocol Specified Criteria|Percentage of Participants With CR or PR With Negative Minimal Residual Disease (MRD) as Assessed by Multiparameter Flow Cytometry|Percentage of Participants With Genetic Abnormality by Abnormality|Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With CR and Incomplete Bone Marrow Recovery (CRi) as Assessed Based on Protocol Specified Criteria|Overall Survival|Progression-free Survival (PFS) as Assessed Based on Protocol Specified Criteria|Treatment-free Survival|Duration of Response as Assessed Based on Protocol Specified Criteria|Percentage of Participants With Cluster of Differentiation (CD)-38 Cells Greater Than [>] or Less Than [<] 30|Percentage of Participants With Positive or Negative ZAP-70|Percentage of Participants With IgH Rearrangement","https://ClinicalTrials.gov/show/NCT00545714"
375,"NCT00016406","S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: cyclophosphamide|Drug: doxorubicin|Drug: paclitaxel|Procedure: surgery","Southwest Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","399","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000068630|S0012|U10CA032102","May 6, 2001","May 2001","February 2012","January 23, 2013","January 2013","No Study Results Posted","null","September 2006","Comparison of microscopic pathologic response rates|Toxicity|Comparison of delivered dose intensity|Correlation of microscopic pathologic complete response with clinical complete response at the primary tumor site","https://ClinicalTrials.gov/show/NCT00016406"
376,"NCT00379015","Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: trastuzumab|Drug: cyclophosphamide|Drug: docetaxel|Drug: epirubicin hydrochloride|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Translational Research Informatics Center, Kobe, Hyogo, Japan","Female","20 Years to 65 Years   (Adult)","Phase 2","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000496448|TUSM-BRI-BC04-01","September 19, 2006","January 2006","March 2016","September 27, 2016","September 2016","No Study Results Posted","null","March 2016","Pathological complete response|Clinical response|Pathological response of axillary lymph nodes|Recurrence-free survival|Overall survival|Adverse event","https://ClinicalTrials.gov/show/NCT00379015"
377,"NCT02388594","A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients","Recruiting","No Results Available","Human Immunodeficiency Virus (HIV)","Drug: ZFN Modified CD4+ T Cells|Drug: Cyclophosphamide","University of Pennsylvania|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Senior)","Phase 1","15","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SB-728mR|U01AI104400","February 24, 2015","February 2015","December 2018","May 1, 2017","May 2017","No Study Results Posted","null","December 2017","Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT02388594"
378,"NCT00357500","Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer","Completed","Has Results","Central Nervous System Tumor, Pediatric|Leukemia|Lymphoma|Neuroblastoma|Sarcoma|Unspecified Childhood Solid Tumor, Protocol Specific","Drug: celecoxib|Drug: cyclophosphamide|Drug: etoposide|Drug: fenofibrate|Drug: thalidomide","Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Boston Children’s Hospital","All","up to 21 Years   (Child, Adult)","Phase 2","101","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04-343|P30CA006516|CDR0000487628","July 26, 2006","January 2005","December 2013","September 19, 2014","September 2014","December 13, 2012","null","February 2013","Therapy Completion Rate|27-Week Progression-Free Survival|27-Week Overall Survival|Best Response","https://ClinicalTrials.gov/show/NCT00357500"
379,"NCT00553306","Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma","Completed","No Results Available","Recurrent Melanoma|Stage IV Melanoma","Biological: therapeutic autologous lymphocytes|Biological: aldesleukin|Drug: cyclophosphamide|Procedure: biopsy|Other: immunohistochemistry staining method|Other: flow cytometry|Genetic: polymerase chain reaction","Fred Hutchinson Cancer Research Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2179.00|NCI-2010-01281","November 2, 2007","September 2007","March 2012","February 13, 2017","February 2017","No Study Results Posted","null","August 2010","Safety and toxicity as assessed by NCI CTC version 3.0|Antitumor effects of CD4+ and CD8+ antigen-specific T-cells|Duration of in vivo persistence of adoptively transferred CD8+ antigen-specific T cell clones in the presence or absence of transferred CD4+ T cells|In vivo antitumor efficacy of the infused autologous antigen-specific CD4+ T cells","https://ClinicalTrials.gov/show/NCT00553306"
380,"NCT00190671","A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients","Completed","Has Results","Breast Cancer","Drug: pemetrexed|Drug: cyclophosphamide|Drug: pemetrexed","Eli Lilly and Company","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","103","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","4029|H3E-MC-JMDV","September 12, 2005","June 2005","March 2008","November 17, 2009","November 2009","March 17, 2009","null","March 2008","Best Tumor Response|Time to Progressive Disease|Progression Free Survival|Pharmacokinetics - Maximum Observed Drug Concentration (Cmax)|Pharmacokinetics - Area Under the Curve (AUC)|Pharmacokinetics - Clearance (CL)|Pharmacokinetics - Volume of Distribution|Pharmacokinetics - Half-Life (t½)","https://ClinicalTrials.gov/show/NCT00190671"
381,"NCT03154749","TC (Docetaxel/Carboplatin) Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer","Recruiting","No Results Available","Triple-Negative Breast Cancer","Drug: TC (docetaxel/carboplatin) versus EC followed by T (epirubicin/cyclophosphamide followed by docetaxe)","Guangdong General Hospital","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","20170512","May 12, 2017","September 1, 2016","September 1, 2019","May 15, 2017","May 2017","No Study Results Posted","null","September 1, 2018","PCR","https://ClinicalTrials.gov/show/NCT03154749"
382,"NCT01339663","Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma","Completed","No Results Available","Recurrent Melanoma|Stage IV Melanoma","Drug: cyclophosphamide|Biological: aldesleukin|Biological: autologous tumor cell vaccine|Other: laboratory biomarker analysis|Other: immunologic technique|Other: immunohistochemistry staining method|Genetic: polymerase chain reaction|Biological: therapeutic autologous lymphocytes","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2481.00|NCI-2011-00383|K12CA076930","April 18, 2011","March 2012","null","April 17, 2014","April 2014","No Study Results Posted","null","December 2012","Treatment-related dose limiting toxicity (DLT) as defined by Grade 3 or greater unexpected toxicity by the NCI Common Toxicity Criteria (CTC) v4.0|In vivo persistence of adoptively transferred T cells|Clinical response","https://ClinicalTrials.gov/show/NCT01339663"
383,"NCT02248597","Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases","Recruiting","No Results Available","Graft Versus Host Disease|Hematopoietic/Lymphoid Cancer","Drug: fludarabine phosphate|Drug: busulfan|Drug: cyclophosphamide|Procedure: allogeneic hematopoietic stem cell transplantation|Drug: tacrolimus|Drug: mycophenolate mofetil","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CCCWFU 97214|NCI-2014-01898|P30CA012197","September 23, 2014","January 2015","January 2018","February 20, 2017","February 2017","No Study Results Posted","null","January 2018","12 month disease free survival probability|Rate of acute GvHD|Rate of chronic GvHD|Overall survival|Relapse (or death)|Relapse-free mortality","https://ClinicalTrials.gov/show/NCT02248597"
384,"NCT02412423","Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors","Recruiting","No Results Available","Hematopoietic Stem Cell Transplantation","Drug: post-transplantation cyclophosphamide","Peking University People's Hospital","All","Child, Adult, Senior","Phase 4","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","2015PHB016-01","April 5, 2015","March 2015","March 2017","September 26, 2016","September 2016","No Study Results Posted","null","August 2016","rate of acute GVHD|rate of non-relapse mortality|rate of relapse|probability of survival","https://ClinicalTrials.gov/show/NCT02412423"
385,"NCT00004908","Radiation Therapy and Cyclophosphamide Plus Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: cyclophosphamide|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Northwestern University|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU 87H5T|NU-87H5T|NCI-G00-1693","March 7, 2000","November 1999","June 2002","August 25, 2011","August 2011","No Study Results Posted","null","June 2002","","https://ClinicalTrials.gov/show/NCT00004908"
386,"NCT00343785","Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant","Completed","Has Results","Aplastic Anemia","Drug: cyclophosphamide|Biological: anti-thymocyte globulin|Drug: cyclosporine|Procedure: allogeneic bone marrow transplantation|Drug: methotrexate|Genetic: DNA analysis|Other: flow cytometry|Genetic: polymorphism analysis|Other: laboratory biomarker analysis","Fred Hutchinson Cancer Research Center|National Heart, Lung, and Blood Institute (NHLBI)","All","up to 65 Years   (Child, Adult)","Phase 2","21","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2054.00|NCI-2010-01781|P01HL036444","June 22, 2006","February 2006","August 2012","March 16, 2017","March 2017","January 26, 2017","null","May 2012","Incidence of Chronic GVHD|Number of Days to Neutrophil Recovery to >500/uL|Overall Survival","https://ClinicalTrials.gov/show/NCT00343785"
387,"NCT01857115","Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Cyclophosphamide|Drug: Dexamethasone","Stichting Hemato-Oncologie voor Volwassenen Nederland|Fondazione Neoplasie Sangue Onlus","All","65 Years to 99 Years   (Adult, Senior)","Phase 1|Phase 2","63","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IST-CAR-561","April 17, 2013","April 2013","April 2019","May 9, 2016","May 2016","No Study Results Posted","wCCyd","November 2013","Identification of Dose-limiting toxicity (DLT)|Partial Response (PR)|Response rate (RR)|Progression free-survival (PFS)|Time to progression (TTP)|Duration of response (DOR)|Overall survival (OS)|Time to next therapy (TTNT)|Responses|Response and survival|Maintenance","https://ClinicalTrials.gov/show/NCT01857115"
388,"NCT01547741","Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Paclitaxel","NSABP Foundation Inc|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","1871","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP-B-49|NCI-2012-00701","March 6, 2012","April 2012","May 2019","October 21, 2015","October 2015","No Study Results Posted","null","December 2017","Invasive disease-free survival (IDFS)|Disease-free survival (DFS-DCIS)|Overall survival (OS)|Recurrence-free interval (RFI)|Toxicity of each regimen|Molecular predictors of efficacy","https://ClinicalTrials.gov/show/NCT01547741"
389,"NCT01378533","The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC","Unknown status","No Results Available","Breast Cancer","Drug: epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF","Chinese Academy of Medical Sciences","Female","18 Years to 65 Years   (Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CH-BC-012","June 17, 2011","May 2011","June 2013","December 27, 2011","December 2011","No Study Results Posted","null","May 2013","3 years DFS|Toxicity as assessed by NCI CTCAE v3.0","https://ClinicalTrials.gov/show/NCT01378533"
390,"NCT00001626","Comparing Therapies for the Treatment of Severe Aplastic Anemia","Completed","No Results Available","Aplastic Anemia|Hematologic Disease","Drug: Antithymocyte globulin &amp; Cyclosporin A|Drug: Cyclophosphamide &amp; Cyclosporin A","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","15 Years and older   (Child, Adult, Senior)","Phase 3","33","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","970117|97-H-0117","November 3, 1999","May 2, 1997","March 3, 2008","May 12, 2017","October 11, 2016","No Study Results Posted","null","September 30, 2002","Compare the sustained response proportions among patients with SAA treated with immunosuppressive therapy with either ATG/CSA or high dose cyclophosphamide and CSA.|Overall and event-free survival rate.","https://ClinicalTrials.gov/show/NCT00001626"
391,"NCT01697293","Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer","Recruiting","No Results Available","Breast Adenocarcinoma|Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Procedure: Therapeutic Conventional Surgery|Drug: Triciribine Phosphate","Albert Einstein College of Medicine, Inc.|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","56","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-269|NCI-2013-01311|11-051|TCN-PM|PTX-200-BC-1501.1|PTX-200|007884|P30CA013330|R01CA098473","September 13, 2012","January 2012","January 2018","January 13, 2016","January 2016","No Study Results Posted","null","January 2017","Pathologic response (RCB score 0-1), assessed using the criteria of Chevallier (Phase II)|Recommended phase II dose of triciribine phosphate, based on the incidence of dose-limiting toxicity graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase I)|Clinical complete response and partial response, based on tumor measurements obtained by physical exam","https://ClinicalTrials.gov/show/NCT01697293"
392,"NCT00281931","Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia","Terminated","No Results Available","Prolymphocytic Leukemia","Biological: rituximab|Drug: cyclophosphamide|Drug: fludarabine phosphate","German CLL Study Group","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","21","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","PLL1|EU-20563","January 24, 2006","September 1999","October 2006","September 23, 2016","September 2016","No Study Results Posted","null","April 2006","Overall survival|Progression-free survival|Toxicity","https://ClinicalTrials.gov/show/NCT00281931"
393,"NCT00609167","Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma","Completed","Has Results","Multiple Myeloma and Plasma Cell Neoplasm","Drug: bortezomib|Drug: cyclophosphamide|Drug: dexamethasone","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","63","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000583225|P30CA015083|MC0686|06-002613|NCI-2010-02147","January 31, 2008","December 2006","November 2010","May 13, 2011","May 2011","November 5, 2010","null","January 2009","Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of Treatment|Progression Free Survival (PFS)|Overall Survival (OS)|Number of Participants Who Responded to Treatment (Complete Response,CR; Near Complete Response, nCR; Very Good Partial Response, VGPR; or Partial Response, PR) After 4 Cycles|Duration of Response|Number of Participants Who Responded to Treatment (CR, nCR, VGPR or PR) After 8 Cycles|Number of Participants Who Responded to Treatment (CR, nCR, VGPR or PR) After 12 Cycles|Number of Participants With Severe Adverse Events|Participants Who Successfully Completed Collection of Peripheral Blood Stem Cells for Transplant","https://ClinicalTrials.gov/show/NCT00609167"
394,"NCT00410163","Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients","Completed","Has Results","Leukaemia, Lymphocytic, Chronic","Drug: Ofatumumab 500mg|Drug: Ofatumumab 1000mg|Drug: Fludarabine|Drug: Cyclophosphamide","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","111774|Hx-CD20-407|The BIFROST trial","December 11, 2006","January 2007","May 2013","December 19, 2013","November 2013","July 28, 2011","BIFROST","March 2009","Number of Participants (Par.) With Complete Remission (CR), Measured From Start of Treatment Until 3 Months After Last Infusion|Number of Participants (Par.) Who Were Classified as Responders and Non-responders|Duration of Response|Progression-Free Survival|Time to Next Anti-chronic Lymphocytic Leukemia (CLL) Therapy or Death|Median Percent Change in Tumor Size From Baseline (Visit 2, Wk 0) at Visits 9, 21, 25, 29, 33, 34, 35, and 37|Median Percent Change in CD5+CD19+ and CD5+CD20+ Cells in Peripheral Blood From Onset of Course 3 Throughout Follow-up (FU) Compared to Screening|Number of Participants Who Experienced Any Adverse Event From First Treatment (Visit 2) to Visit 43 (Month 60)|Number of Participants With Positive Human Anti-human Anti Bodies (HAHA) at Visits 1, 21, 35, and 39|Number of Participants Who Reported Myelosuppression (Anemia, Leukopenia, Neutropenia, and Thrombocytopenia)|Percent Change From Screening (Visit 1) in Complement (CH50) Levels at Visit 9 (Week 4)|Number of Participants Classified as Responders Having CR Who Tested Negative for Minimal Residual Disease (MRD)|Ctrough and Cmax at the First Infusion (Visit 2, Week 0) and Sixth Infusion (Visit 29, Week 20)|AUC(0-inf) and AUC(0-672) After the First Infusion (Visit 2, Week 0) and Sixth Infusion (Visit 29, Week 20)|t1/2 After the First Infusion (Visit 2, Week 0) and Sixth Infusion (Visit 29, Week 20)|CL After the First Infusion (Visit 2, Week 0) and Sixth Infusion (Visit 29, Week 20)|Vss After the First Infusion (Visit 2, Week 0) and Sixth Infusion (Visit 29, Week 20)|Number of Participants With Progression or Death","https://ClinicalTrials.gov/show/NCT00410163"
395,"NCT00312208","Docetaxel in Breast Cancer","Completed","Has Results","Breast Cancer","Drug: docetaxel, doxorubicin, cyclophosphamide|Drug: Docetaxel,doxorubicin, cyclophosphamide","Sanofi|Cancer International Research Group (CIRG)","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","3299","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TAX_GMA_301|BCIRG 005","April 5, 2006","November 2001","October 2013","December 4, 2013","December 2013","October 29, 2009","null","October 2008","Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival)|Death From Any Cause (Overall Survival)","https://ClinicalTrials.gov/show/NCT00312208"
396,"NCT02583828","Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients","Recruiting","No Results Available","Breast Neoplasms|Neoplasm Metastasis","Drug: Cyclophosphamide 50mg|Drug: Letrozole 2.5 mg","Capital Medical University","Female","65 Years and older   (Adult, Senior)","","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","LET+CTX","October 13, 2015","June 2015","December 2019","February 3, 2017","February 2017","No Study Results Posted","null","September 2018","Progression free survival(PFS) of the subjects|Safety of each treatment regimen for the subjects|Evaluate the quality of life for the subjects in the each treatment regimen|Compare disease control rate for the subjects","https://ClinicalTrials.gov/show/NCT02583828"
397,"NCT00062140","Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer","Completed","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Drug: cyclophosphamide|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 1","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","1797.00|FHCRC-1797.00|CDR0000304522","June 5, 2003","April 2003","July 2004","September 20, 2010","September 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00062140"
398,"NCT01131195","Metronomic Therapy in Metastatic Breast Cancer.","Active, not recruiting","No Results Available","Breast Cancer","Biological: bevacizumab, Paclitaxel|Biological: Bevacizumab, Cyclophosphamide, Capecitabine","Swiss Group for Clinical Cancer Research","Female","18 Years and older   (Adult, Senior)","Phase 3","142","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SAKK 24/09|SWS-SAKK-24-09|EU-21025|CDR0000669252","May 25, 2010","July 19, 2010","June 30, 2019","May 2, 2017","May 2017","No Study Results Posted","null","December 14, 2012","Incidence of grade 3-5 adverse events|Objective response (OR)|Disease control (DC)|Progression-free survival (PFS)|Overall survival (OS)|Time to specific grade 3-5 adverse events","https://ClinicalTrials.gov/show/NCT01131195"
399,"NCT00073918","Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","Completed","Has Results","Anaplastic Large Cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia","Drug: cyclophosphamide|Drug: etoposide|Radiation: iodine I 131 tositumomab|Procedure: quality-of-life assessment|Procedure: peripheral blood stem cell transplantation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 2","111","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1368.00|NCI-2009-01469|P01CA044991","December 10, 2003","February 1999","null","December 2, 2016","December 2016","December 2, 2016","null","July 2014","Progression-free Survival|5 Year Overall Survival|Response Rate|Toxicity as Assessed by Common Terminology Criteria (CTC) v 2.0","https://ClinicalTrials.gov/show/NCT00073918"
400,"NCT02502864","Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide","Recruiting","No Results Available","Breast Cancer","Drug: Standard of Care: Docetaxel|Drug: Standard of Care: Cyclophosphamide|Other: Function Assessment of Cancer Therapy (FACT) Surveys","H. Lee Moffitt Cancer Center and Research Institute|Saladax Biomedical, Inc.","Female","65 Years and older   (Adult, Senior)","Phase 4","52","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-18118","July 15, 2015","January 26, 2016","April 2018","April 27, 2017","April 2017","No Study Results Posted","null","January 2018","Rate of Achieving Targeted Area Under the Curve (AUC)|Incidence of Grade 3 and 4 Neutropenia and Febrile Neutropenia|Association Between Scores - Chemotherapy Risk Assessment Scale for High-Age Patients|Association Between Scores - Instrumental Activities of Daily Living|Association Between Scores - Cumulative Illness Rating Scale for Geriatrics","https://ClinicalTrials.gov/show/NCT02502864"
401,"NCT02629120","High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease","Recruiting","No Results Available","X-Linked Chronic Granulomatious Disease","Drug: Campath|Drug: Busulfan|Other: allogeneic peripheral blood allograft infusion|Drug: cyclophosphamide","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","4 Years to 65 Years   (Child, Adult)","Early Phase 1","50","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","160032|16-I-0032","December 10, 2015","December 3, 2015","December 1, 2030","May 20, 2017","May 11, 2017","No Study Results Posted","null","December 1, 2025","Reduced incidence of graft failure or rejection (Engraftment as defined by >20% engraftment by oxidase positive neutrophils in at least 95% of participants by Day 100)|Same or reduced rate of Graft versus Host Disease of <10%|Establish stable mixed chimerism.|Improve rapidity of immune reconstitution.","https://ClinicalTrials.gov/show/NCT02629120"
402,"NCT00074139","Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer","Withdrawn","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","18 Years to 69 Years   (Adult, Senior)","Phase 1","0","Other|NIH","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CWRU040314|CDR0000343609|CWRU-AVEN-1103|AVENTIS-XRP6976D/1001","December 10, 2003","September 2003","December 2003","March 4, 2014","March 2014","No Study Results Posted","null","December 2003","","https://ClinicalTrials.gov/show/NCT00074139"
403,"NCT02914470","Carboplatin-cyclophosphamide Combined With Atezolizumab","Recruiting","No Results Available","Breast Cancer|Cervix Cancer|Ovarian Cancer|Endometrial Cancer","Drug: carbplatin, cyclophophamide, atezolizumab","The Netherlands Cancer Institute|Roche Pharma AG","All","18 Years and older   (Adult, Senior)","Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","N16LOG","September 6, 2016","January 2017","September 2017","April 13, 2017","April 2017","No Study Results Posted","PROLOG","July 2017","Toxicity; Incidence of toxicity, graded according to National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.03|Overall Response Rate","https://ClinicalTrials.gov/show/NCT02914470"
404,"NCT00075582","Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma","Active, not recruiting","Has Results","Adult Rhabdomyosarcoma|Embryonal Childhood Rhabdomyosarcoma|Embryonal-botryoid Childhood Rhabdomyosarcoma|Previously Untreated Childhood Rhabdomyosarcoma","Procedure: conventional surgery|Drug: dactinomycin|Drug: cyclophosphamide|Drug: vincristine sulfate|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 49 Years   (Child, Adult)","Phase 3","390","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ARST0331|NCI-2009-00425|COG-ARST0331|CDR0000347078|U10CA098543","January 9, 2004","September 2004","null","November 2, 2016","October 2016","December 16, 2013","null","September 2012","Estimated Percentage of Patients Failure Free at 5 Years (95% Confidence Interval)|Estimated Percentage of Patients With Stage 1, Clinical Group IIB or C (Node Positive) or Stage 2 Group I or Stage 2 Group II Disease Treated With Regimen 1 Failure-free at 5 Years|Estimated Percentage of Patients With Low-risk Rhabdomyosarcoma Treated With Regimen 2 Therapy Failure Free at 5 Years (95% Confidence Interval).|Rate of Local Failure for Patients Who Receive Reduced Doses of Radiation Therapy|Rate of Second-look Surgery and the Proportion of Patients Who Are Tumor-free or With Microscopic Tumor Only Following Second-look Surgeries|Rate of Local Failure for Patients With Clinical Group III Disease When the Radiotherapy Dose is Reduced After Second-look Surgical Resection.","https://ClinicalTrials.gov/show/NCT00075582"
405,"NCT03143049","Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma","Not yet recruiting","No Results Available","Relapse Multiple Myeloma","Drug: PCD|Drug: PD","National University Hospital, Singapore|Celgene|International Myeloma Foundation (IMF)","All","21 Years to 99 Years   (Adult, Senior)","Phase 3","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","AMN003","April 13, 2017","June 1, 2017","June 1, 2022","May 3, 2017","March 2017","No Study Results Posted","null","June 1, 2018","Progression free survival (PFS)|Overall response rate (ORR)|Overall survival (OS)|Duration of response (DOR)|Number of Participants affected by Adverse Events","https://ClinicalTrials.gov/show/NCT03143049"
406,"NCT01526512","Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: metroCX","Fudan University","Female","18 Years to 80 Years   (Adult, Senior)","Phase 2","72","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","metroCX","January 29, 2012","December 2011","July 2013","February 5, 2012","February 2012","No Study Results Posted","null","July 2013","PFS|Biomarker|Efficacy|Safety","https://ClinicalTrials.gov/show/NCT01526512"
407,"NCT01143545","Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas","Completed","No Results Available","Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma","Biological: Allogeneic Tumor Cell Vaccine (K562)|Drug: Celecoxib|Drug: cyclophosphamide","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1","10","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","100138|10-C-0138","June 11, 2010","May 26, 2010","March 19, 2015","May 12, 2017","January 25, 2017","No Study Results Posted","null","February 9, 2015","Tabulation of toxicity type and grade|To ascertain if K526-GM vaccines induce immunity to CT antigens commonly expressed in thoracic malignancies.|To determine if metronomic oral CP and celecoxib reduce the number, percentage and function of CD4+ CD25+ Fox P3+ regulatory T cells (T reg) in peripheral blood of thoracic oncology patients.","https://ClinicalTrials.gov/show/NCT01143545"
408,"NCT00987480","Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine","Active, not recruiting","No Results Available","Aplastic Anemia|Leukemia|Myelodysplastic Syndrome","Drug: Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.|Device: CliniMACS device","Memorial Sloan Kettering Cancer Center|Boston Children’s Hospital|Children's Hospital Medical Center, Cincinnati|Children's Hospital and Health System Foundation, Wisconsin|Rockefeller University|Fred Hutchinson Cancer Research Center","All","Child, Adult, Senior","Phase 2","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08-031","September 30, 2009","September 2009","September 2017","August 15, 2016","August 2016","No Study Results Posted","null","September 2017","The incidence and quality of engraftment and hematopoietic reconstitution|The incidence of early transplant related mortality|The incidence and severity of acute GvHD and chronic GVHD.|The incidence of overall survival and disease-free survival over time","https://ClinicalTrials.gov/show/NCT00987480"
409,"NCT00075634","Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma","Completed","No Results Available","Recurrent Neuroblastoma|Unspecified Childhood Solid Tumor, Protocol Specific","Drug: decitabine|Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Biological: filgrastim|Biological: pegfilgrastim|Other: laboratory biomarker analysis|Other: pharmacological study","National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 1","21","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01807|CDR0000347393|COG-ADVL0215|ADVL0215|U01CA097452","January 9, 2004","December 2003","null","September 27, 2013","September 2013","No Study Results Posted","null","September 2007","MTD of decitabine, based on incidence of DLT graded according to NCI CTCAE version 3.0 (Part A)|Caspase-8 expression in bone marrow or tumor biopsy samples (Part B)|Objective response rate|Percent of apoptotic cells as assessed by a TUNEL assay","https://ClinicalTrials.gov/show/NCT00075634"
410,"NCT00819806","CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors","Completed","No Results Available","NY-ESO-1-expressing Tumors","Biological: Vaccine only|Biological: Vaccine + cyclophosphamide|Biological: Vaccine only|Biological: Vaccine + cyclophosphamide|Biological: Vaccine only|Biological: Vaccine + cyclophosphamide","Hassane M. Zarour, MD|National Cancer Institute (NCI)|University of Pittsburgh","All","18 Years and older   (Adult, Senior)","Phase 1","21","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","05-140|1R01CA112198-01","January 7, 2009","January 2009","January 2015","January 13, 2016","January 2016","No Study Results Posted","null","May 2012","Toxicity profile of the 6 regimens|Detect and quantitate immune responses|Evaluate tumor response","https://ClinicalTrials.gov/show/NCT00819806"
411,"NCT00118274","Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma","Unknown status","No Results Available","Melanoma (Skin)","Biological: incomplete Freund's adjuvant|Biological: melanoma helper peptide vaccine|Biological: multi-epitope melanoma peptide vaccine|Biological: tetanus toxoid helper peptide|Drug: cyclophosphamide","University of Virginia|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","173","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000430929|UVACC-HIC-11491|UVACC-34104|UVACC-MEL-44|UVACC-GCRC-CLS013|UVACC-HITC-02620|MDA-2005-0070","July 8, 2005","March 2005","null","February 6, 2009","November 2008","No Study Results Posted","null","February 2010","Safety if less than 33% of patients experience a dose-limiting toxicity up to week 52|Immunogenicity by Elispot assay up to week 52","https://ClinicalTrials.gov/show/NCT00118274"
412,"NCT00413959","VELCADE®,Rituximab,Cyclophosphamide and Decadron (VRCD Regimen)","Terminated","Has Results","Lymphoma, Non-Hodgkin|Lymphoma, B-Cell","Drug: VELCADE®|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Decadron","Oncology Specialists, S.C.|Millennium Pharmaceuticals, Inc.","All","18 Years to 90 Years   (Adult, Senior)","Phase 2","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0606","December 19, 2006","August 2006","January 2011","October 17, 2013","October 2013","May 7, 2013","VRCD","January 2011","Overall Response Rate Using This Regimen in Patients With Low-grade B-Cell Non-Hodgkin's Lymphoma.|Overall Survival","https://ClinicalTrials.gov/show/NCT00413959"
413,"NCT00193115","Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Docetaxel|Drug: Doxorubicin|Drug: Cyclophosphamide","SCRI Development Innovations, LLC|Aventis Pharmaceuticals","Female","18 Years and older   (Adult, Senior)","Phase 2","32","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI BRE 69|11251","September 12, 2005","March 2004","January 2009","August 3, 2010","January 2009","No Study Results Posted","null","June 2005","Treatment-related toxicities|Overall response rate|Overall survival","https://ClinicalTrials.gov/show/NCT00193115"
414,"NCT02789332","Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency","Active, not recruiting","No Results Available","Breast Cancer|Triple Negative Breast Neoplasms|HRpos Breast Neoplasms|BRCA 1 /2 and / or HRD","Drug: PwO|Drug: PwCb|Drug: EC|Procedure: Surgery after neoadjuvant Therapy|Other: Stratification","German Breast Group|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","102","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GBG90","May 23, 2016","September 2016","November 2018","September 14, 2016","September 2016","No Study Results Posted","GeparOla","November 2018","response by pCR =ypT0/is ypN0|response by pCR =ypT0/is ypN0 in stratified subgroups|response by pCR according to other definitions|response by pCR in HRD high versus tBRCA|Response rate by sono and/or mammo|Breast Conservation rate|Toxicity of treatment","https://ClinicalTrials.gov/show/NCT02789332"
415,"NCT00682305","Allogeneic Stem Cell Transplantation (SCT) With Treosulfan, VP-16 and Cyclophosphamid for Patients With Acute Lymphoblastic Leukemia (ALL)","Completed","No Results Available","Acute Lymphoblastic Leukemia","Procedure: Hematopoietic stem cell transplantation","Universitätsklinikum Hamburg-Eppendorf","All","18 Years to 65 Years   (Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TreoALL","May 16, 2008","March 2007","August 2013","May 12, 2015","May 2015","No Study Results Posted","null","January 2013","Evaluation of engraftment at day +28 and non-relapse mortality at day +100 and at 1 year after SCT|*Incidence of aGvHD on day +100/ cGvHD at 1 and 2 yrs after SCT/ relapse at 2 yrs after SCT *Toxicity *Disease-free survival at 2 yrs after SCT *overall survival at 2 yrs. after SCT","https://ClinicalTrials.gov/show/NCT00682305"
416,"NCT01090128","Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer","Terminated","No Results Available","Stages II-III Breast Cancer","Drug: Nanoparticle Albumin Bound Paclitaxel|Drug: doxorubicin|Drug: cyclophosphamide","University of Utah|Celgene Corporation","Female","18 Years and older   (Adult, Senior)","Phase 1","27","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","HCI53989","March 17, 2010","September 2008","March 24, 2017","March 29, 2017","March 2017","No Study Results Posted","NAC","March 24, 2017","Type, incidence, severity, timing, seriousness and relatedness of adverse events and laboratory abnormalities|Pathologic complete response|Overall clinical response rate (OcRR)","https://ClinicalTrials.gov/show/NCT01090128"
417,"NCT01106235","Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma","Terminated","No Results Available","Stage IV Melanoma","Biological: therapeutic autologous lymphocytes|Biological: aldesleukin|Drug: cyclophosphamide|Procedure: biopsy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","12","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2390.00|NCI-2010-00146","April 8, 2010","April 2010","null","December 20, 2011","December 2011","No Study Results Posted","null","November 2011","Safety and toxicity as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 3.0|Functional and numeric in vivo persistence of adoptively transferred IL-21 modulated CTL and factors contributing to immunopotentiation in patients receiving IL-21 modulated CTL following cyclophosphamide conditioning|In vivo persistence and anti-tumor effect of the infused IL-21 modulated CTL","https://ClinicalTrials.gov/show/NCT01106235"
418,"NCT00546156","Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Paclitaxel|Drug: Bevacizumab","Ian E. Krop, MD, PhD|Genentech, Inc.|Massachusetts General Hospital|Brigham and Women's Hospital|New Hampshire Oncology-Hematology PA|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 2","104","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-130","October 17, 2007","October 2007","December 2012","March 22, 2013","March 2013","March 22, 2013","null","October 2011","Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population.|Decrease in Interstitial Fluid Pressure.","https://ClinicalTrials.gov/show/NCT00546156"
419,"NCT00711828","Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma","Active, not recruiting","Has Results","Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia","Drug: Bortezomib|Biological: Rituximab|Drug: Cyclophosphamide|Drug: Dexamethasone|Other: Questionnaire Administration|Other: Quality-of-Life Assessment","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","21","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC0883|NCI-2011-02991|P30CA015083","July 8, 2008","August 2008","null","April 13, 2016","March 2016","January 16, 2015","null","November 2013","Proportion of Responses (Complete Response or Partial Response)|Overall Survival|Progression-free Survival|Duration of Response|Time to Treatment Failure|Adverse Events","https://ClinicalTrials.gov/show/NCT00711828"
420,"NCT00908232","Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD","Completed","Has Results","Multiple Myeloma","Drug: Cyclophosphamide|Drug: Bortezomib|Drug: Dexamethasone|Drug: Lenalidomide","Janssen-Cilag International NV","All","18 Years and older   (Adult, Senior)","Phase 2","163","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CR013165|26866138MMY2045|2007-001462-33","May 21, 2009","May 2008","August 2011","January 14, 2015","January 2015","May 4, 2012","SEQUENTIAL","August 2011","Overall Best Confirmed Response|Median Time to First Confirmed Response|Progression Free Survival|Time to Progression|One Year Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00908232"
421,"NCT00203502","Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Bevacizumab|Drug: Cyclophosphamide|Drug: Docetaxel","University of Arkansas|Genentech, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UARK 2004-59","September 12, 2005","September 2005","February 2015","May 2, 2016","May 2016","October 21, 2015","null","February 2015","Percentage of Participants With Pathological Complete Response.|Number of Participants With Clinical Complete Response in Breast and the Axillary Lymph Nodes After the Completion of Chemotherapy and Bevacizumab.|Percentage of Participants With Grade 3 or 4 Adverse Events|To Measure the Change in Left Ventricular Ejection Fraction (LVEF) From Baseline|Percentage of Participants With Pathologic Complete Response (pCR) Among Those With Triple Negative Breast Cancer","https://ClinicalTrials.gov/show/NCT00203502"
422,"NCT01263704","A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia","Completed","No Results Available","Lymphocytic Leukemia, Chronic","Drug: cyclophosphamide|Drug: fludarabine|Drug: rituximab [MabThera/Rituxan]","Hoffmann-La Roche","All","65 Years and older   (Adult, Senior)","Phase 2","42","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ML25464","December 17, 2010","July 17, 2011","April 3, 2017","April 19, 2017","April 2017","No Study Results Posted","null","April 3, 2017","Overall Response Rate (according to National Cancer Institute - Working Group [NCI-WG] guidelines)|Safety: Incidence of adverse events (especially neutropenic fever, infection rate, number of hospitalization days, thrombocytopenia >/= grade 3, neutropenia >/= grade 3))|Progression-free survival (according to NCI-WG guidelines)|Quality of life: Functional Assessment of Chronic Illness Therapy (FACIT) questionnaire","https://ClinicalTrials.gov/show/NCT01263704"
423,"NCT00002953","Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: paclitaxel","Medical Research Council|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","704","Other","Interventional","Primary Purpose: Treatment","CDR0000065426|MRC-UKCCCR-AB01|EU-97002","November 1, 1999","December 1996","November 2005","December 3, 2013","December 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002953"
424,"NCT03023046","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","Recruiting","No Results Available","Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|Philadelphia Chromosome Positive","Drug: Cyclophosphamide|Drug: Dasatinib|Drug: Doxorubicin|Drug: Etoposide|Drug: Imatinib Mesylate|Other: Laboratory Biomarker Analysis|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","28","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","9770|NCI-2016-02050|P30CA015704","January 10, 2017","February 23, 2017","December 1, 2022","March 30, 2017","March 2017","No Study Results Posted","null","December 1, 2019","Complete minimal residual disease (MRD) response rate|Incidence of adverse events as assessed by Common Terminology Criteria for Adverse Events|Next-Generation Gene Sequencing|Overall survival (OS)|Presence or absence of MRD assessed by multiparameter flow cytometry (MFC) or high-throughput sequencing (HTS)|Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT03023046"
425,"NCT01477021","Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery","Completed","No Results Available","Adult Liposarcoma|Adult Synovial Sarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma","Drug: cyclophosphamide|Biological: NY-ESO-1-specific T cells|Other: laboratory biomarker analysis","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","6","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2537.00|NCI-2011-03549|P30CA015704","November 17, 2011","January 2012","null","December 9, 2014","December 2014","No Study Results Posted","null","September 2013","Incidence of treatment-related toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Antitumor efficacy as determined by CT scan","https://ClinicalTrials.gov/show/NCT01477021"
426,"NCT00005984","Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia","Terminated","No Results Available","Leukemia","Drug: cyclophosphamide|Drug: filgrastim|Drug: recombinant interferon alfa|Procedure: peripheral blood stem cell transplantation|Procedure: radiation therapy","Masonic Cancer Center, University of Minnesota","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","22","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1996LS183|UMN-MT-1996-11","July 5, 2000","August 2000","September 2005","May 25, 2011","May 2011","No Study Results Posted","null","September 2005","Time to hemopoietic recovery after transplantation|Detection of the Philadelphia chromosome or the BCR/ABL gene abnormality in post-transplantation marrow samples|Time to initial hospital discharge|Peritransplantation toxicity|Quality of life at various time points|Cause of death","https://ClinicalTrials.gov/show/NCT00005984"
427,"NCT00258960","Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Liposomal Doxorubicin|Drug: Cyclophosphamide|Drug: Trastuzumab","Spanish Breast Cancer Research Group|Schering-Plough","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","49","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEICAM/2004-05","November 24, 2005","February 2006","July 2008","September 25, 2009","September 2009","No Study Results Posted","null","null","To evaluate objective response rate|To evaluate the profile of toxicity|To evaluate time to progression|To evaluate overall survival|To determinate duration of response|To determinate time to failure of treatment","https://ClinicalTrials.gov/show/NCT00258960"
428,"NCT02214381","A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response","Recruiting","No Results Available","Early Primary Breast Cancer in the Elderly.","Drug: Myocet|Drug: Cyclophosphamide|Drug: Paclitaxel","West German Study Group|TEVA","Female","70 Years and older   (Senior)","Phase 2","300","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","WSG-AM06 / ADAPT Elderly","July 31, 2014","July 2014","July 2021","June 18, 2015","June 2015","No Study Results Posted","null","July 2016","Comparison of pCR rates in patients with early response and no severe toxicity (Group 1) and in other patients (Group 2).|Incidence of febrile neutropenia (FN) after 1 x MC in patients with primary prophylaxis (PP) vs. others.|Toxicity in the 4 x MC versus 2 x MC followed 6 x Pac arm as measured by adverse events.|Number of pCR in non-responders to MC.|G-CSF use in terms of primary or secondary prophylaxis per patient including occurence febrile neutropenia per patient per cycle","https://ClinicalTrials.gov/show/NCT02214381"
429,"NCT00719888","Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease","Recruiting","No Results Available","Acute Biphenotypic Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia in Remission|Adult Acute Lymphoblastic Leukemia in Complete Remission|Aggressive Non-Hodgkin Lymphoma|Burkitt Lymphoma|Childhood Acute Lymphoblastic Leukemia in Complete Remission|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Lymphoblastic Lymphoma|Mantle Cell Lymphoma|Myelofibrosis|Pancytopenia|Plasma Cell Myeloma|Prolymphocytic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Anemia With Excess Blasts","Drug: Cyclophosphamide|Drug: Cyclosporine|Procedure: Double-Unit Umbilical Cord Blood Transplantation|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Radiation: Total-Body Irradiation|Procedure: Umbilical Cord Blood Transplantation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","6 Months to 45 Years   (Child, Adult)","Phase 2","75","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2010.00|NCI-2010-00190|FHCRC 2010.00|Protocol 2010|2010|P30CA015704","July 19, 2008","November 2005","null","January 11, 2017","January 2017","No Study Results Posted","null","June 2017","Overall survival|Chimerism analysis|Incidence of chronic GVHD|Incidence of clinically significant infections|Incidence of grade II-IV and III-IV acute GVHD|Incidence of neutrophil engraftment|Incidence of platelet recovery|Incidence of relapse|Incidence of transplant-related mortality|Progression-free survival","https://ClinicalTrials.gov/show/NCT00719888"
430,"NCT01660542","An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer","Completed","No Results Available","Locally Advanced Breast Cancer","Drug: Neoadjuvant Chemotherapy with Docetaxel","Yonsei University","Female","20 Years to 70 Years   (Adult, Senior)","Phase 4","96","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","4-2011-0068","August 5, 2012","April 2011","June 2015","October 30, 2016","October 2016","No Study Results Posted","null","June 2015","Pathologic Complete Response","https://ClinicalTrials.gov/show/NCT01660542"
431,"NCT00562978","Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Biological: filgrastim|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: yttrium Y 90 ibritumomab tiuxetan","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","54","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","98153|P30CA033572|P01CA030206|CHNMC-98153|CDR0000574716","November 22, 2007","September 1999","December 2017","January 12, 2017","January 2017","No Study Results Posted","null","December 2017","Response|Toxicity|Duration of response (phase II)|Overall survival (phase II)|Disease-free survival (phase II)","https://ClinicalTrials.gov/show/NCT00562978"
432,"NCT00513695","Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer","Active, not recruiting","Has Results","Inflammatory Breast Cancer|Male Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer","Drug: sunitinib malate|Drug: paclitaxel|Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Biological: filgrastim|Procedure: therapeutic conventional surgery|Other: laboratory biomarker analysis|Other: flow cytometry","University of Washington|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","68","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","6488|NCI-2010-00607","August 8, 2007","June 2007","null","March 24, 2017","March 2017","March 24, 2017","null","August 2012","Microscopic Pathologic CR (pCR) Rate|Clinical Complete Response and Correlation With Plasma VEGF, Soluble VCAM (sVCAM), and Circulating Endothelial Cells (CECs) Levels|Relapse Rate|Time to Disease Progression|Overall Survival|Number and Percent of Subjects Reporting Adverse Events","https://ClinicalTrials.gov/show/NCT00513695"
433,"NCT01542255","Metronomic Therapy in Patients With Metastatic Melanoma","Terminated","Has Results","Metastatic Melanoma","Drug: vinblastine|Drug: Cyclophosphamide|Drug: dacarbazine","Dartmouth-Hitchcock Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D1010|22362","January 17, 2012","June 2010","January 2013","September 8, 2014","September 2014","August 28, 2014","null","January 2013","Progression Free Survival|Clinical Response Rate","https://ClinicalTrials.gov/show/NCT01542255"
434,"NCT01177371","High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma","Completed","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With T(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With T(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With T(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Adult Pure Erythroid Leukemia (M6b)|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Burkitt Lymphoma|Childhood Acute Erythroleukemia (M6)|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Monoblastic Leukemia (M5a)|Childhood Acute Monocytic Leukemia (M5b)|Childhood Acute Myeloblastic Leukemia With Maturation (M2)|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)|Childhood Acute Myeloid Leukemia in Remission|Childhood Acute Myelomonocytic Leukemia (M4)|Childhood Acute Promyelocytic Leukemia (M3)|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|De Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-Cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult Non-Hodgkin Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia","Drug: busulfan|Drug: cyclophosphamide|Procedure: allogeneic bone marrow transplantation|Drug: methylprednisolone|Drug: methotrexate|Drug: cyclosporine","Case Comprehensive Cancer Center","All","Child, Adult, Senior","Phase 2","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU1494T|NCI-2010-01793","August 5, 2010","March 1988","February 2010","August 5, 2010","August 2010","No Study Results Posted","null","February 2000","Response rate|Toxicity as assessed by NCI CTC and engraftment (bone marrow) toxicity criteria","https://ClinicalTrials.gov/show/NCT01177371"
435,"NCT00134082","Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Biological: Hodgkin's antigens-GM-CSF-expressing cell vaccine|Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1|Phase 2","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0528 , CDR0000441037|P50CA096888|P30CA006973|JHOC-J0528|NA_00035358","August 22, 2005","July 2005","December 2017","October 30, 2015","October 2015","No Study Results Posted","null","October 2017","Safety and tolerability|Immunologic response|Relapse-free survival at 3 years|Overall survival at 3 years|Patterns of cellular immune reconstitution","https://ClinicalTrials.gov/show/NCT00134082"
436,"NCT01855750","A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Drug: Ibrutinib|Drug: Placebo|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone (or equivalent)","Janssen Research & Development, LLC|Pharmacyclics LLC.","All","18 Years and older   (Adult, Senior)","Phase 3","841","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Treatment","CR102118|PCI-32765DBL3001|U1111-1139-6222|2013-000959-40","May 14, 2013","September 3, 2013","June 16, 2022","May 4, 2017","May 2017","No Study Results Posted","null","June 18, 2018","Event-free survival|Progression-free survival|Overall survival|Complete response rate|Time to worsening symptoms in the Lym subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)|Oral plasma clearance of ibrutinib|Oral volume of distribution at steady state of ibrutinib|Area under the plasma concentration-time curve of ibrutinib|Minimum observed plasma concentration of ibrutinib|Number of participants affected by an adverse event","https://ClinicalTrials.gov/show/NCT01855750"
437,"NCT01974440","A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Drug: Bendamustine|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: PCI-32765 (Ibrutinib)|Drug: Placebo","Janssen Research & Development, LLC|Pharmacyclics LLC.","All","18 Years and older   (Adult, Senior)","Phase 3","403","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","CR102786|PCI-32765FLR3001|2013-003093-27","October 28, 2013","January 31, 2014","October 9, 2021","May 4, 2017","May 2017","No Study Results Posted","null","October 9, 2017","Progression-free survival|Overall survival|Complete response rate|Overall response rate|Duration of response|Participants with change in patient-reported lymphoma symptoms and concerns as measured by the Lym subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)|Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT)","https://ClinicalTrials.gov/show/NCT01974440"
438,"NCT02538926","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","Not yet recruiting","No Results Available","B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Recurrent T Lymphoblastic Leukemia/Lymphoma|Refractory B Lymphoblastic Lymphoma|Refractory T Lymphoblastic Lymphoma|T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma","Drug: Asparaginase|Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Drug: Imatinib Mesylate|Other: Laboratory Biomarker Analysis|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","71","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","9459|NCI-2015-01402|CC9459|P30CA015704","August 31, 2015","July 1, 2017","July 31, 2020","April 24, 2017","April 2017","No Study Results Posted","null","July 31, 2019","Complete minimal residual disease response rate|Overall response rate (complete response + partial response)|Overall survival|Progression-free survival|Incidence of adverse events, graded using the National Cancer Institute Common Terminology Criteria for Adverse Events","https://ClinicalTrials.gov/show/NCT02538926"
439,"NCT00132522","EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide","Completed","No Results Available","Ovarian Cancer|Colorectal Cancer|Carcinoma, Non-small-cell Lung|Prostate Cancer","Drug: EMD 273066","EMD Serono","All","18 Years and older   (Adult, Senior)","Phase 1","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 62206-015","August 19, 2005","May 2005","April 2009","October 23, 2013","October 2013","No Study Results Posted","null","June 2008","efficacy|safety","https://ClinicalTrials.gov/show/NCT00132522"
440,"NCT01707004","Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","Active, not recruiting","No Results Available","Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia","Drug: decitabine|Drug: fludarabine phosphate|Drug: busulfan|Drug: cyclophosphamide|Drug: tacrolimus|Drug: mycophenolate mofetil|Biological: filgrastim|Radiation: total-body irradiation|Procedure: allogeneic bone marrow transplantation|Other: laboratory biomarker analysis","University of Wisconsin, Madison|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HO11421|NCI-2012-01325|2012-0217-CP002|2012-0217-CP005|P30CA014520","October 8, 2012","May 2013","May 2018","January 9, 2017","January 2017","No Study Results Posted","null","May 2017","Overall survival|Neutrophil recovery defined as achieving an absolute neutrophil count (ANC) greater than or equal to 500/ul for three consecutive measurements on different days|Platelet recovery defined as the first day of a platelet count greater than 20,000/mm^3 with no platelet transfusions in the preceding 7 days|Primary graft failure defined as less than 5% donor chimerism in the cluster of differentiation (CD)3 and CD33 selected cell populations at any time after transplantation|Cumulative incidence of grade III-IV acute GVHD determined by the standard bone marrow transplant (BMT) Clinical Trials Network criteria (BMTCTN)|Cumulative incidence of chronic GVHD according to BMTCTN|Complete remission after transplantation|Time to relapse/progression","https://ClinicalTrials.gov/show/NCT01707004"
441,"NCT00433511","Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer","Active, not recruiting","No Results Available","Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Male Breast Carcinoma|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer","Biological: Bevacizumab|Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Other: Placebo|Other: Quality-of-Life Assessment","National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|North Central Cancer Treatment Group","All","18 Years and older   (Adult, Senior)","Phase 3","4950","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00561|ECOG-E5103|CDR0000528955|E5103|U10CA180820|U10CA021115","February 8, 2007","December 2009","null","September 30, 2016","June 2016","No Study Results Posted","null","September 2016","Disease-free survival|Incidence of adverse events graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0|Overall survival|Quality of life, measured by average total score for the Functional Assessment of Cancer Therapy-Breast","https://ClinicalTrials.gov/show/NCT00433511"
442,"NCT01362790","SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma","Active, not recruiting","No Results Available","Mesothelioma|Adenocarcinoma of Lung|Pancreatic Neoplasms","Drug: Pentostatin|Drug: Cyclophosphamide|Biological: SS1(dsFv)PE38 - lot 073I0809|Biological: SS1(dsFv)PE38 - lot FIL129J01","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 1|Phase 2","55","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","110160|11-C-0160","May 27, 2011","May 11, 2011","September 4, 2017","April 20, 2017","September 26, 2016","No Study Results Posted","null","August 3, 2016","Objective response rate stratified by tumor type|SS1P antibody formation|Grade and description of adverse events|determine RP2D in drug lot FIL129J01|Overall survival|Progression-free survival|Duration of response","https://ClinicalTrials.gov/show/NCT01362790"
443,"NCT00577122","Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer","Completed","Has Results","Estrogen Receptor-negative Breast Cancer|Progesterone Receptor-negative Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer","Drug: Medroxyprogesterone progesterone acetate (MPA)|Drug: Medroxyprogesterone with Cyclophosphamide + Methotrexate","Indiana University|Translational Breast Cancer Research Consortium","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","0607-18 IUCRO-0154|TBCRC 007","December 18, 2007","July 2007","December 2011","September 24, 2014","September 2014","September 16, 2014","null","December 2011","Clinical Benefit Rate (CR + PR + SD > 6 Months).|Grade 3 or 4 Adverse Events Related to Treatment|MPA Trough Level > 50 ng/mL When Have Clinical Benefit|MPA Trough Concentration","https://ClinicalTrials.gov/show/NCT00577122"
444,"NCT00005940","Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission","Active, not recruiting","No Results Available","Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)","Radiation: iodine I 131 monoclonal antibody BC8|Drug: busulfan|Drug: cyclophosphamide|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Drug: cyclosporine|Drug: methotrexate|Other: laboratory biomarker analysis","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","16 Years to 55 Years   (Child, Adult)","Phase 2","18","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1470.00|NCI-2013-01361|FHCRC-1470.00|NCI-H00-0056|1470|CDR0000067778|P30CA015704|P01CA044991","July 5, 2000","October 1999","null","November 14, 2016","November 2016","No Study Results Posted","null","January 2006","Disease-free survival (DFS)|Overall survival (OS)|Relapse of AML patients|Transplant-related mortality","https://ClinicalTrials.gov/show/NCT00005940"
445,"NCT00024440","Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Biological: filgrastim|Biological: oblimersen sodium|Drug: cyclophosphamide|Drug: fludarabine phosphate","Genta Incorporated|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","null","Industry","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000068932|GENTA-GL303|UCLA-0104008","September 13, 2001","July 2001","February 2007","January 3, 2014","October 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00024440"
446,"NCT00080847","S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma","Terminated","No Results Available","Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma","Biological: oblimersen sodium|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","19 Years to 59 Years   (Adult)","Phase 2","160","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03031|S0349|U10CA032102|CDR0000356049","April 7, 2004","March 2004","null","January 4, 2013","January 2013","No Study Results Posted","null","June 2007","1 year PFS|Overall survival|Response|1-year PFS in patients who are bcl2+|Overall survival in patients who are bcl2+|Response in patients who are bcl2+","https://ClinicalTrials.gov/show/NCT00080847"
447,"NCT00856492","S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: bevacizumab|Biological: pegfilgrastim|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel albumin-stabilized nanoparticle formulation","Southwest Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000636131|S0800|U10CA032102","March 4, 2009","April 2010","December 2016","May 8, 2015","May 2015","No Study Results Posted","null","August 2015","Pathological complete response rate|Overall survival|Time to treatment failure|Disease-free survival","https://ClinicalTrials.gov/show/NCT00856492"
448,"NCT00576979","Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","Active, not recruiting","No Results Available","Leukemia","Drug: cyclophosphamide|Drug: etoposide|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: intensity-modulated radiation therapy|Radiation: tomotherapy","City of Hope Medical Center|National Cancer Institute (NCI)","All","7 Years to 55 Years   (Child, Adult)","Phase 1|Phase 2","87","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","05021|CHNMC-05021|CDR0000579141|NCI-2010-00427|R01CA154491","December 18, 2007","February 2, 2008","October 2017","April 24, 2017","April 2017","No Study Results Posted","null","October 2017","Maximum tolerated dose of intensity-modulated radiotherapy (Phase I)|Toxicity as assessed by NCI CTCAE v3.0 (Phase I)|Overall survival (Phase II)|Relapse-free survival (Phase II)|Event-free survival (Phase II)|Treatment-related mortality (Phase II)|Relapse rate (Phase II)|Fraction of patients experiencing 3-5 mucositis (Phase II)|Infection (Phase II)|Acute and chronic graft-versus-host disease (Phase II)","https://ClinicalTrials.gov/show/NCT00576979"
449,"NCT03103555","Treatment of Adult-Onset Immunodeficiency With Bortezomib","Recruiting","No Results Available","Adult-onset Immunodeficiency","Drug: Bortezomib|Drug: Cyclophosphamide","Mahidol University|Ministry of Health, Thailand","All","21 Years to 60 Years   (Adult)","Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Treatment AOI with Bortezomib","April 1, 2017","February 27, 2017","November 1, 2019","April 1, 2017","April 2017","No Study Results Posted","null","November 1, 2018","Titers of anti-interferon-gamma antibody after treatment with bortezomib|Titers of anti-interferon-gamma antibody after treatment with bortezomib and cyclophosphamide|Adverse event|Disease relapse","https://ClinicalTrials.gov/show/NCT03103555"
450,"NCT02203643","Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.","Recruiting","No Results Available","MULTIPLE MYELOMA (MM)","Drug: Carfilzomib|Drug: Cyclophosphamide|Drug: Lenalidomide|Drug: Dexamethasone","Silvio Aime|University of Turin, Italy","All","18 Years and older   (Adult, Senior)","Phase 2","477","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UNITO-MM-01 / FORTE","June 30, 2014","February 2015","October 2020","October 24, 2016","October 2016","No Study Results Posted","FORTE","October 2016","Efficacy in term of at least Very Good Partial Response (VGPR)|sCR rate|Safety as incidence of grade 3/4 adverse events|Survival|Correlation between tumor response and outcome with baseline prognostic factors.|Minimal Residual Disease (MRD)|Survival after relapse","https://ClinicalTrials.gov/show/NCT02203643"
451,"NCT01040871","Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma","Completed","Has Results","Diffuse Large B-Cell Lymphoma","Drug: VELCADE|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Drug: Vincristine","Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years and older   (Adult, Senior)","Phase 2","164","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","26866138-LYM-2034","December 29, 2009","January 2010","August 2012","December 11, 2013","December 2013","July 5, 2013","null","June 2012","Complete Response (CR) Rate|Overall Response Rate|Rate of Durable Response|Rate of Durable Complete Response|Subsequent Anti-lymphoma Therapy Rate at 1-year|Progression-free Survival (PFS)Rate at 1-year|Overall Survival Rate at 1-year|Change in Fatigue and Patient Utility Scores","https://ClinicalTrials.gov/show/NCT01040871"
452,"NCT01527149","Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","Recruiting","No Results Available","Stage I Mantle Cell Lymphoma|Stage II Contiguous Mantle Cell Lymphoma|Stage II Non-Contiguous Mantle Cell Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Mantle Cell Lymphoma","Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Methotrexate|Biological: Ofatumumab|Drug: Vincristine Sulfate","Roswell Park Cancer Institute|National Cancer Institute (NCI)|National Comprehensive Cancer Network","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","37","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","I 201611|NCI-2011-03562|P30CA016056","December 12, 2011","December 7, 2011","October 5, 2019","March 30, 2017","March 2017","No Study Results Posted","null","October 5, 2018","Proportion of patients experiencing a complete response|Ability of the induction and consolidation therapy to get 70% of patients to autologous stem cell transplantation|Change in surface CD20 levels, Ki67, and additional cytogenetic abnormalities|Change of serum complement component (C)3, C4, and complement CH50 (CH50) levels|Frequency of adverse events|Minimal residual disease (MRD) in peripheral blood and bone marrow biopsy/aspiration samples|Overall survival (OS)|Progression-free survival (PFS)|Proliferation signature using quantitative real-time RT-PCR|Proportion of patients who experience complete remission as assessed by HSFCM|Time-to-tumor progression (TTP)","https://ClinicalTrials.gov/show/NCT01527149"
453,"NCT00553683","Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer","Unknown status","No Results Available","Breast Cancer|Colorectal Cancer|Gastric Cancer|Liver Cancer|Melanoma (Skin)|Metastatic Cancer|Ovarian Cancer|Pancreatic Cancer","Drug: cyclophosphamide|Drug: poly ICLC|Procedure: hepatic artery embolization|Radiation: 3-dimensional conformal radiation therapy","Rutgers, The State University of New Jersey","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000573370|UMDNJ-0120070076","November 2, 2007","October 2007","July 2014","January 11, 2014","January 2014","No Study Results Posted","null","February 2014","Overall tolerability|Progression-free survival at 6, 12, and 24 months|Overall survival at 6, 12, and 24 months","https://ClinicalTrials.gov/show/NCT00553683"
454,"NCT03128359","High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant","Not yet recruiting","No Results Available","Acute Leukemia|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Graft Versus Host Disease|Hodgkin Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma|Secondary Myelodysplastic Syndrome","Drug: Busulfan|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Procedure: Hematopoietic Cell Transplantation|Other: Laboratory Biomarker Analysis|Drug: Melphalan Hydrochloride|Drug: Mycophenolate Mofetil|Procedure: Peripheral Blood Stem Cell Transplantation|Other: Quality-of-Life Assessment|Drug: Tacrolimus|Radiation: Total-Body Irradiation","City of Hope Medical Center|National Cancer Institute (NCI)","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","38","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Supportive Care","16419|NCI-2017-00480","March 24, 2017","June 2017","June 2019","April 20, 2017","April 2017","No Study Results Posted","null","June 2019","GRFS|Acute graft versus host disease (aGVHD) of grades 2-4 and 3-4 graded according to the Consensus Grading|Change in quality of life as assessed by SF-36, Functional Assessment of Cancer Therapy Bone Marrow Transplant questionnaire|Change in quality of life as assessed by the MD Anderson Symptom Inventory questionnaire|Chronic graft versus host disease (cGVHD) graded according to the National Institutes of Health Consensus Staging|Cumulative incidence of relapse/progression|Incidence of adverse events graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 Toxicity Scale|Incidence of adverse events graded using the Berman Toxicity Scale|Microbiologically documented infections|Non-relapse Mortality (NRM)|Overall Survival (OS)|Progression Free Survival (PFS)|Time to hematological recovery in terms of neutrophil (absolute neutrophil count >= 500/ul, 1.0 x 10^3/ul) and platelet (20 x 10^3/ul and 100 x 10^3/ul) engraftment time","https://ClinicalTrials.gov/show/NCT03128359"
455,"NCT02955810","Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)","Recruiting","No Results Available","Multiple Myeloma","Drug: Daratumumab|Drug: Cyclophosphamide|Drug: Bortezomib|Drug: Dexamethasone","National University of Ireland, Galway, Ireland|Janssen Pharmaceuticals|Cancer Trials Ireland","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","16-BCNI-001","October 18, 2016","November 2016","November 2020","November 25, 2016","November 2016","No Study Results Posted","CyBorD-Dara","November 2017","MTD|The rate of Complete Response (CR) post Autologous Stem Cell Transplantation (ASCT)|Safety and Tolerability as assessed by adverse events|Complete Response Rate at the end of induction, ASCT, consolidation and maintenance|Best Overall Response|Minimal Residual Disease (MRD) negative rate at the end of induction, ASCT, consolidation and maintenance|Progression Free Survival (PFS) at the end of maintenance phase|Overall Survival (OS) at the end of maintenance phase|Clinical Benefit Rate (CBR)","https://ClinicalTrials.gov/show/NCT02955810"
456,"NCT01304797","Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: MM-302 Monotherapy|Drug: MM-302 in combination with trastuzumab|Drug: MM-302 in combination with trastuzumab q3w|Drug: MM-302 in combination with trastuzumab and cyclophosphamide","Merrimack Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1","75","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MM-302-02-01-01","February 24, 2011","March 2011","January 2017","January 4, 2017","January 2017","No Study Results Posted","null","August 2016","The severity and the number of adverse events related to escalating doses of the MM-302.|The severity and the number of adverse events related to escalating doses of the MM-302 in combination with trastuzumab with or without cyclophosphamide|Objective response rate of MM-302|The pharmacokinetics of MM-302 as determined by measuring AUC, Tmax and Cmax|Immunogenicity of MM-302 by confirming whether MM-302 elicits an immune response or not","https://ClinicalTrials.gov/show/NCT01304797"
457,"NCT01569750","A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma","Completed","No Results Available","CD20-positive B-cell Non-Hodgkin Lymphoma","Drug: Part 1, Cohort 1|Drug: Part 1, Cohort 2|Drug: Part 1, Cohort 3|Drug: Part 2, Cohort 1|Drug: Part 2, Cohort 2","Janssen Research & Development, LLC|Pharmacyclics LLC.","All","18 Years and older   (Adult, Senior)","Phase 1","33","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR100844|PCI-32765DBL1002|2012-000546-35","March 30, 2012","June 2012","September 2014","September 4, 2015","September 2015","No Study Results Posted","null","September 2014","Part 1 maximum tolerated dose of ibrutinib|The number of participants affected by a dose-limiting toxicity|Number of participants with potential drug-drug interactions between ibrutinib and vincristine|Overall response rate|Duration of response|Progression-free survival|Mean plasma concentrations of ibrutinib|Maximum observed plasma concentration of ibrutinib|Time to reach the maximum plasma concentration of ibrutinib|Area under the plasma concentration-time curve from time 0 to 24 hours of ibrutinib|Elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of ibrutinib|Elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of vincristine|Partial area under the plasma concentration versus time curve of vincristine|The number of participants with pharmacodynamic markers of ibrutinib in peripheral blood mononuclear cells|The number of participants with biomarkers predictive of clinical response|The number of participants affected by an adverse event","https://ClinicalTrials.gov/show/NCT01569750"
458,"NCT00523159","IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease","Completed","No Results Available","Renal Cell Carcinoma","Drug: Endoxana, IMA901, Leukine|Drug: IMA901 and Leukine","immatics Biotechnologies GmbH","All","18 Years and older   (Adult, Senior)","Phase 2","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT Nr: 2006-006370-25","August 30, 2007","May 2007","August 2009","July 9, 2012","February 2010","No Study Results Posted","IMA901-202","August 2009","Disease control rate|Tumor response rates and SD rate|Duration of response|Time to response|TTP|PFS and OS|DCR|Immune response|Effect of cyclophosphamide pre-treatment on immune response|Safety","https://ClinicalTrials.gov/show/NCT00523159"
459,"NCT01542203","Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer","Unknown status","No Results Available","Breast Cancer","","University of Texas Southwestern Medical Center|Texas Tech University Health Sciences Center","Female","18 Years and older   (Adult, Senior)","","18","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","STU 062011-056","February 20, 2012","March 2012","null","February 29, 2012","January 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01542203"
460,"NCT00774852","Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis","Completed","Has Results","Lupus Nephritis|Lupus Erythematosus, Systemic","Drug: abatacept|Drug: cyclophosphamide|Drug: azathioprine|Drug: prednisone|Drug: abatacept placebo|Drug: azathioprine placebo","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)","All","16 Years and older   (Child, Adult, Senior)","Phase 2","137","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","DAIT ITN034AI","October 16, 2008","November 2008","June 2014","January 15, 2016","January 2016","August 18, 2014","ACCESS","December 2012","Number of Participants With Complete Response|Number of Participants With Partial Response|Number of Participants With a Complete or Partial Response|Number of Participants Who Achieved a Complete Response by Week 24 and Maintained the Complete Response Through Week 52|Number of Participants Fulfilling the Proteinuria and Prednisone Criteria of a Complete Response|Number of Participants Fulfilling the Proteinuria and Prednisone Criteria of a Partial Response|Number of Participants Who Achieved No Response at 24 Weeks and Continued in the Study|Number of Participants Who Achieved No Response at 24 Weeks and Continued in the Study , Achieving a Complete or Partial Response|Lupus Disease Activity - Participants Who Were Anti-dsDNA Positive at Baseline and Negative at Week 104|Lupus Disease Activity - Negative Anti-dsDNA|Lupus Disease Activity - Presence of Hypocomplementemia|Lupus Disease Activity - Frequency of Flares|Lupus Disease Activity - Patient Global Assessment|Lupus Disease Activity - Patient Global Assessment Percent Change From Baseline|Lupus Disease Activity - SF-36 Scores|Lupus Disease Activity - SF-36 Scores Percent Change From Baseline|Lupus Disease Activity - Total BILAG-2004|Proportion of Vaccinated Participants With a Competent Immune Response","https://ClinicalTrials.gov/show/NCT00774852"
461,"NCT01396200","Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine","Completed","No Results Available","Myeloma","Drug: Hydroxychloroquine|Drug: Rapamycin","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Senior)","Early Phase 1","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","UPCC 09411","July 14, 2011","June 2011","October 2012","February 25, 2013","February 2013","No Study Results Posted","null","October 2012","Number of Participants with Adverse Events|Toxicities and response to the regimen","https://ClinicalTrials.gov/show/NCT01396200"
462,"NCT00774202","Study of Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP","Completed","No Results Available","Immune Thrombocytopenic Purpura","Drug: Rituxan and Cyclophosphamide, Vincristine and Prednisone|Drug: Higher Dose of Rituximab","Weill Medical College of Cornell University|Biogen|Genentech, Inc.","All","12 Years to 100 Years   (Child, Adult, Senior)","Phase 2|Phase 3","17","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant|Primary Purpose: Treatment","0301005964","October 15, 2008","November 2003","February 2008","January 31, 2017","January 2017","No Study Results Posted","null","February 2008","Our primary objective is therefore to compare the efficacy and safety of higher doses of Rituxan with a regimen combining standard doses of Rituxan + CVP|efacy|Effacy of the 2 groups","https://ClinicalTrials.gov/show/NCT00774202"
463,"NCT02354547","A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors","Recruiting","No Results Available","Neoplasm","Genetic: SGT-53|Drug: Topotecan|Drug: Cyclophosphamide","SynerGene Therapeutics, Inc.","All","12 Months to 21 Years   (Child, Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SGT53-01-2","December 18, 2014","December 2014","November 2019","May 15, 2017","May 2017","No Study Results Posted","null","November 2018","Dose limiting toxicities (DLT)|Recommended phase 2 dose (RP2D)|Tolerability of systemic intravenous infusion (assessed by any adverse events related to infusion of study drugs according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.)|Anti-tumor activity (evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1.)|Concentration of SGT-53 over time will be characterized by Cmax and clearance (Pharmacokinetic will be performed to evaluate the concentration of SGT-53 in patient's blood over time)","https://ClinicalTrials.gov/show/NCT02354547"
464,"NCT01244906","Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant","Completed","Has Results","Hematologic Neoplasms","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NSH 911","November 18, 2010","December 2010","December 2014","April 9, 2015","January 2015","January 29, 2015","null","April 2014","Incidence of GVHD|Incidence of Absolute Neutrophil Count (ANC)/Platelet Engraftment|Number of Participants With Non-Relapse Mortality|Number of Patients With Disease Free Survival at 2 Years|Number of Patients to Achieve Full Donor Chimerism|Number of Patients With Overall Survival at 2 Years.","https://ClinicalTrials.gov/show/NCT01244906"
465,"NCT02793544","HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide","Recruiting","No Results Available","Myelodysplastic Syndrome (MDS)|Chronic Lymphocytic Leukemia (CLL)|Chemotherapy-sensitive Lymphoma|Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma|Acute Myelogenous Leukemia (AML)|Acute Biphenotypic Leukemia (ABL)|Acute Undifferentiated Leukemia (AUL)","Drug: Fludarabine|Drug: Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5|Radiation: Total Body Irradiation (TBI) 200cGy on Day -1|Procedure: Infusion of non-T-cell depleted bone marrow on Day 0|Drug: Busulfan|Drug: Cyclophosphamide 50mg/kg/day IV on Days -2,-1|Drug: Cyclophosphamide 50mg/kg/day IV on Days -5,-4|Radiation: Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1|Drug: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4|Drug: Sirolimus|Drug: Mycophenolate mofetil|Drug: G-CSF|Drug: Pre-HCT Mesna on Days -6 and -5|Drug: Pre-HCT Mesna on Days -2 and -1|Drug: Pre-HCT Mesna on Days -5 and -4|Drug: Post-HCT Mesna","Center for International Blood and Marrow Transplant Research|National Marrow Donor Program|Resource for Clinical Investigation in Blood and Marrow Transplantation","All","15 Years to 70 Years   (Child, Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","15-MMUD","May 31, 2016","August 2016","null","February 3, 2017","February 2017","No Study Results Posted","null","December 2019","Overall Survival|Progression-free survival|Transplant-related mortality|Cumulative incidence of neutrophil recovery|Cumulative incidence of platelet recovery|Cumulative incidence of primary graft failure|Donor Chimerism|Peripheral blood chimerism|Cumulative incidence of acute GVHD|Cumulative incidence of chronic GVHD|Cumulative incidences of viral reactivations and infections|Cumulative incidence of relapse/progression|Cumulative incidences of thrombotic microangiopathy (TMA) and hepatic veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS)|Proportion of subjects proceeding to transplant|Donor Selection Characteristics|Time from search to donor identification|Subgroup analysis of HIV-positive subjects|Donor clonal hematopoiesis","https://ClinicalTrials.gov/show/NCT02793544"
466,"NCT00002482","Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer","Unknown status","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Biological: antibody therapy|Biological: biological therapy|Biological: muromonab-CD3|Drug: cyclophosphamide","St. Vincent Medical Center - Los Angeles|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000077247|SVMC-ONC-121|NCI-V90-0206","November 1, 1999","June 1991","null","November 5, 2013","July 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002482"
467,"NCT01025089","Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma","Active, not recruiting","No Results Available","Thymoma|Thymic Carcinoma|Clinical Masaoka Stage II to IVA","Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide","Memorial Sloan Kettering Cancer Center|Eli Lilly and Company|M.D. Anderson Cancer Center|City of Hope National Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","09-038","December 2, 2009","December 2009","December 2018","April 4, 2017","April 2017","No Study Results Posted","null","December 2018","To determine the frequency of complete pathologic response to neo-adjuvant therapy with cisplatin, doxorubicin, cyclophosphamide (CAP) and cetuximab in patients with clinical Masaoka stage II-IVa thymoma and thymic carcinomas.|To determine the toxicity (CTCAE v.3) of neo-adjuvant therapy with CAP and cetuximab|To measure the radiographic response rate to cetuximab alone after 4 weeks|To determine the radiographic response rate to CAP and cetuximab|To determine the complete resection rate (R0) after neo-adjuvant therapy with CAP and cetuximab|To correlate percentage of pathologic response to unidimensional and volumetric radiographic response","https://ClinicalTrials.gov/show/NCT01025089"
468,"NCT01206881","Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: pegylated liposomal doxorubicin","Herlev Hospital|Rigshospitalet, Denmark|Odense University Hospital|Aarhus University Hospital","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PO5903, EudraCT 2008-007951-29","September 13, 2010","March 2009","June 2011","June 30, 2011","June 2011","No Study Results Posted","null","May 2011","clinical response rate|pathological response rate, response rate as defined by PET-CT scan, mammography and ultrasound, evaluation of toxicity of the combination regimen","https://ClinicalTrials.gov/show/NCT01206881"
469,"NCT00125606","Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide","Terminated","No Results Available","Acute Myeloid Leukemia","Procedure: conditioning for allogeneic HSCT","University Hospital Muenster|Technische Universität Dresden|Philipps University Marburg Medical Center|Universitätsklinikum Hamburg-Eppendorf|Hannover Medical School|Ludwig-Maximilians - University of Munich|University Hospital, Essen|Johann Wolfgang Goethe University Hospital|Deutsche Klinik fuer Diagnostik|Charite University, Berlin, Germany","All","18 Years to 60 Years   (Adult)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AML_CR2_allo_HSCT","July 26, 2005","October 2004","July 2011","December 17, 2012","December 2012","No Study Results Posted","null","July 2011","treatment related mortality|event free survival|overall survival|cumulative incidence of acute and chronic graft-versus-host disease (GvHD)|activity index (ECOG)|organ function","https://ClinicalTrials.gov/show/NCT00125606"
470,"NCT02566993","Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer","Recruiting","No Results Available","Small-cell Lung Cancer","Drug: Lurbinectedin (PM01183)|Drug: Doxorubicin (DOX)|Drug: Cyclophosphamide (CTX)|Drug: Vincristine (VCR)|Drug: Topotecan","PharmaMar","All","18 Years and older   (Adult, Senior)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","PM1183-C-003-14","September 24, 2015","July 2016","null","May 17, 2017","January 2017","No Study Results Posted","ATLANTIS","June 2019","Progression-free survival (PFS)|Overall survival (OS)|Overall survival rate 12, 18 & 24 months","https://ClinicalTrials.gov/show/NCT02566993"
471,"NCT00085423","Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma","Completed","Has Results","Melanoma (Skin)","Biological: aldesleukin|Biological: sargramostim|Drug: cyclophosphamide|Drug: fludarabine phosphate","Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000370788|P30CA023108|DMS-0320|DMS-16531","June 10, 2004","February 2004","February 2010","April 9, 2013","April 2013","January 26, 2012","null","December 2008","Number of partiCIPANTS WITH OBJECTIVE RESPONSE AS MEASURED BY RECIST|Number of Participants With Lymphocyte Recovery as Measured by Blood Count|Time to Progression as Measured by RECIST","https://ClinicalTrials.gov/show/NCT00085423"
472,"NCT00438841","Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma","Unknown status","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Drug: bortezomib|Drug: cyclophosphamide|Drug: dexamethasone|Drug: thalidomide","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","43","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000536219|FHCRC-2123.00","February 20, 2007","August 2006","null","March 12, 2009","March 2009","No Study Results Posted","null","December 2008","Response rate|Safety and tolerability","https://ClinicalTrials.gov/show/NCT00438841"
473,"NCT00003658","Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers","Completed","No Results Available","Leukemia|Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: pentostatin","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other|NIH","Interventional","Primary Purpose: Treatment","98-083|CDR0000066751|NCI-G98-1482","November 1, 1999","September 1998","October 2005","June 24, 2013","June 2013","No Study Results Posted","null","October 2005","","https://ClinicalTrials.gov/show/NCT00003658"
474,"NCT00317876","Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi's Anemia","Completed","No Results Available","Fanconi Anemia","Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 1","25","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","1288.00|FHCRC-1288.00|CDR0000481264","April 24, 2006","June 1998","null","April 18, 2012","April 2012","No Study Results Posted","null","July 2003","Conditioning-related toxicity|Graft rejection","https://ClinicalTrials.gov/show/NCT00317876"
475,"NCT01955187","Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy","Recruiting","No Results Available","MEMBRANOUS NEPHROPATHY","Drug: TACROLIMUS|Drug: RITUXIMAB|Drug: METHYLPREDNISOLONE|Drug: CYCLOPHOSPHAMIDE","Hospital Universitario 12 de Octubre|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Hospital Universitario Fundación Alcorcón|Fundación para la Investigación Biomédica Hospital Universitario 12 de Octubre|Biobanco REDinREN|ERA-EDTA|REDinREN|Sociedad Española de Nefrología|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa|University Hospital, Aachen","All","18 Years and older   (Adult, Senior)","Phase 3","106","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","STARMEN 01-2013|2013-000226-55","September 19, 2013","January 2014","April 2019","August 18, 2016","August 2016","No Study Results Posted","STARMEN","December 2018","Proportion of patients with complete and/or partial remission.|Proportion of patients with limited response|Proportion of patients with increase of baseline serum creatinine ≥ 50%|Proportions of patients with relapses|Proportion of patients with drug-related adverse events","https://ClinicalTrials.gov/show/NCT01955187"
476,"NCT00343863","Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer","Completed","No Results Available","Male Breast Cancer|Nausea and Vomiting|Stage I Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer","Drug: palonosetron hydrochloride|Drug: cyclophosphamide|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Procedure: quality-of-life assessment|Procedure: nausea and vomiting therapy|Procedure: management of therapy complications|Drug: ondansetron hydrochloride|Other: survey administration","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","41","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","6140|NCI-2010-00801","June 22, 2006","January 2006","December 2010","May 7, 2013","May 2013","No Study Results Posted","null","December 2010","Proportion of patients achieving a complete response|Proportion of patients achieving complete response|Number of emetic episodes daily|Time to first emetic episode|Time to first administration of rescue medication|Number of doses of rescue medications used|Side effects of antiemetic medications used|Severity of nausea|Quality of life","https://ClinicalTrials.gov/show/NCT00343863"
477,"NCT00087178","Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: adriamycin|Drug: epirubicin|Drug: fluorouracil","NSABP Foundation Inc|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","2722","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP B-36|U10CA012027","July 8, 2004","May 2004","May 2016","June 3, 2016","June 2016","No Study Results Posted","null","March 2014","Disease free survival or no breast cancer (BC) at time of local recurrence (LR) after mastectomy, LR in the ipsilateral breast following lumpectomy, regional or distant recurrence, contralateral BC, 2nd primary cancer, or death|Survival|Adverse events|Quality of Life|Post chemotherapy amenorrhea|Change in LVEF at the 12-month evaluation|HER-2 and Topo II gene amplification|Recurrence-free interval|Distant recurrence-free interval","https://ClinicalTrials.gov/show/NCT00087178"
478,"NCT00847171","Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: allogeneic GM-CSF-secreting breast cancer vaccine|Biological: trastuzumab|Drug: cyclophosphamide|Other: flow cytometry|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: biopsy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0885 CDR0000634155|P30CA006973|JHOC-NA_00021048|JHOC-J0885","February 18, 2009","December 2008","June 2013","May 24, 2013","May 2013","No Study Results Posted","null","June 2013","Safety (local and systemic toxicity) as assessed by NCI CTCAE v3.0|Immunologic response (HER2/neu-specific immune response and delayed-type hypersensitivity response to HER2/neu-derived peptides)|Clinical benefit as assessed by rate of progression-free survival","https://ClinicalTrials.gov/show/NCT00847171"
479,"NCT02873819","Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity","Recruiting","No Results Available","Squamous Cell Carcinoma of the Oral Cavity","Drug: GL-0817|Drug: Hiltonol|Drug: Sargramostim|Drug: cyclophosphamide|Drug: Placebo","Gliknik Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","GL0817-01|2016-001256-22","August 8, 2016","March 30, 2017","March 2020","April 5, 2017","April 2017","No Study Results Posted","null","March 2020","Disease-free interval|Disease-free survival (DFS)|Overall survival (OS)|Disease-free interval in a per protocol analysis|Adverse event profile","https://ClinicalTrials.gov/show/NCT02873819"
480,"NCT00801060","Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)","Terminated","No Results Available","Chronic Lymphocytic Leukemia","Drug: Lumiliximab + FCR|Drug: FCR","Biogen","All","18 Years and older   (Adult, Senior)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","152CL202|EUDRACT NO: 2008-002204-25","December 2, 2008","February 2008","September 2010","September 17, 2015","April 2011","No Study Results Posted","null","June 2010","To evaluate the safety and tolerability of FCR+L compared with FCR alone in subjects with previously untreated CLL.|To evaluate the efficacy of FCR+L compared with FCR alone in subjects with previously untreated CLL.","https://ClinicalTrials.gov/show/NCT00801060"
481,"NCT00004175","Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Procedure: conventional surgery","Northwestern University|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU 98B1|NU-98B1|NCI-G99-1643","December 10, 1999","November 1998","June 2005","May 31, 2012","May 2012","No Study Results Posted","null","September 2004","","https://ClinicalTrials.gov/show/NCT00004175"
482,"NCT00228358","Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine","Completed","No Results Available","HER2-positive Breast Cancer|Recurrent Breast Cancer|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Stage IV Breast Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor","Drug: ex vivo-expanded HER2-specific T cells|Drug: cyclophosphamide|Biological: denileukin diftitox|Other: flow cytometry|Other: immunoenzyme technique","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","8","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","6223|NCI-2009-01547","September 13, 2005","June 2003","null","November 7, 2014","November 2014","No Study Results Posted","null","May 2011","Feasibility of expanding HER2 specific T cells ex vivo to achieve a target T cell expansion of 1x10^10 HER2 specific T cells|Safety of infusing HER2 specific T cells|Number of patients in whom the precursor frequency of antigen specific T cells is increased by 10-fold over baseline within one week after the last infusion|Number of patients in whom an immune response is demonstrated if baseline immune response was below detection|HER2 specific CD4+ or CD8+ precursor frequencies as assessed by cytokine flow cytometry or ELISPOT|Anti-tumor effects of HER2 specific T cells as assessed by RECIST criteria|Persistence of T cell immune augmentation in vivo after adoptive transfer of HER2 specific T cells","https://ClinicalTrials.gov/show/NCT00228358"
483,"NCT03096275","Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis","Recruiting","No Results Available","Takayasu Arteritis","Drug: MMF|Drug: CYC|Drug: Glucocorticoids|Drug: MTX|Drug: AZA","Chinese SLE Treatment And Research Group|Peking Union Medical College Hospital","All","18 Years and older   (Adult, Senior)","Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","PUMCHCSTAR-006","March 13, 2017","March 16, 2017","December 1, 2018","April 4, 2017","April 2017","No Study Results Posted","CommittedTA","October 1, 2018","Proportion of patients with complete remission|Proportion of patients with partial remission|Safety profile of MMF combined with MTX|Rate of complications","https://ClinicalTrials.gov/show/NCT03096275"
484,"NCT00103792","Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)","Unknown status","No Results Available","Wegener's Granulomatosis|Vasculitis","Drug: mycophenolate mofetil|Drug: cyclophosphamide","University Medical Center Groningen","All","18 Years and older   (Adult, Senior)","Phase 3","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","WG-MMF-1|UMCG-ANCA-MMF-1","February 14, 2005","December 2004","January 2012","February 12, 2009","February 2009","No Study Results Posted","null","January 2010","remission induction rate|disease free survival after 2 and 4 years|time to remission|cumulative organ damage|side-effects|ANCA titres over time","https://ClinicalTrials.gov/show/NCT00103792"
485,"NCT02465983","Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer","Active, not recruiting","No Results Available","Pancreatic Cancer","Biological: CART-meso-19 T cells|Drug: Cyclophosphamide","University of Pennsylvania|University of California, San Francisco","All","18 Years and older   (Adult, Senior)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CART-meso-19|UPCC 19214|UCSF CC144520","May 28, 2015","May 2015","January 2018","October 10, 2016","October 2016","No Study Results Posted","null","September 2017","Safety of IV administration of CART-meso-19 with cyclophosphamide as lymphodepleting chemotherapy in patients with pancreatic cancer using the NCI CTCAE v4.03 criteria","https://ClinicalTrials.gov/show/NCT02465983"
486,"NCT00005970","Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer","Active, not recruiting","No Results Available","Breast Adenocarcinoma|HER2 Positive Breast Carcinoma|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer","Drug: Aromatase Inhibition Therapy|Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Drug: Tamoxifen Citrate|Biological: Trastuzumab","National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|Canadian Cancer Trials Group|Southwest Oncology Group","Female","18 Years and older   (Adult, Senior)","Phase 3","3000","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2012-01849|ECOG-N9831|CAN-NCIC-MA28|SWOG-N9831|MA.28|NCCTG-N9831|CALGB-49909|CDR0000067953|GUMC-00224|N9831|U10CA180821|U10CA025224","July 5, 2000","May 19, 2000","null","May 23, 2017","May 2017","No Study Results Posted","null","May 1, 2020","Duration of DFS|Overall survival","https://ClinicalTrials.gov/show/NCT00005970"
487,"NCT00004896","Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Drug: busulfan|Drug: cyclophosphamide|Procedure: allogeneic bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Radiation: radiation therapy","Northwestern University|National Cancer Institute (NCI)","All","16 Years to 60 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","NU 91H4T|NU-91H4T|NCI-G00-1686","March 7, 2000","October 1999","August 2004","June 8, 2012","June 2012","No Study Results Posted","null","August 2004","","https://ClinicalTrials.gov/show/NCT00004896"
488,"NCT02828592","Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia","Recruiting","No Results Available","Severe Aplastic Anemia","Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total Body Irradiation|Drug: Rabbit ATG|Drug: Cyclophosphamide","Northside Hospital, Inc.","All","1 Year to 75 Years   (Child, Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NSH 1158","July 6, 2016","September 2016","September 2020","December 12, 2016","December 2016","No Study Results Posted","null","August 2018","Demonstrate sustained engraftment after T-cell replete HLA-mismatched haploidentical bone marrow transplantation by collecting chimerism tests monthly following transplant|Determine the incidence of regimen-related mortality at 100 days post transplantation by recording treatment-related adverse events|Determine the incidence of grade 2-4 and 3-4 acute graft versus host disease at 100 days post transplantation by assessing signs and symptoms of GVHD throughout post-transplant course|Determine incidence of chronic GVHD at 6 months and 1 year post transplantation by assessing signs and symptoms of GVHD throughout post-transplant course|Estimate overall survival at 100 days and 1 year post transplantation by collecting survival information at those time points","https://ClinicalTrials.gov/show/NCT02828592"
489,"NCT00107094","Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Abraxane","Celgene Corporation","Female","18 Years to 70 Years   (Adult, Senior)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CA030","April 5, 2005","March 2005","null","July 18, 2007","July 2007","No Study Results Posted","null","null","Safety/tolerability endpoints:|incidence of treatment-emergent/related adverse events and serious adverse events|laboratory abnormalities|nadir of myelosuppression|incidence of patients experiencing dose modifications, dose interruptions, and/or premature discontinuation of study drug","https://ClinicalTrials.gov/show/NCT00107094"
490,"NCT03135951","Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy","Not yet recruiting","No Results Available","Breast Cancer|Pharmacokinetics","Drug: SPI-2012","Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Senior)","Phase 1","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SPI-GCF-301-PK","April 20, 2017","May 2017","December 2017","April 26, 2017","April 2017","No Study Results Posted","null","December 2017","Peak Plasma Concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03|Population slope of the relationship between the change from baseline in QTc intervals and plasma concentrations of SPI-2012","https://ClinicalTrials.gov/show/NCT03135951"
491,"NCT00208975","Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab","Terminated","Has Results","Lymphoma","Drug: Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF","Emory University|Bayer","All","18 Years and older   (Adult, Senior)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1048-2001","September 13, 2005","July 2002","September 2011","May 25, 2012","May 2012","March 16, 2012","null","December 2009","Number of Patients's Who Had Complete Response and Partial Response to the Treatment of Fludarabine and Cyclophosphamide Followed by GM-CSF and Rituximab.","https://ClinicalTrials.gov/show/NCT00208975"
492,"NCT01283386","A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status","Completed","No Results Available","Lymphocytic Leukemia, Chronic","Drug: chlorambucil|Drug: cyclophosphamide|Drug: fludarabine|Drug: rituximab [MabThera]","Hoffmann-La Roche","All","60 Years and older   (Adult, Senior)","Phase 4","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML25137","January 18, 2011","April 2011","March 2016","November 1, 2016","November 2016","No Study Results Posted","null","March 2016","Therapy response rate|Duration of response|Overall survival|Progression-free survival|Event-free survival|Safety:Incidence of adverse events|Laboratory predictors of response","https://ClinicalTrials.gov/show/NCT01283386"
493,"NCT02204241","Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients","Recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Cyclophosphamide|Drug: Dexamethasone","Stichting Hemato-Oncologie voor Volwassenen Nederland|Fondazione Neoplasie Sangue Onlus","All","65 Years and older   (Adult, Senior)","Phase 1|Phase 2","71","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IST-CAR-601","July 4, 2014","June 2014","June 2019","May 9, 2016","May 2016","No Study Results Posted","CCD","June 2015","Dose Limiting Toxicity (DLT)|Response rate (RR)|Progression-free survival (PFS)|Time to progression (TTP)|Duration of response (DOR)|Overall survival (OS)|Time to next therapy (TTNT)|Responses|Response and survival|Maintenance|Adverse event","https://ClinicalTrials.gov/show/NCT02204241"
494,"NCT00445900","Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia","Completed","No Results Available","Chronic Myeloproliferative Disorders|Secondary Myelofibrosis","Drug: cyclophosphamide|Drug: prednisone|Drug: thalidomide|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: biopsy","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","22","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000530973|P30CA015083|MC028A|1360-03","March 7, 2007","October 2004","October 2006","March 16, 2011","March 2011","No Study Results Posted","null","October 2006","Confirmed response, defined as a complete or partial response in ≥ 1 of 3 response categories (i.e., anemia, thrombocytopenia, or splenomegaly or hepatomegaly)|Constitutional symptom status and bone marrow morphology|Overall survival|Progression-free survival|Time to progression|Duration of response|Toxicity as measured by NCI CTC v 2.0","https://ClinicalTrials.gov/show/NCT00445900"
495,"NCT01966289","SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)","Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: CY|Biological: GVAX|Drug: SGI-110","Sidney Kimmel Comprehensive Cancer Center","All","18 Years to 100 Years   (Adult, Senior)","Phase 1","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","J13138|NA_00087578","October 10, 2013","December 2013","December 2019","May 2, 2017","May 2017","No Study Results Posted","null","December 2018","Difference in CD45RO+ tumor infiltrating lymphocytes (TILs) measured by immunohistochemistry in pre and post-treatment tumor biopsies from patients with metastatic colorectal cancer|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Overall Survival (OS)|Time To Progression (TTP)|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01966289"
496,"NCT01091831","Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Cyclophosphamide|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Melphalan","Fondazione Neoplasie Sangue Onlus","All","18 Years to 65 Years   (Adult)","Phase 3","389","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RV-MM-EMN-441","March 22, 2010","July 2009","July 2019","May 9, 2016","May 2016","No Study Results Posted","null","July 2019","Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01091831"
497,"NCT01612247","Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy","Unknown status","No Results Available","Breast Cancer","Drug: Cyclophosphamide and Methotrexate and Aspirin","University of Vermont|Maimonides Medical Center|Dartmouth-Hitchcock Medical Center","Female","18 Years and older   (Adult, Senior)","","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","V1010","May 30, 2012","February 2011","February 2014","June 4, 2012","May 2012","No Study Results Posted","null","February 2013","Toxicity and Safety|Biomarker Analysis","https://ClinicalTrials.gov/show/NCT01612247"
498,"NCT00544167","Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Paclitaxel|Drug: Sorafenib","SCRI Development Innovations, LLC|Bayer","Female","18 Years and older   (Adult, Senior)","","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI BRE 112","October 15, 2007","May 2007","April 2011","March 25, 2013","March 2013","December 19, 2012","null","January 2008","The Safety and Tolerability of Protocol Treatment, Defined as the Percentage of Patients Experiencing Severe or Life-threatening Side Effects Per CTCAE Version 3.0.","https://ClinicalTrials.gov/show/NCT00544167"
499,"NCT02643420","RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide","Recruiting","No Results Available","Neutropenia|Breast Cancer","Drug: SPI-2012|Drug: Pegfilgrastim","Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Senior)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SPI-GCF-301","December 29, 2015","December 2015","October 2018","May 2, 2017","May 2017","No Study Results Posted","ADVANCE","October 2018","Duration of severe neutropenia (DSN) in Cycle 1|Time to Absolute Neutrophil Count (ANC) Recovery in Cycle 1|Depth of ANC Nadir, defined as the patient's lowest ANC in Cycle 1|Incidence of Febrile Neutropenia (FN) in patients during Cycle 1","https://ClinicalTrials.gov/show/NCT02643420"
500,"NCT00544232","Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)","Completed","No Results Available","Breast Cancer","Drug: Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa|Drug: Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa","German Breast Group|Pharmacia|Amgen|Bristol-Myers Squibb","Female","18 Years to 65 Years   (Adult)","Phase 3","720","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GBG 49","October 15, 2007","August 2002","September 2006","February 12, 2016","February 2016","No Study Results Posted","null","September 2006","Relapse-free survival time and overall survival","https://ClinicalTrials.gov/show/NCT00544232"
501,"NCT00397800","Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: fludarabine phosphate|Radiation: yttrium Y 90 ibritumomab tiuxetan","Technische Universität München","All","50 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000515982|KRDI-TUM-R-F-015-V-0030-I|EU-20633","November 9, 2006","June 2005","May 2013","August 27, 2012","August 2012","No Study Results Posted","null","May 2008","Dose-limiting toxicity|Response|Survival","https://ClinicalTrials.gov/show/NCT00397800"
502,"NCT01150513","Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: EC-T|Drug: TP","Chinese Academy of Medical Sciences","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","320","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CH-BC-007","June 14, 2010","June 2009","April 2016","February 11, 2017","February 2017","No Study Results Posted","null","January 2016","Disease Free Survival (DFS) of 3 years|Safety Profiles","https://ClinicalTrials.gov/show/NCT01150513"
503,"NCT00278525","Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma","Completed","Has Results","SYSTEMIC SCLERODERMA","Drug: standard of care|Procedure: stem cell transplantation","Northwestern University","All","up to 60 Years   (Child, Adult)","Phase 2","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DI Scl.Randomized2004","January 15, 2006","September 2005","December 2012","March 28, 2014","March 2014","April 9, 2013","null","September 2011","Time to Treatment Failure|Disease Improvement","https://ClinicalTrials.gov/show/NCT00278525"
504,"NCT00474747","Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation in Aplastic Anemia","Active, not recruiting","No Results Available","Aplastic Anemia","Drug: Antithymocyte Globulin|Drug: Cyclophosphamide|Drug: Fludarabine|Radiation: Total Body Irradiation (TBI)|Procedure: Bone Marrow Transplant","M.D. Anderson Cancer Center|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 1|Phase 2","94","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0513|NCI-2010-00908","May 16, 2007","February 2006","null","January 10, 2017","January 2017","No Study Results Posted","null","February 2019","Optimal dose level of cyclophosphamide based on assessments of graft failure, toxicity and early death|Two-year post-transplant survival","https://ClinicalTrials.gov/show/NCT00474747"
505,"NCT01124526","Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma","Completed","No Results Available","Non Hodgkin Lymphoma","Drug: Rituximab Fludarabine Cyclophosphamide","Asociacion Espanola de Hematologia y Hemoterapia","All","18 Years to 75 Years   (Adult, Senior)","Phase 4","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LNHF-03.|04-0199|2004/254","February 10, 2009","September 2004","July 2008","May 14, 2010","May 2010","No Study Results Posted","null","July 2007","Time to progression disease|Free-disease period|Overall survival|Safety of RFC|Molecular monitoring of clinical response","https://ClinicalTrials.gov/show/NCT01124526"
506,"NCT01671319","Dose Dense TC + Pegfilgrastim Support for Breast Cancer","Completed","No Results Available","Female Breast Cancer","Drug: docetaxel + cyclophosphamide + pegfilgrastim","University of Wisconsin, Madison|Amgen","Female","18 Years and older   (Adult, Senior)","Phase 2","41","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CO10104","August 5, 2011","June 2011","April 2013","July 2, 2013","July 2013","No Study Results Posted","ddTC","April 2013","Tolerability and Feasibility for dose dense schedule","https://ClinicalTrials.gov/show/NCT01671319"
507,"NCT00737685","Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)","Unknown status","No Results Available","Anemia, Aplastic","Drug: cyclophosphamide, fludarabine , thymoglobulin","The Korean Society of Pediatric Hematology Oncology","All","up to 25 Years   (Child, Adult)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KSPHO-SCT0401","August 18, 2008","January 2006","December 2012","March 23, 2012","March 2012","No Study Results Posted","null","August 2012","To evaluate the engraftment potential, incidence and severity of acute graft versus host disease,toxicity of conditioning regimen for UBMT in SAA.|To evaluate overall and EFS follow-up of 1 year after UBMT/PBSCT.|To evaluate chronic GVHD and immunologic recovery after UBMT/PBSCT. and the efficacy of UBMT/PBSCT before immuno-suppressive therapy with anti-thymocyte globulin in severe aplastic anemia and long term toxicity of non-TBI based conditioning","https://ClinicalTrials.gov/show/NCT00737685"
508,"NCT00939653","T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)","Terminated","No Results Available","Relapsed Acute Myelogenous Leukemia","Drug: clofarabine|Drug: etoposide|Drug: cyclophosphamide|Drug: filgrastim|Drug: cytarabine","Therapeutic Advances in Childhood Leukemia Consortium|Genzyme, a Sanofi Company","All","1 Year to 21 Years   (Child, Adult)","Phase 2","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","T2007-002","July 13, 2009","July 2009","July 2011","March 7, 2012","March 2012","No Study Results Posted","null","July 2011","AML disease status after chemotherapy evaluated by bone marrow aspirates/biopsies and complete blood count.","https://ClinicalTrials.gov/show/NCT00939653"
509,"NCT00544765","Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: TAC|Drug: NX","German Breast Group|Roche Pharma AG|Sanofi|Amgen|University Hospital, Frankfurt","Female","18 Years and older   (Adult, Senior)","Phase 3","2014","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GBG 24","July 20, 2007","September 2002","February 2008","February 9, 2016","February 2016","No Study Results Posted","GeparTrio","February 2008","Determination of pCR rates|To determine the toxicity and compliance to each arm|To determine the breast conservation rate in each arm|To determine the disease-free and overall survival in each arm|To determine the specificity and sensitivity of a presurgical core biopsy to predict the degree of pathologic tumor regression","https://ClinicalTrials.gov/show/NCT00544765"
510,"NCT00393107","Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab","Completed","No Results Available","Follicular Lymphoma","Drug: rituximab|Drug: rituximab,fludarabine, cyclophosphamide","Gruppo Italiano Studio Linfomi","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","54","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FR2|FolRec02|GislFR2","October 25, 2006","March 2000","August 2006","October 25, 2006","October 2006","No Study Results Posted","null","null","Toxicity during the treatment period|Efficacy evaluated in terms of complete and partial response 1 month after the end of therapy|Efficacy evaluated in terms of molecular response ( bone marrow Bcl2 negativity after treatment)","https://ClinicalTrials.gov/show/NCT00393107"
511,"NCT03088709","Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide","Recruiting","No Results Available","Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Myelodysplastic Syndrome|Non-hodgkin Lymphoma|Chronic Lymphocytic Leukemia","Drug: Cyclophosphamide|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Other: Haploidentical Stem Cell Transplantation","Loyola University","All","16 Years to 90 Years   (Child, Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Prevention","208941","February 22, 2017","January 20, 2017","January 31, 2021","April 20, 2017","April 2017","No Study Results Posted","null","January 31, 2020","Chimerism|Neutrophil engraftment|Platelet engraftment|Grade 3 to 4 acute graft-verus-host disease (GVHD)|Frequency and severity of chronic GVHD|Disease status with blast counts (immature blood cell count) above 5%|Survival status by patient contact|Immune reconstitution|Grade 3 through 5 Adverse Events","https://ClinicalTrials.gov/show/NCT03088709"
512,"NCT00407888","Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery","Completed","No Results Available","Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer","Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Biological: filgrastim|Drug: paclitaxel albumin-stabilized nanoparticle formulation|Biological: trastuzumab|Other: laboratory biomarker analysis|Procedure: quality-of-life assessment","University of Washington|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","60","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","6141|NCI-2010-02117","December 4, 2006","May 2006","null","May 7, 2013","May 2013","No Study Results Posted","null","May 2009","Disease-free survival following a dose-intensive weekly regimen of Adriamycin + oral cyclophosphamide augmented with G-CSF support followed by Abraxane and Herceptin|Delivered dose intensity of the regimen|Toxicity associated with this regimen|Time to treatment failure|Overall survival|Incidence and severity of delayed nausea and vomiting with this regimen","https://ClinicalTrials.gov/show/NCT00407888"
513,"NCT00994968","Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Drug: tegafur-gimeracil-oteracil potassium|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery","Yonsei University|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","49","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000650694|YONSEI-YCC-BR09-01","October 13, 2009","July 2009","null","October 28, 2010","October 2009","No Study Results Posted","null","null","Rate of pathologic complete response|Safety and tolerability|Rate of overall radiologic response|Rate of breast-conserving procedure|Disease-free survival|Relevant pharmacogenomics and biomarker(s) which may be useful to predict any responses to the anticancer treatments","https://ClinicalTrials.gov/show/NCT00994968"
514,"NCT00001473","Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides","Completed","No Results Available","Vasculitis|Wegener's Granulomatosis","","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","","100","NIH","Observational","","950091|95-I-0091","November 3, 1999","March 1995","March 2004","March 3, 2008","March 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001473"
515,"NCT00978913","Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma","Completed","No Results Available","Breast Cancer|Malignant Melanoma","Biological: DC vaccine","Inge Marie Svane|Herlev Hospital","All","18 Years and older   (Adult, Senior)","Phase 1","31","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AA 0914","September 16, 2009","September 2009","May 2014","August 18, 2015","August 2015","No Study Results Posted","null","August 2013","to evaluate the toxicity of the vaccine in combination with Cyclophosphamide|to investigate the clinical tumor response and the duration|to evaluate the duration of tumor and immunoresponse|to evaluate immune response","https://ClinicalTrials.gov/show/NCT00978913"
516,"NCT02846428","To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: 5-Fluorouracil|Drug: Capecitabine|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Epirubicin","Hoffmann-La Roche","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","182","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML16986","July 25, 2016","March 2004","December 2011","July 25, 2016","July 2016","No Study Results Posted","null","December 2011","Percentage of participants with pathological complete tumor response Assessed by Expert Blinded Independent Review according to the Sataloff classification\n|Percentage of participants with pathological complete tumor response Assessed by Investigator according to the Sataloff classification|Percentage of participants with breast conserving surgery|Percentage of participants with objective clinical response, assessed by World Health Organization (WHO) criteria|Percentage of participants with clinical response, assessed by WHO criteria|Percentage of participants with disease progression, assessed by WHO criteria|Percentage of participants with abnormalities in bilateral mammography|Percentage of participants who died|Percentage of participants with abnormal left ventricular ejection fraction (LVEF)|Percentage of participants with abnormal liver ultrasound|Percentage of participants with abnormal Chest X-Ray|Overall survival|Disease free survival, according to WHO criteria","https://ClinicalTrials.gov/show/NCT02846428"
517,"NCT02117024","A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer","Active, not recruiting","No Results Available","Non Small Cell Lung Cancer","Drug: Viagenpumatucel-L|Drug: Metronomic Cyclophosphamide|Drug: Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)","Heat Biologics","All","18 Years and older   (Adult, Senior)","Phase 2","123","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","HS110-201","April 15, 2014","July 2014","September 2018","April 21, 2017","April 2017","No Study Results Posted","null","September 2017","Overall survival (OS)|Safety|Disease Control Rate (DCR)|6-Month Disease Control Rate (6mDCR)|Overall Response Rate (ORR)|Progression-Free Survival (PFS)|Time to Progression (TTP)|Survival at 6 months|Survival at 12 months|Immune Response","https://ClinicalTrials.gov/show/NCT02117024"
518,"NCT00072319","Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: paclitaxel|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Pharmacia|Amgen","Female","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH|Industry","Interventional","Primary Purpose: Treatment","03-092|P30CA008748|MSKCC-03092","November 4, 2003","August 2003","November 2006","March 1, 2013","March 2013","No Study Results Posted","null","November 2006","","https://ClinicalTrials.gov/show/NCT00072319"
519,"NCT02517918","Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma","Recruiting","No Results Available","Solid Tumor|Osteosarcoma","Drug: Sirolimus combined with CP, MT and ZA","Institut Bergonié|Reliable Cancer Therapies|Pfizer","All","13 Years and older   (Child, Adult, Senior)","Phase 1","26","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IB 2014-01","February 19, 2015","February 2015","August 2018","November 8, 2016","November 2016","No Study Results Posted","METZOLIMOS","February 2017","Maximum tolerated dose (MTD) evaluated on the first cycle (D1 to D28) of sirolimus when administered in association with CP, MT and ZA|Recommended phase II dose (RP2D) of sirolimus when administered in association with CP, MT and ZA|Documentation of any observed antitumor activity|PK measurements expressed as Area Under Curve for CP|PK measurements expressed as Area Under Curve for MT|PK measurements expressed as Area Under Curve for Sirolimus|PK measurements expressed as half-life for CP|PK measurements expressed as half-life for MT|PK measurements expressed as half-life for Sirolimus|PK measurements expressed as concentration peak for CP|PK measurements expressed as concentration peak for MT|PK measurements expressed as concentration peak for Sirolimus|Dose Limiting Toxicities (DLT) of sirolimus when administered in association with CP, MT and ZA|Safety profile of sirolimus when administered in association with CP, MT and ZA evaluated by monitoring the AEs through the NCI-CTC v4|Pharmacokinetics (PK) of sirolimus when administered in association with CP, MT and ZA|Predictive biomarkers (PD) of sirolimus when administered in association with CP, MT and ZA|Antitumor activity of sirolimus when administered in association with CP, MT and ZA in terms of 6-month objective response rate (ORR) as per RECIST 1.1|Antitumor activity of sirolimus when administered in association with CP, MT and ZA in terms of 6 month best objective response rate (ORR) as per RECIST v1.1|Antitumor activity of sirolimus when administered in association with CP, MT and ZA in terms of 6-month Non-progression rate (NPR) as per RECIST 1.1|Antitumor activity of sirolimus when administered in association with CP, MT and ZA in terms of 1-year Progression-free survival (PFS) as per RECIST 1.1|Antitumor activity of sirolimus when administered in association with CP, MT and ZA in terms of Growth modulation index (GMI)|Antitumor activity of sirolimus when administered in association with CP, MT and ZA in terms of 1-year Overall Survival (OS)|Exploration of blood cytokines levels (INFγ, TNFα, TGFβ, IL2, 4, 6, 10) (ELISA)|Exploration of blood VEGF, PIGF and TPS-1 levels (ELISA)|Exploration of lymphocytes subpopulations monitoring, CD8+, CD4+,Treg ratio (flow cytometry)|Exploration of bone biomarkers such as PTH, vitamin D3, osteoclast activator and cytokine mediating Th1 immunity levels)","https://ClinicalTrials.gov/show/NCT02517918"
520,"NCT01285817","A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.","Recruiting","No Results Available","Solid Tumours.","Drug: celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,","Assistance Publique Hopitaux De Marseille","All","4 Years to 21 Years   (Child, Adult)","Phase 2","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-12|2010-021792-81","January 6, 2011","November 2010","March 2016","October 22, 2015","October 2015","No Study Results Posted","SFCE METRO 01","November 2015","Anti-tumour efficacy|Safety AND Pharmacodynamic Study","https://ClinicalTrials.gov/show/NCT01285817"
521,"NCT00396682","Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular Carcinoma","Completed","No Results Available","Advanced HCC","Drug: Cyclophosphamide","Hannover Medical School","All","18 Years and older   (Adult, Senior)","Phase 3","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HAN-HCC-002|DFG - KFO 119","November 6, 2006","February 2007","December 2008","February 3, 2009","February 2009","No Study Results Posted","null","December 2008","Frequency of CD4+CD25+regulatory T cells|Tumor specific immune responses|Toxicity|Function and Phenotype of CD4+CD25+ regulatory T cells|Tumor response|Survival","https://ClinicalTrials.gov/show/NCT00396682"
522,"NCT01003054","Autologous Transplantation for Chronic Myelogenous Leukemia","Completed","No Results Available","Chronic Myelogenous Leukemia","Drug: Busulfan|Drug: Cyclophosphamide|Drug: Imatinib Mesylate|Procedure: Autologous Stem Cell Transplantation","M.D. Anderson Cancer Center","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID02-672","October 26, 2009","March 2005","October 2009","October 31, 2011","October 2011","No Study Results Posted","null","December 2007","Number of participants with CML alive in cytogenetic remission at one year following treatment","https://ClinicalTrials.gov/show/NCT01003054"
523,"NCT01282216","Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide","Completed","No Results Available","Transplant-Related Cancer","Biological: Hepatitis A|Biological: PCV 13","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","61","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J10140|P01CA015396|NA_00044665","January 13, 2011","April 2011","October 2016","October 14, 2016","October 2016","No Study Results Posted","null","October 2016","To determine whether the vaccine-specific T cell immunity observed in the patient is augmented when the vaccine is also given to the bone marrow donor|To characterize vaccine-specific antibody titers in the transplant recipient.","https://ClinicalTrials.gov/show/NCT01282216"
524,"NCT00364754","Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer","Completed","No Results Available","Metastatic/Recurrent Breast Cancer","Drug: Tesmilifene (YMB 1002)","YM BioSciences","Female","18 Years to 55 Years   (Adult)","Phase 1","28","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","YMB1002 202","August 15, 2006","May 2004","January 2006","April 18, 2014","April 2014","No Study Results Posted","null","January 2006","The distribution of the pharmacokinetic variables will be summarized by treatment. The variables AUC and CMAX expressed as geometric means and ratios of geometric means on the original scale of measurement.|Adverse experiences will be collected and graded using the NCI Expanded Common Terminology Criteria for Adverse Events version 3.0.|Blood pressure, temperature, pulse and respiration will be tabulated across time and shift tables will be presented.|The tesmilifene concentration, haematology and biochemistry values will be tabulated across time.|Although response is not the endpoint of this trial, patients with measurable disease will be assessed by standard institutional criteria.","https://ClinicalTrials.gov/show/NCT00364754"
525,"NCT00591851","Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility","Completed","Has Results","Breast Cancer","Drug: AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)","Memorial Sloan Kettering Cancer Center|Amgen|Genentech, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04-126","December 26, 2007","December 2004","June 2008","November 24, 2014","November 2014","November 24, 2014","null","June 2008","Cardiac Saftey","https://ClinicalTrials.gov/show/NCT00591851"
526,"NCT00278538","Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus","Active, not recruiting","No Results Available","Systemic Lupus Erythematosus","Biological: Hematopoietic stem cell transplantation","Northwestern University","All","15 Years to 60 Years   (Child, Adult)","Phase 2","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DI SLE.Auto2003","January 15, 2006","August 2005","December 2018","January 12, 2017","January 2017","No Study Results Posted","null","December 2017","The primary efficacy outcome is overall survival and the proportion of participants who achieve and maintain remission after transplant.","https://ClinicalTrials.gov/show/NCT00278538"
527,"NCT00001384","A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients","Completed","No Results Available","Breast Cancer|Breast Neoplasms","Drug: Adriamycin|Drug: cyclophosphamide|Drug: G-CSF|Drug: paclitaxel","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","35","NIH","Interventional","Primary Purpose: Treatment","940145|94-C-0145","November 3, 1999","May 1994","February 2001","March 3, 2008","April 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001384"
528,"NCT01019876","Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases","Unknown status","No Results Available","Bone Marrow Failure|Osteopetrosis|Fanconi Anemia|Severe Combined Immunodeficiency","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Cyclophosphamide 40|Drug: Cyclophosphamide 30","Columbia University","All","up to 30 Years   (Child, Adult)","Phase 2|Phase 3","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AAAB0170|CHNY-01-509","November 23, 2009","June 2002","May 2013","October 18, 2011","October 2011","No Study Results Posted","null","May 2012","This study is to determine the toxicity of administering a fludarabine/cyclophosphamide (Flu/CY) or busulfan (Bu)/Flu based conditioning regimen followed by allogeneic stem cell transplant.|To determine the risk of disease progression (including neuropsychological deterioration in patients with metabolic non-malignant diseases) following a Flu/CY or Bu/Flu based conditioning regimen.|To measure immune reconstitution following a Flu/CY or Bu/Flu based conditioning regimen and AlloSCT in patients with selected non-malignant diseases.|To estimate the incidence and severity of GVHD following a Flu/Cy or Bu/Flu based conditioning regimen|To determine metabolic/immune (gene/protein) reconstitution by standard biochemical/PCR assays in patients","https://ClinicalTrials.gov/show/NCT01019876"
529,"NCT00074282","Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia","Unknown status","No Results Available","Leukemia","Biological: filgrastim|Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: lenalidomide|Drug: pentostatin","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","110","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000343796|ECOG-2903","December 10, 2003","December 2004","null","November 9, 2012","November 2012","No Study Results Posted","null","October 2014","Response (CR, nPR, PR) rate in all patients treated with PCR|Minimal-residual disease (MRD) as assessed by both flow cytometry and real-time allele-specific oligonucleotide polymerase chain reaction (RT-PCR)|Toxicity as measured by CTCAE criteria every month|Overall survival and progression-free survival as measured by Kaplan-Meier method during study treatment|Rate of molecular complete remission (MCR) after the treatment of PCR and alemtuzumab (before May 2011) or lenalidomide after May 2011) in patients who achieve a CR or nPR","https://ClinicalTrials.gov/show/NCT00074282"
530,"NCT00002475","Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Kidney Cancer|Lung Cancer|Malignant Mesothelioma|Pancreatic Cancer","Biological: allogeneic tumor cell vaccine|Biological: autologous tumor cell vaccine|Biological: recombinant interferon alfa|Biological: recombinant interferon gamma|Biological: sargramostim|Drug: cyclophosphamide","St. Vincent Medical Center - Los Angeles|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Primary Purpose: Treatment","SVMC-ONC-222|CDR0000076913|NCI-V91-0075","November 1, 1999","April 1991","June 2009","July 9, 2013","November 2008","No Study Results Posted","null","December 2007","Clinical response (patients with evaluable disease)|Duration of response (patients with evaluable disease)|Survival (patients with evaluable disease)|Time to recurrence (patients without evaluable disease)|Survival (patients without evaluable disease)","https://ClinicalTrials.gov/show/NCT00002475"
531,"NCT00352872","Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer","Unknown status","No Results Available","Breast Cancer","","Indiana University School of Medicine|Indiana University","Female","18 Years to 45 Years   (Adult)","Phase 4","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0501-37","July 13, 2006","February 2005","February 2010","May 25, 2010","May 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00352872"
532,"NCT00546377","Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer","Completed","Has Results","Leukemia|Lymphoma","Biological: filgrastim|Biological: pegfilgrastim|Biological: rituximab|Biological: sargramostim|Drug: cyclophosphamide|Drug: mitoxantrone hydrochloride|Drug: pentostatin|Genetic: fluorescence in situ hybridization|Genetic: gene rearrangement analysis|Genetic: polymerase chain reaction|Genetic: protein expression analysis|Other: flow cytometry|Procedure: biopsy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1|Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05-077|MSKCC-05077","October 17, 2007","July 2005","May 2014","April 7, 2016","April 2016","December 17, 2015","null","May 2014","Overall Response|Maximum Tolerated Dose (MTD) of Mitoxantrone","https://ClinicalTrials.gov/show/NCT00546377"
533,"NCT00493649","Adj TC + Herceptin Early Stage Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Taxotere|Drug: Cytoxan|Drug: Herceptin","US Oncology Research|Sanofi","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","493","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-038|11270","June 27, 2007","June 2007","April 2013","September 15, 2016","September 2016","January 12, 2016","null","April 2013","Disease-free Survival (DFS) Rate at 2 Years in TOP2A-amplified and in TOP2A-nonamplified HER2+ ESBC Patients Treated With TC+H.|Overall Survival (OS) Rate at 2 Years in TOP2A-amplified and in TOP2A-nonamplified HER2+ ESBC Patients Treated With TC+H.|DFS by cMyc Expression in This Population of HER2+ ESBC Patients Treated With TC+H.|OS by cMyc Expression in This Population of HER2+ ESBC Patients Treated With TC+H.","https://ClinicalTrials.gov/show/NCT00493649"
534,"NCT00772486","A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL","Unknown status","No Results Available","Chronic Lymphocytic Leukemia","Biological: ISF35","Memgen, LLC|The Leukemia and Lymphoma Society","All","18 Years and older   (Adult, Senior)","Phase 1","12","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLL-35-104","October 14, 2008","September 2008","null","November 18, 2010","November 2010","No Study Results Posted","null","April 2011","Assess toxicity, tolerability, and safety of repeat administration of three infusions of 3x10^8 ISF35 given intravenously in combination with a standard course of three treatments of fludarabine, rituximab and cyclophosphamide (FCR).|Explore the anti-leukemia activity of the repeat administration of ISF35 and FCR by evaluating reduction in leukemia count, reduction in lymphadenopathy and splenomegaly, improvement in bone marrow function, and response duration.|Assess induction of B and T cell anti-leukemia immune responses, antibody production against autologous CLL B cells, changes in bystander leukemia cell phenotype, and expression of genes and proteins related to apoptosis","https://ClinicalTrials.gov/show/NCT00772486"
535,"NCT02413320","Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer","Recruiting","No Results Available","Triple-negative Breast Cancer","Drug: Paclitaxel|Drug: Carboplatin|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Docetaxel","University of Kansas Medical Center","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-IIT-Neoadjuvant-BRST-TNBC","April 6, 2015","July 2015","December 2017","January 4, 2017","January 2017","No Study Results Posted","NeoSTOP","July 2017","Pathological complete response rates|Minimal residual disease rates","https://ClinicalTrials.gov/show/NCT02413320"
536,"NCT00641095","Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: fludarabine phosphate|Genetic: fluorescence in situ hybridization|Other: immunohistochemistry staining method|Other: immunologic technique|Other: laboratory biomarker analysis","Derriford Hospital|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","550","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CRUK-UCL-MCLIII|CDR0000589227|EUDRACT-2006-001965-41|MREC-02/6/31|EU-20824","March 20, 2008","December 2006","null","August 9, 2013","November 2008","No Study Results Posted","null","September 2010","Overall survival|Progression-free survival|Toxicity|Tumor response","https://ClinicalTrials.gov/show/NCT00641095"
537,"NCT00478452","Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients","Completed","No Results Available","Ovarian Cancer","Biological: DC-Ova|Biological: DC Ova with Cyclophosphamide","University of Pennsylvania|Fox Chase Cancer Center","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","14","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","707800|UPCC 01803","May 22, 2007","August 2005","August 2008","April 12, 2017","April 2017","No Study Results Posted","DC-Ova","August 2008","","https://ClinicalTrials.gov/show/NCT00478452"
538,"NCT03042585","Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL","Recruiting","No Results Available","Relapsed Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma","Radiation: Total body irradiation","Loyola University","All","18 Years and older   (Adult, Senior)","","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","108993","January 4, 2017","June 2006","December 2019","February 2, 2017","February 2017","No Study Results Posted","null","December 2019","Determine the frequency and severity of adverse events by evaluating grade 3 and grade 4 adverse events.|Blood work will be used to evaluate recovery of white blood cells, red blood cells and platelets.|Pulmonary Function Test will be used to evaluate side effects of total body irradiation|CT scan or physical exam will be used to evaluate progression free survival.|Mucositis measured by investigators.|Number of participants with Grade 4 through 5 Adverse Events that are related to study treatment, grading according to NCI CTCAE Version 3.|Mucositis measured by oral mucositis questionnaires","https://ClinicalTrials.gov/show/NCT03042585"
539,"NCT02455141","Adjuvant Treatment of EC Followed by wP and wPCb in Triple-Negative Breast Cancer","Recruiting","No Results Available","Breast Neoplasm","Drug: Epirubicin plus Cyclophosphamide|Drug: Paclitaxel|Drug: Paclitaxel plus Carboplatin","Shanghai Jiao Tong University School of Medicine","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","970","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RJBC1501","May 2, 2015","July 2015","December 2020","October 22, 2016","October 2016","No Study Results Posted","TPPC","June 2020","Disease-free survival|Overall Survival|Incidence of neutropenia fever|Incidence of grade 3-4 side effects","https://ClinicalTrials.gov/show/NCT02455141"
540,"NCT00001676","Cyclophosphamide and Fludarabine to Treat Lupus Nephritis","Completed","No Results Available","Glomerulonephritis|Lupus Nephritis|Systemic Lupus Erythematosus","Drug: SQ Fludarabine","National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 1","15","NIH","Interventional","Primary Purpose: Treatment","980055|98-AR-0055","November 3, 1999","January 1998","November 2002","March 3, 2008","November 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001676"
541,"NCT01992653","A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma","Active, not recruiting","No Results Available","Lymphoma, Non Hodgkin","Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Obinutuzumab|Drug: Polatuzumab Vedotin|Drug: Prednisolone|Drug: Prednisone|Drug: Rituximab","Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","85","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GO29044|2013-003541-42","October 28, 2013","November 2013","December 2018","February 7, 2017","February 2017","No Study Results Posted","null","December 2018","Percentage of Participants with Adverse Events|Percentage of Participants with Dose Limiting Toxicities|Maximum Tolerated Dose (MTD) of Polatuzumab Vedotin|Percentage of Participants with Objective Response (CR or Partial Response [PR]), as Assessed by Investigator using Cheson Criteria|Percentage of Participants with Anti-Polatuzumab Vedotin Antibodies|Percentage of Participants with Anti-Obinutuzumab Antibodies|Area Under the Concentration-Time Curve of Polatuzumab Vedotin|Maximum concentration (Cmax) of Polatuzumab Vedotin|Clearance (CL) of Polatuzumab Vedotin|Terminal Half-Life (t1/2) of Polatuzumab Vedotin|Steady-State Volume of Distribution (Vss) of Polatuzumab Vedotin|Plasma Levels of Cyclophosphamide|Plasma Levels of Doxorubicin|Percentage of Participants with Complete Response (CR), as Assessed by Investigator using Cheson Criteria|Peripheral Neuropathy Symptom Severity: Therapy-Induced Neuropathy Assessment Scale (TINAS) Overall Neuropathy Severity Score|Peripheral Neuropathy Symptom Interference: TINAS Numbness/Tingling Item Score|Duration of Response, as Assessed by Investigator Using Cheson Criteria|Progression Free Survival, as Assessed by Investigator Using Cheson Criteria|Event Free Survival, as Assessed by Investigator Using Cheson Criteria|Relative Dose Intensity of Polatuzumab Vedotin (Ratio of the Amount of Drug Actually Administered to the Amount Planned)|Overall Survival","https://ClinicalTrials.gov/show/NCT01992653"
542,"NCT00747877","High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy","Unknown status","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Drug: cyclophosphamide|Drug: melphalan|Procedure: autologous hematopoietic stem cell transplantation","Leeds Cancer Centre at St. James's University Hospital|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","460","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","LCC-HM05/7287|CDR0000612567|EU-20873|ISRCTN60123120|EudraCT-2006-005890-24","September 4, 2008","April 2008","null","August 9, 2013","June 2009","No Study Results Posted","null","April 2012","Time to disease progression|Response rate to bortezomib, doxorubicin hydrochloride, and dexamethasone (PAD)|Overall response rate following randomized treatments|Overall survival|Progression-free survival|Toxicity and safety of autologous stem cell transplantation|Toxicity and safety of weekly cyclophosphamide|Toxicity and safety of PAD therapy|Feasibility of stem cell collection|Pain|Quality of life","https://ClinicalTrials.gov/show/NCT00747877"
543,"NCT00712881","Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: MYOCET® Plus Cyclophosphamide and Trastuzumab, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles|Drug: Free Doxorubicin Plus Cyclophosphamide, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles","Cephalon|Teva Pharmaceutical Industries","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","126","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","C19562/2037|2008-000709-12","July 8, 2008","October 2008","December 2015","February 5, 2016","February 2016","No Study Results Posted","null","September 2015","Pathological complete response (pCR) in breast, upon histologic examination.|Assess the proportion of patients who achieve an objective response [Complete Response (CR) or Partial Response (PR)] as defined by WHO guidelines.|Occurrence of class III or IV (NYHA) congestive heart failure (CHF) at any time during the study.|Reduction from baseline left ventricular ejection fraction (LVEF) ﻿at any time during the study.|Occurrence of adverse events throughout the study, characterized by NCI CTCAE version 3 guidelines.|Assess the proportion of patients with progression-free survival (PFS) 5 years after being randomly assigned to treatment.|Assess the proportion of patients who achieve pathological complete response (pCR) in breast and axillary lymph node.|Assess the proportion of patients with conservative surgery.","https://ClinicalTrials.gov/show/NCT00712881"
544,"NCT00869973","Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients","Terminated","No Results Available","Emesis","Drug: Aprepitant|Drug: dexamethasone","S. Maria Hospital, Terni","Female","18 Years and older   (Adult, Senior)","Phase 3","580","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","IGAR-02-2009|2008-001237-95","March 25, 2009","September 2009","July 2012","January 22, 2013","October 2009","No Study Results Posted","null","July 2012","Percentage of complete responses (no vomiting and no rescue treatment) on days 2-5 after chemotherapy administration|Evaluation of the impact on quality of life of the two antiemetic regimens|Evaluation of the prognostic factors of delayed emesis in patients receiving a combination of aprepitant, palonosetron and dexamethasone for the prevention of acute emesis","https://ClinicalTrials.gov/show/NCT00869973"
545,"NCT00094380","Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)","Completed","No Results Available","Lupus Erythematosus, Systemic|Lupus Nephritis","Drug: CTLA4-IgG4m (RG2077)|Drug: Cyclophosphamide","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","6","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DAIT ITN002AI","October 16, 2004","September 2004","January 2006","January 10, 2017","January 2017","No Study Results Posted","null","January 2006","Safety, as measured by the occurrence of adverse events|Renal function|Lupus serology|SLE disease activity","https://ClinicalTrials.gov/show/NCT00094380"
546,"NCT02210104","Adoptive Therapy Using Antigen-Specific CD4 T-Cells","Not yet recruiting","No Results Available","Melanoma|Sarcoma","Drug: Ipilimumab|Drug: Cyclophosphamide|Biological: CD4+ T cells","M.D. Anderson Cancer Center|National Institutes of Health (NIH)|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013-0669|R01CA104711-09","August 4, 2014","December 2016","null","August 9, 2016","August 2016","No Study Results Posted","null","December 2019","Maximum Tolerated Dose (MTD) of Adoptively Transferred CD4 T Cells|Clinical Response","https://ClinicalTrials.gov/show/NCT02210104"
547,"NCT00789581","A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Ixabepilone (Ixempra)|Drug: Paclitaxel (Taxol)","SCRI Development Innovations, LLC|Bristol-Myers Squibb","Female","18 Years and older   (Adult, Senior)","Phase 3","614","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SCRI BRE 145|TITAN","November 11, 2008","December 2008","November 2016","March 1, 2017","March 2017","November 7, 2016","TITAN","December 2015","Disease-free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00789581"
548,"NCT02685111","Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)","Not yet recruiting","No Results Available","Breast Cancer|Neutropenia|Febrile Neutropenia","Drug: Filgrastim|Drug: Peg-filgrastim","Asan Medical Center|Kyowa Hakko Kirin Co., Ltd","Female","19 Years to 70 Years   (Adult, Senior)","Phase 2","162","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","AMC 2015-1143","February 10, 2016","February 2016","March 2019","February 13, 2016","February 2016","No Study Results Posted","null","December 2018","Cumulative incidence of febrile neutropenia|Incidence of febrile neutropenia at each cycle|Rates of anti-microbial use|Duration of anti-microbial use|Cumulative dose of chemotherapeutic agents|Delay rate of next chemotherapy cycle due to inadequate neutrophil recovery|Duration of delay of next chemotherapy cycle due to inadequate neutrophil recovery","https://ClinicalTrials.gov/show/NCT02685111"
549,"NCT00408967","Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.","Terminated","No Results Available","Ovarian Cancer","Drug: Tucotuzumab celmoleukin (EMD 273066)","EMD Serono","Female","18 Years and older   (Adult, Senior)","Phase 2","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 62206-016","December 6, 2006","December 2006","June 2007","June 27, 2014","October 2013","No Study Results Posted","null","May 2007","","https://ClinicalTrials.gov/show/NCT00408967"
550,"NCT00652691","Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer","Active, not recruiting","No Results Available","Ovarian Cancer|Peritoneal Cavity Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: topotecan hydrochloride|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Mayo Clinic|National Cancer Institute (NCI)","Female","18 Years to 70 Years   (Adult, Senior)","Phase 1","48","Other|NIH","Interventional","Primary Purpose: Treatment","976101|P30CA015083|1056-98","April 3, 2008","August 1998","December 2017","March 21, 2017","April 2016","No Study Results Posted","null","December 2017","Maximum tolerated dose of topotecan hydrochloride|Toxicity according to NCI criteria","https://ClinicalTrials.gov/show/NCT00652691"
551,"NCT00066482","Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors","Completed","No Results Available","Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor","Biological: bleomycin sulfate|Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: conventional surgery|Biological: MESNA","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","","19","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AGCT01P1|CDR0000316244","August 6, 2003","July 2004","null","October 15, 2013","October 2013","No Study Results Posted","null","April 2007","Feasibility of adding cyclophosphamide to a PEB backbone|Maximum tolerated dose|Estimate the response rate","https://ClinicalTrials.gov/show/NCT00066482"
552,"NCT00868413","Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","Completed","No Results Available","Chronic Lymphocytic Leukemia","Drug: ABT-263|Drug: FCR|Drug: BR","AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie","All","18 Years and older   (Adult, Senior)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","M10-458","March 20, 2009","November 2009","May 2013","June 5, 2013","May 2013","No Study Results Posted","null","May 2013","Assess the safety profile, characterize pharmacokinetics, and determine the MTD and recommended Phase 2 dose (RPTD) of ABT-263 when administered in combination with either FCR or BR in subjects with relapsed or refractory CLL.|Evaluate preliminary data regarding progression-free survival (PFS), tumor response rate and overall survival (OS) when ABT-263 is administered in combination with either FCR or BR.","https://ClinicalTrials.gov/show/NCT00868413"
553,"NCT02294552","Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT","Active, not recruiting","No Results Available","Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Lymphoma|Myelodysplastic Syndromes|Chronic Lymphocytic Leukemia|Immune System Diseases","Drug: Cyclophosphamide|Drug: Busulfan|Drug: Fludarabine monophosphate|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Procedure: Allogeneic hematopoietic stem cell transplantation","St. Petersburg State Pavlov Medical University","All","18 Years to 65 Years   (Adult)","Phase 2","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PTCy-2014","October 30, 2014","October 2014","November 2017","January 8, 2016","January 2016","No Study Results Posted","null","November 2016","Incidence of acute and chronic GVHD, requiring treatment|Incidence of primary graft failure|Non-relapse mortality analysis|Overall survival analysis|Event-free survival analysis|Relapse rate analysis|Toxicity based NCI CTC grades|Infectious complications, including analysis of severe bacterial, fungal and viral infections incidence","https://ClinicalTrials.gov/show/NCT02294552"
554,"NCT00005866","S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes","Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)","All","16 Years to 55 Years   (Child, Adult)","Phase 3","240","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","S9920|U10CA032102","June 2, 2000","February 2000","March 2006","March 5, 2015","March 2015","No Study Results Posted","null","March 2004","Event-free survival","https://ClinicalTrials.gov/show/NCT00005866"
555,"NCT00074178","Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: pegfilgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: etoposide phosphate|Drug: methotrexate","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","16 Years to 75 Years   (Child, Adult, Senior)","Phase 2","22","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IRB00000935|5729-2|ONC-99055-L|935|OHSU-5729-2","December 10, 2003","January 2000","July 2006","April 19, 2017","April 2017","No Study Results Posted","Protocol-B","July 2006","Survival as measured by clinical and radiographic response at 5 years after study treatment|Overall survival as measured by clinical and radiographic response|Progression-free survival as measured by clinical and radiographic response until tumor progression|Quality of Life (QOL) as measured by EORTC QOL before and after study treatment, every 6 months for 2 years, and then annually","https://ClinicalTrials.gov/show/NCT00074178"
556,"NCT00022516","Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Cyclophosphamide|Drug: Methotrexate","International Breast Cancer Study Group","All","18 Years to 120 Years   (Adult, Senior)","Phase 3","1086","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000068827|IBCSG-22-00|2005-005666-36|EU-20119","August 10, 2001","November 2000","August 2016","August 5, 2016","August 2016","November 6, 2015","22-00","January 2015","Disease-free Survival|Overall Survival|Distant Recurrence-free Interval|Breast Cancer-free Interval","https://ClinicalTrials.gov/show/NCT00022516"
557,"NCT00003870","Monoclonal Antibody Therapy, Cyclophosphamide, and Total-Body Irradiation Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Recurrent Acute Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Drug: cyclophosphamide|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation|Radiation: iodine I 131 monoclonal antibody BC8|Radiation: radiation therapy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","2 Years to 55 Years   (Child, Adult)","Phase 2","40","Other|NIH","Interventional","Primary Purpose: Treatment","1298.00|FHCRC-1298.00|NCI-H99-0029|CDR0000067034","November 1, 1999","February 1999","November 2001","March 31, 2010","March 2010","No Study Results Posted","null","November 2001","","https://ClinicalTrials.gov/show/NCT00003870"
558,"NCT01349101","A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors","Recruiting","No Results Available","Hematological Malignancies","Radiation: Total Body Irradiation|Drug: Cyclophosphamide|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Drug: Fludarabine|Drug: Busulfan|Genetic: Hematopoietic stem cell transplantation","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 2","81","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","11D.51|2010-54","April 26, 2011","February 10, 2011","February 2020","May 17, 2017","May 2017","No Study Results Posted","null","January 2019","Successful Engraftment Using Cyclophosphamide Post-Transplant|Incidence of Grade III-IV GVHD|Incidence of GVHD Unresponsive to Corticosteroids and Photopheresis|Transplant-Related Mortality","https://ClinicalTrials.gov/show/NCT01349101"
559,"NCT02349178","Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT","Terminated","No Results Available","Leukemia, Acute Lymphoblastic|Acute Myeloid Leukemia","Drug: Clofarabine|Drug: Cyclophosphamide|Drug: Etoposide","Medical College of Wisconsin|American Family Children’s Hospital|Nationwide Children's Hospital","All","up to 39 Years   (Child, Adult)","Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Bridging","January 23, 2015","December 2014","December 2018","May 5, 2017","May 2017","No Study Results Posted","null","December 2018","Minimal residual disease","https://ClinicalTrials.gov/show/NCT02349178"
560,"NCT00798070","Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients","Active, not recruiting","No Results Available","Breast Cancer","Drug: dtEC→dtT|Drug: FEC→T","Karolinska University Hospital|Swedish Breast Cancer Group|Austrian Breast & Colorectal Cancer Study Group|German Breast Group","Female","18 Years to 65 Years   (Adult)","Phase 3","2017","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PANTHER SBG2004-1|2007-002061-12|ISRCTN39017665|ABCSG25|GBG53","November 24, 2008","February 2007","January 2022","November 16, 2016","November 2016","No Study Results Posted","PANTHER","April 2016","Breast cancer relapse-free survival|Distant disease-free survival|Event-free survival|Overall survival|Health-related quality of life and toxicity analyses according to CTC|Outcome in relation to tumour biological factors and polymorphism patterns|BCRFS in arm A in relation to given dose levels","https://ClinicalTrials.gov/show/NCT00798070"
561,"NCT00006042","Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: filgrastim|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","up to 70 Years   (Child, Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068057, J9966|P30CA006973|JHOC-J9966|JHOC-99110501|NCI-G00-1816","July 5, 2000","December 1999","null","March 9, 2010","March 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006042"
562,"NCT01255319","Cyclophosphamide, Fludarabine and Antithymocyte Globulin Conditioning in Myelodysplastic Syndrome (MDS)","Unknown status","No Results Available","Myelodysplastic Syndrome","","Cooperative Study Group A for Hematology","All","15 Years and older   (Child, Adult, Senior)","","15","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Allo-038","November 30, 2010","November 2010","November 2014","December 6, 2010","December 2010","No Study Results Posted","CyFluATG","November 2012","feasibility and efficacy|progression-free survival, and overall survival","https://ClinicalTrials.gov/show/NCT01255319"
563,"NCT00941720","Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma","Active, not recruiting","Has Results","Multiple Myeloma and Plasma Cell Neoplasm","Drug: busulfan|Drug: cyclophosphamide|Procedure: autologous hematopoietic stem cell transplantation","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","71","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CASE1A07|P30CA043703","July 17, 2009","June 11, 2009","May 2018","April 13, 2017","April 2017","February 13, 2014","null","February 28, 2013","Relapse-free Survival|Overall Survival|Pulmonary Toxicity","https://ClinicalTrials.gov/show/NCT00941720"
564,"NCT00358657","Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders","Recruiting","No Results Available","Immunodeficiency Syndrome|Non-Cancer Diagnosis|Severe Aplastic Anemia","Procedure: Allogeneic Bone Marrow Transplantation|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Sirolimus|Drug: Tacrolimus|Radiation: Total-Body Irradiation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)","All","up to 54 Years   (Child, Adult)","Phase 2","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2032.00|NCI-2010-00192|2032|P01HL122173|P30CA015704","July 28, 2006","May 2006","null","May 22, 2017","May 2017","No Study Results Posted","null","March 2018","Graft rejection/failure rate|Incidence of grade III/IV acute GVHD preceding diagnosis of chronic GVHD|Transplant related mortality|Proportion of patients who achieve greater than 5% donor T-cell chimerism","https://ClinicalTrials.gov/show/NCT00358657"
565,"NCT00669877","Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma","Completed","No Results Available","Burkitt's Lymphoma|Burkitt'S-like Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Dexamethasone|Drug: G-CSF|Drug: Cytarabine|Drug: Methotrexate","M.D. Anderson Cancer Center","All","Child, Adult, Senior","Phase 2","56","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID02-229|NCI-2010-01455","April 28, 2008","August 2002","null","October 8, 2015","October 2015","No Study Results Posted","null","October 2015","Number of Patients with Complete Remission (CR) + Disease-Free Survival","https://ClinicalTrials.gov/show/NCT00669877"
566,"NCT02362165","CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma","Recruiting","No Results Available","Multiple Myeloma","Drug: Cyclophosphamide|Drug: Bortezomib|Drug: Dexamethasone|Drug: Doxorubicin","Sun Yat-sen University","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","236","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SYSUCC-MM-308","February 8, 2015","April 2015","May 2018","April 18, 2016","April 2016","No Study Results Posted","null","April 2018","At least very good partial response rate (according to the criteria IMWG) after four cycles of induction therapy|complete response rate(according to the criteria IMWG) after four cycles of induction therapy|At least partial response rate (according to the criteria IMWG) after four cycles of induction therapy","https://ClinicalTrials.gov/show/NCT02362165"
567,"NCT00317785","Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases","Completed","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes","Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Drug: mycophenolate mofetil|Drug: sirolimus|Drug: tacrolimus|Other: pharmacological study|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","50","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","1998.00|FHCRC-1998.00|CDR0000471840","April 24, 2006","May 2005","null","May 5, 2010","May 2010","No Study Results Posted","null","November 2007","Non-relapse mortality (NRM) at 200 days|Overall survival|Relapse rate|Sinusoidal obstruction syndrome (SOS)|Acute renal failure|Respiratory failure|Cause of death","https://ClinicalTrials.gov/show/NCT00317785"
568,"NCT01049425","Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer","Active, not recruiting","No Results Available","Primary Breast Cancer|Her2 Non-overexpressing","Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Cyclophosphamide|Drug: Docetaxel","West German Study Group|Sanofi|Amgen","Female","18 Years to 75 Years   (Adult, Senior)","Phase 3","2448","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","WSG AM04","January 12, 2010","January 2009","December 2016","June 18, 2015","June 2015","No Study Results Posted","planB","July 2011","disease-free survival in patients treated with either 6 cycles of Docetaxel / Cyclophosphamide chemotherapy or 4 cycles of EC followed by 4 cycles of Docetaxel as adjuvant treatment","https://ClinicalTrials.gov/show/NCT01049425"
569,"NCT00004464","Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria","Unknown status","No Results Available","Aplastic Anemia|Paroxysmal Hemoglobinuria, Nocturnal","Drug: cyclophosphamide|Drug: filgrastim","Johns Hopkins University|Office of Rare Diseases (ORD)","All","up to 70 Years   (Child, Adult, Senior)","","25","Other","Interventional","Primary Purpose: Treatment","199/13895|JHOC-96011702|JHOC-9611","October 18, 1999","February 1996","null","March 28, 2007","March 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004464"
570,"NCT00336414","Five-Year Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis","Withdrawn","No Results Available","Systemic Lupus Erythematosus Nephritis","Drug: cyclophosphamide-prednisone-azathioprine","Istituto Giannina Gaslini","All","1 Year to 18 Years   (Child, Adult)","Phase 3","159","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind|Primary Purpose: Treatment","IGG-PRINTO-003","June 12, 2006","June 2006","June 2007","June 27, 2007","June 2007","No Study Results Posted","null","null","Primary: 50% improvement in at least 2 core set variables with no more tha 1 of the remaining variables worsened by> 30%|core set variables:|physician’s global assessment of disease activity on a 10 cm visual analogue scale; global disease activity measure by the mean of the European Consensus Lupus Activity parent’s/patient’s global assessment of overall well-being on a 10 cm VAS;|health-related quality of life assessment.|Change over time in the individual components of the JSLE|core set of variables; time to proteinuria disappearance; frequency of drop-out from|suggested steroids use; frequency of drop-out for inefficacy of treatment.","https://ClinicalTrials.gov/show/NCT00336414"
571,"NCT02192775","UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus","Recruiting","No Results Available","Multiple Myeloma","Drug: MV-NIS","University of Arkansas","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","203081","July 2, 2014","March 2015","August 2017","October 6, 2016","October 2016","No Study Results Posted","null","August 2017","The effectiveness of MV-NIS therapy as measured by the International Myeloma Working Group (IMWG) guidelines","https://ClinicalTrials.gov/show/NCT02192775"
572,"NCT01145976","Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia","Unknown status","No Results Available","Aplastic Anemia","Drug: Cy-ATG|Drug: Flu-ATG","Cooperative Study Group A for Hematology","All","15 Years to 65 Years   (Child, Adult)","Phase 3","98","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","C-021","May 19, 2010","March 2010","February 2016","September 6, 2012","September 2012","No Study Results Posted","CyATG-FluATG","February 2015","regimen-related toxicities(RRT)|Overall feasibility","https://ClinicalTrials.gov/show/NCT01145976"
573,"NCT00099281","DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer","Terminated","No Results Available","Breast Cancer|Metastases","Drug: YMB 1002","YM BioSciences","Female","16 Years and older   (Child, Adult, Senior)","Phase 3","700","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","YMB1002 02","December 10, 2004","May 2004","June 2006","February 27, 2007","February 2007","No Study Results Posted","null","null","Overall survival|Response rate|Progression-free survival|Toxicity|Neurocognitive function","https://ClinicalTrials.gov/show/NCT00099281"
574,"NCT00630253","Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia","Recruiting","No Results Available","Fanconi Anemia","Biological: Anti-Thymocyte Globulin|Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: Hematopoietic Stem Cell Transplantation|Drug: Methylprednisolone|Drug: Filgrastim|Drug: Cyclosporine|Drug: Mycophenolate Mofetil","Masonic Cancer Center, University of Minnesota","All","up to 59 Years   (Child, Adult)","Phase 1|Phase 2","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MT2000-09|0001M34441","March 5, 2008","February 17, 2000","June 2019","March 28, 2017","March 2017","No Study Results Posted","null","December 2018","Graft failure|Incidence of Acute Graft-Versus-Host Disease (GVHD)|Overall survival|Incidence of Chronic Graft-Versus-Host Disease (GVHD)|Transplant Related Deaths","https://ClinicalTrials.gov/show/NCT00630253"
575,"NCT00849472","Treatment With Pazopanib for Neoadjuvant Breast Cancer","Completed","Has Results","Neoplasms, Breast","Drug: doxorubicin + cyclophosphamide|Drug: paclitaxel + pazopanib|Procedure: surgery|Drug: pazopanib monotherapy","GlaxoSmithKline|NSABP Foundation Inc","Female","18 Years and older   (Adult, Senior)","Phase 2","101","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","110264|NSABP FB-6","February 12, 2009","July 2009","April 2013","January 30, 2014","December 2013","December 6, 2012","null","December 2011","Number of Participants With Pathologic Complete Response (pCR) in the Breast and Nodes|Number of Participants With Pathologic Complete Response (pCR) in the Breast|Number of Participants With Clinical Complete Response (cCR) in the Breast and Nodes at the Completion of the Doxorubicin and Cyclophosphamide (AC) Period|Number of Participants With Clinical CR (cCR) in the Breast and Nodes at the Completion of the AC and Weekly Paclitaxel (WP) + Pazopanib Preoperative Periods|Invasive Recurrence-free Interval (IRFI)|Number of Participants With Cardiac Toxicity (Per Common Terminology Criteria for Adverse Events Version 3) at the Completion of the AC Period|Number of Participants With Cardiac Toxicity (Per CTCAE Version 3) at the Completion of the AC and Weekly Paclitaxel (WP) + Pazopanib Preoperative Periods|Number of Participants With Cardiac Toxicity (Per CTCAE Version 3.0) During the Postoperative Pazopanib Period|Participants With Normal Thyroid Stimulating Hormone (TSH) Levels at Baseline Who Had an Elevated TSH Level at Least Once During the Study and During the Individual Study Periods|Number of Participants With the Indicated Radiotherapy-related Complications|Number of Participants With Recurrence Events","https://ClinicalTrials.gov/show/NCT00849472"
576,"NCT01898117","Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Bevacizumab as First-line Treatment in Advanced Triple Negative Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Carbo/cyclo|Drug: Carbo/cyclo + bevacizumab|Drug: Paclitaxel|Drug: Paclitaxel + Bevacizumab","The Netherlands Cancer Institute|Borstkanker Onderzoek Groep|Roche Pharma AG","All","Child, Adult, Senior","Phase 2","304","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: No masking|Primary Purpose: Treatment","M13TNB|2013-001484-23|NL44403.031.13","June 27, 2013","July 2013","December 2029","April 13, 2017","April 2017","No Study Results Posted","Triple-B","December 2019","Determine PFS in the different VEGFR2 levels|Validate the BRCA-like test|Improvement of PFS by adding bevacicumab|Define predictive biomarkers for PFS gain|Determine PFS|Overall survival (OS)|Toxicity of all study regimens","https://ClinicalTrials.gov/show/NCT01898117"
577,"NCT00436709","Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: bevacizumab|Biological: pegfilgrastim|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel albumin-stabilized nanoparticle formulation|Other: flow cytometry|Other: immunoenzyme technique|Other: immunologic technique|Other: laboratory biomarker analysis|Procedure: adjuvant therapy|Procedure: immunoscintigraphy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","75","Other|NIH","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000529855|MSKCC-06019","February 15, 2007","July 2006","null","January 3, 2014","June 2007","No Study Results Posted","null","null","Safety|Noncardiac toxicity|Time to tumor recurrence|Overall survival","https://ClinicalTrials.gov/show/NCT00436709"
578,"NCT01354522","TAC Versus TCX as Adjuvant Treatment for Node-Positive Her2-Negative Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: Docetaxel, Doxorubicin, Cyclophosphamide|Drug: Docetaxel, Cyclophosphamide, Capecitabine","Peking Union Medical College Hospital","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PUMCH-Breast-TCX","May 9, 2011","May 2011","null","January 14, 2014","January 2014","No Study Results Posted","null","December 2014","disease-free survival|Overall survival|Adverse event rate (CTCAE v. 3.0)","https://ClinicalTrials.gov/show/NCT01354522"
579,"NCT02053597","TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen","Withdrawn","No Results Available","Breast Cancer","Drug: Doxorubicin|Drug: paclitaxel","Jules Bordet Institute","Female","18 Years to 40 Years   (Adult)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CE2142|2013-000173-77","January 27, 2014","October 2014","July 2015","September 16, 2015","September 2015","No Study Results Posted","TRIUMPH","July 2015","Change from baseline in ovarian function|Change from baseline in menstrual function|Ovarian reserve|Occurence of Adverse Events|Impact of treatment on the behavior of menstruation after menses resumption|Evaluate the impact of a cyclophosphamide-free regimen on sexual function|Evaluate the impact of the regimen on peripheral neurotoxicity|Pregnancy rate after cessation of chemotherapy|Event-free survival","https://ClinicalTrials.gov/show/NCT02053597"
580,"NCT00070278","Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: gemcitabine hydrochloride|Drug: paclitaxel|Genetic: comparative genomic hybridization|Genetic: microarray analysis|Genetic: mutation analysis|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Cambridge University Hospitals NHS Foundation Trust|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","800","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CRUK-neo-tAnGo|CDR0000331863|EU-20316","October 3, 2003","January 2005","null","August 6, 2013","January 2009","No Study Results Posted","null","September 2007","Complete pathological response after 4 courses|Survival|Disease-free survival|Effect of prognostic factors","https://ClinicalTrials.gov/show/NCT00070278"
581,"NCT02971982","PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia","Recruiting","No Results Available","Treatment","Drug: rituximab /Dexamethasone/cyclophosphamide|Drug: Velcade/Dexamethasone/cyclophosphamide","The First Affiliated Hospital of Soochow University","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","myeloma-02","October 19, 2016","October 2016","December 2018","November 20, 2016","October 2016","No Study Results Posted","null","October 2018","Investigators try to compare the very good partial remission (VGPR) rate at the end of the research.|Investigators try to compare the complete remission (CR) rates at the end of the research.|Investigators try to compare Overall remission rate (MR+CR + VGPR + partial remission (PR) rate) at the end of the research.|Investigators try to compare major reaction rate (MRR, PR+VGPR+CR) at the end of the research.","https://ClinicalTrials.gov/show/NCT02971982"
582,"NCT00381004","FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia","Completed","Has Results","Chronic Lymphocytic Leukemia","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Sargramostim|Drug: Rituximab","M.D. Anderson Cancer Center|Bayer","All","Child, Adult, Senior","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-0267","September 25, 2006","September 2006","December 2014","December 14, 2015","December 2015","July 20, 2015","null","December 2014","Participant Overall Response Rate (ORR) at 6 Months Includes Complete Remissions, Partial Remission, or Nodule Partial Remissions.|Number of Participants With Overall Response Includes Complete Remissions, Partial Remission, or Nodule Partial Remissions.|Number of Participants Progression-free","https://ClinicalTrials.gov/show/NCT00381004"
583,"NCT02785250","Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer","Recruiting","No Results Available","Recurrent Epithelial Ovarian Cancer|Recurrent Fallopian Tube Cancer|Recurrent Peritoneal Cancer","Biological: DPX-Survivac|Drug: Cyclophosphamide|Drug: Epacadostat (INCB024360)","ImmunoVaccine Technologies, Inc.|Incyte Corporation","Female","18 Years and older   (Adult, Senior)","Phase 1","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ONC-DPX-Survivac-06","May 18, 2016","April 2016","May 2018","August 17, 2016","August 2016","No Study Results Posted","null","May 2018","Safety as measured by adverse event reporting (CTCAE)|Cell mediated immunity as measured by the antigen specific response in peripheral blood|Evaluation of treatment-induced changes in tumor infiltrating lymphocytes|Objective Response Rate|Duration of Response|Time to Progression|Overall Survival","https://ClinicalTrials.gov/show/NCT02785250"
584,"NCT01685411","Busulfan and Cyclophosphamide Followed By ALLO BMT","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome","Drug: Allopurinol|Drug: Keppra|Drug: Busulfan|Drug: Cyclophosphamide|Drug: Cyclosporine A|Drug: Mycophenolate mofetil|Biological: Allogeneic hematopoietic stem cell transplant|Biological: Filgrastim|Biological: antithymocyte globulin","Masonic Cancer Center, University of Minnesota","All","up to 44 Years   (Child, Adult)","","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2011OC139|MT2011-20C","September 5, 2012","January 2013","September 2025","August 15, 2016","August 2016","No Study Results Posted","null","September 2025","Disease Free Survival|Days to Neutrophil Engraftment|Incidence of Acute Graft-Versus-Host Disease|Incidence of Chronic Graft-Versus-Host Disease|Incidence of Treatment-Related Toxicity|Incidence of Relapse|Incidence of Engraftment Failure|Overall Survival","https://ClinicalTrials.gov/show/NCT01685411"
585,"NCT00005908","Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer","Completed","Has Results","Breast Cancer|Breast Neoplasm","Drug: Docetaxel - Dose A|Drug: Anastrozole|Drug: cyclophosphamide|Drug: Docetaxel - Dose B|Drug: Doxorubicin hydrochloride|Drug: Tamoxifen Citrate|Drug: Capecitabine - Dose B|Drug: Capecitabine - Dose A","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","30","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","000149|00-C-0149","June 13, 2000","June 2000","January 2008","March 13, 2013","March 2013","February 14, 2012","null","January 2008","Number of Participants With Adverse Events|Overall Clinical Response Rate|Complementary Deoxyribonucleic Acid (cDNA) Expression|Number of Participants, e.g. Responders and Non-responders With a Percent Change in Expression Patterns After Chemotherapy With Changes in Expression Patterns After Chemotherapy in Preclinical Models","https://ClinicalTrials.gov/show/NCT00005908"
586,"NCT01516307","Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects","Active, not recruiting","No Results Available","Metastatic Breast Cancer","Biological: OPT-822/OPT-821(30 μg/100 μg) + Cyclophosphamide|Biological: Phosphate Buffer Saline (PBS) + Cyclophosphamide","OBI Pharma, Inc","Female","21 Years and older   (Adult, Senior)","Phase 2","349","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","OPT-822-001","January 19, 2012","December 2011","August 2019","March 2, 2017","March 2017","No Study Results Posted","null","August 2016","Progression Free Survival (PFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT01516307"
587,"NCT02812940","Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT","Recruiting","No Results Available","Graft-versus-Host Disease","Drug: Everolimus","University of Cologne","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","Uni-Koeln 1717","June 19, 2016","April 2016","December 2018","June 24, 2016","June 2016","No Study Results Posted","OCTET-Ever","June 2018","Incidence of acute GvHD III-IV° until day +100 after allogenic stem cell transplantation|Incidence of acute GvHD II-IV° until day +100 after allogenic stem cell transplantation|Incidence of severe chronic GvHD|Incidence of overall chronic GvHD|Relapse incidence|Non-relapse mortality|Overall survival|Immune reconstitution|Engraftment|Chimerism","https://ClinicalTrials.gov/show/NCT02812940"
588,"NCT00001426","A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer","Completed","No Results Available","Ovarian Neoplasm","Drug: Cyclophosphamide|Drug: Paclitaxel|Drug: Cisplatin|Drug: G-CSF","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Senior","Phase 2","47","NIH","Interventional","Primary Purpose: Treatment","950055|95-C-0055","November 3, 1999","February 3, 1995","November 7, 2013","April 19, 2017","November 7, 2013","No Study Results Posted","null","October 15, 2007","","https://ClinicalTrials.gov/show/NCT00001426"
589,"NCT01451580","Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer","Unknown status","No Results Available","Metastatic Breast Cancer","Drug: Lipo-Dox","TTY Biopharm","All","20 Years and older   (Adult, Senior)","Phase 2","47","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label","LD0411","October 11, 2011","September 2005","null","October 12, 2011","October 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT01451580"
590,"NCT00002837","High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: Filgrastim (G-CSF)|Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Paclitaxel|Procedure: Peripheral Blood Stem Cell Transplantation","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb","All","15 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","21","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM95-156|P30CA016672|MDA-DM-95156|NCI-V96-1017|CDR0000065052","November 1, 1999","September 1995","January 2002","July 27, 2012","July 2012","No Study Results Posted","null","January 2002","Maximum Tolerated Doses (MTD) of 4 courses Doxorubicin, Paclitaxel, + Cyclophosphamide followed by PBSC and G-CSF Support","https://ClinicalTrials.gov/show/NCT00002837"
591,"NCT00010413","Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus","Completed","No Results Available","Pemphigus","Drug: cyclophosphamide|Drug: filgrastim","Johns Hopkins University|Office of Rare Diseases (ORD)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","35","Other","Interventional","Primary Purpose: Treatment","199/15674|JHOC-J9912|JHOC-99022610","February 2, 2001","April 1999","null","October 1, 2008","October 2008","No Study Results Posted","null","August 2007","","https://ClinicalTrials.gov/show/NCT00010413"
592,"NCT00856180","Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies","Completed","Has Results","Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer","Drug: Bevacizumab|Drug: Cyclophosphamide","Dana-Farber Cancer Institute|Massachusetts General Hospital|Brigham and Women's Hospital|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08-148","February 25, 2009","February 2009","January 2014","April 13, 2016","March 2016","April 13, 2016","null","April 2010","Therapy Completion Rate|Grade 3-5 Gastrointestinal Perforation|Clinical Benefit Response Rate|Progression-Free Survival (PFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00856180"
593,"NCT00425438","A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.","Terminated","Has Results","Lupus Nephritis","Drug: Mycophenolate Mofetil|Drug: Corticosteroids|Drug: Azathioprine|Drug: Cyclophosphamide","Hoffmann-La Roche","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML19978","January 22, 2007","March 2007","April 2008","September 22, 2014","September 2014","August 14, 2014","null","April 2008","Complete Response (CR) by the End of Treatment - Percentage of Participants With an Event|Complete Response|Percentage of Participants With Treatment Response Event by End of Treatment|Percentage of Participants With a Decrease of 25% or 50% in Glomerular Filtration Rate (GFR)|Percentage of Participants Terminating Treatment|Time to Treatment Failure","https://ClinicalTrials.gov/show/NCT00425438"
594,"NCT00003868","Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia","Completed","No Results Available","Leukemia","Drug: cyclophosphamide|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: iodine I 131 monoclonal antibody BC8|Radiation: radiation therapy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","2 Years to 55 Years   (Child, Adult)","Phase 2","40","Other|NIH","Interventional","Primary Purpose: Treatment","1297.00|FHCRC-1297.00|NCI-H99-0028|CDR0000067032","November 1, 1999","February 1999","March 2005","August 20, 2010","August 2010","No Study Results Posted","null","March 2005","","https://ClinicalTrials.gov/show/NCT00003868"
595,"NCT00010387","Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease","Completed","No Results Available","Anemia, Hemolytic, Autoimmune|Felty Syndrome|Purpura, Thrombocytopenic|Autoimmune Diseases","Drug: cyclophosphamide|Drug: filgrastim","Johns Hopkins University|Office of Rare Diseases (ORD)","All","Child, Adult, Senior","Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment","199/15672|JHOC-J9881|JHOC-99012906","February 2, 2001","March 1999","null","September 8, 2008","September 2008","No Study Results Posted","null","August 2007","","https://ClinicalTrials.gov/show/NCT00010387"
596,"NCT00611351","Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer","Completed","No Results Available","Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Secondary Myelofibrosis","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: mycophenolate mofetil|Drug: tacrolimus|Genetic: polymerase chain reaction|Genetic: polymorphism analysis|Other: flow cytometry|Other: laboratory biomarker analysis|Other: pharmacogenomic studies|Other: pharmacological study|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","University of Nebraska|National Cancer Institute (NCI)","All","19 Years to 65 Years   (Adult)","Phase 2","5","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","122-05|P30CA036727|UNMC-12205","February 7, 2008","June 2005","September 2008","February 3, 2011","February 2011","No Study Results Posted","null","February 2008","Transplantation-related mortality at 100 days post-transplantation|Incidence of grade II-IV acute graft-versus-host-disease (GVHD)|Incidence of chronic GVHD|Event-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00611351"
597,"NCT01788020","Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia","Recruiting","No Results Available","Waldenström's Macroglobulinemia","Drug: Dexamethasone, Rituximab, Cyclophosphamide|Drug: Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib","University of Ulm","All","18 Years and older   (Adult, Senior)","Phase 3","380","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ECWM-1|2013-000506-37","February 1, 2013","November 2013","December 2022","May 27, 2015","May 2015","No Study Results Posted","null","December 2017","Progression Free Survival|Complete Response rate|Time to treatment failure|Remission duration|Overall survival|Overall response rate","https://ClinicalTrials.gov/show/NCT01788020"
598,"NCT02342613","Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation","Recruiting","No Results Available","Hematologic Malignancies|Graft-Versus-Host Disease","Biological: Activated PTCy-MILs","Sidney Kimmel Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J1484|IRB00039074","January 15, 2015","February 2015","February 2020","October 12, 2016","October 2016","No Study Results Posted","null","February 2020","Feasibility of generating activated marrow infiltrating lymphocytes (MILs) from patients previously treated with PTCy (PTCy-MILs) who have relapsed disease involving the bone marrow","https://ClinicalTrials.gov/show/NCT02342613"
599,"NCT00002809","Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Biological: filgrastim|Biological: sargramostim|Biological: therapeutic immune globulin|Drug: cyclophosphamide|Drug: methotrexate|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","Temple University","All","17 Years to 60 Years   (Child, Adult)","Phase 2","10","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000064937|TUHSC-2803|NCI-V96-0950","November 1, 1999","August 1996","December 2003","September 30, 2010","September 2010","No Study Results Posted","null","December 2003","","https://ClinicalTrials.gov/show/NCT00002809"
600,"NCT00208923","Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies","Completed","No Results Available","Hematologic Malignancies","Drug: Busulfan, Cyclophosphamide and Fludarabine","Emory University","All","18 Years and older   (Adult, Senior)","Phase 2","55","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0709-1997","September 13, 2005","July 1998","October 2007","April 5, 2012","April 2012","No Study Results Posted","null","October 2007","Assess activity of preparative regimen in patients with CML, AML, RAEB, RAEB-t, CLL, NHL, HD, in all patients with refractory anemia, ringed sideroblasts, undergoing allogeneic stem cell transplantation from volunteer matched unrelated donor (VUD).|Determine disease-free and overall survival.","https://ClinicalTrials.gov/show/NCT00208923"
601,"NCT00005891","Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Fanconi's Anemia","Completed","No Results Available","Fanconi's Anemia","Drug: cyclophosphamide|Procedure: Allogeneic Bone Marrow Transplantation","Fairview University Medical Center|Office of Rare Diseases (ORD)","All","up to 54 Years   (Child, Adult)","","null","Other","Interventional","Primary Purpose: Treatment","199/15099|UMN-MT-1982-10|UMN-MT-8210","June 2, 2000","March 2000","null","June 23, 2005","July 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005891"
602,"NCT01849380","Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer","Not yet recruiting","No Results Available","Breast Neoplasms|Neoadjuvant Therapy","Drug: S-1|Drug: 5-FU","Shandong University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 4","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BEST T-01","May 6, 2013","June 2013","June 2018","May 6, 2013","May 2013","No Study Results Posted","null","October 2013","Pathological complete response|Disease-free Survival|Tolerability and safety","https://ClinicalTrials.gov/show/NCT01849380"
603,"NCT00278421","Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","German High-Grade Non-Hodgkin's Lymphoma Study Group","All","18 Years to 60 Years   (Adult)","Phase 3","592","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000459685|DSHNHL-2004-2|EU-205110|EUDRACT-2005-00521738|DSHNHL-FLYER-6664","January 16, 2006","November 2005","October 2016","October 25, 2016","November 2015","No Study Results Posted","null","October 2016","Time to treatment failure (TTF) measured from day 1 of course 1 of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) therapy up to 3 years on study with life-long follow-up|Complete response (CR) rate duration until first relapse|Progression rate during treatment|Survival|Tumor control measured from day 1 of course 1 of CHOP therapy (non-tumor related events are censored)|Disease-free survival measured from day 1 of course 1 of CHOP therapy|Safety (adverse events, serious adverse events) assessed at 3 months after treatment","https://ClinicalTrials.gov/show/NCT00278421"
604,"NCT00002844","Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Drug: Cyclophosphamide|Procedure: Allogeneic Bone Marrow Transplantation|Procedure: Autologous Bone Marrow Transplantation|Radiation: Total Body Irradiation (TBI)","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","16 Years to 65 Years   (Child, Adult)","Phase 2","49","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM90-106|P30CA016672|MDA-DM-90106|NCI-G96-1034|CDR0000065081","November 1, 1999","March 1991","June 2002","July 27, 2012","July 2012","No Study Results Posted","null","July 2000","Effectiveness of high dose cyclophosphamide, total body irradiation and bone marrow transplantation for chronic lymphocytic leukemia","https://ClinicalTrials.gov/show/NCT00002844"
605,"NCT00722137","Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma","Active, not recruiting","Has Results","Mantle Cell Lymphoma","Drug: Rituximab 375 mg/m^2|Drug: Cyclophosphamide 750 mg/m^2|Drug: Doxorubicin 50 mg/m^2|Drug: VELCADE 1.3 mg/m^2|Drug: Prednisone 100 mg/m^2|Drug: Vincristine 1.4 mg/m^2","Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Takeda","All","18 Years and older   (Adult, Senior)","Phase 3","487","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","26866138-LYM-3002|26866138-LYM-3002CTIL|2007-005669-37|0970313683","July 23, 2008","May 2008","June 2017","January 3, 2017","January 2017","November 8, 2014","null","January 2014","Progression Free Survival (PFS)|Time to Progression (TTP)|Duration of Response|Time to Next Anti-lymphoma Treatment (TTNT)|Treatment-free Interval (TFI)|Overall Response Rate (ORR)|Overall Complete Response (CR + CRu)|Overall Survival (OS)|18-Month Survival|Number of Participants Experiencing an Adverse Event (AE)","https://ClinicalTrials.gov/show/NCT00722137"
606,"NCT00002653","Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma","Unknown status","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Drug: carmustine|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: melphalan|Drug: prednisone|Radiation: radiation therapy","Medical Research Council|National Cancer Institute (NCI)","All","65 Years to 74 Years   (Adult, Senior)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000064187|MRC-LEUK-MYEL-VIII|EU-94031","November 1, 1999","September 1993","null","December 18, 2013","October 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002653"
607,"NCT00135954","Treatment of Patients With Idiopathic Membranous Nephropathy","Completed","No Results Available","Glomerulonephritis, Membranous","Drug: Cyclophosphamide and steroids","Radboud University","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RUNMN01","August 25, 2005","July 1997","July 2008","January 27, 2014","February 2007","No Study Results Posted","null","July 2008","renal function (serum creatinine)|proteinuria|side effects","https://ClinicalTrials.gov/show/NCT00135954"
608,"NCT00911716","TC Avastin. ICORG 08-10, V6","Completed","No Results Available","Breast Cancer","Biological: bevacizumab|Drug: cyclophosphamide|Drug: docetaxel|Procedure: adjuvant therapy","Cancer Trials Ireland","All","18 Years and older   (Adult, Senior)","","106","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08-10 ICORG|ICORG-08-10|EUDRACT-2008-004552-76|EU-20915","May 30, 2009","October 2008","September 2015","October 20, 2015","October 2015","No Study Results Posted","null","July 2010","Percentage of patients experiencing heart failure|Measurements of left ventricular ejection fraction by echocardiography or MUGA|Non comparative efficacy by disease-free and overall survival|Topo II overexpression","https://ClinicalTrials.gov/show/NCT00911716"
609,"NCT02865135","Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer","Recruiting","No Results Available","Cancer of Head and Neck|Cancer of Cervix|Cancer of Anus","Drug: DPX-E7 vaccine|Drug: Cyclophosphamide","Dana-Farber Cancer Institute|Stand Up To Cancer","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","44","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","15-578","July 14, 2016","December 2016","May 2023","May 19, 2017","May 2017","No Study Results Posted","null","May 2019","Number of Participants Experiencing Adverse Events Related to Treatment|Overall Response Rate|Overall Survival Rate|Progression Free Survival Rate","https://ClinicalTrials.gov/show/NCT02865135"
610,"NCT01140373","Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)","Recruiting","No Results Available","Prostate Cancer","Biological: engineered autologous T cells|Drug: cyclophosphamide","Memorial Sloan Kettering Cancer Center|United States Department of Defense","Male","18 Years and older   (Adult, Senior)","Phase 1","18","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-036","June 7, 2010","June 2010","June 2018","January 16, 2017","January 2017","No Study Results Posted","null","June 2018","The safety and tolerability of immunotherapy|Changes in bone metastases|Changes in biomarkers of bone metastasis and metabolism|Changes in circulating tumor cells|Humoral and cell-mediated immunity to PSMA and other known prostate cancer antigens|To assess patterns of change in PSA.|To track the persistence, accumulation, and migration of genetically retargeted anti-PSMA autologous T cells","https://ClinicalTrials.gov/show/NCT01140373"
611,"NCT00645606","Fludarabine, Cyclophosphamide, and Rituximab Followed by Rituximab or Observation in Older Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Biological: Rituximab","University Hospital, Tours|FCGCLL-WM|Roche Pharma AG|French Innovative Leukemia Organisation","All","66 Years and older   (Senior)","Phase 3","542","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000589684|CHRUT-LLC-2007-SA|CHRUT-PHRN05-CD|INCA-RECF0497|2007-001015-28","March 26, 2008","December 2007","October 2015","October 16, 2015","October 2015","No Study Results Posted","LLC2007SA","February 2014","Three-year progression-free survival|Event-free survival|Disease-free survival|Overall survival|Time to next treatment|Overall response rate, complete response, and partial response according to NCI criteria|Rates of phenotypic response (minimal residual disease)|Rates of treatment-related adverse events|Pharmacokinetics of rituximab during induction and maintenance|Quality of life","https://ClinicalTrials.gov/show/NCT00645606"
612,"NCT00005892","Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia","Completed","No Results Available","Fanconi's Anemia|Myelodysplastic Syndromes|Leukemia, Nonlymphocytic, Acute|Leukemia, Lymphocytic, Acute","Drug: cyclophosphamide|Procedure: Allogeneic Bone Marrow Transplantation","Fairview University Medical Center|Office of Rare Diseases (ORD)","All","up to 54 Years   (Child, Adult)","","null","Other","Interventional","Primary Purpose: Treatment","199/15100|UMN-MT-1985-01|UMN-MT-8501","June 2, 2000","March 2000","null","June 23, 2005","July 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005892"
613,"NCT02057770","Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","Recruiting","No Results Available","Leukemia, Myeloid, Acute","Drug: busulfan|Drug: fludarabine phosphate|Radiation: total-body irradiation (TBI)|Procedure: Stem cell transplant|Drug: cyclophosphamide|Drug: tocilizumab","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","Phase 1","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","201401080","February 5, 2014","February 28, 2014","November 30, 2019","April 11, 2017","April 2017","No Study Results Posted","null","August 31, 2018","Event Free Survival (EFS) rate|Overall Survival (OS)|Rate of Leukemia Free Survival (LFS)|Transplant Related Mortality (TRM) Rate|Time to neutrophil engraftment|Incidence of acute GVHD|Incidence of chronic GVHD|Time to platelet engraftment|Rate of CRS with and without tocilizumab prophylaxis","https://ClinicalTrials.gov/show/NCT02057770"
614,"NCT02243371","GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab","Active, not recruiting","No Results Available","Previously Treated Metastatic Adenocarcinoma of the Pancreas","Biological: CRS-207|Biological: GVAX|Drug: nivolumab|Drug: CY","Sidney Kimmel Comprehensive Cancer Center|Bristol-Myers Squibb|Stand Up To Cancer|Aduro BioTech|American Association for Cancer Research","All","18 Years and older   (Adult, Senior)","Phase 2","96","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J14113|ADU-CL-06|IRB00043936","September 15, 2014","December 2014","null","August 31, 2016","August 2016","No Study Results Posted","null","January 2019","Overall survival (OS) in metastatic pancreatic cancer patients treated with cyclophosphamide (CY)/nivolumab/GVAX pancreas vaccine followed by nivolumab/CRS-207 (Arm A) versus patients treated with CY/GVAX pancreas vaccine followed by CRS-207 (Arm B)|Number of patients experiencing treatment-related toxicities|Progression-free survival (PFS) by RECIST 1.1 in metastatic pancreatic cancer patients treated with CY/GVAX/CRS-207/nivolumab (Arm A) versus patients treated with CY/GVAX/CRS-207 (Arm B)|Immune-related progression-free survival (irPFS) by IRRC in metastatic pancreatic cancer patients treated with CY/GVAX/CRS-207/nivolumab (Arm A) versus patients treated with CY/GVAX/CRS-207 (Arm B)|Time to progression (TTP) by RECIST 1.1 and IRRC in metastatic pancreatic cancer patients treated with CY/GVAX/CRS-207/nivolumab (Arm A) versus patients treated with CY/GVAX/CRS-207 (Arm B)|Response rate measured by RECIST 1.1 in metastatic pancreatic cancer patients treated with CY/GVAX/CRS-207/nivolumab (Arm A) versus patients treated with CY/GVAX/CRS-207 (Arm B)|Tumor marker kinetics (CA 19-9) in metastatic pancreatic cancer patients treated with CY/GVAX/CRS-207/nivolumab (Arm A) versus patients treated with CY/GVAX/CRS-207 (Arm B)","https://ClinicalTrials.gov/show/NCT02243371"
615,"NCT02120157","Phase II Trial of Myeloablative Conditioning & Transplantation of Partially HLA-mismatched Marrow With Post-transplant Cyclophosphamide for Peds Pts w/ Hematologic Malignancies","Recruiting","No Results Available","Myeloablative Conditioning|HLA-mismatched Bone Marrow Transplantation|Graft Survival|Transplantion, Bone Marrow","Drug: Cyclophosphamide|Radiation: TBI|Drug: Busulfan|Other: Unmanipulated Bone Marrow|Drug: Tacrolimus|Drug: Mycophenolate mofetil","Sidney Kimmel Comprehensive Cancer Center","All","6 Months to 25 Years   (Child, Adult)","Phase 2","31","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","J13161|NA_00091665","April 16, 2014","August 2014","January 2019","April 5, 2017","April 2017","No Study Results Posted","null","May 2018","Incidence of Mortality|Donor Cell Engraftment","https://ClinicalTrials.gov/show/NCT02120157"
616,"NCT00494780","Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients","Completed","Has Results","Lymphoma, Follicular","Drug: Ofatumumab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisolone, Prednisone or equivalent","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","111775|Hx-CD20-409|The MUNIN trial","June 29, 2007","June 2007","September 2010","June 26, 2014","May 2014","July 28, 2011","MUNIN","April 2009","Number of Participants With the Indicated Overall Best Response (OBR) at Visit 26 (3 Months After the Last Infusion of Ofatumumab)|Number of Participants With Complete Remission (CR) at Visit 26|Median Percent Change From Visit 1 (Screening, Week -2) in Tumor Size at Visit 33 (24 Months After the Last Infusion of Ofatumumab)|Time to New Anti-follicular Lymphoma (FL) Therapy|Progression-Free Survival (PFS)|Duration of Response|Percent Change From Visit 1 (Screening) in Peripheral CD19+ and CD20+ Cell Counts at Visit 33 (24 Months After the Last Infusion of Ofatumumab)|Number of Participants Who Experienced Any Adverse Event (AEs) From First Treatment to Visit 33 (24 Months After Last Infusion)|Number of Participants With Positive Human Anti-human Antibodies (HAHA) at Visits 1, 28, and 33|Median Percent Change From Visit 1 (Screening) in Serum Complement (CH50) Levels at Visit 22|Number of Participants Who Had a Conversion of BCL-2 t(14;18)-Positive to Negative by Polymerase Chain Reaction (PCR) in Peripheral Blood and Bone Marrow Aspirate and Its Durability Post-therapy|Cmax and Ctrough at the Sixth Infusion (Week 15, Visit 22)|AUC(0-inf) and AUC(0-504) After the Sixth Infusion (Week 15, Visit 22)|Half Life (t1/2) of Ofatumumab at the Sixth Infusion (Week 15, Visit 22)|CL After the Sixth Infusion (Week 15, Visit 22)|Vss at the Sixth Infusion (Week 15, Visit 22)","https://ClinicalTrials.gov/show/NCT00494780"
617,"NCT00354822","Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.","Terminated","No Results Available","Lymphoma, Non-Hodgkin","Drug: Zevalin","A.O. Ospedale Papa Giovanni XXIII|Regional Hospital of Bolzano","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EUDRACT 2005-000699-41","July 19, 2006","August 2005","August 2009","September 17, 2009","September 2009","No Study Results Posted","Z0105","August 2009","achievement and duration of complete or partial reduction of lymphnodes six weeks after the end of treatment with zevalin|overall and event free survival","https://ClinicalTrials.gov/show/NCT00354822"
618,"NCT02158091","A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL","Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia","Drug: IPI-145|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab","Dana-Farber Cancer Institute|Infinity Pharmaceuticals, Inc.","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","32","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","14-193","June 4, 2014","July 2014","July 2021","November 2, 2016","November 2016","No Study Results Posted","null","October 2017","Rate of minimal residual disease negative complete response (MRD-negative CR) in the bone marrow|Determination of the maximum tolerated dose (MTD) of IPI-145 with FCR|Duration of Response|Number of Participants with Serious and Non-Serious Adverse Events|Overall Response Rate|Complete response rate|Partial response rate|Rate of minimal residual disease (MRD) in the peripheral blood|Established CLL prognostic factors","https://ClinicalTrials.gov/show/NCT02158091"
619,"NCT00110695","Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer","Completed","No Results Available","Breast Neoplasms","Drug: Nanoparticle albumin bound paclitaxel followed by FEC","NSABP Foundation Inc|Celgene Corporation","Female","18 Years and older   (Adult, Senior)","Phase 2","66","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP FB-AX-003","May 12, 2005","April 2005","July 2008","March 24, 2010","March 2010","No Study Results Posted","null","December 2006","pathologic complete response rate in the breast for patients with locally advanced breast cancer (LABC) who receive Abraxane|pathologic complete response rate in the breast and axillary nodes (pCR breast and nodes) in all patients|complete clinical response rate (cCR) of the sequential regimen in patients who present with palpable measurable disease|complete clinical and imaging response rate (ciCR) of the sequential regimen in all patients|complete clinical response rate (cCR)of Abraxane in patients who present with palpable measurable disease|toxicity of the sequential chemotherapy regimen|toxicity of the sequential chemotherapy regimen when administered concurrently with trastuzumab|2-year progression-free survival|2-year overall survival (OS)|exploration of molecular and genetic correlates of response","https://ClinicalTrials.gov/show/NCT00110695"
620,"NCT00525603","CFAR Study in Patients With Chronic Lymphocytic Leukemia","Completed","Has Results","Leukemia|Chronic Lymphocytic Leukemia","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Alemtuzumab|Drug: Rituximab","M.D. Anderson Cancer Center|Bayer","All","up to 69 Years   (Child, Adult, Senior)","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0269","September 4, 2007","June 2005","July 2011","January 25, 2013","January 2013","October 4, 2012","null","July 2011","Overall Participant Response","https://ClinicalTrials.gov/show/NCT00525603"
621,"NCT01824693","Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia","Active, not recruiting","No Results Available","Juvenile Myelomonocytic Leukemia","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Busulfan|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Drug: Mycophenolate Mofetil|Other: Pharmacological Study|Drug: Tacrolimus","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Months to 18 Years   (Child, Adult)","Phase 2","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ASCT1221|NCI-2013-00738|COG-ASCT1221|U10CA180886|U10CA098543","April 2, 2013","June 2013","June 2022","January 11, 2017","January 2017","No Study Results Posted","null","June 2022","EFS|TRM|Graft failure rates|Relapse/non-response rates","https://ClinicalTrials.gov/show/NCT01824693"
622,"NCT01342289","Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide","Recruiting","No Results Available","Hodgkin's Lymphoma|Leukemia|Myelodysplastic Syndrome(MDS)|Multiple Myeloma|Non Hodgkin's Lymphoma","Procedure: Bone Marrow Transplant","Sidney Kimmel Comprehensive Cancer Center","All","6 Months to 75 Years   (Child, Adult, Senior)","Phase 1|Phase 2","140","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J1151|NA_00048378","April 21, 2011","July 2011","June 2022","May 17, 2016","May 2016","No Study Results Posted","null","June 2018","Evaluate the safety of reduced-duration tacrolimus (from Day 5 through either To estimate the number of patients with GVHD as a measure of the safety of reduced-duration tacrolimus|To estimate the tolerability of reduced-duration tacrolimus on patients following nonmyeloablative transplant.|Incidence of GVHD","https://ClinicalTrials.gov/show/NCT01342289"
623,"NCT01766375","the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient","Unknown status","No Results Available","Acute Myeloid Leukemia","Drug: Cyclosporin A,mycophenolate mofetil,Methotrexate","Guangxi Medical University","All","18 Years to 50 Years   (Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GuangXi-AML- HSCT-2012-07","December 28, 2012","August 2012","June 2016","January 9, 2013","January 2013","No Study Results Posted","IDBUCY","January 2016","2-year disease-free survival (DFS) rates|2-year overall survival (OS) rates","https://ClinicalTrials.gov/show/NCT01766375"
624,"NCT02115204","4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF","Completed","No Results Available","Breast Cancer","Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Methotrexate|Drug: 5-fluorouracil","West German Study Group|AGO Germany","Female","18 Years to 65 Years   (Adult)","Phase 3","2011","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EC-Doc","April 8, 2014","June 2000","August 2010","June 18, 2015","June 2015","No Study Results Posted","null","August 2005","Comparison of event-free survival|Comparison of overall survival|Comparison of toxicity (measured as number of adverse events)|Comparison of quality of life|Comparison of cost effectiveness across the applied regimens in relation to event-free survival","https://ClinicalTrials.gov/show/NCT02115204"
625,"NCT02300571","Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant","Recruiting","No Results Available","Hematological Malignancies","","Fondazione del Piemonte per l'Oncologia","All","18 Years to 65 Years   (Adult)","","60","Other","Observational","Observational Model: Case-Only","HDCTX 2013","November 21, 2014","September 2013","December 2017","January 17, 2017","August 2016","No Study Results Posted","null","June 2017","Incidence of the observed GVHD rate and infections|Overall survival|Progression-free survival","https://ClinicalTrials.gov/show/NCT02300571"
626,"NCT01427114","R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)","Active, not recruiting","No Results Available","Lymphoma","Drug: rituximab, cyclophosphamide, vincristine, and prednisolone","Konkuk University Medical Center|Seoul St. Mary's Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KUH1010258","August 30, 2011","July 2011","August 2016","September 2, 2015","September 2015","No Study Results Posted","null","August 2014","complete response rate|Progression free survival|Overall survival|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","https://ClinicalTrials.gov/show/NCT01427114"
627,"NCT00482391","Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer","Completed","Has Results","Breast Cancer","Biological: trastuzumab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: lapatinib ditosylate|Drug: paclitaxel|Other: laboratory biomarker analysis","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Dana-Farber Cancer Institute|GlaxoSmithKline","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","95","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","07-013|MSKCC-07013","June 4, 2007","March 2007","July 2011","April 6, 2017","April 2017","December 22, 2015","null","July 2011","Number of Patients Who Completed All Planned Therapy|Number of Patients Who Were Evaluated for Toxicity","https://ClinicalTrials.gov/show/NCT00482391"
628,"NCT01539083","Velcade (Bortezomib) Consolidation After Transplant","Active, not recruiting","Has Results","Multiple Myeloma","Drug: Thalidomide|Drug: Bortezomib|Drug: Cyclophosphamide|Drug: Dexamethasone|Drug: Prednisolone","Janssen Scientific Affairs, LLC","All","18 Years and older   (Adult, Senior)","Phase 3","258","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CR018751|26866138-MMY-2073","November 23, 2011","January 13, 2012","February 28, 2018","May 15, 2017","May 2017","December 16, 2016","VCAT","December 30, 2015","Consolidation Phase: Percentage of Participants With Complete Response (CR) and Very Good Partial Response (VGPR) at Month 12|Consolidation Phase: Percentage of Participants With Complete Response (CR) at Months 3, 6, 9 and 12|Consolidation Phase: Percentage of Participants With Stringent Complete Response (sCR) at Months 3, 6, 9 and 12|Consolidation Phase: Progression Free Survival (PFS)|Consolidation Phase: Disease-free Survival (DFS)|Consolidation Phase: Overall Survival (OS)|Consolidation Phase: Change From Baseline in AQOL-6D Scores at the End of the Consolidation Phase|Consolidation Phase: Change From Baseline in FACT/GOG-NTX Total Score at the End of the Consolidation Phase","https://ClinicalTrials.gov/show/NCT01539083"
629,"NCT00261313","ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Neulasta|Drug: Aranesp","Amgen","Female","18 Years and older   (Adult, Senior)","Phase 2","80","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20040137","December 2, 2005","December 2005","December 2007","February 25, 2010","February 2010","No Study Results Posted","null","June 2007","The proportion of subjects experiencing any delay in any cycle of chemotherapy over the course of the study|Febrile neutropenic events and adverse event profile will be assessed|To assess chemotherapy and subject dose delays and reductions which are specific and/or non specific to haematological toxicities|Frequency of red blood cell (RBC) transfusions","https://ClinicalTrials.gov/show/NCT00261313"
630,"NCT00016458","Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis","Completed","No Results Available","Systemic Sclerosis","Drug: anti-thymocyte globulin|Drug: cyclophosphamide","Fred Hutchinson Cancer Research Center|Office of Rare Diseases (ORD)","All","up to 64 Years   (Child, Adult)","Phase 2","20","Other","Interventional","Primary Purpose: Treatment","199/15818|FHCRC-1473.00","May 6, 2001","June 2000","null","September 2, 2008","September 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00016458"
631,"NCT03152318","A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2","Not yet recruiting","No Results Available","Malignant Glioma of Brain|Astrocytoma|Malignant Astrocytoma|Oligodendroglioma|Anaplastic Oligodendroglioma of Brain (Diagnosis)|Mixed Oligo-Astrocytoma|Ependymoma|Ganglioglioma|Pylocytic/Pylomyxoid Astrocytoma","Drug: rQNestin34.5v.2|Drug: Cyclophosphamide|Procedure: Stereotactic biopsy","Dana-Farber Cancer Institute|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Senior)","Phase 1","108","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: No masking|Primary Purpose: Treatment","16-557","May 9, 2017","June 1, 2017","August 1, 2023","May 12, 2017","May 2017","No Study Results Posted","null","April 1, 2020","Maximum Tolerated Dose|MRI Changes in Permeability|MRI Changes in Volume|MRI Changes in Flow|Viral Shedding in Saliva|HSV1 Viremia|HSV1 Antibody Response","https://ClinicalTrials.gov/show/NCT03152318"
632,"NCT01105273","Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia","Completed","No Results Available","Aplastic Anemia","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: Fludarabine|Drug: Cyclophosphamide|Procedure: CD3±CD19 depleted hematopoietic stem cell transplantation","Asan Medical Center","All","up to 21 Years   (Child, Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMCPHO-SCT0802","April 8, 2010","July 2009","July 2012","December 30, 2012","December 2012","No Study Results Posted","null","July 2012","To assess the engraftment rate and survival of CD3±CD19 depleted haploidentical peripheral blood stem cell transplantation after conditioning with fludarabine, cyclophosphamide and anti-thymocyte globulin.|To assess engraftment and graft failure|To estimate the risk of acute GVHD|To assess treatment related mortality|To estimate overall survival","https://ClinicalTrials.gov/show/NCT01105273"
633,"NCT00602459","Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia","Active, not recruiting","Has Results","Chronic Lymphocytic Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia","Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Biological: Rituximab","National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group|Southwest Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 2","418","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2009-00441|NCIC CTG C10404|CAN-NCIC-CL3|SWOG C10404|CDR0000584205|ECOG-10404|ECOG 10404|NCIC-CTG-C10404|SWOG-C10404|CALGB 10404|CALGB-10404|U10CA180821|U10CA031946","January 23, 2008","January 2008","null","February 15, 2017","February 2017","December 19, 2016","null","December 2014","2-Year Progression Free Survival (PFS) Rate|Induction Response Rate in Patients Without Del(11q22.3)|Induction Response Rates in Patients With Del(11q22.3)|PFS Rate of Patients With Del(11q22.3)|Time-to-progression in Patients Without Del(11q22.3)|Time-to-progression in Patients With Del(11q22.3)","https://ClinicalTrials.gov/show/NCT00602459"
634,"NCT00001272","A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients","Completed","No Results Available","Ovarian Neoplasms","Drug: taxol","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Senior","Phase 1","60","NIH","Interventional","Primary Purpose: Treatment","910232|91-C-0232","November 3, 1999","September 1991","May 2000","March 3, 2008","June 1999","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001272"
635,"NCT00174707","Study of Docetaxel in Breast Cancer Patients","Completed","No Results Available","Breast Neoplasms","Drug: epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile|Drug: epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile|Drug: epidoxorubicine, docetaxel, cyclophosphamide","Sanofi","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","998","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TAX_IT1_302|TAX_IT_216","September 12, 2005","December 1997","December 2007","December 4, 2009","December 2009","No Study Results Posted","null","December 2007","Invasive Disease-Free Survival (IDFS) - with exclusion of ductal carcinoma in situ- DCIS- either collateral or ipsilateral, according to STEEP in adjuvant breast cancer trial: Standardized Definitions for Efficacy Endpoints|Recurrence-Free Survival (RFS)|Overall Survival (OS)|Distant Disease-Free Survival (DDFS)","https://ClinicalTrials.gov/show/NCT00174707"
636,"NCT00464646","Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Trastuzumab|Drug: Bevacizumab","NSABP Foundation Inc|Genentech, Inc.|International Drug Development Institute","Female","18 Years and older   (Adult, Senior)","Phase 2","105","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP FB-5","April 19, 2007","May 2007","May 2014","July 17, 2014","July 2014","August 24, 2012","null","December 2009","Number of Patients With Pathological Complete Response (pCR) in the Breast and Nodes for Patients With HER2-positive LABC Following Neoadjuvant Treatment (Cohort A)|Cardiac Event Rate as Determined by LVEF Assessment|pCR in the Breast (Cohort A)|Clinical Complete Response (cCR)|Grade 3 and 4 Toxicities, Including Toxicities Associated With Radiation Therapy(RT)|Recurrence-free Survival|Overall Survival|Percentage of Surgical Complications (From Mastectomy, Lumpectomy, and Axillary Staging Procedures) (Cohort A)","https://ClinicalTrials.gov/show/NCT00464646"
637,"NCT00124813","Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma","Unknown status","No Results Available","Multiple Myeloma","Drug: thalidomide|Drug: idarubicin","University Hospital, Bonn","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","T-CID","July 27, 2005","August 2002","November 2010","February 1, 2010","February 2010","No Study Results Posted","null","May 2010","Induction therapy: response rate, overall survival, death rate|Maintenance therapy: progression-free survival, overall survival, number of patients discontinuing therapy due to toxicity|Induction therapy: number of patients discontinuing therapy due to toxicity, number of patients experiencing toxicity grade 3 or 4|Maintenance therapy: dose intensity, number of patients experiencing toxicity grade 3 or 4","https://ClinicalTrials.gov/show/NCT00124813"
638,"NCT03153410","Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas","Not yet recruiting","No Results Available","Pancreatic Cancer","Drug: Cyclophosphamide|Drug: GVAX|Drug: Pembrolizumab|Drug: IMC-CS4","Sidney Kimmel Comprehensive Cancer Center|Merck Sharp & Dohme Corp.|Eli Lilly and Company","All","18 Years to 100 Years   (Adult, Senior)","Early Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","J1766|IRB00130267","May 11, 2017","September 2017","September 2019","May 11, 2017","May 2017","No Study Results Posted","null","September 2019","CD8 T cell density in the primary tumor after neoadjuvant administration of combination immunotherapy by immunohistochemistry (IHC)|Number of participants experiencing study drug-related toxicities|Overall survival (OS)|Disease free survival (DFS)|Objective response rate (ORR) by immune-related RECIST criteria (irRC)|Surgical resectability rate of borderline resectable pancreatic cancer (BRPC)|Pathologic response rate of patients with BRPC|Progression free survival (PFS)","https://ClinicalTrials.gov/show/NCT03153410"
639,"NCT02251548","A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia","Recruiting","No Results Available","Chronic Lymphocytic Leukemia|Leukemia","Drug: Ibrutinib|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab","Dana-Farber Cancer Institute|Pharmacyclics LLC.","All","18 Years to 65 Years   (Adult)","Phase 2","85","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","14-296","September 23, 2014","October 2014","September 2020","April 10, 2017","April 2017","No Study Results Posted","iFCR","September 2017","Rate of MRD Negative Complete Response|Rate of MRD-negative CR|Percentage of Overall Response Rate|Percentage of Complete Response Rate|Percentage Rate of Partial Response|Rate of Progression Free of Survival|Rate of Overall Survival|Time to MRD-negativity|Number of Participants with Serious and Non-Serious Adverse Events|Association of established CLL prognostic factors including FISH cytogenetics, IGHV mutation status, and TP53 mutation with clinical response","https://ClinicalTrials.gov/show/NCT02251548"
640,"NCT00010400","Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome","Completed","No Results Available","Systemic Lupus Erythematosus|Antiphospholipid Antibody Syndrome","Drug: Cyclophosphamide|Drug: filgrastim","Johns Hopkins University|Office of Rare Diseases (ORD)","All","18 Years to 70 Years   (Adult, Senior)","","35","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","199/15673|JHOC-J9717|JHOC-97022128","February 2, 2001","April 1997","null","June 23, 2005","July 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00010400"
641,"NCT01219907","Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer","Withdrawn","No Results Available","HER2-positive Breast Cancer|Male Breast Cancer|Stage IV Breast Cancer","Biological: HER-2/neu peptide vaccine|Drug: cyclophosphamide|Biological: ex vivo-expanded HER2-specific T cells|Other: laboratory biomarker analysis|Other: flow cytometry|Other: immunoenzyme technique","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","7266|NCI-2010-01792","September 22, 2010","June 2012","null","May 15, 2013","May 2013","No Study Results Posted","null","June 2014","Ability to expand HER-2-specific T cells ex vivo from memory T cell subsets which are derived from patients with advanced HER-2 expressing cancer|Safety and systemic toxicity as assessed at regular time points by NCI common toxicity criteria (CTCAE v 4.0). Stopping rules for the study protect patients against therapy with a rate of severe toxicity of 20% or greater.|Extent to which to HER-2-specific T cell immunity can be boosted successfully with adoptive immunotherapy will be defined by quantitative assessment of HER-2-specific CD8+ T cells assessed by cytokine flow cytometry (CFC), Elispot, and tetramer staining|Persistence of T cell immune augmentation in vivo after adoptive transfer of HER-2-specific T cells as assessed by presence of HER-2-specific central memory T cells and effector memory T cells|Anti-tumor effects of HER-2-specific T cells as assessed by RECIST criteria","https://ClinicalTrials.gov/show/NCT01219907"
642,"NCT00772668","Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Treating Patients With Stage III or Stage IV Follicular Lymphoma or Marginal Zone Lymphoma","Terminated","Has Results","Lymphoma","Drug: Rituximab|Drug: Bortezomib|Drug: Cyclophosphamide|Drug: Prednisone","University of Miami","All","17 Years to 120 Years   (Child, Adult, Senior)","","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20070963|SCCC-2006120","October 12, 2008","September 2008","February 2011","December 14, 2016","December 2016","January 18, 2013","null","February 2011","Overall Response Rate, According to the International Workshop Criteria (IWC)|Progression-free Survival as Assessed by RECIST Criteria|Overall Survival|Safety and Tolerance to Rituximab, Cyclophosphamide, Bortezomib, and Prednisone","https://ClinicalTrials.gov/show/NCT00772668"
643,"NCT02336386","CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma","Unknown status","No Results Available","Extramedullary Plasmacytoma","Drug: CDD|Drug: CDD Plus Bortezomib","Beijing Chao Yang Hospital|Peking University People's Hospital","All","18 Years and older   (Adult, Senior)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CMA-MM","January 8, 2015","December 2014","December 2016","January 12, 2015","January 2015","No Study Results Posted","null","December 2016","Number of patients with overall hematologic response|Number of patients with EMP response|Overall survival|Time from diagnosis ofEMP to the date of death|Progression free survival|Time from date of diagnosis of EMP to the date of first documentation of disease|Number of adverse events","https://ClinicalTrials.gov/show/NCT02336386"
644,"NCT00114816","Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: capecitabine|Drug: docetaxel","Finnish Breast Cancer Group|Hoffmann-La Roche|Sanofi|AstraZeneca","Female","18 Years to 65 Years   (Adult)","Phase 3","1500","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FBCG Protocol No. 01-2003|Roche protocol number MO17728","June 17, 2005","January 2004","April 2007","May 18, 2007","May 2007","No Study Results Posted","null","null","Recurrence-free survival|Adverse event rate (CTCAE v. 3.0)|Overall survival","https://ClinicalTrials.gov/show/NCT00114816"
645,"NCT02869217","Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors","Recruiting","No Results Available","NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients|Synovial Sarcoma|Melanoma|Esophageal Cancer|Ovarian Cancer|Lung Cancer|Bladder Cancer|Liver Cancer","Drug: Cyclophosphamide|Biological: TBI-1301","University Health Network, Toronto|Takara Bio Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1301-02","August 9, 2016","September 2016","null","September 7, 2016","September 2016","No Study Results Posted","null","March 2018","Safety profile (i.e. adverse events, presence/absence of RCR, analysis of clonality and PK of TBI-1301) assessed by CTCAE v.4.0 and laboratory testings.|Recommended phase 2 (RP2D) dose o TBI-1301 when administered following cyclophosphamide pre-treatment|Evidence of efficacy (i.e. anti-tumor effect) of TBI-1301 measured using RECIST v1.1","https://ClinicalTrials.gov/show/NCT02869217"
646,"NCT02951819","A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma","Recruiting","No Results Available","Multiple Myeloma","Drug: Daratumumab|Drug: Cyclophosphamide|Drug: Bortezomib|Drug: Dexamethasone","Janssen Scientific Affairs, LLC","All","18 Years and older   (Adult, Senior)","Phase 2","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CR108235|54767414MMY2012","October 31, 2016","November 9, 2016","December 25, 2020","April 28, 2017","April 2017","No Study Results Posted","null","February 20, 2018","Complete Response plus Very Good Partial (CR+VGPR) Response Rate|Overall Response Rate (ORR)|Time to Very Good Partial Response (VGPR) or Better|Time to Partial Response or Better|Duration of Response (DoR)|Progression Free Survival (PFS) Rate|Overall Survival Rate|Number of Subjects with Adverse Events (AEs) as a Measure of Safety and Tolerability|Infusion Reaction Profile of Split-Dose Infusions of Daratumumab","https://ClinicalTrials.gov/show/NCT02951819"
647,"NCT01088022","Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells Harvesting","Unknown status","No Results Available","Nausea|Vomiting","Drug: Aprepitant, Palonosetron, Dexamethasone|Drug: Placebo, Palonosetron, Dexamethasone","Azienda Ospedaliera di Perugia","All","18 Years and older   (Adult, Senior)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Care Provider, Investigator)|Primary Purpose: Prevention","PG-APRE1","March 16, 2010","April 2010","April 2013","March 16, 2010","March 2010","No Study Results Posted","PG-APRE1","March 2013","Patient's daily diary (days 1 through 5). The FLIE 8 questionnaire will be completed on days 1 and 6. Safety parameters: medical history, clinical examination and weight, vital signs, laboratory tests.","https://ClinicalTrials.gov/show/NCT01088022"
648,"NCT01632150","Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","Completed","Has Results","Relapsed and/or Refractory Multiple Myeloma","Biological: Elotuzumab|Biological: Thalidomide|Biological: Dexamethasone|Biological: Cyclophosphamide","Bristol-Myers Squibb|AbbVie","All","18 Years and older   (Adult, Senior)","Phase 2","51","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CA204-010|2011-005121-49","June 28, 2012","May 2012","March 2016","March 17, 2017","March 2017","December 22, 2015","null","October 2013","Percentage of Participants Who Received Treatment Including Cyclophosphamide and Had Grade 3 or Higher Nonhematologic Adverse Events (AEs)|Percentage of All Participants Who Received Treatment Without Cyclophosphamide and Had Grade 3 or Higher Nonhematologic Adverse Events (AEs)|Percentage of All Participants Who Received Treatment Including Cyclophosphamide and Had 1 Dose Reduction or Discontinued Due to an Adverse Event|Percentage of All Participants Who Received Treatment Without Cyclophosphamide and Had 1 Dose Reduction or Discontinued Due to an Adverse Event","https://ClinicalTrials.gov/show/NCT01632150"
649,"NCT02260934","Rituximab and Belimumab for Lupus Nephritis","Recruiting","No Results Available","Lupus Nephritis","Biological: Rituximab|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Methylprednisolone|Drug: Diphenhydramine|Drug: Acetaminophen|Biological: Rituximab|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Methylprednisolone|Drug: Diphenhydramine|Drug: Acetaminophen|Biological: Belimumab","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)","All","18 Years and older   (Adult, Senior)","Phase 2","40","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","DAIT ITN055AI|CALIBRATE","October 6, 2014","October 2014","June 2019","March 29, 2017","March 2017","No Study Results Posted","CALIBRATE","June 2018","Proportion of participants who experience at least one Grade 3 or higher infectious adverse event.|Proportion of participants with B cell reconstitution.|Proportion of participants with hypogammaglobulinemia.|Proportion of participants with a complete response.|Proportion of participants with an overall response (complete or partial response).|Proportion of participants with complete response.|Proportion of participants with an overall response (complete or partial response)|Proportion of participants with complete response (cumulative complete response)|Proportion of participants with sustained complete response(representing ""clinical tolerance"").|The proportion of participants with an overall response (complete or partial response)|Proportion of participants with treatment failure.|Frequency of non-renal flares.|Anti-dsDNA antibodies and C3, C4 levels.|Frequency of any event leading to death.|Frequency of Grade 2 or greater leukopenia.|Frequency of Grade 2 or greater thrombocytopenia.|Frequency of premature ovarian failure.|Frequency of malignancy.|Frequency of venous thromboembolic event (deep venous thrombosis or pulmonary embolism).|Frequency of disease- or study medication-related event leading to hospitalization.|Frequency of infusion reactions (within 24 hours of infusion) that result in the cessation of further infusions (including cytokine-release allergic reaction).","https://ClinicalTrials.gov/show/NCT02260934"
650,"NCT01731587","Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer","Withdrawn","No Results Available","Non-small Cell Lung Cancer (NSCLC) Stage III","Other: Biological: MUC1 peptide specific immunotherapy|Drug: Cyclophosphamide (CPA)","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 1","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Basic Science","EMR 63325-019|2012-001435-31","October 11, 2012","January 2001","null","February 27, 2017","February 2017","No Study Results Posted","FINGERPRINT","null","Immune response defined as change from baseline in serum cytokine levels after L-BLP25 administration at Week 1, 4 and 8|Evaluation of a cellular immune response following treatment with L-BLP25|Change from baseline in alternative immune or inflammatory serum soluble immune mediators such as interferon alpha (IFNα), transforming growth factor beta (TGFβ), or C-reactive protein (CRP) at 6, 12, and 24 hours after L-BLP25 administration.|Number of subjects with adverse events (AEs)","https://ClinicalTrials.gov/show/NCT01731587"
651,"NCT00948090","PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients","Completed","Has Results","Lymphoma","Drug: IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)","Otsuka Pharmaceutical Development & Commercialization, Inc.|Center for International Blood and Marrow Transplant Research","All","18 Years to 65 Years   (Adult)","Phase 2","207","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","273-08-201","July 28, 2009","January 2010","June 2013","July 1, 2014","July 2014","May 21, 2014","null","May 2013","Number of Progression Events in 2 Years.|Number of Death Events in 2 Years.|Number of Transplant-related Death Events Until Day 100.|Overall Response Rate","https://ClinicalTrials.gov/show/NCT00948090"
652,"NCT00152191","A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC)","Completed","No Results Available","Breast Cancer","Drug: UFT (uracil, tegafur)|Drug: cyclophosphamide, methotrexate, and fluorouracil","Taiho Pharmaceutical Co., Ltd.","Female","18 Years to 75 Years   (Adult, Senior)","Phase 3","1300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","01023001","September 7, 2005","October 1996","January 2008","July 6, 2011","July 2011","No Study Results Posted","null","October 2007","Relapse-free survival|Overall survival, adverse events, and the quality of life","https://ClinicalTrials.gov/show/NCT00152191"
653,"NCT02623972","A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer","Recruiting","No Results Available","Inflammatory Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","Drug: Eribulin|Drug: Adriamycin|Drug: Cyclophosphamide","Dana-Farber Cancer Institute|Eisai Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","15-292","December 2, 2015","December 2015","February 2023","November 18, 2016","November 2016","No Study Results Posted","null","February 2019","Pathologic Complete Response|Disease Free Survival|Time to Treatment Failure|Overall Survival|Pathologic disease response at mastectomy will be reported as ""residual disease burden (RCB)"".|RT-qPCR assessment of gene expression of 10-EMT-related genes and 15-genes involved in modulating vessel phenotype or EC-PVC interactions will be compared following treatment with eribulin.|To correlate changes in imaging (Ktrans ve, vp, and initial area under the curve (iAUC)) with genomic changes determined on core biopsies of the breast sampled at the same time points.","https://ClinicalTrials.gov/show/NCT02623972"
654,"NCT02225795","Pilot Study of Stem Cell Transplantation for Children and Young Adults With Refractory Crohn's Disease.","Recruiting","No Results Available","Crohn's Disease","Other: Hematopoietic stem cell transplantation","TriStar Health","All","10 Years to 30 Years   (Child, Adult)","","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT 12","July 28, 2014","August 2014","December 2019","March 28, 2016","March 2016","No Study Results Posted","null","August 2019","To determine the feasibility and toxicity of immunoablation with HSCT and post-HSCT infusion of cyclophosphamide in children and young adults with refractory Crohn's disease (CD).|1. Incidence of viral reactivations - CMV and EBV|2. Incidence of invasive fungal infections|3. Immune reconstitution after HSCT|4. Evaluate the efficacy and benefit of HSCT in this population at 1 year post HSCT, by serial assessments of clinical activity of CD, assessment of disease severity- CDAI scores and length of steroid free remissions.","https://ClinicalTrials.gov/show/NCT02225795"
655,"NCT01370772","Intensified Rituimab Prephase Before FCR in Untreated B-CLL","Completed","No Results Available","B-cell Chronic Lymphocytic Leukemia CLL","Drug: Rituximab|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Fludarabine","French Innovative Leukemia Organisation|Roche Pharma AG","All","18 Years to 65 Years   (Adult)","Phase 2","140","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CLL 2010 FMP","May 23, 2011","May 2011","March 2016","March 15, 2016","March 2016","No Study Results Posted","null","September 2014","complete response rates according to IWCLL 2008 guidelines with undetectable minimal residual disease|To determine and compare the progression free survival PFS|evaluate the immunophenotypic response rate after high dose Rituximab alone prephase in DenseR-FC|To evaluate FcyRs polymorphisms influence on clinical response|To determine the pharmacokinetics of rituximab and determine the PK-PD relationship of rituximab based on biomarkers.|To evaluate the safety profile of higher doses of rituximab|To determine the event-free survival EFS|To determine and compare the disease-free survival DFS|To determine the overall survival OS|To determine the time to next treatment TTNT","https://ClinicalTrials.gov/show/NCT01370772"
656,"NCT01869192","Phase II Trial for Large ER-Negative Breast Cancers","Active, not recruiting","No Results Available","Malignant Neoplasm of Female Breast","Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Capecitabine|Radiation: Radiation Therapy","University of Colorado, Denver","Female","18 Years and older   (Adult, Senior)","Phase 2","61","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-0824.cc","May 28, 2013","March 2003","August 2017","January 13, 2017","January 2017","No Study Results Posted","null","August 2017","DNA-damaging regimen vs. a mitotic spindle|Clinical response rate|Overall survival|Ratio of breast conserving|Pathological response","https://ClinicalTrials.gov/show/NCT01869192"
657,"NCT00140075","Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer","Completed","No Results Available","Adenocarcinoma","Drug: Epirubicin with Cyclophosphamide, followed by a Taxane|Drug: Epirubicin with a Taxane","Pfizer","Female","18 Years and older   (Adult, Senior)","Phase 3","606","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","378-ONC-0030-184","August 29, 2005","November 2000","August 2006","May 24, 2011","May 2011","No Study Results Posted","null","August 2006","Disease free survival at 3 years|Assess safety in both treatment arms at 3 years|Compare overall survival between the 2 treatment arms at 3 years","https://ClinicalTrials.gov/show/NCT00140075"
658,"NCT02513186","Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant","Recruiting","No Results Available","Plasma Cell Myeloma","Drug: lenalidomide|Drug: bortezomib|Drug: cyclophosphamide|Drug: dexamethasone|Drug: isatuximab","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 1","44","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","TCD13983|2014-001251-23|U1111-1154-6102","July 16, 2015","September 30, 2015","September 18, 2024","May 11, 2017","May 2017","No Study Results Posted","CyBorDSAR","September 18, 2024","Assessment of dose-limiting toxicities (DLTs) in VCDI cohort|Overall response rate (VCDI)|Complete response rate (VCDI)|Overall response rate (VRDI)|Complete response rate (VRDI)|Number of patients with adverse events (AEs)|Number of patients with clinically significant changes in laboratory tests according to the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 4.03 grade scaling|Number of patients with clinically significant changes in vital signs according to the NCI-CTC version 4.03 grade scaling|Assessment of PK parameter: Partial area under the serum concentration time curve (AUC)|Assessment of PK parameter: Maximum observed concentration (Cmax)|Levels of human antidrug antibodies (ADA)|Duration of response - time","https://ClinicalTrials.gov/show/NCT02513186"
659,"NCT01222052","6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients","Active, not recruiting","No Results Available","Breast Cancer","Drug: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel","Martin-Luther-Universität Halle-Wittenberg|German Breast Group","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","4150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GBG 42","October 15, 2010","January 2002","February 2019","September 3, 2012","September 2012","No Study Results Posted","NNBC3-Europe","February 2009","Disease-Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT01222052"
660,"NCT00429026","Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation","Terminated","Has Results","Renal Cell Cancer","Drug: Fludarabine|Drug: Melphalan|Drug: Cyclophosphamide|Procedure: Stem Cell Transplant","M.D. Anderson Cancer Center","All","up to 65 Years   (Child, Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-0364","January 29, 2007","January 2004","March 2008","February 26, 2013","February 2013","February 26, 2009","null","March 2008","Survival Rate","https://ClinicalTrials.gov/show/NCT00429026"
661,"NCT00424203","Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery","Completed","No Results Available","Breast Cancer|Cognitive/Functional Effects|Depression|Malnutrition|Psychosocial Effects of Cancer and Its Treatment","Drug: AC regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Procedure: adjuvant therapy|Procedure: cognitive assessment|Procedure: management of therapy complications|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment","UNICANCER","Female","70 Years and older   (Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000523419|FRE-FNCLCC-GERICO-06-0502|EU-20667|EUDRACT-2005-000069-20","January 16, 2007","January 2006","November 2011","September 2, 2013","September 2013","No Study Results Posted","null","January 2008","Percentage of patients maintaining their independence as assessed by Activities of Daily Living (ADL) score on 6 items after the fourth course of chemotherapy|Impact of adjuvant chemotherapy on ADL score, quality of life, treatment acceptability, toxicity, and survival (recurrence-free, progression-free, and overall survival)","https://ClinicalTrials.gov/show/NCT00424203"
662,"NCT00626626","Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation","Terminated","No Results Available","Leukemia|Myelodysplastic Syndrome|Chronic Myelogenous Leukemia|Lymphoma|Hodgkin's Lymphoma|Multiple Myeloma","Drug: Dose Level I|Drug: Dose Level 2","Milton S. Hershey Medical Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","25223|PSU25223","February 20, 2008","May 2007","January 2010","January 8, 2013","January 2013","No Study Results Posted","null","January 2010","Establish the safety of Clofarabine and cyclophosphamide preceding allogeneic hematopoietic engraftment. Assess the efficacy of Clofarabine and cyclophosphamide as conditioning for promoting allogeneic hematopoietic engraftment.|Observe disease free and overall survivals in acute leukemia and lymphoma patients receiving allogeneic hematopoietic transplant after Clofarabine and cyclophosphamide conditioning.","https://ClinicalTrials.gov/show/NCT00626626"
663,"NCT02271464","Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer","Unknown status","No Results Available","Metastatic Colorectal Cancer","Drug: Maintenance:BEVACIZUMAB|Drug: Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE","Azienda Ospedaliero, Universitaria Pisana","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","222","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MOMA261111|2011-006332-23","October 20, 2014","March 2012","March 2016","March 10, 2015","March 2015","No Study Results Posted","MOMA","June 2015","progression-free survival (PFS)|Best overall response rate (ORR)|Duration of response|Resection rate|Time to strategy failure (TSF)|Time to 2nd progressive disease|Overall survival (OS)|Toxicity rate|Overall toxicity rate","https://ClinicalTrials.gov/show/NCT02271464"
664,"NCT00621452","Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma","Completed","No Results Available","B-cell Chronic Lymphocytic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia","Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Biological: aldesleukin|Genetic: polymerase chain reaction|Genetic: gene rearrangement analysis|Procedure: lymph node biopsy|Biological: genetically engineered lymphocyte therapy|Procedure: bone marrow aspiration|Other: flow cytometry|Other: laboratory biomarker analysis|Other: enzyme-linked immunosorbent assay","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 1","12","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2154.00|NCI-2010-00416","February 21, 2008","August 2007","null","August 4, 2014","August 2014","No Study Results Posted","null","January 2014","Feasibility of transfecting and expanding the necessary numbers of T cells and the types of problems and toxicities which might be encountered, graded according the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0|Comparison of the percentages of CD20-specific T cells and malignant B cells present in the blood before and after each T cell infusion|Immune response as assessed by ELISA and percent chromium release in cytotoxicity assays|Absolute numbers of T cells expressing the chimeric T Cell receptor (cTCR) per cubic uL of blood","https://ClinicalTrials.gov/show/NCT00621452"
665,"NCT02027935","Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4","Recruiting","No Results Available","Melanoma","Drug: Cyclophosphamide|Procedure: CD8+ T Cells|Drug: Interleukin-2|Drug: Ipilimumab","M.D. Anderson Cancer Center|Cancer Prevention Research Institute of Texas|American Association for Cancer Research","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-1055|R1301|SU2C-AACR-OT 1012|NCI-2014-01040","January 2, 2014","January 2015","null","September 12, 2016","September 2016","No Study Results Posted","null","January 2019","Overall Response","https://ClinicalTrials.gov/show/NCT02027935"
666,"NCT01415336","AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: Doxorubicin, Cyclophosphamide|Drug: doxorubicin, Capecitabine","Peking Union Medical College Hospital","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PUMCH-Breast- AX","August 9, 2011","March 2010","null","August 10, 2011","August 2011","No Study Results Posted","null","March 2013","disease-free survival|Overall survival|Adverse event rate (CTCAE v. 3.0)","https://ClinicalTrials.gov/show/NCT01415336"
667,"NCT02595242","Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma","Withdrawn","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","0","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CSPC-HE1505/PRO/Ⅰ","November 2, 2015","June 2015","June 2017","May 22, 2017","May 2017","No Study Results Posted","null","December 2016","ORR(Objective response rate)","https://ClinicalTrials.gov/show/NCT02595242"
668,"NCT00286819","Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: the FEC75 and 95 regimen","Central European Cooperative Oncology Group","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CECOG/Breast.2.2.005","February 3, 2006","April 2005","September 2006","May 15, 2012","May 2012","No Study Results Posted","null","null","The primary objective of this randomized phase II is to determine the relative dose intensity (RDI) of six adjuvant cycles of FEC75 and FEC90 regimens given every 14 days with pegfilgrastim (Neulasta) support in subjects with early breast cancer.|- Incidence of dose delays and dose reductions of planned chemotherapy due to neutropenic events|-Toxicity and tolerability|-disease Free survival (As neither radiotherapy nor hormone therapy are specified and will be carried out according to institutional guidelines, DST has t be interpreted with caution)|- Quality of life","https://ClinicalTrials.gov/show/NCT00286819"
669,"NCT00343447","Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia","Withdrawn","No Results Available","Leukemia","Biological: autologous tumor cell vaccine|Biological: rituximab|Drug: cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0579 CDR0000481362|P30CA006973|JHOC-J0579|JHOC-NA_00000982","June 22, 2006","August 2006","May 2007","May 1, 2012","May 2012","No Study Results Posted","null","May 2007","Efficacy and toxicity|T-cell response to early versus late vaccine therapy comprising KGEL and autologous tumor cells","https://ClinicalTrials.gov/show/NCT00343447"
670,"NCT02954055","MEtronomic TrEatment Option in Advanced bReast cAncer","Not yet recruiting","No Results Available","Breast Cancer","Drug: Paclitaxel|Drug: Cyclophosphamide|Drug: Capecitabine|Drug: Vinorelbine","International Breast Cancer Study Group","Female","18 Years and older   (Adult, Senior)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IBCSG 54-16|2016-002200-39","September 26, 2016","May 2017","October 2020","April 21, 2017","April 2017","No Study Results Posted","METEORA-II","April 2020","Time to treatment failure (TTF) compared between treatment groups.|Frequency of targeted adverse events (safety and tolerability).|Disease control|Progression free survival (PFS)|Overall Survival","https://ClinicalTrials.gov/show/NCT02954055"
671,"NCT00601796","Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer","Completed","Has Results","Lung Cancer","Biological: Vaccine Treatment|Drug: Cyclophosphamide|Drug: All-trans retinoic acid (ATRA)","H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Senior)","Phase 2","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MCC-14744|P30CA076292|NIH-OBA-0608-801","January 19, 2008","October 2006","June 2012","May 15, 2013","February 2013","February 27, 2013","null","June 2012","Number of Evaluable Participants With Tumor Response|Median Time to Progression (TTP)|Median Overall Survival (OS)|Number of Participants With Serious Adverse Events (SAEs)","https://ClinicalTrials.gov/show/NCT00601796"
672,"NCT02115152","Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer","Not yet recruiting","No Results Available","Stage II Breast Cancer|Stage III Breast Cancer","Drug: fluorouracil|Drug: capecitabine|Drug: cyclophosphamide|Drug: Epirubicin","Guangxi Medical University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","JLiu","March 24, 2014","June 2014","null","April 14, 2014","April 2014","No Study Results Posted","null","June 2018","pathologic response rates (pCR)|DFS(Disease free survial)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","https://ClinicalTrials.gov/show/NCT02115152"
673,"NCT00669890","Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML","Terminated","No Results Available","Acute Myeloid Leukemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic Syndrome","Drug: Gemtuzumab Ozogamicin|Drug: Busulfan|Drug: Cyclophosphamide|Drug: Thymoglobulin|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Drug: Methotrexate","New York Medical College","All","up to 30 Years   (Child, Adult)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AAAA2533|CHNY-01-515","April 29, 2008","May 2004","December 2013","April 20, 2015","April 2015","No Study Results Posted","High Risk","December 2012","Maximal tolerated dose or tolerable dose of Gemtuzumab Ozogamicin (anti-CD33 immunotoxin) therapy combined with Busulfan/ Cyclophosphamide in the conditioning regimen prior to AlloSCT in patients with high risk CD33+ AML/JMML/MDS|Changes, if applicable, of minimal residual disease (cytogenetics, FISH, RT-PCR) in patients with high risk CD33+ AML/JMML/MDS after AlloSCT.|Progression Free Survival (PFS), overall survival (OS), and disease free survival (DFS), (if applicable), following GO, Bu/CY and AlloSCT in patients with high risk CD33+ AML/JMML/MDS.|Quality of life before and after GO, Bu/CY conditioning and AlloSCT in patients with high risk CD33+ AML/JMML/MDS","https://ClinicalTrials.gov/show/NCT00669890"
674,"NCT00841828","Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients","Unknown status","No Results Available","Breast Cancer","Drug: Epirubicin, Cyclophosphamide, Taxotere, Herceptín, Lapatinib","Spanish Breast Cancer Research Group|GlaxoSmithKline","Female","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","102","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GEICAM/2006-14|Nº EudraCT 2007-007031-13","February 9, 2009","February 2009","December 2013","June 7, 2013","June 2013","No Study Results Posted","null","December 2011","Complete pathological response Rate|Toxicity assessment","https://ClinicalTrials.gov/show/NCT00841828"
675,"NCT01936064","The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients","Recruiting","No Results Available","Haematological Abnormality","Dietary Supplement: Jobelyn + Cyclophosphamide-Epirubicin6|Drug: Placebo + Cyclophosphamide - Epirubicin 6","Lagos State University","Female","Child, Adult, Senior","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","LASUTH/09/2012|HEALTH FOREVER PRODUCT LTD","May 18, 2013","October 2016","January 2018","October 29, 2016","October 2016","No Study Results Posted","null","October 2017","Natural Killer Cells Expression|Use of health related quality of life measures tool Safety Fractor-36 and self reporting questionnaires|Hematocrit Changes","https://ClinicalTrials.gov/show/NCT01936064"
676,"NCT02698891","Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer","Recruiting","No Results Available","Early Stage Breast Cancer","Drug: Paclitaxel|Drug: Neulasta|Drug: Cyclophosphamide|Drug: Doxorubicin","Dana-Farber Cancer Institute","All","18 Years to 65 Years   (Adult)","Phase 2","125","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","15-516","March 2, 2016","April 2016","August 2023","January 3, 2017","January 2017","No Study Results Posted","null","December 2019","Rate of Paclitaxel Treatment Completion|Incidence of grade 3-5 neutropenia|Rate of other toxicities grade 3-4 among the 4 cycles of Paclitaxel|Rate of Chemotherapy Dose Reductions|Median Chemotherapy Cycle length|Percentage of participants who receive > 85% of planned chemotherapy doses|Percentage of Participants who received all planned chemotherapy cycles|Incidence of febrile neutropenia|Total cost ($United States) of omitting Neulasta using planned treatment|Rate of hypersensitivity reactions on cycles 3-4 of Paclitaxel, when steroid is avoided","https://ClinicalTrials.gov/show/NCT02698891"
677,"NCT00296010","Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer","Terminated","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: methotrexate|Drug: pegylated liposomal doxorubicin hydrochloride|Procedure: adjuvant therapy|Radiation: radiation therapy","International Breast Cancer Study Group","Female","66 Years and older   (Senior)","Phase 3","77","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000463710|IBCSG-32-05|BIG-CASA|2005-003434-18|BIG-1-05|EU-205112","February 23, 2006","August 2005","December 2011","August 25, 2015","August 2015","No Study Results Posted","CASA","December 2011","Breast cancer free interval by physical examination, laboratory tests, and investigations every 2 weeks for 16 weeks during treatment, every 3-6 months for 5 years, then annually as indicated after completion of study treatment|Adverse events assessed by CTCAE v3.0 every 2 weeks for 16 weeks during treatment, every 3-6 months for 5 years, then annually after completion of study treatment|Quality of life assessed by Casa QL form, Mini-Cog, and VES-13 at baseline and at 2, 6, and 12 months after completion of study treatment|Disease-free survival by physical examination, laboratory tests, and investigations every 2 weeks for 16 weeks during treatment, every 3-6 months for 5 years, then annually as indicated after completion of study treatment|Overall survival by physical examination, laboratory tests, and investigations every 2 weeks for 16 weeks during treatment, every 3-6 months for 5 years, then annually as indicated after completion of study treatment|Sites of failure by physical examination, laboratory tests, and investigations every 2 weeks for 16 weeks during treatment, every 3-6 months for 5 years, then annually as indicated after completion of study treatment|Second (non-breast) malignancy by physical examination, laboratory tests, and investigations every 2 weeks for 16 weeks during treatment, every 3-6 months for 5 years, then annually as indicated after completion of study treatment|Causes of death prior to breast cancer recurrence by physical examination, laboratory tests, and investigations every 2 wks for 16 wks during treatment, every 3-6 mo. for 5 yrs, then annually as indicated after completion of study treatment","https://ClinicalTrials.gov/show/NCT00296010"
678,"NCT02001519","Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant Chemotherapy","Completed","No Results Available","Breast Cancer","Drug: AC4-CDDP4","Asan Medical Center","Female","20 Years and older   (Adult, Senior)","Phase 2","88","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TNBC AC-CDDP","July 5, 2012","March 2012","July 2014","November 29, 2014","November 2013","No Study Results Posted","PACER","February 2014","pathologic complete response (pCR) rate|Overall response rate (ORR) by radiologic evaluation|Complete metabolic response (CMR) rate after 2 cycles of AC|3 year disease free survival (3yr-DFS)|Rate of breast conservation","https://ClinicalTrials.gov/show/NCT02001519"
679,"NCT00083031","Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: bevacizumab|Drug: cyclophosphamide|Drug: methotrexate","Dana-Farber Cancer Institute|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000361807|DFCI-03083","May 14, 2004","November 2002","null","February 6, 2009","September 2005","No Study Results Posted","null","null","Clinical response rate (complete and partial) as measured by RECIST criteria|Progression-free survival","https://ClinicalTrials.gov/show/NCT00083031"
680,"NCT00278408","Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","German High-Grade Non-Hodgkin's Lymphoma Study Group","All","18 Years to 60 Years   (Adult)","Phase 3","700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000459796|DSHNHL-2004-3|EUDRACT-2005-005218-19|EU-205111","January 16, 2006","November 2005","November 2015","January 20, 2016","November 2015","No Study Results Posted","null","November 2015","Time to treatment failure (TTF) measured from day 1 of course 1 of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy up to 3 years on study with life-long follow-up|Complete response (CR) rate until first relapse|Progression rate during treatment|Survival|Tumor control measured from day 1 of course 1 of CHOP therapy (non-tumor related events are censored)|Disease-free survival measured from day 1 of course 1 of CHOP therapy|Relapse-free survival of patients with complete response (CR) or unconfirmed complete response (CRu) following complete immunochemotherapy|Safety (adverse events, serious adverse events) assessed at 3 months after completion of study treatment|Consolidating radiotherapy","https://ClinicalTrials.gov/show/NCT00278408"
681,"NCT01509300","HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors","Unknown status","No Results Available","Acute Leukemia|Myelodysplastic Syndrome|Solid Tumors","Biological: anti-thymocyte globulin|Biological: filgrastim|Radiation: Total body irradiation|Drug: Fludarabine|Drug: cyclophosphamide|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Drug: Rituximab","Asan Medical Center","All","up to 21 Years   (Child, Adult)","Phase 1|Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMCPHO-SCT0902","January 5, 2012","January 2012","March 2014","January 12, 2012","January 2012","No Study Results Posted","null","December 2013","Transplantation-related mortality and overall survival of TBI, Fludarabine, Cyclophosphamide and anti-thymocyte globulin for engraftment of CD3 depleted haploidentical peripheral blood stem cells.|Engraftment and graft failure rates|Incidence of acute GVHD|Treatment related mortality|Relapse rate and overall survival","https://ClinicalTrials.gov/show/NCT01509300"
682,"NCT00176839","Stem Cell Transplantation for Hematological Malignancies","Terminated","Has Results","Leukemia, Lymphocytic, Acute|AML|MDS","Procedure: Stem Cell Transplant|Drug: Busulfan|Drug: Cyclophosphamide|Drug: Melphalan|Drug: G-CSF|Drug: ATG","Masonic Cancer Center, University of Minnesota","All","up to 35 Years   (Child, Adult)","Phase 2|Phase 3","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2000LS040|MT2000-12|0005M52481","September 12, 2005","June 7, 2000","February 2012","February 17, 2017","February 2017","January 11, 2013","null","February 2012","Probability of Long-term Disease-free Survival (DFS)|Probability of Engraftment|Incidence of Acute Graft-versus-host Disease (GVHD)|Incidence Chronic Graft-versus-host Disease (GVHD)|Incidence of Regimen-related Toxicity 100 Days Post Transplant|Incidence of Relapse","https://ClinicalTrials.gov/show/NCT00176839"
683,"NCT00365417","Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Bevacizumab|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Capecitabine|Drug: Docetaxel","NSABP Foundation Inc|Genentech, Inc.|Hoffmann-La Roche|International Drug Development Institute","Female","18 Years and older   (Adult, Senior)","Phase 2","45","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP FB-4","August 15, 2006","August 2006","November 2009","October 5, 2015","October 2015","August 21, 2009","null","February 2008","Pathologic Complete Response (pCR) in the Breast|pCR in the Breast and Nodes|Clinical Response Rate (cRR) of the Sequential Regimen|Reported Adverse Events|Cardiac Events|Progression-free Survival|Overall Survival|Percentage of Surgical Complications Defined as Wound Dehiscence, Infection, Seroma, Hematoma","https://ClinicalTrials.gov/show/NCT00365417"
684,"NCT02572492","Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support","Recruiting","No Results Available","Multiple Myeloma","Drug: Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan|Drug: Carfilzomib/dexamethasone maintenance|Drug: Observation without carfilzomib/dexamethasone maintenance","Henrik Gregersen|Nordic Myeloma Study Group|Aalborg Universitetshospital","All","18 Years and older   (Adult, Senior)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NMSG#20/13|2013-003789-15","October 6, 2015","January 2015","April 2019","October 7, 2015","October 2015","No Study Results Posted","CARFI","December 2017","Comparison of time to progression after high-dose melphalan with stem cell support (HDT) performed at diagnosis and time to progression after a salvage HDT combined with carfilzomib-cyclophosphamide-dexamethasone|Comparison of time to progression between carfilzomib-dexamethasone maintenance and observation in patients treated with salvage HDT.|Adverse events assessed by CTCAE v4.0 in carfilzomib-cyclophosphamide-dexamethasone induction regime and carfilzomib as part of the high-dose melphalan conditioning|Response rates of carfilzomib-cyclophosphamide-dexamethasone induction therapy and HDT|Time to marrow regeneration (neutrophil- and platelet recovery) after the HDT|Adverse events assessed by CTCAE v4.0 in maintenance treatment with carfilzomib-dexamethasone|Comparison of overall survival between carfilzomib-dexamethasone maintenance and observation in patients treated with a salvage HDT|Quality of life assessed by EORTC QLQ-MY20 and EORTC QLQ-C30","https://ClinicalTrials.gov/show/NCT02572492"
685,"NCT02937662","Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML","Recruiting","No Results Available","Acute Myeloid Leukemia","Drug: Idarubicin|Drug: Cytarabine|Drug: Cyclophosphamide|Drug: Physician-Directed Regimens without Cyclophosphamide","Institute of Hematology & Blood Diseases Hospital","All","up to 60 Years   (Child, Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IHBDH-IIT2016006","October 17, 2016","October 2016","December 2018","May 22, 2017","May 2017","No Study Results Posted","null","November 2018","Complete Remission Rate|Overall Survival(OS)|Relapse-Free Survival(RFS)|Time to Treatment Failure(TTF)","https://ClinicalTrials.gov/show/NCT02937662"
686,"NCT01532856","Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years","Unknown status","No Results Available","Multiple Myeloma","Drug: Thalidomide, Cyclophosphamide, Dexamethasone|Drug: Thalidomide, Dexamethasone|Drug: Thalidomide, Melphalan, Prednisone","Grupo de Estudos Multicentricos em Onco-Hematologia","All","18 Years and older   (Adult, Senior)","Phase 3","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GBRAM0002","February 10, 2012","January 2007","June 2012","February 14, 2012","February 2012","No Study Results Posted","null","December 2011","Response rate|Duration of response|overall survival|event-free survival|progression free-survival","https://ClinicalTrials.gov/show/NCT01532856"
687,"NCT00238173","Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors","Terminated","No Results Available","Bone Marrow Suppression|Brain and Central Nervous System Tumors|Drug/Agent Toxicity by Tissue/Organ|Long-term Effects Secondary to Cancer Therapy in Children","Biological: filgrastim|Drug: acetylcysteine|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide phosphate|Drug: mannitol|Drug: sodium thiosulfate","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","1 Year to 18 Years   (Child, Adult)","Phase 1","2","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IRB00002050|OHSU-8522|OHSU-SOL-04085-L|OHSU-IRB-2050","October 12, 2005","December 2004","February 17, 2006","April 19, 2017","April 2017","No Study Results Posted","null","February 17, 2006","To assess toxicity and the maximally tolerated dose of N-acetylcysteine administered in conjunction with carboplatin, cyclophosphamide and etoposide phosphate BBBD, and delayed high dose sodium thiosulfate, in children with malignant brain tumors.","https://ClinicalTrials.gov/show/NCT00238173"
688,"NCT02199184","Burkitt Leukemia - Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Ofatumumab (EPOCH - O)","Recruiting","No Results Available","Leukemia","Drug: Ofatumumab|Drug: Etoposide|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Rituximab|Drug: Pegfilgrastim|Drug: G-CSF|Behavioral: Phone Calls","M.D. Anderson Cancer Center","All","Child, Adult, Senior","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2014-0123|NCI-2014-01707","July 22, 2014","January 2015","January 2019","February 28, 2017","February 2017","No Study Results Posted","null","January 2019","Complete Response (CR) Rate for Patients with Newly Diagnosed Burkitt Leukemia|Complete Response (CR) Rate for Patients with Relapsed/Refractory Burkitt Leukemia","https://ClinicalTrials.gov/show/NCT02199184"
689,"NCT02294344","The Clinical Efficacy of DFPP in Patients With AAGN","Terminated","No Results Available","Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","Other: DFPP&CTX|Drug: CTX","Zhi-Hong Liu, M.D.|Nanjing University School of Medicine","All","18 Years to 75 Years   (Adult, Senior)","","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NJCT1403","June 3, 2014","June 2014","November 2018","May 14, 2017","May 2017","No Study Results Posted","null","November 2017","the renal recovery rate|kidney survival","https://ClinicalTrials.gov/show/NCT02294344"
690,"NCT00597519","A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy","Completed","Has Results","Cancer|Leukemia|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma","Drug: Fludarabine, Cyclophosphamide|Procedure: Transplantation","Memorial Sloan Kettering Cancer Center","All","4 Years to 50 Years   (Child, Adult)","Phase 2","28","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-014|CA23766","December 26, 2007","March 2006","September 2015","January 14, 2016","January 2016","January 14, 2016","null","September 2015","Overall Response","https://ClinicalTrials.gov/show/NCT00597519"
691,"NCT00245089","Vincristine, Dactinomycin, and Cyclophosphamide in Treating Patients With Embryonal Rhabdomyosarcoma","Unknown status","No Results Available","Sarcoma","Biological: dactinomycin|Drug: cyclophosphamide|Drug: vincristine sulfate","Japan Rhabdomyosarcoma Study Group|National Cancer Institute (NCI)","All","up to 17 Years   (Child)","Phase 2","41","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","JRSG-UHA-PED03-02|CDR0000450162","October 25, 2005","May 2004","null","August 9, 2013","July 2009","No Study Results Posted","null","April 2011","Disease-free survival at 3 years after study registration|Overall survival at 3 years after study registration|Toxicity by NCI CTC at 3 years after study registration","https://ClinicalTrials.gov/show/NCT00245089"
692,"NCT00005798","Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Carboplatin|Drug: Cyclophosphamide|Drug: Thiotepa","H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)","Female","15 Years to 64 Years   (Child, Adult)","Phase 2","209","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MCC-11072|IRB-3898|NCI-G00-1760","June 2, 2000","July 1995","July 2007","October 24, 2012","October 2012","No Study Results Posted","CTC","August 2001","relapse-free survival|Rate of Grade III/IV toxicities","https://ClinicalTrials.gov/show/NCT00005798"
693,"NCT00391066","Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)","Terminated","No Results Available","Chronic Lymphocytic Leukemia","Drug: FCR + Lumiliximab|Drug: FCR","Biogen","All","18 Years and older   (Adult, Senior)","Phase 2","627","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","152CL201","October 19, 2006","November 2006","December 2010","September 17, 2015","April 2011","No Study Results Posted","LUCID","July 2010","Complete Response (CR) rate|Time to event variables (progression free survival, duration of response, time to next therapy, time to progression and overall survival)|Response variables","https://ClinicalTrials.gov/show/NCT00391066"
694,"NCT02094794","Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Lymphocytic or Myelogenous Leukemia","Recruiting","No Results Available","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia","Drug: etoposide|Drug: cyclophosphamide|Radiation: total marrow irradiation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: allogeneic bone marrow transplantation","City of Hope Medical Center|National Cancer Institute (NCI)","All","16 Years to 60 Years   (Child, Adult)","Phase 2","46","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","14012|NCI-2014-00639|R01CA154491","March 20, 2014","April 29, 2014","November 2017","March 13, 2017","March 2017","No Study Results Posted","null","November 2017","Incidence of toxicity, scored on both the Bearman Scale and National Cancer Institute Common Terminology Criteria version 4.03 (Safety lead-in segment)|PFS|OS|Time to relapse/progression|Complete response (CR) proportion|NRM|Incidence of infection|Incidence of toxicities, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03|Incidence of acute GVHD (aGVHD) of grades 2-4, graded according to the Consensus Grading|Incidence of aGVHD of grades 3-4, graded according to the Consensus Grading|Incidence of chronic GVHD, scored according to National Institute of Health Consensus staging","https://ClinicalTrials.gov/show/NCT02094794"
695,"NCT02256150","A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis","Recruiting","No Results Available","Lupus Nephritis","Drug: Mizoribine (MZR)|Drug: Cyclophosphamide (CTX)","Asahi Kasei Pharma Corporation","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","HE-69-C-Lu-301","October 1, 2014","November 2014","March 2018","January 30, 2017","August 2016","No Study Results Posted","null","March 2018","Total Remission rate|Complete Remission rate|Partial Remission rate|Changes of Overall Remission rate|Changes of Complete Remission rate|Changes of partial remission rate|Treatment failure rate|Changes and percentage change of 24 hours urine protein and serum albumin from the baseline|Changes of and percentage change of SCr, eGFR and BUN from the baseline|Changes of immunological test (C3, Anti-DNA antibody, ANA, Anti-Sm antibody and Anti-phospholipid antibody) from baseline|Changes of SLE-DAI score from baseline|Progression to End-Stage Renal Disease or Doubling of SCr through the study.","https://ClinicalTrials.gov/show/NCT02256150"
696,"NCT00033293","Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma","Completed","Has Results","Disseminated Neuroblastoma|Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Regional Neuroblastoma|Stage 4S Neuroblastoma","Biological: therapeutic immune globulin|Other: clinical observation|Drug: cyclophosphamide|Drug: prednisone|Procedure: magnetic resonance imaging|Other: laboratory biomarker analysis|Drug: Corticotropin-Releasing Hormone","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 8 Years   (Child)","Phase 3","53","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ANBL00P3|NCI-2009-00399|CDR0000069271|COG-ANBL00P3|U10CA013539|U10CA098543","April 9, 2002","March 2004","June 2014","April 18, 2017","June 2015","January 28, 2016","null","December 2013","Number of Responders|Motor Coordination as Assessed by Neurological Examination and Vineland Adaptive Behavior Scale (VABS)|Functional Outcome as Assessed by Age-appropriate Neuropsychological Testing|Biology of Neuroblastoma Associated Opsoclonus-myoclonus-ataxia (OMA) Syndrome Specifically by MRI Findings, Anti-neuronal Antibodies, Cerebrospinal Fluid (CSF) Findings and Tumor Biology|Long-term Prognosis for Neurologic Recovery by Neurological Examination|Tumor Outcome in Terms of Event-free Survival (EFS) Rate Defined as a Relapse or Progression of Neuroblastoma, a Second Malignancy, or Death|Tumor Outcome in Terms of Overall Survival (OS) Rate","https://ClinicalTrials.gov/show/NCT00033293"
697,"NCT02257697","A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome","Recruiting","No Results Available","Nephrotic Syndrome","Drug: Mizoribine (MZR)|Drug: Cyclophosphamide (CTX)","Asahi Kasei Pharma Corporation","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","238","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","HE-69-C-Ne-302","October 2, 2014","November 2014","December 2017","January 30, 2017","January 2017","No Study Results Posted","null","December 2017","Total Remission rate|Complete Remission rate|Partial Remission rate|Changes of Overall Remission rate|Changes of Complete Remission rate|Changes of Partial Remission rate|Treatment failure rate|Changes and percentage change of 24 hours urine protein and serum albumin from the baseline|Changes of and percentage change of SCr, eGFR and BUN from the baseline|Progression to End-Stage Renal Disease or Doubling of SCr through the study","https://ClinicalTrials.gov/show/NCT02257697"
698,"NCT02029638","Bone Marrow Transplantation (BMT) and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance","Active, not recruiting","No Results Available","Kidney Transplantation","Biological: Antithymocyte globulin (ATG)|Drug: Fludarabine|Drug: Low dose Pre-transplant cyclophosphamide|Radiation: Total Body Irradiation|Drug: Acetaminophen|Drug: Diphenhydramine|Drug: Methylprednisolone|Biological: Bone Marrow|Drug: MESNA|Drug: Mycophenolate mofetil (MMF)|Drug: Prednisone|Drug: Filgrastim|Drug: High dose post-transplant cyclophosphamide","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)","All","18 Years to 65 Years   (Adult)","Phase 2","3","NIH|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DAIT ITN054ST|ACCEPTOR","December 30, 2013","January 2014","August 2017","December 7, 2016","December 2016","No Study Results Posted","null","August 2017","The proportion of participants who achieve operational tolerance|The incidence of graft versus host disease (GVHD) in transplanted participants|The incidence of engraftment syndrome in transplanted participants|The proportion of transplanted participants who die.|The proportion of transplanted participants with acute renal allograft rejection|The histological severity of biopsies demonstrating acute rejection as measured by Banff Grade per Banff 2007 Classification Renal Allograft Pathology1.|The proportion of transplanted participants with chronic T cell-mediated or antibody-mediated rejection.|Time from transplant to the first episode of acute rejection requiring treatment.|The incidence of adverse events including infection, wound complications, post-transplant diabetes, hemorrhagic cystitis and malignancy.|The proportion of transplanted participants who develop donor specific antibody after initiation of immunosuppression withdrawal|The proportion of transplanted participants who develop donor specific antibody at any time during trial participation|The time to absolute neutrophil recovery.|The time to platelet count recovery.|The proportion of transplanted participants who remain off immunosuppression for at least 52 weeks including those in whom the 52 week biopsy was not performed.|The proportion of participants who remain free from return to immunosuppression for the duration of the study.|In participants who complete tacrolimus withdrawal: Immunosuppression-free duration|In participants who complete tacrolimus withdrawal: Time from completion of tacrolimus withdrawal to first episode of acute rejection or presumed acute rejection|In participants who complete tacrolimus withdrawal: Time from completion of tacrolimus withdrawal to first diagnosis of chronic T cell mediated or antibody-mediated rejection.|The severity of graft versus host disease (GVHD) in transplanted participants|The duration of graft versus host disease (GVHD) in transplanted participants|The duration of engraftment syndrome in transplanted participants|The severity of adverse events including infection, wound complications, post-transplant diabetes, hemorrhagic cystitis and malignancy.|The duration of adverse events including infection, wound complications, post-transplant diabetes, hemorrhagic cystitis and malignancy.","https://ClinicalTrials.gov/show/NCT02029638"
699,"NCT00470301","Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer","Completed","Has Results","Breast Cancer|Male Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer","Drug: tipifarnib|Drug: paclitaxel|Drug: doxorubicin|Drug: cyclophosphamide","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","60","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00239|06-12-487|7868|P30CA013330|N01CM62202|N01CM62204","May 3, 2007","April 2007","September 2013","May 6, 2015","February 2014","May 6, 2015","null","September 2013","Recommended Phase II Dose of Tipifarnib When Combined With Weekly Sequential Paclitaxel (Phase I)|Pathologic Complete Response Rate (pCR) Evaluated Using RECIST (Phase II)","https://ClinicalTrials.gov/show/NCT00470301"
700,"NCT02248428","Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma","Recruiting","No Results Available","Multiple Myeloma","Drug: Clarithromycin|Drug: Thalidomide|Drug: Cyclophosphamide|Drug: Dexamethasone","Jinling Hospital, China","All","18 Years and older   (Adult, Senior)","Phase 3","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NAB20140324","September 22, 2014","April 2012","September 2018","September 20, 2016","September 2016","No Study Results Posted","CTd","September 2017","Percentage of Participants With Very Good Partial Remission (VGPR) or Better|Median Progression Free Survival (PFS) in months|2 Year Overall Survival (OS) Rate|Number of participants with adverse events","https://ClinicalTrials.gov/show/NCT02248428"
701,"NCT02406222","Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)","Recruiting","No Results Available","Multiple Myeloma","Drug: Pomalidomide|Drug: Dexamethasone|Drug: Cyclophosphamide","University of Leeds|Myeloma UK|Celgene","All","18 Years and older   (Adult, Senior)","Phase 2","250","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HM13/10758","February 18, 2015","March 2016","March 2023","May 11, 2016","May 2016","No Study Results Posted","MUKseven","March 2019","To determine whether the addition of cyclophosphamide to pomalidomide and dexamethasone (CPD) improves progression-free survival in patients with relapsed refractory myeloma (RRMM) in the UK, compared to pomalidomide and dexamethasone (Pd) alone|Maximum response overall|Response to treatment|Clinical benefit rate overall|Time to maximum response|Duration of response|Progression-free survival|Overall survival|Treatment compliance measured by treatment delays and missed treatment doses.|Safety and Toxicity measured by adverse reaction and serious adverse event reporting","https://ClinicalTrials.gov/show/NCT02406222"
702,"NCT00946023","Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab","Terminated","No Results Available","Lymphoma|B-cell Lymphoma|Non Hodgkin Lymphoma|Chronic Lymphocytic Leukemia","Drug: Bone marrow transplantation","Sidney Kimmel Comprehensive Cancer Center","All","1 Year to 75 Years   (Child, Adult, Senior)","Phase 2","135","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0941|NA_00025589","July 21, 2009","July 2009","August 2015","September 20, 2013","September 2013","No Study Results Posted","null","July 2013","Event-free survival|Longer-term event-free survival, overall survival, relapse, nonrelapse mortality, and incidence of acute and chronic graft versus host disease|Feasibility of selecting donors based on favorable Fc receptor polymorphism status","https://ClinicalTrials.gov/show/NCT00946023"
703,"NCT00687648","Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: anastrozole|Drug: cyclophosphamide|Drug: exemestane|Drug: letrozole|Drug: methotrexate|Drug: prednisolone","National Cancer Centre, Singapore|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","70","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000595712|SINGAPORE-NCC0706","May 30, 2008","May 2008","null","June 16, 2009","June 2009","No Study Results Posted","null","April 2010","Clinical benefit response rate (complete response, partial response, or stable disease for > 24 weeks)|Time to progression|Overall survival|Safety and toxicity|Correlation between tumor response and markers of angiogenesis|Relative contribution of methotrexate and prednisolone to metronomic chemotherapy as assessed by change in circulating endothelial progenitor cell, VEGF, and VEGFR levels during serial addition of each drug","https://ClinicalTrials.gov/show/NCT00687648"
704,"NCT00688740","Docetaxel in Node Positive Adjuvant Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Docetaxel|Drug: 5-fluorouracil|Drug: Doxorubicin|Drug: Cyclophosphamide","Sanofi|Cancer International Research Group (CIRG)","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","1491","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC6041|XRP6976D-316|BCIRG001","May 29, 2008","June 1997","January 2010","February 14, 2011","February 2011","January 25, 2011","TAX316","January 2010","Number of Participants With Disease-Free Survival Events|Number of Participants With Overall Survival Events|Number of Participants With Second Primary Malignancies (Toxicity)","https://ClinicalTrials.gov/show/NCT00688740"
705,"NCT00003782","Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes","Completed","Has Results","Breast Cancer","Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin","NSABP Foundation Inc|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","5351","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP B-30|CDR0000066914","November 1, 1999","March 1999","December 2012","January 11, 2013","January 2013","August 24, 2012","null","December 2008","Overall Survival|Disease Free Survival|Toxicities Among the 3 Regimens|Quality of Life Among Breast Cancer Patients|Amenorrhea in Premenopausal Women","https://ClinicalTrials.gov/show/NCT00003782"
706,"NCT02183805","Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer","Recruiting","No Results Available","Carcinoma Breast Stage IV","Drug: Abraxane,Cyclophosphamide,Carboplatin","Sun Yat-sen University","Female","18 Years to 65 Years   (Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SYSUCC-004","July 1, 2014","June 2014","December 2019","February 28, 2017","February 2017","No Study Results Posted","null","December 2019","Progression free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02183805"
707,"NCT02414269","Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin","Recruiting","No Results Available","Malignant Pleural Disease|Mesothelioma|Metastases|Lung Cancer|Breast Cancer","Genetic: iCasp9M28z T cell infusions|Drug: cyclophosphamide","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","15-007","April 2, 2015","May 2015","April 2018","April 6, 2017","April 2017","No Study Results Posted","null","April 2018","Composite measure of severity and number of adverse events (AEs); changes in clinical laboratory test findings (hematologic and chemistry); and physical examination.|Changes in serum levels of the biomarker soluble mesothelin related peptide (SMRP)","https://ClinicalTrials.gov/show/NCT02414269"
708,"NCT00636441","Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer","Terminated","Has Results","Early-Stage Breast Cancer","Drug: Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)","Duke University|United States Department of Defense","Female","18 Years and older   (Adult, Senior)","Phase 2","56","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00001345|W81XWH-07-1-0394|BC060228-W81XWH-07-1-0394","March 9, 2008","April 2008","April 2013","November 16, 2015","October 2014","May 7, 2014","null","April 2013","Pathologic Complete Response (pCR) Rate in Patients With HER2-negative Early-stage Breast Cancer|Probabilities of Being Sensitive to AC and TC as Determined by the Patient's Genomic Signatures|Percentage of Patients Who Had Breast-conserving Surgery With Negative Margins|To Percentage of Patients Who Had Breast-conserving Surgery at First Attempt.|Clinical Response Using WHO Criteria|Disease-free Survival|Sites of Recurrence|Overall Survival|Economic Impact of Using Genomic Assessment to Guide Management.|Patients' Perceptions of Participating in a Clinical Trial Evaluating Cancer Genomics for PST of Early-stage Breast Cancer.","https://ClinicalTrials.gov/show/NCT00636441"
709,"NCT01925131","S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia","Recruiting","No Results Available","Acute Leukemias of Ambiguous Lineage|B-cell Adult Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma","Drug: cyclophosphamide|Drug: vincristine sulfate|Drug: prednisone|Biological: inotuzumab ozogamicin|Other: laboratory biomarker analysis","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","38","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","S1312|NCI-2013-01368|U10CA180888|U10CA032102","August 15, 2013","April 2014","January 2023","February 23, 2017","February 2017","No Study Results Posted","null","January 2022","MTD of inotuzumab ozogamicin with CVP defined as the highest dose studied in which the incidence of dose-limiting toxicities is < 33% using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0|Response rate (CR+CRi)|Frequency of toxicities graded according to NCI CTCAE version 4.0|Severity of toxicities graded according to NCI CTCAE version 4.0","https://ClinicalTrials.gov/show/NCT01925131"
710,"NCT00021255","Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer","Completed","Has Results","Breast Neoplasms","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Herceptin|Drug: Carboplatin","Sanofi|Cancer International Research Group (CIRG)","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","3222","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TAX_GMA_302|BCIRG 006","July 11, 2001","April 2001","December 2014","September 26, 2016","September 2016","June 15, 2016","null","December 2014","Percentage of Participants With Disease Free Survival at 5 Years|Percentage of Participants With Disease Free Survival at 10 Years|Overall Survival- Percentage of Participants Who Survived at 10 Years","https://ClinicalTrials.gov/show/NCT00021255"
711,"NCT00861705","Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery","Completed","Has Results","Estrogen Receptor Negative|HER2/Neu Negative|Male Breast Carcinoma|Progesterone Receptor Negative|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Triple-Negative Breast Carcinoma","Biological: Bevacizumab|Drug: Carboplatin|Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","454","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-01172|CALGB-40603|CALGB 40603/CTSU 40603|CDR0000636850|CALGB 40603|U10CA180821|U10CA031946","March 12, 2009","May 2009","August 2014","September 28, 2015","August 2015","January 12, 2015","null","August 2014","Pathologic Complete Response (pCR) in the Breast. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is).|Pathologic Complete Response (pCR) in the Breast and Axilla. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is) Plus the Absence of Any Tumor Deposit >0.2 mm in Sampled Axillary Nodes (ypT0/isN0).|Pathologic Stage in the Breast and in the Breast Plus Axilla as Measured by American Joint Committee on Cancer (AJCC) Tumor Node Metastasis (TNM) Staging Criteria (Version 6)|Radiographic Response Assessed by Tumor Measurement|Clinical Response Assessed by Tumor Measurement|Overall Survival|Recurrence-free Survival|Time to First Failure, Defined as First Instance of Ipsilateral Invasive Breast Tumor Recurrence, Local/Regional Invasive Breast Cancer Recurrence, Distant Recurrence, or Death From Any Cause|Incidence and Severity of Post-op Complications, Namely Excessive Bleeding, Delayed Wound Healing, and Wound Dehiscence.","https://ClinicalTrials.gov/show/NCT00861705"
712,"NCT00641381","Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Other: pharmacological study|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","City of Hope Medical Center|National Cancer Institute (NCI)","All","10 Years to 60 Years   (Child, Adult)","","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","99067|P30CA033572|CHNMC-99067|CDR0000589621|NCI-2010-00431","March 21, 2008","May 2000","October 2017","January 27, 2017","January 2017","No Study Results Posted","null","October 2017","Number of days to engraftment as defined by the standard operating procedures of the department of biostatistics at the City of Hope|Feasibility and treatment-associated toxicity of this regimen|Ability to mobilize adequate numbers of peripheral blood stem cells (2.5 x 10e6 CD34+cells)|Disease-free and overall survival|HIV viral load, CD4+/CD8+ counts, and immune recovery","https://ClinicalTrials.gov/show/NCT00641381"
713,"NCT01009970","Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone|Drug: Doxorubicin","Fondazione Italiana Linfomi ONLUS","All","18 Months and older   (Child, Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IIL-HEART01|2009-012143-42","November 6, 2009","May 2010","May 2012","October 12, 2011","October 2011","No Study Results Posted","null","May 2011","Feasibility of R-COMP in cardiopathic patients|Response rates|Progression free survival|Overall Survival","https://ClinicalTrials.gov/show/NCT01009970"
714,"NCT00507442","Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients","Completed","Has Results","Multiple Myeloma","Drug: VELCADE (bortezomib)|Drug: dexamethasone|Drug: cyclophosphamide|Drug: Revlimid (lenalidomide)","Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","158","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","C05008","July 25, 2007","August 2007","November 2010","July 18, 2013","April 2012","November 28, 2011","EVOLUTION","October 2010","Number of Patients With Combined Complete Response and Very Good Partial Response|Number of Patients With Adverse Events (AEs)|Number of Patients With Overall Response|Number of Patients With Stringent Complete Response Rate|Number of Patients With Complete Response Rate + Near Complete Response Rate|Duration of Response|Time to Disease Progression|Time to Response|Progression-free Survival|Probability of 1-year Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00507442"
715,"NCT00134004","Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer","Completed","Has Results","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","6 Months to 74 Years   (Child, Adult, Senior)","Phase 2","210","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0457 CDR0000440990|P01CA015396|P30CA006973|JHOC-J0457|JHOC-04072704","August 22, 2005","October 2004","January 2015","September 2, 2015","September 2015","June 26, 2015","null","January 2015","Transplant-related Mortality|Relapse Rate|Progression-free Survival|Graft Failure Rate|Hematologic and Non-hematologic Toxicities as Measured by NCI Common Toxicity Criteria for Adverse Events, v 3.0 Weekly Until 1 Year After Transplantation","https://ClinicalTrials.gov/show/NCT00134004"
716,"NCT03161379","Phase 2 GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT Followed by Resection for Patients With Borderline Resectable Pancreatic Cancer","Not yet recruiting","No Results Available","Pancreatic Cancer","Drug: Cyclophosphamide|Drug: Nivolumab|Drug: GVAX Pancreas Vaccine|Radiation: Stereotactic Body Radiation (SBRT)","Sidney Kimmel Comprehensive Cancer Center","All","18 Years to 100 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","J1756|IRB00130075","May 18, 2017","September 2017","September 2019","May 18, 2017","May 2017","No Study Results Posted","null","September 2019","Pathologic complete response (pCR) rate at surgical resection.|Number of subjects who receive an R0 surgical resection.|Objective response rate (ORR)|Overall survival (OS)|Distant metastasis free survival (DMFS)|Number of drug related adverse events","https://ClinicalTrials.gov/show/NCT03161379"
717,"NCT00003910","Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia","Terminated","Has Results","Leukemia","Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Prednisone","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","59","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067089|U10CA021115|E5998","November 1, 1999","July 1999","March 2012","October 6, 2015","October 2012","October 16, 2012","null","December 2010","Complete, Partial, and Overall Response Rates of Treatment With MTX, and Also With CY for Patients Failing to Respond to MTX|Clinical Response","https://ClinicalTrials.gov/show/NCT00003910"
718,"NCT00971763","Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma","Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: gemcitabine hydrochloride|Drug: prednisolone|Drug: vincristine sulfate","University College, London","All","18 Years and older   (Adult, Senior)","Phase 2","62","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000644293|UCL/05/154|2005-003888-23|EU-20951","September 3, 2009","March 2006","July 2011","December 3, 2014","September 2009","No Study Results Posted","null","July 2011","Overall response rate|Toxicity|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00971763"
719,"NCT01015456","The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis","Terminated","No Results Available","Lupus Nephritis","Drug: mycophenolate sodium|Drug: cyclophosphamide","Chulalongkorn University|Clinical Research Collaborative Network|Health Intervention and Technology Assessment Program (HITAP)","All","16 Years to 60 Years   (Child, Adult)","Phase 3","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-001|Lupus Research Unit|CRCN|HITAP","November 17, 2009","January 2010","January 2013","October 9, 2014","October 2014","No Study Results Posted","CONTROL","January 2013","Efficacy of enteric-coated Mycophenolate Sodium at 12 months in the treatment of lupus nephritis|The cost-effectiveness of using enteric-coated Mycophenolate Sodium as compared to standard treatment|The ratio of patients with declined renal function|Time to remission","https://ClinicalTrials.gov/show/NCT01015456"
720,"NCT02594267","A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)","Recruiting","No Results Available","Peripheral T-Cell Lymphoma (PTCL)","Drug: Pralatrexate Injection","Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Senior)","Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SPI-FOL-101","September 25, 2015","October 2015","April 2018","March 10, 2017","March 2017","No Study Results Posted","null","April 2017","Maximum Tolerated Dose|Number of participants with treatment emergent adverse events (TEAEs) using CTCAE version 4.03|Objective Response Rate|Plasma concentration of pralatrexate in combination with CHOP|Pharmacokinetics: Area Under the Curve (AUC)|Pharmacokinetics: Maximum Concentration (Cmax)|Pharmacokinetics: Time to Maximum concentration (Tmax)|Pharmacokinetics: Clearance (CL)","https://ClinicalTrials.gov/show/NCT02594267"
721,"NCT01705691","Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer","Completed","No Results Available","Breast Cancer|HER2-negative Breast Cancer","Drug: Paclitaxel|Drug: Eribulin|Drug: Doxorubicin|Drug: Cyclophosphamide","NSABP Foundation Inc|Eisai Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP FB-9","October 8, 2012","September 2012","October 2015","January 20, 2016","January 2016","No Study Results Posted","null","March 2014","Pathologic complete response rate (ypCR) following neoadjuvant therapy in breast and axillary lymph nodes|ypCR nodes|Clinical overall response (cOR)(complete and partial) assessed by physical exam and MRI at the completion of WP or eribulin (before AC)|Clinical Complete Response (ycCR) following neoadjuvant therapy assessed by physical exam at the completion of neoadjuvant chemotherapy|Recurrence Free Interval (RFI): The time to occurrence of inoperable progressive disease and local, regional, and distant recurrence.|2-year Overall Survival (OS): Death from any cause from time of randomization through 2 years after randomization.|Adverse events experienced by participants as a measure of toxicity.","https://ClinicalTrials.gov/show/NCT01705691"
722,"NCT00555048","Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer","Terminated","Has Results","Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: alemtuzumab|Drug: busulfan|Drug: cyclophosphamide|Drug: methotrexate|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 50 Years   (Child, Adult)","Phase 1|Phase 2","1","Other|NIH","Interventional","Primary Purpose: Treatment","1981.00|P30CA015704|FHCRC-1981.00|CDR0000574145","November 6, 2007","September 2007","null","April 17, 2017","April 2017","April 17, 2017","null","October 2010","Lowest Dose of Alemtuzumab Associated With Transplant-related Mortality|Life-threatening Infection|Grades III-IV Acute Graft-vs-host Disease (GVHD)|Overall Survival|Disease Relapse|Extensive Chronic GVHD|Graft Failure","https://ClinicalTrials.gov/show/NCT00555048"
723,"NCT00174655","BIG 02/98 Docetaxel - Breast Cancer","Completed","No Results Available","Breast Neoplasms","Drug: Doxorubicine + docetaxel sequential|Drug: doxorubicine + cyclophosphamide sequential|Drug: doxorubicine + cyclophosphamide combined|Drug: doxorubicine + docetaxel combined","Sanofi","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","2887","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RP56976_PR_315","September 9, 2005","June 1998","September 2011","November 9, 2011","November 2011","No Study Results Posted","null","September 2011","DFS of docetaxel arms versus non toxanes arm (DFS: interval from the date of randomization to the date of local, regional or metastatic relapse or the date of second primary cancer or death for any cause whichever occurs first.|DFS sequential/combined arms|Safety NCI common toxicity criteria","https://ClinicalTrials.gov/show/NCT00174655"
724,"NCT00003088","Combination Chemotherapy in Treating Patients With Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","2005","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-9741|U10CA031946|CDR0000065788","November 1, 1999","September 1997","June 2003","July 1, 2016","July 2016","No Study Results Posted","null","April 2003","Disease free survival","https://ClinicalTrials.gov/show/NCT00003088"
725,"NCT02004262","Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting","Completed","No Results Available","2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer","Biological: GVAX Pancreas Vaccine|Biological: CRS-207|Drug: gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib|Drug: cyclophosphamide","Aduro Biotech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","303","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ADU-CL-04","October 23, 2013","January 2014","August 2016","April 27, 2017","April 2017","No Study Results Posted","ECLIPSE","January 2016","Overall survival in subjects receiving test treatments|Adverse events in each treatment arm treatment regimen","https://ClinicalTrials.gov/show/NCT02004262"
726,"NCT00789776","Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer","Active, not recruiting","No Results Available","Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Aggressive Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Previously Treated Myelodysplastic Syndrome|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Indolent Adult Non-Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Small Lymphocytic Lymphoma|Waldenstrom Macroglobulinemia","Procedure: Allogeneic Bone Marrow Transplantation|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Biological: Natural Killer Cell Therapy|Drug: Tacrolimus|Radiation: Total-Body Irradiation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|The Wayne D. Kuni and Joan E. Kuni Foundation","All","Child, Adult, Senior","Phase 1|Phase 2","42","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2230.00|NCI-2010-00106|P01CA078902|P30CA015704","November 12, 2008","October 2008","null","June 7, 2016","June 2016","No Study Results Posted","null","June 2017","Dose-limiting toxicity (Phase I)|Relapse (Phase II)|Acute GvHD (Phase II)|Chronic extensive GvHD (Phase II)|Contribution of KIR ligand alloreactivity to relapse (Phase II)|Engraftment (Phase II)|Evaluation of rejection (Phase II)|NK cell infusion on post-transplant immune reconstitution (Phase II)|Non-relapse mortality (Phase II)|Overall survival (Phase II)|Progression (Phase II)","https://ClinicalTrials.gov/show/NCT00789776"
727,"NCT01329640","Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)","Terminated","No Results Available","Locally Advanced HER2-positive Breast Cancer","Device: Drug: Paclitaxel; trastuzumab; doxorrubicin; cyclophosphamide","Instituto do Cancer do Estado de São Paulo|Fundação Faculdade de Medicina","Female","18 Years and older   (Adult, Senior)","Phase 2","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NP 17/2010 TraQ-Me 01","November 8, 2010","September 2010","September 2012","May 20, 2014","May 2014","No Study Results Posted","null","September 2011","INCIDENCE OF FEBRILE NEUTROPENIA|TUMOR SIZE","https://ClinicalTrials.gov/show/NCT01329640"
728,"NCT01417000","Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Biological: GVAX Pancreas|Biological: CRS-207|Drug: Cyclophosphamide","Aduro Biotech, Inc.|Johns Hopkins University","All","18 Years and older   (Adult, Senior)","Phase 2","93","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ADU-CL-01","August 10, 2011","September 2011","October 2016","April 27, 2017","April 2017","No Study Results Posted","null","September 2012","Overall survival in subjects receiving test treatments|To assess safety of the cyclophosphamide, GVAX Pancreas vaccine, and CRS-207 treatment regimen|To assess the immune response","https://ClinicalTrials.gov/show/NCT01417000"
729,"NCT00863330","Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma","Terminated","Has Results","Melanoma (Skin)","Biological: Tumor Infiltrating Lymphocytes (TIL)","Aurora Health Care","All","18 Years and older   (Adult, Senior)","Phase 2","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000636885|STLMC-L-0839","March 17, 2009","February 2009","July 2012","December 16, 2014","December 2014","December 3, 2014","null","July 2012","Primary Objective","https://ClinicalTrials.gov/show/NCT00863330"
730,"NCT00937300","T-cell Based Immunotherapy for Head and Neck Cancer","Withdrawn","No Results Available","Squamous Cell Carcinoma|Head and Neck Cancer","Biological: cyclophosphamide, fludarabine, T-cell infusion, and Interleukin-2","Inge Marie Svane|Herlev Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HH0908","July 10, 2009","June 2009","June 2011","November 22, 2011","November 2011","No Study Results Posted","null","June 2011","toxicity|immune response","https://ClinicalTrials.gov/show/NCT00937300"
731,"NCT00007904","Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel|Drug: tamoxifen citrate|Procedure: adjuvant therapy|Radiation: radiation therapy","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","16","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU1100|P30CA043703|05-00-23|NCI-G00-1877|NCI-2010-01068","January 6, 2001","July 2000","September 2012","September 28, 2012","September 2012","No Study Results Posted","null","June 2006","To determine the safety of administering continuous infusion paclitaxel with dose intense cyclophosphamide|To determine the incidence of febrile neutropenia with the first cycle of therapy.|To determine days of neutrophil counts below 500/uL on this regimen during the first treatment cycle.|To evaluate dose delays and dose reductions of this regimen.|To determine disease-free and overall survival of this regimen.|Quality of life as assessed by Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire|Correlation of Her2/neu overexpression with disease-free and overall survival","https://ClinicalTrials.gov/show/NCT00007904"
732,"NCT00782379","Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer","Completed","Has Results","Leukemia|Lymphoma|Myelodysplastic Syndromes","Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Northside Hospital, Inc.","All","18 Years to 60 Years   (Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000617648|BMTGG-NSH-864","October 29, 2008","October 2008","April 2012","October 28, 2013","March 2013","March 18, 2013","null","April 2011","Incidence of Graft Rejection for Patients at Day 100|Number of Patients Who Experienced Severe Graft-versus-host Disease (GVHD)(Grade 3 or 4)|Overall Survival at Day 100|Non-relapse Mortality at 1 Year After Peripheral Blood Stem Cell Transplantation (PBSCT)|Achievement of >90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 30 Post-transplantation|Non-relapse Mortality at Day 100 After Peripheral Blood Stem Cell Transplantation (PBSCT)|Achievement of >90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 60 Post-transplantation|Achievement of >90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 90 Post-transplantation|Overall Survival at 12 Months|Disease Free Survival at 12 Months|Disease Free Survival at Day 100","https://ClinicalTrials.gov/show/NCT00782379"
733,"NCT00255684","Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer","Terminated","Has Results","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Biological: graft-versus-tumor induction therapy|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","University of Rochester","All","up to 75 Years   (Child, Adult, Senior)","","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000448637|URCC-U19403|URCC-RSRB-10063","November 18, 2005","December 2003","June 2016","September 28, 2016","September 2016","May 18, 2016","null","March 2013","Number of Participants Who Survived 100 Days or Longer|Number of Participants Who Developed Acute Graft Versus Host Disease","https://ClinicalTrials.gov/show/NCT00255684"
734,"NCT02650986","Gene-Modified T Cells in Treating Patients With Locally Advanced or Stage IV Solid Tumors Expressing NY-ES0-1","Not yet recruiting","No Results Available","Adult Solid Neoplasm","Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Biological: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL|Biological: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","I 258514|NCI-2015-02080|P30CA016056","December 21, 2015","June 1, 2017","October 20, 2019","May 8, 2017","May 2017","No Study Results Posted","null","October 20, 2018","Dose-limiting toxicity using Common Toxicity Criteria|Feasibility based on potential problems in the manufacturing of NY-ESO-1/ dnTGFβRII engineered cells|Expression of the NY-ESO-1 TCR transgenic protein in peripheral blood mononuclear cells (PBMC)|Replication competent retrovirus (RCR)|Tumor response (complete and partial response) as determined by RECIST 1.1","https://ClinicalTrials.gov/show/NCT02650986"
735,"NCT01088750","Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma","Recruiting","No Results Available","Lymphoma","Drug: cyclophosphamide|Drug: prednisolone|Drug: vinblastine sulfate|Other: watchful waiting|Procedure: therapeutic conventional surgery","Christine Mauz-Körholz|Deutsche Krebshilfe e.V., Bonn (Germany)|Euronet Worldwide|Martin-Luther-Universität Halle-Wittenberg","All","up to 17 Years   (Child)","Phase 4","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000667369|EURONET-PHL-LP1|EUDRACT-2007-004092-19|EU-21011","March 16, 2010","November 2009","December 2018","December 2, 2016","December 2016","No Study Results Posted","null","December 2018","Event-free survival|Significant upstaging at relapse defined as development of B-symptoms, extranodal disease, or relapse higher than stage II|Overall survival|Toxicity|Complications of surgery","https://ClinicalTrials.gov/show/NCT01088750"
736,"NCT00003136","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer","Completed","No Results Available","Ovarian Cancer|Primary Peritoneal Cavity Cancer","Biological: filgrastim|Drug: amifostine trihydrate|Drug: carboplatin|Drug: cyclophosphamide|Procedure: peripheral blood stem cell transplantation","University of Chicago","Female","up to 65 Years   (Child, Adult)","Phase 1|Phase 2","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","8433|UCCRC-8433|ALZA-97-005-ii|NCI-V97-1357","November 1, 1999","December 1996","October 2001","February 8, 2013","February 2013","No Study Results Posted","null","December 2000","Maximum tolerated dose","https://ClinicalTrials.gov/show/NCT00003136"
737,"NCT01503905","Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer Nos Premenopausal","Drug: Docetaxel|Drug: epirubicin|Drug: cyclophosphamide|Procedure: Modified radical mastectomy or breast-conserving Surgery|Drug: Docetaxel (post-operative)|Drug: Epirubicin (post-operative)|Drug: Cyclophosphamide (post-operative)|Radiation: Radiation therapy|Drug: Herceptin （post-operative)|Drug: Tamoxifen (post-operative)","Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","Female","18 Years and older   (Adult, Senior)","","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BCSCO001","December 29, 2011","December 2011","December 2021","May 23, 2016","May 2016","No Study Results Posted","null","May 2018","Progression-free survival of patients.|Overall survival of the patients|The pathological remission rate of patients after neoadjuvant chemotherapy.|The clinical remission rate of patients after neoadjuvant chemotherapy","https://ClinicalTrials.gov/show/NCT01503905"
738,"NCT00550771","Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)","Completed","Has Results","Breast Neoplasm","Drug: doxorubicin, cyclophosphamide, paclitaxel, trastuzumab|Drug: PLD, cyclophosphamide, trastuzumab, paclitaxel","Merck Sharp & Dohme Corp.","Female","18 Years and older   (Adult, Senior)","Phase 2","181","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P05048","October 29, 2007","July 2007","August 2010","October 1, 2015","October 2015","August 26, 2011","null","August 2010","Number of Participants Who Experienced Cardiac Events (Level 1 or 2), or Inability to Administer Trastuzumab Either During the 8 Cycles of Chemotherapy or According to Package Insert for a Total Duration of 1 Year|Number of Participants Who Experienced Cardiac Events (Level 1 or 2) or Inability to Administer Trastuzumab During the 8 Cycles of Chemotherapy|Number of Participants Who Experienced Cardiac Events (Level 1 or 2) or Inability to Administer Trastuzumab During 1 Year of Trastuzumab Therapy|Number of Participants Who Survived Without Relapse","https://ClinicalTrials.gov/show/NCT00550771"
739,"NCT00302549","To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class III-IV LN","Completed","No Results Available","Lupus Nephritis","Drug: FK506","Nanjing University School of Medicine|Sun Yat-sen University","Female","18 Years to 65 Years   (Adult)","","61","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NJCT-0602","March 13, 2006","May 2004","February 2006","May 25, 2010","July 2008","No Study Results Posted","null","May 2005","To compare the efficacy of FK506 vs intravenous cyclophosphamide pulses in the treatment of class III-IV LN|To compare the safety and tolerability of FK506 vs intravenous cyclophosphamide pulses in the treatment of class III-IV LN and to explore the dosing of FK506 and its effective range of blood concentration.","https://ClinicalTrials.gov/show/NCT00302549"
740,"NCT00002831","Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia","Completed","No Results Available","Leukemia","Biological: Filgrastim|Drug: Busulfan|Drug: Cyclophosphamide|Drug: Cyclosporine|Drug: Decitabine (DAC)|Drug: Methotrexate|Drug: Methylprednisolone|Drug: Tacrolimus|Procedure: Allogeneic Bone Marrow Transplantation|Procedure: Peripheral Blood Stem Cell Transplantation","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","15 Years to 55 Years   (Child, Adult)","Phase 1|Phase 2","24","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM94-064|P30CA016672|MDA-DM-94064|NCI-G96-0999|CDR0000065033","November 1, 1999","July 1994","December 2002","July 27, 2012","July 2012","No Study Results Posted","null","December 2002","Maximum Tolerated Dose","https://ClinicalTrials.gov/show/NCT00002831"
741,"NCT00937625","T-cell Based Immunotherapy for of Melanoma","Completed","No Results Available","Melanoma","Biological: cyclophosphamide, fludarabine, T-cells, Interleukin-2","Inge Marie Svane|Herlev Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","31","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MM0909","July 10, 2009","June 2009","January 2015","August 17, 2015","August 2015","No Study Results Posted","null","January 2015","toxicity|immune response|tumor response","https://ClinicalTrials.gov/show/NCT00937625"
742,"NCT00801580","My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia","Unknown status","No Results Available","Lymphoid Leukemia","Drug: doxorubicin liposomal","University of Bologna","All","18 Years and older   (Adult, Senior)","Phase 2","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ALL0206|Eudract: 2007-003884-30","December 2, 2008","March 2008","September 2010","September 14, 2009","September 2009","No Study Results Posted","null","September 2010","Type, frequency, severity, timing and relatedness of adverse events (AE)|CR rate after any treatment cycle and at the end of the study|The percentage of hematological responders after any treatment cycle|The percentage of cytogenetic and molecular responders after any treatment cycle in patients for whom genetic markers of minimal residual disease are available|Relapse free survival at month 6 and 12|Overall survival at month 6 and 12|The percentage of patients submitted to SCT after CR re-induction","https://ClinicalTrials.gov/show/NCT00801580"
743,"NCT00416910","Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia","Terminated","No Results Available","Chronic Lymphocytic Leukemia","Biological: Filgrastim|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Mitoxantrone","German CLL Study Group","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","83","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GCLLSG-CLL6|CDR0000455571|EU-20558|AMGEN-GCLLSG-CLL6|MEDAC-GCLLSG-CLL6","December 27, 2006","July 1999","September 2007","September 23, 2016","September 2016","No Study Results Posted","null","September 2003","","https://ClinicalTrials.gov/show/NCT00416910"
744,"NCT02461316","Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia","Completed","No Results Available","Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Cancer","Other: No intervention","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","","22","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ML25066","June 1, 2015","July 2009","December 2011","November 1, 2016","November 2016","No Study Results Posted","null","December 2011","Percentage of Adverse Events (AEs)|Percentage of Serious Adverse Events (SAEs)","https://ClinicalTrials.gov/show/NCT02461316"
745,"NCT00278109","Radiation Therapy, Cyclophosphamide, and Doxorubicin in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery","Unknown status","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Procedure: adjuvant therapy|Radiation: radiation therapy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","39 Years and older   (Adult, Senior)","Phase 1|Phase 2","42","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0381 CDR0000446085|P30CA006973|JHOC-J0381|JHOC-04032201","January 16, 2006","July 2004","null","March 28, 2014","March 2014","No Study Results Posted","null","May 2015","Potential acute, late skin, and subcutaneous toxicity|Local control rate|Cosmetic effects","https://ClinicalTrials.gov/show/NCT00278109"
746,"NCT03063983","Clinical Trial Evaluating Metronomic Chemotherapy in Patients With Metastatic Osteosarcoma","Recruiting","No Results Available","Osteosarcoma","Drug: Cyclophosphamide|Drug: Methotrexate","Grupo de Apoio ao Adolescente e a Crianca com Cancer","All","up to 30 Years   (Child, Adult)","Phase 2","158","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GLATO2017","January 27, 2017","January 2, 2017","January 31, 2022","March 9, 2017","March 2017","No Study Results Posted","GLATO2017","January 2, 2019","Efficacy and toxicity of adding metronomic therapy in disease event-free survival.|Efficacy and toxicity of adding metronomic therapy in overall survival|Cardiotoxicity (occurrence of cardiotoxicity)|Immunohistochemistry (expression of VEGF)","https://ClinicalTrials.gov/show/NCT03063983"
747,"NCT01598129","ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers","Completed","Has Results","Malignant Solid Tumour","Genetic: ONCOS-102","Targovax Oy|Targovax ASA","All","18 Years and older   (Adult, Senior)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Oncos-C1","April 19, 2012","April 2012","October 2013","October 21, 2016","October 2016","June 11, 2014","null","October 2013","Number of Participants With Any (Serious and Non-Serious) Adverse Event Measured to Assess Safety and Tolerability.|Recommended Phase 2 Dose by Identification of Any Dose Limiting Toxicities|To Determine the Safety, Tolerability and Adverse Event Profile of CGTG-102 With Low-dose CPO. To Obtain Preliminary Evidence of Antitumour Activity.","https://ClinicalTrials.gov/show/NCT01598129"
748,"NCT00769522","FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia","Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia","Biological: Rituximab|Drug: Bendamustine|Drug: Cyclophosphamide|Drug: Fludarabine","German CLL Study Group|Roche Pharma AG|Mundipharma Pte Ltd.","All","18 Years and older   (Adult, Senior)","Phase 3","564","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CLL10|CDR0000616169|2007-007587-21","October 8, 2008","September 2008","January 2018","September 30, 2016","September 2016","No Study Results Posted","null","July 2011","Progression-free survival rate after 24 months|Minimal residual disease, complete response rates, and partial response rates|Duration of remission|Event-free survival|Overall survival|Overall response rate|Response rates in and survival times in biological subgroups|Toxicity rates|Quality of life|Standard safety analysis","https://ClinicalTrials.gov/show/NCT00769522"
749,"NCT01883297","""Re-Stimulated"" Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","Recruiting","No Results Available","Recurrent, Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","Biological: Re-stimulated tumor-infiltrating lymphocytes (TILs)|Biological: Interleukin-2|Drug: Cyclophosphamide","University Health Network, Toronto","All","18 Years and older   (Adult, Senior)","Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","TILs-001-DC","June 11, 2013","January 2015","December 2023","April 28, 2017","April 2017","No Study Results Posted","null","June 2023","Number occurrences and severity of side effects|Clinical response to treatment|Number of patients with an immunity and no immunity to the study treatment","https://ClinicalTrials.gov/show/NCT01883297"
750,"NCT01186640","Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)","Completed","No Results Available","T-cell-prolymphocytic Leukemia","Drug: Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab|Drug: Alemtuzumab","German CLL Study Group|Genzyme, a Sanofi Company|University of Cologne","All","18 Years and older   (Adult, Senior)","Phase 2","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","T-PLL2|2008-001421-34","August 20, 2010","June 2010","May 2014","September 23, 2016","September 2016","No Study Results Posted","null","May 2014","Remission Rate|Overall Survival Time","https://ClinicalTrials.gov/show/NCT01186640"
751,"NCT02096614","Investigator Initiated Phase 1 Study of TBI-1201","Recruiting","No Results Available","Solid Tumors","Drug: TBI-1201|Drug: Cyclophosphamide|Drug: Fludarabine","Mie University|Takara Bio Inc.|Shionogi|Fiverings Co., Ltd.|Statcom Co. Ltd.","All","20 Years and older   (Adult, Senior)","Phase 1","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1201-01","March 19, 2014","April 2014","null","March 23, 2016","March 2016","No Study Results Posted","null","February 2017","Incidence and grade of adverse events (CTCAE)|Appearance of replication competent retrovirus by PCR|Appearance of clonality by LAM-PCR|Kinetics of TBI-1201 in blood by realtime-PCR and flow cytometry","https://ClinicalTrials.gov/show/NCT02096614"
752,"NCT02366546","Investigator Initiated Phase 1 Study of TBI-1301","Recruiting","No Results Available","Solid Tumors","Drug: TBI-1301|Drug: Cyclophosphamide|Drug: Fludarabine","Mie University|Takara Bio Inc.|Shionogi|Fiverings Co., Ltd.|Statcom Co. Ltd.","All","20 Years and older   (Adult, Senior)","Phase 1","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1301-01","February 12, 2015","March 2015","null","March 23, 2016","March 2016","No Study Results Posted","null","March 2017","Incidence and grade of adverse events (CTCAE)|Appearance of replication competent retrovirus by PCR|Appearance of clonality by LAM-PCR|Kinetics of TBI-1301 in blood by realtime-PCR","https://ClinicalTrials.gov/show/NCT02366546"
753,"NCT00093795","Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Gemcitabine|Drug: Paclitaxel|Drug: Doxorubicin","NSABP Foundation Inc|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","4894","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP B-38|U10CA012027","October 6, 2004","October 2004","June 2016","November 28, 2016","August 2016","No Study Results Posted","null","March 2012","Disease-free survival: any recurrence, contralateral breast cancer, second primary cancer, death from any cause prior to recurrence or second primary cancer|Survival: any death|Recurrence-free interval: time to first local, regional, or distant recurrence|Distant recurrence-free interval; the time to distant disease recurrence only|Toxicity assessed by adverse events","https://ClinicalTrials.gov/show/NCT00093795"
754,"NCT01481194","ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Doxorubicin|Drug: Bortezomib|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Cyclophosphamide","Vejle Hospital|The University of Hong Kong","All","18 Years and older   (Adult, Senior)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SDU/VS-HKU/CTC-2011-01","November 21, 2011","November 2011","December 2019","December 14, 2016","December 2016","No Study Results Posted","ACVDL","May 2014","Response rate|Complete response rate|Very good partial response rate|Time to progression|Progression free survival","https://ClinicalTrials.gov/show/NCT01481194"
755,"NCT00002707","Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed","Completed","No Results Available","Breast Cancer","Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Doxorubicin|Drug: Tamoxifen","NSABP Foundation Inc|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","2411","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP B-27|CDR0000064521","November 1, 1999","December 1995","February 2010","February 2, 2010","February 2010","No Study Results Posted","null","June 2002","Determine if 4 cycle of pre-op or post-op Taxotere given after 4 cycles of pre-op AC will more effectively prolong survival (S) than does 4 cycles of pre-op AC alone.|Prolonging disease-free survival (DFS).|Clinical loco-regional tumor response to preoperative chemotherapy.|Pathologic loco-regional tumor response to pre-op chemotherapy.|Breast conservation assessment.|Evaluate if post-op Taxotere is of benefit in patients who received pre-op AC and, if so, whether it is of benefit in certain subgroups of patients.","https://ClinicalTrials.gov/show/NCT00002707"
756,"NCT01807182","Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma","Recruiting","No Results Available","Stage III Skin Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma","Biological: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Biological: Therapeutic Tumor Infiltrating Lymphocytes","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2643.00|NCI-2013-00486|P30CA015704","March 6, 2013","July 26, 2013","null","January 19, 2017","January 2017","No Study Results Posted","null","October 2017","Clinical response, assessed using Response Evaluation Criteria in Solid Tumors 1.1 definitions for complete response, partial response, stable disease, and progressive disease|In vivo persistence of adoptively transferred T cells following TIL infusion|Incidence of adverse events, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Percent expression of biomarkers","https://ClinicalTrials.gov/show/NCT01807182"
757,"NCT01048892","Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features","Completed","No Results Available","Adrenocortical Carcinoma|Gastrointestinal Carcinoid Tumor|Kidney Cancer|Neuroblastoma|Retinoblastoma|Sarcoma","Biological: Seneca Valley virus-001|Drug: cyclophosphamide|Other: laboratory biomarker analysis|Other: pharmacological study","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 1","22","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ADVL0911|COG-ADVL0911|CDR0000663520","January 13, 2010","September 2009","null","January 29, 2014","January 2014","No Study Results Posted","null","June 2013","Safety and tolerability|Recommended phase II dose of Seneca Valley virus-001 (NTX-010)|Tumor response|Viral titers in blood and stool|Development of antibodies to NTX-010","https://ClinicalTrials.gov/show/NCT01048892"
758,"NCT00070200","Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma","Completed","No Results Available","Neuroblastoma","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: isotretinoin|Drug: melphalan|Drug: topotecan hydrochloride|Drug: vincristine sulfate|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","Phase 1","31","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ANBL02P1|CDR0000330140|COG-ANBL02P1","October 3, 2003","March 2004","December 2013","February 12, 2014","February 2014","No Study Results Posted","null","September 2006","Proportion of patients who are classified as a ""success""|Number of toxic deaths|Proportion of patients with dose limiting toxicities during induction cycle 1 and 2|Tumor contamination of PBSCs|Inability to adequately mobilize PBSCs|Assessment of response","https://ClinicalTrials.gov/show/NCT00070200"
759,"NCT00309842","Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases","Recruiting","No Results Available","Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Myelofibrosis|MDS|Refractory Anemia|Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Non-Hodgkin's Lymphoma|Leukemia|Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes","Biological: filgrastim|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Radiation: total-body irradiation","Masonic Cancer Center, University of Minnesota","All","up to 55 Years   (Child, Adult)","Phase 2","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005LS043|UMN-MT2005-10|UMN-0507M71475","March 29, 2006","July 2005","October 2017","December 7, 2016","December 2016","No Study Results Posted","null","October 2017","Overall survival|Patients Who Died Due to Transplant|Chimerism|Neutrophil Engraftment|Platelet Engraftment|Acute Graft-Versus-Host Disease|Number of Patients with Chronic Graft-Versus-Host Disease","https://ClinicalTrials.gov/show/NCT00309842"
760,"NCT02217163","A Single Arm Study of Carfilzomib in Transplant Eligible High Risk Multiple Myeloma","Recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib, Cyclophosphamide, Dexamethasone","Singapore General Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SGHMM1","August 12, 2014","October 2014","September 2018","October 8, 2014","October 2014","No Study Results Posted","null","September 2016","Progression Free Survival|Minimal residual disease negativity","https://ClinicalTrials.gov/show/NCT02217163"
761,"NCT01413100","Scleroderma Treatment With Autologous Transplant (STAT) Study","Recruiting","No Results Available","Systemic Scleroderma","Biological: Anti-Thymocyte Globulin|Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Biological: Filgrastim|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Plerixafor|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2533.00|NCI-2011-01190|2533|P30CA015704","August 8, 2011","September 15, 2011","null","January 18, 2017","January 2017","No Study Results Posted","STAT","September 1, 2019","EFS of patients undergoing chemotherapy and transplant|All-cause mortality|Change in cardiac function|Change in renal function over time|Disease progression|Health care utilization as assessed by UCSD Healthcare Utilization surveys|HRQOL as measured by the PROMIS-29 version 1.0|HRQOL as measured by the SF-36|HRQOL as measured by the SGRQ|HRQOL as measured by the SHAQ|Improvement in pulmonary function|Infectious complications|Non-progression mortality|Overall survival|Regimen-related toxicities|Time of initiation of putative disease-modifying antirheumatic drugs (DMARDS) to modify disease|Time to treatment failure|Treatment-related mortality|Work productivity Survey (WPS)","https://ClinicalTrials.gov/show/NCT01413100"
762,"NCT01527422","Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL","Completed","No Results Available","Lymphoma|Non Hodgkin's Lymphoma","Drug: Cyclophosphamide, Doxorubicin, Vincristine and Prednisone","Fernando Cabanillas|Genzyme, a Sanofi Company|Auxilio Mutuo Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","","February 3, 2012","January 2006","March 2011","February 3, 2012","February 2012","No Study Results Posted","CHOP-R","November 2010","Phase I-II Study of Dose Dense of PEG-Filgrastim and GM-CSF combined with CHOP-R","https://ClinicalTrials.gov/show/NCT01527422"
763,"NCT00562640","Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)","Active, not recruiting","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer","Biological: filgrastim|Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Other: laboratory biomarker analysis","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","Female","18 Years to 120 Years   (Adult, Senior)","Phase 1","21","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-155|MSKCC-06155","November 21, 2007","October 2007","December 2017","December 14, 2016","December 2016","No Study Results Posted","null","December 2017","Safety and tolerability as assessed by NCI CTCAE v3.0|Mean tolerated dose of autologous WT1 peptide-specific T cells|Quantitation of alterations in the concentration of peptide-specific T cells in the blood at defined intervals post infusion|Effects of the adoptively transferred T cells on the growth and progression of advanced ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer","https://ClinicalTrials.gov/show/NCT00562640"
764,"NCT00245141","Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma","Unknown status","No Results Available","Sarcoma","Biological: dactinomycin|Drug: cyclophosphamide|Drug: vincristine sulfate|Radiation: radiation therapy","Japan Rhabdomyosarcoma Study Group|National Cancer Institute (NCI)","All","up to 17 Years   (Child)","Phase 2","32","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","JRSG-UHA-PED03-01|CDR0000453316","October 25, 2005","May 2004","null","August 9, 2013","July 2009","No Study Results Posted","null","April 2011","Disease-free survival as measured by Kaplan-Meier method 3 years after study entry|Overall survival as measured by Kaplan-Meier method 3 years after study entry|Progression-free survival as measured by Kaplan-Meier method during events|Complete response rate (orbit, group III only) at completion of study treatment|Rate of toxicity as measured by NCI-CTC v 2.0 3 years after study entry","https://ClinicalTrials.gov/show/NCT00245141"
765,"NCT00911183","Rituximab, Cyclophosphamide, Vincristine Sulfate, and Prednisone With or Without Liposome-Encapsulated Doxorubicin Citrate in Treating Older Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: filgrastim|Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: liposome-encapsulated doxorubicin citrate|Drug: prednisone|Drug: vincristine sulfate","Institut Bergonié|National Cancer Institute (NCI)","All","70 Years and older   (Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000636032|IB-FRAIL06|INCA-RECF0892|IB-2008-25|EUDRACT-2008-001506-16","May 29, 2009","October 2008","null","July 21, 2009","July 2009","No Study Results Posted","null","October 2010","Complete remission rate at 6 months|Toxicity|Progression-free survival, event-free survival, and overall survival|Overall response rate|Duration of complete remission|Acute side effects as assessed by the International CTC scale|Geriatric condition as assessed by the following questionnaires: the Cumulative Illness Rating Scale-Geriatric, the Mini Nutritional Assessment, the Instrumental Activities of Daily Living, the QLQ-C30, the Mini Mental State Examination, and the Geri ...","https://ClinicalTrials.gov/show/NCT00911183"
766,"NCT02434146","Topical Phenylephrine Solution in Preventing Oral Mucosa in Bone Marrow Transplant Patients Receiving Cyclophosphamide and Total Body Radiation Therapy","Terminated","Has Results","Neoplasm|Oral Mucosa|Transplant-Related Disorder","Drug: Topical Phenylephrine Solution","University of Wisconsin, Madison|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","3","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Supportive Care","UW14068|NCI-2015-00576|P30CA014520|2015-0062","April 24, 2015","May 14, 2015","January 25, 2017","March 16, 2017","March 2017","March 16, 2017","null","January 25, 2017","Area Under the Curve (AUC) for the Oral Mucositis Severity|Duration of Grade 2 Oral Mucositis|Duration of Grade 3 Oral Mucositis|Efficacy Response Rate for Preventing Oral Mucositis With Sufficient Accuracy|Incidence of Adverse Events, Graded According to the Common Terminology Criteria for Adverse Events Version 4.0|Maximum Tolerated Dose (MTD), Defined as the Highest Dose Level of Phenylephrine Applied to the Oral Mucosa Where 0/3, 0/6, or 1/6 Patients Experience a Dose-limiting Toxicity|Recommended Phase IIa Dose|Time to Onset of Grade 2 Oral Mucositis|Time to Onset of Grade 3 Oral Mucositis","https://ClinicalTrials.gov/show/NCT02434146"
767,"NCT00004088","Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma","Active, not recruiting","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Biological: recombinant interferon alfa|Drug: busulfan|Drug: cyclophosphamide|Drug: melphalan|Drug: pamidronate disodium|Drug: thalidomide|Procedure: peripheral blood stem cell transplantation","City of Hope Medical Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","70","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","99021|P30CA033572|CHNMC-IRB-99021|NCI-G99-1583|CDR0000067301","December 10, 1999","April 13, 1999","February 2018","March 1, 2017","March 2017","No Study Results Posted","null","February 2018","Assess feasibility and toxicities of tandem cycle high-dose melphalan and busulfan/cyclophosphamide followed by autologous peripheral blood progenitor cell rescue.","https://ClinicalTrials.gov/show/NCT00004088"
768,"NCT01313429","Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum","Completed","No Results Available","Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancies","Drug: Cyclophosphamide|Biological: Allogenic tumor Cell Vaccine (K562)|Drug: Celecoxib","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 1","19","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","110111|11-C-0111","March 10, 2011","February 23, 2011","June 20, 2014","May 12, 2017","April 14, 2017","No Study Results Posted","null","June 20, 2014","Summary of adverse events|Number and description of immunologic responses to a panel of CT antigens in vaccinated patients|Paired t test analysis of difference between number and percentage of T reg cells at baseline and at treatment conclusion","https://ClinicalTrials.gov/show/NCT01313429"
769,"NCT00129376","Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients","Completed","No Results Available","Breast Cancer","Drug: docetaxel","Spanish Breast Cancer Research Group|Sanofi","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","63","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEICAM 2002-03","August 10, 2005","December 2002","July 2005","September 7, 2005","August 2005","No Study Results Posted","null","null","Pathological complete response|Clinical response rate|Toxicity|Disease-free survival|Overall survival|Molecular markers and correlation with response","https://ClinicalTrials.gov/show/NCT00129376"
770,"NCT01227408","Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer","Withdrawn","No Results Available","Breast Cancer","Drug: doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate","University of Southern California|CTI BioPharma","Female","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","1B-08-7","January 8, 2009","February 2009","February 2011","April 29, 2017","April 2017","No Study Results Posted","null","February 2010","Response|Toxicity","https://ClinicalTrials.gov/show/NCT01227408"
771,"NCT00230282","Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia","Completed","Has Results","Leukemia|B-cell Leukemia|Chronic Leukemia|Chronic Lymphocytic Leukemia (CLL)","Drug: Alemtuzumab|Drug: Fludarabine|Drug: Cytoxan","Steven E. Coutre|Bayer|Stanford University","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB-13053|31185|80071|HEMCLL0001","September 28, 2005","July 2004","October 2011","September 25, 2014","September 2014","August 27, 2014","null","December 2010","Number of Subjects Maintaining Partial Response (PR) or Complete Response (CR)|Duration of Response","https://ClinicalTrials.gov/show/NCT00230282"
772,"NCT00603460","DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer","Withdrawn","No Results Available","Ovarian Cancer|Primary Peritoneal Cancer","Biological: DCVax-L and T Cells","University of Pennsylvania|Northwest Biotherapeutics","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Other","UPCC 01808","January 16, 2008","January 2012","March 2013","April 28, 2017","April 2017","No Study Results Posted","null","January 2013","Disease status will be assessed with CT (or MRI) of chest/abdomen/pelvis at enrollment, after vaccine 2 and at the conclusion of the study . Rates of disease progression will be recorded at the time of study conclusion.","https://ClinicalTrials.gov/show/NCT00603460"
773,"NCT02953184","Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy","Recruiting","No Results Available","Antineoplastic Combined Chemotherapy Protocols","Drug: Pegylated Liposomal Doxorubicin|Drug: Cyclophosphamide|Drug: Taxotere|Drug: Dexrazoxane (DZR)|Drug: vitamin B|Drug: Doxorubicin|Procedure: Breast Conserved Surgery|Procedure: Modified Radical Mastectomy|Procedure: Sentinel Lymph Node Biopsy（SLNB）","Jilin University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","160","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2016yx238","October 8, 2016","November 2016","November 2020","November 15, 2016","November 2016","No Study Results Posted","null","November 2019","improvement of pathological complete response（PCR)|Tolerance according to Common Terminology Criteria Adverse Events (CTCAE) Version 4.0|Clinical Response Rate","https://ClinicalTrials.gov/show/NCT02953184"
774,"NCT00314977","Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.","Completed","No Results Available","Breast Cancer","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Docetaxel","Radboud University|Sanofi|Amgen","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IKO 2005-01 / BOOG 2007-02","April 14, 2006","February 2006","null","March 17, 2010","March 2010","No Study Results Posted","INTENS","April 2009","The pathologic complete response rate to neoadjuvant chemotherapy.|The delivered chemotherapy dose and dose-intensity of both chemotherapy regimens|The tolerability (grade 3/4 CTC toxicities) of both chemotherapy regimens.|The clinical responses of neoadjuvant chemotherapy correlated to pathological responses after neoadjuvant chemotherapy.|The value of breast MRI in evaluating response to neoadjuvant chemotherapy as compared to clinical palpation, ultrasound techniques and histo-pathological outcome.|The false-negative rate of the sentinel node biopsy after neoadjuvant chemotherapy.|The disease-free and overall survival after 3 and 5 years follow-up.|The relation between pCR and DFS/OS.|The feasibility of the criteria for reporting pathological tumour response in surgical breast and axillary node resection specimens.|The prognostic and predictive value of tumour- and molecular markers, including ER, PgR, c-erbB2, microarray and other tumour characteristic analyses.","https://ClinicalTrials.gov/show/NCT00314977"
775,"NCT01292135","Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)","Completed","Has Results","B-cell Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma","Drug: PCI-32765","Pharmacyclics LLC.","All","18 Years and older   (Adult, Senior)","Phase 1","33","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PCYC-1108-CA|PCI-32765","February 2, 2011","February 2011","May 2013","July 17, 2014","July 2014","February 28, 2014","null","November 2012","Incidence of Prolonged Hematologic Toxicity Started in Cycle 1|Incidence of Adverse Events Requiring Dose Delay or Discontinuation of Ibrutinib|Overall Incidence of Grade ≥3 Adverse Events (AEs) Per NCI CTCAE V4.0|Overall Incidence of Serious Adverse Events (SAEs)|Overall Response Rate (Complete Response [CR] + Complete Response With Incomplete Marrow Recovery [CRi] + Nodular Partial Response [nPR] + Partial Response [PR])|Sustained Hematologic Improvement in Subjects With Neutropenia, Anemia, or Thrombocytopenia at Baseline|Progression Free Survival Rate at 12 Months","https://ClinicalTrials.gov/show/NCT01292135"
776,"NCT02086942","Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.","Recruiting","No Results Available","Multiple Myeloma","Drug: Bortezomib|Drug: cyclophosphamide|Drug: Dexamethasone","Yongping Zhai|Jinling Hospital, China","All","18 Years and older   (Adult, Senior)","Phase 2","94","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NAB20130806","March 12, 2014","August 2013","August 2017","September 20, 2016","September 2016","No Study Results Posted","null","August 2017","the rate of complete remission|progression free survival|Adverse Events|overall response rates (ORR)|duration of response|overall survival (OS)","https://ClinicalTrials.gov/show/NCT02086942"
777,"NCT01313884","Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma","Terminated","Has Results","Bone Cancer|Ewing's Sarcoma","Drug: Irinotecan|Drug: Vincristine|Drug: Temozolomide|Drug: Doxorubicin|Drug: Cytoxan|Drug: Pegfilgrastim|Drug: Mesna","Stanford University|Amgen","All","13 Years and older   (Child, Adult, Senior)","Phase 2","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB-20323|SU-03082011-7559|SARCOMA0007","March 10, 2011","May 2011","July 2014","December 7, 2016","December 2016","December 7, 2016","null","July 2014","Overall Response Rate (Partial and Complete Response)|Progression Free Survival","https://ClinicalTrials.gov/show/NCT01313884"
778,"NCT00500890","Treatment of Tumors of the Choroid Plexus Epithelium","Active, not recruiting","No Results Available","Choroid Plexus Tumors","Drug: Carboplatin|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Vincristine|Radiation: Radiation Therapy","M.D. Anderson Cancer Center","All","Child, Adult, Senior","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0398|NCI-2012-01568","July 11, 2007","September 2005","null","October 18, 2016","October 2016","No Study Results Posted","null","September 2018","Main Phase: Overall Survival After Start of Additional Treatment","https://ClinicalTrials.gov/show/NCT00500890"
779,"NCT00049413","Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma","Completed","No Results Available","Leukemia|Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: pentostatin","Hoag Memorial Hospital Presbyterian|Cancer Biotherapy Research Group","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000258096|CBRG-NIP-0201|NCI-V02-1712|SUPEREN-CBRG-NIP-0201","November 12, 2002","June 2002","December 2005","May 10, 2011","May 2011","No Study Results Posted","null","December 2004","","https://ClinicalTrials.gov/show/NCT00049413"
780,"NCT00742300","Autologous Hematopoietic Stem Cell Transplantation for Refractory Autoimmune Diseases","Unknown status","No Results Available","Autoimmune Diseases","Procedure: Autologous hematopoietic stem cell transplantation","Charite University, Berlin, Germany","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","null","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT-0198","August 26, 2008","January 1998","null","November 21, 2008","November 2008","No Study Results Posted","ASTRAD","null","Disease-free survival|Overall Survival|Immune Reconstitution|Organ-specific response parameters|Serological Response (Autoantibodies)","https://ClinicalTrials.gov/show/NCT00742300"
781,"NCT00715208","Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma","Completed","Has Results","Relapsed Follicular Lymphoma","Drug: rituximab|Drug: cyclophosphamide|Drug: doxorubicin|Drug: VELCADE|Drug: prednisone","Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","55","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","C05012","July 11, 2008","September 2008","March 2011","April 26, 2013","April 2013","February 3, 2012","null","February 2011","Number of Patients With Complete Response (CR)|Number of Participants With Overall Response (OR)|Percentage of Participants With Progression-free Survival (PFS) at 1 Year|Duration of Response|Number of Patients Who Experienced at Least One Serious Adverse Event","https://ClinicalTrials.gov/show/NCT00715208"
782,"NCT00150878","Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission","Terminated","No Results Available","Acute Myeloid Leukemia","Other: Conditioning therapy","University Hospital Carl Gustav Carus","All","18 Years to 60 Years   (Adult)","Phase 3","198","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9005-2003","September 6, 2005","December 2003","December 2010","June 19, 2013","June 2013","No Study Results Posted","null","December 2009","Treatment-related mortality at 12 months after transplantation|Disease-free and Overall survival|Grade 3-4 extramedullary toxicity","https://ClinicalTrials.gov/show/NCT00150878"
783,"NCT00428142","Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: bortezomib|Drug: cyclophosphamide|Drug: prednisone|Drug: vincristine sulfate","NCIC Clinical Trials Group|Canadian Cancer Trials Group","All","18 Years and older   (Adult, Senior)","Phase 2","95","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LY13|CAN-NCIC-LY13|CDR0000527275","January 25, 2007","December 2006","January 2012","November 26, 2012","November 2012","No Study Results Posted","null","April 2011","Complete response rate|Incidence of severe grade 3 or 4 neurotoxicity or neuropathic pain during the first 4 courses of treatment|Overall response rate|Response duration in patients with observed responses|Time to progression|Overall survival|Toxicity|Quality of life","https://ClinicalTrials.gov/show/NCT00428142"
784,"NCT02419742","Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen","Recruiting","No Results Available","Breast Cancer","Drug: Carboplatin|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Doxorubicin|Drug: Paclitaxel|Drug: Trastuzumab","Hoffmann-La Roche","Female","18 Years and older   (Adult, Senior)","Phase 4","109","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ML28714","March 23, 2015","August 18, 2015","December 8, 2021","May 1, 2017","May 2017","No Study Results Posted","null","December 8, 2021","Percentage of Participants Experiencing Clinically Significant Changes in Cardiac Function As Determined by Left Ventricular Ejection Fraction (LVEF) Measurements Using Echocardiography|Percentage of Participants With Adverse Events|Disease Free Survival (DFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02419742"
785,"NCT00254592","Neoadjuvant Treatment of Breast Cancer","Active, not recruiting","Has Results","Breast Cancer","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Carboplatin|Drug: Nab-paclitaxel|Drug: GM-CSF|Drug: Trastuzumab|Drug: Bevacizumab","University of California, Irvine","Female","18 Years and older   (Adult, Senior)","Phase 2","43","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCI 05-38|2005-4550","November 15, 2005","October 2005","January 2017","November 15, 2016","November 2016","August 28, 2009","null","July 2013","Overall Clinical Response to the Dose Dense Regimen","https://ClinicalTrials.gov/show/NCT00254592"
786,"NCT00777673","Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.","Unknown status","No Results Available","Breast Cancer","Drug: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim","University of Tennessee Cancer Institute|National Comprehensive Cancer Network|Celgene Corporation|Genentech, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BRE 01-08","October 20, 2008","October 2008","October 2013","January 3, 2013","January 2013","No Study Results Posted","null","January 2013","Pathological complete response (pCR) in the breast|Rate of near pCR/pCR of breast, axillary Ns & non axillary SNs cRR with nab-paclitaxel + carbo with bev cRR post neoadj Tx Rate of breast conserving surgery Safety & tolerability Disease free survival Identify gene(s) that may predict pCR to Tx","https://ClinicalTrials.gov/show/NCT00777673"
787,"NCT03068624","Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma","Not yet recruiting","No Results Available","Melanoma and Other Malignant Neoplasms of Skin","Biological: CD 8+ T Cells|Drug: Cyclophosphamide|Drug: Interleukin-2|Drug: Ipilimumab","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2016-0414","February 24, 2017","June 2017","June 2021","April 20, 2017","April 2017","No Study Results Posted","null","June 2021","Maximum Tolerated Dose (MTD) of Autologous CD8+ Antigen-Specific T Cells in Metastatic Uveal Melanoma Participants|Response of Autologous CD8+ T Cells Against SLC45A2 in Metastatic Uveal Melanoma Participants","https://ClinicalTrials.gov/show/NCT03068624"
788,"NCT00485979","Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients","Completed","No Results Available","Breast Neoplasms","Drug: larotaxel (XRP9881)|Drug: docetaxel|Drug: trastuzumab","Sanofi","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EFC10073|EudraCT 2006-006473-24","June 12, 2007","June 2007","August 2010","June 27, 2011","June 2011","No Study Results Posted","SATIN","August 2010","Pathological response will be assessed according to Chevallier criteria for patients who underwent surgery.|Clinical Response Rate, Rate of breast conservation, Progression-Free Survival, Overall Survival, pathological response according to NSABP and Sataloff criteria for patients who underwent surgery|Safety and tolerability profile","https://ClinicalTrials.gov/show/NCT00485979"
789,"NCT02997813","Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies","Completed","No Results Available","Multiple Myeloma|Blood Stem Cell Transplant Failure","","Intergroupe Francophone du Myelome","All","18 Years and older   (Adult, Senior)","","112","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","IFM2014-05","December 16, 2016","June 2015","December 2016","December 16, 2016","December 2016","No Study Results Posted","MOZOBIL","December 2015","Total cost of stem cell mobilization procedure (including remobilisation if applicable)|Number of visits for administration of mobilizing agents|Duration (days) of administration of mobilizing agents|Agents used as mobilizing agents|Attainment of CD34+ target (yes, no) (min 2.106 cells/kg, ideal >4.106cells/kg)|Number of days needed to meet CD34+ target level (min 2.106 cells/kg, ideal >4.106cells/kg)","https://ClinicalTrials.gov/show/NCT02997813"
790,"NCT00486759","A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma","Terminated","Has Results","B-cell Lymphoma","Drug: Bevacizumab|Drug: Rituximab|Drug: CHOP|Drug: Placebo","Hoffmann-La Roche|Genentech, Inc.","All","18 Years to 79 Years   (Adult, Senior)","Phase 3","787","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","BO20603","June 14, 2007","July 2007","November 2011","November 28, 2012","November 2012","November 28, 2012","null","November 2011","Progression-free Survival (PFS)|Overall Survival|Overall Response (OR) Assessed According to the Revised Response Criteria for Malignant Lymphoma","https://ClinicalTrials.gov/show/NCT00486759"
791,"NCT01675765","Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma","Active, not recruiting","No Results Available","Malignant Pleural Mesothelioma","Biological: Immunotherapy plus chemotherapy|Biological: Immunotherapy with cyclophosphamide plus chemotherapy","Aduro Biotech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ADU-CL-02","August 23, 2012","August 2012","June 2017","January 25, 2017","January 2017","No Study Results Posted","null","June 2017","Number of subjects reporting adverse events|Induction of immune response to mesothelin by enzyme-linked immunosorbent spot (ELISPOT) assay|Objective tumor response|Time to progression|Serum mesothelin as correlate of therapeutic response","https://ClinicalTrials.gov/show/NCT01675765"
792,"NCT00275015","Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia","Completed","No Results Available","Chronic Lymphocytic Leukemia","Biological: filgrastim|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","German CLL Study Group","All","18 Years to 60 Years   (Adult)","Phase 2","169","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CLL3|EU-20553","January 10, 2006","January 1998","April 2012","February 23, 2017","April 2007","No Study Results Posted","null","null","Safety of autologous peripheral stem cell transplantation (PBSCT) as measured by a treatment-related mortality of < 5% at 12 months following transplant|Feasibility of PBSCT as measured by > 50% of included patients proceeding to transplant|Safety of mobilization comprising dexamethasone, carmustine, cytarabine, etoposide, and melphalan (Dexa-BEAM) as measured by a treatment-related mortality of < 5% before transplant phase|Efficacy of Dexa-BEAM mobilization as measured by the amount of CD34+ cells > 4x10e6/kg at harvest|Complete clinical remissions by NIH criteria at 3 months following transplant|Molecular remissions by CDR3 PCR at 3 months following transplant|Progression-free survival by NIH criteria at 5 years from study entry","https://ClinicalTrials.gov/show/NCT00275015"
793,"NCT00055679","Combination Chemotherapy in Treating Women With Stage I Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: fluorouracil","UNICANCER","Female","18 Years to 65 Years   (Adult)","Phase 3","1512","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PACS05 UC-0140-0106|FRE-FNCLCC-PACS-05/0106|EU-20239","March 6, 2003","August 2002","June 2013","June 17, 2013","June 2013","No Study Results Posted","null","June 2012","Efficacy, in terms of 5-year survival|Event free survival|Toxicity|Biological factors significant for prognosis and prediction of survival","https://ClinicalTrials.gov/show/NCT00055679"
794,"NCT00280241","Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia","Completed","Has Results","Chronic Lymphocytic Leukemia","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab","University of Pittsburgh|Genentech, Inc.|Biogen","All","18 Years and older   (Adult, Senior)","Phase 2","65","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","03-136","January 19, 2006","June 2004","January 2013","January 5, 2016","January 2016","January 5, 2016","null","February 2008","Tolerability of Rituximab, Cyclophosphamide and Fludarabine in Patients With Previously Untreated CLL/SLL|Efficacy of Rituximab, Cyclophosphamide and Fludarabine in Patients With Previously Untreated CLL/SLL|Overall Survival Rate|Duration of Response","https://ClinicalTrials.gov/show/NCT00280241"
795,"NCT02450058","Adjuvant FEC Versus EP in Breast Cancer (MIG5)","Completed","No Results Available","Breast Cancer|Chemotherapy, Adjuvant","Drug: 5-fluorouracil|Drug: epirubicin|Drug: cyclophosphamide|Drug: epirubicin|Drug: paclitaxel","IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","1055","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","OMI96.018","May 14, 2015","November 1996","May 2012","May 18, 2015","May 2015","No Study Results Posted","MIG5","May 2012","overall survival|event free survival|toxicity as measured according to the World Health Organization Criteria","https://ClinicalTrials.gov/show/NCT02450058"
796,"NCT02732678","Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO)","Not yet recruiting","No Results Available","Angiosarcoma","Drug: PROPRANOLOL","Assistance Publique Hopitaux De Marseille","All","15 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-005177-21|2015-29","March 29, 2016","May 2016","May 2019","April 8, 2016","April 2016","No Study Results Posted","PROPAN","May 2018","toxicity of each tested propranolol dose level in association to cyclophosphamide assessed according to NCI-CTC AE Version 4.0|Non-progression rate","https://ClinicalTrials.gov/show/NCT02732678"
797,"NCT01022138","Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Women With HER2/Neu-Negative Metastatic Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Biological: HER2Bi-armed activated T cells|Drug: Cyclophosphamide|Other: Laboratory biomarker analysis","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","Female","18 Years to 120 Years   (Adult, Senior)","Phase 2","63","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CDR0000657998|P30CA022453|WSU-2009-085","November 26, 2009","February 2011","January 2018","May 19, 2017","May 2017","No Study Results Posted","null","January 2018","Progression-free survival|Overall survival|Toxicity|Cytokine responses, phenotypic markers of differentiation, specificity, and antitumor cytotoxicity in blood and tumor samples (if accessible)|Correlation between immunotherapy-induced changes in immune functions and clinical endpoints","https://ClinicalTrials.gov/show/NCT01022138"
798,"NCT00006252","Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma","Completed","No Results Available","Leukemia|Lymphoma","Drug: fludarabine phosphate|Drug: Cyclophosphamide|Biological: PBSC|Drug: G-CSF|Biological: Donor lymphocytes","Cancer and Leukemia Group B|National Cancer Institute (NCI)|Alliance for Clinical Trials in Oncology","All","up to 69 Years   (Child, Adult, Senior)","Phase 2","47","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-109901|U10CA031946|CDR0000068185","September 11, 2000","February 2001","October 2011","July 15, 2016","July 2016","No Study Results Posted","null","January 2007","Treatment-related mortality within the first 6 months post-transplant|Response|Percentage of patients achieving complete donor chimerism or mixed donor chimerism|Survival","https://ClinicalTrials.gov/show/NCT00006252"
799,"NCT01246856","MIBG Scintigraphy and Strain Echocardiography in the Detection of Subclinical Cardiovascular Effects One Year After (Neo)Adjuvant Breast Cancer Treatment With Docetaxel, Doxorubicin and Cyclophosphamide (TAC): a Pilot Study","Unknown status","No Results Available","Breast Cancer","","Radboud University","Female","18 Years and older   (Adult, Senior)","","150","Other","Observational","Observational Model: Cohort","UMCNONCO201005","November 22, 2010","November 2010","null","September 9, 2011","September 2011","No Study Results Posted","TOXTAC","October 2011","","https://ClinicalTrials.gov/show/NCT01246856"
800,"NCT00324623","Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma","Completed","No Results Available","Melanoma (Skin)","Biological: Melan-A VLP vaccine, IMP321 adjuvant|Biological: adoptive immunotherapy|Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate","Prof. Serge Leyvraz|Centre Hospitalier Universitaire Vaudois","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000468827|CHUV-CEPO-ITA-02|EU-20607","May 10, 2006","September 2005","null","November 19, 2012","November 2012","No Study Results Posted","null","November 2011","Phenotype, function, and T-cell receptor repertoire|Tumor response|Toxicity","https://ClinicalTrials.gov/show/NCT00324623"
801,"NCT00190489","A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer|Neoplasm Metastasis","Drug: AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles|Drug: Docetaxel 60mg/m2 every 21 days for 6 cycles|Drug: AC and Docetaxel 60mg/m2 alternately q21 days for 6 cycles","Japan Clinical Oncology Group|Ministry of Health, Labour and Welfare, Japan","Female","20 Years to 75 Years   (Adult, Senior)","Phase 3","450","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JCOG9802|C000000179","September 12, 2005","January 1999","May 2006","August 31, 2016","August 2016","No Study Results Posted","null","May 2006","time to treatment failure|overall survival|progression-free survival|response rate|adverse events","https://ClinicalTrials.gov/show/NCT00190489"
802,"NCT00427336","Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia","Completed","Has Results","Aplastic Anemia","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Antithymocyte Globulin","M.D. Anderson Cancer Center","All","up to 70 Years   (Child, Adult, Senior)","","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IDP00-266","January 25, 2007","December 2000","August 2009","September 20, 2011","September 2011","September 20, 2011","null","August 2009","Number of Patients With Engraftment Response","https://ClinicalTrials.gov/show/NCT00427336"
803,"NCT01149902","Study of Chemo-Immunotherapy in Head and Neck Cancer Patients","Unknown status","No Results Available","Head and Neck Cancer","Biological: Cyclophosphamide, Docetaxel, Dendritic cells, OK-432","University of Yamanashi","All","20 Years and older   (Adult, Senior)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","631","June 22, 2010","July 2010","null","August 23, 2011","June 2010","No Study Results Posted","null","March 2012","The safety and feasibility of chemo-immunotherapy|The number and function of immune effector cells in treated patients","https://ClinicalTrials.gov/show/NCT01149902"
804,"NCT00070018","S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma","Active, not recruiting","Has Results","Lymphoma","Biological: rituximab|Drug: Cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy|Biological: Yttrium-90 ibritumomab tiuxetan|Biological: Indium-111 ibritumomab tiuxetan","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","46","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CDR0000329864|U10CA032102|S0313","October 3, 2003","February 2004","November 2018","April 20, 2017","April 2017","March 5, 2012","null","November 2010","Progression-free Survival","https://ClinicalTrials.gov/show/NCT00070018"
805,"NCT00877006","Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study","Active, not recruiting","Has Results","Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma","Drug: bendamustine|Drug: rituximab|Drug: vincristine|Drug: prednisone|Drug: cyclophosphamide|Drug: doxorubicin","Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","All","18 Years and older   (Adult, Senior)","Phase 3","447","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","C18083/3064/NL/MN","April 3, 2009","April 2009","March 2017","November 14, 2016","November 2016","March 25, 2014","null","March 2012","Percentage of Participants With Complete Response (CR) at End of Treatment Period|Percentage of Participants With Overall Response at End of Treatment Period|Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs at End of Treatment Period|Worst Overall Common Terminology Criteria for Adverse Events (CTCAE) Grades for Serum Chemistry Laboratory Test Results|Worst Overall CTCAE Grade for Hematology Laboratory Test Results|Clinically Significant Abnormal Vital Signs|Potentially Clinically Significant Abnormal Weight|Eastern Cooperative Oncology Group (ECOG) Performance Status at the End of Treatment Period|Therapeutic Classification of Prior Medications|Therapeutic Classification of Concomitant Medications|Change From Baseline to End of Treatment in the Global Health Status Score of the European Organization for Research and Treatment of Cancer (EORTC) 30-item Core Quality of Life Questionnaire (QLQ-C30)|Progression-free Survival and Event-free Survival at End of Follow-up|Overall Survival at End of Follow-up|Median Duration of Response at End of Follow-up","https://ClinicalTrials.gov/show/NCT00877006"
806,"NCT02081183","A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis","Terminated","Has Results","Lupus Nephritis","Drug: Mycophenolate mofetil (MMF)|Drug: Cyclophosphamide, Maintenance Phase|Drug: Cyclophosphamide, Induction Phase|Drug: Prednisone","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18989","March 5, 2014","March 2006","December 2008","June 17, 2014","June 2014","June 17, 2014","null","December 2008","Creatinine Clearance|Urinary Protein|Serum Creatinine|Serum Albumin","https://ClinicalTrials.gov/show/NCT02081183"
807,"NCT01231906","Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma","Active, not recruiting","No Results Available","Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)|Childhood Supratentorial Primitive Neuroectodermal Tumor|Ewing Sarcoma of Bone|Extraosseous Ewing Sarcoma|Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Peripheral Primitive Neuroectodermal Tumor of the Kidney|Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor","Drug: vincristine sulfate|Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Drug: ifosfamide|Drug: etoposide|Drug: topotecan hydrochloride|Other: laboratory biomarker analysis","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 50 Years   (Child, Adult)","Phase 3","693","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","AEWS1031|NCI-2011-02611|COG-AEWS1031|CDR0000687639|U10CA098543","October 29, 2010","November 2010","September 2019","February 8, 2017","February 2017","No Study Results Posted","null","September 2019","EFS|Overall survival|Relative risk for death|Histological response, in terms of event free survival after local control in patients who received local control therapy|Positron emission tomography (PET)-determined response, in terms of event free survival after local control|Probabilities of identifying tumors of at least 200 ml|Extent of tumor necrosis according to the necrosis grading criteria in patients who have surgical resection of tumor|Radiological response of soft tissue component of mass by PET|Differences associated with local control modality on risk for EFS event, according to surgery only v. radiation therapy only v. surgery and radiation therapy|Number and proportion of patients who experience any grade 2 or higher musculoskeletal event (ME), or surgery required to treat a complication of local therapy|Proportion of patients who have tumor present at the margin of resection on risk for EFS event in patients undergoing surgery","https://ClinicalTrials.gov/show/NCT01231906"
808,"NCT01088789","A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine","Recruiting","No Results Available","Pancreatic Cancer","Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.","Sidney Kimmel Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","72","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J09100, NA_00031401|NA_00031401","March 1, 2010","April 2010","April 2023","January 11, 2017","January 2017","No Study Results Posted","null","April 2023","Disease free overall survival.","https://ClinicalTrials.gov/show/NCT01088789"
809,"NCT00002488","Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy","Unknown status","No Results Available","Lymphoma","Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide","Ottawa Regional Cancer Centre|National Cancer Institute (NCI)","All","18 Years to 64 Years   (Adult)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000077375|CAN-OTT-9106|NCI-V92-0013","November 1, 1999","December 1991","null","September 16, 2013","April 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002488"
810,"NCT00003352","Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: Taxotere|Drug: Adriamycin","NSABP Foundation Inc|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","89","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP BP-58|NSABP-BP-58","November 1, 1999","June 1998","December 2002","December 10, 2012","December 2012","No Study Results Posted","null","September 2000","Best over-all tumor response that occurs during 6 cycles of chemotherapy|Survival|Time to first response|Time to progression|Duration of response|Completion of at least four cycles of chemotherapy|Toxicity profile","https://ClinicalTrials.gov/show/NCT00003352"
811,"NCT00192764","High Dose CHOP in Lymphoma","Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: high-dose cyclophosphamide","Rambam Health Care Campus","All","18 Years to 65 Years   (Adult)","Phase 2","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RonHDCHOP.CTIL","September 13, 2005","December 1996","September 2010","September 21, 2010","September 2010","No Study Results Posted","null","null","Failure-free survival|overall survival|response rate|toxicity","https://ClinicalTrials.gov/show/NCT00192764"
812,"NCT00138229","Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma","Terminated","No Results Available","Melanoma (Skin)","Biological: aldesleukin|Biological: filgrastim|Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","6","NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","050194|05-C-0194|NCI-P6573|CDR0000440165","August 29, 2005","July 2005","April 2007","March 28, 2012","March 2012","No Study Results Posted","null","null","Tumor regression|Rate of repopulation of CD25-positive T-regulatory cells|Toxicity","https://ClinicalTrials.gov/show/NCT00138229"
813,"NCT00668616","Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes","Completed","No Results Available","Breast Cancer","Drug: Cyclophosphamide, Epirubicin, Paclitaxel|Drug: Epirubicin, Paclitaxel, Filgrastim","North Eastern Germany Society of Gynaecologic Oncology","Female","18 Years to 75 Years   (Adult, Senior)","Phase 3","1034","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","170200","April 25, 2008","March 2000","July 2009","July 28, 2010","July 2010","No Study Results Posted","null","July 2005","progression-free time|toxicity|overall survival","https://ClinicalTrials.gov/show/NCT00668616"
814,"NCT02705703","Consolidation Therapy in Patients With Metastatic Solid Malignancies","Not yet recruiting","No Results Available","Cancer|Metastatic Solid Malignancies","Biological: TAPA-pulsed DC vaccine|Drug: Cyclophosphamide|Other: Granulocyte Macrophage Colony Stimulating Factor","Kiromic, LLC","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","23","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KiroVAX004","March 7, 2016","December 2016","September 2017","November 3, 2016","November 2016","No Study Results Posted","null","May 2017","Number of adverse events due to administration of TAPA-pulse DC vaccine|Immunological efficacy as indicated by T-cell cytokine levels|Immunological efficacy as determined by a positive delayed type hypersensitivity (DTH) skin test","https://ClinicalTrials.gov/show/NCT02705703"
815,"NCT02390063","VAccination in Prostate caNCEr (VANCE)","Recruiting","No Results Available","Prostate Cancer","Biological: ChAdOx1.5T4|Biological: MVA.5T4|Drug: Cyclophosphamide","University of Oxford","Male","18 Years and older   (Adult, Senior)","Phase 1","48","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: No masking|Primary Purpose: Treatment","VANCE01","March 10, 2015","June 2015","March 2019","May 17, 2017","May 2017","No Study Results Posted","null","March 2018","Vaccine safety and immunogenicity|Cellular and humoral immune response with CHAMVA|Cellular and humoral immune response with MVA|PSA level change secondary to vaccination|MRI or Gleason score change secondary to vaccination|Regulatory T-cell response","https://ClinicalTrials.gov/show/NCT02390063"
816,"NCT01341496","Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal","Terminated","No Results Available","Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancy","Biological: Epigenetically Modified Autologous Tumor|Drug: Cyclophosphamide|Drug: Celecoxib","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 1","41","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","110148|11-C-0148","April 22, 2011","April 18, 2011","July 21, 2016","May 12, 2017","July 21, 2016","No Study Results Posted","null","May 12, 2016","tabulation and grade of observed patient toxicities attributed to the vaccine, and report of the fractions of patients who encounter these toxicities at the various grades|Determine if 5 or greater of the first 20 vaccinated patients undergoing thoracic metastasectomy have successful tumor cell line development|Number and characteristics of immunologic responses to a panel of CT antigens in vaccinated patients","https://ClinicalTrials.gov/show/NCT01341496"
817,"NCT00010335","Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders","Completed","No Results Available","Systemic Sclerosis|Systemic Lupus Erythematosus|Dermatomyositis|Juvenile Rheumatoid Arthritis|Autoimmune Diseases","Procedure: Stem Cell Transplantation|Device: CD34 selection","Fred Hutchinson Cancer Research Center","All","2 Years to 18 Years   (Child, Adult)","Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1353.00|FHCRC-1353.00|199/15575","February 2, 2001","November 2000","May 2011","March 4, 2015","March 2015","No Study Results Posted","null","July 2010","Mortality|Immune reconstitution, engraftment, efficacy, late-effects","https://ClinicalTrials.gov/show/NCT00010335"
818,"NCT00053092","Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma","Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: fludarabine phosphate","Institute of Cancer Research, United Kingdom|Australasian Leukaemia and Lymphoma Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","82","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000269136|NCRI-LY05|ALLG-LY05|EU-20230|NCRILG-LY05","January 27, 2003","October 2002","February 2009","December 17, 2013","June 2007","No Study Results Posted","null","null","Response rate|Time to disease progression|Toxicity|Overall survival","https://ClinicalTrials.gov/show/NCT00053092"
819,"NCT01535183","Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents","Unknown status","No Results Available","Brain Tumor","Drug: Irinotecan combination chemotherapy","Seoul National University Hospital","All","up to 19 Years   (Child, Adult)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SNUCH-1201","February 7, 2012","January 2012","December 2016","July 11, 2014","July 2014","No Study Results Posted","null","September 2016","To evaluate response rate (more than stable disease) of combination chemotherapy|To evaluate adverse event|To evaluate progression-free survival","https://ClinicalTrials.gov/show/NCT01535183"
820,"NCT00129935","EC (Epirubicin, Cyclophosphamide) Followed by T (Docetaxel) Versus ET (Epirubicin, Docetaxel) Followed by X (Capecitabine) as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer Patients","Completed","No Results Available","Breast Cancer","Drug: epirubicin|Drug: docetaxel|Drug: capecitabine","Spanish Breast Cancer Research Group|Sanofi|Hoffmann-La Roche|Pfizer","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","1382","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GEICAM 2003-10","August 11, 2005","February 2004","February 2012","February 6, 2007","February 2007","No Study Results Posted","null","null","5-year disease-free survival|Overall survival|Toxicity|Quality of life|Single nucleotide polymorphisms (SNPs) as treatment predictive factors|Molecular prognostic markers in tissue","https://ClinicalTrials.gov/show/NCT00129935"
821,"NCT02276300","HER2-Peptide Vaccination of Patients With Solid Tumors","Recruiting","No Results Available","Gastric Cancer|Breast Cancer","Drug: Cyclophosphamide|Drug: Sargramostim|Drug: HER2-Peptid-Vakzine|Drug: Imiquimod","Technische Universität München","All","18 Years and older   (Adult, Senior)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ATZ-1068-KRA-20I","September 25, 2014","December 2014","April 2017","March 16, 2016","March 2016","No Study Results Posted","HER2","September 2016","Safety and tolerability of HER2-derived peptide vaccination measured by clinical and chemical parameters.","https://ClinicalTrials.gov/show/NCT02276300"
822,"NCT02605915","Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer","Recruiting","No Results Available","HER2-Positive Metastatic Breast Cancer|HER2-Negative Metastatic Breast Cancer|Locally Advanced or Early Breast Cancer","Drug: Atezolizumab|Drug: Carboplatin|Drug: Docetaxel|Drug: Pertuzumab|Drug: Trastuzumab|Drug: Trastuzumab emtansine|Drug: Doxorubicin|Drug: Cyclophosphamide","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 1","98","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GO29831|2015-002113-29","November 12, 2015","December 31, 2015","September 30, 2018","May 16, 2017","May 2017","No Study Results Posted","null","September 30, 2018","Percentage of Participants With Dose Limiting Toxicities (DLT) - Cohort 1A, 1B, 1C, 1D, 1F|Percentage of Participants With DLT - Cohort 1E|Percentage of Participants With Adverse Events (AEs) According to National Cancer Institute Common Terminology Criteria for AEs, Version 4.0 (NCI CTCAE V4.0)|Maximum Serum Concentration (Cmax) of Atezolizumab|Minimum Serum Concentration (Cmin) of Atezolizumab|Cmin of Trastuzumab|Cmin of Trastuzumab Emtansine|Cmin of Pertuzumab|Cmin of Doxorubicin|Cmin of Cyclophosphamide|Percentage of Participants With Anti-Therapeutic Antibody (ATA) Response to Atezolimumab|Percentage of Participants With Anti-Therapeutic Antibody (ATA) Response to Trastuzumab|Percentage of Participants With Anti-Therapeutic Antibody (ATA) Response to Trastuzumab Emtansine|Percentage of Participants With Anti-Therapeutic Antibody (ATA) Response to Pertuzumab|Number of Treatment Cycles Received|Percentage of Participants With Various Dose Intensity|Plasma Concentration of Doxorubicin|Plasma Concentration of Cyclophosphamide|Plasma Concentration of 4-Hydroxycyclophosphamide|Plasma Concentration of Docetaxel","https://ClinicalTrials.gov/show/NCT02605915"
823,"NCT01856192","Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","Active, not recruiting","No Results Available","CD20 Positive|Stage II Diffuse Large B-Cell Lymphoma|Stage III Diffuse Large B-Cell Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","345","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2013-00959|E1412|ECOG-E1412|U10CA180820|U10CA021115","May 14, 2013","August 27, 2013","null","May 24, 2017","May 2017","No Study Results Posted","null","January 15, 2018","PFS|CR rate based on PET-CT scan|OS|Overall RR based on PET-CT scan","https://ClinicalTrials.gov/show/NCT01856192"
824,"NCT03113500","Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","Not yet recruiting","No Results Available","Adult T-Cell Leukemia/Lymphoma|Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Angioimmunoblastic T-Cell Lymphoma|CD30-Positive Neoplastic Cells Present|Enteropathy-Associated T-Cell Lymphoma|Hepatosplenic T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified","Drug: Brentuximab Vedotin|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Drug: Prednisone","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","44","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","17058|NCI-2017-00573","April 10, 2017","June 2017","June 2019","April 10, 2017","April 2017","No Study Results Posted","null","June 2019","Complete response (CR) rate after CHEP-BV induction therapy|CR rate after BV consolidation therapy|Incidence of adverse events after CHEP-BV induction therapy|Incidence of adverse events of BV consolidation after CHEP-BV induction therapy and ASCT|Incidence of adverse events of BV consolidation after CHEP-BV induction therapy without ASCT|Overall response rate after induction therapy|Overall survival|Progression-free survival","https://ClinicalTrials.gov/show/NCT03113500"
825,"NCT00575406","Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma","Completed","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: liposomal Doxorubicin|Drug: Vincristin|Drug: Prednisolone","Arbeitsgemeinschaft medikamentoese Tumortherapie","All","18 Years and older   (Adult, Senior)","Phase 2","94","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NHL-14|EudraCT 2007-004970-24","December 17, 2007","December 2007","January 2012","August 29, 2013","August 2013","No Study Results Posted","NHL-14","January 2012","Reduction of cardiotoxicity in the R-COMP arm versus R-CHOP|Significance of serial NT-proBNP measurements for determination of anthracycline-dependent cardiotoxicity|Feasibility of evaluation with Haematopoietic Cell Transplantation Comorbidity Index (HCT-CI)|Rate of Complete Responses|Difference in Overall Survival at 3 and 5 yrs|Difference in Event-free Survival at 3 and 5 yrs|Difference in Progression-free Survival at 3 and 5 yrs|Difference in cause-specific death","https://ClinicalTrials.gov/show/NCT00575406"
826,"NCT00256360","Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: dose dense with neulasta","Universitaire Ziekenhuizen Leuven|St-Augustinus Wilrijk","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","117","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-001876-11","November 16, 2005","September 2005","May 2006","December 8, 2014","December 2014","No Study Results Posted","null","null","To assess the feasibility of FEC and docetaxel based sequential regimens given in dose-dense fashion (FEC every 10-11 days and docetaxel every 14 days) with pegfilgrastim in patients with high-risk primary breast cancer.|To assess the safety and tolerability of FEC and docetaxel regimens including (febrile) neutropenia","https://ClinicalTrials.gov/show/NCT00256360"
827,"NCT00596154","Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma","Active, not recruiting","No Results Available","CNS Lymphoma|CNS Brain Cancer|Non-Hodgkin's Lymphoma","Other: Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide","Memorial Sloan Kettering Cancer Center","All","18 Years to 72 Years   (Adult, Senior)","Phase 2","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","04-129","January 7, 2008","December 2004","December 2018","April 17, 2017","April 2017","No Study Results Posted","PCNSL","December 2018","to evaluate the safety and efficacy of the use of R-MPV followed by high-dose chemotherapy using thiotepa, cyclophosphamide and busulfan with stem cell rescue in patients with newly diagnosed PCSNL.|to evaluate response rates with the combination of rituximab and MPV as induction chemotherapy.","https://ClinicalTrials.gov/show/NCT00596154"
828,"NCT01403285","Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma","Terminated","No Results Available","Glioblastoma","Drug: Cyclophosphamide|Biological: IMA950 plus GM-CSF|Biological: IMA950|Drug: Imiquimod","immatics Biotechnologies GmbH|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","6","Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IMA950-102|11C0192","July 21, 2011","August 2011","April 2014","May 16, 2014","May 2014","No Study Results Posted","null","April 2014","Safety and tolerability of IMA950 administered with granulocyte macrophage colony stimulating factor (GM-CSF) and topical imiquimod together following a single low-dose application of cyclophosphamide.|Immunogenicity of IMA950|Immune status parameters|Biomarker assessment and correlation to clinical and immunological response|Clinical anti-tumor activity (response rate, 6-month progression-free survival)|Influence of corticosteroids on immunogenicity of IMA950|Health-related quality of life","https://ClinicalTrials.gov/show/NCT01403285"
829,"NCT02446964","Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia","Recruiting","No Results Available","Adult Acute Lymphoblastic Leukemia in Complete Remission|Acute Myeloid Leukemia in Remission|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Childhood Acute Lymphoblastic Leukemia in Complete Remission","Procedure: Bone Marrow Transplantation|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Tacrolimus|Radiation: Total Marrow Irradiation","City of Hope Medical Center|National Cancer Institute (NCI)","All","12 Years to 60 Years   (Child, Adult)","Phase 1","24","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","14106|NCI-2015-00788|114382","May 14, 2015","June 5, 2015","June 2018","May 9, 2017","May 2017","No Study Results Posted","null","June 2018","Incidence of dose-limiting toxicity (DLT) scored on both the Bearman Scale and National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03|Maximum tolerated dose of TMLI when given in combination with fludarabine phosphate and cyclophosphamide, defined as the highest dose where 6 patients have been treated and at most one patient experiences DLT|Complete remission proportion|Immune reconstitution of B, T and NK cells|Incidence of acute GVHD of grades 2-4 and 3-4|Incidence of chronic GVHD|Incidence of infection|Minimal residual disease|Non-relapse mortality (NRM)|Overall survival|Progression-free survival|Incidence of grade 3-5 adverse events per CTCAE v4.03","https://ClinicalTrials.gov/show/NCT02446964"
830,"NCT02709993","Consolidation Therapy in Patients With Hematologic Malignancies","Not yet recruiting","No Results Available","Cancer|Hematologic Malignancies","Biological: TAPA-pulsed DC vaccine|Drug: Cyclophosphamide|Other: Granulocyte Macrophage Colony Stimulating Factor","Kiromic, LLC","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","23","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KiroVAX001","March 7, 2016","December 2016","September 2017","November 3, 2016","November 2016","No Study Results Posted","null","May 2017","Number of adverse events due to administration of TAPA-pulse DC vaccine|Immunological efficacy as indicated by T-cell cytokine levels|Immunological efficacy as determined by a positive delayed type hypersensitivity (DTH) skin test","https://ClinicalTrials.gov/show/NCT02709993"
831,"NCT00354835","Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma","Active, not recruiting","No Results Available","Adult Malignant Mesenchymoma|Adult Rhabdomyosarcoma|Childhood Alveolar Rhabdomyosarcoma|Childhood Botryoid-Type Embryonal Rhabdomyosarcoma|Childhood Embryonal Rhabdomyosarcoma|Childhood Malignant Mesenchymoma|Non-Metastatic Childhood Soft Tissue Sarcoma|Stage I Adult Soft Tissue Sarcoma|Stage II Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Untreated Childhood Rhabdomyosarcoma","Drug: Irinotecan Hydrochloride|Biological: Dactinomycin|Drug: Cyclophosphamide|Drug: Vincristine Sulfate|Radiation: Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Questionnaire Administration","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 49 Years   (Child, Adult)","Phase 3","481","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ARST0531|NCI-2009-00427|COG-ARST0531|CDR0000487560|U10CA098543|U10CA180886","July 19, 2006","December 2006","null","February 1, 2016","February 2016","No Study Results Posted","null","September 2014","Failure-free survival (FFS)|Response rate (RR) (complete or partial response)|Overall survival (OAS)|Long-term FFS of patients with intermediate-risk RMS treated with VAC and early (Week 4) radiotherapy compared to delayed (Week 10) radiotherapy, using IRSIV for historic comparison|Local control of patients with intermediate-risk RMS treated with VAC and early (Week 4) radiotherapy compared to delayed (Week 10) radiotherapy, using IRSIV for historic comparison|Overall survival of patients with intermediate-risk RMS treated with VAC and early (Week 4) radiotherapy compared to delayed (Week 10) radiotherapy, using IRSIV for historic comparison|Incidence of toxicity associated with concurrent VI and radiotherapy|Acute and late effects of VAC as delivered on this study to D9803 VAC|Change in FDG PET maximum standard uptake value (SUVmax)|Incidence of toxicity related to VI treatment in patients with UGT1A1 genotype|Incidence of toxicity related to VAC treatment in patients with CYP2B6 genotypes|Incidence of toxicity related to VAC treatment in patients with CYP2C9 genotypes|Incidence of toxicity related to VAC treatment in patients with GSTA1 genotypes|Gene expression analysis|Bladder function by disease-free patient/parent self report using a 14 point questionnaire","https://ClinicalTrials.gov/show/NCT00354835"
832,"NCT00354744","High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma","Active, not recruiting","Has Results","Sarcoma","Biological: dactinomycin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: irinotecan hydrochloride|Drug: vincristine sulfate|Procedure: conventional surgery|Radiation: radiation therapy|Biological: filgrastim","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 49 Years   (Child, Adult)","Phase 3","109","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ARST0431|CDR0000489215|COG-ARST0431","July 19, 2006","July 2006","null","September 14, 2016","September 2016","September 3, 2013","null","January 2010","Tumor Response Rate|Estimate of the Percent of Patients Event Free at 4 Years Following Study Entry|Early Disease Control|Feasibility|Toxicity","https://ClinicalTrials.gov/show/NCT00354744"
833,"NCT02838225","DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Docetaxel, Doxorubicin|Drug: Docetaxel, Doxorubicin, Cyclophosphamide","Peking Union Medical College Hospital","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PUMCH-BREAST-DA vs DAC","July 17, 2016","January 2009","null","July 17, 2016","July 2016","No Study Results Posted","null","January 2016","Disease-free survival|Adverse event rate (CTCAE v. 3.0)|Overall survival","https://ClinicalTrials.gov/show/NCT02838225"
834,"NCT01830244","IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: Nab-Paclitaxel","Barwon Health","Female","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ALCC12.01","March 27, 2013","April 2013","June 2020","August 2, 2016","January 2016","No Study Results Posted","Neonab","September 2015","Pathological complete response in the breast|Pathologic Response rate in breast and axillary lymph nodes|Rate of pathologic complete response and near complete response in the breast combined|Breast conservation rate|Progression Free Survival|Safety and tolerability","https://ClinicalTrials.gov/show/NCT01830244"
835,"NCT02871869","Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma","Recruiting","No Results Available","Diffuse, Large B-Cell, Lymphoma","Drug: vindesine|Drug: cyclophosphamide|Drug: Epirubicin|Drug: prednisone tablets|Drug: Cinobufacini Tablets|Drug: Rituximab","Xinjiang Medical University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","316","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","XinjiangMU2016(015)V2.0","August 12, 2016","September 2016","December 2021","March 29, 2017","March 2017","No Study Results Posted","null","September 2018","3-year Progression-free survival (PFS) defined as the ratio of study subjects who had disease progression or died within 3 years from the start of randomization|Overall response rate (ORR) that defined as the total ratio of study subjects with complete response, complete response unconfirmed and partial response after treatment. ORR=(CR+ CRu+ PR)cases/total cases×100%.|3-year overall survival rate (OS) that defined as the ratio of study subjects who survived 3 years after randomization|Safety that evaluated by rates of all adverse reactions caused by Cinobufacini Tablets and the changes of all indexes before and after treatment|Relationship between synergistic effect of Cinobufacini Tablets and expression of Na+/K+-ATPase α3","https://ClinicalTrials.gov/show/NCT02871869"
836,"NCT00070564","S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer","Active, not recruiting","Has Results","Breast Cancer","Biological: pegfilgrastim|Drug: AC regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","3294","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CDR0000334899|S0221|U10CA032102","October 3, 2003","November 2003","January 2027","March 3, 2017","March 2017","January 9, 2017","null","January 2015","Disease-free Survival|Overall Survival|Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs|Disease-free Survival Comparison Between 2 Treatments in HR-positive, HER-2 Negative Group|Overall Survival Comparison Between 2 Treatments in HR-positive, HER-2 Negative Group|Disease-free Survival Comparison Between 2 Treatments in HR-negative, HER-2 Negative Group|Overall Survival Comparison Between 2 Treatments in HR-negative, HER-2 Negative Group|Disease-free Survival Comparison Between 2 Treatments in HER2-positive Group|Overall Survival Comparison Between 2 Treatments in HER-2 Positive Group.","https://ClinicalTrials.gov/show/NCT00070564"
837,"NCT01190787","Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: velcade subcutaneous melphalan prednisone|Drug: velcade cyclophosphamide prednisone|Drug: velcade prednisone","Stichting Hemato-Oncologie voor Volwassenen Nederland|Fondazione Neoplasie Sangue Onlus","All","18 Years and older   (Adult, Senior)","Phase 2","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","26866138MMY2069","August 27, 2010","July 2010","May 2019","May 9, 2016","May 2016","No Study Results Posted","null","May 2012","Very Good Partial Response, Complete response rate , Partial response rate|Progression free survival|Time to progression|Time to Next Therapy|Overall survival|Time to response|Duration of response|Response rate","https://ClinicalTrials.gov/show/NCT01190787"
838,"NCT01031030","Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)","Unknown status","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: methotrexate|Other: laboratory biomarker analysis|Procedure: adjuvant therapy","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|National Cancer Institute (NCI)","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","800","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","IRST-IBIS-03|CDR0000661068","December 11, 2009","November 1997","null","August 1, 2013","December 2009","No Study Results Posted","null","December 2010","Overall survival|Disease-free survival|Toxicity|Quality of life|Efficacy in subgroups of patients","https://ClinicalTrials.gov/show/NCT01031030"
839,"NCT02901145","Nivolumab in Relapsed Pediatric Solid Tumors","Not yet recruiting","No Results Available","Antibodies, Neoplasm","Drug: Nivolumab,low dose cyclophosphamide","Hadassah Medical Organization","All","1 Year to 21 Years   (Child, Adult)","Phase 1|Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0506-15-HMO","September 11, 2016","November 2016","March 2020","September 14, 2016","September 2016","No Study Results Posted","null","November 2019","Event free survival|Overall survival|evaluation of predictors for response","https://ClinicalTrials.gov/show/NCT02901145"
840,"NCT00107380","S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma","Completed","Has Results","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: tositumomab and iodine I 131 tositumomab","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","86","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000415955|S0433|U10CA032102","April 5, 2005","November 2005","December 2015","February 4, 2016","February 2016","December 23, 2013","null","November 2013","Progression-free Survival (PFS) at 2 Years|Response Rate (Complete, Complete Unconfirmed, and Partial)|Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug","https://ClinicalTrials.gov/show/NCT00107380"
841,"NCT03164993","Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer","Recruiting","No Results Available","Cancer, Breast|Triple Negative Breast Cancer","Drug: Atezolizumab|Drug: Pegylated liposomal doxorubicin|Drug: Cyclophosphamide|Other: Placebo","Oslo University Hospital|Hoffmann-La Roche|Norwegian Cancer Society|St. Olavs Hospital|Helse Stavanger HF|University Hospital of North Norway","All","18 Years and older   (Adult, Senior)","Phase 2","75","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","ML39079_ALICE","May 12, 2017","June 1, 2017","March 1, 2024","May 22, 2017","May 2017","No Study Results Posted","ALICE","November 1, 2020","Assessment of toxicity of combined treatment with Atezolizumab, pegylated liposomal doxorubicin and cyclophosphamide|Progression-free survival (PFS)|Objective tumor response rate|Overall survival|Duration of response|Durable tumor response rate (DRR; >6 months)|Patient reported outcome","https://ClinicalTrials.gov/show/NCT03164993"
842,"NCT00902044","Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma","Recruiting","No Results Available","Sarcoma","Genetic: Autologous HER2-specific T cells|Drug: Fludarabine|Drug: Cyclophosphamide","Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine","All","Child, Adult, Senior","Phase 1","36","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","24489-HEROS|HEROS","May 13, 2009","July 2009","July 2030","September 16, 2016","September 2016","No Study Results Posted","null","July 2017","Number of patients with dose limiting toxicity after one injection of HER2-specific T cells|Number of patients with dose limiting toxicity after one injection of HER2-specific T cells after receiving lymphodepleting chemotherapy|Frequency of HER2-specific T cells pre and post injection|Change in tumor size from pre to post injection","https://ClinicalTrials.gov/show/NCT00902044"
843,"NCT00334867","Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma","Withdrawn","No Results Available","Sarcoma","Drug: cyclophosphamide|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: topotecan hydrochloride|Drug: vincristine sulfate|Procedure: conventional surgery|Procedure: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 50 Years   (Child, Adult)","Phase 3","0","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","AEWS0531|COG-AEWS0531|CDR0000483611","June 7, 2006","December 2005","null","June 27, 2013","June 2013","No Study Results Posted","null","January 2006","Event-free survival|Survival form study enrollment","https://ClinicalTrials.gov/show/NCT00334867"
844,"NCT00017628","Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis","Completed","No Results Available","Multiple Sclerosis","Drug: cyclophosphamide|Drug: filgrastim|Drug: methylprednisolone|Procedure: Autologous Stem Cell Transplantation","Northwestern Memorial Hospital|Office of Rare Diseases (ORD)","All","up to 59 Years   (Child, Adult)","Phase 1","20","Other","Interventional","Primary Purpose: Treatment","199/14975|NU-95MS1","June 6, 2001","April 2001","null","June 23, 2005","July 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00017628"
845,"NCT00047281","Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: celecoxib|Drug: cyclophosphamide|Drug: etoposide|Drug: thalidomide","Dana-Farber Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000257584|DFCI-01278|NCI-G02-2117|CELGENE-2001-P-001757/3","October 3, 2002","March 2002","null","November 22, 2008","November 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00047281"
846,"NCT00466531","Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19","Active, not recruiting","No Results Available","Leukemia","Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","06-138|MSKCC-06138","April 25, 2007","March 21, 2007","December 2018","May 9, 2017","May 2017","No Study Results Posted","null","December 2018","Safety (phase I)|efficacy of the two CD19-targeted T cell methods (phase II)|Antileukemic effect|Comparison of in vivo survival of patients receiving genetically modified anti-CD19 T cells after T-cell infusion with vs without lymphodepleting therapy","https://ClinicalTrials.gov/show/NCT00466531"
847,"NCT00129922","Fluorouracil, Epirubicin, and Cyclophosphamide (FEC) Versus FEC Plus Paclitaxel as Adjuvant Treatment for Node Positive Breast Cancer Patients","Completed","No Results Available","Breast Cancer","Drug: paclitaxel","Spanish Breast Cancer Research Group|Bristol-Myers Squibb|Pfizer|Hoffmann-La Roche","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","1250","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GEICAM 9906","August 10, 2005","November 1999","July 2007","September 26, 2005","August 2005","No Study Results Posted","null","null","5-year disease-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00129922"
848,"NCT00028665","Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","12 Years to 65 Years   (Child, Adult)","Phase 2","37","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU1499|P30CA043703|CWRU-030040|NCI-G01-2040","January 4, 2002","June 2000","null","June 9, 2010","June 2010","No Study Results Posted","null","March 2005","Total CD34 cells|T and B lymphocyte counts|Disease response|Engraftment","https://ClinicalTrials.gov/show/NCT00028665"
849,"NCT00268853","A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin","Completed","No Results Available","Diffuse Large-Cell Lymphoma","Drug: CPOP-R|Drug: CHOP-R","CTI BioPharma","All","18 Years and older   (Adult, Senior)","Phase 2","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PIX203","December 21, 2005","November 2005","May 2012","January 15, 2015","July 2012","No Study Results Posted","RAPID","May 2012","The primary objective is to show that the response rate for CPOP-R is not inferior to that of CHOP-R.|The secondary objective is to compare the overall survival, event free survival and cardiac safety of the 2 treatments. Other comparisons will include duration of response, overall objective response rate, and time to treatment failure (TTF).","https://ClinicalTrials.gov/show/NCT00268853"
850,"NCT00003549","S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer","Completed","No Results Available","Neuroendocrine Carcinoma of the Skin","Drug: CMF regimen|Drug: cyclophosphamide|Drug: fluorouracil|Drug: methotrexate","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000066606|U10CA032102|S9716","November 1, 1999","October 1998","January 2003","October 5, 2012","October 2012","No Study Results Posted","null","September 2001","","https://ClinicalTrials.gov/show/NCT00003549"
851,"NCT02143830","HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy","Recruiting","No Results Available","Fanconi Anemia|Severe Marrow Failure|Myelodysplastic Syndrome (MDS)|Acute Myelogenous Leukemia (AML)","Drug: Busulfan|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: rabbit ATG|Drug: G-CSF|Biological: Peripheral blood stem cell","Children's Hospital Medical Center, Cincinnati|Memorial Sloan Kettering Cancer Center|Fred Hutchinson Cancer Research Center","All","3 Months and older   (Child, Adult, Senior)","Phase 2","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2013-7501","April 28, 2014","April 2014","May 2020","May 9, 2017","May 2017","No Study Results Posted","RAFA","May 2019","Graft Failure or Rejection|Post-transplant severe morbidity and mortality","https://ClinicalTrials.gov/show/NCT02143830"
852,"NCT01184885","A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy","Completed","Has Results","Lymphoid Malignancies (New or Relapsed)|Acute Lymphoblastic Leukemia|Burkitt Lymphoma|Lymphoblastic Lymphoma|Mantle Cell Lymphoma|Adult T-cell Leukemia/Lymphoma","Drug: Hyper-CVAD|Drug: Sirolimus","Sidney Kimmel Cancer Center at Thomas Jefferson University|American Society of Clinical Oncology|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09G.474|2009-35","August 17, 2010","July 2010","April 2013","October 19, 2016","October 2016","November 13, 2013","null","March 2011","Number of Participants With Count Recovery That Allows for Starting a Phase II Study to Evaluate Response Rates and Survival|Induction Mortality|Complete Response","https://ClinicalTrials.gov/show/NCT01184885"
853,"NCT00193479","Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma","Completed","Has Results","Non-Hodgkins Lymphoma","Drug: Cyclophosphamide|Drug: Mitoxantrone|Drug: Vincristine|Drug: Prednisone|Drug: Rituximab","SCRI Development Innovations, LLC|Genentech, Inc.|Amgen","All","18 Years and older   (Adult, Senior)","Phase 2","51","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI LYM 28","September 12, 2005","April 2003","February 2010","January 8, 2014","January 2014","January 8, 2014","null","July 2008","Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment","https://ClinicalTrials.gov/show/NCT00193479"
854,"NCT01982682","Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor","Active, not recruiting","No Results Available","Hematopoietic/Lymphoid Cancer","Radiation: Total-Body Irradiation (TBI)|Biological: Donor Lymphocyte Infusion (DLI)|Drug: Cyclophosphamide|Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT)|Drug: Mycophenolate mofetil","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","13D.352|2013-031","November 6, 2013","November 4, 2013","May 1, 2018","May 15, 2017","May 2017","No Study Results Posted","null","April 7, 2017","Disease free survival (DFS)|Incidence of graft failure|Incidence of severe GVHD|Non-relapse mortality","https://ClinicalTrials.gov/show/NCT01982682"
855,"NCT01909752","Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer","Unknown status","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Cyclophosphamide|Biological: DRibble vaccine|Drug: Imiquimod|Drug: GM-CSF|Biological: HPV vaccine","UbiVac|National Cancer Institute (NCI)|Providence Cancer Center, Earle A. Chiles Research Institute|Providence Health & Services|Mayo Clinic|Louisiana State University Health Sciences Center in New Orleans","All","18 Years and older   (Adult, Senior)","Phase 2","48","Industry|NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UbiVac DPV-001|R44CA121612","July 24, 2013","July 2013","December 2016","May 26, 2015","May 2015","No Study Results Posted","null","July 2016","Identify the regimen that produces the strongest antibody response|Safety|Progression free survival|Immune response and progression-free survival correlation.","https://ClinicalTrials.gov/show/NCT01909752"
856,"NCT00002502","Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: busulfan|Drug: cyclophosphamide|Drug: cytarabine|Procedure: allogeneic bone marrow transplantation","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","up to 55 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","92-103|CDR0000077927|NCI-H92-0143","November 1, 1999","July 1992","May 2000","June 26, 2013","June 2013","No Study Results Posted","null","May 2000","","https://ClinicalTrials.gov/show/NCT00002502"
857,"NCT00309478","Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-Positive Patients","Completed","No Results Available","Early-Stage Breast Cancer","Drug: cyclophosphamide|Drug: Methotrexate|Drug: Fluorouracil|Drug: Goserelin|Drug: Tamoxifen","Austrian Breast & Colorectal Cancer Study Group","Female","19 Years and older   (Adult, Senior)","Phase 3","1099","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ABCSG-5","March 31, 2006","December 1990","null","May 18, 2006","June 1999","No Study Results Posted","null","null","Disease-free survival|Overall survival|Toxicities","https://ClinicalTrials.gov/show/NCT00309478"
858,"NCT02586038","Study of MLN9708 Plus Oral Dexamethasone or Plus Oral Cyclophosphamide and Dexamethasone or Plus Bendamustine and Dexamethasone or Plus Oral Thalidomide and Dexamethasone Followed by Maintenance With MLN9708 in Newly Diagnosed Elderly Multiple Myeloma Patients","Recruiting","No Results Available","Multiple Myeloma","Drug: MLN9708|Drug: Dexamethasone|Drug: Cyclophosphamide|Drug: Bendamustine|Drug: Thalidomide","Silvio Aime|University of Turin, Italy","All","65 Years and older   (Adult, Senior)","Phase 2","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UNITO-EMN10","October 21, 2015","October 2015","October 2020","May 9, 2016","May 2016","No Study Results Posted","null","October 2017","Progression Free Survival (PFS)|Response rate|Toxicity|Progression Free Survival-2 (PFS-2)|Time To Progression (TTP)|Time to Next Therapy (TNT)","https://ClinicalTrials.gov/show/NCT02586038"
859,"NCT01300247","A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)","Completed","Has Results","Lymphocytic Leukemia, Chronic","Drug: Fludarabine|Drug: Obinutuzumab|Drug: Bendamustine|Drug: Cyclophosphamide","Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GAO4779g|GO01298","February 14, 2011","May 2011","December 2015","December 8, 2016","December 2016","May 18, 2016","null","January 2013","Number of Participants With Human Anti-Human Antibodies (HAHAs)|Area Under the Plasma Concentration-Time Curve (AUC) of Obinutuzumab|Maximum Plasma Concentration (Cmax) of Obinutuzumab|Trough Plasma Concentration (Ctrough) of Obinutuzumab|Clearance of Obinutuzumab|Volume of Distribution of Obinutuzumab|Half-Life of Obinutuzumab|Percentage of Participants With Objective Response, Assessed According to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Guidelines|Duration of Objective Response (DOR), Assessed by the Investigator According to IWCLL Guidelines|Percentage of Participants Who Were Alive and Progression Free|Percentage of Participants Who Were Alive|Percentage of Participants Who Had B-Cell Depletion|Percentage of Participants Who Had B-Cell Recovery","https://ClinicalTrials.gov/show/NCT01300247"
860,"NCT00003958","Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma","Completed","No Results Available","Adult Malignant Mesenchymoma|Adult Rhabdomyosarcoma|Alveolar Childhood Rhabdomyosarcoma|Childhood Malignant Mesenchymoma|Embryonal Childhood Rhabdomyosarcoma|Embryonal-botryoid Childhood Rhabdomyosarcoma|Nonmetastatic Childhood Soft Tissue Sarcoma|Previously Untreated Childhood Rhabdomyosarcoma|Stage I Adult Soft Tissue Sarcoma|Stage II Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma","Biological: dactinomycin|Drug: vincristine sulfate|Drug: cyclophosphamide|Procedure: therapeutic conventional surgery|Radiation: radiation therapy|Drug: topotecan hydrochloride|Biological: filgrastim|Biological: sargramostim|Other: laboratory biomarker analysis","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 49 Years   (Child, Adult)","Phase 3","702","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D9803|NCI-2012-02302|IRS-D9803|COG-D9803|POG-D9803|CDR0000067157|CCG-D9803|U10CA098543","November 1, 1999","September 2002","null","June 13, 2013","June 2013","No Study Results Posted","null","October 2007","Long-term failure-free survival (FFS) between the two treatment groups|Overall survival between treatments|Rate of second look surgery|Proportion of patients rendered tumor-free or with microscopic tumor only|Estimation of the rate of local failure for the patients who undergo second look surgery","https://ClinicalTrials.gov/show/NCT00003958"
861,"NCT00244127","Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.","Unknown status","No Results Available","Aggressive Non-Hodgkin's Lymphoma in the Elderly.","Drug: Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP)","Zeneus Pharma","All","65 Years and older   (Adult, Senior)","Phase 2","75","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Myocet 018|The MYOCAN Study","October 24, 2005","October 2002","null","October 26, 2005","October 2005","No Study Results Posted","null","null","Response rate","https://ClinicalTrials.gov/show/NCT00244127"
862,"NCT01539902","Phase 2 Study of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis","Unknown status","No Results Available","Lupus Nephritis","Biological: Human Umbilical Cord derived MSCs|Drug: Cyclophosphamide","CytoMed & Beike","All","16 Years to 65 Years   (Child, Adult)","Phase 2","25","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","CT 11-03","February 22, 2012","February 2012","May 2013","March 5, 2012","March 2012","No Study Results Posted","hUC-MSC-SLE","March 2013","Efficacy and Safety","https://ClinicalTrials.gov/show/NCT01539902"
863,"NCT00516425","Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: pegfilgrastim|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Genetic: proteomic profiling|Other: diagnostic laboratory biomarker analysis|Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry|Other: pharmacological study|Other: surface-enhanced laser desorption/ionization-time of flight mass spectrometry|Procedure: adjuvant therapy","Charing Cross Hospital|National Cancer Institute (NCI)","Female","70 Years and older   (Senior)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","UKM-CCH-ACTION|CDR0000561076|ICR-CTSU/2006/10004-ACTION|EU-20751|EUDRACT-2005-005721|ISRCTN41708421|BIG-205","August 14, 2007","January 2007","null","August 6, 2013","September 2007","No Study Results Posted","null","null","Relapse-free interval|Physical, functional, and breast cancer concerns as measured by the Trial Outcome Index (TOI)|Total FACT-AN score|Total FACT-F score|Disease-free survival|Overall survival|Cause-specific survival|Distant disease-free survival|Safety and tolerability (overall and for each treatment schedule)|Treatment compliance (overall and for each treatment schedule)|Quality of life|Total FACT-B score|Individual subscales on activities of daily living","https://ClinicalTrials.gov/show/NCT00516425"
864,"NCT00544219","PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Procedure: positron emission tomography","Swiss Group for Clinical Cancer Research","All","18 Years to 80 Years   (Adult, Senior)","","156","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 38/07|SWS-SAKK-38-07|EU-20763|EUDRACT-2007-001806-26|CDR0000569869","October 13, 2007","September 2007","January 2016","June 14, 2016","June 2016","No Study Results Posted","null","September 2012","Event-free survival|Overall survival during follow-up|Objective response|Positron emission tomography (PET) results|Histological results of remaining PET-positive lesion(s) after treatment","https://ClinicalTrials.gov/show/NCT00544219"
865,"NCT00434031","CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer","Withdrawn","No Results Available","Breast Cancer","Drug: docetaxel|Drug: cyclophosphamide|Drug: trastuzumab|Drug: liposomal doxorubicin","National Cancer Institute, Naples","All","18 Years to 65 Years   (Adult)","Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CETRA|EudraCT number: 2006-003993-85","February 9, 2007","September 2007","null","July 27, 2012","July 2012","No Study Results Posted","CETRA","null","complete pathologic response rate|toxicity of neoadjuvant treatment|predictive ability of noninvasive diagnostic methods for results of neoadjuvant treatment","https://ClinicalTrials.gov/show/NCT00434031"
866,"NCT02567435","Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","Suspended","No Results Available","Alveolar Rhabdomyosarcoma|Botryoid-Type Embryonal Rhabdomyosarcoma|Embryonal Rhabdomyosarcoma|Rhabdomyosarcoma|Sclerosing Rhabdomyosarcoma|Spindle Cell Rhabdomyosarcoma|Untreated Childhood Rhabdomyosarcoma","Drug: Cyclophosphamide|Biological: Dactinomycin|Drug: Irinotecan Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Questionnaire Administration|Radiation: Radiation Therapy|Drug: Temsirolimus|Drug: Vincristine Sulfate","National Cancer Institute (NCI)","All","up to 40 Years   (Child, Adult)","Phase 3","387","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2015-01644|ARST1431|U10CA180886","October 2, 2015","May 23, 2016","null","May 23, 2017","May 2017","No Study Results Posted","null","November 1, 2022","EFS|OS","https://ClinicalTrials.gov/show/NCT02567435"
867,"NCT00770224","S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Biological: rituximab|Biological: tositumomab|Drug: cyclophosphamide|Drug: doxorubicin|Drug: prednisone|Drug: vincristine|Radiation: tositumomab","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","87","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000615104|S0801|U10CA032102","October 8, 2008","April 2009","December 2017","October 10, 2016","October 2016","No Study Results Posted","null","April 2017","3-year progression-free survival (PFS)|5-year Progression-free Survival|5-year overall survival|Response rate|Safety profile as assessed by NCI CTCAE v4.0","https://ClinicalTrials.gov/show/NCT00770224"
868,"NCT02670252","BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT","Recruiting","No Results Available","Allogeneic Hematopoietic Stem Cell Transplantation|Busulfan|Total Body Irradiation|Acute Lymphocytic Leukemia","Drug: Busulfan (BU)|Drug: Cyclophosphamide (CY)|Radiation: Total Body Irradiation (TBI)","Nanfang Hospital of Southern Medical University|Sun Yat-sen University","All","14 Years to 65 Years   (Child, Adult)","Phase 2|Phase 3","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BUCY vs TBICY-ALL-2016","January 28, 2016","January 2016","December 2019","May 9, 2017","January 2016","No Study Results Posted","null","December 2018","overall survival (OS)|leukemia relapse rate|disease-free survival (DFS)|transplant-related mortality (TRM)","https://ClinicalTrials.gov/show/NCT02670252"
869,"NCT00073879","Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation","Completed","No Results Available","Kidney Cancer","Biological: alemtuzumab|Biological: graft-versus-tumor induction therapy|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Baylor College of Medicine","All","Child, Adult, Senior","","null","Other","Interventional","Primary Purpose: Treatment","CDR0000328247|BCM-H-8447","December 10, 2003","April 2003","April 2004","January 27, 2015","January 2015","No Study Results Posted","null","April 2004","Number of patients with treatment related mortality","https://ClinicalTrials.gov/show/NCT00073879"
870,"NCT01750073","Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer","Recruiting","No Results Available","Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2-negative Breast Cancer|HER2-positive Breast Cancer|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage IA Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-negative Breast Cancer","Drug: paclitaxel|Drug: cyclophosphamide|Biological: trastuzumab|Procedure: therapeutic conventional surgery|Radiation: radiation therapy|Drug: doxorubicin hydrochloride|Other: laboratory biomarker analysis","University of Nebraska|National Cancer Institute (NCI)","Female","19 Years and older   (Adult, Senior)","Phase 2","125","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","264-12|NCI-2012-01372|P30CA036727","December 12, 2012","December 2012","null","December 12, 2012","December 2012","No Study Results Posted","null","December 2017","pCR, determined from the surgical specimen and is defined as the absence of invasive carcinoma in both the breast and axilla at microscopic examination of the resection specimen, regardless of the presence of carcinoma in situ|Overall incidence and severity of toxicities, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Clinical complete response|Failure-free survival (FFS)|Overall survival (OAS)|Identification of gene expression profile signatures that correlate with clinical response as measured by pCR","https://ClinicalTrials.gov/show/NCT01750073"
871,"NCT01212887","Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer","Terminated","No Results Available","Breast Cancer|Colorectal Cancer|Gastric Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Biological: MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes|Biological: aldesleukin|Drug: cyclophosphamide|Drug: fludarabine phosphate|Other: laboratory biomarker analysis|Other: pharmacological study","Cancer Research UK","All","18 Years and older   (Adult, Senior)","Phase 1","14","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000685060|CRUK-PH1/105|CRUK-MFEz|EUDRACT-2005-004085-16|EU-21070","September 30, 2010","August 2007","April 2010","February 27, 2012","February 2012","No Study Results Posted","null","April 2010","Percentage of patients (goal is 50%) who are evaluable for MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes survival|Adverse event according to CTCAE version 3 criteria|Dose of MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes that gives the highest frequency in the circulation as measured by the primary assays (recommended phase II dose)|Presence of cells with a functional chimeric immune receptor on bCEA binding assay|Partial response or complete response on CT scans at 6, 12, 24, and 52 weeks as defined by RECIST criteria|Long-term follow up for insertional mutagenesis","https://ClinicalTrials.gov/show/NCT01212887"
872,"NCT02273583","Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Patients With High-grade, Operable, Non-metastatic Osteosarcoma of the Extremity","Recruiting","No Results Available","High Grade Osteosarcoma","Drug: continuous oral cyclophosphamide and methotrexate","Grupo de Apoio ao Adolescente e a Crianca com Cancer","All","up to 30 Years   (Child, Adult)","Phase 2","738","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GLATO 2006","July 7, 2014","May 2006","null","February 10, 2016","February 2016","No Study Results Posted","null","June 2013","Event-Free Survival|Overall survival","https://ClinicalTrials.gov/show/NCT02273583"
873,"NCT00129389","FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients","Unknown status","No Results Available","Breast Cancer","Drug: FAC|Drug: paclitaxel","Spanish Breast Cancer Research Group|Bristol-Myers Squibb","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","1929","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GEICAM 2003-02","August 10, 2005","September 2003","December 2013","November 21, 2012","November 2012","No Study Results Posted","null","December 2013","Disease-free survival|Overall survival|Toxicity","https://ClinicalTrials.gov/show/NCT00129389"
874,"NCT02744742","G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT","Recruiting","No Results Available","Myelodysplastic Syndrome|Allogeneic Hematopoietic Stem Cell Transplantation|Conditioning","Drug: Decitabine|Drug: Busulfan (BU)|Drug: Cyclophosphamide (CY)|Drug: Granulocyte Colony-Stimulating Factor(G-CSF)","Nanfang Hospital of Southern Medical University|Sun Yat-sen University","All","14 Years to 65 Years   (Child, Adult)","Phase 2|Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","G-CSF+Dec+BUCYvsBUCY-MDS-2016","April 18, 2016","April 2016","March 2020","May 10, 2017","April 2016","No Study Results Posted","null","March 2019","overall survival (OS)|leukemia relapse rate|disease-free survival (DFS)|transplant-related mortality (TRM)","https://ClinicalTrials.gov/show/NCT02744742"
875,"NCT00656123","Vaccine Therapy and Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Liver Metastases Due to Colorectal Cancer","Unknown status","No Results Available","Colorectal Cancer|Metastatic Cancer","Biological: GM-K562 cell vaccine|Biological: allogeneic tumor cell vaccine|Drug: cyclophosphamide|Genetic: gene expression analysis|Genetic: protein analysis|Other: immunoenzyme technique|Other: immunologic technique|Other: laboratory biomarker analysis","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000589230|JHOC-J0745|JHOC-NA_00009345","April 9, 2008","March 2008","null","December 17, 2013","July 2009","No Study Results Posted","null","February 2009","Safety and toxicity after course 2|Cellular vaccine response","https://ClinicalTrials.gov/show/NCT00656123"
876,"NCT02981524","Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer","Not yet recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: CY|Biological: GVAX|Drug: Pembrolizumab","Sidney Kimmel Comprehensive Cancer Center","All","18 Years to 100 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","J16154|IRB00114053","December 1, 2016","May 2017","March 2025","April 26, 2017","April 2017","No Study Results Posted","null","March 2021","Antitumor activity measured as objective response rate (ORR, assessed by RECIST 1.1)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Progression Free Survival (PFS)|Overall Survival (OS)|The duration of response among subjects who demonstrate an objective response to treatment with CY/GVAX in combination with pembrolizumab.","https://ClinicalTrials.gov/show/NCT02981524"
877,"NCT01340430","Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer","Active, not recruiting","No Results Available","HER-2 Positive Breast Cancer","Drug: Trastuzumab","Lucia Del Mastro,MD|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","Female","18 Years and older   (Adult, Senior)","Phase 2","43","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NEOHER-021|2010-021600-24","April 6, 2011","March 2011","May 2025","October 31, 2016","October 2016","No Study Results Posted","null","December 2015","pathologic complete response|safety and tolerability|cardiotoxicity|disease free survival|overall survival|rate of conversion from radical to conservative surgery|potential biomarkers of trastuzumab resistance","https://ClinicalTrials.gov/show/NCT01340430"
878,"NCT00079105","A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years","Completed","No Results Available","Lymphoma","Biological: bleomycin sulfate|Drug: cyclophosphamide|Drug: etoposide|Drug: mitoxantrone hydrochloride|Drug: prednisolone|Drug: procarbazine hydrochloride|Drug: vinblastine sulfate","Newcastle-upon-Tyne Hospitals NHS Trust","All","60 Years to 120 Years   (Adult, Senior)","Phase 2","175","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CDR0000354225|UON-SHIELD|EU-20346","March 8, 2004","January 2004","December 2010","March 29, 2017","March 2017","No Study Results Posted","null","December 2010","Disease-free survival by routine imaging|Overall survival by routine imaging","https://ClinicalTrials.gov/show/NCT00079105"
879,"NCT01205217","Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer","Withdrawn","No Results Available","Neoplasms, Breast","Drug: Lapatinib|Drug: Trastuzumab|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Paclitaxel","GlaxoSmithKline","Female","18 Years and older   (Adult, Senior)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","113957","September 17, 2010","December 2010","December 2010","March 1, 2012","February 2012","No Study Results Posted","ELATE","December 2010","Pathologic complete response (pCR) in the breast|pCR rate in the breast and axilla|Overall response rate (complete plus partial response) in the breast and axilla according to RECIST 1.1 criteria|The breast conservation rate","https://ClinicalTrials.gov/show/NCT01205217"
880,"NCT00489281","Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant in Treating Patients With Sickle Cell Anemia and Other Blood Disorders","Active, not recruiting","No Results Available","Sickle Cell Disease","Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: Sirolimus|Procedure: Allogeneic bone marrow transplantation|Radiation: total-body irradiation|Drug: Levetiracetam","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","2 Years to 70 Years   (Child, Adult, Senior)","Phase 2","42","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","J0676 CDR0000540593|P30CA006973|P01CA015396|JHOC-J0676|JHOC-NA_00002479","June 20, 2007","May 2007","December 2018","January 26, 2017","January 2017","No Study Results Posted","null","May 2018","Transplant-related mortality at day 100 and 1 year after bone marrow transplantation (BMT)|Risk-stratified estimates of 2-year progression-free survival|Time to recovery of circulating neutrophils and platelets after chemotherapy|Donor chimerism at 30, 60, 180, and 365 days after bone marrow transplant|Development of graft-vs-host disease","https://ClinicalTrials.gov/show/NCT00489281"
881,"NCT02001506","Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: FEC3-D3","Asan Medical Center","Female","20 Years and older   (Adult, Senior)","Phase 3","560","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-0116","November 19, 2013","November 2012","November 2020","January 17, 2015","December 2013","No Study Results Posted","Neo-shorter","November 2015","pathologic complete response (pCR) between two arms|3 year-disease free survival between two arms","https://ClinicalTrials.gov/show/NCT02001506"
882,"NCT00062036","Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma","Completed","No Results Available","Melanoma (Skin)","Biological: aldesleukin|Biological: filgrastim|Biological: incomplete Freund's adjuvant|Biological: interleukin-2 gene|Biological: therapeutic tumor infiltrating lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1|Phase 2","33","NIH","Interventional","Masking: No masking|Primary Purpose: Treatment","030162|03-C-0162|NCI-5855|CDR0000304438","June 5, 2003","June 2003","September 2008","January 24, 2017","March 2012","No Study Results Posted","null","February 2007","Survival|Clinical tumor regression|Toxicity profile","https://ClinicalTrials.gov/show/NCT00062036"
883,"NCT00242996","Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Biological: sargramostim|Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Procedure: adjuvant therapy|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","44","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","J0376 CDR0000447158|P30CA006973|JHOC-J0376|WIRB-20040009","October 20, 2005","March 2004","null","October 14, 2016","October 2016","No Study Results Posted","null","April 2017","2-year event free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00242996"
884,"NCT01646736","Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis","Unknown status","No Results Available","Nephritis, Lupus","Drug: Tripterygium wilfordii Hook F|Drug: Cyclophosphamide|Drug: GC","Peking Union Medical College Hospital","All","18 Years to 65 Years   (Adult)","Phase 2|Phase 3","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","T2WILN","July 18, 2012","July 2012","December 2013","July 19, 2012","July 2012","No Study Results Posted","null","July 2013","Renal Response|Renal Function|Serum Albumin Level|Complement|Anti-dsDNA","https://ClinicalTrials.gov/show/NCT01646736"
885,"NCT00002649","Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma","Completed","No Results Available","Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma","Biological: aldesleukin|Biological: filgrastim|Drug: cyclophosphamide|Drug: etoposide|Radiation: radiation therapy|Procedure: peripheral blood stem cell transplantation|Procedure: bone marrow ablation with stem cell support","National Cancer Institute (NCI)","All","16 Years to 60 Years   (Child, Adult)","Phase 3","206","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03072|SWOG-9438|U10CA032102|CDR0000064175","November 1, 1999","May 1995","null","February 27, 2013","February 2013","No Study Results Posted","null","November 2006","Overall survival|Disease-free survival|Frequency and severity of toxicity associated with post-transplant aldesleukin therapy","https://ClinicalTrials.gov/show/NCT00002649"
886,"NCT00096382","Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma","Completed","Has Results","Melanoma (Skin)","Biological: aldesleukin|Biological: filgrastim|Biological: therapeutic tumor infiltrating lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Radiation: radiation therapy","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","34","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","040288|04-C-0288|NCI-7025|NCI-PRMC-P6273|CDR0000393480","November 9, 2004","September 2004","January 2009","October 6, 2015","September 2015","November 20, 2012","null","January 2009","Clinical Tumor Regression|Safety","https://ClinicalTrials.gov/show/NCT00096382"
887,"NCT02844322","The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia","Recruiting","No Results Available","Waldenström Macroglobulinemia","Drug: Bortezomib|Drug: Rituximab","Institute of Hematology & Blood Diseases Hospital","All","18 Years to 85 Years   (Adult, Senior)","Phase 4","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IIT2015005-EC-2","July 17, 2016","May 2016","May 2020","July 25, 2016","July 2016","No Study Results Posted","BDH-WM01","November 2019","overall response rate|progress-free survival","https://ClinicalTrials.gov/show/NCT02844322"
888,"NCT00538395","Intensive Sequential Chemotherapy With Adriamycin Taxol and Cytoxan in the Treatment of Locally Advanced Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: Adriamycin, Taxol and Cytoxan","King Faisal Specialist Hospital & Research Center","All","Child, Adult, Senior","","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RAC #981-020","October 1, 2007","September 2007","September 2013","December 11, 2011","December 2011","No Study Results Posted","null","September 2012","Effectiveness","https://ClinicalTrials.gov/show/NCT00538395"
889,"NCT00726700","Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma","Completed","No Results Available","Lymphoma","Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","German High-Grade Non-Hodgkin's Lymphoma Study Group|National Cancer Institute (NCI)","All","61 Years to 80 Years   (Adult, Senior)","Phase 2","109","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","DSHNHL-2003-2|CDR0000454473|EU-20534","July 31, 2008","May 2004","February 2012","August 1, 2013","July 2012","No Study Results Posted","null","null","Side effects|Adherence to therapy regimens|Antitumor effectivity","https://ClinicalTrials.gov/show/NCT00726700"
890,"NCT01114048","Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)","Unknown status","No Results Available","Multiple Myeloma","Drug: Thalidomide, cyclophosphamide, dexamethasone, bortezomib","Chonnam National University Hospital","All","18 Years to 65 Years   (Adult)","Phase 2","78","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KMM-97","April 28, 2010","March 2010","null","September 21, 2011","September 2011","No Study Results Posted","KMM-97","March 2012","response rate for induction chemotherapy","https://ClinicalTrials.gov/show/NCT01114048"
891,"NCT01790737","First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Cyclophosphamide|Drug: Filgrastim","Kuopio University Hospital|Helsinki University Central Hospital|Tampere University Hospital|Turku University Hospital|Oulu University Hospital|Mikkeli Central Hospital|Kymenlaakso Central Hospital Kotka Finland|Jyväskylä Central Hospital|Central Hospital of Kanta-Hame|Satakunta Central Hospital|Kainuu and Länsi-Pohja Central Hospital|Celgene Corporation","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","KUH5101424|2012-001051-39","February 4, 2013","January 2013","December 2017","May 23, 2017","May 2017","No Study Results Posted","FMG-MM02","December 2017","Immunophenotypic response|Progression free survival","https://ClinicalTrials.gov/show/NCT01790737"
892,"NCT02423928","Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer","Recruiting","No Results Available","Prostate Cancer","Biological: Dendritic cell based cryoimmunotherapy|Drug: Cyclophosphamide|Drug: ipilimumab","Alden Cancer Therapy II|Haukeland University Hospital|Norwegian Radium Hospital","Male","18 Years and older   (Adult, Senior)","Phase 1","20","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACT2001|2014-001898-14","April 15, 2015","May 2015","December 2017","July 19, 2016","July 2016","No Study Results Posted","CryoIT","May 2017","Composite measure of the safety and toxicity profile, including definition of the Maximum Tolerated Dose.","https://ClinicalTrials.gov/show/NCT02423928"
893,"NCT03101748","3HT With Taxol for Metastatic Breast Cancer","Not yet recruiting","No Results Available","Malignant Neoplasm of Breast","Drug: Neratinib|Drug: Paclitaxel|Drug: Pertuzumab|Drug: Trastuzumab|Drug: Doxorubicin|Drug: Cyclophosphamide","M.D. Anderson Cancer Center|Puma Biotechnology, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","99","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2016-0537|NCI-2017-00813","March 30, 2017","June 2017","June 2025","May 23, 2017","May 2017","No Study Results Posted","null","June 2025","Maximum Tolerated Dose (MTD) of Neratinib in Combination with Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive (HER2+) Primary Metastatic or Locally Advanced Breast Cancer|Pathologic Complete Response (pCR) Rate of Neratinib in Combination with Paclitaxel, Pertuzumab, and Trastuzumab Followed by Doxorubicin and Cyclophosphamide (AC) in HER2+ Locally Advanced Inflammatory Breast Cancer (IBC) Patients|Pathologic Complete Response (pCR) Rate of Neratinib in Combination with Paclitaxel Followed by Doxorubicin and Cyclophosphamide in HER2-Negative/ER-Positive (HER2-/ER+) Locally Advanced Inflammatory Breast Cancer (IBC) Patients|Progression Free Survival (PFS) Rate of HER2+ Primary de novo Metastatic and Locally Advanced Inflammatory Breast Cancer (IBC) Patients, and HER2-/ER+ IBC Patients Treated with Neratinib Plus Anthracycline and Taxane Based Chemotherapy","https://ClinicalTrials.gov/show/NCT03101748"
894,"NCT00004010","Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease","Completed","No Results Available","Lymphoma","Biological: bleomycin sulfate|Biological: filgrastim|Drug: ABVD regimen|Drug: cyclophosphamide|Drug: dacarbazine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: procarbazine hydrochloride|Drug: vinblastine sulfate|Drug: vincristine sulfate|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 2","99","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","59704|COG-59704|CDR0000067222","November 1, 1999","October 1999","June 2008","February 25, 2014","February 2014","No Study Results Posted","null","October 2003","Estimate the rate of BEACOPP )((Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone) specific toxicity in pediatric patients|Obtain preliminary estimates of response to BEACOPP ((Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)","https://ClinicalTrials.gov/show/NCT00004010"
895,"NCT00005622","Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Multiple Myeloma and Malignant Plasma Cell Neoplasms|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Drug: cyclophosphamide|Radiation: TBI","H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)","All","15 Years to 50 Years   (Child, Adult)","Phase 2","72","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MCC-11282|IRB-4189|NCI-G00-1755","May 2, 2000","May 1996","July 2009","October 24, 2012","October 2012","No Study Results Posted","null","September 2005","event free survival (EFS)|Incidence of graft versus host disease","https://ClinicalTrials.gov/show/NCT00005622"
896,"NCT02408016","Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma","Recruiting","No Results Available","Advanced Pleural Malignant Mesothelioma|HLA-A*0201 Positive Cells Present|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Pleural Malignant Mesothelioma|Stage III Non-Small Cell Lung Cancer|Stage III Pleural Mesothelioma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Pleural Mesothelioma","Biological: Aldesleukin|Biological: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Procedure: Therapeutic Conventional Surgery","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","20","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2727.00|NCI-2015-00329|2727|P30CA015704","March 31, 2015","May 20, 2015","null","April 26, 2017","April 2017","No Study Results Posted","null","December 2017","Evidence and nature of toxicity based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Feasibility of naive T cell (TN) and central memory T cell (TCM) subsets, measured as the proportion of patients for which T cells are successfully generated and infused and whether only TN or TCM could be generated|Persistence of transduced T cells|Frequency of transferred T cells at biopsied tumor sites between the Tn and Tcm groups|Functional capacity of transferred cells, measured by production of intracellular cytokines|TTP based on RECIST criteria and immune-related response criteria","https://ClinicalTrials.gov/show/NCT02408016"
897,"NCT00014755","Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis","Completed","No Results Available","Multiple Sclerosis","Drug: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: filgrastim|Drug: prednisone|Procedure: peripheral blood stem cell transplantation|Procedure: irradiation","Fred Hutchinson Cancer Research Center|Office of Rare Diseases (ORD)","All","18 Years to 60 Years   (Adult)","Phase 1","35","Other","Interventional","Primary Purpose: Treatment","199/15796|FHCRC-1164.00","April 10, 2001","December 1997","null","June 23, 2005","April 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00014755"
898,"NCT02522234","A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","Recruiting","No Results Available","Neutropenia","Biological: F-627|Drug: TAC regimen","Generon (Shanghai) Corporation Ltd.|Fudan University|Sun Yat-sen University","Female","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","12","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SP-CDR-1-1301","August 10, 2015","March 2014","December 2015","August 10, 2015","August 2015","No Study Results Posted","null","August 2015","Number of participants with adverse events/abnormal laboratory value as measure of safety and tolerability of rh G-CSF Fc fusion protein (F-627) in female patients wiht breast cance receiving adjuvant chemotherapy.|Parameter of Peak Plasma Concentration as a measure of pharmacokinetics profile of F-627.|Parameter of Area Under Plasma Concentration versus Time Curve as a measure of pharmacokinetics profile of F-627.|Parameter of Clearance as a measure of pharmacokinetics profile of F-627.|Absolute Neutrophil Count changes over time as measure of pharmacodynamics of F-627.","https://ClinicalTrials.gov/show/NCT02522234"
899,"NCT00337246","Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Biological: rituximab|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mitoxantrone hydrochloride","Cancer Research UK|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","56","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CTRU-NCRI-UKCLL01-FCM/FCM-R|CDR0000485181|EU-20626|ROCHE-NCRI-UKCLL01-FCM/FCM-R|ISRCTN77546448|EUDRACT-2004-003982-34","June 13, 2006","July 2005","March 2011","August 1, 2013","May 2007","No Study Results Posted","null","null","Overall response rate as measured by NCI Response Criteria|Proportion of patients with undetectable minimal residual disease|Progression-free survival at 2 years|Overall survival at 2 years|Toxicity","https://ClinicalTrials.gov/show/NCT00337246"
900,"NCT00453388","Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia","Active, not recruiting","Has Results","Acute Myeloid Leukemia in Remission|de Novo Myelodysplastic Syndrome|Fanconi Anemia|Previously Treated Myelodysplastic Syndrome","Procedure: Allogeneic Bone Marrow Transplantation|Drug: Cyclophosphamide|Drug: Cyclosporine|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Radiation: Total-Body Irradiation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)","All","Child, Adult, Senior","Phase 2","6","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2064.00|NCI-2010-00238|P30CA015704","March 27, 2007","February 2007","null","April 18, 2017","April 2017","April 10, 2017","null","June 2013","Number of Patients Who Engraft at Each Dose of TBI Used|Incidence of Grades III-IV Acute GVHD|Incidence of Transplant-related Mortality|Incidence of Adverse Events","https://ClinicalTrials.gov/show/NCT00453388"
901,"NCT00091104","Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma","Completed","No Results Available","Melanoma (Skin)","Biological: MART-1:27-35 peptide vaccine|Biological: aldesleukin|Biological: filgrastim|Biological: incomplete Freund's adjuvant|Biological: therapeutic autologous lymphocytes|Biological: therapeutic tumor infiltrating lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: autologous hematopoietic stem cell transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation|Radiation: total-body irradiation","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","136","NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","040251|04-C-0251|NCI-6974|CDR0000383246","September 7, 2004","July 2004","October 2010","March 14, 2012","March 2012","No Study Results Posted","null","August 2010","Safety|Tumor regression|In vivo survival of transplanted cells|Clinical response","https://ClinicalTrials.gov/show/NCT00091104"
902,"NCT00003606","Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin|Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: etoposide|Radiation: radiation therapy","UNICANCER|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","216","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066683|FRE-FNCLCC-95012|EU-98021","November 1, 1999","March 1998","null","February 6, 2009","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003606"
903,"NCT00255710","Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer","Completed","No Results Available","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: filgrastim|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","60","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Supportive Care","CDR0000449652|P01CA015396|P30CA006973|JHOC-J0169|WIRB-20020304","November 18, 2005","July 2002","null","March 16, 2010","March 2010","No Study Results Posted","null","null","Post-transplant immunosuppression regimen with ≤ 20% incidence of a grade II-IV graft-versus-host-disease (GVHD) and < 10% incidence of nonengraftment (< 5% donor chimerism) at day 60 following transplant|Incidence and severity of acute GVHD at day 60 following transplant|Frequency of mixed chimerism defined as any detectable donor cells at day 60 following transplant","https://ClinicalTrials.gov/show/NCT00255710"
904,"NCT01925612","Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)","Active, not recruiting","No Results Available","Lymphoma, B-cell|Lymphoma, Large B-cell, Diffuse","Drug: brentuximab vedotin|Drug: brentuximab vedotin|Drug: rituximab|Drug: vincristine|Drug: cyclophosphamide|Drug: prednisone|Drug: doxorubicin","Seattle Genetics, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","87","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SGN35-017","August 15, 2013","August 2013","September 2019","January 23, 2017","January 2017","No Study Results Posted","null","September 2017","Complete remission rate|Incidence of adverse events|Incidence of laboratory abnormalities|Objective response rate|Progression-free survivial|Overall survival","https://ClinicalTrials.gov/show/NCT01925612"
905,"NCT03056339","Umbilical & CB Derived CAR-Engineered NK Cells for B Lymphoid Malignancies","Not yet recruiting","No Results Available","B-Lymphoid Malignancies|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Non-hodgkin Lymphoma","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Mesna|Biological: iC9/CAR.19/IL15-Transduced CB-NK Cells|Drug: AP1903","M.D. Anderson Cancer Center|Bellicum Pharmaceuticals","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2016-0641","February 14, 2017","June 2017","June 2022","April 20, 2017","April 2017","No Study Results Posted","null","June 2022","Optimal NK Cell Dose Level of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Killer (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies|Toxicity of Chimeric antigen receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood natural killer (CB-NK) cells in patients with relapsed/refractory CD19+ B lymphoid malignancies|Efficacy of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Killer (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies|Response of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Killer (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies","https://ClinicalTrials.gov/show/NCT03056339"
906,"NCT00284336","Caelyx Adjuvant in Elderly Breast Cancer","Completed","No Results Available","Breast Cancer|Elderly","Drug: Caelyx|Drug: endoxan","Universitaire Ziekenhuizen Leuven","Female","65 Years and older   (Adult, Senior)","Phase 2","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-002995-13|S28720 UZ KUL","December 23, 2005","January 2006","April 2007","December 8, 2014","December 2014","No Study Results Posted","null","null","Investigate the effect on cardiac strain rate imaging (SRI) of Caelyx|The relation between cardiac SRI and classical ejection fraction measurement.|The relation between strain rate and blood markers such as troponin-I and BNP|To assess the tolerability of Caelyx containing regimens in elderly breast cancer patients.","https://ClinicalTrials.gov/show/NCT00284336"
907,"NCT00002474","Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer","Completed","No Results Available","Ovarian Cancer","Drug: carboplatin|Drug: cyclophosphamide|Drug: mitoxantrone hydrochloride|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support","Loyola University|National Cancer Institute (NCI)","Female","up to 64 Years   (Child, Adult)","Phase 2","null","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","LUMC-3007|CDR0000076845|NCI-V91-0058","November 1, 1999","February 1991","October 2005","May 29, 2013","March 2003","No Study Results Posted","null","null","Response rate|Response duration|Overall survival|Nonhematopoietic toxicity","https://ClinicalTrials.gov/show/NCT00002474"
908,"NCT02593227","Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer","Recruiting","No Results Available","Breast Cancer","Biological: Low dose FRα vaccine|Drug: Cyclophosphamide|Biological: High dose FRα vaccine","Tapimmune Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","FRV-002","October 27, 2015","April 2016","December 2020","April 25, 2017","April 2017","No Study Results Posted","null","October 2017","Immune response|Folate receptor alpha expression|Relapse Free Survival|Safety and tolerability (treatment emergent adverse events and injection site reactions)","https://ClinicalTrials.gov/show/NCT02593227"
909,"NCT00070083","Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma","Completed","No Results Available","Lymphoma","Biological: oblimersen sodium|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","British Columbia Cancer Agency|National Cancer Institute (NCI)","All","19 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000329985|BCCA-NCI-5818|NCI-5818","October 3, 2003","July 2003","null","April 4, 2009","June 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00070083"
910,"NCT00589316","Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome","Active, not recruiting","No Results Available","Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|CD45-Positive Neoplastic Cells Present|Chronic Myelomonocytic Leukemia|Previously Treated Myelodysplastic Syndrome|Refractory Anemia With Excess Blasts|Refractory Anemia With Ring Sideroblasts|Refractory Cytopenia With Multilineage Dysplasia|Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts","Procedure: Allogeneic Bone Marrow Transplantation|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Radiation: Iodine I 131 Monoclonal Antibody BC8|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Drug: Tacrolimus|Radiation: Total-Body Irradiation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","26","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2186.00|NCI-2010-00404|2186.00p|P01CA044991|P30CA015704","January 3, 2008","October 5, 2007","October 1, 2024","May 22, 2017","May 2017","No Study Results Posted","null","October 1, 2016","Maximum tolerated dose of 131 I-BC8 antibody defined as the dose that is associated with a true dose limiting toxicity (DLT) rate of 25%, graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3|Disease-free survival|Overall survival|Rates of acute GVHD|Rates of disease relapse|Rates of disease-free survival|Rates of donor chimerism|Rates of engraftment|Rates of immune reconstitution","https://ClinicalTrials.gov/show/NCT00589316"
911,"NCT02671708","IDA+BUCY vs BUCY Conditioning Regimen for Low-risk and Intermediate-risk AML Undergoing Auto-HSCT","Recruiting","No Results Available","Autologous Hematopoietic Stem Cell Transplantation|Acute Myeloid Leukemia|Conditioning","Drug: Idarubicin（IDA）|Drug: Busulfan (BU)|Drug: Cyclophosphamide (CY)","Nanfang Hospital of Southern Medical University|Sun Yat-sen University","All","14 Years to 65 Years   (Child, Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IDA+BUCY vs BUCY-AML-2016","January 30, 2016","January 2016","December 2019","May 9, 2017","January 2016","No Study Results Posted","null","December 2018","overall survival (OS)|leukemia relapse rate|disease-free survival (DFS)|transplant-related mortality (TRM)","https://ClinicalTrials.gov/show/NCT02671708"
912,"NCT00404066","Phase II Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer","Completed","No Results Available","Breast Cancer|Metastatic Breast Cancer","Drug: Lapatinib|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: pegfilgrastim|Drug: filgrastim|Drug: dexamethasone|Drug: trastuzumab","George Albert Fisher|GlaxoSmithKline|Sanofi|Stanford University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","21","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BRSADJ0002|96692","November 22, 2006","October 2006","March 2011","November 6, 2012","March 2011","No Study Results Posted","null","December 2010","Pathologic complete response|Radiological complete response|Rate of breast conserving surgery|Side effects and toxicity profile of Docetaxel and GW572016 (Lapatinib)|Disease free survival","https://ClinicalTrials.gov/show/NCT00404066"
913,"NCT00002773","Vaccine Therapy, Chemotherapy, and GM-CSF in Treating Patients With Advanced Pancreatic Cancer","Completed","No Results Available","Pancreatic Cancer","Biological: allogeneic tumor cell vaccine|Biological: recombinant interferon alfa|Biological: sargramostim|Drug: cyclophosphamide","St. Vincent Medical Center - Los Angeles|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","SVMC-ONC-222P|CDR0000064749|NCI-V96-0886","November 1, 1999","May 1996","April 2004","July 9, 2013","April 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002773"
914,"NCT02897700","Clinical Outcome of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast","Recruiting","No Results Available","Breast Cancer","Drug: Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate|Drug: cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM)|Drug: Placebo","Shanghai Jiao Tong University School of Medicine|Shanghai 10th People's Hospital|China-Japan Union Hospital, Jilin University|Ganzhou City People's Hospital","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BCA-81472709","August 25, 2016","January 2013","December 2018","September 12, 2016","September 2016","No Study Results Posted","COC-IDCB","December 2017","Incidence of treatment-emergent adverse events|Circulating concentrations of tumor microenvironment-specific soluble factors","https://ClinicalTrials.gov/show/NCT02897700"
915,"NCT00210470","A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer","Completed","Has Results","Squamous Cell Carcinoma of the Head and Neck","Biological: IRX-2|Drug: Cyclophosphamide|Drug: Indomethacin|Drug: Zinc|Drug: Omeprazole","IRX Therapeutics","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","27","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRX-2 2005-A","September 13, 2005","July 2005","December 2010","May 22, 2012","May 2012","January 6, 2012","null","December 2010","Number of Participants With Adverse Events and Serious Adverse Events|Clinical and Histological Tumor Responses|Evaluate Patient Tolerance of Surgery and Post-operative Adjuvant Therapy;|Immune Competence as Measured by Lymphocyte Infiltration|Disease-free Survival|Overall Survival|Correlation of Tumor Response or Immune Competence (Lymphocyte Infiltration) With Disease-Free Survival or Overall Survival","https://ClinicalTrials.gov/show/NCT00210470"
916,"NCT01008150","Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: Paclitaxel|Drug: Trastuzumab|Drug: Neratinib|Drug: Doxorubicin|Drug: Cyclophosphamide","NSABP Foundation Inc|Puma Biotechnology, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","141","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP FB-7","November 3, 2009","October 2010","June 2017","October 5, 2015","October 2015","No Study Results Posted","null","September 2015","Pathologic Complete Response in breast and axillary lymph nodes. As measured by no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes after neoadjuvant chemotherapy|Pathologic complete response in breast. As measured by no histologic evidence of invasive tumor cells in the surgical breast specimen|Clinical complete response. As measured by physical exam; resolution of all target and non-target lesions identified at baseline and no new lesions or other signs of disease progression|Recurrence-free interval|Overall survival|Toxicity|Correlative science studies","https://ClinicalTrials.gov/show/NCT01008150"
917,"NCT03106662","Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies","Recruiting","No Results Available","Hematopoietic Stem Cell Transplantation","Biological: mesenchymal stem cells|Drug: cyclophosphamide administration","Ankara University|The Scientific and Technological Research Council of Turkey","All","18 Years and older   (Adult, Senior)","Phase 3","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","213S196","November 13, 2015","October 2014","October 2017","April 8, 2017","April 2017","No Study Results Posted","null","July 2017","Effect of mesenchymal stem cells on overall survival in haploidentical stem cell transplantation|Effect of mesenchymal stem cells on graft versus host disease incidence in haploidentical stem cell transplantation|Effect of mesenchymal stem cells on graft failure incidence in haploidentical stem cell transplantation","https://ClinicalTrials.gov/show/NCT03106662"
918,"NCT00718549","A Study of Maintenance Treatment With MabThera (Rituximab) in Patients With Progressive B-cell Chronic Lymphocytic Leukemia","Completed","No Results Available","Lymphocytic Leukemia, Chronic","Drug: cladribine|Drug: cyclophosphamide|Drug: rituximab [MabThera/Rituxan]|Drug: rituximab [MabThera/Rituxan]|Drug: rituximab [MabThera/Rituxan]","Hoffmann-La Roche","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","128","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ML21283|2008-001140-39","July 16, 2008","July 2009","September 2015","November 1, 2016","November 2016","No Study Results Posted","null","September 2015","Progression-free survival in the maintenance phase|Complete response and partial response in induction phase","https://ClinicalTrials.gov/show/NCT00718549"
919,"NCT00149214","Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens","Completed","Has Results","Breast Cancer","Drug: pemetrexed|Drug: cyclophosphamide|Drug: doxorubicin|Drug: docetaxel","Eli Lilly and Company","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","257","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","7113|H3E-MC-S080","September 2, 2005","September 2005","March 2011","March 15, 2012","March 2012","February 11, 2009","null","February 2008","Number of Participants With a Pathological Complete Response|Number of Participants With a Clinical Tumor Response After the First Sequence of Chemotherapy|Number of Participants With a Clinical Tumor Response After the Second Sequence of Chemotherapy|Number of Patients With Histologically Negative Axillary Lymph Node Status at Surgery|Disease-free Survival","https://ClinicalTrials.gov/show/NCT00149214"
920,"NCT00436566","Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery","Completed","Has Results","Breast Cancer|Cardiac Toxicity","Biological: trastuzumab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: lapatinib ditosylate|Drug: paclitaxel|Genetic: gene expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: fluorophotometry|Other: laboratory biomarker analysis|Other: mass spectrometry|Procedure: adjuvant therapy|Procedure: quality-of-life assessment","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","122","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000533793|P30CA015083|RC0639|06-004049","February 15, 2007","March 2007","null","November 20, 2012","November 2012","October 22, 2012","null","April 2009","Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment|Adverse Event Profile as Measured by NCI CTCAE v 3.0|Cumulative Incidence (CI) of Cardiac Events|Number of Patients Who Experience >= 10 Percent Drop in Left Ventricular Ejection Fraction (LVEF) Between Two Time Points|Disease-free Survival (DFS)|Overall Survival (OS)|Comparison of Selected Quality-of-life Questionnaires|Quality-of-life|Incidence of Pulmonary Events","https://ClinicalTrials.gov/show/NCT00436566"
921,"NCT00002941","Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Drug: mesna|Procedure: peripheral blood stem cell transplantation","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 2","69","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A5962|COG-A5962|CCG-A5962|POG-A5962|CCG-5962|CDR0000065390","November 1, 1999","April 1998","March 2007","July 31, 2014","July 2014","No Study Results Posted","null","November 2002","Failure-free survival rate|Estimating parameters relevant to recovery of normal bone marrow function|Predictive value of MRD assessment","https://ClinicalTrials.gov/show/NCT00002941"
922,"NCT01530607","Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Standard cyclophosphamide|Drug: Goserelin (Zoladex)","King Faisal Specialist Hospital & Research Center","Female","18 Years to 50 Years   (Adult)","Phase 3","416","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2091-013","January 23, 2012","November 2009","November 2012","February 24, 2016","February 2012","No Study Results Posted","null","November 2012","The study is to compare the rate of premature ovarian failure at two years following standard adjuvant or neoadjuvant chemotherapy","https://ClinicalTrials.gov/show/NCT01530607"
923,"NCT00963872","Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer","Terminated","Has Results","Leukemia|Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes","Drug: cyclophosphamide|Drug: fludarabine phosphate|Radiation: Total body irradiation|Biological: Umbilical cord blood unit with C3a fragment|Biological: Unmanipulated UCB Unit","Masonic Cancer Center, University of Minnesota|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","31","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008UC097|MT2008-15|0809M46361|RC1HL099447","August 21, 2009","March 2010","August 2013","October 13, 2015","October 2015","April 22, 2015","null","August 2012","Number of Patients With the Complement 3a (C3a) Unit Predominating|Neutrophil Engraftment|Donor Chimerism in Blood|Incidence of Grades II-IV Graft-vs-host Disease|Non-Relapse Mortality|Overall Survival|Bone Marrow Chimerism|Chronic Graft-Versus-Host Disease|Relapse of Disease|Disease Progression|Platelet Recovery|Incidence of Grades III-IV Graft-vs-host Disease|Non-relapse Mortality|Overall Survival at Day 720|Donor Chimerism","https://ClinicalTrials.gov/show/NCT00963872"
924,"NCT00167180","Post Transplant Donor Lymphocyte Infusion","Active, not recruiting","No Results Available","Leukemia, Myeloid, Chronic|Lymphomas|Multiple Myeloma|Myelodysplastic Syndrome|Leukemia, Lymphocytic, Acute|Leukemia, Lymphocytic, Chronic|AML","Procedure: Donor Lymphocyte Infusion|Drug: Induction Chemotherapy + DLI","Masonic Cancer Center, University of Minnesota","All","1 Year to 70 Years   (Child, Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2004LS006|MT2003-15|0401M55207","September 9, 2005","January 2004","December 2016","February 23, 2016","February 2016","No Study Results Posted","null","February 2016","Overall survival|Disease-free Survival|Complete Remission|Acute Graft-Versus-Host Disease|Bone marrow aplasia","https://ClinicalTrials.gov/show/NCT00167180"
925,"NCT00079261","Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma|Small Intestine Cancer","Drug: CHOP regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: gemcitabine hydrochloride|Drug: prednisone|Drug: vincristine sulfate","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","25","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","EORTC-20021","March 8, 2004","January 2004","null","September 20, 2012","September 2012","No Study Results Posted","null","March 2007","Complete response as assessed by Cheson criteria|Toxicity as assessed by CTC 2.0|Proportion of courses given as scheduled|Freedom from treatment failure as assessed by Cheson criteria","https://ClinicalTrials.gov/show/NCT00079261"
926,"NCT02806375","PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis","Recruiting","No Results Available","Primary Myelofibrosis|Myeloproliferative Disorders","Procedure: Allogeneic hematopoietic stem cell transplantation|Drug: Busulfan|Drug: Fludarabine monophosphate|Drug: Cyclophosphamide|Drug: Ruxolitinib|Drug: Ruxolitinib","St. Petersburg State Pavlov Medical University","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04/16-n","June 8, 2016","January 2016","December 2018","December 14, 2016","December 2016","No Study Results Posted","null","December 2017","Incidence of acute graft-versus-host disease, grades II-IV|Incidence of chronic GVHD, moderate and severe (NIH criteria)|Incidence of primary or secondary graft failure|Non-relapse mortality analysis|Overall survival analysis|Event-free survival analysis|Relapse rate analysis|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03|Infectious complications, including analysis of severe bacterial, fungal and viral infections incidence","https://ClinicalTrials.gov/show/NCT02806375"
927,"NCT00486564","Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma","Completed","No Results Available","Neuroblastoma","Drug: Nifurtimox","University of Vermont|St. Louis University","All","up to 21 Years   (Child, Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","V0610","June 12, 2007","November 2006","June 2009","October 22, 2009","October 2009","No Study Results Posted","null","November 2007","Test the safety of nifurtimox in children with relapsed or refractory neuroblastoma alone and in combination with cyclophosphamide and topotecan.|To evaluate the pharmacokinetic profile of nifurtimox alone and in combination with cyclophosphamide and topotecan.|To determine the response rate to treatment with nifurtimox combined with cyclophosphamide/topotecan","https://ClinicalTrials.gov/show/NCT00486564"
928,"NCT00003116","High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","4 Years to 55 Years   (Child, Adult)","Phase 2","66","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU1995T|P30CA043703|CASE-CWRU-1995|NCI-G97-1354|CASE1995T","November 1, 1999","May 1997","June 2009","June 9, 2010","June 2010","No Study Results Posted","null","March 2006","Hematopoietic reconstitution measured daily during transplant","https://ClinicalTrials.gov/show/NCT00003116"
929,"NCT00671658","Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia|Acute Lymphoblastic Leukemia","Drug: Rituximab|Drug: Cyclophosphamide (CTX)|Drug: Doxorubicin|Drug: Vincristine|Drug: Dexamethasone|Drug: Methotrexate (MTX)|Drug: Cytarabine|Drug: G-CSF|Drug: Mesna|Drug: Pegylated asparaginase|Drug: Pegfilgrastim|Drug: Solumedrol","M.D. Anderson Cancer Center","All","Child, Adult, Senior","Phase 2","220","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID02-230","April 30, 2008","November 2002","July 2013","August 23, 2013","August 2013","No Study Results Posted","null","July 2013","Overall Response Rate","https://ClinicalTrials.gov/show/NCT00671658"
930,"NCT00398489","Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery","Unknown status","No Results Available","Breast Cancer","Biological: trastuzumab|Drug: anastrozole|Drug: cyclophosphamide|Drug: docetaxel|Drug: epirubicin hydrochloride|Drug: goserelin acetate|Drug: tamoxifen citrate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Technische Universität München|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","94","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000516034|KRDI-TUM-HED-324-PAE-0090-I|EU-20634|EUDRACT-2005-000967-24","November 9, 2006","October 2006","null","November 6, 2010","September 2008","No Study Results Posted","null","null","Rate of pathologic complete remission (pCR) after neoadjuvant therapy comprising docetaxel and trastuzumab (Herceptin®) in women with locally advanced, HER2-positive, operable breast cancer|Rate of pCR after neoadjuvant docetaxel in women with locally advanced, HER2-negative, operable breast cancer|Tolerability of treatment as measured by the nature and frequency of adverse events in women with HER2-positive or HER2-negative disease|Identification of predictive markers|Rate of breast conserving therapy versus mastectomy in comparison to preoperative evaluation|Correlation of clinical/sonographical response with pathological response, including lymph node status|Rate of clinical complete remission (cCR) after neoadjuvant therapy comprising docetaxel and trastuzumab in women with locally advanced, HER2-positive, operable breast cancer|Rate of cCR after neoadjuvant docetaxel in women with locally advanced, HER2-negative, operable breast cancer|Disease-free survival after 2.5 and 5 years|Overall-survival after 2.5 and 5 years","https://ClinicalTrials.gov/show/NCT00398489"
931,"NCT00499083","Paclitaxel, Cyclophosphamide, and Doxorubicin Followed by Autologous Dendritic Cells and Surgery With or Without Radiation Therapy and/or Hormone Therapy in Treating Women With Stage II or Stage III Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: therapeutic autologous dendritic cells|Drug: aromatase inhibition therapy|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel|Drug: tamoxifen citrate|Genetic: gene expression analysis|Genetic: protein expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: adjuvant therapy|Procedure: biopsy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","University of Nebraska|National Cancer Institute (NCI)","Female","19 Years and older   (Adult, Senior)","Phase 2","30","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","072-06|P30CA036727|UNMC-07206","July 10, 2007","May 2006","null","July 6, 2011","July 2011","No Study Results Posted","null","December 2011","Pathological complete response|Inflammatory cell infiltration|Antibody-dependent cell-mediated cytotoxicity|Influence of tumor COX-2 and VEGF expression on dendritic cell-mediated tumor-specific immunity","https://ClinicalTrials.gov/show/NCT00499083"
932,"NCT00003679","Combination Chemotherapy in Treating Women With Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Drug: tamoxifen citrate|Procedure: conventional surgery|Radiation: radiation therapy","Scottish Cancer Therapy Network|National Cancer Institute (NCI)","Female","18 Years to 60 Years   (Adult)","Phase 3","350","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066780|SCTN-BR9809|EU-98053","November 1, 1999","November 1998","null","November 5, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003679"
933,"NCT00090051","FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients","Completed","Has Results","Chronic Lymphocytic Leukemia","Drug: Rituximab|Drug: Fludarabine Phosphate|Drug: Cyclophosphamide","Hoffmann-La Roche|Biogen|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 3","552","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","102-14|BO17072","August 23, 2004","July 2003","June 2012","May 29, 2013","May 2013","December 22, 2009","null","July 2008","Progression-free Survival (PFS) as Assessed by the Independent Review Committee (IRC)|Number of Participants With Progression-free Survival (PFS) Events Assessed by the Independent Review Committee (IRC)|Final Analysis: Time to Progression-Free Survival Event|Overall Survival (OS)|Number of Participants With Overall Survival (OS) Events|Event-free Survival (EFS)|Number of Participants With Event-free Survival (EFS) Events|Disease-free Survival (DFS)|Number of Participants With Disease-free Survival (DFS) Events|Final Analysis: Time to Overall Survival Event|Final Analysis: Time to Event-Free Survival Event|Final Analysis: Percentage of Participants With Complete Response|Final Analysis: Time to Disease-Free Survival Event|Final Analysis: Duration of Response|Final Analysis: Time to New Chronic Lymphocytic Leukemia (CLL) Treatment","https://ClinicalTrials.gov/show/NCT00090051"
934,"NCT00753220","Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer","Terminated","Has Results","Prostate Cancer","Biological: VDC2008|Drug: Cyclophosphamide","Bostwick Laboratories|Prostate Institute of America|Community Memorial HealthCenter|HemaCare Corporation","Male","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","7","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CRITICAL001","September 12, 2008","August 2009","December 2011","November 3, 2014","November 2014","July 25, 2013","CRITICAL","May 2011","Maximum Tolerated Dose (MTD)","https://ClinicalTrials.gov/show/NCT00753220"
935,"NCT00003068","High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer","Completed","No Results Available","Breast Cancer|Drug/Agent Toxicity by Tissue/Organ","Drug: amifostine trihydrate|Drug: cyclophosphamide|Drug: mitoxantrone hydrochloride|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation","University of Arizona|National Cancer Institute (NCI)","All","16 Years to 70 Years   (Child, Adult, Senior)","Phase 2","30","Other","Interventional","Primary Purpose: Treatment","CDR0000065742|UARIZ-HSC-9728|ALZA-UARIZ-HSC-9728|NCI-V97-1329","November 1, 1999","June 1997","November 2002","January 30, 2013","May 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003068"
936,"NCT03123770","Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer","Drug: Pegylated liposomal doxorubicin|Drug: Cyclophosphamide|Drug: Epirubicin|Drug: Docetaxel","Zhejiang University|Second Affiliated Hospital, School of Medicine, Zhejiang University|First Affiliated Hospital of Zhejiang University|Sir Run Run Shaw Hospital|Women's Hospital School Of Medicine Zhejiang University|Zhejiang Cancer Hospital|Zhejiang Provincial People’s Hospital|Zhejiang Provincial Hospital of TCM|First People's Hospital of Hangzhou|Hangzhou Hospital of Traditional Chinese Medicine|First Affiliated Hospital of Wenzhou Medical Univeristy|Ningbo No. 1 Hospital|Jinhua Central Hospital","Female","18 Years to 70 Years   (Adult, Senior)","Phase 4","384","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ESNDBCP","April 14, 2017","December 2016","December 2021","April 18, 2017","April 2017","No Study Results Posted","ESNDBCP","December 2021","Pathological complete response rate|Side effects|Overall survival","https://ClinicalTrials.gov/show/NCT03123770"
937,"NCT00354419","Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant","Terminated","No Results Available","Aplastic Anemia","Radiation: total-body irradiation|Drug: cyclophosphamide|Biological: anti-thymocyte globulin|Drug: cyclosporine|Procedure: umbilical cord blood transplantation|Drug: mycophenolate mofetil|Procedure: bone marrow aspiration|Genetic: DNA analysis|Biological: filgrastim","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 40 Years   (Child, Adult)","Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2030.00|NCI-2010-00191","July 19, 2006","February 2006","null","January 3, 2011","January 2011","No Study Results Posted","null","December 2010","Toxicity|Engraftment","https://ClinicalTrials.gov/show/NCT00354419"
938,"NCT00399399","CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors","Unknown status","No Results Available","Churg-Strauss Syndrome","Drug: azathioprine|Drug: cyclophosphamide","Hospices Civils de Lyon","All","15 Years to 90 Years   (Child, Adult, Senior)","Phase 4","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","95.067","November 13, 2006","July 1996","null","November 13, 2006","November 2006","No Study Results Posted","null","null","Number of events (failures, relapses and/or deaths) occurring in each group, defining the disease-free survival rate, measured at study end (mean follow-up of 5 years)|Overall survival, relapse rate and adverse events, measured at study end (mean follow-up of 5 years)","https://ClinicalTrials.gov/show/NCT00399399"
939,"NCT00400075","CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors","Unknown status","No Results Available","Polyarteritis Nodosa|Microscopic Polyangiitis","Drug: azathioprine|Drug: cyclophosphamide","Hospices Civils de Lyon","All","15 Years to 90 Years   (Child, Adult, Senior)","Phase 4","124","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","95.067/2","November 14, 2006","July 1996","null","November 15, 2006","November 2006","No Study Results Posted","null","null","Number of events (failures, relapses and/or deaths) occurring in each group, defining the disease-free survival rate, measured at study end (mean follow-up of 5 years)|Overall survival, relapse rate and adverse events, measured at study end (mean follow-up of 5 years)","https://ClinicalTrials.gov/show/NCT00400075"
940,"NCT00944047","Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression","Active, not recruiting","No Results Available","Breast Cancer","Drug: nab-paclitaxel|Drug: trastuzumab|Drug: Doxorubicin|Drug: cyclophosphamide","University of Kansas Medical Center|Celgene Corporation","Female","18 Years and older   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","11368","July 16, 2009","July 2009","April 2017","January 20, 2017","January 2017","No Study Results Posted","null","January 2014","Pathologic Complete Response|Assessment of cardiac safety by comparing left ventricular ejection fraction by echocardiogram from baseline to completion of treatment and assessment of reduction in primary tumor size response after first two cycles of chemotherapy with pCR rate.","https://ClinicalTrials.gov/show/NCT00944047"
941,"NCT00787761","Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer","Completed","Has Results","Myeloproliferative Disorders|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methotrexate|Drug: tacrolimus|Procedure: nonmyeloablative allogeneic HSCT","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000618483|BMTGG-NSH-807","November 7, 2008","April 2007","May 2012","August 29, 2012","August 2012","July 9, 2012","null","July 2010","Achievement of > 90% (Full) Donor Chimerism in the T-cell Lineage as Measured by PCR at Day 30 Post-transplantation|T-cell and Myeloid Chimerism at Days 90 Post-transplantation (>90% Chimerism)|T-cell and Myeloid Chimerism at Days 180 Post-transplantation (>90%)|Number of Patients Who Experience Severe (Grade 3 or 4) Acute Graft-versus-host Disease|Number of Patients Experiencing Extensive Chronic Graft Versus Host Disease (GVHD)|Non-relapse Mortality (NRM) at Day 180 Post-transplantation|Disease-free Survival (DFS) at 24 Months|Overall Survival (OS) at 24 Months","https://ClinicalTrials.gov/show/NCT00787761"
942,"NCT02792491","Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over","Active, not recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone","Pusan National University Hospital","All","up to 65 Years   (Child, Adult)","Phase 2","57","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Elderly RD_R-CHOP","June 2, 2016","August 2012","December 2017","June 7, 2016","June 2016","No Study Results Posted","null","December 2017","3 year progression free survival rate|Overall response rate|Overall survival|Toxicity profile","https://ClinicalTrials.gov/show/NCT02792491"
943,"NCT01918124","A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer","Unknown status","No Results Available","Prosthesis Survival","Radiation: radiotherapy|Drug: Cisplatin|Drug: Cisplatin and Doxorubicin and Cyclophosphamide|Drug: Paclitaxel and Carboplatin","Fan Ming|Fudan University","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","070148-7","July 29, 2013","January 2008","January 2014","August 6, 2013","August 2013","No Study Results Posted","EC-0701","January 2014","Disease Free Survival(DFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT01918124"
944,"NCT01247701","Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies","Recruiting","No Results Available","Myeloid Hematological Malignancies","Drug: Busulfan|Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: Cord Blood Stem Cell Infusion","Baylor College of Medicine|Texas Children's Hospital|Center for Cell and Gene Therapy, Baylor College of Medicine","All","up to 17 Years   (Child)","","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","26558-UCAML","November 22, 2010","November 2010","November 2027","February 27, 2017","February 2017","No Study Results Posted","UCAML","November 2024","Overall survival at 1 year after UCB transplant in pediatric patients.|Number of participants with severe acute GVHD Grade III-IV as an assessment of safety.|Number of participants with chronic GvHD as an assessment of safety.|Assess relapse rate after transplant.|To evaluate donor engraftment after transplant.|Assessment of platelet count recovery.|Assessment of neutrophil count recovery.","https://ClinicalTrials.gov/show/NCT01247701"
945,"NCT02844062","Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme","Recruiting","No Results Available","Glioblastoma Multiforme","Biological: anti-EGFRvIII CAR T cells|Drug: cyclophosphamide|Drug: Fludarabine","Beijing Sanbo Brain Hospital|Marino Biotechnology Co., Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SBNK-2016-015-01","July 22, 2016","July 2016","July 2019","July 22, 2016","July 2016","No Study Results Posted","null","July 2018","Safety of infusion of autologous anti-EGFRvIII CAR T cells with cyclophosphamide and fludarabine as lymphodepleting chemotherapy in patients with recurrent glioblastoma using the NCI CTCAE V4.0 criteria.|Treatment Responses Rate|Overall Survival Rate|Progression-free Survival Rate|Persistence of CAR T cells in patients","https://ClinicalTrials.gov/show/NCT02844062"
946,"NCT02425306","Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma","Recruiting","No Results Available","Melanoma","Biological: 6MHP|Drug: Montanide ISA-51|Drug: polyICLC|Drug: Cyclophosphamide","Craig L Slingluff, Jr|Ludwig Institute for Cancer Research|Cancer Research Institute, New York City|University of Virginia","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","17860","April 20, 2015","May 2015","November 2017","January 24, 2017","January 2017","No Study Results Posted","Mel63; CHAMP","August 2017","Number of Adverse events|Immunogenicity-CD4+ T cell responses|Immunogenicity-modification of the tumor microenvironment (Part 2 only)|Immunogenicity-CD8+ T cell responses","https://ClinicalTrials.gov/show/NCT02425306"
947,"NCT02556931","Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies","Recruiting","No Results Available","Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Small Lymphocytic Lymphoma|Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Chronic Myeloid Leukemia|Chronic Myeloproliferative Disorders|Multiple Myeloma|Plasma Cell Neoplasm|Plasma Cell Dyscrasia|Myelofibrosis|Polycythemia Vera|Essential Thrombocythemia|Plasma Cell Leukemia","Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total body irradiation|Drug: Tacrolimus|Drug: Mycophenolate mofetil","Sidney Kimmel Comprehensive Cancer Center","All","Child, Adult, Senior","Phase 2","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","J15165|IRB00080399","September 21, 2015","December 2015","December 2019","April 11, 2017","April 2017","No Study Results Posted","null","March 2019","Percentage of participants who are able to stop prophylactic tacrolimus (D90 cohort)|Percentage of participants who are able to stop prophylactic tacrolimus (D60 cohort)|Incidence of grades III-IV acute GVHD, Days 90-180 (D90)|Incidence of grades III-IV acute GVHD, Days 60-180 (D60)|Incidence of chronic GVHD, Days 90-180 (D90)|Incidence of chronic GVHD, Days 60-180 (D60)|Incidence of graft failure, Days 90-180 (D90)|Incidence of graft failure, Days 60-180 (D60)|Incidence of relapse, Days 90-180 (D90)|Incidence of relapse, Days 60-180 (D60)|Incidence of non-relapse mortality, Days 90-180 (D90)|Incidence of non-relapse mortality, Days 60-180 (D60)|Incidence of grades III-IV acute GVHD, Day 360 (D90)|Incidence of grades III-IV acute GVHD, Day 360 (D60)|Incidence of chronic GVHD, Day 360 (D90)|Incidence of chronic GVHD, Day 360 (D60)|Incidence of graft failure, Day 360 (D90)|Incidence of graft failure, Day 360 (D60)|Incidence of relapse, Day 360 (D90)|Incidence of relapse, Day 360 (D60)|Incidence of non-relapse mortality, Day 360 (D90)|Incidence of non-relapse mortality, Day 360 (D60)","https://ClinicalTrials.gov/show/NCT02556931"
948,"NCT02025881","Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma","Recruiting","No Results Available","High-risk Medulloblastoma","Drug: Carboplatin + etoposide|Drug: Thiotepa|Drug: Cyclophosphamide + Busilvex","Gustave Roussy, Cancer Campus, Grand Paris","All","up to 5 Years   (Child)","Phase 1|Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-004842-14|2012/1908","December 30, 2013","September 2013","September 2022","June 8, 2016","June 2016","No Study Results Posted","HR MB-5","September 2018","Phase I - Maximum Tolerated Dose|Phase II - Event Free Survival|Radiotherapy-free survival without event|Overall Survival","https://ClinicalTrials.gov/show/NCT02025881"
949,"NCT00812669","CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7","Active, not recruiting","No Results Available","Leukemia","Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: fludarabine phosphate|Genetic: cytogenetic analysis|Genetic: fluorescence in situ hybridization|Genetic: gene expression analysis|Genetic: mutation analysis|Genetic: protein expression analysis|Other: flow cytometry|Other: laboratory biomarker analysis","Cancer Trials Ireland","All","up to 64 Years   (Child, Adult)","Phase 2","145","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CTRIAL-IE (ICORG) 07-01|2008-001250-40|EU-20898","December 19, 2008","August 2008","null","May 23, 2017","May 2017","No Study Results Posted","null","June 2021","Complete remission rate by NCI response criteria and minimal residual disease (MRD) analysis|Time to treatment failure (TFF)|Overall survival|Predictive value of immunophenotype, FISH, and hypermutation analysis in determining TTF and OS|Acute and chronic toxicity as assessed by NCI criteria","https://ClinicalTrials.gov/show/NCT00812669"
950,"NCT01292603","A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia","Active, not recruiting","Has Results","Lymphocytic Leukemia, Chronic","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: rituximab [MabThera]|Drug: rituximab [MabThera]|Drug: rituximab [MabThera]","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 1","240","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BO25341|2010-021380-32","February 8, 2011","April 18, 2011","November 14, 2017","April 13, 2017","April 2017","September 23, 2015","null","May 7, 2014","Part 1: Subcutaneous Rituximab Dose Resulting in Trough Concentration (Ctrough) Levels Non-Inferior to Intravenous Rituximab|Part 2: Rituximab C Trough Levels at Cycle 5|Part 2: Observed Area Under the Serum Concentration-Curve (AUC) of Rituximab at Cycle 6|Part 2: Maximum Observed Concentration (Cmax) of Rituximab at Cycle 6|Part 2: Time to Cmax (Tmax) of Rituximab at Cycle 6|Part 2: Terminal Half-Life of Rituximab at Cycle 6|Part 1: Percentage of Participants and Nurses Recording a Preference For Either SC or IV Administration|Part 2: Physician/Nurse Opinion on Time Savings With Rituximab SC Compared With Rituximab IV|Part 2: Physician/Nurse Opinion on Convenience of Rituximab SC Compared With Rituximab IV|Part 1: Percentage of Participants With Anti-Rituximab Antibodies|Part 2: Percentage of Participants With Anti-Rituximab Antibodies|Part 1: Total Cluster Differentiation19 Positive (CD19+) B-Cell Counts by Visit|Part 1: Percentage of Participants With Total B-Cell Depletion by Visit|Part 2: Total CD19+ B-Cell Counts by Visit|Part 2: Percentage of Participants With Total B-Cell Depletion by Visit","https://ClinicalTrials.gov/show/NCT01292603"
951,"NCT03142646","Safety and Efficacy Evaluation of IM19 CAR-T Cells","Recruiting","No Results Available","Leukemia","Biological: IM19 CAR-T","Beijing Immunochina Medical Science & Technology Co., Ltd.","All","4 Years to 65 Years   (Child, Adult)","Phase 1","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","001","June 6, 2016","August 30, 2016","October 1, 2018","May 4, 2017","April 2017","No Study Results Posted","IM19CAR-T","June 1, 2018","Occurrence of study related adverse events|Overall response rate","https://ClinicalTrials.gov/show/NCT03142646"
952,"NCT02863913","PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer","Not yet recruiting","No Results Available","Invasive Bladder Cancer Stage IV","Biological: PD-1 Knockout T Cells|Drug: Cyclophosphamide|Drug: IL-2","Peking University|Cell Biotech Co., Ltd.","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","11007965938","August 1, 2016","September 2016","September 2019","August 8, 2016","August 2016","No Study Results Posted","null","September 2019","Number of participants with Adverse Events and/or Dose Limiting Toxicities as a Measure of Safety and tolerability of dose of PD-1 Knockout T cells using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients|Response Rate:Response will be evaluated according to RECIST v1.1|Progression free survival - PFS|Overall Survival - OS|Peripheral blood circulating tumor DNA|Temporal Interleukin-2 change in the peripheral blood|Temporal Interferon-γ change in the peripheral blood|Temporal Interleukin-6 change in the peripheral blood","https://ClinicalTrials.gov/show/NCT02863913"
953,"NCT02867345","PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer","Not yet recruiting","No Results Available","Hormone Refractory Prostate Cancer","Biological: PD-1 Knockout T Cells|Drug: Cyclophosphamide|Drug: IL-2","Peking University|Cell Biotech Co., Ltd.","Male","45 Years to 85 Years   (Adult, Senior)","Phase 1","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","11007965939","August 11, 2016","November 2016","December 2020","August 12, 2016","August 2016","No Study Results Posted","null","November 2020","Number of participants with Adverse Events and/or Dose Limiting Toxicities as a Measure of Safety and tolerability of dose of PD-1 Knockout T cells using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients|Response Rate:Response will be evaluated according to RECIST v1.1|Progression free survival - PFS|Overall Survival - OS|Peripheral blood circulating tumor DNA|Temporal Interleukin-2 change in the peripheral blood|Temporal Interferon-γ change in the peripheral blood|Temporal Interleukin-6 change in the peripheral blood","https://ClinicalTrials.gov/show/NCT02867345"
954,"NCT01055496","Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma, B-Cell","Drug: inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone|Drug: inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone","Pfizer|UCB Pharma","All","18 Years and older   (Adult, Senior)","Phase 1","104","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","3129K2-1105|B1931003","January 21, 2010","March 2010","March 2014","March 31, 2014","March 2014","No Study Results Posted","null","July 2013","To determine the tolerability, the initial safety profile, as evaluated by an analysis of laboratory results and adverse event (AE) reporting.|Determination of MTD or recommended dose of the immunochemotherapeutic regimens R-CVP or R-GDP given in combination with inotuzumab ozogamicin in subjects with CD22-positive NHL.|To obtain preliminary information on the antitumor activity of R-CVP or R-GDP in combination with inotuzumab ozogamicin as measured by ORR, progression-free survival, and overall survival data in MTD confirmation/expanded efficacy cohorts|To evaluate PK of 0.8 mg/m2 of inotuzumab ozogamicin when combined with R CVP or with R-GDP|To develop a molecular predictor of response to inotuzumab ozogamicin plus R-CVP or R-GDP.","https://ClinicalTrials.gov/show/NCT01055496"
955,"NCT02867332","PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.","Not yet recruiting","No Results Available","Metastatic Renal Cell Carcinoma","Biological: PD-1 Knockout T Cells|Drug: Cyclophosphamide|Drug: IL-2","Peking University|Cell Biotech Co., Ltd.","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","11007965940","August 11, 2016","November 2016","November 2020","August 11, 2016","August 2016","No Study Results Posted","null","November 2020","Number of participants with Adverse Events and/or Dose Limiting Toxicities as a Measure of Safety and tolerability of dose of PD-1 Knockout T cells using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients|Response Rate:Response will be evaluated according to RECIST v1.1|Progression free survival - PFS|Overall Survival - OS|Peripheral blood circulating tumor DNA|Temporal Interleukin-2 change in the peripheral blood|Temporal Interferon-γ change in the peripheral blood|Temporal Interleukin-6 change in the peripheral blood","https://ClinicalTrials.gov/show/NCT02867332"
956,"NCT03006302","Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer","Not yet recruiting","No Results Available","Metastatic Pancreatic Adenocarcinoma","Drug: Epacadostat|Drug: Pembrolizumab|Biological: CRS-207|Drug: CY|Biological: GVAX","Sidney Kimmel Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","J16173|IRB00118520","December 28, 2016","June 2017","June 2023","May 3, 2017","May 2017","No Study Results Posted","null","February 2021","Recommended Dose of Epacadostat|6 Month Survival|Number of patients experiencing treatment related toxicities|Overall Survival (OS)|Progression Free Survival (PFS)|immune-related Progression Free Survival (irPFS)|Objective Response Rate (ORR)|immune-related Objective Response Rate (irORR)|Best Overall Response (BOR)|immune-related Best Overall Response (irBOR)|Time to Objective Response (TTOR)|immune-related Time to Objective Response (irTTOR)|Duration of Response (DOR)|immune-related Duration of Response (irDOR)|Duration of Clinical Benefit (DCB)|immune-related Duration of Clinical Benefit (irDCB)|Disease Control Rate (DCR)|immune-related Disease Control Rate (irDCR)|Tumor Marker (CA19-9) Kinetics","https://ClinicalTrials.gov/show/NCT03006302"
957,"NCT03029273","NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC","Recruiting","No Results Available","Lung Cancer, Nonsmall Cell, Recurrent","Drug: Cyclophosphamide|Biological: Anti-NY-ESO-1 TCR transduced T cells","Guangzhou Institute of Respiratory Disease|Xiangxue Life Science Research Center|Guangdong Xiangxue Precision Medical Technology Co., Ltd|Guangzhou Xiangxue Pharmaceutical Co., Ltd","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2016-63","January 20, 2017","March 2017","December 2017","January 20, 2017","January 2017","No Study Results Posted","null","December 2017","Number of participants with adverse events|Number of participants with clinical responses","https://ClinicalTrials.gov/show/NCT03029273"
958,"NCT01240538","Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors","Completed","No Results Available","Unspecified Childhood Solid Tumor, Protocol Specific","Biological: wild-type reovirus|Drug: cyclophosphamide|Other: laboratory biomarker analysis|Other: pharmacological study","National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 1","26","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-02617|CDR0000688938|ADVL1014|U01CA097452","November 11, 2010","December 2010","null","May 9, 2014","January 2014","No Study Results Posted","null","April 2014","Maximum-tolerated dose (MTD), defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicity (DLT), graded using the NCI CTCAE v. 4.0|Time course of viral clearance of wild-type reovirus|Development of neutralizing antibodies to wild-type reovirus|Disease response, assessed according to Response Evaluation Criteria in Solid Tumors (RECIST)","https://ClinicalTrials.gov/show/NCT01240538"
959,"NCT03159585","To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Solid Tumors","Recruiting","No Results Available","Bone Sarcoma|Soft Tissue Sarcoma|Melanoma|Liver Cancer|Esophageal Cancer|Breast Cancer|Thyroid Cancer|Ovarian Cancer","Drug: Cyclophosphamide|Biological: TAEST16001","Zhujiang Hospital|Xiangxue Life Science Research Center|Guangdong Xiangxue Precision Medical Technology Co., Ltd|Guangzhou Xiangxue Pharmaceutical Co., Ltd","All","14 Years to 75 Years   (Child, Adult, Senior)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","TS20161229","May 15, 2017","June 1, 2017","May 31, 2019","May 17, 2017","May 2017","No Study Results Posted","null","May 31, 2019","adverse events|clinical response rate","https://ClinicalTrials.gov/show/NCT03159585"
960,"NCT00615173","Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus Nephritis","Completed","No Results Available","Kidney Diseases|Lupus Nephritis|Tacrolimus|Induction Phase|Maintenance Phase","Drug: tacrolimus (FK506)|Drug: cyclophosphamide or azathioprine","Sun Yat-sen University","All","14 Years to 65 Years   (Child, Adult)","Phase 3","81","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SYSU-PRGLN-001","February 1, 2008","July 2006","September 2008","October 27, 2008","October 2008","No Study Results Posted","null","September 2008","Remission rate|Renal function, proteinuria, relapse.","https://ClinicalTrials.gov/show/NCT00615173"
961,"NCT00377637","A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.","Completed","Has Results","Lupus Nephritis","Drug: Mycophenolate mofetil (MMF)|Drug: Cyclophosphamide|Drug: Azathioprine|Drug: Placebo to Azathioprine|Drug: Placebo to Mycophenolate mofetil|Drug: Corticosteroid","Hoffmann-La Roche|Aspreva Pharmaceuticals","All","12 Years to 75 Years   (Child, Adult, Senior)","Phase 3","370","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","WX17801","September 15, 2006","July 2005","March 2010","October 31, 2011","October 2011","August 11, 2011","null","March 2007","Induction Phase: Number of Patients Showing Treatment Response|Maintenance Phase: Kaplan-Meier Estimates of Percentage of Participants Treatment Failure Free, by Time Interval|Induction Phase: Number of Participants Achieving Complete Remission|Induction Phase: Change From Baseline to Week 24 in Serum Creatinine|Induction Phase: Change From Baseline to Week 24 in 24-hour Urine Protein|Induction Phase: Change From Baseline to Week 24 in Serum Albumin|Induction Phase: Change in Renal British Isles Lupus Assessment Group (BILAG) Score|Induction Phase: Change From Baseline in Short-Form Health Survey (SF-36) Domain and Component Scores|Maintenance Phase: Events Contributing to the Primary Endpoint: Number of Deaths|Maintenance Phase: Events Contributing to the Primary Endpoint: Number of Participants With End-stage Renal Disease (ESRD)|Maintenance Phase: Events Contributing to the Primary Endpoint: Number of Participants With Sustained Doubling of Serum Creatinine|Maintenance Phase: Events Contributing to the Primary Endpoint: Kaplan-Meier Estimates of Percentage of Participants Renal Flare Free, by Time Interval|Maintenance Phase: Events Contributing to the Primary Endpoint: Kaplan-Meier Estimates of Percentage of Participants Not Receiving Rescue Therapy|Maintenance Phase: Participants With Major Extra-renal Flare","https://ClinicalTrials.gov/show/NCT00377637"
962,"NCT00070447","Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma","Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: yttrium Y 90 ibritumomab tiuxetan","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000334470|ECOG-E1499","October 3, 2003","November 2003","June 2006","January 27, 2014","October 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00070447"
963,"NCT00005898","Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia","Completed","No Results Available","Fanconi's Anemia","Drug: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: filgrastim|Drug: fludarabine|Drug: methylprednisolone","University of Minnesota - Clinical and Translational Science Institute|Office of Rare Diseases (ORD)","All","up to 34 Years   (Child, Adult)","Phase 1|Phase 2","30","Other","Interventional","Primary Purpose: Treatment","199/15109|UMN-MT-1999-05|UMN-MT9905","June 2, 2000","February 2000","null","June 23, 2005","July 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005898"
964,"NCT00739141","Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.","Recruiting","No Results Available","Leukemia|Myelodysplastic Syndrome|Non-Hodgkins Lymphoma|Chronic Myelogenous Leukemia|Hodgkins Lymphoma","Other: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft","Memorial Sloan Kettering Cancer Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08-087","August 19, 2008","August 2008","August 2017","December 7, 2016","December 2016","No Study Results Posted","null","August 2017","To obtain a preliminary estimate of disease-free survival at 1 year post UCBT.|The speed of neutrophil and platelet recovery post allograft|The incidence and speed of donor-derived engraftment and contribution of each UCB unit to engraftment.","https://ClinicalTrials.gov/show/NCT00739141"
965,"NCT00121134","Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Bevacizumab|Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Capecitabine","Harold J. Burstein, MD, PhD|Genentech, Inc.|Beth Israel Deaconess Medical Center|Indiana University School of Medicine|University of California, San Francisco|University of North Carolina|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Senior)","","164","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","05-055","July 13, 2005","June 2005","May 2011","November 26, 2013","November 2013","August 8, 2013","null","May 2009","The Completion Rate of 1 Year of Bevacizumab Therapy for All Four Cohorts","https://ClinicalTrials.gov/show/NCT00121134"
966,"NCT01444118","A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients","Terminated","No Results Available","Carcinoma, Non-Small-Cell Lung","Biological: Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)","Bioven Europe|Bioven Sdn. Bhd.","All","20 Years to 65 Years   (Adult)","Phase 3","null","Industry","Interventional","Masking: Open Label","BV-NSCLC-001","September 29, 2011","November 2011","December 2014","July 20, 2015","July 2015","No Study Results Posted","NSCLC","December 2014","Overall Survival (OS)|To establish the safety of an EGF cancer vaccine in inoperable, late stage (IIIb/IV) NSCLC patients.","https://ClinicalTrials.gov/show/NCT01444118"
967,"NCT03030976","A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)","Recruiting","No Results Available","Systemic Lupus Erythematosus (SLE)","Drug: cyclophosphamide|Drug: anti-CD19-CAR-T cells","Shanghai GeneChem Co., Ltd.|RenJi Hospital","All","18 Years to 69 Years   (Adult, Senior)","Phase 1","5","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CD19-CART for SLE","January 22, 2017","March 2017","March 2018","February 4, 2017","January 2017","No Study Results Posted","null","January 2018","Safety of CAR-T cell（i.v.）by number of patients with adverse event|Number of patients with tumor response|3. Detection of transferred T cells in the circulation using quantitative -PCR","https://ClinicalTrials.gov/show/NCT03030976"
968,"NCT00002594","Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors","Completed","No Results Available","Brain Tumor|Central Nervous System Tumor","Biological: Sargramostim|Drug: cyclophosphamide|Drug: melphalan|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","Children's Oncology Group|National Cancer Institute (NCI)","All","2 Years to 25 Years   (Child, Adult)","Phase 2","31","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9430|COG-P9430|POG-9430|CDR0000063784","November 1, 1999","September 1994","March 2007","July 23, 2014","July 2014","No Study Results Posted","null","September 2003","Progression-free survival","https://ClinicalTrials.gov/show/NCT00002594"
969,"NCT03003520","A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma","Recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: Durvalumab|Drug: Rituximab|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Lenalidomide","Celgene","All","18 Years and older   (Adult, Senior)","Phase 2","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","MEDI4736-DLBCL-001|2015-005173-20","December 22, 2016","February 28, 2017","July 1, 2024","May 19, 2017","May 2017","No Study Results Posted","null","June 22, 2021","Progression Free Survival at 24 months|Treatment-Emergent Adverse Events (AEs)|Clinical response to study treatment in biomarker-defined subpopulations","https://ClinicalTrials.gov/show/NCT03003520"
970,"NCT03003676","A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade","Recruiting","No Results Available","Advanced or Unresectable Melanoma Progressing After PD1 Blockade","Biological: ONCOS-102|Drug: Cyclophosphamide|Drug: Pembrolizumab","Targovax Oy|Targovax ASA","All","18 Years and older   (Adult, Senior)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ONCOS C824","December 19, 2016","December 2016","null","January 10, 2017","January 2017","No Study Results Posted","null","July 2018","Safety of sequential treatment with ONCOS-102 followed by pembrolizumab by assessment of laboratory parameters (routine haematology and biochemistry), vital signs and recording of adverse events.|Objective response rates by RECIST 1.1 and irRECIST.|Changes in immune cell subsets in tumor tissue before and after ONCOS-102 and pembrolizumab.|Changes in immune cell subsets in peripheral blood before and after ONCOS-102 and pembrolizumab.|Correlation of Tumour Infiltrating Lymphocytes (TILs) and Overall Response Rate (ORR).|Progression Free Survival (PFS) assessed by RECIST 1.1 and irRECIST.|Clinical benefit rate, defined as any confirmed objective response by RECIST 1.1 or stable disease.|Clinical benefit rate, defined as any objective response by irRECIST criteria or immune-related stable disease.|Change in size in individual lesions.","https://ClinicalTrials.gov/show/NCT03003676"
971,"NCT01279902","Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL","Active, not recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Rituximab plus CHOP Immunochemotherapy","Asan Medical Center","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC_NHL01","August 3, 2010","August 2010","January 2017","July 25, 2016","July 2016","No Study Results Posted","null","August 2016","Disease-free survival|Overall survival|any adverse events as a measure of safety and tolerability","https://ClinicalTrials.gov/show/NCT01279902"
972,"NCT02648282","Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer","Recruiting","No Results Available","Pancreatic Cancer","Drug: Cyclophosphamide|Drug: GVAX|Drug: Pembrolizumab|Radiation: SBRT","Sidney Kimmel Comprehensive Cancer Center|Merck Sharp & Dohme Corp.","All","18 Years to 100 Years   (Adult, Senior)","Phase 2","54","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","J15237|IRB00083132","January 5, 2016","July 2016","July 2020","March 21, 2017","March 2017","No Study Results Posted","null","July 2020","Distant Metastasis Free Survival (DMFS)|Overall Survival (OS)|Local Progression Free Survival (LPFS)|Number of participants experiencing immune-related toxicities (IRAEs)","https://ClinicalTrials.gov/show/NCT02648282"
973,"NCT00024102","Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Standard Treatment|Drug: capecitabine","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|NCIC Clinical Trials Group","Female","65 Years and older   (Adult, Senior)","Phase 3","633","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-49907|U10CA031946|CAN-NCIC-MAC1|CDR0000068891","September 13, 2001","September 2001","November 2012","July 12, 2016","July 2016","November 20, 2012","null","May 2008","Relapse-free Survival Rates at 2.4 Years|Overall Survival Rate at 2.4 Years|Number of Participants With Grade 3, 4 or 5 Adverse Event at Least Possibly Related to Treatment.","https://ClinicalTrials.gov/show/NCT00024102"
974,"NCT02980965","Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer Female","Drug: letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel|Drug: fluorouracil, epirubicin, cyclophosphamide, docetaxel","Fudan University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","213","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCET-trial","November 26, 2016","May 2013","May 2018","November 30, 2016","November 2016","No Study Results Posted","null","December 2016","objective response rate (ORR)|Ki67 proliferation marker changes|pathologic complete response (pCR)|Miller-Payne based response rate|Disease-free survival (DFS)","https://ClinicalTrials.gov/show/NCT02980965"
975,"NCT02994927","A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis","Recruiting","No Results Available","ANCA-Associated Vasculitis","Drug: CCX168|Drug: Prednisone|Drug: Cyclophosphamide|Biological: Rituximab|Drug: Azathioprine","ChemoCentryx","All","18 Years and older   (Adult, Senior)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","CL010_168","December 11, 2016","December 2016","October 2019","May 15, 2017","May 2017","No Study Results Posted","ADVOCATE","June 2019","Remission|Sustained remission|Adverse events coded by MedDRA|Glucocorticoid-induced toxicity|Response rapidity|Health-related quality of life|Estimated glomerular filtration rate (eGFR)|Urinary albumin:creatinine ratio (UACR)|Urinary monocyte chemoattractant protein-1 (MCP-1):creatinine ratio|Vasculitis Damage Index","https://ClinicalTrials.gov/show/NCT02994927"
976,"NCT01082133","Multicenter Transplant Study for Fanconi Anemia","Completed","No Results Available","Fanconi Anemia","Drug: Chemotherapy|Biological: Miltenyi CliniMACS","Children's Hospital Medical Center, Cincinnati","All","Child, Adult, Senior","Phase 2","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Multicenter FA SCT","March 5, 2010","October 2009","July 2015","June 28, 2016","June 2016","No Study Results Posted","null","July 2015","The primary objectives are: The incidence and quality of engraftment and hematopoietic reconstitution. The incidence of early transplant related mortality The incidence and severity of acute GvHD (graft versus host disease) and chronic GvHD.|The incidence of overall survival and disease free survival over time.","https://ClinicalTrials.gov/show/NCT01082133"
977,"NCT00556192","Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus","Completed","No Results Available","Systemic Lupus Erythematosus","Drug: rituximab","Chinese University of Hong Kong","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SLE-2005-006","November 8, 2007","June 2006","December 2009","February 10, 2012","February 2012","No Study Results Posted","null","December 2009","-Estimated glomerular filtration rate(FRR) of >90 mil/minute.1.73m2 -Urinary protein:urinary creatinine ratio of <0.2 -Inactive urinary sediment|-The estimated GFR,urinary protein values and urinary sediment -Changes in disease activity score(SLEDAI) -Other clinical features -Duration of B-cell depletion","https://ClinicalTrials.gov/show/NCT00556192"
978,"NCT00787527","SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma","Completed","Has Results","Lymphoma","Drug: Zolinza (vorinostat)|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-0484","November 6, 2008","November 2008","December 2012","September 2, 2014","September 2014","September 2, 2014","null","December 2012","Phase I Maximum Tolerated Dose (MTD) of Vorinostat|Number of Participants With Dose Limiting Toxicity for Determination Phase I (Schedule A) MTD of Vorinostat|Phase II MTD of Vorinostat","https://ClinicalTrials.gov/show/NCT00787527"
979,"NCT00281983","Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia","Completed","No Results Available","Chronic Lymphocytic Leukemia","Biological: alemtuzumab|Biological: anti-thymocyte globulin|Biological: filgrastim|Biological: rituximab|Biological: therapeutic allogeneic lymphocytes|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: methotrexate|Drug: mycophenolate mofetil|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","German CLL Study Group","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CLL3X|EU-20554|MEDAC-FLUD.10/CLL","January 24, 2006","June 2000","July 2010","February 23, 2017","April 2007","No Study Results Posted","null","null","Feasibility as measured by the proportion of eligible patients completing the transplant procedure successfully|Safety as measured by a treatment-related mortality of < 25% at 2 years following transplant|Clinical remission rate by NIH criteria at 12 months following transplant|Minimal residual disease negativity rate as measured by high-resolution flow or CDR PCR at 12 months following transplant|Chimerism as measured by STR-PCR at 12 months following transplant|Event-free and overall survival at 5 years following transplant","https://ClinicalTrials.gov/show/NCT00281983"
980,"NCT00002628","Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: mesna|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation","St. Louis University|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","50","Other","Interventional","Primary Purpose: Treatment","CDR0000064017|SLUMC-7915|NCI-V95-0608","November 1, 1999","November 1994","null","January 9, 2014","April 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002628"
981,"NCT01275677","Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","Active, not recruiting","No Results Available","Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Positive|Progesterone Receptor Negative|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIC Breast Cancer","Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Other: Quality-of-Life Assessment|Biological: Trastuzumab","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","3260","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2011-02572|NSABP-B-47|CDR0000692574|U10CA012027|U10CA180868","January 11, 2011","January 6, 2011","null","May 24, 2017","May 2017","No Study Results Posted","null","August 31, 2017","IDFS|BCFS|Change in HER2 mRNA level|DFS-DCIS|DRFI|Fcgamma receptor polymorphism|Incidence of adverse events using the National Cancer Institute CTCAE v4.0|OS|RFI","https://ClinicalTrials.gov/show/NCT01275677"
982,"NCT00959231","Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease","Unknown status","No Results Available","Hematopoietic/Lymphoid Cancer","Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Other: laboratory biomarker analysis|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: total-body irradiation","Cancer Research UK|National Cancer Institute (NCI)","All","2 Years to 60 Years   (Child, Adult)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000643641|CRUK-UCL-RIC-UCBT|EUDRACT-2004-003845-41|EU-20946","August 13, 2009","January 2009","null","August 23, 2013","April 2010","No Study Results Posted","null","August 2012","Non-relapse mortality at day 100|Incidence of grades II-IV and III-IV acute graft-vs-host disease (GVHD) at day 100 and chronic GVHD at 1 year|Mixed chimerism|Hemopoietic recovery","https://ClinicalTrials.gov/show/NCT00959231"
983,"NCT00194779","Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery","Completed","No Results Available","Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|HER2-positive Breast Cancer|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer","Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Drug: paclitaxel|Biological: filgrastim|Drug: capecitabine|Drug: methotrexate|Drug: vinorelbine tartrate|Procedure: needle biopsy|Procedure: therapeutic conventional surgery|Other: immunohistochemistry staining method|Biological: trastuzumab|Drug: tamoxifen citrate|Drug: letrozole|Other: laboratory biomarker analysis","University of Washington|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","50","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","6278|NCI-2011-00934","September 13, 2005","October 2003","null","May 7, 2013","May 2013","No Study Results Posted","null","June 2010","Combined rate of microscopic pCR and macroscopic pathologic complete response (mCR)|Number and percent of patients reporting grade 2, 3, 4, or fatal toxicities of these regimens, need for dose reduction, or treatment interruption or discontinuation|Correlation of molecular markers with response|Relapse rate in patients with operable breast cancer treated with neoadjuvant chemotherapy for 12 weeks followed by weekly paclitaxel for 12 weeks and adjuvant chemotherapy|Time to progression|OS in patients with operable breast cancer treated with neoadjuvant chemotherapy for 12 weeks followed weekly paclitaxel for 12 weeks and adjuvant chemotherapy with XMN|Disease-free survival|Clinical response to neoadjuvant therapy|Clinical response to paclitaxel|Clinical response to adjuvant therapy","https://ClinicalTrials.gov/show/NCT00194779"
984,"NCT03022123","The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma","Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: PL-doxorubicin and epirubicin","Hebei Medical University Fourth Hospital","Female","18 Years to 65 Years   (Adult)","","270","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CSPC-DMS- DLBCL -02","January 9, 2017","November 2016","March 2018","January 13, 2017","October 2016","No Study Results Posted","null","November 2017","overall response rate","https://ClinicalTrials.gov/show/NCT03022123"
985,"NCT00151281","Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma","Unknown status","No Results Available","Non-Hodgkin's Lymphoma","Drug: Rituximab, Thalidomide, Prednisone, Etoposide, Procarbazine, Cyclophosphamide","Weill Medical College of Cornell University","All","18 Years and older   (Adult, Senior)","Phase 2","46","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","047080073974","September 6, 2005","November 2004","December 2009","June 16, 2010","June 2010","No Study Results Posted","null","December 2009","effect of drug combination on mantle cell lymphoma","https://ClinicalTrials.gov/show/NCT00151281"
986,"NCT02489448","Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer","Recruiting","No Results Available","Breast Neoplasms","Drug: MEDI4736","Yale University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","61","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1409014537","July 1, 2015","November 2015","October 2019","July 12, 2016","July 2016","No Study Results Posted","null","October 2018","Pathologic Complete Response (pCR)","https://ClinicalTrials.gov/show/NCT02489448"
987,"NCT00119262","Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer","Completed","Has Results","Male Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer","Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Biological: bevacizumab|Drug: paclitaxel|Biological: filgrastim|Biological: pegfilgrastim|Radiation: radiation therapy|Drug: tamoxifen citrate|Drug: aromatase inhibition therapy","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","226","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02977|U10CA021115|E2104","July 12, 2005","October 2005","September 2009","April 29, 2014","December 2012","April 4, 2011","null","August 2009","Congestive Heart Failure Rate|Proportion of Patients With Absolute Decrease in Left Ventricular Ejection Fraction (LVEF) Levels Post Doxorubicin and Cyclophosphamide(AC)|Proportion of Patients With Absolute Decrease in LVEF Levels Post Bevacizumab","https://ClinicalTrials.gov/show/NCT00119262"
988,"NCT00007813","Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors","Unknown status","No Results Available","Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Liver Cancer|Neuroblastoma|Ovarian Cancer|Sarcoma|Testicular Germ Cell Tumor","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","up to 35 Years   (Child, Adult)","Phase 1","36","Other","Interventional","Primary Purpose: Treatment","CDR0000064263|JHOC-9512|NCI-V95-0688","January 6, 2001","May 1995","null","February 6, 2009","December 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00007813"
989,"NCT00002521","Combination Chemotherapy and Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Procedure: syngeneic bone marrow transplantation|Radiation: radiation therapy","Temple University","All","15 Years to 70 Years   (Child, Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000078282|TUHSC-2161|NCI-V93-0248","November 1, 1999","February 1993","February 2000","September 30, 2010","September 2010","No Study Results Posted","null","February 2000","","https://ClinicalTrials.gov/show/NCT00002521"
990,"NCT00003927","Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Biological: filgrastim|Drug: amifostine trihydrate|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 59 Years   (Adult)","","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","99002|P30CA033572|CHNMC-IRB-99002|ALZA-CHNMC-IRB-99002|NCI-G99-1527|CDR0000067115","November 1, 1999","April 22, 1999","January 2018","April 24, 2017","April 2017","No Study Results Posted","null","January 2018","Feasibility of high dose chemotherapy in advance breast cancer patients.","https://ClinicalTrials.gov/show/NCT00003927"
991,"NCT00679029","Combination Chemotherapy and Bevacizumab in Treating Women With HER2/Neu-Negative Stage II or Stage III Breast Cancer","Unknown status","No Results Available","HER2-negative Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer","Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Biological: bevacizumab|Drug: paclitaxel|Drug: gemcitabine hydrochloride|Other: laboratory biomarker analysis|Biological: pegfilgrastim","University of Nebraska|National Cancer Institute (NCI)","Female","19 Years and older   (Adult, Senior)","Phase 2","26","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","412-07|NCI-2009-01693|P30CA036727","May 15, 2008","May 2008","null","August 8, 2011","August 2011","No Study Results Posted","null","December 2013","Feasibility as assessed by the proportion of patients with study drug-associated adverse events leading to dose holds or reductions summarized using percentages and 95% confidence intervals|Toxicity as assessed by NCI Common Toxicity Criteria v3.0|Disease-free survival as assessed by the Kaplan and Meier method|Overall survival as assessed by the Kaplan and Meier method","https://ClinicalTrials.gov/show/NCT00679029"
992,"NCT00349674","WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides","Unknown status","No Results Available","Systemic Wegener's Granulomatosis","Drug: Azathioprine: 2 mg/kg/day|Drug: methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week","Hospices Civils de Lyon","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","126","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","97.129","July 6, 2006","January 1999","null","October 9, 2007","October 2007","No Study Results Posted","null","null","Safety/Efficacy|Frequency of severe adverse events in each arm. Hypothesis based upon NIH data was a rate of 6% severe adverse event with methotrexate compared to 30% with azathioprine (24% in one study on RA and 46% in one study on Sjögren syndrome).|Evaluation was planned after the last included patient has completed the assigned trial regimen (after 12 months of maintenance regimen or because of drug withdrawal).|Relapse-free survival rate.|Cumulative event-free survival rate (adverse event- and relapse-free survival rate).|Health quality assessment using HAQ and SF36.|Efficacy of induction therapy with pulsed cyclophosphamide.|Second evaluation of the same outcome parameters is planned 5 years after the last included patient has completed the assigned trial regimen.","https://ClinicalTrials.gov/show/NCT00349674"
993,"NCT02572596","Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients","Recruiting","No Results Available","Multiple Myeloma","Drug: rhTPO|Drug: CTX|Drug: -CSF","Wang Guorong|Beijing Chao Yang Hospital","All","10 Years to 70 Years   (Child, Adult, Senior)","","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","MM-TPO-01","September 17, 2015","January 1, 2013","December 31, 2018","February 8, 2017","February 2017","No Study Results Posted","null","December 31, 2017","Number of CD34+ stem/progenitor cells that are mobilized|rate of mobilization success|rate of mobilization optimal","https://ClinicalTrials.gov/show/NCT02572596"
994,"NCT00134017","Combination Chemotherapy, Tacrolimus, and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant For Hematologic Cancer","Active, not recruiting","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: busulfan|Drug: cyclophosphamide|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: bone marrow ablation with stem cell support","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","92","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0373 CDR0000440164|P01CA015396|P30CA006973|JHOC-03121504|JHOC-J0373","August 22, 2005","May 2004","null","October 17, 2016","October 2016","No Study Results Posted","null","April 2017","Dose Finding|Immune reconstitution and disease control","https://ClinicalTrials.gov/show/NCT00134017"
995,"NCT00256243","Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer","Completed","Has Results","Inflammatory Breast Cancer|Locally Advanced Breast Cancer","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Paclitaxel|Drug: Carboplatin|Drug: GM-CSF|Drug: Trastuzumab","University of California, Irvine","Female","18 Years and older   (Adult, Senior)","Phase 2","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCI 03-70|2004-3517","November 17, 2005","April 2004","July 2012","January 28, 2014","January 2014","August 28, 2009","null","March 2011","Clinical Response Rate|Microscopic Pathological Response Rate","https://ClinicalTrials.gov/show/NCT00256243"
996,"NCT00354172","Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.","Terminated","Has Results","Leukemia|Myelodysplastic Syndromes","Biological: aldesleukin|Biological: filgrastim|Biological: natural killer cell (NK) therapy|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: methylprednisolone|Drug: mycophenolate mofetil|Procedure: Umbilical Cord Blood Transplantation (UCBT)|Radiation: Total body irradiation (TBI)","Masonic Cancer Center, University of Minnesota","All","up to 45 Years   (Child, Adult)","Phase 2","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMN-2005LS058|MT2005-18|0509M73449","July 19, 2006","February 2006","August 2008","November 6, 2012","November 2012","November 30, 2009","null","August 2008","Number of Participants (Patients) Who Were Disease-free and Alive at 6 Months|Number of Participants (Patients) Who Were Disease-free and Alive at 12 Months|Number of Patients Who Were Disease-free and Alive at 24 Months|Number of Participants (Patients) Who Died Due to Transplant.|Number of Participants (Patients) Who Attained Neutrophil Engraftment|Number of Participants (Patients) Who Attained Platelet Engraftment|Number of Participants (Patients) With Acute Graft-versus-host Disease (GVHD) Grade II-IV|Number of Participants (Patients) With Acute Graft-versus-Host Disease at Grade III-IV|Number of Participants (Patients) With Chronic Graft-Versus-Host Disease|Number of Participants (Patients) Who Died by 12 Months|Number of Participants (Patients) Who Died by 24 Months|Number of Participants (Patients) Who Experienced Relapse by 12 Months|Number of Participants (Patients) Who Experienced Relapse by 24 Months|Number of Participants (Patients) With Successful Natural Killer Cell Expansion|Chimerism After Double Umbilical Cord Blood Transplant (UCBT)","https://ClinicalTrials.gov/show/NCT00354172"
997,"NCT00612716","Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia","Recruiting","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm","Drug: busulfan|Drug: cyclophosphamide|Biological: Stem cell infusion|Radiation: Total body irradiation","Masonic Cancer Center, University of Minnesota","All","up to 55 Years   (Child, Adult)","Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","1999LS060|9909M18181|UMN-MT1999-14","February 9, 2008","October 6, 1999","December 2020","February 17, 2017","February 2017","No Study Results Posted","null","December 2017","Engraftment failure|Time to engraftment|Incidence and severity of acute graft-versus-host disease|Persistence or relapse of malignancy|Overall Survival|Incidence and severity of chronic GVHD.","https://ClinicalTrials.gov/show/NCT00612716"
998,"NCT02280694","Low Dose Metronomic Poly-chemotherapy for Metastatic CRC","Recruiting","No Results Available","Colorectal Cancer","Drug: Capecitabine|Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Celecoxib","HaEmek Medical Center, Israel","All","18 Years to 85 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0035-14-EMC","October 29, 2014","January 2015","January 2018","March 30, 2016","March 2016","No Study Results Posted","LDMchemoCRC","January 2018","The median progression free survival (mPFS)","https://ClinicalTrials.gov/show/NCT02280694"
999,"NCT00968162","Sickle Cell Disease Conditioning for Bone Marrow Transplant","Completed","No Results Available","Bone Marrow Transplantation|Sickle Cell Disease","Drug: fludarabine","Emory University","All","up to 18 Years   (Child, Adult)","Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IRB00011048|BMT for SCD","August 11, 2009","February 2009","January 11, 2016","January 25, 2017","January 2017","No Study Results Posted","null","March 2014","Modify the standard dose of busulfan, cyclophosphamide and anti-thymocyte globulin conditioning regimen by adding fludarabine in order to determine the feasibility of reducing the total dose of cyclophosphamide from its present standard of 200 mg/kg.|To gain insight into the processes that give rise to neurologic problems following bone marrow transplantation and to develop surrogate outcomes.","https://ClinicalTrials.gov/show/NCT00968162"
1000,"NCT00004218","Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Drug: chlorambucil|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: fludarabine phosphate|Drug: prednisolone|Drug: vincristine sulfate","Leukemia Research Fund|Medical Research Council|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000067454|LRF-CLL4|LRG-MRC-LEUK-CLL4|EU-99030|MRC-LEUK-CLL4|EUDRACT-58585610|ISRCTN58585610","January 28, 2000","October 1999","July 2007","December 17, 2013","January 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004218"
1001,"NCT00525876","Non-Myeloablative Allogeneic Stem Cell Transplantation","Completed","Has Results","Lymphoma","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Rituximab|Drug: Alemtuzumab|Procedure: Allogeneic Stem Cell Infusion","M.D. Anderson Cancer Center","All","up to 70 Years   (Child, Adult, Senior)","","49","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-0309","September 4, 2007","January 2005","September 2010","November 2, 2011","November 2011","November 2, 2011","null","September 2010","Overall Survival at 100 Days Post Transplant (Number of Surviving Participants)","https://ClinicalTrials.gov/show/NCT00525876"
1002,"NCT02766868","Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse ALL","Recruiting","No Results Available","Lymphoblastic Leukemia, Acute, Adult","Drug: FACE-Flu/Bu/Cy","Shanghai Jiao Tong University School of Medicine","All","16 Years to 59 Years   (Child, Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RJH-2015-RefactoryALL-SCT","May 9, 2016","January 2016","July 2019","July 28, 2016","July 2016","No Study Results Posted","null","January 2019","disease-free survival","https://ClinicalTrials.gov/show/NCT02766868"
1003,"NCT00002819","Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer","Terminated","No Results Available","Ovarian Cancer","Drug: carboplatin|Drug: cyclophosphamide|Drug: mitoxantrone hydrochloride|Drug: paclitaxel|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Gynecologic Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Southwest Oncology Group|Cancer and Leukemia Group B","Female","up to 65 Years   (Child, Adult)","Phase 3","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000064983|GOG-164|CLB-9791|E-G0164|SWOG-G0164","November 1, 1999","November 1996","null","April 10, 2013","May 2007","No Study Results Posted","null","February 2000","","https://ClinicalTrials.gov/show/NCT00002819"
1004,"NCT00290641","Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes","Biological: filgrastim|Biological: graft-versus-tumor induction therapy|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI)","All","up to 45 Years   (Child, Adult)","","68","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","2000LS068|MT2000-25","February 9, 2006","April 2001","January 2006","October 9, 2012","October 2012","No Study Results Posted","null","January 2006","Engraftment as measured by an absolute neutrophil count of donor origin > 0.5 x 109 /L for 3 days by day 42|Incidence and severity of acute or chronic graft-versus-host-disease, relapse, or mortality at day 100|Survival and event-free survival by Kaplan-Meier estimation at 1 and 2 years after umbilical cord blood (UCB) transplant","https://ClinicalTrials.gov/show/NCT00290641"
1005,"NCT02161783","Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation","Recruiting","No Results Available","Primary Graft Failure|Secondary Graft Failure","Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total Body Irradiation|Biological: Hematopoietic stem cell infusion","Masonic Cancer Center, University of Minnesota","All","Child, Adult, Senior","","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013OC003|MT2013-06C","June 10, 2014","October 2014","July 2021","August 15, 2016","August 2016","No Study Results Posted","null","October 2020","Rate of donor engraftment|Rate of treatment related mortality|Rate of survival|Incidence of acute graft-versus-host disease|Incidence of chronic graft-versus-host disease","https://ClinicalTrials.gov/show/NCT02161783"
1006,"NCT00197912","Dendritic Cell Based Therapy of Malignant Melanoma","Completed","No Results Available","Advanced Melanoma","Biological: tumor antigen loaded autologous dendritic cells","Herlev Hospital","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MM0413","September 12, 2005","September 2004","April 2010","April 23, 2010","July 2009","No Study Results Posted","null","April 2010","Primary aim of the study is to evaluate tolerability and safety of the treatment|Secondary aims: evaluation of treatment induced immune response and clinical response.","https://ClinicalTrials.gov/show/NCT00197912"
1007,"NCT02105766","Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure","Recruiting","No Results Available","Sickle Cell Disease|Thalassemia|Stem Cell Transplantation|Graft vs Host Disease","Drug: Alemtuzumab|Drug: Sirolimus|Drug: Cyclophosphamide|Drug: Pentostatin|Drug: Radiotherapy","National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","16 Years to 80 Years   (Child, Adult, Senior)","Phase 1|Phase 2","162","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","140077|14-H-0077","April 1, 2014","March 13, 2014","August 31, 2021","May 12, 2017","April 6, 2017","No Study Results Posted","null","August 31, 2021","Determine regimen failure rate, defined as graft rejection, severe GVHD (acute GVHD grade 3 or higher or extensive chronic GVHD), or prolonged donor red cell aplasia ( greater than 2 years post -HSCT)|Examine the level of chimerism required to maintain both graft survival as well as hematologic normalcy using a regimen containing pentostatin, cyclophosphamide, alemtuzumab, and low total body irradiation.","https://ClinicalTrials.gov/show/NCT02105766"
1008,"NCT02936375","Iguratimod as Treatment for Active Lupus Nephritis","Not yet recruiting","No Results Available","Lupus Nephritis","Drug: Iguratimod|Drug: Cyclophosphamide|Drug: Azathioprine","RenJi Hospital","All","18 Years to 65 Years   (Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","[2016]128k","October 12, 2016","March 2017","null","October 26, 2016","October 2016","No Study Results Posted","null","January 2019","renal remission rate|Renal remission rate|Renal flare rate|Number of participants with treatment-related adverse events|SLEDAI-2K score|BILAG score|PGA","https://ClinicalTrials.gov/show/NCT02936375"
1009,"NCT02055820","A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma","Recruiting","No Results Available","Non-Hodgkin's Lymphoma","Drug: CHOP|Drug: GDC-0199|Drug: obinutuzumab|Drug: rituximab [MabThera/Rituxan]","Hoffmann-La Roche|AbbVie","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","248","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GO27878","February 4, 2014","June 2014","August 2019","November 1, 2016","November 2016","No Study Results Posted","null","August 2019","Safety: Incidence of dose-limiting toxicities|Complete response (CR) defined by PET/CT scan and bone marrow examination|Relative dose intensity|Objective response (partial or complete response) rate|Response duration, defined as time from first documented response until relapse or death.|Safety: Incidence of adverse events|Progression-free survival|Overall survival|CR defined by CT scan and bone marrow examination|Pharmacokinetics: plasma concentration-time profile of GDC-0199","https://ClinicalTrials.gov/show/NCT02055820"
1010,"NCT00003388","Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: methotrexate|Drug: pegylated liposomal doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","38","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066385|E-3D97","November 1, 1999","February 1999","null","January 26, 2010","January 2010","No Study Results Posted","null","April 2003","","https://ClinicalTrials.gov/show/NCT00003388"
1011,"NCT01389427","Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).","Completed","No Results Available","Mantle Cell Lymphoma Refractory","Drug: Torisel dose 15 mg and R-CHOP|Drug: Torisel dose 15 mg and R-FC|Drug: Torisel dose 15 mg and R-DHA|Drug: Torisel dose 25 mg and R-CHOP|Drug: Torisel dose 50 mg and R-CHOP|Drug: Torisel dose 75 mg and R-CHOP|Drug: Torisel dose 25 mg and R-FC|Drug: Torisel dose 50 mg and R-FC|Drug: Torisel dose 75 mg and R-FC|Drug: Torisel dose 25 mg and R-DHA|Drug: Torisel dose 50 mg and R-DHA|Drug: Torisel 75 mg and R-DHA","The Lymphoma Academic Research Organisation|French Innovative Leukemia Organisation","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","41","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","T³","July 4, 2011","November 2011","September 2015","March 8, 2017","March 2017","No Study Results Posted","T³","May 2015","Incidence of Dose Limiting Toxicities (DLT)|Complete Response Rate(CR) after 4 cycles and at the end of treatment|Progression-free survival (PFS)|Duration of Response|Overall Response at the end of treatment|Overall Survival (OS)|Safety of association Temsirolimus with the three chemotherapy regimens","https://ClinicalTrials.gov/show/NCT01389427"
1012,"NCT02080195","Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)","Recruiting","No Results Available","Lupus Erythematosus|Graft-versus-host Disease","Drug: Cyclophosphamide|Drug: Sodium-2-mercapto ethane sulphonate|Drug: Fludarabine monophosphate|Drug: Tacrolimus|Drug: Mofetil|Drug: Rabbit antithymocyte globulin","Sidney Kimmel Comprehensive Cancer Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J13134|NA_00082453","February 28, 2014","October 2014","September 2018","September 30, 2016","September 2016","No Study Results Posted","null","September 2018","The feasibility of the conditioning regimen and post transplantation cyclophosphamide in refractory SLE patients with donors having various degrees of matching|Evaluation of the improvement in the RIFLE score with the goal as target organ complete response with no worsening in any other organ|The overall survival (OS) and event-free survival (EFS)|The incidences of primary and secondary graft failure|The cumulative incidence of acute and chronic graft versus-host disease (GVHD)","https://ClinicalTrials.gov/show/NCT02080195"
1013,"NCT02145039","Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases","Recruiting","No Results Available","Acute Leukemias|Burkitt's Lymphoma|Chronic Myelogenous Leukemia","Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total Body Irradiation|Biological: Haploidentical stem cell transplant","Masonic Cancer Center, University of Minnesota","All","up to 74 Years   (Child, Adult, Senior)","","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013OC116|MT2013-33C","May 20, 2014","October 2014","June 2020","August 15, 2016","August 2016","No Study Results Posted","null","June 2020","2 year survival|Incidence of hematopoietic engraftment|Incidence of chimerism|Incidence of acute GVHD at 100 days|Incidence of chronic GVHD at 1 year|Incidence of transplant related mortality (TRM)","https://ClinicalTrials.gov/show/NCT02145039"
1014,"NCT00310089","AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Biological: pegfilgrastim|Drug: cediranib maleate|Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Other: laboratory biomarker analysis|Procedure: conventional surgery|Procedure: neoadjuvant therapy","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","","33","NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000466185|NCI-06-C-0057|NCI-7088","March 29, 2006","January 2006","July 2007","June 18, 2013","January 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00310089"
1015,"NCT02065362","TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC","Active, not recruiting","No Results Available","EBV-positive Nasopharyngeal Carcinoma","Biological: DNR.NPC-specific T cells|Biological: DNR.NPC-specific T cells + cyclophosphamide + fludarabine","Baylor College of Medicine|National Cancer Institute (NCI)|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System|Texas Children's Hospital","All","Child, Adult, Senior","Phase 1","14","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","33954: RESIST-NPC|P01CA094237","February 14, 2014","February 2015","February 2033","May 17, 2017","May 2017","No Study Results Posted","null","February 2018","Number of subjects with a dose limiting toxicity|Amount of T cells in the blood after the infusions","https://ClinicalTrials.gov/show/NCT02065362"
1016,"NCT02876107","A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC)","Recruiting","No Results Available","Malignant Neoplasm of Breast","Procedure: Breast Core Biopsy|Drug: Paclitaxel|Drug: Carboplatin|Drug: Panitumumab|Drug: Doxorubicin|Drug: Cyclophosphamide|Procedure: Mammogram|Procedure: Ultrasound|Other: Follow Up","M.D. Anderson Cancer Center|Amgen","Female","18 Years and older   (Adult, Senior)","Phase 2","72","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2016-0177","August 18, 2016","October 2016","null","October 6, 2016","October 2016","No Study Results Posted","null","October 2023","Complete Pathologic Response (pCR) Rate|Disease-Free Survival (DFS) Rate","https://ClinicalTrials.gov/show/NCT02876107"
1017,"NCT00124111","A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: pegfilgrastim|Drug: cyclophosphamide|Drug: methotrexate|Drug: 5-fluorouracil","Amgen","All","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label","20030156","July 25, 2005","null","null","February 25, 2010","February 2010","No Study Results Posted","null","null","To assess the relative dose intensity (RDI) of IV CMF Day 1 and 8 schedule given every 28 days with pegfilgrastim support in subjects with Stage I-III breast cancer.|Incidence of febrile neutropenic events over all cycles|Incidence of dose delays and dose reductions of planned chemotherapy due to neutropenic events|Safety profile over all cycles","https://ClinicalTrials.gov/show/NCT00124111"
1018,"NCT00601003","Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma","Recruiting","No Results Available","Neuroblastoma|Medulloblastoma","Drug: Nifurtimox|Drug: Cyclophosphamide|Drug: Topotecan","Giselle Sholler|Bayer|Spectrum Health Hospitals","All","up to 21 Years   (Child, Adult)","Phase 2","100","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","V0706","January 14, 2008","February 2008","December 2020","April 25, 2017","April 2017","No Study Results Posted","null","December 2018","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Best Radiological Response in Participants using the RECIST criteria|Evaluate the correlation between the pharmacologic serum levels of nifurtimox (in combination with cyclophosphamide and topotecan) with tumor response.|Quality of life and neurocognitive evaluation/questionnaire.|Biology studies to include: genomic analysis of cells pre- and post- treatment, correlation of in vitro response to in vivo response, flow cytometry of tumor burden in bone marrow and biomarker development.","https://ClinicalTrials.gov/show/NCT00601003"
1019,"NCT01415882","Ixazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib","Recruiting","No Results Available","Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma","Drug: Cyclophosphamide|Drug: Dexamethasone|Drug: Ixazomib Citrate|Other: Laboratory Biomarker Analysis","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","144","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MC1181|NCI-2011-02303|11-001516 00|Mod11-001516-50|P30CA015083","August 5, 2011","January 2012","null","September 12, 2016","September 2016","No Study Results Posted","null","July 2017","Proportion of confirmed responses with ixazomib citrate alone (Arm A only-closed to accrual as of addendum 5), ixazomib citrate with dexamethasone (Arms B + C), or ixazomib citrate with dexamethasone and cyclophosphamide (Arm D)|Confirmed response rate with the addition of dexamethasone (Arm A only)|Event-free survival|Incidence of adverse events, graded according to NCI CTCAE version 3.0|Overall survival","https://ClinicalTrials.gov/show/NCT01415882"
1020,"NCT00683670","Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma","Completed","No Results Available","Melanoma","Drug: cyclophosphamide|Biological: Mature dendritic cell vaccine","University of Pennsylvania","All","18 Years and older   (Adult, Senior)","Phase 1","17","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","07-0652 / 826850","May 19, 2008","August 2008","June 2016","February 21, 2017","February 2017","No Study Results Posted","null","June 2016","Immunological response based on measuring increased numbers of peptide specific CD8+ T cells as calculated by the tetramer assay.|Safety and tolerability of the mature dendritic cell vaccine as measured by adverse events|Time to progression|Regulatory T cell depletion after cyclophosphamide administration.|Safety and side effect profile of mDC administered to patients given after a single dose of cyclophosphamide.|Clinical response rate using RECIST criteria","https://ClinicalTrials.gov/show/NCT00683670"
1021,"NCT00054340","Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder","Completed","No Results Available","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 1|Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Supportive Care","1723.00|FHCRC-1723.00|CDR0000270397","February 5, 2003","October 2002","September 2006","May 12, 2010","May 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00054340"
1022,"NCT00337987","A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma","Completed","Has Results","Peripheral T-Cell Lymphoma","Drug: Ontak|Drug: CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy","Yale University|Eisai Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","49","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0507000369","June 15, 2006","November 2005","January 2008","February 9, 2015","February 2015","January 28, 2015","null","December 2007","Number of Patients That Achieved a Complete Response or a Partial Response (PR)|Number of Patients That Achieved a Complete Response (CR)","https://ClinicalTrials.gov/show/NCT00337987"
1023,"NCT02527746","Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","Completed","No Results Available","Neutropenia|Breast Cancer","Biological: F-627|Drug: EC regimen","Generon (Shanghai) Corporation Ltd.|Fudan University","Female","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","18","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-F-627-CH1","July 23, 2015","December 2012","February 2014","August 17, 2015","August 2015","No Study Results Posted","null","December 2013","Number of participants with adverse events as measure of safety and tolerability of F-627 in female patients wiht breast cancer receiving adjuvant chemotherapy.|Maximum Plasma Concentration as a measure of pharmacokinetics profile of F-627.|Area Under the Curve as a measure of pharmacokinetics profile of F-627.|Clearance and Mean Residence Time as a measure of pharmacokinetics profile of F-627.|Absolute Neutrophil Count changes over time as measure of pharmacodynamics of F-627.","https://ClinicalTrials.gov/show/NCT02527746"
1024,"NCT00186225","Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors","Completed","No Results Available","Blood Cancer|Blood and Marrow Transplant (BMT)","Procedure: ablative allogeneic hematopoietic cell transplantation","Stanford University","All","up to 50 Years   (Child, Adult)","","250","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT22|75268","September 13, 2005","November 1989","May 2010","July 23, 2010","July 2010","No Study Results Posted","null","June 2007","oxicity and efficacy of TBI and cyclophosphamide as preparation for hematopoietic cell transplantation from partially matched and unrelated donors.|Overall Survival|Event Free Survival","https://ClinicalTrials.gov/show/NCT00186225"
1025,"NCT00167206","Stem Cell Transplantation for Fanconi Anemia","Terminated","Has Results","Fanconi Anemia","Procedure: Hematopoietic Stem Cell Transplant|Procedure: Thymic Shielding During Radiation|Procedure: Total Body Irradiation|Drug: Cyclophosphamide, Fludarabine","Masonic Cancer Center, University of Minnesota","All","up to 18 Years   (Child, Adult)","Phase 1|Phase 2","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0312M54991|MT2003-18","September 9, 2005","March 2004","December 2008","November 30, 2009","November 2009","July 7, 2009","null","December 2008","Number of Patients Who Exhibited Hematopoietic Recovery and Engraftment|Number of Patients Who Exhibited Secondary Graft Failure|Number of Patients With Acute Graft Versus-Host Disease (aGVHD)|Number of Patients With Chronic Graft Versus-Host Disease (GVHD)|Number of Patients Who Exhibited Regimen-related Toxicity (RRT)|Immune Reconstitution - Mean Value (1 Year)|Immune Reconstitution - Mean Value (2 Years)|Number of Patients Alive at 1 Year|Number of Patients Alive at 2 Years","https://ClinicalTrials.gov/show/NCT00167206"
1026,"NCT00003217","Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia|Lymphoma","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: methotrexate|Drug: vincristine sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 1","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9517|POG-9517|CDR0000066078","November 1, 1999","March 1998","September 2006","July 23, 2014","July 2014","No Study Results Posted","null","October 2004","Event Free Survival","https://ClinicalTrials.gov/show/NCT00003217"
1027,"NCT02156726","Observational Study of Low Dose FCR in Elderly/Comorbid CLL/SLL: The Q-lite Project","Unknown status","No Results Available","Chronic Lymphocytic Leukemia","Drug: low-dose FCR","Czech CLL Study Group","All","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Q-lite","May 24, 2014","March 2011","July 2015","June 3, 2014","May 2014","No Study Results Posted","Q-lite","October 2014","Toxicity|Overall response rate|Complete response rate|Progression-free survival|Overall survival|Quality of life","https://ClinicalTrials.gov/show/NCT02156726"
1028,"NCT00651755","Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients","Completed","Has Results","Lymphoma","Drug: Aprepitant|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Rituximab|Drug: Ondansetron","M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","","23","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-1033","March 31, 2008","March 2008","September 2011","June 28, 2013","June 2013","February 8, 2013","null","September 2011","Geometric Mean Area Under Curve (AUC) of Analyte, Cyclophosphamide (CP), in Aprepitant Treatment and Control Group|Geometric Mean Area Under Curve (AUC) of Analyte, 2-dechloro-cyclophosphamide(2-deCI-CP), in Aprepitant Treatment and Control Group|Geometric Mean Area Under Curve (AUC) of Analyte, 4-hydroxy-cyclophosphamide (4-OH-CP), in Aprepitant Treatment and Control Group|Geometric Mean Area Under Curve (AUC) of Analyte, Vincristine (VC), in Aprepitant Treatment and Control Group|Geometric Mean Area Under Curve (AUC) of Analyte,Prednisone (PR), in Aprepitant Treatment and Control Group|Geometric Mean Area Under Curve (AUC) of Analyte, Prednisolone (PL), in Aprepitant Treatment and Control Group","https://ClinicalTrials.gov/show/NCT00651755"
1029,"NCT00002481","Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: etoposide|Procedure: autologous bone marrow transplantation|Radiation: radiation therapy","St. Luke's Medical Center|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000077128|STLMC-ABMR-9001|NCI-V91-0112","November 1, 1999","March 1990","null","December 17, 2013","May 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002481"
1030,"NCT02468739","Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: EC-T or TC plus GM1|Drug: EC-T or TC plus placebo","Sun Yat-sen University","Female","18 Years to 65 Years   (Adult)","Phase 3","190","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","GM-EBC","May 14, 2015","May 2015","October 2016","December 19, 2016","December 2016","No Study Results Posted","null","October 2016","Rates of grade 2 or more chronic cumulative neurotoxicity of both arm|Rates of chronic cumulative neurotoxicity of both arms|Rates of grade 2 or more chronic cumulative neurotoxicity of both arms|Time to grade 2 or more neurotoxicity of both arms|Rates of dose reduction or withdrawal due to oxaliplatin induced neurotoxicity of both arms|Rates of acute neurotoxicity of both arms|Rates of 3 year disease free survival of both arms","https://ClinicalTrials.gov/show/NCT02468739"
1031,"NCT02759822","Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias","Recruiting","No Results Available","Leukemia, Myeloid, Acute|Precursor Cell Lymphoblastic Leukemia-Lymphoma","Procedure: Haploidentical Stem Cell Transplantation","Leonardo Javier Arcuri|Instituto Nacional de Cancer, Brazil","All","1 Year to 60 Years   (Child, Adult)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CEMO/INCA-Haplo-01","April 22, 2016","April 2016","null","April 29, 2016","April 2016","No Study Results Posted","null","April 2021","Overall Survival|Cumulative incidence of leukemia relapse|Transplant Related Mortality|Cumulative Incidence of acute Graft Versus Host Disease|Cumulative Incidence of chronic Graft Versus Host Disease|Cumulative Incidence of Infectious Complications","https://ClinicalTrials.gov/show/NCT02759822"
1032,"NCT00450801","R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma","Completed","Has Results","Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Doxorubicin|Drug: Etoposide|Drug: Ifosfamide|Drug: Leucovorin|Drug: Methotrexate|Drug: Thalidomide|Drug: Vincristine|Drug: Mesna|Drug: Filgrastim (G-CSF)|Drug: Granisetron|Drug: Decadron","University of Miami","All","18 Years and older   (Adult, Senior)","Phase 2","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20030165|SCCC-2003027|WIRB-20051242","March 20, 2007","April 2004","July 2015","October 12, 2015","October 2015","August 7, 2015","null","July 2015","Progression-free Survival Rate|Overall Survival Rate|Response Rate|Number of Patients Experiencing Adverse Events.","https://ClinicalTrials.gov/show/NCT00450801"
1033,"NCT03158935","The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial","Not yet recruiting","No Results Available","Advanced Ovarian Cancer|Malignant Melanoma","Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: Pembrolizumab|Biological: Tumor-Infiltrating Lymphocytes (TILs)|Biological: Interleukin-2 (IL-2)","University Health Network, Toronto|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ACTIVATE","May 9, 2017","June 2017","June 2019","May 16, 2017","May 2017","No Study Results Posted","ACTIVATE","December 2018","Monitoring of serious adverse events to determine the safety of initiating pembrolizumab following lymphodepleting chemotherapy, TIL administration, and low dose IL-2 injections within 35 days of TIL infusion.|Overall Response Rate|Overall and Progression Free Survival|Safety profile of pembrolizumab therapy given after or in combination with ACT in patients with advanced melanoma and ovarian cancer using CTCAE v4.0","https://ClinicalTrials.gov/show/NCT03158935"
1034,"NCT00462332","Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia","Completed","Has Results","Leukemia","Drug: Fludarabine|Drug: Campath|Procedure: Transplant|Drug: Campath|Drug: Fludarabine|Drug: Campath|Drug: Campath","Gruppo Italiano Malattie EMatologiche dell'Adulto","All","up to 60 Years   (Child, Adult)","Phase 2","86","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LLC0405|2005-002476-15","April 18, 2007","May 2007","June 2011","August 20, 2013","August 2013","August 20, 2012","LLC0405","June 2011","Number of Patients With Complete Response|Toxicity|Length of Survival|Event-free Survival|Disease-free Survival","https://ClinicalTrials.gov/show/NCT00462332"
1035,"NCT00756470","Phase II Neoadjuvant in Inflammatory Breast Cancer","Terminated","Has Results","Breast Cancer","Drug: Lapatinib|Drug: Paclitaxel|Drug: 5-Fluorouracil (5-FU)|Drug: Epirubicin|Drug: Cyclophosphamide","M.D. Anderson Cancer Center|GlaxoSmithKline","Female","18 Years and older   (Adult, Senior)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007-0818","September 19, 2008","October 2008","October 2013","November 4, 2014","November 2014","October 30, 2014","null","October 2013","Rate of Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy|Number of Participants With pCR After Completion of All Protocol Specified Therapy & Surgery (Surgical Population)","https://ClinicalTrials.gov/show/NCT00756470"
1036,"NCT03066947","BriaVax™ in Metastatic or Locally Recurrent Breast Cancer","Recruiting","No Results Available","Breastcancer|Breast Neoplasm","Biological: BriaVax™|Drug: Cyclophosphamide|Biological: Interferon-alpha-2b","BriaCell Therapeutics Corporation|Cancer Insight, LLC","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","0001","February 16, 2017","March 10, 2017","March 2020","March 10, 2017","March 2017","No Study Results Posted","null","February 2020","Incidence of Treatment Emergent Adverse Events [Safety]|Duration of Treatment Emergent Adverse Events [Safety]|Relationship of Adverse Events to BriaVax [Safety]|Objective Tumor Response Rate|Rate of Non-progression of Tumors|Durability of Tumor Response","https://ClinicalTrials.gov/show/NCT03066947"
1037,"NCT02613026","Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer","Completed","No Results Available","Breast Neoplasms","Drug: Pirarubicin|Drug: Docetaxel|Drug: Cyclophosphamide","307 Hospital of PLA","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AT2009","November 3, 2015","July 2009","February 2015","November 22, 2015","November 2015","No Study Results Posted","null","March 2013","pathological complete response rate|clinical response rate|Percentage of changes in hormone receptors status after treatment|Number of relative prognostic factors which influence pCR","https://ClinicalTrials.gov/show/NCT02613026"
1038,"NCT00052936","Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: CHOP regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","German High-Grade Non-Hodgkin's Lymphoma Study Group|National Cancer Institute (NCI)","All","61 Years to 80 Years   (Adult, Senior)","Phase 3","1580","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000269015|DSHNHL-1999-1A|EU-20243","January 24, 2003","January 2001","null","March 11, 2010","June 2007","No Study Results Posted","null","null","Time to treatment failure at 3 years within the study and then periodically after study completion|Complete response rate at 3 years within the study and then periodically after study completion|Progression rate|Survival|Tumor control|Disease-free survival","https://ClinicalTrials.gov/show/NCT00052936"
1039,"NCT02574728","Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors","Recruiting","No Results Available","Cancer","Drug: Sirolimus|Drug: Celecoxib|Drug: Etoposide|Drug: Cyclophosphamide","Emory University","All","12 Months to 30 Years   (Child, Adult)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IRB00082488","October 2, 2015","June 2015","June 2020","February 14, 2017","February 2017","No Study Results Posted","AflacST1502","June 2020","Change in radiographic response to treatment for solid tumors|Change in radiographic response to treatment for central nervous system (CNS) tumors|Number of adverse events","https://ClinicalTrials.gov/show/NCT02574728"
1040,"NCT00550784","Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","Completed","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: melphalan|Drug: paclitaxel|Drug: topotecan hydrochloride|Genetic: TdT-mediated dUTP nick end labeling assay|Genetic: gene expression analysis|Other: immunohistochemistry staining method|Other: pharmacological study|Procedure: peripheral blood stem cell transplantation","City of Hope Medical Center|National Cancer Institute (NCI)","Female","up to 60 Years   (Child, Adult)","Phase 1","8","Other|NIH","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","00067|P30CA033572|CHNMC-00067|CCC-PHI-31|CDR0000567474","October 22, 2007","January 2001","October 2014","October 3, 2014","October 2014","No Study Results Posted","null","October 2014","Toxicity|Tumor response|Reason patient is removed from study|Disease progression|Overall survival|Progression-free survival|Time to progression","https://ClinicalTrials.gov/show/NCT00550784"
1041,"NCT02772822","A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients","Not yet recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: SCT400 plus CHOP|Drug: Rituximab plus CHOP","Sinocelltech Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","SCT400NHL3","May 6, 2016","June 2016","December 2019","May 11, 2016","May 2016","No Study Results Posted","null","June 2019","Overall response rate(ORR) after completion of treatment|Complete remission(CR) plus complete remission/unconfirmed(CRu) after completion of treatment|Progression-free survival(PFS)|Event-free survival(EFS) at 1 year and directly after an event, whichever comes first. The events are defined as progressive disease, relapse, death from any cause, or new anticancer treatment|Duration of remission(DOR) measured from prior achievement of complete remission or partial remission to occurrence of an event or at 1 year, whichever comes first. The events are defined as progressive disease, relapse of death from any cause|Overall survival(OS)|Comparison of adverse events(AEs) between the two study arms|Number of participants with seropositive for human anti-chimeric antibody(HACA) between the two study arms","https://ClinicalTrials.gov/show/NCT02772822"
1042,"NCT00670358","Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma","Recruiting","No Results Available","Lymphoma","Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: lenalidomide|Drug: prednisone|Drug: vincristine sulfate|Genetic: polymorphism analysis|Other: laboratory biomarker analysis","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1|Phase 2","47","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC078E|P30CA015083|RV-NHL-PI-0325|07-007992|NCI-2009-01196","April 30, 2008","August 2008","null","October 10, 2016","October 2016","No Study Results Posted","null","May 2017","Toxicity as assessed by NCI CTCAE v3.0 (Phase I)|Event-free survival at 12 months (Phase II)|Overall response rate|Overall complete response rate|Event-free survival|Overall survival|Progression-free survival|Duration of response|Immune function before and after treatment as assessed by T-, B-, and NK-cell quantification|Correlation of immune function with clinical outcomes","https://ClinicalTrials.gov/show/NCT00670358"
1043,"NCT00578435","Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis","Completed","No Results Available","Genetic Disorders|Sickle Cell Anemia","Procedure: Busulfan, Cyclophosphamide, BMD","Memorial Sloan Kettering Cancer Center","All","1 Year and older   (Child, Adult, Senior)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","94-005","December 18, 2007","January 1994","August 2008","September 10, 2008","September 2008","No Study Results Posted","null","August 2008","Define the role of bone marrow transplantation for the treatment of sickle cell disease and the reversibility of sickle cell vasculopathy and organ damage, good risk thalassemia major and Diamond-Blackfan Anemia.","https://ClinicalTrials.gov/show/NCT00578435"
1044,"NCT00446173","Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia","Withdrawn","No Results Available","Leukemia","Drug: Busulfan|Drug: Cyclophosphamide|Drug: G-CSF|Drug: GM-CSF","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","21 Years to 65 Years   (Adult)","Phase 2","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-0710","March 9, 2007","March 2007","January 2009","August 21, 2015","August 2015","No Study Results Posted","null","January 2009","Time to absolute neutrophil count (ANC) recovery to 500|Survival Time","https://ClinicalTrials.gov/show/NCT00446173"
1045,"NCT00270894","Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients","Completed","Has Results","Breast Neoplasm","Drug: epirubicin|Drug: cyclophosphamide|Drug: docetaxel|Drug: trastuzumab","Accelerated Community Oncology Research Network|Aventis Pharmaceuticals","Female","18 Years and older   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACORN ALSSNBC0401","December 28, 2005","November 2005","August 2011","March 15, 2012","March 2012","November 18, 2011","null","August 2011","Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule|Frequency of Grade 3 or 4 Hematologic and Nonhematologic Toxicities|Pathologic Response|Clinical Response Prior to Surgery|Left Ventricular Ejection Fraction (LVEF)|Progression-free Survival (PFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00270894"
1046,"NCT00336791","Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: 5-Fluorouracil|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Paclitaxel|Drug: Epirubicin","M.D. Anderson Cancer Center|Breast Cancer Research Foundation","All","Child, Adult, Senior","Phase 3","273","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-0321","June 12, 2006","September 2003","September 2010","February 13, 2012","February 2012","No Study Results Posted","null","August 2007","Pathologic Complete Response Rate in breast and axillary lymph nodes","https://ClinicalTrials.gov/show/NCT00336791"
1047,"NCT01762449","Morbidity and Mortality Follow Up for the Scleroderma Lung Study","Completed","No Results Available","Scleroderma","Other: Followup survey","Duke University","All","18 Years and older   (Adult, Senior)","","158","Other","Observational","Observational Model: Cohort","Pro00026357","January 4, 2013","July 2012","August 2013","January 22, 2014","January 2014","No Study Results Posted","null","June 2013","Time to death or first organ failure","https://ClinicalTrials.gov/show/NCT01762449"
1048,"NCT02781467","A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)","Recruiting","No Results Available","Leukemia, Myeloid, Acute","Biological: PNK-007|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Human recombinant Interleukin-2 (rhIL-2)","Celgene","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","28","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CCT-PNK-007-AML-001","May 20, 2016","July 25, 2016","December 30, 2019","March 31, 2017","March 2017","No Study Results Posted","null","December 30, 2019","Dose-Limiting Toxicity (DLT)|Maximum Tolerated Dose (MTD)|Adverse Events (AEs)|Complete remission with incomplete platelet recovery (CRp)|Complete remission (CR)","https://ClinicalTrials.gov/show/NCT02781467"
1049,"NCT01795976","NY-ESO-1 T Cells in OG Cancer","Active, not recruiting","No Results Available","Oesophageal Cancer","Genetic: NY-ESO-1 T cells|Drug: cyclophosphamide|Drug: Fludarabine|Biological: Interleukin 2","Fiona Thistlethwaite|The Christie NHS Foundation Trust|Erasmus Medical Center|Ospedale San Raffaele|University College London Hospitals|Karolinska University Hospital|The Netherlands Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 2","28","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","12_DOG14_22","January 10, 2013","October 2014","August 2019","February 6, 2017","February 2017","No Study Results Posted","ATTACK-OG","December 2018","Response rate to New York esophageal squamous cell carcinoma (NYESO) T cells|Response rate to NYESO T cells|Feasibility and tolerability of NY-ESO-1 targeted cell therapy|Evaluation of the progression free survival","https://ClinicalTrials.gov/show/NCT01795976"
1050,"NCT02118285","Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer","Suspended","No Results Available","Ovarian Cancer|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: NK cells|Biological: IL-2|Drug: INCB024360","Masonic Cancer Center, University of Minnesota|Incyte Corporation","Female","18 Years and older   (Adult, Senior)","Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2012LS101|MT2013-11","March 26, 2014","April 2014","April 2020","December 12, 2016","December 2016","No Study Results Posted","null","August 2017","Maximum tolerated dose of INCB024360|Initial tumor response|Duration of tumor response|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02118285"
1051,"NCT02742051","A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Everolimus|Drug: Letrozole|Drug: Fluorouracil|Drug: Epirubicin|Drug: Cyclophosphamide","Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","50102016015","April 7, 2016","June 2016","July 2019","May 9, 2017","May 2017","No Study Results Posted","null","July 2019","Objective response rate|Response rate by clinical palpation|Pathological complete response (pCR) rate|Breast-conserving surgery rate|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Peripheral blood CD8+ T cell percentage change in relation to neoadjuvant therapy|Peripheral blood T helper cell percentage change in relation to neoadjuvant therapy|Peripheral blood regulatory T cell percentage change in relation to neoadjuvant therapy|Peripheral blood NK cell percentage change in relation to neoadjuvant therapy","https://ClinicalTrials.gov/show/NCT02742051"
1052,"NCT00698009","Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma","Terminated","Has Results","Neuroblastoma","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Natural Killer Cell Infusion|Drug: Mesna|Drug: Interleukin-2","M.D. Anderson Cancer Center","All","Child, Adult, Senior","Phase 2","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-0752","June 12, 2008","June 2008","June 2012","October 23, 2012","October 2012","October 23, 2012","null","June 2012","Participant Disease Response|Number of Participants Infused Haploidentical Donor-derived Natural Killer (NK) Cells and Low-dose Interleukin-2 (IL-2)","https://ClinicalTrials.gov/show/NCT00698009"
1053,"NCT00877110","Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma","Active, not recruiting","No Results Available","Neuroblastoma|Bone Marrow, Sympathetic Nervous System","Drug: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8","Memorial Sloan Kettering Cancer Center","All","Child, Adult, Senior","Phase 1","71","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","09-011|MSKCC09011 FDR004128","April 6, 2009","April 2, 2009","April 2018","May 1, 2017","May 2017","No Study Results Posted","null","April 2018","Assess the feasibility and safety of administering allogeneic haploidentical NK infusions with 3F8 in patients with high-risk NB|Estimate the anti-NB effect of allogeneic NK infusions plus 3F8|Assess the impact of KIR/HLA immunogenetics on disease response to NK/3F8|Assess the relationship between CD16 polymorphism and ADCC in vitro","https://ClinicalTrials.gov/show/NCT00877110"
1054,"NCT01171378","Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's Syndrome","Unknown status","No Results Available","Richter's Syndrome","Drug: Ofatumumab","University of Oxford|GlaxoSmithKline|Cancer Research UK|Oxford University Hospitals NHS Trust|NCRI CLL Subgroup","All","18 Years and older   (Adult, Senior)","Phase 2","35","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OCTO_018|OFT113560|2009-016459-23","July 22, 2010","April 2011","April 2016","May 27, 2015","May 2015","No Study Results Posted","CHOP-OR","February 2015","Objective response|Overall survival|Progression free survival|Duration of response|Time to next DLBCL therapy|Reduction in Tumour Size|Patient reported outcomes|Safety","https://ClinicalTrials.gov/show/NCT01171378"
1055,"NCT00121199","Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma","Completed","Has Results","Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma","Biological: rituximab|Biological: bevacizumab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","73","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03062|S0515|U10CA032102","July 19, 2005","June 2005","December 2010","May 6, 2014","December 2012","October 30, 2012","null","December 2010","Progression-free Survival at 1 Year|Progression-free Survival at 2 Year|Objective Response (Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR))|Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug","https://ClinicalTrials.gov/show/NCT00121199"
1056,"NCT02221310","Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS","Recruiting","No Results Available","Acute Myelogenous Leukemia|Myelodysplastic Syndrome","Drug: Gemtuzumab Ozogamicin","New York Medical College","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NYMC-515|L-10,349","July 31, 2014","November 2011","June 2021","May 5, 2017","May 2017","No Study Results Posted","null","June 2019","Response rate","https://ClinicalTrials.gov/show/NCT02221310"
1057,"NCT00941330","Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers","Completed","Has Results","Breast Cancer","Drug: Exemestane|Drug: Docetaxel|Drug: Cytoxan","Emory University|Pfizer","All","18 Years and older   (Adult, Senior)","Phase 2","31","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IRB00012969|WCI1534-08","July 15, 2009","July 2009","May 2015","February 24, 2017","February 2017","December 7, 2016","null","May 2015","Pathologic Complete Response|Response Rate by Imaging","https://ClinicalTrials.gov/show/NCT00941330"
1058,"NCT00750971","Autologous Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus (ASSIST)","Recruiting","No Results Available","Systemic Lupus Erythematosus","Procedure: Immunoablation and Autologous Hematopoietic Stem Cell Transplantation","Charite University, Berlin, Germany","All","18 Years to 60 Years   (Adult)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CT-1306","September 10, 2008","August 2008","August 2020","March 17, 2017","March 2017","No Study Results Posted","ASSIST","July 2020","SLEDAI|Serologic response (autoantibodies)|Immune Reconstitution|Organ-specific response parameters","https://ClinicalTrials.gov/show/NCT00750971"
1059,"NCT00878254","Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma","Recruiting","No Results Available","Mantle-Cell Lymphoma","Biological: G-CSF|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Doxorubicin|Drug: Etoposide|Drug: Ifosfamide|Drug: Leucovorin|Drug: Mesna|Drug: Methotrexate|Drug: Vincristine","University of Miami","All","19 Years to 72 Years   (Adult, Senior)","Phase 2","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","20080803|SCCC-2008043","April 7, 2009","March 25, 2009","December 2019","March 16, 2017","March 2017","No Study Results Posted","null","December 2019","Rate of Progression-Free Survival (PFS)|Rate of Overall Survival (OS)|Rate of Response to Protocol Therapy|Rate of Treatment-Related Toxicity in Study Participants","https://ClinicalTrials.gov/show/NCT00878254"
1060,"NCT00549848","Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","Active, not recruiting","No Results Available","Acute Lymphoblastic Leukemia","Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine|Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib","St. Jude Children's Research Hospital|National Cancer Institute (NCI)|Enzon Pharmaceuticals, Inc.|National Institute of General Medical Sciences (NIGMS)","All","up to 18 Years   (Child, Adult)","Phase 3","600","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","TOTXVI|R01CA140729|F32CA141762|R37CA036401|R01CA090246|Aspar PK-PD-T16|NCI-2011-01254|P50GM115279","October 25, 2007","October 29, 2007","November 30, 2020","April 7, 2017","April 2017","No Study Results Posted","null","November 30, 2020","Continuous complete remission of patients receiving high-dose and conventional dose PEG-asparaginase.|Event-free survival|Overall survival|Level of minimal residual disease (MRD) on the 15th day of remission induction|Time to CNS relapse or the last follow up since diagnosis","https://ClinicalTrials.gov/show/NCT00549848"
1061,"NCT02053545","Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion","Recruiting","No Results Available","Leukemia|Lymphoma|MDS","Drug: Conditioning Regimen & GVHD Prophylaxis","Ann & Robert H Lurie Children's Hospital of Chicago","All","Child, Adult, Senior","Phase 1|Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCT 0813 Haplo","December 31, 2013","December 2013","December 2018","July 25, 2016","July 2016","No Study Results Posted","null","December 2018","Cumulative non-relapse mortality at 100 days and 365 days post haplo-identical transplant|Cumulative acute and chronic GVHD, cumulative relapse rates, and overall survival and event free survival","https://ClinicalTrials.gov/show/NCT02053545"
1062,"NCT01146834","Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma","Recruiting","No Results Available","Multiple Myeloma","Drug: bortezomib (Velcade)|Drug: cyclophosphamide|Drug: G-CSF","Weill Medical College of Cornell University|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 3","180","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","1005011049|X05324","June 16, 2010","March 2011","December 2022","February 16, 2017","February 2017","No Study Results Posted","null","July 2022","Percentage of patients able to collect >6 x 106 CD34+ cells/kg in < 2 collections.","https://ClinicalTrials.gov/show/NCT01146834"
1063,"NCT02419170","Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)","Withdrawn","No Results Available","Carcinoma, Non-Small-Cell-Lung|Non-Small Cell Lung Cancer|Nonsmall Cell Lung Cancer","Procedure: Standard of care surgery|Procedure: Apheresis|Drug: Cyclophosphamide|Biological: Personalized mature dendritic cell vaccine","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","15-x043","February 4, 2015","July 2016","October 2023","July 14, 2016","July 2016","No Study Results Posted","null","October 2019","Immunological response as measured by increased numbers of peptide specific CD8+ T cells as calculated by the tetramer assay|Safety and tolerability of vaccine as measured by adverse events experienced and graded by NCI CTCAE Version 4.0|Time to progression (TTP)","https://ClinicalTrials.gov/show/NCT02419170"
1064,"NCT01839097","Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)","Completed","No Results Available","Peripheral T-cell Lymphoma","Drug: Belinostat|Drug: CHOP","Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Senior)","Phase 1","23","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SPI-BEL-12-104","April 9, 2013","May 2013","January 2016","April 18, 2016","April 2016","No Study Results Posted","null","January 2016","Maximum Tolerated Dose (MTD)|Safety and tolerance|Overall Response Rate|Effectiveness of study drug","https://ClinicalTrials.gov/show/NCT01839097"
1065,"NCT01336933","Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma","Unknown status","No Results Available","Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma","Drug: prednisone|Drug: cyclophosphamide|Drug: etoposide|Drug: vincristine sulfate|Drug: pralatrexate|Other: laboratory biomarker analysis|Genetic: comparative genomic hybridization|Genetic: gene expression analysis|Genetic: nucleic acid sequencing|Genetic: mutation analysis|Other: immunohistochemistry staining method|Genetic: microarray analysis|Genetic: RNA analysis","University of Nebraska|National Cancer Institute (NCI)|Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Senior)","Phase 2","34","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","569-10|NCI-2011-00254|P30CA036727","March 23, 2011","July 2011","null","January 20, 2013","January 2013","No Study Results Posted","null","December 2015","CR rate of CEOP and P treatment|Overall response rates (complete response rates + partial response rates)|EFS|OS|Safety and tolerability of the regimen|Percent of patients who intended to receive transplant versus those who actually proceeded with transplant|Ability to collect peripheral blood stem cells","https://ClinicalTrials.gov/show/NCT01336933"
1066,"NCT01762202","Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.","Active, not recruiting","No Results Available","B-cell Lymphoid Leukemia|Young Patients","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Ofatumumab","Gruppo Italiano Malattie EMatologiche dell'Adulto","All","18 Years to 65 Years   (Adult)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLL0911|2011-005329-27","January 4, 2013","November 2013","November 2017","August 16, 2016","August 2016","No Study Results Posted","CLL0911","November 2015","Number of complete responses.|Number of overall responses.|Number of patients in progression-free survival.|Number of patients needing a new CLL Treatment.|Number of patients in overall survival|Number of toxic events.|Outcome of patients according to clinical and biologica variables.","https://ClinicalTrials.gov/show/NCT01762202"
1067,"NCT02627248","Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery","Recruiting","No Results Available","Breast Cancer","Drug: Huaier Granule|Drug: Epirubicin|Drug: Docetaxel|Drug: Cyclophosphamide","Shandong University","Female","18 Years and older   (Adult, Senior)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HECT002","December 3, 2015","October 2015","October 2025","December 8, 2015","December 2015","No Study Results Posted","null","October 2025","Pathologic complete response (pCR)|Clinical Complete Response (cCR)|Disease-free survival (DFS)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02627248"
1068,"NCT01451489","The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis","Terminated","No Results Available","FSGS","Drug: FK506|Drug: Cyclophosphamide","Nanjing University School of Medicine","All","14 Years to 65 Years   (Child, Adult)","","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NJCT-1101","August 5, 2011","October 13, 2011","October 29, 2016","March 22, 2017","March 2017","No Study Results Posted","FSGS","March 23, 2016","the rates of the complete remission during the induction phase|the total remission rates","https://ClinicalTrials.gov/show/NCT01451489"
1069,"NCT00028730","Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer","Completed","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: thiotepa|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","Phase 2","25","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-105|P30CA008748|P01CA033049|P01CA023766|MSKCC-01105|NCI-H01-0083","January 4, 2002","August 2001","June 2008","December 21, 2015","December 2015","No Study Results Posted","null","July 2006","Minimal transplantation related mortality|High disease-free survival at 2 years","https://ClinicalTrials.gov/show/NCT00028730"
1070,"NCT00002772","S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer","Terminated","No Results Available","Breast Cancer","Biological: filgrastim|Drug: carboplatin|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel|Drug: tamoxifen citrate|Drug: thiotepa|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B","Female","18 Years and older   (Adult, Senior)","Phase 3","602","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000064747|S9623|U10CA032102","November 1, 1999","July 1996","February 2004","January 22, 2013","January 2013","No Study Results Posted","null","February 2004","","https://ClinicalTrials.gov/show/NCT00002772"
1071,"NCT00182793","Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer","Completed","Has Results","Breast Cancer","Biological: trastuzumab|Drug: carboplatin|Drug: cyclophosphamide|Drug: melphalan|Drug: thiotepa|Procedure: adjuvant therapy|Procedure: autologous-autologous tandem hematopoietic stem cell transplantation|Procedure: bone marrow ablation with stem cell support|Radiation: radiation therapy","City of Hope Medical Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","32","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","05042|P30CA033572|CDR0000442105","September 15, 2005","July 2005","October 2014","January 31, 2017","January 2017","January 31, 2017","null","October 2014","5-Year Relapse-free Survival Rate|5-Year Overall Survival Rate","https://ClinicalTrials.gov/show/NCT00182793"
1072,"NCT00578864","Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma","Completed","Has Results","Neuroblastoma","Drug: Protracted Oral Etoposide|Drug: Adriamycin and Cyclophosphamide|Drug: IV Cisplatin and IV Bolus Etoposide","Baylor College of Medicine|Texas Children's Hospital","All","Child, Adult, Senior","Phase 2","13","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","H20255|PEPI","December 19, 2007","March 2007","March 2015","June 25, 2015","June 2015","October 5, 2012","PEPI","July 2009","Response Rate Associated With Two Cycles of Cisplatin With Protracted Oral Etoposide When Administered as Up-front Window Therapy to Previously Untreated Children With High Risk Neuroblastoma Tumors.|Rate of Toxicities Associated With Cisplatin With Protracted Oral Etoposide When Administered as Up-front Window Therapy to Previously Untreated Children With High Risk Neuroblastoma.|Overall Survival in Children With High Risk Neuroblastoma Treated on This Regimen.|Percentage of Patients Who Have Surgery After the Second Cycle of Induction Therapy|Event Free Survival in Children With High Risk Neuroblastoma Treated on This Regimen.","https://ClinicalTrials.gov/show/NCT00578864"
1073,"NCT00860548","SCOT Scleroderma Treatment Alternative Registry (STAR Registry)","Completed","No Results Available","Scleroderma, Systemic|Sclerosis","Drug: currently available therapy in the community","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 69 Years   (Adult, Senior)","","19","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","DAIT SCSSc-02|SCOT","March 11, 2009","June 2005","March 2016","April 3, 2017","April 2017","No Study Results Posted","null","March 2016","Event-free survival (EFS)|Functional status as determined by the Modified Scleroderma Health Assessment Questionnaire (m-HAQ/S-HAQ)|Mortality due to any cause|Medical therapies and procedures (including hospitalizations)|Diagnosis and treatment for pulmonary hypertension|Need for hyperalimentation|Amputation whether surgical or auto-amputation|Hospitalization or surgery","https://ClinicalTrials.gov/show/NCT00860548"
1074,"NCT01554852","Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen|Drug: Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen|Drug: Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen|Drug: Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen|Drug: Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen|Drug: Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen|Drug: Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance|Drug: Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance|Drug: High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)","University of Leeds|Celgene|Merck Sharp & Dohme Corp.|Amgen","All","18 Years and older   (Adult, Senior)","Phase 3","4420","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT number: 2009-010956-93","February 21, 2012","May 2010","December 2019","June 10, 2016","June 2016","No Study Results Posted","Myeloma XI","September 2017","Overall survival|Progression-free survival|Response|Toxicity","https://ClinicalTrials.gov/show/NCT01554852"
1075,"NCT02855359","Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma","Recruiting","No Results Available","Diffuse, Large B-Cell, Lymphoma|Follicular Lymphoma, Grade 3b|Transformed Lymphoma / DLBCL","Drug: denintuzumab mafodotin|Drug: rituximab|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Drug: prednisone","Seattle Genetics, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SGN19A-004","July 28, 2016","August 2016","April 2022","May 1, 2017","May 2017","No Study Results Posted","null","September 2019","Part B Outcome Measure: Complete Response Rate (CR)|Part A and Part B Outcome Measure: Incidence of adverse events|Part A and Part B Outcome Measure: Incidence of laboratory abnormalities|Event-free survival (EFS) between study arms in Part B.|Progression-free survival (PFS) between study arms in Part B.|Overall survival (OS) between study arms in Part B.|Objective response rate (ORR) at End Of Treatment (EOT) between study arms in Part B.|Duration of objective response and of complete response (CR) between study arms in Part B.","https://ClinicalTrials.gov/show/NCT02855359"
1076,"NCT00003114","Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease","Completed","No Results Available","Lymphoma","Biological: filgrastim|Drug: cyclophosphamide|Drug: etoposide|Drug: lomustine|Drug: procarbazine hydrochloride|Radiation: radiation therapy","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","5","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU2496|P30CA043703|CWRU-2496|AMC-4A-90|NCI-G97-1351","November 1, 1999","July 1997","February 2003","June 9, 2010","June 2010","No Study Results Posted","null","June 2002","Determine the objective response rate, response duration, and survival of patients receiving lomustine/etoposide/cyclophosphamide/procarbazine (CECP) for stage IIB-IV AIDS-related Hodgkin's disease.","https://ClinicalTrials.gov/show/NCT00003114"
1077,"NCT03118492","Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis","Not yet recruiting","No Results Available","Secondary Myelofibrosis","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Glycosylated Recombinant Human G-CSF AVI-014|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Drug: Mycophenolate Mofetil|Drug: Tacrolimus|Radiation: Total-Body Irradiation","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","16420|NCI-2017-00613","April 13, 2017","October 2017","October 2020","April 13, 2017","April 2017","No Study Results Posted","null","October 2020","Incidence of adverse events assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03|Incidence of unacceptable adverse event assessed by NCI CTCAE version 4.0|Cumulative incidence of acute GvHD assessed by Keystone Consensus criteria|Cumulative incidence of chronic GvHD assessed by NIH Consensus Criteria|Cumulative incidence of relapse/progression|Graft failure-free survival|Neutrophil recovery|Non-relapse mortality|Overall survival|Platelet recovery|Progression-free survival","https://ClinicalTrials.gov/show/NCT03118492"
1078,"NCT02428751","R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma","Recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: Pegylated liposomal doxorubicin|Drug: Doxorubicin|Drug: Rituximab|Drug: Cyclophophamide|Drug: Vincristine|Drug: Prednisone","Wenqi Jiang|Sun Yat-sen University","All","60 Years to 80 Years   (Adult, Senior)","Phase 3","216","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","308-2015-005","April 17, 2015","September 2015","May 2020","November 17, 2015","November 2015","No Study Results Posted","null","March 2020","event-free survival (EFS)|overall response rate (ORR)|complete remission (CR) rate|overall survival (OS)","https://ClinicalTrials.gov/show/NCT02428751"
1079,"NCT01661400","Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors","Recruiting","No Results Available","Glioma|Neuroectodermal Tumors, Primitive|Wilms Tumor|Rhabdomyosarcoma|Sarcoma, Ewing|Osteosarcoma|Retinoblastoma","Drug: Metronomic Cyclophosphamide|Drug: Thalidomide","Washington University School of Medicine","All","6 Months to 21 Years   (Child, Adult)","Early Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","201209088","July 30, 2012","October 2012","February 2021","November 1, 2016","November 2016","No Study Results Posted","ASCR","February 2018","Safety|Toxicity|Radiographic marker of neovascularization|Best overall response","https://ClinicalTrials.gov/show/NCT01661400"
1080,"NCT01458730","Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma","Active, not recruiting","No Results Available","Central Nervous System Lymphoma","Drug: Immunochemotherapy","University of Aarhus|Nordic Cancer Union|Roche Pharma AG|Mundipharma Pte Ltd.|Schering-Plough","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","66","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT No 2006-004772-12","September 15, 2011","May 2007","October 2020","November 15, 2012","November 2012","No Study Results Posted","null","October 2010","Overall survival|response rate|neurotoxicity","https://ClinicalTrials.gov/show/NCT01458730"
1081,"NCT00246103","Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies","Completed","No Results Available","Neoplasms, Advanced","Drug: Valproic acid|Drug: Epirubicin|Drug: 5-fluorouracil|Drug: Cyclophosphamide.","H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Pfizer","All","18 Years and older   (Adult, Senior)","Phase 1","82","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-13693|USFIRB#101881","October 28, 2005","March 2004","April 2008","February 20, 2017","January 2009","No Study Results Posted","null","April 2008","Maximum Tolerated Dose (MTD)","https://ClinicalTrials.gov/show/NCT00246103"
1082,"NCT01094548","Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy","Completed","Has Results","Multiple Myeloma","Biological: Tecemotide (L-BLP25)|Biological: Tecemotide (L-BLP25)|Drug: Single low dose cyclophosphamide|Drug: Multiple low dose cyclophosphamide","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 2","34","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR63325-008","March 24, 2010","January 2008","March 2012","January 24, 2016","January 2016","October 15, 2015","null","February 2011","Number of Participants With Overall Induced Mucinous Glycoprotein-1 (MUC-1)-Specific Immune Response|Number of Participants With Baseline Immune Response and Initial Increase of MUC1 Specific Immune Response|Number of Participants With Overall Induced Immune Response by Human Leukocyte-associated Antigen (HLA) Type|Percentage of Participants With Objective Clinical Response (Complete Response [CR], or Partial Response [PR], or Minimal Response [MR]|Time to Progression (TTP)|Time to Anti-tumor Therapy|Number of Participants With Treatment Emergent Adverse Events (TEAEs),Serious TEAEs, TEAEs of Grade 3 or 4 According to NCI-CTCAE v3.0, TEAEs Leading to Discontinuation and Injection Site Reactions (ISRs)","https://ClinicalTrials.gov/show/NCT01094548"
1083,"NCT02889523","Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell Lymphoma Patients Treated by Chemiotherapy","Recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: Tazemetostat|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Doxorubicin|Drug: Prednisolone","The Lymphoma Academic Research Organisation|Epizyme, Inc.","All","60 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","133","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Epi-RCHOP","July 11, 2016","October 2016","January 2020","November 16, 2016","November 2016","No Study Results Posted","Epi-RCHOP","June 2017","Phase I : Number of Dose Limiting Toxicities|Phase II : Number of Serious Adverse Events (SAE) et Adverse Events (AE)|Phase II : Complete Response Rate|Phase I : Serum concentration of CHOP components in presence/absence of Tazemetostat|Phase I : Serum concentration of Tazemetostat and its metabolite (EZH 6930) in presence of CHOP|Phase II : Overall response rate (ORR)|Phase II : progression free survival (PFS)|Phase II : serum concentration of R-CHOP components in the presence/absence of tazemetostat|Phase II : serum concentration of tazemetostat and its metabolite (EZH-6930) in the presence of R-CHOP","https://ClinicalTrials.gov/show/NCT02889523"
1084,"NCT00847444","Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as Well as Life Style Intervention","Unknown status","No Results Available","Breast Cancer","Drug: Drug-based intervention|Behavioral: Lifestyle-based Intervention","Philip Hepp|Ludwig-Maximilians - University of Munich","Female","18 Years and older   (Adult, Senior)","Phase 3","3547","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SUCCESS-C Trial","February 17, 2009","February 2009","September 2016","April 17, 2013","April 2013","No Study Results Posted","SUCCESS-C","September 2011","The first primary objective of this study is to compare disease free survival after randomisation in patients treated with a combination of 5-FU/Epirubicine/Cyclophosphamide followed by Docetaxel vs. Docetaxel/Cyclophosphamide|The second primary objective of this study is to compare disease free survival after randomisation in patients with vs. without lifestyle intervention","https://ClinicalTrials.gov/show/NCT00847444"
1085,"NCT00887536","A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: bevacizumab|Drug: docetaxel|Drug: doxorubicin|Drug: cyclophosphamide|Drug: pegfilgrastim","NSABP Foundation Inc|Genentech, Inc.|US Oncology Research","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","3900","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NSABP B-46-I|USOR 07132","April 23, 2009","May 2009","January 2022","May 4, 2017","April 2017","No Study Results Posted","null","December 2017","Invasive disease-free survival(IDFS)relative to the TAC chemotherapy regimen alone|Invasive disease-free survival (IDFS) relative to the TAC chemotherapy regimen|Disease-free survival (DFS-DCIS) relative to the TC alone regimen|Overall survival (OS) relative to the TC alone regimen|OS relative to the TAC regimen|Recurrence-free interval (RFI) relative to the TC alone regimen|RFI relative to the TAC regimen|Develop molecular predictive markers for the degree of benefit from TCB over TC or TAC|Provide the efficacy data from Group 1 patients and Group 2 patients enrolled in B-46-I/07132 to US Oncology Research, Inc. (USOR) for a planned combined analysis with efficacy data from patients receiving the same regimens in the USOR 06-090 trial|Toxicity associated with each of the regimens|Determine the role of topoisomerase II alpha (TOP2A) in prognosis and prediction of degree of benefit from TAC over TC|Develop predictive markers for benefit from doxorubicin","https://ClinicalTrials.gov/show/NCT00887536"
1086,"NCT01139359","Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma","Withdrawn","No Results Available","Lymphoma","Drug: darinaparsin|Drug: CHOP","Ziopharm","All","18 Years and older   (Adult, Senior)","Phase 1","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SGL1003","June 4, 2010","June 2010","June 2011","July 18, 2012","July 2012","No Study Results Posted","null","June 2011","Define Toxicity profile|Maximum Tolerated Dose","https://ClinicalTrials.gov/show/NCT01139359"
1087,"NCT02512679","Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells","Terminated","Has Results","Stem Cell Transplantation|Bone Marrow Transplantation|Peripheral Blood Stem Cell Transplantation|Allogeneic Transplantation|Genetic Diseases|Thalassemia|Pediatrics|Diamond-Blackfan Anemia|Combined Immune Deficiency|Wiskott-Aldrich Syndrome|Chronic Granulomatous Disease|X-linked Lymphoproliferative Disease|Metabolic Diseases","Drug: Cyclophosphamide Dose Level 1|Drug: Cyclophosphamide Dose Level 2|Drug: Cyclophosphamide Dose Level 3|Drug: Cyclophosphamide Dose Level 4","Children's Hospital Los Angeles|Lucile Packard Children's Hospital","All","3 Months and older   (Child, Adult, Senior)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCI-06-00177","May 21, 2015","February 2007","February 2014","January 12, 2017","January 2017","January 29, 2016","null","September 2013","Number of Participants With Neutrophil Engraftment (=/>500 Cells/uL) and Platelet Engraftment (>20K Cell/uL) at 30 Days|Number of Participants With Disease Recurrence at 1 Year Post-transplant|Number of Participants Who Developed Severe Mucositis, Veno-occlusive Disease (VOD), Toxicity of the Kidney, Liver, or Gastrointestinal (GI) Tract up to 1 Year Post-transplant|Number of Participants Who Developed Graft-Versus-Host-Disease (GVHD) as Determined by the Glucksberg Scale|Number of Participants Who Were Disease Progression-Free and Death-Free at 1 Year Post-transplant","https://ClinicalTrials.gov/show/NCT02512679"
1088,"NCT02482090","TIL Therapy for Metastatic Ovarian Cancer","Active, not recruiting","No Results Available","Metastatic Ovarian Cancer","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: TIL infusion|Drug: Interleukin-2","Inge Marie Svane|Herlev Hospital","Female","18 Years to 70 Years   (Adult, Senior)","Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","GY1508","June 23, 2015","July 2015","July 2017","February 23, 2017","February 2017","No Study Results Posted","null","December 2016","Number and type of reported adverse events|Treatment related immune responses|Objective response rate|Overall Survival|Progression free survival","https://ClinicalTrials.gov/show/NCT02482090"
1089,"NCT01129323","Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia","Withdrawn","No Results Available","Severe Aplastic Anemia","Drug: Cyclophosphamide, Fludarabine, Rabbit ATG","City of Hope Medical Center","All","up to 21 Years   (Child, Adult)","","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07081","April 21, 2010","November 2009","null","March 23, 2012","March 2012","No Study Results Posted","null","September 2011","Engraftment rate|Relapse|Development of Graft vs. Host Disease|Evaluation of the occurrence of secondary malignancies|Overall survival|Evaluation of treatment feasibility|Evaluation of toxicities","https://ClinicalTrials.gov/show/NCT01129323"
1090,"NCT02427620","A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma","Recruiting","No Results Available","Lymphoma","Drug: Ibrutinib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Dexamethasone|Drug: Mesna|Drug: Vincristine|Drug: Doxorubicin|Drug: G-CSF|Drug: Methotrexate|Drug: Cytarabine|Drug: Citrovorum","M.D. Anderson Cancer Center|Pharmacyclics LLC.","All","18 Years to 65 Years   (Adult)","Phase 2","100","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2014-0559|NCI-2015-00960","April 15, 2015","June 2015","June 2021","March 3, 2017","March 2017","No Study Results Posted","null","June 2021","Overall Response|Toxicity of Ibrutinib and Rituximab|Progression Free Survival (PFS) of Ibrutinib plus Rituximab with Rituximab - Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD)","https://ClinicalTrials.gov/show/NCT02427620"
1091,"NCT03017404","A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Doxorubicin Hydrochloride Liposome Injection|Drug: Cyclophosphamide|Drug: docetaxel","Hebei Medical University Fourth Hospital","Female","18 Years to 70 Years   (Adult, Senior)","","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CSPC-DMS-BC-02","January 9, 2017","May 2015","July 2016","January 10, 2017","January 2017","No Study Results Posted","null","May 2016","maximum tolerated dose","https://ClinicalTrials.gov/show/NCT03017404"
1092,"NCT00510367","Primary Breast Cancer Occurring Concomitant With Pregnancy","Active, not recruiting","No Results Available","Breast Cancer|Pregnancy","Drug: 5-Fluorouracil|Drug: Cyclophosphamide|Drug: Doxorubicin","M.D. Anderson Cancer Center","Female","Child, Adult, Senior","","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID01-193|NCI-2012-01578","July 31, 2007","August 2001","null","October 18, 2016","October 2016","No Study Results Posted","null","August 2018","Response of Multimodality (Chemotherapy, Surgery and Radiation Therapy) Treatment of Primary Breast Cancer in Pregnant Participants|Outcome of Children Exposed to Chemotherapy While in Their Mother's Womb","https://ClinicalTrials.gov/show/NCT00510367"
1093,"NCT02529852","A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Drug: Lenalidomide|Drug: Obinutuzumab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","M.D. Anderson Cancer Center|Celgene|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","59","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2015-0069|NCI-2015-01517","August 18, 2015","November 4, 2015","November 2021","May 11, 2017","May 2017","No Study Results Posted","null","November 2021","Maximum Tolerated Dose (MTD) of Lenalidomide, Obinutuzumab, and CHOP|Overall Response Rate","https://ClinicalTrials.gov/show/NCT02529852"
1094,"NCT02842099","Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: TA or TAC|Drug: X","Peking Union Medical College Hospital","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PUMCH-BREAST-X prolong therapy","July 17, 2016","January 2014","null","July 21, 2016","July 2016","No Study Results Posted","null","January 2020","Disease-free survival|Adverse event rate (CTCAE v. 3.0)|Overall survival","https://ClinicalTrials.gov/show/NCT02842099"
1095,"NCT01026116","A Randomized Trial Comparing Epirubicin/Cyclophosphamide Followed by Weekly Paclitaxel Versus Epirubicin/Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old","Recruiting","No Results Available","Breast Neoplasms","Drug: A|Drug: B","Fudan University","Female","18 Years to 40 Years   (Adult)","Phase 3","1664","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SHBCC09007","December 3, 2009","December 2009","null","December 3, 2009","December 2009","No Study Results Posted","PAY","December 2017","disease-free survival|overall survival","https://ClinicalTrials.gov/show/NCT01026116"
1096,"NCT00933127","S8809-S9800-S9911-S9704-A Study of Blood and Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone","Completed","No Results Available","Lymphoma","Genetic: DNA analysis|Genetic: polymerase chain reaction|Genetic: polymorphism analysis|Other: laboratory biomarker analysis","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","142","Other|NIH","Observational","Time Perspective: Retrospective","CDR0000630578|SWOG-S8809-S9800-S9911-S9704-A","July 3, 2009","December 2008","June 2012","July 23, 2014","July 2014","No Study Results Posted","null","June 2012","Association of Fc-gamma (Fcγ) receptor genotypes with overall and/or progression-free survival and clinical response|Novel polymorphisms in Fcγ receptors for predictive and prognostic significance","https://ClinicalTrials.gov/show/NCT00933127"
1097,"NCT00001507","Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer","Completed","No Results Available","Breast Neoplasm|Neoplasm Metastasis","Drug: Monoclonal Antibody 3A1|Drug: Monoclonal Antibody 95-5-49|Drug: Monoclonal Antibody 95-6-22|Device: Baxter Isolex 3001 Stem Cell Selection System|Device: Ceprate SC","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 1","107","NIH","Interventional","Primary Purpose: Treatment","960104|96-C-0104","November 3, 1999","July 12, 1996","June 20, 2014","April 19, 2017","June 20, 2014","No Study Results Posted","null","June 30, 1998","","https://ClinicalTrials.gov/show/NCT00001507"
1098,"NCT01314833","Efficacy Study of Adjuvant Chemotherapy for Chinese Primary Breast Cancer Patients","Active, not recruiting","No Results Available","Breast Cancer","Drug: Docetaxel Cyclophosphamide|Drug: Cyclophosphamide Fluorouracil Epirubicin Docetaxel|Drug: Epirubicin Cyclophosphamide Paclitaxel","Fudan University|Chinese Anti-Cancer Association","Female","40 Years to 65 Years   (Adult)","Phase 3","3200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Fudan BC Adjuvant CT1","March 9, 2011","June 2010","December 2018","March 14, 2011","July 2010","No Study Results Posted","null","June 2010","Disease Free Survival|Overall Survival|Recurrence Free Survival|Adverse Events","https://ClinicalTrials.gov/show/NCT01314833"
1099,"NCT00636155","EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Terminated","Has Results","Lymphoma, Small Lymphocytic|Leukemia, Lymphocytic, Chronic","Drug: cenersen sodium|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Fludarabine","David Rizzieri|Eleos, Inc.|Duke University","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00001363","January 22, 2008","February 2008","May 2012","November 26, 2012","November 2012","May 29, 2012","null","August 2011","Number of Patients With an Overall Response (Complete Response + Partial Response)|Progression Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00636155"
1100,"NCT01891578","Evaluation of Immunological Reconstitution After Haploidentical Bone Marrow Transplantation","Unknown status","No Results Available","Lymphoma","","Armando Santoro, MD|Istituto Clinico Humanitas","All","18 Years and older   (Adult, Senior)","","23","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ONC/OSS-04/2010","May 27, 2013","January 2011","December 2013","June 28, 2013","June 2013","No Study Results Posted","null","December 2013","Evaluation of T lymphocytes and NK cells absolute number|Evaluation of discrete T-cells populations|Evaluation of antigen-specific T cell populations|Evaluation of antigen-specific T lymphocyte's functionality|Evaluation of cytokines production by IL-2 and anti-CD16 activated NK cells","https://ClinicalTrials.gov/show/NCT01891578"
1101,"NCT00897091","S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil","Completed","No Results Available","Breast Cancer","Genetic: comparative genomic hybridization|Genetic: microarray analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: diagnostic laboratory biomarker analysis","Southwest Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","","750","Other|NIH","Observational","Time Perspective: Retrospective","CDR0000528264|S8814A-ICSC|GHI-01-024|U10CA032102","May 9, 2009","July 2006","October 2007","May 28, 2013","May 2013","No Study Results Posted","null","October 2007","Disease-free survival|Overall survival|Distant disease-free recurrence","https://ClinicalTrials.gov/show/NCT00897091"
1102,"NCT00203372","Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)","Completed","No Results Available","Breast Cancer","Drug: Bevacizumab 7.5 and TAC|Drug: Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)|Drug: Bevacizumab 15 and TAC|Drug: Placebo 15 and TAC","Translational Oncology Research International|Genentech, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","6","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","TORI B-02|10-001419","September 12, 2005","May 2005","null","October 9, 2015","February 2011","No Study Results Posted","null","June 2012","•To evaluate the safety and toxicity of the TAC regimen with the addition of bevacizumab given as preoperative therapy to patients with Stage II or Stage III breast cancer|•To estimate change from baseline expression of HIF1α as a measure of tumor angiogenesis, after a single dose of bevacizumab as compared to placebo|•To estimate the rate of CHF in patients receiving TAC with or without bevacizumab|•To estimate the rates of left ventricular ejection fraction (LVEF) changes as measured by either a decrease of > 15% from baseline, or > 10% to a value below the lower limit of normal (for the institution), in patients receiving TAC or TAC + bevacizumab|•To investigate the clinical efficacy of TAC and TAC plus bevacizumab by estimating the clinical objective response rate (CR + PR), pathologic complete response rate (pCR), and rate of breast-conserving surgery (BCS)|•To estimate the rate of post-surgical wound healing complications in patients who receive surgery after TAC or TAC plus bevacizumab","https://ClinicalTrials.gov/show/NCT00203372"
1103,"NCT00544505","Pre-operative Chemotherapy in Operable Breast Cancer, Phase III Study Comparing a Short Intensive Pre-operative Chemotherapy With the Same Therapy Initiated Shortly After Surgery(Peri-operatively)(POCOB)EORTC 10902)","Unknown status","No Results Available","Breast Cancer","Drug: Fluorouracil/Epirubicin/Cyclophosphamide","King Faisal Specialist Hospital & Research Center","Female","up to 70 Years   (Child, Adult, Senior)","","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RAC#931-006","October 15, 2007","September 2007","September 2013","December 11, 2011","December 2011","No Study Results Posted","null","September 2012","Efficacy","https://ClinicalTrials.gov/show/NCT00544505"
1104,"NCT00141648","Chemotherapy and Radiotherapy for Osteolymphoma","Completed","No Results Available","Osteolymphoma","Drug: Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.|Radiation: Radiotherapy","Trans-Tasman Radiation Oncology Group (TROG)|Australasian Leukaemia and Lymphoma Group|Australasian Radiation Oncology Lymphoma Group|Wesley Research Institute","All","17 Years and older   (Child, Adult, Senior)","","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TROG 99.04|ALLG LY-02","August 30, 2005","September 2000","February 2008","September 29, 2009","September 2009","No Study Results Posted","null","February 2007","Overall Survival. The time from registration to the date of death|Time to local or regional failure. Measured from registration.|Pathological fracture rate. Measured from registration.","https://ClinicalTrials.gov/show/NCT00141648"
1105,"NCT02844309","The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM","Recruiting","No Results Available","Waldenström Macroglobulinemia","Drug: Thalidomide","Institute of Hematology & Blood Diseases Hospital","All","18 Years to 85 Years   (Adult, Senior)","Phase 4","44","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IIT2015004-EC-2","July 17, 2016","May 2016","May 2020","July 25, 2016","July 2016","No Study Results Posted","BDH-WM02","November 2019","Overall response rate|progress-free survival","https://ClinicalTrials.gov/show/NCT02844309"
1106,"NCT00179816","Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors","Unknown status","No Results Available","Ewing's Sarcoma|Soft Tissue Sarcoma|Hepatoblastoma|Hodgkin's Disease|Germ Cell Tumor","Drug: High-Dose Chemotherapy with Tandem PBSC Rescue.","Ann & Robert H Lurie Children's Hospital of Chicago","All","up to 21 Years   (Child, Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT 0499 Solid","September 10, 2005","April 1999","September 2012","October 7, 2010","October 2010","No Study Results Posted","null","September 2012","Determine the feasibility and toxicity of tandem PBSC rescue following high dose chemotherapy as consolidation in pediatric patients with high risk solid tumors.|Evaluate length of remission and long term disease free survival in chemotherapy responsive high-risk pediatric solid tumor patients treated using this approach.|Evaluate correlation between cell dose and time to engraftment in high-risk pediatric solid tumor patients treated using this approach.","https://ClinicalTrials.gov/show/NCT00179816"
1107,"NCT02609386","IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity","Recruiting","No Results Available","Squamous Cell Carcinoma of the Oral Cavity","Biological: IRX-2|Drug: Cyclophosphamide|Drug: Indomethacin|Dietary Supplement: Zinc-containing multivitamin|Drug: Omeprazole","IRX Therapeutics","All","18 Years and older   (Adult, Senior)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IRX-2 2015-A","September 10, 2015","December 2015","December 2019","February 17, 2017","February 2017","No Study Results Posted","INSPIRE","February 2019","Change in Event-Free Survival from baseline|Change in Overall Survival from baseline|Change in safety from baseline in each Regimen using a pre-approved questionnaire (case report form)|Change in tumor size from baseline to surgery|Change in lymphocyte infiltrates in tumor comparing pre-treatment biopsy and surgical specimens","https://ClinicalTrials.gov/show/NCT02609386"
1108,"NCT00665457","Biomarkers in Women Receiving Chemotherapy and Celecoxib for Stage II or Stage III Breast Cancer That Can Be Removed by Surgery","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: capecitabine|Drug: celecoxib|Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Genetic: gene expression analysis|Genetic: polymorphism analysis|Genetic: protein expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: imaging biomarker analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: pharmacogenomic studies|Procedure: dynamic contrast-enhanced magnetic resonance imaging|Procedure: needle biopsy|Procedure: neoadjuvant therapy|Procedure: radiomammography|Procedure: ultrasound imaging","University of Nebraska|National Cancer Institute (NCI)","Female","19 Years and older   (Adult, Senior)","Phase 2","3","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","085-04|P30CA036727|UNMC-08504","April 22, 2008","April 2004","July 2009","June 17, 2013","June 2013","No Study Results Posted","null","July 2009","Safety|Efficacy in terms of pathologic complete response, progression-free and overall survival, and time to treatment failure|Determine mRNA and protein levels of TP, TS, COX-2, MMP-2, MDR-1, and VEGF before and after treatment|Correlate baseline expression of TS, TP, VEGF, MDR, COX-2 and MMP-2 to tumor response|Correlate specific molecule markers to clinical outcome","https://ClinicalTrials.gov/show/NCT00665457"
1109,"NCT02359162","Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage","Recruiting","No Results Available","Lymphoma, Extranodal NK-T-Cell","Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Pegaspargase|Drug: Etoposide|Drug: Vincristine|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Prednisone|Radiation: IMRT","Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SYSUCC-NK-308","February 4, 2015","May 2015","June 2018","October 18, 2016","October 2016","No Study Results Posted","null","June 2018","progression free survival|complete remission rate|overall survival|safety, as measured by adverse events","https://ClinicalTrials.gov/show/NCT02359162"
1110,"NCT00586014","High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Procedure: High-Dose Sequential Chemotherapy followed by ASCT","Duke University","All","18 Years and older   (Adult, Senior)","Phase 2","91","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0074","December 21, 2007","May 1997","February 2008","July 7, 2014","May 2013","No Study Results Posted","null","January 2006","To evaluate the progression free survival at one year in multiple myeloma patients who receive sequentially administered high dose cyclophosphamide and VP-16 followed by high-dose BCNU (Carmustine) plus Melphalan|To evaluate the response rates of multiple myeloma patients to this sequentially administered high dose chemotherapy.|To evaluate the safety and toxicity of this sequential high dose chemotherapy program in multiple myeloma patients.","https://ClinicalTrials.gov/show/NCT00586014"
1111,"NCT02778763","Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis","Completed","No Results Available","Breast Cancer","Drug: CBLB612|Drug: Placebo","BioLab 612 LLC|Cleveland BioLabs, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Prevention","BL-612-BC1","March 17, 2016","December 2015","July 2016","July 19, 2016","July 2016","No Study Results Posted","null","July 2016","Duration of ANC <1.0 x 103/μl (Grade 3-4)|Duration of ANC <0.5 x 103/μl (Grade 4)|Maximum level of ANC decrease (nadir)|Time to recovery of ANC level ≥1.5 x 103/μl|Incidence of febrile neutropenia (simultaneous drop of ANC <0.5 x 103/μl and body temperature >38.0°C)|Safety evaluation as measured by treatment-related adverse events as assessed by CTCAE v4.0|Duration of thrombocytopenia <50 x 103/μl|Duration of thrombocytopenia <25 x 103/μl|Duration of thrombocytopenia <10 x 103/μl|Maximum decrease of platelet level (nadir)|Time to platelet level recovery ≥75 x 103/μl|Changes in comparison with baseline level CD34+ by FACS|Changes in comparison with baseline level absolute reticulocyte count|Change of concentration of G-CSF by ELISA","https://ClinicalTrials.gov/show/NCT02778763"
1112,"NCT02636322","Smart Start: Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma","Recruiting","No Results Available","Lymphoma","Drug: Rituximab|Drug: Ibrutinib|Drug: Lenalidomide|Drug: Etoposide|Drug: Prednisone|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Doxorubicin","M.D. Anderson Cancer Center|Celgene|Janssen Scientific Affairs, LLC","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2015-0147|NCI-2016-00017","December 17, 2015","March 2016","March 2023","May 23, 2017","May 2017","No Study Results Posted","null","March 2023","Overall Response Rate (ORR) of Rituximab, Lenalidomide, and Ibrutinib in Participants With High Risk Diffuse Large B-Cell Lymphoma|Complete Response Rate (CRR) of Rituximab, Lenalidomide, and Ibrutinib combined with CHOP or EPOCH in Participants With High Risk Diffuse Large B-Cell Lymphoma","https://ClinicalTrials.gov/show/NCT02636322"
1113,"NCT00161564","A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone","Withdrawn","No Results Available","Idiopathic Thrombocytopenic Purpura (ITP)","Drug: Rituximab","Weill Medical College of Cornell University|Genentech, Inc.","All","12 Years and older   (Child, Adult, Senior)","Phase 2","null","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","U2735S","September 8, 2005","February 2004","null","May 15, 2008","May 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00161564"
1114,"NCT01182415","High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma","Completed","No Results Available","Non-Hodgkin's Lymphoma|CNS Lymphoma","Procedure: High-dose chemotherapy with autologous stem cell transplant","Massachusetts General Hospital|Genentech, Inc.|Otsuka America Pharmaceutical|Dana-Farber Cancer Institute","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","09-444","April 30, 2010","June 2010","December 2016","March 21, 2017","March 2017","No Study Results Posted","null","December 2015","Proportion of patients with CNS involvement by B-cell NHL, relapsed PCNSL, or relapsed PIOL who are alive and progression-free at one year|1-year progression free survival (PFS)|1-year Event free Survival (EFS)|1-year overall survival (OS)|Overall response rate","https://ClinicalTrials.gov/show/NCT01182415"
1115,"NCT02506777","Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.","Recruiting","No Results Available","Breast Cancer","Drug: metformin|Drug: Fluoruracil|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: melatonin","Petrov Research Institute of Oncology","Female","18 Years and older   (Adult, Senior)","Phase 2","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","MBC1","July 21, 2015","July 2015","August 2017","April 3, 2017","April 2017","No Study Results Posted","MBC1","August 2017","Response rate|Pathomorphological response|Adverse events incidence","https://ClinicalTrials.gov/show/NCT02506777"
1116,"NCT00849745","Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases","Terminated","No Results Available","Systemic Lupus Erythematosus|Systemic Sclerosis","Procedure: Nonmyeloablative allogeneic stem cell transplant","Duke University","All","18 Years to 69 Years   (Adult, Senior)","Phase 1","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00010324","February 22, 2009","January 2003","July 2015","June 21, 2016","June 2016","No Study Results Posted","null","July 2015","Engraftment|Graft versus Host Disease|Toxicity|Mortality|Response Rate|Immune Function Post-engraftment|Progression Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00849745"
1117,"NCT00429182","Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer","Completed","Has Results","Breast Cancer|Metastatic Breast Carcinoma|Invasive Breast Carcinoma","Drug: Carboplatin|Drug: Cyclophosphamide|Drug: Thiotepa|Procedure: Stem Cell Transplant","M.D. Anderson Cancer Center","All","18 Years to 55 Years   (Adult)","Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-0280","January 29, 2007","June 2007","February 2012","February 28, 2013","February 2013","February 28, 2013","null","February 2012","Number of Participants With Reduction in CTCs Following High-dose Chemotherapy With Purged Autologous Stem Cell Products|Median Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT00429182"
1118,"NCT00068601","S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer","Completed","Has Results","Breast Cancer|Infertility|Menopausal Symptoms","Drug: cyclophosphamide|Drug: goserelin acetate","Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|International Breast Cancer Study Group","Female","18 Years to 49 Years   (Adult)","Phase 3","257","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Supportive Care","CDR0000327758|S0230|CALGB-40401|IBCSG-34-05|U10CA037429","September 10, 2003","October 2003","September 2016","February 15, 2017","February 2017","December 16, 2016","null","January 2014","Rate of Premature Ovarian Failure at 2 Years|Rate of Ovarian Dysfunction at 2 Years|Rate of Ovarian Dysfunction at 1 Year","https://ClinicalTrials.gov/show/NCT00068601"
1119,"NCT00120198","Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients","Terminated","No Results Available","Non-Hodgkin's Lymphoma","Drug: CDOP plus rituximab","Geriatric Oncology Consortium|Tibotec Pharmaceutical Limited","All","65 Years and older   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GOC-LY-010","July 8, 2005","March 2005","September 2006","November 15, 2007","November 2007","No Study Results Posted","null","null","To evaluate the feasibility and tolerability of CDOP plus rituximab in elderly patients with previously untreated NHL.|Tumor response|duration of response|median time to disease progression|overall survival","https://ClinicalTrials.gov/show/NCT00120198"
1120,"NCT01642771","Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: 5-Fu/epirubicin/CTX following Docetaxel|Drug: Docetaxel/capecitabine followed by XEC","China Breast Cancer Clinical Study Group","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","636","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","EBC protocol 1.1","July 4, 2012","June 2012","May 2020","April 18, 2017","April 2017","No Study Results Posted","null","December 2019","5-year disease free survival|Number of Participants with Adverse Events as a Measure of Safety|FACT-B scale scores as a Measure of living quality|5-year relapse free survival, distant disease free survival and overall survival as measures of efficacy","https://ClinicalTrials.gov/show/NCT01642771"
1121,"NCT02954939","The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis","Recruiting","No Results Available","Lupus Nephritis","Drug: MMF-MMF|Drug: CTX-AZA","The University of Hong Kong","All","18 Years to 80 Years   (Adult, Senior)","","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science","UW12-389","September 13, 2016","March 2012","null","November 1, 2016","November 2016","No Study Results Posted","null","March 2019","Lymphocyte subset profile (CD8+ T cells, CD4+ Th1, Th2, Th17 & Treg), Naïve & memory B cells, plasma cells|serum cytokine profile (IL-2, IL-5, IL-6, IL-7, IL-10, IL-17, IL-21, IL-23, IFN-alpha, IFN-gamma, TGF-beta)","https://ClinicalTrials.gov/show/NCT02954939"
1122,"NCT00934739","A Study of High-Risk Oral Cavity Cancer","Terminated","No Results Available","Oral Cavity Cancer","Drug: Thalidomide, Celebrex|Drug: Cyclophosphamide, Dexamethasone","National Health Research Institutes, Taiwan|National Taiwan University Hospital|Chang Gung Memorial Hospital|Mackay Memorial Hospital|Changhua Christian Hospital|Sun Yat-sen University|National Cheng-Kung University Hospital|Kaohsiung Veterans General Hospital.|Buddhist Tzu Chi General Hospital|Chi Mei Medical Hospital","All","up to 70 Years   (Child, Adult, Senior)","Phase 2|Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","T1306","July 7, 2009","June 2007","December 2012","February 23, 2015","July 2009","No Study Results Posted","null","December 2012","The primary endpoint is the tumor-free survival that is defined as the duration between the dates of operation and the date of disease recurrence.|Physical examinations, lab abnormality and other toxicities graded by the NCI Common Toxicity Criteria will be examined to evaluate safety profiles of the study treatments.","https://ClinicalTrials.gov/show/NCT00934739"
1123,"NCT01236573","Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes","Terminated","Has Results","Skin Cancer|Metastatic Melanoma","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: IL-12 transduced TIL","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","18 Years to 66 Years   (Adult, Senior)","Phase 1|Phase 2","34","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","110011|11-C-0011","November 5, 2010","October 2010","March 2015","October 26, 2015","October 2015","August 20, 2015","null","March 2015","Maximum Tolerated Dose (MTD)|Response (Complete Response (CR) + Partial Response (PR)) to Therapy|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT01236573"
1124,"NCT01071239","Hematopoietic Stem Cell Transplant for Fanconi Anemia","Active, not recruiting","No Results Available","Fanconi Anemia","Device: CliniMACs device","Medical College of Wisconsin|Memorial Sloan Kettering Cancer Center","All","Child, Adult, Senior","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FA 08/89","May 20, 2009","April 2009","May 2019","April 5, 2016","April 2016","No Study Results Posted","FA","May 2018","To measure the incidence and quality of engraftment and hematopoietic reconstitution.|The incidence of early transplant related mortality and incidence and severity of acute and chronic GVHD","https://ClinicalTrials.gov/show/NCT01071239"
1125,"NCT02013375","SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD","Active, not recruiting","No Results Available","Sickle Cell Disease","Procedure: Haploidentical Transplant|Drug: Alemtuzumab|Radiation: Total Body Irradiation|Drug: Cyclophosphamide|Drug: Sirolimus","Damiano Rondelli, MD|University of Illinois at Chicago","All","16 Years to 60 Years   (Child, Adult)","Phase 2","110","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2013-0849","December 11, 2013","February 5, 2014","October 1, 2018","April 19, 2017","April 2017","No Study Results Posted","SCD-Haplo","October 1, 2018","Engraftment Rate|Acute & Chronic Complications|Overall & Disease-Free Survival|Morbidity & Mortality","https://ClinicalTrials.gov/show/NCT02013375"
1126,"NCT01036087","Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: Panitumumab|Drug: Nab-paclitaxel|Drug: Carboplatin|Drug: 5-Fluorouracil|Drug: Epirubicin|Drug: Cyclophosphamide","M.D. Anderson Cancer Center|Celgene Corporation|Amgen","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2008-0372|NCI-2012-00935","December 17, 2009","November 2010","November 2018","April 27, 2017","April 2017","No Study Results Posted","null","November 2018","Pathologic Complete Response (CR) Rate","https://ClinicalTrials.gov/show/NCT01036087"
1127,"NCT02127905","Unrelated HSCT in Patients With Fanconi Anemia","Enrolling by invitation","No Results Available","Fanconi Anemia","Biological: CD34+ selected cells","Neena Kapoor, M.D.|Children's Hospital Los Angeles","All","8 Weeks to 21 Years   (Child, Adult)","","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCI-10-00176","October 19, 2012","March 2011","March 2017","July 27, 2015","July 2015","No Study Results Posted","null","March 2017","Peripheral blood CBC counts for engraftment evaluation|Chimerism assay for engraftment evaluation|Graft Versus Host Disease (GVHD) surveillance after HSCT","https://ClinicalTrials.gov/show/NCT02127905"
1128,"NCT02879669","A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma","Recruiting","No Results Available","To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy","Biological: ONCOS-102|Drug: Pemetrexed/cisplatin|Drug: Cyclophosphamide","Targovax Oy|Theradex|Targovax ASA","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ONCOS C719|2015-005143-13","July 13, 2016","June 2016","null","April 28, 2017","April 2017","No Study Results Posted","null","December 2018","Number of patients with any (Serious and Non-Serious) Adverse Event measured to assess safety and tolerability|To determine and compare tumour-specific immunological activation in the peripheral blood in the experimental group and the control group. Number of patients in the respective arms with induction of Tumor specific CD8+ T Cells in PBMC|To determine and compare immunological activation in tumour mass in the experimental group and the control Group. Number of patients in the respective arms with infiltration of CD8+ T Cells into tumours|To determine and compare overall response rate in the experimental group and the control group by number of patients with PD, SD, PR and CR in the respective arms|To determine and compare progression-free survival (PFS) in the experimental group and the control group by median time to progression in the respective arms|To determine and compare overall survival (OS) in the experimental group and the control group|To analyse immunological activation by comparing patients with and without presence of tumour antigen recognizing CD8+ T cells|To analyse clinical outcome by time to event endpoints (OS and PFS)","https://ClinicalTrials.gov/show/NCT02879669"
1129,"NCT01959477","Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant","Completed","No Results Available","Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Childhood Anaplastic Large Cell Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage IA Mycosis Fungoides/Sezary Syndrome|Stage IB Mycosis Fungoides/Sezary Syndrome|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage II Childhood Hodgkin Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIA Mycosis Fungoides/Sezary Syndrome|Stage IIB Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IIIA Mycosis Fungoides/Sezary Syndrome|Stage IIIB Mycosis Fungoides/Sezary Syndrome|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Hodgkin Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Stage IVA Mycosis Fungoides/Sezary Syndrome|Stage IVB Mycosis Fungoides/Sezary Syndrome|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia","Drug: busulfan|Drug: etoposide|Drug: cyclophosphamide|Procedure: peripheral blood stem cell transplantation|Procedure: autologous hematopoietic stem cell transplantation","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","2 Years and older   (Child, Adult, Senior)","Early Phase 1","33","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE1412|NCI-2013-01829|CASE 1412|P30CA043703","October 8, 2013","March 2014","April 2015","August 12, 2015","August 2015","No Study Results Posted","null","January 2015","Feasibility of performing real-time TDM, determined by the proportion of enrolled patients who are able to have an area under curve (AUC) for busulfan calculated|Incidence of adverse events including mucositis, liver toxicity, seizures, and pulmonary toxicity, graded using NCI CTCAE version 4.0|Proportion of patients who would not have achieved desired busulfan level with weight-based busulfan dosing","https://ClinicalTrials.gov/show/NCT01959477"
1130,"NCT00004898","Radiation Therapy and Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With High-Grade Lymphoma or Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia|Lymphoma","Biological: filgrastim|Drug: cyclophosphamide|Drug: etoposide|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Northwestern University|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 1|Phase 2","6","Other|NIH","Interventional","Primary Purpose: Treatment","NU 91H5T|NU-91H5I|NCI-G00-1687","March 7, 2000","October 1999","July 2003","June 8, 2012","June 2012","No Study Results Posted","null","July 2003","","https://ClinicalTrials.gov/show/NCT00004898"
1131,"NCT00103558","Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)","Completed","No Results Available","Chronic Lymphocytic Leukemia","Drug: Lumiliximab with FCR","Biogen","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","31","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","152-30","February 10, 2005","March 2004","March 2010","September 17, 2015","May 2010","No Study Results Posted","null","January 2010","Characterize the safety profile|Evaluate the pharmacokinetics of lumiliximab and rituximab","https://ClinicalTrials.gov/show/NCT00103558"
1132,"NCT01868269","Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)","Recruiting","No Results Available","Opsoclonus Myoclonus Syndrome|Neuroblastoma","Drug: Dexamethasone acetate|Drug: dexamethasone and cyclophosphamide|Drug: dexamethasone and rituximab","Institut Curie","All","6 Months to 8 Years   (Child)","Phase 3","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IC 2011-02","May 27, 2013","April 18, 2013","April 2026","April 4, 2017","August 2016","No Study Results Posted","null","February 2022","The response to treatment schedule as defined by the percentage of patients with disappearance of all symptoms.","https://ClinicalTrials.gov/show/NCT01868269"
1133,"NCT01181999","Rituximab Augmentation Following R-CHOP Induction Chemotherapy in Extremely Elderly Patients With Diffuse Large B Cell Lymphoma","Unknown status","No Results Available","Lymphoma, Large B-cell, Diffuse","Drug: rituximab","Chonnam National University Hospital|Samsung Medical Center|Asan Medical Center|Severance Hospital","All","70 Years and older   (Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML25393","August 11, 2010","August 2010","September 2014","September 21, 2011","July 2010","No Study Results Posted","null","March 2012","the overall response rate|Number of patients with adverse events|progression-free survival","https://ClinicalTrials.gov/show/NCT01181999"
1134,"NCT02905188","Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)","Not yet recruiting","No Results Available","Hepatocellular Carcinoma","Genetic: GLYCAR T cells|Drug: Cytoxan|Drug: Fludarabine","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System","All","18 Years and older   (Adult, Senior)","Phase 1","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-38942 GLYCAR|GLYCAR","September 14, 2016","January 2018","January 2036","September 21, 2016","September 2016","No Study Results Posted","GLYCAR","February 2021","Number of Patients with Dose Limiting Toxicity|Percent of Patients with best response as either complete remission or partial remission|Median T cell persistence","https://ClinicalTrials.gov/show/NCT02905188"
1135,"NCT03054298","CAR T Cells in Mesothelin Expressing Cancers","Recruiting","No Results Available","Lung Adenocarcinoma|Ovarian Cancer|Peritoneal Carcinoma|Fallopian Tube Cancer|Mesotheliomas Pleural|Mesothelioma Peritoneum","Biological: Hu-CART meso cells","University of Pennsylvania","All","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","826085","February 9, 2017","March 1, 2017","March 2021","May 8, 2017","May 2017","No Study Results Posted","null","March 2021","Number of participants with treatment-related adverse events as assessed by CTCAE v4.03|Clinical anti-tumor effect by standard criteria (RECIST)|Clinical anti-tumor effect by standard criteria [modified RECIST for mesothelioma]|Progression-free survival|Progression overall survival","https://ClinicalTrials.gov/show/NCT03054298"
1136,"NCT00328861","Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer","Completed","Has Results","Metastatic Melanoma|Metastatic Kidney Cancer","Drug: Natural Killer (NK) Lymphocytes|Biological: IL-2|Drug: Cyclophosphamide|Drug: Fludarabine","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","8","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","060169|06-C-0169","May 20, 2006","May 2006","April 2009","October 4, 2012","October 2012","October 4, 2012","null","July 2007","Objective Response|Safety","https://ClinicalTrials.gov/show/NCT00328861"
1137,"NCT02533700","CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL","Recruiting","No Results Available","Peripheral T-Cell Lymphoma|Angioimmunoblastic T Cell Lymphoma|ALK-negative Anaplastic Large Cell Lymphoma|Enteropathy Associated T Cell Lymphoma|Subcutaneous Panniculitis Like T Cell Lymphoma|Acute Adult T-Cell Leukemia/Lymphoma","Drug: CEOP/IVE/GDP chemotherapy regimen|Drug: CEOP chemotherapy regimen for 6 cycles","Shandong Provincial Hospital","All","16 Years to 70 Years   (Child, Adult, Senior)","Phase 4","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment","WXin","July 18, 2015","September 2015","December 2017","April 18, 2016","April 2016","No Study Results Posted","null","September 2017","Percentage of patients with complete remission （CR）","https://ClinicalTrials.gov/show/NCT02533700"
1138,"NCT00278642","Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders","Terminated","No Results Available","Pemphigus","Biological: Hematopoietic stem cell transplantation","Richard Burt, MD|Northwestern University","All","18 Years to 60 Years   (Adult)","Phase 1","1","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DIAD Derm.Auto2001","January 16, 2006","September 2002","September 2011","April 4, 2013","April 2013","No Study Results Posted","null","September 2011","Percent surface area involved New skin or mucosal blister development Immune suppressive medication requirements Survival","https://ClinicalTrials.gov/show/NCT00278642"
1139,"NCT00876616","Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis","Completed","No Results Available","Lupus Nephritis","Drug: Tacrolimus+Mycophenolate mofetil|Drug: Cyclophosphamide","Zhi-Hong Liu, M.D.|Ruijin Hospital|West China Hospital|RenJi Hospital|China Medical University, China|Huashan Hospital|The First Affiliated Hospital with Nanjing Medical University|Beijing Friendship Hospital|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Nanjing University School of Medicine","All","18 Years to 65 Years   (Adult)","","362","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NJCT-0901","April 6, 2009","April 2009","February 2012","August 28, 2013","August 2013","No Study Results Posted","null","May 2011","To assess the efficacy of FK506 combined with MMF vs intravenous CTX pulses in treatment of class Ⅲ, Ⅳ,Ⅴ, Ⅲ+Ⅴand Ⅳ+Ⅴ LN.|To investigate the other efficacy indicators of FK506 combined with MMF vs intravenous CTX pulses in the treatment of class Ⅲ, Ⅳ,Ⅴ, Ⅲ+Ⅴand Ⅳ+Ⅴ LN.","https://ClinicalTrials.gov/show/NCT00876616"
1140,"NCT01719835","CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study","Recruiting","No Results Available","Peripheral T-cell Lymphoma NOS|Anaplastic Large Cell Lymphoma, ALK-Negative|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic Gamma/ Delta T-cell Lymphoma","Drug: Cyclophosphamide|Drug: Gemcitabine|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisolone|Drug: methylprednisolone|Drug: Cisplatin","Royal Marsden NHS Foundation Trust|Cancer Research UK","All","18 Years and older   (Adult, Senior)","Phase 2","186","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RMH CCR: 3549|2011-004146-18","April 12, 2012","March 2012","August 2022","October 30, 2012","October 2012","No Study Results Posted","CHEMO-T","March 2017","complete response rate (CR/CRu)|Toxicity|Overall Survival|Progression Free survival|Metabolic Complete Response Rate","https://ClinicalTrials.gov/show/NCT01719835"
1141,"NCT02917083","CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)","Not yet recruiting","No Results Available","Hodgkin's Lymphoma|Non-Hodgkin Lymphoma","Genetic: CAR T Cells|Drug: Cyclophosphamide|Drug: Fludarabine","Baylor College of Medicine|The Methodist Hospital System|Texas Children's Hospital","All","12 Years to 75 Years   (Child, Adult, Senior)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","H-37966, RELY-30|RELY-30","September 23, 2016","May 2017","February 2035","April 11, 2017","April 2017","No Study Results Posted","RELY-30","April 2020","Number of Patients with Dose-Limiting Toxicities (DLT)|Median Number of T cells transduced with the vector|Overall Response Rate|Mean Number of T cells transduced with the vector","https://ClinicalTrials.gov/show/NCT02917083"
1142,"NCT01315132","A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies","Recruiting","No Results Available","Hematological Malignancies|Leukemia|Lymphoma|Multiple Myeloma|Hodgkin's Disease","Device: Matched Sibling Allogeneic Transplantation","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 2","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","08D.85|2007-61","March 11, 2011","April 2008","January 2021","October 18, 2016","October 2016","No Study Results Posted","null","January 2020","Overall Survival|Engraftment, immune reconstitution, GVHD","https://ClinicalTrials.gov/show/NCT01315132"
1143,"NCT00278616","Hematopoietic Stem Cell Transplantation in Patients With Antiphospholipid Syndrome","Withdrawn","No Results Available","ANTIPHOSPHOLIPID SYNDROME","Biological: Stem Cell Transplantation","Richard Burt, MD|Northwestern University","All","18 Years to 55 Years   (Adult)","Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NU APS AUTO 2004","January 16, 2006","August 2005","October 2011","April 9, 2012","April 2012","No Study Results Posted","null","October 2011","Toxicity; Survival;Disease improvement;Time to disease progression;","https://ClinicalTrials.gov/show/NCT00278616"
1144,"NCT01363388","A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis","Completed","No Results Available","Vasculitis","Drug: Placebo|Drug: CCX168","ChemoCentryx","All","18 Years and older   (Adult, Senior)","Phase 2","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CL002_168","May 26, 2011","August 2011","January 2016","July 25, 2016","July 2016","No Study Results Posted","null","October 2015","Safety of CCX168 in subjects with AAV|Efficacy of CCX168 in subjects with AAV|Systemic corticosteroid use","https://ClinicalTrials.gov/show/NCT01363388"
1145,"NCT03070327","BCMA Targeted CAR T Cells for the Treatment of Multiple Myeloma","Recruiting","No Results Available","Multiple Myeloma","Biological: EGFRt/BCMA-41BBz CAR T cell|Drug: Cyclophosphamide","Memorial Sloan Kettering Cancer Center|Juno Therapeutics, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","17-025","February 28, 2017","February 27, 2017","February 2019","May 9, 2017","May 2017","No Study Results Posted","null","February 2019","MTD of gene-modified T cells","https://ClinicalTrials.gov/show/NCT03070327"
1146,"NCT00115414","Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)","Completed","No Results Available","Breast Cancer|Fever|Neutropenia","Drug: pegfilgrastim|Drug: docetaxel|Drug: doxorubicin|Drug: cyclophosphamide","Amgen","Female","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","20020778","June 22, 2005","null","null","July 31, 2008","July 2008","No Study Results Posted","null","null","Neutropenia|Disease Response|Adverse Events","https://ClinicalTrials.gov/show/NCT00115414"
1147,"NCT00493870","TAC Versus TC for Adjuvant Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: Docetaxel|Drug: Doxorubicin|Drug: Cyclophosphamide","US Oncology Research|Sanofi","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","1296","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","06090|11271","June 27, 2007","May 2007","May 2017","September 15, 2016","September 2016","No Study Results Posted","null","May 2015","to compare the 3-year DFS of adjuvant TC versus TAC as treatment for early stage HER2-negative breast cancer.","https://ClinicalTrials.gov/show/NCT00493870"
1148,"NCT00278564","Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases","Terminated","No Results Available","MYOPATHY","Biological: hematopoietic stem cell transplantation","Northwestern University","All","16 Years to 65 Years   (Child, Adult)","Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NU FDA IIM.Auto2003","January 15, 2006","September 2005","July 2016","July 13, 2016","July 2016","No Study Results Posted","null","July 2016","Toxicity;Survival;Disease improvement defined by muscle strength (one or more in MRC scale) and improvement of muscle derived enzymes (normalization) or improvement of pulmonary function tests","https://ClinicalTrials.gov/show/NCT00278564"
1149,"NCT02816112","Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia","Recruiting","No Results Available","Early Stage Breast Cancer","Drug: Ciprofloxacin|Drug: Neupogen","Ottawa Hospital Research Institute","All","19 Years and older   (Adult, Senior)","Phase 4","176","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","OTT 16-03","June 24, 2016","September 2016","August 2019","September 27, 2016","September 2016","No Study Results Posted","REaCT-TC2","August 2018","Febrile neutropenia|Treatment-related hospitalization|Chemotherapy dose reduction|Chemotherapy dose delay|Chemotherapy discontinuation|Microbiologic infections","https://ClinicalTrials.gov/show/NCT02816112"
1150,"NCT00005581","Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: paclitaxel","IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|National Cancer Institute (NCI)","Female","up to 70 Years   (Child, Adult, Senior)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000067266|INRC-GONO-MIG-5|NCI-V99-1562","May 2, 2000","June 2000","null","December 17, 2013","June 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005581"
1151,"NCT00001630","Treatment of Autoimmune Thrombocytopenia (AITP)","Completed","No Results Available","Autoimmune Disease|Autoimmune Hemolytic Anemia|Thrombocytopenia","Device: Isolex 300i","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult)","Phase 1","29","NIH","Interventional","Allocation: Non-Randomized|Masking: No masking|Primary Purpose: Treatment","970154|97-H-0154","November 3, 1999","July 21, 1997","June 11, 2009","January 24, 2017","March 21, 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001630"
1152,"NCT01868828","A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma","Unknown status","No Results Available","Multiple Myeloma","Drug: PAD|Drug: VCD|Other: ASCT","Peking University People's Hospital","All","up to 65 Years   (Child, Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PAD VS VCD Clinical Protocol","May 22, 2013","May 2013","May 2017","June 4, 2013","June 2013","No Study Results Posted","null","May 2015","Complete Response Rate|Safety|Overall Response Rate|Time To Response|1-year Survival Rate|Overall Survival","https://ClinicalTrials.gov/show/NCT01868828"
1153,"NCT02162771","To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan","Active, not recruiting","No Results Available","Lymphoma, Follicular","Biological: rituximab|Biological: CT-P10","Celltrion","All","18 Years and older   (Adult, Senior)","Phase 3","134","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CT-P10 3.3|2013-004493-96","May 29, 2014","June 2014","June 2020","February 11, 2016","February 2016","No Study Results Posted","rituximab","February 2017","Pharmacokinetics|Efficacy","https://ClinicalTrials.gov/show/NCT02162771"
1154,"NCT02274506","Infusion of Allogeneic, 3rd Party CD19-specific T Cells","Withdrawn","No Results Available","Blood And Marrow Transplantation|Leukemia|Lymphoma","Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: T-Cell Infusion","M.D. Anderson Cancer Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2011-0235","October 22, 2014","July 2014","null","October 22, 2014","October 2014","No Study Results Posted","null","July 2018","Maximum Tolerated Dose (MTD) of CD19-Specific T Cells","https://ClinicalTrials.gov/show/NCT02274506"
1155,"NCT01271907","Drosophila-generated CTL","Terminated","Has Results","Metastatic Cutaneous Melanoma","Drug: fludarabine|Drug: cyclophosphamide|Drug: Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL|Drug: Aldesleukin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","3","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","110052|11-C-0052","January 6, 2011","December 2010","April 2012","October 13, 2015","October 2015","November 7, 2012","null","April 2012","Clinical Response|Safety of Drosophila Generated PBL Administered in Combination With a Lymphodepleting Preparative Regimen and Supportive Systemic Aldesleukin","https://ClinicalTrials.gov/show/NCT01271907"
1156,"NCT00960115","Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy","Completed","Has Results","Non-small Cell Lung Cancer","Biological: Tecemotide (L-BLP25)|Drug: Single low dose cyclophosphamide|Biological: Placebo|Other: Saline","Merck KGaA|Merck Serono Co., Ltd., Japan","All","20 Years and older   (Adult, Senior)","Phase 1|Phase 2","178","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","EMR063325_009","August 5, 2009","December 2008","June 2015","September 21, 2015","September 2015","September 21, 2015","null","May 2014","Overall Survival (OS) Time|Time To Progression (TTP) - Investigator Read|Progression Free Survival (PFS) Time - Investigator Read|Time to Treatment Failure (TTF)","https://ClinicalTrials.gov/show/NCT00960115"
1157,"NCT01749293","Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation","Terminated","No Results Available","Hematologic Malignancies","Procedure: Haploidentical Transplant|Drug: Fludarabine|Drug: Busulfan|Radiation: Total Body Irradiation|Drug: Cyclophosphamide","University of Illinois at Chicago","All","10 Years to 75 Years   (Child, Adult, Senior)","Phase 2","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-0170","November 20, 2012","August 2012","June 2017","May 26, 2015","May 2015","No Study Results Posted","null","June 2017","Engraftment Rate|Overall & Event-Free Survival|Toxicity|HLA Disparity","https://ClinicalTrials.gov/show/NCT01749293"
1158,"NCT02354690","Vemurafenib and TIL Therapy for Metastatic Melanoma","Recruiting","No Results Available","Metastatic Melanoma","Drug: Vemurafenib|Drug: Lymphodepleting chemotherapy|Drug: TIL infusion|Drug: Interleukin-2","Inge Marie Svane|Herlev Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MM1414","January 26, 2015","November 2014","November 2017","February 22, 2016","February 2016","No Study Results Posted","null","November 2016","Number of reported adverse events|Treatment related immune responses|Objective response rate|Overall survival|Progression free survival","https://ClinicalTrials.gov/show/NCT02354690"
1159,"NCT00477412","Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma","Active, not recruiting","No Results Available","Mantle Cell Lymphoma|Lymphoma","Drug: Bortezomib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Methotrexate|Drug: Cytarabine|Drug: Doxorubicin","M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc.","All","18 Years to 79 Years   (Adult, Senior)","Phase 1","110","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-0697|NCI-2010-00884","May 21, 2007","April 2007","null","August 17, 2016","August 2016","No Study Results Posted","null","April 2017","Maximum Tolerated Dose (MTD) of Bortezomib Added to Combination of Rituximab, Methotrexate, and Cytarabine Alternating with Bortezomib, Rituximab-HyperCVAD|Median Time to Failure (TTF)","https://ClinicalTrials.gov/show/NCT00477412"
1160,"NCT01493453","A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy","Unknown status","No Results Available","CD19 Positive Non-Hodgkin Lymphoma","Genetic: aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine","Professor Robert Hawkins|The Christie NHS Foundation Trust","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05_DOG05_18","December 14, 2011","March 2008","December 2014","November 25, 2013","November 2013","No Study Results Posted","CD19","May 2014","To asses aCD19z T cell survival and aCD19z T cell toxicity in patients, & The dose of aCD19z T cells required to give optimal survival of these cells in the circulation|To assess whether aCD19z T cells in the circulation are functional","https://ClinicalTrials.gov/show/NCT01493453"
1161,"NCT01532635","A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives","Terminated","Has Results","Hematologic Malignancy|Leukemia|Acute Lymphoblastic Leukemia|ALL|Acute Myelogenous Leukemia|AML|Chronic Lymphocytic Leukemia|CLL|Lymphoma|Hodgkin's Lymphoma|Non-hodgkin's Lymphoma|Myeloma","Radiation: Total Body Irradiation (TBI)|Biological: Donor Lymphocyte Infusion (DLI)|Drug: Cyclophosphamide (CY)|Drug: Tacrolimus|Drug: Mycophenolate Mofetil (MMF)|Biological: Hematopoietic Stem Cell Transplant (HSCT)","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 2","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11D.570|2011-101","February 6, 2012","March 2012","May 2013","October 19, 2016","October 2016","November 3, 2014","null","February 2013","One Year Relapse-Free Survival|Chimerism Assessment|Assessment of Dominance|Relapse Rates|Engraftment|Immune Reconstitution|Non-relapse Morbidity and Mortality|Tolerance of DLI|Assessment for Tumor Escape Mechanisms","https://ClinicalTrials.gov/show/NCT01532635"
1162,"NCT01064375","Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer","Active, not recruiting","No Results Available","Colorectal Cancer","Biological: tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope)|Device: Derma Vax (electroporation device)|Biological: GM-CSF|Drug: Cyclophosphamide","Maria Liljefors|Karolinska Institutet|Swedish Institute for Infectious Disease Control|Cyto Pulse Sciences, Inc.|Karolinska University Hospital","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","El-porCEA|2009-009863-75","February 5, 2010","December 2009","October 2017","May 5, 2015","May 2015","No Study Results Posted","El-porCEA","February 2017","To evaluate the safety and immunogenicity of a DNA immunisation approach where tetwtCEA DNA will be administered in combination with electroporation.|To assess the efficiency of boosting immunological responses to CEA by intradermal administration of tetwtCEA DNA in combination with electroporation in subjects already vaccinated with CEA DNA|To compare effects (safety and immunogenicity) of additional adjuvance with GM-CSF","https://ClinicalTrials.gov/show/NCT01064375"
1163,"NCT00152178","The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)","Completed","No Results Available","Breast Cancer","Drug: UFT (uracil, tegafur) and tamoxifen|Drug: CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen","Taiho Pharmaceutical Co., Ltd.","Female","20 Years to 65 Years   (Adult)","Phase 3","680","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","91023033","September 8, 2005","July 1996","August 2008","July 6, 2011","July 2011","No Study Results Posted","null","April 2008","Relapse-free survival|Overall survival, adverse events, and the quality of life","https://ClinicalTrials.gov/show/NCT00152178"
1164,"NCT00656669","Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer","Completed","Has Results","Breast Cancer","Drug: sunitinib alone|Drug: sunitinib plus paclitaxel|Drug: doxorubicin and cyclophosphamide","Indiana University|Pfizer","All","18 Years and older   (Adult, Senior)","","23","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0802-15/1011003564; IUCRO-0215","April 7, 2008","April 2008","September 2010","July 21, 2014","July 2014","June 18, 2014","null","September 2010","Change in Interstitial Fluid Pressure (IFP) Induced by Sunitinib Monotherapy|Change in Interstitial Fluid Pressure (IFP) Induced by Paclitaxel Plus Sunitinib After Sunitinib Monotherapy|Pathological Complete Response (pCR) Rate for Patients Treated With Sunitinib/Paclitaxel Followed by AC as Neoadjuvant Therapy for Breast Cancer|To Evaluate the Safety of Paclitaxel Plus Sunitinib When Given in Combination as Neoadjuvant Therapy","https://ClinicalTrials.gov/show/NCT00656669"
1165,"NCT03126864","Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia","Not yet recruiting","No Results Available","Hematopoietic/Lymphoid Cancer|Acute Myeloid Leukemia","Procedure: Leukapheresis|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: CD33-CAR-T Cell Infusion","M.D. Anderson Cancer Center|Intrexon Corporation","All","1 Year to 80 Years   (Child, Adult, Senior)","Phase 1","36","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2016-0341","April 20, 2017","June 2017","June 2021","April 20, 2017","April 2017","No Study Results Posted","null","June 2021","Recommended Phase II Dose (RP2D) of CD33-CAR-T Cells|Disease Response to CD33-CAR-T Cells","https://ClinicalTrials.gov/show/NCT03126864"
1166,"NCT02223312","Therapy for Progressive and/or Refractory Hematologic Malignancies","Not yet recruiting","No Results Available","Cancer|Hematologic Malignancies","Biological: TAPA-pulsed DC vaccine","Kiromic, LLC","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","23","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KiroVAX002","August 11, 2014","December 2016","September 2017","November 3, 2016","November 2016","No Study Results Posted","null","May 2017","Number of adverse events that occur due to toxicity of low-dose CYP followed by TAPA-pulsed DC therapy and low-dose GM-CSF administration|Immunological efficacy as indicated by T-cell cytokine levels|Immunological efficacy as determined by a positive delayed type hypersensitivity (DTH) skin test","https://ClinicalTrials.gov/show/NCT02223312"
1167,"NCT01622361","Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: Adriamycin+Cyclophosphamide>Docetaxel|Drug: GnRHa with Tamoxifen","Asan Medical Center|Korean Breast Cancer Study Group","Female","20 Years and older   (Adult, Senior)","Phase 3","290","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KBCSG012","June 13, 2012","June 2012","February 2016","September 26, 2013","September 2013","No Study Results Posted","NEST","February 2016","Response Rate|Pathologic complete response","https://ClinicalTrials.gov/show/NCT01622361"
1168,"NCT03107988","Study of Lorlatinib (PF-06463922)","Not yet recruiting","No Results Available","Neuroblastoma","Drug: Lorlatinib|Drug: Cyclophosphamide|Drug: Topotecan","New Approaches to Neuroblastoma Therapy Consortium|Pfizer|University of Southern California","All","1 Year to 90 Years   (Child, Adult, Senior)","Phase 1","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","N2015-02","March 21, 2017","May 2017","December 2020","April 4, 2017","April 2017","No Study Results Posted","null","May 2020","Recommended phase 2 dose of lorlatinib administered orally to children and adolescents|Toxicities of lorlatinib as a single agent and in combination with topotecan and cyclophosphamide. Will be based on the CTCAE criteria and used to measure the severity of adverse events|Pharmacokinetics: AUC for lorlatinib and metabolite|Pharmacokinetics: Clearance for lorlatinib and metabolite|Pharmacokinetics: Cmax for lorlatinib and metabolite|Pharmacokinetics: Tmax for lorlatinib and metabolite|Pharmacokinetics:Terminal half-life for lorlatinib and metabolite|Evaluation of overall response|Evaluation of soft tissue response|Evaluation of bone response|Evaluation of bone marrow response","https://ClinicalTrials.gov/show/NCT03107988"
1169,"NCT00388349","Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease","Completed","No Results Available","Lymphoma, Hodgkin Disease|Lymphoma|Hodgkin Disease|Lymphoma: Hodgkin","Drug: Gemcitabine|Drug: Vinorelbine|Drug: Carmustine|Drug: Etoposide|Drug: Cyclophosphamide|Procedure: Autologous hematopoietic stem cell transplantation.","Stanford University|National Institutes of Health (NIH)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","146","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT135|1K23AI052413-01A1|77535|CA 49605","October 12, 2006","September 2001","September 2010","August 27, 2013","August 2013","No Study Results Posted","null","March 2008","Estimate freedom from progression,event-free survival and overall survival of the gemcitabine/vinorelbine and high dose chemotherapy regimen with AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL TRA among patients with refractory or recurrent Hodgkin's disease.|Assess non-hematologic toxicity and determine phase II dose of gemcitabine in combination with vinorelbine followed by high dose carmustine, etoposide and cyclophosphamide and autologous hematopoietic stem cell transplantation (AHCT)|Assess the pulmonary toxicity of a novel preparatory regimen containing gemcitabine, vinorelbine, carmustine, etoposide and cyclophosphamide in a phase II study.","https://ClinicalTrials.gov/show/NCT00388349"
1170,"NCT03118986","RCT of Olanzapine for Control of CIV in Children Receiving HSCT Conditioning","Not yet recruiting","No Results Available","Vomiting in Infants and/or Children|Nausea|Hematopoietic System--Cancer","Drug: Olanzapine|Drug: Placebo Oral Tablet","The Hospital for Sick Children","All","30 Months to 18 Years   (Child, Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Supportive Care","1000053716","March 16, 2017","April 2017","November 2021","April 13, 2017","April 2017","No Study Results Posted","null","June 2021","Rate of complete chemotherapy induced vomiting (CIV) control during the acute phase|complete CINV control|Safety profile of olanzapine based on toxicities|Safety profile of olanzapine based on weight|Safety profile of olanzapine based on PAERs|Safety profile of olanzapine based on prolactin|Safety profile of olanzapine based on amylase|Safety profile of olanzapine based on creatine phophotase|Safety profile of olanzapine based on triglycerides|Impact of olanzapine on HSCT outcomes on incidence of veno-occlusive disease|Impact of olanzapine on HSCT outcomes on incidence of GVHD|Impact of olanzapine on HSCT outcomes on severity of GVHD|Association between PeNAT and MAT scores","https://ClinicalTrials.gov/show/NCT03118986"
1171,"NCT01858571","Low Dose Chemotherapy Versus Best Supportive Care in Progressive Pediatric Malignancies","Completed","No Results Available","Malignant Childhood Neoplasm","Drug: Low dose chemotherapy","All India Institute of Medical Sciences, New Delhi","All","5 Years to 18 Years   (Child, Adult)","Phase 3","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider|Primary Purpose: Treatment","IEC/NP-63/2013","May 17, 2013","October 2013","January 2017","January 24, 2017","January 2017","No Study Results Posted","null","July 2016","Progression free survival|Overall Survival","https://ClinicalTrials.gov/show/NCT01858571"
1172,"NCT00301652","MMF Versus CTX in the Induction Treatment of ANCA Associated Vasculitis","Completed","No Results Available","Vasculitis|Anti-Neutrophil Cytoplasmic Antibody","Drug: mycophenolate mofetil","Nanjing University School of Medicine","All","18 Years to 65 Years   (Adult)","","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NJCT-0607","March 10, 2006","June 2003","December 2005","June 7, 2010","March 2009","No Study Results Posted","null","April 2004","The efficacy of MMF compared to CTX in inducing remission and improving renal function in subjects with ANCA associated vasculitis.","https://ClinicalTrials.gov/show/NCT00301652"
1173,"NCT01848197","Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer|Paclitaxel|Epirubicin|Cyclophosphamide","Drug: paclitaxel","Taizhou Hospital","Female","18 Years to 70 Years   (Adult, Senior)","","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ZJTC0001","May 2, 2013","May 2013","December 2020","May 6, 2013","May 2013","No Study Results Posted","PATEN","December 2018","disease-free survival|overall survival","https://ClinicalTrials.gov/show/NCT01848197"
1174,"NCT01032681","EMD 521873 in Advanced Solid Tumors, MTD Finding","Completed","No Results Available","Non-Hodgkin Lymphoma","Biological: EMD 521873|Biological: EMD 521873|Biological: EMD 521873","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 1","66","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR62235_001","December 11, 2009","December 2006","January 2012","July 30, 2014","October 2012","No Study Results Posted","null","February 2011","Assess the safety and tolerability of EMD 521873|To determine whether the MTD is reached with EMD 521873 doses of up to 1.5 mg/kg given alone or in combination with fixed, low-dose CPA in patients with metastatic or locally advanced solid tumors or B-cell non-Hodgkin lymphoma|Characterize the PK profile of EMD 521873 alone or in combination with fixed lowdose CPA|Evaluate the immunogenicity of EMD 521873 alone or in combination with CPA measured by the induction of o Specific antibodies against the genetically modified IL-2 o Fc-IL2-specific antibodies o Anti-idiotype antibodies|Collect evidence of best overall response, changes in serum tumor marker levels and best clinical response after treatment with EMD 521873 alone or in combination with CPA|Evaluate survival|Evaluate biological responses to EMD 521873 alone or in combination with CPA as measured by o Absolute cell numbers and ratios of lymphocyte subsets in defined combinations o Change in serum level of sIL2R and neopterin","https://ClinicalTrials.gov/show/NCT01032681"
1175,"NCT01653717","CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)","Active, not recruiting","No Results Available","Advanced Cancers|Leukemia","Procedure: Leukapheresis|Drug: Fludarabine|Drug: Cyclophosphamide|Procedure: T-cell Infusion","M.D. Anderson Cancer Center","All","18 Years to 80 Years   (Adult, Senior)","Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2011-1169|NCI-2013-01084","July 27, 2012","June 2013","June 2019","May 3, 2017","May 2017","No Study Results Posted","null","June 2019","Maximum Tolerated Dose (MTD) of CD19-specific T-cells|Clinically Successful T-Cell Production","https://ClinicalTrials.gov/show/NCT01653717"
1176,"NCT00005024","Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease","Unknown status","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: granisetron hydrochloride","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Supportive Care","CDR0000067540|UCLA-9904005|SB-BRL43694A/513|NCI-G00-1674","April 6, 2000","null","null","January 3, 2014","June 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005024"
1177,"NCT01445821","Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial","Recruiting","No Results Available","Scleroderma","Procedure: Cytoxan rATG/Fludarabine/HSCT|Procedure: Cytoxan rATG/HSCT","Northwestern University","All","17 Years to 60 Years   (Child, Adult)","Phase 3","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ASSIST IIb","September 29, 2011","September 2011","September 2018","March 9, 2017","March 2017","No Study Results Posted","DIScl2011","December 2017","2.1 Time to Treatment Failure|survival","https://ClinicalTrials.gov/show/NCT01445821"
1178,"NCT01385891","Clove In The Treatment Of Relapsed Or Resistant Acute Leukemia In Children","Completed","No Results Available","Acute Leukemia","Drug: Clofarabine VP 16 ciclophospahamide","Istituto Giannina Gaslini","All","1 Month to 20 Years   (Child, Adult)","Phase 2|Phase 3","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CM001|2008-004487-39","June 21, 2011","August 2008","February 2010","July 6, 2011","July 2008","No Study Results Posted","CLOVE","December 2009","response to treatment|Number of patients with toxicity as a measure of safety and tolerability","https://ClinicalTrials.gov/show/NCT01385891"
1179,"NCT01898039","Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients","Unknown status","No Results Available","Malignant Melanoma","Biological: A2/4-1BBL melanoma vaccine|Procedure: DNP sensititzation|Drug: Cyclophosphamide","Hadassah Medical Organization","All","Child, Adult, Senior","Phase 1|Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0419-12-HMO-CTIL","May 9, 2013","May 2013","null","July 10, 2013","June 2013","No Study Results Posted","null","April 2016","grade 2-4 adverse events according to CTCEA criteria|monitoring anti-tumor immune response|overall survival and disease free survival","https://ClinicalTrials.gov/show/NCT01898039"
1180,"NCT03101709","The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma","Recruiting","No Results Available","B Cell Lymphoma","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: CART-19","Henan Cancer Hospital|The Beijing Pregene Science and Technology Company, Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","HenanCH109","March 30, 2017","August 2016","July 2019","April 4, 2017","March 2017","No Study Results Posted","null","July 2018","safety as assessed by the occurence of study related adverse events|efficacy assessed by anti-tumor activity of CART-19 cells|duration of CART-19","https://ClinicalTrials.gov/show/NCT03101709"
1181,"NCT02924753","The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).","Recruiting","No Results Available","B-cell Acute Lymphoblastic Leukemia","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: CART-19 cells","Henan Cancer Hospital|The Beijing Pregene Science and Technology Company, Ltd.","All","4 Years to 70 Years   (Child, Adult, Senior)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HenanCH080","September 29, 2016","September 2016","July 2019","October 4, 2016","October 2016","No Study Results Posted","null","September 2017","safety as assessed by the occurrence of study related adverse events.|efficacy|duration of CART-19","https://ClinicalTrials.gov/show/NCT02924753"
1182,"NCT00016276","Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer","Terminated","No Results Available","Cardiac Toxicity|Inflammatory Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IV Breast Cancer","Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Drug: paclitaxel|Biological: trastuzumab|Procedure: therapeutic conventional surgery|Radiation: radiation therapy|Drug: tamoxifen citrate|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","396","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02380|CLB-49808|U10CA031946|CDR0000068617","May 6, 2001","May 2001","null","January 15, 2013","January 2013","No Study Results Posted","null","March 2005","Median number of positive axillary lymph nodes|Pathologic complete response (CR) rate in the breast and axilla|Cardiac toxicity, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0|Disease-free survival|Occurrence of grade 3 or higher late cardiac or neurological toxicity, or secondary acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS)|Clinical/radiographic response in the breast and axilla after doxorubicin hydrochloride and cyclophosphamide with or without dexrazoxane hydrochloride|Clinical/radiographic response in the breast and axilla after paclitaxel with or without trastuzumab|Time to local/regional recurrence|Time to completion of treatment through radiotherapy|Rate of breast conservation for patients considered ""candidates"" prior to treatment|Overall survival","https://ClinicalTrials.gov/show/NCT00016276"
1183,"NCT02641314","Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma","Recruiting","No Results Available","Neuroblastoma Recurrent","Drug: metronomic therapy","University of Cologne","All","2 Years to 20 Years   (Child, Adult)","Phase 2","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Uni-Koeln-1495|2011-004593-29","December 15, 2015","October 2016","March 2020","October 24, 2016","October 2016","No Study Results Posted","METRO-NB2012","October 2018","non-inferiority of EFS compared to historical control group|disease control rate at 6 months|Overall survival|Quality of life|hospitalization days|number of transfusion days|drop-out rate|disease control rate at 12 months","https://ClinicalTrials.gov/show/NCT02641314"
1184,"NCT01448096","Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma","Recruiting","No Results Available","Large B Cell Diffuse Lymphoma","Drug: Rituximab|Procedure: Prophylactic intrathecal chemotherapy","Chonbuk National University Hospital|Consortium for Improving Survival on Lymphoma","Female","20 Years to 75 Years   (Adult, Senior)","Phase 2","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Chonbuk058","October 5, 2011","August 2011","December 2018","January 6, 2017","January 2017","No Study Results Posted","null","December 2018","progression-free survival|overall survival|Number of patients with CNS recurrence|Number of patients with adverse events","https://ClinicalTrials.gov/show/NCT01448096"
1185,"NCT02833805","NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia","Recruiting","No Results Available","Severe Aplastic Anemia|Aplastic Anemia|Bone Marrow Failure|Immunosuppression","Drug: Thymoglobulin|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total body irradiation|Drug: Tacrolimus|Drug: Mycophenolate mofetil","Sidney Kimmel Comprehensive Cancer Center","All","Child, Adult, Senior","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","J1688|IRB00107139","July 12, 2016","August 2016","August 2020","May 1, 2017","May 2017","No Study Results Posted","null","August 2020","Overall survival and engraftment at one year|Overall survival at one year|Probability of neutrophil recovery|Probability of platelet recovery|Incidence of primary graft failure|Incidence of secondary graft failure|Incidence of grades II-IV acute GVHD, Day 100|Incidence of grades III-IV acute GVHD, Day 100|Incidence of chronic GVHD, one year|Estimate full donor chimerism|Estimate GVHD-free relapse-free survival (GRFS)|Estimate transplant-related mortality","https://ClinicalTrials.gov/show/NCT02833805"
1186,"NCT03146533","CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.","Recruiting","No Results Available","B Cell Lymphoma","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: CD19 CART","Shenzhen Second People's Hospital|The Beijing Pregene Science and Technology Company, Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","FirstShenzhen01","May 7, 2017","May 2017","October 2019","May 16, 2017","April 2017","No Study Results Posted","null","April 2019","safety as assessed by the occurence of study related adverse events|observe the maximum tolerated dose (MTD)|objective response rate|disease control rate|overall survival|Progression-Free Survival|Determine duration of in vivo survival of CD19 CART cells|Peripheral blood cytokines|subgroup of T cell","https://ClinicalTrials.gov/show/NCT03146533"
1187,"NCT01646034","High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: carboplatin, thiotepa, and cyclophosphamide|Drug: chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)","The Netherlands Cancer Institute","Female","18 Years and older   (Adult, Senior)","Phase 3","86","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","N12OLG|2012-000838-19","June 14, 2012","September 2014","July 2019","April 13, 2017","April 2017","No Study Results Posted","Oligo","July 2017","Event free survival|Difference in median overall survival|Difference in percentage of patients with grade >2 hematologic toxicity (CTCAE v4.0)|Difference in percentage of patients with grade >2 non-hematologic toxicity (CTCAE v4.0)","https://ClinicalTrials.gov/show/NCT01646034"
1188,"NCT01067989","Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer","Terminated","No Results Available","Chemotherapy|Breast Cancer, Metastatic","Drug: Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)","HaEmek Medical Center, Israel","Female","18 Years to 80 Years   (Adult, Senior)","Phase 2","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0078-09-EMC","February 11, 2010","March 2010","April 2014","July 6, 2015","July 2015","No Study Results Posted","null","April 2014","To determine the efficacy by rate of clinical benefit (CB): rate of response (RR) + rate of Stable Disease (SD)|Plasma Levels of angiogenic growth factors","https://ClinicalTrials.gov/show/NCT01067989"
1189,"NCT02897050","Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Docetaxel|Drug: Capecitabine|Drug: Cyclophosphamide (tablet)|Drug: Fluorouracil|Drug: Epirubicin|Drug: Cyclophosphamide (injection)","Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","186","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BCCT2016001","September 7, 2016","September 2016","September 2023","March 23, 2017","March 2017","No Study Results Posted","null","September 2020","Pathological complete response (pCR) rate|Ultrasound response rate|Breast-conserving surgery rate|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Tumor Ki67 reduction rate in relation to neoadjuvant therapy|Tumor CD31 reduction rate in relation to neoadjuvant therapy|Peripheral blood CD8+ T cell percentage change in relation to neoadjuvant therapy|Peripheral blood regulatory T cell percentage change in relation to neoadjuvant therapy|Peripheral blood tumor specific T cell (CTL) percentage change in relation to neoadjuvant therapy|Peripheral blood T helper cell percentage change in relation to neoadjuvant therapy","https://ClinicalTrials.gov/show/NCT02897050"
1190,"NCT02858999","Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70","Completed","No Results Available","Multiple Myeloma","Drug: PAD-VCD","Centre Hospitalier Universitaire, Amiens","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AOL09-DR-ROYER","August 4, 2016","January 2010","September 2016","November 30, 2016","November 2016","No Study Results Posted","LPP","July 2016","Disease-free survival","https://ClinicalTrials.gov/show/NCT02858999"
1191,"NCT02562365","Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer","Recruiting","No Results Available","Ovarian Cancer","Drug: Etoposide, Cyclophosphamide, Carboplatin","Xiaohua Wu MD|Fudan University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","130","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FUSCC-OC1501","September 27, 2015","November 2015","November 2023","December 2, 2016","December 2016","No Study Results Posted","ACTS","November 2021","overall survival|Progression-Free-Survival|Health-related quality of life","https://ClinicalTrials.gov/show/NCT02562365"
1192,"NCT02500576","MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2)","Recruiting","No Results Available","Melanoma","Drug: Cyclophosphamide|Drug: Mesna|Drug: Fludarabine|Procedure: TIL (T-cells)|Drug: IL-2|Drug: MK-347|Behavioral: Questionnaires|Behavioral: Phone Calls","M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.|Prometheus Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","36","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2014-0922|NCI-2015-01395","July 14, 2015","August 7, 2015","August 1, 2020","May 5, 2017","May 2017","No Study Results Posted","null","August 1, 2020","Overall Response Rate (ORR)","https://ClinicalTrials.gov/show/NCT02500576"
1193,"NCT01995344","TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment","Not yet recruiting","No Results Available","Metastatic Melanoma","Drug: Cyclophosphamide|Drug: Fludarabine|Genetic: Tumour Infiltrating Lymphocytes|Drug: Interleukin-2","The Christie NHS Foundation Trust|National Institute for Health Research, United Kingdom","All","18 Years and older   (Adult, Senior)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","11_DOG14_12|2013-001071-20","November 21, 2013","October 2013","December 2018","November 21, 2013","November 2013","No Study Results Posted","METILDA","October 2018","Disease response according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria|Disease response according to RECIST criteria","https://ClinicalTrials.gov/show/NCT01995344"
1194,"NCT02224872","Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia","Recruiting","No Results Available","Severe Aplastic Anemia|Bone Marrow Failure Syndromes","Procedure: Bone marrow transplant|Drug: Thymoglobulin|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: TBI|Drug: Mesna|Drug: Tacrolimus|Drug: Mycophenolic acid mofetil","Sidney Kimmel Comprehensive Cancer Center","All","up to 73 Years   (Child, Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J1424|IRB00031590","August 18, 2014","August 2014","null","May 17, 2016","May 2016","No Study Results Posted","null","August 2019","Is this type of transplantation for SAA feasible and safe?|Number of patients that have survived at one year|Number of patients that have acheived full donor chimerism by day 60 after transplant|Number of patients that expired due to non-relapsed-related mortality following transplant|Major toxicities related to transplant|Number of patients that expired due to transplant related mortality|Number of patients with primary or secondary graft failure following transplant|Number of patients with grade II-IV or grade III-IV acute GVHD|Number of patients with chronic GVHD|Length of time required for patients to recover ANC and platelet counts after transplant|Length of GVHD free, relapse free survival (GRFS) in patients","https://ClinicalTrials.gov/show/NCT02224872"
1195,"NCT01706666","Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant","Active, not recruiting","Has Results","Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma","Drug: bortezomib|Drug: cyclophosphamide|Drug: lenalidomide|Other: laboratory biomarker analysis|Drug: dexamethasone|Procedure: quality-of-life assessment","Mayo Clinic","All","18 Years and older   (Adult, Senior)","Phase 2","3","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MC1186|NCI-2012-01579","October 11, 2012","December 2012","May 2018","June 6, 2016","January 2016","April 27, 2016","null","July 2014","Proportion of Patients Experiencing a Stringent Complete Response (sCR) After 12 Cycles, 24 Months|Survival Time|Progression-free Survival","https://ClinicalTrials.gov/show/NCT01706666"
1196,"NCT01192555","Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma","Active, not recruiting","No Results Available","Neuroblastoma","Biological: Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells)|Drug: Cytoxan (Cyclophosphamide)","Baylor College of Medicine|Texas Children's Hospital|Center for Cell and Gene Therapy, Baylor College of Medicine","All","Child, Adult, Senior","Phase 1|Phase 2","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-26652-ATOMIC","August 16, 2010","September 2010","September 2026","December 6, 2016","December 2016","No Study Results Posted","ATOMIC","July 2012","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Number of Participants with Disease Progression as a Measure of Efficacy|Participants with T-cell changes as a Measure of Immune Response|Analysis of Immunologic Measurements","https://ClinicalTrials.gov/show/NCT01192555"
1197,"NCT00525759","Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel|Drug: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid","Sheffield Teaching Hospitals NHS Foundation Trust","Female","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","STH14707","September 5, 2007","July 2007","January 2010","November 3, 2010","November 2010","No Study Results Posted","ANZAC","January 2010","Increase in apoptotic index between diagnostic core biopsy and repeat core biopsy taken on day 5|Reduction in Ki67 immunostaining between preoperative core biopsy, repeat core biopsy on day 5, +/- day 21, and operative specimen|Changes in serum angiogenesis markers between pre-treatment and operative time points|Changes in bone biochemical markers between pre-treatment, treatment and operative timepoints|Detection of, and changes in, circulating tumour cells in peripheral blood taken pre-treatment, during treatment and following treatment","https://ClinicalTrials.gov/show/NCT00525759"
1198,"NCT02987244","Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma","Recruiting","No Results Available","T Cell Non-Hodgkin's Lymphoma","Drug: Chidamide|Drug: Cyclophosphamide|Drug: Epirubicin|Drug: Vindesine|Drug: Etoposide|Drug: Prednisone","Peking Union Medical College Hospital|Chinese PLA General Hospital|Peking University First Hospital|Peking University Third Hospital|Beijing Cancer Hospital|Tianjin Medical University Cancer Institute and Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PUMCH-NHL-002","December 2, 2016","March 2016","March 2023","December 6, 2016","December 2016","No Study Results Posted","null","March 2020","2 years progression-free survival|5 years overall survival（OS）|overall response rate(ORR) and complete remission rate(CR）|adverse events","https://ClinicalTrials.gov/show/NCT02987244"
1199,"NCT02623582","CD123 Redirected Autologous T Cells for AML","Active, not recruiting","No Results Available","Relapsed or Refractory Acute Myeloid Leukemia","Biological: Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes|Drug: Cyclophosphamide","University of Pennsylvania","All","18 Years and older   (Adult, Senior)","Early Phase 1","7","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UPCC 04415","December 3, 2015","December 2015","null","September 15, 2016","September 2016","No Study Results Posted","null","December 2018","Number of Adverse Events","https://ClinicalTrials.gov/show/NCT02623582"
1200,"NCT01370694","Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)","Terminated","Has Results","Follicular Lymphoma","Drug: MK-8808|Drug: cyclophosphamide|Drug: vincristine|Drug: prednisolone","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","8808-001|2011-000386-13","May 18, 2011","August 2011","December 2014","April 25, 2016","April 2016","October 23, 2015","null","December 2014","Number of Participants Experiencing Clinical and Laboratory Adverse Events (AEs) During MK-8808/CVP Combination Therapy|Number of Participants Experiencing Clinical and Laboratory AEs During MK-8808 Maintenance Therapy|Maximum Concentration (Cmax) of Plasma Levels of MK-8808 When Used in Combination With CVP|Cmax of Plasma Levels of MK-8808 During Single Agent Maintenance Therapy|Lowest Concentration (Ctrough) of Plasma Levels of MK-8808 When Used in Combination With CVP|Ctrough of Plasma Levels of MK-8808 When Used as Single Agent Maintenance|Clinical Response of Tumor to MK-8808/CVP Combination Therapy","https://ClinicalTrials.gov/show/NCT01370694"
1201,"NCT02926053","TIL Therapy for Metastatic Renal Cell Carcinoma","Recruiting","No Results Available","Metastatic Renal Cell Carcinoma","Procedure: Surgical removal of tumor tissue for T cell production|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: TIL infusion|Drug: Interleukin-2","Inge Marie Svane|Herlev Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UG1617","October 5, 2016","December 2016","December 2018","December 13, 2016","December 2016","No Study Results Posted","null","December 2017","Number and type of reported adverse events|Treatment related immune responses|Objective response rate|Overall Survival|Progression free survival","https://ClinicalTrials.gov/show/NCT02926053"
1202,"NCT01371630","Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)","Recruiting","No Results Available","Leukemia|Acute Lymphoblastic Leukemia","Drug: Inotuzumab Ozogamycin|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Mesna|Drug: Vincristine|Drug: Dexamethasone|Drug: Pegfilgrastim|Drug: Methotrexate|Drug: Ara-C|Drug: 6-Mercaptopurine|Drug: Prednisone|Drug: Citrovorum","M.D. Anderson Cancer Center|Pfizer","All","Child, Adult, Senior","Phase 1|Phase 2","206","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2010-0991|NCI-2011-01123","June 9, 2011","August 2011","September 2018","March 20, 2017","March 2017","No Study Results Posted","null","September 2018","Phase I: Maximum Tolerated Dose (MTD) of Inotuzumab Ozogamycin in Combination With Low-Intensity Chemotherapy|Phase II: Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT01371630"
1203,"NCT01679041","High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment","Terminated","No Results Available","Multiple Sclerosis","Drug: Alemtuzumab|Drug: Fludarabine|Drug: Cyclophosphamide","Seah Lim M.D.|Texas Oncology Cancer Center","All","18 Years to 60 Years   (Adult)","Phase 2","1","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20112015","August 29, 2012","November 2012","November 2013","November 21, 2013","November 2013","No Study Results Posted","null","November 2013","To evaluate the toxicity of autologous HPC transplant in patients with multiple sclerosis that have failed at least two lines of disease modifier therapy|To evaluate the effectiveness of high dose chemotherapy with HPC transplant for multiple sclerosis sclerosis that has failed at least two lines of therapy","https://ClinicalTrials.gov/show/NCT01679041"
1204,"NCT02385955","Phase II Study of Myeloablative Double Unit Umbilical Cord Blood Transplantation in Adult Patients","Not yet recruiting","No Results Available","Hematologic Malignancy","Procedure: Myeloablative double unit cord blood transplantation","Seoul National University Hospital|The Korean Society of Blood and Marrow Transplantation","All","18 Years to 65 Years   (Adult)","Phase 2","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KSBMT200809","January 20, 2015","April 2015","April 2019","March 10, 2015","March 2015","No Study Results Posted","null","April 2017","Overall survival|Progression-free survival|Time to relapse or progression|Time to engraftment|Acute graft-versus-host disease|Chronic graft-versus-host disease|Non-relapse mortality|Other transplant-related serious adverse events","https://ClinicalTrials.gov/show/NCT02385955"
1205,"NCT00924326","CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma","Active, not recruiting","No Results Available","Primary Mediastinal B-cell Lymphoma|Diffuse, Large B-cell Lymphoma|Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma|Mantle Cell","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-CD19-CAR PBL","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","43","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","090082|09-C-0082","June 17, 2009","February 12, 2009","December 31, 2020","May 12, 2017","January 11, 2017","No Study Results Posted","null","December 31, 2019","Determine the safety and feasibility of the administration of anti-CD19-CAR engineered peripheral blood lymphocytes with a nonmyeloablative conditioning regimen in patients with B-cell malignancies.|Determine the in vivo survival of the cryopreserved anti-CD19- CAR-transduced T cells.|Determine if the treatment regimen can cause regression of B-cell malignancies.","https://ClinicalTrials.gov/show/NCT00924326"
1206,"NCT00809276","Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY","Completed","Has Results","Lymphoma|Multiple Myeloma|Leukemia|Myelodysplastic Syndrome","Drug: Busulfan, Fludarabine, Cytoxan","Sidney Kimmel Comprehensive Cancer Center|M.D. Anderson Cancer Center|Fred Hutchinson Cancer Research Center|Otsuka Pharmaceutical Co., Ltd.","All","up to 65 Years   (Child, Adult)","Phase 1|Phase 2","92","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0844|NA_00017193","December 16, 2008","May 2009","December 2011","January 29, 2015","January 2015","December 19, 2014","null","December 2011","To Determine the Optimal Regimen of Post-graft Immunosuppression With High-dose Cy Following Fludarabine, Busulfan, and Transplantation of Fully HLA-matched Bone Marrow That Leads to an Acceptable Incidence of Grades III/IV Acute GVHD","https://ClinicalTrials.gov/show/NCT00809276"
1207,"NCT02734771","A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Brentuximab vedotin|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone","Patrick Reagan|Seattle Genetics, Inc.|University of Rochester","All","75 Years and older   (Senior)","Phase 2","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ULYM15105|IST-2014-100578","April 6, 2016","June 2016","June 2020","March 23, 2017","March 2017","No Study Results Posted","BV mini CHP","June 2018","Percent of Subjects Completing Regimen|Overall Survival|Progression Free Survival|Overall Response Rate|Complete Response Rate","https://ClinicalTrials.gov/show/NCT02734771"
1208,"NCT02328950","A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome","Recruiting","No Results Available","Myelodysplastic Syndromes|Leukemia, Myeloid, Acute|Precursor Cell Lymphoblastic Leukemia-Lymphoma","Drug: Fludarabine and Cytarabine followed by IV busulfan and cyclophosphamide","Fujian Medical University","All","1 Year to 65 Years   (Child, Adult)","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FA5Bucy-SCT-01","December 28, 2014","December 2014","December 2017","February 16, 2016","February 2016","No Study Results Posted","null","September 2016","Relapse rate at one year after allo-SCT|Even free survival","https://ClinicalTrials.gov/show/NCT02328950"
1209,"NCT00002554","Monoclonal Antibody Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia in Remission or First Relapse","Completed","No Results Available","Leukemia","Drug: busulfan|Drug: cyclophosphamide|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation|Radiation: radioimmunotherapy","Fred Hutchinson Cancer Research Center","All","16 Years to 55 Years   (Child, Adult)","Phase 2","30","Other","Interventional","Primary Purpose: Treatment","832.00|CDR0000063421|NCI-V94-0393","November 1, 1999","November 1993","December 1999","March 29, 2010","March 2010","No Study Results Posted","null","December 1999","","https://ClinicalTrials.gov/show/NCT00002554"
1210,"NCT00796562","Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy","Completed","No Results Available","MDS|Leukemias|Lymphomas","Drug: Busulfan|Drug: Cyclophosphamide|Radiation: Total body irradiation","Sidney Kimmel Comprehensive Cancer Center|Otsuka Pharmaceutical Co., Ltd.|National Center for Research Resources (NCRR)","All","6 Months to 65 Years   (Child, Adult)","Phase 2","96","Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening","J0820|NA_00015795|KL2RR025006","November 20, 2008","November 2008","December 2016","December 13, 2016","December 2016","No Study Results Posted","mylehaplo","December 2016","To estimate the incidence of donor cell engraftment following myeloablative, HLA-mismatched BMT for patients with high risk hematologic malignancies.|To estimate overall survival, relapse, non-relapse mortality, and event-free survival in patients receiving myeloablative conditioning and transplantation of partially human leukocyte antigen (HLA)-mismatched bone marrow from first-degree relatives","https://ClinicalTrials.gov/show/NCT00796562"
1211,"NCT00326417","Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)","Completed","Has Results","Anemia, Aplastic","Drug: Fludarabine|Drug: Cyclophosphamide 150mg|Drug: Cyclophosphamide 100mg|Drug: Cyclophosphamide 50mg","Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program","All","up to 65 Years   (Child, Adult)","Phase 1|Phase 2","97","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMTCTN0301|U01HL069294|5U01HL069294-05|5U24CA076518","May 12, 2006","January 2006","January 2016","October 3, 2016","August 2016","August 10, 2016","null","September 2015","Disease-free Survival (DFS)|Cumulative Incidence of Graft Failure|Acute Graft vs Host Disease (GVHD)|Chronic GVHD|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00326417"
1212,"NCT00931229","Incidence of Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients","Active, not recruiting","No Results Available","Non-Hodgkin's Lymphoma","Drug: entecavir","National Health Research Institutes, Taiwan|National Taiwan University Hospital|Mackay Memorial Hospital|China Medical University Hospital|Chi Mei Medical Hospital|Taichung Veterans General Hospital|Kaohsiung Veterans General Hospital.|Kaohsiung Medical University","All","18 Years to 75 Years   (Adult, Senior)","","202","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","T1408","June 29, 2009","June 2009","December 2017","November 8, 2016","December 2011","No Study Results Posted","null","December 2017","enroll 150 patients","https://ClinicalTrials.gov/show/NCT00931229"
1213,"NCT02932956","Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)","Not yet recruiting","No Results Available","Solid Tumors","Genetic: GAP T cells|Drug: Cytoxan|Drug: Fludara","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital","All","1 Year to 18 Years   (Child, Adult)","Phase 1","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-39410- GAP|GAP","October 12, 2016","March 2018","May 2036","January 5, 2017","January 2017","No Study Results Posted","GAP","April 2021","Number of Patients with Dose Limiting Toxicity|Percent of Patients with best response as either complete remission or partial remission|Median T cell persistence","https://ClinicalTrials.gov/show/NCT02932956"
1214,"NCT01606878","Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma","Recruiting","No Results Available","Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Neuroblastoma|Unspecified Childhood Solid Tumor, Protocol Specific","Drug: crizotinib|Drug: cyclophosphamide|Drug: topotecan hydrochloride|Drug: vincristine sulfate|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Other: pharmacological study|Other: laboratory biomarker analysis|Other: pharmacogenomic studies|Other: questionnaire administration","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 1","65","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ADVL1212|NCI-2012-01968|U01CA097452","May 24, 2012","March 2013","null","May 10, 2017","May 2017","No Study Results Posted","null","October 2018","Adverse events as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|MTD of crizotinib administered with combination chemotherapy based on the incidence of dose-limiting toxicity (DLT) at which fewer than one-third of patients experience DLT, as assessed by NCI CTCAE version 4.0|Pharmacokinetic parameters of crizotinib administered with combination chemotherapy","https://ClinicalTrials.gov/show/NCT01606878"
1215,"NCT00005960","Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy","Unknown status","No Results Available","Pain|Prostate Cancer","Biological: filgrastim|Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Procedure: pain therapy","Amgen|National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Primary Purpose: Treatment","CDR0000067942|AMGEN-GCSF-980282|NCI-V00-1595","July 5, 2000","October 1999","null","December 3, 2013","January 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005960"
1216,"NCT02324088","Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer","Completed","No Results Available","Inflammatory Breast Cancer","Drug: Docetaxel|Drug: Cyclophosphamide|Drug: Epirubicin","UNICANCER","Female","18 Years to 60 Years   (Adult)","Phase 3","174","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","PEGASE 7/0002","December 14, 2014","October 2000","January 2015","May 3, 2017","May 2017","No Study Results Posted","PEGASE07","December 2012","disease-free survival rate","https://ClinicalTrials.gov/show/NCT02324088"
1217,"NCT01141959","Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients","Completed","No Results Available","Leukemia|Hodgkin Disease|Non-Hodgkin Lymphoma|Myelodysplastic Syndrome|Multiple Myeloma","","Fred Hutchinson Cancer Research Center|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Senior)","","11","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","FHCRC-2373.00|IR-7093|R01HL091744-02S1","June 8, 2010","May 2010","December 2011","March 9, 2015","March 2015","No Study Results Posted","null","December 2011","Donor T-cell chimerism|Exposure to cyclophosphamide, fludarabine, and mycophenolate mofetil and their breakdown products","https://ClinicalTrials.gov/show/NCT01141959"
1218,"NCT00930891","Bevacizumab in Extensive Small Cell Lung Cancer","Completed","No Results Available","Small Cell Lung Cancer","Drug: Standard Chemotherapy (PCDE or PE)|Drug: Experimental Treatment (PCDE or PE + bevacizumab)|Drug: Prerandomization Chemotherapy (PCDE or PE)","Intergroupe Francophone de Cancerologie Thoracique","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","143","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IFCT-0802|2009-010187-42","July 1, 2009","September 2009","July 2013","March 9, 2016","March 2016","No Study Results Posted","CPC","July 2012","Response rate (complete response + partial response)|Progression-free survival|Complete response length|Quality of life|Toxicities","https://ClinicalTrials.gov/show/NCT00930891"
1219,"NCT00075387","Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors","Recruiting","No Results Available","Glioma","Drug: Carboplatin|Drug: Cyclophosphamide|Drug: Etoposide Phosphate|Other: Quality-of-Life Assessment|Drug: Sodium Thiosulfate","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Investigator|Primary Purpose: Supportive Care","IRB00000922|NCI-2013-00781|MR00041590|CR00023930|eIRB #922|CR00018679|ONC-02019-L|CR00021317|CR00022743|P30CA069533","January 9, 2004","March 2003","April 2019","April 19, 2017","April 2017","No Study Results Posted","null","April 2018","Rate of platelet toxicities (ie. platelet count less than 20,000), graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) version 3.0|Change in hearing levels, if any, at the higher frequencies in the standard testing range (4000 and 8000 Hz), and at higher frequencies above standard testing (9000 to 16000 Hz) based on American Speech-Language-Hearing Association (ASHA) criteria|Erythrocyte counts|Granulocyte count|Number of dose reductions and transfusions due to platelet toxicity|Quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 and QLQ-Brain Module (BN)-20|Time to disease progression|Time to response|Tumor response (complete response [CR] + partial response [PR] + stable disease [SD]) assessed by neurologic exams, radiographic studies, and steroid dose","https://ClinicalTrials.gov/show/NCT00075387"
1220,"NCT00002788","High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Biological: filgrastim|Drug: cyclophosphamide|Drug: dexamethasone|Drug: etoposide|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","17 Years to 65 Years   (Child, Adult)","Phase 1","15","Other|NIH","Interventional","Primary Purpose: Treatment","962.00|FHCRC-962.00|NCI-H96-0925|CDR0000064852","August 3, 2000","October 1995","September 2002","September 13, 2010","September 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002788"
1221,"NCT01446211","Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis","Terminated","No Results Available","Wegeners Granulomatosis","Drug: Gusperimus + glucocorticoids|Drug: cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids","Nordic Pharma SAS","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","4","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NO005-NK103|2011-001219-30","September 20, 2011","November 2011","January 2015","May 28, 2015","January 2015","No Study Results Posted","SPARROW","November 2012","Response rate|Time to response|Response duration|Frequency of severe relapses|Vasculitis Damage Index (VDI) score change|Glomerular Filtration Rate (eGFR) change|Frequency of Adverse Events (AEs) and Serious Adverse Event (SAEs)|Frequency of severe infection|Pharmacokinetic parameters at selected sites|Short-Form-36 (SF-36)|Total corticosteroid exposure|Questionnaire EQ-5D|Frequency of non-severe relapses","https://ClinicalTrials.gov/show/NCT01446211"
1222,"NCT03081910","Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen","Not yet recruiting","No Results Available","T-cell Acute Lymphoblastic Lymphoma|T-non-Hodgkin Lymphoma|T-cell Acute Lymphoblastic Leukemia","Genetic: CD5.CAR/28zeta CAR T cells|Drug: Fludarabine|Drug: Cytoxan","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System|Texas Children's Hospital","All","up to 75 Years   (Child, Adult, Senior)","Phase 1","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","H40466, MAGENTA","March 8, 2017","June 1, 2017","June 1, 2036","March 10, 2017","March 2017","No Study Results Posted","MAGENTA","July 15, 2021","Number of Patients with dose limiting toxicity|Overall Response Rate","https://ClinicalTrials.gov/show/NCT03081910"
1223,"NCT02596971","A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma, Lymphoma Follicular","Drug: Atezolizumab|Drug: Bendamustine|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Obinutuzumab|Drug: Prednisone|Drug: Vincristine|Drug: Rituximab","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 1","92","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BO29563|2015-001364-19","November 3, 2015","December 31, 2015","January 31, 2020","March 13, 2017","March 2017","No Study Results Posted","null","January 31, 2020","Percentage of Participants With CR at EOI, as Determined by the Independent Review Committee (IRC) Using Lugano 2014 Criteria|Percentage of Participants With Adverse Events|Percentage of Participants With CR at EOI, as Determined by the Investigator Using Lugano 2014 Criteria|Percentage of Participants With CR at EOI, as Determined by the IRC Using Modified Cheson 2007 Criteria|Percentage of Participants With CR at EOI, as Determined by the Investigator Using Modified Cheson 2007 Criteria|Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the IRC Using Modified Cheson 2007 Criteria|Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the Investigator Using Modified Cheson 2007 Criteria|Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the IRC Using Lugano 2014 Criteria|Percentage of Participants With Objective Response (CR or PR) at EOI, as Determined by the Investigator Using Lugano 2014 Criteria|Percentage of Participants With Best Response of CR or PR During Study, as Determined by Investigator Using Modified Cheson 2007 Criteria|Observed Serum Obinutuzumab Concentration|Observed Serum Atezolizumab Concentration|Observed Serum Rituximab Concentration|Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab|Percentage of Participants With Human Anti-Chimeric Antibodies (HACAs) to Rituximab|Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab","https://ClinicalTrials.gov/show/NCT02596971"
1224,"NCT00186849","Therapy for Children With Advanced Stage High Risk Neuroblastoma","Completed","No Results Available","Neuroblastoma","Drug: Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin|Procedure: Peripheral Blood Stem Cell Transplant","St. Jude Children's Research Hospital|National Institutes of Health (NIH)","All","up to 18 Years   (Child, Adult)","Phase 2","30","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NB-97","September 12, 2005","October 1997","April 2001","May 19, 2009","May 2009","No Study Results Posted","null","April 2001","Response rate|Feasibility/toxicity of an intensification phase of high-dose chemotherapy with topotecan and cyclophosphamide followed by autologous peripheral blood stem cell transplant","https://ClinicalTrials.gov/show/NCT00186849"
1225,"NCT02581007","RIC Transplant Using Haplo Donors","Recruiting","No Results Available","Chronic Myelogenous Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Myelofibrosis|CMML|Multiple Myeloma","Drug: Fludarabine|Drug: Melphalan|Drug: Cyclophosphamide|Procedure: peripheral blood stem cell transplant","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NSH 1132","October 16, 2015","November 2015","February 2018","March 16, 2017","March 2017","No Study Results Posted","null","February 2018","Graft Rejection|Overall Survival|Overall survival|Relapse incidence|GVHD incidence","https://ClinicalTrials.gov/show/NCT02581007"
1226,"NCT02676622","Autologous Stem Cell Transplant for Refractory Crohn's Disease","Withdrawn","No Results Available","Crohn's Disease","Drug: mobilization of stem cells to prepare for Leukapheresis|Other: Leukapheresis- Collection of stem cells|Drug: Preparative regimen 4-6 weeks after Leukapheresis|Other: Stem Cell Transplant|Drug: Low-dose IL-2 administration","Nationwide Children's Hospital","All","12 Years to 29 Years   (Child, Adult)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IRB1100448","April 21, 2013","April 2013","April 2013","February 2, 2017","February 2017","No Study Results Posted","null","April 2013","The primary endpoint of the study is feasibility and safety of the autologous HSCT and low dose IL-2 post-HSCT, as evaluated by day +100 TRM (transplant related mortality) and incidence of severe toxicity.|Secondary endpoints are evaluations of the effects of HSCT on clinical and laboratory manifestations of Crohn's Disease, i.e. frequency of and types of transplant related complications that were observed.","https://ClinicalTrials.gov/show/NCT02676622"
1227,"NCT02445404","Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL","Recruiting","No Results Available","Peripheral T-cell Lymphoma","Drug: CHOP|Drug: fractionated ICED","Samsung Medical Center","All","19 Years to 65 Years   (Adult)","Phase 2","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2014-12-011","May 12, 2015","April 2015","December 2019","April 8, 2017","April 2017","No Study Results Posted","null","December 2019","progression free survival|Overall survival|overall response rate|Response duration|Toxicity profiles","https://ClinicalTrials.gov/show/NCT02445404"
1228,"NCT02132949","A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer","Active, not recruiting","Has Results","Breast Cancer","Drug: 5-Fluorouracil|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Doxorubicin|Drug: Epirubicin|Drug: paclitaxel|Drug: Pertuzumab|Drug: Trastuzumab","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","401","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","WO29217","May 6, 2014","July 2014","December 2020","March 1, 2017","March 2017","March 1, 2017","null","March 3, 2016","Percentage of Participants With New York Heart Association (NYHA) Class III and IV Heart Failure During the Neoadjuvant Treatment Period|Percentage of Participants With Drop in Left Ventricular Ejection Fraction (LVEF) of at Least 10 Percentage Points From Baseline and to Below 50% During the Neoadjuvant Treatment Period|Percentage of Participants With NYHA Class III and IV Heart Failure During the Adjuvant Treatment Period at Primary Completion Date (03 March 2016)|Percentage of Participants With Drop in LVEF of at Least 10 Points From Baseline and to Below 50% During the Adjuvant Treatment Period at Primary Completion Date (03 March 2016)|Percentage of Participants With NYHA Class III and IV Heart Failure at the End of Study|Percentage of Participants With Drop in LVEF of at Least 10 Points From Baseline and to Below 50% at End of Study|Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Pertuzumab|Percentage of Participants With Total Pathological Complete Response (tpCR) Evaluated at the Time of Surgery Based on Local Pathologist's Assessment After Surgery|Percentage of Participants With Clinical Response as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 During the Neoadjuvant Treatment Period|Event-Free Survival Determined by the Investigator According to RECIST v1.1|Invasive Disease Free Survival (iDFS) Determined by the Investigator According to RECIST v1.1|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02132949"
1229,"NCT00496873","Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan","Completed","Has Results","Lymphoma","Drug: Cytoxan|Drug: Nipent|Drug: Rituxan","M.D. Anderson Cancer Center|Astex Pharmaceuticals|Pharmatech","All","18 Years and older   (Adult, Senior)","Phase 2","100","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-0818|NCI-2010-00635","July 3, 2007","June 2005","December 2014","July 13, 2016","July 2016","July 13, 2016","null","December 2014","Participant Response Rate According to the International Working Group (IWG) Response Criteria for Non Hodgkin's Lymphoma (NHL), Cheson 1999|Number of Participants With Complete Response (CR)/Complete Response Unconfirmed (CRu) With Low-grade Lymphoma (N=83) After 6-9 Cycles of PCR Therapy|3-Year Progression-Free Survival","https://ClinicalTrials.gov/show/NCT00496873"
1230,"NCT00049504","Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer","Completed","Has Results","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hematopoietic/Lymphoid Cancer|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage II Multiple Myeloma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Childhood Hodgkin Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia","Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: tacrolimus|Drug: mycophenolate mofetil|Genetic: polymerase chain reaction|Genetic: fluorescence in situ hybridization|Genetic: polymorphism analysis|Genetic: gene expression analysis|Radiation: total-body irradiation|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","53","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","1667.00|NCI-2010-00166","November 12, 2002","January 2002","February 2014","April 10, 2017","April 2017","April 10, 2017","null","March 2011","Donor Engraftment (Chimerism)|Incidence of Grades III-IV Acute GVHD|Non-relapse-related Mortality","https://ClinicalTrials.gov/show/NCT00049504"
1231,"NCT02107963","A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors","Completed","No Results Available","Sarcoma|Osteosarcoma|Neuroblastoma|Melanoma","Biological: Anti-GD2-CAR engineered T cells|Drug: AP1903|Drug: Cyclophosphamide","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","1 Year to 35 Years   (Child, Adult)","Phase 1","15","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","140059|14-C-0059","April 5, 2014","February 6, 2014","January 31, 2017","May 12, 2017","January 31, 2017","No Study Results Posted","null","January 31, 2017","Determine the feasibility of producing anti-GD2-CAR cells meeting the established release criteria and to assess the safety of administering escalating doses of autologous anti-GD2-CAR (anti-GD2.28.z.OX40.ICD9) engineered T cells in children and...|Determine antitumr effects|Persistence of anti-GD2 CAR T cells and correlate with anti-tumor effects|Evaluate prevalencew of GD2 expression|Evaluate effectiveness of AP1903 to mediate clearance of anti-GD2 CAR T cells|Assess toxicity of AP1903","https://ClinicalTrials.gov/show/NCT02107963"
1232,"NCT02379195","Peginterferon and TIL Therapy for Metastatic Melanoma","Recruiting","No Results Available","Metastatic Melanoma","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: TIL infusion|Drug: Interleukin-2|Drug: Peginterferon alfa-2b","Inge Marie Svane|Herlev Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MM1413","February 27, 2015","November 2014","November 2016","February 22, 2016","February 2016","No Study Results Posted","null","November 2016","Number and type of reported adverse events|Treatment related immune responses|Objective response rate|Overall survival|Progression free survival","https://ClinicalTrials.gov/show/NCT02379195"
1233,"NCT01962636","Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases","Not yet recruiting","No Results Available","Acute Myeloid Leukemia (AML)|Acute Lymphocytic Leukemia (ALL)|Chronic Myelogenous Leukemia|Plasma Cell Leukemia|Myelofibrosis|Myelodysplasia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Marginal Zone B-Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-Cell Lymphoma|Prolymphocytic Leukemia|Diffuse Large B Cell Lymphoma|Lymphoblastic Lymphoma|Burkitt's Lymphoma|Non-Hodgkin Lymphoma|Multiple Myeloma","Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total Body Irradiation|Drug: Cyclosporine A|Drug: Mycophenylate mofetil|Biological: Umbilical cord blood","Masonic Cancer Center, University of Minnesota","All","up to 55 Years   (Child, Adult)","","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013OC013","October 10, 2013","December 2016","October 2023","August 15, 2016","August 2016","No Study Results Posted","null","October 2023","Survival at 1 year post-transplant|Incidence of neutrophil engraftment at day 42.|Platelet engraftment at 1 year.|Pattern of chimerism after transplant.|Incidence of graft failure.|Incidence of acute graft versus host disease at 100 days.|Incidence of chronic graft versus host disease at 1 year.|Incidence of transplant related mortality at 6 months.|Incidence of disease free survival|Incidence of overall survival.","https://ClinicalTrials.gov/show/NCT01962636"
1234,"NCT00003696","Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: paclitaxel","Commissie Voor Klinisch Toegepast Onderzoek|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","250","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066803|CKVO-9802|DUT-KWF-CKVO-9802|EU-98059","November 1, 1999","October 1998","null","September 16, 2013","November 2001","No Study Results Posted","null","null","Progression-free survival|Overall survival|Response rate|Duration of response|Toxicity","https://ClinicalTrials.gov/show/NCT00003696"
1235,"NCT00095862","Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers","Suspended","No Results Available","Breast Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Biological: allogeneic GM-CSF-secreting breast cancer vaccine|Biological: recombinant interferon alfa|Drug: cyclophosphamide","Wiseman Research Initiatives, LLC|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","24","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000393552|WRI-GEV-007","November 9, 2004","November 2004","null","December 17, 2013","October 2011","No Study Results Posted","null","December 2014","Safety, tolerability, and feasibility|Clinical response|Time to progression|Survival|Correlation of clinical response with immunological response","https://ClinicalTrials.gov/show/NCT00095862"
1236,"NCT02187367","Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Biological: EGF Vaccine","Bioven Europe|Bioven Sdn. Bhd.","All","18 Years and older   (Adult, Senior)","Phase 3","418","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BV-NSCLC-002|2013-005335-25","July 7, 2014","May 2015","March 2020","January 26, 2017","January 2017","No Study Results Posted","EGF","February 2020","Overall Survival (OS)|Safety of EGF Cancer Vaccine as assessed by Adverse Events (AEs)|Progression-Free Survival (PFS)|Survival Rate|Time to Progression (TTP)|Response Rate (RECIST criteria)|Safety of EGF Cancer Vaccine by Laboratory Assessment|Safety of EGF Cancer Vaccine assessed by Vital Signs|Safety of EGF Cancer Vaccine as assessed by Physical Examination|Quality of Life (QoL)","https://ClinicalTrials.gov/show/NCT02187367"
1237,"NCT00925652","Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer","Terminated","No Results Available","Breast Cancer","Drug: Bevacizumab|Drug: Cyclophosphamide|Drug: Methotrexate|Behavioral: Diet Intervention|Behavioral: Diet and Exercise Intervention","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Translational Breast Cancer Research Consortium|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","55","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","09-134|AVF 4571s; TBCRC 012","June 19, 2009","September 2010","September 2017","October 20, 2015","October 2015","No Study Results Posted","ABCDE","September 2017","Recurrence-free survival|Feasibility of bevacizumab and metronomic chemotherapy administration.|To characterize the side effects and tolerability of bevacizumab and metronomic chemotherapy|Overall survival","https://ClinicalTrials.gov/show/NCT00925652"
1238,"NCT00069238","Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas","Active, not recruiting","Has Results","Lymphoma, T-Cell|Lymphoma, Extranodal NK-T-Cell","Biological: Alemtuzumab (Campath)|Drug: EPOCH","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","17 Years and older   (Child, Adult, Senior)","Phase 2","31","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","030304|03-C-0304","September 17, 2003","September 2003","March 2018","August 1, 2016","August 2016","October 7, 2015","null","June 2009","Maximum Tolerated Dose (MTD) of Alemtuzumab|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00069238"
1239,"NCT00003269","Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors","Completed","No Results Available","Breast Cancer|Drug/Agent Toxicity by Tissue/Organ|Lung Cancer|Lymphoma|Ovarian Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Biological: sargramostim|Drug: amifostine trihydrate|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide","Scripps Health","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CDR0000066165|SCRF-98014|ALZA-97-49-ii|NCI-V98-1396","November 1, 1999","February 1998","January 2001","January 6, 2011","January 2011","No Study Results Posted","null","January 2001","duration of neutropenia|incidence of nephrotoxicity|incidence of ototoxicity","https://ClinicalTrials.gov/show/NCT00003269"
1240,"NCT00578461","T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE","Terminated","Has Results","Leukemia|Cancer|Lymphoma|Lymphoma, Hodgkin|Lymphoma, Non-Hodgkin","Drug: Ara C|Drug: Mesna|Drug: Cyclophosphamide|Radiation: TBI-Total Body Irradiation","Baylor College of Medicine|Texas Children's Hospital","All","up to 64 Years   (Child, Adult)","","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-19164 REGKINE","December 19, 2007","October 2007","May 2013","March 24, 2016","March 2016","August 28, 2014","REGKINE","May 2013","Median Percentage of Treg Cells at 1 Year Post Transplant","https://ClinicalTrials.gov/show/NCT00578461"
1241,"NCT01459887","Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma","Completed","No Results Available","Diffuse Large B Cell Lymphoma","Drug: CHOP combined with CMAB304|Drug: CHOP, CMAB304","Shanghai CP Guojian Pharmaceutical Co.,Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","278","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","304NHL-050617","October 18, 2011","September 2006","February 2011","October 25, 2011","October 2011","No Study Results Posted","null","December 2010","overall response rate|event-free survival","https://ClinicalTrials.gov/show/NCT01459887"
1242,"NCT01690325","Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)","Recruiting","No Results Available","Breast Cancer","Drug: Docetaxel|Drug: Trastuzumab|Drug: Bevacizumab|Drug: Epirubicin|Drug: Cyclophosphamid","West German Study Group|Roche Pharma AG|Sanofi","Female","18 Years to 65 Years   (Adult)","Phase 2","94","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","WSG-AM05","September 18, 2012","September 2012","September 2022","June 18, 2015","June 2015","No Study Results Posted","null","August 2017","Rate of pathological complete response (pCR) following neoadjuvant therapy in group A and group B","https://ClinicalTrials.gov/show/NCT01690325"
1243,"NCT02666898","Phase II Trial GA101 Inbrutinib B CLL","Recruiting","No Results Available","Leukemia, Lymphocytic, Chronic, B-Cell","Drug: GA101|Drug: Ibrutinib|Drug: Cyclophosphamide|Drug: Fludarabine","French Innovative Leukemia Organisation|Roche Pharma AG|Janssen-Cilag Ltd.","All","18 Years and older   (Adult, Senior)","Phase 2","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ICLL07GAI","October 26, 2015","October 2015","April 2020","January 16, 2017","January 2017","No Study Results Posted","ICLL07GAI","December 2017","Study treatment response|progression free survival|overall survival|time to next treatment","https://ClinicalTrials.gov/show/NCT02666898"
1244,"NCT00004174","Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: cyclophosphamide|Drug: paclitaxel|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Northwestern University|National Cancer Institute (NCI)","All","up to 60 Years   (Child, Adult)","Phase 1","30","Other|NIH","Interventional","Primary Purpose: Treatment","NU 96B1|NU-96B1|NCI-G99-1641","December 10, 1999","October 1999","May 2008","July 9, 2013","July 2013","No Study Results Posted","null","May 2008","","https://ClinicalTrials.gov/show/NCT00004174"
1245,"NCT01462513","L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases","Active, not recruiting","No Results Available","Colon Carcinoma|Rectum Carcinoma","Biological: L-BLP25|Biological: Placebo","Prof. Dr. Carl Schimanski|Johannes Gutenberg University Mainz","All","18 Years and older   (Adult, Senior)","Phase 2","122","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","LICC01","October 27, 2011","August 2011","December 2017","July 13, 2015","July 2015","No Study Results Posted","LICC","December 2017","Comparative evaluation of recurrence-free survival (RFS) time and 3 year overall survival (OS) time between the treatment groups (L-BLP25 plus cyclophosphamide versus placebo and saline infusion).|Safety / Tolerability|Recurrence-free survival time in the subgroup of MUC1 positive cancers|Overall survival time in a subgroup of MUC1 positive cancers","https://ClinicalTrials.gov/show/NCT01462513"
1246,"NCT02774291","Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1","Not yet recruiting","No Results Available","HLA-A2 Positive Cells Present|Metastatic Malignant Neoplasm|Metastatic Malignant Neoplasm in the Brain","Biological: Aldesleukin|Biological: Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes|Drug: Cyclophosphamide|Biological: Filgrastim|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis","Albert Einstein College of Medicine, Inc.|National Cancer Institute (NCI)","All","18 Years to 66 Years   (Adult, Senior)","","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-5254|NCI-2015-01781|P30CA013330","May 13, 2016","August 2016","January 2018","August 15, 2016","August 2016","No Study Results Posted","null","January 2018","Incidence of toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|In vivo survival of TCR gene-engineered cells|Objective response rate, graded according to RECIST criteria","https://ClinicalTrials.gov/show/NCT02774291"
1247,"NCT02566395","Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Chronic Myelogenous Leukemia|Non-Hodgkin Lymphoma|Hodgkin Lymphoma","Radiation: Radiation|Drug: Cyclophosphamide|Biological: Donor Lymphocyte Infusion (DLI)|Biological: Haploidentical Stem Cell Transplantation","Northwell Health|New York Blood Center","All","2 Years to 21 Years   (Child, Adult)","Phase 3","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","14-551","September 30, 2015","December 2014","December 2018","January 3, 2017","January 2017","No Study Results Posted","null","December 2017","Hematopoietic engraftment|2-Year disease-free survival|Grade II-IV GvHD|Grade III-IV GvHD|Relapse rate","https://ClinicalTrials.gov/show/NCT02566395"
1248,"NCT01106950","Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)","Terminated","Has Results","Leukemia, Myelogenous, Acute","Biological: Natural Killer Cells|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Denileukin diftitox|Procedure: Donor lymphapheresis|Drug: IL-2","Masonic Cancer Center, University of Minnesota","All","2 Years and older   (Child, Adult, Senior)","Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2010LS010|MT2010-02|1003M79954","April 19, 2010","July 2010","December 2012","June 25, 2013","June 2013","May 6, 2013","null","October 2011","Percent of Patients With Successful Expansion of Natural Killer Cells After Infusion|Percent of Patients With Complete Remission of Disease|Percent of Patients With Disease Free Survival|Percent of Patients With Incidence of Relapse|Number of Patients With Treatment-Related Death|Percent of Patients With Natural Killer Cell Expansion Versus KIR Genotype Versus Treg Depletion","https://ClinicalTrials.gov/show/NCT01106950"
1249,"NCT02684708","Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents","Recruiting","No Results Available","Classical Hodgkin Lymphoma","Drug: cyclophosphamide, vincristine, prednisone, dacarbazine|Drug: cyclo, vcr, pred, dacarb,etop and doxo","Prof. Dr. Christine Mauz-Körholz|Deutsche Krebshilfe e.V., Bonn (Germany)|Euronet Worldwide|University of Giessen","All","up to 25 Years   (Child, Adult)","Phase 3","2200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EuroNet-PHL-C2","November 19, 2015","October 2015","September 2021","December 2, 2016","December 2016","No Study Results Posted","null","September 2021","Event-free survival|Overall survival|Progression-free survival|CTC (common toxicity criteria) grading during any individual treatment element including assessment of osteonecrosis|Time from day of PET imaging until decision on response category at ERA or LRA, respectively|Time from last day of chemotherapy to first day of radiotherapy in patients with radiotherapy indication|Time from last dose of prednisone/prednisolone in OEPA to start of the first consolidation cycle","https://ClinicalTrials.gov/show/NCT02684708"
1250,"NCT00587925","Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer","Completed","No Results Available","Breast Cancer|Osteoporosis","Other: Bone Mineral Density","Memorial Sloan Kettering Cancer Center","Female","Child, Adult, Senior","","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","05-024","December 22, 2007","March 2005","February 2009","February 25, 2009","February 2009","No Study Results Posted","null","February 2009","To estimate the rate of change in bone mineral density in postmenopausal women undergoing adjuvant chemotherapy with dose dense doxorubicin, cyclophosphamide and paclitaxel (AC-T or A-T-C) for early stage breast cancer.|To estimate the rate of change in markers of bone metabolism in postmenopausal women undergoing adjuvant chemotherapy with doxorubicin, cyclophosphamide and paclitaxel (AC-T or A-T-C) for early stage breast cancer.","https://ClinicalTrials.gov/show/NCT00587925"
1251,"NCT00683241","A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer","Completed","No Results Available","Ovarian Cancer|Peritoneal Cancer","Biological: DCVac-L","Abramson Cancer Center of the University of Pennsylvania|Northwest Biotherapeutics|University of California, San Francisco","Female","18 Years and older   (Adult, Senior)","Phase 1","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UPCC 11807","May 19, 2008","November 2007","December 2009","February 25, 2013","February 2013","No Study Results Posted","null","December 2009","To determine the feasibility and safety of administering DCVax-L intradermally combined with intravenous bevacizumab and oral metronomic cyclophosphamide in patients with recurrent ovarian or primary peritoneal cancer.|To assess the immunogenicity of DCVax-L administered intradermally in patients with recurrent ovarian or recurrent primary peritoneal cancer, combined with intravenous bevacizumab and oral metronomic cyclophosphamide.","https://ClinicalTrials.gov/show/NCT00683241"
1252,"NCT01969032","Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer","Completed","No Results Available","Triple Negative Breast Cancer","Drug: Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine","Russian Academy of Medical Sciences","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LATN-2ICR","October 21, 2013","August 2011","September 2014","November 4, 2014","November 2014","No Study Results Posted","null","May 2014","The pathological complete response rate to two consequent induction preoperative chemotherapy regimens|Disease-free survival","https://ClinicalTrials.gov/show/NCT01969032"
1253,"NCT00002679","Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel|Drug: tamoxifen citrate|Radiation: radiation therapy","Yale University","All","18 Years and older   (Adult, Senior)","Phase 2","89","Other","Interventional","Primary Purpose: Treatment","CDR0000064337|YALE-HIC-7374|NCI-V95-0720","November 1, 1999","February 1994","January 2002","August 24, 2009","August 2009","No Study Results Posted","null","January 2002","","https://ClinicalTrials.gov/show/NCT00002679"
1254,"NCT02320383","CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients","Recruiting","No Results Available","Chronic Lymphocytic Leucemia","Biological: GA101 (Obinutuzumab)|Drug: Bendamustine","Munich Municipal Hospital|German CLL Study Group","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLLR3","September 1, 2014","September 2014","September 2022","October 5, 2016","October 2016","No Study Results Posted","null","September 2021","Evaluate the efficacy of two regimens of immunochemotherapy, i.e. Response rates of Fludarabine, Cyclophosphamide plus GA101 (FCG) and Bendamustine plus GA101 (BG), in patients with relapsed or refractory CLL.|MRD levels|Progression free survival (PFS)|Event-free survival (EFS)|Overall survival (OS)|Duration of response in patients with CR/ CRi, clinical CR / clinical CRi or nPR/ PR|Time to next anti-leukemia treatment|Overall response rate in biological defined risk groups|Complete response rate|Safety parameters during induction and maintenance phase","https://ClinicalTrials.gov/show/NCT02320383"
1255,"NCT00076752","Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus","Completed","Has Results","Lupus Erythematosus, Systemic","Drug: fludarabine phosphate|Drug: cyclophosphamide|Biological: Rituxan (rituximab)|Biological: filgrastim|Drug: methylprednisolone|Other: immunologic technique|Other: laboratory biomarker analysis|Procedure: autologous hematopoietic stem cell transplantation|Drug: Diphenhydramine|Drug: Mesna","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","15 Years to 40 Years   (Child, Adult)","Phase 2","9","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","040095|04-C-0095","February 2, 2004","January 30, 2004","October 15, 2013","April 9, 2017","April 2017","March 25, 2014","null","October 15, 2013","Relapse-free Complete Clinical Response|Number of Participants With Adverse Events|Anti-Nuclear Antibody|Extractable Nuclear Antigen (ENA)|Anti-Double Stranded Deoxyribonucleic Acid (DNA) Antibody|Anti-Smith-Ribonuclear Protein Antibody|White Blood Cells|Absolute Neutrophil Count|Absolute Lymphocyte Count|Platelet Count|Cluster of Differentiation 3 (CD3) + Cells|Cluster of Differentiation 4 (CD4) + Cells|Cluster of Differentiation 8 (CD8) + Cells|Cluster of Differentiation 19 (CD19) + Cells|Natural Killer Cells|Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)","https://ClinicalTrials.gov/show/NCT00076752"
1256,"NCT00622895","Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis","Recruiting","No Results Available","Systemic Scleroderma|Severe Systemic Sclerosis","Drug: fludarabine phosphate|Drug: Mycophenolic Acid|Drug: tacrolimus|Radiation: total-body irradiation|Procedure: bone marrow transplantation|Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation|Procedure: quality-of-life assessment|Other: laboratory biomarker analysis|Other: flow cytometry|Procedure: biopsy|Drug: cyclophosphamide","Fred Hutchinson Cancer Research Center|National Institute of Allergy and Infectious Diseases (NIAID)","All","up to 70 Years   (Child, Adult, Senior)","Phase 1|Phase 2","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2067.00|NCI-2011-01352|R01AI041721","February 22, 2008","September 2006","null","March 7, 2017","March 2017","No Study Results Posted","null","March 2018","Event-free survival (EFS)|EFS|Overall survival|Treatment-related mortality|Regimen-related toxicity (greater than or equal to Grade III) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0|Incidence of definite and probable viral, fungal, and bacterial infections in each patient|Quality of life as assessed by the Modified Scleroderma Health Assessment Questionnaire (SHAQ)|Quality of life as assessed by the Medical Outcome Short Form (36) Health Survey instrument (SF-36)|Skin score and pulmonary function tests|Incidence of graft rejection|Incidence and severity of graft-versus-host disease (GVHD)|Incidence of disease-modifying antirheumatic drugs (DMARDs) initiated post transplant to modify disease","https://ClinicalTrials.gov/show/NCT00622895"
1257,"NCT00578344","Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP","Terminated","No Results Available","Sickle Cell Disease|Hemoglobin SC","Drug: Busulfan|Biological: Campath 1H|Drug: Cyclophosphamide and MESNA","Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System","All","up to 40 Years   (Child, Adult)","","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-16447-SCALLOP|SCALLOP","December 19, 2007","July 2005","July 2012","April 22, 2014","April 2014","No Study Results Posted","SCALLOP","July 2012","Evaluate recovery of organ function in patients with sickle cell disease (SCD) or sickle hemoglobin variants after undergoing allogeneic SCT/BMT from HLA genotype identical donors and if they can be improved or reversed.|Evaluate the use of PET scan examination in assessing metabolic function of organs in patients with SCD, hemoglobin SC, or hemoglobin Sb0/+ after undergoing allogeneic SCT/BMT from HLA genotype identical donors.|Evaluate response to immunization after BMT in patients with SCD, hemoglobin SC, or hemoglobin Sb0/+.","https://ClinicalTrials.gov/show/NCT00578344"
1258,"NCT02310997","Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)","Terminated","No Results Available","Leukaemia|Lymphoma|Other Haematological Diseases","Other: Umbilical Cord Blood Transplant|Drug: Cyclophosphamide|Radiation: Total body irradiation|Drug: Busulfan|Drug: Melphalan|Drug: Fludarabine","University College, London|Cancer Research UK","All","up to 45 Years   (Child, Adult)","Phase 2","11","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCL/09/0128|2009-011818-21","September 18, 2014","July 2011","May 2015","May 26, 2015","May 2015","No Study Results Posted","MAC UCBT","May 2015","Non-relapse mortality at 100 days post transplant|Overall survival at 1 year|Time course of mixed chimerism established by the donor graft|Recovery from neutropenia and cytopenia|Incidence of acute and chronic GVHD|Incidence of relapse","https://ClinicalTrials.gov/show/NCT02310997"
1259,"NCT01943188","Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer","Terminated","No Results Available","Clear Cell Renal Cell Carcinoma|Recurrent Renal Cell Cancer|Stage IV Renal Cell Cancer","Radiation: stereotactic body radiation therapy|Drug: cyclophosphamide|Biological: therapeutic autologous lymphocytes|Other: laboratory biomarker analysis","Stanford University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","2","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","RENAL0027|NCI-2013-01688|P30CA124435","September 11, 2013","May 2014","null","March 13, 2017","March 2017","No Study Results Posted","null","March 2016","Frequency of treatment-related grade 3-5 toxicities, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Overall survival (OS)|Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT01943188"
1260,"NCT00960063","A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)","Terminated","Has Results","Neoplasms|Solid Tumors|Bone Cancer|Kidney Tumor|Neuroblastoma","Drug: Temozolomide|Drug: Vincristine|Drug: Ifosfamide|Drug: Irinotecan|Biological: Robatumumab|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Etoposide","Merck Sharp & Dohme Corp.","All","up to 21 Years   (Child, Adult)","Phase 1","4","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P05883|MK-7454-006","August 14, 2009","November 2009","December 2010","January 7, 2016","January 2016","November 19, 2015","null","December 2010","Number of Participants With Dose Limiting Toxicities|Best Overall Response Based on Response Evaluation Criteria in Solid Tumors (RECIST)|Maximum Observed Concentration (Cmax) of Robatumumab|Plasma Level of Insulin-like Growth Factor-I (IGF-I)|Number of Participants Who Developed Anti-robatumumab Antibodies|Time to Maximum Observed Concentration (Tmax) of Robatumumab|Area Under the Curve at the Time of Final Quantifiable Sample (AUCtf) for Robatumumab|Area Under the Curve During a Dosing Interval τ (AUCτ) for Robatumumab|Plasma Level of Insulin-like Growth Factor-2 (IGF-II)|Plasma Level of Insulin-like Growth Factor Binding Protein-2 (IGFBP-2)|Plasma Level of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3)","https://ClinicalTrials.gov/show/NCT00960063"
1261,"NCT02727387","Protocol for the Treatment of Metastatic Ewing Sarcoma","Recruiting","No Results Available","Ewing's Sarcoma (ES)","Drug: TEMIRI|Drug: ADM|Drug: IFO|Drug: CYC|Drug: ETO|Drug: BUMEL|Drug: VIN","Italian Sarcoma Group","All","up to 40 Years   (Child, Adult)","Phase 2","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ISG/AIEOP EW-2","March 23, 2016","May 2009","May 2020","March 17, 2017","March 2017","No Study Results Posted","EW-2","May 2018","Overall Survival (OS)|Event Free Survival (DFS)|Safety - Incidence and grade of treatment-emergent Adverse Events|Quality of life","https://ClinicalTrials.gov/show/NCT02727387"
1262,"NCT00002627","Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: mesna|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation","St. Louis University|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","30","Other","Interventional","Primary Purpose: Treatment","CDR0000064016|SLUMC-8038|NCI-V95-0607","November 1, 1999","November 1994","null","January 9, 2014","July 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002627"
1263,"NCT02650648","Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma","Recruiting","No Results Available","Neuroblastoma|High-Risk","Drug: cyclophosphamide|Biological: NK cells|Biological: hu3F8|Drug: rIL-2","Memorial Sloan Kettering Cancer Center","All","Child, Adult, Senior","Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","15-272|5415","January 6, 2016","January 2016","null","September 14, 2016","September 2016","No Study Results Posted","null","January 2021","The number patient responses observed at each dose level","https://ClinicalTrials.gov/show/NCT02650648"
1264,"NCT01507103","Tecemotide (L-BLP25) in Rectal Cancer","Completed","Has Results","Rectal Cancer","Biological: Tecemotide (L-BLP25)|Drug: cyclophosphamide (CPA)|Other: Chemoradiotherapy","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 2","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EMR 63325-013|2011-000847-25","January 6, 2012","February 2012","June 2014","January 12, 2017","January 2017","September 21, 2015","SPRINT","June 2014","Change From Baseline in Tumor Immune Response Evaluated by Immunohistochemical (IHC) Analysis of Tumor Infiltrating Lymphocytes (TILs) at Week 14 (Post-surgery)|Immunological Response to Treatment in Relation to Microsatellite Instability (MSI) Status: Number of Subjects Per MSI Category|Change From Baseline in Interferon (IFN)-Gamma Secretion of Mononuclear Cells in Response to MUC1 by Enzyme-linked Immunosorbent Spot (ELISpot) at Post-baseline|Change From Baseline in IFN-gamma Secretion of Mononuclear Cells in Response to Carcinoembryonic Antigen (CEA) by ELISpot at Post-baseline|Change From Baseline in Peritumoral Immune Response at Week 14 (Post-surgery)|Change From Baseline in Immunological Response in Peripheral Blood at Week 18 (Follow-up / end-of Trial)","https://ClinicalTrials.gov/show/NCT01507103"
1265,"NCT00000596","Diffuse Fibrotic Lung Disease","Completed","No Results Available","Lung Diseases|Pulmonary Fibrosis|Sarcoidosis","Drug: prednisone|Drug: cyclophosphamide|Drug: dapsone","National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","402","October 27, 1999","June 1978","January 1983","November 25, 2013","February 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00000596"
1266,"NCT00176826","T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders","Unknown status","Has Results","Hemophagocytic Lymphohistiocytosis|X-Linked Lymphoproliferative Disorders|Chediak-Higashi Syndrome|Griscelli Syndrome|Immunologic Diseases|Langerhans-Cell Histiocytosis|Hematologic Diseases","Procedure: Stem Cell Transplant|Drug: Myeloablative conditioning regimen","Masonic Cancer Center, University of Minnesota","All","up to 55 Years   (Child, Adult)","Phase 2|Phase 3","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMN-MT2000-21|0010M66781","September 12, 2005","September 2000","July 2015","April 22, 2015","April 2015","March 27, 2014","null","August 2012","Time to Transplant Engraftment|Number of Patients With Treatment Related Mortality.|Number of Patients Surviving (Disease-free)|Number of Patients With Grade II-IV Graft-Versus-Host Disease (GVHD)|Number of Patients With Graft Failure|Number of Patients With III-IV Graft-Versus-Host Disease (GVHD)","https://ClinicalTrials.gov/show/NCT00176826"
1267,"NCT00002522","Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Procedure: syngeneic bone marrow transplantation|Radiation: radiation therapy","Temple University","All","15 Years to 70 Years   (Child, Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000078283|TUHSC-2162|NCI-V93-0249","November 1, 1999","February 1993","February 2002","September 30, 2010","September 2010","No Study Results Posted","null","February 2002","","https://ClinicalTrials.gov/show/NCT00002522"
1268,"NCT00950300","A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer","Completed","Has Results","Breast Cancer","Drug: 5-Fluorouracil|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Epirubicin|Drug: Herceptin IV [trastuzumab]|Drug: Herceptin SC [trastuzumab]","Hoffmann-La Roche","Female","18 Years and older   (Adult, Senior)","Phase 3","596","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BO22227|2008-007326-19","July 30, 2009","October 2009","January 2017","February 9, 2017","February 2017","November 4, 2016","null","July 2011","Observed Serum Trough Concentration (Ctrough) of Trastuzumab Prior to Surgery|Percentage of Participants With Pathological Complete Response (pCR)|Observed Ctrough of Trastuzumab After Surgery|Predicted Ctrough of Trastuzumab Prior to Surgery|Predicted Ctrough of Trastuzumab After Surgery|Number of Participants With Ctrough of Trastuzumab >20 μg/mL Prior to Surgery|Number of Participants With Ctrough of Trastuzumab >20 μg/mL After Surgery|Maximum Serum Concentration (Cmax) of Trastuzumab Prior to Surgery|Time of Maximum Serum Concentration (Tmax) of Trastuzumab Prior to Surgery|Area Under the Concentration-Time Curve From 0 to 21 Days (AUC21d) of Trastuzumab Prior to Surgery|Cmax of Trastuzumab After Surgery|Tmax of Trastuzumab After Surgery|AUC21d of Trastuzumab After Surgery|Percentage of Participants With Total Pathological Complete Response (tpCR)|Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0, Among Those With Measurable Disease at Baseline|Time to Response According to RECIST Version 1.0, Among Those With Measurable Disease at Baseline|Percentage of Participants Who Experienced a Protocol-Defined Event as of Clinical Cutoff in January 2014|Event-Free Survival (EFS) as of Clinical Cutoff in January 2014|Percentage of Participants Who Died as of Clinical Cutoff in January 2014|Overall Survival (OS) as of Clinical Cutoff in January 2014|Percentage of Participants With Anti-Drug Antibodies (ADAs) Against Trastuzumab|Percentage of Participants With ADAs Against Recombinant Human Hyaluronidase (rHuPH20)","https://ClinicalTrials.gov/show/NCT00950300"
1269,"NCT00186810","Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease","Completed","No Results Available","Sickle Cell Disease","Drug: Busulfan, Cyclophosphamide, Horse ATG|Procedure: Allogeneic stem cell transplant","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCALLO","September 9, 2005","December 1992","October 2007","May 28, 2009","May 2009","No Study Results Posted","null","February 2006","To evaluate engraftment, GVHD, hematopoietic and immune reconstitution, and regimen-related mortality and morbidity in patients with severe sickle cell disease undergoing transplant using either HLA matched sibling bone marrow or cord blood grafts.","https://ClinicalTrials.gov/show/NCT00186810"
1270,"NCT01099436","Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Drug: zoledronic acid|Procedure: neoadjuvant therapy","Borstkanker Onderzoek Groep|Dutch Cancer Society|Amgen|Sanofi|Novartis","Female","18 Years and older   (Adult, Senior)","Phase 3","250","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BOOG-2010-01|CDR0000669246|BOOG-NEO-ZOTAC|2009-016932-11","April 6, 2010","April 2010","September 2013","July 15, 2014","July 2014","No Study Results Posted","NEO-ZOTAC","April 2012","Pathologic complete response after neoadjuvant chemotherapy with or without zoledronic|Correlation of clinical response with pathological responses of both treatment arms|Disease-free survival|Overall survival|Safety and tolerability|Heterogeneity of the ER/PR and HER2 measurement in core biopsy and the surgical specimen","https://ClinicalTrials.gov/show/NCT01099436"
1271,"NCT02876302","Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer","Recruiting","No Results Available","Inflammatory Breast Cancer (IBC)","Drug: Ruxolitinib|Drug: Paclitaxel|Drug: Doxorubicin|Drug: Cyclophosphamide","Dana-Farber Cancer Institute|Incyte Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","64","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","16-151","August 9, 2016","April 26, 2017","February 2024","April 27, 2017","April 2017","No Study Results Posted","null","February 2020","Assess JAK Inhibition With Ruxolitinib On pStat3+ Expression|Determine Pathologic Complete Response rate (pCR) after preoperative therapy|Correlate effects on pSTAT3+ and STAT3 gene expression with pCR|Assess changes in pSTAT3 level and STAT3 gene expression following treatment|Asses difference in pCR rate following preoperative treatment|Determine efficacy defined as Disease-Free Survival (DFS)|Determine efficacy defined as Time to Treatment Failure (TTF)|Determine efficacy defined as Overall Survival (OS)|Assess Residual Cancer Burden (RCB) differences after preoperative therapy|Describe changes in IL-6 plasma levels during treatment|Describe changes in CRP plasma levels during treatment|Assess distribution of CD44+/CD24- stem cell population in tumor pre- and post-exposure to ruxolotinib|Assess pSTAT level and STAT3gene expression when ruxolitinib is withdrawn|Asses pSTAT3 level and STAT3 gene expression after combination ruxolitinib with paclitaxel","https://ClinicalTrials.gov/show/NCT02876302"
1272,"NCT00001212","Drug Therapy in Lupus Nephropathy","Completed","No Results Available","Nephrotic Syndrome|Systemic Lupus Erythematosus","Drug: prednisone|Drug: cyclophosphamide|Drug: cyclosporin A","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","45","NIH","Interventional","Primary Purpose: Treatment","860204|86-DK-0204","November 3, 1999","November 1986","September 2004","April 8, 2008","April 2008","No Study Results Posted","null","null","Time to complete or partial remission of proteinuria.|Change in glomerular filtration rate|Adverse Effects|Time to relapse of nephritic syndrome","https://ClinicalTrials.gov/show/NCT00001212"
1273,"NCT03121001","Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease","Recruiting","No Results Available","Sickle Cell Disease","Drug: ATG|Drug: fludarabine|Drug: cyclophosphamide|Radiation: Total body irradiation|Procedure: Stem cell infusion|Drug: Sirolimus|Drug: mycophenolate mofetil","University of Illinois at Chicago","All","16 Years to 60 Years   (Child, Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2016-1152","April 14, 2017","April 28, 2017","October 28, 2026","May 17, 2017","May 2017","No Study Results Posted","null","October 28, 2026","Estimate the number of patients who engraft by Day +60|Disease free survival|Overall survival|Adverse Effects","https://ClinicalTrials.gov/show/NCT03121001"
1274,"NCT00574587","Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis","Active, not recruiting","No Results Available","Breast Cancer","Drug: Vorinostat|Drug: Paclitaxel|Drug: Trastuzumab|Drug: Doxorubicin|Drug: Cyclophosphamide|Procedure: Mastectomy or Lumpectomy|Drug: Post surgery therapy (Trastuzumab)","Albert Einstein College of Medicine, Inc.|Merck Sharp & Dohme Corp.","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","54","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-10-374|NYCC1|NCI-2013-01216","December 13, 2007","December 2007","January 2016","July 13, 2015","July 2015","No Study Results Posted","null","May 2014","To determine the recommended phase II dose of vorinostat in combination with weekly paclitaxel/trastuzumab|To determine the pathological CR rate in patients with Her2/neu positive locally advanced breast cancer.","https://ClinicalTrials.gov/show/NCT00574587"
1275,"NCT00925548","STRIDE - STimulating Immune Response In aDvanced brEast Cancer","Terminated","Has Results","Breast Cancer","Biological: Tecemotide (L-BLP25) and Hormonal Treatment|Biological: Placebo of tecemotide (L-BLP25) and Hormonal Treatment|Drug: cyclophosphamide|Drug: sodium chloride (NaCl)","EMD Serono","Female","18 Years and older   (Adult, Senior)","Phase 3","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EMR 200038-010|2008-005544-17","June 17, 2009","September 2009","August 2010","July 23, 2014","July 2014","June 24, 2014","STRIDE","August 2010","Progression-Free Survival (PFS)|Overall Survival (OS) Time|Percentage of Participants With Objective Tumor Response|Duration of Response|Percentage of Participants With Clinical Benefit|Time to Progression (TTP)|Time to Chemotherapy|Functional Assessment of Cancer Therapy-Breast (FACT-B) Questionnaire|European Questionnaire-5 Dimensions (EQ-5D) Questionnaire|Number of Participant Utilizing Healthcare Resources|Serum Carcinoma Antigen (CA) 15-3 Levels","https://ClinicalTrials.gov/show/NCT00925548"
1276,"NCT01897441","Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer","Recruiting","No Results Available","Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer","Drug: Cyclophosphamide|Other: Cytology Specimen Collection Procedure|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Biological: Trastuzumab","Albert Einstein College of Medicine, Inc.|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","132","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","13-02-079|NCI-2013-01194|P30CA013330","July 9, 2013","June 2013","null","January 13, 2016","January 2016","No Study Results Posted","null","January 2016","Changes in senescence and secondary biomarkers, including TMEM, mena, and 67LR|Changes in quantitative biomarker levels in patients with chemotherapy-responsive and -resistant tumors, including senescence, cell death, TMEM, mena, and 67LR","https://ClinicalTrials.gov/show/NCT01897441"
1277,"NCT02096588","Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin","Recruiting","No Results Available","Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer","Drug: Simvastatin|Drug: Doxorubicin/cyclophosphamide","Sidney Kimmel Comprehensive Cancer Center","Female","18 Years and older   (Adult, Senior)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","J13160|NA_00091900","March 14, 2014","May 2014","April 2021","April 11, 2017","April 2017","No Study Results Posted","null","October 2019","Change in echocardiographic Global Longitudinal Strain (GLS)|Number of participants with adverse events as a measure of safety and tolerability|Recurrence free survival (RFS) with concurrent simvastatin","https://ClinicalTrials.gov/show/NCT02096588"
1278,"NCT02521441","A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.","Recruiting","No Results Available","Neutropenia","Biological: F-627|Biological: Filgrastim|Drug: Epirubicin and Cyclophosphamide","Generon (Shanghai) Corporation Ltd.|Fudan University|RenJi Hospital|Affiliated Tumor Hospital of Guangzhou Medical University|Nanfang Hospital of Southern Medical University|Qingdao University|Tongji Hospital|The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","150","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SP-CDR-1-1302","August 10, 2015","May 2014","December 2015","August 11, 2015","August 2015","No Study Results Posted","null","October 2015","The duration of moderate or severe (grade 3 and 4, respectively) neutropenia post chemotherapy as measure of efficacy of F-627 compared to Filgrastim in female patients wiht breast cance receiving adjuvant chemotherapy.|The incidence rates of Grade 3 and Grade 4 neutropenia (ANC < 1.0 × 109/L and < 0.5 × 109/L, respectively) for all chemotherapy cycles.|The duration in days of Grade 3 and Grade 4 neutropenia (ANC <1.0 × 109/L and ANC <0.5 × 109/L, respectively) for cycle 2 to 4.|The incidence rates of febrile neutropenia (FN; defined as a decrease in neutrophils associated with fever) for each chemotherapy cycle.|The depth of the ANC nadir for chemotherapy Cycles 1 to 4.|Number of participants with adverse events, changes from baseline of labarotory values as measure of safety of F-627 comparated to Filgrastim in female patients wiht breast cance receiving chemotherapy.","https://ClinicalTrials.gov/show/NCT02521441"
1279,"NCT01199432","Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: 5-FU（intravenous infusion）+epirubicin+cyclophosphamide|Drug: 5-FU（intravenous bolus）+epirubicin+cyclophosphamide|Drug: epirubicin+cyclophosphamide","Tao OUYANG|Peking University","Female","18 Years to 65 Years   (Adult)","Phase 4","501","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BCP06","September 9, 2010","October 2010","December 2014","June 9, 2015","June 2014","No Study Results Posted","null","July 2014","Pathologic complete response （PCR）|Number of Participants with Ⅲ° and Ⅳ° Adverse Events According to NCI-CTC|Number of patients undergoing breast conserving surgery","https://ClinicalTrials.gov/show/NCT01199432"
1280,"NCT01775475","Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma","Recruiting","No Results Available","AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Stage III AIDS-related Lymphoma|Stage IV AIDS-related Lymphoma","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Drug: lomustine|Drug: etoposide|Drug: cyclophosphamide|Drug: procarbazine hydrochloride|Other: laboratory biomarker analysis","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","90","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-068|NCI-2012-01695|U01CA121947","January 23, 2013","September 2016","January 2021","September 29, 2016","June 2016","No Study Results Posted","null","January 2021","Overall survival|Overall response rate|Progression-free survival|Frequency and severity of adverse events, assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Proportion of patients who complete treatment|Proportion of patients who are adherent to antiretroviral therapy|Proportion of patients who are adherent to chemotherapy|Effects of therapy on HIV control, measured as the change in CD4 count and HIV load","https://ClinicalTrials.gov/show/NCT01775475"
1281,"NCT00002784","High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: CMF regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: mesna|Drug: methotrexate|Drug: tamoxifen citrate|Procedure: peripheral blood stem cell transplantation|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy","International Breast Cancer Study Group","Female","16 Years to 65 Years   (Child, Adult)","Phase 3","344","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000064834|IBCSG-15-95|EU-96021","November 1, 1999","June 1996","December 2011","April 3, 2013","July 2012","No Study Results Posted","15-95","August 2011","Disease-free survival.|Overall survival.|Toxicity.|Quality of life.","https://ClinicalTrials.gov/show/NCT00002784"
1282,"NCT00003859","Surgery Plus Radiation Therapy With or Without Chemotherapy in Treating Children With Primitive Neuroectodermal Tumors of the CNS","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: vincristine sulfate|Procedure: surgical procedure|Radiation: radiation therapy","Societe Internationale d'Oncologie Pediatrique|National Cancer Institute (NCI)","All","3 Years to 16 Years   (Child)","Phase 3","230","Other","Interventional","Primary Purpose: Treatment","CDR0000067022|SIOP-PNET-III|EU-99003|UKCCSG-9102","November 1, 1999","April 1992","April 2003","December 3, 2013","April 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003859"
1283,"NCT02118311","Treg Cells for AGVHD in Non-myeloablative UCB Transplant","Withdrawn","No Results Available","Hematologic Malignancies","Biological: T Regulatory cells|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total Body Irradiation","Masonic Cancer Center, University of Minnesota|National Institutes of Health (NIH)|National Cancer Institute (NCI)","All","18 Years to 69 Years   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","2013LS091|MT2013-27|P01CA065493","March 26, 2014","June 2016","September 2018","June 14, 2016","June 2016","No Study Results Posted","null","September 2018","Incidence of grade II-IV acute graft-versus-host disease|Incidence of double and single unit chimerism|Incidence of grade III-IV acute graft-versus-host disease|Incidence of viral and fungal infections|Survival|Incidence of neutrophil recovery|Incidence of treatment related mortality|Incidence of platelet recovery|Incidence of chronic GVHD|Incidence of relapse","https://ClinicalTrials.gov/show/NCT02118311"
1284,"NCT00002509","High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: mesna|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Temple University|Fox Chase Cancer Center","Female","15 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000078064|TUHSC-1992|NCI-V92-0205","November 1, 1999","November 1991","December 2003","September 30, 2010","September 2010","No Study Results Posted","null","December 2003","","https://ClinicalTrials.gov/show/NCT00002509"
1285,"NCT00496665","ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer","Completed","No Results Available","Metastatic Breast Cancer","Drug: Vandetanib|Drug: Cyclophosphamide|Drug: Methotrexate","Dana-Farber Cancer Institute|AstraZeneca|Massachusetts General Hospital|Brigham and Women's Hospital","All","18 Years and older   (Adult, Senior)","Phase 1","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-402","July 3, 2007","July 2007","March 2009","November 14, 2013","November 2013","No Study Results Posted","null","August 2008","To determine the safety and tolerability of combination therapy with ZD6474 (Zactima) and metronomic chemotherapy|To determine the response rate of combination therapy with ZD6474 (Zactima) and metronomic chemotherapy in patients with measurable disease.","https://ClinicalTrials.gov/show/NCT00496665"
1286,"NCT00176917","Stem Cell Transplantation for Hurler","Completed","Has Results","Mucopolysaccharidosis I|Mucopolysaccharidosis VI|Mannosidosis|Mucolipidosis Type II (I-cell Disease)","Procedure: Stem Cell Transplant|Drug: Busulfan, Cyclophosphamide, ATG","Masonic Cancer Center, University of Minnesota","All","Child, Adult, Senior","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMN-MT1999-07|0104M93821","September 12, 2005","May 1999","May 2010","November 6, 2012","November 2012","July 28, 2009","null","May 2008","Mean Percentage of Donor Cells in Study Population (Chimerism).|Number of Patients Surviving on Study|Number of Patients Who Failed Engraftment.|Number of Patients With Grade III-IV Acute Graft-versus-host Disease (aGVHD).","https://ClinicalTrials.gov/show/NCT00176917"
1287,"NCT02529813","CD19+ CAR T Cells for Lymphoid Malignancies","Recruiting","No Results Available","Leukemia|Lymphoma","Drug: Fludarabine monophosphate|Drug: Cyclophosphamide|Procedure: T Cell Infusion","M.D. Anderson Cancer Center|Ziopharm|Intrexon Corporation","All","1 Year to 80 Years   (Child, Adult, Senior)","Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2013-1018|NCI-2015-01492","August 18, 2015","December 2015","December 2021","January 18, 2017","January 2017","No Study Results Posted","null","December 2021","Maximum Tolerated Dose (MTD) of Genetically Modified CD19-Specified T Cells","https://ClinicalTrials.gov/show/NCT02529813"
1288,"NCT02959905","Treatment of Metastatic Melanoma With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)","Recruiting","No Results Available","Metastatic Melanoma","Biological: TSA-CTL(Tumor Specific Antigen Induced Cytotoxic Lymphocyte)|Drug: Cyclophosphamide|Drug: Cyclophosphamide|Drug: Fludarabine","BGI, China|Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BGI-001|2016-FXY-040|B2016-039","October 21, 2016","December 2016","March 2018","January 8, 2017","November 2016","No Study Results Posted","null","March 2018","Evaluate the number of participants with adverse events and make a detailed list of adverse events see the adverse event module.|Objective Response which is determined by the Response Evaluation Criteria in Solid Tumors (RECIST) in Patients With Metastatic Melanoma.","https://ClinicalTrials.gov/show/NCT02959905"
1289,"NCT02678143","Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease","Recruiting","No Results Available","Sickle Cell Disease","Drug: Alemtuzumab|Drug: Cyclophosphamide|Drug: Mycophenolate mofetil|Drug: Sirolimus|Drug: Fludarabine|Radiation: Total body irradiation|Procedure: Hematopoietic stem cell transplant","Washington University School of Medicine","All","19 Years and older   (Adult, Senior)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","201602019","February 4, 2016","April 26, 2016","May 31, 2020","February 23, 2017","February 2017","No Study Results Posted","null","May 31, 2020","Safety and tolerability of treatment regimen as measured by grade 3, 4, and 5 toxicities|Feasibility of treatment regimen as measured by accrual|Feasibility of treatment regimen as measured by patient compliance to treatment and follow-up|Rate of engraftment|Incidence of acute graft-versus-host disease|Incidence of chronic graft-versus-host disease|Incidence of infectious complications|Incidence of transplant related mortality|Incidence of engraftment failure|Overall survival rate|Event-free survival rate","https://ClinicalTrials.gov/show/NCT02678143"
1290,"NCT00038844","Safety and Efficacy of Campath in Nonmyeloablative Transplantation","Completed","No Results Available","Lymphoma|Leukemia","Drug: Campath-1 H (Alemtuzumab)|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab","M.D. Anderson Cancer Center","All","up to 70 Years   (Child, Adult, Senior)","","65","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID01-200","June 5, 2002","June 2001","September 2010","October 31, 2011","October 2011","No Study Results Posted","null","December 2007","Number of Participants Surviving 100 days post-transplant","https://ClinicalTrials.gov/show/NCT00038844"
1291,"NCT02504047","Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units","Recruiting","No Results Available","Hematologic Neoplasms","Procedure: T-Cell replete haplo-transplant","University of Calgary|The Canadian Blood and Marrow Transplant Group","All","Child, Adult, Senior","","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","26110","July 17, 2015","February 2014","July 2019","August 31, 2016","August 2016","No Study Results Posted","null","July 2018","Six month survival, free from relapse, graft failure and grade III/IV acute GVHD|Incidence of Grade III/IV Acute Graft Versus Host Disease|Incidence of Chronic Extensive Graft Versus Host Disease|Cumulative incidence of non-relapse mortality at 1 year|Graft failure rate (ANC < 0.5 and low donor chimerism)|Overall and Disease Free Survival|Relapse Rate|Patients remaining on immune suppression at 1 year|Incidence of CMV and EBV reactivation requiring treatment","https://ClinicalTrials.gov/show/NCT02504047"
1292,"NCT00409188","Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)","Completed","Has Results","Non-small Cell Lung Cancer","Biological: Tecemotide (L-BLP25)|Drug: Single low dose cyclophosphamide|Drug: Placebo","EMD Serono|Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 3","1513","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EMR 63325-001","December 7, 2006","January 2007","April 2015","October 19, 2015","October 2015","July 23, 2015","START","April 2012","Overall Survival|Time To Symptom Progression (TTSP) as Measured by the Lung Cancer Symptom Scale (LCSS)|Time To Progression (TTP)|One-, Two- and Three-year Survival Rate|Number of Participants With Treatment Emergent Adverse Events and Injection Site Reactions","https://ClinicalTrials.gov/show/NCT00409188"
1293,"NCT01324596","A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib","Completed","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: Intravenous|Drug: Bortezomib","University Hospital Southampton NHS Foundation Trust|Janssen-Cilag Ltd.","All","18 Years and older   (Adult, Senior)","Phase 3","1132","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RHMCAN0749","March 25, 2011","April 2011","June 2015","April 14, 2016","April 2016","No Study Results Posted","REMoDL-B","April 2015","Progression Free Survival|Overall survival|Event-free survival|Disease-free survival|Time to progression|Response duration|Complete and overall response rates|Evaluation of toxicity (according to CTCAE version 4.0)|Quality of life and assessment of peripheral neuropathy","https://ClinicalTrials.gov/show/NCT01324596"
1294,"NCT00162656","Treatment of Mature B-cell Lymphoma/Leukaemia","Completed","No Results Available","B-Cell Lymphoma","Drug: half cyclophosphamide|Drug: without COPADM3|Drug: mini CYVE, without 3 maintenance courses|Drug: LMB B|Drug: LMB C","Gustave Roussy, Cancer Campus, Grand Paris","All","6 Months to 20 Years   (Child, Adult)","Phase 3","848","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FAB LMB96","September 7, 2005","May 1996","May 2011","March 27, 2012","March 2012","No Study Results Posted","null","May 2004","Event free survival|Survival|long term toxicity","https://ClinicalTrials.gov/show/NCT00162656"
1295,"NCT00302003","Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma","Active, not recruiting","Has Results","Childhood Favorable Prognosis Hodgkin Lymphoma|Childhood Lymphocyte Depletion Hodgkin Lymphoma|Childhood Mixed Cellularity Hodgkin Lymphoma|Childhood Nodular Sclerosis Hodgkin Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage II Childhood Hodgkin Lymphoma","Radiation: radiation therapy|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Drug: cyclophosphamide|Drug: ifosfamide|Drug: vinorelbine tartrate|Drug: dexamethasone|Drug: etoposide phosphate|Drug: cisplatin|Drug: cytarabine|Biological: filgrastim","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","287","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AHOD0431|NCI-2009-00377|CDR0000459962|U10CA098543|COG-AHOD0431","March 9, 2006","February 2006","null","December 16, 2016","August 2016","June 29, 2016","null","March 2012","Event Free Survival Without Receiving Radiation Therapy (EFSnoRT).|Intensive Therapy Free Survival (ITFS).|Event Free Survival (EFS)|Overall Survival","https://ClinicalTrials.gov/show/NCT00302003"
1296,"NCT02641847","TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature","Recruiting","No Results Available","Triple Negative Breast Cancer|Breast Cancer","Drug: docetaxel|Drug: doxorubicin or epirubicin|Drug: cyclophosphamide|Drug: gemcitabine|Drug: cisplatin","Fudan University","Female","18 Years to 65 Years   (Adult)","Phase 2|Phase 3","503","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1506147-4","December 22, 2015","July 2015","null","December 24, 2015","December 2015","No Study Results Posted","null","June 2021","Recurrence free survival|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Disease free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02641847"
1297,"NCT02530515","Trial of Immune Reconstitution With Activated T-Cells Following Lymphodepleting Chemotherapy in Patients With Chronic Lymphocytic Leukemia (CLL)","Recruiting","No Results Available","Leukemia|Chronic Lymphocytic Leukemia","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Fludarabine monophosphate|Drug: Bendamustine|Biological: Activated T-Cell Infusion|Drug: Lenalidomide|Behavioral: Phone Calls","M.D. Anderson Cancer Center","All","Child, Adult, Senior","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2014-0830|NCI-2015-01546","August 19, 2015","December 2015","null","October 6, 2016","October 2016","No Study Results Posted","null","December 2020","Success of Autologous T Cells for Immune Restoration in Participants with Chronic Lymphocytic Leukemia (CLL)|Feasibility of Autologous T Cells for Immune Restoration in Participants with Chronic Lymphocytic Leukemia (CLL)|Immune Reconstitution Following Infusion of Activated T-cells in Participants with Chronic Lymphocytic Leukemia in the Lenalidomide and Non-Lenalidomide Arms","https://ClinicalTrials.gov/show/NCT02530515"
1298,"NCT00124514","Triptorelin for Ovary Protection in Childhood Onset Lupus","Completed","No Results Available","Systemic Lupus Erythematosus","Drug: Triptorelin pamoate","Children's Hospital Medical Center, Cincinnati|Watson Pharmaceuticals","Female","9 Years to 21 Years   (Child, Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic","2008-1045|FD-R-00239","July 26, 2005","June 2003","March 2014","July 25, 2014","July 2014","No Study Results Posted","null","March 2014","To determine the dose of triptorelin that will maintain complete ovarian suppression between monthly injections|To optimize the time interval at triptorelin injection and infusion of cyclophosphamide","https://ClinicalTrials.gov/show/NCT00124514"
1299,"NCT01145209","A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","Active, not recruiting","No Results Available","Small Lymphocytic Lymphoma|CLL (Chronic Lymphocytic Leukemia)","Drug: Fludarabine Phosphate|Biological: Ofatumumab|Drug: Cyclophosphamide","National Heart, Lung, and Blood Institute (NHLBI)|University of Virginia|GlasoSmithKline|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","32","NIH|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","100141|10-H-0141","June 15, 2010","June 9, 2010","December 31, 2017","May 12, 2017","April 18, 2017","No Study Results Posted","null","October 31, 2017","2-year progression -free survival rate|response rate (complete response and partial response); toxicity profile; rate of minimal residual disease positivity after completion of induction therapy; rate of conversion to minimal residual disease negativity after consolidation therapy","https://ClinicalTrials.gov/show/NCT01145209"
1300,"NCT01818063","Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer","Active, not recruiting","No Results Available","Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-negative Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-negative Breast Cancer","Drug: Paclitaxel|Drug: Carboplatin|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Veliparib","Sidney Kimmel Cancer Center at Thomas Jefferson University|Susan G. Komen Breast Cancer Foundation|Thomas Jefferson University","Female","18 Years and older   (Adult, Senior)","Phase 2","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","12G.376|2012-47","March 21, 2013","April 25, 2013","January 2019","May 10, 2017","May 2017","No Study Results Posted","null","April 2018","Pathologic complete response (PCR)|Overall clinical response|Relapse free survival","https://ClinicalTrials.gov/show/NCT01818063"
1301,"NCT01414855","A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)","Completed","Has Results","Lymphoma, B-Cell","Drug: obinutuzumab|Drug: cyclophosphamide|Drug: doxorubicin|Drug: prednisone|Drug: vincristine","Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","GAO4915g","August 10, 2011","August 31, 2011","December 23, 2016","April 13, 2017","April 2017","February 5, 2015","null","December 31, 2013","Complete Response (CR) Rate as Assessed by the Investigator at the End of Treatment|Overall Response Rate (ORR) as Assessed by the Investigator at the End of Treatment|Complete Response (CR) Rate as Assessed by the Independent Review Facility (IRF) at the End of Treatment|Overall Response Rate (ORR) as Assessed by the IRF at the End of Treatment|Progression-Free Survival (PFS) as Assessed by the Investigator|Duration of Response (DOR)|Percentage of Participants With Adverse Events as a Measure of Safety|Number of Participants With Grade 3 to 4 Infusion-Related (IRR) Adverse Events (AE) in Participants Receiving Shorter Duration Infusion (SDI)|Pharmacokinetics (PK): Maximum Concentration Observed (Cmax) for Obinutuzumab|Pharmacokinetics: Terminal Half-Life (t1/2) for Obinutuzumab|Pharmacokinetics: Clearance (Cl) for Obinutuzumab|Pharmacokinetics: Volume of Distribution (V) for Obinutuzumab|Pharmacokinetics: Area Under the Concentration-Time Curve 7 Day (AUC7day)|Pharmacodynamics: Peripheral Blood CD19-positive B-cell Count","https://ClinicalTrials.gov/show/NCT01414855"
1302,"NCT02285062","Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma","Recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: lenalidomide|Drug: Placebo|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: prednisone|Drug: vincristine","Celgene","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","560","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","CC-5013-DLC-002|2013-004054-21","November 4, 2014","January 21, 2015","September 30, 2022","May 23, 2017","May 2017","No Study Results Posted","ROBUST","June 30, 2018","Progression Free Survival|Overall Survival|Complete Response Rate|Duration of Complete Response|Time to Next Lymphoma Treatment|Objective Response Rate|Health Related Quality of Life|Event Free Survival","https://ClinicalTrials.gov/show/NCT02285062"
1303,"NCT02792114","T-Cell Therapy for Advanced Breast Cancer","Recruiting","No Results Available","Breast Cancer|Metastatic HER2-negative Breast","Drug: Cyclophosphamide|Biological: Mesothelin-targeted T cells|Drug: AP1903","Memorial Sloan Kettering Cancer Center|United States Department of Defense","Female","18 Years and older   (Adult, Senior)","Phase 1","24","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","16-040","June 2, 2016","June 2016","June 2019","April 19, 2017","April 2017","No Study Results Posted","null","June 2019","Maximum tolerated does (MTD)","https://ClinicalTrials.gov/show/NCT02792114"
1304,"NCT00176930","Stem Cell Transplant for Hematological Malignancy","Recruiting","No Results Available","Leukemia, Myeloid, Chronic|AML|Leukemia, Lymphocytic, Acute|MDS|Leukemia, Lymphocytic, Chronic|JMML|Hodgkin's Disease|Non-hodgkin's Lymphoma|Multiple Myeloma","Procedure: Stem Cell Transplant|Drug: Cyclophosphamide|Radiation: Total Body Irradiation|Drug: Busulfan","Masonic Cancer Center, University of Minnesota","All","up to 55 Years   (Child, Adult)","","350","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2001LS049|MT2001-02|0107M05202","September 12, 2005","October 2001","December 2017","August 15, 2016","August 2016","No Study Results Posted","null","December 2017","Disease-Free Survival|Time to Neutrophil Engraftment|Incidence of Acute Graft-Versus-Host Disease|Incidence of Chronic GVHD|Persistence or relapse of malignancy|Overall Survival|Engraftment Failure","https://ClinicalTrials.gov/show/NCT00176930"
1305,"NCT01895244","Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis","Recruiting","No Results Available","Scleroderma|Cardiac Involvement|Autologous Stem Cell Transplantation","Drug: Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells","University Hospital Tuebingen","All","18 Years to 65 Years   (Adult)","Phase 2","44","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AST MOMA","July 1, 2013","September 2012","September 2020","October 24, 2016","October 2016","No Study Results Posted","AST-MOMA","September 2018","Overall survival|Treatment related mortality|Time to engraftment|Progression free survival|Efficacy","https://ClinicalTrials.gov/show/NCT01895244"
1306,"NCT02520479","""Sandwich"" Chemotherapy With Radiotherapy in Newly Diagnosed, Stage IE to IIE, ENKTL","Recruiting","No Results Available","Treatment Refusal","Drug: P-CHOP|Radiation: Radiotherapy|Drug: P-CHOP","Sun Yat-sen University","All","18 Years to 69 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NK-SYSUCC","August 4, 2015","June 2013","June 2018","October 18, 2016","October 2016","No Study Results Posted","null","December 2016","complete remission rate|progression free survival|overall survival|Hematological and non-hematological safety as a measure of adverse events according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","https://ClinicalTrials.gov/show/NCT02520479"
1307,"NCT01955460","Study of Lymphodepletion Plus Adoptive Cell Transfer With TGF-beta Resistant (DNRII) and NGFR Transduced T-Cells Followed by High Dose Interleukin-2 in Participants With Metastatic Melanoma","Recruiting","No Results Available","Melanoma","Drug: Cyclophosphamide|Drug: Mesna|Drug: Fludarabine monophosphate|Biological: T-Cells|Drug: Interleukin-2 (IL-2)","M.D. Anderson Cancer Center|Cancer Prevention Research Institute of Texas","All","12 Years and older   (Child, Adult, Senior)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-0758|RP110553-P4|NCI-2014-01211","September 27, 2013","October 2014","null","December 12, 2016","December 2016","No Study Results Posted","null","October 2019","Feasibility of Producing Sufficient Quantities of TFGâ-DNRII and NGFR Transduced TIL for Treatment of Metastatic Melanoma|Response of Autologous TGFb Resistant (DNRII Transduced) and NGFR Transduced TIL in Participants with Metastatic Melanoma","https://ClinicalTrials.gov/show/NCT01955460"
1308,"NCT00295893","Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Biological: trastuzumab|Drug: carboplatin|Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Drug: paclitaxel","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","105","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","05015|P30CA033572|CDR0000455631","February 23, 2006","September 2005","February 2018","February 10, 2017","February 2017","No Study Results Posted","null","February 2018","Complete response rate|Feasibility|Quality of life and neuropathy assessment of prognostic and predictive markers as measured by FACT exploratory methods at 1 year","https://ClinicalTrials.gov/show/NCT00295893"
1309,"NCT00513292","Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery","Active, not recruiting","Has Results","HER2/Neu Positive|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer","Drug: Cyclophosphamide|Drug: Epirubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Procedure: Therapeutic Conventional Surgery|Biological: Trastuzumab","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","280","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00341|CDR0000559039|ACOSOG-Z1041|Z1041|U10CA012027","August 6, 2007","July 2007","null","November 14, 2016","November 2016","July 14, 2015","null","June 2012","pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy|Combined pCR Rate in the Breast and Axillary Lymph Nodes Defined as no Evidence of Invasive Tumor Remaining in Either the Breast or Axillary Nodes at Surgery Following Completion of Chemotherapy|Asymptomatic Decreases From Baseline in Left Ventricular Ejection Fraction (LVEF) at Week 12|Asymptomatic Decreases From Baseline in LVEF at Week 24|LVEFs From Regularly Scheduled Multi Gated Acquisition Scan (MUGA)/Echo Scans as Reported at 12 Week|Change in LVEFs (From Regularly Scheduled Multi Gated Acquisition Scan (MUGA)/Echo Scans) From Baseline and at 24 Week|Breast Conservation Rates|Disease-free Survival (DFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00513292"
1310,"NCT00005986","Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia","Terminated","No Results Available","Leukemia","Drug: busulfan|Drug: cyclophosphamide|Drug: filgrastim|Drug: recombinant interferon alfa|Procedure: in vitro-treated peripheral blood stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: radiation therapy","Masonic Cancer Center, University of Minnesota","All","18 Years to 65 Years   (Adult)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000067974|UMN-MT-9507","July 5, 2000","August 2000","null","July 13, 2011","July 2011","No Study Results Posted","null","September 2004","","https://ClinicalTrials.gov/show/NCT00005986"
1311,"NCT00004125","Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Drug: paclitaxel|Drug: tamoxifen citrate|Radiation: radiation therapy","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|North Central Cancer Treatment Group|Southwest Oncology Group|Cancer and Leukemia Group B","Female","18 Years and older   (Adult, Senior)","Phase 3","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000067353|E1199|CLB-49906|NCCTG-E1199|SWOG-E1199","December 10, 1999","October 1999","null","January 28, 2010","January 2010","No Study Results Posted","null","May 2007","","https://ClinicalTrials.gov/show/NCT00004125"
1312,"NCT02486952","MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma","Completed","Has Results","Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma","Drug: Cyclophosphamide|Drug: Hydroxydaunorubicin|Drug: Oncovin|Drug: Prednisone|Drug: Rituximab","Hoffmann-La Roche|Serbian Lymphoma Group","All","18 Years and older   (Adult, Senior)","","154","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ML20390","June 29, 2015","August 2005","January 2011","January 22, 2016","January 2016","November 17, 2015","null","January 2011","Probability of Event Free Survival (EFS)|Percentage of Participants Who Were Alive","https://ClinicalTrials.gov/show/NCT02486952"
1313,"NCT00581776","Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma","Completed","Has Results","Mantle Cell Lymphoma","Drug: Bortezomib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Dexamethasone","University of Wisconsin, Madison","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HO05401","December 19, 2007","May 2005","May 2015","May 12, 2016","May 2016","December 9, 2010","null","November 2012","Overall Response Rate (ORR) at the Completion of Induction Chemotherapy, Which is the Percent of Complete Responses (CR) Plus Percent of Partial Responses (PR).|Complete Response Rate (CR) at the End of Induction Chemotherapy|3 Year Progression Free Survival|3 Year Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00581776"
1314,"NCT00343798","A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies","Completed","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Previously Treated Myelodysplastic Syndromes|Prolymphocytic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma","Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: cyclosporine|Drug: mycophenolate mofetil|Other: ex-vivo umbilical cord blood expansion|Procedure: double-unit umbilical cord blood transplantation|Procedure: biopsy|Other: immunologic technique|Other: diagnostic laboratory biomarker analysis","Fred Hutchinson Cancer Research Center|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Damon Runyon Cancer Research Foundation","All","6 Months to 45 Years   (Child, Adult)","Phase 1","23","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2044.00|NCI-2010-00236|R43HL106868|R24HL074445|RC2HL101844","June 22, 2006","April 2006","null","February 10, 2015","February 2015","No Study Results Posted","null","July 2013","Severe (grades 3 and 4) acute GVHD|Grade greater than or equal to 3 infusional toxicity|Graft failure as defined by failure to achieve ANC greater than or equal to 500/mm^3 of donor origin","https://ClinicalTrials.gov/show/NCT00343798"
1315,"NCT02807103","Rituximab in Eosinophilic Granulomatosis With Polyangiitis","Recruiting","No Results Available","Eosinophilic Granulomatosis With Polyangiitis (EGPA)","Drug: Rituximab|Drug: Placebo-rituximab|Drug: Cyclophosphamide|Drug: Placebo-cyclophosphamide","Assistance Publique - Hôpitaux de Paris|French Vasculitis Study Group (FVSG)","All","18 Years and older   (Adult, Senior)","Phase 3","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P140915|2016-000275-25","May 20, 2016","December 2016","June 2020","December 12, 2016","December 2016","No Study Results Posted","REOVAS","December 2019","Number of patients in complete remission (defined by a Birmingham Vasculitis Activity Score (BVAS) of 0 and a prednisone dose ≤7.5 mg/day )|Number of adverse events|Area under the curve for corticosteroids|Number of sequelae assessed by the Vasculitis Damage Index|ANCA titers and CD19+cells|Health Assessment Questionnaire (HAQ) score|Short Form-36 score","https://ClinicalTrials.gov/show/NCT02807103"
1316,"NCT02957968","Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca","Recruiting","No Results Available","Locally Advanced Breast Cancer|Invasive Adenocarcinoma of the Breast|Breast Cancer Stage II|Breast Cancer Stage III|Breast Cancer Stage IV","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Paclitaxel|Drug: Carboplatin","Virginia Commonwealth University|Merck Sharp & Dohme Corp.|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-15-11083|NCI-2016-01980","November 3, 2016","January 24, 2017","December 31, 2018","May 3, 2017","May 2017","No Study Results Posted","null","December 31, 2018","Percent of tumor and stroma with infiltrating lymphocytes from baseline pre-treatment biopsy to post-immunotherapy biopsy following administration of decitabine followed by pembrolizumab.|All adverse events (AEs) reported during and after immune treatment (ie, decitabine and pembrolizumab)|Percentage of patients meeting criteria for LPBC following treatment with decitabine and pembrolizumab compared to the percentage before treatment.|Proportion of patients with pCR in the breast and post-therapy lymph nodes.|Proportion of patients with no or minimal residual disease in the resected breast and axillary specimen.|The proportion of patients with cCR|Enumeration of T cells and immune cell subsets|Evaluation of expression of PD-L1 within tumor, stroma, and infiltrating immune cells at baseline and following immunotherapy.|Correlation of intensity of PD-L1 expression by assay as it relates to pCR rates from chemotherapy.|Evaluation of MDSC identified in blood samples post-decitabine and post-pembrolizumab compared to MDSC found in blood samples collected at baseline.","https://ClinicalTrials.gov/show/NCT02957968"
1317,"NCT02293109","Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma","Recruiting","No Results Available","Contiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia","Drug: carfilzomib|Drug: cyclophosphamide|Drug: vincristine sulfate|Drug: doxorubicin hydrochloride|Drug: dexamethasone|Drug: methotrexate|Drug: cytarabine|Drug: leucovorin calcium|Drug: methylprednisolone|Biological: rituximab|Other: laboratory biomarker analysis","University of California, Davis|Amgen","All","18 Years to 64 Years   (Adult)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCDCC#246|NCI-2014-02245","November 13, 2014","December 2015","December 2019","August 9, 2016","August 2016","No Study Results Posted","null","December 2016","Maximum tolerated dose of carfilzomib with hyper-CVAD, defined as the dose that produces dose limiting toxicity in 17% or fewer (1/6) of patients, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4|Rate of remission|Rate of minimal residual disease (MRD) in bone marrow aspirate samples|Rate of MRD in bone marrow aspirate samples","https://ClinicalTrials.gov/show/NCT02293109"
1318,"NCT01855828","Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer","Recruiting","No Results Available","Her2-Positive Breast Cancer","Drug: Pertuzumab|Drug: Trastuzumab|Drug: Paclitaxel|Drug: 5-fluorouracil|Drug: Epirubicin|Drug: Cyclophosphamide","Lajos Pusztai|Genentech, Inc.|Yale University","All","18 Years to 65 Years   (Adult)","Phase 2","64","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1305012136","May 13, 2013","September 2013","June 2017","April 12, 2016","April 2016","No Study Results Posted","null","December 2016","Pathologic Complete Response|Safety|Clinical Response|Residual Cancer burden score","https://ClinicalTrials.gov/show/NCT01855828"
1319,"NCT01273181","MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes","Terminated","Has Results","Metastatic Cancer|Metastatic Renal Cancer|Metastatic Melanoma","Biological: PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes|Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","9","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","110062|11-C-0062","January 7, 2011","December 2010","December 2012","October 6, 2015","October 2015","February 14, 2013","null","December 2012","Toxicity Profile|Clinical Tumor Regression (Complete Response (CR) + Partial Response (PR)) in Patients With Metastatic Cancer","https://ClinicalTrials.gov/show/NCT01273181"
1320,"NCT02626455","Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)","Recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: Copanlisib (BAY 80-6946)|Drug: Placebo|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Bendamustine|Drug: Prednisone","Bayer","All","18 Years and older   (Adult, Senior)","Phase 3","676","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","17833|2015-001088-38","November 3, 2015","January 6, 2016","December 31, 2024","May 12, 2017","May 2017","No Study Results Posted","CHRONOS-4","September 30, 2021","Evaluation whether copanlisib in combination with standard immunochemotherapy, is superior to placebo and standard immunochemotherapy assessed by the prolongation of progression free survival (PFS) - applicable to Phase III part|Determination of the recommended Phase III dose (RP3D) of copanlisib in combination with standard immunochemotherapy assessed by the occurrence of dose-limiting toxicity s (DLTs) / adverse events (AEs) - applicable to safety run-in part|Objective tumor response rate (ORR)|Duration of tumor response (DOR)|Complete tumor response rate (CRR)|Time to tumor progression (TTP)|Overall survival (OS)|Time to deterioration in disease-related physical symptoms (DRS-P) of at least 3 points as measured by by the FLymSI-18 (Lymphoma Symptom Index -18) questionnaire|Time to improvement in DRS-P of at least 3 points, as measured by the FLymSI-18 questionnaire, will be evaluated for patients with a baseline DRS-P score of 30 points or less|Time to next anti-lymphoma treatment (TTNT)|Radiological and clinical indicators of treatment efficacy: Progression free survival (PFS)|Radiological and clinical indicators of treatment efficacy:Objective tumor response rate (ORR)|Radiological and clinical indicators of treatment efficacy:Duration of tumor response (DOR)|Radiological and clinical indicators of treatment efficacy: Complete tumor response rate (CRR)|Radiological and clinical indicators of treatment efficacy: Time to tumor progression (TTP)|Radiological and clinical indicators of treatment efficacy: Time to next anti-lymphoma treatment (TTNT)|Radiological and clinical indicators of treatment efficacy: Overall survival (OS)|Number of participants with adverse events as a measure of safety and tolerability|Radiological and clinical indicators of treatment efficacy: ""time to deterioration"" in disease-related symptoms - physical (DRS-P) will be assessed using the NCCN-FACT Lymphoma Symptom Index-18 (FLymSI-18) questionnaire|Radiological and clinical indicators of treatment efficacy: Time to improvement"" in disease-related symptoms - physical (DRS-P) will be assessed using the FLymSI-18 questionnaire","https://ClinicalTrials.gov/show/NCT02626455"
1321,"NCT01015443","Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population","Terminated","Has Results","Non-Small Cell Lung Cancer","Biological: Tecemotide|Drug: Single low dose cyclophosphamide|Drug: Placebo|Other: Saline|Other: Best Supportive Care (BSC)","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 3","285","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EMR63325-012","October 1, 2009","December 2009","June 2015","September 16, 2016","September 2016","June 17, 2016","INSPIRE","June 2015","Overall Survival (OS) Time|Time to Symptom Progression (TTSP)|Time to Progression (TTP)|Progression Free Survival (PFS)|Time to Treatment Failure (TTF)|Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death","https://ClinicalTrials.gov/show/NCT01015443"
1322,"NCT00376519","Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases","Terminated","No Results Available","Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Secondary Myelofibrosis","Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: Treg cell infusion|Procedure: umbilical cord blood transplantation|Radiation: total-body irradiation","Masonic Cancer Center, University of Minnesota","All","18 Years to 45 Years   (Adult)","Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMN-2005LS011|UMN-0502M67473|UMN-MT2005-01","September 13, 2006","May 2007","March 2008","November 6, 2012","November 2012","No Study Results Posted","null","March 2008","Maximum tolerated dose of T-regulatory cells|Incidence of neutrophil recovery|Incidence of double chimerism|Incidence of grades II-IV and III-IV acute graft-versus-host disease (GVHD)|Incidence of chronic graft-versus-host disease|Survival|Incidence of Platelet Recovery","https://ClinicalTrials.gov/show/NCT00376519"
1323,"NCT01746992","CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma","Recruiting","No Results Available","ALK-negative Anaplastic Large Cell Lymphoma|Peripherial T Cell Lymphoma,Not Otherwise Specified|Angioimmunoblastic T Cell Lymphoma|Enteropathy Associated T Cell Lymphoma|Hepatosplenic T Cell Lymphoma|Subcutaneous Panniculitis Like T Cell Lymphoma","Drug: Cyclophosphamide 750mg/m2|Drug: Vincristine 1.4mg/m2|Drug: Doxorubicin 50mg/m2|Drug: prednisone 60mg/m2|Drug: ifosfamide 2000mg/m2|Drug: pirarubicin 50mg/m2|Drug: pirarubicin 25mg/m2|Drug: Etoposide phosphate 100mg/m2|Drug: methotrexate 1500mg/m2","Ruijin Hospital","All","18 Years to 65 Years   (Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CTOP","December 4, 2012","September 2012","December 2018","November 24, 2013","November 2013","No Study Results Posted","null","September 2015","complete remission rate|3-year PFS|overall response rate|3-year os","https://ClinicalTrials.gov/show/NCT01746992"
1324,"NCT02694224","Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer","Drug: vismodegib|Drug: Paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide","Clinica Universidad de Navarra, Universidad de Navarra","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SHH (Sonic HedgeHog)-CM","January 12, 2016","April 2016","December 2018","May 11, 2016","May 2016","No Study Results Posted","SHH-CM","December 2017","Number of patients with treatment-related adverse events as assessed by CTCAE v4.0|Molecular changes in breast|Pathologic complete response (pCR)|Clinical complete response (cCR)|European Organisation for Research and Treatment of Cancer Quality of Life questionnaire C30 (EORTC QOL-C30)","https://ClinicalTrials.gov/show/NCT02694224"
1325,"NCT03086564","A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT)","Not yet recruiting","No Results Available","Hepatocellular Carcinoma","Biological: ADCC & TACE|Procedure: TACE","Yuehua Huang|Third Affiliated Hospital, Sun Yat-Sen University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","huangyuehuateam","March 10, 2017","May 1, 2017","May 1, 2020","March 22, 2017","March 2017","No Study Results Posted","null","May 1, 2020","Imaging signs|Alpha-fetoprotein (AFP)|Glypican-3","https://ClinicalTrials.gov/show/NCT03086564"
1326,"NCT00005834","S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma","Terminated","No Results Available","Multiple Myeloma","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: dexamethasone|Drug: etoposide|Drug: thalidomide","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","19","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","S9922|U10CA032102","June 2, 2000","April 2000","November 2007","March 5, 2015","March 2015","No Study Results Posted","null","November 2003","PFS","https://ClinicalTrials.gov/show/NCT00005834"
1327,"NCT00014573","Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: aldesleukin|Biological: autologous tumor cell vaccine|Biological: filgrastim|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: paclitaxel|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000068559|P30CA022453|WSU-D-1654|WSU-07-92-98-P04-FB|NCI-G01-1937","April 10, 2001","August 1998","October 2004","April 5, 2013","April 2013","No Study Results Posted","null","October 2004","","https://ClinicalTrials.gov/show/NCT00014573"
1328,"NCT01028716","Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","Recruiting","No Results Available","Acute Biphenotypic Leukemia|Acute Erythroid Leukemia in Remission|Acute Leukemia in Remission|Acute Megakaryoblastic Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia in Remission|Acute Myeloid Leukemia With FLT3/ITD Mutation|Acute Myeloid Leukemia With Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1|Acute Myeloid Leukemia With Inv(3)(q21q26.2); RPN1-EVI1|Acute Myeloid Leukemia With Multilineage Dysplasia|Acute Myeloid Leukemia With t(6;9)(p23;q34); DEK-NUP214|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Complete Remission|B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)|B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1|Burkitt Lymphoma|Childhood Acute Lymphoblastic Leukemia in Complete Remission|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Myelodysplastic Syndrome|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma|Secondary Acute Myeloid Leukemia|T Lymphoblastic Lymphoma","Drug: Cyclophosphamide|Biological: Filgrastim|Drug: Fludarabine Phosphate|Procedure: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Tacrolimus|Radiation: Total-Body Irradiation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2372.00|NCI-2009-01433|2372|P30CA015704","December 8, 2009","February 2010","null","January 9, 2017","January 2017","No Study Results Posted","null","August 2017","Cumulative incidence of non-relapse mortality, defined as death without evidence of disease progression|Incidence of chronic GVHD|Incidence of grades III/IV acute GVHD|Relapse of malignancy after transplantation|Donor cell engraftment|Infections|Neutrophil recovery|Platelet recovery|Primary graft failure|Progression-free survival|Secondary graft failure|Toxicity of treatment regimen","https://ClinicalTrials.gov/show/NCT01028716"
1329,"NCT00652899","Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer","Terminated","Has Results","Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer","Biological: Allopurinol|Drug: Cyclophosphamide|Drug: Fludarabine phosphate|Radiation: total-body irradiation|Biological: Allogeneic natural killer cells|Biological: Aldesleukin","Masonic Cancer Center, University of Minnesota","Female","18 Years and older   (Adult, Senior)","Phase 2","14","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007LS138|UMN-MT2007-19R|UMN-WCC-53|UMN-0712M23462","April 3, 2008","March 2008","August 2009","November 6, 2012","November 2012","August 20, 2010","null","August 2009","Number of Patients With In Vivo Expansion of Infused Allogeneic Natural Killer (NK) Cell Product|Number of Patients Per Disease Response|Median Number of Days to Progression|Median Overall Survival Number of Days Patients Alive After Treatment","https://ClinicalTrials.gov/show/NCT00652899"
1330,"NCT01175785","Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies","Completed","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes","Procedure: umbilical cord blood transplantation|Drug: fludarabine phosphate|Drug: cyclophosphamide|Procedure: ex vivo-expanded cord blood progenitor cell infusion|Radiation: total-body irradiation|Drug: cyclosporine|Drug: mycophenolate mofetil|Other: laboratory biomarker analysis","Fred Hutchinson Cancer Research Center|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)","All","6 Months to 45 Years   (Child, Adult)","Phase 2","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2378.00|NCI-2010-01426|2378|P30CA015704|RC2HL101844","August 3, 2010","August 2010","null","April 5, 2017","April 2017","No Study Results Posted","null","August 2014","Time to neutrophil engraftment|Time to platelet engraftment|Overall survival|Event-free survival|Incidence of severe (grades 3-4) acute GVHD|Incidence of grade greater than or equal to 3 infusional toxicity|Primary graft failure|Secondary graft failure","https://ClinicalTrials.gov/show/NCT01175785"
1331,"NCT00022178","Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin","Unknown status","No Results Available","Carcinoma of Unknown Primary","Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: vincristine sulfate","The Christie NHS Foundation Trust|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068792|CHNT-VAC-VS-ECF|EU-20041","August 10, 2001","December 1998","null","September 19, 2013","February 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00022178"
1332,"NCT00433537","Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma","Completed","Has Results","Contiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Stage I Mantle Cell Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Mantle Cell Lymphoma","Drug: bortezomib|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine|Drug: dexamethasone|Biological: filgrastim|Biological: pegfilgrastim|Procedure: Autologous stem cell transplantation (ASCT)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","77","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02966|E1405|U10CA021115","February 8, 2007","May 2007","June 2013","October 24, 2014","January 2014","October 24, 2014","null","June 2013","Complete Response (CR) Rate|2-year Progression-free Survival (PFS)|3-year Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00433537"
1333,"NCT00303719","Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy","Active, not recruiting","No Results Available","Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma|Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine|Drug: mycophenolate mofetil|Procedure: stem cell transplantation|Radiation: total body irradiation|Drug: filgrastim","Masonic Cancer Center, University of Minnesota","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","344","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2001LS058|UMN-MT2001-10|0108M06725","March 15, 2006","March 26, 2002","December 2019","April 24, 2017","April 2017","No Study Results Posted","null","June 15, 2017","Neutrophil and Donor Cell Engraftment|Serious Adverse Events|Transplant Related Mortality|Overall Survival|Acute Graft-Versus-Host Disease","https://ClinicalTrials.gov/show/NCT00303719"
1334,"NCT00618813","Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors","Completed","Has Results","Ewing Sarcoma of Bone|Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","Other: radiation therapy|Other: therapeutic conventional surgery|Drug: etoposide|Drug: ifosfamide|Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Drug: vincristine sulfate|Drug: topotecan hydrochloride|Biological: filgrastim","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","","35","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AEWS07P1|NCI-2009-00371|CDR0000586282|U10CA098543|COG-AEWS07P1","February 19, 2008","March 2008","null","September 11, 2014","September 2014","December 17, 2013","null","March 2010","Incidence of Death|Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Enrollment to Week 12|Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Week 13 to Week 22|Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Week 23 to Week 28|Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Week 29 to Week 37|Event Free Survival","https://ClinicalTrials.gov/show/NCT00618813"
1335,"NCT00133991","Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia","Completed","No Results Available","Leukemia|Lymphoma","Biological: filgrastim|Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cytarabine|Drug: leucovorin calcium|Drug: methotrexate|Drug: prednisone|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","30 Years and older   (Adult, Senior)","Phase 2","21","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000439521, J0409|P50CA096888|P30CA006973|JHOC-J0409|JHOC-04-05-13-01","August 22, 2005","March 2005","July 2012","April 16, 2014","April 2014","No Study Results Posted","null","July 2010","Overall response rate|Event-free survival (EFS) at 1 year|Overall survival (OS) at 1 year|Toxicity and overall tolerability|Median EFS and OS|EFS and OS at 3 years|Predictors of relapse and death, including age, disease stage, International Prognostic Index, and history of CNS involvement by lymphoma","https://ClinicalTrials.gov/show/NCT00133991"
1336,"NCT00017641","Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus","Unknown status","No Results Available","Systemic Lupus Erythematosus","Drug: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: filgrastim|Procedure: CD34+ Peripheral Blood Stem Cell Reinfusion","Northwestern Memorial Hospital|Office of Rare Diseases (ORD)","All","up to 59 Years   (Child, Adult)","Phase 1","10","Other","Interventional","Primary Purpose: Treatment","199/14976|NU-95LU1","June 6, 2001","April 2001","null","June 23, 2005","November 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00017641"
1337,"NCT02406092","Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A","Active, not recruiting","No Results Available","Non-Hodgkin Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Fludarabine","Hoffmann-La Roche","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","121","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ML28964","March 23, 2015","October 13, 2015","May 30, 2021","April 20, 2017","April 2017","No Study Results Posted","null","May 30, 2021","Percentage of Participants With Administration-Associated Reactions (AARs)|Event-Free Survival (EFS) as Assessed by Investigator According to International Working Group (IWG) Response Criteria|Progression-Free Survival (PFS) as Assessed by Investigator According to IWG Response Criteria|Overall Survival (OS)|Disease-Free Survival (DFS) as Assessed by Investigator According to IWG Response Criteria|Percentage of Participants With CR/CRu as Assessed by Investigator According to IWG Response Criteria|Healthcare Professional Questionnaire Score|Patient-Reported Rituximab Administration Questionnaire (RASQ) Score","https://ClinicalTrials.gov/show/NCT02406092"
1338,"NCT02343536","A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma","Recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular","Drug: Oral Azacitidine|Drug: Rituximab|Drug: cyclophosphamide|Drug: Vincristine|Drug: Prednisone","Celgene","All","18 Years and older   (Adult, Senior)","Phase 1","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CC-486-DLBCL-001","January 16, 2015","April 29, 2015","March 1, 2020","May 9, 2017","May 2017","No Study Results Posted","null","April 30, 2018","Maximum Tolerated Dose (MTD)|Maximal Administered Dose (MAD)|Adverse Event (AE)|Pharmacokinetics- Cmax|Pharmacokinetics - AUC|Pharmacokinetics - Tmax|Pharmacokinetics - t1/2|Pharmacokinetics CL/F|Pharmacokinetics - Vz/F|Overall response rate (ORR)|Complete response (CR) rate|Progression free survival (PFS)","https://ClinicalTrials.gov/show/NCT02343536"
1339,"NCT02005783","Study of Danggui Buxue Decoction in Preventing Neutropenia","Completed","No Results Available","Grade 3/4 Neutropenia|Febrile Neutropenia","Drug: DBD|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Docetaxel","Shanghai Jiao Tong University School of Medicine","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","RJBC1302","December 4, 2013","October 2013","October 2015","December 29, 2015","May 2015","No Study Results Posted","DIPE","August 2015","incidence of grade 3/4 neutropenia|times of grade 3/4 neutropenia per cycle of chemotherapy|incidence of febrile neutropenia|the time to neutropenia recovery","https://ClinicalTrials.gov/show/NCT02005783"
1340,"NCT02661035","Allo HSCT Using RIC for Hematological Diseases","Recruiting","No Results Available","Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Plasma Cell Leukemia|Myelodysplastic Syndromes|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|B-Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-Cell Lymphoma|Prolymphocytic Leukemia|Lymphoblastic Lymphoma|Burkitt's Lymphoma|Non-Hodgkin's Lymphoma|Multiple Myeloma|Myeloproliferative Syndromes|Hematological Diseases","Drug: Allopurinol|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: ATG|Radiation: TBI|Drug: Tacrolimus|Drug: MMF|Biological: Peripheral Blood Stem Cells|Biological: Related or Unrelated Bone Marrow Cells","Masonic Cancer Center, University of Minnesota","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","124","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2015LS152","January 19, 2016","March 9, 2017","March 2023","March 9, 2017","March 2017","No Study Results Posted","null","March 2023","Evaluate rates of acute graft-versus-host disease (GVHD) II-IV|Evaluate rates of chronic GVHD|Evaluate neutrophil engraftment without ATG (in siblings)|Evaluate neutrophil engraftment with ATG (in unrelated donors)|Evaluate neutrophil engraftment without ATG (in unrelated donors)|Evaluate relapse without ATG (in siblings) - 1 year|Evaluate relapse without ATG (in siblings) - 2 years|Evaluate relapse with ATG (in unrelated donors) - 1 year|Evaluate relapse with ATG (in unrelated donors) - 2 years|Evaluate relapse without ATG (in unrelated donors) - 1 year|Evaluate relapse without ATG (in unrelated donors) - 2 years|Overall survival|Transplant related mortality (TRM)","https://ClinicalTrials.gov/show/NCT02661035"
1341,"NCT03155191","Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia","Not yet recruiting","No Results Available","Lymphoblastic Leukemia, Acute Adult","Biological: TBI-1501","Takara Bio Inc.","All","16 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","21","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","1501-01","April 14, 2017","June 1, 2017","March 31, 2020","May 15, 2017","May 2017","No Study Results Posted","TBI-1501","March 31, 2019","Phase-I portion: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Phase-II portion: Anti-tumor effect (CR+CRi rate)","https://ClinicalTrials.gov/show/NCT03155191"
1342,"NCT00196872","A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)","Completed","No Results Available","Breast Cancer","Drug: Epirubicine|Drug: Cyclophosphamide|Drug: Taxol|Drug: Xeloda|Drug: Ibandronat","German Breast Group","Female","18 Years to 65 Years   (Adult)","Phase 3","3000","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","GBG 33|GAIN","September 12, 2005","July 2004","June 2014","July 16, 2014","August 2012","No Study Results Posted","null","June 2014","A: To compare the disease-free survival after adjuvant chemotherapy with ""ETC"" (Arm A1) or ""EC-TX"" (Arm A2) in patients with primary node-positive breast cancer.|B: To compare the disease-free survival with (Arm B1) or without ibandronate (Arm B2) treatment for 2 years in patients with primary node-positive breast cancer|To compare overall survival between arms A1 vs. A2 and B1 vs. B2|To evaluate the compliance in arms A1 vs. A2 and in B1|To compare the safety between arms A1 vs. A2 and B1 vs. B2|To assess the rate of responders to erythropoesis stimulating factors in arm A1 and A2|To compare the incidence of secondary primaries between arms A1 vs. A2|To compare the event-free survival in subgroups of hormone sensitive and insensitive disease and in groups with 1-3, 4-9 or 10+ involved nodes between arms A1 vs. A2 and B1 vs. B2|Tertiary objectives:|To determine prognostic factors like TS or TP and others on tumor tissue collected from primary surgery and to correlate them with study treatment effect","https://ClinicalTrials.gov/show/NCT00196872"
1343,"NCT00808899","Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma","Terminated","Has Results","Neuroblastoma","Drug: Temsirolimus|Drug: Irinotecan|Procedure: Surgical Resection of Primary Tumor|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Etoposide|Drug: Cisplatin|Drug: Topotecan|Procedure: PBSC|Radiation: Radiation Therapy|Drug: 13-cis-retinoic acid","St. Jude Children's Research Hospital","All","up to 18 Years   (Child, Adult)","Phase 2","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NB2008","December 11, 2008","December 2008","July 2009","May 25, 2010","May 2010","April 19, 2010","null","July 2009","Complete Response Plus Partial Response","https://ClinicalTrials.gov/show/NCT00808899"
1344,"NCT00578266","Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia","Completed","No Results Available","Anemia, Aplastic","Drug: Cyclophosphamide,Campath IH and TBI","Mayo Clinic","All","up to 60 Years   (Child, Adult)","Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","06-006216","December 17, 2007","February 2007","August 16, 2016","March 23, 2017","March 2017","No Study Results Posted","null","August 16, 2016","1. Engraftment at 6 months, 1 year and 2 years 2.Incidence of graft versus host disease (GVHD), as well as incidence of acute GVHD and chronic GVHD within 6 months and 2 years|Patient survival probability at 100 days, 1 year and 2 years.","https://ClinicalTrials.gov/show/NCT00578266"
1345,"NCT00924001","Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma","Terminated","Has Results","Melanoma|Malignant Melanoma|Melanoma, Experimental","Drug: DMF5 Melanoma Reactive TIL|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","1","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","070210|07-C-0210","June 17, 2009","August 2007","October 2010","October 18, 2012","October 2012","December 22, 2011","null","October 2010","Number of Participants With an Objective Clinical Tumor Regression Response According to RECIST Criteria|Number of Participants With Adverse Events|Number of Participiants With In-vivo Survival of Infused Cells","https://ClinicalTrials.gov/show/NCT00924001"
1346,"NCT01057069","Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: Carboplatin and Paclitaxel|Drug: Doxorubicin, cyclophosphamide|Drug: Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide","The Netherlands Cancer Institute","All","18 Years to 59 Years   (Adult)","Phase 2|Phase 3","310","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","M09TNM|2009-015238-31","January 26, 2010","January 2010","December 2029","April 13, 2017","April 2017","No Study Results Posted","neo-TN","December 2019","Primary endpoint (HRD tumors): Average Neoadjuvant Response Index (NRI) after intensified alkylating therapy in comparison to that after 'standard' neoadjuvant chemotherapy. Primary endpoint (non-HRD tumors): Average Neoadjuvant Response Index (NRI)|Recurrence-free survival and overall survival.","https://ClinicalTrials.gov/show/NCT01057069"
1347,"NCT00003667","Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma","Completed","No Results Available","Sarcoma","Drug: cyclophosphamide|Drug: dexrazoxane hydrochloride|Drug: disaccharide tripeptide glycerol dipalmitoyl|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Procedure: surgical procedure|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","3 Years to 60 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","98-074|CDR0000066764|ENDOREX-MSKCC-98074|MDA-ID-97198|NCI-G98-1487","November 1, 1999","September 1998","August 2000","June 24, 2013","June 2013","No Study Results Posted","null","August 2000","","https://ClinicalTrials.gov/show/NCT00003667"
1348,"NCT00389818","Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma","Completed","Has Results","Lymphoma","Biological: filgrastim|Biological: pegfilgrastim|Biological: rituximab|Biological: sargramostim|Drug: cyclophosphamide|Drug: pegylated liposomal doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","43","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-047|U01CA070019|CDR0000507634","October 18, 2006","January 2007","September 2011","August 27, 2014","August 2014","May 29, 2012","null","September 2011","Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or MRI .|Duration of Response|Median Survival Time|Rate of Bacterial, Fungal, and Opportunistic Infections|Relationship Between MDR-1 Expression and Response to Treatment|Relationship Between Response and Survival and BCL-2 Expression in Tumor Tissue|Relationship Between Development of Bacterial, Fungal, and/or Opportunistic Infections and Baseline CD4 Lymphocyte Count, HIV-1 RNA Level, and Quantitative Immunoglobin Level, or Changes in Quantitative Immunoglobin Levels Over Time|Mortality and Cause of Death|Event-free Survival at 1 Year","https://ClinicalTrials.gov/show/NCT00389818"
1349,"NCT00107198","Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease","Active, not recruiting","Has Results","Childhood Lymphocyte Predominant Hodgkin Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage II Childhood Hodgkin Lymphoma","Drug: doxorubicin hydrochloride|Procedure: conventional surgery|Drug: cyclophosphamide|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Month to 21 Years   (Child, Adult)","","188","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AHOD03P1|NCI-2009-00376|COG-AHOD03P1|CDR0000419921|U10CA098543","April 5, 2005","January 2006","null","December 20, 2016","March 2016","June 30, 2016","null","November 2012","Failure-free Survival (FFS)|Event-free Survival|Cure by Surgery Alone in Stage I Resected Patients|Cure by AV-PC x 3 or AV-PC x 3 + IFRT for Stage I Unresected, Stage I Resected Whose Disease Recurred, and Stage II Patients|Grade 3 or 4 Toxicity","https://ClinicalTrials.gov/show/NCT00107198"
1350,"NCT00004237","Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: mitoxantrone hydrochloride|Drug: vinorelbine tartrate|Procedure: conventional surgery|Radiation: radiation therapy","Royal Marsden NHS Foundation Trust|National Cancer Institute (NCI)","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000067481|RMNHS-TOPIC2|EU-99037","January 28, 2000","October 1998","September 2005","November 5, 2013","May 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004237"
1351,"NCT00303667","Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant","Completed","Has Results","Acute Myelogenous Leukemia","Biological: aldesleukin|Biological: natural killer cells|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: allogeneic hematopoietic stem cell transplantation|Radiation: total body irradiation|Biological: Thymoglobulin|Drug: Cyclosporin A|Drug: cyclophosphamide|Drug: fludarabine phosphate","Masonic Cancer Center, University of Minnesota","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004LS042|UMN-MT2003-23|UMN-IRB-0405M60481","March 15, 2006","January 2005","March 2011","August 10, 2016","November 2011","June 11, 2015","null","March 2011","Disease-free Survival at 6 Months|Disease-free Survival at 1 Year|In Vivo Expansion of a Donor NK Cells NK Cell Product|Number of Patients With Graft Failure|Incidence of Grade III-IV Acute Graft Versus Host Disease|Number of Patients With Treatment-Related Mortality|Incidence of Chronic Graft Versus Host Disease|Number of Patients With Disease Relapse|Incidence of Post-transplant Lymphoproliferative Disorder (PTLD)","https://ClinicalTrials.gov/show/NCT00303667"
1352,"NCT01334502","Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: everolimus|Drug: prednisone|Drug: vincristine sulfate","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","26","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-N1085|CDR0000698584|NCI-2011-02643","April 12, 2011","March 2012","null","July 1, 2016","July 2016","No Study Results Posted","null","February 2020","MTD of everolimus in combination with R-CHOP|Adverse events profile|Toxicity profile|Proportion of patients who have a significant toxicity|Rate of EFS|Overall response rate, CR rate, overall survival, PFS, and duration of response","https://ClinicalTrials.gov/show/NCT01334502"
1353,"NCT00085202","Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor","Active, not recruiting","Has Results","Brain and Central Nervous System Tumors","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: vincristine|Procedure: autologous hematopoietic stem cell transplantation|Radiation: radiation therapy","St. Jude Children's Research Hospital","All","3 Years to 21 Years   (Child, Adult)","Phase 3","416","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SJMB03|NCI-2011-01185","June 10, 2004","August 2003","January 2023","March 31, 2017","January 2017","November 4, 2013","null","December 2016","Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors|Progression-Free Survival (PFS) Compared Between ERBB2 Assessment and Risk Group.|Frequency of Mutations Associated With SHH and WNT Tumors|Reading Decoding Composite Scores in the Intervention and Standard of Care Groups|Number of Average Risk Patients Whose Treatment Failure Included the Posterior Fossa|Mean RT Dose to Specified Target Tissue Volume by Rate and Pattern of Failure, e.g. Local Failure, Distant Failure, Etc.","https://ClinicalTrials.gov/show/NCT00085202"
1354,"NCT02017964","Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma","Completed","No Results Available","Untreated Childhood Medulloblastoma","Drug: Vincristine Sulfate|Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Etoposide|Drug: Carboplatin|Other: Laboratory Biomarker Analysis|Other: Cognitive Assessment","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 47 Months   (Child)","Phase 2","26","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ACNS1221|NCI-2013-02379|COG-ACNS1221|U10CA098543|U10CA180886","December 13, 2013","December 2013","null","May 15, 2017","May 2017","No Study Results Posted","null","December 31, 2016","Progression-free survival (PFS)|Overall Survival|Event-free survival|Response","https://ClinicalTrials.gov/show/NCT02017964"
1355,"NCT03045471","The Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma","Not yet recruiting","No Results Available","To Evaluate the Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma","Drug: R-EPOCH|Drug: R-CHOP","Shanghai Public Health Clinical Center","All","18 Years to 60 Years   (Adult)","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ARL-1","February 3, 2017","March 1, 2017","December 31, 2021","February 6, 2017","February 2017","No Study Results Posted","null","December 31, 2020","progression-free survival|complete response rate|partial response partial response rate|overall response","https://ClinicalTrials.gov/show/NCT03045471"
1356,"NCT00002466","Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer","Completed","No Results Available","Kidney Cancer|Sarcoma","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: vincristine sulfate|Procedure: conventional surgery|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center","All","Child, Adult, Senior","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","90-062|CDR0000076464|NYU-97-6|NCI-V90-0126","November 1, 1999","May 1990","May 2005","June 19, 2013","June 2013","No Study Results Posted","null","May 2005","","https://ClinicalTrials.gov/show/NCT00002466"
1357,"NCT01597219","Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers","Recruiting","No Results Available","Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Acute Myeloid Leukaemia|Acute Lymphoblastic Leukaemia|Myelodysplastic Syndrome|Chronic Myeloid Leukaemia|Chronic Lymphocytic Leukaemia|Acquired Bone Marrow Failure Syndromes|Other Haematological Malignancies; Unrelated HSCT Indicated","Procedure: Reduced intensity haplodentical stem cell transplant|Procedure: Myeloablative haploidentical stem cell transplant","University College, London|Bloodwise","All","16 Years to 70 Years   (Child, Adult, Senior)","Phase 2","78","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","UCL/10/0411","May 10, 2012","March 2013","March 2020","April 26, 2017","April 2017","No Study Results Posted","UK-Haplo","March 2018","Overall survival","https://ClinicalTrials.gov/show/NCT01597219"
1358,"NCT00002854","High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer","Completed","No Results Available","Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: ifosfamide|Drug: mesna|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 55 Years   (Adult)","Phase 1","33","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","94098|P30CA033572|CHNMC-IRB-94098|NCI-V96-1042|CDR0000065102","November 1, 1999","December 1994","August 2015","August 24, 2015","August 2015","No Study Results Posted","null","August 2015","Feasibility of two cycles of high dose chemotherapy with stem cell reinfusion|Toxicity of two cycles of high dose chemothearpy and stem cell reinfusion|Maximum tolerated dose of two cycles of high dose chemothearpy and stem cell reinfusion","https://ClinicalTrials.gov/show/NCT00002854"
1359,"NCT03129828","Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Ibrutinib and Bortezomib + R-CHOP","Prof. Dr. Clemens Schmitt|Charite University, Berlin, Germany|Janssen-Cilag Ltd.","All","61 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","EudraCT-Nr.: 2015-003429-32","April 20, 2017","March 17, 2017","March 31, 2022","April 24, 2017","April 2017","No Study Results Posted","ImbruVeRCHOP","March 31, 2022","2-year progression-free survival|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|1y- and 2y-PFS for patients based on cell-of-origin (COO, i.e. GCB vs. ABC subtype)|number of patients with complete remission in all patients and based on cell-of-origin|Predictive power of markers for Minimal Residual Disease (MRD) over time|Objective Response Rate (ORR) in all patients and based on cell-of-origin|Disease-Free Survival in all patients and based on cell-of-origin|Overall survival in all patients and based on cell-of-origin","https://ClinicalTrials.gov/show/NCT03129828"
1360,"NCT00088530","BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)","Completed","No Results Available","Lymphoma, Non-Hodgkin","Drug: pixantrone, cyclophosphamide, vincristine, rituximab, prednisone|Drug: Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab","CTI BioPharma","All","18 Years and older   (Adult, Senior)","Phase 3","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PIX301","July 28, 2004","July 2004","July 2010","May 20, 2013","May 2013","No Study Results Posted","null","February 2010","Response|toxicity","https://ClinicalTrials.gov/show/NCT00088530"
1361,"NCT02688803","Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)","Recruiting","No Results Available","Breast Cancer","Drug: Dose dense AC-P|Drug: Dose dense AC|Drug: FEC-D","Ottawa Hospital Research Institute","Female","18 Years and older   (Adult, Senior)","","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","20160078-01H","February 18, 2016","August 2016","October 2018","September 15, 2016","September 2016","No Study Results Posted","OTT15-04","October 2017","Percentage of patients who receive chemotherapy in the neoadjuvant/adjuvant setting for TNBC|Participant satisfaction|Percentage of participants who complete study treatment|Hospitalization|Treatment delays","https://ClinicalTrials.gov/show/NCT02688803"
1362,"NCT00002598","Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia","Completed","No Results Available","Leukemia","Biological: recombinant interferon alfa|Biological: sargramostim|Drug: cyclophosphamide|Drug: cytarabine|Drug: etoposide|Drug: methotrexate|Drug: mitoxantrone hydrochloride|Procedure: bone marrow ablation with stem cell support|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center","All","16 Years and older   (Child, Adult, Senior)","Phase 2","30","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","94-070|CDR0000063832|NCI-V94-0541","November 1, 1999","June 1994","June 2004","June 24, 2013","June 2013","No Study Results Posted","null","June 2004","","https://ClinicalTrials.gov/show/NCT00002598"
1363,"NCT00033683","Combination Chemotherapy in Treating Women With Resected Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: CMF regimen|Drug: cyclophosphamide|Drug: docetaxel|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: methotrexate|Drug: tamoxifen citrate|Procedure: adjuvant therapy|Radiation: radiation therapy","Institute of Cancer Research, United Kingdom|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000069311|ICR-TACT|EU-20109","April 9, 2002","February 2001","null","February 6, 2009","June 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00033683"
1364,"NCT00382109","Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission","Active, not recruiting","Has Results","B-cell Childhood Acute Lymphoblastic Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Graft Versus Host Disease|L1 Childhood Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia","Drug: thiotepa|Drug: cyclophosphamide|Drug: tacrolimus|Drug: methotrexate|Drug: sirolimus|Radiation: total body irradiation","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 3","146","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ASCT0431|NCI-2009-01068|CDR0000500131|COG-PBMTC-ONCO51|COG-ASCT0431|U10CA098543","September 26, 2006","March 2007","null","December 16, 2016","September 2016","October 6, 2015","null","May 2011","Estimated Percentage of Participants With Event Free Survival|Rate of Relapses|Estimated Transplant Related Mortality Percentage|Estimated Rate of Acute Graft VS Host Disease (GVHD)|Estimated Rate of Overall Chronic Graft VS Host Disease|Relative Contribution of Resistance by Acute Lymphoblastic Leukemia (ALL) Blasts to Cytolytic Therapy (e.g., Chemotherapy/Irradiation) as a Cause of Relapse Post-transplantation|Relative Contribution of ALL Blasts to the Donor Immune Response as a Cause of Relapse Post Transplantation (Correlating Development of aGVHD With Relapse)|Relative Contribution of ALL Blasts to the Donor Immune Response as a Cause of Relapse Pre-Transplantation (MRD)|Chimerism","https://ClinicalTrials.gov/show/NCT00382109"
1365,"NCT02724579","Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma","Not yet recruiting","No Results Available","Untreated Childhood Medulloblastoma","Drug: Cisplatin|Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Drug: Lomustine|Radiation: Radiation Therapy|Drug: Vincristine Sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 2","45","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACNS1422|NCI-2016-00150|U10CA180886","March 25, 2016","October 2016","null","September 23, 2016","September 2016","No Study Results Posted","null","May 2025","PFS|Change in neurocognitive function (cognitive, social, emotional and behavioral) according to Children Oncology Group Standard Neuropsychological Battery|DNA methylation profiling as real-time classification of WNT-driven medulloblastoma","https://ClinicalTrials.gov/show/NCT02724579"
1366,"NCT02439788","3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA","Not yet recruiting","No Results Available","Neuroblastoma","Drug: cyclophosphamide|Drug: Fludarabine|Genetic: GINAKIT Cells","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital|Alex's Lemonade Stand Foundation","All","1 Year to 18 Years   (Child, Adult)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-33272, GINAKIT","May 7, 2015","August 2016","October 2030","June 17, 2016","June 2016","No Study Results Posted","GINAKIT","September 2019","Number of Patients with dose limiting toxicities|Number of patients with a tumor response|Number of patients with an immunologic response","https://ClinicalTrials.gov/show/NCT02439788"
1367,"NCT01952769","Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma","Active, not recruiting","No Results Available","DIPG","Biological: MDV9300","Hadassah Medical Organization","All","3 Years to 21 Years   (Child, Adult)","Phase 1|Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","antiPD1brainad2- HMO-CTIL","September 15, 2013","February 2014","April 2019","September 11, 2016","October 2015","No Study Results Posted","null","November 2018","treatment related toxicity|progression free survival","https://ClinicalTrials.gov/show/NCT01952769"
1368,"NCT00003972","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Biological: sargramostim|Drug: busulfan|Drug: carboplatin|Drug: cyclophosphamide|Drug: melphalan|Drug: paclitaxel|Drug: tamoxifen citrate|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 3","280","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","1316.00|FHCRC-1316.00|PSOC-1604|NCI-G99-1552|CDR0000067175","November 1, 1999","July 1998","March 2003","March 31, 2010","March 2010","No Study Results Posted","null","March 2003","","https://ClinicalTrials.gov/show/NCT00003972"
1369,"NCT00053768","Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: filgrastim|Drug: EPOCH regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","German High-Grade Non-Hodgkin's Lymphoma Study Group|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 3","552","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000269371|DSHNHL-1999-2|EU-20242","February 5, 2003","April 2002","null","February 6, 2009","June 2007","No Study Results Posted","null","null","Time to treatment failure (TTF) at first relapse, 3 years within study and periodically after study completion|Complete response rate at first relapse, 3 years within study and periodically after study completion|Survival time|Tumor control|Disease-free survival","https://ClinicalTrials.gov/show/NCT00053768"
1370,"NCT03081715","PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer","Recruiting","No Results Available","Esophageal Cancer","Drug: Cyclophosphamide|Drug: Interleukin-2|Other: PD-1 Knockout T Cells","Hangzhou Cancer Hospital|Anhui Kedgene Biotechnology Co.,Ltd","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","HangzhouCH07","March 11, 2017","March 20, 2017","December 30, 2018","March 20, 2017","March 2017","No Study Results Posted","null","February 27, 2018","Incidence of Treatment-Emergent Adverse Events|Response Rate","https://ClinicalTrials.gov/show/NCT03081715"
1371,"NCT00701701","Immune Tolerance Induction Study","Recruiting","No Results Available","Pompe Disease|Glycogen Storage Disease Type II (GSD-II)|Glycogenesis 2 Acid Maltase Deficiency","Biological: Myozyme (alglucosidase alfa)|Biological: Myozyme (alglucosidase alfa)","Genzyme, a Sanofi Company|Sanofi","All","1 Month and older   (Child, Adult, Senior)","Phase 4","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AGLU03707|MSC12817","June 17, 2008","December 2008","June 2017","October 20, 2016","October 2016","No Study Results Posted","null","June 2017","Evaluate the efficacy of ITI regimens as assessed by anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers and antibodies that inhibit the enzymatic activity and/or uptake of Myozyme|Evaluate Pompe disease activity in patients receiving the 2 ITI regimens as measured by overall survival.|Evaluate Pompe disease activity in patients receiving the 2 ITI regimens as measured by respiratory function.|Evaluate Pompe disease activity in patients receiving the 2 ITI regimens as measured by Left ventricular mass index (LVMI).|Evaluate Pompe disease activity in patients receiving the 2 ITI regimens as measured by motor function.|Evaluate Pompe disease activity in patients receiving the 2 ITI regimens as measured by disability index.|Evaluate the safety of the 2 ITI regimens as assessed by the incidence of adverse events (AEs), serious adverse events (SAEs), and clinical laboratory abnormalities.","https://ClinicalTrials.gov/show/NCT00701701"
1372,"NCT00499603","Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer","Active, not recruiting","Has Results","Breast Cancer","Drug: Paclitaxel|Drug: 5-Fluorouracil|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: RAD001","M.D. Anderson Cancer Center|Novartis|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","62","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-0790|NCI-2012-01514|1K23CA121994-1|1K23CA121994","July 9, 2007","July 2007","April 2017","September 12, 2016","September 2016","April 1, 2013","null","April 2012","Number Participants With Inhibition of PI3K/PTEN/AKT Pathway at 48 Hours|Participant Responses Per Treatment Arm at 12 Weeks|Participant Responses Per Treatment Arm at 24 Weeks","https://ClinicalTrials.gov/show/NCT00499603"
1373,"NCT03018223","Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT","Recruiting","No Results Available","Non-Hodgkin's Lymphoma|Acute Leukemia in Remission|Chronic Myeloid Leukemia|Primary Myelofibrosis|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes|Hodgkin Lymphoma|Multiple Myeloma","Drug: Fludarabine|Drug: Busulfan|Drug: Cyclophosphamide|Radiation: Total body irradiation (TBI)|Procedure: Peripheral Blood Hematopoietic Cell Transplantation (HCT)|Drug: Sirolimus (SIR)|Drug: Mycophenolate mofetil (MMF)|Drug: Granulocyte-colony stimulating factor (G-CSF)","H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Senior)","Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Prevention","MCC-18766","January 10, 2017","January 10, 2017","January 2020","February 21, 2017","February 2017","No Study Results Posted","null","January 2020","Incidence of Grade II-IV Acute Graft vs. Host Disease (GVHD)|Incidence of Chronic GVHD|Overall Survival (OS)|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT03018223"
1374,"NCT01946373","T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma","Recruiting","No Results Available","Melanoma","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: T cells|Biological: Interleukin-2|Biological: Dendritic cell vaccine","Karolinska University Hospital","All","18 Years to 74 Years   (Adult, Senior)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MAT-02|2012-000450-63","September 12, 2013","October 2013","null","March 18, 2016","March 2016","No Study Results Posted","null","December 2016","Safety of the T cell therapy, with and without dendritic cell vaccine, as evaluated according to the NCI CTCAE scale version 4.0|Time to disease progression assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.","https://ClinicalTrials.gov/show/NCT01946373"
1375,"NCT00002945","High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia","Completed","No Results Available","Leukemia","Biological: aldesleukin|Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: etoposide|Drug: idarubicin|Drug: melphalan|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Roswell Park Cancer Institute","All","25 Years and older   (Adult, Senior)","Phase 3","61","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000065406|RPCI-DS-96-48","November 1, 1999","December 1996","August 2011","April 12, 2012","April 2012","No Study Results Posted","null","August 2001","To determine the efficacy of 4-6 h and 18-24 h, 20% ALA applications on superficial and nodular epidermally-derived lesions using ca633 nm laser irradiation.","https://ClinicalTrials.gov/show/NCT00002945"
1376,"NCT02234921","Pilot Study of DRibble Vaccine for Prostate Cancer Patients","Recruiting","No Results Available","Adenocarcinoma of the Prostate","Drug: Cyclophosphamide|Biological: DRibble Vaccine|Biological: HPV Vaccinations|Drug: Imiquimod","UbiVac|Providence Health & Services|Providence Cancer Center|Providence Cancer Center, Earle A. Chiles Research Institute","Male","Child, Adult, Senior","Phase 1","6","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","14-116B","September 4, 2014","September 2014","September 2019","May 26, 2015","May 2015","No Study Results Posted","DRibble","September 2018","Safety Assessment|Immune Response|Prostate Cancer Response to DRibble vaccine","https://ClinicalTrials.gov/show/NCT02234921"
1377,"NCT01853631","Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)","Recruiting","No Results Available","Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia","Biological: CD19 CAR T Cells|Drug: Fludarabine|Drug: Cyclophosphamide","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System","All","up to 75 Years   (Child, Adult, Senior)","Phase 1","64","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","H-31970 SAGAN|SAGAN","May 1, 2013","February 2014","February 2033","December 1, 2016","December 2016","No Study Results Posted","SAGAN","February 2018","Number of patients with dose limiting toxicity (DLT)|Survival of CD19.CAR-ATLs|Frequency of the two distinct T cell products post infusion|Number of patients with tumor response|Percentage of circulating modified T cells after additional doses|Function of CD19.CAR-ATLs","https://ClinicalTrials.gov/show/NCT01853631"
1378,"NCT01321008","Stage I/II Nasal NK Cell Lymphoma","Terminated","Has Results","Lymphoma","Radiation: Radiation|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-0035","March 21, 2011","May 2011","May 2013","January 21, 2015","May 2014","May 20, 2014","null","May 2013","Progression-free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01321008"
1379,"NCT02431988","Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Procedure: Leukapheresis|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: CAR19 T-Cells","University College, London","All","16 Years to 65 Years   (Child, Adult)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCL/14/0385|2015-000348-40","March 23, 2015","June 2016","December 2020","September 1, 2016","September 2016","No Study Results Posted","COBALT","December 2018","Feasibility of adequate leucapheresis collection and generation of CAR19 T cells.|Toxicity evaluation following CAR19 T-cell administration.|Efficacy of CAR19 T-cells.|CAR19 T-cell engraftment|B cell compartment|Cytokine profile|Clinical complete response|Eligibility to allogeneic transplantation","https://ClinicalTrials.gov/show/NCT02431988"
1380,"NCT00176904","Stem Cell Transplant for Inborn Errors of Metabolism","Completed","Has Results","Adrenoleukodystrophy|Metachromatic Leukodystrophy|Globoid Cell Leukodystrophy|Gaucher's Disease|Fucosidosis|Wolman Disease|Niemann-Pick Disease|Batten Disease|GM1 Gangliosidosis|Tay Sachs Disease|Sandhoff Disease","Procedure: Stem Cell Transplant|Drug: Busulfan, Cyclophosphamide, Antithymocyte Globulin","Masonic Cancer Center, University of Minnesota","All","Child, Adult, Senior","Phase 2|Phase 3","135","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MT1995-01","September 12, 2005","January 1995","June 2010","November 6, 2012","November 2012","May 17, 2011","null","June 2010","Overall Survival|Overall Donor Engraftment|Number of Patients With Grade II-IV Acute Graft-Versus-Host Disease|Number of Patients With Grade III-IV Acute Graft-Versus-Host Disease|Number of Patients With Chronic Graft-Versus-Host Disease","https://ClinicalTrials.gov/show/NCT00176904"
1381,"NCT01967823","T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer","Recruiting","No Results Available","Synovial Sarcoma|Breast Cancer|Non-Small Cell Lung Cancer|Hepatocellular Cancer","Biological: Anti-NY ESO-1 mTCR PBL|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","43","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","130214|13-C-0214","October 18, 2013","September 25, 2013","July 2, 2018","May 12, 2017","February 9, 2017","No Study Results Posted","null","July 3, 2017","Determine whether objective tumor regression can be mediated in patients with metastatic cancers whose tumors express the NY-ESO-1 Antigen who aer treated with anti-NY ESO-1 Antigen who are treated with anti-NY ESO-1 transduced mTCR PBL|Determine the in vivo survival of TCR gene-engineered cells|Determine the toxicity profile of this treatment regimen","https://ClinicalTrials.gov/show/NCT01967823"
1382,"NCT02561832","A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Olaparib|Drug: Carboplatin|Drug: Anthracycline|Drug: Cyclophosphamide","AstraZeneca","All","18 Years to 130 Years   (Adult, Senior)","Phase 1","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","D081EC00001","August 13, 2015","November 2015","February 2017","February 14, 2017","February 2017","No Study Results Posted","null","February 2017","Part A: Numbers of adverse events (AEs) and serious AEs, vital signs for blood pressure and pulse, and body temperature, ECGs, Physical exams and laboratory parameters which including Biochemistry, Coagulation, Haematology and Urinalysis.|Part B: Pathological complete response (pCR) rate|Part A: Objective response rate (ORR)|Part B: Objective response rate (ORR)|Part A: Time to treatment failure (TTF) preliminary assessment of the anti-tumour activity of olaparib in combination with carboplatin in patients with advanced breast cancer|Part B: pCR2 (Pathological Complete Response)|Part B: Numbers of adverse events (AEs) and serious AEs, vital signs for blood pressure and pulse, and body temperature, ECGs, Physical exams and laboratory parameters which including Biochemistry, Coagulation, Haematology and Urinalysis.|Part B: RCB (Residual Cancer Burden)|Part A and part B: Pharmacokinetic (PK) parameters of Maximum Plasma Concentration (Cmax) of Carboplatin|Part A and part B: Pharmacokinetic (PK) parameters Time of Maximum Plasma Concentration (tmax) of Carboplatin|Part A and part B: Pharmacokinetic (PK) parameters of Area under Curve (AUC) of Carboplatin|Part A and part B: Pharmacokinetic (PK) parameters of Terminal Half Life (t1/2) of Carboplatin|Part A and part B: Pharmacokinetic (PK) parameters of Maximum Plasma Concentration (Clast) of Carboplatin|Part A and part B: Pharmacokinetic (PK) parameters of Area under Curve (AUClast) of Carboplatin","https://ClinicalTrials.gov/show/NCT02561832"
1383,"NCT02950259","Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)","Recruiting","No Results Available","Breast Neoplasm|Breast Neoplasm, Male","Drug: Cyclophosphamide|Drug: Indomethacin|Drug: Omeprazole|Dietary Supplement: Multivitamin","Providence Health & Services|IRX Therapeutics","All","Child, Adult, Senior","Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","16-126B|IRX-2 2016-B","October 28, 2016","February 9, 2017","November 2018","March 1, 2017","March 2017","No Study Results Posted","null","April 2018","Surgical Delays|Tumor Infiltrating Lymphocytes","https://ClinicalTrials.gov/show/NCT02950259"
1384,"NCT02830724","Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","Recruiting","No Results Available","Pancreatic Cancer|Renal Cell Cancer|Breast Cancer|Melanoma|Ovarian Cancer","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin|Biological: Anti-hCD70 CAR PBL","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","113","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","160131|16-C-0131","July 12, 2016","June 16, 2016","July 1, 2021","May 12, 2017","April 20, 2017","No Study Results Posted","null","July 1, 2020","To determine the safety of administering PBL transduced with this anti-CD70 CAR in concert with preparative lymphodepletion and high dose interleukin-2 (IL-2; aldesleukin) and to mediate regression.|Determine the in vivo survival of anti-hCD70 CAR transduced cells|Determine the toxicity of this treatment regimen","https://ClinicalTrials.gov/show/NCT02830724"
1385,"NCT00002461","Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: filgrastim|Biological: sargramostim|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Albert Einstein College of Medicine, Inc.|National Cancer Institute (NCI)","All","15 Years to 65 Years   (Child, Adult)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000075725|AECM-8802027|NCI-V89-0089","November 1, 1999","April 1988","null","February 6, 2009","October 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002461"
1386,"NCT02012088","Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb","Active, not recruiting","No Results Available","Lymphoma","Drug: RCOMP|Drug: RCHOP","Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","All","60 Years and older   (Adult, Senior)","Phase 2","91","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GEL-R-COMP-2013","November 11, 2013","October 2013","August 2021","December 15, 2016","December 2016","No Study Results Posted","null","October 2016","Subclinical cardiac toxicity|Survival|Response rate|Cardiac/cardiovascular toxicity|Toxicity (except cardiac)|Cardiac biomarkers","https://ClinicalTrials.gov/show/NCT02012088"
1387,"NCT00194753","Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12","Completed","No Results Available","Breast Neoplasm","Drug: Paclitaxel|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: G-CSF","University of Washington|Amgen|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","18229-A|00-5889-A 07","September 14, 2005","December 2001","March 2011","September 12, 2012","September 2012","No Study Results Posted","null","March 2011","Delivered dose intensity|Toxicity|Time to treatment failure|Overall survival","https://ClinicalTrials.gov/show/NCT00194753"
1388,"NCT02566304","Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies","Recruiting","No Results Available","Acute Myeloid Leukemia|Acute Myeloid Leukemia in Remission|Aplastic Anemia|Chronic Myelomonocytic Leukemia|Hodgkin Lymphoma|Indolent Non-Hodgkin Lymphoma|Malignant Neoplasm|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Plasma Cell Myeloma|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Ring Sideroblasts|Refractory Cytopenia With Multilineage Dysplasia|Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts","Drug: Fludarabine|Radiation: Total-Body Irradiation|Biological: T Cell-Depleted Donor Lymphocyte Infusion|Drug: Cyclophosphamide|Procedure: Peripheral Blood Stem Cell Transplantation|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Tacrolimus|Drug: Mycophenolate mofetil","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","15D.323|2015-054|NCI-2015-01506","September 30, 2015","November 2015","null","October 18, 2016","October 2016","No Study Results Posted","null","September 2020","Overall Survival (OS)|Relapse Related Mortality (RRM)|Non-Relapse Mortality (NRM)|Incidence and severity of GVHD|Engraftment rates|Lymphoid reconstitution","https://ClinicalTrials.gov/show/NCT02566304"
1389,"NCT02700022","A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas","Suspended","No Results Available","Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma","Drug: Alisertib","UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","LCCC 1503","February 17, 2016","October 2016","January 2021","April 26, 2017","April 2017","No Study Results Posted","null","May 2018","Maximum tolerated dose (MTD)|Toxicity|Rate of Response|Progression free survival","https://ClinicalTrials.gov/show/NCT02700022"
1390,"NCT00157196","Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease","Completed","Has Results","Carcinoma, Non-Small-Cell Lung|Lung Neoplasms","Biological: Tecemotide (L-BLP25)|Drug: Single low dose cyclophosphamide|Other: Best standard of care (BSC)","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 2","22","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","B25-LG-305 / EMR 63325-006","September 8, 2005","April 2005","April 2012","July 23, 2015","July 2015","July 23, 2015","null","September 2007","Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs With CALGB-ECTC Grade 3 or 4, TEAEs Leading to Discontinuation, TEAEs Leading to Death, and Injection Site Reactions (ISRs)|Survival Time|Progression Free Survival (PFS) Time","https://ClinicalTrials.gov/show/NCT00157196"
1391,"NCT02660710","Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma","Recruiting","No Results Available","Diffuse Large B-cell Lymphoma|HIV","Drug: R-CHOP","UNC Lineberger Comprehensive Cancer Center|John E. Fogarty International Center (FIC)|National Institutes of Health (NIH)|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 2","40","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","LCCC 1335|K01TW009488|R21CA180815","January 17, 2016","March 2016","December 2022","May 2, 2017","May 2017","No Study Results Posted","null","March 2021","Number of DLBCL patients receiving R-CHOP who experience NCI grade 3 or 4 non-hematologic toxicities|Number of patients who experience treatment-related death over a course of six cycles|Number of DLBCL patients by HIV status receiving R-CHOP who experience grade 3 or 4 non-hematologic toxicities over a course of six cycles|Number of patients receiving ≥ 90% of the prescribed doses of doxorubicin and cyclophosphamide, respectively among DLBCL patients in Malawi with HIV infection|Number of patients receiving ≥ 90% of the prescribed doses of doxorubicin and cyclophosphamide, respectively among DLBCL patients in Malawi without HIV infection|Number of patients with progression free survival with R-CHOP administered|Number of patients with overall survival with R-CHOP administered|Number of patients with complete response rates with R-CHOP administered|Number of years from treatment initiation until disease progression or death.|Number of years gained after rituximab plus CHOP chemotherapy administered","https://ClinicalTrials.gov/show/NCT02660710"
1392,"NCT01639456","CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission","Withdrawn","No Results Available","Acute Myelogenous Leukemia","Biological: CD3-/CD19- natural killer cells|Biological: CD3-CD56+ natural killer cells|Device: CliniMACS® CD3 and CD19 Reagent System|Device: CliniMACS® CD56 Reagent System|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin","Masonic Cancer Center, University of Minnesota|Miltenyi Biotec GmbH","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2011LS151|MT2011-26","July 10, 2012","October 2013","January 2017","March 4, 2014","March 2014","No Study Results Posted","null","January 2017","Disease-Free Survival|Incidence of Infusional Toxicities|Incidence of Chronic Graft-Versus-Host Disease (GVHD)|Incidence of Acute Graft-Versus-Host Disease (GVHD)|Treatment-Related Mortality|Overall Survival","https://ClinicalTrials.gov/show/NCT01639456"
1393,"NCT00712582","Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma","Active, not recruiting","No Results Available","Non-Hodgkin's Lymphoma","Drug: Etoposide, carboplatin, ifosfamide|Drug: Rituximab, Ifosfamide, Etoposide, Carboplatin|Drug: Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine","Memorial Sloan Kettering Cancer Center|Genentech, Inc.|Columbia University","All","18 Years to 65 Years   (Adult)","Phase 2","101","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","08-026","July 8, 2008","July 2008","July 2017","January 11, 2017","January 2017","No Study Results Posted","null","July 2017","To determine the 2-year PFS and overall survival from the start of induction therapy conditional on attaining either a negative FDG-PET or a negative biopsy at the interim evaluation.|Obtain preliminary data on biodistribution, dosimetry and potential clinical usefulness of the proliferation marker [18F] fluorothymidine (FLT) in pts with diffuse large cell lymphoma, using combined (FDG-PET/CT).|To determine the role of CT volumetric analysis compared to standard unidimensional CT in this patient population.","https://ClinicalTrials.gov/show/NCT00712582"
1394,"NCT00345865","Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Procedure: peripheral blood stem cell transplantation|Radiation: irradiation therapy|Biological: G-CSF|Drug: Cytarabine","Masonic Cancer Center, University of Minnesota","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","421","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2005LS048|UMN-0508M72589|UMN-MT2004-24","June 28, 2006","August 2005","January 2018","May 1, 2017","May 2017","No Study Results Posted","null","January 2018","Percentage of patients achieving complete response|Prospective validation of the previously published formula used to estimate targeted collection of PBSC|Immune reconstitution post-transplant in HIV-positive patients compared to HIV-negative patients|Time to hematopoietic recovery after transplantation|Duration of response|Progression-free and overall survival","https://ClinicalTrials.gov/show/NCT00345865"
1395,"NCT00003211","Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: filgrastim|Drug: amifostine trihydrate|Drug: cisplatin|Drug: cyclophosphamide|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","St. Jude Children's Research Hospital|National Cancer Institute (NCI)","All","3 Years to 20 Years   (Child, Adult)","Phase 2","94","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CDR0000066069|SJCRH-MB-96|SJMB-96|NCI-G98-1387","November 1, 1999","October 1996","June 2007","November 6, 2012","November 2012","No Study Results Posted","null","June 2007","","https://ClinicalTrials.gov/show/NCT00003211"
1396,"NCT01350232","Treatment of Sickle Cell Anemia With Stem Cell Transplant","Terminated","Has Results","Sickle Cell Anemia|Sickle Cell-hemoglobin C Disease|Sickle Cell-β0-thalassemia","Drug: Fludarabine|Drug: Cytarabine|Device: Cellular Infusions|Radiation: Total Body Irradiation|Drug: Cyclophosphamide|Drug: Bortezomib|Drug: Rituximab|Procedure: Plasmapheresis","Sidney Kimmel Cancer Center at Thomas Jefferson University|National Heart, Lung, and Blood Institute (NHLBI)|Thomas Jefferson University","All","18 Years to 45 Years   (Adult)","","2","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09F.327|1-RC2HL101496-0","May 4, 2011","September 2009","August 2011","October 19, 2016","October 2016","November 13, 2014","null","August 2011","Stable Engraftment|Organ Toxicity|Overall Survival|Acute Graft Versus Host Disease|Correction of Hemoglobinopathy|Immune Recovery|Quality of Life|Cytokine Profile","https://ClinicalTrials.gov/show/NCT01350232"
1397,"NCT02548468","Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma","Withdrawn","No Results Available","Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Stage IIB Mycosis Fungoides and Sezary Syndrome|Stage IIIA Mycosis Fungoides and Sezary Syndrome|Stage IIIB Mycosis Fungoides and Sezary Syndrome|Stage IVA Mycosis Fungoides and Sezary Syndrome|Stage IVB Mycosis Fungoides and Sezary Syndrome","Drug: Fludarabine|Radiation: Total-Body Irradiation|Biological: T Cell-Depleted Donor Lymphocyte Infusion|Drug: Cyclophosphamide|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Mycophenolate mofetil|Drug: Tacrolimus","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","15D.237","September 8, 2015","November 20, 2015","March 16, 2017","April 17, 2017","April 2017","No Study Results Posted","null","January 23, 2017","Rate of regimen-related toxicities|Rate for hematopoietic engraftment|Rate for immune reconstitution|Incidence of GVHD|Maximum tolerated dose of DLI, determined according to dose limiting toxicities|Myeloid engraftment rate|Lymphoid engraftment rate|Incidence of GVHD using tacrolimus and mycophenolate mofetil prophylaxis|Progression free survival|Overall survival (OS)|Rate of lymphoid recovery|Incidence of adverse events","https://ClinicalTrials.gov/show/NCT02548468"
1398,"NCT02166463","Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma","Recruiting","No Results Available","Classical Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma","Biological: Bleomycin Sulfate|Drug: Brentuximab Vedotin|Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Drug: Prednisone|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Drug: Vincristine Sulfate","National Cancer Institute (NCI)","All","2 Years to 18 Years   (Child, Adult)","Phase 3","600","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2014-01223|AHOD1331","June 16, 2014","March 16, 2015","null","May 23, 2017","May 2017","No Study Results Posted","null","November 30, 2019","EFS, where events include disease progression or relapse, second malignancy, or death|Proportion of patients experiencing grade 3+ peripheral neuropathy assessed by modified Balis scale|Proportion of patients needing protocol-directed RT defined as patients with SRL or PD|Proportion of patients with early response defined as no slow responding lesions (SRL) and no progressive disease (PD) at all sites determined by PET per Deauville criteria through central review","https://ClinicalTrials.gov/show/NCT02166463"
1399,"NCT00001209","A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors","Completed","No Results Available","Neuroectodermal Tumor, Primitive|Neuroepithelioma|Osteosarcoma|Sarcoma|Sarcoma, Ewing's","Drug: vincristine, adriamycin and cytoxan, alternating with ifosfamide VP-16","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 1","120","NIH","Interventional","Primary Purpose: Treatment","860169|86-C-0169","November 3, 1999","October 1986","August 2000","March 3, 2008","September 1999","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001209"
1400,"NCT02541565","Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma","Recruiting","No Results Available","Composite Lymphoma|Grade 3b Follicular Lymphoma|Stage I Diffuse Large B-Cell Lymphoma|Stage I Follicular Lymphoma|Stage II Diffuse Large B-Cell Lymphoma|Stage II Follicular Lymphoma|Stage III Diffuse Large B-Cell Lymphoma|Stage III Follicular Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma|Stage IV Follicular Lymphoma","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9291|NCI-2015-01309|MK-3475|P30CA015704","August 31, 2015","November 2015","null","November 21, 2016","November 2016","No Study Results Posted","null","September 2018","Incidence of toxicity graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Treatment-related mortality|Event-free survival|Overall survival|Response rate measured by tumor imaging","https://ClinicalTrials.gov/show/NCT02541565"
1401,"NCT00448266","Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD","Terminated","No Results Available","Breast Cancer","Drug: Intensified Cyclophophamide, Carboplatin and Thiotepa|Drug: dose dense adriamycine and cyclophosphamide","The Netherlands Cancer Institute","Female","18 Years to 59 Years   (Adult)","Phase 2|Phase 3","237","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","N06IAA","March 14, 2007","May 2007","null","October 25, 2010","October 2010","No Study Results Posted","null","February 2010","Percentage of tumors with HRD (phase II part)|pCR rate|Comparison of extramedullary toxicity between the treatment arms.|Need for hospitalization.|Recurrence-free survival and overall survival (phase III part).","https://ClinicalTrials.gov/show/NCT00448266"
1402,"NCT02451982","Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer","Recruiting","No Results Available","Pancreatic Cancer","Drug: Cyclophosphamide|Biological: GVAX pancreatic cancer|Drug: Nivolumab","Sidney Kimmel Comprehensive Cancer Center","All","18 Years to 100 Years   (Adult, Senior)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J1568|IRB00050517","May 20, 2015","February 2016","February 2020","January 11, 2017","January 2017","No Study Results Posted","null","February 2018","Median IL17A expression in vaccine-induced lymphoid aggregates found in surgically resected pancreatic tumors|Number of participants experiencing immune-related toxicities (IRAEs)|Overall Survival|Disease Free Survival","https://ClinicalTrials.gov/show/NCT02451982"
1403,"NCT00972478","Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma","Active, not recruiting","Has Results","Stage II Contiguous Adult Diffuse Large Cell Lymphoma|Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate|Drug: Vorinostat","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","83","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-01964|CDR0000653803|S0806|U10CA032102","September 4, 2009","November 2010","null","September 8, 2016","September 2016","September 8, 2016","null","December 2015","Safe Dose of Vorinostat to be Used in Combination With R-CHOP Assessed by CTCAE Version 4.0 (Phase I)|Progression-free Survival (Phase II)|Overall Survival (Phase II)|Response Rate (Complete Response [CR]+Partial Response [PR]) (Phase II)|Toxicity of Vorinostat-R-CHOP in Patients With Newly Diagnosed DLBCL","https://ClinicalTrials.gov/show/NCT00972478"
1404,"NCT02937844","Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme","Recruiting","No Results Available","Glioblastoma Multiforme","Biological: Anti-PD-L1 CSR T cells|Drug: Cyclophosphamide|Drug: Fludarabine","Beijing Sanbo Brain Hospital|Marino Biotechnology Co., Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SBNK-2016-016-01","July 22, 2016","July 2016","July 2019","October 17, 2016","October 2016","No Study Results Posted","null","July 2018","Number of Adverse Events related to CSR T cell infusion|Treatment Responses Rate|Overall Survival Rate|Progression-free Survival Rate","https://ClinicalTrials.gov/show/NCT02937844"
1405,"NCT01539174","Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma","Withdrawn","No Results Available","Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Other: laboratory biomarker analysis|Other: pharmacological study","Fox Chase Cancer Center|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OER-HM-039|NCI-2011-03309","February 15, 2012","null","null","March 1, 2016","March 2016","No Study Results Posted","null","null","PFS following treatment with rituximab intense dosing and CHOP-21 in previously untreated patients with high risk DLBCL|CR in previously untreated patients with high risk DLBCL treated with rituximab intense dosing and CHOP-21","https://ClinicalTrials.gov/show/NCT01539174"
1406,"NCT02750254","Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation","Recruiting","No Results Available","Acute Myeloid Leukemia|Myelodysplastic Syndrome|Acute Lymphocytic Leukemia","Drug: Fludarabine|Radiation: Fractionated total body irradiation|Drug: Busulfan|Drug: Cyclophosphamide|Radiation: Single dose total body irradiation|Drug: Melphalan|Drug: Granulocyte-colony stimulating factor|Procedure: Stem cell transplant|Drug: Azacitidine","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","51","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","201604081","April 18, 2016","June 27, 2016","July 31, 2021","February 14, 2017","February 2017","No Study Results Posted","null","November 30, 2019","Safety of azacitidine (Phase I only) as measured by frequency and grade of adverse events|Maximum tolerated dose of azacitidine (Phase I only)|Grade II-IV acute GvHD rate of azacitidine (Phase II only)|Event-free survival (EFS)|Overall survival (OS)|Disease-free survival (DFS)|Non-relapse mortality (NRM)|Time to neutrophil engraftment|Time to platelet engraftment|Rate of acute GvHD|Rate of chronic GvHD","https://ClinicalTrials.gov/show/NCT02750254"
1407,"NCT02793856","PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer","Recruiting","No Results Available","Metastatic Non-small Cell Lung Cancer","Drug: Cyclophosphamide|Other: PD-1 Knockout T Cells|Drug: Interleukin-2","Sichuan University|Chengdu MedGenCell, Co., Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","15","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MHC001","May 30, 2016","August 2016","April 2018","November 21, 2016","November 2016","No Study Results Posted","null","April 2018","Number of participants with Adverse Events and/or Dose Limiting Toxicities as a Measure of Safety and tolerability of dose of PD-1 Knockout T cells using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients|Response Rate|Progression free survival - PFS|Overall Survival - OS|Peripheral blood circulating tumor DNA|Temporal Interleukin-2 change in the peripheral blood|Temporal Interferon-γ change in the peripheral blood|Temporal tumour necrosis factor-α change in the peripheral blood|Temporal Interleukin-6 change in the peripheral blood","https://ClinicalTrials.gov/show/NCT02793856"
1408,"NCT01593020","Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2","Active, not recruiting","No Results Available","Breast Cancer","Drug: Paclitaxel|Drug: Eribulin|Drug: 5-Fluorouracil|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Doxorubicin","M.D. Anderson Cancer Center|Eisai Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","162","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-0167|NCI-2012-00851","May 3, 2012","August 2012","null","June 7, 2016","June 2016","No Study Results Posted","null","August 2018","Pathologic Complete Response (pCR)","https://ClinicalTrials.gov/show/NCT01593020"
1409,"NCT02125344","A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)","Recruiting","No Results Available","Tubular Breast Cancer Stage II|Tubular Breast Cancer Stage III|Mucinous Breast Cancer Stage II|Breast Cancer Female NOS|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer","Drug: non-pegylated liposomal doxorubicin|Drug: Carboplatin|Drug: Paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Pertuzumab|Drug: Trastuzumab|Drug: Ferric carboxymaltose","German Breast Group|Amgen|Roche Pharma AG|TEVA|Vifor Pharma","Female","18 Years and older   (Adult, Senior)","Phase 3","950","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GBG 84","April 22, 2014","December 2014","July 2016","January 14, 2016","January 2016","No Study Results Posted","null","July 2016","pathological complete response (pCR= ypT0/is ypN0)|Only for those patients randomized for the supportive anemia treatment: frequency of patients reaching hemoglobin (Hb) levels ≥ 11g/dl 6 weeks after treatment start of a first episode of anemia grade ≥2|pcR rates per arm|Clinical and imaging response|Rates of ypT0 ypN0; ypT0 ypN0/+; ypT0/is ypN0/+; ypT(any) ypN0; and the residual cancer burden (RCB) score.|Toxicity and Compliance including incidence of febrile neutropenia|Breast conservation rate|loco-regional invasive recurrence free survival (LRRFS) in both arms and according to stratified subpopulations|distant-disease-free survival (DDFS) in both arms and according to stratified subpopulations.|invasive disease-free survival (IDFS) in both arms and according to stratified subpopulations.|overall survival (OS) in both arms and according to stratified subpopulations.|regional recurrence free survival (RRFS) in patients with initial node-positive axilla|pCR rate and local recurrence free survival (LRFS) in patients with a clinical complete response (cCR) and a negative core biopsy|Correlation of response|Examination and comparison of molecular markers|Examination of PIK3CA mutation|Only for those patients randomized for the supportive anemia treatment: Quality of life|Only for those patients randomized for the supportive anemia treatment: median time to achieve a hemoglobin level ≥11g/dl|Only for those patients randomized for the supportive anemia treatment: frequency of patients with a hemoglobin level ≥11g/dl|Pharmacogenetic substudy|GeparPET substudy|Ovarian function","https://ClinicalTrials.gov/show/NCT02125344"
1410,"NCT00088881","Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma","Terminated","Has Results","Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia","Biological: rituximab|Drug: prednisone|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Radiation: indium In 111 ibritumomab tiuxetan|Radiation: radiation therapy|Procedure: positron emission tomography","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","62","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2012-02957|E3402|U10CA021115","August 4, 2004","December 2004","March 2011","April 20, 2017","April 2017","December 16, 2014","null","March 2011","Complete Response (CR) +Complete Response/Uncertain (CRu) in Patients Treated With R-CHOP Followed by 90-Yttrium -Zevalin™.|Functional CR in Patients Treated With R-CHOP Followed by 90-Yttrium -Zevalin™.|3-year Time to Treatment Failure (TTF) Rate|3-year Overall Survival (OS) Rate","https://ClinicalTrials.gov/show/NCT00088881"
1411,"NCT00533923","Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders","Completed","No Results Available","AML|ALL|CLL|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|Multiple Myeloma|Aplastic Anemia|Myeloproliferative Disorder","Drug: Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF","Beth Israel Deaconess Medical Center|Bayer","All","up to 65 Years   (Child, Adult)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2002P000219","September 20, 2007","December 2002","January 2007","July 14, 2016","July 2016","No Study Results Posted","null","January 2007","Primary objective of study is to determine the safety of non-myeloablative allogenic stem cell transplantation from matched unrelated donors in patients with hematologic malignancies with a focus on the incidence of treatment-related mortality.|Secondary clinical endpoints includes; incidence of graft failure or rejection; incidence and severity of acute and chronic GVHD; tumor response, and long-term overall and disease-free survival.","https://ClinicalTrials.gov/show/NCT00533923"
1412,"NCT00193011","Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Docetaxel|Drug: Cyclophosphamide|Drug: Methotrexate|Drug: 5-Fluorouracil","SCRI Development Innovations, LLC|Aventis Pharmaceuticals","Female","18 Years and older   (Adult, Senior)","Phase 3","150","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCRI BRE 41|GIA 11169","September 12, 2005","March 2002","August 2004","May 2, 2011","May 2011","No Study Results Posted","null","August 2004","disease-free survival|overall survival|toxicity","https://ClinicalTrials.gov/show/NCT00193011"
1413,"NCT02489266","In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma","Withdrawn","No Results Available","Metastatic Melanoma","Biological: AKTi-treated TIL|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","0","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","150153|15-C-0153","July 2, 2015","June 24, 2015","November 30, 2019","May 12, 2017","June 29, 2016","No Study Results Posted","null","November 30, 2018","Determine whether ACT using TIL cultured in a pharmacologic inhibitor of AktKT (during ex vivo expansion) results in enhanced in vivo persistence of TIL after adoptive transfer into autologous patients with advanced melanoma.|Determine whether ACT using a combination of conventional and AKTi-treated TIL can mediate tumor regression by RECIST guidelines in patients with advanced melanoma|Determine the toxicity profile of this treatment regimen.","https://ClinicalTrials.gov/show/NCT02489266"
1414,"NCT02933775","CD19-redirected Autologous Cells (CAR-CD19 T Cells)","Not yet recruiting","No Results Available","CD19 Positive Malignant B-cell Leukemia and Lymphoma","Genetic: CAR-CD19 T cells|Drug: Fludarabine|Drug: Cyclophosphamide","RenJi Hospital|Carsgen Therapeutics, Ltd.","All","18 Years to 65 Years   (Adult)","Phase 1","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CG3001","October 13, 2016","October 2016","January 2020","October 13, 2016","October 2016","No Study Results Posted","null","April 2018","Study related adverse events|Primary engraftment endpoint|Anti-tumor responses|Overall survival","https://ClinicalTrials.gov/show/NCT02933775"
1415,"NCT02757391","T Cell Immunotherapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies","Not yet recruiting","No Results Available","Gastrointestinal Cancer Metastatic","Drug: Standard Chemotherapy|Drug: Cyclophosphamide|Biological: Adoptive T Cell Infusion|Drug: IL-2|Drug: Pembrolizumab|Behavioral: Phone Calls","M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2015-0152|NCI-2016-01058","April 26, 2016","August 2017","August 2021","April 19, 2017","April 2017","No Study Results Posted","null","August 2021","Toxicity of Personalized Adoptive T Cell Therapy in Participants with Advanced Gastrointestinal Malignancies|Persistence of Immune Response After Personalized Adoptive T Cell Therapy in Participants with Advanced Gastrointestinal Malignancies","https://ClinicalTrials.gov/show/NCT02757391"
1416,"NCT02339441","Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis","Completed","No Results Available","Early Diffuse Cutaneous Systemic Sclerosis","Drug: Methotrexate|Drug: Mycophenolate mofetil|Drug: Cyclophosphamide","University of Manchester","All","18 Years and older   (Adult, Senior)","","320","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","10H101429","December 22, 2014","June 2010","March 2016","May 12, 2016","May 2016","No Study Results Posted","ESOS","December 2015","Skin score as measured by modified rodnan skin score|Pulmonary function as measured by right ventricular systolic pressure (RVSP) or pulmonary artery pressure (PAP)|Echocardiographic findings|Cochin hand function|Fatigue as measured by the Functional Assessment of Chronic Illness Therapy (FACIT) scale|Short form 36 questionnaire (SF-36)|Scleroderma Health Assessment Questionnaire|Haemoglobin|Erythrocyte sedimentation rate|Estimated glomerular filtration rate (eGFR)","https://ClinicalTrials.gov/show/NCT02339441"
1417,"NCT00290498","Rituximab-HCVAD in Patients With B-Cell Non-Hodgkin's Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Dexamethasone|Drug: Methotrexate|Drug: Cytarabine|Drug: Prednisone","M.D. Anderson Cancer Center|Genentech, Inc.","All","16 Years to 60 Years   (Child, Adult)","Phase 2","66","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0054|NCI-2012-01355","February 10, 2006","August 2005","null","September 12, 2016","September 2016","No Study Results Posted","null","August 2018","Overall Response","https://ClinicalTrials.gov/show/NCT00290498"
1418,"NCT01857934","Therapy for Children With Advanced Stage Neuroblastoma","Recruiting","No Results Available","Neuroblastoma","Drug: cyclophosphamide|Drug: topotecan|Biological: hu14.18K322A|Procedure: peripheral blood stem cell harvest|Procedure: surgical resection|Drug: cisplatin|Drug: etoposide|Drug: doxorubicin|Drug: vincristine|Drug: busulfan|Drug: melphalan|Biological: peripheral blood stem cell transplantation|Biological: natural killer cell infusion|Radiation: radiation therapy|Biological: GM-CSF|Biological: G-CSF|Drug: mesna|Drug: levetiracetam|Biological: interleukin-2|Drug: Isotretinoin|Device: CliniMACS","St. Jude Children's Research Hospital|Cookies for Kids' Cancer|CURE Childhood Cancer, Inc.","All","up to 18 Years   (Child, Adult)","Phase 2","210","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NB2012|NCI-2013-00034","May 16, 2013","July 5, 2013","July 31, 2021","April 17, 2017","September 2016","No Study Results Posted","null","January 31, 2021","Number of participants with complete or partial response|Event-free survival (EFS)|Feasibility of delivering hu14.18K322A to 6 cycles of induction therapy|Local failure rate|Dose limiting toxicity (DLT) or severe (grade 3 or 4) VoD|Dose limiting toxicity (DLT)","https://ClinicalTrials.gov/show/NCT01857934"
1419,"NCT02345850","Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)","Recruiting","No Results Available","Acute Leukemia|Myelodysplasia","Procedure: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate|Procedure: Mobilized CD34-selected Peripheral Blood Stem Cell graft|Procedure: Unmanipulated Bone Marrow Graft with Cyclophosphamide|Drug: Cyclophosphamide|Drug: Tacrolimus|Drug: Methotrexate","National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)","All","1 Year to 65 Years   (Child, Adult)","Phase 3","345","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Prevention","BMTCTN1301|U01HL069294","January 22, 2015","August 2015","September 2021","February 7, 2017","February 2017","No Study Results Posted","null","September 2020","Chronic GVHD-free, relapse-free survival (CRFS) probability|Incidence of Acute GVHD|Immunosuppression-free Survival|Incidence of Neutrophil Engraftment|Incidence of Platelet Recovery|Incidence of Disease Relapse|Treatment-related Mortality|Incidence of Grade ≥ 3 Toxicity|Incidence of Infections|Immune Reconstitution|Health-Related Quality of Life (HQL)|Overall Survival (OS)|Relapse-free Survival|Chronic GVHD-free Survival","https://ClinicalTrials.gov/show/NCT02345850"
1420,"NCT02287311","Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)","Recruiting","No Results Available","Hodgkin Disease|Non-Hodgkin Lymphoma|Severe Chronic Active Epstein Barr Virus|T/NK-lymphoproliferative Disease","Biological: MABEL CTLs|Drug: Cyclophosphamide|Drug: Fludarabine","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System","All","Child, Adult, Senior","Phase 1","42","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","H-35253 MABEL|MABEL","November 6, 2014","February 2015","March 2023","September 14, 2016","September 2016","No Study Results Posted","MABEL","March 2018","Number of patients with a dose-limiting toxicity (DLT)|Number of ESTs that persist in the patient's blood|Number of increasing ESTs in the patient's blood|Number of ESTs that respond to viral antigens|Percent of pts whose best response is either complete remission or partial remission","https://ClinicalTrials.gov/show/NCT02287311"
1421,"NCT02062359","T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma","Terminated","Has Results","Metastatic Cancer|Metastatic Melanoma","Biological: Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells|Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","2","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","140058|14-C-0058","February 12, 2014","February 2014","February 2016","May 19, 2016","May 2016","April 11, 2016","null","February 2016","Objective Response (Complete Response (CR) + Partial Response (PR)) of Melanoma Tumors|Persistence of Genetically Engineered, Adoptively Transferred Cluster of Differentiation 62L (CD62L) + Derived Lymphocytes|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT02062359"
1422,"NCT02443831","CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Burkitt Lymphoma","Procedure: Leukapheresis|Drug: Lymphodepletion with fludarabine|Drug: Lymphodepletion with cyclophosphamide|Biological: CD19 CAR T-cells","University College, London","All","up to 24 Years   (Child, Adult)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UCL 14/0529","April 29, 2015","April 2016","December 2028","September 1, 2016","September 2016","No Study Results Posted","null","April 2018","Toxicity evaluation following CD19CAR T-cell infusion|Molecular remission|Long term molecular remission|Frequency of circulating CD19 CAR T-cells|Incidence of hypogammaglobulinaemia|Relapse rate|Overall Survival","https://ClinicalTrials.gov/show/NCT02443831"
1423,"NCT00602693","T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma|Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: umbilical cord blood transplantation|Drug: Allopurinol|Drug: fludarabine phosphate|Drug: Cyclophosphamide|Radiation: Total body irradiation|Biological: Treg infusion|Drug: Sirolimus","Masonic Cancer Center, University of Minnesota","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2007LS022|MT2006-01|0701M00303","January 10, 2008","July 23, 2007","April 16, 2015","February 9, 2017","February 2017","No Study Results Posted","null","September 25, 2014","Maximum tolerated dose|Number of patients with detectable Treg cells|Number of Patients with grade II-IV and grade III-IV acute graft versus host disease (GVHD)|Number of patients with sustained donor engraftment|Number of patients with double chimerism|Incidence of neutrophil recovery after umbilical cord blood (UCB) transplantation|Number of Patients with Chronic Graft Versus Host Disease (GVHD)|Number of Patients with disease-free survival|Number of Patients with Fungal and Viral Infections|Incidence of platelet recovery after umbilical cord blood (UCB)|Number of Patients with Disease Relapse|Percent of Patients with Immune Cell Recovery","https://ClinicalTrials.gov/show/NCT00602693"
1424,"NCT00640796","Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors","Completed","No Results Available","Leukemia, Myeloid, Acute|Leukemia, Lymphocytic, Acute, T-Cell|Juvenile Myelomonocytic Leukemia Lymphoblastic|T-cell Lymphoblastic Lymphoma|Myelodysplastic Syndrome","Procedure: Haploidentical donor derived natural killer cell infusion|Drug: Chemotherapy|Device: CliniMACS","St. Jude Children's Research Hospital|National Cancer Institute (NCI)|Assisi Foundation","All","up to 18 Years   (Child, Adult)","Phase 1","22","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NKEXP|R01CA113482","March 14, 2008","September 2008","April 2014","April 23, 2014","April 2014","No Study Results Posted","null","April 2014","To determine the maximum tolerated dose of expanded NK cells in research participants with relapsed or refractory hematologic malignancies and sarcomas.","https://ClinicalTrials.gov/show/NCT00640796"
1425,"NCT02153905","T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive","Recruiting","No Results Available","Metastatic Cancer That Express the MAGE-A3-HLA A01 Antigen|Metastatic Melanoma That Express the MAGE-A3-HLA A01 Antigen|Metastatic Cancer","Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-MAGE-A3 HLAA* 01-restricted TCR","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","102","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","140110|14-C-0110","May 31, 2014","May 13, 2014","November 18, 2018","May 12, 2017","March 21, 2017","No Study Results Posted","null","June 30, 2017","Determine objective response rate of administration of autologous T cells transduced with an anti-MAGE-A3 HLA-A*01-restricted TCR (MAGE-A3-01) TCR and aldesleukin|Determine a safe dose of administration of anti-MAGE-A3 HLA-A*01 restricted TCR T cells and IL2 following a nonmyeloblative but lymphodepleting preparative regimen|Determine the toxicity profile of the treatment regimen|Determine the in vivo survival of TCR gen-engineered cells","https://ClinicalTrials.gov/show/NCT02153905"
1426,"NCT00832338","Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores","Terminated","Has Results","Breast Neoplasms|Breast Cancer|Cancer of the Breast","Drug: Docetaxel with Cytoxan|Drug: Dexamethasone","Emory University|Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","23","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IRB00012185|WCI1505-08","January 29, 2009","April 2009","October 2015","February 24, 2017","February 2017","December 7, 2016","null","October 2015","Response to Pre-operative Docetaxel and Cytoxan (TC)","https://ClinicalTrials.gov/show/NCT00832338"
1427,"NCT00820690","Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: doxorubicin|Drug: cyclophosphamide|Drug: paclitaxel|Procedure: Surgery","Barretos Cancer Hospital|University of Sao Paulo","Female","18 Years to 70 Years   (Adult, Senior)","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","135/2008","January 9, 2009","July 2008","September 2017","August 3, 2015","August 2015","No Study Results Posted","LABC","April 2012","Clinical objective and pathological responses to chemotherapy|Clinical, radiologic and pathologic correlation|Surgery|Overall actuarial survival|Pathologic complete response","https://ClinicalTrials.gov/show/NCT00820690"
1428,"NCT00854139","Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)","Completed","No Results Available","Multiple Myeloma|End Stage Renal Disease","Drug: Cyclophosphamide, anti-thymocyte globulin|Procedure: Kidney transplant|Radiation: Thymic irradiation|Procedure: Bone marrow transplant from a related donor","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NKD01","February 27, 2009","August 2001","July 2014","April 13, 2015","April 2015","No Study Results Posted","null","July 2014","Remission status of multiple myeloma|Renal allograft acceptance and ability to discontinue immunosuppressive therapy|Graft versus host disease (GVHD)|Opportunistic infections|T cell recovery and immune reconstitution","https://ClinicalTrials.gov/show/NCT00854139"
1429,"NCT00646854","Alemtuzumab and CHOP in T-cell Lymphoma","Unknown status","No Results Available","Lymphoma, T-Cell, Peripheral","Drug: CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab|Drug: CHOP14 chemotherapy (see specification under Arm B) plus G-CSF","Aarhus University Hospital|GCP-unit at Aarhus University Hospital, Aarhus, Denmark|University of Aarhus","All","18 Years to 60 Years   (Adult)","Phase 3","308","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-006130-17","February 14, 2008","June 2008","December 2016","January 8, 2015","November 2012","No Study Results Posted","ACT-1","April 2015","Event-free Survival|Overall survival|Overall response rate|Overall response rate related to the CD52 expression|Tumor control or time-to-progression|Safety measured as number of adverse events (AEs) and serious adverse events (SAEs)|Feasibility of successful stem cell harvest i.e. >/=2E6 CD34 positive cells","https://ClinicalTrials.gov/show/NCT00646854"
1430,"NCT00048737","Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies","Completed","Has Results","Lymphoma|Leukemia","Drug: Zevalin Radioimmunotherapy|Drug: Rituximab|Drug: Fludarabine|Drug: Cyclophosphamide|Procedure: Allogeneic Stem Cell Transplantation","M.D. Anderson Cancer Center|Biogen","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID01-233","November 6, 2002","October 2002","December 2011","June 11, 2013","June 2013","April 22, 2013","null","December 2011","Number of Participants With Graft Failure","https://ClinicalTrials.gov/show/NCT00048737"
1431,"NCT01468818","Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma","Terminated","Has Results","Metastatic Melanoma|Skin Cancer","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Young Tumor Infiltrating Lymphocytes (TIL)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","18","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","110260|11-C-0260","October 6, 2011","September 2011","August 2013","May 19, 2016","May 2016","May 19, 2016","null","August 2013","Objective Response in Patients With Metastatic Melanoma|Level of Persistence of the Transferred Cells in Blood","https://ClinicalTrials.gov/show/NCT01468818"
1432,"NCT02111850","T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive","Recruiting","No Results Available","Metastatic Cancer That Express the MAGE-A3-DP4 Antigen","Biological: Anti-MAGE-A3-DP4 TCR|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","107","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","140052|14-C-0052","April 9, 2014","January 27, 2014","December 27, 2024","May 17, 2017","May 11, 2017","No Study Results Posted","null","December 29, 2023","Determine a safe dose of administration and determine if this approach will result in an objective tumor regression|Determine the in vivo survival of TCR gene-engineered cells.","https://ClinicalTrials.gov/show/NCT02111850"
1433,"NCT00006261","Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer","Withdrawn","No Results Available","Breast Cancer","Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","18 Years to 60 Years   (Adult)","Phase 2","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU1199|P30CA043703|CWRU-1199|NCI-G00-1855","September 11, 2000","May 2000","null","June 9, 2010","June 2010","No Study Results Posted","null","null","Tumor response in women with stage IV breast cancer who achieve PR after a mini-conditioning regimen comprising fludarabine and cyclophosphamide, followed by PBSCT and DLI.","https://ClinicalTrials.gov/show/NCT00006261"
1434,"NCT02876978","Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma","Recruiting","No Results Available","Lung Squamous Cell Carcinoma","Genetic: CAR-GPC3 T Cells|Drug: Fludarabine|Drug: Cyclophosphamide","Carsgen Therapeutics, Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CG1003","August 9, 2016","March 2016","April 2019","August 23, 2016","August 2016","No Study Results Posted","null","October 2017","Safety and tolerance: Occurrence of study related adverse events|Engraftment: the DNA vector copies per mL blood of CAR-GPC3 T cells","https://ClinicalTrials.gov/show/NCT02876978"
1435,"NCT02133196","T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer","Recruiting","No Results Available","Metastatic Non-Small Cell Lung Cancer|Squamous Cell Carcinoma|Advanced NSCLC|Adenosquamous Carcinoma|Adenocarcinomas","Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Young TIL","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","85","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","140104|14-C-0104","May 6, 2014","April 17, 2014","February 28, 2020","May 23, 2017","May 16, 2017","No Study Results Posted","null","February 28, 2019","Determine the rate of tumor regression|To determine the phenotypic and functional characteristics of TIL derived from NSCLC.|To determine the toxicity of this treatment regimen.|To determine the feasibility of generating TIL from patients with NSCLC","https://ClinicalTrials.gov/show/NCT02133196"
1436,"NCT02685059","Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Drug: MEDI4736 (Anti PD-L1)|Drug: Placebo|Drug: nab-Paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide","German Breast Group|AstraZeneca|Celgene Corporation","Female","18 Years and older   (Adult, Senior)","Phase 2","174","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","GBG89","January 14, 2016","March 2016","March 2018","February 12, 2016","January 2016","No Study Results Posted","GeparNuevo","March 2018","pathological complete response (pCR= ypT0 ypN0)|pCR rates per arm|Rates of ypT0/is ypN0|Rates of ypT0/is ypN0/+|Rates of ypT(any) ypN0|Rates of ypT0 ypN0/+|Clinical response|Breast conservation rate|Toxicity and compliance as measured by number of participants with treatment-related|Molecular markers and gene expression|Survival","https://ClinicalTrials.gov/show/NCT02685059"
1437,"NCT02390739","Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer","Withdrawn","No Results Available","Metastatic Thyroid Cancer","Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-Thyroglobulin mTCR PBL","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","0","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","150090|15-C-0090","March 17, 2015","March 2, 2015","September 30, 2019","May 12, 2017","March 22, 2017","No Study Results Posted","null","September 28, 2018","Determine a safe dose of administration and determine if this approach will result in an objective tumor regression.","https://ClinicalTrials.gov/show/NCT02390739"
1438,"NCT01454596","CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII","Recruiting","No Results Available","Malignant Glioma|Glioblastoma|Brain Cancer","Biological: Anti-EGFRvIII CAR transduced PBL|Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","107","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","110266|11-C-0266","October 6, 2011","September 26, 2011","December 28, 2029","May 12, 2017","April 20, 2017","No Study Results Posted","null","December 29, 2028","To evaluate the safety of the administration of anti- EGFRvIII CAR engineered peripheral blood lymphocytes in patients receiving the non-myeloablative conditioning regimen, and aldesleukin and todetermine the six month progression free surviv...","https://ClinicalTrials.gov/show/NCT01454596"
1439,"NCT02306161","Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma","Recruiting","No Results Available","Metastatic Ewing Sarcoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Neoplasm in the Bone Marrow|Metastatic Malignant Neoplasm in the Lung|Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone|Peripheral Primitive Neuroectodermal Tumor of Soft Tissues","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Radiation: External Beam Radiation Therapy|Biological: Ganitumab|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Radiation: Stereotactic Radiosurgery|Procedure: Therapeutic Surgical Procedure|Drug: Vincristine Sulfate","National Cancer Institute (NCI)","All","up to 50 Years   (Child, Adult)","Phase 3","330","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2014-02380|AEWS1221|U10CA180886|U10CA098543","December 1, 2014","December 8, 2014","null","May 24, 2017","May 2017","No Study Results Posted","null","December 31, 2018","Time to adverse analytic event (EFS), defined to be disease-related event, diagnosis of a second malignant neoplasm, or death|Bone marrow response rates|Feasibility of SBRT, defined as an individual that has SBRT planned for at least one site, starts the treatment of metastatic disease phase of the protocol and has at least 85% of tumor sites planned to be treated with SBRT receive successful SBRT|Ganitumab pharmacokinetics (PK)|Overall Survival|Overall toxicity of the addition of ganitumab to VDC/IE chemotherapy, using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Risk of death|Sinusoidal obstructive disease (SOS) associated with the addition of ganitumab to VDC/IE|Tolerability of maintenance ganitumab","https://ClinicalTrials.gov/show/NCT02306161"
1440,"NCT00201318","A Randomized Study in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen","Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: Cyclophosphamide Doxorubicin Vincristine Lamivudine","National Health Research Institutes, Taiwan|National Taiwan University Hospital|Mackay Memorial Hospital|National Cheng-Kung University Hospital|Taipei Veterans General Hospital, Taiwan|Chi Mei Medical Hospital","All","20 Years to 70 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","T1401","September 12, 2005","September 2001","October 2005","September 13, 2005","September 2005","No Study Results Posted","null","null","We expect to enter 33 patients per year. Taking into account 10﹪dropout rate, we may finish accrual of patients within 3 years.","https://ClinicalTrials.gov/show/NCT00201318"
1441,"NCT00262210","A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus Carriers","Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: Cyclophosphamide Epirubicin Etoposide Prednisolone","National Health Research Institutes, Taiwan","All","20 Years to 70 Years   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","T1495","December 5, 2005","June 1995","December 1999","December 5, 2005","December 2005","No Study Results Posted","null","null","We expect to enter 25 patients per year and finish accrual of patients within 4 years.","https://ClinicalTrials.gov/show/NCT00262210"
1442,"NCT01208818","Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy","Active, not recruiting","No Results Available","Chronic Renal Failure With Uremic Nephropathy","Drug: Cyclophosphamide + Bortezomib + Dexamethasone regimen|Drug: Bortezomib +Dexamethasone regimen|Device: HCO group|Device: conventional high-flux dialyzer","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Senior)","Phase 3","284","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P081226","September 23, 2010","June 2011","September 2017","June 23, 2016","June 2016","No Study Results Posted","MYRE","September 2015","Prevalence of renal response (if dialysis not mandatory at baseline: strata 1); Prevalence of patients free of dialysis (if dialysis required at baseline; strata 2)|Improvement in renal function|Hematological response|Progression free survival (PFS)|Time to treatment Failure (TTF)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT01208818"
1443,"NCT02561273","Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma","Recruiting","No Results Available","Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Hepatosplenic T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Stage II Angioimmunoblastic T-cell Lymphoma|Stage II Enteropathy-Associated T-Cell Lymphoma|Stage III Angioimmunoblastic T-cell Lymphoma|Stage III Enteropathy-Associated T-Cell Lymphoma|Stage IV Angioimmunoblastic T-cell Lymphoma|Stage IV Enteropathy-Associated T-Cell Lymphoma","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Vincristine Sulfate|Drug: Etoposide|Drug: Prednisone|Drug: Lenalidomide|Procedure: Peripheral Blood Stem Cell Transplantation|Procedure: Autologous Hematopoietic Stem Cell Transplantation|Other: Laboratory Biomarker Analysis","University of Nebraska|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","54","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","511-14|NCI-2015-00088|RV-CL-PTCL-PI-003858|P30CA036727","September 24, 2015","October 2015","null","October 30, 2016","October 2016","No Study Results Posted","null","March 2020","Maximum tolerated dose of lenalidomide and CHOEP, defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients) (Phase I)|Incidence of toxicity graded according to Common Toxicity Criteria (CTC) (Phase I)|Complete response rate (Phase II)|Overall response rate|Incidence of toxicity graded according to CTC (Phase II)|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02561273"
1444,"NCT00177047","Autologous Transplant for Multiple Myeloma","Recruiting","No Results Available","Multiple Myeloma","Procedure: Stem Cell Transplant|Drug: Cyclophosphamide + Mesna|Drug: Melphalan|Biological: Granulocyte-colony stimulating factor","Masonic Cancer Center, University of Minnesota","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2004LS001|MT2003-13|0312M54569","September 13, 2005","April 20, 2004","January 2019","February 17, 2017","February 2017","No Study Results Posted","null","January 2018","Comparison of Percentage of Patients Achieving a Complete Response|Percentage of patients with extended disease-free survival|Comparison of Overall Survival|Transplant related mortality|Incidence of relapse|Incidence of disease progression|Hematologic recovery|Time to Progression|Time to relapse|Time to attainment of CR and CR+PR|Duration of maintenance treatment|Dropout rate from maintenance therapy|Incidence of toxicities|Incidence of infections","https://ClinicalTrials.gov/show/NCT00177047"
1445,"NCT03110640","Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma","Not yet recruiting","No Results Available","B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Hematopoietic/Lymphoid Cancer|Refractory Chronic Lymphocytic Leukemia","Biological: anti-CD19 CAR-T|Drug: Fludarabine|Drug: Cyclophosphamide","First Affiliated Hospital of Wenzhou Medical Univeristy","All","5 Years to 70 Years   (Child, Adult, Senior)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","20170316","April 6, 2017","April 2017","September 2020","April 11, 2017","March 2017","No Study Results Posted","null","September 2019","Safety - incidence of adverse events defined as dose-limited toxicity|Overall complete remission rate|Duration of remission","https://ClinicalTrials.gov/show/NCT03110640"
1446,"NCT02215967","Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma","Recruiting","No Results Available","Myeloma, Plasma-Cell|Myeloma-Multiple","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Anti-BCMA CAR T cells","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 73 Years   (Adult, Senior)","Phase 1","38","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","140168|14-C-0168","August 12, 2014","August 6, 2014","October 31, 2018","May 20, 2017","May 17, 2017","No Study Results Posted","null","October 31, 2017","Determine the safety of administering T cells expressing an BCMA CAR","https://ClinicalTrials.gov/show/NCT02215967"
1447,"NCT00501332","Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy","Unknown status","No Results Available","Chemotherapy-Induced Neutropenia|Breast Cancer","Biological: Maxy-G34","Maxygen Holdings Ltd.|Maxygen ApS|Maxygen, Inc.|Parexel","All","18 Years and older   (Adult, Senior)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MP-CL-30166|EUDRACT No.: 2006-006565-16|PAREXEL 84728","July 12, 2007","July 2007","null","December 19, 2007","December 2007","No Study Results Posted","null","null","To determine the duration of grade 4 neutropenia after administration of Maxy-G34 in chemotherapy cycle 1.|To determine the duration of grade 4 neutropenia after administration of Maxy-G34 in chemotherapy cycles 2-6.|To determine the incidence of grade 4 neutropenia after administration of each of the 6 doses of Maxy-G34.","https://ClinicalTrials.gov/show/NCT00501332"
1448,"NCT01014767","Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors","Suspended","No Results Available","Brain Cancer|Choroid Plexus Tumors","Drug: Carboplatin|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Dactinomycin|Drug: Doxorubicin|Drug: Etoposide|Drug: Irinotecan|Drug: Leucovorin|Drug: Methotrexate|Drug: Temozolomide|Drug: Vincristine","Tufts Medical Center","All","Child, Adult, Senior","Phase 3","190","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CPT-SIOP-2009","November 13, 2009","November 2009","null","July 21, 2016","July 2016","No Study Results Posted","null","October 2013","Time to Disease Progression|Toxicity during first 4 months of therapy","https://ClinicalTrials.gov/show/NCT01014767"
1449,"NCT00126243","Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin’s Lymphoma","Terminated","No Results Available","AIDS Related Lymphoma","Drug: rituximab|Drug: CHOP","French National Agency for Research on AIDS and Viral Hepatitis|Hoffmann-La Roche","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ANRS 085 Rituximab","August 2, 2005","January 1999","October 2003","August 16, 2005","August 2005","No Study Results Posted","null","null","Evaluate the response rate of lymphoma treated|Duration of response|Evaluate the time to progression|Survival|Safety of rituximab in HIV patients with lymphoma when sequentially administered with chemotherapy","https://ClinicalTrials.gov/show/NCT00126243"
1450,"NCT00513955","Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma","Completed","No Results Available","Lymphoma","Drug: bortezomib|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisolone|Drug: vincristine sulfate|Other: questionnaire administration|Procedure: quality-of-life assessment","Plymouth Hospitals NHS Trust","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000559820|NCRN-Ply-26s|EU-20747|ISRCTN200600609024","August 8, 2007","June 2006","October 2014","November 4, 2014","November 2014","No Study Results Posted","null","October 2014","Disease progression|Unacceptable toxicity or tolerability as assessed by NCI CTCAE v3.0","https://ClinicalTrials.gov/show/NCT00513955"
1451,"NCT02194374","Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)","Active, not recruiting","No Results Available","Leukemia","Procedure: ROR1R-CAR-T Cell Infusion|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab|Drug: Bendamustine","M.D. Anderson Cancer Center|CLL Global Research Foundation Alliance","All","18 Years to 85 Years   (Adult, Senior)","Phase 1","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-0932|NCI-2014-01715","July 16, 2014","January 2015","null","July 27, 2016","July 2016","No Study Results Posted","null","January 2019","Maximum Tolerated Dose (MTD) of ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)","https://ClinicalTrials.gov/show/NCT02194374"
1452,"NCT01985841","Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer","Terminated","No Results Available","Breast Cancer","Drug: Bevacizumb|Drug: 5-Fluorouracil|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Docetaxel","Hellenic Oncology Research Group","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","34","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/10.15","September 13, 2013","October 2011","April 2015","October 7, 2015","October 2015","No Study Results Posted","null","April 2015","Number of Patients with Complete Response|Overall Survival|Progression Free Survival","https://ClinicalTrials.gov/show/NCT01985841"
1453,"NCT01585428","Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers","Completed","Has Results","Cervical Cancer|Oropharyngeal Cancer|Vaginal Cancer|Anal Cancer|Penile Cancer","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Young TIL|Drug: Aldesleukin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","29","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","120116|12-C-0116","April 24, 2012","April 13, 2012","August 1, 2016","February 1, 2017","January 2017","February 1, 2017","null","April 9, 2016","Number of Participants With an Objective Clinical Response|Number of Patients With Serious and Non-serious Adverse Events|T Cell Function|Forkhead Box p3 (Foxp53) Levels|Cytokine Release by Bulk Peripheral Blood Lymphocytes (PBL) (+/- Peptide Stimulation)","https://ClinicalTrials.gov/show/NCT01585428"
1454,"NCT00157209","Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)","Completed","Has Results","Lung Neoplasms|Carcinoma, Non-Small-Cell Lung","Biological: Tecemotide (L-BLP25)|Drug: Single low dose cyclophosphamide|Other: Best Supportive Care (BSC)","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 2","171","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","B25-LG-304 / EMR 63325-005","September 8, 2005","August 2000","July 2012","October 19, 2015","October 2015","July 23, 2015","null","March 2006","Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death, and TEAEs With Cancer and Leukemia Group B (CALGB) Toxicity Grade 3 or 4|Overall Survival Time|Functional Assessment of Cancer Therapy (FACT-L) Questionnaire Score|Number of Participants With Positive T-cell Proliferation|Number of Participants With Elevated CA27-29 Antigen Levels","https://ClinicalTrials.gov/show/NCT00157209"
1455,"NCT00003490","Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: sargramostim|Drug: cyclophosphamide|Drug: prednisone|Drug: vincristine sulfate","The Cleveland Clinic|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 2","30","Other","Interventional","Primary Purpose: Treatment","CDR0000066529|CCF-IRB-1863|IMMUNEX-001.0743|NCI-V98-1458","November 1, 1999","October 1998","August 2003","December 3, 2013","March 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003490"
1456,"NCT00950846","Umbilical Cord Blood Transplant for Congenital Pediatric Disorders","Recruiting","No Results Available","Congenital Pediatric Disorders","Drug: Busulfan|Drug: Cytoxan|Drug: Fludarabine|Procedure: Cord Blood Stem Cell Infusion","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital","All","up to 17 Years   (Child)","","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","25064-UCB","July 30, 2009","July 2009","January 2025","February 27, 2017","February 2017","No Study Results Posted","UCB","January 2025","Overall survival at 100 days, 1 year, 3 years, and 5 years after umbilical cord blood transplant in pediatric patients with congenital diseases.|Neutrophil and platelet count recovery at Day 42.|Incidence of severe Grade III-IV acute GvHD at Day 100.|Incidence of chronic GvHD at 1 year.|Engraftment of donor cells at 100 days, 6 months, and 12 months after transplant.","https://ClinicalTrials.gov/show/NCT00950846"
1457,"NCT01257802","GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases","Terminated","No Results Available","Lupus Erythematosus, Systemic|Systemic Vasculitis|Isolated Angiitis of Central Nervous System|Lung Disease With Systemic Sclerosis|Lung Disease Interstitial Diffuse","Drug: depot leuprolide acetate 3.75 mg|Drug: Placebo","Joseph Mccune|National Institutes of Health (NIH)|University of Michigan","Female","18 Years to 40 Years   (Adult)","Phase 3","14","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","HUM00043071","December 9, 2010","May 2011","November 2015","May 11, 2016","May 2016","No Study Results Posted","LUPRON","October 2015","anti-mullerian hormone (AMH) measured as a continuous variable, specifically assessing the intra-person change from study entry (Day 0) to 6-month post-intervention visit|Proportion of patients with AMH of ≤1.0 ng/mL vs >1 ng/mL, presence of menses, presence of either an AMH level of >1 ng/mL OR antral follicle count of >4. Continuous measures include: antral follicle count (AFC), ovarian volume, and FSH.","https://ClinicalTrials.gov/show/NCT01257802"
1458,"NCT02213913","Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","Recruiting","No Results Available","Adult Grade III Lymphomatoid Granulomatosis|B-cell Chronic Lymphocytic Leukemia|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Progressive Hairy Cell Leukemia, Initial Treatment|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage 0 Chronic Lymphocytic Leukemia|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Small Lymphocytic Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Testicular Lymphoma|Untreated Hairy Cell Leukemia|Waldenström Macroglobulinemia","Drug: lenalidomide|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate|Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Biological: rituximab|Other: quality-of-life assessment|Other: laboratory biomarker analysis","University of Chicago|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","46","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13-1406|NCI-2014-01581|IRB13-1406|P30CA014599","August 5, 2014","July 2014","June 2017","August 24, 2016","August 2016","No Study Results Posted","null","June 2017","PFS|MTD of adding lenalidomide to the DA-EPOCH-R regimen as a front-line therapy in patients with DHL lymphomas (using CTCAE v 4.0) (Phase I)|PFS (Phase II)|Add lenalidomide to the DA-EPOCH-R regimen as a front-line therapy in patients with DHL lymphomas (Phase I)|Overall response rate defined as the sum of partial response (PR) and complete response (CR) by computed tomography (CT) of positron emission tomography/CT and/or resolution of marrow-only involvement (if originally involved) (Phase I)|Anti-tumor activity, calculated as the sum of stable disease, PR, and CR according to the Revised Response Criteria for Malignant Lymphoma and Cheson et al (Phase I)|Duration of response, calculated as the duration from detecting any objective response until progression or death from any cause, according to the Revised Response Criteria for Malignant Lymphoma and Cheson et al (Phase I)|Incidence of adverse events, defined as the occurrence of all grades of toxicity (using CTCAE version 4.0)","https://ClinicalTrials.gov/show/NCT02213913"
1459,"NCT00002535","Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma","Completed","No Results Available","Melanoma (Skin)","Biological: aldesleukin|Biological: lymphokine-activated killer cells|Biological: therapeutic tumor infiltrating lymphocytes|Drug: cyclophosphamide|Drug: indomethacin","St. Luke's Medical Center|National Cancer Institute (NCI)","All","17 Years and older   (Child, Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","STLMC-BRM-93004|CDR0000078467|NCI-V93-0295","November 1, 1999","July 1993","July 2004","June 25, 2013","August 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002535"
1460,"NCT01496131","Tecemotide (L-BLP25) in Prostate Cancer","Completed","No Results Available","Prostate Cancer","Radiation: Radiation therapy|Drug: Goserelin|Drug: Cyclophosphamide|Drug: Tecemotide (L-BLP25)","EMD Serono|National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Senior)","Phase 2","28","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","EMR 63325-015|BB-IND 7787","November 3, 2011","October 2011","October 2016","February 15, 2017","February 2017","No Study Results Posted","null","October 2016","Change from Baseline in the Enzyme-linked Immunosorbent Spot (ELISPOT) Level of Mucin-1 specific T-cells at 2 Months After Radiation|Change from Baseline in the ELISPOT Level of Mucin-1 specific T-cells at 6 Months After Radiation|Kaplan-Meier Estimates of Time to Disease Recurrence based on Prostate-specific antigen (PSA) Levels|Percentage of Subjects with a Doubling in Number of T-cells in tumor biopsy from Baseline to Week 27|Percentage of Subjects with a Doubling of Number of T-cells in tumor biopsy from Baseline to Week 40","https://ClinicalTrials.gov/show/NCT01496131"
1461,"NCT03049449","T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas","Recruiting","No Results Available","Lymphoma, Large-Cell, Anaplasitc|Hodgkin Disease|Lymphoma, Hodgkins|Enteropathy-Associated T-Cell Lymphoma|Lymphoma, Extranodal NK-T-Cell","Biological: Anti-CD30-CAR T cells|Drug: Cyclophosphamide|Drug: Fludarabine","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 73 Years   (Adult, Senior)","Phase 1","76","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","170048|17-C-0048","February 9, 2017","January 23, 2017","June 30, 2021","April 11, 2017","February 16, 2017","No Study Results Posted","null","June 30, 2021","Determine the safety and feasibility of administering T cells expressing a novel fully-human anti-CD30 CAR to patients with advanced CD30-expresssing lymphomas.|Evaluate the in vivo persistence and peak blood levels of anti-CD30 CAR T cells after initial and repeated CAR T-cell infusions|Assess for evidence of antilymphoma activity by anti-CD30 CAR T cells","https://ClinicalTrials.gov/show/NCT03049449"
1462,"NCT02659943","T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies","Recruiting","No Results Available","Lymphoma, B-Cell|Lymphoma, Non-hodgkins|Lymphoma, Hodgkins|Leukemia, B-cell","Biological: Anti-CD19-CAR T cells|Drug: Cyclophosphamide|Drug: Fludarabine","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 73 Years   (Adult, Senior)","Phase 1","64","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","160054|16-C-0054","January 20, 2016","January 12, 2016","December 1, 2021","May 12, 2017","April 6, 2017","No Study Results Posted","null","December 1, 2020","Determine the safety and feasibility of administering T cells expressing a novel fully-human anti-CD19 chimeric antigen receptor (CAR)","https://ClinicalTrials.gov/show/NCT02659943"
1463,"NCT01878617","A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma","Recruiting","No Results Available","Medulloblastoma","Radiation: Craniospinal Irradiation with boost to the primary tumor site|Drug: Cyclophosphamide|Drug: Cisplatin|Drug: Vincristine|Drug: Vismodegib|Drug: Pemetrexed|Drug: Gemcitabine|Other: Aerobic Training|Other: Neurocognitive Remediation","St. Jude Children's Research Hospital|Genentech, Inc.|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 2","350","Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SJMB12|NCI-2013-01125|R01CA187079","June 10, 2013","June 23, 2013","December 31, 2026","March 30, 2017","February 2017","No Study Results Posted","null","June 30, 2023","Progression-free survival distribution (Stratum W1)|Progression free survival distribution (Stratum N1)|Change in VO2 peak values|Change in spatial span backward standard score|Compare progression-free survival by strata with prior St. Jude SJMB03 study participants|Compare overall survival by strata with prior St. Jude SJMB03 study participants|Proportion of patients able to complete protocol therapy|Number of patients who go off treatment for reasons other than progressive disease|Number of local failures|Change in hand grip strength|Change in range of motion|Change in overall flexibility|Change in motor proficiency|Change in quality of life (QOL) score|Change in fatigue score|Change in measure of memory function|Change in measure of attention|Change in executive function score|Change in sleep|Association between baseline cognitive performance and sleep quality|Association between baseline cognitive performance and sleep quantity|Association between baseline cognitive performance and fatigue|Longitudinal change in measure of intellectual function|Association of demographic and clinical factors with change in intellectual function|Longitudinal change in measure of academic ability|Association of demographic and clinical factors with change in academic ability|Longitudinal change in measure of attention|Association of demographic and clinical factors with change in attention|Longitudinal change in measure of memory|Association of demographic and clinical factors with change in memory|Longitudinal change in measure of cognitive processing speed function|Association of demographic and clinical factors with change in cognitive processing speed|Longitudinal change in measure of neurocognitive executive function|Association of demographic and clinical factors with change in neurocognitive executive function|Change in measure of processing speed|Change in measure of executive function ability|Change in measure of attention among 3 groups (working memory intervention + physical exercise intervention VS. working memory intervention alone VS. physical training intervention alone)|Change in measure of processing speed among 3 groups (working memory intervention + physical exercise intervention VS. working memory intervention alone VS. physical training intervention alone)|Change in measure of executive function among 3 groups (working memory intervention + physical exercise intervention VS. working memory intervention alone VS. physical training intervention alone)|Change in measure of attention between participants who received computer-based intervention VS. those who did not|Change in measure of working memory between participants who received computer-based intervention VS. those who did not|Change in measure of processing speed between participants who received computer-based intervention VS. those who did not|Change in measure of executive function between participants who received computer-based intervention VS. those who did not","https://ClinicalTrials.gov/show/NCT01878617"
1464,"NCT02365805","Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel|Drug: Epirubicin + Cisplatin + Fluorouracil|Drug: Docetaxel + Ciclofosfamide","Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","Female","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2011-005843-28","December 30, 2014","April 2014","October 10, 2016","March 9, 2017","March 2017","No Study Results Posted","BERNAQ","October 10, 2016","Rate of residual tumor types RCB-0 and RCB-I (good pathological response) at the time of surgery.|Percentaje of patients candidates to conventional mastectomy as indicated by surgeon|Rates of residual tumor types RCB-0, RCB-I, RCB-II and RCB-III pathological response in surgical breast and axillary node resection specimens|Percentage of patients with negative axillary nodes|Complete tumoral response at the time of surgery (WHO criteria).|Percentaje of patients candidates to breast conserving mastectomy as indicated by surgeon|Partial tumoral response at the time of surgery (WHO criteria).","https://ClinicalTrials.gov/show/NCT02365805"
1465,"NCT01920932","Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma","Recruiting","No Results Available","Stage II Childhood Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma","Drug: brentuximab vedotin|Drug: etoposide|Drug: prednisone|Drug: doxorubicin|Drug: cyclophosphamide|Drug: Dacarbazine(R)|Drug: filgrastim|Other: quality of life assessment|Radiation: radiation therapy","St. Jude Children's Research Hospital|Seattle Genetics, Inc.","All","up to 18 Years   (Child, Adult)","Phase 2","77","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","HLHR13|NCI-2013-01123","August 6, 2013","August 12, 2013","April 30, 2025","April 10, 2017","September 2016","No Study Results Posted","null","August 31, 2021","Response rate with PET and CT|Event-free survival|Response rate|Number of adverse events|Local failure rate|Patient quality of life (QoL)|Parent proxy quality of life (QoL)|Correlation of agreement between patient QoL and parent proxy QoL at multiple time points|Correlation of agreement between patient QoL and symptom distress to patients treated on HOD 99 unfavorable at multiple time points","https://ClinicalTrials.gov/show/NCT01920932"
1466,"NCT01010854","Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer","Terminated","No Results Available","Breast Cancer","Drug: VPA FEC100","University of California, San Francisco|H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Senior)","Phase 2","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CC# 087515","November 6, 2009","December 2008","December 2015","May 5, 2014","May 2014","No Study Results Posted","VPA-FEC100","December 2015","Pathologic response at definitive surgery|clinical response based on tumor measurement","https://ClinicalTrials.gov/show/NCT01010854"
1467,"NCT02447055","Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma","Withdrawn","No Results Available","Multiple Myeloma|Myeloma-Multiple","Biological: Tocilizumab|Drug: Melphalan|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Drug: Filgrastim","Washington University School of Medicine","All","18 Years to 70 Years   (Adult, Senior)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201508102","May 13, 2015","December 2015","June 2016","July 8, 2016","July 2016","No Study Results Posted","null","June 2016","Safety and tolerability of regimen as measured by grade and frequency of adverse events|Cumulative incidence and severity of acute GvHD|Cumulative incidence and severity of chronic GvHD|Non-relapse mortality (NRM)|Progression-free survival (PFS)|Overall survival (OS)|Time to neutrophil engraftment|Time to platelet engraftment","https://ClinicalTrials.gov/show/NCT02447055"
1468,"NCT00204659","Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma","Completed","No Results Available","Primary Gastric Diffuse-Large B-Cell Lymphoma","Drug: Rituximab + CHOP chemotherapy","University Hospital Tuebingen|Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","64-03","September 14, 2005","March 2003","September 2008","October 17, 2008","September 2008","No Study Results Posted","null","September 2008","Complete remission rate|Progression-free survival|Overall survival|Toxicity","https://ClinicalTrials.gov/show/NCT00204659"
1469,"NCT01959490","Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer","Active, not recruiting","No Results Available","Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer","Biological: trastuzumab|Biological: Pertuzumab|Drug: docetaxel|Drug: carboplatin|Drug: doxorubicin|Drug: cyclophosphamide|Drug: paclitaxel|Other: laboratory biomarker analysis|Other: pharmacogenomic studies|Drug: Bevacizumab","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","16","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science","CASE14112|NCI-2013-01422|CASE 14112|P30CA043703","August 16, 2013","September 2013","April 2017","November 10, 2016","November 2016","No Study Results Posted","null","November 2016","The number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes.|The number of HER2 positive patients with a pCR predicted by a trastuzumab and pertuzumab response signature|The number of HER2 negative patients with a pCR predicted by the TGF-B response signature|The number of HER2 positive patients with a pCR predicted by the AKT signature and IGF signature.|The number of patients with a pCR predicated by copy number alterations.|The number of patients with a pCR predicted by changes in texture on breast DCE-MRI after a two-week ""run-in"" treatment with trastuzumab, pertuzumab, or bevacizumab","https://ClinicalTrials.gov/show/NCT01959490"
1470,"NCT03096782","Cord Blood (CB) Ex-vivo Mesenchymal Stem Cell (MSC) Expansion + Fucosylation","Not yet recruiting","No Results Available","Hematopoietic/Lymphoid Cancer","Drug: Busulfan|Drug: Rituximab|Drug: ATG|Drug: Fludarabine|Drug: Clofarabine|Radiation: Total Body Irradiation|Procedure: Cord Blood Transplant|Drug: Mycofenolate mofetil|Drug: Tacrolimus|Drug: G-CSF|Drug: Melphalan|Drug: Cyclophosphamide|Drug: Mesna","M.D. Anderson Cancer Center|Mesoblast, Inc.","All","1 Year to 65 Years   (Child, Adult)","Phase 2","25","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2016-0051","March 21, 2017","June 2017","June 2020","April 19, 2017","April 2017","No Study Results Posted","null","June 2020","Feasibility of Cord Blood Infusion Expanded in Mesenchymal Stem Cells (MSC) with Fucosylation|Time to Engraftment|Disease Free Survival","https://ClinicalTrials.gov/show/NCT03096782"
1471,"NCT01265901","IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma","Completed","No Results Available","Metastatic Renal Cell Carcinoma","Drug: Sunitinib|Biological: IMA901 plus GM-CSF|Drug: Cyclophosphamide","immatics Biotechnologies GmbH","All","18 Years and older   (Adult, Senior)","Phase 3","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IMA901-301|2010-022459-45","December 22, 2010","December 2010","July 2015","August 17, 2015","August 2015","No Study Results Posted","null","July 2015","Overall survival|Overall survival in biomarker-defined subgroup|Progression-free survival|Best tumor response|Safety and tolerability|Cellular immunomonitoring","https://ClinicalTrials.gov/show/NCT01265901"
1472,"NCT00376805","Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer","Terminated","Has Results","Breast Cancer","Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total body irradiation|Other: Natural killer cell infusion|Biological: Interleukin-2","Masonic Cancer Center, University of Minnesota","All","18 Years and older   (Adult, Senior)","Phase 2","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UMN-2005LS033|UMN-0505M70037|UMN-MT2005-08","September 13, 2006","April 2006","January 2010","November 6, 2012","November 2012","July 13, 2010","null","September 2009","Number of Patients Who Had Expansion of Natural Killer Cells|Number of Patients by Disease Response|Number of Patients Who Died While on Study|Overall Median Number of Days Patients Alive After Treatment","https://ClinicalTrials.gov/show/NCT00376805"
1473,"NCT01339910","Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)","Terminated","No Results Available","Leukemia, Myelocytic, Acute","Drug: Fludarabine and Busulfan|Drug: Fludarabine and Melphalan|Drug: Busulfan and Fludarabine|Drug: Busulfan and Cyclophosphamide|Drug: Cyclophosphamide and Total Body Irradiation","Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program","All","18 Years to 65 Years   (Adult)","Phase 3","272","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BMTCTN0901|U01HL069294|U01HL069294-05|BMT CTN 0901|5U24CA076518","April 20, 2011","May 2011","January 2018","February 7, 2017","February 2017","No Study Results Posted","null","January 16, 2017","Overall Survival|Disease-Free Survival|Treatment-related Mortality|Neutrophil and Platelet Engraftment|Donor Cell Engraftment|Acute Graft Versus Host Disease (GVHD) of Grades II-IV and III-IV|Chronic GVHD|Incidence of Primary Graft Failure|Incidence of Secondary Graft Failure|Incidence of Toxicities Greater Than Grade 3|Incidence of Infections|Immune Reconstitution|Health-related Quality of Life (HQL)","https://ClinicalTrials.gov/show/NCT01339910"
1474,"NCT02280525","Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma","Recruiting","No Results Available","Leukemia","Drug: Lenalidomide|Drug: Rituximab|Drug: Fludarabine|Drug: Cyclophosphamide|Procedure: NK Cells","M.D. Anderson Cancer Center|The Leukemia and Lymphoma Society|Celgene Corporation","All","18 Years to 80 Years   (Adult, Senior)","Phase 1","44","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2014-0297|P-TRP-1996-14|NCI-2014-02678","October 29, 2014","March 2015","March 2021","April 17, 2017","April 2017","No Study Results Posted","null","March 2021","Maximum Tolerated Dose (MTD) of Natural Killer (NK) Cells with Lenalidomide and Lymphodepleting Chemotherapy|Response Rate of Natural Killer (NK) Cells with Lenalidomide and Lymphodepleting Chemotherapy Determined by Bone Marrow Biopsy/Aspiration","https://ClinicalTrials.gov/show/NCT02280525"
1475,"NCT01096368","Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma","Recruiting","No Results Available","Childhood Infratentorial Ependymoma|Childhood Supratentorial Ependymoma|Newly Diagnosed Childhood Ependymoma","Drug: liposomal vincristine sulfate|Other: clinical observation|Radiation: 3-dimensional conformal radiation therapy|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: cisplatin|Other: laboratory biomarker analysis","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 3","400","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ACNS0831|NCI-2011-02029|COG-ACNS0831|CDR0000668560|U10CA098543","March 30, 2010","March 2010","null","August 30, 2016","August 2016","No Study Results Posted","null","March 2020","Event-free survival (EFS) defined as time to the first occurrence of disease progression, disease recurrence, second malignant neoplasm, or death from any cause|Overall survival (OS)|EFS and OS of children with incompletely resected ependymoma who are unable to achieve a complete response (CR) by post-operative induction chemotherapy or by second surgery|EFS and OS of children with supratentorial classic ependymoma who achieve a complete resection at first or second surgery or children who achieve a CR after induction chemotherapy assigned to observation|Neurologic, neuropsychological, and endocrine long-term sequelae of surgery, conformal radiotherapy, and maintenance chemotherapy|Gene expression signatures and genomic alterations in pediatric ependymoma","https://ClinicalTrials.gov/show/NCT01096368"
1476,"NCT00054665","PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma","Completed","Has Results","B-Cell Lymphoma","Drug: PS-341|Drug: Etoposide|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Filgrastim","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","50","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","030096|03-C-0096","February 5, 2003","February 2003","July 2009","August 10, 2012","August 2012","June 25, 2012","null","September 2008","Clinical Response Rate|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00054665"
1477,"NCT01958996","Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin Lymphoma","Active, not recruiting","No Results Available","High Grade Lymphomas CD20 +","Drug: idarubicin","Poitiers University Hospital","All","65 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","27","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment","OROCIEP","October 7, 2013","January 2009","null","October 10, 2016","October 2016","No Study Results Posted","null","December 2016","Maximum tolerated dose of idarubicin|Remission rate after 4 cycles and 8 cycles","https://ClinicalTrials.gov/show/NCT01958996"
1478,"NCT03044743","PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies","Recruiting","No Results Available","Stage IV Gastric Carcinoma|Stage IV Nasopharyngeal Carcinoma|T-Cell Lymphoma Stage IV|Stage IV Adult Hodgkin Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Interleukin-2","Yang Yang|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","PD-1-KO-EBV-CTL","January 22, 2017","April 7, 2017","March 2022","April 28, 2017","April 2017","No Study Results Posted","null","March 2020","Number of participants with Adverse Events using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients|Response Rate|Progression free survival (PFS)|Overall Survival (OS)|The duration of the normalization of tumor marker|Interferon-γ change of T cells in the peripheral blood stimulated by tumor antigens|Th1/Th2 change in the peripheral blood","https://ClinicalTrials.gov/show/NCT03044743"
1479,"NCT02605460","Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission","Recruiting","No Results Available","Acute Myeloid Leukemia|Acute Lymphoid Leukemia","Drug: Busulfan|Drug: Cyclophosphamide|Drug: CXCR4 Antagonist|Procedure: Hematopoietic Stem Cell Transplantation","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","All","18 Years to 60 Years   (Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INCMNSZ REF 917","November 9, 2015","February 2014","December 2017","September 13, 2016","August 2016","No Study Results Posted","null","June 2017","Overall Survival|Disease Free Survival","https://ClinicalTrials.gov/show/NCT02605460"
1480,"NCT00001498","A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer","Completed","No Results Available","Breast Cancer|Breast Neoplasms","Drug: methotrexate|Drug: leucovorin|Drug: 5-fluorouracil|Drug: cyclophosphamide|Procedure: peripheral blood progenitor cell|Drug: paclitaxel|Drug: doxorubicin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","55","NIH","Interventional","Primary Purpose: Treatment","960032|96-C-0032","November 3, 1999","February 1996","December 2000","March 3, 2008","January 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001498"
1481,"NCT00305682","Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant","Recruiting","No Results Available","Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: Fludarabine|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Radiation: total body irradiation|Drug: Sirolimus","Masonic Cancer Center, University of Minnesota","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","320","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2005LS036|UMN-MT-2005-02|UMN-0507M70121","March 21, 2006","June 2005","June 2018","December 7, 2016","December 2016","No Study Results Posted","null","June 2018","Overall Survival|Incidence of Non-relapse mortality|Chimerism Values|Incidence of neutrophil engraftment|Incidence of platelet engraftment|Incidence of acute graft-versus-host disease (GVHD)|Incidence of Chronic Graft-Versus-Host Disease|Progression-free survival|Incidence of relapse","https://ClinicalTrials.gov/show/NCT00305682"
1482,"NCT01328496","Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen","Completed","Has Results","Hematologic Malignancies|Disorder Related to Transplantation|Hematopoietic Malignancy","Drug: Preparative Regimen","St. Jude Children's Research Hospital|The Hartwell Foundation|Assisi Foundation","All","up to 21 Years   (Child, Adult)","Phase 2","14","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","UCBT01|NCI-2011-03700","March 31, 2011","June 15, 2011","October 31, 2016","March 23, 2017","March 2017","March 23, 2017","null","October 31, 2016","Event Free Survival (EFS) for Research Participants|Number of Observational Arm Participants Engrafted|Number of Observational Arm Patients Who Relapsed|Number of Deaths of Observational Arm Patients|Number of Observational Arm Patients With Transplant-related Mortality (TRM)|Number of Participants With Acute GVHD|Number of Participants With Chronic GVHD|Time to Engraftment of Research Arm Participants|Incidence of Transplant-related Mortality (TRM)|The Number of Participants With Transplant-related Morbidity","https://ClinicalTrials.gov/show/NCT01328496"
1483,"NCT00499616","Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma","Unknown status","No Results Available","Neuroblastoma","Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: topotecan hydrochloride|Drug: Isotretinoin","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 12 Years   (Child)","Phase 3","464","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ANBL0531|COG-ANBL0531|CDR0000554708|NCI-2009-00400","July 10, 2007","October 2007","null","July 18, 2014","July 2014","No Study Results Posted","null","June 2014","Overall survival (OS) rates|Event-free survival (EFS) rate|Second-event-free survival (E2FS) of intermediate risk patients|Overall survival time|Definitive determination of the prognostic ability of 1p and 11q|Comparison between reduce intensity of therapy for patients with stage 4 neuroblastoma and favorable biological features and patients < 1 year of age with stage 4 neuroblastoma treated on COG-A3961|Comparison between reduce intensity of therapy for patients with unfavorable histology neuroblastoma and patients unfavorable histology neuroblastoma treated on COG-A3961|Reduced surgical morbidity for patients with stage 4S neuroblastoma|Outcome of patients with stage 4S neuroblastoma who are unable to undergo biopsy for biology-based risk assignment|Correlation between extent of surgical resection with the maintenance of local control, EFS and/or OS rates, and surgical complication rate|Biological surrogate markers|Proportion of patients with neurologic symptoms overall and type of symptom|Association between surgical biopsy technique with adequacy of tissue acquisition for biologic studies, and with complications associated with the biopsy procedure|Prognostic ability of the INRG image-defined risk factor (IDRF) system","https://ClinicalTrials.gov/show/NCT00499616"
1484,"NCT00584766","Intensive Combo Chemo With Autologous BM Rescue for Metastatic Breast Cancer","Completed","No Results Available","Metastatic Breast Cancer","Procedure: High-dose chemotherapy","University of Oklahoma","Female","18 Years to 55 Years   (Adult)","Phase 2","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OU 8701","December 20, 2007","October 1987","May 2002","May 28, 2015","May 2015","No Study Results Posted","null","May 2002","Quality of maximal response; time to initial disease progression; and overall survival|to determine the optimal timing of CyBCNU-ABMT after initial development of metastatic breast cancer","https://ClinicalTrials.gov/show/NCT00584766"
1485,"NCT02527317","Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: Lipegfilgrastim","Beaumont Hospital","All","18 Years and older   (Adult, Senior)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","B1010","June 3, 2015","January 2015","July 2017","July 22, 2016","August 2015","No Study Results Posted","null","July 2016","incidence of treatment-related neutropenia|incidence of febrile neutropenia","https://ClinicalTrials.gov/show/NCT02527317"
1486,"NCT00455533","Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Ixabepilone|Drug: Paclitaxel|Drug: Cyclophosphamide|Drug: Doxorubicin","Bristol-Myers Squibb","Female","18 Years and older   (Adult, Senior)","Phase 2","384","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA163-100|EUDRACT 2006-003047-24","April 2, 2007","October 2007","December 2009","January 25, 2016","January 2016","March 4, 2011","null","December 2009","Percentage of Participants Achieving Pathologic Complete Response (pCR)|Percentage of Participants Achieving Pathologic Complete Response (pCR) in Biomarker-Defined Populations|Percentage of Participants Achieving Pathologic Complete Response (pCR) in 20- and 26-Gene Model Subgroups|Percentage of Participants Achieving Clinical Objective Response|Percentage of Participants Requiring Breast Conservation Surgery|Percentage of Participants Achieving Combined pCR and Minimal Residual Cancer Burden (RCB) 1|Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]), to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR|Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]) to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR/RCB1|Percentage of Participants With pCR and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-Specified Thresholds|Percentage of Participants With pCR/RCB1 and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-specified Thresholds|Percentage of Participants With pCR and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-specified Thresholds, Estrogen-Receptor (ER) Negative Participants|Prevalence of Biomarker Based on Optimal Threshold (Biomarker Positive Participants)|Overall Safety Summary: Deaths, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Drug-Related AEs, and Most Common Treatment-Related Non-Hematologic Adverse Events (TNAEs) Occuring in >=10% of Participants|Severity of Any Drug-Related AEs and Gastrointestinal AEs by System Organ Class|On-Study Hematology: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase|On-Study Liver Function: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase|On-Study Renal Function: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase|Number of Participants by Dose for AC|Number of Participants by Dose for Ixabepilone/Paclitaxel|Reason for First Dose Reduction of AC|Reason for First Dose Reduction of Ixabepilone/Paclitaxel|Number of Participants With Course Delay and Reason for Delay for AC|Number of Participants With Dose Delay and Reason for Dose Delay for Ixabepilone/Paclitaxel","https://ClinicalTrials.gov/show/NCT00455533"
1487,"NCT01636947","A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","Completed","Has Results","Nausea|Vomiting","Drug: Aprepitant|Drug: Aprepitant Placebo|Drug: Ondansetron|Drug: Dexamethasone|Drug: Ondansetron Placebo|Drug: Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).","Merck Sharp & Dohme Corp.","All","21 Years and older   (Adult, Senior)","Phase 4","494","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","0869-225|MK-0869-225","July 5, 2012","December 2012","August 2014","December 16, 2016","December 2016","July 2, 2015","KMEC","August 2014","The Percentage of Participants With No Vomiting - Overall Stage|Percentage of Participants With a Complete Response - Overall, Acute, and Delayed Stages|Number of Emetic Events - Overall Stage|Percentage of Participants With No Vomiting and No Significant Nausea - Overall Stage|Percentage of Participants With No Impact on Daily Life - Overall Stage|Number of Participants With No Use of a Rescue Therapy - Overall, Acute, and Delayed Stages|Percentage of Participants With One or More Clinical Adverse Event|Percentage of Participants With No Vomiting - Acute and Delayed Stages","https://ClinicalTrials.gov/show/NCT01636947"
1488,"NCT00005613","Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease","Completed","No Results Available","Lymphoma","Drug: cyclophosphamide|Drug: etoposide|Drug: BCNU","H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)","All","15 Years to 55 Years   (Child, Adult)","Phase 2","147","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11306|MCC-11306|IRB-4250|NCI-G00-1746","May 2, 2000","March 1996","June 2010","June 3, 2013","June 2013","No Study Results Posted","CBV","October 2006","relapse rate","https://ClinicalTrials.gov/show/NCT00005613"
1489,"NCT01871766","Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy","Recruiting","No Results Available","Rhabdomyosarcoma","Drug: Vincristine|Drug: Dactinomycin|Drug: Cyclophosphamide|Procedure: Surgical Resection|Procedure: Radiation|Drug: Bevacizumab|Drug: Sorafenib|Drug: Myeloid Growth Factor|Procedure: Lymph Node Sampling|Drug: Irinotecan|Drug: Ifosfamide|Drug: Etoposide|Drug: Etoposide Phosphate|Drug: Doxorubicin|Drug: Dexrazoxane|Drug: ^1^1C-methionine","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","RMS13|NCI-2013-00913","May 30, 2013","December 4, 2013","June 30, 2021","April 25, 2017","January 2017","No Study Results Posted","null","June 30, 2021","Event-free survival (intermediate risk arm)|Event-free survival (high risk arm)|Rate of false negative and false positive the sentinel lymph node procedure (low and intermediate risk arms)|Rate of false negative and false positive the sentinel lymph node procedure (high risk arm)|Local failure rate (low and intermediate risk arms)|Local failure rate (high risk arm)|Patterns of failure (low and intermediate risk arms)|Patterns of failure (high risk arm)|Number of patients that complete all cycles of maintenance chemotherapy (intermediate risk arm)|Number of patients that complete all cycles of maintenance chemotherapy (high risk arm)|Incidence of CTC grade 3 and higher toxicities related to proton bream therapy (low and intermediate and high risk arms)","https://ClinicalTrials.gov/show/NCT01871766"
1490,"NCT00322101","Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia","Completed","Has Results","Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Acute Myeloid Leukemia/Transient Myeloproliferative Disorder|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Childhood Acute Myeloid Leukemia in Remission|Childhood Myelodysplastic Syndromes|de Novo Myelodysplastic Syndromes|Myelodysplastic Syndrome With Isolated Del(5q)|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes","Radiation: total-body irradiation|Procedure: allogeneic hematopoietic stem cell transplantation|Drug: cyclophosphamide|Drug: mycophenolate mofetil|Drug: busulfan|Drug: cyclosporine|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Other: laboratory biomarker analysis|Genetic: cytogenetic analysis|Other: flow cytometry|Genetic: fluorescence in situ hybridization|Other: pharmacological study|Genetic: polymorphism analysis|Drug: tacrolimus|Drug: methotrexate","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)","All","up to 65 Years   (Child, Adult)","Phase 3","25","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1992.00|NCI-2010-00737|P01CA078902|K23HL084054|P01CA018029|P01HL036444","May 2, 2006","January 2006","October 2014","October 23, 2014","October 2014","April 4, 2013","null","April 2012","Overall Survival|Progression-free Survival|Non-relapse Mortality|Donor Cell Engraftment|Incidence of Disease Progression/Relapse|Incidence and Severity of Acute and Chronic Graft-vs-host Disease","https://ClinicalTrials.gov/show/NCT00322101"
1491,"NCT00002600","Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer","Completed","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult)","Phase 1","18","Other","Interventional","Primary Purpose: Treatment","CDR0000063839|JHOC-9434|NCI-V94-0544","November 1, 1999","September 1994","null","April 23, 2011","September 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002600"
1492,"NCT01740557","Study of Lymphodepletion Plus Adoptive Cell Transfer With T-Cells Transduced With CXCR2 and Nerve Growth Factor Receptor (NGFR) Followed by High Dose Interleukin-2 in Patients With Metastatic Melanoma","Recruiting","No Results Available","Melanoma","Drug: Cytoxan|Drug: Mesna|Drug: Fludarabine monophosphate|Procedure: T cell Infusion|Drug: IL-2|Other: Questionnaire","M.D. Anderson Cancer Center|National Institutes of Health (NIH)|National Cancer Institute (NCI)|Prometheus Laboratories|Key Biologics, LLC","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","15","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2009-0471|2R01CA116206-06|NCI-2014-02655","November 30, 2012","January 28, 2015","January 2019","May 10, 2017","May 2017","No Study Results Posted","null","January 2019","Toxicity of CXCR2 Transduced Tumor Infiltrating Lymphocytes (TIL)|Tumor Response using Immune-Related Response Criteria (irRC)","https://ClinicalTrials.gov/show/NCT01740557"
1493,"NCT01205503","Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release","Completed","Has Results","Breast Cancer|Non-Hodgkin's Lymphoma","Drug: Mesna|Drug: Saline|Drug: Doxorubicin|Drug: Cyclophosphamide","Mara Chambers|University of Kentucky","All","18 Years and older   (Adult, Senior)","Phase 2","32","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","10-0431-F1V","September 17, 2010","September 2010","April 2015","January 27, 2016","January 2016","September 18, 2015","null","August 2012","TNF-alpha Levels in Patients Receiving Doxorubicin Containing Chemotherapy|Protein Carbonyl Percent Changes From Baseline in Patients Receiving Doxorubicin Containing Chemotherapy|Plasma HNE Percent Changes From Baseline in Patients Receiving Doxorubicin Containing Chemotherapy|Troponin Levels in Patients Receiving Doxorubicin Containing Chemotherapy|B-type Natriuretic Peptide (BNP) Blood Levels in Patients Receiving Doxorubicin Containing Chemotherapy","https://ClinicalTrials.gov/show/NCT01205503"
1494,"NCT02457650","T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies","Recruiting","No Results Available","Bladder Carcinoma|Breast Cancer|Esophagus Carcinoma|Lung Cancer|Melanoma|Multiple Myeloma|Neuroblastoma|Ovarian Cancer|Synovial Sarcoma|Other Metastatic Solid Cancers","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Anti-NY ESO-1 TCR-transduced T cells","Shenzhen Second People's Hospital|Shenzhen Institute for Innovation and Translational Medicine","All","1 Year and older   (Child, Adult, Senior)","Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201504002","May 12, 2015","April 2015","December 2019","August 1, 2016","August 2016","No Study Results Posted","null","December 2019","Number of participants with Adverse Events|Number of participants with Clinical responses","https://ClinicalTrials.gov/show/NCT02457650"
1495,"NCT00001832","Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma","Completed","Has Results","Melanoma|Neoplasm Metastasis","Drug: gp100:209-217 (210M)|Drug: Montanide ISA-51|Drug: IL-2|Drug: MART-1:26-35(27L)|Biological: Abl cells|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: GCSF (Growth colony stimulating factor)|Procedure: Apheresis","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","7 Years and older   (Child, Adult, Senior)","Phase 2","170","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","990158|99-C-0158","November 3, 1999","August 1999","May 2010","December 19, 2012","December 2012","November 7, 2012","null","May 2010","Clinical Response|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00001832"
1496,"NCT00526292","Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant","Completed","Has Results","Leukemia|Myelodysplastic Syndromes","Biological: natural killer cell therapy|Drug: cyclophosphamide|Drug: fludarabine","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","up to 120 Years   (Child, Adult, Senior)","Phase 2","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","07-035|FD-R-004128","September 5, 2007","August 2007","July 2015","January 14, 2016","January 2016","January 14, 2016","null","July 2015","Treatment Efficacy as Defined by Complete or Partial Remission","https://ClinicalTrials.gov/show/NCT00526292"
1497,"NCT02446431","Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence","Recruiting","No Results Available","Solid Tumor","Drug: Bevacizumab|Drug: Cyclophosphamide|Drug: Valproic Acid|Drug: Temsirolimus","Miller Children's & Women's Hospital Long Beach|Children’s Hospital of Orange County","All","12 Months to 31 Years   (Child, Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","001","April 28, 2015","July 2014","July 2029","May 13, 2015","May 2015","No Study Results Posted","Metronomic","July 2024","5 year Event Free Survival|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Site(s) of relapse|Composite Cost of Treatment|Fatigue scores on the PedsQL Fatigue Scale|Pain scores on the Present Functioning Scale|Quality of Life scores on the PedsQL Quality of Life Scale","https://ClinicalTrials.gov/show/NCT02446431"
1498,"NCT01312376","Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer","Active, not recruiting","No Results Available","Ovarian Carcinoma|Fallopian Tube Cancer|Primary Peritoneal Cancer","Biological: OC-DC vaccine|Drug: Bevacizumab|Drug: cyclophosphamide 300 mg/m2/d for 3 days|Drug: fludarabine 30 mg/m2/d for 3 days|Drug: ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells","Abramson Cancer Center of the University of Pennsylvania","Female","18 Years and older   (Adult, Senior)","Phase 1","12","Other","Interventional","Primary Purpose: Treatment","UPCC 26810, R01 FD 003520|FDA 00PD","March 9, 2011","March 2011","null","July 18, 2016","July 2016","No Study Results Posted","null","October 2015","Dose Limiting Toxicity|Tumor response","https://ClinicalTrials.gov/show/NCT01312376"
1499,"NCT00610883","LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma","Completed","Has Results","Non-Hodgkin's Lymphoma","Drug: LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU","Memorial Sloan Kettering Cancer Center","All","up to 21 Years   (Child, Adult)","Phase 2","17","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","90-042","December 26, 2007","May 1990","December 2008","December 21, 2015","December 2015","December 21, 2015","null","December 2008","Complete Remission","https://ClinicalTrials.gov/show/NCT00610883"
1500,"NCT01410344","Allogeneic Transplant in HIV Patients (BMT CTN 0903)","Active, not recruiting","No Results Available","Leukemia|Lymphoma|HIV","Drug: Fludarabine and Busulfan|Drug: Fludarabine and Melphalan|Drug: Busulfan and Fludarabine|Drug: Cyclophosphamide and Total Body Irradiation","Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program","All","15 Years and older   (Child, Adult, Senior)","Phase 2","18","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","BMTCTN0903|U01HL069294|BMT CTN 0903|5U24CA076518","August 3, 2011","September 2011","April 2018","February 7, 2017","February 2017","No Study Results Posted","null","April 2017","Non-Relapse Mortality|Disease Status Following Transplant|Chimerism|Incidence of Infections|Six Month Overall Survival|Acute Graft-versus-Host Disease (GVHD)|Chronic Graft-versus-Host Disease (GVHD)|Immunologic Reconstitution|Impact of Therapy on the HIV Reservoir|Hematologic Function","https://ClinicalTrials.gov/show/NCT01410344"
1501,"NCT00501826","Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma","Recruiting","No Results Available","Leukemia|Lymphoblastic Lymphoma|Leukemia, Lymphoblastic, Acute","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone|Drug: Methotrexate|Drug: Vincristine|Drug: Nelarabine","M.D. Anderson Cancer Center|Novartis","All","Child, Adult, Senior","Phase 2","100","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2006-0328|NCI-2012-01518","July 12, 2007","July 2007","July 2019","March 23, 2017","March 2017","No Study Results Posted","null","July 2019","Complete Remission (CR) Rate","https://ClinicalTrials.gov/show/NCT00501826"
1502,"NCT00000899","A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients","Completed","No Results Available","HIV Infections","Drug: Nelfinavir mesylate|Drug: Lamivudine|Drug: Filgrastim|Drug: Stavudine|Drug: Cyclophosphamide","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 50 Years   (Adult)","Phase 1","10","NIH","Interventional","Primary Purpose: Treatment","ACTG 380|11341","November 2, 1999","null","October 2001","February 16, 2012","February 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00000899"
1503,"NCT02456350","Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies","Recruiting","No Results Available","Chronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia|Lymphoma","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-CD19-CAR transduced T cells","Shenzhen Second People's Hospital|Shenzhen Institute for Innovation and Translational Medicine","All","1 Year to 85 Years   (Child, Adult, Senior)","Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201504001","May 12, 2015","April 2015","December 2019","August 1, 2016","August 2016","No Study Results Posted","null","December 2019","Number of participants with Adverse Events|Number of participants with Clinical responses","https://ClinicalTrials.gov/show/NCT02456350"
1504,"NCT01822314","Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: Abraxane|Drug: Paclitaxel","Fondazione Michelangelo","Female","18 Years and older   (Adult, Senior)","Phase 3","632","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FM-12-B01|2012-003481-41","March 25, 2013","April 2013","October 2025","October 10, 2016","October 2016","No Study Results Posted","ETNA","September 2016","pathologic Complete Response (pCR)|clinical Overall Response (cOR)|Event Free Survival (EFS)|Distant Event Free Survival (DEFS)|Local Event Free Survival|Regional Event Free Survival|Overall Survival (OS)|Safety and Tolerability","https://ClinicalTrials.gov/show/NCT01822314"
1505,"NCT00696735","High-Dose Therapy Treatment in Patients With Follicular Lymphoma","Completed","No Results Available","Follicular Lymphoma","Procedure: chemotherapy|Procedure: high dose therapy and autologous stem cell transplantation","French Innovative Leukemia Organisation","All","18 Years to 60 Years   (Adult)","Phase 3","172","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GOELAMS 064","June 11, 2008","June 1994","May 2006","October 23, 2008","September 2006","No Study Results Posted","null","May 2003","event free survival|safety","https://ClinicalTrials.gov/show/NCT00696735"
1506,"NCT03084380","Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)","Not yet recruiting","No Results Available","Hepatocellular Carcinoma","Biological: Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs|Drug: Fludarabine|Drug: Cyclophosphamide","Xinqiao Hospital of Chongqing","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","GPC3CAR","March 5, 2017","June 1, 2017","May 31, 2020","March 17, 2017","March 2017","No Study Results Posted","null","May 31, 2019","Safety: Measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0|Efficacy: Overall complete remission rate defined by the standard response criteria|Persistence: Duration of CAR-positive T cells in circulation","https://ClinicalTrials.gov/show/NCT03084380"
1507,"NCT00857389","Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies","Active, not recruiting","No Results Available","Stem Cell Transplantation|Leukemia|Lymphoma","Drug: Thiotepa|Drug: Clofarabine|Drug: Busulfan|Procedure: Allogeneic Stem Cell Transplantation|Drug: Thymoglobulin (ATG)|Drug: G-CSF (Filgrastim)|Drug: Tacrolimus|Drug: Methotrexate|Drug: Cyclophosphamide|Drug: Mesna","M.D. Anderson Cancer Center","All","up to 60 Years   (Child, Adult)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-0363|NCI-2012-01630","March 5, 2009","March 2009","null","November 22, 2016","November 2016","No Study Results Posted","null","March 2018","Relapse-free Survival Rate","https://ClinicalTrials.gov/show/NCT00857389"
1508,"NCT00006184","Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma","Completed","Has Results","Multiple Myeloma","Drug: Myeloma Immunoglobulin Idiotype Vaccine|Drug: Bortezomib|Drug: Cyclophosphamide|Drug: Cyclosporine|Drug: Doxorubicin hydrochloride|Drug: Etoposide|Drug: Fludarabine phosphate|Drug: Prednisone|Drug: Vincristine Sulfate|Drug: Methotrexate|Biological: GMCSF (granulocyte macrophage colony stimulating factor)|Biological: GCSF (granulocyte colony stimulating factor)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","20","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","000201|00-C-0201","August 23, 2000","August 2000","July 2013","March 24, 2014","March 2014","December 13, 2012","null","July 2012","Immune Response|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00006184"
1509,"NCT00486668","A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer","Active, not recruiting","No Results Available","Invasive Breast Cancer","Drug: doxorubicin|Drug: cyclophosphamide|Drug: paclitaxel|Drug: trastuzumab|Drug: lapatinib","NSABP Foundation Inc|GlaxoSmithKline","Female","18 Years and older   (Adult, Senior)","Phase 3","529","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP B-41","June 13, 2007","July 2007","March 2017","June 3, 2016","June 2016","No Study Results Posted","null","June 2012","Determination of pathologic complete response (pCR), defined by the absence of microscopic evidence of invasive tumor cells in the post chemotherapy surgical breast specimen.|The determination of pCR in the surgical breast and lymph node specimens following chemotherapy.|Clinical tumor measurement as assessed by physical exam of the breast and lymph nodes|Determination of cardiac toxicity as measured by the incidence of cardiac events defined as definite or probable cardiac death|Determination of non-cardiac toxicities as measured by frequencies of adverse events categorized using CTCAE v3.0.|Overall survival as measured by time from randomization until death from any cause.|Recurrence-free interval as measured by occurrence of inoperable progressive disease, or from time of surgery to occurrence of local, regional, or distant recurrence in patients with operable disease.|In tumor tissue, a comparison of array comparative genomic hybridization (CGH) data with gene expression profile data to examine coordinated overexpression of amplified genes, especially in HER2 and cMYC loci.","https://ClinicalTrials.gov/show/NCT00486668"
1510,"NCT01176006","Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency","Recruiting","No Results Available","DOCK8 Deficiency","Procedure: Reduced-intensity hematopoietic stem cell|Drug: Fludarabine(Fludara, Berlex Laboratories)|Drug: Cyclophosphamide(CTX, Cytoxan)|Procedure: Total Body Irradiation (TBI)|Drug: Busulfan (Busulfex)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","4 Years to 60 Years   (Child, Adult)","Phase 2","90","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","100174|10-C-0174","August 4, 2010","July 28, 2010","December 31, 2022","May 12, 2017","May 3, 2017","No Study Results Posted","null","December 31, 2021","To determine whether reduced-intensity allogeneic (HSCT) reconstitutes T-lymphocyte, B-lymphocyte, and NK cell populations with normal donor cells and reverses the clinical phenotype of severe recurrent in patients with DOCK8.|To determine the safety|To determine the incidence of acute and chronic graft-versus-host disease|Immune reconstitution|Overall survival, and disease-free survival.","https://ClinicalTrials.gov/show/NCT01176006"
1511,"NCT00278213","Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia","Completed","No Results Available","Prolymphocytic Leukemia","Biological: alemtuzumab|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mitoxantrone hydrochloride","German CLL Study Group","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","17","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","T-PLL1|EU-20562","January 16, 2006","September 2002","December 2009","September 30, 2016","September 2016","No Study Results Posted","null","February 2007","Adverse effects at 2 months after treatment|Remission rate at 2 months after treatment|Overall survival at 2 months after treatment|Progression-free survival at 2 months after treatment|Remission quality at 2 months after treatment","https://ClinicalTrials.gov/show/NCT00278213"
1512,"NCT00797810","Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults","Unknown status","No Results Available","Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma","Drug: Rituximab","University of Bologna","All","18 Years and older   (Adult, Senior)","Phase 4","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HEMOS ALL1105","November 24, 2008","December 2006","null","September 14, 2009","September 2009","No Study Results Posted","null","null","Test of the tolerability and efficacy of new therapy elements to improve remission|Rates, overall survival and remission duration|Administration of anti-CD20 (rituximab ®) together with combination chemotherapy|Combination therapy with high-dose methotrexate and high-dose cytarabine together with conventional cytostatic agents (cycle C)|Prophylactic administration of G-CSF after every cycle of chemotherapy|Localised irradiation after 6 cycles in mediastinal tumor cases, CNS involvement and residual tumor|Test of the age-adapted therapy stratification according to biological age|(18< age <55)|Definition of prognostic factors|Setting up of a central reference pathology panel","https://ClinicalTrials.gov/show/NCT00797810"
1513,"NCT00049439","Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Drug: cyclophosphamide|Drug: etoposide|Drug: lomustine|Drug: procarbazine hydrochloride","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 2","54","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU2498|P30CA043703|CWRU-029828J|CWRU-2498|NCI-G02-2126|CASE-2498","November 12, 2002","March 1998","February 2008","June 9, 2010","June 2010","No Study Results Posted","null","October 2005","Disease response|Quality of life as assessed by the Functional Living Index-Cancer and the Brief Symptom Inventory","https://ClinicalTrials.gov/show/NCT00049439"
1514,"NCT02670109","Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients","Recruiting","No Results Available","Triple-Negative Invasive Breast Carcinoma|Residual Tumor","Drug: Carmustine|Drug: Cyclophosphamide|Drug: Carboplatin|Procedure: Autologous Hematopoietic Stem Cell Transplantation","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","Female","18 Years to 60 Years   (Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INCMNSZ REF 1239","January 28, 2016","November 2015","November 2018","September 13, 2016","August 2016","No Study Results Posted","null","November 2017","Overall Survival|Disease Free Survival","https://ClinicalTrials.gov/show/NCT02670109"
1515,"NCT00186797","Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia","Completed","No Results Available","Aplastic Anemia","Procedure: Allogeneic stem cell transplant|Drug: Fludarabine, Cyclophosphamide","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","","28","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AACD34","September 9, 2005","December 2002","May 2007","April 7, 2010","April 2010","No Study Results Posted","AACD34","September 2005","To learn the safety of stem cell transplantation in patients with unrelated donors or partially matched family donors|To study the effects (good and bad) of this treatment on the patients, the aplastic anemia, and survival|To learn how well the donor bone marrow grows in patients who receive the research treatment|To learn how many patients need extra T-cells or extra stem cells from the donor to help the donor's blood stem cells grow","https://ClinicalTrials.gov/show/NCT00186797"
1516,"NCT01804634","A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors","Recruiting","No Results Available","Refractory and/or Relapsed Metastatic Solid Tumors","Drug: Cyclophosphamide|Drug: Fludarabine|Radiation: low dose total body irradiation|Drug: Melphalan|Drug: Sirolimus","Sidney Kimmel Comprehensive Cancer Center","All","up to 40 Years   (Child, Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J12106","March 1, 2013","February 2013","December 2018","June 16, 2016","June 2016","No Study Results Posted","null","December 2017","Donor cell engraftment|Overall survival|Relapse|Non-Relapse Mortality","https://ClinicalTrials.gov/show/NCT01804634"
1517,"NCT01455259","Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors","Completed","No Results Available","Malignant Melanoma","Biological: AdCD40L","Uppsala University|Uppsala University Hospital","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","002:CD40L","October 11, 2011","September 2011","January 2016","February 16, 2016","February 2016","No Study Results Posted","null","January 2016","All cause adverse events|Immune reactions to adenovirus and spreading of vector|Tumor burden as measured by PET/CT and whole body MR","https://ClinicalTrials.gov/show/NCT01455259"
1518,"NCT00644124","Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma","Completed","No Results Available","Lymphoma, Non-Hodgkin","Drug: aflibercept","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TCD10173|EudraCT 2007-003737-16","March 21, 2008","March 2008","October 2011","May 5, 2016","May 2016","No Study Results Posted","null","October 2011","selected dose of aflibercept based on Dose Limiting Toxicities observed|Adverse events|Response rate|Progression free survival|Biomarkers","https://ClinicalTrials.gov/show/NCT00644124"
1519,"NCT00003412","Interleukin-12 in Treating Women With Metastatic Breast Cancer Who Have Received High-Dose Chemotherapy and Peripheral Stem Cell Transplantation","Unknown status","No Results Available","Breast Cancer","Biological: recombinant interleukin-12","Beth Israel Deaconess Medical Center|National Cancer Institute (NCI)","Female","18 Years to 60 Years   (Adult)","Phase 1","35","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066424|BIH-L97-0252|NCI-T98-0002","November 1, 1999","June 1998","null","September 16, 2013","October 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003412"
1520,"NCT00941928","Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)","Terminated","Has Results","Leukemia|Pediatric Cancer","Drug: Epratuzumab|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Mesna|Procedure: Infusion of NK cells|Drug: Interleukin-2","M.D. Anderson Cancer Center","All","Child, Adult, Senior","Phase 2","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007-0160","July 16, 2009","July 2009","May 2012","May 19, 2014","May 2014","May 22, 2013","null","May 2012","Time to Progression (TTP)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00941928"
1521,"NCT00619879","Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies","Recruiting","No Results Available","Leukemia, Myelogenous, Chronic|Leukemia, Lymphoblastic, Acute|Leukemia, Myelogenous, Acute|Myeloproliferative-Myelodysplastic Diseases|Lymphoma, Malignant","Drug: Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients|Drug: Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies|Other: Hematopoietic Progenitor Cell Transplantation (HPCT)|Radiation: CNS radiation treatment for ALL with prior CNS disease patients","Ann & Robert H Lurie Children's Hospital of Chicago","All","up to 21 Years   (Child, Adult)","Phase 3","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCT 0307","January 8, 2008","March 2007","January 2020","March 29, 2011","March 2011","No Study Results Posted","null","January 2020","Evaluate the morbidity and mortality of hematopoietic progenitor cell transplantation (HPCT) at Children's Memorial Hospital.|Evaluate the effectiveness of graft versus host disease prevention with a combination of anti-thymocyte globulin, continuous infusion cyclosporine, and short course methotrexate for transplants.|Determine the toxicity of a single conditioning regimen consisting of total body irradiation, etoposide, and Cyclophosphamide for patients with transplant eligible lymphoid malignant conditions or myeloid malignant conditions receiving cord blood units.|Determine the toxicity of a single conditioning regimen consisting of Busulfan and Cyclophosphamide for patients with transplant eligible myeloid malignant conditions who are not receiving cord blood units.","https://ClinicalTrials.gov/show/NCT00619879"
1522,"NCT00548899","Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Nexavar (Sorafenib)","German Breast Group|Bayer","Female","18 Years and older   (Adult, Senior)","Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GBG 45|2007-000124-41","October 23, 2007","November 2007","December 2011","March 6, 2015","March 2015","No Study Results Posted","SOFIA","September 2011","to establish the most feasible regimen of EC-P (P-EC) with sorafenib|Safety of preoperative regimen|Determine clinical response rate|Histopathological axillary nodal status after neoadjuvant therapy|Correlate baseline and change in tumor and serum genetic, gene expression and proteomic patterns with clinical and pathological response|pCR rate at surgery","https://ClinicalTrials.gov/show/NCT00548899"
1523,"NCT00144807","ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma","Completed","No Results Available","Diffuse Large Cell Lymphoma","Drug: rituximab|Drug: doxorubicin|Drug: cyclophosphamide|Procedure: autologous stem cell transplantation","Lymphoma Study Association","All","18 Years to 59 Years   (Adult)","Phase 2","128","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LNH03-3B","September 2, 2005","December 2003","April 2012","September 1, 2015","September 2015","No Study Results Posted","null","September 2008","Complete remission rate (CR + CRu)|Event-free survival and overall survival of patients submitted to autologous transplant and of the entire study population","https://ClinicalTrials.gov/show/NCT00144807"
1524,"NCT02213705","Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells","Recruiting","No Results Available","SYSTEMIC SCLERODERMA|ALLOGENEIC MESENCHYMAL STEM CELLS|ADULT","Biological: INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS","Assistance Publique - Hôpitaux de Paris","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MSC Severe Systemic Sclerosis","July 17, 2014","June 2014","June 2019","April 15, 2016","April 2016","No Study Results Posted","MSC","June 2018","toxicity|survival|progression free survival|Rodnan score|Clinical response","https://ClinicalTrials.gov/show/NCT02213705"
1525,"NCT00751868","FEC With G-CSF Support Followed by Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in BC","Completed","No Results Available","Breast Cancer","Drug: Ixabepilone","Consorzio Oncotech","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","47","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GIM9-NEO-ADIXERN","September 11, 2008","September 2008","July 2011","December 16, 2014","December 2014","No Study Results Posted","GIM9","July 2011","Pathologic Complete Response (pCR)|Feasibility/Tolerability for an individual patient is defined as the absence of hematologic toxicities requiring dose reduction as per protocol","https://ClinicalTrials.gov/show/NCT00751868"
1526,"NCT00452985","Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer","Completed","No Results Available","Ovarian Neoplasms","Drug: Docetaxel|Drug: Carboplatin","Sanofi","Female","15 Years to 75 Years   (Child, Adult, Senior)","","30","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","TAX_BD1_601","March 27, 2007","February 2002","November 2010","August 13, 2012","August 2012","No Study Results Posted","OCSTUD","November 2010","Measurements of the disease (assessed clinically and/or by CA-125)|Response rate|Clinical examination including neurologic examination, vital signs (blood pressure, heart rate, temperature), weight, assessment of any residual toxicity due to previous therapy, assessment of performance status.|Adverse events|Progression free survival|Overall survival|Biology and Hematology laboratory determinations","https://ClinicalTrials.gov/show/NCT00452985"
1527,"NCT00186342","Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies","Completed","No Results Available","Acute Disease|Myelodysplastic Syndromes|Leukemia, Myeloid, Chronic|Myeloproliferative Disorders|Blood and Marrow Transplant (BMT)|Myelodysplastic Syndromes (MDS)|Leukemia","Procedure: ablative allogeneic hematopoietic cell transplantation","Stanford University","All","51 Years to 60 Years   (Adult)","","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT45|75274","September 13, 2005","September 1992","January 2009","December 13, 2012","December 2012","No Study Results Posted","null","January 2009","tolerability|efficacy of therapy|compare efficacy of this treatment to historical controls","https://ClinicalTrials.gov/show/NCT00186342"
1528,"NCT02173262","REaCT Integrated Consent Model to Compare Two Standard of Care Regimens","Recruiting","No Results Available","Breast Cancer","Drug: G-CSF|Drug: Ciprofloxacin","Ottawa Hospital Research Institute","Female","19 Years and older   (Adult, Senior)","","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","20140380-01H","June 16, 2014","August 2014","September 2017","September 15, 2016","September 2016","No Study Results Posted","OTT14-03","January 2017","The percentage of randomized patients in each physician's practice|rates of febrile neutropenia","https://ClinicalTrials.gov/show/NCT02173262"
1529,"NCT00336843","Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma","Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: Zevalin-BuCyE","Asan Medical Center|Schering-Plough","All","up to 64 Years   (Child, Adult)","Phase 2","19","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC 2005-276","June 13, 2006","November 2005","May 2010","February 13, 2016","February 2016","No Study Results Posted","null","February 2009","Event-free survival|Overall survival|Toxicity of the treatment combination","https://ClinicalTrials.gov/show/NCT00336843"
1530,"NCT01516567","Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation","Completed","No Results Available","Primary Mediastinal Large B Cell Lymphoma","Drug: Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab","Gustave Roussy, Cancer Campus, Grand Paris|Children's Oncology Group","All","6 Months to 17 Years   (Child)","Phase 2","47","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Inter B-NHL Ritux 2010 Phase 2|2010-019224-31","January 19, 2012","December 2011","April 2016","July 11, 2016","July 2016","No Study Results Posted","null","April 2016","Event free survival|Survival|Acute toxicity|Long term toxicity","https://ClinicalTrials.gov/show/NCT01516567"
1531,"NCT03015974","Registry of IgA Nephropathy in Chinese Children","Recruiting","No Results Available","IgA Nephropathy|Proteinuria in Nephrotic Range|Immunosuppressive Treatment","Drug: Corticosteroid|Drug: Cyclophosphamide|Drug: Mycophenolate mofetil|Drug: Dipyridamole|Drug: ACE Inhibitor or Angiotensin receptor antagonist","Peking University First Hospital|Nanjing PLA General Hospital|Beijing Children's Hospital|Central South University|The Children's Hospital of Zhejiang University School of Medicine|First Affiliated Hospital, Sun Yat-Sen University|Tongji Hospital|Hunan Children's Hospital|Shanghai Children's Hospital|Nanjing Children's Hospital|Children's Hospital of Chongqing Medical University|Shandong Provincial Hospital|Fuzhou General Hospital|Second Affiliated Hospital of Wenzhou Medical University|Children's Hospital of Hebei Province|Guangzhou Women and Children's Medical Center|Jiangxi Province Children's Hospital|Guangzhou First People's Hospital|Xi'an Children's Hospital|Capital Institute of Pediatrics, China|First Hospital of Jilin University|Wuhan Women and Children's Medical Center|Tianjin Children's Hospital|Chengdu Women's and Children's Central Hospital|The First People's Hospital of Yunnan","All","1 Month to 18 Years   (Child, Adult)","","1200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2015[992]","January 3, 2017","January 2016","January 2019","January 9, 2017","January 2017","No Study Results Posted","RACC","January 2018","Improvement of proteinuria|Renal dysfunction|Hypertension|End stage renal disease(ESRD)|Mortality","https://ClinicalTrials.gov/show/NCT03015974"
1532,"NCT02875314","HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors","Recruiting","No Results Available","Medulloblastoma|Central Nervous System Embryonal Tumors","Drug: Induction|Drug: Single Cycle Intensive Chemotherapy|Drug: Tandem 3 Cycle Intensive Chemotherapy","Nationwide Children's Hospital|Children's Hospital Los Angeles","All","up to 10 Years   (Child)","Phase 4","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IRB15-00399","April 27, 2016","September 2015","September 2020","February 6, 2017","February 2017","No Study Results Posted","null","September 2020","Compare tandem consolidation vs. single cycle consolidation A|Compare tandem consolidation vs. single cycle consolidation B|Induction Cycle Reduction|Uniform Treatment Regimen|Therapy-Related Hearing Loss Evaluation A|Therapy-Related Hearing Loss Evaluation B|Neuropsychological effects will be evaluated using age based tests and questionnaires.|Endocrine studies will be conducted using Serum-free T4, TSH, Cortisol, IGF and IGFBP3 laboratory tests.|Physical growth will be evaluated by collecting patient's height, weight and BSA.|The development of second neoplasms will be monitored.|Neuropathology Biorepository and Clinical Database","https://ClinicalTrials.gov/show/NCT02875314"
1533,"NCT00349115","TCD Followed by autoSCT for Newly Diagnosed MM Patients","Unknown status","No Results Available","Multiple Myeloma","Drug: Thalidomide","Korean Multiple Myeloma Working Party|Celgene Corporation","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","43","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KMM53","July 4, 2006","June 2006","June 2008","May 5, 2008","July 2006","No Study Results Posted","null","null","Response rate of TCD induction Therapy|Progression free survival and Overall survival of TCD, followed by high dose chemotherapy and autoPBSCT and TD maintenance|To evaluate toxicities of TCD, followed by high dose chemotherapy and autoPBSCT and TD maintenance.","https://ClinicalTrials.gov/show/NCT00349115"
1534,"NCT01679119","Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisolone|Drug: Rituximab|Drug: Inotuzumab Ozogamicin|Drug: Gemcitabine","University College, London|Pfizer|Cancer Research UK","All","18 Years and older   (Adult, Senior)","Phase 2","132","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","UCL 11/0475","July 23, 2012","October 2013","April 2020","May 3, 2017","May 2017","No Study Results Posted","INCA","October 2017","Progression free survival|Overall response rate|Overall Survival|Treatment toxicity|Quality of life|Performance status post treatment|Co-morbidities of patients","https://ClinicalTrials.gov/show/NCT01679119"
1535,"NCT01663714","Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.","Completed","Has Results","Lymphoma, Non-Hodgkin","Biological: cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab.","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","104514","August 9, 2012","February 2000","February 2012","November 21, 2016","November 2016","September 20, 2012","null","February 2012","Number of Participants (Par.) With Unconfirmed Response (Complete Response, Complete Response/Unconfirmed, or Partial Response), as Assessed by the Investigator|Number of Participants (Par.) With Confirmed Response (Complete Response [CR], Complete Response/Unconfirmed [CRu], or Partial Response [PR]), as Assessed by the Investigator|Number of Participants With Unconfirmed Complete Response (CR), as Assessed by the Investigator|Number of Participants With Confirmed Complete Response (CR), as Assessed by the Investigator|Duration of Response (DOR), as Assessed by the Investigator|DOR for Unconfirmed and Confirmed Complete Response, as Assessed by the Investigator|Time to Progression of Disease or Death, as Assessed by the Investigator|Time to Treatment Failure, as Assessed by the Investigator|Total Body Residence Time (TBRT; Average Amount of Time TST Spends in the Body, Calculated From the Rate of TB Clearance of Radioactivity During the Dosimetric Dose [DD]) of Iodine 131 TST Antibody Following the DD|Time to Nadir for Hematological Parameters: Absolute Neutrophil Count (ANC), Hemoglobin, Platelets, and White Blood Cell (WBC) Count|Time to Recovery (TTR) to Baseline (BL) for Hematologic Laboratory (Lab.) Evaluations|Nadir Values for Absolute Neutrophil Count (ANC)|Nadir Values for Hemoglobin|Nadir Values for Platelet Count|Nadir Values for WBC Count|Number of Participants With the Indicated Grade 3 or Grade 4 Adverse Events (AEs)|Number of Participants With the Indicated Grade 3 or Grade 4 AEs Possibly or Probably Related to Study Drug|Number of Participants With Any Treatment-related Serious Adverse Event (SAE)|Number of Participants With the Indicated Primary Cause of Death|Number of Participants Who Received Any Supportive Care|Number of Participants Who Were Negative for Human Anti-murine Antibodies (HAMA) at Baseline (Study Entry) But Positive or Negative at Month 24|Overall Survival","https://ClinicalTrials.gov/show/NCT01663714"
1536,"NCT00307671","Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years","Completed","No Results Available","Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis|Churg-Strauss Syndrome|Polyarteritis Nodosa","Drug: prednisone, methylprednisolone,cyclophosphamides|Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone|Drug: Mycophenolate mofetil,methotrexate","Assistance Publique - Hôpitaux de Paris","All","65 Years and older   (Adult, Senior)","Phase 4","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P040425","March 27, 2006","July 2005","July 2011","September 9, 2011","March 2007","No Study Results Posted","CORTAGE","July 2011","Number of side effects (morbidity)|Survival|Efficacy of treatment (remission rate)|Relapse rate|Cumulative dose exposure to OCS and AZA|Cumulative BVAS (AUC), VDI, HAQ-DI, SF-36 values","https://ClinicalTrials.gov/show/NCT00307671"
1537,"NCT01055301","S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma","Withdrawn","No Results Available","Multiple Myeloma|Plasma Cell Myeloma","Drug: bortezomib|Drug: cisplatin|Drug: cyclophosphamide|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: lenalidomide|Drug: melphalan|Drug: thalidomide|Genetic: gene expression analysis|Genetic: microarray analysis|Other: laboratory biomarker analysis|Procedure: autologous-autologous tandem hematopoietic stem cell transplantation","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 2","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S0833|U10CA032102","January 22, 2010","July 2011","July 2011","March 5, 2015","March 2015","No Study Results Posted","null","July 2011","Progression-free survival at 3 years|Overall survival|Frequency and severity of toxicities|Gene expression profiling analysis of CD138+ purified plasma cells","https://ClinicalTrials.gov/show/NCT01055301"
1538,"NCT00931645","Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia","Completed","No Results Available","Chronic Lymphocytic Leukemia","Procedure: Autologous stem cell transplantation|Procedure: DHAP rescue and Autologous stem cell transplantation|Procedure: DHAP rescue and F+C","University Hospital, Caen|Direction Générale de la Santé, France","All","18 Years to 65 Years   (Adult)","Phase 3","241","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SFGMTC|PHRC","June 29, 2009","April 2001","December 2008","July 1, 2009","July 2009","No Study Results Posted","Auto-LLC 2001","December 2007","Progression free survival|Overall survival, response after completion of scheduled treatment, tolerance and adverse events, quality of life, prognostic factors for response and survival.","https://ClinicalTrials.gov/show/NCT00931645"
1539,"NCT01015742","Unrelated Double Umbilical Cord Blood Units Transplantation","Unknown status","No Results Available","Leukemia, Myeloid, Acute|Leukemia, Lymphoblastic, Acute|Leukemia, Myeloid, Chronic","Drug: Stem cell Transplantation","Tehran University of Medical Sciences","All","1 Year to 50 Years   (Child, Adult)","Phase 2|Phase 3","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HORCSCT-0902","November 17, 2009","November 2009","January 2013","May 31, 2012","May 2012","No Study Results Posted","null","December 2012","To determine the Benefit and Side Effects of Double Umbilical Cord Blood Units Stem Cell Transplantation in Hematologic Malignancies|Neutrophil and platelet engraftment|Severity of acute graft-vs-host disease(GvHD|Early transplant related mortality|Overall and disease free survival at one years","https://ClinicalTrials.gov/show/NCT01015742"
1540,"NCT00186290","Allo BMT in Advanced Leukemia or High Grade Lymphoma","Completed","No Results Available","Lymphoma, Non-Hodgkin|Leukemia|Blood and Marrow Transplant (BMT)|Lymphomas: Non-Hodgkin","Procedure: ablative allogeneic hematopoietic cell transplantation","Stanford University","All","up to 50 Years   (Child, Adult)","","145","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT34|74165","September 13, 2005","December 1989","October 2009","October 7, 2010","October 2010","No Study Results Posted","null","October 2009","overall survival|disease free survival|early and late toxicities of the treatment regimen","https://ClinicalTrials.gov/show/NCT00186290"
1541,"NCT01949818","Treatment of Diffuse Large B Cell Lymphoma","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Yangzhengxiaoji capsule combined with CHOP regimen|Drug: CHOP regimen","Mingzhi Zhang|Zhengzhou University","All","14 Years to 70 Years   (Child, Adult, Senior)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","hnslblzlzx2011-4","September 20, 2013","September 2012","September 2018","December 28, 2015","December 2015","No Study Results Posted","null","September 2016","Progression-free survival|overall survival","https://ClinicalTrials.gov/show/NCT01949818"
1542,"NCT02354443","A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders","Terminated","No Results Available","Metabolic Disorders","Biological: ProHema-CB Transplant","Fate Therapeutics","All","1 Year to 18 Years   (Child, Adult)","Phase 1","1","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FT1050-05","January 16, 2015","June 2015","December 2018","April 11, 2016","October 2015","No Study Results Posted","PROVIDE","December 2016","Safety profile, assessed primarily by neutrophil engraftment","https://ClinicalTrials.gov/show/NCT02354443"
1543,"NCT01066429","DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma","Unknown status","No Results Available","Diffuse Large B-Cell Lymphoma (DLBCL)","Drug: Dexamethasone and dose-dense immunochemoterapy","Hospital Universitario Principe de Asturias","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DA-EDOCH14-R/07","February 8, 2010","December 2009","December 2012","February 11, 2010","December 2009","No Study Results Posted","null","December 2010","efficacy of the EDOCH14-R scheme at an adjusted dose|hematological and extra-hematological toxicity of the EDOCH14-R scheme","https://ClinicalTrials.gov/show/NCT01066429"
1544,"NCT01857232","Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy","Completed","No Results Available","CINV","Drug: Ondansetron, dexamethasone, fosaprepitant|Drug: Placebo","Acacia Pharma Ltd","All","18 Years and older   (Adult, Senior)","Phase 2","343","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","DN10016","May 16, 2013","October 2013","February 2015","July 28, 2016","July 2016","No Study Results Posted","null","February 2015","Complete Response","https://ClinicalTrials.gov/show/NCT01857232"
1545,"NCT01446562","Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma","Completed","No Results Available","Follicular Lymphoma","Biological: Y90 Ibritumomab Tiuxetan RIT","Sunnybrook Health Sciences Centre","All","18 Years and older   (Adult, Senior)","Phase 2","34","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZEVISS","August 11, 2011","May 2007","May 2016","June 15, 2016","June 2016","No Study Results Posted","ZEVISS","May 2016","The primary endpoint for this study is the complete response rate measured 3 months after the dose of 90Y-RIT|toxicities|Conversion of partial responses to complete responses|Minimal residual disease|Time to treatment failure|Overall survival","https://ClinicalTrials.gov/show/NCT01446562"
1546,"NCT03042429","Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients","Completed","No Results Available","Neuroblastoma","Drug: Cycles N8, N5 and N6|Drug: Cycles N5 and N6","University of Cologne","All","6 Months to 21 Years   (Child, Adult)","Phase 3","360","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: No masking|Primary Purpose: Treatment","UCologne","February 1, 2017","January 1, 2007","December 31, 2016","February 3, 2017","February 2017","No Study Results Posted","NB2004-HR","December 31, 2016","Event free survival|Overall survival|early response|late response","https://ClinicalTrials.gov/show/NCT03042429"
1547,"NCT02763475","NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents","Recruiting","No Results Available","Acute Myeloid Leukemia|Leukemia|Myeloid Leukemia","Drug: cyclophosphamide|Drug: Fludarabine|Procedure: NK cell infusion|Drug: IL-2","Antonio Pérez Martínez|Instituto de Investigación Hospital Universitario La Paz|Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Fundación Mutua Madrileña","All","up to 21 Years   (Child, Adult)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NKCell_LMA_2015|2015-001901-15","April 4, 2016","May 2016","February 2022","November 8, 2016","November 2016","No Study Results Posted","null","February 2022","Relapse-free rate after allogeneic haploidentical NK cell infusion|Adverse events of special interest: administration issues, infections, immunological/allergic/toxic reactions and concomitant drug interactions.|Evaluation of donor phenotype by SS-PCR|Evaluation of patient HLA phenotype by SS-PCR|Evaluation of donor KIR haplotype by PCR|Analysis of Hematopoietic chimerism after NK infusion by PCR or flow cytometry|Ligand expression of the activatory (MICA, MICB and ULBPs) or inhibitory (HLA-1) receptors of the NK cells|NK cytotoxic activity","https://ClinicalTrials.gov/show/NCT02763475"
1548,"NCT00473551","Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies","Terminated","No Results Available","Leukemia|Lymphoma|Myeloma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Mesna|Radiation: Radiation Treatment|Procedure: Stem Cell Transplantation (SCT)|Drug: Sirolimus|Procedure: Anti-third Party Cytolytic T-lymphocytes (CTL)","M.D. Anderson Cancer Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0682","May 11, 2007","May 2007","November 2009","December 16, 2011","December 2011","No Study Results Posted","null","November 2009","Number of Participants achieving engraftment without severe Graft-versus-host disease (GVHD)|Maximally tolerated dose of anti-third party cytolytic T-lymphocytes","https://ClinicalTrials.gov/show/NCT00473551"
1549,"NCT01153971","A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas","Completed","Has Results","Non-Hodgkin's Lymphoma","Drug: rituximab","Hoffmann-La Roche","All","18 Years to 65 Years   (Adult)","Phase 2","47","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18324","June 14, 2010","July 2005","September 2010","June 24, 2015","June 2015","August 4, 2014","null","September 2010","Percentage of Participants Remaining Failure-Free After 2 Years From Treatment Start Date|Percentage of Participants Achieving a Best Overall Response of CR, CRu, or PR by Study Phase|Percentage of Participants Achieving a Response by Response Type and Study Phase|Failure-Free Survival (FFS), Percentage of Participants Estimated to be Free of Documented Disease Progression, Relapse, or Death|FFS - Percentage of Participants With an Event|FFS - Time to Event|Overall Survival (OS) - Percentage of Participants Estimated to be Alive|OS - Percentage of Participants With an Event|OS - Time to Event|Disease-Free Survival (DFS) - Percentage of Participants Estimated to be Disease-Free|DFS - Percentage of Participants With an Event|DFS - Time to Event|Progression-free Survival (PFS) - Percentage of Participants Estimated to Be Progress Free|PFS - Percentage of Participants With an Event|PFS - Time to Event|Duration of Response (DR) - Percentage of Participants Expected to Maintain a Response|DR - Percentage of Participants With an Event|DR - Time to Event","https://ClinicalTrials.gov/show/NCT01153971"
1550,"NCT00239343","Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: gefitinib","AstraZeneca","Female","18 Years and older   (Adult, Senior)","Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","1839IL/0712","October 14, 2005","October 2004","May 2007","January 25, 2011","January 2011","No Study Results Posted","null","May 2007","the complete pathological response rate in the two study groups at trial closure|complete and overall objective tumuor response at trial closure according to the RECIST criteria in the per-protocol population","https://ClinicalTrials.gov/show/NCT00239343"
1551,"NCT00418743","Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)","Unknown status","No Results Available","Small Cell Lung Cancer","","Groupe Francais De Pneumo-Cancerologie|Baxter Healthcare Corporation|Amgen","All","18 Years and older   (Adult, Senior)","Phase 2","138","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","GFPC 05-01","January 4, 2007","December 2005","May 2010","March 8, 2010","March 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00418743"
1552,"NCT00991211","Bendamustine Plus Rituximab Versus CHOP Plus Rituximab","Completed","No Results Available","Non-Hodgkin Lymphomas|Follicular Lymphomas|Immunocytomas|Lymphocytic Lymphomas|Marginal Zone Lymphomas","Drug: Bendamustine|Drug: Standard chemotherapy CHOP + Ritiximab","University of Giessen","All","18 Years and older   (Adult, Senior)","Phase 3","549","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NHL 1-2003","October 6, 2009","January 2004","August 2009","March 13, 2012","October 2009","No Study Results Posted","null","August 2009","Progression free survival|Determination and comparison of remission rates, of toxicity, infectious complications, overall survival, EFS, TTNT, capacity of peripheral blood stem cell mobilization","https://ClinicalTrials.gov/show/NCT00991211"
1553,"NCT00135967","Mycophenolate Mofetil in Membranous Nephropathy","Completed","No Results Available","Glomerulonephritis, Membranous","Drug: mycophenolate mofetil orally 1000 mg twice a day (BID)|Drug: prednisone 0,5 mg/kg orally on alternate days|Drug: intravenous (i.v.) methylprednisolone 1000 mg, total 9","Radboud University|Hoffmann-La Roche","All","18 Years to 75 Years   (Adult, Senior)","Phase 2|Phase 3","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RUNMN02","August 25, 2005","May 2002","null","December 5, 2005","August 2005","No Study Results Posted","null","null","renal function (serum creatinine)|proteinuria|side effects|relapse rate","https://ClinicalTrials.gov/show/NCT00135967"
1554,"NCT00593697","The Synergism Or Long Duration (SOLD) Study","Completed","No Results Available","Breast Neoplasms","Drug: trastuzumab (9 weeks) + docetaxel|Drug: trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)","Finnish Breast Cancer Group","Female","18 Years and older   (Adult, Senior)","Phase 3","2168","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Protocol number FBCSG-01-2007|EudraCT number 2007-002016-26","January 3, 2008","January 2008","November 2014","March 5, 2015","March 2015","No Study Results Posted","SOLD","November 2014","Disease-free survival (DFS)|Overall survival, distant disease-free survival, cardiac event-free disease-free survival, left ventricle ejection fractions, adverse events, quality of life","https://ClinicalTrials.gov/show/NCT00593697"
1555,"NCT00187096","Natural Killer (NK) Cell Transplantation for AML","Completed","Has Results","Acute Myeloid Leukemia","Drug: Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2|Procedure: Natural Killer Cell Infusion|Device: CliniMACS System","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","","49","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NKAML","September 12, 2005","September 2005","March 2013","June 18, 2014","October 2013","October 10, 2012","null","February 2012","Number of Patients Experiencing Grade 3 or 4 Toxicities During Conditioning and up to 100 Days Post-transplant|Proportion of Patients Experiencing Grade 3 or 4 Toxicities During Conditioning and up to 100 Days Post-transplant|Duration of Engraftment of Natural Killer (NK) Cells|Percent of Peak NK Cell Chimerism|Percent of Detectable Donor NK Cells at Day 28|Day That Maximum NK Cell Engraftment Was Reached|Number of KIR-mismatched NK Cells|Number of Participants With Evidence of NK Cells Lysing a Target Cell Line (K562)|Relapse-free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00187096"
1556,"NCT00186680","CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant","Completed","No Results Available","Breast Cancer","Procedure: high dose chemo then auto hematopoietic cell transplant","Stanford University","All","19 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","99","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT86","September 14, 2005","September 1996","June 2005","February 26, 2010","February 2010","No Study Results Posted","null","June 2005","Feasibility and safety|efficiency of mobilization|tumor contamination","https://ClinicalTrials.gov/show/NCT00186680"
1557,"NCT00005867","Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: bleomycin sulfate|Drug: CHOP regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: mitoxantrone hydrochloride|Drug: prednisolone|Drug: vincristine sulfate","Lymphoma Trials Office|National Cancer Institute (NCI)","All","18 Years to 59 Years   (Adult)","Phase 3","310","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","BNLI-CHOPVPMITCEBO-GOODRISK|CDR0000067900|EU-99052","June 2, 2000","January 1998","August 2007","June 25, 2013","March 2007","No Study Results Posted","null","null","Overall survival in patients treated with mitoxantrone, cyclophosphamide, etoposide, vincristine, bleomycin, and prednisolone (PMitCEBO) versus cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)|Failure-free survival, disease specific survival, relapse-free survival, death due to toxicity, response rate, and toxicity at 4 years","https://ClinicalTrials.gov/show/NCT00005867"
1558,"NCT02685657","Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer","Not yet recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Drug: Selumetinib|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Docetaxel","Russian Academy of Medical Sciences|Russian Society of Clinical Oncology","Female","18 Years and older   (Adult, Senior)","Phase 2","164","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ESR-14-10735","February 13, 2016","September 2016","null","February 18, 2016","February 2016","No Study Results Posted","null","January 2018","• Pathological complete response rate|• Overall clinical response rate|• Adverse events rate in both treatment groups","https://ClinicalTrials.gov/show/NCT02685657"
1559,"NCT00825149","A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma","Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: Bendamustine|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Fludarabine|Drug: Obinutuzumab|Drug: Prednisone|Drug: Vincristine","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 1","137","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BO21000|2008-001643-19","January 16, 2009","February 2009","November 2015","November 3, 2016","November 2016","No Study Results Posted","GAUDI","November 2015","Percentage of Participants With Adverse Events (AEs) - Relapsed/Refractory Population|Percentage of Participants With AEs - First-line Population|Percentage of Participants With End of Induction Response, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - Relapsed/Refractory Population|Percentage of Participants With End of Induction Response, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - First-line Population|Percentage of Participants With Best Overall Response, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - Relapsed/Refractory Population|Percentage of Participants With Best Overall Response, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - First-line Population|Percentage of Participants With Best Overall Response of Complete Response, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - Relapsed/Refractory Population|Percentage of Participants With Best Overall Response of Complete Response, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - First-line Population|Number of Participants With Progression-Free Survival (PFS) Events (Disease Progression/Relapse or Death), According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - Relapsed/Refractory Population|Number of Participants With PFS Events (Disease Progression/Relapse or Death), According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - First-line Population|PFS, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - Relapsed/Refractory Population|PFS, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - First-line Population|Number of Participants With Event-Free Survival (EFS) Event (Disease Progression, Death, or Initiation of a New Anti-Lymphoma Therapy), According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - Relapsed/Refractory Population|Number of Participants With EFS Event (Disease Progression, Death, or Initiation of a New Anti-Lymphoma Therapy), According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - Relapsed/Refractory Population|EFS, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - Relapsed/Refractory Population|EFS, According to 2007 Revised Response Criteria for Non Hodgkin's lymphoma - First-line Population|Pharmacokinetics of Obinutuzumab: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) - Relapsed/Refractory Population|Pharmacokinetics of Obinutuzumab: AUClast - First-line Population|Pharmacokinetics of Obinutuzumab: Maximum Observed Plasma Concentration (Cmax) - Relapsed/Refractory Population|Pharmacokinetics of Obinutuzumab: Cmax - First-line Population|Pharmacokinetics of Obinutuzumab: Systemic Clearance at Steady State (CLss) - Relapsed/Refractory Population|Pharmacokinetics of Obinutuzumab: CLss - First-line Population|Pharmacokinetics of Obinutuzumab: AUC From Time Zero to 7 Days (AUC7d) - Relapsed/Refractory Population|Pharmacokinetics of Obinutuzumab: AUC7d - First-line Population|Pharmacokinetics of Obinutuzumab: Volume of Distribution at Steady State (Vss) - Relapsed/Refractory Population|Pharmacokinetics of Obinutuzumab: Vss - First-line Population|Pharmacokinetics of Obinutuzumab: Plasma Half-life (t1/2) - Relapsed/Refractory Population|Pharmacokinetics of Obinutuzumab: t1/2 - First-line Population|Pharmacokinetics of Obinutuzumab: Plasma Trough Concentration (Ctrough) - Relapsed/Refractory Population|Pharmacokinetics of Obinutuzumab: Ctrough - First-line Population|Pharmacodynamics of Obinutuzumab: Number of Participants With Peripheral Blood B-cell Depletion - Relapsed/Refractory Population|Pharmacodynamics of Obinutuzumab: Number of Participants With Peripheral Blood B-cell Depletion - First-line Population|Pharmacodynamics of Obinutuzumab: Time From End of Treatment to B-Cell Recovery - Relapsed/Refractory Population|Pharmacodynamics of Obinutuzumab: Time From End of Treatment to B-Cell Recovery - First-line Population","https://ClinicalTrials.gov/show/NCT00825149"
1560,"NCT00276809","Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia","Completed","No Results Available","Chronic Lymphocytic Leukemia","Biological: alemtuzumab|Biological: filgrastim|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","German CLL Study Group","All","18 Years to 60 Years   (Adult)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CLL3C|EU-20556|MEDAC-GCLLSG-CLL3C","January 12, 2006","June 2001","September 2004","September 23, 2016","September 2016","No Study Results Posted","null","September 2004","Safety and feasibility of CAMPATH-1H included into the myeloablative regimen (cyclophosphamide and TBI) of the CLL3 protocol monitoring of treatment related mortality and morbidity (CTC scale) continuous|Rate and duration of molecular responses MRD levels continuous|Rate and duration of clinical remissions NCIE sponsored remission criteria for CLL continuous|Overall survival time from treatment to death continuous","https://ClinicalTrials.gov/show/NCT00276809"
1561,"NCT02224599","Treatment of Patients With Progressive and/or Refractory Solid Malignancies","Not yet recruiting","No Results Available","Progressive Solid Malignancies|Refractory Solid Malignancies|Cancer","Biological: TAPA-pulsed DC vaccine","Kiromic, LLC","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","23","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Kirovax 003","August 11, 2014","December 2016","September 2017","November 3, 2016","November 2016","No Study Results Posted","null","May 2017","Number of adverse events due to administration of TAPA-pulse DC vaccine|Immunological efficacy as indicated by T-cell cytokine levels|Immunological efficacy as determined by a positive delayed type hypersensitivity (DTH) skin test","https://ClinicalTrials.gov/show/NCT02224599"
1562,"NCT00002942","Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer","Completed","No Results Available","Breast Cancer","Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 3","136","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CDR0000065391|CCCWFU-95496|NCI-G97-1145","November 1, 1999","June 1996","December 2003","January 18, 2017","July 2012","No Study Results Posted","null","January 2000","","https://ClinicalTrials.gov/show/NCT00002942"
1563,"NCT00923845","Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer","Active, not recruiting","Has Results","Renal Cell Carcinoma|Graft-Versus-Host Disease|Engraftment Syndrome","Drug: Pentostatin|Drug: Sirolimus|Drug: Cyclophosphamide|Procedure: Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Procedure: Th2 rapa cells|Procedure: Donor Lymphocyte Harvest|Procedure: Induction Therapy|Procedure: GVHD prophylaxis|Procedure: Donor Hematopoietic Stem Cell Harvest","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","25","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","080088|08-C-0088","June 17, 2009","March 2008","June 2017","July 15, 2016","July 2016","November 16, 2015","null","June 2015","Clinical Regression of Metastatic Renal Cell Carcinoma (Partial Response (PR)) or Complete Remission of Tumor (Complete Response (CR))|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00923845"
1564,"NCT00004145","Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation","University of Chicago|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 2","16","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9581|UCCRC-9581|UCCRC-CTRC-9852|NCI-G99-1618","December 10, 1999","November 1998","August 2011","March 6, 2014","March 2014","No Study Results Posted","null","November 2003","Hematopoetic recovery and toxicities of non-myeloablative allogenic stem cell transplantation Hematopoetic recovery and toxicities of non-myeloablative allogenic stem cell transplantation","https://ClinicalTrials.gov/show/NCT00004145"
1565,"NCT00791037","Vaccine Therapy in Treating Patients With Stage IV Breast Cancer","Completed","Has Results","HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer","Biological: HER-2/neu peptide vaccine|Procedure: leukapheresis|Biological: ex vivo-expanded HER2-specific T cells|Drug: cyclophosphamide|Biological: sargramostim|Other: laboratory biomarker analysis","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","23","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","6658|NCI-2009-01591|R01CA129517","November 13, 2008","October 2008","December 2014","April 17, 2017","April 2017","October 13, 2016","null","July 2013","Evaluate Toxicity of Infusing HER2-specific T Cells as Assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0|Proportion of Patients Whose T Cells Persist at a Level the Same or Greater as the Level After the Final T Cell Infusion and Subsequent Booster Immunizations as Assessed by IFN-gamma (IFN-g) ELISPOT|Development of CD4+ and CD8+ Epitope Spreading|Response of Skeletal or Bone-only Disease by FDG-PET and According to European Organization for Research and Treatment for Cancer (EORTC)","https://ClinicalTrials.gov/show/NCT00791037"
1566,"NCT01724866","Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients","Completed","No Results Available","Neutropenia","Drug: HM10460A (45 μg/kg)|Drug: HM10460A (135 μg/kg)|Drug: HM10460A (270 μg/kg)|Drug: Pegfilgrastim 6mg","Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Senior)","Phase 2","148","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SPI-GCF-12-201","October 24, 2012","January 2013","December 2014","May 26, 2015","May 2015","No Study Results Posted","null","December 2014","Duration of severe neutropenia (DSN) in Cycle 1|Effect of Test Doses of HM10460A","https://ClinicalTrials.gov/show/NCT01724866"
1567,"NCT01516580","Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients","Recruiting","No Results Available","B-cell Non Hodgkin Lymphoma|Mature B-cell Leukemia Burkitt-type","Drug: Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|Drug: Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C","Gustave Roussy, Cancer Campus, Grand Paris|Children's Oncology Group","All","6 Months to 17 Years   (Child)","Phase 3","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Inter B-NHL Ritux 2010 Phase 3|2010-019224-31","January 19, 2012","December 2011","December 2021","February 9, 2016","February 2016","No Study Results Posted","null","June 2019","Event free survival|Survival|Acute toxicity|Long term toxicity","https://ClinicalTrials.gov/show/NCT01516580"
1568,"NCT02644655","Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia","Recruiting","No Results Available","Recurrent B-Cell Tumor|Refractory B-Cell Tumor","Biological: CD19-specific chimeric antigen receptor","Second Military Medical University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EHBHKY2015-02-007","December 12, 2015","September 2015","September 2017","December 31, 2015","September 2015","No Study Results Posted","null","March 2017","Occurrence of adverse events and tumor response rate related to study drug","https://ClinicalTrials.gov/show/NCT02644655"
1569,"NCT02208037","Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)","Active, not recruiting","No Results Available","Acute Leukemia|Chronic Myelogenous Leukemia|Myelodysplasia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Lymphoma, B-Cell|Lymphoma, Follicular|Lymphoma, Large B-Cell, Diffuse|Hodgkin's Lymphoma","Drug: Tacrolimus (ARM with Methotrexate)|Drug: Tacrolimus (ARM with MMF and Cyclophosphamide)|Drug: Methotrexate (ARM with Maraviroc)|Drug: Methotrexate (ARM with Bortezomib)|Drug: Maraviroc|Drug: Bortezomib|Drug: Mycophenolate mofetil|Drug: Cyclophosphamide","National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","279","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","BMTCTN1203|U01HL069294","August 1, 2014","August 2014","December 2018","November 21, 2016","November 2016","No Study Results Posted","null","August 2018","GVHD/progression/relapse after Hematopoietic Stem Cell Transplant|Incidence of Acute GVHD Grades II-IV|Incidence of Chronic GVHD|Immunosuppression-free Survival Rate|Hematologic Recovery (Neutrophils and Platelets)|Donor Cell Engraftment|Immune Reconstitution|Disease Relapse or Progression|Cumulative Incidence of Transplant-Related Mortality|Frequency of Grade 3 or Greater Toxicities|Incidence of Grade 2 and 3 Infections|Overall Survival|Disease-free Survival|GVHD Survival","https://ClinicalTrials.gov/show/NCT02208037"
1570,"NCT01502982","Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)","Completed","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: R-CHOEP14x6+HD-AraC+HD-Mtx","Nordic Lymphoma Group|Amgen","All","18 Years to 64 Years   (Adult)","Phase 2","160","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NLG-LBC-04|2004-003075-37","December 21, 2011","November 2004","May 2014","September 27, 2014","September 2014","No Study Results Posted","CRY-04","December 2013","Time to treatment failure|Number of participants with adverse events|Clinical response rate|Time to progression|Overall survival|Incidence of CNS relapse|Molecular factors important for clinical outcome","https://ClinicalTrials.gov/show/NCT01502982"
1571,"NCT00903812","IMPACT Non Hodgkins Lymphoma (NHL) Study","Completed","No Results Available","Non-Hodgkin's Lymphoma","Other: No intervention","Amgen","All","18 Years and older   (Adult, Senior)","","1837","Industry","Observational","","20060297","May 14, 2009","February 2007","March 2014","July 14, 2014","July 2014","No Study Results Posted","null","December 2008","Proportion of subjects who had an investigator assessed risk of FN ≥20% and received primary prophylaxis G-CSF","https://ClinicalTrials.gov/show/NCT00903812"
1572,"NCT03089203","CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer","Recruiting","No Results Available","Prostate Cancer","Biological: CART T cells|Biological: CART T cells|Drug: Cyclophosphamide 1g/m^2|Biological: CART T cells","University of Pennsylvania","Male","18 Years and older   (Adult, Senior)","Phase 1","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: No masking|Primary Purpose: Treatment","826250","March 20, 2017","March 8, 2017","September 8, 2021","March 23, 2017","March 2017","No Study Results Posted","null","September 8, 2020","I. Adverse Events experienced by subjects infused with CART-PSMA- TGFβRDN cells|II. Assess the clinical anti-tumor effect of CART-PSMA- TGFβRDN cells|III. Assess the clinical anti-tumor effect of CART-PSMA- TGFβRDN cells|IV. Assess the clinical anti-tumor effect of CART-PSMA- TGFβRDN cells","https://ClinicalTrials.gov/show/NCT03089203"
1573,"NCT00000801","Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma","Completed","No Results Available","Lymphoma, Non-Hodgkin|HIV Infections","Drug: Filgrastim|Drug: Vincristine sulfate|Drug: Doxorubicin hydrochloride|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone","National Institute of Allergy and Infectious Diseases (NIAID)","All","16 Years and older   (Child, Adult, Senior)","Phase 2","33","NIH","Interventional","Primary Purpose: Treatment","ACTG 252|ECOG E 1493","November 2, 1999","null","April 1998","October 31, 2012","October 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00000801"
1574,"NCT00060346","Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia","Terminated","Has Results","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Drug: Vincristine","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","16","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000301634|U10CA021115|E1A02","May 6, 2003","June 2004","August 2012","February 11, 2013","February 2013","January 10, 2013","null","December 2011","Objective Response to Treatment","https://ClinicalTrials.gov/show/NCT00060346"
1575,"NCT01585415","Vemurafenib and White Blood Cell Therapy for Advanced Melanoma","Terminated","No Results Available","Metastatic Cancer|Melanoma","Drug: Vemurafenib|Biological: Young TIL|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 66 Years   (Adult, Senior)","Phase 1","12","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","120114|12-C-0114","April 24, 2012","April 9, 2012","June 30, 2017","May 12, 2017","July 21, 2016","No Study Results Posted","null","June 30, 2017","Determine the safety of the administration of vemurafenib in conjunction with ACT consisting of autologous TIL infused along with high dose aldesleukin following a non-myeloablative lymphodepleting preparative regimen.","https://ClinicalTrials.gov/show/NCT01585415"
1576,"NCT02877303","Hyper-CVAD Regimen in Sequential Combination With Blinatumomab as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia","Recruiting","No Results Available","Leukemia|Acute Lymphoblastic Leukemia","Drug: Cyclophosphamide|Drug: MESNA|Drug: Dexamethasone|Drug: Ofatumumab|Drug: Methotrexate|Drug: Doxorubicin|Drug: Vincristine|Drug: Cytarabine|Drug: Rituximab|Drug: Pegfilgrastim|Drug: G-CSF|Drug: Leucovorin|Drug: Blinatumomab|Drug: 6-Mercaptopurine|Drug: Prednisone|Behavioral: Phone Calls","M.D. Anderson Cancer Center|Amgen","All","14 Years and older   (Child, Adult, Senior)","Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2014-0845","August 19, 2016","November 2016","November 2020","March 24, 2017","March 2017","No Study Results Posted","null","November 2020","Relapse-Free Survival","https://ClinicalTrials.gov/show/NCT02877303"
1577,"NCT00022230","Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer","Withdrawn","No Results Available","Breast Cancer","Biological: aldesleukin|Biological: filgrastim|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel","Roger Williams Medical Center","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000068797|RWMC-0633846","August 10, 2001","January 2000","January 2007","May 4, 2015","May 2015","No Study Results Posted","null","January 2007","Toxicity|Disease-free survival|Overall survival|Immune functions","https://ClinicalTrials.gov/show/NCT00022230"
1578,"NCT00290433","Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma","Completed","No Results Available","Lymphoma","Drug: Cyclophosphamide|Drug: Mesna|Drug: Vincristine|Drug: Methotrexate|Drug: Ara-C|Drug: Dexamethasone|Drug: G-CSF|Drug: Doxil","M.D. Anderson Cancer Center|Ortho Biotech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","55","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID03-0004|NCI-2010-00445","February 10, 2006","September 2003","July 2015","July 13, 2015","July 2015","No Study Results Posted","null","July 2015","Progression-Free Survival","https://ClinicalTrials.gov/show/NCT00290433"
1579,"NCT03089411","Collection of Additional Data Followed the Study IFM 2013-04","Active, not recruiting","No Results Available","Myeloma Multiple","","Nantes University Hospital","All","18 Years to 66 Years   (Adult, Senior)","","340","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","RC13_0284_03","March 20, 2017","March 20, 2017","July 15, 2017","March 23, 2017","March 2017","No Study Results Posted","null","July 15, 2017","Number of death","https://ClinicalTrials.gov/show/NCT03089411"
1580,"NCT02134262","Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes","Unknown status","No Results Available","Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","Drug: Cyclophosphamide or Bendamustine|Genetic: Dose Level -1|Genetic: Dose Level 1|Genetic: Dose Level 2|Genetic: Dose Level 3","Jichi Medical University|Takara Bio Inc.","All","20 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JMU-CD19CAR","April 16, 2014","May 2014","March 2017","November 4, 2014","November 2014","No Study Results Posted","null","March 2017","Toxicity Profile|Quality test of CD19-CAR-T|Tumor shrinkage effect|Lymphocyte subset analysis of CD19-CAR-T|Human anti-mouse antibody (HAMA) test","https://ClinicalTrials.gov/show/NCT02134262"
1581,"NCT02529839","Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)","Not yet recruiting","No Results Available","Multiple Sclerosis","Procedure: Autologous bone marrow transplantation|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Alemtuzumab","Hadassah Medical Organization","All","18 Years to 65 Years   (Adult)","","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0105-15-HMO-CTIL","June 10, 2015","October 2015","October 2017","August 19, 2015","April 2015","No Study Results Posted","null","October 2017","Engraftment parameters of Neutrophils and Platelets|Transplant related mortality by Day 100|Changes in the Expanded Disability Status Scale (EDSS score, as compared to baseline)|Overall survival (OS) at 1 year|Progression-free survival (PFS) at 1 year|Changes in MRI activity","https://ClinicalTrials.gov/show/NCT02529839"
1582,"NCT00945724","Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis","Recruiting","No Results Available","Large B-cell Diffuse Lymphoma of Testis","Drug: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate","International Extranodal Lymphoma Study Group (IELSG)","Male","18 Years to 80 Years   (Adult, Senior)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IELSG30|EudraCT Number 2009-011789-26","July 23, 2009","April 2009","December 2019","January 23, 2017","January 2017","No Study Results Posted","IELSG30","December 2017","Adverse events assessments|Activity of the drugs","https://ClinicalTrials.gov/show/NCT00945724"
1583,"NCT00719472","A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)","Completed","Has Results","Non-Hodgkin's Lymphoma","Drug: Rituximab|Drug: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)|Drug: CVP (cyclophosphamide, vincristine, prednisone)|Drug: Analgesic/antipyretic and antihistamine drugs","Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 3","451","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","U4391g","July 18, 2008","July 2008","May 2011","April 10, 2017","April 2017","May 24, 2012","RATE","May 2011","Percentage of Patients Who Developed Grade 3 or 4 Infusion-related Reactions (IRR) Resulting From Faster Infusion of Rituximab During Days 1 and 2 of Cycle 2|Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 1|Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 2 Through Cycle 6 or 8 (End of Study)|Duration of Rituximab Infusion Including Dose Interruption Times|Maximum Serum Concentration (Cmax) of Rituximab Post-dose at the First Alternative Dosing Rate (Cycle 2) and the Last Cycle (Either Cycle 6 or 8)|Percentage of Patients Who Had Undetectable Levels of CD19+ Lymphocytes at Cycle 2 and Either Cycle 6 or 8 (Last Cycle)","https://ClinicalTrials.gov/show/NCT00719472"
1584,"NCT00365274","SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma","Terminated","Has Results","Anaplastic Large Cell Lymphoma","Drug: Cyclophosphamide|Drug: Doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Drug: SGN-30","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","6","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00162|2005-0627|N01CM62202|N01CM17003","August 16, 2006","August 2006","May 2010","May 29, 2014","November 2013","September 13, 2013","null","May 2010","Objective Response Rate (ORR)","https://ClinicalTrials.gov/show/NCT00365274"
1585,"NCT00634881","Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia","Completed","No Results Available","Chronic Lymphocytic Leukemia","Biological: Alemtuzumab i.v.|Biological: Alemtuzumab s.c.","German CLL Study Group","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","13","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLL2i|CDR0000587746","March 12, 2008","November 2003","January 2010","November 22, 2016","September 2016","No Study Results Posted","null","January 2010","Dose-limiting toxicity|Maximum tolerated dose|Rate of complete minimal residual disease response|Rate of immunophenotypic remission using 4-color flow cytometry|Rate of infections (especially CMV infections and reactivations)|Rate of severe hematologic and non-hematologic side effects|Pharmacokinetics of alemtuzumab (after IV and subcutaneous administration)|Progression-free survival|Overall survival|Complete remission rate","https://ClinicalTrials.gov/show/NCT00634881"
1586,"NCT01495572","Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells","Terminated","Has Results","Metastatic Melanoma|Skin Cancer","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Aldesleukin|Drug: MART-1 Reactive CD8+ PBL","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","5","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","120045|12-C-0045","December 16, 2011","December 2011","February 2014","October 13, 2015","October 2015","May 8, 2014","null","February 2014","Clinical Tumor Response|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT01495572"
1587,"NCT00886522","Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies","Completed","No Results Available","Hematological Malignancies","Procedure: Intrabone cord blood infusion","St. Orsola Hospital","All","18 Years to 65 Years   (Adult)","Phase 2","23","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","152/2008/U/Sper","April 22, 2009","April 2009","May 2013","April 14, 2016","April 2016","No Study Results Posted","IBCB","May 2012","Proportion of transplanted patients with successful engraftment at day +42|Clinical response with the analysis of global survival, survival without relapse, relapse incidence|Acute and chronic GVHD incidence|Infection incidence|Chimerism study on selected populations (myeloid, lymphoid, NK)|Studies on immunological reconstitution","https://ClinicalTrials.gov/show/NCT00886522"
1588,"NCT01914718","Dose-adjusted EPOCH-R in MYC Positive DLBCL","Terminated","No Results Available","Diffuse Large B-cell Lymphoma","Drug: DA-EPOCH-R","Fudan University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LMTG 13-02","March 2, 2013","February 2013","December 2017","August 19, 2014","August 2014","No Study Results Posted","null","December 2015","3-year progression-free survival|Objective response rate|3-year overall survival|Toxicity","https://ClinicalTrials.gov/show/NCT01914718"
1589,"NCT02375984","A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas","Recruiting","No Results Available","Metastatic Melanoma","Biological: Tumor Infiltrating Lymphocytes (TIL)","John Wayne Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 2","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","TIL-TREATMENT-0614","February 25, 2015","February 2015","February 2018","February 3, 2017","February 2017","No Study Results Posted","TIL","February 2018","Clinical Response|Quality of Life","https://ClinicalTrials.gov/show/NCT02375984"
1590,"NCT01690702","Study of Nab-Paclitaxel in High Risk Early Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Epirubicin|Drug: nab-Paclitaxel|Drug: Cyclophosphamide|Drug: Docetaxel","German Breast Group|Celgene Corporation|Amgen","Female","18 Years and older   (Adult, Senior)","Phase 3","2886","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GBG 68","August 29, 2012","September 2012","December 2020","February 9, 2016","February 2016","No Study Results Posted","GAIN-2","January 2020","invasive disease-free survival (IDFS)|locoregional relapse-free survival (LRRFS)|overall survival (OS)|distant disease-free survival (DDFS)|local relapse-free survival (LRFS)|regional relapse-free survival (RRFS)|brain metastasis free survival (in the subgroup of TNBC and HER2+)|compliance|safety|side effects of taxane|treatment effects by intrinsic subtypes|Ovarian substudy|Pharmacogenetic substudy|biology of lymph node metastases","https://ClinicalTrials.gov/show/NCT01690702"
1591,"NCT00795678","Chemotherapeutic Agents in Brain/Breast","Completed","No Results Available","Breast Cancer|Metastatic Cancer","Drug: capecitabine|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: gemcitabine hydrochloride|Drug: lapatinib ditosylate|Drug: paclitaxel|Drug: vinorelbine ditartrate|Drug: Trastuzumab","Case Comprehensive Cancer Center|United States Department of Defense|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","","10","Other|U.S. Fed|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CASE4107|P30CA043703|CASE 4107","November 20, 2008","September 2008","April 2013","July 31, 2013","July 2013","No Study Results Posted","null","April 2013","Concentration of drug","https://ClinicalTrials.gov/show/NCT00795678"
1592,"NCT00187161","Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL","Completed","No Results Available","Non-Hodgkin Lymphoma|Acute Lymphoblastic Leukemia, Mature B-Cell","Drug: Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin","St. Jude Children's Research Hospital","All","up to 18 Years   (Child, Adult)","Phase 2","68","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SJBCII","September 13, 2005","November 1994","January 2007","June 3, 2008","June 2008","No Study Results Posted","null","null","The purpose of this study is estimate the complete response, event-free survival, and overall survival in patients with small non-cleaved cell non-Hodgkin lymphoma or large cell NHL, or Burkitt leukemia/B-cell ALL treated with a modified LMP-89 regimen.","https://ClinicalTrials.gov/show/NCT00187161"
1593,"NCT00091611","Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer","Terminated","No Results Available","Kidney Neoplasms","Drug: IL-2 (interleukin-2)|Drug: OKT3|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Mesna","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 1","3","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","040277|04-C-0277","September 11, 2004","September 2004","March 2008","October 25, 2012","October 2012","No Study Results Posted","null","April 2006","Determine whether Adoptive Lymphocyte Transfer in Conjunction with Preparative Lympho-depletion Chemotherapy and Interleukin-2 (IL-2) May result in Clinical Tumor Regression in Metastatic Renal Cancer","https://ClinicalTrials.gov/show/NCT00091611"
1594,"NCT00392327","Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma","Recruiting","No Results Available","Untreated Childhood Medulloblastoma|Untreated Childhood Pineoblastoma|Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor","Radiation: Radiation Therapy|Drug: Vincristine Sulfate|Drug: Carboplatin|Drug: Cisplatin|Drug: Cyclophosphamide|Biological: Filgrastim|Drug: Isotretinoin|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 3","400","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ACNS0332|NCI-2009-00336|COG-ACNS0332|CDR0000511991|R01CA114567|U10CA180886|U10CA098543","October 25, 2006","March 2007","null","August 19, 2016","August 2016","No Study Results Posted","null","June 2018","Event-free survival (EFS) percentage|Tumor response to radiation therapy with or without carboplatin|Time to death","https://ClinicalTrials.gov/show/NCT00392327"
1595,"NCT02647255","Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy","Enrolling by invitation","No Results Available","Glomerulonephritis, IGA|Kidney Diseases|Acute Renal Insufficiency|Rapidly Progressive Glomerulonephritis","Procedure: Plasma Exchange (PE)|Drug: Methylprednisolone pulse","Peking University First Hospital","All","14 Years to 65 Years   (Child, Adult)","Phase 2|Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","RESCUE","December 21, 2015","December 2015","December 2019","April 4, 2017","April 2017","No Study Results Posted","RESCUE","December 2018","End-stage renal disease or death|Renal remission|Proteinuria remission","https://ClinicalTrials.gov/show/NCT02647255"
1596,"NCT02063022","Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma","Recruiting","No Results Available","Ewing's Sarcoma","Drug: Standard treatment (as per protocol ISG SSG III)|Drug: Intensified chemotherapy","Italian Sarcoma Group","All","up to 40 Years   (Child, Adult)","Phase 3","220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ISG/AIEOP EW-1","February 21, 2013","February 2009","December 2017","April 26, 2017","March 2017","No Study Results Posted","EW-1","December 2017","Event Free Survival (EFS)|Disease Free Survival (DFS)|Metastasis Free Survival|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02063022"
1597,"NCT00005797","Bone Marrow Transplant in Treating Patients With Hematologic Cancers","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Multiple Myeloma and Malignant Plasma Cell Neoplasms|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Drug: busulfan|Drug: Cyclophosphamide|Drug: VP-16|Radiation: Fractionated Total Body Irradiation (FTBI)","H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)","All","15 Years to 55 Years   (Child, Adult)","Phase 2","125","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MCC-11281|MCC-IRB-4188|NCI-G00-1759","June 2, 2000","March 1993","July 2007","October 24, 2012","October 2012","No Study Results Posted","null","July 2007","Relapse-free survival","https://ClinicalTrials.gov/show/NCT00005797"
1598,"NCT02420717","Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)","Recruiting","No Results Available","Leukemia","Drug: Ruxolitinib|Drug: Dasatinib|Drug: Rituximab|Drug: G-CSF|Drug: Pegfilgrastim|Drug: Methotrexate|Drug: Cytarabine|Drug: Cyclophosphamide|Drug: Mesna|Drug: Doxorubicin|Drug: Vincristine|Drug: Dexamethasone|Drug: Solumedrol|Drug: 6-mercaptopurine|Drug: Prednisone|Drug: Leucovorin","M.D. Anderson Cancer Center|Incyte Corporation","All","10 Years and older   (Child, Adult, Senior)","Phase 2","92","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2014-0521|NCI-2015-00779","April 15, 2015","July 2015","null","November 18, 2016","November 2016","No Study Results Posted","null","July 2023","Response Rate (CR/CRi) of Ruxolitinib or Dasatinib in Combination With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)","https://ClinicalTrials.gov/show/NCT02420717"
1599,"NCT01759732","Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic Anemia","Unknown status","No Results Available","Acquired Aplastic Anemia","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: anti-thymocyte globulin|Biological: filgrastim|Radiation: Total body irradiation|Procedure: CD3-depleted hematopoietic cell transplantation","Asan Medical Center","All","up to 21 Years   (Child, Adult)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMCPHO-SCT1202","December 30, 2012","September 2012","December 2015","December 30, 2012","December 2012","No Study Results Posted","null","December 2014","To assess engraftment rate and survival of haploidentical stem cell transplantation with fixed dose of T cells after in vitro T cell depletion using CD3 monoclonal antibody for children with acquired severe aplastic anemia|To assess engraftment and graft failure|To estimate the risk of acute GVHD|To assess treatment related mortality|To estimate overall survival and failure free survival","https://ClinicalTrials.gov/show/NCT01759732"
1600,"NCT01998906","A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Trastuzumab|Drug: Doxorubicin|Drug: Paclitaxel|Drug: CMF","Hoffmann-La Roche","Female","18 Years and older   (Adult, Senior)","Phase 3","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MO16432","November 25, 2013","May 2002","July 2012","October 24, 2014","October 2014","July 18, 2014","null","July 2012","Event-Free Survival (EFS) - Percentage of Participants With an Event|Event-Free Survival|Percentage of Participants Event Free at 1 Year|Percentage of Participants Event Free at 2 Years|Percentage of Participants Event Free at 3 Years|Percentage of Participants With Breast Pathological Complete Response (bpCR)|Percentage of Participants With Total Pathological Complete Response (tpCR)|Percentage of Participants Achieving Either Complete Response (CR) or Partial Response (PR) According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) Criteria|Overall Survival (OS) - Percentage of Participants With an Event|Overall Survival|Percentage of Participants Surviving at 1 Year|Percentage of Participants Surviving at 2 Years|Percentage of Participants Surviving at 3 Years","https://ClinicalTrials.gov/show/NCT01998906"
1601,"NCT01319565","Prospective Randomized Study of Cell Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction w/1200 TBI","Active, not recruiting","No Results Available","Metastatic Melanoma|Skin Cancer","Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Young Tumor Infiltrating Lymphocytes|Procedure: 1200 Gy Irradiation","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 66 Years   (Adult, Senior)","Phase 2","102","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","110123|11-C-0123","March 18, 2011","March 9, 2011","June 1, 2020","May 12, 2017","December 12, 2016","No Study Results Posted","null","June 1, 2019","Determine the objective response rate and survival of melanoma patients receiving young TL plus aldesleukin treatment following either chemo preparative regimen alon or the same chemotherapy preparative regimen plus total body radiation","https://ClinicalTrials.gov/show/NCT01319565"
1602,"NCT00801281","First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.","Active, not recruiting","No Results Available","Follicular Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone 1|Drug: Prednisone 2","Polish Lymphoma Research Group","All","18 Years and older   (Adult, Senior)","Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","R-CVP/CHOP","December 2, 2008","February 2007","June 2017","February 21, 2017","February 2016","No Study Results Posted","PLRG4","June 2017","Event Free Survival|Response Rate","https://ClinicalTrials.gov/show/NCT00801281"
1603,"NCT00923390","Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor","Terminated","No Results Available","Renal Cancer|Kidney Cancer","Genetic: 2G-1 TCR Retroviral Vector-Transduced lyn|Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: (PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 1","5","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","090092|09-C-0092","June 17, 2009","March 2, 2009","August 24, 2012","May 12, 2017","August 24, 2012","No Study Results Posted","null","August 24, 2012","Determine if the administration of T-cells retrovirally transduced with the 2G-1 TCR, with preparative chemotherapy and IL-2, can cause the regression of metastatic RCC, and to identify the maximum tolerated dose for the 2G-1 TCr transduced cell...|Determine the toxicities of these T-cells administered in the above fashion, and to determine TCR and vector presence in the post treatment phase.","https://ClinicalTrials.gov/show/NCT00923390"
1604,"NCT00167219","Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)","Recruiting","No Results Available","Juvenile Myelomonocytic Leukemia","Biological: Stem Cell Transplant|Drug: Preparative Regimen","Masonic Cancer Center, University of Minnesota","All","up to 18 Years   (Child, Adult)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","1999LS073|MT1999-20|9911M24961","September 9, 2005","November 18, 1999","December 2020","February 17, 2017","February 2017","No Study Results Posted","null","December 2020","Determine probability of long-term disease free survival in JMML|Secondary outcome measures are the incidence of neutrophil engraftment, graft-versus-host disease (GVHD), regimen-related toxicity, and relapse.","https://ClinicalTrials.gov/show/NCT00167219"
1605,"NCT00002498","Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: CMF regimen|Drug: cyclophosphamide|Drug: fluorouracil|Drug: methotrexate|Drug: mitoxantrone hydrochloride","Leiden University Medical Center|National Cancer Institute (NCI)","All","70 Years and older   (Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000077804|DUT-KWF-CKVO-9008|EU-92006","November 1, 1999","July 1992","null","December 17, 2013","May 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002498"
1606,"NCT00036868","Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: trastuzumab|Drug: CMF regimen|Drug: cyclophosphamide|Drug: fluorouracil|Drug: methotrexate","European Organisation for Research and Treatment of Cancer - EORTC","Female","18 Years and older   (Adult, Senior)","Phase 2","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-10995-16999|EORTC-10995|EORTC-16999|IDBBC-EORTC-10995","May 13, 2002","February 2002","null","June 6, 2013","June 2013","No Study Results Posted","null","June 2009","Clinical heart failure rate measured by New York Heart Association classification, LVEF, and ECG|Response rate by RECIST|Duration of response by RECIST|Time to progression|Toxicity measured by CTC v2.0","https://ClinicalTrials.gov/show/NCT00036868"
1607,"NCT00578539","T-Reg Cell Kinetics, Stem Cell Transplant, REGALE","Terminated","Has Results","Leukemia|Hodgkin Lymphoma|Non Hodgkin Lymphoma|Myeloproliferative Disorders","Drug: ARA C|Drug: Cyclophosphamide|Drug: MESNA|Radiation: Total Body Irradiation (TBI)|Biological: Campath-1h|Procedure: Stem Cell Infusion","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital","All","Child, Adult, Senior","","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-21079-REGALE|REGALE","December 19, 2007","October 2007","May 2013","March 24, 2016","March 2016","August 28, 2014","REGALE","May 2013","Median Percentage of Treg Cells at 1 Year Post Transplant","https://ClinicalTrials.gov/show/NCT00578539"
1608,"NCT00003012","Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: CMF regimen|Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: methotrexate","Scottish Cancer Therapy Network|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","1000","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065590|SCTN-BR9601|EU-97013","November 1, 1999","October 1996","null","November 5, 2013","November 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003012"
1609,"NCT00723125","Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Abraxane|Drug: Carboplatin|Drug: Avastin","William Sikov|Yale University|Brown University","Female","19 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BrUOG-BR-211A","July 15, 2008","September 2008","June 2014","October 14, 2014","October 2014","July 17, 2014","null","June 2014","Pathological Complete Response Rates at Surgery|Measure of Safety and Tolerability According to CTC Version 3.0","https://ClinicalTrials.gov/show/NCT00723125"
1610,"NCT00067002","Randomized Double Cord Blood Transplant Study","Completed","No Results Available","Leukemia, Lymphocytic, Acute|Leukemia, Myelocytic, Acute|Leukemia, Myeloid, Chronic|Lymphoma, Non-Hodgkin","Procedure: Expanded allogeneic cord blood (CB)|Procedure: One Unmanipulated and One Expanded Cord Blood Unit|Drug: Rituxan|Drug: Melphalan|Drug: Thiotepa|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Mesna|Radiation: Total body irradiation (TBI)","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Cellgenix","All","1 Month to 80 Years   (Child, Adult, Senior)","Phase 2","110","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ID02-407|CA061508|NCI-2012-01299","August 8, 2003","April 2003","July 2016","July 15, 2016","July 2016","No Study Results Posted","null","July 2016","Time To Engraftment|Engraftment","https://ClinicalTrials.gov/show/NCT00067002"
1611,"NCT00005804","Bone Marrow Transplantation in Treating Patients With Hematologic Cancer","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Small Intestine Cancer","Drug: cyclophosphamide|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 50 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","1467.00|FHCRC-1467.00|NCI-H00-0054|CDR0000067780","June 2, 2000","October 1999","August 2002","March 31, 2010","March 2010","No Study Results Posted","null","August 2002","","https://ClinicalTrials.gov/show/NCT00005804"
1612,"NCT00002553","Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer","Completed","No Results Available","Leukemia|Lymphoma","Drug: cyclophosphamide|Procedure: allogeneic bone marrow transplantation|Radiation: low-LET cobalt-60 gamma ray therapy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 55 Years   (Child, Adult)","Phase 2","50","Other|NIH","Interventional","Primary Purpose: Treatment","160.06|CDR0000063397|NCI-H94-0372","November 1, 1999","August 1990","June 2003","November 28, 2011","November 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002553"
1613,"NCT01421472","A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer","Completed","Has Results","ER Positive, Her2 Negative Breast Cancer Patients|Triple Negative Breast Cancer Patients","Drug: MM-121|Drug: Paclitaxel","Merrimack Pharmaceuticals|Sanofi","Female","18 Years and older   (Adult, Senior)","Phase 2","196","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MM-121-02-02-07 (ARD11918)","August 19, 2011","August 2011","June 2014","March 30, 2016","March 2016","February 14, 2016","null","December 2013","Number of Participants With Pathologic Complete Response (pCR) (Rate of pCR)","https://ClinicalTrials.gov/show/NCT01421472"
1614,"NCT00670878","Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: 3 x FEC 3 x DOC / Gemcitabine|Drug: 3 x FEC 3 x DOC","Ludwig-Maximilians - University of Munich","Female","18 Years and older   (Adult, Senior)","Phase 3","799","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","SUCCESS-B","April 30, 2008","June 2008","null","March 31, 2012","March 2012","No Study Results Posted","null","October 2011","Disease free survival|Overall survival time after randomization|Distant disease free survival|Toxicity|Changes in quality of life over time as defined by EORTC QLQ-C30 and QLQBR23 questionnaire|Skeletal related events|Incidence of secondary primaries|Endpoints of adjunct translational research program","https://ClinicalTrials.gov/show/NCT00670878"
1615,"NCT00002858","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer","Unknown status","No Results Available","Lung Cancer","Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Radiation: radiation therapy","Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute (NCI)","All","up to 69 Years   (Child, Adult, Senior)","Phase 3","280","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065122|FRE-CPC014|EU-96009","November 1, 1999","March 1993","null","February 6, 2009","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002858"
1616,"NCT02268045","Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma","Active, not recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Biological: RTXM83","mAbxience S.A|Pisa Farmacética|Laboratorios de Productos Éticos C.E.I.S.A.|Laboratorio Elea S.A.C.I.F. y A.|Tecnoquímicas S.A.|Innogene Kalbiotech Pte. Ltd|Libbs Farmacêutica Ltda|Key Oncologics (Pty) Ltd|Nanolek LLC|Actoverco","All","18 Years to 65 Years   (Adult)","Phase 3","256","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","RTXM83-AC-01-11","September 19, 2014","May 2013","July 2017","December 22, 2016","May 2016","No Study Results Posted","null","May 2016","Response Rate|To evaluate Event Free Survival (EFS) in both treatment arms|To evaluate Safety in both arms|To demonstrate comparable pharmacokinetics of RTXM83 and Rituximab|To demonstrate comparable pharmacodynamics|To compare immunogenicity between both arms","https://ClinicalTrials.gov/show/NCT02268045"
1617,"NCT00394251","Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Adriamycin and Cytoxan (AC)|Drug: ABI-007|Drug: Taxol|Drug: Bevacizumab|Drug: pegfilgrastim","Celgene Corporation|Celgene","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","197","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CA045","October 30, 2006","August 2006","February 2008","August 8, 2013","August 2013","November 2, 2010","null","March 2007","Participants With Treatment-Emergent Toxicities With a Frequency >=20% at 3 Months Post Chemotherapy|Participants With Treatment-Emergent Toxicities With a Frequency >=20% at 6 Months Post Chemotherapy|The Cumulative Dose of Taxane Delivered During Study|Mean Taxane Dose Intensity Per Week|Percent of Protocol Taxane Dose|Summary of Participant Treatment Exposure, Dose Interruptions, Dose Reductions, and Dose Delays|Myelosuppression During Taxane Dosing Cycles|Change From Baseline in Percent Left Ventricular Ejection Fraction (% LVEF) at the Final Evaluation|Summary of Participants' Most Severe Grade for Liver and Renal Function Laboratory Adverse Experiences During Study (All Treatment Cycles)","https://ClinicalTrials.gov/show/NCT00394251"
1618,"NCT02637375","A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer","Withdrawn","No Results Available","Breast Cancer","Drug: Ganetespib|Drug: Paclitaxel|Drug: Doxorubicin|Drug: Cyclophosphamide","University of Chicago","Female","18 Years and older   (Adult, Senior)","","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB15-0848","December 17, 2015","May 2016","December 2018","May 26, 2016","May 2016","No Study Results Posted","null","December 2018","Change in GR protein|Pathological Complete Response (pCR) rate|Ganetespib toxicity","https://ClinicalTrials.gov/show/NCT02637375"
1619,"NCT02809573","Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients","Not yet recruiting","No Results Available","Peripheral T-cell Lymphoma","Drug: Chidamide|Drug: cyclophosphamide|Drug: adriacin|Drug: vincristine|Drug: prednisone","Chipscreen Biosciences, Ltd.","All","18 Years to 65 Years   (Adult)","Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDM103","June 17, 2016","July 2016","December 2019","June 20, 2016","June 2016","No Study Results Posted","null","July 2019","dose-limiting toxicity (DLT)|Adverse events|complete response rate|Duration of response|Progression free survival|Objective response rate|Overall survival|Area under the concentration versus time curve (AUC)|Peak plasma concentration (Cmax)|Time of Cmax (Tmax)","https://ClinicalTrials.gov/show/NCT02809573"
1620,"NCT00003553","Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer","Unknown status","No Results Available","Kidney Cancer","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: methotrexate|Drug: mycophenolate mofetil","National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","80","NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000066610|NHLBI-97-H-0196","November 1, 1999","January 1999","null","June 23, 2009","June 2009","No Study Results Posted","null","December 2009","Graft vs tumor effect as measured by CT scan at days 30, 60, and 100 following transplant|Disease-free survival as measured by CT scan at 6 months and 1 year","https://ClinicalTrials.gov/show/NCT00003553"
1621,"NCT01369875","Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma","Completed","Has Results","Metastatic Melanoma|Skin Cancer","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Aldesleukin|Biological: Tumor Infiltrating Lymphocytes","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","2","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","110163|11-C-0163","June 8, 2011","May 2011","November 2012","October 6, 2015","September 2015","February 14, 2013","null","November 2012","Clinical Tumor Regression.|Toxicity","https://ClinicalTrials.gov/show/NCT01369875"
1622,"NCT01993719","Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma","Recruiting","No Results Available","Metastatic Melanoma","Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Young Tumor Infiltrating Lymphocytes (Young TIL)|Drug: Keytruda (pembrolizumab) - ONLY FOR RETREATMENT","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","64","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","140022|14-C-0022","November 22, 2013","November 19, 2013","September 30, 2019","May 12, 2017","March 28, 2017","No Study Results Posted","null","October 1, 2018","Determine if there is a difference in the rate of response between patients who have received prior anti-PD1 and those who have not.|Evaluate progression free and overall survival.|Evaluate the safety and efficacy of pembrolizumab in combination with TIL therapy.","https://ClinicalTrials.gov/show/NCT01993719"
1623,"NCT02876510","ACTolog in Patients With Solid Cancers","Not yet recruiting","No Results Available","Cancer|Solid Tumor","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: IMA101 T-cell product|Biological: Recombinant human interleukin-2|Diagnostic Test: IMA101_Detect","Immatics US, Inc.|M.D. Anderson Cancer Center","All","18 Years to 65 Years   (Adult)","Phase 1","31","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IMA101-101","August 8, 2016","July 1, 2017","August 31, 2019","May 15, 2017","May 2017","No Study Results Posted","ACTolog","February 28, 2019","Incidence of adverse events (Safety and tolerability)|Incidence of successfully manufactured personalized T-cell products per patient (Feasibility of the ACTolog process)|Peripheral T-cell persistence (assessment of frequency of T-cells over time)|T-cell functionality as assessed by cellular immunomonitoring|Incidence of clinical responders|Description of overall survival (OS)|Description of progression-free survival (PFS)|Determine and report the success rate of completely evaluable results of IMA101_Detect from all biopsies collected","https://ClinicalTrials.gov/show/NCT02876510"
1624,"NCT01822652","3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN","Active, not recruiting","No Results Available","Neuroblastoma","Genetic: iC9-GD2 T Cell Lymphocytes-frozen cells|Genetic: iC9-GD2 T Cell Lymphocytes-fresh cells|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: pembrolizumab|Genetic: iC9-GD2 T Cell Lymphocytes-fresh cells","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System|Solving Kids’ Cancer|The EVAN Foundation|National Cancer Institute (NCI)|Kids' Cancer Research Foundation","All","Child, Adult, Senior","Phase 1","11","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-31493 GRAIN|P01CA094237","March 28, 2013","August 2013","October 2030","January 9, 2017","January 2017","No Study Results Posted","GRAIN","December 2015","Dose limiting toxicities at 6 weeks post T cell infusion|To evaluate the expansion and persistence of 3rd generation iC9-GD2 T cells|Time to progression of disease|Change in serum cytokine and chemokine levels","https://ClinicalTrials.gov/show/NCT01822652"
1625,"NCT00570180","Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Drug: Bortezomib","University Health Network, Toronto|Princess Margaret Hospital, Canada|Ortho Biotech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","26866138-MMY-2016|t4;14 trial PMH","December 6, 2007","November 2007","September 2016","December 1, 2016","December 2016","No Study Results Posted","null","September 2015","To determine the time to progression (TTP) with this treatment regimen|To determine the objective response rate/duration following DBd induction and Cybor P post induction therapy|To determine PFS|To determine overall survival|To determine the safety profile of this regimen","https://ClinicalTrials.gov/show/NCT00570180"
1626,"NCT00003204","Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma","Completed","No Results Available","Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Small Lymphocytic Lymphoma","Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: vincristine sulfate|Drug: prednisone|Biological: rituximab|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","515","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02972|E1496|U10CA021115|CDR0000066056","May 2, 2000","March 1998","null","February 26, 2013","February 2013","No Study Results Posted","null","May 2006","Time to treatment failure","https://ClinicalTrials.gov/show/NCT00003204"
1627,"NCT00368355","T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Non Hodgkins Lymphoma|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Chronic Myelogenous Leukemia|Hemophagocytic Lymphohistiocytosis (HLH)|Familial Hemophagocytic Lymphohistiocytosis (FLH)|Viral-associated Hemophagocytic Syndrome (VAHS)|X-linked Lymphoproliferative Disease (XLP)","Drug: Ara-C|Drug: Cyclophosphamide|Biological: Campath-1H|Radiation: Total Body Irradiation|Procedure: Stem Cell Infusion","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System","All","up to 55 Years   (Child, Adult)","Phase 2","87","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-8701-MOHEL|MOHEL","September 21, 2005","April 2000","December 2018","December 21, 2016","December 2016","No Study Results Posted","MOHEL","December 2017","Number of patients with severe acute GVHD|Number of patients with engraftment|Number of patients with severe Chronic GVHD|Assessment of immune reconstitution","https://ClinicalTrials.gov/show/NCT00368355"
1628,"NCT00002544","Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: docetaxel|Drug: mitoxantrone hydrochloride","Arbeitsgemeinschaft fur Internistische Onkologie|National Cancer Institute (NCI)","Female","up to 80 Years   (Child, Adult, Senior)","Phase 3","300","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","GER-AIO-01/92|CDR0000063279|EU-93011","November 1, 1999","May 1993","November 2002","August 1, 2013","April 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002544"
1629,"NCT01779206","ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Paclitaxel","West German Study Group","Female","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","4936","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","WSG-AM06 / ADAPT HR+/HER2-","January 25, 2013","May 2012","null","May 18, 2015","May 2015","No Study Results Posted","ADAPT","August 2015","Identification of a responder sub-population with intermediate and high risk, which due to therapy has outcome comparable to HR+/RS≤11|Overall survival","https://ClinicalTrials.gov/show/NCT01779206"
1630,"NCT02298946","AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy in People With Metastatic Colorectal Cancer","Completed","No Results Available","Colorectal Cancer|Colorectal Neoplasms|Colorectal Carcinoma","Drug: AMP-224|Radiation: Stereotactic Body Radiation Therapy(SBRT)|Drug: Cyclophosphamide","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 1","17","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","150021|15-C-0021","November 21, 2014","November 13, 2014","April 7, 2017","May 12, 2017","April 7, 2017","No Study Results Posted","null","July 13, 2016","To assess safety, tolerability and feasibility of AMP-224 in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer|To evaluate response rate, progression-free survival and overall survival in patients with colorectal cancer during and following treatment with AMP-224 in combination with SBRT|To characterize the pharmacokinetic (PK) parameters of AMP-224 in combination with SBRT in patients with metastatic colorectal cancer","https://ClinicalTrials.gov/show/NCT02298946"
1631,"NCT00064116","Combination Chemotherapy With or Without Rituximab in Treating Patients With Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: CHOP regimen","NCIC Clinical Trials Group|Canadian Cancer Trials Group","All","18 Years to 60 Years   (Adult)","Phase 3","824","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LY9|CAN-NCIC-LY9|ROCHE-CAN-NCIC-LY9|MINT-M39045|CDR0000309053","July 8, 2003","May 2001","January 2014","June 23, 2014","June 2014","No Study Results Posted","null","December 2010","Time to treatment failure (TTF) at 3 years|Complete remission rate after completion of treatment|Overall survival at 3 years|Tumor control measured by TTF with non-tumor events censored at 3 years|Disease-free survival (DFS) measured by TTF after an event during and directly after treatment at 3 years|Progression rate determined by dividing the number of patients with disease progression by number of patients with evaluable outcome at 3 years|Time to progression measured at 3 years|Toxicity assessed by NCI CTC v2.0 after completion of treatment","https://ClinicalTrials.gov/show/NCT00064116"
1632,"NCT01144403","A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.","Terminated","Has Results","Diffuse Large B-Cell Lymphoma","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Mitoxantrone|Drug: Rituximab","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML22489|2009-011433-27","June 14, 2010","June 2010","August 2014","August 31, 2016","July 2016","June 20, 2016","null","August 2014","Overall Response Rate (ORR)|Overall Survival (OS)|Progression-free Survival (PFS)|Number of Participant With Adverse Event (AE)","https://ClinicalTrials.gov/show/NCT01144403"
1633,"NCT00578643","Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease","Recruiting","No Results Available","Chronic Granulomatous Disease","Drug: Busulfan|Biological: Alemtuzumab|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Cyclosporine|Procedure: Stem Cell Infusion","Baylor College of Medicine|Texas Children's Hospital","All","Child, Adult, Senior","Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","14771-MUNCHR","December 19, 2007","March 2004","July 2018","January 20, 2017","January 2017","No Study Results Posted","MUNCHR","November 2017","Number of patients that have engraftment after transplant.|Estimating the risk for acute and chronic GVHD and regimen related morbidity/mortality for patients with CGD following SCT from 5/6 or 6/6 HLA-matched unrelated or 5/6 or 6/6 HLA phenotype-matched related donors.|Examining the potential for reversal of organ toxicity (e.g. lung, liver, intestine) following engraftment and stable normal neutrophil function.","https://ClinicalTrials.gov/show/NCT00578643"
1634,"NCT00569985","Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Biological: lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous hematopoietic stem cell transplantation","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","04047|CHNMC-04047|NCI-2012-00437","December 7, 2007","June 2007","July 2017","February 17, 2017","February 2017","No Study Results Posted","null","July 2017","Safety of treatment using the National Cancer Institute (NCI) hematologic Common Terminology Criteria for Adverse Events (CTCAE) version 3.0|Survival of shI-TAR-CCR5RZ-marked cells in the peripheral blood, demonstrated by presence of transgene by Q-PCR using primers specific for rHIV7-shI-TAR-CCR5RZ in serial samples of peripheral blood|Determination of RNA transgene expression in samples of peripheral blood mononuclear cells (PBMCs) or marrow before and after infusion, analyzed by Northern blotting/hybridization|Analysis of vector rescue by HIV|Ability to obtain suitable numbers of lentiviral vector treated HPC-A|Determination of replication competent lentivirus (RCL) and HIV-1/vector recombination","https://ClinicalTrials.gov/show/NCT00569985"
1635,"NCT00379574","Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL","Completed","Has Results","Lymphoma, Large-Cell, Diffuse|Lymphoma, B-Cell","Drug: Bortezomib|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisolone|Drug: Lenograstim","Asan Medical Center|Janssen Korea, Ltd., Korea","All","15 Years to 70 Years   (Child, Adult, Senior)","Phase 1|Phase 2","49","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC 2006-276","September 21, 2006","September 2006","January 2011","March 13, 2013","March 2013","February 4, 2011","null","January 2011","Number of Patients Who Achieved Complete Response|Number of Patients Who Experienced Adverse Events","https://ClinicalTrials.gov/show/NCT00379574"
1636,"NCT02845999","Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab","Completed","No Results Available","Gastrointestinal Metastatic Cancer","Biological: allogenic immunotherapy based on Natural Killer cells adoptive transfer|Biological: cetuximab|Drug: Cyclophosphamide|Drug: fludarabine|Drug: interleukin-2","Centre Hospitalier Universitaire de Besancon|National Cancer Institute, France","All","18 Years to 65 Years   (Adult)","Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","N2005/48-A","December 1, 2011","November 2009","null","July 22, 2016","March 2016","No Study Results Posted","NK-EGFR01","January 2013","number of patients with clinical or biological grade 3 or 4 treatment-related adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02845999"
1637,"NCT00039546","Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery","Unknown status","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: gemcitabine hydrochloride|Drug: paclitaxel|Procedure: adjuvant therapy","Cancer Research Campaign Clinical Trials Centre|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CRC-TU-TANGO|CDR0000069396|EU-20058","June 6, 2002","August 2001","null","August 6, 2013","May 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00039546"
1638,"NCT03151044","R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL","Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: High-dose Epirubicin Combined with CVP ± Rituximab|Drug: Standard-dose Epirubicin Combined with CVP ± Rituximab","FENG Ji-feng|Chinese Anti-Cancer Association|Jiangsu Cancer Institute & Hospital","All","18 Years to 60 Years   (Adult)","Phase 3","408","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2015NL-078","May 9, 2017","July 2016","July 2017","May 10, 2017","May 2017","No Study Results Posted","null","July 2017","Objective Response Rate (ORR)|Time to response (TRR)|Duration of response (DOR)|Progression-free survival (PFS)|Overall survival(OS)","https://ClinicalTrials.gov/show/NCT03151044"
1639,"NCT00968253","RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia","Completed","No Results Available","Leukemia|Acute Lymphocytic Leukemia","Drug: Everolimus (RAD001)|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Doxorubicin|Drug: Dexamethasone|Drug: Mesna|Drug: Methotrexate|Drug: Ara-C (Cytarabine)|Drug: Methylprednisone|Drug: G-CSF","M.D. Anderson Cancer Center|Novartis","All","10 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","24","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-0100|NCI-2011-01814","August 27, 2009","November 2009","December 2015","December 7, 2015","December 2015","No Study Results Posted","null","December 2015","Maximum Tolerated Dose [MTD]|Complete and Overall Response Rate","https://ClinicalTrials.gov/show/NCT00968253"
1640,"NCT02159495","Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","Recruiting","No Results Available","Adult Acute Myeloid Leukemia in Remission|Donor|Early Relapse of Acute Myeloid Leukemia|Late Relapse of Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Blastic Plasmacytoid Dendritic Cell Neoplasm","Drug: cyclophosphamide|Biological: Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes|Other: laboratory biomarker analysis|Biological: Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes|Drug: Fludarabine Phosphate","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","60","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","13272|NCI-2014-01147","June 6, 2014","December 1, 2015","December 2017","March 13, 2017","March 2017","No Study Results Posted","null","December 2017","Dose-limiting toxicity (DLT) defined as any grade 3 or higher toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Incidence of adverse events as assessed by NCI CTCAE version 4.0|Disease response (CR or CRi)|Engraftment of transferred CD123+ CAR T cells|CAR123-specific antibody level|Duration of response|Progression Free Survival (PFS)|Survival","https://ClinicalTrials.gov/show/NCT02159495"
1641,"NCT02579005","Radio-Immuno-Modulation in Lung Cancer","Not yet recruiting","No Results Available","Lung Cancer","Other: Patients with a living donor|Other: Patients with a UCB donor","Hopital du Sacre-Coeur de Montreal|Maisonneuve-Rosemont Hospital","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-634","October 7, 2015","July 2016","December 2019","May 12, 2016","May 2016","No Study Results Posted","RIM","December 2018","Incidence of treatment-related adverse events|Immune responses - T cell infiltration|Immune responses - Tumor cell phenotype|Immune responses - tumor infiltrating T cell phenotype|Immune responses - origin of tumor infiltrating T cells","https://ClinicalTrials.gov/show/NCT02579005"
1642,"NCT00333008","A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.","Unknown status","No Results Available","Diffuse Large B Cell Lymphoma|Lymphoma, Non-Hodgkin","Drug: Doxil|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone|Drug: Rituximab|Drug: Pegfilgrastim","The Alvin and Lois Lapidus Cancer Institute|Ortho Biotech Products, L.P.","All","18 Years and older   (Adult, Senior)","Phase 2","27","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LY-012006","May 31, 2006","May 2006","null","September 25, 2006","September 2006","No Study Results Posted","null","null","Safety assessment: National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTACAE) v3.0|Efficacy: tumor evaluations every three (q 3) cycles","https://ClinicalTrials.gov/show/NCT00333008"
1643,"NCT01287741","A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)","Active, not recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Obinutuzumab|Drug: Prednisolone|Drug: Rituximab|Drug: Vincristine","Hoffmann-La Roche|Fondazione Italiana Linfomi ONLUS","All","18 Years and older   (Adult, Senior)","Phase 3","1418","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BO21005|2010-024194-39","January 31, 2011","July 2011","November 2016","October 20, 2016","October 2016","No Study Results Posted","null","April 2016","Progression-Free Survival, Assessed by the Investigator According to a Modified Version of the Revised Response Criteria for Malignant Lymphoma|Progression-Free Survival, Assessed by the Independent Review Committee (IRC) According to a Modified Version of the Revised Response Criteria for Malignant Lymphoma|Overall Survival|Percentage of Participants With Overall Response, Assessed by the Investigator According to a Modified Version of the Revised Response Criteria for Malignant Lymphoma|Percentage of Participants With Overall Response, Assessed by the Independent Review Committee (IRC) According to a Modified Version of the Revised Response Criteria for Malignant Lymphoma|Percentage of Participants With Complete Response at the End of Treatment, Assessed by Investigator According to a Modified Version of the Revised Response Criteria for Malignant Lymphoma|Percentage of Participants With Complete Response at the End of Treatment, Assessed by IRC According to a Modified Version of the Revised Response Criteria for Malignant Lymphoma|Event-Free Survival According to a Modified Version of the Revised Response Criteria for Malignant Lymphoma|Disease-Free survival, Assessed by Investigator According to a Modified Version of the Revised Response Criteria for Malignant Lymphoma|Duration of Response, Assessed by the Investigator According to a Modified Version of the Revised Response Criteria for Malignant Lymphoma|Time to Next Anti-Lymphoma Treatment|Percentage of Participants With Adverse Events|Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab Among First 100 Randomized Participants|Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma Subscale Score|Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Score|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Core 30 Domain Scores|Medical Resource Utilization: Percentage of Participants Who Are Hospitalized|Progression-Free Survival, Assessed by the IRC According to a Modified Version of the Revised Response Criteria for Malignant Lymphoma|Medical Resource Utilization: Length of Hospital Stay|Medical Resource Utilization: Percentage of Participants Who Use Any Subsequent Drug Therapy|Medical Resource Utilization: Percentage of Participants Who Undergo Medical and Surgical Procedures|Medical Resource Utilization: Percentage of Participants Who Receive Medical Treatments|Trough Concentration of Obinutuzumab in Japanese Participants|Clearance of Obinutuzumab in Japanese Participants","https://ClinicalTrials.gov/show/NCT01287741"
1644,"NCT02532777","The Research of Standard Diagnosis and Treatment for HSPN in Children","Recruiting","No Results Available","Henoch-Schoenlein Purpura Nephritis","Drug: Prednisone|Drug: Cyclophosphamide(CTX)|Drug: Mycophenolate mofetil(MMF)|Drug: Leflunomide(LEF)|Drug: Angiotensin-converting enzyme inhibitor(ACEI)|Drug: Methylprednisolone","Nanjing Children's Hospital","All","2 Years to 16 Years   (Child)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","AZhang","August 20, 2015","August 2015","July 2018","October 29, 2016","October 2016","No Study Results Posted","null","February 2018","Disappearance of proteinuria|Disappearance of hematuria|Renal function","https://ClinicalTrials.gov/show/NCT02532777"
1645,"NCT03161054","Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas","Not yet recruiting","No Results Available","Aggressive Non-Hodgkin Lymphoma","Drug: Prednisone|Drug: Vinorelbine|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Rituximab","Fondazione Italiana Linfomi ONLUS","All","65 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","FIL_DEVEC","May 18, 2017","June 2017","May 2020","May 18, 2017","May 2017","No Study Results Posted","null","December 2019","Complete Remission Rate (CRR)|Incidence of adverse events|Overall response rate (ORR)|Clinical Benefit|Progression Free Survival (PFS)|Event Free Survival (EFS)|Disease Free Survival (DFS)|Overall Survival (OS)|Patient-Reported Outcome (PRO)","https://ClinicalTrials.gov/show/NCT03161054"
1646,"NCT00460421","A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT","Completed","Has Results","Leukemia","Drug: Palifermin|Radiation: Total Body irradiation|Drug: Chemotherapy","Swedish Orphan Biovitrum","All","1 Year to 16 Years   (Child)","Phase 1","27","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","20010133","April 12, 2007","August 2006","May 2011","November 4, 2014","November 2014","May 30, 2012","null","May 2011","Incidence of Dose Limiting Toxicities (DLTs)|Incidence of Serum Palifermin Antibody Formation|Incidence of Severe Adverse Events (AEs)|Incidence of Laboratory Abnormalities|Pharmacokinetics of Palifermin, Clearence (CL) After the 1st Intravenous (IV) Bolus Injection for Multiple Dose Levels|Pharmacokinetics of Palifermin, Volume of Distribution at Steady State (Vss) After the 1st IV Bolus Injection for Multiple Dose Levels|Pharmacokinetics of Palifermin, Terminal Half-life (t½,z) After the 1st IV Bolus Injection for Multiple Dose Levels|Pharmacokinetics of Palifermin, t½,z After the 3rd IV Bolus Injection for Multiple Dose Levels|Pharmacokinetics of Palifermin, Area Under the Concentration Time Curve From Zero to the End of the Dosing Interval (AUCtau) After the 1st IV Bolus Injection for Multiple Dose Levels|Pharmacokinetics of Palifermin, AUCtau After the 3rd IV Bolus Injection for Multiple Dose Levels|Long-Term Follow-Up: Incidence of Secondary Malignancies|Long-Term Follow-Up: Progression Free Survival|Long-Term Follow-Up: Overall Survival","https://ClinicalTrials.gov/show/NCT00460421"
1647,"NCT01905943","A Safety And Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participant With Chronic Lymphocytic Leukemia","Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia","Drug: Bendamustine|Drug: Chlorambucil|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Obinutuzumab","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","979","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MO28543|2013-000087-29","July 19, 2013","November 2013","October 2018","October 17, 2016","October 2016","No Study Results Posted","null","October 2018","Number of participants with adverse events (AEs) and serious adverse events (SAEs) based on the national cancer institute common terminology criteria for AEs, Version 4.0 (NCI-CTCAE, v4.0)|Number of participants with minimal residual disease (MRD)-negativity as assessed by flow cytometry|Percentage of participants with overall response as determined by the investigator|Progression-free survival (PFS)|Time to response (TTR)|Event-free survival (EFS) as assessed by the investigator|Percentage of participants with best overall response (BOR) as determined by the investigator|Overall survival (OS)|Time to new anti-leukemia therapy (TTNT)|Duration of response (DoR)","https://ClinicalTrials.gov/show/NCT01905943"
1648,"NCT01159288","Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes","Unknown status","No Results Available","Non Small Cell Lung Cancer","Biological: Dex2","Gustave Roussy, Cancer Campus, Grand Paris","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","47","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IGR Dex2","July 8, 2010","December 2009","December 2014","April 3, 2012","July 2010","No Study Results Posted","CSET 1437","December 2014","Progression free survival","https://ClinicalTrials.gov/show/NCT01159288"
1649,"NCT00302523","Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy","Completed","No Results Available","Idiopathic Membranous Nephropathy","Drug: Tacrolimus","Nanjing University School of Medicine","All","18 Years to 60 Years   (Adult)","","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NJCT-0603","March 13, 2006","March 2006","December 2009","February 2, 2012","February 2012","No Study Results Posted","null","December 2008","To explore the potential role of tacrolimus in the treatment of membranous nephropathy.|To investigate the safety and tolerability of tacrolimus vs intravenous CTX pulse.","https://ClinicalTrials.gov/show/NCT00302523"
1650,"NCT02858804","EDOCH Alternating With DHAP for New Diagnosed Younger MCL","Recruiting","No Results Available","Mantle Cell Lymphoma","Drug: Etoposide|Drug: Doxorubicin|Drug: Dexamethasone|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Cisplatin|Drug: Rituximab|Drug: Thalidomide|Drug: Prednisone","Institute of Hematology & Blood Diseases Hospital","All","18 Years to 65 Years   (Adult)","Phase 4","55","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IIT2015007-EC-1","July 17, 2016","January 2016","June 2020","August 3, 2016","August 2016","No Study Results Posted","BDH-MCL01","December 2019","progression free survival|complete remission|overall survival","https://ClinicalTrials.gov/show/NCT02858804"
1651,"NCT02181478","Intra-Osseous Co-Transplant of UCB and hMSC","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndromes|Myelofibrosis|Relapsed Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Relapsed Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Lymphoid Malignancies|Chronic Myelogenous Leukemia","Drug: cyclophosphamide|Drug: fludarabine phosphate|Radiation: total-body irradiation|Drug: cyclosporine|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Procedure: mesenchymal stem cell transplantation","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE1Z14|NCI-2014-01316|P30CA043703","July 2, 2014","July 2015","null","September 28, 2016","September 2016","No Study Results Posted","null","March 2017","Number of patients with BM cellularity failure: Measure of feasibility|Number of patients with ANC failure without evidence of disease: Measure of feasibility|Number of patients with hematopoietic recovery without evidence of donor umbilical cord blood engraftment: Measure of feasibility|Incidence of toxicities assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Rate of neutrophil recovery|Rate of platelet recovery|Median time of neutrophil recovery|Median time of platelet recovery","https://ClinicalTrials.gov/show/NCT02181478"
1652,"NCT03017131","Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","Not yet recruiting","No Results Available","Fallopian Tube Carcinoma|Ovarian Carcinoma|Peritoneal Carcinoma","Biological: Aldesleukin|Drug: Cyclophosphamide|Drug: Decitabine|Biological: Genetically Engineered NY-ESO-1-specific T Lymphocytes|Other: Laboratory Biomarker Analysis","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","i 283616|NCI-2016-01477|P30CA016056|P50CA159981","October 19, 2016","June 1, 2017","October 2020","May 4, 2017","May 2017","No Study Results Posted","null","October 2019","Incidence of adverse events as defined by National Cancer Institute Common Terminology Criteria for Adverse Events version 4|Occurance of target antigens and or major histocompatibility complex (MHC) loss variants upon disease recurrence|Clinical response rates|Duration of response|Detection of post infusion T cell persistence|Overall Survival (OS)|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT03017131"
1653,"NCT01119066","HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Multiple Myeloma","Radiation: total body irradiation|Drug: Thiotepa|Drug: Cyclophosphamide|Drug: Busulfan|Drug: Melphalan|Drug: Fludarabine|Drug: Clofarabine|Procedure: (CliniMACS) T-cell depleted PBSC Transplant","Memorial Sloan Kettering Cancer Center","All","up to 69 Years   (Child, Adult, Senior)","Phase 2","400","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","10-050","May 4, 2010","May 2010","May 2018","January 9, 2017","January 2017","No Study Results Posted","null","May 2018","To assess the incidence of durable hematopoietic engraftment for T-cell depleted transplants fractionated by the CliniMACS system administered after each of the four disease targeted cytoreduction regimens.|To assess the incidence and severity of acute and chronic GVHD following T-cell depleted, CD34+ progenitor cell enriched transplants fractionated by the CliniMACS system.|To assess the incidence of non-relapse mortality (transplant-related mortality) following each cytoreduction regimen and a transplant fractionated by the CliniMACS system.|To estimate the probability of survival and disease-free survival (DFS)|To determine the proportion of patients receiving optimal CD34+ (> 5x106/kg) and CD3+ (<1x105/kg) cell doses the proportion recurring suboptimal doses (< 2x106/kg) CD34+ cells; and the proportion of patients receiving CD3+ T-cell doses > 1x105/kg.|To correlate doses of CD34+ progenitors and CD3+ T cells with engraftment, graft vs. host disease and non-relapse mortality.","https://ClinicalTrials.gov/show/NCT01119066"
1654,"NCT02988466","Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic","Recruiting","No Results Available","Hematologic Malignancies","Biological: Haplo HCT <55 years old|Biological: Haplo HCT ≥55 years old|Drug: GVHD Prophylaxis","Masonic Cancer Center, University of Minnesota","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","44","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2016LS092|MT2016-15","December 7, 2016","January 24, 2017","January 2021","January 26, 2017","January 2017","No Study Results Posted","null","January 2021","Disease-free survival (DFS)|Incidence of grade II-IV and grade III-IV acute graft versus-host-disease (GVHD)|Treatment related mortality (TRM)|Relapse incidence|Incidence of serious fungal and viral infection","https://ClinicalTrials.gov/show/NCT02988466"
1655,"NCT01804127","Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL","Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: R-CHOP","Fudan University","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","196","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LMTG 13-01","March 2, 2013","February 2013","December 2017","March 2, 2013","March 2013","No Study Results Posted","null","December 2015","3-year progression-free survival|Objective response rate|3-year overall survival","https://ClinicalTrials.gov/show/NCT01804127"
1656,"NCT00787722","Hematopoietic Stem Cell Transplant in Devic's Disease","Recruiting","No Results Available","Devic's Disease","Procedure: Hematopoietic stem cell transplantation","Northwestern University","All","16 Years to 65 Years   (Child, Adult)","Phase 1|Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","DIAD Devic's Disease Auto 2008","October 31, 2008","October 2008","October 2018","March 9, 2017","March 2017","No Study Results Posted","null","October 2017","Survival|Visual Acuity|Decreased weakness in limb (MRS)|Self-administered quality of life exams (FACT-BMT and SF-36)|Number of acute attacks|Time to confinement to wheelchair|Time to legal blindness(visual acuity of 20/200 or less in the better eye with best correction possible|Disability scores|NMO-IgG aquaporin- 4 autoantibody titer","https://ClinicalTrials.gov/show/NCT00787722"
1657,"NCT00690560","Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma","Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: yttrium Y 90 ibritumomab tiuxetan","Centre Antoine Lacassagne","All","65 Years to 80 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000589530|CALACASS-3RCHOPZ|INCA-RECF0624|EUDRACT-2006-006179-19|CALACASS-2006/27","June 3, 2008","May 2007","October 2010","February 8, 2015","February 2015","No Study Results Posted","null","March 2010","Event-free survival|Overall survival|Relapse-free survival in responding patients|Rate of disease progression|Response rate|Toxicities","https://ClinicalTrials.gov/show/NCT00690560"
1658,"NCT00719849","Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease","Terminated","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Radiation: total body irradiation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 69 Years   (Child, Adult, Senior)","Phase 2","13","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2012.00|FHCRC-2012.00|CDR0000597623|T32CA009515","July 19, 2008","November 2005","December 2009","February 18, 2014","February 2014","No Study Results Posted","null","November 2008","Probability of survival at 1 year|Probability of survival at 2 years|Incidence of non-relapse mortality at 6 months|Chimerism at days 7, 14, 21, 28, 56, and 80, at 6 months, and at 1 and 2 years|Incidence of neutrophil engraftment at day 42|Incidence of platelet engraftment at 6 months|Incidence of acute graft-versus-host-disease (GVHD) at day 100 and extensive chronic GVHD at 1 year|Incidence of clinically significant infections at 6 months and at 1 and 2 years|Probability of progression-free survival at 1 and 2 years|Incidence of relapse at 1 and 2 years","https://ClinicalTrials.gov/show/NCT00719849"
1659,"NCT00897871","Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer","Unknown status","No Results Available","Unspecified Childhood Solid Tumor, Protocol Specific","Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide phosphate|Genetic: gene expression analysis|Genetic: polymorphism analysis|Other: pharmacological study","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","up to 2 Years   (Child)","","60","Other","Observational","","CCLG-PK-2006-09|CDR0000560121|EU-20742|EUDRACT-2006-002845-36","May 9, 2009","February 2007","null","August 9, 2013","June 2009","No Study Results Posted","null","null","Pharmacokinetic parameters|Pharmacokinetic modelling comparing pharmacokinetic parameters to investigate the key factors involved in determining individual exposures to parent drugs and metabolites|Influence of pharmacokinetic parameters and genotype for metabolizing enzyme on event-free survival|Influence of pharmacokinetic parameters and genotype for metabolizing enzyme on toxicity","https://ClinicalTrials.gov/show/NCT00897871"
1660,"NCT02960646","Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation","Recruiting","No Results Available","Leukemia","Drug: Rituximab|Drug: Melphalan|Drug: Fludarabine|Radiation: Total body irradiation (TBI)|Procedure: Stem Cell Infusion|Drug: Cyclophosphamide|Drug: G-CSF","M.D. Anderson Cancer Center","All","18 Years to 60 Years   (Adult)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2014-0738|NCI-2016-01915","November 8, 2016","January 18, 2017","January 1, 2020","April 20, 2017","April 2017","No Study Results Posted","null","January 1, 2020","Treatment Failure of a Modified Peripheral Blood (PB) Graft for Haploidentical Transplantation","https://ClinicalTrials.gov/show/NCT02960646"
1661,"NCT01367288","Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers","Completed","No Results Available","Locally Advanced Breast Cancer|Ductal Histologic Type|Without Her2 Overexpression.","Drug: Zometa + Neoadjuvant therapy|Drug: Neoadjuvant therapy","Hospices Civils de Lyon","Female","18 Years and older   (Adult, Senior)","Phase 2","53","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2009.568","September 17, 2010","April 2010","April 2014","May 28, 2014","May 2014","No Study Results Posted","NEOZOL","April 2014","Decrease in serum VEGF concentration treatment|Change in CTC|Change in serum markers of apoptosis|Change in serum tumor markers|Change in tumor markers of apoptosis and proliferation|Change in circulating gamma-delta T-cell activation|Therapeutic complications|Assessment of tumor response|Assessment of histological tumor response|Breast conservation rate|Assessment of the intermediate tumor response|Assessment of the markers studied in the complementary study","https://ClinicalTrials.gov/show/NCT01367288"
1662,"NCT00002576","Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: mitoxantrone hydrochloride|Drug: prednisolone|Drug: vincristine sulfate","Cancer Research Campaign Clinical Trials Centre|National Cancer Institute (NCI)","All","65 Years and older   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CRC-TU-NH3003|CDR0000063660|EU-93028|ISRCTN39268693","November 1, 1999","November 1992","January 2001","August 6, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002576"
1663,"NCT02487316","A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib","Withdrawn","No Results Available","Systemic Anaplastic Large-Cell Lymphoma","Drug: crizotinib","Jun Zhu|Peking University First Hospital|Peking University People's Hospital|Peking University Third Hospital|Peking Union Medical College Hospital|Beijing Hospital|Chinese PLA General Hospital|First Hospitals affiliated to the China PLA General Hospital|Air Force General Hospital of the PLA|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Anhui Provincial Hospital|Zhejiang University|Peking University","All","18 Years to 65 Years   (Adult)","Phase 4","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PKU-2015052005","June 30, 2015","July 2015","December 2017","December 28, 2016","December 2016","No Study Results Posted","null","November 2017","complete remission rate|disease-free survival|overall survival|objective response rate|incidence of >/Grade 3 non-hematology toxicity adverse events|QOL assessment","https://ClinicalTrials.gov/show/NCT02487316"
1664,"NCT00115700","Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma","Active, not recruiting","No Results Available","Follicular Lymphoma","Drug: Cyclophosphamide|Radiation: Radiotherapy|Drug: Vincristine|Drug: Prednisolone|Drug: Rituximab","Trans-Tasman Radiation Oncology Group (TROG)|Australasian Leukaemia and Lymphoma Group","All","18 Years and older   (Adult, Senior)","Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","TROG 99.03|ALLG NHLLOW5","June 23, 2005","February 2000","December 2022","February 15, 2017","February 2017","No Study Results Posted","null","December 2021","Progression Free Survival (PFS). Period from the date of randomisation to 1st progression of disease or death from any cause.|Pre- and post-treatment prevalence of the t(14;18) translocation, in peripheral blood and bone marrow between arms|Overall Survival (OS)|Location of first relapse|To compare time to evolution to higher histological grade|Freedom from progression.|Acute and late toxicities and secondary malignances","https://ClinicalTrials.gov/show/NCT00115700"
1665,"NCT00270881","Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies","Completed","No Results Available","Acute Myelogenous Leukemia|Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome","Procedure: Cord blood transplantation|Radiation: TBI|Drug: cyclophosphamide|Drug: cytarabine","Keio University","All","20 Years to 55 Years   (Adult)","Phase 1|Phase 2","33","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KSGCT-CB2005","December 28, 2005","January 2006","January 2011","April 5, 2012","April 2012","No Study Results Posted","null","January 2009","Non-relapse mortality at 1 year|Engraftment|Disease free survival|Overall survival|Incidence of acute and chronic graft-versus-host disease|Incidence of infectious complication|Duration of hospitalization|Immune reconstitution after transplantation","https://ClinicalTrials.gov/show/NCT00270881"
1666,"NCT01564056","Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment","Recruiting","No Results Available","Breast Cancer","Drug: HORMONOTHERAPY|Drug: CHEMOTHERAPY then HORMONOTHERAPY","UNICANCER","Female","70 Years and older   (Senior)","Phase 3","2000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GERICO11/PACS10|2011-004744-22|UC-0103/1102","March 23, 2012","March 2012","March 2026","August 31, 2015","August 2015","No Study Results Posted","ASTER 70s","March 2020","Overall survival|Specific overall survival|Disease-free survival (DFS)|Event-free survival (ESF)|Toxicity|Geriatric Assessment|Four-Year Mortality Index for Older Adults(Lee Score)|Quality of life|Usefulness of GG by RT-PCR|Cost-effectiveness analysis","https://ClinicalTrials.gov/show/NCT01564056"
1667,"NCT02449252","Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma","Recruiting","No Results Available","Follicular Lymphoma","Radiation: Consolidation involved-site radiotherapy (ISRT)|Radiation: Consolidation involved-field radiotherapy (IFRT)|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Drug: prednisone","Wuhan University","All","18 Years to 65 Years   (Adult)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","WUCC-NHL01 Trial","May 7, 2015","October 2015","October 2025","December 11, 2015","December 2015","No Study Results Posted","null","October 2019","Progression-free survival - PFS|Adverse events with grade 3 or 4 - AEs|Overall survival - OS|Rate of in-field progression|Rate of out-field progression|Rate of regional failure","https://ClinicalTrials.gov/show/NCT02449252"
1668,"NCT00217425","Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms","Completed","Has Results","Lymphoma","Biological: bevacizumab|Drug: cyclophosphamide|Drug: doxorubicin|Drug: prednisone|Drug: vincristine","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","46","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000441194|U10CA021115|E2404","September 20, 2005","July 2006","March 2014","April 8, 2014","April 2014","February 20, 2014","null","April 2012","12-Month Progression-Free Survival (PFS)|Overall Response Rate|3-Year Overall Survival","https://ClinicalTrials.gov/show/NCT00217425"
1669,"NCT00209222","Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL","Unknown status","No Results Available","Lymphoma, Mantle-Cell","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Cisplatinum|Drug: Ara-C|Drug: Dexamethasone|Drug: BCNU|Drug: Melphalan|Drug: Etoposide|Drug: G-CSF|Procedure: chemotherapy: R-CHOP|Procedure: chemotherapy: R-DHAP|Procedure: chemotherapy: Dexa-BEAM|Procedure: stem cell harvest|Procedure: total body irradiation|Procedure: high-dose chemotherapy: Cyclophosphamide|Procedure: high-dose chemotherapy: Ara-C /Melphalan","European Mantle Cell Lymphoma Network|German Low Grade Lymphoma Study Group|Lymphoma Study Association","All","18 Years to 65 Years   (Adult)","Phase 3","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MCL2004-2","September 13, 2005","July 2004","December 2014","September 7, 2012","July 2009","No Study Results Posted","null","December 2014","time to treatment failure after start of therapy|complete remission (CR) rate|overall survival|progression-free survival|adverse events|serious infectious complications","https://ClinicalTrials.gov/show/NCT00209222"
1670,"NCT03103971","huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia","Not yet recruiting","No Results Available","Adult B Acute Lymphoblastic Leukemia|CD19 Positive|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Adult Acute Lymphoblastic Leukemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma","Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (huJCAR014)|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis|Other: Pharmacological Study","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","66","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","9364|NCI-2017-00421|P30CA015704","March 27, 2017","July 17, 2017","July 17, 2033","April 27, 2017","April 2017","No Study Results Posted","null","July 17, 2019","Incidence of toxicity graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03|Dose-limiting toxicity (DLT) rates|Maximum concentration (Cmax) of huJCAR014 cells in blood.|Time to maximum concentration (Tmax), of huJCAR014 cells in blood.|Area under the curve of huJCAR014 cells in blood.|Presence of huJCAR014 cells in bone marrow|Complete Response (CR) rate|Partial response (PR) rate|Objective response rate (ORR) defined as the proportion of patients with a best response of either CR or PR|Duration of response (DOR), defined as the time from date of first response to relapse/progression or death|Progression-free Survival (PFS)|Event-free survival (EFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT03103971"
1671,"NCT00038610","Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia","Completed","Has Results","Leukemia","Drug: Imatinib Mesylate|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Dexamethasone|Drug: Methotrexate|Drug: Cytarabine|Drug: Mesna|Drug: G-CSF","M.D. Anderson Cancer Center|Novartis Pharmaceuticals","All","15 Years and older   (Child, Adult, Senior)","Phase 2","54","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID01-006|NCI-2012-01487","June 3, 2002","March 2001","July 2014","August 19, 2015","August 2015","August 19, 2015","null","July 2014","Response To Induction Therapy With Hyper-CVAD Plus Imatinib Mesylate|Disease-Free Survival Rate at 2-year and 5-year.|Overall Survival Rate at 2-year and 5-year.","https://ClinicalTrials.gov/show/NCT00038610"
1672,"NCT00288002","Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: trastuzumab|Drug: capecitabine|Drug: cyclophosphamide|Drug: docetaxel|Drug: epirubicin hydrochloride|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","German Breast Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","1500","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000455125|GBG-GEPARQUATTRO|GBG-40|EU-205101|AVENTIS-GBG-GEPARQUATTRO|ROCHE-AVENTIS-GBG-GEPARQUATTRO|EUDRACT-2005-001546-17","February 6, 2006","January 2005","null","August 23, 2013","July 2009","No Study Results Posted","null","null","Pathologic complete response","https://ClinicalTrials.gov/show/NCT00288002"
1673,"NCT00634179","A Phase I/II Trial of VR-CHOP in Lymphoma Patients","Completed","Has Results","Lymphoma, B-Cell|Follicular Lymphoma","Drug: Bortezomib|Biological: Rituximab|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone","Emory University|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","37","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB00002996|X05215","February 11, 2008","February 2008","November 2015","September 21, 2016","September 2016","February 17, 2016","null","November 2015","Maximal Tolerated Doses of Bortezomib and Vincristine When Used in Combination of Bortezomib, Rituximab and the CHOP Chemotherapy Regimen (Phase I)|An Estimate of the Overall Response Rate (ORR)(Complete Response [CR] + CR Unconfirmed [CRu] + Partial Response [PR]) to Bortezomib and Rituximab (VR)-CHOP According to International Workshop to Standardize Response Criteria (IWRC) Criteria","https://ClinicalTrials.gov/show/NCT00634179"
1674,"NCT02212574","Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma","Recruiting","No Results Available","Medulloblastoma","Drug: Lomustine|Drug: Vincristine|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Mesna|Drug: Vincristine","Sidney Kimmel Comprehensive Cancer Center","All","3 Years to 18 Years   (Child, Adult)","","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","J1403|NA_00091840","July 7, 2014","March 2015","August 2019","April 26, 2017","April 2017","No Study Results Posted","null","August 2018","Progression Free Survival|Patterns of Failure","https://ClinicalTrials.gov/show/NCT02212574"
1675,"NCT00977691","Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia","Active, not recruiting","No Results Available","Peripheral Blood Stem Cell Transplantation|Anemia, Sickle Cell|Graft-Versus-Host Disease|Sirolimus (Rapamune )|Alemtuzumab (Campath )","Procedure: PBMC Transplant|Drug: Alemtuzumab (Campath )|Drug: Sirolimus (Rapamune )|Drug: Cyclophosphamide (Cytoxan )|Procedure: Low Dose Irradiation","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","2 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","56","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","090225|09-H-0225","September 15, 2009","September 1, 2009","August 1, 2017","May 12, 2017","February 23, 2017","No Study Results Posted","null","August 1, 2017","1 year post-transplant w/ sustained donor type hemoglobin for pts w/sickle cell dx or are transfusion-independent for pts w/thalassemia and not have severe graft-versus-host disease.|1) The level of chimerism required to maintain both graft survival as well as hematologic normalcy; 2) Incidence of acute and chronic GVHD; 3) Disease-free survival and overall survival; 4) Relapse rate and graft rejection rate.","https://ClinicalTrials.gov/show/NCT00977691"
1676,"NCT00109031","Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)","Completed","Has Results","Cancer|Lymphoma|Leukemia","Drug: palifermin|Radiation: Total Body Irradiation|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Placebo","Swedish Orphan Biovitrum|Amgen","All","18 Years and older   (Adult, Senior)","Phase 3","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Supportive Care","20040212","April 22, 2005","January 2005","December 2010","September 12, 2014","September 2014","January 24, 2014","null","February 2006","Number of Participants With Severe Oral Mucositis (WHO Grade 3 and 4)|Duration of Severe Oral Mucositis (WHO Grade 3 and 4)|Area Under the Curve (AUC) of Mouth and Throat Soreness Score|Number of Participants With Parenteral or Transdermal Opioid Analgesic Use|Number of Participants With WHO Grades 2, 3 or 4 Oral Mucositis|Duration of WHO Grade 2, 3 or 4 Oral Mucositis|Number of Participants With WHO Grade 4 Oral Mucositis","https://ClinicalTrials.gov/show/NCT00109031"
1677,"NCT00440583","The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP","Completed","No Results Available","Diffuse Large B-cell Lymphoma","Drug: chemotherapy followed by Zevalin","Mahidol University|Bayer","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TH011101","February 26, 2007","September 2006","May 2012","January 28, 2015","January 2015","No Study Results Posted","null","September 2011","- Determine the 2-years progression-free survival of consolidation therapy with Yt90-Zevalin.|Determine the response duration(time to progression)after therapy.|Determine safety and tolerability of Yt90-Zevalin consolidation therapy.","https://ClinicalTrials.gov/show/NCT00440583"
1678,"NCT00017381","Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma","Completed","No Results Available","Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Waldenström Macroglobulinemia","Biological: rituximab|Drug: cyclophosphamide|Biological: filgrastim|Radiation: yttrium Y 90 ibritumomab tiuxetan|Procedure: peripheral blood stem cell transplantation","National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Early Phase 1","30","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-03156|J0004","June 6, 2001","April 2001","null","January 8, 2013","January 2013","No Study Results Posted","null","December 2007","MTD, defined in terms of clinical toxicities graded using the CTC version 2.0","https://ClinicalTrials.gov/show/NCT00017381"
1679,"NCT00976989","A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Pertuzumab|Drug: Trastuzumab|Drug: FEC|Drug: Docetaxel|Drug: TCH","Hoffmann-La Roche","Female","18 Years and older   (Adult, Senior)","Phase 2","225","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BO22280|2009-012019-17","September 14, 2009","November 2009","January 2016","December 12, 2016","May 2016","March 28, 2016","null","June 2011","Safety: Percentage of Participants With Symptomatic Cardiac Events as Assessed by the Investigator|Safety: Percentage of Participants With Left Ventricular Ejection Fraction (LVEF) Decline During Pre-operative (Neoadjuvant) Period|Efficacy: Percentage of Participants With Complete Pathological Response (pCR)|Efficacy: Clinical Response Rate|Efficacy: Time to Clinical Response|Efficacy: Percentage of Participants Achieving Breast Conserving Surgery|Efficacy: Percentage of Participants Without an Overall Survival (OS) Event|Efficacy: Percentage of Participants Without a Disease-Free Survival (DFS) Event|Efficacy: Percentage of Participants Without a Progression-Free Survival (PFS) Event|Safety: Percentage of Participants With Cardiac Symptoms Associated With Symptomatic Left Ventricular Systolic Dysfunction (LVSD)|Safety: Percentage of Participants With Asymptomatic Left Ventricular Ejection Fraction (LVEF) Events|Safety: Maximum Decrease in Left Ventricular Ejection Fraction (LVEF) Measures","https://ClinicalTrials.gov/show/NCT00976989"
1680,"NCT00309569","Randomized Study Comparing Pre- and Postoperative Vs. Conventional Adjuvant Treatment in Receptor-Negative Patients","Completed","No Results Available","Early Stage Breast Cancer","Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Fluorouracil|Drug: Epirubicine","Austrian Breast & Colorectal Cancer Study Group","Female","18 Years to 80 Years   (Adult, Senior)","Phase 3","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ABCSG-7","March 31, 2006","October 1991","null","March 31, 2006","October 1999","No Study Results Posted","null","null","Overall survival|Recurrence-free survival|Rate of breast-conserving procedures","https://ClinicalTrials.gov/show/NCT00309569"
1681,"NCT01860937","T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","Active, not recruiting","No Results Available","Relapsed B-Cell Acute Lymphoblastic Leukemia","Procedure: leukapheresis or collection of PBMCs|Drug: cyclophosphamide based chemotherapy regimens|Biological: modified T cells","Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital","All","up to 26 Years   (Child, Adult)","Phase 1","23","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: No masking|Primary Purpose: Treatment","13-052","May 21, 2013","May 2013","May 2018","April 19, 2017","April 2017","No Study Results Posted","null","May 2018","safety|assess the persistence of modified T cells|the development of B cell aplasia","https://ClinicalTrials.gov/show/NCT01860937"
1682,"NCT00048893","Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer","Terminated","Has Results","Breast Neoplasms|Metastases, Neoplasm","Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine|Biological: recombinant vaccinia-CEA(6D)/TRICOM vaccine|Biological: filgrastim|Biological: sargramostim|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: fludarabine phosphate|Drug: paclitaxel|Drug: Mesna","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","37","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","030040|03-C-0040","November 8, 2002","November 2002","June 2011","March 20, 2012","March 2012","October 25, 2011","null","June 2011","Event-free Survival as Measured by Clinical Evaluation and Tumor Measurements by Imaging|Number of Participants With Adverse Events|Log Change in Precursor Frequency as Measured by Elispot.|Log Change of CD4 CEA-specific Immune Responses and Their Kinetics as a Surrogate Marker for Clinical Anti-tumor Activity of the Vaccines|Immune Response to the Vaccine in Those Patients With Late Recovery of Thymic Function|Number of Months of Progression Free Survival|Number of Participants With an Immune Response as a Result of the Salvage Immunization Schedule|Number of Participants With a Clinical Response","https://ClinicalTrials.gov/show/NCT00048893"
1683,"NCT02761915","A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART)","Recruiting","No Results Available","Relapsed or Refractory Neuroblastoma","Genetic: 1RG-CART/m^2 (Dose Level 1)|Genetic: 1RG-CART/m^2 (Dose Level 2)|Genetic: 1RG-CART/m^2 (Dose Level 3)|Genetic: 1RG-CART/m^2 (Dose Level 4)|Drug: Cyclophosphamide|Drug: Fludarabine|Genetic: 1RG-CART/m^2 (Dose Level 5)","Cancer Research UK","All","1 Year and older   (Child, Adult, Senior)","Phase 1","27","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: No masking|Primary Purpose: Treatment","1RG - CART CRUKD15001","February 24, 2016","February 2016","February 2023","March 17, 2017","March 2017","No Study Results Posted","null","February 2023","Feasibility of 1RG-CART therapy assessed as the percentage of patients who commence T-cell processing and are subsequently evaluable for 1RG-CART engraftment at Day 14.|Safety and tolerability of 1RG-CART therapy|1RG-CART cell counts in peripheral blood and infiltration of 1RG-CART into tumour and bone marrow|1RG-CART counts in the peripheral blood|Assessment of tumour response from baseline|Progression free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02761915"
1684,"NCT01537536","Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: EndoTAG-1","Jules Bordet Institute","Female","18 Years and older   (Adult, Senior)","Phase 2","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IJBNeoEndoTAG-1","September 20, 2011","November 2011","November 2012","June 14, 2013","February 2012","No Study Results Posted","EndoTAG-1","September 2012","MRI-estimated tumour volume at the end of neoadjuvant EndoTAG-1 + paclitaxel administration vs. baseline.|Rate of pathological complete response (pCR).","https://ClinicalTrials.gov/show/NCT01537536"
1685,"NCT00542191","Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin|Procedure: Definitive Surgery|Radiation: Radiotherapy","Leo W. Jenkins Cancer Center","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LJCC 07-03","October 9, 2007","July 2007","June 2018","October 23, 2014","October 2014","No Study Results Posted","null","December 2016","1) Pathologic response|1) Clinical response 2) Disease free survival (DFS) 3) Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00542191"
1686,"NCT01087294","Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation","Suspended","No Results Available","Leukemia, B-cell|Lymphoma, Hodgkins|Lymphoma, Non-hodgkins|Lymphoma, B-Cell","Procedure: Allogeneic stem cell transplant|Biological: Anti-CD19-chimeric-antigen-receptor- transduced T cell|Drug: Cyclophosphamide|Drug: Pentostatin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","42","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","100054|10-C-0054","March 13, 2010","February 3, 2010","March 1, 2019","May 12, 2017","March 1, 2017","No Study Results Posted","null","March 1, 2018","To assess the safety of allogeneic anti-CD19-CAR","https://ClinicalTrials.gov/show/NCT01087294"
1687,"NCT00176852","Stem Cell Transplant for Hemoglobinopathy","Active, not recruiting","Has Results","Sickle Cell Disease|Thalassemia|Severe Congenital Neutropenia|Diamond-Blackfan Anemia|Shwachman-Diamond Syndrome","Drug: Busulfan, Fludarabine, ATG, TLI|Drug: Busulfan, Cyclophosphamide, ATG, GCSF|Drug: Campath, Fludarabine, Cyclophosphamide|Radiation: Total Body Irradiation|Procedure: Stem cell infusion","Masonic Cancer Center, University of Minnesota|National Marrow Donor Program","All","up to 50 Years   (Child, Adult)","Phase 2|Phase 3","22","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","MT2002-07|0206M26241","September 12, 2005","June 2002","January 2019","March 28, 2017","March 2017","March 28, 2017","null","March 2014","Number of Patients Who Experienced Grade 3-5 Treatment Related Toxicity|The Incidence of Chimerism at 100 Days|The Incidence of Chimerism at 6 Months|The Incidence of Chimerism at 1 Year|The Incidence of Grade 2-4 Acute Graft Versus Host Disease (Acute GVHD)|The Incidence of Grade 3-4 Acute Graft Versus Host Disease (Acute GVHD)|The Incidence of Chronic Graft Versus Host Disease (Chronic GVHD)|Change in the Patient's Quality of Life as Compared to the Pre-Transplant Assessment|Determine Physical Characteristics and Biologic Effects of Mixed Populations of Donor and Host Red Blood Cells|Determine the Concentration of Campath in the Serum|Overall Survival|Disease Free Survival","https://ClinicalTrials.gov/show/NCT00176852"
1688,"NCT00004135","Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer","Completed","No Results Available","Kidney Cancer|Melanoma (Skin)","Biological: filgrastim|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation","University of Chicago|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 2","19","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9672|UCCRC-9672|UCCRC-CTRC-9866|NCI-G99-1612","December 10, 1999","February 1999","August 2007","March 6, 2014","March 2014","No Study Results Posted","null","October 2004","Complete Response Rate","https://ClinicalTrials.gov/show/NCT00004135"
1689,"NCT01904136","NK Cells to Prevent Disease Relapse for Patients High Risk Myeloid Malignancies","Recruiting","No Results Available","Leukemia|Myeloproliferative Diseases","Drug: Melphalan|Drug: Fludarabine|Procedure: Expanded NK Cell Infusion|Procedure: Bone Marrow Transplant|Drug: Mesna|Drug: Cyclophosphamide|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Drug: G-CSF|Radiation: Total Body Irradiation (TBI)","M.D. Anderson Cancer Center|Cancer Prevention Research Institute of Texas","All","2 Years to 65 Years   (Child, Adult)","Phase 1|Phase 2","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2012-0708|NCI-2013-02183|RP110553 05-07-04832|P01 - 5P01","July 17, 2013","April 2014","April 2020","March 24, 2017","March 2017","No Study Results Posted","null","April 2020","Maximum Tolerated Dose (MTD) of Expanded Natural Killer (NK) Cells|Treatment Related Mortality","https://ClinicalTrials.gov/show/NCT01904136"
1690,"NCT02757885","Transplantation Using Reduced Intensity Approach for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow","Recruiting","No Results Available","Sickle Cell Disease","Procedure: Bone Marrow Transplant (BMT)|Procedure: Bone Marrow Harvest (Donation)|Drug: Hydroxyurea|Drug: Thiotepa|Drug: Fludarabine monophosphate|Drug: Cyclophosphamide|Other: Rabbit Anti-thymocyte Globulin|Radiation: Total Body Irradiation","Emory University","All","15 Years to 40 Years   (Child, Adult)","Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB00080955","April 28, 2016","April 2016","null","December 14, 2016","December 2016","No Study Results Posted","TRANSFORM","December 2020","Event-free Survival (EFS) Rate|Primary Graft Rejection Rate|Late Graft Rejection Rate|Rate of Disease Recurrence|Overall Survival Rate|Cumulative Incidence of Neutrophil Engraftment and Platelet Engraftment|Chimerism Rate following Hematopoietic Cell Transplantation for Sickle Cell Disease|Frequency of Idiopathic Pneumonia Syndrome (IPS)|Veno-occlusive Disease (VOD) Rate|Rate of Central Nervous System (CNS) Toxicity|Infection Rate|Frequency of Stroke","https://ClinicalTrials.gov/show/NCT02757885"
1691,"NCT02191930","Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma","Recruiting","No Results Available","Hodgkin Lymphoma","Drug: B-CAP|Drug: Brentuximab Vedotin","University of Cologne","All","60 Years to 99 Years   (Adult, Senior)","Phase 2","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","B-CAP","July 11, 2014","September 2015","October 2018","May 10, 2017","May 2017","No Study Results Posted","B-CAP","October 2017","Objective response rate","https://ClinicalTrials.gov/show/NCT02191930"
1692,"NCT00025363","Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma","Completed","No Results Available","Alveolar Childhood Rhabdomyosarcoma|Embryonal Childhood Rhabdomyosarcoma|Embryonal-botryoid Childhood Rhabdomyosarcoma|Previously Treated Childhood Rhabdomyosarcoma|Recurrent Childhood Rhabdomyosarcoma","Drug: vincristine sulfate|Drug: irinotecan hydrochloride|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: ifosfamide|Drug: etoposide|Drug: tirapazamine|Biological: filgrastim|Biological: sargramostim|Other: pharmacological study|Other: pharmacogenomic studies|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","up to 20 Years   (Child, Adult)","Phase 2","150","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01864|ARST0121|U10CA098543|CDR0000068954","October 11, 2001","November 2001","null","January 16, 2013","January 2013","No Study Results Posted","null","October 2007","Response at week 6 of investigational window therapy (unfavorable risk patients)|Incidence of DLT when tirapazamine is given in combination with cyclophosphamide and doxorubicin, graded according to the NCI CTC v 2.0|Incidence of toxicities associated with the two administration schedules of irinotecan in combination with vincristine, graded according to the NCI CTC v 2.0 (unfavorable risk patients)|Blood metabolite SN-38 levels (unfavorable risk patients)|Progression-free survival|Survival","https://ClinicalTrials.gov/show/NCT00025363"
1693,"NCT01265849","Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity","Recruiting","No Results Available","Squamous Cell Carcinoma of the Oral Cavity|Squamous Cell Carcinoma of the Soft Palate","Biological: LI plus CIZ|Other: Standard of Care (SOC)|Biological: LI + SOC","CEL-SCI Corporation|Teva Pharmaceutical Industries|Orient Europharma Co., Ltd.","All","18 Years and older   (Adult, Senior)","Phase 3","880","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CS001P3|2010-019952-35","December 22, 2010","December 2010","December 2017","August 11, 2016","August 2016","No Study Results Posted","IT-MATTERS","December 2017","Overall Survival (OS) in LI + CIZ + SOC vs. SOC|Progression Free Survival (PFS) in LI + CIZ + SOC vs.SOC|Local regional control (LRC) in LI + CIZ + SOC vs. SOC|Quality of Life (QOL) in LI + CIZ + SOC vs. SOC","https://ClinicalTrials.gov/show/NCT01265849"
1694,"NCT00625729","Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia","Terminated","Has Results","Leukemia|Lymphoma","Biological: aldesleukin|Biological: allogeneic natural killer cells|Biological: rituximab|Drug: cyclophosphamide|Drug: fludarabine phosphate","Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","6","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007LS064|MT2007-12|UMN-0707M13561|P01CA065493","February 26, 2008","January 2008","April 2010","November 6, 2012","November 2012","July 2, 2010","null","December 2009","Number of Patients Exhibiting Natural Killer Cell Expansion|Number of Patients With Interleukin-15 Production and NK Cell Expansion|Number of Patients With Overall Response|Number of Patients Whose Disease Progressed After Treatment|Number of Patients With Adequate Natural Killer Cells Infused|Number of Patients With Overall Survival","https://ClinicalTrials.gov/show/NCT00625729"
1695,"NCT00924287","Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer","Terminated","Has Results","Metastatic Cancer","Drug: in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Mesna","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","1","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","090041|09-C-0041","June 17, 2009","November 2008","December 2010","October 6, 2015","October 2015","January 5, 2012","null","December 2010","Number of Participants With an Objective Clinical Tumor Regression Response|Number of Participants With Adverse Events|Number of Participants With In Vivo Survival of Transfused Cells","https://ClinicalTrials.gov/show/NCT00924287"
1696,"NCT00667927","Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission","Completed","No Results Available","Acute Myeloid Leukemia","Drug: Busulfan|Drug: Cyclophosphamide|Drug: Mesna","St. Jude Children's Research Hospital","All","1 Year to 18 Years   (Child, Adult)","Phase 1","17","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMLREM","April 24, 2008","March 1991","January 2008","April 25, 2008","April 2008","No Study Results Posted","null","January 1995","To estimate the continuous complete remission rate at 2 years for children with AML in first complete remission treated with Autologous Bone Marrow Transplant (ABMT).","https://ClinicalTrials.gov/show/NCT00667927"
1697,"NCT00004171","Peripheral Stem Cell Transplantation Following Radiation Therapy in Treating Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: busulfan|Drug: cyclophosphamide|Procedure: peripheral blood stem cell transplantation","Northwestern University|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU 87H6T|NU-87H6T|NCI-G99-1638","December 10, 1999","October 1999","June 2002","June 8, 2012","June 2012","No Study Results Posted","null","June 2002","","https://ClinicalTrials.gov/show/NCT00004171"
1698,"NCT01457131","Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer","Terminated","No Results Available","Metastatic Cancer|Metastatic Melanoma|Metastatic Renal Cancer","Drug: Fludarabine|Drug: Cyclophosphamide|Other: IL-12 &amp; Anti-NY ESO1 TCR PBL","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 1","2","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","120006|12-C-0006","October 12, 2011","October 6, 2011","August 7, 2013","May 12, 2017","August 2, 2013","No Study Results Posted","null","August 7, 2013","To evaluate the safety of the IL-12 and anti-NY-ESO-1 engineered PBL in patients receiving a non-myeloablative conditioning regimen, and to determine if patients with metastatic cancer will have clinical tumor regression following this regimen.|To determine the in vivo survival of cotransduced gene-engineered cells.","https://ClinicalTrials.gov/show/NCT01457131"
1699,"NCT00990496","A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)","Terminated","No Results Available","Glioblastoma Multiforme","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: CMV Specific Cytotoxic T Lymphocytes (CTL)","Penn State University","All","5 Years to 65 Years   (Child, Adult)","Phase 1|Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","31717|PSHCI #09-045","October 5, 2009","September 2009","February 2011","August 18, 2011","August 2010","No Study Results Posted","null","February 2011","To determine the incidence of tumor responses, as defined as stable disease, partial, or complete responses after the infusion of CMV CTL.|To determine the duration and magnitude of donor chimerism post infusion by micro chimerism assays.|To determine the incidence of increases in CMV pp65 or IE-1 T cells post infusion of allogeneic CMV CTL of GBM patients.|To determine safety of allogeneic CTL infusions in this patient population.","https://ClinicalTrials.gov/show/NCT00990496"
1700,"NCT00169130","ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma","Completed","No Results Available","Lymphoma, Large-Cell, Diffuse","Drug: doxorubicin|Drug: cyclophosphamide|Procedure: Autologous stem cell transplantation","Lymphoma Study Association|Fondation ARC","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","300","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LNH98-B2","September 12, 2005","October 1999","null","July 12, 2007","July 2007","No Study Results Posted","null","null","Event free survival.|Complete response rate at the end of treatment.|Disease-free survival for complete responders.|Overall survival.","https://ClinicalTrials.gov/show/NCT00169130"
1701,"NCT00589602","T-Cell Depletion, Donor HSCT, and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases","Unknown status","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Malignant Plasma Cell Neoplasms|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Secondary Myelofibrosis","Biological: peripheral blood lymphocyte therapy|Drug: cyclophosphamide|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation","The Cleveland Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","13","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCF-6501|P30CA043703","January 1, 2008","January 2004","null","October 18, 2013","October 2013","No Study Results Posted","null","December 2015","Treatment-related mortality (TRM)|The rate and severity of acute GVHD|Duration of absolute neutropenia|Ability to receive T-cell add backs|Relapse and relapse-free survival","https://ClinicalTrials.gov/show/NCT00589602"
1702,"NCT02451774","Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction","Recruiting","No Results Available","Acute Lymphoblastic Leukemia","Drug: Pentoxifylline Plus Chemotherapy|Drug: Placebo Plus Chemotherapy","Ramón Óscar González-Ramella, Ph.D|Instituto de Investigacion en Cancer de la Infancia y la Adolescencia|Hospital Civil Juan I. Menchaca|Centro de Investigacion Biomedica de Occidente|University of Guadalajara","All","1 Year to 18 Years   (Child, Adult)","Phase 2|Phase 3","44","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IICIA -PTX02","February 9, 2015","January 2015","December 2019","October 24, 2016","October 2016","No Study Results Posted","PTX-II","December 2017","Apoptosis measure by Flow Cytometry|Senescence measure by Flow Cytometry|Safety measure by Common Terminology Criteria for Adverse Events version 4.0","https://ClinicalTrials.gov/show/NCT02451774"
1703,"NCT01319981","Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia","Recruiting","No Results Available","Leukemia","Drug: Rituximab|Drug: Imatinib|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Mesna|Drug: VSLI|Drug: Solu-Medrol|Drug: Methotrexate|Drug: Ara-C|Drug: G-CSF|Drug: Pegfilgrastim|Drug: Dexamethasone","M.D. Anderson Cancer Center|Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Senior)","Phase 2","65","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2008-0598|NCI-2011-00861","March 18, 2011","March 2013","null","January 30, 2017","January 2017","No Study Results Posted","null","March 2019","Number of Patients With Complete Remission at One Year","https://ClinicalTrials.gov/show/NCT01319981"
1704,"NCT01468740","Prospective Study on HIV-related Hodgkin Lymphoma","Unknown status","No Results Available","HIV-associated Hodgkin Lymphoma","Drug: Doxorubicin|Drug: Bleomycin|Drug: Vinblastine|Drug: Dacarbazine|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Procarbazine|Drug: Prednisone","Harlachinger Krebshilfe e.V.|Deutsche AIDS Gesellschaft e.V.","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","130","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HIV-HL 2004","November 1, 2011","March 2004","July 2012","November 7, 2011","November 2011","No Study Results Posted","null","February 2012","Number of patients with World Health Organization (WHO) grade 3 and grade 4 toxicity|Treatment related mortality|Overall Survival|Progression-free survival|Complete remission rate","https://ClinicalTrials.gov/show/NCT01468740"
1705,"NCT00851110","Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors","Terminated","No Results Available","High-Risk Breast Cancer","Procedure: stem cell reinfusion|Drug: Chemotherapy","University Medical Center Groningen","Female","18 Years to 50 Years   (Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","METc 2004/110|CKTO 2005-15","February 23, 2009","October 2004","null","February 24, 2009","February 2009","No Study Results Posted","null","null","Maximum degree of non-hematological toxicity.|Total number of hospital days|Quality of life evaluations during and following high-dose chemotherapy (up to 1 year)","https://ClinicalTrials.gov/show/NCT00851110"
1706,"NCT01045889","High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High Risk","Completed","No Results Available","HIV-related Lymphoma|HIV Infections","Other: Rituximab and CHOP regimen + PBSCT","Azienda Ospedaliera Spedali Civili di Brescia","All","18 Years to 60 Years   (Adult)","Phase 2","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ema2_LNH e HIV","January 8, 2010","January 2007","May 2016","August 18, 2016","August 2016","No Study Results Posted","HDT-HIV","May 2016","Overall survival|Partial and complete responses","https://ClinicalTrials.gov/show/NCT01045889"
1707,"NCT03093168","BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma","Recruiting","No Results Available","Multiple Myeloma","Biological: Anti-BCMA CAR-T cells|Drug: Fludarabine|Drug: Cyclophosphamide","The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine|Xinqiao Hospital of Chongqing","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","anti-BCMA CART","March 15, 2017","February 15, 2017","February 2020","March 27, 2017","March 2017","No Study Results Posted","null","September 2019","Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0|Overall complete remission rate defined by the standard response criteria for malignant lymphoma for each arm|Duration of CAR-positive T cells in circulation|Total number of CAR-positive T cells infiltrated into lymphoma tissue","https://ClinicalTrials.gov/show/NCT03093168"
1708,"NCT02685670","Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma","Recruiting","No Results Available","Hematopoietic/Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma","Biological: anti-CD19 CAR-T|Drug: Fludarabine|Drug: Cyclophosphamide","The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine|Xinqiao Hospital of Chongqing|Xuzhou Medical University","All","5 Years to 70 Years   (Child, Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","DHHUTCM20160106","February 14, 2016","February 2016","December 2019","March 14, 2017","March 2017","No Study Results Posted","MatchCART","December 2017","Safety (incidence of adverse events defined as dose-limited toxicity)|Overall complete remission rate|Survival of CAR T cells in circulation measured by flow cytometry and PCR|Duration of remission|Overall survival","https://ClinicalTrials.gov/show/NCT02685670"
1709,"NCT01015261","Allogenic Bone Marrow Transplantation (BMT) Compare With Cytoreduction and Chemotherapy in Acute Lymphoblastic Leukemia (ALL) Patients","Completed","No Results Available","Acute Lymphoblastic Leukemia","Procedure: Bone Marrow Transplantation|Procedure: Chemotherapy","Tehran University of Medical Sciences","All","16 Years to 50 Years   (Child, Adult)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HORCSCT-0903","November 17, 2009","October 2008","September 2010","November 19, 2010","November 2010","No Study Results Posted","null","March 2010","Efficacy of allogenic BMT compare with cytoreduction and chemotherapy in ALL patient|Overall Survival after BMT compare with chemotherapy.|Disease Free Survival after BMT compare with chemotherapy","https://ClinicalTrials.gov/show/NCT01015261"
1710,"NCT00039481","Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors","Completed","No Results Available","Cardiac Toxicity|Unspecified Childhood Solid Tumor, Protocol Specific","Biological: oblimersen sodium|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Biological: filgrastim|Other: laboratory biomarker analysis|Other: pharmacological study","National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 1","15","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01872|ADVL0211|U01CA097452|CDR0000069387","June 6, 2002","November 2002","null","January 16, 2013","January 2013","No Study Results Posted","null","October 2005","Dose-limiting toxic effects and recommended phase II dose, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0|Change in pharmacokinetic behavior of this regimen|Antitumor activity|Biologic activity of oblimersen in mononuclear cells and tumor tissues, in terms of B-cell lymphoma 2 (bcl-2) and related protein expression","https://ClinicalTrials.gov/show/NCT00039481"
1711,"NCT02483767","Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Drug: goserelin|Drug: standard chemotherapy","Peking Union Medical College Hospital","Female","18 Years to 45 Years   (Adult)","Phase 3","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","PUMCH-BC-ovarian suppression","June 9, 2015","June 2015","June 2022","June 24, 2015","June 2015","No Study Results Posted","POF","June 2017","ovarian failure|Ovarian dysfunction|Time to the resumption of menstrual activity|pregnancy|DFS OS|FSH,E2,AMH","https://ClinicalTrials.gov/show/NCT02483767"
1712,"NCT01087398","Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis","Unknown status","No Results Available","Osteopetrosis","Drug: Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)|Procedure: Stem Cell Transplantation|Drug: Cyclosporin, Methotrexate (GVHD prophylaxis)","Tehran University of Medical Sciences","All","up to 5 Years   (Child)","Phase 2|Phase 3","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HORCSCT-0905","March 13, 2010","September 2009","December 2012","May 31, 2012","May 2012","No Study Results Posted","null","November 2012","Overall Survival and Progressive Free Survival in patient with infantile Osteopetrosis who receive allogeneic HSCT|One year overall survival after allogeneic HSCT|One year Progressive Free Survival after allogeneic HSCT|Transplantation Related Mortality (TRM) after allogeneic HSCT|Acute and chronic GVHD rate after allogeneic HSCT","https://ClinicalTrials.gov/show/NCT01087398"
1713,"NCT03018626","R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL","Not yet recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: Rituximab|Drug: Etoposide|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Vindesine|Drug: Bleomycin","Nanfang Hospital of Southern Medical University","All","18 Years to 60 Years   (Adult)","Phase 3","402","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NFL2016-B1","November 2, 2016","February 2017","January 2021","January 10, 2017","January 2017","No Study Results Posted","null","January 2020","Progression-free survival|Overall survival|Complete remission rate","https://ClinicalTrials.gov/show/NCT03018626"
1714,"NCT02111863","Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma","Terminated","No Results Available","Melanoma|Skin Cancer","Drug: Aldesleukin|Drug: Fludarabine|Drug: Cylcophosphamide|Biological: 4-1BB Selected TIL","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","6","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","140062|14-C-0062","April 9, 2014","February 21, 2014","December 31, 2018","May 12, 2017","July 21, 2016","No Study Results Posted","null","December 28, 2017","To determine the safety and objective response rate of patients with metastatic melanoma receiving ACT using 4-1BB selected TIL plus aldesleukin treatment following a chemotherapy preparative regimen.|To determine the survival of patients receiving this treatment regimen.","https://ClinicalTrials.gov/show/NCT02111863"
1715,"NCT00082641","Vaccine Therapy With Either Neoadjuvant or Adjuvant Chemotherapy and Adjuvant Radiation Therapy in Treating Women With p53-Overexpressing Stage III Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: autologous dendritic cell-adenovirus p53 vaccine","University of Nebraska|National Cancer Institute (NCI)|H. Lee Moffitt Cancer Center and Research Institute","Female","19 Years and older   (Adult, Senior)","Phase 1|Phase 2","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","371-02|MCC-UNMC-37102|UNMC-37102|CDR0000354507|NCI-2012-01019","May 14, 2004","January 2004","null","May 14, 2013","May 2013","No Study Results Posted","null","December 2014","Safety and toxicity|Immune response|Importance of vaccine timing on antigen-specific immune responses","https://ClinicalTrials.gov/show/NCT00082641"
1716,"NCT00966498","Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors","Terminated","No Results Available","High Risk Solid Tumors|Recurrent Solid Tumors","Procedure: Peripheral Blood Stem Cell Transplant","Emory University","All","up to 35 Years   (Child, Adult)","","3","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1023-2003|PBSCT for ST","August 11, 2009","May 2003","July 2011","December 9, 2013","December 2013","No Study Results Posted","null","July 2011","To determine the feasibility and toxicity of tandem high dose chemotherapy and peripheral blood stem cells rescue in patients with high-risk or recurrent solid tumors.","https://ClinicalTrials.gov/show/NCT00966498"
1717,"NCT03023358","Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients","Not yet recruiting","No Results Available","Peripheral T Cell Lymphoma","Drug: chidamide|Drug: cyclophosphamide|Drug: liposomal doxorubicin|Drug: vincristine|Drug: prednisone","Nanfang Hospital of Southern Medical University","All","18 Years and older   (Adult, Senior)","Phase 3","174","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDOP201602","November 3, 2016","February 2017","March 2019","January 13, 2017","January 2017","No Study Results Posted","null","March 2019","complete remission rate|disease free survival|overall survival|time to progression","https://ClinicalTrials.gov/show/NCT03023358"
1718,"NCT00314106","Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma","Completed","Has Results","Metastatic Melanoma","Biological: Melanoma Reactive TIL|Drug: Cyclophosphamide|Biological: IL-2|Drug: Fludarabine|Radiation: 1200 total body irradiation (TBI)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","26","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","060136|06-C-0136","April 11, 2006","April 2006","March 2009","September 18, 2012","September 2012","September 18, 2012","null","February 2009","Complete Response|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00314106"
1719,"NCT00712452","Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve","Terminated","No Results Available","Infertility","Other: Biology and ultrasonography after chemotherapy|Other: Biology and ultrasonography after chemotherapy|Other: Biology and ultrasonography after chemotherapy","Assistance Publique - Hôpitaux de Paris","Female","18 Years to 35 Years   (Adult)","","19","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","P070707","July 2, 2008","June 2008","June 2009","May 13, 2013","May 2013","No Study Results Posted","IROCHIM","June 2009","AMH level and antral follicle count|AMH level and antral follicle count at each visit|Hormonal status (Estradiol, LH, FSH and progesterone levels)|Menstrual cyclicity|pregnancy|infertility treatment if required","https://ClinicalTrials.gov/show/NCT00712452"
1720,"NCT01356290","Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma","Recruiting","No Results Available","Medulloblastoma","Drug: Bevacizumab|Drug: Thalidomide|Drug: Celecoxib|Drug: Fenofibric acid|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Etoposide phosphate|Drug: Liposomal cytarabine","Medical University of Vienna","All","up to 19 Years   (Child, Adult)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MUV-MEMMAT-01","May 17, 2011","April 2014","April 2022","May 15, 2017","May 2017","No Study Results Posted","MEMMAT","April 2019","Efficacy|Overall survival rate|Progression free survival rate|Toxicity|Feasibility|Quality of life|Prognostic factors|Angiogenic factors","https://ClinicalTrials.gov/show/NCT01356290"
1721,"NCT00801216","High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement","Unknown status","No Results Available","B-Cell Lymphomas","Drug: High-dose sequential chemotherapy and autologous transplant","IRCCS San Raffaele|Mundipharma K.K.","All","19 Years to 65 Years   (Adult)","Phase 2","38","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SCNSL1|IIL-SCNSL-1","November 28, 2008","January 2007","January 2012","December 2, 2008","October 2008","No Study Results Posted","SCNSL1","January 2010","Event-free survival|Response duration|Overall survival|Tolerability|Neurotoxicity","https://ClinicalTrials.gov/show/NCT00801216"
1722,"NCT01875601","NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors","Completed","No Results Available","Solid Tumors|Brain Tumors|Sarcoma|Pediatric Cancers|Neuroblastoma","Biological: Recombinant human interleukin-15 (rhIL-15)|Biological: NK Cell Infusion","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","2 Years to 25 Years   (Child, Adult)","Phase 1","16","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","130152|13-C-0152","June 11, 2013","May 21, 2013","September 8, 2015","May 12, 2017","October 27, 2016","No Study Results Posted","null","September 8, 2015","Toxicity|Feasibility|Antitumor activity","https://ClinicalTrials.gov/show/NCT01875601"
1723,"NCT02162420","Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia","Recruiting","No Results Available","Dyskeratosis Congenita|Aplastic Anemia","Drug: Alemtuzumab|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total Body Irradiation|Biological: Stem Cell Transplant|Drug: Anti-thymocyte globulin","Masonic Cancer Center, University of Minnesota","All","up to 70 Years   (Child, Adult, Senior)","","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013OC127|MT2013-34C","June 10, 2014","January 2015","July 2024","August 15, 2016","August 2016","No Study Results Posted","null","July 2024","Incidence of neutrophil engraftment|Incidence of regimen related mortality|Incidence of acute graft-versus-host disease|Incidence of chronic graft-versus-host disease","https://ClinicalTrials.gov/show/NCT02162420"
1724,"NCT00467961","Stem Cell Transplantation for Patients With Cancers of the Blood","Completed","Has Results","CML (Chronic Myelogenous Leukemia)|CLL (Chronic Lymphocytic Leukemia)|AML (Acute Myelogenous Leukemia)|Acute Lymphocytic Leukemia|MDS (Myelodysplastic Syndrome)","Device: Miltenyi system","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","61","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","070136|07-H-0136","April 28, 2007","April 2007","November 2012","December 22, 2014","December 2014","December 22, 2014","null","November 2012","To Determine if Selective T Cell Depletion Using the Photodepletion Procedure Can Substantially Reduce the Rate of Severe Acute GVHD (Grade III/IV) After Matched Sibling Transplantation Followed by Low-dose or no Immunosuppression.|Secondary Objectives Include Determining the Rate od Standard Transplant Outcome Variables: Toxicity, Relapse, Graft Rejection, Disease Free Survival.","https://ClinicalTrials.gov/show/NCT00467961"
1725,"NCT01118026","Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma","Recruiting","No Results Available","Lymphoma","Drug: ABVD|Drug: BEACOPP|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 2","100","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CALGB-50801|CDR0000669076|NCI-2011-02034","May 5, 2010","September 2010","null","May 15, 2017","May 2017","No Study Results Posted","null","July 2017","Progression-free survival at 36 months from enrollment|Complete response rate|Standard uptake values (SUVs) for target sites measured at baseline, after course 2, and after completion of therapy|Determination of the optimal cutoff for absolute decrease in maximum SUV body weight (SUVbw) and SUV lean body mass (SUVlbm), relative uptake in tumor vs various reference anatomic sites, IHP criteria as well as various cutoffs for post-therapy maxim ...|Volumetric vs 2-dimensional (2-D) measurement changes for target lesions between baseline and after course 2, at the end of chemotherapy, and after IFRT|Comparison of qualitative and semiquantitative fludeoxyglucose-PET findings/changes, 2-D and volumetric CT changes, and combinatorial analyses (PET + dedicated CT data) with molecular parameters and conventional parameters","https://ClinicalTrials.gov/show/NCT01118026"
1726,"NCT02379585","Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer","Terminated","No Results Available","Breast Cancer","Drug: Doxorubicin|Drug: cyclophosphamide|Drug: paclitaxel|Drug: docetaxel|Drug: Trastuzumab|Drug: Pertuzumab","Western Regional Medical Center","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1145332","January 12, 2015","January 2013","August 2015","September 23, 2015","September 2015","No Study Results Posted","STEFNE","August 2015","Evaluate pathological complete remission rate at the time of surgery, or partial pathological response rate (defined as residual invasive disease of 1cm) at the time of surgery or at the time of biopsy upon completion of planned chemotherapy.|The effect of short-term fasting on the toxicity of neoadjuvant chemotherapy in breast cancer patients according to the NCI common toxicity criteria (Version 4.03)|Pathological complete remission rate at the time of surgery, or partial pathological response rate at the time of surgery or at the time of biopsy upon completion of planned chemotherapy for triple-negative breast cancer|Changes in plasma insulin abnormalities after short-term fasting and chemotherapy|Biomarker changes in breast cancer (biopsy or residual tumor) before and after neoadjuvant chemotherapy|Nutritional status assessment with Patient Generated Subjective Global Assessment (aPG-SGA) before and after neoadjuvant chemotherapy|To investigate changes in glucose after short-term fasting and chemotherapy|To investigate changes in Insulin-like growth factor-1 (IGF1) after short-term fasting and chemotherapy|To investigate changes in plasma blood-based tumor-related abnormalities in DNA after short-term fasting and chemotherapy","https://ClinicalTrials.gov/show/NCT02379585"
1727,"NCT00416676","Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma","Unknown status","No Results Available","Neuroblastoma","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: vincristine sulfate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","1 Year and older   (Child, Adult, Senior)","Phase 3","30","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CCLG-NB-1993-01|CDR0000454571|EU-20594","December 27, 2006","null","null","August 1, 2013","December 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00416676"
1728,"NCT00273364","Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study","Active, not recruiting","No Results Available","Multiple Sclerosis","Procedure: Hematopoietic Stem Cell Therapy|Drug: Standard treatment with a conventional drug","Northwestern University|Uppsala University|Sheffield Teaching Hospitals NHS Foundation Trust|University of Sao Paulo","All","18 Years to 55 Years   (Adult)","Phase 3","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","DI MS.Randomized2004","January 5, 2006","January 2006","December 2018","May 19, 2017","May 2017","No Study Results Posted","null","December 2017","EDSS","https://ClinicalTrials.gov/show/NCT00273364"
1729,"NCT00006461","Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor","Completed","No Results Available","Untreated Childhood Medulloblastoma|Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor","Drug: cisplatin|Drug: cyclophosphamide|Drug: vincristine sulfate|Drug: etoposide|Procedure: therapeutic conventional surgery|Radiation: 3-dimensional conformal radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 3 Years   (Child)","Phase 3","82","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P9934|NCI-2012-02362|CDR0000068269|POG-P9934|COG-P9934|U10CA098543","November 6, 2000","October 2000","null","August 7, 2013","August 2013","No Study Results Posted","null","September 2007","Event-free survival rate|Acute and chronic toxicities associated with the treatment regimens|Neuropsychological and neuroendocrine effects of this systemic chemotherapy, surgery, and local, conformal radiation|Feasibility and validity of a centralized telephone interview based data collection method for neuropsychological evaluations|Incidence of atypical teratoid and/or rhabdoid tumor","https://ClinicalTrials.gov/show/NCT00006461"
1730,"NCT02449278","The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma","Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Radiation: Consolidation involved-site radiotherapy (ISRT)|Radiation: Consolidation involved-field radiotherapy (IFRT)|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Drug: prednisone","Wuhan University","All","18 Years to 65 Years   (Adult)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","WUCC-NHL04 Trial","May 7, 2015","October 2015","October 2025","December 11, 2015","December 2015","No Study Results Posted","null","October 2019","Progression-free survival - PFS|Adverse events with grade 3 or 4 - AEs|Overall survival - OS|Rate of in-field progression|Rate of out-field progression|Rate of regional failure","https://ClinicalTrials.gov/show/NCT02449278"
1731,"NCT00001379","Treatment and Natural History Study of Lymphomatoid Granulomatosis","Recruiting","No Results Available","Lymphomatoid Granulomatosis|Granulomatosis, Lymphomatoid|Non-Hodgkins Lymphoma|Lymphoproliferative Disorder","Biological: Interferon|Drug: Rituxan and EPOCH","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","12 Years to 120 Years   (Child, Adult, Senior)","Phase 2","90","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","940074|94-C-0074","November 3, 1999","February 9, 1994","February 1, 2022","May 12, 2017","March 27, 2017","No Study Results Posted","null","February 1, 2020","Overall response and long-term efficacy","https://ClinicalTrials.gov/show/NCT00001379"
1732,"NCT00352976","TBI Dose De-escalation for Fanconi Anemia","Recruiting","No Results Available","Fanconi Anemia","Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: Total Body Irradiation|Procedure: Bone Marrow Transplantation|Drug: Mycophenolate Mofetil|Drug: Sirolimus","Masonic Cancer Center, University of Minnesota","All","Child, Adult, Senior","Phase 2|Phase 3","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MT2006-05|0605M85788","July 14, 2006","May 18, 2006","December 2018","February 13, 2017","February 2017","No Study Results Posted","null","December 2018","Incidence of neutrophil recovery (absolute neutrophil count ≥500/µL for three consecutive days) .|Incidence of grade ≥3 regimen related toxicity .|Incidence of secondary graft failure at 100 days.|Incidence of acute graft-versus-host disease (GVHD)|Incidence of chronic GVHD .|Probability of survival .|Incidence of infections .|Immune reconstitution .","https://ClinicalTrials.gov/show/NCT00352976"
1733,"NCT00668564","Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism","Terminated","Has Results","Hurler's Syndrome|Maroteaux-Lamy Syndrome|Sly Syndrome|Alpha Mannosidosis|Fucosidosis|Aspartylglucosaminuria|Sphingolipidoses|Krabbe Disease|Wolman's Disease|Niemann-Pick Disease Type B|Niemann-Pick Disease, Type C","Procedure: Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Campath-1H|Drug: Busulfan","Masonic Cancer Center, University of Minnesota","All","up to 21 Years   (Child, Adult)","Phase 2","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MT2008-02|0801M25202","April 25, 2008","March 2008","February 2010","November 6, 2012","November 2012","June 14, 2011","null","February 2010","Number of Patients Achieving Engraftment|Overall Survival","https://ClinicalTrials.gov/show/NCT00668564"
1734,"NCT00872625","Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: docetaxel|Drug: epirubicin hydrochloride|Drug: fluorouracil|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery|Radiation: hypofractionated radiation therapy|Radiation: image-guided radiation therapy|Radiation: radiation therapy|Radiation: stereotactic radiosurgery","Centre Antoine Lacassagne","Female","18 Years and older   (Adult, Senior)","Phase 1","26","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000633331|CALACASS-CYBERNEO|CALACASS-2006/24|INCA-RECF0621|EUDRACT-2006-A00250-51","March 28, 2009","April 2007","December 2010","February 8, 2015","February 2015","No Study Results Posted","null","April 2009","Maximum-tolerated dose of radiotherapy","https://ClinicalTrials.gov/show/NCT00872625"
1735,"NCT01777152","ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas","Active, not recruiting","No Results Available","Anaplastic Large-Cell Lymphoma|Non-Hodgkin Lymphoma|T-Cell Lymphoma","Drug: brentuximab vedotin|Drug: doxorubicin|Drug: prednisone|Drug: vincristine|Drug: cyclophosphamide","Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 3","452","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","SGN35-014|2012-002751-42","January 23, 2013","January 2013","December 2019","February 9, 2017","February 2017","No Study Results Posted","ECHELON-2","December 2017","Progression-free survival per independent review facility (IRF)|Progression-free survival per IRF in patients with systemic anaplastic large cell lymphoma (sALCL)|Complete remission rate per IRF at end of treatment|Overall survival|Objective response rate per IRF at end of treatment|Type, incidence, severity, seriousness, and relatedness of adverse events|Incidence of laboratory abnormalities","https://ClinicalTrials.gov/show/NCT01777152"
1736,"NCT02250937","Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)","Recruiting","No Results Available","Acute Myeloid Leukemia|Myelodysplastic Syndrome","Drug: Busulfan|Drug: Fludarabine|Drug: Cladribine|Procedure: Stem Cell Transplant|Drug: G-CSF|Drug: Methotrexate|Drug: Cyclophosphamide","M.D. Anderson Cancer Center","All","2 Years to 70 Years   (Child, Adult, Senior)","Phase 2","116","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2014-0431|NCI-2014-02324","September 24, 2014","October 27, 2014","October 2019","March 20, 2017","March 2017","No Study Results Posted","null","October 2019","Progression-Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT02250937"
1737,"NCT00866749","Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma","Active, not recruiting","No Results Available","Lymphoblastic Leukemia|Lymphoblastic Lymphoma","Drug: Daunorubicin|Drug: Vincristine|Drug: PEG-asparaginase|Drug: Intrathecal Methotrexate|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Mercaptopurine|Drug: Methotrexate|Drug: Doxorubicin|Drug: Thioguanine","M.D. Anderson Cancer Center","All","12 Years to 40 Years   (Child, Adult)","Phase 2","125","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-0375|NCI-2012-01650","March 19, 2009","September 2006","null","November 7, 2016","November 2016","No Study Results Posted","null","October 2018","3-Year Event-Free Survival (EFS) Rate|Efficacy Monitoring by Patient Response","https://ClinicalTrials.gov/show/NCT00866749"
1738,"NCT00931918","Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients","Completed","Has Results","Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)","Drug: Bortezomib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Millennium Pharmaceuticals, Inc.|Takeda","All","18 Years and older   (Adult, Senior)","Phase 2","206","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","C05013|U1111-1183-0186","July 1, 2009","October 2009","August 2015","November 14, 2016","November 2016","August 11, 2016","null","August 2015","Progression-Free Survival (PFS) in Patients With Non-germinal Center B-cell-like (Non-GCB) Diffuse Large B-cell Lymphoma (DLBCL)|Progression-Free Survival Rate|Overall Survival|Overall Response Rate (ORR)|Complete Response Rate|Duration of Response|Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Negative Rate|Time to Progression (TTP)|Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) by Category|Percentage of Participants With Chemistry and Hematology Laboratory Values Grade 3 or Higher","https://ClinicalTrials.gov/show/NCT00931918"
1739,"NCT00433420","Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: pegfilgrastim|Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: paclitaxel|Procedure: adjuvant therapy","Gruppo Italiano Mammella (GIM)|National Cancer Institute (NCI)","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","2000","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","GIM-2|CDR0000528056|EU-20681","February 8, 2007","April 2003","null","August 1, 2013","May 2007","No Study Results Posted","null","null","Disease-free survival|Overall survival|Toxicity","https://ClinicalTrials.gov/show/NCT00433420"
1740,"NCT00004323","Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia","Completed","No Results Available","Aplastic Anemia","Drug: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: mesna|Drug: methotrexate|Drug: methylprednisolone","National Center for Research Resources (NCRR)|University of California, Los Angeles","All","up to 55 Years   (Child, Adult)","Phase 2","10","NIH|Other","Interventional","Primary Purpose: Treatment","199/11863|UCLA-94020602","October 18, 1999","February 1995","null","June 23, 2005","April 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004323"
1741,"NCT00085735","Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma","Completed","No Results Available","Untreated Childhood Medulloblastoma","Drug: Cisplatin|Radiation: Craniospinal Irradiation|Drug: Cyclophosphamide|Radiation: Involved-Field Radiation Therapy|Other: Laboratory Biomarker Analysis|Drug: Lomustine|Other: Quality-of-Life Assessment|Radiation: Radiation Therapy|Drug: Vincristine Sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 3","549","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ACNS0331|NCI-2009-00335|COG-ACNS0331|CDR0000365506|U10CA098543","June 14, 2004","April 2004","March 2016","February 9, 2017","February 2017","No Study Results Posted","null","March 2016","Event-free survival (EFS)|Time to death from any cause / overall survival (OS)|Local posterior fossa (LPF) failure rate|Non-local posterior fossa (NLPF) failure rate|Non-posterior fossa (NPF) failure rate|Post-treatment endocrine function (growth hormone (GH) and thyroid stimulating hormone (TSH)) as measured by laboratory assessment) .|Post-treatment grade 3+ hearing loss as measured by CTCAE v4|Post-treatment neurocognitive function as measured by the estimated full-scale IQ (FSIQ) and also the metacognition index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF)|Incidence of grade 3+ hearing loss at 1-year post treatment as assessed by CTCAE Version 4|Incidence of endocrine dysfunction as measured by growth hormone stimulation test at the completion of therapy.|Time to death from any cause / overall survival (OS) by molecular subgroup based on methylation arrays|Time to recurrence, progression or death due to cancer / progression-free survival (PFS) by molecular subgroup based on methylation arrays|Compliance rates for all eligible and evaluable patients enrolled","https://ClinicalTrials.gov/show/NCT00085735"
1742,"NCT02167958","Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source","Recruiting","No Results Available","Leukemia|MDS|Myelofibrosis|Lymphoma","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Mesna|Radiation: Total Body Irradiation|Other: Hematopoietic stem cell infusion|Drug: Tacrolimus|Drug: Mycophenolate|Drug: G-CSF","University of Pittsburgh","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","13-131","June 17, 2014","November 2014","July 2020","May 3, 2017","May 2017","No Study Results Posted","null","July 2019","Acute GvHD|Chronic Graft-versus-Host Disease|Nonrelapse Mortality (NRM)|Relapse of Malignancy|Neutrophil Recovery|Primary graft failure|Secondary graft failure|Platelet recovery|Donor Cell Engraftment|Progression-free Survival|Infections","https://ClinicalTrials.gov/show/NCT02167958"
1743,"NCT01280526","A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas","Completed","No Results Available","Peripheral T Cell Lymphoma","Drug: Romidepsin and CHOP|Drug: Romidepsin and CHOP|Drug: Romidepsin and CHOP|Drug: Romidepsin and CHOP","The Lymphoma Academic Research Organisation","All","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","37","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Ro-CHOP","January 14, 2011","January 2011","March 2014","May 21, 2014","May 2014","No Study Results Posted","Ro-CHOP","November 2012","Incidence of Dose Limiting Toxicities|Complete Response Rate(CR) at the end of treatment|Progression-free survival (PFS)|Duration of Response|Safety of association Romidepsin-CHOP|Overall Response at the end of treatment|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT01280526"
1744,"NCT02722668","UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","Recruiting","No Results Available","Acute Leukemia|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia/Lymphoma|Burkitt's Lymphoma|Natural Killer Cell Malignancies|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome|Large-cell Lymphoma|Hodgkin Lymphoma|Multiple Myeloma|Relapsed Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Marginal Zone B-cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-cell Lymphoma|Prolymphocytic Leukemia|Bone Marrow Failure Syndromes|Myeloproliferative Neoplasms/Myelofibrosis|Biphenotypic/Undifferentiated/Prolymphocytic Leukemias|MRD Positive Leukemia|Leukemia or MDS in Aplasia|Relapsed T-Cell Lymphoma|Relapsed Multiple Myeloma|Plasma Cell Leukemia","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: MMF|Drug: Sirolimus|Radiation: TBI|Biological: Umbilical cord blood cell infusion|Biological: ATG","Masonic Cancer Center, University of Minnesota","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","162","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2015LS149|MT2015-17","March 24, 2016","May 15, 2017","December 2029","May 16, 2017","May 2017","No Study Results Posted","null","May 2028","Probability of Acute Graft Versus Host Disease (GVHD)|Incidence of Acute GVHD|Transplant related mortality|Chimerism|Neutrophil Engraftment","https://ClinicalTrials.gov/show/NCT02722668"
1745,"NCT02727803","Personalized Natural Killer (NK) Cell Therapy in Cord Blood Transplantation (CBT)","Recruiting","No Results Available","Leukemia|Lymphoma|Myeloma|Myeloproliferative Diseases","Drug: Busulfan|Drug: Fludarabine|Drug: Clofarabine|Drug: Rabbit ATG|Radiation: Total Body Irradiation (TBI)|Procedure: Cord Blood Infusions|Drug: Rituximab|Drug: Cyclophosphamide|Procedure: Natural Killer Cell Infusion|Drug: Melphalan|Drug: Mesna","M.D. Anderson Cancer Center","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-0313|NCI-2016-00584","March 25, 2016","May 2016","null","December 13, 2016","December 2016","No Study Results Posted","null","May 2020","Progression Free Survival (PFS) Time in C2C2 Participants|Progression Free Survival (PFS) Time in C1 Participants","https://ClinicalTrials.gov/show/NCT02727803"
1746,"NCT00169156","A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma","Completed","No Results Available","Untreated T-cell Angioimmunoblastic Lymphoma","Drug: Rituximab|Drug: Prednisone|Drug: Doxorubicine|Drug: Cyclophosphamide|Drug: Vincristine","Lymphoma Study Association|Hoffmann-La Roche","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","27","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","RAIL|2005-002602-37","September 12, 2005","December 2005","November 2012","March 9, 2017","March 2017","No Study Results Posted","null","December 2008","Overall Response Rate (ORR)|Event-free survival (EFS) relapse for complete responders, disease progression, early discontinuation of treatment for toxicity or modification of treatment.|Overall survival (OS)|Time to progression (TTF)|Disease-free survival (DFS).|number of SAE","https://ClinicalTrials.gov/show/NCT00169156"
1747,"NCT02752815","Reduced Chemotherapy in Low Risk DLBCL","Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Epirubicin|Drug: Vincristine|Drug: Prednisone","Ruijin Hospital","All","14 Years to 75 Years   (Child, Adult, Senior)","Phase 4","290","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NHL-006","April 20, 2016","April 2016","June 2019","October 30, 2016","October 2016","No Study Results Posted","null","April 2018","Progression free survival|Overall survival|Complete Response rate|Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02752815"
1748,"NCT00003203","Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors","Completed","No Results Available","Brain Tumors|Central Nervous System Tumors|Neuroblastoma","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: vincristine sulfate|Procedure: adjuvant therapy|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 2","168","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A9971|COG-A9971|CCG-99701|CDR0000066055","November 1, 1999","March 1998","March 2012","August 22, 2013","August 2013","No Study Results Posted","null","October 2007","Event Free Survival|Survival","https://ClinicalTrials.gov/show/NCT00003203"
1749,"NCT00002838","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Biological: Filgrastim (G-CSF)|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Procedure: Peripheral Blood Stem Cell Transplantation","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 1|Phase 2","13","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM95-194|P30CA016672|MDA-DM-95194|NCI-V96-1018|CDR0000065053","November 1, 1999","December 1995","July 2002","July 27, 2012","July 2012","No Study Results Posted","null","July 2002","Feasibility + Toxicity of Combination Chemotherapy Plus Peripheral Stem Cell Transplantation","https://ClinicalTrials.gov/show/NCT00002838"
1750,"NCT00676806","A Phase II Study of Umbilical Cord Blood Transplantation","Terminated","Has Results","Leukemia|Lymphoma|Multiple Myeloma|Aplastic Anemia","Biological: Umbilical Cord Blood After Myeloablative Conditioning|Biological: Umbilical Cord Blood After Reduced-Intensity Conditioning","Tufts Medical Center","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","7","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UCBT001","May 9, 2008","July 2005","July 2014","November 30, 2016","November 2016","May 2, 2016","null","July 2013","Number of Participants With Neutrophil Engraftment|Proportion of Subjects With Platelet Engraftment|Incidence of Acute GVHD|Infectious Complications in UCB Recipients.|Incidence of Chronic GVHD","https://ClinicalTrials.gov/show/NCT00676806"
1751,"NCT01670084","Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia","Withdrawn","No Results Available","B-cell Adult Acute Lymphoblastic Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia","Drug: nilotinib|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: methotrexate|Drug: cytarabine|Drug: prednisone|Drug: mesna|Drug: dexamethasone|Drug: leucovorin calcium","Mayo Clinic","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MC1184|NCI-2012-01061","August 17, 2012","December 2012","September 2017","October 29, 2015","October 2015","No Study Results Posted","null","September 2015","Disease-free survival rate, defined as a patient who is alive and relapse-free, in patients who achieve a CR during the first 2 courses out to 2 years|Overall survival time, defined as the time from registration to death due to any cause out to 2 years|Complete response (CR) rate estimated by the number of patients achieving an objective status of CR during the first 2 courses of treatment divided by the total number of evaluable patients|Complete response (CR) as defined for all evaluable patients who have achieved a CR as the date at which the patient's objective status is first noted to be a CR to the earliest date relapse is documented out to 4 years|Maximum grade for each type of adverse event, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0","https://ClinicalTrials.gov/show/NCT01670084"
1752,"NCT00670748","Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer","Terminated","Has Results","Metastatic Melanoma|Metastatic Renal Cell Cancer|Metastatic Cancer","Biological: Anti-NY ESO-1 T-cell receptor PBL|Drug: aldesleukin|Drug: Cyclophosphamide|Drug: fludarabine phosphate|Biological: ALVAC NY ESO-1 vaccine","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 66 Years   (Adult, Senior)","Phase 2","45","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","080121|08-C-0121","May 1, 2008","April 2008","July 2016","October 26, 2016","October 2016","May 19, 2016","null","May 2013","Clinical Response Per the Response Evaluation Criteria in Solid Tumors (RECIST)|Number of Participants With In Vivo Survival of T-Cell Receptor (TCR)-Engineered Cells|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00670748"
1753,"NCT02828358","Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement","Recruiting","No Results Available","Acute Leukemia of Ambiguous Lineage|Childhood B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia","Drug: Azacitidine|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Daunorubicin Hydrochloride|Drug: Dexamethasone|Drug: Hydrocortisone Sodium Succinate|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Mercaptopurine|Drug: Methotrexate|Drug: Pegaspargase|Other: Pharmacological Study|Drug: Prednisolone|Drug: Thioguanine|Drug: Vincristine Sulfate","National Cancer Institute (NCI)","All","up to 364 Days   (Child)","","116","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2016-00973|AALL15P1|U10CA180886","July 7, 2016","March 2017","null","April 18, 2017","April 2017","No Study Results Posted","null","November 2019","Incidence of adverse events of azacitidine and combination chemotherapy, graded according to Common Terminology Criteria for Adverse Events 4.0|Biologic activity, defined as global DNA methylation change in PBMCs","https://ClinicalTrials.gov/show/NCT02828358"
1754,"NCT00412360","Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)","Completed","Has Results","Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome|Natural Killer Cell Lymphoblastic Leukemia/Lymphoma","Biological: Single Umbilical Cord Blood Unit Transplant|Biological: Double Umbilical Cord Blood Unit Transplant|Radiation: Total Body Irradiation|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Cyclosporine A|Drug: Mycophenolate Mofetil","Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program","All","1 Year to 21 Years   (Child, Adult)","Phase 3","224","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMTCTN0501|2U01HL069294|5U24CA076518","December 14, 2006","December 2006","October 2014","June 27, 2016","May 2016","August 28, 2015","null","March 2014","Overall Survival|Disease-free Survival|Neutrophil Engraftment|Acute Graft-versus-host Disease (GVHD)|Chronic GVHD|Treatment-related Mortality|Infections|Relapse|Platelet Engraftment|Engraftment Syndrome|Chimerism|Immune Reconstitution","https://ClinicalTrials.gov/show/NCT00412360"
1755,"NCT03117751","Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Acute Lymphoblastic Lymphoma","Drug: Prednisone|Drug: Vincristine|Drug: Daunorubicin|Drug: Pegaspargase|Drug: Erwinase®|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Mercaptopurine|Drug: Dasatinib|Drug: Methotrexate|Drug: Blinatumomab|Drug: Ruxolitinib|Drug: Bortezomib|Drug: Dexamethasone|Drug: Doxorubicin|Drug: Etoposide|Drug: Clofarabine|Drug: Vorinostat|Drug: Idarubicin","St. Jude Children's Research Hospital|Bristol-Myers Squibb|Incyte Corporation|Shire","All","1 Year to 18 Years   (Child, Adult)","Phase 2|Phase 3","1000","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Outcomes Assessor|Primary Purpose: Treatment","TOT17|NCI-2017-00582","March 27, 2017","March 29, 2017","March 31, 2028","April 12, 2017","March 2017","No Study Results Posted","null","September 30, 2026","Event-free survival of ALL patients (EFS)|Rate of allergic reactions to pegaspargase in B-ALL patients|Proportion of patients with CEP72TT genotype who develop two or more episodes of Grade 2 or higher neuropathy during Continuation|Cumulative incidence of Grade 2 or higher neuropathy in patients with CEP72 CC or CT genotype|5-year overall survival (OS) of ALL patients compared to historical controls|EFS of LLy patients|5-year OS of LLy patients|Comparison of minimum residual disease (MRD) in B-ALL patients|Number of patients with dose-limiting toxicities (DLT) of ruxolitinib in patients with early T cell precursor leukemia|Maximum tolerated dose (MTD) of ruxolitinib|Comparison of MRD measurements between flow cytometry and sequencing|Log hazard ratio of the association of low level of MRD and treatment outcome|Comparison of bone marrow and peripheral blood MRD|Isolated CNS relapse in CNS1b patients|Level of clonal diversity and rise of leukemic clones during treatment|Number and type of germline or somatic genomic variants associated with drug resistance|Comparison of drug sensitivity of ALL cells between diagnosis and relapse in vitro and in vivo|Magnitude change in spatial span backward standard score (SSB)|Change in bone mineral density (BMD) in the tibia|Change in markers of bone turnover","https://ClinicalTrials.gov/show/NCT03117751"
1756,"NCT00096460","Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)","Terminated","Has Results","Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Follicular Lymphoma","Drug: Cyclophosphamide and Rituximab|Drug: Filgrastim|Radiation: Chemotherapy or Radiation therapy|Drug: Non-myeloablative Conditioning regimen|Procedure: Allogeneic transplant|Procedure: Autologous transplant|Drug: Rituximab maintenance therapy|Drug: GVHD Prophylaxis","Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program","All","up to 75 Years   (Child, Adult, Senior)","Phase 2|Phase 3","30","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BMTCTN0202|U01HL069294|BMT CTN 0202|5U24CA076518","November 9, 2004","August 2004","March 2009","August 1, 2016","August 2016","August 16, 2011","null","March 2006","Lymphoma Progression-free Survival","https://ClinicalTrials.gov/show/NCT00096460"
1757,"NCT00871689","Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML","Terminated","Has Results","Leukemia","Biological: aldesleukin|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: umbilical cord blood transplantation|Radiation: total-body irradiation","Masonic Cancer Center, University of Minnesota","All","up to 45 Years   (Child, Adult)","Phase 2","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008LS110|MT2008-36|0810M51781","March 27, 2009","January 2009","October 2011","July 18, 2012","July 2012","June 11, 2012","null","March 2010","Number of Patients With Neutrophil Engraftment|Number of Patients With Grade III-IV Acute Graft-Versus-Host (GVHD) Disease|Incidence of Primary Graft Failure|Number of Patients With Acute Graft-Versus-Host (GVHD) Disease|Number of Patients With Transplant-Related Death (TRD)|Number of Patients With Complete Remission of Disease|Median Overall Survival|Number of Patients With Successful Natural Killer Expansion","https://ClinicalTrials.gov/show/NCT00871689"
1758,"NCT01871441","Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies","Completed","No Results Available","Malignant Neoplasm","Radiation: Total-body irradiation|Biological: Donor lymphocytes infusion (DLI)|Drug: Cyclophosphamide|Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT)|Drug: Tacrolimus|Drug: Mycophenolate mofetil","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 2","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","13D.127|2012-104","June 4, 2013","May 17, 2013","October 20, 2016","May 10, 2017","May 2017","No Study Results Posted","null","December 12, 2013","Disease-free survival (DFS)|Rate of relapse and GVHD in maternal recipients whose only eligible donors are offspring|Rate of grade III-IV GVHD in female recipients with male donors|The rates of grade III-IV GVHD in female recipients with male donors will be computed with corresponding exact binomial 95% confidence intervals.","https://ClinicalTrials.gov/show/NCT01871441"
1759,"NCT01594177","Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy","Completed","No Results Available","Unilateral HER2 Positive Breast Cancer","Drug: Afatinib|Drug: Trastuzumab|Drug: Paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide","German Breast Group|Boehringer Ingelheim","Female","18 Years and older   (Adult, Senior)","Phase 2","65","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GBG 70|2011-004704-38","May 3, 2012","May 2012","March 2014","March 12, 2014","March 2014","No Study Results Posted","DAFNE","March 2014","Pathological Complete Response|Response Rate by Physical Examination and Imaging Tests|Conservation Rate|Number of Participants with (Serious) Adverse Events as a Measure of Safety and Tolerability|Number of Participants with Skin Toxicity and Diarrhea as (Serious) Adverse Events as a Measure of Safety and Tolerability and Pathological Complete Response|Translational Research","https://ClinicalTrials.gov/show/NCT01594177"
1760,"NCT02441803","Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)","Recruiting","No Results Available","Leukemia","Drug: Busulfan|Drug: Fludarabine|Drug: Clofarabine|Radiation: Total Body Irradiation (TBI)|Drug: Thymoglobulin|Biological: Stem Cell Infusion|Drug: Cyclophosphamide|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Drug: Decitabine|Drug: Cytarabine|Drug: Idarubicin","M.D. Anderson Cancer Center","All","18 Years to 60 Years   (Adult)","Phase 2","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2014-0358|NCI-2015-00849","May 5, 2015","September 2015","null","September 7, 2016","September 2016","No Study Results Posted","null","September 2022","Overall Response (OR)|Treatment-Related Mortality (TRM)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02441803"
1761,"NCT00043979","Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas","Completed","Has Results","Sarcoma","Drug: F-18 Fluorodeoxyglucose|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: cyclosporine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Drug: prednisone|Drug: sirolimus|Drug: tacrolimus|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation|Drug: Filgrastim|Procedure: Peripheral Blood Stem Cell donation","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","5 Years to 35 Years   (Child, Adult)","Phase 2","60","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","020259|02-C-0259","August 15, 2002","August 2002","April 2012","September 12, 2013","September 2013","April 3, 2013","null","April 2012","Number of Participants With Engraftment|Toxicity|Number of Participants With Acute and Chronic GVHD","https://ClinicalTrials.gov/show/NCT00043979"
1762,"NCT02142049","Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma","Active, not recruiting","No Results Available","Diffuse Large B Cell Lymphoma Relapsed|Diffuse Large B Cell Lymphoma Refractory","Drug: Ibrutinib, DA-EPOCH-R|Drug: Ibrutinib, Lenalidomide, DA-EPOCH-R","Pharmacyclics LLC.|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","56","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PCYC-1124-CA","May 12, 2014","May 2014","June 2017","October 26, 2016","October 2016","No Study Results Posted","null","April 2017","Number of Dose-Limiting Toxicities as a Measure of Safety and Tolerability|Number of Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy|Number of Patients with Adverse Events as a Measure of Safety and Tolerability|Duration of Response (DOR), Progression Free Survival (PRF) and Overall Survival (OS) as a Measure of Efficacy","https://ClinicalTrials.gov/show/NCT02142049"
1763,"NCT02724163","International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia","Recruiting","No Results Available","Acute Myeloid Leukaemia","Drug: Gemtuzumab ozogamicin|Drug: Liposomal daunorubicin|Drug: Mitoxantrone|Drug: Fludarabine|Drug: Cytarabine|Drug: Busulfan|Drug: Cyclophosphamide","University of Birmingham|Assistance Publique - Hôpitaux de Paris|Cancer Research UK|National Cancer Institute, France|Pfizer","All","up to 17 Years   (Child)","Phase 3","700","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","RG_14-088|2014-005066-30","January 8, 2016","April 2016","December 2032","May 1, 2017","May 2017","No Study Results Posted","Myechild01","December 2031","Incidence of dose limiting toxicities (DLTs).|Event Free Survival (EFS).|Relapse free survival (RFS).|Early treatment related adverse reactions.|The nature, incidence and severity of adverse events (AEs) (gemtuzumab ozogamicin dose finding study).|Response measured by bone marrow assessment using morphology and minimal residual disease (MRD) assessment (gemtuzumab ozogamicin dose finding study).|Serum pharmacokinetic (PK) parameters of gemtuzumab ozogamicin: Clearance (CL) (gemtuzumab ozogamicin dose finding study)|Serum pharmacokinetic (PK) parameters of gemtuzumab ozogamicin: Volume of distribution (Vd) (gemtuzumab ozogamicin dose finding study)|Complete remission (CR) (R1 & R2).|Reasons for failure to achieve CR (R1 & R2).|Cumulative Incidence of Relapse (CIR) (all randomisations).|Death in CR (DCR) (R1, R2 & R3).|Event Free Survival (EFS) (R1, R2 & R3).|Overall Survival (OS) (all randomisations).|Incidence of toxicities (all randomisations).|Incidence of cardiotoxicity (R1, R2 & R4 only).|Incidence of bilirubin of grade 3 of higher (R2 & R4 only).|Incidence of Veno-Occlusive Disease (R2 & R4 only).|Minimal Residual Disease (MRD) clearance after course 1 & 2 (R1 & R2 only).|Time to haematological recovery (all randomisations).|Days in hospital after each course of treatment (all randomisations).|Incidence of mixed chimerism at day 100 post-transplant (R4 only).|Treatment Related Mortality (TRM) (R4 only).|Gonadal function (R4 only).","https://ClinicalTrials.gov/show/NCT02724163"
1764,"NCT00002696","Combination Chemotherapy in Treating Women With Stage III Breast Cancer","Suspended","No Results Available","Breast Cancer","Drug: CAF regimen|Drug: CMF regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: fluorouracil|Drug: methotrexate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Grupo Oncologico Cooperativo del Sur|National Cancer Institute (NCI)","Female","21 Years to 75 Years   (Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","GOCS-08-BR-95-III|CDR0000064471|NCI-F95-0036","November 1, 1999","October 1995","null","August 1, 2013","April 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002696"
1765,"NCT00349778","High -Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Drug: cyclophosphamide|Drug: etoposide|Drug: BCNU Melphalan","Stanford University","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","49","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT183|97115","July 5, 2006","August 2006","April 2010","October 7, 2010","October 2010","No Study Results Posted","null","April 2009","Evaluate the risk of interstitial pneumonitis with the current dosing of BCNU and melphalan|Remission rate, event-free survival, overall survival and relapse","https://ClinicalTrials.gov/show/NCT00349778"
1766,"NCT00146588","Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer","Completed","No Results Available","Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer","Drug: Cyclophosphamide|Drug: Epirubicin|Drug: Capecitabine","Craig A. Bunnell, MD, MPH|Dana-Farber Cancer Institute|Massachusetts General Hospital|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Pharmacia","Female","18 Years and older   (Adult, Senior)","","55","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-036","September 6, 2005","April 2002","December 2004","March 23, 2015","October 2014","No Study Results Posted","null","December 2004","To determine the feasibility of administering cytoxan, epirubicin, and capecitabine to women with Stage I/II/IIIA breast cancer.","https://ClinicalTrials.gov/show/NCT00146588"
1767,"NCT01159236","Molecular Triaging of Newly Diagnosed Breast Cancer","Withdrawn","No Results Available","Breast Cancer","Drug: Paclitaxel|Drug: Fluorouracil|Drug: Doxorubicin|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Bevacizumab","M.D. Anderson Cancer Center","Female","18 Years and older   (Adult, Senior)","","0","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-0765","July 7, 2010","September 2010","null","July 27, 2012","July 2012","No Study Results Posted","null","null","Pathological Response Rate in Patients","https://ClinicalTrials.gov/show/NCT01159236"
1768,"NCT00003519","Combination Chemotherapy in Treating Women With Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group|North Central Cancer Treatment Group|Cancer and Leukemia Group B","Female","18 Years and older   (Adult, Senior)","Phase 3","2778","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066563|E2197|CLB-49802|NCCTG-E2197|SWOG-E2197","November 1, 1999","August 1998","null","January 27, 2010","January 2010","No Study Results Posted","null","January 2007","","https://ClinicalTrials.gov/show/NCT00003519"
1769,"NCT02116530","Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy","Active, not recruiting","Has Results","Hematopoietic/Lymphoid Cancer|Nausea and Vomiting|Unspecified Adult Solid Tumor, Protocol Specific","Drug: Olanzapine|Drug: Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)|Drug: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)|Other: Placebo","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","401","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Supportive Care","A221301|NCI-2014-00446|U10CA031946","April 15, 2014","August 2014","null","February 27, 2017","February 2017","December 7, 2016","null","April 2015","Proportion of Patients With no Nausea|Median Nausea Scores|Proportion of Patients With Complete Response|Mean Scores of Potential Toxicities Related to Olanzapine as Measured by the Nausea and Vomiting Daily Diary/Questionnaire|Frequency of Rescue Medication","https://ClinicalTrials.gov/show/NCT02116530"
1770,"NCT03050216","QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML","Recruiting","No Results Available","Acute Myeloid Leukemia","Biological: ALT-803","Masonic Cancer Center, University of Minnesota","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2016LS056|MT2016-05","February 8, 2017","May 16, 2017","September 2020","May 17, 2017","May 2017","No Study Results Posted","null","September 2020","Rate of complete remission with incomplete platelet recovery|Incidence of in vivo expansion ≥100 of donor derived NK cells per uL blood|ALT-803 associated toxicity assessment|Treatment related mortality","https://ClinicalTrials.gov/show/NCT03050216"
1771,"NCT01583686","CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer","Recruiting","No Results Available","Cervical Cancer|Pancreatic Cancer|Ovarian Cancer|Mesothelioma|Lung Cancer","Drug: Fludarabine|Biological: Anti-mesothelin CAR|Drug: Cycolphosphamide|Drug: Aldesleukin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","136","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","120111|12-C-0111","April 20, 2012","March 30, 2012","December 31, 2019","May 12, 2017","February 9, 2017","No Study Results Posted","null","December 31, 2018","Determine a safe dose of administration and determine if this approach will result in an objective tumor regression.|Determine the in vivo survival of CAR gene-engineered cells.","https://ClinicalTrials.gov/show/NCT01583686"
1772,"NCT02395822","MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients","Suspended","No Results Available","Acute Myelogenous Leukemia","Biological: IL-15","Masonic Cancer Center, University of Minnesota","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2014LS092","February 16, 2015","October 2015","June 2019","November 15, 2016","November 2016","No Study Results Posted","null","December 2018","< 5% marrow blast, no circulating peripheral blasts and neutrophil count of > 1 x 10^9/L|In vivo expansion (>100) of NK cells (defined at CD56+/CD3- lymphocytes)|IL-15 associated toxicity assessment|Treatment related mortality|Number of subjects achieving complete response with in vivo donor derived NK cell expansion of > 100 donor derived NK cells.","https://ClinicalTrials.gov/show/NCT02395822"
1773,"NCT00083915","DTPACE Followed by Tandem Transplant With MEL 200 Versus MEL/DTPACE Hybrid and DTPACE Consolidation","Completed","Has Results","Multiple Myeloma","Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Adriamycin|Drug: Etoposide|Drug: Melphalan|Drug: Thalidomide|Drug: Dexamethasone","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 3","97","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UARK 2001-12","June 3, 2004","June 2001","June 2010","July 7, 2011","July 2011","July 7, 2011","null","June 2010","Transplant With DT PACE-Melphalan Regimen of Chemotherapy vs. Transplant With Melphalan Alone.|Side Effects With DT PACE-Melphalan vs Side Effects With Melphalan Alone","https://ClinicalTrials.gov/show/NCT00083915"
1774,"NCT00586755","Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma","Completed","No Results Available","Mantle Cell Lymphoma","Procedure: Intensive Induction-BMT","Duke University","All","18 Years and older   (Adult, Senior)","Phase 2","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2165","December 21, 2007","February 1998","November 2008","July 16, 2014","July 2014","No Study Results Posted","null","October 2007","Disease Free Survival (DFS)|Progression Free Survival (PFS)|Response to the induction regimen|Response to the transplant phase of therapy|Toxicity of the trial|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00586755"
1775,"NCT03076437","Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies","Recruiting","No Results Available","Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Lymphoma","Combination Product: Drugs and Anti-CD19-CAR transduced T cells","Shenzhen Institute for Innovation and Translational Medicine|Dongguan People's Hospital","All","1 Year to 80 Years   (Child, Adult, Senior)","Phase 1|Phase 2","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SIITM20160115","March 7, 2017","January 15, 2016","December 31, 2019","March 7, 2017","March 2017","No Study Results Posted","null","December 31, 2019","Number of participants with Adverse Events|Number of participants with Clinical responses","https://ClinicalTrials.gov/show/NCT03076437"
1776,"NCT00001251","Phase I Study of Intrathecal Mafosfamide","Completed","No Results Available","Leukemia|Lymphoma|Meningeal Neoplasm","Drug: Mafosfamide","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 1","65","NIH","Interventional","Primary Purpose: Treatment","900095|90-C-0095","July 7, 2006","November 1989","November 2003","August 16, 2013","November 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001251"
1777,"NCT00301821","Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma","Completed","Has Results","Lymphoma","Biological: epratuzumab|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","107","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-N0489|NCI-2012-02685|CDR0000459932","March 9, 2006","January 2006","April 2015","July 1, 2016","July 2016","March 13, 2015","null","October 2008","Event-free Survival After 12 Months|Overall Survival|Progression-free Survival (PFS)|Overall Response Rate (ORR)","https://ClinicalTrials.gov/show/NCT00301821"
1778,"NCT00186355","Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma, Non-Hodgkin","Procedure: high dose chemo then auto hematopoietic cell transplant","Stanford University|National Institutes of Health (NIH)","All","up to 75 Years   (Child, Adult, Senior)","","97","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT4IJ|77063|12170","September 13, 2005","October 2003","February 2010","May 10, 2012","May 2012","No Study Results Posted","null","March 2007","PCR positivity in peripheral blood cell collections after cyclophosphamide|Enrichment of hematopoietic stem cells","https://ClinicalTrials.gov/show/NCT00186355"
1779,"NCT00008034","Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: capecitabine|Drug: cyclophosphamide|Drug: epirubicin hydrochloride","European Organisation for Research and Treatment of Cancer - EORTC","Female","18 Years to 70 Years   (Adult, Senior)","Phase 1","15","Other","Interventional","Primary Purpose: Treatment","EORTC-10991|IDBBC-10991-CEX","January 6, 2001","February 2000","null","July 17, 2012","July 2012","No Study Results Posted","null","December 2000","","https://ClinicalTrials.gov/show/NCT00008034"
1780,"NCT00578292","Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO","Terminated","No Results Available","Thalassemia","Drug: Busulfan|Drug: Fludarabine|Drug: Campath 1H|Drug: Cyclophosphamide|Drug: MESNA","Baylor College of Medicine|Texas Children's Hospital","All","up to 64 Years   (Child, Adult)","","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-14539-THALLO|THALLO","December 19, 2007","February 2004","May 2016","July 20, 2016","July 2016","No Study Results Posted","THALLO","May 2016","Evaluate engraftment.|To evaluate the occurrence of transient and stable mixed hematopoietic chimerism (HC) after unrelated donor SCT, and its effect on the recurrence of clinically measurable thalassemia.|To measure hematopoietic and immune reconstitution, and assess the effects on infectious complications.|Toxicities.|Loss of chimerism.|GVHD|Morbidity and mortality post-transplant.","https://ClinicalTrials.gov/show/NCT00578292"
1781,"NCT00572169","UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Velcade|Drug: Thalidomide|Drug: Dexamethasone|Drug: Adriamycin|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Etoposide","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 3","177","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","72023","December 11, 2007","November 2006","August 2017","October 11, 2016","October 2016","No Study Results Posted","null","August 2017","To find out if outcomes of participants in this study will be better when compared to individuals who participated in Total Therapy II, especially those with chromosome abnormalities.|To find out if outcomes and incidence of toxicities of participants in this study will be better when compared to individuals who participated in Total Therapy III.","https://ClinicalTrials.gov/show/NCT00572169"
1782,"NCT00923351","Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma","Active, not recruiting","Has Results","Neuroblastoma|Sarcoma|Rhabdomyosarcoma-Embryonal|Rhabdomyosarcoma- Alveolar|Neuroectodermal Tumors, Primitive, Peripheral","Drug: Tumor Purged/CD25 Depleted Lymphocytes|Biological: Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Drug: rhIL-7|Biological: Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","19 Months to 35 Years   (Child, Adult)","Phase 1|Phase 2","44","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","070206|07-C-0206","June 17, 2009","August 2007","July 2017","August 24, 2016","August 2016","July 9, 2013","null","August 2012","Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay|Toxicity|Overall Survival","https://ClinicalTrials.gov/show/NCT00923351"
1783,"NCT00929591","SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: endocrine therapy|Drug: endocrine-modulating drug therapy|Drug: fluorouracil|Drug: tamoxifen citrate|Radiation: brachytherapy|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|North Central Cancer Treatment Group|Cancer and Leukemia Group B|NCIC Clinical Trials Group","Female","18 Years and older   (Adult, Senior)","Phase 3","1558","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000075692|U10CA032102|SWOG-8814|CAN-NCIC-MA9|CLB-9194|EST-4188|NCCTG-883051|INT-0100","June 26, 2009","May 1989","March 2010","January 23, 2013","January 2013","No Study Results Posted","null","August 2005","Disease-free survival|Overall survival|Toxicity/morbidity of treatment","https://ClinicalTrials.gov/show/NCT00929591"
1784,"NCT03032783","A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity","Recruiting","No Results Available","Hematopoietic and Lymphoid Cell Neoplasm","Radiation: Total-Body Irradiation|Procedure: Donor Lymphocyte Infusion|Drug: Cyclophosphamide|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 2","42","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","16D.606","January 24, 2017","January 31, 2017","July 24, 2020","April 24, 2017","April 2017","No Study Results Posted","null","July 24, 2020","Overall Survival (OS)|Incidence of graft failure|Incidence of non-relapse mortality","https://ClinicalTrials.gov/show/NCT03032783"
1785,"NCT00206518","Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients","Active, not recruiting","No Results Available","Breast Cancer","Drug: Taxotere/Docetaxel|Drug: Adriamycin/Cytoxan|Drug: doxorubicin","Baylor Breast Care Center|Baylor College of Medicine","Female","18 Years and older   (Adult, Senior)","Phase 2","175","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","H 16039","September 14, 2005","September 2004","September 2017","August 26, 2016","August 2016","No Study Results Posted","TACAC","October 2016","assess pathological tumor response to neoadjuvant chemotherapy (Taxotere and AC) and to validate that pathological response strongly correlates with prospectively-determined regimen-specific gene expression profiles of sensitivity and resistance|determine time to tumor progression; median overall survival; and document toxicities associated with the chemotherapy regimens","https://ClinicalTrials.gov/show/NCT00206518"
1786,"NCT00580333","Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer","Active, not recruiting","Has Results","Breast Cancer","Drug: cisplatin|Drug: bevacizumab|Drug: doxorubicin|Drug: cyclophosphamide|Drug: paclitaxel","Massachusetts General Hospital|Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","51","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","06-202|AVF36335","December 20, 2007","September 2007","June 2017","March 22, 2017","March 2017","April 2, 2014","null","December 2010","Pathologic Complete Response Rate After Preoperative Therapy With Cisplatin and Bevacizumab in ER-, PR-, Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early Breast Cancer.|Clinical Overall and Complete Response Rates After Preoperative Therapy With Cisplatin and Bevacizumab|Toxicity of Administering Bevacizumab in Combination With Standard Adjuvant Chemotherapy.|Patients With Miller-Payne (MP) Score 3, 4, or 5 Response","https://ClinicalTrials.gov/show/NCT00580333"
1787,"NCT01472146","ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer","Completed","No Results Available","Breast Cancer|Breast Disease|Neoplasms|Neoplasms by Site","Drug: Zo-Nantax","Susanne Crocamo|Instituto Nacional de Cancer, Brazil","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","58","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Zo-neo2011","September 20, 2011","October 2011","May 2017","May 4, 2017","May 2017","No Study Results Posted","null","July 2016","Evaluate the residual cancer burden (RCB)|Assessing the tolerance to standard neoadjuvant treatment plus zolendronic acid,according to the common toxicity criteria Terminology Criteria for Adverse Events version 3.0.|Assessment of the difference in gene expression according to treatment response|Prediction of pathological response by MRI calculated from the sequence of apparent diffusion coefficient (ADC)","https://ClinicalTrials.gov/show/NCT01472146"
1788,"NCT01358877","A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: 5-Fluorouracil|Drug: Carboplatin|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Doxorubicin|Drug: Epirubicin|Drug: Paclitaxel|Drug: Pertuzumab|Drug: Placebo|Drug: Trastuzumab","Hoffmann-La Roche|Genentech, Inc.|Breast International Group","All","18 Years and older   (Adult, Senior)","Phase 3","4805","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","BO25126|TOC4939G|2010-022902-41|BIG 04-11","May 20, 2011","November 8, 2011","December 1, 2023","April 20, 2017","April 2017","No Study Results Posted","APHINITY","December 19, 2016","Invasive Disease-Free Survival (IDFS) Duration (Excluding Second Primary Non-Breast Cancers as IDFS Event), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings|IDFS Duration (Including Second Primary Non-Breast Cancers as IDFS Event), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings|Disease-Free Survival (DFS) Duration (Including Second Primary Non-Breast Cancers or Contralateral or Ipsilateral Ductal Carcinoma in-Situ as an Event), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings|Overall Survival (OS)|Recurrence-Free Interval (RFI), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings|Distant Recurrence-Free Interval (DRFI), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings|Percentage of Participants with Adverse Events|Percentage of Participants with Asymptomatic or Mildly Symptomatic (NYHA Class II) Drop in Left Ventricular Ejection Fraction (LVEF) of at least 10 Points from Baseline and to Below 50%|LVEF Measurements Over the Course of the Study|European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Score|European Organisation for Research and Treatment of Cancer Breast Cancer Module Quality of Life (EORTC QLQ BR23) Functional Scale Score|European Quality of Life-5 Dimensions (EQ-5D) Questionnaire Score|Percentage of Participants with Both a Heart Failure of New York Heart Association (NYHA) Class III or IV and a Drop in Left Ventricular Ejection Fraction (LVEF) of at least 10 Points from Baseline and to Below 50 Percent (%)","https://ClinicalTrials.gov/show/NCT01358877"
1789,"NCT02472392","Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma","Completed","No Results Available","EWINGS SARCOMA","Drug: Rabbit anti-thymocyte globulin|Drug: Busulfan|Drug: Melphalan|Drug: Fludarabine|Drug: Cyclophosphamide","University of Louisville","All","up to 30 Years   (Child, Adult)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","13.0167","June 4, 2015","April 2013","December 2016","May 8, 2017","May 2017","No Study Results Posted","Ewing/Allo","December 2016","Toxicity assessed by safety labs and close monitoring from the study staff","https://ClinicalTrials.gov/show/NCT02472392"
1790,"NCT01641406","""Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer""","Unknown status","No Results Available","Infiltrating Duct and Lobular Carcinoma In Situ|Invasive Lobular Breast Carcinoma|Inflammatory Breast Carcinoma","Drug: Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|Drug: Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|Drug: Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab","Auxilio Mutuo Cancer Center","Female","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NAC CCAM 11-01","July 11, 2012","March 2011","March 2013","July 12, 2012","July 2012","No Study Results Posted","NACprotocol","January 2013","The primary objective is to obtain a RCB rate of 0-1 in at least 66%","https://ClinicalTrials.gov/show/NCT01641406"
1791,"NCT02782754","Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma","Recruiting","No Results Available","Intracranial Germinoma","Drug: Carboplatin|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Bleomycin|Radiation: Reduced dose of radiotherapy","Samsung Medical Center","All","3 Years to 30 Years   (Child, Adult)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2012-10-101","May 23, 2016","January 2013","null","May 23, 2016","May 2016","No Study Results Posted","null","December 2017","Rate of late sequelae|Rate of event free survival","https://ClinicalTrials.gov/show/NCT02782754"
1792,"NCT00450385","Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)","Terminated","No Results Available","Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Drug: Vincristine|Genetic: Lymphoma Tissue Specimen","University of Miami","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","59","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","20061138|SCCC-2006069|WIRB-20070073","March 20, 2007","February 2007","May 2016","June 1, 2016","June 2016","No Study Results Posted","R-CHOP","May 2016","Estimated Rate of Overall Survival at 30 Months in DLBCL Patients Receiving R-CHOP Therapy.|Estimated Rate of Overall Survival at 24-Months in DLBCL Patients receiving R-CHOP Therapy|Estimated Overall Survival Rate in DLBCL Patients Receiving R-CHOP Therapy|Estimated Time to Treatment Failure in DLBCL Patients Receiving R-CHOP Therapy|Overall Response Rate of Study Participants to Protocol Therapy","https://ClinicalTrials.gov/show/NCT00450385"
1793,"NCT01664975","Treatment of Peripheral T-cell Lymphoma","Completed","Has Results","Peripheral T-cell Lymphoma","Drug: GDPT regimen|Drug: CHOP regimen","Mingzhi Zhang|Zhengzhou University","All","14 Years to 70 Years   (Child, Adult, Senior)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","hnslblzlzx2011-3","August 10, 2012","August 2011","April 2016","August 10, 2016","August 2016","August 10, 2016","null","April 2016","Progression-free Survival|Response Rate|Overall Survival|Median Survival Time","https://ClinicalTrials.gov/show/NCT01664975"
1794,"NCT02419495","Phase IB of Selinexor in Combination With Standard Chemotherapy in Patients With Advanced Malignancies","Active, not recruiting","No Results Available","Advanced Cancers","Drug: Selinexor|Drug: Carboplatin|Drug: Paclitaxel|Drug: Eribulin|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Pemetrexed|Drug: Topotecan|Drug: Irinotecan|Drug: 5-FU|Drug: Capecitabine|Drug: Oxaliplatin|Drug: Olaparib|Drug: Pembrolizumab","M.D. Anderson Cancer Center|Karyopharm Therapeutics Inc","All","18 Years and older   (Adult, Senior)","Phase 1","142","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2014-0640|NCI-2015-00693","April 14, 2015","June 26, 2015","June 2019","March 10, 2017","March 2017","No Study Results Posted","null","June 2019","Maximum Tolerated Dose (MTD)|Disease Control","https://ClinicalTrials.gov/show/NCT02419495"
1795,"NCT02918292","Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)","Not yet recruiting","No Results Available","Severe Aplastic Anemia","Drug: Antithymocyte Globulin|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total Body Irradiation (TBI)|Procedure: UCB HSCT|Procedure: Haplo HSCT|Drug: Tacrolimus|Drug: Mycophenolate mofetil (MMF)|Drug: G-CSF","Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","60","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BMTCTN1502|2U10HL069294-11|5U24CA076518","September 27, 2016","September 2017","February 2022","February 7, 2017","February 2017","No Study Results Posted","CHAMP","February 2021","Overall Survival (OS)|Neutrophil Recovery|Platelet Recovery|Alive with Sustained Engraftment|Incidences of Graft Failure|Incidences of graft-vs-host-disease (GVHD)|Immune Reconstitution|Incidences of Infection|Health Related Quality of Life (HR-QoL)","https://ClinicalTrials.gov/show/NCT02918292"
1796,"NCT02013817","CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy","Completed","Has Results","Lymphocytic Leukemia, Chronic","Drug: rituximab [MabThera/Rituxan]|Drug: fludarabine|Drug: cyclophosphamide","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","43","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML18434","December 3, 2013","October 2005","September 2012","September 3, 2014","September 2014","July 22, 2014","null","September 2012","Percentage of Participants With a Best Clinical Response of Clinical Remission (CR)|Percentage of Participants With the Best Clinical Response by Visit (Clinical Assessment)|Percentage of Participants With the Best Clinical Response by Visit (Clinical + Radiological Assessment)|Time to Next Treatment - Percentage of Participants With an Event|Time to Next Treatment - Time to Event|Percentage of Participants With Adverse Events (AEs)","https://ClinicalTrials.gov/show/NCT02013817"
1797,"NCT00140595","ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1","Completed","No Results Available","Diffuse Large-Cell Lymphoma","Drug: rituximab|Drug: doxorubicin|Drug: cyclophosphamide","Lymphoma Study Association|Amgen","All","18 Years to 59 Years   (Adult)","Phase 3","380","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LNH03-2B","August 31, 2005","December 2003","January 2009","March 3, 2011","March 2011","No Study Results Posted","null","January 2009","Event-free survival (EFS), events defined as death from any cause, relapse for complete responders (CR) and unconfirmed complete responders (CRu), progression during or after treatment, changes of therapy during allocated treatment.|Response rate at the end of the treatment, progression rate, relapse rate, disease-free survival for complete responders, overall survival, neuromeningeal relapse rate and additional toxicities with ACVBP+rituximab combination","https://ClinicalTrials.gov/show/NCT00140595"
1798,"NCT03145480","Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients","Not yet recruiting","No Results Available","Richter Syndrome","Drug: Obinutuzumab|Drug: Ibrutinib|Other: CHOP","Northwell Health|Pharmacyclics LLC.","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","43","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","16-727","April 4, 2017","May 30, 2017","December 2023","May 5, 2017","May 2017","No Study Results Posted","null","December 2020","Overall Response Rate (ORR)|Number of participants with improved hemoglobin and platelet counts.|Progression free survival (PFS)|Quality of Life","https://ClinicalTrials.gov/show/NCT03145480"
1799,"NCT01004497","First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL","Completed","No Results Available","Acute Lymphoblastic Leukemia","Drug: Dasatinib|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Daunorubicin|Drug: Dexamethasone|Drug: Cytarabine|Drug: Mitoxantrone","The Catholic University of Korea","All","15 Years to 65 Years   (Child, Adult)","Phase 2","51","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","KC09MIMS0255","October 29, 2009","March 2010","April 2015","May 28, 2015","May 2015","No Study Results Posted","ALL","April 2014","To determine the clinical efficacy of dasatinib plus conventional chemotherapy for newly diagnosed Ph-positive ALL in terms of major molecular response rate|To evaluate the long-term clinical outcomes (including transplant outcomes) in terms of treatment toxicity, relapse, disease-free survival, and overall survival","https://ClinicalTrials.gov/show/NCT01004497"
1800,"NCT00867178","Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System","Active, not recruiting","No Results Available","Untreated Childhood Medulloblastoma|Untreated Childhood Pineoblastoma|Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor","Radiation: 3-Dimensional Conformal Radiation Therapy|Drug: Carboplatin|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Etoposide Phosphate|Drug: Isotretinoin|Other: Laboratory Biomarker Analysis|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Thiotepa|Drug: Vincristine Sulfate|Drug: Vorinostat","National Cancer Institute (NCI)","All","2 Months to 47 Months   (Child)","","62","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2012-03167|PBTC-026|U01CA081457|UM1CA081457","March 20, 2009","February 25, 2009","null","May 23, 2017","May 2017","No Study Results Posted","null","December 30, 2017","Dose-limiting toxicity of proposed vorinostat as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Feasibility in terms of completing 3 courses of induction therapy|Prognostic value of histopathological classification of pediatric medulloblastoma by single-nucleotide polymorphism (SNP) analysis and gene expression analysis|Overall survival (OS)|Predictive values of biological markers in CSF, plasma and urine in the context of a feasibility study|Progression-free survival (PFS)|Response rate of this approach in patients with measurable residual disease (primary site and/or metastatic sites)","https://ClinicalTrials.gov/show/NCT00867178"
1801,"NCT01814046","Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma","Active, not recruiting","No Results Available","Metastatic Ocular Melanoma|Metastatic Uveal Melanoma","Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Young TIL","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","16 Years to 75 Years   (Child, Adult, Senior)","Phase 2","23","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","130093|13-C-0093","March 15, 2013","March 1, 2013","May 1, 2019","May 4, 2017","January 31, 2017","No Study Results Posted","null","May 1, 2017","Determine whether objective reponses can be mediated in patients with ocular melonoma treated with young TIL with or without high dose aldesleukin|To study immunologic correlates associated with Young TIL therapy for ocular melanoma|To determine the toxicity of this treatment regimen","https://ClinicalTrials.gov/show/NCT01814046"
1802,"NCT00209209","Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL","Active, not recruiting","No Results Available","Lymphoma, Mantle-Cell","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Fludarabine|Drug: Interferon-alpha|Drug: pegylated formula Interferon-alpha 2b|Procedure: chemotherapy: R-CHOP|Procedure: chemotherapy: R-FC|Procedure: Interferon maintenance|Procedure: Rituximab maintenance","European Mantle Cell Lymphoma Network|German Low Grade Lymphoma Study Group|Lymphoma Study Association|HOVON - Dutch Haemato-Oncology Association|Nordic Lymphoma Group","All","60 Years and older   (Adult, Senior)","Phase 3","570","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","MCL2004-1","September 13, 2005","January 14, 2004","December 2018","March 6, 2017","March 2017","No Study Results Posted","MCLelderly","December 2018","First randomisation: Reduction of lymphoma mass measured by the complete remission (CR) rate|Second randomisation: progression-free survival after end of initial chemotherapy|Survival after registration / first randomisation / second randomisation|Survival after start / end of initial therapy|Time to treatment failure after start of initial therapy|Progression free survival after registration / first randomisation / second randomisation|Side-effects of initial therapy|Side-effects of maintenance therapy","https://ClinicalTrials.gov/show/NCT00209209"
1803,"NCT00022945","Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma","Completed","No Results Available","Mantle Cell Lymphoma","Drug: Iodine-131 Anti-B1 Antibody|Drug: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)","Corixa Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CP-99-037","August 16, 2001","null","null","June 23, 2005","January 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00022945"
1804,"NCT01218867","CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer","Completed","Has Results","Metastatic Cancer|Metastatic Melanoma|Renal Cancer","Biological: Anti-VEGFR2 CAR CD8 plus PBL|Drug: Cyclophosphamide|Biological: Aldesleukin|Drug: Fludarabine","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","24","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","110013|11-C-0013","October 8, 2010","October 2010","February 2016","November 8, 2016","October 2016","April 15, 2016","null","February 2016","Response to Therapy|Number of Participants With Adverse Events|In Vivo Survival of Chimeric T Cell Receptor (CAR) Gene-engineered Cells","https://ClinicalTrials.gov/show/NCT01218867"
1805,"NCT00509496","Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes","Terminated","Has Results","Skin Cancer|Melanoma","Drug: fludarabine phosphate|Drug: cyclophosphamide|Biological: aldesleukin|Biological: autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes|Biological: autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","21","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","070174|07-C-0174","July 30, 2007","June 2007","July 2012","January 4, 2013","December 2012","October 31, 2012","null","July 2011","Clinical Tumor Regression.|Toxicity","https://ClinicalTrials.gov/show/NCT00509496"
1806,"NCT01746849","Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation","Recruiting","No Results Available","Leukemia|Multiple Myeloma|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma","Biological: Palifermin|Biological: Lupron|Procedure: peripheral blood stem cell transplantation|Radiation: Total-Body Irradiation (TBI)|Drug: Thiotepa|Drug: Cyclophosphamide","Memorial Sloan Kettering Cancer Center|Swedish Orphan Biovitrum","All","18 Years to 60 Years   (Adult)","Phase 2","120","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","12-077","December 7, 2012","December 2012","December 2018","May 18, 2017","May 2017","No Study Results Posted","null","December 2018","a CD4+ T cell count of greater than 200|Overall Survival|Transplant Related Mortality|Incidence of infections|Relapse","https://ClinicalTrials.gov/show/NCT01746849"
1807,"NCT01848132","Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.","Active, not recruiting","No Results Available","Diffuse, Large B-Cell, Lymphoma","Drug: Bortezomib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Drug: Vincristine","Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Janssen-Cilag, S.A.","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","121","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BRCAP-GELTAMO12|2012-005138-12","May 3, 2013","October 2013","March 2017","January 4, 2017","January 2017","No Study Results Posted","null","March 2017","Proportion of patients with Event-Free Survival at 2 years.|Event-Free survival at 2 years in the different subtypes of DLBCL|Overall survival at 2 years|Overall response rate and complete remissions|Toxicity according to the CTC criteria|To evaluate the predictive value for EFS of interim PET/CT evaluation|To identify clinical and biological prognostic factors for response and survival.","https://ClinicalTrials.gov/show/NCT01848132"
1808,"NCT00524303","Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.","Completed","Has Results","Neoplasms, Breast","Drug: Trastuzumab|Drug: Paclitaxel|Drug: FEC75|Drug: Lapatinib","GlaxoSmithKline","Female","18 Years and older   (Adult, Senior)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LPT109096","August 31, 2007","August 2007","August 2015","September 23, 2016","March 2016","July 14, 2011","null","October 2010","Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy|Percentage of Participants With Clinical Complete Response (cCR) at 26 Weeks or at End of Treatment (EOT) or Early Withdrawal|Percentage of Participants (Par.) With Disease-free Survival (DFS) at the End of 5 Years From Randomization|Number of Participants With the Indicated Electrocardiogram (ECG) Status at Baseline and at EOT or Early Withdrawal|Cumulative Number of Participants With at Least One Decrease of More Than or Equal to 20% in Left Ventricular Ejection Fraction (LVEF) at the Indicated Time Points Compared to LVEF at Baseline","https://ClinicalTrials.gov/show/NCT00524303"
1809,"NCT02978495","Neoadjuvant Carboplatin in Triple Negative Breast Cancer","Recruiting","No Results Available","BRCA1 Hereditary Breast and Ovarian Cancer Syndrome","Drug: Doxorubicin|Drug: Carboplatin|Drug: Paclitaxel|Drug: Cyclophosphamide","Barretos Cancer Hospital","Female","18 Years and older   (Adult, Senior)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BarretosCH - 20162","November 24, 2016","May 17, 2017","December 2022","May 17, 2017","May 2017","No Study Results Posted","null","December 2019","Pathological complete response (pCR), defined as absence of invasive cancer in the breast and axillary lymph nodes.|Disease free survival (DFS)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02978495"
1810,"NCT02890602","Erythropoietin for Management of Anemia Caused by Chemotherapy","Active, not recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Darbepoetin alfa|Drug: R-CHOP","Kosin University Gospel Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","53","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","EPOMA","August 18, 2016","September 2012","December 2017","September 7, 2016","September 2016","No Study Results Posted","null","December 2016","Hematopoietic response|Quality of life as measured by Functional Assessment of Cancer Therapy Scales for anemia|Adverse events as measured by CTCAE v3.0|Proportion of patients requiring red blood cell transfusions|Mean time to response of hemoglobin","https://ClinicalTrials.gov/show/NCT02890602"
1811,"NCT00101010","Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma","Completed","No Results Available","Lymphoma","Biological: Filgrastim|Biological: Pegfilgrastim|Biological: Rituximab|Drug: Cyclophosphamide|Drug: Pegylated liposomal doxorubicin hydrochloride|Drug: Prednisone|Drug: Vincristine Sulfate","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Ortho Biotech, Inc.","All","61 Years and older   (Adult, Senior)","Phase 2","80","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000407533|MDA-CCOP-2004-0305|NCI-6485|2004-0305|NCI-2009-00064|2U10CA045809","January 7, 2005","September 2005","null","September 10, 2014","September 2014","No Study Results Posted","null","September 2014","Disease response (complete, complete unconfirmed, and partial responses) after courses 4 and 8|Cardiac toxicity as measured by LVEF on ECHO after courses 4 and 8|Survival Rate|Disease-free survival","https://ClinicalTrials.gov/show/NCT00101010"
1812,"NCT00963729","Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: docetaxel|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: letrozole","Imperial College London|National Cancer Institute (NCI)","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","756","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","ICCRU-NEOcent-C-21-07|CDR0000641383|EU-20936|EUDRACT-2006-003596-12|ISRCTN77234840","August 20, 2009","September 2008","March 2011","August 9, 2013","August 2011","No Study Results Posted","null","March 2010","Feasibility of patient recruitment (pilot)|Feasibility of tissue collection (pilot)|Ultrasound (or mammogram) response rate|Clinical response rate|Radiologic response rate by ultrasound (pilot)|Quality of life|Pathological complete response rate (pCR) defined as no residual invasive or pre-invasive carcinoma in breast or axilla (pilot)|Plasma DNA changes in relation to treatment response|Rate of conservation surgery|Degree of pathological response|Ki-67 changes and its relationship to treatment response|Length of time to maximum response within the treatment period|Tolerability of the various treatments|Disease-free survival|Overall survival|MRI response","https://ClinicalTrials.gov/show/NCT00963729"
1813,"NCT01696669","Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults","Active, not recruiting","No Results Available","Ewing's Sarcoma","Drug: Chemotherapy|Procedure: Surgery|Radiation: Radiotherapy","Grupo Espanol de Investigacion en Sarcomas","All","up to 40 Years   (Child, Adult)","Phase 2","43","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEIS-21|2009-016027-62","June 30, 2011","April 2010","December 2016","August 17, 2015","August 2015","No Study Results Posted","null","December 2016","Progression Free Survival|Objective response rate (ORR)|Assessment of disease progression|evaluate the toxicity and tolerance to the treatment Gemcitabine + Docetaxel in high risk patients, and toxicity and tolerance of mP6 treatment in all patients.|Assessment of bone marrow condition.|Study the impact of patients treated with Cardioxane in cardioprotection","https://ClinicalTrials.gov/show/NCT01696669"
1814,"NCT00741455","Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies","Active, not recruiting","No Results Available","Hematologic Malignancies","Procedure: Chemotherapy followed by Stem Cell Transplantation","Dartmouth-Hitchcock Medical Center","All","18 Years to 75 Years   (Adult, Senior)","","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","D0345","August 25, 2008","June 2004","December 2017","May 4, 2016","May 2016","No Study Results Posted","null","January 2014","Rates of successful engraftment.|Complete donor chimerism|Graft-versus-host disease (acute and chronic)|Mortality|Toxicity|Tumor Response Rate","https://ClinicalTrials.gov/show/NCT00741455"
1815,"NCT00136084","Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia","Completed","Has Results","Leukemia, Myelocytic, Acute","Drug: Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone|Drug: Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine","St. Jude Children's Research Hospital|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","238","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AML02|5R01CA113482","August 24, 2005","August 2002","June 2012","November 2, 2012","November 2012","March 5, 2010","null","July 2008","Minimal Residual Disease (MRD).|Proportion of Minimal Residual Disease (MRD)+ Patients Who Become MRD- After One Course of Gemtuzumab Ozogamicin (GO)|Proportion of MRD Reduction After One Course of Cytarabine + Daunomycin + Etoposide (ADE) + GO|Proportion of Patients Experienced Toxicity of Cytarabine + Daunomycin + Etoposide (ADE) + GO.|To Estimate the Overall Event-free Survival (EFS) of AML Patients Who Undergo Risk-adapted and Genotype-directed Therapy|To Assess Whether Inhibition of DNA Synthesis is Greater After High-dose Ara-C (HDAC) Than After Low-dose Ara-C (LDAC) Therapy|Relationship of Inhibition of DNA Synthesis and Clinical Response","https://ClinicalTrials.gov/show/NCT00136084"
1816,"NCT00040482","High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis","Completed","No Results Available","Multiple Sclerosis","Drug: Cyclophosphamide|Drug: ATG|Drug: MESNA|Procedure: Radiation therapy","Baylor College of Medicine|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine","All","18 Years to 60 Years   (Adult)","Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H7156|Multiple Sclerosis","June 26, 2002","April 1999","August 2005","April 9, 2007","April 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00040482"
1817,"NCT01093235","Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer","Unknown status","No Results Available","Breast Cancer|Cardiac Toxicity|Perioperative/Postoperative Complications","Biological: bevacizumab|Drug: cyclophosphamide|Drug: docetaxel|Drug: epirubicin hydrochloride|Drug: fluorouracil|Procedure: assessment of therapy complications|Procedure: neoadjuvant therapy|Procedure: quality-of-life assessment|Procedure: therapeutic conventional surgery","Cambridge University Hospitals NHS Foundation Trust|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","800","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000668530|CRCA-CCTC-WCTU-ARTemis|ISRCTN68502941|EUDRACT-2008-002322-11|EU-21017|MREC-08/H1102/104","March 24, 2010","April 2009","null","March 24, 2010","March 2010","No Study Results Posted","null","April 2012","Complete pathological response rates (tumor and lymph nodes)|Disease-free survival|Overall survival|Pathological complete response rate in breast alone|Radiological response after 3 and 6 courses of chemotherapy|Rate of breast conservation|Toxicities, including cardiac safety and surgical complications (wound healing, bleeding, and thrombosis)|Quality of life","https://ClinicalTrials.gov/show/NCT01093235"
1818,"NCT00002875","Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma","Completed","No Results Available","Brain Tumors|Central Nervous System Tumors","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: lomustine|Drug: mesna|Drug: vincristine sulfate|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy","Children's Oncology Group|National Cancer Institute (NCI)|Pediatric Oncology Group","All","3 Years to 22 Years   (Child, Adult)","Phase 3","421","Other|NIH","Interventional","Allocation: Randomized|Masking: Single Blind|Primary Purpose: Treatment","A9961|CCG-A9961|POG-A9961|CDR0000065160","November 1, 1999","December 1996","January 2011","July 31, 2014","July 2014","No Study Results Posted","null","February 2006","Event Free Survival","https://ClinicalTrials.gov/show/NCT00002875"
1819,"NCT00186875","Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia","Completed","Has Results","Acute Lymphoblastic Leukemia|Lymphoma, Lymphoblastic","Drug: Etoposide, cytarabine, vincristine, dexamethasone|Drug: methotrexate, teniposide, PEG-asparaginase|Drug: mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine|Drug: L-asparaginase, erwinia asparaginase|Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy|Procedure: Hematopoietic Stem Cell Transplant|Procedure: Natural Killer (NK) Cell Transplant","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","Phase 2","47","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ALLR17|NCI-2011-01256","September 1, 2005","November 2003","August 2016","April 11, 2017","September 2016","October 25, 2013","null","August 2016","Response Rate|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT00186875"
1820,"NCT00079144","Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma","Completed","No Results Available","Melanoma (Skin)","Biological: NY-ESO-1 peptide vaccine|Biological: aldesleukin|Biological: filgrastim|Biological: incomplete Freund's adjuvant|Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate","National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 2","null","NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000354491|NCI-04-C-0104|NCI-6233","March 8, 2004","January 2004","August 2005","June 18, 2013","May 2005","No Study Results Posted","null","null","Clinical tumor regression|Survival of infused lymphocytes|Long-term immune status","https://ClinicalTrials.gov/show/NCT00079144"
1821,"NCT00000689","Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma","Completed","No Results Available","Lymphoma, Non-Hodgkin|HIV Infections","Drug: Bleomycin sulfate|Drug: Vincristine sulfate|Drug: Doxorubicin hydrochloride|Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Cytarabine|Drug: Leucovorin calcium|Drug: Sargramostim|Drug: Dexamethasone","National Institute of Allergy and Infectious Diseases (NIAID)","All","13 Years and older   (Child, Adult, Senior)","Phase 1","18","NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","ACTG 074|11048","November 2, 1999","null","March 1991","April 26, 2012","April 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00000689"
1822,"NCT02199041","Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen","Recruiting","No Results Available","Hematological Malignancies","Drug: Cyclophosphamide|Drug: Thiotepa|Drug: Fludarabine|Drug: Melphalan|Drug: Mesna|Biological: G-CSF|Drug: Mycophenolate mofetil|Drug: Tacrolimus|Drug: Methylprednisolone|Radiation: Total lymphoid irradiation|Biological: Lymphocyte infusions|Device: CliniMACS","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","Phase 2","49","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","HAPCORD|NCI-2014-00526","July 9, 2014","July 11, 2014","August 30, 2020","March 30, 2017","August 2016","No Study Results Posted","null","September 30, 2019","Rate of neutrophil engraftment|Incidence of malignant relapse|Event-free survival|Overall survival|Incidence by severity of acute and chronic graft versus host disease (GVHD) in the first 100 days after HCT|Incidence of transplant-related mortality (TRM)|Incidence of transplant-related morbidity|Incidence of secondary graft failure","https://ClinicalTrials.gov/show/NCT02199041"
1823,"NCT00006055","Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases","Unknown status","No Results Available","Purpura, Schoenlein-Henoch|Graft Versus Host Disease|Anemia, Hemolytic, Autoimmune|Rheumatoid Arthritis|Churg-Strauss Syndrome|Hypersensitivity Vasculitis|Wegener's Granulomatosis|Systemic Lupus Erythematosus|Giant Cell Arteritis|Pure Red Cell Aplasia|Juvenile Rheumatoid Arthritis|Polyarteritis Nodosa|Autoimmune Thrombocytopenic Purpura|Takayasu Arteritis","Drug: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: filgrastim|Drug: methylprednisolone|Drug: prednisone|Procedure: Autologous Peripheral Blood Stem Cell Transplantation","Fairview University Medical Center|Office of Rare Diseases (ORD)","All","1 Year to 55 Years   (Child, Adult)","","10","Other","Interventional","Primary Purpose: Treatment","199/15105|UMN-MT-1996-15|UMN-MT-9615","July 5, 2000","March 2000","null","June 23, 2005","October 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006055"
1824,"NCT00290667","Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma","Completed","No Results Available","Lymphoma","Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Other: pharmacological study|Radiation: radiation therapy","German High-Grade Non-Hodgkin's Lymphoma Study Group","All","61 Years to 80 Years   (Adult, Senior)","Phase 2","586","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000454505|DSHNHL-2004-1|EU-20536|DSHNHL-CHOP-R-ESC|EUDRACT-2005-00529-68","February 9, 2006","February 2004","November 2015","November 25, 2015","November 2015","No Study Results Posted","null","December 2013","Pharmacokinetics (in first 20 patients of each cohort with a distinct variation of the rituximab schedule) assessed on days -4, -1, 10, 29, 57, 99, 155, 239, 267, 295, 407, and 491 of treatment|Safety and treatment related deaths at 3 months after study completion|Toxicity assessed by NCI criteria, adverse events, serious adverse events, protocol adherence, and treatment-related deaths at 3 months after study completion|Time to treatment failure assessed at 2 years within the study and periodically thereafter|Complete response rate assessed at 2 years within the study and periodically thereafter|Progression rate|Survival time|Progression-free survival","https://ClinicalTrials.gov/show/NCT00290667"
1825,"NCT02928991","Fludarabine Based RIC for Bone Marrow Failure Syndromes","Recruiting","No Results Available","Bone Marrow Failure Syndromes","Other: MRD-BMT with Fludarabine-based RIC for Acquired AA|Other: MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia|Other: MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia","Children's Hospital of Philadelphia","All","up to 22 Years   (Child, Adult)","Early Phase 1","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","14-011465|14BT057","October 7, 2016","April 2015","April 2020","October 27, 2016","October 2016","No Study Results Posted","null","April 2020","Rate of graft failure|Time to neutrophil engraftment|Transplant-related mortality|Rate of overall survival|Rate of disease free survival","https://ClinicalTrials.gov/show/NCT02928991"
1826,"NCT02280811","T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers","Completed","No Results Available","Vaginal Cancer|Cervical Cancer|Anal Cancer|Penile Cancer|Oropharyngeal Cancer","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: E6 TCR|Drug: Aldesleukin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","12","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","150005|15-C-0005","October 30, 2014","October 14, 2014","June 28, 2016","January 24, 2017","September 26, 2016","No Study Results Posted","null","June 28, 2016","To determine the objective tumor response rate and duration in patients with metastatic or recurrent/refractory HPV-16+ cancers treated with autologous T cells expressing the E6 TCR plus aldesleukin following a lymphocyte-depleting preparative r...","https://ClinicalTrials.gov/show/NCT02280811"
1827,"NCT02880293","Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor","Recruiting","No Results Available","Hematologic Malignancy","Drug: melphalan|Drug: fludarabine|Drug: thiotepa|Drug: Cyclophosphamide|Drug: Mesna|Drug: Mycophenolate Mofetil|Drug: Filgrastim|Drug: Tacrolimus","Memorial Sloan Kettering Cancer Center","All","18 Years to 75 Years   (Adult, Senior)","","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","16-1237","August 23, 2016","August 23, 2016","August 2019","March 21, 2017","March 2017","No Study Results Posted","null","August 2019","proportion of patients undergoing an allo HCT transplant who have a KIR favorable donor.","https://ClinicalTrials.gov/show/NCT02880293"
1828,"NCT01864109","Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma","Recruiting","No Results Available","Newly Diagnosed Ewing Sarcoma","Drug: Cyclophosphamide|Device: Doxorubicin|Drug: Vincristine|Device: Ifosfamide|Drug: Etoposide|Procedure: Surgery|Radiation: Radiation Therapy*|Drug: Temozolomide|Drug: Irinotecan","Memorial Sloan Kettering Cancer Center","All","1 Year to 40 Years   (Child, Adult)","Phase 2","83","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","13-068","May 23, 2013","May 2013","May 2019","May 19, 2017","May 2017","No Study Results Posted","null","May 2019","event free survival of patients with localized disease|event free survival of patients with metastatic disease|adverse event profile","https://ClinicalTrials.gov/show/NCT01864109"
1829,"NCT00363090","Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: alemtuzumab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Other: flow cytometry|Other: pharmacological study","Toronto Sunnybrook Regional Cancer Centre|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","84","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000491451|TSRCC-164-2006","August 10, 2006","September 2006","null","September 19, 2013","June 2009","No Study Results Posted","null","December 2010","Toxicity as assessed by NCI Common Toxicity Criteria Version 3.0|Safety|Dose-limiting toxicities|Pharmacokinetics of alemtuzumab|Efficacy as assessed by clinical, radiologic, pathologic, and laboratory measurements|Overall response rate|Progression-free survival|Overall survival|Effects of treatment on T- and B-cell reconstitution by flow cytometry at baseline and at 3, 6, and 12 months","https://ClinicalTrials.gov/show/NCT00363090"
1830,"NCT00630565","Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia","Recruiting","No Results Available","Leukemia","Biological: sargramostim|Drug: busulfan|Drug: cyclophosphamide|Drug: dexamethasone|Drug: etoposide|Procedure: bone marrow transplantation|Procedure: hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation","Masonic Cancer Center, University of Minnesota","All","up to 70 Years   (Child, Adult, Senior)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","MT2006-13|0607M89052","March 6, 2008","July 26, 2006","December 2021","February 17, 2017","February 2017","No Study Results Posted","null","December 2019","Engraftment|Disease Response|Time to Treatment Failure|Percent of patients with various late effects|Disease-free survival|Number of Patients with Adequate Cells Collected","https://ClinicalTrials.gov/show/NCT00630565"
1831,"NCT00505921","Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma","Terminated","Has Results","Lymphoma","Drug: Campath-1H|Drug: G-CSF|Drug: GM-CSF|Drug: BCNU|Drug: Stem Cell Transplant|Drug: Preparative Regimen for Allogenic Stem Cell Transplantation|Drug: Cytarabine|Drug: Etoposide|Drug: Melphalan|Drug: Campath|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Low dose total body irradiation","M.D. Anderson Cancer Center|Bayer","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","27","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","ID02-645","July 20, 2007","March 2003","November 2009","November 8, 2011","November 2011","September 30, 2011","null","November 2009","Participant Progression Free Survival at 2 Years","https://ClinicalTrials.gov/show/NCT00505921"
1832,"NCT00740467","Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders","Unknown status","No Results Available","Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Precancerous Condition","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation","Institut Paoli-Calmettes|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000592923|IPC-ITT-06-01|INCA-RECF0627|EUDRACT-2006-001369-14","August 22, 2008","January 2008","null","January 27, 2010","July 2009","No Study Results Posted","null","January 2010","Incidence of graft acceptance","https://ClinicalTrials.gov/show/NCT00740467"
1833,"NCT02605421","Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma","Recruiting","No Results Available","Neuroblastoma","Drug: Thiotepa|Drug: Cyclophosphamide|Drug: Melphalan|Drug: Etoposide|Drug: Carboplatin|Biological: Autologous Stem Cell Infusion|Biological: Granulocyte colony stimulating factor","Masonic Cancer Center, University of Minnesota","All","up to 30 Years   (Child, Adult)","Phase 2","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2015LS108","November 12, 2015","June 2016","January 2023","February 17, 2017","February 2017","No Study Results Posted","null","January 2020","Progression Free Survival|Time to Engraftment|Relapse|Overall Survival","https://ClinicalTrials.gov/show/NCT02605421"
1834,"NCT00387959","Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma","Completed","Has Results","Leukemia|Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: total-body irradiation","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","17","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-066|MSKCC-06066","October 12, 2006","July 2006","April 2014","December 22, 2015","December 2015","December 22, 2015","null","April 2014","Survival at 1 Year After Transplantation","https://ClinicalTrials.gov/show/NCT00387959"
1835,"NCT00896519","GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: rituximab|Biological: sargramostim|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Genetic: gene expression analysis|Genetic: gene rearrangement analysis|Genetic: polymerase chain reaction|Other: R-CHOP regimen|Other: laboratory biomarker analysis","French Innovative Leukemia Organisation|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","GOELAMS-FL2008-RCHOP-GM|CDR0000637105|FL2008-RCHOP-GM|EUDRACT2007-007056-33|RECF0907","May 8, 2009","March 2009","null","August 1, 2013","July 2009","No Study Results Posted","null","March 2011","Overall objective tumor response rate|Time to treatment progression|Overall survival|Duration of response|Time to next treatment|Safety profile|Influence of FcγR polymorphisms on clinical response and overall survival|Monitoring of FcγR expressing cells during treatment|Quantitative monitoring of the molecular biological marker bcl-2 in peripheral blood and bone marrow by PCR assay","https://ClinicalTrials.gov/show/NCT00896519"
1836,"NCT01341301","Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies","Completed","No Results Available","Hematologic Malignancy","Radiation: Total Body Irradiation|Biological: Donor Lymphocyte Infusion (DLI)|Drug: Cyclophosphamide|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Procedure: Allogeneic hematopoietic stem cell transplantation|Other: Laboratory biomarker analysis","Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10D.06|2009-41","April 21, 2011","May 2010","January 2014","December 15, 2014","December 2014","No Study Results Posted","null","November 2013","Overall survival|Relapse free survival (RFS)|Consistency and pace of engraftment|Pace of T-cell and B-cell immune recovery|Regimen related toxicities graded according to the National Cancer Institute (NCI) Common Toxicity Criteria, version 3.0|Incidence and severity of GVHD, graded according to standard criteria","https://ClinicalTrials.gov/show/NCT01341301"
1837,"NCT02423915","Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention","Recruiting","No Results Available","Leukemia|Lymphoma","Drug: Rituximab|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total Body Radiation|Procedure: Fucosylated Regulatory T Cells|Procedure: Cord Blood Infusions|Drug: Mycophenolate mofetil|Drug: Sirolimus|Procedure: Bone Marrow Aspiration|Drug: G-CSF|Procedure: Non-Fucosylated Regulatory T Cells","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas","All","up to 80 Years   (Child, Adult, Senior)","Phase 1|Phase 2","47","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2014-0150|NCI-2015-00705|1R44CA192601-01A1|RP160121","April 15, 2015","July 30, 2015","July 2019","April 21, 2017","April 2017","No Study Results Posted","null","July 2019","Severe Infusional Toxicity|Safety of Administering Fucosylated Umbilical Cord Blood (CB) Regulatory T cells (Tregs) in a CBT, MRD, or MUD Transplant|Time to Severe Graft Versus Host Disease (GVHD) or Death","https://ClinicalTrials.gov/show/NCT02423915"
1838,"NCT01849783","Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma","Recruiting","No Results Available","Extramedullary Plasmacytoma|Isolated Plasmacytoma of Bone|Light Chain Deposition Disease|Primary Systemic Amyloidosis|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma","Drug: dexamethasone|Drug: cisplatin|Drug: doxorubicin|Drug: cyclophosphamide|Drug: etoposide|Drug: bortezomib|Drug: thalidomide|Drug: melphalan|Procedure: autologous stem cell transplant","University of Iowa|National Cancer Institute (NCI)","All","65 Years to 85 Years   (Adult, Senior)","Phase 2","41","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","201208755|NCI-2013-00883|10120146|P30CA086862","May 6, 2013","April 2013","December 2017","February 20, 2017","February 2017","No Study Results Posted","null","June 2017","PFS|Severe complications (ICU admission, death), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0|Percentage of participants able to complete full course of therapy|Complete response (CR) rate using the International Myeloma Working group uniform response criteria|Event free survival|Time to progression|Overall survival","https://ClinicalTrials.gov/show/NCT01849783"
1839,"NCT00002755","Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: CMF regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: fluorouracil|Drug: methotrexate|Drug: tamoxifen citrate|Drug: thiotepa|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy","Scottish Cancer Therapy Network|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","600","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000064692|SCTN-BR9405|EU-95048","November 1, 1999","November 1995","June 1999","November 5, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002755"
1840,"NCT00338377","Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","Recruiting","No Results Available","Melanoma","Biological: Dendritic Cell Immunization|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: T-Cells|Biological: Interleukin-2|Drug: Mesna|Biological: Intrathecal T-Cells|Biological: Intrathecal Interleukin-2","M.D. Anderson Cancer Center|Prometheus Laboratories|Key Biologics, LLC|National Cancer Institute (NCI)","All","12 Years and older   (Child, Adult, Senior)","Phase 2","189","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2004-0069|NCI-2012-01368|5R01CA187076-02","February 10, 2006","February 2006","null","January 18, 2017","January 2017","No Study Results Posted","null","February 2019","Objective Response (OR)|Longitudinal Immune Response","https://ClinicalTrials.gov/show/NCT00338377"
1841,"NCT01148446","R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL","Completed","No Results Available","Elderly Patients (>65 Years)|Diffuse Large B Cell Lymphoma (DLBCL)","Drug: Cyclophosphamide|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Prednisone|Drug: Epirubicin|Drug: Vinblastine|Drug: Rituximab|Drug: G-CSF","Fondazione Italiana Linfomi ONLUS","All","66 Years to 80 Years   (Senior)","Phase 3","226","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IIL ANZINTER3","June 21, 2010","January 2003","null","June 21, 2010","June 2010","No Study Results Posted","ANZINTER3","January 2006","Event Free Survival (EFS)|Complete Remission (CR) rate|Disease Free Survival (DFS)|Multidimensional Evaluation Scale for the definition of ""frail"" and ""non frail"" patients","https://ClinicalTrials.gov/show/NCT01148446"
1842,"NCT00003974","Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma","Completed","No Results Available","Lung Cancer|Malignant Mesothelioma","Biological: lung tumor associated antigen|Drug: DetoxPC|Drug: chemotherapy|Drug: cyclophosphamide","Roswell Park Cancer Institute","All","20 Years to 70 Years   (Adult, Senior)","Phase 1","20","Other","Interventional","Primary Purpose: Treatment","CDR0000067177|RPCI-DS-96-25","November 1, 1999","August 1997","November 2000","March 3, 2011","March 2011","No Study Results Posted","null","June 1998","","https://ClinicalTrials.gov/show/NCT00003974"
1843,"NCT01390584","Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma","Terminated","No Results Available","Lymphoma","Biological: bleomycin sulfate|Drug: ABVD regimen|Drug: BEACOPP regimen|Drug: cyclophosphamide|Drug: dacarbazine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: procarbazine hydrochloride|Drug: vinblastine|Drug: vincristine sulfate|Other: laboratory biomarker analysis|Procedure: computed tomography|Radiation: fludeoxyglucose F 18|Radiation: selective external radiation therapy","American College of Radiology Imaging Network|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","200","Other|NIH","Interventional","Masking: No masking|Primary Purpose: Treatment","CDR0000702859|ECOG-E2410, ACRIN 6700|U01CA079778|U01CA080098","July 7, 2011","April 2012","January 2014","March 16, 2017","March 2017","No Study Results Posted","null","January 2014","36-month progression-free survival|PET-positive rate|PET-negative rate|Complete response|Toxicity of response-adapted chemotherapy","https://ClinicalTrials.gov/show/NCT01390584"
1844,"NCT00109837","S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","Completed","Has Results","Leukemia","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin|Drug: dexamethasone|Drug: doxorubicin|Drug: leucovorin|Drug: mercaptopurine|Drug: methotrexate|Drug: mitoxantrone|Drug: Asparaginase|Drug: prednisone|Drug: thioguanine|Drug: vincristine|Radiation: radiation therapy|Drug: allopurinol|Drug: bactrim","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years to 64 Years   (Adult)","Phase 2","79","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S0333|U10CA032102","May 3, 2005","April 2005","November 2014","March 5, 2015","March 2015","April 4, 2012","null","November 2010","Continuous Complete Remission at 1 Year|Toxicity","https://ClinicalTrials.gov/show/NCT00109837"
1845,"NCT01359592","S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma","Recruiting","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Other: R-CHOP regimen|Other: laboratory biomarker analysis|Radiation: fludeoxyglucose F 18|Radiation: selective external radiation therapy|Radiation: yttrium Y 90 ibritumomab tiuxetan","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","155","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000700624|S1001|U10CA032102","May 21, 2011","September 2011","null","July 21, 2016","July 2016","No Study Results Posted","null","June 2020","Five-year PFS rate of patients with DLBCL|PFS within the PET+ and PET- subgroups of patients with newly diagnosed limited-stage DLBCL|Toxicity of protocol treatments|Overall survival of patients with DLBCL|Association of germinal center B-cell subtype (GCB) vs stromal-1 vs stromal-2 gene expression signatures with PFS or overall survival","https://ClinicalTrials.gov/show/NCT01359592"
1846,"NCT02702960","Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)","Recruiting","No Results Available","Fibrolamellar Hepatocellular Carcinoma|Hepatocellular Carcinoma (Fibrolamellar Variant)|Hepatocellular Carcinoma","Procedure: living related donor partial liver transplantation|Radiation: Total body irradiation|Procedure: Bone marrow transplant from same donor|Drug: Cyclophosphamide|Drug: Mesna|Drug: Filgrastim|Drug: Tacrolimus|Drug: mycophenolate mofetil|Drug: Prednisone|Drug: Antithymocyte globulin|Drug: fludarabine","Sidney Kimmel Comprehensive Cancer Center|Fibrolamellar Cancer Foundation","All","16 Years to 65 Years   (Child, Adult)","Phase 2","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J15171|IRB00080373","February 26, 2016","March 2016","January 2020","May 17, 2016","May 2016","No Study Results Posted","null","July 2019","1 year disease-free survival (at 1 year after BMT)|Occurrence of Graft versus Host Disease|Death|Liver allograft failure","https://ClinicalTrials.gov/show/NCT02702960"
1847,"NCT01964391","A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: Trastuzumab|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Paclitaxel|Drug: Docetaxel|Drug: Carboplatin|Drug: Neo-adjuvant chemotherapy","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","174","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ML28851","October 8, 2013","February 28, 2014","November 30, 2018","March 30, 2017","March 2017","No Study Results Posted","null","November 30, 2018","Participant Satisfaction Questionnaire Score|Percentage of Participants with Adverse Events (AEs)|Healthcare Professional Experience and Satisfaction Questionnaire Score|Overall Survival (OS)|Disease-Free Survival (DFS)|Number of Days on Trastuzumab Treatment|Total Daily Dose of Trastuzumab|Cumulative Dose of Trastuzumab|Duration of Treatment, Follow-up, and Safety Observation","https://ClinicalTrials.gov/show/NCT01964391"
1848,"NCT00352209","Cardiomyopathy Following Stem Cell Transplantation","Completed","No Results Available","Cardiomyopathy","","National Institutes of Health Clinical Center (CC)","All","18 Years to 80 Years   (Adult, Senior)","","null","NIH","Observational","","060158|06-CC-0158","July 13, 2006","May 2, 2006","May 16, 2007","January 24, 2017","May 16, 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00352209"
1849,"NCT00801918","Denileukine Diftitox for Relapsed ALCL","Withdrawn","No Results Available","Anaplastic Large-Cell Lymphoma","Drug: Denileukin Diftitox|Drug: Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide","Columbia University","All","2 Years to 24 Years   (Child, Adult)","Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AAAC8963","December 3, 2008","December 2008","June 2012","May 14, 2013","October 2009","No Study Results Posted","null","December 2011","Toxicity|Determine response rate|Evaluate safety of combination of Denileukin Diftitox and ICE chemotherapy|Biology Studies of ALCL","https://ClinicalTrials.gov/show/NCT00801918"
1850,"NCT01424982","Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)","Recruiting","No Results Available","Leukemia","Drug: Cyclophosphamide|Drug: Mesna|Drug: Doxorubicin|Drug: Vincristine|Drug: Dexamethasone|Drug: Ponatinib|Drug: G-CSF (Filgrastim)|Drug: Rituximab|Drug: Methotrexate|Drug: Cytarabine|Drug: Solu-medrol ( Methyl Prednisolone)|Drug: Citrovorum (Leucovorin)|Drug: Prednisone|Drug: Pegfilgrastim (Neulasta)","M.D. Anderson Cancer Center|Ariad Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","100","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2011-0030|NCI-2011-02941","August 24, 2011","October 2011","October 2019","April 17, 2017","April 2017","No Study Results Posted","null","October 2019","Participants' Median Event-Free Survival (EFS)","https://ClinicalTrials.gov/show/NCT01424982"
1851,"NCT02400567","Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women","Active, not recruiting","No Results Available","Neoadjuvant Operable Breast Cancer","Drug: Fluorouracile|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Letrozole|Drug: Palbociclib","UNICANCER|Pfizer|NanoString Technologies, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","125","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NeoPal - UC-0140/1404|2014-002560-33|CARMINA04|NEOPAL","August 5, 2014","January 2015","April 2019","May 3, 2017","May 2017","No Study Results Posted","NeoPAL","January 2018","Evaluation of the number of patients with a Residual Cancer Burden (RCB) 0-I index as a measure of efficacy|Evaluation of the clinical response in each treatment arm as defined by clinical and ultrasound examination.|Determination of the number and type of Adverse Events as a Measure of Safety and Tolerability|Correlation of the PAM50 risk of recurrence (ROR) score to its ability to predict RCB as defined in outcome 1|Calculation of the rates of breast conservation therapy in the two arms with regard to the initially planned surgery.","https://ClinicalTrials.gov/show/NCT02400567"
1852,"NCT00225173","Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease","Terminated","No Results Available","Hodgkin Disease","Drug: Doxorubicin|Drug: Vinblastine|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Vincristine|Drug: Bleomycin|Drug: Gemcitabine|Drug: Vinorelbine|Drug: Prednisone","Stanford University|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","45","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","G6HD|NIH/CA56060","September 21, 2005","October 2001","September 2006","August 26, 2014","September 2005","No Study Results Posted","null","September 2005","Freedom from progression","https://ClinicalTrials.gov/show/NCT00225173"
1853,"NCT00324831","GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma","Suspended","No Results Available","Lymphoma","Drug: autologous immunoglobulin idiotype-KLH conjugate vaccine|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: rituximab|Drug: sargramostim|Drug: vincristine|Procedure: Intervention/procedure|Procedure: antibody therapy|Procedure: biological therapy|Procedure: chemotherapy|Procedure: colony-stimulating factor therapy|Procedure: cytokine therapy|Procedure: monoclonal antibody therapy|Procedure: non-specific immune-modulator therapy|Procedure: therapeutic procedure|Procedure: tumor cell derivative vaccine|Procedure: vaccine therapy","Favrille|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","480","Industry","Interventional","Allocation: Randomized|Masking: Double-Blind|Primary Purpose: Treatment","CDR0000466677|FAV-ID-11|FAV-WIRB-20051774","May 10, 2006","null","null","December 17, 2013","March 2007","No Study Results Posted","null","null","Disease-free survival as measured by the Kaplan-Meier method at 3 years|Disease-free survival as measured by the Kaplan-Meier method at 2 years|Duration of response (complete or partial response)|Overall disease-free survival","https://ClinicalTrials.gov/show/NCT00324831"
1854,"NCT00455312","SCT for Dyskeratosis Congenita or SAA","Active, not recruiting","No Results Available","Dyskeratosis Congenita|Aplastic Anemia","Drug: Campath 1H|Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: Total Body Irradiation|Procedure: Stem Cell Transplantation|Drug: antithymocyte globulin|Drug: Methylprednisolone","Masonic Cancer Center, University of Minnesota","All","up to 70 Years   (Child, Adult, Senior)","Phase 2|Phase 3","33","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MT2006-06|0612M98727","March 30, 2007","August 2007","November 2016","January 21, 2016","January 2016","No Study Results Posted","null","March 2015","Neutrophil Engraftment|Incidence of Regimen Related Mortality at 100 days|Incidence of Chronic GVHD|Incidence of Late Secondary Malignancies|Incidence of grade 2-4 and 3-4 acute graft versus host disease (GVHD)|Overall Survival|Incidence of Pulmonary Complications","https://ClinicalTrials.gov/show/NCT00455312"
1855,"NCT00871481","Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma","Completed","No Results Available","Recurrent Melanoma|Stage IV Melanoma","Biological: ipilimumab|Drug: cyclophosphamide|Procedure: biopsy|Biological: aldesleukin|Other: immunohistochemistry staining method|Genetic: polymerase chain reaction|Other: immunoenzyme technique|Biological: therapeutic cytotoxic T lymphocytes","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Single Blind (masked role unspecified)|Primary Purpose: Treatment","2225.00|NCI-2010-00108|K12CA076930","March 27, 2009","February 2009","October 2013","April 17, 2017","April 2017","No Study Results Posted","null","September 2013","Numeric frequency and functional persistence of transferred CTL|Toxicity assessment of study treatment, assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0|Responses to non-targeted T cell antigens","https://ClinicalTrials.gov/show/NCT00871481"
1856,"NCT01966471","A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: Trastuzumab Emtansine|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Paclitaxel|Drug: Epirubicin|Drug: Doxorubicin|Drug: Docetaxel|Drug: Cyclophosphamide|Drug: 5-Fluorouracil","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","1846","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BO28407|2012-004902-82","October 17, 2013","January 2014","January 2024","February 24, 2017","February 2017","No Study Results Posted","null","January 2024","Invasive Disease-Free Survival (IDFS) in the Overall Population|IDFS in the Node-Positive Subpopulation|IDFS Plus Second Primary Non-Breast Cancer|Disease-Free Survival (DFS)|Distant Recurrence-Free Interval (DRFI)|Overall Survival (OS)|Percentage of Participants With Adverse Events|Percentage of Participants With Decrease in Left Ventricular Ejection Fraction (LVEF) From Baseline Over Time|European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score|EORTC Quality of Life Questionnaire-Breast Cancer 23 (QLQ-BR23) Score|Time to Clinically Meaningful Deterioration in the Global Health Status/ Quality of Life and Functional (Physical, Role, and Cognitive) Subscales of the QLQ-C30 From First HER2-Targeted Treatment","https://ClinicalTrials.gov/show/NCT01966471"
1857,"NCT01303887","A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients","Unknown status","No Results Available","Follicular Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisolone|Drug: Fludarabine","University of Liverpool|Royal Liverpool and Broadgreen University Hospitals NHS Trust|Cancer Research UK|Roche Pharma AG","All","60 Years and older   (Adult, Senior)","Phase 3","680","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ISRCTN99217456|2008-004759-31","February 24, 2011","October 2009","September 2016","May 4, 2011","October 2010","No Study Results Posted","PACIFICO","September 2016","Toxicity|Progression-free survival|Response rates (overall, complete and partial) following initial therapy|Response rates following maintenance therapy|Response duration|Overall survival|Time to next treatment|Rate of large cell transformation|Response to second-line therapy|Number of treatment cycles delivered|Cumulative dose of individual drugs administered|Quality of life|Cost effectiveness","https://ClinicalTrials.gov/show/NCT01303887"
1858,"NCT00074165","Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen","Terminated","Has Results","Brain and Central Nervous System Tumors|Drug/Agent Toxicity by Tissue/Organ|Lymphoma|Thrombocytopenia","Drug: Rituxan|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Etoposide phosphate|Drug: Carboplatin|Drug: Sodium thiosulfate|Drug: Neupogen|Drug: Neulasta|Drug: Cytarabine","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Months to 75 Years   (Child, Adult, Senior)","Phase 2","17","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IRB00000641|5R01CA137488-15|ONC-02059-LX|641|7465|OHSU-641","December 10, 2003","January 2003","December 2010","April 19, 2017","April 2017","October 10, 2011","null","June 2010","Number of Participants With a Complete Response Rate to Chemotherapy Regimen Assessed by Radiographic Response at 2 Years.|Number of Participants With Overall Survival Assessed by Clinical and Radiographic Response|Progression-free Survival Assessed by Clinical and Radiographic Response From First Day of Treatment Until Tumor Progression|Quality of Life Assessed by EORTC QOL Before Treatment and Then Every 3 Months|Ototoxicity Assessed by Audiology Hearing Test Done Monthly During Treatment|Effect of Sodium Thiosulfate (STS) on Granulocytes and Erythrocytes Assessed by Complete Blood Count Lab Values Done Weekly During Treatment","https://ClinicalTrials.gov/show/NCT00074165"
1859,"NCT01682226","Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies","Recruiting","No Results Available","Leukemia|Myelodysplastic Syndrome|Lymphoma","Device: CliniMACS Fractionation system (Arm A)|Device: CliniMACS Fractionation system (Arm B)","Memorial Sloan Kettering Cancer Center","All","2 Years to 70 Years   (Child, Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","12-153","September 6, 2012","September 2012","September 2017","December 14, 2016","December 2016","No Study Results Posted","null","September 2017","number of days to neutrophil recovery|Overall survival","https://ClinicalTrials.gov/show/NCT01682226"
1860,"NCT01901146","Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: ABP 980|Drug: trastuzumab|Drug: epirubicin|Drug: cyclophosphamide|Drug: paclitaxel|Procedure: Lumpectomy or mastectomy with sentinel node or axillary node dissection","Amgen|Actavis Inc.","Female","18 Years and older   (Adult, Senior)","Phase 3","827","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","20120283|2012-004319-29","May 20, 2013","April 29, 2013","January 27, 2017","April 6, 2017","April 2017","No Study Results Posted","Lilac","May 5, 2016","Determination of pathologic complete response (pCR), defined by the absence of invasive tumor|Event-free survival|Overall survival|Change in left ventricular ejection fraction (LVEF)|Subject incidence of adverse events|Incidence of anti-drug antibody and neutralizing antibody formation","https://ClinicalTrials.gov/show/NCT01901146"
1861,"NCT00101101","Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma","Active, not recruiting","Has Results","Lymphoma","Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Dexamethasone|Biological: Autologous Tumor Cell-Based Vaccine|Drug: IL-2","H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Lymphoma Research Foundation|Novartis","All","18 Years and older   (Adult, Senior)","Phase 2","43","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-13840|0406-654","January 7, 2005","July 2004","October 2017","March 17, 2017","March 2017","June 20, 2013","null","October 2012","Rate of Immunological Response to Vaccination|Occurrence of Related Serious Adverse Events (SAEs)|Median Event Free Survival (EFS)","https://ClinicalTrials.gov/show/NCT00101101"
1862,"NCT00020722","Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer","Terminated","Has Results","Breast Cancer","Biological: therapeutic autologous lymphocytes|Drug: Ifosfamide, carboplatin, and etoposide (ICE) regimen|Drug: Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)|Procedure: Leukapheresis|Procedure: peripheral blood stem cell transplantation (PBSCT)","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","Female","18 Years to 120 Years   (Adult, Senior)","Phase 2","7","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000068707|P30CA022453|WSU-2007-033|RWMC-0634246","July 11, 2001","August 2007","March 2013","February 15, 2016","February 2016","February 9, 2015","null","March 2013","Disease-free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT00020722"
1863,"NCT02122081","Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies","Recruiting","No Results Available","Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia","Radiation: radiation therapy|Drug: cyclophosphamide|Biological: anti-thymocyte globulin|Drug: tacrolimus|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Other: laboratory biomarker analysis","Ohio State University Comprehensive Cancer Center","All","18 Years to 75 Years   (Adult, Senior)","","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OSU-13219|NCI-2014-00763","April 22, 2014","June 2015","null","September 30, 2016","September 2016","No Study Results Posted","null","November 2017","TRM, defined as death occurring in a patient from causes other than disease relapse|Rate of grade II/III organ toxicity, defined by the Bearman Regimen-Related Toxicities Scale|TRM|Donor chimerism|Incidence of aGVHD, graded according to Ohio State University Bone Marrow Transplant (OSU BMT) Program policy|Incidence of chronic GVHD, scored according to the OSU BMT Program policy|Cumulative incidence of grade II organ toxicity|Incidence of hematopoietic recovery|Incidence of graft failure|Rate of infectious complications|Incidence of relapse|Overall survival|Progression-free survival|Immune reconstitution","https://ClinicalTrials.gov/show/NCT02122081"
1864,"NCT01843868","Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP","Unknown status","No Results Available","Lymphoma, Non-Hodgkin","Drug: Standard anti-emetics in conjunction with R-CHOP","Australasian Leukaemia and Lymphoma Group|Merck Sharp & Dohme (Australia) Pty Limited","All","18 Years and older   (Adult, Senior)","","130","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","ALLG SC03|ACTRN12611001269921","April 24, 2013","May 2013","December 2015","April 28, 2013","April 2013","No Study Results Posted","null","December 2015","Complete Response, Acute Phase (Day 1), Cycle 1|Complete Response, Delayed Phase (Days 2 to 11), Cycle 1|Complete Response - Cycle 2 and beyond|No Significant Nausea - Cycle 2 and beyond|Failure of standard anti-emetic prophylaxis, Day 1 to Day 11, Cycle 1 and beyond|Frequency of common adverse events associated with anti-emetics|Severity of common adverse events associated with anti-emetics","https://ClinicalTrials.gov/show/NCT01843868"
1865,"NCT00866307","Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)","Completed","Has Results","B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia","Drug: pegaspargase|Drug: cytarabine|Drug: vincristine sulfate|Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Drug: prednisone|Drug: dexamethasone|Drug: methotrexate|Drug: daunorubicin hydrochloride|Drug: mercaptopurine|Drug: thioguanine|Radiation: prophylactic cranial irradiation|Other: laboratory biomarker analysis","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 30 Years   (Child, Adult)","","104","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","AALL08P1|NCI-2009-01169|COG-AALL08P1|CDR0000636174|U10CA098543","March 19, 2009","February 2009","June 2014","February 7, 2017","February 2017","August 1, 2016","null","June 2014","AALL08P1 Safety Outcome|AALL08P1 Feasibility Outcome","https://ClinicalTrials.gov/show/NCT00866307"
1866,"NCT00365365","Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Doxorubicin and cyclophosphamide (AC) + bevacizumab|Drug: Docetaxel (T) + bevacizumab|Drug: Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab|Drug: Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab|Drug: Bevacizumab and trastuzumab maintenance therapy|Drug: Bevacizumab maintenance therapy","Sanofi","Female","18 Years and older   (Adult, Senior)","Phase 2","214","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DOCET_L_00714","August 16, 2006","August 2006","October 2011","August 16, 2012","January 2012","August 16, 2012","null","October 2011","Cardiac Safety - Number of Participants With Grade 3-4 Clinical Congestive Heart Failure (CHF)|Safety - Number of Participants With Adverse Events (AE)|Disease-free Survival (DFS) Rate","https://ClinicalTrials.gov/show/NCT00365365"
1867,"NCT00017108","Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia","Unknown status","No Results Available","Leukemia","Drug: chlorambucil|Drug: cyclophosphamide|Drug: fludarabine phosphate","European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000068650|EORTC-06992-CLL-3","June 6, 2001","March 2001","null","July 23, 2008","June 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00017108"
1868,"NCT00003992","Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2","Completed","No Results Available","Breast Cancer","Biological: trastuzumab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel|Drug: tamoxifen citrate","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","200","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02305|E-2198|CDR0000067197","November 1, 1999","August 1999","March 2009","May 31, 2013","March 2013","No Study Results Posted","null","January 2007","","https://ClinicalTrials.gov/show/NCT00003992"
1869,"NCT01005914","Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","Terminated","Has Results","Leukemia","Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: imatinib mesylate|Drug: methotrexate|Drug: methylprednisolone|Drug: pegaspargase|Drug: vincristine sulfate","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 2","11","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000642363|P30CA069533|OHSU-4913|ENZON-OHSU-4913","October 30, 2009","June 2009","May 2014","February 12, 2015","February 2015","October 28, 2014","null","March 2013","Complete Response Rate After Course 1 of Pegaspargase When Administered in Combination With Hyper-CVAD Regimen|Grade 3 and 4 Toxicity Associated With the Combination of Peg-Asparaginase and Hyper-CVAD Which Include: Allergic Reactions, Elevated Liver Enzymes, Hyperbilirubinemia, Hyperglycemia, Central Nervous System (CNS) Thrombosis, and Pancreatitis.|2-year Progression-free Survival|Proportion of Patients Who Achieve Complete Response or Partial Response After Courses 1 and 2|Overall Survival|Rate of Minimal Residual Disease|Half-life of Pegaspargase","https://ClinicalTrials.gov/show/NCT01005914"
1870,"NCT00577629","Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma","Active, not recruiting","Has Results","Lymphoma, B-Cell","Drug: cyclophosphamide|Drug: etoposide|Drug: rituximab|Drug: cytarabine|Drug: doxorubicin|Drug: tositumomab","Duke University|GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00007096|GSK-103421|5762","December 18, 2007","June 2005","February 2021","June 20, 2016","June 2016","March 4, 2013","null","February 2012","1 Year Progression-free Survival Rate|Disease-free Survival in Patients With a Complete Response (CR or CRu)|Overall Survival|Overall Response|Secondary Malignancies","https://ClinicalTrials.gov/show/NCT00577629"
1871,"NCT00536978","Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies","Completed","Has Results","Lymphoma|Leukemia","Drug: ARA-C|Drug: BCNU|Drug: Campath-1H|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Fludarabine|Drug: Melphalan|Drug: Rituximab|Other: Allogeneic Stem Cell Transplantation|Radiation: Total body radiation (TBI)|Drug: Methotrexate|Drug: Tacrolimus|Procedure: Adback NK or T Cell","M.D. Anderson Cancer Center","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-0230","September 27, 2007","September 2007","November 2010","April 23, 2012","April 2012","April 23, 2012","null","November 2010","6-month Treatment Related Mortality (TRM)|One-year Disease-free Survival (DFS)","https://ClinicalTrials.gov/show/NCT00536978"
1872,"NCT00195871","Safety and Efficacy of an Adult Acute Lymphoblastic Leukemia Chemotherapy for Adult Lymphoblastic Lymphoma","Unknown status","No Results Available","Lymphoblastic Lymphoma","Drug: Prednisone, vincristine, daunorubicin , cyclophosphamide , L.-asparaginase, cytosine-arabinoside, methotrexate, etoposide|Procedure: hematopoietic stem cell allograft","Centre Henri Becquerel","All","18 Years to 59 Years   (Adult)","Phase 2","155","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LL03","September 12, 2005","February 2004","December 2015","November 6, 2013","November 2013","No Study Results Posted","null","June 2014","Event free survival|Disease Free Survival ; Complete response rate ; Overall Survival ; Progression rate; Relapse rate ; Central Nervous System or meningeal relapse rate ; medullary relapse rate ; toxicities.","https://ClinicalTrials.gov/show/NCT00195871"
1873,"NCT00061893","Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors","Completed","Has Results","Sarcoma","Drug: celecoxib|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: vinblastine sulfate|Drug: vincristine sulfate|Procedure: conventional surgery|Radiation: radiation therapy|Drug: MESNA|Drug: Filgrastim","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 50 Years   (Child, Adult)","Phase 2","38","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AEWS02P1|CDR0000302409","June 5, 2003","April 2004","December 2013","September 16, 2014","September 2014","January 17, 2013","null","April 2008","Occurrence of Severe Toxicity|Event Free Survival","https://ClinicalTrials.gov/show/NCT00061893"
1874,"NCT01570348","Crohn's Allogeneic Transplant Study","Active, not recruiting","No Results Available","Crohn Disease","Procedure: Allogeneic Bone Marrow Transplantation|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Drug: Mycophenolic Acid|Other: Quality-of-Life Assessment|Drug: Tacrolimus|Radiation: Total-Body Irradiation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Institutes of Health (NIH)","All","18 Years to 60 Years   (Adult)","Phase 2","2","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2551.00|NCI-2011-03286|2551|P30CA015704","April 2, 2012","July 2012","null","June 23, 2016","June 2016","No Study Results Posted","CATS","July 2017","Event-free survival (EFS)|Development of infectious complications|Disease activity|EFS|Incidence and severity of GVHD|Incidence of disease-modifying drugs for CD initiated post-transplant|Incidence of graft rejection|Overall survival|Quality of life measured using the previously validated Short Inflammatory Bowel Disease Questionnaire|Regimen-related toxicity graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4|Treatment-related mortality (TRM)","https://ClinicalTrials.gov/show/NCT01570348"
1875,"NCT01203228","Dose-reduced Versus Standard Conditioning in MDS/sAML","Terminated","No Results Available","Myelodysplastic Syndromes|Secondary Acute Myeloid Leukemia","Other: Reduced Intensity Conditioning|Other: Myeloablative conditioning","European Group for Blood and Marrow Transplantation|Pierre Fabre Medicament","All","18 Years to 65 Years   (Adult)","Phase 3","129","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-002011-24|EBMT 42205525","September 15, 2010","May 2004","February 2015","April 2, 2015","April 2015","No Study Results Posted","RICMAC","January 2015","non-relapse mortality|organ related toxicity of conditioning|Incidence of aGVHD|incidence of cGVHD|overall survival|event-free survival|cumulative incidence of relapse|VOD|infection incidence|Haematopoeitic recovery","https://ClinicalTrials.gov/show/NCT01203228"
1876,"NCT03100877","Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma","Not yet recruiting","No Results Available","Plasma Cell Leukemia in Remission|Plasma Cell Myeloma","Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Biological: Filgrastim|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Procedure: Leukapheresis|Drug: Melphalan|Biological: Palifermin|Radiation: Total Marrow Irradiation","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","63","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","16464|NCI-2017-00512","March 29, 2017","June 2017","June 2020","April 3, 2017","April 2017","No Study Results Posted","null","June 2020","Complete Response (CR) post-Autologous Stem Cell Transplantation (ASCT) (Phase II)|Maximum Tolerated Dose (MTD) of mel/TMI (Phase I)","https://ClinicalTrials.gov/show/NCT03100877"
1877,"NCT00187005","Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","Terminated","No Results Available","Acute Lymphoblastic Leukemia","Drug: Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase|Drug: L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine","St. Jude Children's Research Hospital","All","up to 18 Years   (Child, Adult)","Phase 3","53","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TOTXIV","September 12, 2005","July 1998","July 2002","March 29, 2011","June 2008","No Study Results Posted","null","July 2002","To determine if CNS irradiation can be safely omitted with early intensification of systemic and intrathecal chemotherapy.","https://ClinicalTrials.gov/show/NCT00187005"
1878,"NCT02870907","Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)","Recruiting","No Results Available","Retinoblastoma","Other: Observation|Drug: Etoposide|Drug: Vincristine|Radiation: Orbital irradiation|Drug: Carboplatin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Carboplatin|Drug: Etoposide|Drug: Carboplatin|Drug: Thiotepa|Drug: Vincristine|Drug: Cyclophosphamide|Procedure: Cytapheresis|Drug: Carboplatin|Drug: Etoposide|Drug: Thiotepa|Procedure: Peripheral bood stem cell transplantation","Institut Curie","All","2 Months to 10 Years   (Child)","Phase 2","125","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IC 2009-04","August 9, 2016","March 2010","September 2026","August 12, 2016","July 2016","No Study Results Posted","null","March 2026","Rate of extra ocular relapses|Evaluate long term and acute toxicities of adjuvant chemotherapy and orbital irradiation if necessary.|Number of patient with secondary bilateralisation|Evaluate the different histopathological risk factors frequency|To determine tumors genomic|Evaluate sensitivity of MRI in detecting extra ocular extension","https://ClinicalTrials.gov/show/NCT02870907"
1879,"NCT02753647","Chidamide Plus R-CHOP in Elderly DLBCL","Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Chidamide","Ruijin Hospital","All","61 Years to 75 Years   (Adult, Senior)","Phase 2","49","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CR-CHOP","April 19, 2016","April 2016","April 2019","October 8, 2016","October 2016","No Study Results Posted","null","October 2017","Complete response rate|Progression free survival rate|Overall survival rate|Overall response rate|Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02753647"
1880,"NCT01880385","Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer","Unknown status","No Results Available","Inflammatory Breast Cancer","Biological: Bevacizumab|Drug: Cyclophosphamide|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: Docetaxel|Biological: Trastuzumab","Association Tunisienne de lutte Contre le Cancer|Hoffmann-La Roche|Sanofi","Female","20 Years to 75 Years   (Adult, Senior)","Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML25168","May 25, 2011","March 2011","April 2017","June 14, 2013","June 2013","No Study Results Posted","Beva","September 2013","pathologic Complete Response (pCR)|Toxicity as assessed by CTCAE v3.0|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01880385"
1881,"NCT02449265","Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma","Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Radiation: Consolidation involved-site radiotherapy (ISRT)|Radiation: Consolidation involved-field radiotherapy (IFRT)|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Drug: prednisone","Wuhan University","All","18 Years to 65 Years   (Adult)","Phase 3","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","WUCC-NHL03 Trial","May 7, 2015","October 2015","October 2025","December 11, 2015","December 2015","No Study Results Posted","null","October 2019","Progression-free survival - PFS|Adverse events with grade 3 or 4 - AEs|Overall survival - OS|Rate of in-field progression|Rate of out-field progression|Rate of regional failure","https://ClinicalTrials.gov/show/NCT02449265"
1882,"NCT03092453","Dendritic Cell Vaccination in Patients With Advanced Melamona","Recruiting","No Results Available","Melanoma","Biological: Mature DC vaccine|Drug: Cyclophosphamide 300mg/m^2|Drug: Pembrolizumab","University of Pennsylvania","All","18 Years and older   (Adult, Senior)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","826433|17616","March 7, 2017","May 1, 2017","December 2018","May 1, 2017","May 2017","No Study Results Posted","null","December 2018","Immune response measuring increased numbers of peptide specific T cells as calculated by the tetramer assay.|Clinical response|Time to progression|Safety and side effects of vaccine per CTCAE 4.0","https://ClinicalTrials.gov/show/NCT03092453"
1883,"NCT01807611","Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy","Recruiting","No Results Available","Leukemia|Lymphoma","Radiation: Total Lymphoid Irradiation|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Thiotepa|Drug: Melphalan|Biological: HPC,A Infusion|Biological: TC-NK Infusion|Biological: G-CSF|Drug: Mesna|Device: CliniMACS|Drug: Mycophenolate mofetil","St. Jude Children's Research Hospital|Assisi Foundation","All","up to 21 Years   (Child, Adult)","Phase 2","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","HAPNK1|NCI-2013-00609","March 5, 2013","May 16, 2013","July 31, 2020","March 24, 2017","March 2017","No Study Results Posted","null","July 31, 2019","Rate of successful engraftment|Incidence of malignant relapse|Event-free survival|Overall survival|Incidence of acute and chronic graft versus host disease (GVHD)|Rate of transplant-related mortality (TRM)|Severity of acute and chronic graft versus host disease (GVHD)","https://ClinicalTrials.gov/show/NCT01807611"
1884,"NCT01147016","Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery","Active, not recruiting","No Results Available","Breast Cancer","Biological: HER2Bi-armed activated T cells|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel|Other: laboratory biomarker analysis|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","8","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000675211|P30CA022453|WSU-2010-056","June 17, 2010","July 2010","June 2017","December 5, 2016","December 2016","No Study Results Posted","null","June 2017","Pathologic complete response|Recurrence-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01147016"
1885,"NCT00217503","Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma","Completed","No Results Available","Lymphoma","Biological: bevacizumab|Biological: filgrastim|Biological: pegfilgrastim|Drug: bortezomib|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ganciclovir|Drug: valganciclovir|Drug: zidovudine","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","15","NIH","Interventional","Primary Purpose: Treatment","CDR0000441214|NCI-05-C-0203|NCI-P6330","September 20, 2005","July 2005","June 2007","June 18, 2013","April 2007","No Study Results Posted","null","null","Response to therapy as measured by overall, disease-free, and progression-free survival each month|Effects of high-dose zidovudine and ganciclovir on tumor cells measured by various assays after 2 weeks of study treatment","https://ClinicalTrials.gov/show/NCT00217503"
1886,"NCT00000658","A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma, Non-Hodgkin|HIV Infections","Drug: Bleomycin sulfate|Drug: Vincristine sulfate|Drug: Doxorubicin hydrochloride|Drug: Cyclophosphamide|Drug: Allopurinol|Drug: Methotrexate|Drug: Cytarabine|Drug: Leucovorin calcium|Drug: Sargramostim|Drug: Dexamethasone","National Institute of Allergy and Infectious Diseases (NIAID)|Schering-Plough","All","12 Years and older   (Child, Adult, Senior)","Phase 3","250","NIH|Industry","Interventional","Masking: Open Label|Primary Purpose: Treatment","ACTG 142|11117","November 2, 1999","null","February 1996","April 26, 2012","April 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00000658"
1887,"NCT00038402","Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Herceptin|Drug: Taxol|Drug: Fluorouracil|Drug: Cytoxan|Drug: Epirubicin","M.D. Anderson Cancer Center|Genentech, Inc.","All","Child, Adult, Senior","Phase 3","74","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID99-146","May 30, 2002","April 2001","July 2011","July 19, 2012","July 2012","No Study Results Posted","null","November 2004","Number of Participants Achieved Pathological Complete Remission","https://ClinicalTrials.gov/show/NCT00038402"
1888,"NCT02228512","Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas","Withdrawn","No Results Available","Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease|Primary Effusion Lymphoma","Drug: Pomalidomide|Drug: Rituximab|Drug: Prednisone|Drug: Etoposide|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 1|Phase 2","0","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","140176|14-C-0176","August 27, 2014","August 15, 2014","May 5, 2015","May 12, 2017","May 5, 2015","No Study Results Posted","null","May 5, 2015","(Phase I) To determine the maximum tolerated dose and/or recommended phase II dose of pomalidomide in combination with DA-EPOCH-R.|(Phase II) Evaluate overall survival in treatment naive patients with primary effusion lymphoma treated with pomalidomide in combination with modified DA-EPOCH-RP|Evaluate response rates and progression free survival","https://ClinicalTrials.gov/show/NCT02228512"
1889,"NCT00352027","Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma","Active, not recruiting","Has Results","Hodgkin's Lymphoma","Drug: Adriamycin®|Drug: Vinblastine|Drug: Nitrogen Mustard|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Bleomycin|Drug: Etoposide|Drug: Prednisone|Biological: G-CSF|Procedure: Radiotherapy","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","Phase 2","81","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","HOD05|NCI-2011-01253","July 13, 2006","July 2006","November 2022","April 11, 2017","September 2016","April 27, 2016","null","May 2015","3-year Event-Free Survival Probability|Disease Failure Rate Within Radiation Fields|Local and Distant Failure for Children Treated With Tailored-field Radiation|Prognostic Factors for Treatment Failure: Age|Describe Toxicities, Particularly the Frequency and Severity of Late Effects of Therapy|Patient Quality of Life (QoL), PedsQL v.4.0: Total Score|Patient Quality of Life (QoL), PedsQl v.4.0: Physical Functioning|Patient Quality of Life (QoL), PedsQL v.4.0: Psychosocial Health|Patient Quality of Life (QoL), PedsQL v.4.0: Emotional Functioning|Patient Quality of Life (QoL), PedsQL v.4.0:Social Functioning|Patient Quality of Life (QoL), PedsQL v.4.0: School Functioning|Patient Quality of Life (QoL), PedsQL v.3.0: Total Score|Patient Quality of Life (QoL), PedsQL v.3.0: Pain and Hurt|Patient Quality of Life (QoL), PedsQL v.3.0: Nausea|Patient Quality of Life (QoL), PedsQL v.3.0: Procedural Anxiety|Patient Quality of Life (QoL), PedsQL v.3.0: Treatment Anxiety|Patient Quality of Life (QoL), PedsQL v.3.0: Worry|Patient Quality of Life (QoL), PedsQL v.3.0: Cognitive Problems|Patient Quality of Life (QoL), PedsQL v.3.0: Perceived Physical Appearance|Patient Quality of Life (QoL), PedsQL v.3.0: Communication|Patient Quality of Life (QoL), Symptom Distress Scale|Parent Proxy Quality of Life (QoL), PedsQL v.4.0: Total Score|Parent Proxy Quality of Life (QoL), PedsQL v.4.0: Physical Functioning|Parent Proxy Quality of Life (QoL), PedsQL v.4.0: Psychosocial Health|Parent Proxy Quality of Life (QoL), PedsQL v.4.0: Emotional Functioning|Parent Proxy Quality of Life (QoL), PedsQL v.4.0: Social Functioning|Parent Proxy Quality of Life (QoL), PedsQL v.4.0: School Functioning|Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Total Score|Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Pain and Hurt|Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Nausea|Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Procedural Anxiety|Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Treatment Anxiety|Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Worry|Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Cognitive Problems|Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Perceived Physical Appearance|Parent Proxy Quality of Life (QoL), PedsQL v.3.0: Communication|Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: Total Score|Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: Physical Functioning|Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: Psychosocial Health|Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: Emotional Functioning|Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: Social Functioning|Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.4.0: School Functioning|Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Total Score|Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Pain and Hurt|Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Nausea|Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Procedural Anxiety|Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Treatment Anxiety|Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Worry|Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Cognitive Problems|Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Perceived Physical Appearance|Correlation of Agreement Between Patient QoL and Parent Proxy QoL at Multiple Time Points, PedsQL v.3.0: Communication|Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: Total Score|Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: Physical Functioning|Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: Psychosocial Health|Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: Emotional Functioning|Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: Social Functioning|Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.4.0: School Functioning|Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Total Score|Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Pain and Hurt|Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Nausea|Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Procedural Anxiety|Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Treatment Anxiety|Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Worry|Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Cognitive Problems|Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Perceived Physical Appearance|Association Between Patient-Reported QoL and Symptom Distress, PedsQL v.3.0: Communication|3-year Event-free Survival (EFS) Probability|3-year Overall Survival (OS) Probability|3-year Local Failure-free Survival Probability|Toxicities With Grade >1|Prognostic Factors for Treatment Failure: Gender|Prognostic Factors for Treatment Failure: Histology|Prognostic Factors for Treatment Failure: Stage","https://ClinicalTrials.gov/show/NCT00352027"
1890,"NCT02049151","Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer","Terminated","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: Tecemotide|Drug: Placebo|Drug: Cyclophosphamide (CPA)|Drug: Saline (sodium chloride)","EMD Serono","All","18 Years and older   (Adult, Senior)","Phase 3","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","EMR 63325-021|2013-003760-30","January 27, 2014","March 2014","July 2015","February 12, 2017","November 2016","June 30, 2016","START2","July 2015","Overall Survival|Time to Symptom Progression (TTSP)|Progression Free Survival (PFS)|Time to Progression (TTP)|Number Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, National Cancer Institute-Common Toxicity Criteria (NCI−CTC)Grade 3/4 TEAEs, TEAEs Leading to Permanent Discontinuation, TEAEs Leading to Death, Injection Site Reactions (ISRs)","https://ClinicalTrials.gov/show/NCT02049151"
1891,"NCT00390793","Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)","Active, not recruiting","No Results Available","Acute Lymphoblastic Leukemia|Leukemia","Drug: Cyclophosphamide|Drug: Vincristine|Drug: Doxorubicin|Drug: Dexamethasone|Drug: Dasatinib|Drug: Methotrexate|Drug: Ara-C","M.D. Anderson Cancer Center|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 2","115","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2006-0478|NCI-2010-00518","October 18, 2006","September 2006","August 2018","March 24, 2017","March 2017","No Study Results Posted","null","August 2018","Event-Free Survival (CR rates and disease-free survivals)","https://ClinicalTrials.gov/show/NCT00390793"
1892,"NCT02153580","Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia","Active, not recruiting","No Results Available","Post-transplant Lymphoproliferative Disorder|B-Cell Prolymphocytic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma|B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma|Recurrent Lymphoplasmacytic Lymphoma","Drug: cyclophosphamide|Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Other: laboratory biomarker analysis|Drug: Bendamustine Hydrochloride|Drug: Etoposide|Drug: Fludarabine Phosphate","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","48","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13351|NCI-2014-01168","May 30, 2014","September 2014","null","July 29, 2016","July 2016","No Study Results Posted","null","September 2017","Toxicity profile of T-cell infusion as defined by all toxicities associated with T cells at the probably or definite levels|Dose-limiting toxicity rate at the recommended phase II dose assessed using CTCAE v4.0|Detection of transferred T cells in the circulation for at least 28 days by quantitative-polymerase chain reaction|Disease response by physical exam, lab data, radiographic imaging and, in the case of stratum 2 (CLL/PLL) and leukemic phase NHL patients by flow cytometry and bone marrow biopsy|CD19 B cell aplasia/immunoglobulin G levels","https://ClinicalTrials.gov/show/NCT02153580"
1893,"NCT01181271","Tandem Auto-Allo Transplant for Lymphoma","Completed","Has Results","Diffuse, Large B-Cell, Lymphoma|Lymphoma, Low-Grade|T-Cell Lymphoma|Mantle-Cell Lymphoma|Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Lymphoma, Small Lymphocytic","Drug: Busulfan (conditioning for AUTO transplant)|Drug: Etoposide (conditioning for AUTO transplant)|Drug: Cyclophosphamide (conditioning for AUTO transplant)|Drug: Mesna (prior to AUTO transplant)|Other: autologous (auto) peripheral blood stem cell transplantation|Drug: Neupogen|Drug: Fludarabine (conditioning for ALLO Transplant)|Drug: Busulfan (conditioning for ALLO Transplant)|Other: non-myeloablative allogeneic (allo) transplant|Drug: Tacrolimus|Drug: Sirolimus|Drug: Methotrexate","Massachusetts General Hospital|Dana-Farber Cancer Institute","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","42","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","10-057","August 12, 2010","August 2010","February 2016","January 19, 2017","January 2017","January 19, 2017","null","February 2014","Peripheral Blood All-cell Donor Chimerism|Number of Days After Allogeneic Transplant Until Absolute Neutrophil Count Was Equal to or Greater Than 500/uL|Cumulative Incidence of Grades II to IV Acute Graft Versus Host Disease (GVHD)|Cumulative Incidence of Extensive Chronic Graft-versus-host-disease|Cumulative Incidence of Non-relapse Mortality|Cumulative Incidence of Disease Relapse|Estimated Two Year Progression Free Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants|Estimated Two Year Overall Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants|Estimated Two Year Progression Free Survival Rate for All Participants|Estimated Two Year Overall Survival Rate for All Participants|Estimated Two Year Progression Free Survival Rate for Participants Undergoing Only Autologous Transplant|Estimated Two Year Overall Survival Rate for Participants Undergoing Only Autologous Transplant","https://ClinicalTrials.gov/show/NCT01181271"
1894,"NCT00580372","UARK 89-001 Phase II Study of Intensive ""TOTAL THERAPY"" For Untreated or Minimally Treated Patients With Multiple Myeloma","Completed","Has Results","Multiple Myeloma","Drug: VAD|Drug: High-Dose cyclophosphamide|Procedure: Hemopoietic stem cell procurement|Drug: EDAP|Procedure: Autologous Hemopoietic Stem Cell Transplant 1|Procedure: Autologous Hemopoietic Stem Cell Transplant 2|Drug: Maintenance","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 2","231","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01332","December 18, 2007","August 2002","October 2015","August 1, 2016","August 2016","August 1, 2016","null","October 2015","Percentage of Participants That Are Relapse-free 5 Years After Initial Therapy","https://ClinicalTrials.gov/show/NCT00580372"
1895,"NCT01043640","Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders","Active, not recruiting","Has Results","Mucopolysaccharidosis|Hurler Syndrome|Hunter Syndrome|Maroteaux-Lamy Syndrome|Sly Syndrome|Alpha Mannosidosis|Fucosidosis|Aspartylglucosaminuria|Adrenoleukodystrophy (ALD)|Krabbe Disease|Metachromatic Leukodystrophy (MLD)|Sphingolipidoses|Peroxisomal Disorders","Drug: Campath-1H|Drug: Cyclophosphamide|Drug: Busulfan|Procedure: Allogeneic stem cell transplantation|Drug: Cyclosporine A|Drug: Mycophenolate Mofetil","Masonic Cancer Center, University of Minnesota","All","up to 21 Years   (Child, Adult)","Phase 2","46","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2009LS088|MT2009-19","January 5, 2010","December 2009","June 2017","March 31, 2017","March 2017","March 31, 2017","null","June 2015","Number of Patients With Donor Derived Engraftment|Number of Patients With Grade 0 Graft-Versus-Host Disease (GVHD)|Number of Patients With Grade 1 Graft-Versus-Host Disease (GVHD)|Number of Patients With Grade 2 Graft-Versus-Host Disease (GVHD)|Number of Patients With Grade 3 Graft-Versus-Host Disease (GVHD)|Number of Patients With Grade 4 Graft-Versus-Host Disease (GVHD)|Number of Patients Who Died Peri-Transplant|Donor Cell Chimerism Following Transplant","https://ClinicalTrials.gov/show/NCT01043640"
1896,"NCT02627573","Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT","Recruiting","No Results Available","Leukemia, Chronic Myeloid|Myelodysplastic Syndromes|Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative","Procedure: Unrelated allogeneic stem cell transplantation|Drug: Busulfan|Drug: Fludarabine monophosphate|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Drug: Cyclophosphamide|Drug: Thymoglobulin","St. Petersburg State Pavlov Medical University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","06/15-n","December 4, 2015","July 2015","July 2017","December 14, 2016","December 2016","No Study Results Posted","null","July 2017","Incidence of primary graft failure|Incidence of acute GVHD, grades II-IV|Incidence of chronic GVHD, moderate and severe (NIH criteria)|Non-relapse mortality analysis|Event-free survival analysis|Overall survival analysis|Relapse rate analysis|Toxicity (NCI CTCAE 4.03)|Infectious complications, including analysis of severe bacterial, fungal and viral infections incidence","https://ClinicalTrials.gov/show/NCT02627573"
1897,"NCT00000361","Autoimmunity in Inner Ear Disease","Terminated","No Results Available","Hearing Loss, Sensorineural","Drug: Corticosteroids|Drug: Methotrexate","National Institute on Deafness and Other Communication Disorders (NIDCD)","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","null","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","NIDCD-1158|U01DC003209","November 2, 1999","March 1998","November 2002","April 21, 2006","April 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00000361"
1898,"NCT01798004","Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","Suspended","Has Results","Disseminated Neuroblastoma|Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Regional Neuroblastoma|Stage 4S Neuroblastoma","Drug: cyclophosphamide|Drug: topotecan hydrochloride|Drug: cisplatin|Drug: etoposide|Drug: vincristine sulfate|Drug: doxorubicin hydrochloride|Radiation: external beam radiation therapy|Drug: busulfan|Drug: melphalan|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Other: pharmacological study|Other: laboratory biomarker analysis|Biological: filgrastim|Drug: mesna","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","","150","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ANBL12P1|NCI-2012-02211|COG-ANBL12P1|U10CA098543|U10CA180886","January 6, 2013","April 2013","October 2018","February 9, 2017","November 2016","December 19, 2016","null","July 2015","The Tolerability of BuMel Regimen","https://ClinicalTrials.gov/show/NCT01798004"
1899,"NCT00559104","Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","Completed","Has Results","Lymphoma","Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation|Drug: G-CSF","City of Hope Medical Center|National Cancer Institute (NCI)","All","16 Years to 59 Years   (Child, Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","97133|P30CA033572|CHNMC-97133|CDR0000573523","November 15, 2007","October 1998","July 2011","July 17, 2015","July 2015","July 17, 2015","null","July 2011","Progression|Mortality|Short-term and Long-term Treatment-related Toxicities","https://ClinicalTrials.gov/show/NCT00559104"
1900,"NCT02790515","Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation","Recruiting","No Results Available","Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Myeloid Sarcoma|Chronic Myeloid Leukemia (CML)|Juvenile Myelomonocytic Leukemia (JMML)|Myelodysplastic Syndrome (MDS)|Non-Hodgkin Lymphoma (NHL)","Drug: Anti-thymocyte globulin (rabbit)|Drug: Blinatumomab|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: G-CSF|Drug: Melphalan|Drug: Mesna|Drug: Rituximab|Drug: Tacrolimus|Drug: Thiotepa|Biological: HPC,A Infusion|Device: CliniMACS","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","Phase 2","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","REF2HCT|NCI-2016-00812","May 31, 2016","June 14, 2016","June 30, 2020","March 29, 2017","March 2017","No Study Results Posted","null","June 30, 2019","The number of patients engrafted by day +30 post-transplant|The number of patients experiencing Blinatumomab permanent discontinuation due to toxicity|The estimate of cumulative incidence of relapse|The cumulative incidence of acute and chronic Graft-Versus-Host Disease (GVHD)|The cumulative incidence of transplant related mortality","https://ClinicalTrials.gov/show/NCT02790515"
1901,"NCT02532400","Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer","Drug: Neoadjuvant endocrine therapy|Drug: Neoadjuvant chemotherapy","Ruijin Hospital","Female","18 Years and older   (Adult, Senior)","Phase 3","252","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","RJBC1505","August 17, 2015","March 2016","December 2018","April 10, 2017","April 2016","No Study Results Posted","COMPETE","September 2018","Overall response rate(ORR)|Pathological complete response(pCR)|Breast conserving surgery(BCS) rate|Incidence of neutropenia fever|Incidence of hot flushes/flashes|Incidence of osteoporosis|Incidence of grade 3-4 adverse events","https://ClinicalTrials.gov/show/NCT02532400"
1902,"NCT00608517","Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil","Terminated","Has Results","Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methylprednisolone|Radiation: total-body irradiation","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","up to 50 Years   (Child, Adult)","","6","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","VICC BMT 0552|VU-VICC-BMT-0552","January 31, 2008","September 2005","May 2011","May 12, 2014","May 2012","October 11, 2010","null","March 2008","Number of Participants With 100-day Non-relapse Mortality|Number of Participants With Sustained Donor Engraftment of Umbilical Cord Blood Stem Cells|Number of Participants With Acute Graft-versus-host Disease (GVHD)|Number of Participants Who Relapsed at 1 Year|Number of Subjects With All-cause Mortality|Overall Survival|Number of Participants With Chronic Graft Versus Host Disease (GVHD)","https://ClinicalTrials.gov/show/NCT00608517"
1903,"NCT02531308","Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)","Terminated","Has Results","Diffuse Large B-Cell Lymphoma","Drug: Metformin|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: pegfilgrastim","Rush University Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LYM2014-MET-R-CHOP","July 27, 2015","July 2015","July 2016","December 1, 2016","December 2016","December 1, 2016","DLBCL","July 2016","Progression Free Survival","https://ClinicalTrials.gov/show/NCT02531308"
1904,"NCT01796002","Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma","Recruiting","No Results Available","Peripheral T-cell Lymphoma","Drug: Romidepsin + CHOP|Drug: CHOP","The Lymphoma Academic Research Organisation","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","420","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","Ro-CHOP Study","January 31, 2013","January 2013","July 2024","March 8, 2017","March 2017","No Study Results Posted","null","July 2019","The primary efficacy endpoint is Progression Free Survival (PFS) using the response criteria for malignant lymphoma (1999) by a RAC","https://ClinicalTrials.gov/show/NCT01796002"
1905,"NCT01193842","Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas","Active, not recruiting","No Results Available","AIDS-Related Diffuse Large Cell Lymphoma|AIDS-Related Plasmablastic Lymphoma|AIDS-Related Primary Effusion Lymphoma|Grade 3b Follicular Lymphoma|HIV Infection|Plasmablastic Lymphoma|Primary Effusion Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage II Contiguous Adult Diffuse Large Cell Lymphoma|Stage II Grade 3 Contiguous Follicular Lymphoma|Stage II Grade 3 Non-Contiguous Follicular Lymphoma|Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Grade 3 Follicular Lymphoma","Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate|Drug: Vorinostat","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","110","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2011-02508|AMC #75|CDR0000683379|AMC-075|U01CA121947","September 1, 2010","October 6, 2010","null","May 23, 2017","May 2017","No Study Results Posted","null","July 1, 2017","Complete response rate assessed by Response Evaluation Criteria in Solid Tumors (Phase II)|Incidence of adverse events (AEs) for each treatment arm assessed by CTCAE v4.0 (Phase II)|Recommended phase II dose of vorinostat determined according to dose-limiting toxicities graded using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) (Phase I)|Change in CD8 cell counts (Phase I)|Changes in CD4 cell counts (Phase I)|Changes in EBV viral load|Changes in HHV-8 viral load|Changes in HIV viral load|Event-free survival (EFS) (Phase II)|Overall survival (OS) (Phase II)|Percentage of plasma associated HIV-1 RNA (Phase I)|Pharmacokinetic profile and the parameters of clearance and the AUC (area under the curve) (Phase I)|Tumor response rate (Phase I)","https://ClinicalTrials.gov/show/NCT01193842"
1906,"NCT00054587","Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: Trastuzumab|Drug: Cyclophosphamide|Drug: docetaxel|Drug: Epirubicin|Drug: Fluorouracil","UNICANCER","Female","18 Years to 64 Years   (Adult)","Phase 3","3010","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UC-0140/0005 - PACS 04|FRE-FNCLCC-PACS-04/0005|EU-20236|PACS04","February 5, 2003","June 2001","December 2009","July 18, 2013","July 2013","No Study Results Posted","null","June 2009","Progression Free Survival|Herceptin safety|Overall survival","https://ClinicalTrials.gov/show/NCT00054587"
1907,"NCT01181258","Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies","Completed","Has Results","Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia","Drug: Rituximab|Biological: Interleukin-2|Biological: Natural killer cells|Drug: Cyclophosphamide|Drug: Methylprednisolone|Drug: Fludarabine","Masonic Cancer Center, University of Minnesota","All","Child, Adult, Senior","Phase 2","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2009LS083|MT2009-15|1002M77545","August 12, 2010","August 2010","July 2016","April 10, 2017","January 2016","April 10, 2017","null","September 2015","Objective Response Rate|Serious Adverse Events|Time to Disease Progression|Patients With Expansion of NK Cells","https://ClinicalTrials.gov/show/NCT01181258"
1908,"NCT00179842","Immune Ablation and Stem Cell Support for Crohn's Disease","Withdrawn","No Results Available","Crohn Disease","Procedure: Stem Cell Transplant","Ann & Robert H Lurie Children's Hospital of Chicago","All","Child, Adult, Senior","Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT 1202","September 10, 2005","null","December 2008","September 21, 2015","January 2009","No Study Results Posted","null","null","To investigate the safety and efficacy of treating severe CD with high dose cyclophosphamide and antithymocyte globulin rescued with T cell depleted autologous stem cells. Data will be used to evaluate the efficiency of a future phase III protocol.","https://ClinicalTrials.gov/show/NCT00179842"
1909,"NCT01779050","Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells","Active, not recruiting","No Results Available","Breast Neoplasms","Drug: Doxorubicin|Biological: Trastuzumab|Drug: Cyclophosphamide|Drug: Paclitaxel|Drug: Epirubicin|Drug: Docetaxel|Drug: Carboplatin|Drug: Fluorouracil","Washington University School of Medicine","Female","18 Years and older   (Adult, Senior)","Phase 2","7","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","201309084","January 25, 2013","December 19, 2013","October 31, 2019","January 26, 2017","January 2017","No Study Results Posted","null","October 31, 2019","Recurrence Rate at 3 years|Death rate at 3 years|Elimination of ERBB2 overexpressing bone marrow DTCs","https://ClinicalTrials.gov/show/NCT01779050"
1910,"NCT00911222","Epidemiological EMESIS-Registry","Completed","No Results Available","Antiemetic Therapy","Other: non-interventional","iOMEDICO AG|Arbeitsgemeinschaft fur Internistische Onkologie|ASORS|Arbeitskreis Klinische Studien|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","","1035","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IOM-143","May 28, 2009","October 2008","August 2009","December 23, 2014","December 2014","No Study Results Posted","EMESIS","May 2009","Efficacy of anti-emetic therapies dependent on the rate ""complete and major control"" of nausea and emesis in moderately and highly emetogenic chemotherapy regimens.","https://ClinicalTrials.gov/show/NCT00911222"
1911,"NCT00031590","Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma","Terminated","No Results Available","Brain Tumors|Central Nervous System Tumors|Medulloblastoma|Primitive Neuroectodermal Tumor","Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Lomustine|Drug: Vincristine|Drug: Mesna|Radiation: Craniospinal Radiation","Children's Hospital of Philadelphia","All","3 Years to 30 Years   (Child, Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","00-002301|CHP-693","March 8, 2002","April 2001","May 2011","September 30, 2015","September 2015","No Study Results Posted","null","May 2011","Evaluate Rate of Late Neurotoxic Effects","https://ClinicalTrials.gov/show/NCT00031590"
1912,"NCT02559154","Modified Bortezomib-based Combination Therapy for Multiple Myeloma","Recruiting","No Results Available","Multiple Myeloma","Drug: Bortezomib|Drug: Dexamethasone|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Mitoxsnteone|Drug: Thalidomide","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","All","18 Years to 80 Years   (Adult, Senior)","Phase 4","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2010K059","September 21, 2015","July 2010","December 2017","April 24, 2017","April 2017","No Study Results Posted","null","August 2017","disease responses to treatment","https://ClinicalTrials.gov/show/NCT02559154"
1913,"NCT02909751","Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Epirubicin 90 mg/m2 iv|Drug: Cyclophosphamide 600 mg/m2 iv|Drug: Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv|Drug: Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)|Drug: Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)|Dietary Supplement: Tocotrienol 300 mg x 3 daily","Vejle Hospital","Female","18 Years and older   (Adult, Senior)","Phase 2","78","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NeoToc","September 16, 2016","September 2016","March 2019","September 16, 2016","September 2016","No Study Results Posted","NeoToc","September 2018","Pathological complete response|Correlation of changes in NK-cells with pathological complete response|Correlation of changes in ctDNA with pathological complete response|Number of patients with grade 3-4 side effects","https://ClinicalTrials.gov/show/NCT02909751"
1914,"NCT01025778","Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia","Completed","No Results Available","Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia","Drug: Clofarabine for remission induction|Drug: Etoposide for remission induction|Drug: Cyclophosphamide for remission induction|Drug: Clofarabine in conditioning before transplantation|Drug: Thiotepa in conditioning before transplantation|Drug: Melfalan in conditioning before transplantation|Procedure: Haploidentical transplantation of T-cell depleted graft|Procedure: Donor lymphocyte infusion","Lund University Hospital","All","1 Year to 21 Years   (Child, Adult)","Phase 2","7","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BUS2009/1","December 3, 2009","December 2009","December 2012","March 30, 2015","March 2015","No Study Results Posted","null","December 2012","Event free survival|Evaluation of induction efficacy by response rate and the number of children proceeding to transplant|Tolerance, safety and quality of life|Hematological and immunological recovery|Incidence of graft versus host disease","https://ClinicalTrials.gov/show/NCT01025778"
1915,"NCT03036904","Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma","Drug: Venetoclax|Drug: Rituximab|Drug: Etoposide|Drug: Vincristine Sulfate|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Doxorubicin Hydrochloride","Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center","All","18 Years to 80 Years   (Adult, Senior)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","1607017413","January 27, 2017","February 6, 2017","August 2020","April 26, 2017","April 2017","No Study Results Posted","V+DA-EPOCH-R","February 2018","Determination of the maximal tolerated dose (MTD)|Determination of dose limiting toxicity (DLT)|Define incidence and severity of adverse events, defined according to CTCAE v 4.0.|Overall response rate|Complete response rate|Event-free survival|Progression Free Survival|Overall survival","https://ClinicalTrials.gov/show/NCT03036904"
1916,"NCT01847001","Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy","Recruiting","No Results Available","Locally Advanced Malignant Neoplasm|Breast Cancer","Drug: Propranolol|Other: DOT imaging|Drug: Paclitaxel|Drug: Nab-paclitaxel|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Doxorubicin|Drug: Cyclophosphamide|Procedure: Surgery|Drug: Premedication|Drug: Anti-nausea therapy|Drug: Pegfilgrastim","Columbia University","Female","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","AAAI9158|UL1TR000040","April 23, 2013","October 2012","October 2016","October 27, 2016","October 2016","No Study Results Posted","null","October 2016","Percentage of patients who are compliant with taking > 80% take the drug while on chemotherapy.|Number of Patients with Adverse Events|Change in DOT-derived parameters|Changes in tumor proliferation|Changes in angiogenesis|Changes in stress levels","https://ClinicalTrials.gov/show/NCT01847001"
1917,"NCT00005089","S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","71","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067707|S0014|U10CA032102","April 6, 2000","April 2000","April 2014","January 12, 2017","January 2017","No Study Results Posted","null","November 2004","Progression-free survival","https://ClinicalTrials.gov/show/NCT00005089"
1918,"NCT01055314","Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma","Completed","No Results Available","Adult Rhabdomyosarcoma|Childhood Alveolar Rhabdomyosarcoma|Childhood Embryonal Rhabdomyosarcoma|Metastatic Childhood Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma|Untreated Childhood Rhabdomyosarcoma","Biological: Cixutumumab|Drug: Cyclophosphamide|Biological: Dactinomycin|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Drug: Ifosfamide|Drug: Irinotecan Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Temozolomide|Drug: Vincristine Sulfate Liposome","National Cancer Institute (NCI)","All","up to 49 Years   (Child, Adult)","Phase 2","179","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-02005|CDR0000663937|COG-ARST08P1|ARST08P1|U10CA180886|U10CA098543","January 22, 2010","January 2010","September 2014","May 22, 2015","September 2014","No Study Results Posted","null","September 2014","Feasibility of the addition of cixutumumab to chemotherapy determined by patient enrollment|Feasibility of the addition of temozolomide to chemotherapy determined by patient enrollment|Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events version 4.0|Event-free survival|Response rate assessed by Response Evaluation Criteria for Solid Tumors (RECIST)","https://ClinicalTrials.gov/show/NCT01055314"
1919,"NCT02073097","Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma","Recruiting","No Results Available","Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma","Drug: carfilzomib|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Other: laboratory biomarker analysis","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CASE3413|NCI-2014-00249|P30CA043703","February 25, 2014","October 2014","October 2017","April 7, 2017","April 2017","No Study Results Posted","null","October 2017","Recommended Phase II dose (Phase I)|Progression Free Survival (Phase II)|Overall Survival (Phase II)|Complete Response Rate (Phase II)|Partial Response Rate (Phase II)","https://ClinicalTrials.gov/show/NCT02073097"
1920,"NCT02797717","Treatment for Classical Hodgkin Lymphoma in Children and Adolescents","Recruiting","No Results Available","Classical Hodgkins Lymphoma in Children and Adolescents.","Radiation: Radiotherapy:|Drug: Vincristine|Drug: Etoposide|Drug: Prednisone|Drug: Doxorubicin|Drug: Dacarbazine|Drug: Cyclophosphamide","GALIA AVRAHAMI|University of Giessen|Rabin Medical Center","All","1 Month to 18 Years   (Child, Adult)","","2200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","scmci160509ctil","April 12, 2016","November 2015","December 2027","June 13, 2016","June 2016","No Study Results Posted","EuroNet-PHL-C2","December 2022","Increase event free survival rate from 88% to 93%|comparison of haematotoxicity between arm A and arm B","https://ClinicalTrials.gov/show/NCT02797717"
1921,"NCT01000285","EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma","Completed","Has Results","Leukemia-Lymphoma, Adult T-Cell","Drug: Bortezomib|Drug: Etoposide|Drug: Vincristine|Drug: Doxorubicin|Drug: Prednisone|Drug: Cyclophosphamide|Drug: Raltegravir","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","09-1758 / 201108212","October 19, 2009","September 2010","April 2016","February 8, 2017","February 2017","October 19, 2016","ATLL","May 2014","Tolerability of Treatment as Measured by Number of Participants With Grade 3 or Higher Adverse Events|Efficacy of Treatment as Measured by Best Overall Response|Time to Progression|Effects of on HTLV-1 DNA After Treatment as Measured by Proviral Loads|Relation of NFκB Gene Expression Profile on Response|Effects of HTLV-1 RNA Load After Treatment as Measured by Hbz Messenger RNA|Effects of HTLV-1 Integrase Gene Sequence After Treatment as Measured by Nucleotide Divergence|Effects of HTLV-1 Integration Sites After Treatment","https://ClinicalTrials.gov/show/NCT01000285"
1922,"NCT01200758","A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous (IV) in Participants With Follicular Non-Hodgkin's Lymphoma","Active, not recruiting","Has Results","Non-Hodgkin's Lymphoma","Drug: Rituximab SC|Drug: Rituximab IV|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone/Prednisolone","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","410","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BO22334|2010-021377-36","September 10, 2010","February 2011","November 2017","January 23, 2017","January 2017","July 7, 2015","null","June 2012","Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab|Stage II: Percentage of Participants With Overall Response at the End of Induction Treatment|Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Induction Treatment|Stage I: Percentage of Participants With Overall Response at the End of Induction Treatment|Stage I: Percentage of Participants With Complete Response at the End of Induction Treatment|Stage II: Percentage of Participants With Complete Response at the End of Induction Treatment|Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Induction Treatment|Stage I and II (Pooled): Percentage of Participants With Complete Response at the End of Maintenance Treatment|Stage I and II (Pooled): Percentage of Participants With Overall Response at the End of Maintenance Treatment|Stage 1 and II (Pooled): Progression-Free Survival (PFS)|Percentage of Participants With Disease Progression or Death|Stage I and II (Pooled): Event-Free Survival|Stage I and II (Pooled): Median Time to Overall Survival (OS)|Stage 1: Observed Area Under the Serum Concentration-Time Curve (AUC) of IV and SC Rituximab at Cycle 7|Stage I: Maximum Serum Concentrations (Cmax) of IV and SC Rituximab at Cycle 7|Stage I and II (Pooled): Trough Serum Concentrations (Ctrough) of Rituximab at Each Induction Treatment Cycle|Stage I and II (Pooled): Ctrough of Rituximab at Each Maintenance Treatment Cycle|Stage I and II (Pooled): Rituximab Levels 12 Weeks, 24 Weeks, and 36 Weeks After the Last Rituximab Administration|Percentage of Participants With B-Cell Depletion by Cycle for Induction Phase|Percentage of Participants With B-Cell Depletion by Cycle for Maintenance Phase|Stage I and II (Pooled): Percentage of Participants Positive for Human Anti-Chimeric Antibodies (HACAs)|Stage I and II (Pooled): Percentage of Participants Who Saved Time of Staff as Per Physician/Nurse Opinions With Each Administration of Rituximab SC as Compared to Rituximab IV at the End of Cy 8, 15 and 20|Stage I and II (Pooled): Percentage of Participants With Preferred Rituximab SC Formulations as Compared to IV Formulation as Assessed by Physician/Nurse at the End of Cy 8, 15, and 20","https://ClinicalTrials.gov/show/NCT01200758"
1923,"NCT02784054","Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor","Recruiting","No Results Available","Intracranial Non-germinomatous Germ Cell Tumor","Drug: Carboplatin|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Bleomycin|Drug: Thiotepa|Drug: Melphalan|Radiation: Reduced dose radiotherapy","Samsung Medical Center","All","3 Years to 30 Years   (Child, Adult)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2013-07-146","May 24, 2016","April 2014","null","May 24, 2016","May 2016","No Study Results Posted","null","March 2018","Rate of event free survival|Rate of late adverse events","https://ClinicalTrials.gov/show/NCT02784054"
1924,"NCT00004031","SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: CHOP regimen|Drug: carmustine|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group","All","15 Years to 65 Years   (Child, Adult)","Phase 3","397","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000065658|S9704|U10CA032102","December 10, 1999","July 1997","null","May 22, 2013","May 2013","No Study Results Posted","null","July 2010","Survival|Progression-free survival","https://ClinicalTrials.gov/show/NCT00004031"
1925,"NCT00274924","Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma","Active, not recruiting","Has Results","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: prednisone|Drug: vincristine","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","100","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000455012|U10CA021115|E3404","January 10, 2006","April 2006","March 2019","October 6, 2015","October 2015","January 9, 2014","null","June 2013","2-year Progression-Free Survival (PFS)|5-year Overall Survival","https://ClinicalTrials.gov/show/NCT00274924"
1926,"NCT01451515","NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma","Terminated","No Results Available","Lymphoblastic Lymphoma","Drug: Prednisone|Drug: Vincristine|Drug: Daunorubicin|Drug: PEG-asparaginase|Drug: Erwinia asparaginase|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Thioguanine|Drug: Clofarabine|Drug: Methotrexate|Drug: Mercaptopurine|Drug: Dexamethasone|Drug: Hydrocortisone|Drug: Etoposide","St. Jude Children's Research Hospital|National University, Singapore","All","up to 21 Years   (Child, Adult)","Phase 2","23","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NHL16|NCI-2012-00496","August 17, 2011","May 25, 2012","June 30, 2021","April 11, 2017","April 2017","No Study Results Posted","null","June 30, 2021","Event-free survival (EFS).|Overall survival (OS).|Percentage of lymphoblastic cells in bone marrow at diagnosis (MDD) and at day 8 of therapy (MRD).","https://ClinicalTrials.gov/show/NCT01451515"
1927,"NCT01251107","Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma","Completed","No Results Available","Hodgkin Lymphoma","Drug: Bleomycin|Drug: Etoposide|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Procarbazine|Drug: Prednisone|Drug: Doxorubicin|Drug: Bleomycin|Drug: Vinblastine|Drug: Dacarbazine","Fondazione Michelangelo","All","17 Years to 60 Years   (Child, Adult)","Phase 3","331","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","41/99","November 26, 2010","March 2000","November 2009","August 11, 2015","February 2011","No Study Results Posted","null","November 2009","Freedom from first progression at 5 years|Freedom from second progression at 5 years|Overall survival at 5 years|Number of participants with acute adverse events at initial therapy and at salvage therapy as a measure of safety and tolerability|Number of participants long term sequelae","https://ClinicalTrials.gov/show/NCT01251107"
1928,"NCT02652468","TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma","Recruiting","No Results Available","Lymphoma","Drug: Fludarabine Phosphate|Drug: Mesna|Drug: Cyclophosphamide|Radiation: Total nodal irradiation|Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Mycophenolate Mofetil|Drug: Tacrolimus|Biological: Rituximab","University of Wisconsin, Madison|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","","14","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UW14113|2014-0996|P30CA014520|NCI-2015-02269","January 5, 2016","March 2016","December 2018","November 29, 2016","November 2016","No Study Results Posted","null","December 2017","Rate of engraftment, as defined as absolute neutrophil count >= 500/mcl for 3 consecutive measurements on different days and platelet count > 20,000/mm^3 with no platelet transfusions in the preceding 7 days|Incidence of grade III-IV acute GVHD as determined by IBMTR Severity Index criteria|Incidence of chronic GVHD|Incidence of graft failure|Treatment-related mortality|Progression-free survival|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02652468"
1929,"NCT00025545","Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>","Completed","No Results Available","Leukemia","Drug: cyclophosphamide|Drug: methotrexate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 55 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","1099.00|FHCRC-1099.00|NCI-H01-0078|CDR0000068972","October 11, 2001","March 1996","October 2002","May 12, 2010","May 2010","No Study Results Posted","null","October 2002","","https://ClinicalTrials.gov/show/NCT00025545"
1930,"NCT02784015","Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma","Recruiting","No Results Available","Unresectable Localized Soft Tissue Sarcoma","Drug: Cisplatin|Drug: Etoposide|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Ifosfamide|Drug: Carboplatin|Radiation: Radiotherapy|Drug: Thiotepa|Drug: Melphalan","Samsung Medical Center","All","up to 18 Years   (Child, Adult)","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-07-115","May 24, 2016","May 2016","null","May 24, 2016","May 2016","No Study Results Posted","null","May 2020","Rate of event free survival|Rate of adverse events","https://ClinicalTrials.gov/show/NCT02784015"
1931,"NCT00004181","Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Multiple Myeloma and Plasma Cell Neoplasm","Drug: busulfan|Drug: cyclophosphamide|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","Northwestern University|National Cancer Institute (NCI)","All","15 Years to 55 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU 92H3T|NU-92H3T|NCI-G99-1639","January 21, 2000","October 1999","August 2004","June 8, 2012","June 2012","No Study Results Posted","null","August 2004","","https://ClinicalTrials.gov/show/NCT00004181"
1932,"NCT00871013","UARK 2008-03 Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)","Recruiting","No Results Available","Myeloma","Drug: Melphalan|Drug: Velcade|Drug: Thalidomide|Drug: Dexamethasone|Drug: Cisplatin|Drug: Adriamycin|Drug: Cyclophosphamide|Drug: Etoposide","University of Arkansas","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","108053","March 27, 2009","March 2009","March 2018","April 18, 2017","April 2017","No Study Results Posted","null","March 2018","The primary objective of this study is to assess the continued complete and near complete response rate (CR/nCR) at two years after initiation of therapy. .","https://ClinicalTrials.gov/show/NCT00871013"
1933,"NCT02379520","HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA","Recruiting","No Results Available","Human Papillomavirus-Related Carcinoma|Human Papillomavirus Positive Oropharyngeal Carcinoma|Human Papillomavirus Positive Cervical Carcinoma|Human Papillomavirus Positive Anal Carcinoma|Human Papillomavirus Positive Vulvar Carcinoma|Human Papillomavirus Positive Penile Carcinoma","Biological: HPV Specific T Cells|Drug: Cytoxan|Drug: Fludarabine|Biological: Nivolumab","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System","All","18 Years and older   (Adult, Senior)","Phase 1","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","H-36021 HESTIA","February 25, 2015","September 2015","October 2033","February 2, 2017","February 2017","No Study Results Posted","HESTIA","October 2018","Number of Patients with DLT|Number of HPVST cells in Blood|Number of Patients with Tumor Response|Number of HPVSTs in the blood that have been transduced with a dominant-negative receptor for TGFβ","https://ClinicalTrials.gov/show/NCT02379520"
1934,"NCT00869232","UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","Enrolling by invitation","No Results Available","Multiple Myeloma","Drug: Velcade|Drug: Melphalan|Drug: Thalidomide|Drug: Dexamethasone|Drug: Cisplatin|Drug: Adriamycin|Drug: Cyclophosphamide|Drug: Etoposide","University of Arkansas","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","106952","March 24, 2009","October 2008","October 2017","October 11, 2016","October 2016","No Study Results Posted","null","October 2017","Accelerate and sustain, at 2 years from starting therapy|48hrs after melphalan 10mg/m2, gene expression profiling (GEP) examinations of CD138-purified MM plasma cells (PC)and of bone marrow biopsy (BX)samples","https://ClinicalTrials.gov/show/NCT00869232"
1935,"NCT02661503","HD21 for Advanced Stages","Recruiting","No Results Available","Classical Hodgkin Lymphoma","Drug: Bleomycin|Drug: Etoposide|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Procarbazine|Drug: Prednisone|Drug: Brentuximab Vedotin|Drug: Dacarbazine|Drug: Dexamethasone","University of Cologne","All","18 Years to 60 Years   (Adult)","Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","Uni-Koeln-1762|2014-005130-55","January 19, 2016","July 2016","September 2025","May 10, 2017","May 2017","No Study Results Posted","null","March 2020","Progression Free Survival|Treatment Related Morbidity","https://ClinicalTrials.gov/show/NCT02661503"
1936,"NCT02161692","Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors","Completed","No Results Available","Testicular Neoplasms|Germ Cell Tumors","Drug: Cyclophosphamide|Drug: Etoposide|Drug: Cisplatin|Drug: Bleomycin|Drug: Carboplatin","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","Male","18 Years to 75 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","INT48/96","June 10, 2014","December 1996","April 2009","June 11, 2014","June 2014","No Study Results Posted","null","May 2007","Evidence of disease progression confirmed by computed tomography (CT) scan and/or serum tumor markers.|Overall survival","https://ClinicalTrials.gov/show/NCT02161692"
1937,"NCT00004188","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma","Completed","No Results Available","Neuroblastoma","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: isotretinoin|Drug: melphalan|Drug: topotecan hydrochloride|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","Phase 3","495","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A3973|COG-A3973|CCG-A3973|POG-A3973|CCG-39703|FHCRC-1631.00|CDR0000067429","January 21, 2000","February 2001","null","May 16, 2013","May 2013","No Study Results Posted","null","October 2007","Event-free survival rate|Rate of occurrence of toxic (non disease-related) deaths where a toxic death will be ""counted"" if it occurs prior to the initiation of the immunotherapy|Time to engraftment|CD34 content|Tumor content as measured by reverse transcriptase polymerase chain reaction","https://ClinicalTrials.gov/show/NCT00004188"
1938,"NCT00005824","Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Procedure: peripheral blood stem cell transplantation","AIDS Malignancy Consortium|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","AMC-020|CDR0000067835","June 2, 2000","November 2000","April 2006","February 1, 2016","February 2016","No Study Results Posted","null","July 2004","","https://ClinicalTrials.gov/show/NCT00005824"
1939,"NCT02756546","Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis","Completed","No Results Available","Systemic Lupus Erythematosis","Drug: Cyclophosphamide|Drug: Hydroxychloroquine|Drug: Hydrocortisone","Cairo University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","BC (1016)","April 26, 2016","September 2014","December 2015","April 27, 2016","April 2016","No Study Results Posted","null","September 2015","MicroRNAs expression level","https://ClinicalTrials.gov/show/NCT02756546"
1940,"NCT00136565","Study of Bortezomib Combined With ACVBP in Peripheral T-Cell Lymphoma","Unknown status","No Results Available","Peripheral T-Cell Lymphoma","Drug: Velcade + ACVBP regimen","Lymphoma Study Association|Janssen-Cilag International NV","All","18 Years to 65 Years   (Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LNH05-1T|Janssen: i061-341-03|Eudract: 2005-001563-66","August 26, 2005","November 2005","November 2008","November 6, 2007","November 2007","No Study Results Posted","null","null","Efficacy measured by event-free survival (EFS), events being defined as disease progression, institution of a new treatment for the lymphoma, relapse after complete response (CR), or death from any cause|Efficacy|Response rate to treatment: complete response (CR + complete response unconfirmed [CRu]) and partial response (PR) rates, using the standard response criteria (Cheson and al.)|Progression free survival (PFS)|Duration of response in complete responders (CR + CRu)|Overall survival (OS)|Safety: safety evaluations will be based on collection of adverse events (AEs), physical examination findings and clinical laboratory results.","https://ClinicalTrials.gov/show/NCT00136565"
1941,"NCT02405676","BNHL-2015 for Children or Adolescents in China","Recruiting","No Results Available","Mature B-cell Non-Hodgkin Lymphoma","Drug: Prednisone,Vincristine, Cyclophosphamide|Drug: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Drug: Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone|Drug: Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone|Drug: Rituximab","Children's Cancer Group, China|Tongji Hospital|Nanjing Children's Hospital|West China Second University Hospital|Xiangya Hospital of Central South University|Qilu Hospital of Shandong University|Children’s Hospital of Sochow University, China|Tianjin Medical University Cancer Institute and Hospital","All","up to 16 Years   (Child)","Phase 2|Phase 3","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCCG-BNHL-2015","February 26, 2015","January 2015","December 2024","July 27, 2016","July 2016","No Study Results Posted","BNHL-2015","June 2021","Event free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02405676"
1942,"NCT00004092","Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer","Completed","Has Results","Breast Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation","City of Hope Medical Center|National Cancer Institute (NCI)","All","up to 60 Years   (Child, Adult)","Phase 2","72","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","98096|U01CA063265|P30CA033572|CHNMC-IRB-98096|CHNMC-PHII-18|NCI-H99-0038|CDR0000067305","December 10, 1999","May 1999","December 2013","July 7, 2015","July 2015","July 7, 2015","null","December 2013","Five-Year Relapse-free Survival|Five-Year Overall Survival","https://ClinicalTrials.gov/show/NCT00004092"
1943,"NCT02660762","Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL","Recruiting","No Results Available","Leukaemia,Lymphoblastic","Drug: Vincristine|Drug: Daunorubicin|Drug: Pegaspargase|Drug: Prednisone|Drug: Intrathecal Methotrexate|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: 6-Mercaptopurine|Drug: Methotrexate|Drug: Etoposide|Drug: dexamethasone|Drug: thioguanine|Drug: intrathecal cytarabine","Sun Yat-sen University","All","18 Years to 35 Years   (Adult)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SYSUCC-ALL-5010","January 13, 2016","January 2010","January 2018","October 19, 2016","October 2016","No Study Results Posted","null","January 2017","progression free survival|overall survival|complete remission rate|Incidence of Treatment-Emergent Adverse Events classified according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE)|Minimal Residual Disease (MRD) monitoring","https://ClinicalTrials.gov/show/NCT02660762"
1944,"NCT00498316","Cord Blood Expansion on Mesenchymal Stem Cells","Completed","No Results Available","Myelodysplastic Syndrome|Leukemia","Procedure: Cord Blood Infusion|Drug: Busulfan|Drug: Fludarabine|Drug: Rituximab|Other: ATG|Drug: Cyclophosphamide|Drug: Clofarabine|Radiation: Total Body Irradiation (TBI)|Drug: Melphalan|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Drug: G-CSF","M.D. Anderson Cancer Center|ViaCell|National Institutes of Health (NIH)|National Cancer Institute (NCI)","All","1 Year to 80 Years   (Child, Adult, Senior)","Phase 1","98","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-0781|NCI-2011-02823|RP100469 02|1P01CA148600-01A1|5R01CA061508-20","July 6, 2007","July 2007","October 2016","October 27, 2016","October 2016","No Study Results Posted","null","October 2016","Engraftment and Time to Engraftment","https://ClinicalTrials.gov/show/NCT00498316"
1945,"NCT00005946","Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: filgrastim|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: etoposide","University of Maryland","All","up to 120 Years   (Child, Adult, Senior)","Phase 1","null","Other","Interventional","Primary Purpose: Treatment","MSGCC-9951|CDR0000067863|NCI-V00-1588","July 5, 2000","October 2000","June 2002","March 28, 2017","March 2017","No Study Results Posted","null","June 2002","","https://ClinicalTrials.gov/show/NCT00005946"
1946,"NCT02652455","Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma","Recruiting","No Results Available","Melanoma (Skin)|Skin Cancer","Drug: Nivolumab|Procedure: Surgery to Remove Tumor for Growth of TIL|Drug: CD137|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: TIL Infusion|Drug: Interleukin-2","H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Prometheus Inc.|Lion Biotechnologies","All","18 Years and older   (Adult, Senior)","Early Phase 1","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-18377","January 8, 2016","March 2, 2016","August 2019","May 18, 2017","May 2017","No Study Results Posted","null","August 2019","Occurrence of Study Related Adverse Events","https://ClinicalTrials.gov/show/NCT02652455"
1947,"NCT00098839","Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)","Completed","Has Results","Recurrent Childhood Acute Lymphoblastic Leukemia","Drug: L-asparaginase|Drug: doxorubicin hydrochloride|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate|Biological: epratuzumab|Drug: cytarabine|Drug: prednisone|Drug: pegaspargase|Drug: dexrazoxane hydrochloride|Drug: methotrexate|Drug: etoposide|Drug: cyclophosphamide|Drug: leucovorin calcium|Biological: filgrastim","Children's Oncology Group|National Cancer Institute (NCI)","All","2 Years to 31 Years   (Child, Adult)","Phase 1|Phase 2","134","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ADVL04P2|NCI-2011-01624|COG-ADVL04P2|CDR0000396777|U10CA098543","December 8, 2004","February 2005","April 2011","February 7, 2017","February 2017","March 3, 2015","null","April 2011","Remission Re-induction (CR2) Rate|Event-free Survival Rate|Rate of Minimal Residual Disease (MRD) < 0.01%|Pharmacokinetics","https://ClinicalTrials.gov/show/NCT00098839"
1948,"NCT01118091","Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...","Completed","Has Results","Skin Cancer|Melanoma|Metastatic Melanoma","Biological: Aldesleukin|Biological: CD8 enriched Young TIL","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","12","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","100117|10-C-0117","May 5, 2010","April 2010","April 2012","October 6, 2015","September 2015","November 9, 2012","null","April 2012","Response Rate|Progression Free Survival|Toxicity","https://ClinicalTrials.gov/show/NCT01118091"
1949,"NCT01652014","Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies","Withdrawn","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia","Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation|Procedure: double-unit umbilical cord blood transplantation|Radiation: total-body irradiation|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey","All","18 Years to 65 Years   (Adult)","Phase 2","0","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","021002|NCI-2011-03187|0220100266|P30CA072720","July 20, 2012","January 2014","January 2017","July 13, 2016","July 2016","No Study Results Posted","null","January 2017","Engraftment of white blood cells (WBC) (absolute neutrophil count > 500/mm^3)|Non-relapse mortality|Platelet engraftment rate (non-transfusion dependent)|Transplant related mortality|Rates of infection requiring hospitalization or prolongation of hospitalization|Incidence of steroid-refractory acute GVHD|Incidence of extensive chronic GVHD|Total time on immunosuppressive therapy|Time to CD4 count > 200/mm^3","https://ClinicalTrials.gov/show/NCT01652014"
1950,"NCT02639650","Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor","Not yet recruiting","No Results Available","Gestational Trophoblastic Neoplasms","Drug: Etoposide|Drug: actinomycin D|Drug: methotrexate|Drug: vincristine|Drug: cyclophosphamide|Drug: Paclitaxel|Drug: Cisplatin|Drug: Carboplatin","Weiguo Lv|First Affiliated Hospital of Zhongshan Medical University|Shandong University|Huazhong University of Science and Technology|Women's Hospital School Of Medicine Zhejiang University","Female","up to 60 Years   (Child, Adult)","Phase 3","214","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","ZJHGTN1211","December 13, 2015","March 2016","March 2021","December 20, 2015","December 2015","No Study Results Posted","null","March 2019","complete remission rate in firstline treatment|Severity of adverse events as assessed by the WHO|Overall Survival Rate (OR)|Ovarian functional evaluation|The pregnancy rate","https://ClinicalTrials.gov/show/NCT02639650"
1951,"NCT00040937","S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma","Completed","Has Results","Multiple Myeloma","Biological: filgrastim|Biological: sargramostim|Drug: cyclophosphamide|Drug: dexamethasone|Drug: melphalan|Drug: prednisone|Drug: thalidomide|Procedure: peripheral blood stem cell transplantation","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 2","147","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S0204|U10CA032102","July 8, 2002","June 2002","October 2015","October 26, 2016","October 2016","October 31, 2012","null","October 2008","Overall Survival|Assess Toxicity of Thalidomide/Dexamethasone as a Pre-transplant Induction Regimen.","https://ClinicalTrials.gov/show/NCT00040937"
1952,"NCT02070406","Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies","Recruiting","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Drug: cyclophosphamide|Drug: fludarabine phosphate|Biological: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Biological: dendritic cell vaccine therapy|Biological: aldesleukin|Radiation: fludeoxyglucose F 18|Procedure: positron emission tomography|Other: laboratory biomarker analysis","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 1","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13-001624|NCI-2014-00221|P30CA016042","February 21, 2014","July 2014","null","September 7, 2016","September 2016","No Study Results Posted","null","February 2019","Incidence of toxicity as defined using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0|Maximum tolerable dose (MTD) based on the number of subjects experiencing dose limiting toxicities (DLTs)|Feasibility of NY-ESO-1 TCR cells, determined by incidence of preparation not meeting the lot release criteria|Transgenic cell persistence, analyzed using immune monitoring and molecular techniques|NY-ESO-1 TCR transgenic cell tumor trafficking (imaging), assessed using 18F-FDG PET|Antitumor activity, assessed using RECIST","https://ClinicalTrials.gov/show/NCT02070406"
1953,"NCT00107614","DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients","Terminated","Has Results","Waldenstrom Macroglobulinemia","Drug: DT PACE + Rituxan","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UARK 2002-10","April 5, 2005","November 2002","February 2008","August 24, 2011","August 2011","April 15, 2011","null","February 2008","Response Rates to a Brief Remission Induction Treatment With One or Two Courses of Melphalan-based High-dose Treatment (HDT)","https://ClinicalTrials.gov/show/NCT00107614"
1954,"NCT00039195","Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma","Completed","Has Results","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: prednisone|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb|Genentech, Inc.","All","18 Years to 64 Years   (Adult)","Phase 2","98","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-142|MSKCC-01142|NCI-G02-2069","June 6, 2002","November 2006","January 2010","June 29, 2016","June 2016","December 15, 2015","null","January 2010","Progression Free Survival","https://ClinicalTrials.gov/show/NCT00039195"
1955,"NCT00466258","LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)","Completed","No Results Available","HIV Infections|Diffuse Large B Cell Lymphoma","Drug: R-CHOP|Drug: Highly active antiretroviral therapy|Drug: Central nervous system (CNS) prophylaxis|Drug: Prophylaxis of opportunistic infections and support treatment","PETHEMA Foundation","All","18 Years to 70 Years   (Adult, Senior)","Phase 4","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-003750-23|LINFOTARGAM","April 25, 2007","October 2006","November 2009","November 23, 2009","November 2009","No Study Results Posted","LINFOTARGAM","May 2009","treatment toxicity according to the CTC criteria (version 3.0) of the National Cancer Institute (NCI)|opportunistic and non-opportunistic infections rate after 6 cycles of treatment with R-CHOP administered every 14 days and HAART in patients with DLBCL and HIV infection|adherence to the treatment with 6 cycles of R-CHOP considering the delays in the administration of the cycles and the reductions in the doses of chemotherapy (planned dose administered in predicted term)|efficacy of the treatment in patients with DLBCL and HIV infection after 6 cycles of treatment with R-CHOP administered every 14 days|global response and complete remission rate|duration of the response|event-free survival probability in 5 years|global survival probability in 5 years|predictive factors of the response after 6 cycles of treatment with R-CHOP administered every 14 days in patients with DLBCL and HIV infection|impact of the therapeutic combination of R-CHOP and HAART in the parameters of the HIV infection (HIV viral load and CD4+ lymphocyte count)","https://ClinicalTrials.gov/show/NCT00466258"
1956,"NCT00003141","Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors","Completed","No Results Available","Brain Tumors|Central Nervous System Tumors|Neuroblastoma|Sarcoma","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: thiotepa|Drug: vincristine sulfate|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 2 Years   (Child)","Phase 1","94","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","99703|COG-99703|CCG-99703|CDR0000065924","November 1, 1999","March 1998","October 2011","March 27, 2014","March 2014","No Study Results Posted","null","December 2007","Feasibility|Maximal tolerated dose of thiotepa for consolidation therapy|Overall rates of significant toxicities including grade IV ototoxicity, electrolytic wasting (grade IV), and hemorrhagic cystitis (grade IV)|Event Free Survival","https://ClinicalTrials.gov/show/NCT00003141"
1957,"NCT03061656","Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma","Active, not recruiting","No Results Available","High Risk Neuroblastoma","Drug: Cyclophosphamide|Drug: Carboplatin|Drug: Etoposide|Radiation: 131I-MIBG|Drug: Thiotepa|Drug: Melphalan","Samsung Medical Center|Ministry of health & welfare, Republic of Korea","All","up to 21 Years   (Child, Adult)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2011-10-020","February 20, 2017","January 1, 2009","December 31, 2018","February 20, 2017","February 2017","No Study Results Posted","null","December 31, 2013","Rate of event free survival|Rate of treatment-related adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT03061656"
1958,"NCT00336024","Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma","Completed","No Results Available","Untreated Childhood Medulloblastoma|Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor","Drug: etoposide|Drug: cyclophosphamide|Drug: cisplatin|Biological: filgrastim|Drug: carboplatin|Drug: thiotepa|Drug: methotrexate|Drug: leucovorin calcium|Drug: vincristine sulfate|Procedure: autologous hematopoietic stem cell transplantation|Other: laboratory biomarker analysis|Procedure: quality-of-life assessment","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 2 Years   (Child)","Phase 3","96","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ACNS0334|NCI-2009-00338|COG-ACNS0334|U10CA098543","June 8, 2006","August 2007","December 31, 2016","February 14, 2017","February 2017","No Study Results Posted","null","December 31, 2016","Complete response (CR) rate|Time to treatment failure defined as disease progression or recurrence, death from any cause, or occurrence of a second malignant neoplasm|Toxicity rates of acute, chronic, and late effects of the two intense regimens|Rates of gastrointestinal and nutritional toxicities|Quality of life and neuropsychological (NP) scores as assessed by the Children Oncology Group (COG) Standard Neuropsychological and Behavioral Battery|Gene expression profiling by northern blotting or by gel electrophoresis","https://ClinicalTrials.gov/show/NCT00336024"
1959,"NCT01697527","Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies","Recruiting","No Results Available","Malignant Neoplasm","Biological: aldesleukin|Drug: fludarabine phosphate|Drug: cyclophosphamide|Other: laboratory biomarker analysis|Biological: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Biological: dendritic cell vaccine therapy|Radiation: fludeoxyglucose F 18|Procedure: positron emission tomography","Jonsson Comprehensive Cancer Center","All","16 Years and older   (Child, Adult, Senior)","Phase 2","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12-000153|NCI-2012-01548","September 28, 2012","November 2012","null","September 7, 2016","September 2016","No Study Results Posted","null","October 2018","Clinical response|NY-ESO-1 TCR transgenic cell persistence, quantitated in PBMC samples|NY-ESO-1 TCR transgenic cell tumor trafficking","https://ClinicalTrials.gov/show/NCT01697527"
1960,"NCT00793845","Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma","Active, not recruiting","No Results Available","Neuroblastoma","Drug: Cyclophosphamide|Drug: Etoposide|Drug: Carboplatin|Drug: Thiotepa|Drug: Melphalan|Radiation: Total body irradiation","Samsung Medical Center","All","Child, Adult, Senior","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2008-07-002","November 17, 2008","August 2008","January 2018","May 1, 2017","October 2016","No Study Results Posted","null","January 2015","Overall survival and event-free survival, short-term and long-term toxicity of tandem high-dose chemotherapy and autologous stem cell transplantation","https://ClinicalTrials.gov/show/NCT00793845"
1961,"NCT02767674","Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Rituximab|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","The First Affiliated Hospital with Nanjing Medical University","All","70 Years to 90 Years   (Senior)","Phase 3","614","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JSPH-002","May 7, 2016","May 2016","July 2019","May 7, 2016","May 2016","No Study Results Posted","null","December 2017","overall response rate|progression free survival|overall survival","https://ClinicalTrials.gov/show/NCT02767674"
1962,"NCT00723099","Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer","Suspended","No Results Available","Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Aggressive Non-Hodgkin Lymphoma|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Indolent Non-Hodgkin Lymphoma|Malignant Lymphoma, Large Cell Type|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Recurrent Chronic Lymphocytic Leukemia|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Follicular Lymphoma|Refractory Hodgkin Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Small Lymphocytic Lymphoma|T-Cell Non-Hodgkin Lymphoma","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Cyclosporine|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Radiation: Total-Body Irradiation|Procedure: Umbilical Cord Blood Transplantation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 69 Years   (Child, Adult, Senior)","Phase 2","85","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2239.00|NCI-2009-01551|2239|P30CA015704","July 25, 2008","June 2008","null","February 14, 2017","February 2017","No Study Results Posted","null","September 2017","Overall survival|Incidence of chronic GVHD for each arm|Incidence of clinically significant infections|Incidence of grade II-IV and III-IV acute GVHD for each arm|Incidence of graft failure/rejection|Incidence of neutrophil engraftment|Incidence of non-relapse mortality|Incidence of platelet engraftment|Incidence of relapse or disease progression|Progression-free survival","https://ClinicalTrials.gov/show/NCT00723099"
1963,"NCT00096135","Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes","Completed","Has Results","Leukemia","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: etoposide|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: pegaspargase|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","18 Months to 29 Years   (Child, Adult)","","168","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","AALL02P2|COG-AALL02P2|NCI-2011-01623","November 9, 2004","November 2004","null","February 14, 2017","February 2017","July 10, 2015","null","September 2013","Event-free Survival","https://ClinicalTrials.gov/show/NCT00096135"
1964,"NCT00258427","Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia","Recruiting","No Results Available","Fanconi Anemia","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methylprednisolone|Biological: Hematopoietic stem cell transplantation","Masonic Cancer Center, University of Minnesota","All","up to 44 Years   (Child, Adult)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2002LS014|MT2002-02|0202M18741","November 22, 2005","March 26, 2002","January 2019","February 17, 2017","February 2017","No Study Results Posted","null","January 2018","Percent of Graft Failure|Incidence of Acute and Chronic Graft-Versus-Host Disease|Incidence of Relapse|Incidence of Major Infections|Transplant-Related Toxicity|Overall Survival|Incidence of Chronic Graft-Versus-Host Disease","https://ClinicalTrials.gov/show/NCT00258427"
1965,"NCT03125642","Auto Stem Cell Transplant for Lymphoma Patients","Recruiting","No Results Available","Non-Hodgkin Lymphoma|Hodgkin Lymphoma","Drug: Etoposide|Drug: BCNU|Drug: AraC|Drug: Melphalan|Procedure: Peripheral blood stem cell transplantation|Biological: G-CSF|Drug: Cyclophosphamide|Radiation: Total Body Irradiation","Masonic Cancer Center, University of Minnesota","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2016LS132|MT2016-11C","April 19, 2017","April 20, 2017","April 30, 2026","April 24, 2017","April 2017","No Study Results Posted","null","April 30, 2023","Progression Free Survival Comparison|Overall Survival|Treatment related mortality|Secondary malignancies|Neutrophil engraftment|Platelet engraftment","https://ClinicalTrials.gov/show/NCT03125642"
1966,"NCT00775931","Allogeneic Transplantation For Severe Osteopetrosis","Unknown status","No Results Available","Severe Osteopetrosis","Procedure: umbilical cord blood transplantation|Drug: Campath-1H|Radiation: Total Lymphoid Irradiation|Drug: Cyclophosphamide|Drug: Busulfan|Drug: Fludarabine monophosphate|Procedure: marrow graft transplantation","Masonic Cancer Center, University of Minnesota","All","up to 45 Years   (Child, Adult)","Phase 2|Phase 3","23","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MT2008-20|0808M42261","October 16, 2008","August 2008","October 2015","April 22, 2015","April 2015","No Study Results Posted","null","October 2015","Estimate the rate of donor engraftment for patients treated by hematopoietic stem cell transplantation|Estimate Peri-transplant mortality (deaths)|Transplant related toxicity|Graft-versus-host disease (incidence and severity)|Tolerance of Campath-1H administration|Clinical Disease Monitoring","https://ClinicalTrials.gov/show/NCT00775931"
1967,"NCT00890656","Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage","Completed","Has Results","Acute Lymphoblastic Leukemia","Drug: Cyclophosphamide (CTX)|Drug: Vincristine|Drug: Doxorubicin|Drug: Decadron|Drug: G-CSF|Drug: Methotrexate (MTX)|Drug: Ara-C|Drug: Pegaspargase","M.D. Anderson Cancer Center|Enzon Pharmaceuticals, Inc.","All","Child, Adult, Senior","Phase 2","90","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ID03-0166","April 29, 2009","June 2003","January 2011","February 17, 2012","February 2012","July 25, 2011","null","January 2011","Number of Participants With Complete Remission","https://ClinicalTrials.gov/show/NCT00890656"
1968,"NCT02660281","URMC Related Haplo-identical Donor BMT","Recruiting","No Results Available","Hematological Disease|Immune Deficiencies|Solid Tumors|Myelofibrosis|Multiple Myeloma|Lymphoma","Radiation: Total Body Irradiation 1200 cGy|Drug: Fludarabine|Drug: Pre-Stem Cell Infusion Cyclophosphamide|Drug: Pre-Stem Cell Infusion Mesna|Drug: Busulfan|Drug: Melphalan|Procedure: Stem Cell Infusion|Drug: Post-Stem Cell Infusion Cyclophosphamide|Drug: Post-Stem Cell Infusion Mesna","University of Rochester","All","6 Months to 75 Years   (Child, Adult, Senior)","Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UBMT 15056","November 24, 2015","October 2015","October 2026","December 21, 2016","December 2016","No Study Results Posted","HaploOnly","October 2025","The number of days from the date of the stem cell infusion to engraftment of absolute neutrophils (ANC) and platelets (PLT) will be determined based on daily CBC and differential counts.|Rate of non-engraftment and secondary graft failure|Percentage of subjects who develop acute graft-versus-host disease.|Assess the Maximum Overall Grades 0- IV of acute GvHD and Maximum Severity (0-4) by involved organ system in patients who develop acute graft-versus-host disease.|Percentage of subjects who develop chronic graft-versus-host disease.|Assess the Maximum Grade: Limited versus Extensive; Maximum Severity: Mild, Moderate or Severe) of chronic GvHD in patients who develop chronic graft-versus-|Disease-free survival|Time to relapsed disease|Immune reconstitution","https://ClinicalTrials.gov/show/NCT02660281"
1969,"NCT01659658","Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis","Recruiting","No Results Available","Relapsed or Refractory Systemic Light Chain Amyloidosis","Drug: IXAZOMIB|Drug: Dexamethasone|Drug: Melphalan|Drug: Cyclophosphamide|Drug: Thalidomide|Drug: Lenalidomide","Millennium Pharmaceuticals, Inc.|Takeda","All","18 Years and older   (Adult, Senior)","Phase 3","248","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","C16011|2011-005468-10|U1111-1164-7621|C16011-CTIL|NL41603.028.12","August 2, 2012","December 26, 2012","September 1, 2018","March 22, 2017","March 2017","No Study Results Posted","null","September 1, 2018","Percentage Of Participants With Overall Hematologic Response|2-Year Vital Organ (Heart Or Kidney) Deterioration And Mortality Rate|Percentage Of Participants With Complete Hematologic Response|Overall Survival|Progression Free Survival (PFS)|Hematologic Disease Progression Free Survival|Time To Vital Organ (Heart Or Kidney) Deterioration And Mortality Rate|Percentage Of Participants With Best Vital Organ (Cardiac And/Or Kidney) Response|Vital Organ Progression Free Survival|Duration of Hematologic Response|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Time To Treatment Failure (TTF)|Time To Subsequent Anticancer Treatment|Change From Baseline In SF-36 General Health Survey Score|Change From Baseline In Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) Score|Change From Baseline In Amyloidosis Symptom Scale Score|EuroQol 5-Dimensional (EQ-5D) Questionnaire Score|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for IXAZOMIB and its metabolite MLN2238|Number of Medical Encounters Participant Experiences","https://ClinicalTrials.gov/show/NCT01659658"
1970,"NCT02845596","Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia","Recruiting","No Results Available","Severe Aplastic Anemia","Drug: cyclosporine|Procedure: Matched Unrelated Donor Hematopoietic Stem Cell Transplant|Drug: horse anti-thymocyte globulin (ATG)|Drug: rabbit anti-thymocyte globulin (ATG)|Drug: methotrexate|Drug: fludarabine|Drug: cyclophosphamide|Radiation: low-dose total body irradiation (TBI)|Procedure: Immunosuppressive Therapy (IST)","Andrew Dietz|Children's Hospital Los Angeles","All","up to 25 Years   (Child, Adult)","","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","TransIT NMD 1601","May 9, 2016","August 2016","May 2020","August 30, 2016","August 2016","No Study Results Posted","null","May 2020","Percentage of patients randomized to HSCT that actually complete HSCT|Time from screening consent to randomization|Number of patients that fail to receive their primary assigned therapy (HSCT or IST).|Reasons why patients fail to receive their primary assigned therapy (HSCT or IST).|Treatment-related mortality at one year from randomization in both arms|Overall Survival at one year from randomization in both arms|Time from randomization to neutrophil recovery in both arms|Time from randomization to platelet recovery in both arms|Time from randomization to red blood cell recovery in both arms|Time from randomization to cessation of immune suppression recovery in both arms|Rates of primary and secondary graft rejection in the MUD HSCT arm|Rates of grade II-IV and III-IV acute GVHD, and extensive chronic GVHD in the MUD HSCT arm|Rates of IST response|Rates of IST relapse|Rates of secondary MDS or AML in both treatment arms.|Rates of other secondary malignancies in both treatment arms.|Development of symptomatic PNH in both treatment arms.|Incidence of significant infection in both treatment arms|Time to immune reconstitution in the HSCT arm","https://ClinicalTrials.gov/show/NCT02845596"
1971,"NCT00382694","Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients","Unknown status","No Results Available","Multiple Myeloma","Drug: Fludarabine","Nordic Myeloma Study Group","All","18 Years to 64 Years   (Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","NMSG#13/03","September 28, 2006","May 2005","December 2006","September 28, 2006","September 2006","No Study Results Posted","null","null","The toxicity and safety of Fludarabine when added to induction therapy by registration of side effects and adverse events in accordance with the common toxicity criteria (CTC).|Quantification of clonal cells in bone marrow and blood by flow cytometry (MRD) and to study new potential prognostic markers identified by cytomic, genomic and proteomic analysis.|Estimation of the efficacy of Fludarabine when added to induction chemotherapy (CyDex) in patients with multiple myeloma by clinical end points: disease response and progression free survival","https://ClinicalTrials.gov/show/NCT00382694"
1972,"NCT01979536","Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma","Suspended","No Results Available","Anaplastic Large Cell Lymphoma, ALK-Positive|CD30-Positive Neoplastic Cells Present|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma","Drug: Brentuximab Vedotin|Drug: Crizotinib|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Drug: Methotrexate","National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 2","140","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2013-02167|COG-ANHL12P1|ANHL12P1|U10CA180886|U10CA098543","November 4, 2013","November 8, 2013","null","May 23, 2017","May 2017","No Study Results Posted","null","September 30, 2020","EFS|Occurrence of grade 3+ non-hematologic adverse events, using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Changes on levels of MRD","https://ClinicalTrials.gov/show/NCT01979536"
1973,"NCT02670616","Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma","Recruiting","No Results Available","Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma","Drug: Ibrutinib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: vincristine|Drug: Prednisolone","Samsung Medical Center","All","19 Years and older   (Adult, Senior)","Phase 2","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-04-027","January 28, 2016","May 2016","June 2020","May 18, 2016","May 2016","No Study Results Posted","null","June 2020","complete response rate|Time to progression|Overall survival|Number of subjects with Adverse Events as a measure of safety and tolerability","https://ClinicalTrials.gov/show/NCT02670616"
1974,"NCT02951728","Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Decitabine","Ruijin Hospital","All","15 Years to 75 Years   (Child, Adult, Senior)","Phase 1|Phase 2","58","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DR-CHOP","October 24, 2016","October 2016","October 2019","October 30, 2016","October 2016","No Study Results Posted","DR-CHOP","October 2018","maximum tolerated dose|complete response rate|Overall response rate|Event-free survival|Overall survival|Progression-free survival|Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02951728"
1975,"NCT00005964","Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","59","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-C59910|U10CA031946|CLB-C59910|CDR0000067947","July 5, 2000","May 2000","March 2006","July 12, 2016","July 2016","No Study Results Posted","null","March 2006","Response rate","https://ClinicalTrials.gov/show/NCT00005964"
1976,"NCT01363128","Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL)","Recruiting","No Results Available","Leukemia","Drug: Cyclophosphamide|Drug: Mesna|Drug: Doxorubicin|Drug: Vincristine|Drug: Dexamethasone|Drug: Ofatumumab|Drug: Methotrexate|Drug: Cytarabine","M.D. Anderson Cancer Center|Novartis Pharmaceuticals","All","Child, Adult, Senior","Phase 2","80","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2010-0708|NCI-2011-01061","May 27, 2011","July 12, 2011","July 2019","April 3, 2017","April 2017","No Study Results Posted","null","July 2019","Event-Free Survival (EFS)","https://ClinicalTrials.gov/show/NCT01363128"
1977,"NCT00602667","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: Induction Chemotherapy|Drug: Low-Risk Therapy|Drug: High-Risk Therapy|Drug: Intermediate-Risk Therapy","St. Jude Children's Research Hospital|University of Florida|National Cancer Institute (NCI)|The Pew Charitable Trusts","All","up to 5 Years   (Child)","Phase 2","293","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SJYC07|R01CA154619|NCI-2011-01193","January 10, 2008","December 17, 2007","April 30, 2023","May 22, 2017","May 2017","No Study Results Posted","null","April 30, 2018","Progression-free survival|DNA methylation in peripheral blood or tissue|Event-free survival|Chromosomal abnormalities|Gene expression patterns|Molecular abnormalities by tumor type|Number of successful collections for frozen and fixed tumor samples|Event free survival compared to historical controls|Overall survival compared to historical controls|Rate of disease progression|Objective response rate|Number of participants who successfully complete induction therapy|Number of participants who successfully complete consolidation therapy|Sustained objective response rate|Percent of total scheduled doses received during oral maintenance therapy|Change in neurostructure, especially white matter volume and integrity|Percent of PET scans with loss of signal intensity|Pharmacokinetic variables of methotrexate|Pharmacokinetic variables of intravenous and oral cyclophosphamide and its metabolites by age, gender, race, and weight|Number of participants who successfully achieve target systemic exposure of intravenous topotecan|Pharmacokinetic variables of intravenous and oral topotecan by age, gender, race and weight|Pharmacokinetic variables of oral erlotinib by age, gender, race and weight|Change in concentration of cerebrospinal fluid (CSF) neurotransmitters|Change in neurocognitive performance|Number and type of genetic polymorphisms|Pharmacogenetic variation on CNS transmitters|Change in neuropsychological performance|Change in quantitative magnetic resonance (MR) measures in the frontal lobe|Change in neurocognitive performance in attention, working memory, and fluency|Change in quantitative MR measures in the right frontal-parietal regions|Change in neurocognitive performance in visual-spatial reasoning and processing speed|Number of participants with endocrinopathy|Longitudinal change in growth hormone secretion","https://ClinicalTrials.gov/show/NCT00602667"
1978,"NCT00983944","Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma","Withdrawn","No Results Available","Lymphoma","Biological: bleomycin sulfate|Biological: rituximab|Drug: EPOCH regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate","Kristie Blum|Ohio State University Comprehensive Cancer Center","All","10 Years and older   (Child, Adult, Senior)","Phase 2","0","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","OSU-08178|NCI-2011-03123","September 23, 2009","September 2009","null","October 14, 2015","October 2015","No Study Results Posted","null","null","Complete response rate|Two-year progression-free survival|Overall survival|Toxicity as assessed by NCI CTCAE v3.0|Immunohistochemical staining results|Correlation of soluble CD30 levels with disease activity in PMLCL","https://ClinicalTrials.gov/show/NCT00983944"
1979,"NCT00013650","Effects of an Anti-Inflammatory Drug in Alzheimer's Disease","Completed","No Results Available","Alzheimer's Disease","Drug: Cyclophosphamate","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","50 Years to 95 Years   (Adult, Senior)","Phase 1","60","NIH","Interventional","Primary Purpose: Treatment","010128|01-M-0128","March 27, 2001","March 22, 2001","April 21, 2008","January 24, 2017","April 21, 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00013650"
1980,"NCT00003573","Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma","Completed","No Results Available","Brain Tumors|Central Nervous System Tumors","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: vincristine sulfate|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 2","53","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9631|POG-9631|CDR0000066640","November 1, 1999","November 1998","March 2008","July 24, 2014","July 2014","No Study Results Posted","null","October 2007","Assess the efficacy of oral etoposide at 50 mg/m2/day given concurrently with radiotherapy followed with dose intensive adjuvant chemotherapy in children with newly diagnosed high stage medulloblastoma","https://ClinicalTrials.gov/show/NCT00003573"
1981,"NCT01788137","A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients","Recruiting","No Results Available","T-cell Lymphoma Adults|Previously Untreated|High Risk","Drug: chemotherapy (CHOP)|Drug: chemotherapy(c-ATT)","Sun Yat-sen University|Chinese Academy of Medical Sciences|Fudan University|Tianjin Medical University Cancer Institute and Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","380","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CSWOG0002","December 24, 2008","January 2008","December 2017","December 10, 2015","December 2015","No Study Results Posted","null","April 2017","5-year overall survival|DFS|RR rate|CR rate|PR rate|progression of disease rate|SAEs|quality of life","https://ClinicalTrials.gov/show/NCT01788137"
1982,"NCT02228772","Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|B-cell Adult Acute Lymphoblastic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia","Drug: MLN 9708|Drug: Vincristine|Drug: Cytarabine|Drug: Doxorubicin|Drug: Mercaptopurine|Drug: Cyclophosphamide|Drug: Methotrexate","Massachusetts General Hospital|Millennium Pharmaceuticals, Inc.","All","51 Years to 75 Years   (Adult, Senior)","Phase 1","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","14-200","August 23, 2014","December 2014","July 2020","February 28, 2017","February 2017","No Study Results Posted","null","October 2017","Maximum Dose Tolerated of MLN 9708|Percentage of Patient with Complete Remission (CR) rate at the end of induction therapy|Percentage of Participants with Disease Free Survival|Rate of Overall survival (OS)|Complete Remission Rate|Rate of Toxicity","https://ClinicalTrials.gov/show/NCT02228772"
1983,"NCT01464606","International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry","Recruiting","No Results Available","Pleuropulmonary Blastoma","Drug: Vincristine|Drug: Dactinomycin|Drug: Cyclophosphamide|Drug: Ifosfamide|Drug: Doxorubicin","Children's Hospitals and Clinics of Minnesota","All","up to 21 Years   (Child, Adult)","","125","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PPB Reg Tx-Biol-001","September 29, 2011","September 2011","September 2018","February 1, 2016","February 2016","No Study Results Posted","null","September 2016","Event-free survival|Overall response to chemotherapy, and survival","https://ClinicalTrials.gov/show/NCT01464606"
1984,"NCT02775292","Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1","Recruiting","No Results Available","Adult Solid Neoplasm|Childhood Solid Neoplasm|Metastatic Neoplasm","Biological: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Biological: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL|Biological: NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine|Procedure: Positron Emission Tomography","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 1","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","15-001433|NCI-2016-00201|Ribas NYESO + Nivolumab Cancer|P30CA016042","May 13, 2016","January 3, 2017","June 2019","April 25, 2017","November 2016","No Study Results Posted","NYM","June 2018","Incidence of adverse events, defined following the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Maximum tolerated dose based on dose-limiting toxicity using the Common Toxicity Criteria|Feasibility of generating NY-ESO-1 TCR cells and/or NY-ESO 1(157-165) peptide pulsed DC vaccine, determined by the incidence of preparation not meeting the lot release criteria|Transgenic cell persistence","https://ClinicalTrials.gov/show/NCT02775292"
1985,"NCT00299182","Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: AMG 531|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Doxorubicin|Drug: Dexamethasone|Drug: Methotrexate|Drug: Cytarabine|Drug: Placebo","M.D. Anderson Cancer Center|Amgen","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2005-0146","March 3, 2006","March 2006","April 2012","September 4, 2014","September 2014","No Study Results Posted","null","April 2012","Optimal biologic dose (OBD) of AMG 531 given to treat thrombocytopenia (low platelet counts) in participants who have received chemotherapy|Number of Participants with Adverse Events","https://ClinicalTrials.gov/show/NCT00299182"
1986,"NCT03136406","QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy","Not yet recruiting","No Results Available","Pancreatic Cancer","Drug: Cyclophosphamide|Drug: Oxaliplatin|Drug: Capecitabine|Drug: 5-Fluorouracil|Drug: Leucovorin|Drug: nab-paclitaxel|Biological: bevacizumab|Biological: avelumab|Biological: ALT-803|Biological: aNK for Infusion|Biological: ETBX-011|Biological: GI-4000","NantCell, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","80","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","QUILT-3.039","April 19, 2017","May 2017","December 2018","April 26, 2017","April 2017","No Study Results Posted","null","October 2018","Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.|Objective response rate by RECIST|Objective response rate by irRC|Progression-free survival by RECIST during Phase 1b|Progression-free survival by irRC during Phase 1b|Overall survival|Patient-reported outcomes of pancreatic cancer symptoms|Progression-free survival by RECIST during Phase 2|Progression-free survival by irRC during Phase 2|Duration of response|Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months).|Incidence of treatment-emergent AEs, SAEs, graded using the NCI CTCAE Version 4.03.","https://ClinicalTrials.gov/show/NCT03136406"
1987,"NCT00846833","Haploidentical NK Cell Infusion in Malignant Melanoma","Completed","No Results Available","Melanoma","Biological: Haploidentical NK cell","Seoul National University Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-0808-024-253","February 17, 2009","February 2009","April 2012","June 6, 2012","June 2012","No Study Results Posted","null","February 2011","To determine the maximum-tolerated dose of haploidentical NK cells|To assess NK cell infusion-related toxicity|To evaluate response rate|To determine immune reconstitution after NK cell infusion","https://ClinicalTrials.gov/show/NCT00846833"
1988,"NCT02223208","Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study","Recruiting","No Results Available","Peripheral T-cell Lymphomas (PTCL)|PTCL-NOS|Angioimmunoblastic T-cell Lymphoma (AITL)|ALK- Anaplastic Large Cell Lymphoma (ALCL)","Drug: Ro-CHOEP-21 (PHASE I)|Drug: Ro-CHOEP-21 (PHASE II)","Fondazione Italiana Linfomi ONLUS","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","110","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","FIL_PTCL13","July 21, 2014","September 2014","March 2023","February 14, 2017","February 2017","No Study Results Posted","FIL_PTCL13","September 2017","Dose-limiting toxicity (DLT) of Ro-CHOEP-21 (Phase I endpoint)|Progression Free Survival (PFS) of Ro-CHOEP-21 (Phase II endpoint)|Proportion of patients reaching SCT (Phase I endpoint)|ORR = Overall response rate (Phase I endpoint)|Overall Response Rate (ORR) and Complete Response (CR)(Phase II endpoint)|Event free survival (EFS) (Phase II endpoint)|Overall survival (OS) (Phase II endpoint)|Progression Free Survival (PFS) and Overall Survival (OS) (Phase II endpoint)|Toxicities (Phase II endpoint)|Higher toxicities (Phase II endpoint)|Treatment-related mortality (TRM) (Phase II Endpoint)|Graft-versus-host disease (GVHD) (Phase II endpoint)","https://ClinicalTrials.gov/show/NCT02223208"
1989,"NCT00002565","Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: bleomycin sulfate|Drug: CHOP regimen|Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: idarubicin|Drug: ifosfamide|Drug: mesna|Drug: methylprednisolone|Drug: mitoxantrone hydrochloride|Drug: prednisone|Drug: vincristine sulfate","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","15 Years and older   (Child, Adult, Senior)","Phase 3","61","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000063574|MDA-DM-94017|NCI-T94-0040D|DM94-017","November 1, 1999","May 1994","February 2007","October 5, 2012","October 2012","No Study Results Posted","null","February 2007","","https://ClinicalTrials.gov/show/NCT00002565"
1990,"NCT00268567","Induction Treatment of Proliferative Lupus Nephritis With Leflunomide Combined With Prednisone","Completed","No Results Available","Nephritis, Lupus","Drug: leflunomide combined with prednisone","Peking University","All","16 Years and older   (Child, Adult, Senior)","Phase 2|Phase 3","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CLLNT-2002HL0133","December 21, 2005","October 2002","null","December 21, 2005","October 2004","No Study Results Posted","null","null","complete remission of renal disease at 6 months|partial remission at 6 months and adverse events","https://ClinicalTrials.gov/show/NCT00268567"
1991,"NCT01093586","Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","Completed","No Results Available","Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Erythroleukemia (M6a)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Adult Pure Erythroid Leukemia (M6b)|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Burkitt Lymphoma|Childhood Acute Erythroleukemia (M6)|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)|Childhood Acute Monoblastic Leukemia (M5a)|Childhood Acute Monocytic Leukemia (M5b)|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Juvenile Myelomonocytic Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Previously Treated Myelodysplastic Syndromes|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Secondary Myelofibrosis|Splenic Marginal Zone Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia|T-cell Large Granular Lymphocyte Leukemia|Waldenstrom Macroglobulinemia","Procedure: double-unit umbilical cord blood transplantation|Other: cytogenetic analysis|Procedure: bone marrow aspiration|Other: fluorescence in situ hybridization|Drug: busulfan|Drug: cyclophosphamide|Drug: anti-thymocyte globulin|Drug: methylprednisolone|Drug: cyclosporine|Drug: mycophenolate mofetil|Other: flow cytometry|Procedure: allogeneic hematopoietic stem cell transplantation","Case Comprehensive Cancer Center","All","12 Years to 64 Years   (Child, Adult)","Phase 2","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE3Z07|NCI-2009-01319","March 24, 2010","March 2009","December 2015","December 18, 2015","December 2015","No Study Results Posted","null","December 2015","Overall survival|Hematologic engraftment|Disease-free and overall survival|Duration of response|Transplant related mortality|Recurrence or relapse|Occurrence of serious infections|Immune reconstitution|Toxicity related to UCB transplantation and cytoreduction as assessed by CTC v3.0|Incidence of acute graft-versus-host disease (GVHD)|Incidence of chronic GVHD","https://ClinicalTrials.gov/show/NCT01093586"
1992,"NCT03036488","Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","Recruiting","No Results Available","Triple Negative Breast Neoplasms","Biological: Pembrolizumab|Drug: Carboplatin|Drug: Paclitaxel|Drug: Doxorubicin|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Placebo","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 3","855","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","3475-522|2016-004740-11|173567","January 27, 2017","March 7, 2017","March 14, 2025","May 18, 2017","May 2017","No Study Results Posted","null","November 1, 2018","Pathological complete response (pCR) rate using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery|Event-free Survival (EFS) as assessed by Investigator|pCR rate using an alternative definition, ypT0 ypN0 (i.e., no invasive or noninvasive residual in breast or nodes) at the time of definitive surgery|pCR rate using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery in participants with tumors expressing programmed cell death - ligand 1 (PD-L1)|EFS in participants with tumors expressing PD-L1|pCR rate using an alternative definition, ypT0 ypN0 (i.e., no invasive or noninvasive residual in breast or nodes) at the time of definitive surgery in participants with tumors expressing PD-L1|pCR rate using an alternative definition, ypT0/Tis (i.e., absence of invasive cancer in the breast irrespective of ductal carcinoma in situ or nodal involvement) at the time of definitive surgery|Overall survival (OS)|Percentage of participants who experience an adverse event (AE)|Percentage of participants who discontinue study treatment due to an AE","https://ClinicalTrials.gov/show/NCT03036488"
1993,"NCT01700946","Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","Recruiting","No Results Available","Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood B-Lymphoblastic Lymphoma","Drug: dexamethasone|Drug: vincristine sulfate|Biological: rituximab|Drug: clofarabine|Drug: cyclophosphamide|Drug: etoposide|Biological: aldesleukin|Drug: pegaspargase|Drug: methotrexate|Drug: mercaptopurine|Drug: cytarabine|Drug: mitoxantrone|Drug: teniposide|Drug: vinblastine|Biological: natural killer cell infusion|Other: laboratory biomarker analysis|Drug: therapeutic hydrocortisone|Procedure: allogeneic hematopoietic stem cell transplantation|Device: CliniMACS","St. Jude Children's Research Hospital|Cookies for Kids' Cancer|Assisi Foundation","All","up to 21 Years   (Child, Adult)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ALLR18|NCI-2012-00587","October 1, 2012","April 15, 2013","October 31, 2021","April 17, 2017","November 2016","No Study Results Posted","null","October 31, 2021","3-year overall survival rate of patients with relapsed ALL|3-year event-free survival rates in patients with relapsed ALL|Proportion of participants with positive minimal residual disease|Mean of CD20 expression levels|Median CD20 expression levels","https://ClinicalTrials.gov/show/NCT01700946"
1994,"NCT00039130","Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia","Completed","Has Results","Leukemia|Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: leucovorin calcium|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate|Drug: Allopurinol","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 2","105","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-10002|U10CA031946|CDR0000069354","June 6, 2002","May 2002","October 2014","July 1, 2016","July 2016","October 16, 2014","null","September 2010","Complete Response Rate|2 Year Event Free Survival|2 Year Overall Survival","https://ClinicalTrials.gov/show/NCT00039130"
1995,"NCT00003953","Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: CMF regimen|Drug: docetaxel|Drug: doxorubicin hydrochloride|Drug: tamoxifen citrate|Procedure: autologous bone marrow transplantation|Procedure: surgical procedure|Radiation: radiation therapy","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","39","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU2198|P30CA043703|CWRU-2198|NCI-G99-1537","November 1, 1999","February 1999","January 2013","January 25, 2013","January 2013","No Study Results Posted","null","November 2001","Determine the clinical response of these patients to treatment|Pathological Response|Detection of circulating tumor cells|Tumor response correlates with HER2/neu expression of the primary tumor.","https://ClinicalTrials.gov/show/NCT00003953"
1996,"NCT02259348","Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation","Terminated","Has Results","Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Myeloid Sarcoma|Chronic Myelogenous Leukemia (CML)|Juvenile Myelomonocytic Leukemia (JMML)|Myelodysplastic Syndrome (MDS)|Non-Hodgkin Lymphoma (NHL)","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: G-CSF|Biological: Interleukin-2|Drug: Melphalan|Drug: Thiotepa|Drug: Rituximab|Biological: Natural killer cell therapy|Biological: T-cell depleted HPC transplant|Biological: CD45RA-depleted HPC transplant","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","Phase 2","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","REFNK1|NCI-2014-01925","October 3, 2014","October 2014","March 2016","November 2, 2016","September 2016","March 10, 2016","null","April 2015","Percentage of Participants Engrafted by Day 42 Post-transplant|Incidence of Malignant Relapse|Event-free Survival (EFS)|Overall Survival (OS)|Incidence and Severity of Acute GvHD|Incidence and Severity of Chronic GvHD|Rate of Transplant-related Mortality (TRM)","https://ClinicalTrials.gov/show/NCT02259348"
1997,"NCT01044745","Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","Unknown status","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Graft Versus Host Disease|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage I Small Lymphocytic Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Waldenström Macroglobulinemia","Drug: rituximab|Drug: mycophenolate mofetil|Drug: tacrolimus|Drug: anti-thymocyte globulin|Procedure: allogeneic hematopoietic stem cell transplantation|Other: laboratory biomarker analysis|Biological: graft versus host disease prophylaxis/therapy|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: busulfan|Radiation: total-body irradiation|Biological: graft-versus-tumor induction therapy|Biological: immunosuppressive therapy","University of Nebraska|National Cancer Institute (NCI)","All","19 Years to 75 Years   (Adult, Senior)","Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","083-09|NCI-2009-01552|P30CA036727","January 7, 2010","December 2009","null","May 28, 2014","May 2014","No Study Results Posted","null","December 2014","Incidence of grades II-IV acute GVHD|Event-free survival|Overall survival|Transplant-related mortality (TRM) defined as any mortality after transplantation except mortality from relapsed disease","https://ClinicalTrials.gov/show/NCT01044745"
1998,"NCT01621477","T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant","Terminated","Has Results","Acute Lymphoblastic Leukemia|Acute Myelocytic Leukemia|Chronic Myelocytic Leukemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic Syndrome|Hodgkin or Non-Hodgkin Lymphoma|Sarcoma, Myeloid","Drug: clofarabine|Drug: cytarabine|Drug: busulfan|Drug: Plerixafor|Drug: cyclophosphamide|Drug: antithymocyte globulin (rabbit)|Biological: stem cells|Drug: Tacrolimus|Drug: mycophenolate mofetil","St. Jude Children's Research Hospital|Assisi Foundation","All","up to 21 Years   (Child, Adult)","Phase 2","34","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HAP3R|NCI-2012-00554","June 8, 2012","August 2012","December 2015","December 28, 2016","December 2016","October 17, 2016","null","December 2015","One-year Survival (OS)|Incidence of Malignant Relapse|Event-Free Survival (EFS)|Disease-Free Survival (DFS)|Incidence and Severity of Acute Graft Versus Host Disease (GVHD)|Incidence and Severity of Chronic Graft Versus Host Disease (GVHD)|Number of Participants With Transplant Related Mortality (TRM)","https://ClinicalTrials.gov/show/NCT01621477"
1999,"NCT02481310","Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma","Not yet recruiting","No Results Available","Adult Burkitt Lymphoma|B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma|MYC Gene Mutation|Plasmablastic Lymphoma","Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Drug: Ixazomib Citrate|Other: Laboratory Biomarker Analysis|Drug: Methotrexate|Drug: Prednisone|Biological: Rituximab|Drug: Therapeutic Hydrocortisone|Drug: Vincristine Sulfate","Northwestern University|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","55","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NU 14H09|NCI-2015-00400|X16042|STU00200596|P30CA060553","May 26, 2015","September 2015","null","August 19, 2015","August 2015","No Study Results Posted","null","July 2017","For phase I of the study, the dose-limiting toxicity of ixazomib given with DA-EPOCH-R will be evaluated|For phase II of the study, 12-month PFS (Progression Free Survival) of ixazomib given with DA-EPOCH-R will be measured|Frequency of toxicity|Severity of toxicity|Response rate and OS (Overall Survival)|Assess the predictive value of FDG-PET/CT scans on PFS","https://ClinicalTrials.gov/show/NCT02481310"
2000,"NCT02114229","Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","Recruiting","No Results Available","Malignant Rhabdoid Tumor|Atypical Teratoid Rhabdoid Tumor","Drug: alisertib|Drug: methotrexate|Drug: cisplatin|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: topotecan|Drug: vincristine|Procedure: Surgical resection|Radiation: Radiation therapy","St. Jude Children's Research Hospital|Millennium Pharmaceuticals, Inc.","All","up to 21 Years   (Child, Adult)","Phase 2","180","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ATRT|NCI-2014-00901","April 11, 2014","May 14, 2014","May 31, 2027","May 1, 2017","November 2016","No Study Results Posted","SJATRT","May 31, 2023","Sustained response rate of pediatric participants with recurrent or refractory AT/RT treated with alisertib (stratum A1)|Sustained response rate of pediatric participants with recurrent or refractory MRT treated with alisertib (stratum A2)|3-year progression free survival rate (stratum B1)|1-year progression free survival rate (stratum B2)|3-year progression free survival rate (stratum C1)|1-year progression free survival rate (stratum C2)|Single dose and steady state pharmacokinetics and pharmacodynamics of alisertib|Duration of objective response by stratum A1 and A2|1-year progression-free survival (PFS) by stratum A1 and A2|5-year Progression-free survival (PFS) rate in patients with newly diagnosed AT/RT (strata B1, B2, B3, C1, C2)|5-year Overall survival (OS) rate in patients with newly diagnosed AT/RT (strata B1, B2, B3, C1, C2)|Proportion of local and distant failure in strata B1, B2, B3, C1 and C2","https://ClinicalTrials.gov/show/NCT02114229"
2001,"NCT01946529","Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors","Active, not recruiting","Has Results","Desmoplastic Small Round Cell Tumor|Ewing Sarcoma of Bone or Soft Tissue|Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor","Drug: vincristine|Drug: doxorubicin|Drug: cyclophosphamide|Drug: ifosfamide|Drug: etoposide|Drug: temozolomide|Drug: temsirolimus|Drug: bevacizumab|Drug: sorafenib|Procedure: surgery|Radiation: radiation","St. Jude Children's Research Hospital|University of Tennessee Health Science Center|University of Florida|Nemours Children's Clinic","All","up to 25 Years   (Child, Adult)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ESFT13|NCI-2013-01657","September 16, 2013","November 2013","July 2026","April 11, 2017","August 2016","June 30, 2016","null","August 2015","Response to Window Therapy (2 Courses) for Group B (High-risk) - ESFT Participants|Overall Survival|Progression-free Survival|Time to Progression|Local Failure Rate","https://ClinicalTrials.gov/show/NCT01946529"
2002,"NCT00554788","Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma","Active, not recruiting","No Results Available","Extraocular Retinoblastoma","Procedure: autologous bone marrow transplantation|Procedure: autologous hematopoietic stem cell transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Biological: filgrastim|Drug: carboplatin|Drug: vincristine sulfate|Drug: thiotepa|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 10 Years   (Child)","Phase 3","60","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ARET0321|NCI-2009-00421|COG-ARET0321|CDR0000573987|U10CA180886|U10CA098543","November 6, 2007","February 2008","March 31, 2018","May 5, 2017","May 2017","No Study Results Posted","null","March 31, 2018","Failure-free survival (FFS)|Response rate to the induction phase of the regimen using a modified version of the international criteria for neuroblastoma response|Incidence of adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0","https://ClinicalTrials.gov/show/NCT00554788"
2003,"NCT00278512","Hematopoietic Stem Cell Support in Vasculitis","Terminated","No Results Available","Vasculitis","Biological: Autologous Stem Cell Transplant|Biological: Allogeneic Stem Cell Transplant","Northwestern University","All","16 Years to 60 Years   (Child, Adult)","Phase 1","7","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DIAD Vasculitis.Auto2002","January 15, 2006","August 2003","June 2016","July 11, 2016","July 2016","No Study Results Posted","null","June 2016","Survival;Change in Birmingham vasculitis activity score (BVAS) (8,9); Change in Vasculitis Damage Index (VDI) (10)","https://ClinicalTrials.gov/show/NCT00278512"
2004,"NCT01174121","Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","Recruiting","No Results Available","Metastatic Colorectal Cancer|Metastatic Gastric Cancer|Metastatic Pancreatic Cancer|Metastatic Hepatocellular Carcinoma|Metastatic Cholangiocarcinoma","Biological: Young TIL|Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Pembrolizumab","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","290","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","100166|10-C-0166","July 31, 2010","July 7, 2010","December 27, 2024","May 12, 2017","May 3, 2017","No Study Results Posted","null","December 29, 2023","To determine the rate of tumor regression in patients in cohort 3 with metastatic digestive tract, urothelial, breast, and ovarian/endometrial cancers who receive autologous, minimally cultured tumor infiltrating lymphocytes (TIL) plus aldesleuk...|To determine the toxicity of this treatment regimen.|To evaluate the safety and efficacy of pembrolizumab in combination with the TIL therapy","https://ClinicalTrials.gov/show/NCT01174121"
2005,"NCT00040651","Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients","Terminated","No Results Available","Scleroderma|Systemic Sclerosis","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Thymoglobulin|Procedure: Leukapheresis|Procedure: Self bone marrow transplant","National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|University of Pittsburgh|Amgen|Genzyme, a Sanofi Company","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","15","NIH|Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","N01 AR92239|NIAMS-047","July 5, 2002","July 2002","March 2007","December 19, 2007","December 2007","No Study Results Posted","null","March 2007","Non-hematologic toxicity experienced|Clinical and laboratory responses to chemotherapy and self bone marrow transplant","https://ClinicalTrials.gov/show/NCT00040651"
2006,"NCT02878018","Cohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura Nephritis","Enrolling by invitation","No Results Available","Henoch-Schonlein Purpura Nephritis","Drug: Qi ji shen kang lotion;Zhubai lotion;More Kidney lotion|Drug: Angiotensin-converting enzyme inhibitor orangiotensin II receptor blocker ;Tripterygium Glycosides;Adrenocorticotropic hormone ;Other Immunosuppressant","Liaoning University of Traditional Chinese Medicine|First Hospital of China Medical University|Shengjing Hospital","All","5 Years to 18 Years   (Child, Adult)","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ZJ16813","August 17, 2016","September 2016","May 2020","November 23, 2016","November 2016","No Study Results Posted","CSTCMDTCHSPN","December 2016","Urine protein|24-hour urinary protein excretion|Urine erythrocyte|Creatinine clearance rate and Serum creatinine|Number of patients with hormone therapy|Number of patients with immunosuppressant therapy","https://ClinicalTrials.gov/show/NCT02878018"
2007,"NCT00559754","A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.","Completed","Has Results","Breast Cancer","Drug: bevacizumab [Avastin]|Drug: Docetaxel|Drug: Standard chemotherapy","Hoffmann-La Roche","Female","18 Years and older   (Adult, Senior)","Phase 2","72","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML20382","November 15, 2007","December 2007","September 2010","November 5, 2014","November 2014","May 16, 2014","null","September 2010","Percentage of Participants With Pathological Complete Response (pCR)|Percentage of Participants With Objective Clinical Response|Percentage of Participants With Breast-Conserving Surgery|Percentage of Participants With pCR by Proliferation of Ki67|Percentage of Participants With pCR by Kisspeptin (KISS1) Amplification|Percentage of Participants With pCR by KISS1 Protein Expression|Percentage of Participants With pCR by Vascular Endothelial Growth Factor Receptor (VEGFR) Amplification|Percentage of Participants With pCR by VEGFR Protein Expression|Percentage of Participants With pCR by Hypoxia Inducible Factor (HIF) Protein Expression|Percentage of Participants With pCR by Endothelial Nitric Oxide Synthase (ENOS) Protein Expression|Percentage of Participants With pCR by Angiotension Protein Expression|Percentage of Participants With pCR by Vascular Endothelial Growth Factor (VEGF) Gene Expression|Percentage of Participants With pCR by VEGFR Gene Expression|Percentage of Participants With pCR by Phosphorylated AKT (pAKT) Gene Expression|Percentage of Participants With pCR by HIF Gene Expression|Percentage of Participants With pCR by Insulin-Like Growth Factor (IGF) Gene Expression|Percentage of Participants With pCR by ENOS Gene Expression|Percentage of Participants With pCR by Phosphorylated MAP Kinase (pMAPK) Gene Expression|Percentage of Participants With pCR by Angiotensin II Receptor Type I (AGTR) Gene Expression|Percentage of Participants With pCR by KISS1 Gene Expression|Percentage of Participants With pCR by RKISS1 Gene Expression","https://ClinicalTrials.gov/show/NCT00559754"
2008,"NCT01760655","Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies","Recruiting","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Juvenile Myelomonocytic Leukemia|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Refractory Cytopenia With Multilineage Dysplasia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia","Drug: Fludarabine phosphate|Drug: Thiotepa|Radiation: Total body irradiation|Biological: Therapeutic allogeneic lymphocytes|Drug: Cyclophosphamide|Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT)|Procedure: Peripheral blood stem cell transplantation|Drug: Tacrolimus|Drug: Mycophenolate mofetil","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12D.501|2012-67","January 2, 2013","December 2012","January 2020","October 19, 2016","October 2016","No Study Results Posted","null","January 2018","Disease-free survival (DFS)|Overall survival|Incidence of Regimen Related Toxicity|Immune reconstitution|Incidence and degree of GVHD|Engraftment rates","https://ClinicalTrials.gov/show/NCT01760655"
2009,"NCT00058578","Stem Cell Transplant to Treat Patients With Systemic Sclerosis","Completed","No Results Available","Systemic Sclerosis","Drug: Cyclophosphamide|Drug: Mesna|Drug: G-CSF|Procedure: Leukopheresis|Procedure: Total Body Irradiation","Baylor College of Medicine|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine","All","18 Years to 65 Years   (Adult)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H7157|Systemic Sclerosis","April 8, 2003","June 1999","June 2004","April 9, 2007","April 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00058578"
2010,"NCT00362531","Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome","Completed","No Results Available","Idiopathic Membranous Nephropathy|Nephrotic Syndrome","Drug: tacrolimus combined with prednisone","Peking University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","null","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PRGNSCN01-0","August 9, 2006","November 2004","January 2007","August 9, 2006","January 2006","No Study Results Posted","null","null","complete remission of renal disease at 12 months|partial remission at 12 months and adverse events","https://ClinicalTrials.gov/show/NCT00362531"
2011,"NCT01858922","Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A","Recruiting","No Results Available","Hodgkin Disease","Drug: ABVE-PC|Drug: DECA","Baylor College of Medicine|Texas Children's Hospital","All","Child, Adult, Senior","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","H-30993 TXCH-HD-12A|TXCH-HD-12A","May 17, 2013","December 2012","March 2021","April 6, 2017","April 2017","No Study Results Posted","TXCH-HD-12A","June 2019","Response to therapy from Day 1 of Treatment|Changes in Frequency of Regulatory Cell Population|Function of Regulatory Cell Population","https://ClinicalTrials.gov/show/NCT01858922"
2012,"NCT00393185","Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis","Withdrawn","No Results Available","Primary Biliary Cirrhosis","Biological: Non-myeloablative Hematopoietic Stem Cell Transplantation","Richard Burt, MD|Northwestern Memorial Hospital|Northwestern University","All","18 Years to 55 Years   (Adult)","Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PBC","October 24, 2006","January 2006","January 2012","October 4, 2012","October 2012","No Study Results Posted","null","January 2012","No liver-related death or LTx over the 2-year (extended to 5 years) follow-up; Normalization of serum alkaline phosphatase over 6 months;Amelioration of PBC histological stage with reduction of both inflammation and fibrosis scores 42","https://ClinicalTrials.gov/show/NCT00393185"
2013,"NCT00282425","Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis","Terminated","No Results Available","Scleroderma","Biological: Hematopoietic stem cell transplantation","Richard Burt, MD|Northwestern University","All","18 Years to 55 Years   (Adult)","Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DIAD Scl.Allo2005","January 24, 2006","May 2005","December 2012","December 14, 2012","December 2012","No Study Results Posted","null","December 2012","Survival; Disease improvement;Time to disease progression","https://ClinicalTrials.gov/show/NCT00282425"
2014,"NCT00084838","Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT","Completed","Has Results","Central Nervous System Tumor, Pediatric","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: temozolomide|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate|Radiation: radiation therapy|Drug: Dactinomycin","Dana-Farber Cancer Institute|National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","Phase 2","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-294 DFCI|P30CA006516","June 10, 2004","February 2003","March 2013","December 18, 2015","December 2015","December 14, 2012","null","February 2008","2-yr Overall Survival|Pre-Radiation Therapy Chemotherapeutic Response","https://ClinicalTrials.gov/show/NCT00084838"
2015,"NCT00003270","Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer","Active, not recruiting","No Results Available","Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methylprednisolone|Procedure: bone marrow ablation with stem cell support|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","Roswell Park Cancer Institute","All","5 Years to 50 Years   (Child, Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","DS 97-26","November 1, 1999","September 4, 1997","October 1, 2018","April 24, 2017","April 2017","No Study Results Posted","null","October 1, 2017","To determine the safety, efficacy and toxicity of using cord blood as a source for stem cell transplantation in patients with hematologic malignancies.","https://ClinicalTrials.gov/show/NCT00003270"
2016,"NCT03147612","Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)","Not yet recruiting","No Results Available","Acute Lymphoblastic Leukemia","Drug: Ponatinib|Drug: Cyclophosphamide|Drug: Mesna|Drug: Rituximab|Drug: Vincristine|Drug: Dexamethasone|Drug: G-CSF|Drug: Methotrexate (intrathecally)|Drug: Cytarabine (intrathecally)|Drug: Methotrexate|Drug: Cytarabine","M.D. Anderson Cancer Center|Ariad Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2016-0402","May 5, 2017","August 2017","August 2023","May 8, 2017","May 2017","No Study Results Posted","null","August 2023","Complete Molecular Response (CMR) in Newly Diagnosed Ph-Positive and/or BCR-ABL-Positive Participants|Overall Response (OR)in Relapsed/Refractory Acute Lymphoblastic Leukemia|Event-Free Survival","https://ClinicalTrials.gov/show/NCT03147612"
2017,"NCT03167164","QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy","Not yet recruiting","No Results Available","Merkel Cell Carcinoma","Biological: Avelumab|Biological: Bevacizumab|Drug: Capecitabine|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: 5-fluorouracil|Drug: Leucovorin|Drug: nab-Paclitaxel|Drug: omega-3-acid ethyl esters|Radiation: Stereotactic Body Radiation Therapy|Biological: ALT-803|Biological: ETBX-051|Biological: ETBX-061|Biological: GI-6301|Biological: haNK","NantCell, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","67","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","QUILT-3.045","May 23, 2017","August 2017","March 2019","May 23, 2017","May 2017","No Study Results Posted","null","January 2019","Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.|Objective response rate by RECIST Version 1.1|Objective response rate by irRC|Progression-free survival by RECIST Version 1.1|Progression-free survival by irRC|Overall survival|Duration of response|Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months)|Quality of life by patient-reported outcome using Functional Assessment of Cancer Therapy-Melanoma (FACT-M) Questionnaire|Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03","https://ClinicalTrials.gov/show/NCT03167164"
2018,"NCT00064337","S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis","Unknown status","No Results Available","Multiple Myeloma|Plasma Cell Myeloma","Biological: filgrastim|Drug: cyclophosphamide|Drug: dexamethasone|Drug: melphalan|Drug: thalidomide|Procedure: peripheral blood stem cell transplantation","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","100","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S0115|U10CA032102","July 8, 2003","January 2004","November 2015","April 1, 2015","April 2015","No Study Results Posted","null","May 2012","Overall survival|Hematologic response|Qualitative and quantitative toxicity|Prognostic significance of cytogenetic markers","https://ClinicalTrials.gov/show/NCT00064337"
2019,"NCT00577993","Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients","Active, not recruiting","No Results Available","Lymphoma","Drug: Fludarabine|Drug: Novantrone|Drug: Decadron|Drug: Rituximab|Drug: Interferon|Drug: Doxorubicin|Drug: Vincristine|Drug: Bleomycin|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Cisplatin|Drug: Ara-C|Drug: Methyl-Prednisolone|Drug: Procarbazine|Drug: Prednisone","M.D. Anderson Cancer Center|Genentech, Inc.","All","up to 76 Years   (Child, Adult, Senior)","Phase 3","210","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DM97-261|NCI-2010-01566","December 18, 2007","March 1998","null","September 12, 2016","September 2016","No Study Results Posted","null","December 2018","To study and compare molecular response rates with the FND regimen followed by rituximab (chimeric anti-CD20 antibody) and interferon versus FND plus rituximab concurrently, followed by interferon|To study the toxicity of these two regimens, including their effects on B- and T- cell subsets, immunoglobulins, and patterns of infections.|Compare failure-free and overall survival rates|To identify and treat with a separate strategy those follicular lymphoma patients without bcl-2 mbr or mcr gene rearrangement (""germline"" patients)","https://ClinicalTrials.gov/show/NCT00577993"
2020,"NCT00278590","Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus","Withdrawn","No Results Available","Systemic Lupus Erythematosus","Biological: Allogeneic Stem Cell Transplantation","Northwestern University","All","18 Years to 50 Years   (Adult)","Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DI SLE.Allo2004","January 16, 2006","July 2004","July 2015","January 12, 2017","January 2017","No Study Results Posted","null","July 2015","Survival, disease free survival, number of relapses, organ function","https://ClinicalTrials.gov/show/NCT00278590"
2021,"NCT00582725","R-CHOP + GM-CSF for Previously Untreated LCL in Elderly","Completed","No Results Available","Lymphoma, Large B-Cell, Diffuse","Drug: R-CHOP+GM-CSF","University of Wisconsin, Madison","All","60 Years and older   (Adult, Senior)","Phase 2","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HO02401","December 19, 2007","March 2002","November 2010","May 23, 2014","May 2014","No Study Results Posted","null","December 2005","Response Rate to Therapy","https://ClinicalTrials.gov/show/NCT00582725"
2022,"NCT03167177","QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy","Not yet recruiting","No Results Available","Melanoma","Biological: Avelumab|Biological: Bevacizumab|Drug: Capecitabine|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: 5-fluorouracil|Drug: Leucovorin|Drug: nab-paclitaxel|Biological: Nivolumab|Drug: omega-3-acid ethyl esters|Radiation: Stereotactic Body Radiation Therapy|Biological: ALT-803|Biological: ETBX-011|Biological: ETBX-051|Biological: ETBX-061|Biological: GI-6207|Biological: GI-6301|Biological: haNK","NantCell, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","67","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","QUILT-3.046","May 23, 2017","August 2017","March 2019","May 24, 2017","May 2017","No Study Results Posted","null","January 2019","Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.|Objective response rate by RECIST Version 1.1|Objective response rate by irRC|Progression-free survival by irRC|Progression-free survival by RECIST Version 1.1|Overall survival|Duration of response|Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months)|Quality of life by patient-reported outcome using Functional Assessment of Cancer Therapy - Melanoma (FACT-M) Questionnaire","https://ClinicalTrials.gov/show/NCT03167177"
2023,"NCT02049424","Observational Study in Patients Who Underwent an Haploidentical Transplantation With T-repleted Bone Marrow","Terminated","No Results Available","Hematologic Malignancy","","Istituto Clinico Humanitas","All","18 Years and older   (Adult, Senior)","","9","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ONC/OSS-03/2011","June 28, 2013","March 2011","November 2013","January 28, 2014","January 2014","No Study Results Posted","null","November 2013","toxicity evaluation","https://ClinicalTrials.gov/show/NCT02049424"
2024,"NCT00027846","Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma","Active, not recruiting","Has Results","Brain Tumor|Central Nervous System Tumor","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: vincristine sulfate|Radiation: radiation therapy|Drug: Mesna|Procedure: therapeutic conventional surgery","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 2","378","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ACNS0121|CDR0000069086|NCI-2012-02431|COG-ACNS0121","December 7, 2001","August 2003","null","January 11, 2017","January 2017","May 27, 2016","null","January 2010","Event-free Survival|Overall Survival|Rate of Gross-total or Near-total Resection and Second Surgery After Chemotherapy|Event-free Survival (EFS)|Local Control and Patterns of Failure","https://ClinicalTrials.gov/show/NCT00027846"
2025,"NCT00566696","Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies","Active, not recruiting","Has Results","Leukemia, Acute Lymphocytic (ALL)|Leukemia, Myeloid, Acute(AML)|Leukemia, Myeloid, Chronic(CML)|Juvenile Myelomonocytic Leukemia (JMML)|Hemoglobinuria, Paroxysmal Nocturnal (PNH)|Hodgkin Lymphoma|Lymphoma, Non-Hodgkin (NHL)|Myelodysplastic Syndrome (MDS)","Device: CliniMACS|Procedure: Stem cell transplantation|Drug: Fludarabine|Drug: Thioplex®|Drug: L-phenylalanine mustard|Drug: Mycophenolate mofetil|Drug: Rituxan™|Drug: Alemtuzumab|Drug: Cyclophosphamide|Drug: Anti-thymocyte globulin (Rabbit)|Drug: G-CSF|Drug: Muromonab","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","Phase 2","73","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","HIFLEX|NCI-2011-03670","November 29, 2007","December 2007","December 2018","April 6, 2017","April 2017","January 27, 2016","null","January 2015","Event-free Survival (EFS)|Overall Survival (OS)|Disease-Free Survival (DFS)|Incidence of Non-hematologic Regimen-related Toxicities|Incidence of Regimen-related Mortality|To Estimate the Cumulative Incidence of Relapse for Research Participants Who Receive This Study Treatment.|To Estimate the Rate of Overall Grade III-IV Acute GVHD, and the Rate and Severity of Chronic GVHD in Research Participants.","https://ClinicalTrials.gov/show/NCT00566696"
2026,"NCT02950051","Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation","Recruiting","No Results Available","Chronic Lymphocytic Leukemia","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Rituximab|Drug: Bendamustine|Drug: Venetoclax|Biological: Obinutuzumab|Drug: Ibrutinib","German CLL Study Group|Stichting Hemato-Oncologie voor Volwassenen Nederland|Nordic CLL Study Group (NCLLSG)|Swiss Group for Clinical Cancer Research","All","18 Years and older   (Adult, Senior)","Phase 3","920","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CLL13|2015-004936-36","October 27, 2016","October 2016","January 2024","February 8, 2017","October 2016","No Study Results Posted","GAIA","January 2023","Miminimal residual disease (MRD) negativity rate in peripheral blood (PB)|Progression free survival (PFS)|MRD negativity rate in PB|MRD levels in PB|MRD levels in bone marrow (BM)|PFS|Overall response rate (ORR)|Rate of complete responses (CR) / complete responses with incomplete bone marrow recovery(CRi)","https://ClinicalTrials.gov/show/NCT02950051"
2027,"NCT00637819","Leflunomide in Systemic Lupus Erythematosus","Completed","No Results Available","Systemic Lupus Eythematosus (SLE)","Drug: Leflunomide","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HWA486_6014","March 11, 2008","January 2003","July 2004","March 27, 2008","March 2008","No Study Results Posted","null","null","number of patients who are able to achieve complete remission, defined as a SLEDAI of 0|number of patients who are able to achieve partial remission, as defined by a SLEDAI of 1-3","https://ClinicalTrials.gov/show/NCT00637819"
2028,"NCT00003595","Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: CHOP regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","120","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02279|AMC-010|CPMC-IRB-9691|CWRU-AMC-1400|UCLA-9810029|CDR0000066666","November 1, 1999","January 1999","null","February 7, 2013","May 2007","No Study Results Posted","null","April 2006","","https://ClinicalTrials.gov/show/NCT00003595"
2029,"NCT00003185","Biological Therapy in Treating Patients With Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: autologous tumor cell vaccine|Biological: sargramostim|Biological: tumor-draining lymph node lymphocyte therapy|Drug: cyclophosphamide|Procedure: conventional surgery","The Cleveland Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066013|CCF-BB-IND-6154|NCI-H98-0008","November 1, 1999","August 1997","July 1998","December 3, 2013","December 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003185"
2030,"NCT00001335","New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma","Completed","No Results Available","Ewing's Sarcoma|Neuroblastoma|Rhabdomyosarcoma","Drug: ADR-529|Drug: Topotecan|Drug: G-CSF","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","90","NIH","Interventional","Primary Purpose: Treatment","930125|93-C-0125","November 3, 1999","April 1993","January 2002","March 3, 2008","January 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001335"
2031,"NCT01384513","A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies","Recruiting","No Results Available","Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Aplastic Anemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Myelodysplastic Syndromes|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Essential Thrombocythemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Juvenile Myelomonocytic Leukemia|Mastocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Anemia|Refractory Anemia With Ringed Sideroblasts|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Waldenström Macroglobulinemia","Drug: Fludarabine|Drug: Busulfan|Radiation: Total Body Irradiation (TBI)|Biological: Donor Lymphocyte Infusion (DLI)|Drug: Cyclophosphamide (CY)|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Device: Allogeneic hematopoietic stem cell transplantation|Procedure: Peripheral blood stem cell transplantation (PBSCT)","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11D.247|2011-31","June 27, 2011","August 2011","July 2019","October 18, 2016","October 2016","No Study Results Posted","null","January 2018","Overall Survival (OS) in patients with haploidentical family donors with hematological malignancies in morphological or radiographic remission or with chemosensitive, indolent diseases|Treatment Related Mortality (TRM)|Incidence and severity of GVHD, graded according to standard criteria|Relapse Rate|Engraftment Rates|Incidence of Treatment Related Mortality (TRM)|Relapse Related Mortality|Lymphoid Reconstitution","https://ClinicalTrials.gov/show/NCT01384513"
2032,"NCT02553460","Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I","Recruiting","No Results Available","Acute Lymphoblastic Leukemia","Drug: ITMHA|Drug: Dexamethasone|Drug: Mitoxantrone|Drug: Pegaspargase|Drug: Asparaginase Erwinia Chrysanthemi|Drug: Bortezomib|Drug: Vorinostat|Drug: Cyclophosphamide|Drug: Mercaptopurine|Drug: Methotrexate|Drug: Leucovorin Calcium|Drug: Cytarabine|Drug: Etoposide|Drug: Vincristine","St. Jude Children's Research Hospital|Gateway for Cancer Research|Texas Children's Hospital","All","up to 365 Days   (Child)","Phase 1|Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","TINI|NCI-2015-01493","September 16, 2015","January 29, 2016","October 31, 2031","May 4, 2017","May 2017","No Study Results Posted","null","February 29, 2020","Probability of treatment-related mortality (TRM) during induction or reinduction therapy|3-year event free survival (EFS)|5-year event free survival (EFS)|10-year event free survival (EFS)|3-year overall survival (OS)|5-year overall survival (OS)|10-year overall survival (OS)|Compare minimal residual disease (MRD) positivity using flow cytometry|Compare minimal residual disease (MRD) positivity using PCR|Mean MRD levels compared to the Interfant99 study (NCT00015873)|Median MRD levels compared to the Interfant99 study (NCT00015873)","https://ClinicalTrials.gov/show/NCT02553460"
2033,"NCT01049854","CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant","Recruiting","No Results Available","Leukemia|Lymphoma|Bone Marrow Failure|Immunodeficiencies|Histiocytosis|Sickle Cell Disease|Beta Thalassemia|Inborn Errors of Metabolism","Drug: Full Intensity with TBI|Drug: Full Intensity|Drug: Reduced Intensity|Drug: Reduced Intensity (Fanconi)","New York Medical College","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","35","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","L 10,321|NYMC 525","May 5, 2008","September 2011","December 2018","March 21, 2017","March 2017","No Study Results Posted","null","December 2017","The safety CD34+ stem cell selection|Immune reconstitution (T, B, DC) following CD34+ selection","https://ClinicalTrials.gov/show/NCT01049854"
2034,"NCT03085368","A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin","Recruiting","No Results Available","HER2-positive Breast Cancer","Drug: lapatinib/herceptin","Peking Union Medical College Hospital|EddingPharm Oncology Co., LTD.","Female","18 Years to 80 Years   (Adult, Senior)","Phase 2|Phase 3","482","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","lapatinib","March 19, 2017","March 1, 2017","March 1, 2021","March 19, 2017","March 2017","No Study Results Posted","null","May 1, 2018","DFS|OS","https://ClinicalTrials.gov/show/NCT03085368"
2035,"NCT02066220","International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma","Recruiting","No Results Available","Brain Tumors","Radiation: Radiotherapy without Carboplatin|Drug: Reduced-intensity maintenance chemotherapy|Radiation: Radiotherapy with Carboplatin|Drug: Maintenance chemotherapy","Universitätsklinikum Hamburg-Eppendorf|Deutsche Kinderkrebsstiftung","All","3 Years to 21 Years   (Child, Adult)","Phase 2|Phase 3","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SIOP PNET 5 MB|2011-004868-30","February 7, 2014","June 2014","April 2024","May 5, 2017","May 2017","No Study Results Posted","null","April 2024","3-year Event-Free Survival (EFS)|Overall survival|Pattern of relapse|Late effects of therapy on endocrine function|Late effects of therapy on audiology|Late effects of therapy on neurology|Late effects of therapy on quality of survival|Progression-free survival|Feasibility of carboplatin treatment|Residual tumor|Leukoencephalopathy grading","https://ClinicalTrials.gov/show/NCT02066220"
2036,"NCT00509288","Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes","Completed","Has Results","Melanoma|Skin Cancer","Biological: autologous anti-MART-1 F5 T-cell receptor|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Aldesleukin|Biological: autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","24","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","070175|07-C-0175","July 30, 2007","June 2007","July 2012","December 27, 2012","December 2012","November 14, 2012","null","July 2011","Clinical Tumor Regression.|Toxicity","https://ClinicalTrials.gov/show/NCT00509288"
2037,"NCT00625898","BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab","Terminated","No Results Available","Breast Cancer","Drug: Docetaxel|Drug: Trastuzumab|Drug: Carboplatin|Drug: Bevacizumab|Drug: 5-Fluorouracil|Drug: Epirubicin|Drug: Cyclophosphamide","NSABP Foundation Inc|Cancer International Research Group (CIRG)|Hoffmann-La Roche|Genentech, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 3","3509","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP B-44-I|CIRG (TRIO) 011|Roche BO20906|BETH","February 21, 2008","April 2008","July 2014","July 7, 2014","July 2014","No Study Results Posted","BETH","June 2013","Invasive Disease-free Survival (IDFS)|Invasive disease-free survival (IDFS) within chemotherapy cohorts|Disease-free survival (DFS)|Overall survival (OS)|Recurrence-free interval (RFI)|Distant recurrence-free interval (DRFI)|Cardiac toxicity. Cumulative incidence of severe cardiac events defined as definite or probable cardiac death, or NYHA Class III or IV CHF|Non-cardiac toxicity. Frequencies of adverse events categorized using the NCI CTCAE v3.0.|Identification of biomarkers (from tumor and serum/plasma) predictive for the level of benefit from the addition of bevacizumab to standard adjuvant systemic treatment for HER2-positive breast cancer as well as for cardiac toxicity","https://ClinicalTrials.gov/show/NCT00625898"
2038,"NCT00004567","Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes","Completed","No Results Available","Vasculitis|Wegener's Granulomatosis","Drug: Mycophenolate Mofetil","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","75","NIH","Interventional","Primary Purpose: Treatment","000075|00-I-0075","February 11, 2000","February 2000","June 2004","March 3, 2008","June 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004567"
2039,"NCT00005578","Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease","Completed","No Results Available","Cardiac Toxicity|Lymphoma","Biological: bleomycin sulfate|Biological: filgrastim|Drug: cyclophosphamide|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","219","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single Blind|Primary Purpose: Treatment","9425|COG-9425|CDR0000065359|P9425","May 2, 2000","March 1997","June 2008","July 23, 2014","July 2014","No Study Results Posted","null","October 2004","Diffusing capacity of the lungs for carbon monoxide (DLCO)","https://ClinicalTrials.gov/show/NCT00005578"
2040,"NCT00027573","Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer","Completed","No Results Available","Kidney Cancer","Biological: filgrastim|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methotrexate|Drug: tacrolimus|Procedure: peripheral blood stem cell transplantation","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","up to 60 Years   (Child, Adult)","Phase 2","36","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-90003|U10CA031946|CDR0000069044","December 7, 2001","October 2001","June 2006","July 12, 2016","July 2016","No Study Results Posted","null","June 2006","Overall response rate|Overall survival|Disease-free survival|Treatment-related mortality|Percentage of donor chimerism in patients treated","https://ClinicalTrials.gov/show/NCT00027573"
2041,"NCT02782546","Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation","Recruiting","No Results Available","Acute Myeloid Leukemia","Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Single dose total body irradiation|Procedure: Graft cell infusion|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Drug: G-CSF|Procedure: CIML NK cell infusion|Drug: ALT-803|Procedure: Leukapheresis","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","201610088","May 22, 2016","January 30, 2017","February 28, 2022","April 11, 2017","April 2017","No Study Results Posted","null","April 30, 2020","Leukemia free survival rate (LFS)|Rate of overall survival (OS)|Incidence of relapse in patients who are found to be CR (complete remission)|Incidence of post transplant-related mortality (TRM)|Incidence of TRM|Time to neutrophil engraftment|Time to platelet engraftment|Engraftment rates|Incidence and severity of acute graft-versus host disease (GvHD) rates|Incidence and severity of chronic graft-versus host disease (GvHD) rates","https://ClinicalTrials.gov/show/NCT02782546"
2042,"NCT02298283","Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD","Recruiting","No Results Available","Hodgkin Lymphoma","Drug: brentuximab vedotin|Drug: Cyclophosphamide|Drug: Adriamycin|Drug: Oncovin|Drug: Bleomycin|Drug: Etoposide|Drug: Procarbazine|Drug: Prednisone|Drug: G-CSF|Radiation: 30 Grays","The Lymphoma Academic Research Organisation","All","18 Years to 65 Years   (Adult)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","BRAPP2","November 13, 2014","April 2015","February 2021","March 8, 2017","March 2017","No Study Results Posted","BRAPP2","August 2020","Progression free survival (PFS)|Complete Response rate (CR rate)|Overall survival","https://ClinicalTrials.gov/show/NCT02298283"
2043,"NCT02519114","Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma","Recruiting","No Results Available","Multiple Myeloma","Procedure: Donor Bone Marrow stem cell transplantation","Maastricht University Medical Center","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NL49476.000","May 28, 2015","August 2015","June 2017","February 9, 2017","February 2017","No Study Results Posted","null","June 2017","Progression free survival (scale)|Response rate (scale)|Incidence of graft failure, engraftment and time to neutrophil and platelet recovery (hematology)|Incidence and Severity of Acute and Chronic GVHD (scale)|Non-Relapse Mortality (number)|Evaluation of infections after haploBMT and T cell reconstitution (scale)|NK cell repertoire reconstitution and maturation rates including alloreactivity (facs)|NK cell repertoire in the Bone Marrow before and after transplantation (facs)|Cost calculation (euro)|Quality of Life (questionnaire)","https://ClinicalTrials.gov/show/NCT02519114"
2044,"NCT00005785","Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer","Completed","No Results Available","Hematologic Neoplasm|HIV Infection","Drug: GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 1","30","NIH","Interventional","Primary Purpose: Treatment","990167|99-DK-0167","June 3, 2000","September 1999","November 2001","March 3, 2008","November 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005785"
2045,"NCT00569101","A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis","Unknown status","No Results Available","Lupus Nephritis","Drug: tacrolimus","Seoul National University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-0706-049-211|20070217867","December 4, 2007","September 2007","March 2008","December 4, 2007","December 2007","No Study Results Posted","null","null","Reducing proteinuria","https://ClinicalTrials.gov/show/NCT00569101"
2046,"NCT00039351","Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: cyclophosphamide|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","70 Years and older   (Senior)","Phase 2","32","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","EORTC-20992","June 6, 2002","March 2002","null","September 20, 2012","September 2012","No Study Results Posted","null","January 2005","","https://ClinicalTrials.gov/show/NCT00039351"
2047,"NCT00901615","Lenalidomide and R-CHOP in B-cell Lymphoma","Unknown status","No Results Available","Lymphoma, Large B-Cell, Diffuse|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone B-Cell Lymphoma","Drug: Lenalidomide and R-CHOP","Lymphoma Study Association","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","R2CHOP-1","May 13, 2009","January 2009","January 2012","March 3, 2011","March 2011","No Study Results Posted","R2CHOP-1","January 2012","Incidence of Dose Limiting Toxicities|Complete response rate and Overall response rate at the end of treatment|Complete and Overall response rates after induction|Progression-Free Survival and Overall survival|Duration of response|Collection of adverse events","https://ClinicalTrials.gov/show/NCT00901615"
2048,"NCT01412879","S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma","Terminated","No Results Available","Lymphoma","Biological: rituximab|Drug: bendamustine hydrochloride|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: leucovorin calcium|Drug: methotrexate|Drug: vincristine sulfate","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 2","53","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000707601|S1106|U10CA032102","August 6, 2011","November 2011","null","October 10, 2016","October 2016","No Study Results Posted","null","February 2016","PFS at 2 years|Toxicity of R-HCVAD/MTX/Ara-C and autologous stem cell transplant (ASCT) or R-bendamustine and ASCT|Response rate (complete and partial response)|Overall survival","https://ClinicalTrials.gov/show/NCT01412879"
2049,"NCT00006417","Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease","Completed","No Results Available","Chronic Granulomatous Disease","Procedure: Stem cell transplantation","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","10","NIH","Interventional","Primary Purpose: Treatment","010013|01-I-0013","October 24, 2000","October 2000","November 2004","March 3, 2008","November 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006417"
2050,"NCT01395563","Strength Training on Pancreatic Cancer","Withdrawn","No Results Available","Pancreatic Neoplasms|Cachexia|Myopathy","Behavioral: strength training","German Cancer Research Center|Heidelberg University|Technische Universität München","All","Child, Adult, Senior","","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","GermanCRC","December 4, 2009","January 2009","December 2011","March 12, 2015","March 2015","No Study Results Posted","STOPC","December 2011","muscle mass and strength|quality of life","https://ClinicalTrials.gov/show/NCT01395563"
2051,"NCT01232062","Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients","Completed","No Results Available","Breast Neoplasms|Neoplasm Metastasis","","Beijing Cancer Hospital","Female","18 Years to 45 Years   (Adult)","","46","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","HD+DC-CIK","October 29, 2010","August 2010","October 2013","July 22, 2015","July 2015","No Study Results Posted","DC-CIK","May 2011","response to chemotherapy|Time to disease progression|survival rates|clinical benefit response","https://ClinicalTrials.gov/show/NCT01232062"
2052,"NCT01395056","Study of Chemotherapy With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients","Completed","No Results Available","Breast Neoplasms|Neoplasm Metastasis","","Beijing Cancer Hospital","Female","18 Years to 80 Years   (Adult, Senior)","","23","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CTX+TSPA+CBP","July 14, 2011","July 2011","June 2015","July 20, 2015","July 2015","No Study Results Posted","DCCIK","December 2014","progression-free survival|clinical benefit response and overall survival","https://ClinicalTrials.gov/show/NCT01395056"
2053,"NCT02879513","Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response to Neoadjuvant Chemotherapy","Recruiting","No Results Available","Invasive Ductal Breast Cancer|Tubular Breast Cancer|Mucinous Breast Cancer|Inflammatory Breast Cancer","Drug: Paclitaxel|Drug: Cisplatin|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: 5-fluoruracil","RenJi Hospital","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","290","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","RenJiH-BC-003","July 17, 2016","January 2014","December 2022","March 26, 2017","March 2017","No Study Results Posted","null","December 2017","Disease-free survival (DFS)|overall survival (OS)|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|regional recurrence free survival (RRFS)|local recurrence free survival (LRFS)|distant-disease- free survival (DDFS)","https://ClinicalTrials.gov/show/NCT02879513"
2054,"NCT01571518","Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy","Unknown status","No Results Available","Neutropenia","Drug: late leukostim|Drug: early leukostim","Hyuk moon Kim|Dong-A Pharmaceutical Co., Ltd.|Sunchonhang University","Female","20 Years to 70 Years   (Adult, Senior)","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","2011-91","March 29, 2012","April 2012","October 2013","April 3, 2012","April 2012","No Study Results Posted","null","October 2013","frequency of neutropenia","https://ClinicalTrials.gov/show/NCT01571518"
2055,"NCT01369888","Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma","Terminated","Has Results","Metastatic Melanoma|Skin Cancer","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Tumor Infiltrating Lymphocytes|Drug: IL-15","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 66 Years   (Adult, Senior)","Phase 1|Phase 2","3","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","110170|11-C-0170","June 8, 2011","May 2011","May 2014","January 26, 2015","January 2015","January 15, 2015","null","May 2014","Phase 1: Maximum Tolerated Dose (MTD) of Intravenous Recombinant IL-15 as a Daily Intravenous Bolus for 10 Consecutive Days in Patients With Metastatic Melanoma Who Have Received a Lymphodepleting Chemotherapy and ACT TIL.|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT01369888"
2056,"NCT01047072","Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis","Withdrawn","No Results Available","Systemic Scleroderma","Drug: fludarabine phosphate|Radiation: total-body irradiation|Drug: tacrolimus|Drug: mycophenolate mofetil|Biological: rituximab|Drug: cyclophosphamide|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium|National Cancer Institute (NCI)|Fred Hutchinson Cancer Research Center","All","18 Years to 65 Years   (Adult)","Phase 2","0","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2363.00|NCI-2012-00139","January 11, 2010","null","null","October 29, 2012","October 2012","No Study Results Posted","null","September 2017","Event-free survival|Overall survival|Time to progression|Incidence of initiation of any SSC disease-modifying therapy other than that specified in the protocol treatment arms|Incidence of definite and probable viral, fungal, and bacterial infections|Median time to engraftment as defined as having greater than or equal to 5% donor T cells in the peripheral blood (donor T cell chimerism)|Rate of primary graft failure|Rate of secondary graft failure|Probability of acute and chronic GVHD","https://ClinicalTrials.gov/show/NCT01047072"
2057,"NCT00006413","Stem Cell Transplantation to Treat Systemic Mastocytosis","Completed","No Results Available","Mastocytosis","Procedure: Stem cell transplantation","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","2 Years to 80 Years   (Child, Adult, Senior)","Phase 2","25","NIH","Interventional","Primary Purpose: Treatment","010010|01-H-0010","October 17, 2000","October 13, 2000","December 14, 2006","January 24, 2017","December 14, 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006413"
2058,"NCT01393366","Facing Obstacles to RDI (Relative Dose Intensity) Through Telephone Intervention Strategy","Completed","No Results Available","Chronic Lymphocytic Leukemia","Other: Telephone Intervention|Other: Usual Practice","University Hospital, Toulouse","All","18 Years and older   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Supportive Care","1030903","July 5, 2011","September 2011","December 2016","February 21, 2017","February 2017","No Study Results Posted","FORTIS","December 2015","Evaluation of RDI|Evaluation of Toxicity grade III-IV","https://ClinicalTrials.gov/show/NCT01393366"
2059,"NCT00001764","Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions","Completed","No Results Available","Vasculitis|Wegener's Granulomatosis","Drug: Mycophenolate Mofetil","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 1","50","NIH","Interventional","Primary Purpose: Treatment","980092|98-I-0092","November 3, 1999","April 1998","June 2004","March 3, 2008","June 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001764"
2060,"NCT00001765","Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease","Completed","No Results Available","Chronic Granulomatous Disease","Device: Nexell Isolex with T-cell Depletion|Device: Baxter isolex 300i","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 1","60","NIH","Interventional","Primary Purpose: Treatment","980104|98-I-0104","November 3, 1999","April 1998","February 2005","March 3, 2008","February 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001765"
2061,"NCT00441025","The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL","Terminated","No Results Available","Peripheral T-Cell Lymphoma","Drug: Alemtuzumab","Mahidol University|Bayer","All","15 Years to 65 Years   (Child, Adult)","Phase 2","4","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TH 011002","February 26, 2007","September 2006","August 2009","June 24, 2009","February 2007","No Study Results Posted","null","null","To determine the effectiveness of alemtuzumab given in combination with CHOP in terms of the rates of objective response rate (ORR:complete remission[CR] and|partial remission[PR]),progressive disease-free(PFS) and overall survivals(OS)|in patients newly diagnosed with PTCL.|To determine the safety profiles of alemtuzumab given in combination with CHOP","https://ClinicalTrials.gov/show/NCT00441025"
2062,"NCT01678430","A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment","Recruiting","No Results Available","Chronic Lymphocytic Leukaemia","Drug: Ofatumumab|Drug: Chlorambucil|Drug: Bendamustine","University of Liverpool|GlaxoSmithKline|Napp Pharmaceuticals Limited|Chugai Pharma USA","All","18 Years and older   (Adult, Senior)","Phase 3","670","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","OMB114578|2011-000919-22|009988575","August 30, 2012","December 2011","December 2017","October 12, 2012","August 2012","No Study Results Posted","RIAltO","December 2017","Progression-free survival|Duration of response|Overall survival|Time to treatment failure|Toxicity|Treatment dose administered|Quality of life|Health Economic analysis|Analysis of frailty and co-morbidity|Predictive value of biomarkers|Response","https://ClinicalTrials.gov/show/NCT01678430"
2063,"NCT00006734","Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor","Completed","No Results Available","Sarcoma","Biological: filgrastim|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: vincristine sulfate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: brachytherapy|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group","All","up to 50 Years   (Child, Adult)","Phase 3","587","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AEWS0031|COG-AEWS0031|CDR0000068323|A7983","December 6, 2000","May 2001","null","May 16, 2013","May 2013","No Study Results Posted","null","August 2006","Event-free survival","https://ClinicalTrials.gov/show/NCT00006734"
2064,"NCT00118209","Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma","Active, not recruiting","No Results Available","Large B Cell Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Drug: prednisone|Drug: etoposide|Drug: filgrastim|Drug: pegfilgrastim","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","13","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-50303|CDR0000433265|NCI-2009-00480|U10CA031946|U10CA180821","July 8, 2005","May 2005","null","July 1, 2016","July 2016","No Study Results Posted","null","May 2018","Event-free survival|Response rate|Overall survival|Whether the gene expression signatures that were previously associated with survival following CHOP therapy are associated with survival in either of the treatment arms of the prospective trial","https://ClinicalTrials.gov/show/NCT00118209"
2065,"NCT00002571","SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma","Completed","No Results Available","Lymphoma","Biological: bleomycin sulfate|Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: prednisone|Drug: trimethoprim-sulfamethoxazole|Drug: vincristine sulfate|Radiation: radiation therapy|Drug: Intrathecal cytarabine","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","52","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000063620|SWOG-9320|U10CA032102","November 1, 1999","June 1994","July 2011","January 22, 2013","January 2013","No Study Results Posted","null","November 2003","Response","https://ClinicalTrials.gov/show/NCT00002571"
2066,"NCT00131313","Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.","Unknown status","No Results Available","Chronic Lymphocytic Leukemia","Drug: Nipent, Cytoxan, Rituxan","East Valley Hematology and Oncology Medical Group|Mena, Raul, M.D.|Pharmatech Oncology|Astex Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 4","180","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","POI-02818|NIP-02-005","August 16, 2005","January 2003","April 2009","August 17, 2005","August 2005","No Study Results Posted","null","null","Efficacy response rate|Time to progression|Time to treatment failure|Toxicity|Incidence and severity of adverse events","https://ClinicalTrials.gov/show/NCT00131313"
2067,"NCT00553202","Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia","Active, not recruiting","Has Results","Leukemia","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Drug: methylprednisolone|Drug: tacrolimus|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","Phase 2","158","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AAML05P1|COG-AAML05P1|NCI-2009-00321","November 2, 2007","January 2008","null","January 6, 2017","July 2016","October 31, 2016","null","June 2016","Overall Survival (OS)|Cumulative Incidence of NK Cell Reconstitution","https://ClinicalTrials.gov/show/NCT00553202"
2068,"NCT02799147","GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia","Recruiting","No Results Available","Leukemia, Acute Lymphoblastic|Acute Myeloid Leukemia|Mixed-Lineage Acute Leukemias","Procedure: Allogeneic stem cell transplantation|Drug: Fludarabine monophosphate|Drug: Busulfan|Drug: Bendamustine","St. Petersburg State Pavlov Medical University","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","05/16-n","June 9, 2016","June 2016","June 2019","December 14, 2016","December 2016","No Study Results Posted","null","June 2018","Engraftment rate|Relapse rate analysis|Non-relapse mortality analysis|Incidence of acute GVHD, grades II-IV|Incidence of chronic GVHD, moderate and severe (NIH criteria)|Overall survival analysis|Event-free survival analysis|Toxicity (NCI CTCAE 4.03)|Infectious complications, including analysis of severe bacterial, fungal and viral infections incidence","https://ClinicalTrials.gov/show/NCT02799147"
2069,"NCT03104595","Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer","Not yet recruiting","No Results Available","Febrile Neutropenia","Drug: EC-18","Enzychem Lifesciences Corporation","Female","19 Years to 85 Years   (Adult, Senior)","Phase 2","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: No masking|Primary Purpose: Treatment","EC-18-201","February 24, 2017","June 2017","March 2019","May 16, 2017","May 2017","No Study Results Posted","null","September 2018","Duration of Grade 4 neutropenia","https://ClinicalTrials.gov/show/NCT03104595"
2070,"NCT00005988","Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy","Completed","No Results Available","Graft Versus Host Disease|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myeloma","Drug: cyclophosphamide|Drug: cyclosporine|Drug: leucovorin calcium|Drug: methotrexate|Drug: methylprednisolone|Procedure: in vitro-treated bone marrow transplantation|Radiation: radiation therapy","Dana-Farber Cancer Institute|National Cancer Institute (NCI)","All","up to 40 Years   (Child, Adult)","Phase 1","5","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","99-205|P30CA006516|GENE-C9909-38|NCI-G00-1801|CDR0000067977","July 5, 2000","February 2000","March 8, 2002","March 30, 2017","March 2017","No Study Results Posted","null","June 16, 2001","Incidence of primary graft failure|Incidence of hyperacute GVHD|Incidence of Grade D acute GVHD|Incidence of adverse events","https://ClinicalTrials.gov/show/NCT00005988"
2071,"NCT01994850","A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas","Recruiting","No Results Available","CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30 Positive Diffuse Large B-cell Lymphoma or CD30 Positive Grey Zone Lymphoma","Drug: brentuximab vedotin","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","32","Other","Interventional","Primary Purpose: Treatment","UPCC 17413","November 20, 2013","November 2013","null","September 23, 2016","September 2016","No Study Results Posted","null","November 2018","Number of Adverse Events","https://ClinicalTrials.gov/show/NCT01994850"
2072,"NCT02682693","Denosumab as an add-on Neoadjuvant Treatment (GeparX)","Recruiting","No Results Available","Breast Cancer Female NOS|Tubular Breast Cancer Stage II|Mucinous Breast Cancer Stage II|Invasive Ductal Breast Cancer|HER2 Positive Breast Cancer|Inflammatory Breast Cancer|Tubular Breast Cancer Stage III","Drug: Denosumab|Drug: nab-Paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Carboplatin|Drug: Trastuzumab|Drug: Pertuzumab","German Breast Group|Amgen|Celgene Corporation","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","778","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: No masking|Primary Purpose: Treatment","GBG 88","January 27, 2016","February 13, 2017","December 2018","February 22, 2017","February 2017","No Study Results Posted","GeparX","December 2018","pcR rates of neoadjuvant treatment with or without denosumab in addition to nab-paclitaxel and EC.|pcR (ypT0 ypN0) rates of nab-Paclitaxel weekly for 12 weeks or 2 of 3 weeks for 12 weeks|To test for interaction of denosumab treatment with RANK expression.|To assess the pCR rates per arm for both randomizations separately for TNBC and HR-/HER2+ tumors.","https://ClinicalTrials.gov/show/NCT02682693"
2073,"NCT01746173","CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma","Terminated","Has Results","T-cell Non-Hodgkin Lymphoma","Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Etoposide|Drug: Prednisone|Drug: Filgrastim|Drug: Plerixafor|Procedure: Stem Cell Collection|Drug: Palifermin|Drug: Gemcitabine|Drug: Busulfan|Drug: Melphalan|Procedure: Stem Cell Transplant","Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","12-388","December 4, 2012","February 2013","October 2014","January 11, 2017","January 2017","October 4, 2016","null","October 2014","24-month Progression-Free Survival Rate|Induction Response","https://ClinicalTrials.gov/show/NCT01746173"
2074,"NCT02198248","Low-dose Glucocorticoid Vasculitis Induction Study","Recruiting","No Results Available","Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis|Microscopic Polyangiitis|Wegener Granulomatosis","Drug: Rituximab|Drug: Glucocorticoids","Chiba University|National Hospital Organization Chiba East Hospital","All","20 Years and older   (Adult, Senior)","Phase 4","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","G25051|UMIN000014222","July 18, 2014","October 2014","September 2019","July 25, 2016","July 2016","No Study Results Posted","LoVAS","March 2018","Proportion of the patients achieving remission|Time to remission|Overall survival, disease free survival, time to end-stage renal disease, time to the first serious adverse event|Proportions of death, relapse, end-stage renal disease and the composite of these|Proportions of severe relapse|Birmingham Vasculitis Activity Score (BVAS) version 3|Vasculitis Damage Index (VDI)|Short-Form 36 (SF-36)|Patient global assessment (visualised analogue scale)|Accumulative dose of glucocorticoids|Numbers of events of adverse events/serious adverse events, proportions of the patients with adverse events/serious adverse events|Proportions of the patients with new onset diabetes mellitus|Proportion of the patients with new onset insomnia|Proportion of the patients with new onset bone fracture, bone density|Number of infections, proportions of the patients with infection|Proportions of the patients with new onset hypertension|Proportions of the patients with new onset hyperlipidemia|Proportions of patients achieving remission and discontinuance of glucocorticoids","https://ClinicalTrials.gov/show/NCT02198248"
2075,"NCT00028964","Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer","Completed","No Results Available","Breast Cancer|Drug/Agent Toxicity by Tissue/Organ","Dietary Supplement: Chinese herbs|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Procedure: adjuvant therapy","University of California, San Francisco|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","null","Other|NIH","Interventional","Allocation: Randomized|Masking: Double-Blind|Primary Purpose: Supportive Care","CDR0000069154|UCSF-CRO-97755|UCSF-IND-54870|NCI-G01-2042","January 4, 2002","February 2001","February 2005","February 20, 2011","February 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00028964"
2076,"NCT00005893","Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders","Completed","No Results Available","Neutropenia|Sickle Cell Anemia|Thalassemia Major|Red-Cell Aplasia, Pure","Drug: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Procedure: Bone marrow transplantation","Fairview University Medical Center|Office of Rare Diseases (ORD)","All","Child, Adult, Senior","","null","Other","Interventional","Primary Purpose: Treatment","199/15101|UMN-MT-1994-18|UMN-MT-9418","June 2, 2000","June 2000","null","June 23, 2005","July 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005893"
2077,"NCT03157037","An Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease (GOOD-IDES)","Recruiting","No Results Available","Anti-Glomerular Basement Membrane Disease","Biological: HMed-IdeS","Mårten Segelmark|Hansa Medical AB|Linkoeping University","All","18 Years and older   (Adult, Senior)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","GOOD-IDES-01","May 11, 2017","March 1, 2017","March 1, 2019","May 15, 2017","May 2017","No Study Results Posted","GOOD-IDES","March 1, 2019","Proportion of patients with independent renal function at 6 months|The proportion of subjects with independent renal function, defined as no need for dialysis at 3 months, as compared to historical controls.|Renal function at 3 and 6 months|Number of days with anti-GBM antibodies above a toxic level|Disappearance of haematuria|Change in proteinuria during the study|Number of PLEXs needed|Renal histology|Anti-IdeS antibodies (ADA)|Pharmacodynamics (IgG degradation)|Pharmacokenetics","https://ClinicalTrials.gov/show/NCT03157037"
2078,"NCT00386321","Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma","Terminated","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)","Chulalongkorn University|Bayer","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","10","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TH011103","October 10, 2006","April 2006","January 2010","November 17, 2010","November 2010","No Study Results Posted","null","July 2007","2-year progression-free survival and overall survival of patients|Response rate (partial response, complete unconfirmed response, and complete response)in patients|2-year progression-free survival, overall survival and response rate in BCL-2 positive patients","https://ClinicalTrials.gov/show/NCT00386321"
2079,"NCT01393756","Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma","Completed","No Results Available","Follicular Lymphoma","Drug: Lenalidomide and R-CHOP","The Lymphoma Academic Research Organisation|Centre Henri Becquerel","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","(R2-CHOP2)","July 4, 2011","December 2010","November 2015","February 16, 2016","February 2016","No Study Results Posted","R2-CHOP2","July 2013","Complete Response Rate (CR+CRu)|Overall survival|Duration of response","https://ClinicalTrials.gov/show/NCT01393756"
2080,"NCT00072280","Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma","Terminated","Has Results","Sarcoma","Biological: dactinomycin|Drug: cyclophosphamide|Drug: etoposide|Drug: ifosfamide|Drug: vincristine sulfate|Procedure: Conventional Surgery|Biological: MESNA (mercaptoethane sulfonate)|Biological: Filgrastim","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 2 Years   (Child)","Phase 2","7","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ARST03P1|CDR0000339565|NCI-2012-02561|COG-ARST03P1","November 4, 2003","November 2004","March 2008","September 16, 2014","September 2014","September 23, 2013","null","March 2008","Failure-free Survival (FFS) in ""Chemotherapy Plus Possible Surgery"" Arm","https://ClinicalTrials.gov/show/NCT00072280"
2081,"NCT02337985","Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma","Recruiting","No Results Available","AIDS-Related Burkitt Lymphoma|AIDS-Related Diffuse Large B-cell Lymphoma|AIDS-Related Plasmablastic Lymphoma|AIDS-Related Primary Effusion Lymphoma|HIV Infection|AIDS Related Non-Hodgkin Lymphoma","Drug: Prednisone|Biological: Rituximab|Drug: Etoposide|Drug: Doxorubicin Hydrochloride|Drug: Vincristine Sulfate|Drug: Cyclophosphamide|Biological: Filgrastim|Biological: Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","14004|NCI-2014-02416|U01CA183012","December 23, 2014","August 3, 2015","March 2018","May 1, 2017","May 2017","No Study Results Posted","null","March 2018","Incidence of adverse events related to R-EPOCH, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03|Incidence of adverse events related to lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic stem/progenitor cells infusion, graded using the NCI CTCAE version 4.03|Ability to obtain suitable numbers of lentiviral vector treated HSPC as determined by cell count|Presence of transgene in peripheral blood by digital droplet PCR|Transgene ribonucleic acid expression by Northern blotting/hybridization and quantitative real-time PCR assay|HIV reservoir as determined by HIV-1 reverse transcriptase (RT)-PCR, DNA PCR, and DNA 2 long terminal repeat circle PCR|HIV integration analysis by number of reads and loci|Vector transgene sequences in peripheral blood mononuclear cells|Change in of shI-TAR-CCR5RZ-marked cells in bone marrow","https://ClinicalTrials.gov/show/NCT02337985"
2082,"NCT02771743","Response-based Treatment of High-risk Neuroblastoma","Recruiting","No Results Available","Newly Diagnosed High Risk Neuroblastoma","Drug: Cisplatin|Drug: Doxorubicin|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Ifosfamide|Drug: Carboplatin|Procedure: Tandem HDCT/auto-SCT|Radiation: Radiotherapy|Drug: Interleukin-2|Drug: Isotretinoin|Radiation: MIBG","Samsung Medical Center","All","Child, Adult, Senior","Phase 2","54","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2015-02-064","May 12, 2016","April 2015","March 2023","May 23, 2016","May 2016","No Study Results Posted","null","March 2020","Rate of event free survival|Rate of late adverse effects","https://ClinicalTrials.gov/show/NCT02771743"
2083,"NCT00040248","Daclizumab to Treat Wegener's Granulomatosis","Completed","No Results Available","Wegener's Granulomatosis","Drug: Daclizumab","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","75","NIH","Interventional","Primary Purpose: Treatment","020213|02-I-0213","June 22, 2002","June 2002","May 2005","March 3, 2008","May 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00040248"
2084,"NCT03004287","2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","Not yet recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Thalidomide|Drug: Dexamethasone|Drug: Daratumumab|Drug: Cisplatin|Drug: Adriamycin|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Melphalan|Procedure: ASCT|Drug: Lenalidomide|Drug: Bortezomib","University of Arkansas|Janssen, LP","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","206241","December 19, 2016","June 1, 2017","January 2021","May 15, 2017","May 2017","No Study Results Posted","null","January 2021","Measure the progression-free survival in patients with high risk multiple myeloma","https://ClinicalTrials.gov/show/NCT03004287"
2085,"NCT00278655","Hematopoietic Stem Cell Therapy for Patients With Multiple Sclerosis","Terminated","Has Results","Multiple Sclerosis","Biological: Hematopoietic stem cell transplantation","Northwestern University","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DIAD MS.Auto2002","January 16, 2006","June 2003","May 2012","March 31, 2014","March 2014","April 9, 2013","null","December 2011","Disease Progression|Survival","https://ClinicalTrials.gov/show/NCT00278655"
2086,"NCT00727194","Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis","Terminated","Has Results","Myasthenia Gravis","Drug: eculizumab|Drug: Placebo","Alexion Pharmaceuticals","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","14","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C08-001","July 30, 2008","October 2008","July 2011","December 19, 2016","December 2016","March 22, 2016","null","March 2011","Quantitative Myasthenia Gravis (QMG): The Primary Efficacy Endpoint in This Study Was the Percentage of Patients With a 3-point Reduction From Baseline in the QMG Total Score for Disease Severity.|Mean Change From Baseline in QMG Total Score|Change From Baseline in the MGFA Post-Intervention Status (PIS)|Change From Baseline in the MG-Activity of Daily Living Profile (MG-ADL)|Change From Baseline in the QoL Instrument, SF-36.|Change From Baseline in Respiratory Function Tests to Characterize the Degree of Involvement of Respiratory Muscles.|Change From Baseline to the End of Treatment (16 Weeks) in the Two Most Affected QMG Items for Disease Severity (Individual Test Item: Double Vision)|Change From Baseline to the End of Treatment (16 Weeks) in the Two Most Affected QMG Items for Disease Severity (Individual Test Item: Ptosis)","https://ClinicalTrials.gov/show/NCT00727194"
2087,"NCT01266668","The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL)","Completed","No Results Available","Lymphoma, Large B-Cell, Diffuse","","Chonbuk National University Hospital","All","20 Years to 85 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","Chonbuk 011","December 21, 2010","February 2010","June 2011","November 28, 2011","November 2011","No Study Results Posted","null","May 2011","Overall Survival|Progression-free survival","https://ClinicalTrials.gov/show/NCT01266668"
2088,"NCT00003552","Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma","Terminated","No Results Available","Stage IV Melanoma|Recurrent Melanoma","Drug: allogeneic lymphocytes|Drug: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: fludarabine","National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)","null","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","null","NIH","Interventional","Primary Purpose: Treatment","CDR0000066609|NHLBI-98-H-0006","March 1, 2007","January 1999","October 2002","April 27, 2015","December 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003552"
2089,"NCT02314273","Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL","Completed","No Results Available","Pancytopenia Due to Chemotherapy","Drug: rhIL-11","Shanghai Children's Medical Center|Xiamen Amoytop Biotech Co., Ltd.","All","up to 18 Years   (Child, Adult)","Phase 4","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TBK-10-01","July 25, 2014","September 2011","April 2014","December 8, 2014","November 2014","No Study Results Posted","null","April 2014","platelet infusion|hemorrhagic tendency|infection|remission rate|platelet Count","https://ClinicalTrials.gov/show/NCT02314273"
2090,"NCT00002829","Bone Marrow Transplantation in Treating Patients With Lymphoma","Completed","No Results Available","Lymphoma","Biological: Recombinant Interferon Alfa|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Mesna|Procedure: Bone Marrow Transplantation|Radiation: Radiation Therapy","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","15 Years to 60 Years   (Child, Adult)","Phase 2","45","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM94-009|P30CA016672|MDA-DM-94009|NCI-G96-0994|CDR0000065027","November 1, 1999","February 1994","April 2002","July 26, 2012","July 2012","No Study Results Posted","null","April 2002","Number of Patients with Response","https://ClinicalTrials.gov/show/NCT00002829"
2091,"NCT00040469","Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies","Terminated","No Results Available","Sickle Cell Anemia|Hemoglobinopathy|Thalassemia","Drug: Campath -1H|Drug: Dilantin|Drug: Busulfan|Drug: Cyclophosphamide","Baylor College of Medicine|The Methodist Hospital System|Texas Children's Hospital|Center for Cell and Gene Therapy, Baylor College of Medicine","All","up to 64 Years   (Child, Adult)","Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H6847|Scallo2","June 26, 2002","August 2000","null","April 9, 2007","April 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00040469"
2092,"NCT00004036","Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer","Unknown status","No Results Available","Chronic Myeloproliferative Disorders|Drug/Agent Toxicity by Tissue/Organ|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific","Biological: sargramostim|Drug: amifostine trihydrate|Drug: carboplatin|Drug: cyclophosphamide","The Cleveland Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Primary Purpose: Supportive Care","CDR0000066347|CCF-IRB-1907|IMMUNEX-001.G9701|NCI-V98-1424","December 10, 1999","November 1997","null","December 18, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004036"
2093,"NCT00278629","Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy","Active, not recruiting","No Results Available","Chronic Inflammatory Demyelinating Polyneuropathy","Biological: hematopoietic stem cell transplantation","Northwestern University","All","18 Years to 65 Years   (Adult)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NU FDA CIDP.AUTO2003","January 16, 2006","March 2005","December 2018","March 9, 2017","March 2017","No Study Results Posted","null","December 2017","Survival;Disease improvement;","https://ClinicalTrials.gov/show/NCT00278629"
2094,"NCT00058422","Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Biological: darbepoetin alfa|Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: indium In 111 ibritumomab tiuxetan|Radiation: yttrium Y 90 ibritumomab tiuxetan","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","60 Years to 120 Years   (Adult, Senior)","Phase 2","65","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","02-090|MSKCC-02090","April 7, 2003","February 2003","February 2018","March 1, 2017","March 2017","No Study Results Posted","null","February 2018","Overall survival|Progression-free survival|Event-free survival|incidence of adverse experiences|Conversion rate to complete remission","https://ClinicalTrials.gov/show/NCT00058422"
2095,"NCT00530075","Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis","Completed","Has Results","Wegener's Granulomatosis","Drug: Gusperimus","Nippon Kayaku Co.,Ltd.","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","45","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","102","September 14, 2007","December 2003","February 2006","January 16, 2017","September 2007","April 18, 2016","null","February 2006","Remission of Vasculitis|Duration of Clinical Response|Haematuria|Creatinine|ANCA|CRP|Vasculitis Damage Index (VDI)|SF-36","https://ClinicalTrials.gov/show/NCT00530075"
2096,"NCT02419469","Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","Active, not recruiting","No Results Available","Leukemia|Precursor-B Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Lymphoma","Drug: Cytarabine|Drug: Daunorubicin|Drug: Vincristine|Drug: Prednisone|Drug: PEG asparaginase|Drug: Ofatumumab|Drug: Rituximab|Drug: Methotrexate|Drug: Cyclophosphamide|Drug: Mercaptopurine|Drug: Doxorubicin|Drug: Dexamethasone acetate|Drug: Thioguanine","M.D. Anderson Cancer Center|Jazz Pharmaceuticals","All","12 Years to 30 Years   (Child, Adult)","Phase 2","1","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2014-0396|NCI-2015-00967","April 14, 2015","November 13, 2015","November 2018","May 23, 2017","May 2017","No Study Results Posted","null","November 2018","Event Free Survival (EFS)","https://ClinicalTrials.gov/show/NCT02419469"
2097,"NCT00562965","Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)","Terminated","No Results Available","Lymphoma, Follicular","Drug: inotuzumab ozogamicin|Drug: rituximab|Drug: rituximab|Drug: cyclophosphamide|Drug: vincristine|Drug: prednisone/prednisolone|Drug: mitoxantrone|Drug: fludarabine|Drug: dexamethasone","Pfizer|UCB Pharma","All","18 Years and older   (Adult, Senior)","Phase 3","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Health Services Research","3129K4-3301|B1931006","November 21, 2007","November 2007","April 2011","December 22, 2012","December 2012","No Study Results Posted","null","April 2011","To assess efficacy as measured by progression free survival (PFS), with a goal of demonstrating the superiority of inotuzumab ozogamicin when administered in combination with rituximab, compared with an active comparator arm.|To assess the safety and tolerability of inotuzumab ozogamicin in combination with rituximab. To assess the population pharmacokinetics (PK) of inotuzumab ozogamicin in combination with rituximab, and to evaluate factors affecting drug metabolism.|To evaluate the efficacy of inotuzumab ozogamicin in combination with rituximab using the following endpoints and analyses: Overall Response Rate and Overall Survival|QT assessment","https://ClinicalTrials.gov/show/NCT00562965"
2098,"NCT02518750","Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Lymphoma, Non-Hodgkin's|Leukemia, T-Cell|Leukemia, B-Cell","Drug: Dexamethasone|Drug: Panobinostat|Drug: Liposomal vincristine|Drug: Mitoxantrone|Drug: Peg-asparaginase|Drug: Bortezomib|Drug: Intrathecal Triples|Drug: High-dose methotrexate|Drug: 6-Mercaptopurine|Drug: High-dose cytarabine|Drug: Nelarabine|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Clofarabine","St. Jude Children's Research Hospital|Novartis Pharmaceuticals|Spectrum Pharmaceuticals, Inc","All","up to 21 Years   (Child, Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","TSALV|NCI-2015-00935","July 16, 2015","November 23, 2016","April 30, 2019","March 30, 2017","August 2016","No Study Results Posted","null","April 30, 2019","Complete Remission (CR) Rate|Block A Minimal Residual Disease (MRD)|Block B Minimal Residual Disease (MRD)|Block C Minimal Residual Disease (MRD)|Proportion of relevant toxicities","https://ClinicalTrials.gov/show/NCT02518750"
2099,"NCT02135510","MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy","Recruiting","No Results Available","Solid Tumors","Drug: metoclopramide|Drug: dexamethason|Drug: palonosetron","VU University Medical Center|Medisch Centrum Alkmaar|Zaans Medisch Centrum|Waterland Hospital|Tergooiziekenhuizen locatie Hilversum|Ziekenhuis Amstelland|Gemini Ziekenhuis","All","18 Years and older   (Adult, Senior)","Phase 3","450","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2011/366","May 1, 2014","June 2013","July 2017","March 20, 2017","March 2017","No Study Results Posted","MEDEA","July 2017","efficacy|tolerability|cost-effectiveness","https://ClinicalTrials.gov/show/NCT02135510"
2100,"NCT01796197","Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa","Recruiting","No Results Available","Breast Cancer","Drug: Trastuzumab|Drug: Pertuzumab|Drug: Paclitaxel|Drug: Doxorubicin|Drug: Cyclophosphamide|Procedure: Mastectomy|Radiation: Radiation Therapy","Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","12-497","February 20, 2013","March 2013","March 2020","April 27, 2017","April 2017","No Study Results Posted","null","June 2018","Pathologic complete response rate|Assess residual cancer burden|Assess toxicity of protocol therapy|Determine efficacy of therapy|Assess microarray analysis on pre-treatment biopsy specimens|Assess microarray analysis on residual disease|Identify early adaptive responses","https://ClinicalTrials.gov/show/NCT01796197"
2101,"NCT00041132","S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma","Completed","Has Results","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin|Drug: leucovorin|Drug: methotrexate|Drug: vincristine","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years to 69 Years   (Adult, Senior)","Phase 2","56","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000069445|U10CA032102|S0213","July 8, 2002","September 2002","June 2011","October 3, 2012","October 2012","March 5, 2012","null","November 2007","Progression-free Survival|Response|Overall Survival","https://ClinicalTrials.gov/show/NCT00041132"
2102,"NCT00395655","Hydralazine and Valproate Added to Chemotherapy for Breast Cancer","Terminated","No Results Available","Locally Advanced Breast Cancer","Drug: Hydralazine and magnesium valproate administration|Procedure: Core-needle biopsy of the breast","National Institute of Cancerología|National Council of Science and Technology, Mexico|Psicofarma S.A. de C.V.","Female","18 Years and older   (Adult, Senior)","Phase 2","43","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","005/012/ICI","November 1, 2006","June 2005","August 2006","November 1, 2006","November 2006","No Study Results Posted","null","null","Global DNA methylation|Histone Deacetylase Activity|Global gene expression|Pathological response|Hydralazine plasma levels|Valproic acid plasma levels","https://ClinicalTrials.gov/show/NCT00395655"
2103,"NCT03054896","A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R for Patients With Richter's Syndrome","Recruiting","No Results Available","Richter Syndrome","Drug: Venetoclax|Other: DA-EPOCH-R","Dana-Farber Cancer Institute|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","16-596","February 10, 2017","March 8, 2017","September 1, 2023","March 15, 2017","March 2017","No Study Results Posted","null","September 1, 2020","Rate of Complete Response by 2008 IW-CLL Response Criteria|Partial Response Rate by 2008 IW-CLL Response Criteria|Progression Free Survival|Overall Survival Rate|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT03054896"
2104,"NCT00012207","Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","Completed","No Results Available","Leukemia|Lymphoma","Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Drug: prednisone|Drug: vincristine sulfate|Procedure: adjuvant therapy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 1","12","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","1503.00|FHCRC-1503.00|NCI-G01-1921|CDR0000068494","March 3, 2001","September 2000","July 2010","August 20, 2010","August 2010","No Study Results Posted","null","null","Safety and toxicity by NCI CTC toxicity scale in patients w/ recurr. or refract. CD20+ follicular lymphoma who are not candidates for high dose chemoradiotx and stem cell transplant during each infusion, weekly for 4 wks and then monthly for a yr|Duration of in vivo persistence of adoptively transferred CD20-specific CD8+ T cell clones by flow cytometry and quantitative polymerase chain reaction (qPCR) during each infusion, weekly for 4 weeks, and then monthly for a year|Trafficking of CD8+ CD20-specific T cell clones to lymph nodes by Gamma camera imaging during each infusion, weekly for 4 weeks, and then monthly for a year|Development of host anti-scFvFc:zeta (and anti-NeoR) immune responses by ELISA and chromium release assays during each infusion, weekly for 4 weeks, and then monthly for a year|Tumor responses to cyclophosphamide, vincristine, and prednisone (CVP) and to cytotoxic T-lymphocyte (CTL) infusions by Cheson criteria during each infusion, weekly for 4 weeks, and then monthly for a year","https://ClinicalTrials.gov/show/NCT00012207"
2105,"NCT00282438","Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis","Terminated","Has Results","Sarcoidosis","Biological: Autologous hematopoietic stem cell transplantation|Biological: Allogeneic stem cell transplantation","Northwestern University","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","2","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NU FDA SARC.2003","January 24, 2006","December 2003","August 2015","January 3, 2017","September 2016","September 12, 2016","null","August 2015","Toxicity|Survival|Time to Disease Progression|Disease Improvement","https://ClinicalTrials.gov/show/NCT00282438"
2106,"NCT02776605","Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia","Recruiting","No Results Available","ALL","Drug: Prednisone|Drug: Vincristine|Drug: Daunorubicin|Drug: Prednisone|Drug: Ponatinib|Drug: Mercaptopurine|Drug: Methotrexate|Drug: VP-16|Drug: ARA-C:|Drug: TIT|Drug: Ponatinib|Procedure: Autologous transplantation|Procedure: Allo transplantation","PETHEMA Foundation","All","18 Years to 55 Years   (Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PONALFIL","May 16, 2016","June 2016","December 2024","December 8, 2016","December 2016","No Study Results Posted","PONALFIL","January 2018","Overall response|Event free survival","https://ClinicalTrials.gov/show/NCT02776605"
2107,"NCT02670317","Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.","Terminated","No Results Available","Lymphoma, B-Cell","Drug: Obinutuzumab|Drug: Ibrutinib|Drug: CHOP","Fondazione Italiana Linfomi ONLUS","All","18 Years to 60 Years   (Adult)","Phase 2","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","FIL-GALILEO|2015-005273-20","January 25, 2016","September 2016","February 2017","March 16, 2017","March 2017","No Study Results Posted","FIL-GALILEO","February 2017","The efficacy of G-CHOP-21 in combination with Ibrutinib in terms of 2-yrs PFS (progression-free survival)|The safety of G-CHOP-21 in combination with Ibrutinib in terms of proportion of patients experiencing grade 3 or greater extra-hematologic toxicity or treatment interruption for safety reasons or any toxic death during the 6 cycles of treatment|Overall Survival (OS)|Complete Remission (CR) Rate|Overall Response Rate (ORR)|The Duration Of Response (DOR) after the end of treatment","https://ClinicalTrials.gov/show/NCT02670317"
2108,"NCT00278486","Hematopoietic Stem Cell Transplantation in Autoimmune-Related Retinopathy(ARRON)","Terminated","No Results Available","Retinal Disease","Biological: Hematopoietic stem cell transplantation.","Richard Burt, MD|Northwestern University","All","18 Years to 60 Years   (Adult)","Phase 1","2","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DI ARRON 04","January 15, 2006","August 2004","April 2012","April 4, 2013","April 2013","No Study Results Posted","null","April 2012","Standard Snellen acuity clinical testing and improvement visual fields is done by using Humphrey Automated Machine with 30-2 program or using Kinetic Visual Fields on the Goldman Perimeter)","https://ClinicalTrials.gov/show/NCT00278486"
2109,"NCT02303821","Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia","Recruiting","No Results Available","Acute Lymphoblastic Leukemia (ALL)","Drug: Carfilzomib|Drug: Dexamethasone|Drug: Mitoxantrone|Drug: PEG-asparaginase|Drug: Vincristine|Drug: Intrathecal (IT) Methotrexate|Drug: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)|Drug: 6-Mercaptopurine|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Daunorubicin","Amgen|Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator|Innovative Therapies For Children with Cancer Consortium","All","Child, Adult, Senior","Phase 1","36","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CFZ008|2014‐001633‐84","November 20, 2014","December 2014","December 2017","April 27, 2017","April 2017","No Study Results Posted","null","December 2017","Adverse Events (AEs) and Serious Adverse Events (SAEs)|Key Laboratory Analytes|Vital Signs|Physical Findings|Time to Toxicity|Maximum Tolerated Dose (MTD)|Maximum plasma concentration (Cmax)|Total Plasma Exposure - Area Under the Curve (AUC)|Time to Peak Concentration (Tmax)|Total Plasma Clearance|Plasma Terminal Half-life|Minimal Residual Disease (MRD) Status","https://ClinicalTrials.gov/show/NCT02303821"
2110,"NCT02032277","A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer","Active, not recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Veliparib|Drug: Carboplatin|Drug: Paclitaxel|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Placebo|Drug: Placebo","AbbVie|US Oncology Research|NSABP Foundation Inc|Alliance for Clinical Trials in Oncology|German Breast Group|Grupo Español de Investigación del Cáncer de Mama","Female","18 Years to 99 Years   (Adult, Senior)","Phase 3","624","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","M14-011|2013-002377-21","December 13, 2013","April 2, 2014","September 28, 2026","April 25, 2017","April 2017","No Study Results Posted","null","March 18, 2016","Pathological Complete Response (pCR).|Rate of eligibility for breast conservation after therapy (BCR).|Event Free Survival (EFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT02032277"
2111,"NCT00002718","T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia","Completed","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: methylprednisolone|Drug: thiotepa|Procedure: in vitro-treated bone marrow transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","up to 49 Years   (Child, Adult)","Phase 2","31","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","95-084|P30CA008748|MSKCC-95084|NCI-V96-0809","November 1, 1999","November 1995","October 2008","December 21, 2015","December 2015","No Study Results Posted","null","January 2004","overall disease survival|To correlate progenitor cell doses and doses of clonable T-cells","https://ClinicalTrials.gov/show/NCT00002718"
2112,"NCT02277392","A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer","Withdrawn","No Results Available","Ovarian, Fallopian Tube and Peritoneal Cancer","Biological: Vaccine--‐primed, CD3/CD28--‐costimulated autologous peripheral blood T--‐cells|Biological: SB--‐485232 (Human recombinant Interleukin--‐18)","Abramson Cancer Center of the University of Pennsylvania","Female","18 Years and older   (Adult, Senior)","Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment","UPCC 02814","October 27, 2014","September 2014","null","December 6, 2016","December 2016","No Study Results Posted","null","June 2015","Number of Adverse Events","https://ClinicalTrials.gov/show/NCT02277392"
2113,"NCT01537861","Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma","Terminated","No Results Available","Multiple Myeloma","Drug: Filgrastim|Drug: Bortezomib|Drug: Carfilzomib|Drug: Dexamethasone|Drug: Cyclophosphamide|Drug: Thalidomide|Drug: Lenalidomide|Drug: Pomalidomide","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","Early Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201204086","February 15, 2012","June 2012","December 2014","January 21, 2015","January 2015","No Study Results Posted","null","February 2014","Safety of the combination of G-CSF and bortezomib-, carfilzomib-, or IMID-based treatment regimens in patients with refractory multiple myeloma.|Effects of G-CSF on bone marrow and bone marrow cytokine and chemokine levels. Including: Quantification of marrow osteoblasts and CAR cells, measurement of SDF-1 (CXCL12), IL-6, BAFF, assessment of myeloma cell proliferation and survival in bone marrow|Response rate as defined by the International Myeloma Working Group (IMWG) criteria|Overall survival duration of patients treated on study|Progression-free survival of patients treated on study|Duration of response of patients treated on study","https://ClinicalTrials.gov/show/NCT01537861"
2114,"NCT00006721","S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma","Active, not recruiting","Has Results","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: tositumomab and iodine I 131 tositumomab","Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 3","571","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000068321|U10CA032102|S0016|CALGB-50102","December 6, 2000","March 2001","null","April 21, 2016","April 2016","November 2, 2012","null","September 2011","Progression-free Survival at 2 Years|Progression-free Survival at 5 Years|Overall Survival at 2 Years|Overall Survival at 5 Years|Objective Response (Confirmed and Unconfirmed Complete and Partial Responses)|Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug","https://ClinicalTrials.gov/show/NCT00006721"
2115,"NCT00014222","Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: epoetin alfa|Biological: filgrastim|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: paclitaxel","NCIC Clinical Trials Group|North Central Cancer Treatment Group|Southwest Oncology Group|Cancer and Leukemia Group B|Canadian Cancer Trials Group","Female","up to 60 Years   (Child, Adult)","Phase 3","2104","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MA21|CAN-NCIC-MA21|AMGEN-CAN-NCIC-MA21|NCCTG-CAN-NCIC-MA21|BMS-CAN-NCIC-MA21|JANSSEN-ORTHO-CAN-NCIC-MA21|PFIZER-CAN-NCIC-MA21|SWOG-CAN-NCIC-MA21|CDR0000068520|CALGB-CAN-NCIC-MA21","April 10, 2001","December 2000","March 2014","March 17, 2014","March 2014","No Study Results Posted","null","October 2006","Disease free survival|Overall survival|Safety profile|Quality of Life","https://ClinicalTrials.gov/show/NCT00014222"
2116,"NCT02655458","Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma","Recruiting","No Results Available","Multiple Myeloma","Drug: Elotuzumab|Drug: Lenalidomide|Other: autologous PBMC reconstitution|Other: ASCT","Hearn Jay Cho|Bristol-Myers Squibb|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Senior)","Phase 1","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GCO 15-1275","January 12, 2016","January 2016","December 2017","December 1, 2016","December 2016","No Study Results Posted","null","December 2017","Incidence of completion of treatment|IFE level|sFLC level|Bone marrow MRD analysis|Progression-Free Survival|CyTOF mass cytometry|SPEP level","https://ClinicalTrials.gov/show/NCT02655458"
2117,"NCT02918747","PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage","Recruiting","No Results Available","Lymphoma","Drug: pegaspargase|Drug: Gemcitabine|Drug: Oxaliplatin|Drug: Dexamethasone|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Radiation: IMRT","Hunan Cancer Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","186","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HNCH-NKT-2016","September 25, 2016","September 2016","December 2021","September 27, 2016","September 2016","No Study Results Posted","null","September 2021","Objective response rate（complete remission rate + partial remission rate）|progression free survival|overall survival|Incidence of Treatment-Emergent Adverse Events according to Common Terminology Criteria for Adverse Events v3.0","https://ClinicalTrials.gov/show/NCT02918747"
2118,"NCT01350258","Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps","Terminated","Has Results","Hematologic Malignancies|Acute Leukemia|Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Myeloma|Chronic Myelogenous (or Myeloid) Leukemia (CML) Resistant to STI Therapy","Drug: Fludarabine|Drug: Thiotepa|Radiation: Total Body Irradiation (TBI)|Biological: Donor Lymphocyte Infusion (DLI)|Drug: Melphalan|Device: Hematopoietic stem cell transplantation (HSCT)","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10D.535|2010-40","May 4, 2011","April 2011","August 2012","November 28, 2016","October 2016","October 21, 2014","null","May 2012","Phase 1: Defined Dose of Melphalan (MEL)|Phase 2: Non-Relapse Mortality (NRM)|Relapse Rate|GVHD Incidence and Severity|Engraftment Rate and Lymphoid Reconstitution|Overall Survival","https://ClinicalTrials.gov/show/NCT01350258"
2119,"NCT00117897","Treatment for Subjects With Non-Hodgkin's Lymphoma","Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: pegfilgrastim|Drug: Filgrastim","Amgen","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","null","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","20010157","June 30, 2005","July 2002","February 2004","July 16, 2009","July 2009","No Study Results Posted","null","null","The primary objective was to provide preliminary information on the ability of pegfilgrastim or Filgrastim to support planned dose on time (PDOT) application of CHOP chemotherapy with Rituximab given every 14 days, to subjects with NHL.|The proportion of chemotherapy cycles given at the PDOT in both arms.|Response rates (complete response and partial response) in both arms|The safety profile in cycles 1-6|Subject self-reported outcomes","https://ClinicalTrials.gov/show/NCT00117897"
2120,"NCT00002657","SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant","Completed","No Results Available","Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm","Biological: bleomycin sulfate|Biological: recombinant interferon alfa|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate|Procedure: conventional surgery|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","15 Years and older   (Child, Adult, Senior)","Phase 2","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000064200|SWOG-9239|E-S9239|U10CA032102","November 1, 1999","May 1995","July 2011","January 22, 2013","January 2013","No Study Results Posted","null","November 2003","Response|overall survival","https://ClinicalTrials.gov/show/NCT00002657"
2121,"NCT00342134","Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis","Completed","No Results Available","Multiple Sclerosis","Procedure: Stem Cell Transplanataion","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","34","NIH","Interventional","Primary Purpose: Treatment","999902196|02-N-N196","June 19, 2006","May 1, 2002","May 4, 2011","January 24, 2017","May 4, 2011","No Study Results Posted","null","May 4, 2011","","https://ClinicalTrials.gov/show/NCT00342134"
2122,"NCT00278551","Stem Cell Support in Patients With Rheumatoid Arthritis","Terminated","No Results Available","RHEUMATOID ARTHRITIS","Biological: Immune ablation and hematopoietic stem cell transplant","Richard Burt, MD|Northwestern University","All","18 Years to 60 Years   (Adult)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NU 96RA1","January 15, 2006","June 1997","November 2011","April 4, 2013","April 2013","No Study Results Posted","null","November 2011","Tender joint count; Swollen joint count; Patient's assessment of pain;Patient's global assessment of disease; Physician global assessment;Acute phase reactant value (erythrocyte sedimentation rate).","https://ClinicalTrials.gov/show/NCT00278551"
2123,"NCT02128230","UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","Recruiting","No Results Available","Multiple Myeloma","Drug: MEL-CFZ-TD-PACE","University of Arkansas|Amgen","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","134668","April 29, 2014","August 2014","May 2025","October 6, 2016","October 2016","No Study Results Posted","null","May 2025","The remission rate for participants with high-risk myeloma","https://ClinicalTrials.gov/show/NCT02128230"
2124,"NCT01070862","Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.","Completed","No Results Available","Multiple Myeloma de Novo Treatment","Drug: Thalidomide, Dexamethasone|Drug: Vincristin , Adriamycin, Dexamethasone = VAD|Drug: Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)|Drug: melphalan, endoxan, dexamethasone (MCDex)|Drug: Thalidomide, Dexamethasone","University Hospital, Caen|Laphal","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","020879","February 17, 2010","May 2003","December 2009","February 17, 2010","February 2010","No Study Results Posted","MAG 2002","null","very good partial response rate (monclonal protein decrease of 90 % or more)at the end induction phase (MY-TAG and MY-DECT), progression free survival during consolidation/maintenance treatment (MY-PLAT)|partial response rate (> or = 50%), PFS and OS since diagnosis, safety thalidomide + chemotherapy","https://ClinicalTrials.gov/show/NCT01070862"
2125,"NCT00003389","Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma","Active, not recruiting","Has Results","Lymphoma","Drug: Doxorubicin|Drug: Bleomycin|Drug: Vinblastine|Drug: Dacarbazine|Drug: Vincristine|Drug: Mechlorethamine|Drug: Etoposide|Drug: Prednisone|Drug: Cyclophosphamide|Radiation: Radiotherapy","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 3","854","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000066386|E2496|U10CA021115","November 1, 1999","April 1999","May 2016","September 25, 2015","September 2015","August 5, 2015","null","September 2011","Failure-free Survival at 5 Years|5-year Overall Survival|Incidence of Second Cancers","https://ClinicalTrials.gov/show/NCT00003389"
2126,"NCT01818908","Trial of DA-EPOCH Regimen for NHL With HLH","Unknown status","No Results Available","NHL With Hemophagocytic Lymphohistiocytosis","Drug: DA-EPOCH","The First Affiliated Hospital with Nanjing Medical University","All","15 Years to 80 Years   (Child, Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JSPH-HLH-001","March 23, 2013","June 2012","April 2014","March 23, 2013","March 2013","No Study Results Posted","null","October 2013","overall response rate|Time to Response|progression free survival|overall survival|Number of Participants with Adverse Events","https://ClinicalTrials.gov/show/NCT01818908"
2127,"NCT00392990","Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Drug: Regimen A|Drug: Regimen B","Northwestern University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NU 06H2|P30CA060553|NU-1346-018|ORTHO-NU-06H2|CDR0000509706|STU00004480","October 25, 2006","October 2006","October 2019","March 15, 2017","March 2017","No Study Results Posted","null","October 2018","Response rate: complete remission rate|Overall response rate: disease free and overall survival|Safety of Rituximab plus Magrath regimen in HIV negative and HIV positive subjects|Safety of using doxil in place of adriamycin|Safety of using lower intravenous methotrexate dosing","https://ClinicalTrials.gov/show/NCT00392990"
2128,"NCT01996267","Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2","Active, not recruiting","No Results Available","Breast Cancer|HER2 Positive","Drug: PTC+Pertuzumab|Drug: FEC-T+Pertuzumab","The Netherlands Cancer Institute|Roche Pharma AG|Borstkanker Onderzoek Groep","All","18 Years and older   (Adult, Senior)","Phase 3","437","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","M13TRT","November 18, 2013","December 2013","December 2019","February 2, 2017","February 2017","No Study Results Posted","TRAIN-2","December 2018","Number of patients with pathological complete response|Number of patients with grade >2 adverse events as a measure of safety and tolerability|identify prognostic and predictive biomarkers for pCR","https://ClinicalTrials.gov/show/NCT01996267"
2129,"NCT00392886","Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: methotrexate|Drug: temozolomide|Drug: thiotepa|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Children's Hospital Los Angeles|National Cancer Institute (NCI)","All","up to 10 Years   (Child)","Phase 3","120","Other","Interventional","Primary Purpose: Treatment","CDR0000503990|CHLA-HEAD-START-III|CHLA-HSIII|CHLA-2004-020|CHLA-04.020|UMN-MT2004-06","October 25, 2006","March 2004","null","December 17, 2013","October 2010","No Study Results Posted","null","December 2010","Time to tumor progression, disease recurrence, or death of any cause|Event-free survival at 2 years|Toxicity|Response to induction as assessed by one-time tumor measurements at baseline and after completion of induction chemotherapy|Time to death|Overall survival","https://ClinicalTrials.gov/show/NCT00392886"
2130,"NCT01350245","Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor","Completed","Has Results","Acute Myeloid Leukemia|Myelodysplastic Syndromes|Biphenotypic Leukemia|Acute Lymphocytic Leukemia|Chronic Myeloid Leukemia|Chronic Lymphocytic Leukemia|Plasma Cell Neoplasms|Lymphoma|Hodgkin's Disease|Aplastic Anemia","Radiation: Total Body Irradiation (TBI)|Biological: Donor Lymphocyte Infusion (DLI)|Drug: Cyclophosphamide|Drug: Mycophenolate Mofetil (MMF)|Drug: Tacrolimus|Device: Hematopoietic stem cell transplantation (HSCT)","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 2","28","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10D.219|2010-10","May 4, 2011","July 2010","May 2014","October 19, 2016","October 2016","October 7, 2014","null","May 2013","Disease-Free Survival (DFS)|Probability of Overall Survival at 15 Months Post-treatment","https://ClinicalTrials.gov/show/NCT01350245"
2131,"NCT00520130","Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System","Active, not recruiting","No Results Available","Myelodysplastic Syndrome|Hodgkin's Lymphoma|Non-Hodgkin's Disease|Acute Leukemia|Multiple Myeloma","Biological: Rituximab|Drug: Cyclosporine|Drug: Allogenic stem cell transplant (ASCT)|Drug: Conditioning Chemotherapy|Drug: TMS|Drug: FLAG|Drug: EPOCH-F|Biological: Alemtuzumab","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 74 Years   (Adult, Senior)","Phase 1|Phase 2","92","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","070195|07-C-0195","August 21, 2007","July 2007","March 2017","May 11, 2016","March 2016","No Study Results Posted","null","October 2015","To assess the effects of two biologically distinct GVHD prophylaxis regimens|To determine and monitor incidence, organ severity and overall severity of chronic GVHD|To assess overall safety of these two regimens in this setting, and overall survival.|Study of engraftment kinetics|Toxicities","https://ClinicalTrials.gov/show/NCT00520130"
2132,"NCT01208662","Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65","Recruiting","No Results Available","Multiple Myeloma","Drug: Lenalidomide|Drug: Bortezomib|Drug: Dexamethasone|Procedure: Autologous Stem Cell Transplant","Paul G. Richardson, MD|Celgene Corporation|Millennium Pharmaceuticals, Inc.|Massachusetts General Hospital|Cape Cod Healthcare|Beth Israel Deaconess Medical Center|Emory University|University of Michigan|Fox Chase Cancer Center|Memorial Sloan Kettering Cancer Center|Fred Hutchinson Cancer Research Center|Barbara Ann Karmanos Cancer Institute|Duke University|University of California, San Francisco|University of Chicago|M.D. Anderson Cancer Center|UNC Lineberger Comprehensive Cancer Center|Roswell Park Cancer Institute|Stanford University|University of Mississippi Medical Center|Icahn School of Medicine at Mount Sinai|Wake Forest University Health Sciences|University of Arizona|OHSU Knight Cancer Institute|Eastern Maine Medical Center|University of California, San Diego|University of Alabama at Birmingham|University of Pittsburgh|Ochsner Health System|University of Texas Southwestern Medical Center|State University of New York - Downstate Medical Center|Newton-Wellesley Hospital|Baylor College of Medicine|City of Hope Medical Center|University of Florida|Northwell Health|H. Lee Moffitt Cancer Center and Research Institute|Vanderbilt University Medical Center|Ohio State University|Huntsman Cancer Institute|Columbia University|Dana-Farber Cancer Institute","All","18 Years to 65 Years   (Adult)","Phase 3","660","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","10-106","September 23, 2010","September 2010","September 2018","January 19, 2017","January 2017","No Study Results Posted","DFCI 10-106","September 2018","Primary Outcome|Secondary Outcome|Secondary Outcomes","https://ClinicalTrials.gov/show/NCT01208662"
2133,"NCT01719341","Study of Non-Myeloablative Haplo-identical Haematopoietic Stem Cell Transplantation in Patients With Haematological Malignancies or Acquired Aplastic Anaemia","Unknown status","No Results Available","Haematological Malignancies|Acquired Aplastic Anaemia","","National University Hospital, Singapore","All","18 Years to 70 Years   (Adult, Senior)","","21","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2012/00465","October 30, 2012","September 2012","null","December 10, 2013","December 2013","No Study Results Posted","null","June 2014","1 year overall survival after HLA-Haploidentical transplantation|Progression free survival one and 2 years post-transplantation|Cumulative incidence of relapse/progression at one and 2 years post-transplant","https://ClinicalTrials.gov/show/NCT01719341"
2134,"NCT00303836","Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma","Terminated","No Results Available","Recurrent Melanoma|Stage IV Melanoma","Drug: cyclophosphamide|Drug: fludarabine phosphate|Biological: therapeutic autologous lymphocytes|Procedure: in vitro-treated peripheral blood stem cell transplantation|Biological: gp100 antigen|Biological: MART-1 antigen|Biological: incomplete Freund's adjuvant|Biological: filgrastim|Biological: aldesleukin","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","58","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02684|P6574|NCI-06-C-0028|CDR0000459683|NCI-7547|NCI-P6574","March 15, 2006","November 2005","null","June 5, 2013","June 2013","No Study Results Posted","null","January 2007","Objective clinical response (CR or PR)|Presence of anti-tumor T cells|Recovery of regulatory T cells|Incidence of DLTs and SAEs graded according to CTCAE version 3.0","https://ClinicalTrials.gov/show/NCT00303836"
2135,"NCT00807599","Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L","Active, not recruiting","No Results Available","Multiple Myeloma","Procedure: Stem cell transplant x 1 or x 2|Drug: lenalidomide and dexamethasone","Memorial Sloan Kettering Cancer Center|Tufts Medical Center|Lahey Clinic","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","67","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","08-121","December 11, 2008","December 10, 2008","December 2017","March 2, 2017","March 2017","No Study Results Posted","null","December 2017","The progression free survival (PFS) rate at 2 years after enrollment in untreated patients with multiple myeloma.|The CR+VGPR rate|Overall myeloma response rates|Overall survival","https://ClinicalTrials.gov/show/NCT00807599"
2136,"NCT02181101","Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial","Completed","No Results Available","Breast Neoplasms","Drug: FEC-DocGemzar adjuvant chemotherapy|Drug: FEC-Doc adjuvant chemotherapy|Drug: Zoledronic acid i.v. 2 years|Drug: Zoledronic acid i.v. 5 years","Ludwig-Maximilians - University of Munich|AstraZeneca|Chugai Pharma USA|Eli Lilly and Company|Novartis|Sanofi|Janssen Diagnostics, LLC","Female","18 Years and older   (Adult, Senior)","Phase 3","3754","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SUCCESS-A|2005-000490-21","June 4, 2014","September 2005","September 2013","July 1, 2014","July 2014","No Study Results Posted","null","September 2013","Disease free survival|Overall survival|Number of adverse events related to cancer therapy observed|Quality of life|Number of skeletal/bone-related adverse events observed including osteonecrosis of the jaw|Number of patients who develop malignant disease other than recurrence of the breast cancer treated within the trial|Distant disease free survival","https://ClinicalTrials.gov/show/NCT02181101"
2137,"NCT01724021","A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a","Completed","Has Results","Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma","Drug: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)|Drug: Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)|Drug: Bendamustine|Drug: Rituximab|Drug: Rituximab|Drug: Rituximab|Drug: Rituximab","Hoffmann-La Roche","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","743","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MO28457|2012-003230-17","November 5, 2012","December 2012","January 2015","July 19, 2016","March 2016","May 3, 2016","null","January 2015","Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6|Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8|Number of Participants With Treatment Emergent Adverse Events (AEs)|Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV])|Cancer Therapy Satisfaction Questionnaire (CTSQ) Score|Rituximab Administration Satisfaction Questionnaire (RASQ) Score|Complete Response (CR) Rate|Event-free Survival (EFS)|Disease-free Survival (DFS)|Progression-free Survival (PFS)|Overall Survival (OS)|Percentage of Participants With Anti-Rituximab Antibodies Over Time|Percentage of Participants With Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies Over Time|Summary of Observed Serum Rituximab Concentration","https://ClinicalTrials.gov/show/NCT01724021"
2138,"NCT02054559","R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL","Withdrawn","No Results Available","Diffuse Large B-cell Lymphoma","Drug: R-CHOP|Radiation: Radiotherapy","Asan Medical Center","All","18 Years and older   (Adult, Senior)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC_NHL02","January 29, 2014","null","January 2020","February 20, 2016","February 2016","No Study Results Posted","ASPIRE","January 2020","To compare 3-year event-free survival|To evaluate and compare OS between the two arms|To evaluate and compare the ORR and CR rate|To evaluate and compare disease-free survival (DFS)|To evaluate treatment-failure pattern|Number of Participants with Adverse Events in each arm|To assess patient-reported outcomes (PROs) in both arms|A role of interim PET after 3 cycles of R-CHOP chemotherapy: correlation with PFS and OS","https://ClinicalTrials.gov/show/NCT02054559"
2139,"NCT00176462","CINJALL: Treatment for Children With Acute Lymphocytic Leukemia","Completed","Has Results","Acute Lymphocytic Leukemia","Drug: aminopterin|Drug: L-asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunomycin|Drug: dexamethasone|Drug: 6-mercaptopurine|Drug: methotrexate|Drug: 6-thioguanine|Drug: vincristine|Drug: Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)|Drug: Leucovorin","Rutgers, The State University of New Jersey|National Cancer Institute (NCI)","All","1 Year to 30 Years   (Child, Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","020101|0220003389|P30CA072720","September 12, 2005","February 2001","September 2008","May 12, 2014","May 2014","November 15, 2013","null","September 2008","Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years|To Measure 5-methyltetrahydrofolate, Aminopterin and Methotrexate Uptake in Leukemic Blasts Isolated at Diagnosis","https://ClinicalTrials.gov/show/NCT00176462"
2140,"NCT02621021","A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab","Recruiting","No Results Available","Melanoma","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldeslaukin|Drug: Pembrolizumab|Biological: young TIL","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","16 Years to 70 Years   (Child, Adult, Senior)","Phase 2","170","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","160027|16-C-0027","December 2, 2015","November 25, 2015","September 1, 2021","May 20, 2017","May 9, 2017","No Study Results Posted","null","September 1, 2020","To determine in a prospective randomized trial whether the addition of pembrolizumab to the standard nonmyeloablative conditioningregimen, TIL and high dose IL-2 (ACT TIL) can improve complete response rates in patients with metastatic melano...|To evaluate the safety and efficacy of pembrolizumab in combination with the standard ACT regimen with TIL|To determine the impact of the administration of pembrolizumab in combination with the standard ACT regimen with TIL on overall survival","https://ClinicalTrials.gov/show/NCT02621021"
2141,"NCT00006379","Non-Ablative Allo HSCT For Hematologic Malignancies or SAA","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Precancerous/Nonmalignant Condition|Small Intestine Cancer","Biological: anti-thymocyte globulin|Biological: graft-versus-tumor induction therapy|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","58","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU3Y00|P30CA043703|CWRU-3Y00|05-00-07|NCI-G00-1868","October 4, 2000","June 2000","October 2011","December 7, 2011","December 2011","No Study Results Posted","null","January 2004","Evaluation of Donor Engraftment|Stable donor hematopoietic chimerism|Event free and overall survival","https://ClinicalTrials.gov/show/NCT00006379"
2142,"NCT00374699","Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas","Completed","No Results Available","Peripheral T-Cell Lymphomas|Non-Hodgkin Lymphoma","Drug: Velcade","Samsung Medical Center|Janssen Medical Affairs","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","55","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-07-021","September 7, 2006","April 2006","October 2009","October 12, 2009","June 2007","No Study Results Posted","null","September 2009","To define the dose-limiting toxicity and maximum tolerable dose|To evaluate the overall response rate|To evaluate the safety and tolerability of the treatment combination|To estimate the time to progression and the duration of overall response","https://ClinicalTrials.gov/show/NCT00374699"
2143,"NCT01030900","Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas","Active, not recruiting","No Results Available","Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma","Biological: campath|Biological: Rituximab|Drug: EPOCH","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Senior)","Phase 2","50","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","100011|10-C-0011","December 11, 2009","October 21, 2009","September 1, 2020","May 12, 2017","December 12, 2016","No Study Results Posted","null","September 1, 2020","PFS and OS","https://ClinicalTrials.gov/show/NCT01030900"
2144,"NCT01445535","Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas","Active, not recruiting","No Results Available","T-Cell Peripheral Lymphoma|Gamma Delta Hepatosplenic T-Cell Lymphoma|Subcutaneous Panniculitis-Like T-Cell Lymphoma|NK T-Cell Lymphoma","Biological: Rituximab|Drug: EPOCH|Biological: Siplizumab","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1","15","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","090065|09-C-0065","September 30, 2011","January 12, 2009","October 1, 2018","May 12, 2017","April 6, 2017","No Study Results Posted","null","April 1, 2011","Determination of MTD and toxicity profile","https://ClinicalTrials.gov/show/NCT01445535"
2145,"NCT00583622","Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients","Terminated","Has Results","Ovarian Cancer","Drug: Bevacizumab|Drug: Carboplatin|Drug: Docetaxel|Drug: Gemcitabine|Drug: Melphalan|Procedure: Stem Cell Transplant","M.D. Anderson Cancer Center","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007-0368","December 20, 2007","December 2007","January 2012","April 10, 2013","April 2013","February 26, 2013","null","January 2012","Event-Free (EF) Rate|Participant Response","https://ClinicalTrials.gov/show/NCT00583622"
2146,"NCT00001256","Steroids and Methotrexate to Treat Systemic Vasculitis","Completed","No Results Available","Inflammation|Vasculitis|Wegener's Granulomatosis","Drug: prednisone and methotrexate","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","100","NIH","Interventional","Primary Purpose: Treatment","900086|90-I-0086","November 3, 1999","March 1990","February 2004","March 3, 2008","February 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001256"
2147,"NCT01005745","Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma","Active, not recruiting","Has Results","Metastatic Melanoma","Procedure: Surgery|Drug: Administration of Lymphodepletion|Other: Adoptive Cell Transfer|Drug: High Dose IL-2","H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Senior)","","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-15781","October 27, 2009","October 2009","January 2018","March 17, 2017","March 2017","May 1, 2014","null","January 2014","Number of Participants With Tumor Infiltrating Lymphocytes (TIL) Growth|Number of Participants With Objective Response (OR)","https://ClinicalTrials.gov/show/NCT01005745"
2148,"NCT03000296","Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease","Recruiting","No Results Available","Crohn Disease|Inflammatory Bowel Diseases|Gastroenteritis","Procedure: Autologous Hematopoietic Stem Cell Transplantation","Beneficência Portuguesa de São Paulo","All","14 Years to 70 Years   (Child, Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","autocrohnproject1","December 9, 2016","October 2013","March 2018","December 21, 2016","December 2016","No Study Results Posted","AutoChron","December 2016","Safety of unselected autologous HSCT in refractary Crohn´s patients|CDAI|CRAIG CSS|IBDQ|SF-36|SES|CDEIS|Rutgeerts|HBI","https://ClinicalTrials.gov/show/NCT03000296"
2149,"NCT01690520","Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes","Recruiting","No Results Available","Acute Biphenotypic Leukemia|Acute Erythroid Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Megakaryoblastic Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia in Remission|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts|Pancytopenia|Refractory Anemia|Secondary Acute Myeloid Leukemia","Drug: Cyclophosphamide|Drug: Cyclosporine|Procedure: Double-Unit Umbilical Cord Blood Transplantation|Procedure: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Drug: Thiotepa|Radiation: Total-Body Irradiation|Procedure: Umbilical Cord Blood Transplantation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)","All","6 Months to 65 Years   (Child, Adult)","Phase 2","160","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2603.00|NCI-2012-01572|2603|P30CA015704|P50HL110787","September 19, 2012","December 11, 2012","null","April 18, 2017","April 2017","No Study Results Posted","null","October 2017","Time to engraftment defined as the first 2 consecutive days in which ANC >= 500 in both arms (standard myeloablative CBT with and without off-the-shelf expanded cord blood progenitors)|Incidence and severity of acute and chronic GVHD|Incidence of infectious complications|Non-relapse mortality|Overall survival|Platelet engraftment (20k)","https://ClinicalTrials.gov/show/NCT01690520"
2150,"NCT01510613","Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis","Active, not recruiting","No Results Available","Primary Amyloidosis of Light Chain Type","Drug: Pomalidomide and Dexamethasone","IRCCS Policlinico S. Matteo","All","18 Years and older   (Adult, Senior)","Phase 2","28","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AC-007-IT|2011-001787-22","January 11, 2012","February 2012","December 2016","February 24, 2016","February 2016","No Study Results Posted","null","December 2016","Efficacy of PDex|Safety of PDex","https://ClinicalTrials.gov/show/NCT01510613"
2151,"NCT02499367","Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients","Recruiting","No Results Available","Breast Cancer","Drug: Nivolumab|Radiation: Radiation therapy|Drug: Low dose doxorubicin|Drug: Cyclophosphamide|Drug: Cisplatin","The Netherlands Cancer Institute|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 2","84","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","N15TON","July 6, 2015","August 2015","August 2022","August 30, 2016","August 2016","No Study Results Posted","TONIC","August 2019","Progression free survival|Overall response rate|Clinical benefit rate|Toxicity of all study regimens","https://ClinicalTrials.gov/show/NCT02499367"
2152,"NCT00243165","Lifemel Honey to Reduce Leucopenia During Chemotherapy","Unknown status","No Results Available","Breast Cancer","Behavioral: Lifemel honey intake every day","Rambam Health Care Campus|Zuf Globus Laboratories Ltd.","Female","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Prevention","LifemelCTIL","October 20, 2005","November 2005","null","December 4, 2009","October 2005","No Study Results Posted","null","null","Prevention of myelotoxicity-every week during chemotherapy.","https://ClinicalTrials.gov/show/NCT00243165"
2153,"NCT00135499","R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-Cell Lymphoma","Terminated","No Results Available","Lymphoma, Large-Cell, Diffuse","Drug: CHOP plus rituximab|Drug: ACVBP plus rituximab","Lymphoma Study Association|Fondation ARC","All","60 Years to 65 Years   (Adult)","Phase 3","560","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LNH01-5B","August 25, 2005","January 2002","January 2011","September 7, 2006","September 2006","No Study Results Posted","null","null","event free survival|complete response rate|progression rate|relapse rate|disease-free survival for complete responders|overall survival|neuromeningeal relapse rate|toxicities","https://ClinicalTrials.gov/show/NCT00135499"
2154,"NCT00001901","Etanercept to Treat Wegener's Granulomatosis","Completed","No Results Available","Vasculitis|Wegener's Granulomatosis","Drug: Etanercept","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","60","NIH","Interventional","Primary Purpose: Treatment","990040|99-I-0040","November 3, 1999","February 1999","March 2005","March 3, 2008","March 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001901"
2155,"NCT00001337","Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma (DLBCL)|Primary Mediastinal Large B-cell Lymphoma|Burkitt Lymphoma|Anaplastic Large-Cell Lymphoma|Gray Zone Lymphoma","Drug: EPOCH|Biological: Rituximab","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","12 Years to 100 Years   (Child, Adult, Senior)","Phase 2","348","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","930133|93-C-0133","November 3, 1999","April 30, 1993","March 31, 2022","May 12, 2017","February 15, 2017","No Study Results Posted","null","March 31, 2019","Overall response and PFS","https://ClinicalTrials.gov/show/NCT00001337"
2156,"NCT00513604","Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma","Completed","Has Results","Melanoma|Malignant Melanoma|Melanoma, Experimental|Experimental Melanomas","Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Drug: Cyclophosphamide|Drug: Fludarabine phosphate|Radiation: Total body irradiation","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","158","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","070176|07-C-0176","August 6, 2007","June 2007","November 2012","May 29, 2013","May 2013","February 19, 2013","null","November 2012","Clinical Response|Toxicity","https://ClinicalTrials.gov/show/NCT00513604"
2157,"NCT00079625","Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer","Completed","No Results Available","Breast Neoplasms","Drug: Th2/Tc2 Cells","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","22","NIH","Interventional","Primary Purpose: Treatment","040131|04-C-0131","March 9, 2004","March 5, 2004","August 9, 2013","April 19, 2017","August 9, 2013","No Study Results Posted","null","August 9, 2013","To determine the safety as defined by the incidence of acute graft-versus-host disease and feasibility of administering in vitro generated donor T cells of Th2/Tc2 phenotype to augment a T cell depleted allograft after reduced-intensity conditio...|To determine if the transplantation of a T cell depleted allograft augmented with Th2/Tc2 ell can result in a state of rapid complete donor chimerism after reduced-intensity conditioning regimen.","https://ClinicalTrials.gov/show/NCT00079625"
2158,"NCT00002803","Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma","Completed","No Results Available","Neuroblastoma","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Procedure: conventional surgery","Children's Hospital Medical Center, Cincinnati|National Cancer Institute (NCI)","All","up to 1 Year   (Child)","Phase 2","44","Other","Interventional","Primary Purpose: Treatment","CDR0000064903|GER-NB95-S|EU-96003","November 1, 1999","July 1995","February 2002","December 18, 2013","April 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002803"
2159,"NCT00004230","Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation","Completed","No Results Available","Cancer","Drug: captopril|Drug: cyclophosphamide|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Northwestern University|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","35","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Supportive Care","NU 98CC1|NU-98CC1|NCI-G99-1658","January 28, 2000","October 1999","March 2002","May 31, 2012","May 2012","No Study Results Posted","null","March 2002","","https://ClinicalTrials.gov/show/NCT00004230"
2160,"NCT00051311","Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers","Completed","No Results Available","Hematologic Neoplasms","Procedure: Stem cell transplantation","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","62","NIH","Interventional","Primary Purpose: Treatment","030077|03-C-0077","January 8, 2003","January 3, 2003","September 25, 2014","April 19, 2017","September 25, 2014","No Study Results Posted","null","September 25, 2014","","https://ClinicalTrials.gov/show/NCT00051311"
2161,"NCT00203697","Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study","Unknown status","No Results Available","Idiopathic Pulmonary Fibrosis","Drug: minocycline","University of California, Los Angeles","All","20 Years to 79 Years   (Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment","09-002Kleerup|NIH-NHLBI 1 P50 HL67665-01","September 13, 2005","null","null","September 7, 2006","September 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00203697"
2162,"NCT01132014","Autologous OC-DC Vaccine in Ovarian Cancer","Active, not recruiting","No Results Available","Chemotherapy|Tumor|Ovarian Cancer","Biological: OCDC","Abramson Cancer Center of the University of Pennsylvania","Female","18 Years and older   (Adult, Senior)","Early Phase 1","67","Other","Interventional","Primary Purpose: Treatment","UPCC 19809","May 26, 2010","May 2010","null","February 8, 2016","February 2016","No Study Results Posted","null","July 2015","Safety|Clinical Response|Dose limiting toxicity|Immune Response Immune Response","https://ClinicalTrials.gov/show/NCT01132014"
2163,"NCT00662948","ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)","Suspended","No Results Available","Lymphoma","Drug: Rituximab|Drug: Ibritumomab tiuxetan","PETHEMA Foundation|GELCAB|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ZAR2007","April 8, 2008","December 2008","null","April 23, 2017","May 2016","No Study Results Posted","null","October 2014","Progression free survival|Saffetty of two arms|Quality of life|Global survival|Event free survival|Response rate in two arms","https://ClinicalTrials.gov/show/NCT00662948"
2164,"NCT00323323","CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas","Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: CHOP|Drug: Alemtuzumab|Procedure: Plasma Samples","Ohio State University Comprehensive Cancer Center|Bayer","All","18 Years and older   (Adult, Senior)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","OSU-0303","May 8, 2006","March 2004","October 2016","January 19, 2017","January 2017","No Study Results Posted","null","August 2012","Toxicity and safety of concurrent CHOP and Alemtuzumab|Determine pharmacokinetics of Alemtuzumab|Determine immunosuppressive properties of Alemtuzumab + CHOP|Determine if Fc Receptor-gamma (FcγR) polymorphism is predictive of response or toxicity with Alemtuzumab treatment.","https://ClinicalTrials.gov/show/NCT00323323"
2165,"NCT00002812","Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: idarubicin|Drug: mercaptopurine|Drug: methotrexate|Drug: pegaspargase|Drug: prednisone|Drug: thioguanine|Drug: vincristine sulfate|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 3","2078","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1961|CCG-1961|CDR0000064953","November 1, 1999","September 1996","null","August 23, 2013","August 2013","No Study Results Posted","null","March 2006","Event Free Survival","https://ClinicalTrials.gov/show/NCT00002812"
2166,"NCT00245115","Autologous Peripheral Stem Cell or Bone Marrow Transplant Using Laboratory-Treated Cells in Treating Patients With Acute Leukemia","Active, not recruiting","No Results Available","Leukemia","Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Procedure: in vitro-treated bone marrow transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","up to 70 Years   (Child, Adult, Senior)","","25","Other|NIH","Interventional","Primary Purpose: Treatment","J0563 CDR0000453619|P01CA070970|P30CA006973|JHOC-J0563|JHOC-NA-00000920","October 25, 2005","October 2005","July 2017","October 14, 2016","October 2016","No Study Results Posted","null","December 2007","","https://ClinicalTrials.gov/show/NCT00245115"
2167,"NCT00006390","Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Biological: alemtuzumab|Biological: filgrastim|Drug: cyclophosphamide|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000068272|ECOG-8998","October 4, 2000","February 2001","null","January 26, 2010","January 2010","No Study Results Posted","null","December 2004","","https://ClinicalTrials.gov/show/NCT00006390"
2168,"NCT01652261","Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)","Withdrawn","No Results Available","Hodgkin Lymphoma","Drug: ABVD + FDG-PET/CT Scan treatment adaptation|Drug: BEACOPPesc","European Organisation for Research and Treatment of Cancer - EORTC|Polish Lymphoma Research Group","All","18 Years to 60 Years   (Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-20101-23101|2011-005473-22","July 18, 2012","May 2013","March 2022","June 13, 2014","June 2014","No Study Results Posted","H11","March 2020","Freedom from treatment failure|response at the end of therapy|Progression-free survival|Overall survival|Acute toxicity|Long-term toxicity in terms of second malignancies, cardiovascular and pulmonary events","https://ClinicalTrials.gov/show/NCT01652261"
2169,"NCT00930605","The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)","Completed","No Results Available","Peripheral T-cell Lymphoma","Drug: CHOP regimen alternate with ESHAP regimen|Drug: Alemtuzumab","King Chulalongkorn Memorial Hospital|Bayer","All","15 Years to 65 Years   (Child, Adult)","Phase 2","16","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TH011001","June 29, 2009","January 2005","July 2008","October 4, 2011","October 2011","No Study Results Posted","C+CHOP/ESHAP","November 2006","The response to treatment and the treatment-related toxicity.","https://ClinicalTrials.gov/show/NCT00930605"
2170,"NCT00085098","Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor","Completed","Has Results","Brain Tumor|Central Nervous System Tumor","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 25 Years   (Child, Adult)","Phase 3","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ACNS0232|CDR0000367294|COG-ACNS0232","June 10, 2004","January 2007","May 2009","February 7, 2017","February 2017","June 7, 2013","null","May 2009","Event-free Survival|Response|Toxicity and Safety as Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0|Quality of Life (QOL) and Neurocognitive Assessment (NP)","https://ClinicalTrials.gov/show/NCT00085098"
2171,"NCT00478244","Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa","Terminated","Has Results","Epidermolysis Bullosa","Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: hematopoietic bone marrow transplantation","Masonic Cancer Center, University of Minnesota","All","up to 25 Years   (Child, Adult)","","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MT2006-15|CDR0000546620|UMN-0702M01504","May 23, 2007","April 2007","August 2011","January 4, 2013","January 2013","July 17, 2012","null","August 2011","Number of Patients With Detectable Collagen Type VII|Number of Patients With >70% Donor Chimerism|Number of Patients With Transplant-Related Mortality|Number of Patients With Platelet Engraftment|Number of Patients With Acute Graft-Versus-Host Disease (GVHD)|Number of Patients With Chronic Graft-Versus-Host Disease (cGVHD)|Overall Survival|Number of Patients With Donor Derived Cells in Skin|Number of Patients With Resistance to Blister Formation|Number of Patients With Neutrophil Engraftment","https://ClinicalTrials.gov/show/NCT00478244"
2172,"NCT00331097","ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment","Completed","No Results Available","Breast Cancer","Drug: docetaxel|Drug: cyclophosphamide|Drug: methotrexate|Drug: 5-fluorouracil","National Cancer Institute, Naples","Female","65 Years to 80 Years   (Adult, Senior)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ELDA","May 26, 2006","July 2003","November 2014","March 27, 2017","March 2017","No Study Results Posted","null","May 2014","disease free survival|toxicity|compliance|quality of life|overall survival","https://ClinicalTrials.gov/show/NCT00331097"
2173,"NCT02443077","Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","Recruiting","No Results Available","Activated B-Cell-Like Diffuse Large B-Cell Lymphoma|B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma","Procedure: Autologous Bone Marrow Transplantation|Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Etoposide|Drug: Ibrutinib|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Other: Placebo","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","302","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Treatment","NCI-2015-00668|BMT CTN 1201|A051301|U10CA180821","May 11, 2015","July 6, 2016","null","May 23, 2017","May 2017","No Study Results Posted","null","July 1, 2020","24-month PFS, defined as the proportion of patients who are alive and progression-free 2 years from randomization using the Lugano classification|Incidence of hematologic toxicity of ibrutinib therapy|Incidence of secondary malignancies|OS|PFS|Response rate using the Lugano classification|Time to hematopoietic engraftment (platelet count greater than or equal to 20,000/uL following nadir)|Treatment-related mortality","https://ClinicalTrials.gov/show/NCT02443077"
2174,"NCT00933517","Assessment of the Efficacy of the Neoadjuvant Combination: ""Chemotherapy-Targeted Therapy"" in Breast Cancer.","Completed","No Results Available","Pathological Response Rate","Drug: vectibix|Drug: fluorouracile|Drug: Epirubicine|Drug: cyclophosphamide|Drug: docetaxel","Centre Jean Perrin","Female","18 Years and older   (Adult, Senior)","Phase 2","62","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Getna7/CJP1.0","July 3, 2009","September 2009","October 2011","March 20, 2014","March 2014","No Study Results Posted","TVA","October 2011","To assess the rate of complete histological response, according to Chevallier's classification|the rate of complete histological response, according to Sataloff's classification; the rate of clinical, ultrasound, mammogram response, according to the WHO criteria; progression-free and overall survival; the tolerance.","https://ClinicalTrials.gov/show/NCT00933517"
2175,"NCT01760226","Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies","Active, not recruiting","No Results Available","Diffuse Large B Cell Lymphoma|Post Transplant Lymphoproliferative Disorder|Primary Mediastinal (Thymic) Large B-cell Lymphoma","Drug: DA-EPOCH-R for DLBCL, PTLD, AND PMBCL|Drug: Methotrexate|Drug: Etoposide|Drug: Doxorubicin|Drug: Vincristine|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Prednisone|Drug: G-CSF","Baylor College of Medicine|National Cancer Institute (NCI)|Texas Children's Hospital","All","up to 21 Years   (Child, Adult)","","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","H-30759, DA-EPOCH-R|DA-EPOCH-R|5K12CA090433-12","December 17, 2012","January 2013","January 2026","January 21, 2017","January 2017","No Study Results Posted","DA-EPOCH-R","January 2017","Measure and assess adverse events|Measure and assess immune function","https://ClinicalTrials.gov/show/NCT01760226"
2176,"NCT00854568","Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL","Completed","No Results Available","Lymphoma","Drug: CEOP regimen|Drug: CHOP regimen","Fudan University","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","398","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LMTG 09-01","March 2, 2009","March 2009","February 2013","August 19, 2014","August 2014","No Study Results Posted","null","December 2012","Cardiotoxicity (Class III or IV cardiotoxicity according to New York Heart Association (NYHA) Classification or LVEF abnormality [< 50% or a decrease in absolute LVEF ≥ 10%) by post-treatment RNA])|Objective response rate","https://ClinicalTrials.gov/show/NCT00854568"
2177,"NCT01021800","Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma","Unknown status","No Results Available","Pancreatic Tubular Adenocarcinoma","Biological: MIS","Blood Transfusion Centre of Slovenia","All","30 Years to 70 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MIS","November 27, 2009","April 2009","December 2012","January 12, 2010","November 2009","No Study Results Posted","SYSTHER","December 2011","PROGRESSION FREE SURVIVAL","https://ClinicalTrials.gov/show/NCT01021800"
2178,"NCT00002477","Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer","Unknown status","No Results Available","Ovarian Cancer","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride","Medical Research Council|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","null","Other","Interventional","Primary Purpose: Treatment","CDR0000077026|MRC-ICON1|EU-91002","November 1, 1999","April 1991","null","December 17, 2013","July 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002477"
2179,"NCT00003311","Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: methotrexate|Drug: vincristine sulfate","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 2","19","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000066258|MDA-DM-97200|NCI-T97-0101|DM97-200","November 1, 1999","March 1999","April 2007","October 5, 2012","October 2012","No Study Results Posted","null","April 2007","","https://ClinicalTrials.gov/show/NCT00003311"
2180,"NCT01779531","Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients","Unknown status","No Results Available","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","","Guangdong Academy of Medical Sciences|Chinese Anti-Cancer Association|Guangzhou General Hospital of Guangzhou Military Command|Guangzhou First People's Hospital","Female","18 Years to 70 Years   (Adult, Senior)","","640","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","GGHBCRG","January 24, 2013","January 2013","June 2015","January 28, 2013","January 2013","No Study Results Posted","null","June 2014","Disease free survival after adjuvant chemotherapy within five years|Overall survival after adjuvant chemotherapy within five years|Imaging evaluation after neoadjuvant chemotherapy","https://ClinicalTrials.gov/show/NCT01779531"
2181,"NCT01420679","Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients","Terminated","No Results Available","Peripheral T-cell Lymphoma","Drug: Pralatrexate Injection","Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Senior)","Phase 3","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PDX-017|2010-022230-81","August 18, 2011","August 2011","December 2017","August 11, 2014","August 2014","No Study Results Posted","null","December 2016","Progression-free Survival (PFS)|Overall Survival (OS)|Objective Response to Pralatrexate versus Observation","https://ClinicalTrials.gov/show/NCT01420679"
2182,"NCT00200681","IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Drug: Velcade","Nantes University Hospital","All","18 Years to 65 Years   (Adult)","Phase 3","493","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","BRD 04/11-J","September 12, 2005","June 2005","June 2008","February 4, 2009","February 2009","No Study Results Posted","null","January 2008","To compare the CR rate (with negative or positive immunofixation) obtained with VAD or the Velcade®/dexamethasone combination used as induction treatment in patients up to the age of 65 with newly diagnosed MM, at the end of this induction treatment","https://ClinicalTrials.gov/show/NCT00200681"
2183,"NCT02159716","CART-meso in Mesothelin Expressing Cancers","Active, not recruiting","No Results Available","Metastatic Pancreatic (Ductal) Adenocarcinoma|Epithelial Ovarian Cancer|Malignant Epithelial Pleural Mesothelioma","Biological: CART-meso","University of Pennsylvania","All","18 Years and older   (Adult, Senior)","Phase 1","19","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","UPCC31213","June 6, 2014","June 2014","null","March 16, 2017","March 2017","No Study Results Posted","null","November 2015","Number of Adverse Events","https://ClinicalTrials.gov/show/NCT02159716"
2184,"NCT00425516","Breast Cancer Treated by Neoadjuvant Chemotherapy","Completed","No Results Available","Individualized Chemotherapy","Drug: Taxotere|Drug: 5-Fluorouracil|Drug: Epirubicin|Drug: Cyclophosphamide","Centre Jean Perrin","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","264","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CJP AU651/Afssaps060744","January 22, 2007","January 2007","August 2014","September 30, 2014","February 2007","No Study Results Posted","null","August 2014","Improvement of complete pathological response rate at surgery after 6 chemotherapy cycles|Tolerance according to NCI-CTC criteria|Objective clinical, echographic, mammographic responses after 6 cycles|Breast conservation rate|Study of biological predictive factors of chemosensitivity and resistance by immunological and molecular biology techniques)|Overall and relapse-free survivals","https://ClinicalTrials.gov/show/NCT00425516"
2185,"NCT00003638","Vaccine Therapy in Treating Women With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: Detox-B adjuvant|Biological: THERATOPE STn-KLH vaccine|Biological: keyhole limpet hemocyanin|Drug: cyclophosphamide","Oncothyreon Canada Inc.|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","950","Industry","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066723|BIOMIRA-STn-BR-104|NCI-V98-1489","November 1, 1999","January 1999","December 2008","March 25, 2013","December 2008","No Study Results Posted","null","January 2007","","https://ClinicalTrials.gov/show/NCT00003638"
2186,"NCT03152526","CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR","Not yet recruiting","No Results Available","Acute Myelogenous Leukemia","Device: Interventions","Miltenyi Biotec GmbH|Masonic Cancer Center, University of Minnesota|University of Chicago","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","41","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MT-2014-02","February 28, 2017","June 2017","June 2022","May 11, 2017","May 2017","No Study Results Posted","null","June 2021","The primary endpoint of the study is complete remission (±3 days)|The secondary endpoint is the expansion and persistence of NK cells to be used for the remainder of the study.","https://ClinicalTrials.gov/show/NCT03152526"
2187,"NCT01290120","Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma","Completed","No Results Available","Burkitt Lymphoma|B-ALL","Drug: Chemotherapy-Rituximab combination","Northern Italy Leukemia Group","All","15 Years and older   (Child, Adult, Senior)","Phase 2","182","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NILG 2009-012950-19","February 2, 2011","November 2002","June 2014","September 15, 2014","September 2014","No Study Results Posted","null","June 2014","Overall survival|Disease free survival|Cumulative incidence of relapse|Complete remission rate|Toxicity","https://ClinicalTrials.gov/show/NCT01290120"
2188,"NCT02158702","Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib","Recruiting","No Results Available","Multiple Myeloma|Relapse After Use of Lenalidomide and Bortezomib","Drug: Pomalidomide and Dexamethasone","National University Hospital, Singapore|Celgene","All","21 Years to 99 Years   (Adult, Senior)","Phase 2","15","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2014/00498","June 5, 2014","November 2014","November 2018","June 6, 2016","June 2016","No Study Results Posted","null","August 2017","To assess the progression free survival (PFS) for pomalidomide and dexamethasone in patients who have relapsed and are refractory to lenalidomide and have previously been treated with bortezomib|To assess Overall Response Rate (ORR)|To see if addition of cyclophosphamide with induce additional response in patient who do not achieve an minimal response (MR) after 3 months|To assess Overall Survival (OS)|To assess Duration of Response (DOR)|To assess Safety and Tolerability","https://ClinicalTrials.gov/show/NCT02158702"
2189,"NCT00206466","Biologic Correlative Taxotere/AC","Completed","No Results Available","Breast Cancer","Drug: Taxotere|Drug: Adriamycin/cytoxan","Baylor Breast Care Center|Baylor College of Medicine","Female","18 Years and older   (Adult, Senior)","Phase 2","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-11624","September 13, 2005","April 2002","January 2012","January 24, 2012","January 2012","No Study Results Posted","TAX/AC","April 2006","The primary objective this extension study is to obtain enough additional cases evaluable for microarray analyses to complete our studies to identify profiles of a small number of genes that are predictive of response.|To determine pathologic complete response and to correlate this to a prospectively determined Taxotere gene expression profile;time to tumor progression;overall survival","https://ClinicalTrials.gov/show/NCT00206466"
2190,"NCT02461121","HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk","Completed","No Results Available","Acute Myeloid Leukemia","Genetic: HLA mismatched stem cell|Genetic: HLA matched stem cell|Drug: cyclosporine A|Drug: Mycophenolate mofetil|Drug: Ara-C|Drug: fludarabine|Drug: anti-lymphocyte globulin|Drug: cyclophosphamide","The Affiliated Hospital of the Chinese Academy of Military Medical Sciences","All","9 Years to 59 Years   (Child, Adult)","Phase 3","156","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MST vs NST","May 18, 2015","May 2004","May 2013","June 2, 2015","May 2015","No Study Results Posted","null","May 2013","Overall Survival|treatment-related mortality|donor chimerism or microchimerism|WT1+CD8+CTL|GVHD|disease free survival","https://ClinicalTrials.gov/show/NCT02461121"
2191,"NCT00970385","Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma","Completed","No Results Available","Peripheral T Cell Lymphoma","Drug: CHOP21|Drug: VIP/ABVD|Radiation: Radiotherapy consolidation","University Hospital, Grenoble|French Innovative Leukemia Organisation","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","95","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LTP 95","August 20, 2009","January 1995","September 2008","September 8, 2009","September 2009","No Study Results Posted","LTP","December 2002","Comparison between EFS rate of CHOP/21 versus VIP-rABVD in newly diagnosed PTCL.|Overall survival (OS)|response rate at the end of the treatment|progression free survival (PFS)|hematotoxicity","https://ClinicalTrials.gov/show/NCT00970385"
2192,"NCT00666484","Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma","Completed","No Results Available","Lymphoma|Neurotoxicity","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisolone|Drug: procarbazine hydrochloride|Drug: vincristine sulfate|Radiation: radiation therapy","University College, London","All","18 Years to 30 Years   (Adult)","Phase 2","47","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000593560|UCL/07/005|2007-003080-45|EU-20844","April 24, 2008","March 2008","September 2012","December 3, 2014","December 2014","No Study Results Posted","null","September 2012","Neurotoxicity due to the intensive use of Vinca alkaloids|Response rate|Disease-free survival|Overall survival|Gonadal toxicity","https://ClinicalTrials.gov/show/NCT00666484"
2193,"NCT00281879","Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","Terminated","Has Results","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Unusual Cancers of Childhood","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: busulfan|Drug: carmustine|Drug: cyclophosphamide|Drug: cyclosporine|Drug: cytarabine|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Drug: methotrexate|Drug: methylprednisolone|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: peripheral blood stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","up to 60 Years   (Child, Adult)","Phase 2","200","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000452794|P30CA016058|OHSU-TPI-9695-L|OHSU-540","January 24, 2006","February 2006","March 2008","July 2, 2012","May 2012","May 17, 2012","null","February 2008","Number of Participants With Disease Free Survival (DFS).","https://ClinicalTrials.gov/show/NCT00281879"
2194,"NCT02278887","Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma","Recruiting","No Results Available","Metastatic Melanoma","Procedure: Translational research|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Interleukin-2|Drug: Ipilimumab infusion","The Netherlands Cancer Institute|Copenhagen University Hospital at Herlev|University of Manchester","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","168","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","M14TIL","June 3, 2014","September 2014","September 2020","December 13, 2016","December 2016","No Study Results Posted","TIL","September 2019","Progression free survival|Immune related progression free survival","https://ClinicalTrials.gov/show/NCT02278887"
2195,"NCT01898793","Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","Recruiting","No Results Available","Leukemia, Myeloid, Acute","Drug: Fludarabine|Drug: Cyclophosphamide|Procedure: Leukapheresis|Biological: Cytokine-induced killer cells|Biological: Aldesleukin|Drug: ALT-803","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","48","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","201401085","July 9, 2013","August 11, 2014","December 31, 2020","May 18, 2017","May 2017","No Study Results Posted","null","December 31, 2020","Maximal tolerated or tested dose (MT/TD) of CIML-NK cells (Phase I)|Complete remission rate (CR/CRi) in participants with relapsed AML following CIML NK therapy|Response assessed according to IWG criteria (Phase I and Phase II)|Duration of remission (DOR) (Phase I and Phase II)|Time to progression (Phase I and Phase II)|Disease free survival (DFS) (Phase I and Phase II)|Overall survival (OS) (Phase I and Phase II)|Toxicity as measured by the frequency and incidence of serious adverse events (Phase I and Phase II)","https://ClinicalTrials.gov/show/NCT01898793"
2196,"NCT00187070","Large Cell Lymphoma Pilot Study III","Completed","No Results Available","Lymphoma, Large Cell|Lymphoma, Non-Hodgkin","Drug: Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine|Procedure: Stem cell transplant,|Radiation: Radiation Therapy","St. Jude Children's Research Hospital","All","up to 18 Years   (Child, Adult)","","8","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LCLIII","September 12, 2005","December 1997","July 2001","May 6, 2008","May 2008","No Study Results Posted","null","July 2001","To demonstrate the feasibility of delivery of a multiagent chemotherapy regimen which features a shorter, more direct approach, and includes a phase that incorporates hematopoietic stem cell support for children with large cell lymphoma.","https://ClinicalTrials.gov/show/NCT00187070"
2197,"NCT02206425","Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients","Recruiting","No Results Available","Multiple Myeloma","Drug: Melphalan|Drug: Prednisone|Drug: Cyclophosphamide|Drug: Dexamethasone|Dietary Supplement: Ascorbic acid|Drug: PLD|Drug: Lenalidomide","Oncotherapeutics|Millennium: The Takeda Oncology Company","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","X16041|IISR-2013-M100118","July 30, 2014","September 2014","August 2018","February 27, 2017","February 2017","No Study Results Posted","null","December 2017","Maximum tolerated dose (MTD) for selected regimens|Number of subjects with adverse events|Overall response rate (ORR)|Clinical benefit rate (CBR)|Time to Progression|Progression-free survival (PFS)|Time to response (TTR)|Duration of response (DOR)|Overall survival (OS)|Peripheral Neuropathy (PN)","https://ClinicalTrials.gov/show/NCT02206425"
2198,"NCT01015183","Prevention Chemotherapy Induced Mucositis by Zinc Sulfate","Completed","No Results Available","Mucositis|Bone Marrow Transplantation","Drug: Zinc Sulfate|Drug: Placebo","Tehran University of Medical Sciences","All","Child, Adult, Senior","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","HORCSCT-0904","November 17, 2009","November 2009","June 2011","July 25, 2011","July 2011","No Study Results Posted","null","November 2010","The effect of Zinc Sulfate on prevention of mucositis in patients undergoing bone marrow transplantation|Evaluation of Zinc Sulfate concentration|Evaluation of Zinc Sulfate advance effects","https://ClinicalTrials.gov/show/NCT01015183"
2199,"NCT01341262","THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)","Completed","No Results Available","Multiple Myeloma","Drug: Thalidomide|Drug: Dexamethasone|Drug: Zoledronic acid|Drug: Cyclophosphamide|Drug: Melphalan","Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi","All","18 Years to 65 Years   (Adult)","Phase 2","378","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MM-BO2002","March 31, 2011","March 2002","January 2009","April 22, 2011","March 2011","No Study Results Posted","null","October 2007","Response rate (at least PR, VGPR, nCR and CR) to thal-dex induction|duration of response (partial response, PR, very good partial response, VGPR, complete response, CR)|time to progression (TTP)|progression free survival (PFS)|toxicity of thal-dex (induction and subsequent treatment phases)|Response rate (at least PR, VGPR, nCR and CR) to first ASCT|Response rate (at least PR, VGPR, nCR and CR) to second ASCT|Overall survival (OS)|OS by cytogenetic abnormalities|OS by 18F-FDG PET/CT imaging|TTP by cytogenetic abnormalities|PFS by cytogenetic abnormalities|TTP by 18F-FDG PET/CT imaging|PFS by 18F-FDG PET/CT imaging","https://ClinicalTrials.gov/show/NCT01341262"
2200,"NCT03054883","Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy","Completed","No Results Available","Mantle Cell Lymphoma","","Czech Lymphoma Study Group|Ministry of Health, Czech Republic","All","18 Years and older   (Adult, Senior)","","73","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CLSG-MCL-01","February 9, 2017","April 1, 2012","December 31, 2016","February 13, 2017","February 2017","No Study Results Posted","null","December 31, 2015","Overall response|Progression-free survival and overall survival|Minimal residual disease (MRD) by PCR (polymerase chain reaction) after induction","https://ClinicalTrials.gov/show/NCT03054883"
2201,"NCT02383212","Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies","Recruiting","No Results Available","Advanced Cancer|Advanced Malignancies","Drug: REGN2810|Radiation: Hypofractionated radiotherapy|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Carboplatin|Drug: GM-CSF|Drug: Paclitaxel|Drug: Pemetrexed","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Senior)","Phase 1","560","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","R2810-ONC-1423","February 2, 2015","January 2015","July 2019","May 17, 2017","May 2017","No Study Results Posted","null","July 2019","Incidence of Treatment Emergent Adverse Events (TEAEs)|Incidence of abnormal laboratory findings|Number of participants with dose limiting toxicities (DLTs)|Response Evaluation Criteria in Solid Tumors (RECIST) as measured by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)|Immune-Related Response Criteria (irRC) applied to RECIST measurements","https://ClinicalTrials.gov/show/NCT02383212"
2202,"NCT01704716","High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN)","Recruiting","No Results Available","Neuroblastoma","Drug: Vincristine|Drug: Aldesleukin|Drug: ch14.18/CHO|Drug: Carboplatin|Drug: Etoposide|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: G-CSF|Drug: Busulfan|Drug: Melphalan","St. Anna Kinderkrebsforschung","All","1 Month to 21 Years   (Child, Adult)","Phase 3","2700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HR-NBL-1.7 / SIOPEN","October 5, 2012","February 2002","September 2017","September 26, 2016","September 2016","No Study Results Posted","null","September 2017","Event Free Survival (R1: MAT therapy)|Event Free Survival (R4: immunotherapy)|Complete metastatic response (R3: Induction therapy)|Event free survival (R3: Induction therapy)","https://ClinicalTrials.gov/show/NCT01704716"
2203,"NCT01016795","Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma","Terminated","No Results Available","Malignant Lymphoma","Drug: r-metHuSCF and Filgrastim|Drug: r-metHuSCF and Filgrastim|Drug: Chemotherapy plus Filgrastim","Aalborg Universitetshospital|Herlev Hospital|Rigshospitalet, Denmark|Helsinki University Central Hospital|Turku University Hospital|University Hospital, Linkoeping|Umeå University|Oslo University Hospital|Nordic Lymphoma Group|Amgen","All","18 Years to 65 Years   (Adult)","Phase 2","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SCF 980266|H-KA-99040-GMS","November 18, 2009","January 1999","November 2009","June 24, 2015","November 2009","No Study Results Posted","SCF980266","November 2000","Safety and Toxicity was assessed by morbidity, including unexpected adverse events associated with the priming and the transplantation phases during study, and measured and graded by CTC criteria.|To compare the time dependent level of blood circulating and harvested haematopoietic stem cells and progenitors (PBSC) in patients treated with either a combination of r-metHuSCF and Filgrastim, or conventional chemotherapy plus Filgrastim.","https://ClinicalTrials.gov/show/NCT01016795"
2204,"NCT02061800","CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant","Recruiting","No Results Available","Chronic Myeloid Leukemia (CML)|Acute Myelogenous Leukemia (AML);|Myelodysplastic Syndrome (MDS);|Juvenile Myelomonocytic Leukemia (JMML);|Acute Lymphoblastic Leukemia (ALL);|Lymphoma (Hodgkin's and Non-Hodgkin's)","Device: CliniMACS CD34+ Reagent System|Drug: Thiotepa|Drug: Cyclophosphamide|Drug: Alemtuzumab|Drug: Tacrolimus|Drug: Melphalan|Drug: Busulfan|Drug: Fludarabine|Drug: Methylprednisolone","Diane George, MD|Columbia University","All","up to 22 Years   (Child, Adult)","Phase 1|Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AAAK8060","February 11, 2014","November 2013","December 2018","July 26, 2016","July 2016","No Study Results Posted","null","December 2018","Incidence of acute GVHD|Incidence of chronic GVHD|Severity of acute GVHD|Severity of chronic GVHD|Incidence of primary graft failure|Incidence of secondary graft failure|Time to neutrophil engraftment|Time to immune reconstitution|Incidence of infection complications including bacterial, viral, fungal and atypical mycobacterial and other infections|Time to platelet engraftment","https://ClinicalTrials.gov/show/NCT02061800"
2205,"NCT00586547","Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation","Completed","No Results Available","Leukemia|Cancer","Drug: Ara-C|Drug: Cyclophosphamide|Drug: Mesna|Biological: Campath 1H|Radiation: TBI|Procedure: Stem Cells Infusion|Procedure: T-cell Infusion","Baylor College of Medicine|University of Texas, Southwestern Medical Center at Dallas","All","Child, Adult, Senior","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-9033","December 21, 2007","July 2000","September 2008","December 2, 2009","October 2009","No Study Results Posted","null","September 2008","Determining the number of donor lymphocytes given to recipients of haploidentical stem cell transplants after depletion of recipient-reactive T lymphocytes by ex-vivo treatment with a fixed dose of RFT5-dgA immunotoxin.|To measure their overall and disease free survival.","https://ClinicalTrials.gov/show/NCT00586547"
2206,"NCT00186888","Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma","Active, not recruiting","Has Results","Retinoblastoma|Retinal Neoplasm","Procedure: Enucleation|Drug: Vincristine, Carboplatin|Procedure: Focal Therapies|Radiation: External Beam Radiation|Drug: Vincristine + Topotecan|Drug: Vincristine + Carboplatin + Etoposide|Drug: Vincristine + Cyclophosphamide + Doxorubicin|Drug: Vincristine+Carboplatin+Etoposide|Procedure: Periocular carboplatin|Other: G-CSF","St. Jude Children's Research Hospital|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","107","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","RET5|P01CA023099|NCI-2011-01186","September 12, 2005","February 2005","September 2021","April 11, 2017","June 2016","June 29, 2011","null","November 2013","Stratum B Response to Window Therapy|Stratum B Response Rate of Early Stage Eyes to Window Therapy|Relationship Between Topotecan Clearance (CL) and CYP3A4/5 Genotype in Stratum B Participants.|Relationship Between Topotecan Clearance (CL) and ABCG2/B1 Genotype in Stratum B Participants.|Event-free Survival of Stratum B Patients Responding to Window Treatment|Ocular Survival of Stratum B Patients Responding to Window Treatment|Event-free Survival of Eyes in Stratum B Patients Responding to Window Treatment|Ocular Survival of Eyes in Stratum B Patients Responding to Window Treatment|Event-free Survival of Stratum B Patients Not Responding to Window Treatment|Ocular Survival of Stratum B Patients Not Responding to Window Treatment|Event-free Survival of Eyes in Stratum B Patients Not Responding to Window Treatment|Ocular Survival of Eyes in Stratum B Patients Not Responding to Window Treatment|Event-free Survival of Stratum A Patients|Ocular Survival of Stratum A Patients|Event-free Survival of Eyes of Stratum B Patients|Ocular Survival of Eyes of Stratum B Patients|Event-free Survival of Eyes in Stratum A and Stratum B Patients Based on IC Classification|Ocular Survival of Eyes in Stratum A and Stratum B Patients Based on IC Classification|Event-free Survival Per Eye in Stratum A and Stratum B Patients Based on AJCC Classification|Ocular Survival Per Eye in Stratum A and Stratum B Patients Based on AJCC Classification|Change in Cognitive Functioning|Change in Relevant Daily Living Skills|Change in Parent Report of Social-Emotional Factors|Change in Parenting Stress Index (PSI)|Assessment of School Readiness","https://ClinicalTrials.gov/show/NCT00186888"
2207,"NCT02390648","Efficacy of Ginger as an Adjunctive Prophylaxis for Chemotherapy-induced Nausea and Vomiting","Completed","No Results Available","Chemotherapy-induced Nausea and Vomiting","Drug: Ginger|Drug: Placebo","Mahidol University","All","18 Years and older   (Adult, Senior)","Phase 2","34","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","732/2557(EC1)","March 11, 2015","March 2015","February 2016","March 15, 2016","March 2016","No Study Results Posted","null","February 2016","Nausea score","https://ClinicalTrials.gov/show/NCT02390648"
2208,"NCT01061359","Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer","Completed","Has Results","Breast Neoplasm","Drug: Epirubicin: Observational Study","Pfizer","Female","Child, Adult, Senior","","1981","Industry","Observational","Time Perspective: Prospective","378-ONC-0030-0144|A6051029/MOI99056","February 1, 2010","January 1999","October 2009","December 16, 2010","December 2010","October 14, 2010","null","October 2009","Percentage of Participants With Disease Free Survival (DFS)|Time to Progression (TTP)|Time to Recurrence (DFI)","https://ClinicalTrials.gov/show/NCT01061359"
2209,"NCT00149136","Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.","Unknown status","No Results Available","Acute Lymphocytic Leukemia","Drug: imatinib","Hospices Civils de Lyon","All","55 Years to 90 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label","2002.280","September 6, 2005","August 2002","null","April 26, 2007","April 2007","No Study Results Posted","null","null","Impact of Imatinib on survival in elderly patients with Ph+ALL|Tolerance of Imatinib|Complete remission rate|Minimal Residual Disease after Imatinib treatment|Leukemia free survival|Impact of steroids given before starting chemotherapy|Study of potential resistance mechanisums to Imatinib","https://ClinicalTrials.gov/show/NCT00149136"
2210,"NCT00431080","Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Docetaxel|Drug: Paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: 5-fluoruracil|Drug: Granulocyte-colony stimulating growth factor","Hellenic Oncology Research Group|University Hospital of Crete","Female","18 Years to 75 Years   (Adult, Senior)","Phase 3","478","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/04.22","February 2, 2007","August 2004","October 2007","January 18, 2008","January 2008","No Study Results Posted","null","October 2007","3-year disease-free survival|Overall survival|Recurrence rate|Τoxicity profile|Quality of life between the two treatment arms","https://ClinicalTrials.gov/show/NCT00431080"
2211,"NCT00392834","Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma","Completed","Has Results","Lymphoma","Biological: filgrastim|Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: leucovorin calcium|Drug: liposomal cytarabine|Drug: methotrexate|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","34","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-048|U01CA070019|CDR0000510918","October 25, 2006","September 2006","July 2013","August 27, 2014","August 2014","January 24, 2013","null","July 2011","Overall Survival (OS) at 1 Year|Complete Response Rate|Failure-free Survival (FFS)|Event-free Survival (EFS)|Toxicity|Incidence of Infection-related Deaths|Correlation of C-flip Expression, p53 Mutations, and Multidrug Resistance Expression With OS, FFS, and EFS|Utility of Flow Cytometry in Detecting Leptomeningeal Disease|Degree of Disconcordance Between Flow Cytometry and CNS Cytology Results|Biologic and Prognostic Significance of Epstein-Barr Virus (EBV) at Diagnosis and Correlation With OS, FFS, and EFS|Correlation of EBV Load Measurements With OS, FFS, and EFS","https://ClinicalTrials.gov/show/NCT00392834"
2212,"NCT00126191","Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma","Terminated","Has Results","Burkitt Lymphoma|Non-Hodgkins Lymphoma|Atypical Burkitt Lymphoma","Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Methotrexate|Drug: Leucovorin|Drug: Ifosfamide|Drug: Etoposide|Drug: Cytarabine|Drug: Mesna","Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","04-336","August 2, 2005","July 2005","June 2011","April 17, 2013","April 2013","November 30, 2012","null","December 2009","Response Rates (CR and PR) in Adults With Burkitt/Atypical Burkitt|Disease Free Survival","https://ClinicalTrials.gov/show/NCT00126191"
2213,"NCT00002967","Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: octreotide pamoate|Drug: tamoxifen citrate","NSABP Foundation Inc|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000065472|NSABP-B-29","November 1, 1999","May 1997","March 2006","June 20, 2013","June 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002967"
2214,"NCT00235235","A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer","Terminated","No Results Available","Breast Cancer","Procedure: Biopsy|Procedure: Serum Collection|Procedure: Urine Collection|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Capecitabine|Drug: Vinorelbine|Drug: Gemcitabine","Hoosier Cancer Research Network|United States Department of Defense|Indiana University School of Medicine|Walther Cancer Institute","Female","18 Years and older   (Adult, Senior)","","80","Other|U.S. Fed","Observational","Time Perspective: Prospective","HOG COE-01|Department of Defense BC030400","October 6, 2005","September 2005","December 2010","December 8, 2015","December 2015","No Study Results Posted","null","December 2010","To correlate tumor gene expression (genomic profile) with response to commonly used chemotherapies in patients with advanced breast cancer|To correlate serum and tumor proteomic profiles with response to commonly used chemotherapies.|To compare serum and tissue proteomic analyses.|To compare genomic and proteomic profiles.|To correlate toxicity and/or response with drug-specific pharmacogenomic parameters.","https://ClinicalTrials.gov/show/NCT00235235"
2215,"NCT01432873","Oral Selenium Therapy for the Prevention of Mucositis","Unknown status","No Results Available","Mucositis|Hematopoietic Stem Cell Transplantation","Drug: Oral selenium|Drug: Oral placebo","Tehran University of Medical Sciences","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","76","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HORCSCT-9001","July 25, 2011","June 2011","December 2012","May 31, 2012","May 2012","No Study Results Posted","null","October 2012","The grade of oral mucositis after bone marrow transplantation|Evaluation of selenium concentration and glutathione peroxidase level in serum|Total days of mucositis after BMT","https://ClinicalTrials.gov/show/NCT01432873"
2216,"NCT01499147","Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies","Completed","No Results Available","Acute Myeloid Leukemia|Acute Leukemia|Chronic Myelogenous Leukemia|Malignant Lymphoma|Hodgkin's Disease|Multiple Myeloma|Lymphocytic Leukemia|Myeloproliferative Disorder|Polycythemia Vera|Myelofibrosis|Aplastic Anemia","Drug: fludarabine/busulfan|Drug: fludarabine/ melphalan","University of Illinois at Chicago","All","10 Years to 65 Years   (Child, Adult)","","152","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2000-0117","November 23, 2011","February 2000","May 2013","March 27, 2014","March 2014","No Study Results Posted","null","May 2013","To determine the rate of engraftment.|To determine the rate of moderate to severe (grade 2-4) acute and chronic graft versus host disease (GVHD).|To determine the 100 day transplant-related mortality.","https://ClinicalTrials.gov/show/NCT01499147"
2217,"NCT00636909","Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders","Completed","No Results Available","AML|ALL|CML Chronic Phase, Accelerated Phase, or Blast Crisis|CLL|MDS|RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA|APLASTIC ANEMIA|MULTIPLE MYELOMA|MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)","Drug: Cyclophosphamide|Drug: fludarabine|Drug: cyclosporine|Drug: methotrexate|Biological: G-CSF","Beth Israel Deaconess Medical Center|Amgen","All","up to 65 Years   (Child, Adult)","Phase 2","25","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2001P002293|W-99-0234-FB","March 10, 2008","July 1999","null","April 5, 2017","April 2017","No Study Results Posted","MINI HEME","March 2006","durable engraftment|hematopoeitic reconstitution|evaluate the patterns of post-transplant chimerism among lymphoid and antigen presenting cells|disease free survival and overall survival|incidence of treatment related toxicity and acute and chronic graft versus host disease","https://ClinicalTrials.gov/show/NCT00636909"
2218,"NCT00002529","Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: tamoxifen citrate|Drug: toremifene","International Breast Cancer Study Group","Female","up to 70 Years   (Child, Adult, Senior)","Phase 3","452","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000078385|IBCSG-12-93|EU-93015|NCI-F93-0010","November 1, 1999","May 1993","August 2010","April 3, 2013","July 2012","No Study Results Posted","12-93","August 2010","Overall survival|Disease-free and systemic disease-free survival.|Quality of life|Toxicity","https://ClinicalTrials.gov/show/NCT00002529"
2219,"NCT03009058","Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","Recruiting","No Results Available","Metastatic Cancer","Biological: IMM-101|Drug: Gemcitabine|Drug: Nabpaclitaxel|Drug: Capecitabine|Drug: Folinic Acid|Drug: Fluorouracil|Drug: Irinotecan|Drug: Oxaliplatin|Biological: cetuximab|Biological: Anti-PD1|Biological: Ipilimumab|Drug: Cyclophosphamide","Immodulon Therapeutics Ltd","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","300","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IMM-101-011|2016 001459 28|CANC 32085","December 16, 2016","May 2017","June 2022","May 19, 2017","May 2017","No Study Results Posted","MODULATE","May 2019","Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Number of participants with treatment-related adverse events when IMM-101 is given in combination with a checkpoint blockade inhibitor|Response to treatment|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT03009058"
2220,"NCT01872416","A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer","Unknown status","No Results Available","Small Cell Lung Cancer","Device: Liposomal Doxorubicin Combined With ifosfamide","The First Affiliated Hospital of Guangzhou Medical University","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FAHG20120926A|FAHGuangzhou012","May 17, 2013","October 2012","May 2015","June 17, 2013","June 2013","No Study Results Posted","null","May 2014","objective response rate|progression free survival(PFS）","https://ClinicalTrials.gov/show/NCT01872416"
2221,"NCT00949013","S9313B Study of Tumor Tissue Samples From Women With Early-Stage Breast Cancer Enrolled on Clinical Trial SWOG-9313","Completed","No Results Available","Breast Cancer","Other: immunohistochemistry staining method|Other: laboratory biomarker analysis","Southwest Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","","1600","Other|NIH","Observational","Time Perspective: Retrospective","CDR0000632885|S9313B-ICSC|U10CA032102","July 29, 2009","January 2009","April 2009","May 23, 2014","May 2014","No Study Results Posted","null","April 2009","Correlation of ALDH1 with disease-free survival and overall survival|Correlation of ALDH1 with other biomarkers (TOPOII, HER2, ER, PgR)","https://ClinicalTrials.gov/show/NCT00949013"
2222,"NCT02283983","Evaluation of Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose","Recruiting","No Results Available","Breast Neoplasms","Other: mittens and booties|Other: cooling helmet","Centre Hospitalier Departemental Vendee","Female","18 Years and older   (Adult, Senior)","","302","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Prevention","CHD 097-13","November 3, 2014","December 2014","May 2019","March 21, 2017","March 2017","No Study Results Posted","BANQUISE","May 2018","Evaluation of the occurrence of nail toxicity of grade 2 of Common Toxicity Criteria for Adverse Effects V4.0 evaluated at 8 weeks post infusion of docetaxel.","https://ClinicalTrials.gov/show/NCT02283983"
2223,"NCT03145727","Electric Stimulation on Nausea and Vomit Chemotherapy Induced","Not yet recruiting","No Results Available","Breast Cancer Female|Acupuncture","Device: Placebo Group|Device: Low Frequency Group|Device: High Frequency Group","Federal University of Health Science of Porto Alegre|Irmandade Santa Casa de Misericórdia de Porto Alegre","Female","18 Years to 65 Years   (Adult)","","84","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Participant|Primary Purpose: Treatment","TENS-NV-2017","May 5, 2017","July 1, 2017","October 30, 2018","May 11, 2017","May 2017","No Study Results Posted","TENS-NV","December 30, 2017","Cumulative index of nausea|Cumulative index of episodes of vomiting|Intensity of nausea symptoms|Severity of vomiting episodes|Need for rescue antiemetic|Edmonton Symptom Assessment Scale","https://ClinicalTrials.gov/show/NCT03145727"
2224,"NCT00080444","Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)","Completed","No Results Available","Vomiting","Drug: aprepitant|Drug: ondansetron|Drug: dexamethasone|Drug: placebo to aprepitant|Drug: placebo to dexamethasone|Drug: rescue medication","Merck Sharp & Dohme Corp.","All","12 Years to 17 Years   (Child)","Phase 3","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","0869-097|Formerly-0304AHEC|MK-0869-097|2004_099","March 31, 2004","April 2004","March 2007","August 4, 2014","August 2014","No Study Results Posted","null","September 2006","Percentage of Participants Who Experience Study-drug-related Adverse Events (Cycle 1)|Percentage of Participants Who Experience a Complete Response (CR) to Anti-emetic Therapy (Cycle 1)|Percentage of Participants Who Experience Absence of Nausea (Cycle 1)|Percentage of Participants Who Experience Absence of Vomiting (Cycle 1)|Percentage of Participants Who Experience Serious Adverse Events (Cycles 2-10)|Percentage of Participants Who Experience Study-drug-related Adverse Events (Cycles 2-10)|Percentage of Participants Who Discontinue Study Due to Study-drug-related Adverse Events (Cycles 2-10)|Percentage of Participants Who Experience Serious Adverse Events (Cycle 1)|Percentage of Participants Who Experience Serious Study-drug-related Adverse Events (Cycle 1)|Percentage of Participants Who Discontinue Study Due to Study-drug-related Adverse Events (Cycle 1)|Aprepitant Plasma Drug Concentration Profiles and Pharmacokinetics","https://ClinicalTrials.gov/show/NCT00080444"
2225,"NCT00145626","HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies","Completed","Has Results","Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Myelodysplasia|Chronic Myeloid Leukemia|Histiocytosis","Drug: Chemotherapy and antibodies|Device: Miltenyi Biotec CliniMACS|Procedure: Allogeneic stem cell transplantation","St. Jude Children's Research Hospital|Assisi Foundation","All","up to 24 Months   (Child)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","INFT2|NCI-2011-03671","September 1, 2005","May 2004","July 2016","November 9, 2016","November 2016","June 8, 2015","null","March 2015","One-year Survival|Number of Transplant-Related Adverse Outcomes: Regimen-Related Mortality|Number of Transplant-Related Adverse Outcomes: Engraftment Failure|Number of Transplant-Related Adverse Outcomes: Fatal Acute Graft-Versus Host Disease (GVHD)|Number of Transplant-related Adverse Outcomes|Number of Incidences of Chronic GVHD.|Factors Affecting One-year Survival: Median Age of Donor at HSCT|Factors Affecting One-year Survival: Median Dose of CD34|Factors Affecting One-year Survival: Median Dose of NK Cells|Factors Affecting One-year Survival: Disease Status at HSCT|Factors Affecting One-year Survival: Donor Type|Factors Affecting One-year Survival: Match N/6 HLA Loci|Factors Affecting One-year Survival: Minimal Residual Disease (MRD)|The Kinetics of Lymphohematopoietic Reconstitution.|The Incidence of and Risk Factors for Organ Dysfunction.|The Incidence of and Risk Factors for Long-term Neurocognitive Deficit.|The Frequency of and Clinical Relevance of Minimal Residual Disease (MRD) Before and After Transplantation","https://ClinicalTrials.gov/show/NCT00145626"
2226,"NCT00005090","S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease","Terminated","No Results Available","Lymphoma","Biological: bleomycin sulfate|Drug: carmustine|Drug: cyclophosphamide|Drug: dacarbazine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: vinblastine|Procedure: peripheral blood stem cell transplantation","Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B","All","15 Years to 65 Years   (Child, Adult)","Phase 3","11","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067708|S9901|CLB-59802|E-S9901|U10CA032102","April 6, 2000","April 2000","May 2005","January 22, 2013","January 2013","No Study Results Posted","null","May 2005","Progression-free survival|overall survival","https://ClinicalTrials.gov/show/NCT00005090"
2227,"NCT01810926","T&B Depletion Non Malignant","Unknown status","No Results Available","Graft Versus Host Disease","Biological: polyclonal antibody|Drug: Rituximab|Drug: Treosulfan|Drug: Fludarabine|Drug: Thiotepa|Drug: Cyclosporine A|Drug: Methotrexate|Drug: Methotrexate","Franco Locatelli|University of Milano Bicocca|medac GmbH|Fresenius AG|Bambino Gesù Hospital and Research Institute","All","up to 64 Years   (Child, Adult)","Phase 2","130","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","OPBG_361.11|2011-004730-34","January 16, 2012","September 2011","October 2016","March 12, 2013","March 2013","No Study Results Posted","null","August 2015","Acute graft-versus-host disease (aGVHD) II-IV and chronic GvHD|Chronic graft-versus-host disease (cGVHD)|Treatment related mortality (TRM)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT01810926"
2228,"NCT01299922","Clinical Trial Treatment in Lupus Nephritis","Withdrawn","No Results Available","Lupus Nephritis","Drug: cyclosporine +mycophenolic acid+prednison|Drug: Mycophenolic Acid + prednison","Hospital Universitario Fundación Alcorcón|Hospital Universitario 12 de Octubre|Hospital General Universitario Gregorio Marañon|Hospital Universitario Ramon y Cajal|Hospital Infanta Sofia|Hospital Universitario Infanta Leonor|Hospital Universitario Reina Sofia|Hospital Regional Universitario Carlos Haya|Hospital Universitario Virgen de la Victoria|University Hospital of the Nuestra Señora de Candelaria|Hospital Universitario de Guadalajara. Spain|Hospital San Pedro Alcantara. Caceres. Spain|Hospital Juan Canalejo","All","18 Years and older   (Adult, Senior)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Csa-LES","February 18, 2011","February 2011","October 2014","February 26, 2015","February 2011","No Study Results Posted","Csa-LES","March 2014","the number of complete remissions, between the triple therapy with cyclosporine-prednisone-mycophenolic acid and conventional therapy with mycophenolic acid-prednisone as induction therapy in patients with lupus nephritis type III-IV-V|the number of partial and complete remissions, between triple therapy with prednisone, cyclosporine, mycophenolic acid and prednisone-mycophenolic acid.|the number of patients with adverse effects|the rate (%) of decline of proteinuria in two groups|the decrease in GFR (ml/min/1.73m2) in both groups","https://ClinicalTrials.gov/show/NCT01299922"
2229,"NCT00161590","Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma","Completed","No Results Available","T-Cell Lymphoma|Lymphoma, Non-Hodgkin's","Drug: CHOP and alemtuzumab","Weill Medical College of Cornell University|Bayer","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0204-157","September 7, 2005","July 2004","null","October 21, 2008","October 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00161590"
2230,"NCT02042690","Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients","Active, not recruiting","No Results Available","Acute Lymphoblastic Leukemia","Procedure: Haplo-identical HSCT|Drug: Chemotherapy","Peking University","All","18 Years to 39 Years   (Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ALL-13","November 29, 2013","January 2014","December 2018","January 20, 2014","January 2014","No Study Results Posted","null","December 2017","Disease-free survival|Rate of cumulative incidence of relapse|Overall survival (OS) rate|Number of Adverse Events","https://ClinicalTrials.gov/show/NCT02042690"
2231,"NCT00274794","VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab","The Cleveland Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","55","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CASE-CCF-3600|P30CA043703|CASE-CCF-0467","January 10, 2006","February 2000","May 2006","March 28, 2011","March 2011","No Study Results Posted","null","May 2006","Correlate CD34+ cell yields with the addition of rituximab|Acute toxicity of rituximab, etoposide, and filgrastim (G-CSF)","https://ClinicalTrials.gov/show/NCT00274794"
2232,"NCT00425724","HSP-glomerulonephritis Trial: MP vs CyA","Completed","No Results Available","Purpura, Schoenlein-Henoch","Drug: Methylprednisolone pulses plus prednisone versus Cyclosporine A","Oulu University Hospital","All","2 Years to 18 Years   (Child, Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","25600","January 22, 2007","January 2000","February 2011","August 5, 2011","August 2011","No Study Results Posted","null","February 2007","Disappearance of proteinuria/ hematuria|Renal function (measured by Cr-EDTA-Cl- GFR)|Renal biopsy findings|Need for additional medication","https://ClinicalTrials.gov/show/NCT00425724"
2233,"NCT00455897","CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma","Terminated","No Results Available","Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Lymphoma, Diffuse","Drug: GM-CSF|Drug: CHOP|Drug: Rituximab","Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Dana-Farber Cancer Institute|Bayer","All","18 Years and older   (Adult, Senior)","Phase 2","5","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05-342","April 2, 2007","December 2006","July 2011","October 23, 2012","October 2012","No Study Results Posted","null","July 2011","To determine the safety of GM-CSF when administered in combination with CHOP-R to patients with previously untreated diffuse large B cell non-Hodgkin's lymphoma.|To assess the response rate, 2-year event-free survival and overall survival with CM-CSF and CHOP-R in this patient population|to analyze the biologic activity of GM-CSF at this dosing schedule and timing.","https://ClinicalTrials.gov/show/NCT00455897"
2234,"NCT00325741","Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus","Unknown status","No Results Available","Lupus Erythematosus, Systemic","Procedure: Hematopoietic Cell Transplantation","National Heart, Lung, and Blood Institute (NHLBI)|City of Hope National Medical Center","All","18 Years to 64 Years   (Adult)","Phase 1","15","NIH|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","368|P01HL075462-02","May 12, 2006","June 2004","July 2010","August 6, 2009","August 2009","No Study Results Posted","null","July 2010","Time to achieve complete remission (participants that are off all immunosuppressive therapy without clinical or laboratory evidence of active disease)|Percentage of patients with stable chimerism in all blood and immune cell lineages|Percentage of participants with acute or chronic graft-versus-host disease","https://ClinicalTrials.gov/show/NCT00325741"
2235,"NCT02126046","Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major","Unknown status","No Results Available","Thalassemia Major","Genetic: unrelated CB following haplo-identical hematopoietic stem cells transplantation","Nanfang Hospital of Southern Medical University","All","12 Months to 18 Years   (Child, Adult)","","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NFTM20130101","April 18, 2014","September 2012","March 2016","April 15, 2015","April 2015","No Study Results Posted","null","December 2015","overall survival（OS）|TM-free survival（TFS）|Transplant Related Martality (TRM)|Primary or Secondary Graft Rejection (GR)|The cumulative incidences of acute graft-versus-host disease（GVHD）|The cumulative incidences of chronic graft vesus host disease (cGVHD)","https://ClinicalTrials.gov/show/NCT02126046"
2236,"NCT00001430","A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas","Completed","No Results Available","Hodgkin's Disease|Non Hodgkin's Lymphoma","Procedure: PBSC|Drug: IL-2|Drug: EPOCH II","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","49","NIH","Interventional","Primary Purpose: Treatment","950073|95-C-0073","November 3, 1999","February 1995","January 2002","March 3, 2008","January 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001430"
2237,"NCT00001761","Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis","Completed","No Results Available","Vasculitis|Wegener's Granulomatosis","Drug: Interleukin-10","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 1","15","NIH","Interventional","Primary Purpose: Treatment","980059|98-I-0059","November 3, 1999","February 1998","April 2000","March 3, 2008","January 1999","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001761"
2238,"NCT00784589","Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus","Active, not recruiting","No Results Available","Pemphigus Disease","Drug: General Corticotherapy|Drug: Rituximab","University Hospital, Rouen","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2008/068/HP","November 3, 2008","July 2009","December 2016","November 9, 2016","November 2016","No Study Results Posted","Rituximab 3","December 2013","Number of patients with pemphigus controlled 24 months after the start of Rituximab treatment|Number of patients with pemphigus with both cutaneous and mucosal lesions healing after 6 months of rituximab treatment","https://ClinicalTrials.gov/show/NCT00784589"
2239,"NCT00224614","Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia","Unknown status","No Results Available","Leukemia, Myeloid, Acute","Procedure: Allogenic transplantation","Assistance Publique - Hôpitaux de Paris","All","35 Years to 55 Years   (Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","P040420|AOM04088","September 16, 2005","July 2005","July 2009","December 13, 2005","June 2005","No Study Results Posted","null","null","To show that NMA graft reduces mortality related to the procedure to 10%, compared to 30% waited in the arm of reference (α : 5%; p: 80%; bilateral formulation), 50 patients will be included in each arm|1- global survival, without relapse, and the various complications of the graft at 2 years 2- quality of life 3- the cost. 4- kinetics of the chimerism donor/receiver and his predictive value of the relapse and the reaction of the graft against the host.","https://ClinicalTrials.gov/show/NCT00224614"
2240,"NCT03016806","Combined Cord Blood Transplant","Recruiting","No Results Available","Acute Leukemia|Immune Deficiency Disorder|Congenital Hematological Disorder|Metabolism Disorder|Aplastic Anemia|Myelodysplastic Syndromes|Chronic Leukemia|Lymphoma|Multiple Myeloma|Solid Tumor","Radiation: Total Body Irradiation 1200 cGy|Radiation: Total Body Irradiation 200 cGy|Drug: Cyclophosphamide|Drug: Mesna|Procedure: Cord Blood Infusion|Drug: Busulfan|Drug: Fludarabine|Drug: Melphalan","University of Rochester","All","2 Months to 75 Years   (Child, Adult, Senior)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UBMT 15029","December 26, 2016","June 2015","June 2026","January 7, 2017","January 2017","No Study Results Posted","Cord Tx","June 2025","Engraftment of ANC and Platelets|Rate of non-engraftment and of secondary graft failure|Incidence of acute graft-versus-host disease|Incidence of chronic graft-versus-host disease|Disease-free survival","https://ClinicalTrials.gov/show/NCT03016806"
2241,"NCT01026220","Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma","Active, not recruiting","No Results Available","Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma","Biological: bleomycin sulfate|Drug: doxorubicin hydrochloride|Drug: liposomal vincristine sulfate|Drug: vinorelbine tartrate|Drug: cyclophosphamide|Drug: etoposide phosphate|Drug: prednisone|Biological: filgrastim|Drug: ifosfamide","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","166","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AHOD0831|NCI-2011-01994|CDR0000660550|U10CA098543","December 3, 2009","December 2009","null","November 10, 2016","November 2016","No Study Results Posted","null","March 2012","Second-event-free survival|Safety analysis and monitoring of toxic death|EFS of 93%|Achieve a similar outcome for patients with RER and SER through intensification of therapy for SER patients|Prognostic significance of ""very early response"" as assessed by PET scan|Patterns of relapse after ABVE-PC and risk-adapted RT|Grade 3 and 4 non-hematologic toxicities|Overall survival","https://ClinicalTrials.gov/show/NCT01026220"
2242,"NCT00418535","Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma","Completed","No Results Available","Lymphoma, T-Cell","Drug: Concurrent Radiotherapy (RT)/cisplatin, VIPD","Samsung Medical Center|Korea University Anam Hospital|Asan Medical Center|Gyeongsang National University Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2004-10-08","January 3, 2007","April 2006","July 2009","October 20, 2009","January 2007","No Study Results Posted","null","March 2009","","https://ClinicalTrials.gov/show/NCT00418535"
2243,"NCT00378534","Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants","Completed","Has Results","Chronic Myelogenous Leukemia|Acute Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome","Device: Miltenyi reagent system|Drug: Fludarabine|Drug: Cyclosporine|Drug: Cyclophosphamide","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","10 Years to 75 Years   (Child, Adult, Senior)","Phase 2","115","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","060248|06-H-0248","September 19, 2006","September 2006","April 2014","October 5, 2015","December 2014","December 22, 2014","null","April 2014","Survival and Non-relapse Mortality at Day +200 Using the Miltenyi Reagent System|Standard Transplant Outcome Variables Such as Non-hematologic Toxicity, Incidence and Severity of Acute and Chronic GVHD and Relapse of Disease.","https://ClinicalTrials.gov/show/NCT00378534"
2244,"NCT00301613","Mycophenolate Mofetil (MMF) Versus Intravenous CTX Pulses in the Treatment of Adult Severe HSPN","Completed","No Results Available","Henoch-Schoenlein Purpura|Nephritis","Drug: Mycophenolate mofetil","Nanjing University School of Medicine","All","16 Years to 50 Years   (Child, Adult)","","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NJCT-0605","March 10, 2006","January 2003","January 2006","May 25, 2010","July 2008","No Study Results Posted","null","May 2005","To compare the efficacy,safety, tolerability and relapse of MMF vs CTX in the treatment of severe HSPN","https://ClinicalTrials.gov/show/NCT00301613"
2245,"NCT00001789","BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis","Completed","No Results Available","Glomerulonephritis, Membranoproliferative|Lupus Nephritis","Drug: BG9588","National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","20","NIH","Interventional","Primary Purpose: Treatment","990133|99-AR-0133","November 3, 1999","June 1999","May 2000","March 3, 2008","June 1999","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001789"
2246,"NCT00002548","SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma","Completed","No Results Available","Multiple Myeloma","Biological: recombinant interferon alfa|Drug: carmustine|Drug: cyclophosphamide|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: melphalan|Drug: prednisone|Drug: vincristine sulfate|Procedure: allogeneic bone marrow transplantation|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","899","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SWOG-9321|CLB-9312|E-S9321|INT-0141|U10CA032102","November 1, 1999","January 1994","November 2006","March 5, 2015","March 2015","No Study Results Posted","null","October 2003","survival","https://ClinicalTrials.gov/show/NCT00002548"
2247,"NCT01325194","CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis","Recruiting","No Results Available","Primary Disease","Drug: liposomal cytarabine","Nordic Lymphoma Group|Mundipharma Pte Ltd.|Amgen","All","18 Years to 64 Years   (Adult)","Phase 2","150","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NLG-LBC-05","March 14, 2011","March 2011","December 2017","September 27, 2014","September 2014","No Study Results Posted","CHIC","December 2014","Time to treatment failure|Maximal hematological, gastrointestinal, neuronal and other toxicities|Clinical response rate|Incidence of central nervous system(CNS) relapse in cerebrospinal fluid (CSF )cytology neg/flow cytometry positive cases|Incidence of CNS relapse in a subgroup of patients with more than one extranodal site and elevated lactate dehydrogenase (LDH)|Progression free survival|Overall survival|Molecular predictors|CNS relapse rate","https://ClinicalTrials.gov/show/NCT01325194"
2248,"NCT00567567","Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma","Active, not recruiting","No Results Available","Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Recurrent Neuroblastoma|Regional Neuroblastoma|Stage 4 Neuroblastoma|Stage 4S Neuroblastoma","Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Carboplatin|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Radiation: External Beam Radiation Therapy|Biological: Filgrastim|Drug: Isotretinoin|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Procedure: Peripheral Blood Stem Cell Transplantation|Other: Pharmacological Study|Drug: Thiotepa|Drug: Topotecan Hydrochloride|Drug: Vincristine Sulfate Liposome","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","Phase 3","665","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ANBL0532|NCI-2009-01065|CDR0000576571|COG-ANBL0532|U10CA098543","December 4, 2007","November 2007","null","January 13, 2017","January 2017","No Study Results Posted","null","February 2015","Event-free survival rate|Incidence rate of local recurrence|Response after induction therapy|Duration of greater than or equal to grade 3 neutropenia|Duration of greater than or equal to grade 3 thrombocytopenia|EFS in patients 12-18 months, stage 4, MYCN nonamplified tumor/unfavorable histopathology/diploid DNA content/indeterminant histology/ploidy and patients > 547 days, stage 3, MYCN nonamplified tumor AND unfavorable histopathology/indeterminant histology|Enumeration of peripheral blood cluster of differentiation (CD)3, CD4, and CD8 cells|Neurologic symptom resolution in patients with primary tumors with intraspinal extension|OS in patients 12-18 months, stage 4, MYCN nonamplified tumor/unfavorable histopathology/diploid DNA content/indeterminant histology/ploidy and patients > 547 days, stage 3, MYCN nonamplified tumor AND unfavorable histopathology/indeterminant histology|Peak serum concentration of isotretinoin in patients enrolled on either A3973, ANBL0032, ANBL0931, ANBL0532 and future high risk studies|Pharmacogenetic variants in patients enrolled on either A3973, ANBL0032, ANBL0931, ANBL0532 and future high risk studies|Presence and function of T cells capable of recognizing neuroblastoma|Proportion of patients with neuroblastoma detected in bone marrow and peripheral blood using RT-PCR technique|Response rate|Surgical response|Topotecan systemic clearance|Type of radiotherapy complication|Type of surgical complication","https://ClinicalTrials.gov/show/NCT00567567"
2249,"NCT00450892","Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: docetaxel+lapatinib|Drug: docetaxel + trastuzumab|Drug: docetaxel + trastuzumab + lapatinib","European Organisation for Research and Treatment of Cancer - EORTC|GlaxoSmithKline","Female","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","129","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-10054|GSK-EORTC-10054|2006-000864-94","March 20, 2007","February 2007","July 2013","July 6, 2016","July 2016","No Study Results Posted","null","July 2013","Phase I part: Dose limiting toxicity during cycle 1|Phase II: Pathological complete response rate|Phase I: Changes in apoptosis and proliferation markers.|Phase II: Tolerability, clinical/radiological response rates, breast conserving surgery, pharmacodynamics data","https://ClinicalTrials.gov/show/NCT00450892"
2250,"NCT00986518","T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study","Completed","No Results Available","Colorectal Cancer","Biological: Adaptive autologous cell immunotherapy","Assistance Publique - Hôpitaux de Paris","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P080601","September 29, 2009","October 2012","February 2013","November 21, 2013","September 2013","No Study Results Posted","STARTREK","February 2013","Tumor size of hepatic and/or lung metastases, as measured with tomodensitometry (RECIST 1.1 criteria)|MRI : Assessment of tumor necrosis, cellularity and morphological criteria RECIST 1.1 (functional criteria following injection : DCEMRI and diffusion MRI)|Sonography : assessment of vascular micro-circulation with contrast injection,|Immune cell reconstitution will be assessed through measuring rate of regulatory T-cell reconstitution,|Clinical Exam (WHO-CTC), Vital Signs, Adverse events|Laboratory test: hepatic function, immune function, haematology","https://ClinicalTrials.gov/show/NCT00986518"
2251,"NCT00293072","Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis","Completed","No Results Available","Systemic Lupus Erythematosus|ANCA Associated Vasculitis","Drug: Rituximab","Cambridge University Hospitals NHS Foundation Trust|Roche Pharma AG","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pilot study of Rituximab","February 16, 2006","March 2002","May 2005","February 16, 2006","October 2005","No Study Results Posted","null","null","1. Clinical remission at 6 or 12 months|2. Absence of a severe life threatening adverse event","https://ClinicalTrials.gov/show/NCT00293072"
2252,"NCT02840890","Osteopathy and Prevention of Gastrointestinal Side Effects in Women Treated for Breast Cancer","Recruiting","No Results Available","Breast Cancer","Procedure: osteopathic technique|Procedure: Placebo","Centre Georges Francois Leclerc","Female","18 Years to 99 Years   (Adult, Senior)","","94","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PREDIGOSTEO","April 22, 2016","November 2015","June 2018","July 19, 2016","April 2016","No Study Results Posted","PREDIGOSTEO","November 2017","episode of nausea and / or vomiting|episode of constipation|Quality of life questionnaire(QLQ-C30)","https://ClinicalTrials.gov/show/NCT02840890"
2253,"NCT00863460","Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients","Active, not recruiting","No Results Available","Primary Central Nervous System Lymphoma","Radiation: cranial radiotherapy|Drug: intensive chemotherapy and hematopoietic stem cell rescue|Drug: MTX based chemotherapy","Institut Curie|Ministry of Health, France|Hoffmann-La Roche|Amgen|Pierre Fabre Laboratories","All","18 Years to 60 Years   (Adult)","Phase 2","140","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CRH 07/422/H|EudraCT N° 2007-005378-30","March 16, 2009","October 2008","February 2025","January 23, 2017","January 2017","No Study Results Posted","PRECIS","August 2017","2-years progression-free survival in each arm|Overall response rate at the end of the procedure|Overall survival|Event-free survival|Neurotoxicity","https://ClinicalTrials.gov/show/NCT00863460"
2254,"NCT02861859","Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study","Recruiting","No Results Available","Breast Cancer","Drug: Olanzapine|Drug: Olanzapine Placebo","Ottawa Hospital Research Institute","All","18 Years and older   (Adult, Senior)","Phase 3","362","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OTT 16-05","July 13, 2016","December 2016","December 2020","January 10, 2017","January 2017","No Study Results Posted","null","December 2019","High personal risk of Chemotherapy-induced nausea and vomiting|High personal risk overall total control of Chemotherapy-induced nausea and vomiting|Improvement of patient Health Related Quality of Life by completing a patient diary and quality of life questionnaire in the high risk cohort|Safety of olanzapine with respect to sedation and extrapyramidal side effects in the high risk cohort","https://ClinicalTrials.gov/show/NCT02861859"
2255,"NCT02603679","Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases","Recruiting","No Results Available","Early-Stage Breast Carcinoma|Estrogen Receptor Positive Tumor","Drug: Paclitaxel|Drug: Tamoxifen + Palbociclib|Drug: Aromatase Inhibitor + Palbociclib|Drug: Goserelin + Aromatase Inhibitor + Palbociclib","Thomas Hatschek|Karolinska University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PREDIX LumB","November 4, 2015","February 2015","June 2024","September 6, 2016","September 2016","No Study Results Posted","PREDIX LumB","June 2018","Radiological Objective Response Rate after Completion of the First 12-week Period of Primary Medical Treatment|Pathological Objective Response Rate|Sequencing of Chemotherapy versus Endocrine Treatment plus Palbociclib in relation to Radiological Objective Response Rate after Completion of the 24-week Period of Primary Medical Treatment|Disease-Free Survival|Breast Cancer-Specific Survival|Overall Survival|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Health-Related Quality of Life|Frequency of Breast-Conserving Surgery|Characteristics of the Genome of Previously Untreated Tumors Before and After Exposition to Treatment|Changes of the Proteome of Previously Untreated Tumors Before and After Exposition to Treatment|Quantification of Hormone Receptors Before and After Treatment|Quantification of Proliferation Beforew and After Treatment","https://ClinicalTrials.gov/show/NCT02603679"
2256,"NCT02028650","Randomized Study of HLA-mismatched DSI to Treat Relapse Leukemia After HLA- Matched Transplantation","Completed","No Results Available","Relapse Leukemia","Biological: the first donor's stem cell|Biological: the second donor's stem cell","huishengai|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences","All","9 Years to 67 Years   (Child, Adult, Senior)","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","RL13-307PLAH-AHS","January 1, 2014","February 2005","October 2014","July 12, 2016","July 2016","No Study Results Posted","null","February 2013","Number of Participants with graft versus host diseases|Time to Disease Progression","https://ClinicalTrials.gov/show/NCT02028650"
2257,"NCT00965276","Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer","Completed","No Results Available","Breast Cancer","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","","2500","NIH","Observational","","040088|04-C-0088","August 24, 2009","January 13, 2004","December 14, 2010","January 24, 2017","December 14, 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00965276"
2258,"NCT00005092","Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: Cyclophosphamide|Drug: Psoralen|Drug: Thiotepa|Procedure: Allogeneic bone marrow transplantation|Procedure: In vitro-treated peripheral blood stem cell transplantation (PBSCT)|Radiation: Radiation Therapy (RT)","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","up to 49 Years   (Child, Adult)","Phase 1","7","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM98-283|P30CA016672|MDA-DM-98283|NCI-G00-1742|CDR0000067734","April 6, 2000","March 1999","August 2002","July 27, 2012","July 2012","No Study Results Posted","null","August 2002","Maximum Tolerated Dose (MTD) of T-cells photochemically treated with psoralen and ultraviolet A","https://ClinicalTrials.gov/show/NCT00005092"
2259,"NCT00877747","Early Chemotherapy Intensification in Interim-Positron Emission Tomography (PET) Positive Hodgkin Lymphoma","Active, not recruiting","No Results Available","Hodgkin Lymphoma","","Ospedale Santa Croce-Carle Cuneo","All","16 Years to 80 Years   (Child, Adult, Senior)","","160","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","HD-PET-intens-retr","April 7, 2009","January 2006","October 2015","October 16, 2015","October 2015","No Study Results Posted","null","November 2014","Progression Free Survival|Incidence of progression/relapse|Interim PET positive and negative predictive value","https://ClinicalTrials.gov/show/NCT00877747"
2260,"NCT01858259","Treatment and Prevention of Progression of Interstitial Lung Disease in Systemic Sclerosis","Unknown status","No Results Available","Systemic Sclerosis|Interstitial Lung Diseases","","Gabriela Riemekasten|European Union|University of Giessen|University of Zurich|University of Paris 5 - Rene Descartes|University of Florence|Second University of Naples|University of Basel|University College, London|Charite University, Berlin, Germany|University of Pecs|University of Leeds|Schoen Klinik Hamburg Eilbek","All","Child, Adult, Senior","","1372","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HEALTH-F5-2012-305495-OT3","May 14, 2013","May 2013","June 2016","August 12, 2014","August 2014","No Study Results Posted","null","June 2016","Proportion of patients with 10% decline in FVC|The time to a 15% decline in DLCO or a drop <55% of predicted lung function|The mortality due to lung fibrosis|The need for oxygen support","https://ClinicalTrials.gov/show/NCT01858259"
2261,"NCT01105650","Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer","Completed","Has Results","Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer|Breast Cancer","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Cyclosporine|Biological: Natural killer cells|Drug: IL-2|Drug: Methylprednisolone|Drug: Methylprednisolone|Drug: Interleukin-2","Masonic Cancer Center, University of Minnesota","Female","18 Years and older   (Adult, Senior)","Phase 2","13","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2009LS142|MT2009-30|1003M78876","April 14, 2010","July 2010","April 2014","February 27, 2017","February 2016","January 4, 2017","null","April 2014","Response Rate|Time to Disease Progression|Number of Participants With Progressive Disease at One Year|Overall Survival","https://ClinicalTrials.gov/show/NCT01105650"
2262,"NCT01358747","Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL","Completed","No Results Available","Hodgkin's Lymphoma","Drug: BEACOPPesc|Drug: BEACOPPesc - ABVD - PET2","Centre Hospitalier Universitaire Dijon|The Lymphoma Study Association","All","16 Years to 60 Years   (Child, Adult)","Phase 3","null","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment","Casasnovas PHRC N 2010","May 11, 2011","May 2011","null","May 20, 2014","January 2013","No Study Results Posted","AHL 2011","null","Progression free survival","https://ClinicalTrials.gov/show/NCT01358747"
2263,"NCT02387099","Dose EScalation Induction of EvERolimus","Recruiting","No Results Available","Breast Cancer|Hormone Receptor Positive Tumor","Drug: 3 weeks Dose Induction of Everolimus|Drug: 3 weeks Conventional Everolimus Dosing|Drug: Open Label Phase with conventional 10mg Everolimus Dosing week 4-24|Drug: Standard Care after 24 weeks","German Breast Group|Novartis","Female","18 Years and older   (Adult, Senior)","Phase 2","156","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GBG 86","March 5, 2015","May 2015","March 2018","February 9, 2016","February 2016","No Study Results Posted","Desiree","March 2018","cumulative rate Mucositis grade 2-4 (WHO's oral toxicity scale (OTS))|cumulative rate Mucositis any grade (WHO's oral toxicity scale (OTS))|Patients on conventional dose Everolimus 10mg|Clinical Benefit Rate (CBR)|Safety other than Mucositis|Time to Mucositis grade 2-4 (WHO's oral toxicity scale (OTS))|Cumulative Dose|RDI|QoL FACTB|QoL QSDQ","https://ClinicalTrials.gov/show/NCT02387099"
2264,"NCT02278796","A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)","Recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular|Lymphoma, Mantle-Cell","Drug: BeEAM|Drug: BEAM","University Hospital Inselspital, Berne|Hanusk Krankenhaus Wien","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","98","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EudraCT2014-.003629-16|2014-003629-16","October 15, 2014","April 2015","October 2017","August 18, 2016","August 2016","No Study Results Posted","BEB","October 2017","Number of patients with a clinically meaningful reduction in lung toxicity, defined as a reduction of the diffusion capacity of the lung for carbon monoxide (DLCO) by at least 15%.|Number of patients with acute and late toxicity/adverse events (CTCAE4)|Number of patients with hematologic recovery and engraftment|Change from baseline in ECHO/ECG|Change from baseline in quality of life|Number of patients with overall survival|Number of patients with progression free survival","https://ClinicalTrials.gov/show/NCT02278796"
2265,"NCT01134432","Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia","Completed","No Results Available","Anemia, Hemolytic, Autoimmune","Drug: prednisolone + mabthera|Drug: Prednisolone","Copenhagen University Hospital at Herlev","All","18 Years and older   (Adult, Senior)","Phase 3","65","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AIHA-KA04062-gms","May 28, 2010","March 2005","July 2012","September 9, 2013","September 2013","No Study Results Posted","null","July 2012","Number of patients in each group in complete or partial remission|Side effects","https://ClinicalTrials.gov/show/NCT01134432"
2266,"NCT01595048","Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia","Active, not recruiting","No Results Available","Childhood B Acute Lymphoblastic Leukemia|Childhood Burkitt Leukemia|Childhood Diffuse Large Cell Lymphoma|Mediastinal (Thymic) Large B-Cell Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage IV Childhood Large Cell Lymphoma","Biological: Rituximab|Drug: Prednisone|Drug: Etoposide|Drug: Doxorubicin Hydrochloride|Drug: Cytarabine|Drug: Vincristine Sulfate|Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Methylprednisolone|Drug: Leucovorin Calcium|Drug: Therapeutic Hydrocortisone|Other: Laboratory Biomarker Analysis","Children's Oncology Group|National Cancer Institute (NCI)","All","6 Months to 17 Years   (Child)","Phase 2|Phase 3","640","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ANHL1131|NCI-2012-01963|CDR0000732604|IGR2009/1593|2010-019224-31|U10CA098543|U10CA180886","May 8, 2012","June 2012","December 2020","October 24, 2016","October 2016","No Study Results Posted","null","December 2020","EFS|Survival|Complete remission rate compared between arms by logistic regression|Acute and long-term toxicity as assessed by the National Cancer Institute Common Terminology Criteria version 4.0|Immune reconstitution as assessed by Ig (G, A, and M) levels and lymphocyte counts","https://ClinicalTrials.gov/show/NCT01595048"
2267,"NCT02849912","Signal Detection in Monoclonal and New Agents in Lymphoma","Completed","No Results Available","Lymphoma","Other: questionnaire","Centre Hospitalier Universitaire de Nice","All","18 Years to 90 Years   (Adult, Senior)","","1671","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","12-PP-09","July 22, 2016","April 2015","September 2015","July 26, 2016","July 2016","No Study Results Posted","SIMONAL","April 2015","Health problems|health care use","https://ClinicalTrials.gov/show/NCT02849912"
2268,"NCT02280902","Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases","Recruiting","No Results Available","Immunologic and Inflammatory Diseases","Biological: Blood samples","University Hospital, Bordeaux|Ministry for Health and Solidarity, France","All","18 Years and older   (Adult, Senior)","","217","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CHUBX 2013/25","September 19, 2014","February 2016","February 2020","December 22, 2016","December 2016","No Study Results Posted","INFIM","February 2020","Viral, bacterila, fungal or parasitic infection leading to hospitalization|Biological and immunological markers|Morbidity","https://ClinicalTrials.gov/show/NCT02280902"
2269,"NCT01655875","AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia","Terminated","No Results Available","Pediatric Acute Myeloblastic Leukemia, Relapsed|Pediatric Acute Lymphoblastic Leukemia, Relapsed","Drug: AMD3100","Emory University","All","2 Years to 22 Years   (Child, Adult)","Phase 1","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB00053638|CHOA AMD3100 Pilot","July 27, 2012","June 2012","April 2014","April 4, 2014","April 2014","No Study Results Posted","BMTAMD3100","April 2014","AMD3100 safety|AMD3100 correlative biology analyses","https://ClinicalTrials.gov/show/NCT01655875"
2270,"NCT01268033","Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood","Completed","No Results Available","Childhood Idiopathic Nephrotic Syndrome","Drug: Rituximab|Drug: Placebo","University Hospital, Limoges|Hoffmann-La Roche","All","2 Years to 18 Years   (Child, Adult)","Phase 2|Phase 3","26","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","I08013","December 15, 2010","December 2010","May 2014","March 20, 2015","March 2015","No Study Results Posted","NEPHRUTIX","May 2014","Proteinuria with relapse of nephrotic syndrome (Serum albumin < 30 g/L) within 5 months|- dosing of rituximab for toxicity during and/or after infusion|- dosing of rituximab for pharmacokinetics|- dosing of lymphocyte|Pediatric Quality of life inventory","https://ClinicalTrials.gov/show/NCT01268033"
2271,"NCT01652092","Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies","Recruiting","No Results Available","SCID|Omenn's Syndrome|Reticular Dysgenesis|Wiskott-Aldrich Syndrome|Bare Lymphocyte Syndrome|Common Variable Immunodeficiency|Chronic Granulomatous Disease|CD40 Ligand Deficiency|Hyper IgM Syndrome|X-linked Lymphoproliferative Disease|Hemophagocytic Lymphohistiocytosis|Griscelli Syndrome|Chediak-Higashi Syndrome|Langerhan's Cell Histiocytosis","Drug: Alemtuzumab 0.3 mg|Drug: Cyclophosphamide|Drug: Busulfan|Biological: Stem Cell Transplantation|Drug: Fludarabine phosphate 40 mg|Drug: Melphalan|Drug: Alemtuzumab 0.2 mg|Drug: Busulfan|Drug: Fludarabine phosphate 30 mg|Drug: MESNA","Masonic Cancer Center, University of Minnesota","All","up to 50 Years   (Child, Adult)","","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2012OC055|MT2012-10C","July 25, 2012","September 4, 2012","December 2020","February 17, 2017","February 2017","No Study Results Posted","null","December 2018","Neutrophil Engraftment|Incidence of Graft Failure|Incidence of Chimerism|Incidence of Acute Graft-Versus-Host Disease|Incidence of Chronic Graft-Versus-Host Disease|Incidence of Transplant-Related Mortality|Disease-Free Survival|Overall Survival","https://ClinicalTrials.gov/show/NCT01652092"
2272,"NCT00799799","Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells","Unknown status","No Results Available","Myeloblastic Leukemia","Biological: NK cells","University of Bologna","All","18 Years and older   (Adult, Senior)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NK TRIAL","November 28, 2008","October 2005","December 2009","September 23, 2009","September 2009","No Study Results Posted","null","December 2009","To assess the feasibility of the selection and reinfusion of 5x10E6 haploidentical natural killer (NK) cells /Kg of body weight (target cell dose) in at least 40% of adult patients with active acute myeloblastic leukemia (AML) entering the study|To assess the feasibility of the reinfusion of the minimum accepted cell dose (1x10E6 haploidentical NK cells /Kg) in all patients enrolled into the protocol|To evaluate the microchimerism of AML patients receiving haploidentical human NK cells for adoptive immunotherapy|To evaluate, in vitro and in vivo, the antitumor activity of haploidentical NK cells infused in AML patients|To assess the percentage of patients entering complete remission (CR) after the reinfusion of highly purified haploidentical NK cells|To assess the disease-free and overall survival of AML patients infused with haploidentical NK cells|To assess the safety of infusion of haploidentical NK cells, following immunosuppressive chemotherapy, considered as the incidence of adverse event (graded according to WHO) and clinically significant abnormal laboratory values following reinfusion","https://ClinicalTrials.gov/show/NCT00799799"
2273,"NCT02617485","MabionCD20® Compared to MabThera® in Lymphoma Patients","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Rituximab|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: prednisone","Mabion SA","All","18 Years and older   (Adult, Senior)","Phase 3","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MabionCD20-002NHL","November 12, 2015","December 2015","June 2017","June 1, 2016","May 2016","No Study Results Posted","null","December 2016","Area under the plasma concentration- time curve from time zero to final time point","https://ClinicalTrials.gov/show/NCT02617485"
2274,"NCT01306955","The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease","Unknown status","No Results Available","Behcet's Disease","Drug: methylorednisolone|Other: dextrose water 5%","Tehran University of Medical Sciences","All","10 Years to 70 Years   (Child, Adult, Senior)","Phase 4","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11192","March 1, 2011","February 2010","August 2011","March 1, 2011","March 2011","No Study Results Posted","null","July 2011","OCULAR IBDDAM INDEX|VISUAL ACUITY|Inflammation in retin|Inflammation in posterior chamber|inflammation in anterior chamber","https://ClinicalTrials.gov/show/NCT01306955"
2275,"NCT00427245","Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer","Completed","No Results Available","Breast Cancer|Infertility|Menopausal Symptoms","Drug: cyclophosphamide|Drug: goserelin acetate|Procedure: adjuvant therapy|Procedure: fertility assessment and management|Procedure: neoadjuvant therapy","Anglo Celtic Cooperative Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","400","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Supportive Care","CRUK-OPTION|CDR0000526368|EUDRACT-2004-000133-11|CRUK-BR0402|ISRCTN84856516|EU-20680","January 25, 2007","August 2004","null","August 6, 2013","May 2007","No Study Results Posted","null","null","Rate of premature menopause, defined as cessation of menses during a course of chemotherapy with no recovery for at least 12 months|Incidence of menopausal symptoms|Quality of life|Bone mineral density loss as measured by dual energy X-ray absorptiometry scans at 12, 24, and 36 months and by serum biomarkers|Hormone levels (including follicle-stimulating hormone, luteinizing hormone, beta-inhibin, and estradiol) as measured after course 3, after course 6 or 8 (depending on chemotherapy regimen), at 9 and 12 months, and then annually for up to 5 years|Menstruation history as measured by patient menstrual diary for 24 months from the start of chemotherapy|Incidence of pregnancy","https://ClinicalTrials.gov/show/NCT00427245"
2276,"NCT00278577","Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease","Terminated","No Results Available","CROHN'S DISEASE","Biological: Immune Ablation and Hematopoietic Stem Cell Support","Richard Burt, MD|Northwestern University","All","up to 60 Years   (Child, Adult)","Phase 1","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NU 97CD1","January 15, 2006","April 2001","February 2012","February 4, 2014","April 2013","No Study Results Posted","null","February 2012","11.1 CDAI - If the index worsens by 50 points for more than 4 weeks, the disease will be considered progressive; if it improves by 70 points for more than four weeks, it will be considered improved; otherwise it will be considered stable.","https://ClinicalTrials.gov/show/NCT00278577"
2277,"NCT02765789","Immunoadsorption in Anti-GBM Glomerulonephritis.","Not yet recruiting","No Results Available","Anti-glomerular Basement Membrane Glomerulonephritis","Device: Immunoadsorption (Immunosorba)","University Medical Center Groningen|Fresenius Medical Care North America","All","18 Years and older   (Adult, Senior)","Phase 4","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201500361","May 3, 2016","June 2016","December 2018","May 6, 2016","May 2016","No Study Results Posted","null","December 2018","Number of days that anti-GBM antibody titre is above a toxic level, defined as >30 ELISA units.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Logistic feasibility defined as the time interval between diagnosis and start of first immunoadsorption treatment.|Costs of immunoadsorption (personnel and materials).","https://ClinicalTrials.gov/show/NCT02765789"
2278,"NCT00001193","A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer","Completed","No Results Available","Breast Neoplasms|Neoplasm Metastasis","Procedure: high dose melphalan and autologous bone marrow transplantation","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","200","NIH","Interventional","Primary Purpose: Treatment","840216|84-C-0216","November 3, 1999","November 1984","September 2000","March 3, 2008","August 1999","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001193"
2279,"NCT00447265","Etanercept for the Treatment of Lupus Nephritis","Terminated","Has Results","Lupus Nephritis","Drug: Etanercept|Drug: Lupus Treatment- Standard of Care|Drug: Placebo","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","1","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider)|Primary Purpose: Treatment","DAIT ALN01","March 12, 2007","February 2008","March 2009","February 6, 2013","February 2013","October 7, 2011","null","March 2009","Number of Adverse Events (AEs)Grade 3 or Higher Experienced by Participant During Treatment Phase of Study|Number of Participant Adverse Events (AEs) From Baseline to Early Study Withdrawal Visit|Percent of Participants Who Achieved a Renal Response at Week 24|Time to Participant's Renal Response|Participant Systematic Lupus Erythematosus Disease Activity Index (SLEDAI) Score at Baseline and at Early Study Withdrawal Visit|Number of Participants With a C to B Score Change From Baseline to Week 24 in the British Isles Lupus Assessment Group (BILAG) Mucocutaneous Score|Number of Participants With a B to D Change From Baseline to Week 24 in the British Isles Lupus Assessment Group (BILAG) Musculoskeletal Score|Number of Participants With an A to B Score Change From Baseline to Week 24 in the British Isles Lupus Assessment Group (BILAG) Renal Score|Participant Medical Outcome Study Short-Form 36 (SF-36) Physical Component Score at Baseline and Week 24|Participant Medical Outcome Study Short Form 36 (SF-36) Mental Component Score at Baseline and Week 24","https://ClinicalTrials.gov/show/NCT00447265"
2280,"NCT00084695","Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases","Unknown status","No Results Available","Childhood Langerhans Cell Histiocytosis|Fanconi Anemia|Leukemia|Lymphoma|Myelodysplastic Syndromes|Neuroblastoma|Sarcoma|Unspecified Childhood Solid Tumor, Protocol Specific","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: melphalan|Drug: methylprednisolone|Radiation: radiation therapy","Milton S. Hershey Medical Center|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 2","25","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000365544|PSCI-2003-232","June 10, 2004","September 2003","null","January 9, 2014","October 2008","No Study Results Posted","null","December 2012","Impact of the use of umbilical cord blood as a source of hematopoietic stem cells|Comparison of the incidence of graft-vs-host disease with historical data|Comparison of the incidence of engraftment with historical data","https://ClinicalTrials.gov/show/NCT00084695"
2281,"NCT01238328","Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis","Unknown status","No Results Available","Mucopolysaccharidosis","Drug: Conditioning regimen|Drug: Graft-versus-host disease (GVHD) prophylaxis|Procedure: Stem Cell Transplantation","Tehran University of Medical Sciences","All","up to 8 Years   (Child)","Phase 2|Phase 3","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HORCSCT-0906","November 8, 2010","September 2009","December 2012","May 31, 2012","May 2012","No Study Results Posted","null","September 2012","Overall Survival and Progressive Free Survival in patient with Mucopolysaccharidosis who receive allogeneic Hematopoietic stem cell transplantation (HSCT)|One year overall survival after allogeneic hematopoietic stem cell transplantation (HSCT)|One year Progressive Free Survival after allogeneic hematopoietic stem cell transplantation (HSCT)|Transplantation Related Mortality (TRM) after allogeneic hematopoietic stem cell transplantation (HSCT)|Acute and chronic Graft-versus-host disease (GVHD) rate after allogeneic hematopoietic stem cell transplantation (HSCT)","https://ClinicalTrials.gov/show/NCT01238328"
2282,"NCT00626197","A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)","Completed","No Results Available","Lupus Nephritis|Systemic Lupus Erythematosus","Drug: corticosteroids|Drug: cyclophosphamide|Drug: mycophenolate mofetil|Drug: ocrelizumab|Drug: placebo","Genentech, Inc.|Roche Pharma AG","All","16 Years and older   (Child, Adult, Senior)","Phase 3","381","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator, Outcomes Assessor|Primary Purpose: Treatment","ACT4072g|WA20500","February 20, 2008","February 2008","October 2013","May 9, 2017","May 2017","No Study Results Posted","BELONG","October 2009","Patients who achieve a complete renal response (CRR)|Patients who achieve a partial renal response (PRR)|Proportion of patients who achieve a renal response, major clinical response, or partial clinical response|Proportion of patients who achieve a reduction from baseline in SLEDAI 2K score, no worsening in physician's global assessment, no new BILAG A organ domain score, and no more than 1 new BILAG B organ domain score|Change in SF-36 subscale FACTIT-Fatigue assessment, change from baseline in pain quality, and impact of pain on daily function|Proportion of patients who achieve a CRR or PRR and who have received a daily dose of corticosteroids from Week 24 and average corticosteroid burden","https://ClinicalTrials.gov/show/NCT00626197"
2283,"NCT00925821","Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Procedure: allogeneic stem cell transplant versus second autologous transplantation|Drug: RAD","Wuerzburg University Hospital|ClinAssess GmbH|Celgene Corporation|Amgen|medac GmbH","All","18 Years to 65 Years   (Adult)","Phase 2","146","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DSMM XII","June 16, 2009","June 2009","null","June 27, 2012","June 2012","No Study Results Posted","null","null","Response rate to RAD induction and transplant (stringent CR, CR, very good PR)|Progression-free survival (PFS)|Incidence and relationship of severe adverse events","https://ClinicalTrials.gov/show/NCT00925821"
2284,"NCT00578903","Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia","Terminated","Has Results","Aplastic Anemia","Drug: Cytoxan|Drug: Campath|Radiation: Total Body Irradiation (TBI)|Drug: FK-506|Drug: Methotrexate|Procedure: Stem cell infusion","Baylor College of Medicine|The Methodist Hospital System|Texas Children's Hospital|Center for Cell and Gene Therapy, Baylor College of Medicine","All","up to 60 Years   (Child, Adult)","Phase 2","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","10915-SAA MUD|SAA MUD","December 19, 2007","February 2002","July 2012","March 24, 2016","March 2016","August 4, 2013","null","July 2012","Number of Subjects Alive at 100 Days Post Transplant|Number of Patients With Engraftment Rate at 100 Days Post Transplant|Number of Patients With Acute GVHD at 100 Days Post Transplant|Number of Patients With Chronic GVHD at 2 Years Post Transplant|Number of Subjects Alive at 1 Year Post Transplant|Number of Subjects Alive at 2 Years Post Transplant","https://ClinicalTrials.gov/show/NCT00578903"
2285,"NCT00897026","Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344","Recruiting","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel|Genetic: fluorescence in situ hybridization|Other: immunohistochemistry staining method","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","","1195","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CALGB-9741A-ICSC|U10CA031946|CDR0000589237","May 9, 2009","July 2008","null","June 24, 2016","June 2016","No Study Results Posted","null","January 2100","Disease-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00897026"
2286,"NCT00036985","Combination Chemotherapy With or Without Microwave Thermotherapy Before Surgery in Treating Women With Locally Advanced Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Procedure: thermal ablation therapy","Celsion|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000069346|CELSION-10200201|OU-09533","May 13, 2002","August 2001","null","December 18, 2013","July 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00036985"
2287,"NCT00004169","Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease","Completed","No Results Available","Lymphoma","Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Northwestern University|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU 93H2|NU-93H2|NCI-G99-1636","December 10, 1999","November 1993","January 2007","June 21, 2012","June 2012","No Study Results Posted","null","January 2007","","https://ClinicalTrials.gov/show/NCT00004169"
2288,"NCT02220985","Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD","Recruiting","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Biphenotypic Leukemia|Acute Leukemia of Ambiguous Lineage|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Blastic Plasmacytoid Dendritic Cell Neoplasm|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Lymphoblastic Lymphoma|Myelodysplastic Syndrome With Excess Blasts|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Methotrexate|Drug: Mycophenolate Mofetil|Procedure: Peripheral Blood Stem Cell Transplantation|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Tacrolimus|Drug: Thiotepa|Radiation: Total-Body Irradiation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)","All","up to 60 Years   (Child, Adult)","Phase 2","80","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","2684.00|NCI-2014-01301|K23CA154532|P30CA015704|R01HL121568","August 18, 2014","February 2015","null","March 29, 2017","March 2017","No Study Results Posted","null","February 2019","Graft failure, defined operationally as failure to reach an absolute neutrophil count (ANC) of > 500/ul for 3 consecutive days by day 28 or irreversible decrease in ANC to < 100 after an established donor graft|Occurrence of chronic GHVD, defined operationally as the occurrence of compatible symptoms meeting National Institutes of Health criteria and requiring systemic pharmacological immunosuppression|Presence of acute GVHD grades II-IV, defined operationally as the occurrence of compatible symptoms or signs in the skin, gastrointestinal tract, or liver|Requirement for secondary systemic therapy for acute GVHD management|Requirement of immunosuppression after transplant|Time to completion of all immunosuppression|Time to completion of prednisone|Use of additional immune suppressive agents other than first line therapy (prednisone and tacrolimus/cyclosporine)|Chimerism analysis|Relapse, defined by the presence of malignant cells in marrow, peripheral blood, or extramedullary sites by histopathology|Time to ANC of > 1,000/uL on the first of three consecutive test results|Time to ANC of > 500/uL on the first of three consecutive days|Time to platelet count > 20,000/uL for 3 days without transfusion|Time to platelet count > 50,000/uL for 3 days without transfusion|Transplant related mortality, defined as mortality in any patient for whom there has not been a diagnosis of relapse","https://ClinicalTrials.gov/show/NCT02220985"
2289,"NCT00003425","Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect","Completed","No Results Available","Breast Cancer|Leukemia|Lymphoma|Neuroblastoma|Ovarian Cancer|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific","Biological: filgrastim|Drug: amifostine trihydrate|Drug: cyclophosphamide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation","University of Kentucky","All","14 Years to 70 Years   (Child, Adult, Senior)","Phase 1|Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UKMC-97BMT72|CDR0000066448|ALZA-UKMC-97BMT72|NCI-V98-1455","November 1, 1999","December 1997","null","April 25, 2013","April 2013","No Study Results Posted","null","July 2002","","https://ClinicalTrials.gov/show/NCT00003425"
2290,"NCT00003032","High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: mitoxantrone hydrochloride|Drug: tamoxifen citrate","NCIC Clinical Trials Group|Canadian Cancer Trials Group","Female","16 Years to 60 Years   (Child, Adult)","Phase 3","192","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","MA16|CAN-NCIC-MA16|CDR0000065634","November 1, 1999","April 1997","December 2008","November 7, 2010","November 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003032"
2291,"NCT01121029","Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus","Completed","No Results Available","Type 1 Diabetes Mellitus","Procedure: Autologous hematopoietic stem cell transplantation","Dra. Olga Graciela Cantu Rodriguez|Hospital Universitario Dr. Jose E. Gonzalez","All","2 Years to 35 Years   (Child, Adult)","Phase 1|Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EN10-011","May 11, 2010","May 2010","December 2012","December 6, 2012","December 2012","No Study Results Posted","null","December 2011","C-peptide levels before and after the hematopoietic stem cell transplantation|Serum levels of Hb A1C before and after the hematopoietic stem cell transplantation","https://ClinicalTrials.gov/show/NCT01121029"
2292,"NCT00001561","Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation","Completed","No Results Available","Graft vs Host Disease|Multiple Myeloma","Drug: Myeloma Immunoglobulin Idiotype Vaccine-KLH|Drug: GM-CSF","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","Phase 3","30","NIH","Interventional","Primary Purpose: Treatment","970030|97-C-0030","November 3, 1999","November 1996","September 2005","September 21, 2007","September 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001561"
2293,"NCT00429143","A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative","Completed","Has Results","Hematologic Malignancies","Radiation: Total Body Irradiation (TBI)|Biological: Donor Lymphocyte Infusion (DLI)|Drug: Cyclophosphamide (CY)|Drug: Tacrolimus|Drug: Mycophenolate Mofetil (MMF)|Biological: Hematopoietic Stem Cell Transplant (HSCT)","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06U.20|2005-84","January 29, 2007","January 2006","June 2010","October 19, 2016","October 2016","June 4, 2012","null","August 2009","Overall Survival of Participants|Optimal Dose of CD3+ Donor Lymphocytes (T-cells) for Consistent Engraftment Without GVHD|Engraftment Rates|Lymphoid Recovery|Incidence of Grades III-IV GVHD","https://ClinicalTrials.gov/show/NCT00429143"
2294,"NCT00855452","Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors","Completed","No Results Available","Metastatic Breast Cancer|Malignant Melanoma|Renal Cell Cancer|Gastrointestinal Cancer","Procedure: one - three cycles of cell therapy during 4-6 weeks (3-5x10^7 cells/kg will be given through IV systemically","Hadassah Medical Organization","All","12 Years to 70 Years   (Child, Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0457-08-HMO-CTIL","February 19, 2009","January 2009","May 2014","June 10, 2015","October 2008","No Study Results Posted","rIL-2(LAK)","May 2014","CR:disappearance of disease.PR:<50% decrease in the total tumor load of the lesions SD:<50% reduction and 25% increase in the sum of the products of the longest perpendicular diameters of the measured lesions.PD:>25% increase in the size of lesion.","https://ClinicalTrials.gov/show/NCT00855452"
2295,"NCT00282412","Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism","Terminated","No Results Available","Rheumatoid Arthritis","Biological: Hematopoietic Stem Cell Transplantation","Northwestern University","All","18 Years to 60 Years   (Adult)","Phase 1","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DIAD RA ALLO","January 24, 2006","September 2002","June 2016","July 11, 2016","July 2016","No Study Results Posted","null","June 2016","Tender joint count;Swollen joint count; Patient's global assessment of disease;Patient's assessment of pain;Patient's assessment of physical activity; (Health Assessment Questionnaire [HAQ]); Acute phase reactant value (erythrocyte sedimentation rate).","https://ClinicalTrials.gov/show/NCT00282412"
2296,"NCT02297230","Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics","Completed","No Results Available","Breast Cancer","Radiation: radiation therapy|Drug: Capecitabine|Drug: Trastuzumab|Drug: Paclitaxel","New York University School of Medicine","Female","18 Years to 90 Years   (Adult, Senior)","Phase 1|Phase 2","44","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","10289","October 27, 2014","June 2002","December 2014","May 13, 2015","May 2015","No Study Results Posted","null","December 2014","Feasibility & efficacy of chemo-radiation while targeting treatment, based on: original tumor characteristics; to be followed by [need for] conventional post-operative chemotherapy|To assess the pathological response rate and compare it to that achieved in our previous Phase I-II trials of concurrent chemo-radiation.|To store core biopsies of the original tumor before and after treatment (from the surgical specimen) for future molecular biology studies in LABC.|To acquire descriptive information on patient adherence to therapy and on quality of life during treatment.","https://ClinicalTrials.gov/show/NCT02297230"
2297,"NCT00553358","Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study","Active, not recruiting","Has Results","Neoplasms, Breast","Drug: Lapatinib|Biological: Trastuzumab|Drug: Paclitaxel","Novartis Pharmaceuticals|Breast International Group|SOLTI Breast Cancer Research Group|Novartis","Female","18 Years and older   (Adult, Senior)","Phase 3","455","Industry|Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","EGF106903","November 1, 2007","January 2008","December 2019","August 15, 2016","August 2016","May 26, 2011","Neo ALTTO","May 2010","Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery|Number of Participants With Overall Response at Week 6|Number of Participants With Overall Response at the Time of Surgery|Number of Participants With Negative Lymph Nodes at the Time of Surgery|Number of Participants With Actual Indicated Surgery|Estimate of Treatment Contrast for Change From Baseline in Tumor Size at Week 6 and at Surgery|Number of Participants Starting Paclitaxel Before Completing 6 Weeks of Treatment With Either Lapatinib or Trastuzumab|Overall Survival|Disease-free Survival (DFS)|Number of Participants With Metabolic Response of Complete Response (mCR), Partial Response (mPR), or Stable Disease (mSD) as Determined by Positron Emission Tomography/Computed Tomography (PET/CT)|Number of Participants With the Indicated Biomarker Expression|Number of Circulating Tumor Cells (CTC) in the Bloodstream","https://ClinicalTrials.gov/show/NCT00553358"
2298,"NCT02935257","Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia Using CAR T-cells to Target CD19","Not yet recruiting","No Results Available","Leukemia, Lymphoblastic, Acute","Biological: CD19CAT-41BBZ CAR T-cells","University College, London","All","16 Years to 65 Years   (Child, Adult)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","UCL/16/0530","October 14, 2016","July 2017","November 2024","May 10, 2017","May 2017","No Study Results Posted","ALLCAR19","April 2020","Toxicity evaluated by the incidence of grade 3-5 toxicity causally related to the ATIMP|Feasibility of manufacturing CD19CAR T-cells evaluated by the number of therapeutic products generated","https://ClinicalTrials.gov/show/NCT02935257"
2299,"NCT02382575","Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome","Recruiting","No Results Available","Nephrotic Syndrome","Drug: Rituximab|Drug: Tacrolimus","Nilratan Sircar Medical College","All","3 Years to 16 Years   (Child)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PednephroRCT/PM/NRSMCH-33|CTRI/2015/01/005364","March 3, 2015","March 2015","March 2017","September 21, 2016","September 2016","No Study Results Posted","null","March 2017","12-month relapse-free survival in the intention-to-treat population","https://ClinicalTrials.gov/show/NCT02382575"
2300,"NCT00907348","Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma","Unknown status","No Results Available","Non Hodgkin Lymphoma|Follicular Lymphoma","Drug: LR-CHOP21","Fondazione Italiana Linfomi ONLUS|Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte","All","60 Years to 80 Years   (Adult, Senior)","Phase 2","49","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IIL_REAL07","May 21, 2009","October 2007","January 2012","October 12, 2011","October 2011","No Study Results Posted","REAL07","October 2009","Evaluation of adverse events according with Common Terminology Criteria for Adverse events (CTCAE)|Overall Response Rate (ORR)","https://ClinicalTrials.gov/show/NCT00907348"
2301,"NCT00061581","Experimental Bone Marrow Transplant Protocol","Completed","No Results Available","Acute Lymphocytic Leukemia|Chronic Myeloid Leukemia|Acute Myelocytic Leukemia|Myelodysplastic Syndromes|Myeloproliferative Disorders","Device: Isolex 300i Stem Cell Selection","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","10 Years to 55 Years   (Child, Adult)","Phase 2","14","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","030192|03-H-0192","May 29, 2003","May 19, 2003","December 28, 2007","May 12, 2017","July 14, 2016","No Study Results Posted","null","December 28, 2007","Acute and chronic graft-versus-host disease, transplant-related mortality (TRM), overall mortality, leukemic relapse, CMV reactivation and disease, and graft failure.","https://ClinicalTrials.gov/show/NCT00061581"
2302,"NCT00002630","High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Drug: cyclophosphamide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET photon therapy","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 2","50","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000064030|P30CA015083|928003|V95-0613","November 1, 1999","June 1993","May 2001","May 10, 2011","May 2011","No Study Results Posted","null","February 1999","","https://ClinicalTrials.gov/show/NCT00002630"
2303,"NCT00307645","IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis","Terminated","No Results Available","ANCA Associated Systemic Vasculitis Including Wegener’s|Granulomatosis and Microscopic Polyangiitis and|Renal Limited Vasculitis","Drug: Cyclophosphamide|Drug: Mycophenolate mofetil|Drug: Azathioprine|Drug: Prednisone (and methylprednisolone)","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Senior)","Phase 3","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","P991003","March 27, 2006","May 2003","August 2009","April 7, 2006","March 2003","No Study Results Posted","null","null","the disease-free period, defined as the time between the beginning|of the maintenance therapy (AZA or MMF) and the first relapse (minor or major)|or the end of the protocol (at 48 months)|relapse rate|rate of side-effects and intolerance|cumulative doses (AZA, CS, MMF)|AUC for BVAS, SF-36 or VDI|Evolution of titers of ANCA and CRP","https://ClinicalTrials.gov/show/NCT00307645"
2304,"NCT00006436","EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection","Recruiting","No Results Available","Lymphoma, AIDS-related|Lymphoma, Large B-Cell, Diffuse","Biological: Rituximab|Biological: filgrastim|Drug: EPOCH","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Senior)","Phase 2","80","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","010030|01-C-0030","November 3, 2000","October 30, 2000","March 31, 2021","May 12, 2017","December 29, 2016","No Study Results Posted","null","March 31, 2019","Progression-free survival at 1 year after completion of study treatment","https://ClinicalTrials.gov/show/NCT00006436"
2305,"NCT02438982","Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome","Completed","No Results Available","Nephrotic Syndrome","Drug: Tacrolimus|Drug: Rituximab","Nilratan Sircar Medical College","All","3 Years to 16 Years   (Child)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","pednephro RCT/PM/NRSMCH-54|CTRI/2014/01/004355","May 6, 2015","May 2015","August 2016","March 28, 2017","March 2017","No Study Results Posted","null","August 2016","12-month relapse-free survival","https://ClinicalTrials.gov/show/NCT02438982"
2306,"NCT03077542","Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease","Recruiting","No Results Available","Sickle Cell Disease","Procedure: haploidentical stem cell transplant|Drug: sirolimus|Drug: campath|Drug: pentostatin|Drug: cyclophosphamide","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","2 Years to 80 Years   (Child, Adult, Senior)","Phase 1|Phase 2","84","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","170069|17-H-0069","March 10, 2017","April 6, 2017","August 31, 2026","May 20, 2017","May 15, 2017","No Study Results Posted","null","September 30, 2025","The percentage of patients at 100 days (+/- 1 week) post-transplantwith sustained donor type hemoglobin on hemoglobin electrophoresis (HbS less than 50% when donors have sickle cell trait and <10% when donors have normal hemoglobin), who d...|The level of chimerism required to maintain both graft survival as wellas hematologic normalcy.","https://ClinicalTrials.gov/show/NCT03077542"
2307,"NCT02127268","Thymosin-α1 in Cancer-Related Fatigue","Recruiting","No Results Available","Cancer Related Fatigue|Quality of Life","Drug: Thymosin-α1","Zhigang Zhang|Zhejiang University","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","T-CRF","April 28, 2014","April 2014","April 2018","January 8, 2017","January 2017","No Study Results Posted","null","April 2018","Change in Cancer-Related Fatigue Scale|improvement in Quality of Life","https://ClinicalTrials.gov/show/NCT02127268"
2308,"NCT02018458","Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer","Recruiting","No Results Available","Breast Cancer","Biological: LA TNBC: DC vaccine+Preop chemo|Biological: ER+/HER2-BC:DC vaccine+Preop chemo","Baylor Research Institute","Female","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","013-154","December 4, 2013","May 2014","March 2018","January 12, 2016","January 2016","No Study Results Posted","null","March 2017","Safety of DC vaccine combined with chemotherapy, and DC vaccine combined with chemotherapy|Pathologic complete response rate with DC vaccine|Disease free survival with DC vaccine","https://ClinicalTrials.gov/show/NCT02018458"
2309,"NCT01521689","Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment","Unknown status","No Results Available","Chronic Lymphocytic Leukemia","Drug: Rituximab","Institut Paoli-Calmettes","All","18 Years and older   (Adult, Senior)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LLCR lowdoz / IPC 2009-004","December 22, 2011","December 2011","June 2015","March 19, 2015","March 2015","No Study Results Posted","LLCRlowdoz","June 2015","Residual disease|overall survival|Adverse events|-Quality of life|Immune functions|- Progression free survival|treatment free survival","https://ClinicalTrials.gov/show/NCT01521689"
2310,"NCT00001865","HAT in Eye Complications of Behcet's Disease","Completed","No Results Available","Behcet's Syndrome|Retinal Disease|Uveitis","Drug: Daclizumab","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","26","NIH","Interventional","Primary Purpose: Treatment","990135|99-EI-0135","November 3, 1999","July 1999","June 2004","March 3, 2008","June 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001865"
2311,"NCT00003631","Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma","Completed","Has Results","Lymphoma","Biological: filgrastim|Drug: carboplatin|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: etoposide|Drug: ifosfamide|Drug: melphalan|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","up to 120 Years   (Child, Adult, Senior)","Phase 2","118","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","98-071|CDR0000066714|NCI-G98-1480","November 1, 1999","August 1998","null","December 17, 2015","December 2015","December 17, 2015","null","April 2010","Objective Response","https://ClinicalTrials.gov/show/NCT00003631"
2312,"NCT01358201","PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years","Recruiting","No Results Available","Acute Lymphoblastic Leukemia","Drug: vINCRISTINE|Drug: Dexamethasone|Drug: Methotrexate|Drug: Cytosine arabinoside","PETHEMA Foundation","All","55 Years and older   (Adult, Senior)","Phase 4","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PETHEMA LAL-07FRAIL","May 18, 2011","May 2010","December 2017","December 8, 2016","December 2016","No Study Results Posted","null","May 2017","Efficacy in terms of response rate|Efficacy in terms disease free survival|Efficacy in terms of global survival","https://ClinicalTrials.gov/show/NCT01358201"
2313,"NCT00405860","CellCept in p-ANCA Vasculitis","Completed","No Results Available","MPO-ANCA Vasculitis|Microscopic Polyangiitis","Drug: CellCept (mycophenolate mofetil)","Mayo Clinic|Roche Pharma AG","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1679-02","November 29, 2006","December 2002","July 2008","March 21, 2011","March 2011","No Study Results Posted","null","July 2008","The primary endpoint is successful induction of remission as defined in Appendix 6 within 6 months.|Major relapse necessitating a switch to induction OCS/CYC treatment or more aggressive treatment (e.g. plasma exchange).|Minor relapses that can effectively be controlled by a transient, non-toxic increase in OCS|Intolerance to trial medications and adverse effects. Adverse effects will be monitored","https://ClinicalTrials.gov/show/NCT00405860"
2314,"NCT01873807","HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL","Recruiting","No Results Available","Acute Lymphoblastic Leukemia","Drug: IDA|Radiation: TBI|Drug: CTX|Drug: VP-16","Nanfang Hospital of Southern Medical University","All","16 Years to 65 Years   (Child, Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HIE-ALL-2013","June 6, 2013","May 2013","December 2015","October 7, 2015","October 2015","No Study Results Posted","HITA","December 2015","Event-Free Survival|Transplantation-Related Mortality","https://ClinicalTrials.gov/show/NCT01873807"
2315,"NCT00002510","Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Drug: cyclophosphamide|Drug: etoposide|Drug: mesna|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Temple University|Fox Chase Cancer Center","All","16 Years to 65 Years   (Child, Adult)","Phase 1|Phase 2","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000078066|TUHSC-2049|NCI-V92-0206","November 1, 1999","April 1992","June 2001","September 30, 2010","September 2010","No Study Results Posted","null","June 2001","","https://ClinicalTrials.gov/show/NCT00002510"
2316,"NCT00311246","Trial of Adalimumab in Progressive Sarcoidosis","Terminated","No Results Available","Sarcoidosis","Drug: Adalimumab","University of Chicago|Abbott","All","18 Years to 85 Years   (Adult, Senior)","Phase 2","11","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","14093A","April 3, 2006","April 2006","September 2008","June 28, 2011","June 2011","No Study Results Posted","null","May 2008","The primary objective of this study is to evaluate the efficacy and safety of adalimumab, as measured by pulmonary function, in subjects with chronic sarcoidosis with pulmonary involvement who are symptomatic despite current treatment.|To evaluate the efficacy of adalimumab in improving the symptoms and functional capacity in patients with chronic sarcoidosis with pulmonary involvement who are symptomatic despite current treatment|To assess the effect of adalimumab on quality of life in subjects with chronic sarcoidosis with pulmonary involvement","https://ClinicalTrials.gov/show/NCT00311246"
2317,"NCT01516736","Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim","Completed","No Results Available","Chemotherapy-induced Neutropenia|Breast Cancer","Drug: LA-EP2006|Drug: Peg-Filgrastim|Drug: Docetaxel|Drug: Doxorubicin|Drug: Cyclophosphamide","Sandoz","Female","18 Years and older   (Adult, Senior)","Phase 3","308","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","LA-EP06-302","January 13, 2012","March 2012","December 2013","September 7, 2015","September 2015","No Study Results Posted","PROTECT2","December 2013","Mean duration of Grade 4 neutropenia during Cycle 1 of chemotherapy|Incidence of febrile neutropenia|Incidence, occurrence and severity of (serious) adverse events.","https://ClinicalTrials.gov/show/NCT01516736"
2318,"NCT00146562","Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer","Completed","No Results Available","Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer","Drug: Darbepoetin Alfa|Drug: Pegfilgrastim|Drug: Paclitaxel|Drug: Doxorubicin|Drug: Cyclophosphamide","Harold J. Burstein, MD, PhD|Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Lowell General Hospital|Brigham and Women's Hospital|North Shore Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","109","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","03-154","September 2, 2005","July 2003","May 2007","February 15, 2013","February 2013","No Study Results Posted","null","May 2007","To determine the rate of febrile neutropenia in women treated with dose-dense adjuvant chemotherapy receiving pegfilgrastim every 2 weeks.|To determine the rate of RBC transfusion among patients treated with dose-dense adjuvant chemotherapy receiving darbepoetin every 2 weeks.","https://ClinicalTrials.gov/show/NCT00146562"
2319,"NCT00507780","Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy","Withdrawn","No Results Available","Ovarian Function|Preservation of Ovarian Function","Drug: GnRH antagonist","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","10 Years to 21 Years   (Child, Adult)","Phase 4","0","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double Blind (masked roles unspecified)|Primary Purpose: Prevention","070193|07-CH-0193","July 26, 2007","July 18, 2007","July 22, 2010","January 24, 2017","July 22, 2010","No Study Results Posted","null","July 22, 2010","Antimullerian hormone, ovarian follicle count|Menstrual history","https://ClinicalTrials.gov/show/NCT00507780"
2320,"NCT00950768","Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients","Completed","No Results Available","Multiple Myeloma|Diagnosis","Procedure: Autologous transplantation","Azienda Ospedaliera San Giovanni Battista","All","18 Years to 65 Years   (Adult)","Phase 3","298","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GISMM2001","July 31, 2009","February 2002","June 2009","July 31, 2009","July 2009","No Study Results Posted","null","May 2009","Primary endpoints of the study were Overall Survival defined as the time from diagnosis until death from any cause; Progression Free Survival defined as the time from diagnosis until death from any cause or date of first relapse or progression.|Secondary endpoint was time to progression (TTP) defined as the time from the date of diagnosis to relapse or death from progression.","https://ClinicalTrials.gov/show/NCT00950768"
2321,"NCT00007345","Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma","Completed","Has Results","Cutaneous T Cell Lymphoma|Peripheral T Cell Lymphoma","Drug: Romidepsin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","131","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","010049|01-C-0049","December 16, 2000","March 8, 2001","July 27, 2015","April 13, 2017","April 2017","January 14, 2016","null","January 26, 2015","Number of Participants With a Response|Duration of Response (DOR)|Number of Participants With Adverse Events|Median Number of Cycles of Depsipeptide Administered|Time to Progression|Fold Change in Histone Acetylation|Multidrug Resistance Protein 1 (MDR1) or ATP-binding Cassette Sub-family B Member 1 (ABCB1) Gene Expression","https://ClinicalTrials.gov/show/NCT00007345"
2322,"NCT00001959","Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)","Completed","Has Results","Fibrosis|Focal Glomerulosclerosis|Kidney Failure|Nephrotic Syndrome|Proteinuria","Drug: Pirfenidone","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","21","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","000042|00-DK-0042","January 18, 2000","December 1999","October 2008","May 16, 2014","April 2012","June 16, 2010","null","October 2008","Decrease in GFR During Treatment Period|Proteinuria After Treatment|Proportion of Patients With Positive Change in GFR","https://ClinicalTrials.gov/show/NCT00001959"
2323,"NCT01357733","Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients","Unknown status","No Results Available","Lymphoma, Large B-Cell, Diffuse","Other: Early interim FDG PET/CT after 1 cycle of R-CHOP","The Catholic University of Korea","All","19 Years and older   (Adult, Senior)","","130","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","KC11EISI0293","May 13, 2011","March 2012","March 2016","April 9, 2012","April 2012","No Study Results Posted","null","March 2014","Change from baseline in summed peak standardized uptake value lean (SULpeak) after 3 cycles|Change from baseline in summed SULpeak after 1 cycle|2 year disease free survival|Qualitative response|Quantitative response","https://ClinicalTrials.gov/show/NCT01357733"
2324,"NCT00206453","Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer","Terminated","No Results Available","Breast Cancer","Drug: Taxotere","Baylor Breast Care Center|United States Department of Defense","Female","18 Years and older   (Adult, Senior)","Phase 2","25","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-11058","September 14, 2005","January 2002","January 2005","February 4, 2013","February 2013","No Study Results Posted","null","January 2005","biologic effects of Taxotere|to identify gene expression profiles predictive of response and to further describe the efficacy of Taxotere in women with locally advanced breast cancer|comparison of histologic and molecular markers from sequential core biopsies of primary breast cancers of patients receiving Taxotere|expression arrays will be used","https://ClinicalTrials.gov/show/NCT00206453"
2325,"NCT00002592","Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia","Completed","No Results Available","Leukemia","Biological: c-myb antisense oligonucleotide G4460|Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Procedure: autologous bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation","Abramson Cancer Center of the University of Pennsylvania|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 2","40","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000063772|UPCC-3492|NCI-H94-0532","November 1, 1999","June 1993","August 2002","January 13, 2015","January 2015","No Study Results Posted","null","August 2002","Number of Adberse Events","https://ClinicalTrials.gov/show/NCT00002592"
2326,"NCT01824615","Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma","Unknown status","No Results Available","Ovarian Cancer|Adverse Effects","Drug: Sunitinib","Cathay General Hospital","Female","20 Years to 80 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CT99076|TGOG-101","March 19, 2013","January 2013","January 2016","April 7, 2013","April 2013","No Study Results Posted","null","January 2016","Response rate","https://ClinicalTrials.gov/show/NCT01824615"
2327,"NCT00004853","Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy","Completed","No Results Available","Ewing's Sarcoma|Rhabdomyosarcoma|MPNST|Synovial Sarcoma|High-risk Sarcoma","Biological: Filgrastim|Biological: Filgrastim-SD/01","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","up to 25 Years   (Child, Adult)","Phase 1","29","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","000092|00-C-0092","March 4, 2000","March 3, 2000","May 20, 2009","May 12, 2017","January 27, 2016","No Study Results Posted","null","May 20, 2009","Tolerance and toxicity|PKs|Compare neutrophil function|Compare CD34 positive stem cell mobilization|Compare days of febrile neutropenia, days on antibiotics, and inpatient days resulting from neutropenia|Evaluate the role of functional cardiac MRI and serum troponin T levels in detecting early doxorubicin cardiotoxicity|Assess methods of detecting minimal residual disease|cDNA microarray analysis of gene expression, development of cell lines and xenotransplantation models, and exploration of apoptotic pathways","https://ClinicalTrials.gov/show/NCT00004853"
2328,"NCT01967576","Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma","Active, not recruiting","No Results Available","Pheochromocytoma|Paraganglioma","Drug: Axitinib (AG-013736)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Senior)","Phase 2","14","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","140001|14-C-0001","October 19, 2013","October 15, 2013","October 1, 2017","May 12, 2017","March 31, 2017","No Study Results Posted","null","August 31, 2017","Response rate|Progression- free survival.|Examine the extent of activation of the VEGRF pathway inpheochromocytoma/paraganglioma using a semi-quantitativeimmunohistochemistry assay and examine the relationship withresponse to therapy|Pharmacogenomics analyses|Perform pharmacokinetic analysis for determination of plasma levels of axitinib","https://ClinicalTrials.gov/show/NCT01967576"
2329,"NCT00604201","Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome","Recruiting","No Results Available","Myelodysplastic Syndrome (MDS)|Severe Aplastic Anemia (SAA)","Other: Umbilical Cord Blood|Other: Haploidentical Stem Cells|Device: Miltenvi CliniMACs CD34 Reagent System","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","4 Years to 75 Years   (Child, Adult, Senior)","Phase 2","100","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","080046|08-H-0046","January 8, 2008","January 4, 2008","December 31, 2018","May 20, 2017","May 11, 2017","No Study Results Posted","null","June 30, 2018","Day 42 cord engraftment|200 day treatment related mortality (TRM) and standard transplant outcome variables (non-hematological toxicities, incidence and severity of acute and chronic GVHD, and relapse of disease)","https://ClinicalTrials.gov/show/NCT00604201"
2330,"NCT01339455","Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica","Active, not recruiting","No Results Available","Neuromyelitis Optica","Procedure: AHSCT","University of Calgary","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CHREB ID# 23282","April 18, 2011","March 2011","December 2020","December 30, 2015","December 2015","No Study Results Posted","SCT-NMO","March 2020","Proportion relapse-free at three years|Proportion relapse-free at five years|Relapse count|Disability progression|Retinal nerve fiber layer (RFNL) status|25 foot timed walk test|PASAT|Hospitalization|Overall survival|Time to next relapse","https://ClinicalTrials.gov/show/NCT01339455"
2331,"NCT00131612","An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment","Terminated","No Results Available","Breast Cancer","Drug: FEC 100","AHS Cancer Control Alberta","All","18 Years and older   (Adult, Senior)","","120","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","BR-01-0031 / 17027","August 17, 2005","January 2002","January 2013","February 24, 2016","June 2012","No Study Results Posted","null","December 2005","","https://ClinicalTrials.gov/show/NCT00131612"
2332,"NCT00615602","Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Docetaxel|Drug: Trastuzumab|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: 5-fluoruracil|Drug: Granulocyte-colony stimulating growth factor|Drug: Trastuzumab","Hellenic Oncology Research Group|University Hospital of Crete","Female","18 Years to 75 Years   (Adult, Senior)","Phase 3","489","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CT/04.23","February 1, 2008","October 2004","May 2012","March 3, 2015","March 2015","No Study Results Posted","null","May 2012","3-year disease-free survival|Overall survival|Recurrence rate|Τoxicity profile|Quality of life between the two treatment arms","https://ClinicalTrials.gov/show/NCT00615602"
2333,"NCT01163201","T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies","Withdrawn","No Results Available","Hematologic Malignancy|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia in Blast Crisis|Anemia, Refractory, With Excess of Blasts|Chronic Myeloproliferative Disease|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Marginal Zone B-cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-Cell Lymphoma|Prolymphocytic Lymphoma|Large Cell Non-Hodgkin's Lymphoma|Lymphoblastic Lymphoma|Burkitt's Lymphoma|High Grade Non-Hodgkin's Lymphoma","Biological: Treg cells|Biological: CD3+ Teff cells|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total body irradiation|Biological: Umbilical cord blood transplantation","Masonic Cancer Center, University of Minnesota","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2009LS018|MT2009-03|0910M73595","May 26, 2010","January 2014","January 2015","March 4, 2014","March 2014","No Study Results Posted","null","January 2015","Optimal Cell Dose Mixture|Determine incidence of infusional toxicity|Incidence of neutrophil recovery|Incidence of double and single chimerism|Incidence of Viral and Fungal Infections|1 Year Survival|Incidence of Grade III-IV Acute Graft-Versus-Host Disease|Incidence of Treatment Related Death|Incidence of Platelet Recovery|Incidence of Chronic Graft-Versus-Host Disease|Incidence of Relapse","https://ClinicalTrials.gov/show/NCT01163201"
2334,"NCT01022021","Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine","Completed","No Results Available","Lymphoma","Drug: Rituximab|Drug: Bendamustine","University of Kansas Medical Center|Cephalon","All","18 Years to 70 Years   (Adult, Senior)","Early Phase 1","17","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11908","November 25, 2009","January 2010","August 2015","January 6, 2017","January 2017","No Study Results Posted","null","April 2014","To assess the efficacy of G-CSF induced PBSC mobilization after two cycles of rituximab and Bendamustine (BR) as salvage therapy in patients with relapsed non-Hodgkins lymphoma","https://ClinicalTrials.gov/show/NCT01022021"
2335,"NCT01555281","Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Nelfinavir|Drug: Lenalidomide|Drug: Dexamethasone","Swiss Group for Clinical Cancer Research","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 39/10|2010-022035-11|000001246","March 8, 2012","April 2012","December 2019","December 20, 2016","December 2016","No Study Results Posted","null","December 2019","Phase I: Dose limiting toxicity|Phase II: Overall response|Phase I/II: Frequency and percent of occurrence of adverse events during each cycle of treatment, and within patients|Phase I/II: Disease control, i.e. no progression at 16 weeks after start of trial therapy|Phase I/II: Duration of response|Phase I/II: Overall survival|Phase I/II: Progression free survival|Phase I/II: Time to progression|Phase I: Overall response","https://ClinicalTrials.gov/show/NCT01555281"
2336,"NCT00001737","Cyclosporin Implant to Treat Uveitis","Completed","No Results Available","Eye Disease|Inflammation|Uveitis","Drug: Cyclosporin A Implant","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 1","10","NIH","Interventional","Primary Purpose: Treatment","980110|98-EI-0110","November 3, 1999","May 1998","March 2004","March 3, 2008","March 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001737"
2337,"NCT00275678","Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies","Completed","No Results Available","Blood Stem Cell Transplant","Procedure: Blood stem cell versus bone marrow transplant","Mayo Clinic|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|National Marrow Donor Program|University of Minnesota - Clinical and Translational Science Institute|University of Florida|Duke University|Ann & Robert H Lurie Children's Hospital of Chicago","All","18 Years to 66 Years   (Adult, Senior)","Phase 3","15","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2158-03","January 10, 2006","November 2003","null","June 2, 2010","June 2010","No Study Results Posted","null","September 2009","Two-year survival|Neutrophil Engraftment > 500/mcl|Primary graft failure|Platelet engraftment > 20,000 and 50,000/mcl transfusion independent|Acute GVHD of grades II-IV and III-IV","https://ClinicalTrials.gov/show/NCT00275678"
2338,"NCT00001863","Leflunomide to Treat Uveitis","Completed","No Results Available","Uveitis","Drug: Leflunomide","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","16","NIH","Interventional","Primary Purpose: Treatment","990059|99-EI-0059","November 3, 1999","March 1999","February 2003","March 3, 2008","February 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001863"
2339,"NCT01365559","Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments","Completed","No Results Available","Multiple Myeloma","Drug: Group A: Carfilzomib & Non-IMiD Regimen|Drug: Group B: Carfilzomib & IMiD containing regimen.","Oncotherapeutics|Amgen","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IST-CAR-516","May 31, 2011","May 2, 2011","March 1, 2016","February 27, 2017","February 2017","No Study Results Posted","null","June 13, 2014","Establish MTD, determine DLT and to determine the efficacy as assessed by the overall response rate.|To establish safety and efficacy following treatment.","https://ClinicalTrials.gov/show/NCT01365559"
2340,"NCT00280826","Efalizumab to Treat Uveitis","Completed","Has Results","Uveitis|Macular Edema","Drug: Efalizumab","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 1","6","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","060046|06-EI-0046","January 21, 2006","January 2006","February 2009","January 28, 2011","January 2011","July 15, 2010","null","February 2009","Number of Participants With Systemic Toxicities, Adverse Events, or Infections|Cystoid Macular Edema in the Worse Eye as Assessed by Optical Coherence Tomography (OCT).|Cystoid Macular Edema in the Better Eye as Assessed by Optical Coherence Tomography (OCT).|Change in Visual Acuity in the Worse Eye From Baseline to 16 Weeks|Change in Visual Acuity in the Better Eye From Baseline to 16 Weeks","https://ClinicalTrials.gov/show/NCT00280826"
2341,"NCT01867229","Breast Cancer and Chemo-amennorhea","Unknown status","No Results Available","Breast Cancer","Other: observational","Cliniques universitaires Saint-Luc- Université Catholique de Louvain","Female","Child, Adult, Senior","","500","Other","Observational","Time Perspective: Prospective","UCL-gyneco-001","May 29, 2013","October 2011","December 2014","May 31, 2013","May 2013","No Study Results Posted","chemo-ameno","December 2013","incidence and duration of the amenorrhea induced by chemotherapy","https://ClinicalTrials.gov/show/NCT01867229"
2342,"NCT00079391","Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies","Completed","Has Results","Hematologic Malignancies|Bone Marrow Transplant Rejection","Device: allogeneic hematopoietic stem cell transplantation","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","2 Years to 80 Years   (Child, Adult, Senior)","Phase 2","50","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","040112|04-H-0112","March 8, 2004","January 2004","September 2011","October 5, 2015","June 2014","April 20, 2011","null","December 2008","The Proportion of Patients Who Develop Full Donor T Cell Chimerism at Day 30|Overall Survival|Non Relapse Mortality.|Cumulative Incidence of Relapse|Acute Graft Versus Host Disease (Before Day 60 T Cell Add Back)|Acute GVHD Overall","https://ClinicalTrials.gov/show/NCT00079391"
2343,"NCT00040508","Sirolimus for Focal Segmental Glomerulosclerosis","Completed","No Results Available","Focal Glomerulosclerosis","Drug: Sirolimus","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","30","NIH","Interventional","Primary Purpose: Treatment","020235|02-DK-0235","June 26, 2002","June 2002","January 2005","March 3, 2008","January 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00040508"
2344,"NCT00001144","Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia","Completed","No Results Available","Chronic Myeloid Leukemia|Graft vs Host Disease","Drug: Modified bone marrow stem cell transplantation","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","50","NIH","Interventional","Primary Purpose: Treatment","000001|00-H-0001","November 3, 1999","October 1999","October 2002","October 6, 2008","October 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001144"
2345,"NCT00004990","Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis","Completed","No Results Available","Glomerulonephritis|Nephrotic Syndrome","Drug: Dexamethasone","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","20","NIH","Interventional","Primary Purpose: Treatment","000100|00-DK-0100","March 18, 2000","March 2000","December 2004","March 3, 2008","December 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004990"
2346,"NCT00424489","Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis","Terminated","No Results Available","Myasthenia Gravis","Biological: Hematopoietic Stem Cell Transplantation","Northwestern University","All","15 Years to 65 Years   (Child, Adult)","Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Myasthenia Gravis Auto 2002","January 18, 2007","February 2002","June 2016","July 11, 2016","July 2016","No Study Results Posted","null","June 2016","Survival at 5 years; Osserman score; Quantitative Myasthenia gravis score (QMGS);Improvement is defined as a 50% improvement in QMGS; Deterioration is defined as a 25% deterioration in QMGS","https://ClinicalTrials.gov/show/NCT00424489"
2347,"NCT00005780","Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma","Active, not recruiting","No Results Available","Mantle Cell Lymphoma|Lymphoma, Mantle Cell","Drug: EPOCH-R|Biological: GM-CSF|Drug: Idiotype vaccine","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","26","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","000133|00-C-0133","June 3, 2000","June 1, 2000","June 1, 2018","May 12, 2017","October 25, 2016","No Study Results Posted","null","August 31, 2005","Progression-free survival","https://ClinicalTrials.gov/show/NCT00005780"
2348,"NCT01092182","Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma","Active, not recruiting","No Results Available","Burkitt Lymphoma|Diffuse Large B-cell Lymphoma, c-MYC Positive|Plasmablastic Lymphoma","Drug: EPOCH-R|Drug: EPOCH-RR","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Senior)","Phase 2","38","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","100052|10-C-0052","March 23, 2010","February 19, 2010","February 28, 2023","May 18, 2017","May 16, 2017","No Study Results Posted","null","February 28, 2021","PFS, EFS and OS","https://ClinicalTrials.gov/show/NCT01092182"
2349,"NCT01553981","A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma","Completed","No Results Available","Lung Diseases, Interstitial","Drug: Tadalafil|Drug: Placebo","Sanjay Gandhi Postgraduate Institute of Medical Sciences","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PGI/BE/06/2012","March 11, 2012","March 2012","May 2014","April 20, 2015","April 2015","No Study Results Posted","null","April 2014","Change in FVC (expressed as a percentage of the predicted value)|Improvement in dyspnoea (as measured by Mehler dyspnoea index)|Improvement in 6 min walk test|change in DLCO|change in total lung capacity|change in the disability index of the Health Assessment Questionnaire (S HAQ)|change in the Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36)scores","https://ClinicalTrials.gov/show/NCT01553981"
2350,"NCT01548573","Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment","Terminated","No Results Available","Multiple Myeloma","Drug: DPACE (Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide)|Procedure: Transplant 1 (Velcade, Thalidomide, Dexamethasone, Melphalan)|Procedure: Transplant 2 (Velcade, Gemcitabine, Carmustine, Dexamethasone, Melphalan)|Drug: Consolidation VDT-PACE (Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide)|Drug: Maintenance Year 1 (Velcade, Thalidomide, Dexamethasone OR Velcade, Revlimid, Dexamethasone OR Velcade, Cyclophosphamide, Dexamethasone in 28 day cycles x 12)|Drug: Maintenance Year 2 (Revlimid and Dexamethasone in 28 day cycles x 12)","University of Iowa|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","20","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201202818|7R01CA115399","February 29, 2012","May 2012","March 2014","November 26, 2013","November 2013","No Study Results Posted","null","July 2013","Event-Free Survival (EFS)|Identification of Drug Resistant Genes|Number of grade 3 non-hematologic and grade 4 hematologic serious adverse events associated with the addition of bortezomib, thalidomide, and dexamethasone into autologous transplant regimens.|Overall survival","https://ClinicalTrials.gov/show/NCT01548573"
2351,"NCT02692742","Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia","Recruiting","No Results Available","Chemotherapy-Induced Neutropenia|Myelosuppression|Breast Cancer","Drug: Myelo001|Drug: Placebo","Myelo Therapeutics GmbH","Female","18 Years and older   (Adult, Senior)","Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Supportive Care","CT-MT001-2-2015-1|2015-003610-25","February 23, 2016","March 2016","September 2017","April 27, 2017","April 2017","No Study Results Posted","MyeloConcept","September 2017","Change of Threshold Area over the Curve of Absolute Neutrophil Count (ANC): specified by the threshold line defining grade 1 neutropenia and the individual ANC trajectory|Change of Threshold Area over the Curve of Absolute Neutrophil Count (ANC): specified by the threshold line defining grade 3 neutropenia and the individual ANC trajectory|Treatment success rate: a) Neutropenia grade ≤2, b) No need for G-CSF rescue therapy, c) No early withdrawal (drop-out).|Change of Threshold Area over the Curve of lymphocytes|Change of Threshold Area over the Curve of leukocytes|Change of Threshold Area over the Curve of thrombocytes|Rate of neutropenia grade 1 and higher; 3 and higher|Duration of neutropenia grade 1 and higher; 3 and higher|Rate of patients requiring rescue therapy|Rate of patients developing febrile neutropenia|Rate of patients with chemotherapy dose reduction and/or delay of chemotherapy cycle 2","https://ClinicalTrials.gov/show/NCT02692742"
2352,"NCT00230035","Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)","Withdrawn","No Results Available","Systemic Lupus Erythematosus","Procedure: Leukapheresis|Procedure: Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)|Procedure: Autologous CD34+HPC transplantation (HSCT)|Procedure: Plasmapheresis|Drug: Rabbit anti-thymocyte globulin|Drug: Methylprednisolone|Drug: Growth colony stimulating factor (G-CSF)|Drug: Corticosteroids|Drug: Mycophenolate mofetil|Drug: Azathioprine|Drug: Intravenous immunoglobulin|Drug: Methotrexate|Drug: Rituximab|Drug: Leflunomide","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 60 Years   (Adult)","Phase 2","0","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DAIT SCSLE-01","September 28, 2005","September 2005","null","January 31, 2013","January 2013","No Study Results Posted","null","null","Mortality resulting from treatment, underlying disease, or unrelated causes","https://ClinicalTrials.gov/show/NCT00230035"
2353,"NCT01430013","Trial of Endostar Combined With CHOPT for T Cell Lymphoma","Unknown status","No Results Available","T Cell Lymphoma","Drug: Endostar and CHOPT","Tianjin Medical University Cancer Institute and Hospital|Simcere Pharmaceutical Co., Ltd","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2367240","July 11, 2011","June 2011","December 2015","November 2, 2015","September 2011","No Study Results Posted","null","November 2015","efficacy including overall response rate, progression free survival and overall survival|safety of Endostar combined with CHOPT chemotherapy","https://ClinicalTrials.gov/show/NCT01430013"
2354,"NCT01174108","Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells","Recruiting","No Results Available","Severe Aplastic Anemia|MDS (Myelodysplastic Syndrome)","Device: Miltenyi CD34 Reagent System|Other: Donor derived G-CSF mobilized PBC","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","4 Years to 80 Years   (Child, Adult, Senior)","Phase 2","95","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","100154|10-H-0154","July 31, 2010","July 26, 2010","June 30, 2017","May 24, 2017","May 2, 2017","No Study Results Posted","null","June 30, 2017","Primary endpoint of this study is chronic GVHD by one year.|Transplant related mortality, engraftment, degree of donor-host chimerism, incidence of acute and chronic graft versus host disease (GVHD), transplant related morbidity and overall survival.","https://ClinicalTrials.gov/show/NCT01174108"
2355,"NCT00005596","Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia","Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: pegaspargase|Drug: thioguanine|Drug: vincristine sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 3","1076","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","9905|COG-P9905|POG-9905|CDR0000067704|NCI-2012-02325","May 2, 2000","April 2000","July 2007","May 11, 2016","May 2016","No Study Results Posted","null","July 2005","Improvement in outcome in children receiving multidrug delayed-intensification therapy|Event-free survival, minimal residual disease, and early response|Occurrence of anticipated failures|Total grade 3+ central nervous system (CNS) toxicity rates based on the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0","https://ClinicalTrials.gov/show/NCT00005596"
2356,"NCT00031005","Stem Cell Transplantation to Treat Leukocyte Adhesion Deficiency","Completed","No Results Available","Leukocyte-Adhesion Deficiency Syndrome","Procedure: modified stem cell transplant","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","10","NIH","Interventional","Primary Purpose: Treatment","020126|02-I-0126","February 20, 2002","February 2002","February 2003","March 3, 2008","February 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00031005"
2357,"NCT00043667","Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis","Completed","No Results Available","Uveitis","Drug: Daclizumab","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","15","NIH","Interventional","Primary Purpose: Treatment","020242|02-EI-0242","August 10, 2002","August 2002","October 2004","March 3, 2008","October 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00043667"
2358,"NCT00006515","Late Effects of Treatment for Sarcomas in Children","Completed","No Results Available","Sarcoma","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","7 Years and older   (Child, Adult, Senior)","","39","NIH","Observational","","010037|01-C-0037","November 21, 2000","November 16, 2000","November 18, 2011","January 24, 2017","November 18, 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006515"
2359,"NCT00074490","Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers","Active, not recruiting","No Results Available","Lymphoma|Leukemia|Myeloproliferative Disorders|Multiple Myleoma|Myelodysplastic Syndrome","Drug: Rituximab|Drug: Fludarabine|Drug: Etoposide|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Procedure: PBSC transplantation|Genetic: T cell DLI with sirolimus generated donor TH-2 cells|Drug: Prednisone|Procedure: Allogeneic HSCT|Drug: Filgrastim|Genetic: T-Rapa cell DLI","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","11 Years to 90 Years   (Child, Adult, Senior)","Phase 2","377","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","040055|04-C-0055","June 19, 2006","December 11, 2003","December 31, 2022","May 12, 2017","February 3, 2017","No Study Results Posted","null","December 31, 2021","Safety and feasibility|Graft-versus-host disease rate|Pattern of post-transplantation CD4+ and CD8+ T-cell production of Th1-Th2-type cytokines|Incidence of opportunistic infection","https://ClinicalTrials.gov/show/NCT00074490"
2360,"NCT00050713","Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy","Completed","No Results Available","Membranous Glomerulonephritis|Lupus Membranous Nepropathy","Drug: Sirolimus","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","13 Years and older   (Child, Adult, Senior)","Phase 2","12","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","030071|03-DK-0071","December 17, 2002","December 17, 2002","August 27, 2007","May 12, 2017","July 7, 2015","No Study Results Posted","null","August 27, 2007","The number of patients who are in 1) complete remission or 2) complete or partial remission.|The number of patients who are in Complete or Partial Remission or Limited Response.|Frequency of adverse effects","https://ClinicalTrials.gov/show/NCT00050713"
2361,"NCT00054327","Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer","Completed","Has Results","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Drug: busulfan|Drug: cyclophosphamide|Drug: cytarabine|Radiation: radiation therapy|Drug: Etoposide|Procedure: Stem Cell Transfusion","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","up to 55 Years   (Child, Adult)","Phase 2","34","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU1Y00|P30CA043703|CASE-CWRU-1Y00","February 5, 2003","November 2000","September 2011","June 19, 2013","June 2013","April 30, 2013","null","September 2011","Rates of Durable Engraftment|Graft-versus-host Disease (GVHD)|Incidence of Recurrent Disease|Toxicity as Measured by CTC v2.0","https://ClinicalTrials.gov/show/NCT00054327"
2362,"NCT00089453","Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant","Completed","No Results Available","Multiple Myeloma","Drug: Dexamethasone|Drug: Cyclophosphamide|Drug: Melphalan|Drug: Fludarabine|Drug: Bortezomide|Procedure: Leukapheresis|Drug: Interleukin|Procedure: Infusion #1|Procedure: Leukapheresis #2|Procedure: Infusion #2|Procedure: Auto Graft","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UARK 2003-18","August 5, 2004","September 2003","May 2010","April 17, 2012","April 2012","No Study Results Posted","null","May 2010","To induce anti-myeloma responses in patients with high risk or relapsed myeloma using combination chemo- and immunotherapy comprising sequentially.|To establish the response rate, disease free survival , overall survival , and toxicity of regimen.","https://ClinicalTrials.gov/show/NCT00089453"
2363,"NCT00023192","Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care","Completed","No Results Available","Chronic Granulomatous Disease","Drug: T-Cell Depleted & CD34+Select/w/StemCell Enriched Product","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 3","60","NIH","Interventional","Primary Purpose: Treatment","010242|01-I-0242","August 29, 2001","August 2001","June 2004","March 3, 2008","June 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00023192"
2364,"NCT00114738","EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma","Active, not recruiting","No Results Available","Lymphoma, Mantle Cell|Mantle Cell Lymphoma","Drug: Rituximab (R)|Biological: EPOCH|Drug: Bortezomib (B)|Drug: Bortezomib|Drug: Bortezomib or observation","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Senior)","Phase 2","53","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","050170|05-C-0170","June 17, 2005","June 15, 2005","May 10, 2020","May 12, 2017","January 6, 2017","No Study Results Posted","null","May 10, 2018","PFS and OS","https://ClinicalTrials.gov/show/NCT00114738"
2365,"NCT02616848","Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers","Recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Everolimus|Drug: Eribulin","Istituti Ospitalieri di Cremona","Female","18 Years and older   (Adult, Senior)","Phase 1","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2014-000135-17","November 21, 2015","November 2015","null","November 25, 2015","November 2015","No Study Results Posted","null","November 2015","The recommended dose of everolimus in combination with eribulin in metastatic triple negative breast cancer|Signs of anti-tumor activity of the administered treatment|Maximum Plasma Concentration [Cmax] between everolimus and eribulin|Safety profile of the combination and thus to monitor the potential Adverse Events and vital sign abnormalities;","https://ClinicalTrials.gov/show/NCT02616848"
2366,"NCT02526823","Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma","Recruiting","No Results Available","Lymphoma, Non-Hodgkin;Hodgkin Disease","Drug: R-CHOP/CHOPE or ABVD chemotherapy regimen|Drug: R-CDOP/CDOPE or DBVD chemotherapy regimen","Shandong Provincial Hospital","All","18 Years to 80 Years   (Adult, Senior)","Phase 4","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Participant)|Primary Purpose: Treatment","ShandongPH01","August 11, 2015","August 2015","February 2019","April 17, 2016","April 2016","No Study Results Posted","null","August 2017","Percentage of patients with complete remission （CR）","https://ClinicalTrials.gov/show/NCT02526823"
2367,"NCT01087424","Mini-CHOP and Rituximab in Patients Aged Over 80 Years","Unknown status","No Results Available","Diffuse Large B-cell Lymphoma","Drug: RminiCHOP","Lymphoma Study Association","All","80 Years and older   (Senior)","Phase 2","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LNH03-7B","August 26, 2009","April 2006","April 2010","March 15, 2010","March 2010","No Study Results Posted","null","April 2010","Evaluating efficacy of R-miniCHOP by overall survival|Evaluating R-miniCHOP efficacy by Event free survival","https://ClinicalTrials.gov/show/NCT01087424"
2368,"NCT02299999","SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","Recruiting","No Results Available","Metastatic Breast Cancer","Drug: AZD2014|Drug: AZD4547|Drug: AZD5363|Drug: AZD8931|Drug: Selumetinib|Drug: Vandetanib|Drug: Bicalutamide|Drug: Olaparib|Drug: Anthracyclines|Drug: Taxanes|Drug: cyclophosphamide|Drug: DNA intercalators|Drug: Methotrexate|Drug: vinca alkaloids|Drug: Platinum based chemotherapies|Drug: Bevacizumab|Drug: Mitomycine C|Drug: Eribuline|Drug: MEDI4736","UNICANCER|Fondation ARC|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","1460","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","UC-0105/1304|2013-001652-36","October 1, 2014","April 7, 2014","June 2021","May 2, 2017","May 2017","No Study Results Posted","SAFIR02_Breast","June 2019","Progression-free survival in the targeted drug arm compared to standard maintenance therapy arm|progression-free survival in patients treated with anti-PDL1 antibody (MEDI4736) compared to standard maintenance therapy arm|overall survival in each substudy|overall response rates and changes in tumor size in each substudy|evaluate safety, in each substudy|efficacy (response rate, change in tumor size, progression-free survival, overall survival) and safety of each individual targeted agent (substudy 1)|correlate molecular characteristics in patients with the efficacy endpoints (response rate, progression-free and overall survival) in each substudy","https://ClinicalTrials.gov/show/NCT02299999"
2369,"NCT00080353","Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma","Completed","No Results Available","Melanoma","Drug: IL-2|Drug: gp100:209-217|Drug: OKT3|Drug: rF-go 100P209|Drug: Montanide ISA 51","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","7 Years and older   (Child, Adult, Senior)","Phase 2","58","NIH","Interventional","Primary Purpose: Treatment","040152|04-C-0152","March 27, 2004","March 2004","December 2008","June 12, 2012","June 2012","No Study Results Posted","null","December 2007","","https://ClinicalTrials.gov/show/NCT00080353"
2370,"NCT01528085","Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","Active, not recruiting","No Results Available","Philadelphia Chromsome Positive Acute Lymphoblastic Leukemia","Drug: Nilotinib","Johann Wolfgang Goethe University Hospital","All","55 Years and older   (Adult, Senior)","Phase 2","79","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","EWALL-PH-02|2010-022855-46","February 3, 2012","January 2012","November 2018","September 29, 2015","September 2015","No Study Results Posted","null","July 2017","Evaluation of efficacy of a nilotinib-based induction and consolidation therapy|complete haematological remission|major molecular response in bone marrow|complete molecular response|undetectable BCR-ABL level|Event free survival|Relapse free survival|Progression free survival|T315I or p-loop Mutations|molecular relapse or progression|Overall survival|Tolerability|Death during induction|Death in complete remission","https://ClinicalTrials.gov/show/NCT01528085"
2371,"NCT01799460","Study on Single-nucleotide-polymorphism in Idiopathic Membranous Nephropathy","Unknown status","No Results Available","Idiopathic Membranous Nephropathy","Drug: The Comprehensive Treatment Regimen of Traditional Chinese Medicine|Drug: The immunosuppressive agents","Shanghai University of Traditional Chinese Medicine","All","18 Years to 70 Years   (Adult, Senior)","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ShanghaiMEC-2011|11YZ65","January 8, 2013","December 2010","August 2013","April 22, 2013","April 2013","No Study Results Posted","null","August 2013","Genome-wide single-nucleotide-polymorphism of IMN patients treated by the Comprehensive Treatment Regimen or conventional approach","https://ClinicalTrials.gov/show/NCT01799460"
2372,"NCT00923364","Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC","Active, not recruiting","No Results Available","MDS|Immunodeficiency|GATA2","Drug: Cyclophosphamide (CTX, Cytoxan)|Drug: Fludarabine(Fludara,Berlex Laboratories)|Procedure: Total Body Irradiation (TBI)|Procedure: Allogeneic HSC|Drug: Equine Anti-Thymocyte Globulin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","12 Years to 60 Years   (Child, Adult)","Phase 2","19","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","090096|09-C-0096","June 17, 2009","March 5, 2009","January 30, 2018","January 26, 2017","September 23, 2016","No Study Results Posted","null","January 20, 2018","To determine whether allogeneic HSCT approach results in engraftment and restores normal hematopoiesis by day + 100 in patients with mutations GATA2.|Immune reconstitution|To determine the incidence of acute and chronic graft-versus-hostdisease|Overall survival, and disease-free survival","https://ClinicalTrials.gov/show/NCT00923364"
2373,"NCT00072592","An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies","Completed","No Results Available","Wegener's Granulomatosis","Drug: Rituximab","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 1","10","NIH","Interventional","Primary Purpose: Treatment","040022|04-I-0022","November 4, 2003","October 2003","August 2005","March 3, 2008","August 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00072592"
2374,"NCT00353860","Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances","Completed","No Results Available","Immunosuppression|Leukemia","Device: SOLEX 300i Stem Cell Selection","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","10 Years to 80 Years   (Child, Adult, Senior)","Phase 2","70","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","020111|02-H-0111","July 18, 2006","January 23, 2002","November 29, 2007","May 12, 2017","November 21, 2016","No Study Results Posted","null","November 29, 2007","The proportion of patients with clinically significant acute GHVD (Grade II or higher) following the T depleted PBPC transplant.","https://ClinicalTrials.gov/show/NCT00353860"
2375,"NCT00047060","Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome","Active, not recruiting","No Results Available","Mycosis Fungoides|Sezary Syndrome","Drug: Campath-1H","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","10","NIH","Interventional","Allocation: Non-Randomized|Masking: No masking|Primary Purpose: Treatment","020250|02-H-0250","October 3, 2002","July 30, 2002","December 30, 2017","May 12, 2017","March 31, 2017","No Study Results Posted","null","December 30, 2017","The primary goal is to find the minimal dose of conditioning regimen (of the two considered) which will establish engraftment in greater than 80% of patients.|Assess donor-host chimerism in various hematopoietic and lymphoid cells, dx response, incidence of acute/chronic GVHD, graft failure, assessment of lymphoid subset reconstitution, transplant related morbidity/mortality and dx-free and survival.","https://ClinicalTrials.gov/show/NCT00047060"
2376,"NCT00873093","Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","Completed","Has Results","B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Lymphoblastic Lymphoma|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia","Drug: L-asparaginase|Drug: doxorubicin hydrochloride|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate|Drug: cytarabine|Drug: prednisone|Drug: bortezomib|Drug: pegaspargase|Drug: methotrexate|Drug: etoposide phosphate|Drug: cyclophosphamide|Biological: filgrastim|Drug: leucovorin calcium|Other: laboratory biomarker analysis|Drug: High Dose MTX","National Cancer Institute (NCI)","All","1 Year to 31 Years   (Child, Adult)","Phase 2","148","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2011-01908|AALL07P1|U10CA180886|U10CA098543","March 31, 2009","March 2009","September 2014","November 30, 2016","November 2016","February 9, 2016","null","September 2014","Second Complete Remission Rate at the End of Block 1 Reinduction Chemotherapy|Event Free Survival|Toxic Death Rate|Severe Adverse Events (SAE) Rate.|Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 1|Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 2|Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3","https://ClinicalTrials.gov/show/NCT00873093"
2377,"NCT01724879","Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)","Completed","No Results Available","Philadelphia Positive Acute Lymphoblastic Leukemia","Drug: Dasatinib","Johann Wolfgang Goethe University Hospital","All","18 Years to 55 Years   (Adult)","Phase 2","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GMALL-PH-01|2010-022854-18","February 3, 2012","November 2011","September 2015","February 10, 2016","February 2016","No Study Results Posted","null","September 2015","Treatment-related discontinuation of study treatment (Proportion of Patients)|Molecular complete remission rate (CR)|Hematologic complete remission rate|Grade III and IV txicity by Common Terminology Criteria for Adverse Events Version 3","https://ClinicalTrials.gov/show/NCT01724879"
2378,"NCT00531973","A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging","Unknown status","No Results Available","Breast Cancer","Drug: liposomal doxorubicin|Drug: epirubicin","Catholic University, Italy|Cephalon","Female","18 Years to 65 Years   (Adult)","Phase 4","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LITE Randomized Pilot Study","September 18, 2007","January 2007","December 2009","February 17, 2009","February 2009","No Study Results Posted","LITE","August 2008","Comparison of changes of PW-TDI systolic function parameters. The co-primary end-point ill be the comparison of changes from baseline to 12-month follow-up of PW-TDI diastolic function parameters.|Changes of standard 2-dimensional echocardiography parameters, including LV ejection fraction, peak values of biochemical markers of cardiac damage and heart failure, ie cardiac troponin T and BNP.","https://ClinicalTrials.gov/show/NCT00531973"
2379,"NCT02786719","A Study of High Risk Induction Chemotherapy for Neuroblastoma Without Prophylactic Administration of Myeloid Growth Factors","Recruiting","No Results Available","Neuroblastoma","Drug: Topotecan|Drug: Cyclophosphamide|Drug: Cisplatin|Drug: Etoposide|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Sargramostim","Baylor College of Medicine|Texas Children's Hospital","All","12 Months to 18 Years   (Child, Adult)","","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H-38179 (SPRING)|SPRING","May 23, 2016","June 2016","June 2019","July 18, 2016","June 2016","No Study Results Posted","SPRING","December 2018","the incidence of infections in chemotherapy cycles NOT followed by hematopoietic growth factors|incidence of delay in chemotherapy administration due to prolonged neutrophil recovery|the number of antibiotic days and hospital days due to fever and/or infection|number of platelet transfusions in in patients undergoing induction chemotherapy|the response rate following induction chemotherapy without prophylactic granulocyte colony stimulating factor (G-CSF)","https://ClinicalTrials.gov/show/NCT02786719"
2380,"NCT01270373","NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After?","Active, not recruiting","No Results Available","Breast Cancer","Drug: FAC x 3 followed by Docetaxel x 3|Drug: Docetaxel x 3 followed by FAC x 3","Instituto Nacional de Cancer, Brazil|Sanofi","Female","Child, Adult, Senior","Phase 2","112","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Neo2010","January 4, 2011","August 2010","December 2016","September 1, 2016","September 2016","No Study Results Posted","NeoSAMBA","September 2016","Pathological complete response|Cardiac toxicity","https://ClinicalTrials.gov/show/NCT01270373"
2381,"NCT00869284","Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas","Completed","No Results Available","Lymphoma","Drug: CEEP regimen|Procedure: Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)","French Innovative Leukemia Organisation|Amgen","All","15 Years to 60 Years   (Child, Adult)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GOELAMS 073|no other identification number","March 23, 2009","October 1994","February 2009","March 24, 2009","March 2009","No Study Results Posted","073","July 1999","Complete response|overall survival disease free survival","https://ClinicalTrials.gov/show/NCT00869284"
2382,"NCT00013533","Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies","Completed","No Results Available","Hodgkin Lymphoma|Lymphocytic Leukemia|Mixed Cell Leukemia|Myelodysplastic Syndrome|Non Hodgkin's Lymphoma|CML|ALL|AML|Lymphoma","Procedure: Stem cell transplantation","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","4 Years to 20 Years   (Child, Adult)","Early Phase 1","30","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","010125|01-C-0125","March 20, 2001","March 14, 2001","May 7, 2015","May 12, 2017","May 7, 2015","No Study Results Posted","null","March 1, 2008","To determine the efficacy and safety of this chemotherapy regimen in facilitating donor engraftment after allogeneic bone marrow transplantation (BMT).|Safety/Efficacy|Toxicity of regimen|To determine the toxicity of this non-myelablative allogeneic BMT regimen.|fludarabine-based induction reducing T-cells|immune suppression|IL-7 levels|cytokine profiles|response rates and DFS|incidence and severity of GVHD|response rates, DFS rates, and incidence and severity ofGVHD following withdrawal of immunosuppression and donorlymphocyte infusions (DLI) for patients who developprogressive disease after day +28 post-transplant","https://ClinicalTrials.gov/show/NCT00013533"
2383,"NCT00477906","M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma","Not yet recruiting","No Results Available","Melanoma","Biological: M-Vax- autologous, hapten-modified melanoma vaccine","AVAX Technologies","All","Child, Adult, Senior","Phase 3","387","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A/100/0402","May 22, 2007","July 2016","January 2021","December 2, 2015","December 2015","No Study Results Posted","null","January 2019","Best overall anti-tumor response.|Survival - % patients surviving at two years|Safety","https://ClinicalTrials.gov/show/NCT00477906"
2384,"NCT01947322","Haploidentical NK-cell Infusion in Acute Myeloid Leukemia","Active, not recruiting","No Results Available","Acute Myeloid Leukemia","Drug: Allogenic NK cells infusion","Assistance Publique - Hôpitaux de Paris","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P070505","March 26, 2013","May 2011","September 2015","September 4, 2015","September 2015","No Study Results Posted","NK","December 2012","duration of neutropenia inferior to 500 neutrophils /mm3","https://ClinicalTrials.gov/show/NCT01947322"
2385,"NCT03011528","First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years","Recruiting","No Results Available","Ewing Sarcoma Family of Tumors","Drug: VDC-IE x2|Drug: VDC-IE|Drug: TEMIRI|Drug: Consolidation BuMel|Drug: Maintenance|Procedure: Local treatment by surgery|Radiation: Local treatment by radiotherapy","Institut Curie|UNICANCER","All","2 Years to 50 Years   (Child, Adult)","Phase 2","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IC 2015-13 CombinaiR3","December 6, 2016","December 2016","December 2022","March 23, 2017","March 2017","No Study Results Posted","CombinaiR3","May 2020","Anti-tumour effect of the treatment strategy assessed by the number of patients event-free survival (EFS) at 18 months|Anti-tumour effect of the dose-intensified induction chemotherapy assessed by the response rate of patients|Anti-tumour effect of the dose-intensified induction chemotherapy assessed by the number of patients eligible for consolidation phase|Overall survival (OS) is assessed by the number of patients still alive at the end of the three years of treatment|3-years event-free survival (EFS) is assessed by the number of patients without any event at the end of treatment phase|Number of patients with treatment-related adverse events as assessed by CTCAE v4.03|Number of patients with treatment-related toxicities on laboratory data as assessed by CTCAE v4.03 of the different phases of treatment|18F-FDG PET evaluation efficacy assessed by primary tumour uptake|18F-FDG PET evaluation efficacy assessed by metabolic tumour volume (MTV)|Percentage of circulating tumour cells in blood and bone marrow to correlate with patient outcome (EFS). Ancillary study|Comparison of transcriptomic profiles between those of primary disease and those of bone marrow metastases to determine if they are the same or not. Ancillary study","https://ClinicalTrials.gov/show/NCT03011528"
2386,"NCT01285765","Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+","Recruiting","No Results Available","DLBCL","Drug: RCHOP21","The Lymphoma Academic Research Organisation|CHU de Nancy","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","650","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","LNH 2009-1B","January 14, 2011","December 2010","December 2020","September 8, 2016","September 2016","No Study Results Posted","null","December 2020","Progression Free Survival|DELTA SUV|Overall Survival, EFS, response duration, DFS|prognostic impact of the existence of a high tumor burden at diagnosis (> 10 cm) on PFS|biological factors|Overall Response Rate|Rate of good responders according to results at PET after C2","https://ClinicalTrials.gov/show/NCT01285765"
2387,"NCT00793351","Reduced Intensity Stem Cell Transplantation in Children With Relapsed Neuroblastoma After Autologous Transplantation","Completed","No Results Available","Neuroblastoma","Procedure: Reduced-intensity allogeneic hematopoietic stem cell transplantation","Samsung Medical Center","All","up to 20 Years   (Child, Adult)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2008-08-073","November 17, 2008","September 2008","November 2015","October 17, 2016","November 2015","No Study Results Posted","null","November 2013","tumor response, overall survival, event-free survival","https://ClinicalTrials.gov/show/NCT00793351"
2388,"NCT02176967","Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma","Recruiting","No Results Available","Ganglioneuroblastoma|Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Recurrent Neuroblastoma|Regional Neuroblastoma|Stage 4 Neuroblastoma","Other: Clinical Observation|Drug: Carboplatin|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 17 Months   (Child)","Phase 3","621","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ANBL1232|NCI-2014-00677|U10CA098543|U10CA180886","June 26, 2014","July 2014","null","September 23, 2016","September 2016","No Study Results Posted","null","June 2019","OS (Strata 1-4)|EFS (Stratum 5)|Time to intervention or tumor progression|Type of intervention required|Site of progression|Pharmacokinetic (PK) profile of carboplatin and etoposide in patients with stage Ms disease, including peak concentration, area under the curve, clearance, volume of distribution, half-life, and mean residence time|Genomic profile of tumors|Histology of tumor specimens|Salvage rate (OS) of patients with tumor relapse or disease progression|Procedural complication rate|Rate of reduction in IDRF in L2 tumors","https://ClinicalTrials.gov/show/NCT02176967"
2389,"NCT03085914","A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207)","Recruiting","No Results Available","Advanced or Metastatic Solid Tumors|Advanced or Metastatic Colorectal Cancer (CRC)|Pancreatic Ductal Adenocarcinoma (PDAC)|Non-Small Cell Lung Cancer (NSCLC; Squamous or Nonsquamous)|Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Protein 1 (PD-1) Inhibitor|Advanced or Metastatic Solid Tumor That Progressed on Previous Therapy With a Programmed Cell Death Ligand 1 (PD-L1) Inhibitor","Drug: Epacadostat|Drug: Nivolumab|Drug: Pembrolizumab|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5-Fluorouracil|Drug: Gemcitabine|Drug: nab-Paclitaxel|Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed|Drug: Cyclophosphamide|Drug: Carboplatin","Incyte Corporation","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","332","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","24360-207 / ECHO-207","February 28, 2017","May 2, 2017","October 2022","May 23, 2017","May 2017","No Study Results Posted","null","April 2021","Phase 1: Safety and tolerability assessed by frequency, duration, and severity of adverse events (AEs)|Phase 2: Objective response rate (ORR) based on modified Response Evaluation Criteria in Solid Tumors (mRECIST)|Phase 1: ORR based on mRECIST|Phase 2: Safety and tolerability assessed by frequency, duration, and severity of AEs|Phases 1 and 2: Duration of response (DOR)|Phases 1 and 2: Progression-free survival","https://ClinicalTrials.gov/show/NCT03085914"
2390,"NCT03105336","A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma","Not yet recruiting","No Results Available","Follicular Lymphoma|Marginal Zone Lymphoma|Indolent Non-Hodgkin Lymphoma","Biological: KTE-C19","Kite Pharma, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","KTE-C19-105","April 3, 2017","April 2017","July 2023","April 19, 2017","April 2017","No Study Results Posted","ZUMA-5","December 2018","Objective response rate|Progression Free Survival|Overall Survival|Incidences of AEs|Clinical significant changes in lab values.","https://ClinicalTrials.gov/show/NCT03105336"
2391,"NCT00563953","Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years","Completed","No Results Available","Breast Cancer","Drug: Liposomal pegylated doxorubicine","SOLTI Breast Cancer Research Group|Schering-Plough","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SOLTI0702|2007-001428-11","November 26, 2007","September 2007","August 2016","December 21, 2016","August 2016","No Study Results Posted","CAPRICE","February 2011","Pathological complete response (pCR). pCR is defined as the absence of invasive cancer in the surgical breast specimen. This definition includes evidence of carcinoma in situ only.|Clinical response rate (complete plus partial responses). Clinical response will be assessed by imaging using the WHO criteria.|Breast-conserving surgery: tumorectomy or quadrantectomy with or without lymphadenectomy versus mastectomy.|Axillary node involvement after primary chemotherapy.|Left ventricular ejection fraction measured by echocardiography or MUGA.|Cardiac sign/symptom questionnaire.|Relapse-free survival at 5 years after surgery and overall survival at 5 years after study entry.","https://ClinicalTrials.gov/show/NCT00563953"
2392,"NCT02605694","Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)","Terminated","No Results Available","Lymphoma","Drug: Duvelisib|Drug: Rituximab|Drug: R-CHOP|Drug: Prednisone","Verastem, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","230","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","IPI-145-21|2015-004729-15","November 4, 2015","December 2015","November 2016","March 28, 2017","July 2016","No Study Results Posted","null","November 2016","Progression Free Survival (PFS)|Complete Response Rate (CRR)|Overall Response Rate (ORR)|Overall Survival|Safety (Treatment Emergent Adverse Events (TEAEs) and changes in safety laboratory values as assessed by NCI-CTCAE, version 4.03)|Pharmacokinetics: Evaluate the Duvelisib concentration in plasma sample|Duration of Response|Pharmacokinetics: Evaluate IPI-656 (metabolite) concentration in plasma sample","https://ClinicalTrials.gov/show/NCT02605694"
2393,"NCT03153462","Axicabtagene Ciloleucel Expanded Access Study","Available","No Results Available","Relapsed/Refractory Transplant Ineligible Diffuse Large B Cell Lymphoma|Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma|Relapsed/Refractory Transplant Ineligible Transformed Follicular Lymphoma","Biological: Axicabtagene Ciloleucel","Kite Pharma, Inc.","All","18 Years and older   (Adult, Senior)","","null","Industry","Expanded Access","","KTE-C19-109","May 11, 2017","null","null","May 11, 2017","April 2017","No Study Results Posted","ZUMA-9","null","","https://ClinicalTrials.gov/show/NCT03153462"
2394,"NCT00581854","Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma","Completed","Has Results","Mantle Cell Lymphoma","Drug: modified Hyper-CVAD","University of Wisconsin, Madison","All","18 Years and older   (Adult, Senior)","Phase 2","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HO00401","December 19, 2007","June 2000","March 2010","June 25, 2014","June 2014","December 2, 2011","null","June 2006","Complete Response Rate to Induction Therapy","https://ClinicalTrials.gov/show/NCT00581854"
2395,"NCT00574080","UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide","Terminated","Has Results","Multiple Myeloma","Drug: Dexamethasone|Drug: DPACE/Melphalan","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 3","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-15","December 12, 2007","July 2006","March 2011","June 1, 2011","June 2011","May 4, 2011","null","March 2011","Addition of Bortezomib, Thalidomide, and Dexamethasone to High Dose Chemotherapy Regimen Immediately Before Transplant|Side Effects With Both Transplant Regimens","https://ClinicalTrials.gov/show/NCT00574080"
2396,"NCT00355199","Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.","Completed","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Rituximab-HDS|Drug: Rituximab-CHOP","Gruppo Italiano Terapie Innovative nei Linfomi","All","18 Years to 65 Years   (Adult)","Phase 3","246","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","EUDRACT: 2005-00700-14","July 20, 2006","May 2005","March 2013","March 10, 2017","March 2017","No Study Results Posted","null","March 2013","Event free survival|Complete Remission|Disease Free Survival|Overall Survival|Toxicity|Efficacy of R-HDS conditioning as salvage therapy in patients non-responders after four cycles of R-CHOP 14","https://ClinicalTrials.gov/show/NCT00355199"
2397,"NCT02290132","ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma","Drug: Rabbit Anti－human Thymocyte Globulin (ATG)","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Tang-Du Hospital|The First Affiliated Hospital of Soochow University|The First Affiliated Hospital with Nanjing Medical University","All","18 Years to 60 Years   (Adult)","Phase 4","63","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2013（56）","October 13, 2014","August 2013","July 2017","November 8, 2014","November 2014","No Study Results Posted","HSCT","December 2016","Progress free surviva(PFS) rate at 2 years|Leukocyte engraftment|Platelet engraftment|Donor chimerism:|Relapse incidence (RI)|Overall survival rate|Transplant related mortality(TRM)","https://ClinicalTrials.gov/show/NCT02290132"
2398,"NCT00801931","Double Cord Blood Transplantation","Terminated","No Results Available","Leukemia|Lymphoma|Neuroblastoma|Immunodeficiencies|Anemia","Drug: TBI, Thiotepa, Cyclophosphamide, ATG|Drug: Busulfan, Melphalan, Rabbit ATG|Drug: Busulfan, Fludarabine, Alemtuzumab|Drug: Busulfan, Fludarabine, Rabbit ATG|Drug: Fludarabine, Cyclophosphamide, ATG|Drug: Busulfan, Cyclosphosphamide, Rabbit ATG,","Columbia University","All","up to 30 Years   (Child, Adult)","Phase 1|Phase 2","1","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AAAC3457|CHNY-06-533","May 5, 2008","September 2007","May 2009","July 17, 2013","July 2013","No Study Results Posted","null","May 2009","To determine the safety and toxicity and feasibility of double umbilical cord blood transplantation (DUCBT) in patients with selected malignant and non-malignant.|To quantify the percentage and donor sources of mixed donor chimerism following DUCBT in patients with selected malignant and non-malignant disorders.","https://ClinicalTrials.gov/show/NCT00801931"
2399,"NCT01304849","Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve Outcomes","Completed","No Results Available","Hodgkin's Lymphoma","Drug: Escalated BEACOPP","Cancer Institute WIA","All","12 Years to 65 Years   (Child, Adult)","","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CIA-HL-1","February 25, 2011","January 2011","September 2013","February 2, 2015","February 2015","No Study Results Posted","null","September 2013","Efficacy of interim PET guided therapy strategy interms of EFS in advanced HL|Toxicity of escalated BEACOPP","https://ClinicalTrials.gov/show/NCT01304849"
2400,"NCT02405364","Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib/Lenalidomide/Dexamethasone","University Hospital, Toulouse|Onyx Therapeutics, Inc.|Celgene","All","18 Years to 65 Years   (Adult)","Phase 2","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","12 568 03","October 16, 2013","February 2014","June 2017","February 21, 2017","February 2017","No Study Results Posted","IFM-CRd","June 2017","rate of stringent complete response","https://ClinicalTrials.gov/show/NCT02405364"
2401,"NCT01046825","Mature B-Cell Lymphoma And Leukemia Study III","Recruiting","No Results Available","Mature B-Cell Lymphoma","Drug: COPAD|Drug: COP, COPD M3, CYM|Drug: COP, COPADM8, CYVE","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","Phase 2|Phase 3","122","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SJBC3|NCI-2011-01251","January 8, 2010","September 9, 2010","October 31, 2022","May 19, 2017","May 2017","No Study Results Posted","null","October 31, 2022","Gene differential profiling of Burkitts Lymphoma (BL) vs. non-BL|Catalog and estimate frequencies of copy number variations in childhood lymphomas|Integrated analysis of CNVs and gene expressions|Pattern and frequency of XLP gene mutations presenting with B-cell lymphomas in the United States and selected geographic regions|Pattern of EBV protein expression (e.g., EBNA 3) in EBV-positive lymphomas and to compare patterns of EBV protein expression with clinical, laboratory and outcome data|Complete response rate|Event-free survival|Overall Survival|Percentage of participants who complete therapy with the use of rituximab|Number of possible rituximab-related toxicities","https://ClinicalTrials.gov/show/NCT01046825"
2402,"NCT00678327","Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: bleomycin sulfate|Biological: filgrastim|Biological: pegfilgrastim|Drug: cyclophosphamide|Drug: dacarbazine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisolone|Drug: procarbazine hydrochloride|Drug: vinblastine sulfate|Drug: vincristine sulfate","Cancer Research UK|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","1200","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000593562|CRUK-2007-006064-30|CRUK-07/146","May 9, 2008","August 2008","null","August 23, 2013","June 2009","No Study Results Posted","null","September 2012","3-year progression-free survival|Overall survival|Acute and chronic toxicity as assessed by NCI CTCAE v3.0","https://ClinicalTrials.gov/show/NCT00678327"
2403,"NCT01701674","Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts","Active, not recruiting","Has Results","Metastatic Melanoma","Drug: Ipilimumab|Procedure: Tumor Infiltrating Lymphocytes (TIL)|Drug: Administration of Lymphodepletion|Drug: Cyclophosphamide as Part of Lymphodepletion|Drug: Fludarabine as Part of Lymphodepletion|Drug: High Dose IL-2|Biological: Adoptive Cell Therapy with TIL","H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Lion Biotechnologies","All","18 Years and older   (Adult, Senior)","","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-17057|CA184-213","October 3, 2012","October 3, 2012","November 30, 2017","March 22, 2017","March 2017","March 22, 2017","null","April 21, 2016","Occurrence of Dose Limiting Toxicity (DLT) Events|Rate of Meeting Feasibility Requirements|Overall Response Rate (ORR)|Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01701674"
2404,"NCT02810743","Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: ddAC-CP-Olaparib|Drug: ddAC-mini CTC","The Netherlands Cancer Institute","All","18 Years to 65 Years   (Adult)","Phase 3","174","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","M16BRC","June 16, 2016","August 2016","August 2029","March 29, 2017","January 2017","No Study Results Posted","Subito","August 2019","Overall survival|Recurrence free interval|Incidence of toxicity, graded according to National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.03|cost-effectiveness measured by costs per quality-adjusted life years (QALYs)|Patient reported outcomes|cost-effectiveness measured by incremental cost-effectiveness ratio (ICER)","https://ClinicalTrials.gov/show/NCT02810743"
2405,"NCT01929811","NeoMET Study in Neoadjuvant Treatment of Breast Cancer","Recruiting","No Results Available","pCR Rate|BCT Rate|Safety","Drug: Metformin|Drug: Docetaxel|Drug: Epirubicin|Drug: cyclophosphomide","Shanghai Jiao Tong University School of Medicine","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RJBC1301","August 11, 2013","October 2013","September 2020","October 22, 2016","October 2016","No Study Results Posted","NeoMET","December 2017","pathologic complete response rate|Clinical response rate|safety profile|breast conservation therapy (BCT) rate","https://ClinicalTrials.gov/show/NCT01929811"
2406,"NCT03123718","High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL","Not yet recruiting","No Results Available","DLBCL","Drug: Intrathecal methotrexate|Drug: High-dose intravenous methotrexate","Chonnam National University Hospital|Consortium for Improving Survival of Lymphoma","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","205","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Prevention","HDMTX","April 18, 2017","July 1, 2017","June 30, 2021","April 21, 2017","April 2017","No Study Results Posted","null","June 30, 2021","Cumulative incidence of CNS relapse|Toxicity|Progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT03123718"
2407,"NCT02973191","A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia","Withdrawn","No Results Available","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Drug: JCAR015","Celgene|Juno","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","0","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","JCAR015-ALL-001","November 22, 2016","December 20, 2016","January 24, 2021","April 7, 2017","April 2017","No Study Results Posted","ORBIT","June 25, 2019","Overall Response Rate (ORR)|Minimal residual disease (MRD)|Adverse Events (AEs)|Duration of Minimal residual disease (MRD) response|Relapse-free survival (RFS)|Event-free survival (EFS)|Overall survival (OS)|Percent Minimal residual disease (MRD) negative|Depth of Minimal residual disease (MRD) response|Duration of remission (DOR)|Pharmacokinetics - Cmax|Pharmacokinetics- Tmax|Pharmacokinetics - AUC","https://ClinicalTrials.gov/show/NCT02973191"
2408,"NCT01679860","Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma","Completed","No Results Available","Lymphoma, T-Cell, Peripheral","Procedure: Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT|Drug: Clin B (CHOP- CAMPATH) Chemo-immunotherapy","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","All","18 Years to 60 Years   (Adult)","Phase 2","92","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PTCL-062006-004234-33","August 30, 2012","November 2006","August 2012","September 3, 2012","September 2012","No Study Results Posted","PTCL-06","December 2011","Efficacy|evaluation of OS (overall survival)|DFS (Disease Free Survival)|TRM (Treatment Related Mortality)","https://ClinicalTrials.gov/show/NCT01679860"
2409,"NCT00547196","Study of Four Different Chemotherapy Regimens With or Without Total-Body Irradiation Followed by Umbilical Cord Blood Transplant in Treating Patients With Relapsed or Refractory Hematologic Cancer","Active, not recruiting","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes","Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: melphalan|Drug: mycophenolate mofetil|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: total-body irradiation","City of Hope Medical Center|National Cancer Institute (NCI)","All","up to 120 Years   (Child, Adult, Senior)","","10","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","02165|P30CA033572|CHNMC-02165|CDR0000570249","October 19, 2007","August 2005","September 2017","February 10, 2017","February 2017","No Study Results Posted","null","September 2017","Survival at day 100 after allogeneic hematopoietic stem cell transplantation (HSCT) from umbilical cord blood (UCB)|Incidence and timing of neutrophil engraftment|Incidence and timing of platelet engraftment|Incidence and severity of acute and chronic graft-versus-host-disease|Survival at day 180 after HSCT from UCB transplantation|Disease-free survival|Incidence of primary and secondary engraftment failure|Incidence of transplantation-related complications (e.g., infection, veno-occlusive disease of the liver, or organ toxicity)|Incidence of post-transplantation-related lymphoproliferative disease, secondary myelodysplastic syndromes, and other secondary malignancies|Incidence of relapse|Post-transplantation chimerism|Immune reconstitution","https://ClinicalTrials.gov/show/NCT00547196"
2410,"NCT02464774","Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Procedure: Breast-Conserving Therapy|Procedure: Mastectomy|Drug: Adjuvant Chemotherapy|Radiation: Radiation Therapy","Xiaoming Xie|Sun Yat-sen University","Female","18 Years to 65 Years   (Adult)","","464","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2014-FXY-093","June 1, 2015","July 2015","null","June 3, 2015","June 2015","No Study Results Posted","null","December 2022","Disease-free survival(DFS)|Locoregional recurrence-free survival(LRRFS)|Distant metastasis (DM)","https://ClinicalTrials.gov/show/NCT02464774"
2411,"NCT00393029","Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes","Completed","Has Results","Anti-p53 TCR-Gene","Biological: anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes|Biological: aldesleukin|Biological: filgrastim|Drug: cyclophosphamide|Drug: fludarabine phosphate","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","12","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","070003|07-C-0003","October 25, 2006","October 2006","November 2008","August 10, 2011","August 2011","June 1, 2011","null","November 2008","Clinical Tumor Regression|The Number of Participants With Adverse Events|In Vivo Survival of T-cell Receptor (TCR) Gene-engineered Cells in Participants","https://ClinicalTrials.gov/show/NCT00393029"
2412,"NCT00049517","Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia","Active, not recruiting","Has Results","Leukemia","Biological: sargramostim|Drug: busulfan|Drug: cyclophosphamide|Drug: cytarabine|Drug: gemtuzumab ozogamicin (GO)|Drug: Daunorubicin|Procedure: Autologous HCT|Procedure: Allogeneic HCT","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","16 Years to 60 Years   (Child, Adult)","Phase 3","657","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000258113|U10CA021115|E1900","November 12, 2002","December 2002","January 2019","December 1, 2016","December 2016","January 10, 2013","null","March 2009","Overall Survival (Induction Phase)|Disease-free Survival (Consolidation Phase)|Overall Survival (Consolidation Phase)","https://ClinicalTrials.gov/show/NCT00049517"
2413,"NCT01067300","A Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in the Young With Acute Leukemia Remission","Active, not recruiting","No Results Available","Leukemia","Procedure: Transplantation of unrelated cord blood unit(s)","Assistance Publique Hopitaux De Marseille","All","up to 35 Years   (Child, Adult)","Phase 3","198","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2009-17|2009-A00792-55","February 10, 2010","February 2010","January 2016","September 29, 2015","September 2015","No Study Results Posted","null","January 2016","to compare the incidence of transplantation failure in the two treatment arms.|a cost-effectiveness study, the effectiveness criterion being a decrease in transplantation failure incidence.","https://ClinicalTrials.gov/show/NCT01067300"
2414,"NCT00008008","Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: filgrastim|Biological: sargramostim|Drug: cyclophosphamide|Drug: thiotepa|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","40","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000068362|CPMC-IRB-8017|CPMC-CAMP-013|NCI-G00-1883","January 6, 2001","September 1997","May 2008","February 1, 2013","July 2007","No Study Results Posted","null","June 2005","Response rate|Disease-free interval|Overall survival|Toxicity|Pharmacokinetics|Presence of high-dose thiotepa in the cerebrospinal fluid","https://ClinicalTrials.gov/show/NCT00008008"
2415,"NCT00003163","Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers","Unknown status","No Results Available","Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Biological: sargramostim|Drug: cyclophosphamide|Drug: melphalan|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Medical College of Wisconsin|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","10","Other","Interventional","Primary Purpose: Treatment","CDR0000065959|MCW-96110|MCW-HRRC-29196|NCI-V97-1368","November 1, 1999","September 1997","null","January 3, 2014","October 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003163"
2416,"NCT01461837","Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease","Recruiting","No Results Available","Sickle Cell Disease","Drug: CD34 selected T-cell depleted allogeneic SCT","New York Medical College|Children's Hospital & Research Center Oakland|Medical College of Wisconsin|Washington University School of Medicine|Tufts Medical Center|University of California, San Francisco|University of California, Los Angeles|Miltenyi Biotec GmbH|Ann and Robert H. Lurie Children's Hospital of Chicago","All","2 Years to 20 Years   (Child, Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NYMC526-4090|FD-R-0004090","October 19, 2011","January 2012","April 2019","May 5, 2017","May 2017","No Study Results Posted","HaploSCD","April 2018","Treatment related events|neurological/neurocognitive status|Pulmonary/pulmonary vascular status|Health-related quality of life","https://ClinicalTrials.gov/show/NCT01461837"
2417,"NCT00315133","Safety and Efficacy Study of Autologous Stem Cell Transplantation for Early Onset Type I Diabetes Mellitus","Completed","No Results Available","Type 1 Diabetes Mellitus","Procedure: Immunosuppression and autologous stem cell transplantation","University of Sao Paulo|Northwestern University|Genzyme, a Sanofi Company","All","12 Years to 35 Years   (Child, Adult)","Phase 1|Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HCFMRPUSP","April 13, 2006","December 2003","December 2014","January 13, 2017","January 2017","No Study Results Posted","null","December 2010","C-peptide levels|Transplant-related toxicity|Anti-GAD titres|Exogenous insulin dose|Hemoglobin A1C|Immunologic reconstitution parameters|Quality of Life","https://ClinicalTrials.gov/show/NCT00315133"
2418,"NCT00461747","GEM05 for Patients With Multiple Myeloma Under 65 Years","Completed","No Results Available","Multiple Myeloma","Drug: VBMCP/VBAD/Velcade|Drug: Thalidomide/Dexamethasone|Drug: Velcade/Thalidomide/Dexamethasone","PETHEMA Foundation","All","up to 65 Years   (Child, Adult)","Phase 3","390","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2005-001110-41","April 17, 2007","March 2006","December 2008","September 17, 2009","September 2009","No Study Results Posted","GEM05MENOS65","December 2008","The primary objective is to compare safety and efficacy of three induction treatments: VBMCP-VBAD / Velcade versus Thalidomide / Dexamethasone versus Velcade / Thalidomide / Dexamethasone.|Evaluate the ability of stem cell mobilization after the treatments in order to do an autologous transplant. Otherwise this study wants to compare the safety and efficacy of the maintenance treatments: Interferón a-2b versus Thalidomide","https://ClinicalTrials.gov/show/NCT00461747"
2419,"NCT00686556","Total Marrow Irradiation for Refractory Acute Leukemia","Active, not recruiting","No Results Available","Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome|Multiple Myeloma","Drug: cyclophosphamide|Drug: cyclosporine|Drug: Fludarabine|Drug: mycophenolate mofetil|Radiation: total marrow irradiation|Procedure: umbilical cord blood transplantation|Biological: Granulocyte colony-stimulating factor|Biological: HLA-matched related donor bone marrow","Masonic Cancer Center, University of Minnesota","All","up to 55 Years   (Child, Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2007LS024|MT2006-24|0708M14041","May 29, 2008","August 2012","April 2017","December 7, 2016","December 2016","No Study Results Posted","null","February 2016","Maximum tolerated dose (MTD) of total marrow irradiation (TMI)|Incidence of neutrophil engraftment|Incidence of platelet engraftment|Incidence of complete donor chimerism|Incidence of transplantation-related mortality|Incidence of grade II-IV and grade III-IV acute graft-versus-host disease (GVHD) after transplantation|Incidence of chronic GVHD after transplantation|Incidence of relapse after transplantation|Disease-free survival after transplantation|Durability of remission based on presence of rapid early response after transplantation|Overall survival after transplantation","https://ClinicalTrials.gov/show/NCT00686556"
2420,"NCT02436707","Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","Recruiting","No Results Available","Lymphoma","Drug: Ibrutinib|Drug: Rituximab|Drug: Gemcitabine|Drug: Dexamethasone|Drug: Cisplatin|Drug: Mesna|Drug: Cyclophosphamide|Drug: Etoposide|Drug: G-CSF","Canadian Cancer Trials Group|Janssen, LP","All","16 Years to 65 Years   (Child, Adult)","Phase 2","320","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","LY17","May 4, 2015","May 5, 2015","December 2019","May 8, 2017","March 2017","No Study Results Posted","null","June 2019","Measure overall response rate|Number and severity of adverse events|Transplantation rate|Stem cell collection rate|Event free Survival Rate|Overall Survival","https://ClinicalTrials.gov/show/NCT02436707"
2421,"NCT01683279","A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia","Active, not recruiting","No Results Available","B Cell Leukemia","Biological: Autologous CD19 CAR+ EGFTt + T cells","Seattle Children's Hospital","All","1 Year to 26 Years   (Child, Adult)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","PLAT-01","September 7, 2012","December 2012","January 2031","May 1, 2017","May 2017","No Study Results Posted","null","January 2031","Number of Participant with Adverse Events|Persistence of the CD19 CAR+ T cells|Determine if there is anti-leukemic activity of the CD19 CAR+ T cells","https://ClinicalTrials.gov/show/NCT01683279"
2422,"NCT00723658","S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia","Withdrawn","No Results Available","Lymphoma","Biological: rituximab|Drug: bortezomib|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: melphalan|Drug: thalidomide|Procedure: autologous-autologous tandem hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S0629|U10CA032102","July 26, 2008","September 2008","null","March 5, 2015","March 2015","No Study Results Posted","null","May 2010","Progression-free survival at 3 years|Overall survival|Response rate (complete response, very good partial response, and partial response)|Standard prognostic factors and other potential correlates that may relate to progression, symptomatic disease, and/or survival|Toxicity","https://ClinicalTrials.gov/show/NCT00723658"
2423,"NCT01228331","Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL","Recruiting","No Results Available","Leukemia","Drug: Amsacrine|Drug: Clofarabine|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Daunorubicin hydrochloride|Drug: Dexamethasone|Drug: Doxorubicin hydrochloride|Drug: Etoposide phosphate|Drug: Mercaptopurine|Drug: Methotrexate|Drug: Methylprednisolone|Drug: Pegaspargase|Drug: Thioguanine|Drug: Vincristine sulfate|Radiation: Whole-brain radiation therapy","Universitätsklinikum Hamburg-Eppendorf","All","1 Year to 17 Years   (Child)","Phase 2|Phase 3","660","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000686545|2009-012758-18","October 23, 2010","October 2010","September 2021","May 10, 2016","May 2016","No Study Results Posted","null","September 2016","Safety and efficacy of clofarabine combined with pegaspargase (phase II)|Incidence of infectious complications after administration of daunorubicin hydrochloride vs doxorubicin hydrochloride","https://ClinicalTrials.gov/show/NCT01228331"
2424,"NCT00185614","Mixed Chimera Allo Transplantation in Multiple Myeloma","Completed","No Results Available","Blood Cancer|Multiple Myeloma","Procedure: autologous then nonmyeloablative allogeneic transplant|Drug: cyclophosphamide|Drug: Melphalan|Drug: cyclosporin|Drug: Mycophenolate mofetil","Stanford University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","48","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT109|75190","September 12, 2005","August 2000","April 2010","April 18, 2011","April 2011","No Study Results Posted","null","April 2009","Survival, event-free survival and relapse rate with an intent-to-treat analysis. Results will be compared to allogeneic HCT reported results.|Development of Graft Versus Host Disease (GVHD) in vaccinated patients|Development of GVHD in concurrent myeloma patients receiving allogeneic HCT at our institution who are not candidates for vaccination.","https://ClinicalTrials.gov/show/NCT00185614"
2425,"NCT01188174","Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure","Completed","No Results Available","AML","Drug: Clofarabine","Nantes University Hospital","All","18 Years to 55 Years   (Adult)","Phase 2","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BRD 09/6-C","August 11, 2010","July 2010","December 2014","December 4, 2014","December 2014","No Study Results Posted","setric","December 2014","Evaluation of the survival rate at 2 years after transplantation","https://ClinicalTrials.gov/show/NCT01188174"
2426,"NCT00005585","Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia","Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: pegaspargase|Drug: thioguanine|Drug: vincristine sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 9 Years   (Child)","Phase 3","838","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","9904|COG-P9904|POG-9904|CDR0000067657|NCI-2012-02321","May 2, 2000","April 2000","null","June 7, 2013","June 2013","No Study Results Posted","null","July 2007","Event-free survival|Occurrence of anticipated failures|Grade 3 or greater CNS toxicity rates assessed using NCI CTC version 2.0|Measures of laboratory factors (other than MRD)|Homocysteine levels","https://ClinicalTrials.gov/show/NCT00005585"
2427,"NCT02199301","Tolerance Induction in Living Donor Kidney Transplantation With Hematopoietic Stem Cell Transplantation","Recruiting","No Results Available","End Stage Renal Disease","Procedure: Transplantation Conditioning for BMT","Samsung Medical Center","All","18 Years and older   (Adult, Senior)","","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-07-210","September 10, 2012","December 2011","December 2017","July 22, 2014","September 2012","No Study Results Posted","null","December 2015","Immune Suppression Withdrawal|Graft failure|Allograft Rejection","https://ClinicalTrials.gov/show/NCT02199301"
2428,"NCT01659151","Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma","Active, not recruiting","No Results Available","Metastatic Melanoma","Drug: High Dose Interleukin-2 (IL-2)|Procedure: ACT with TIL Infusion|Drug: Vemurafenib|Drug: Lymphodepletion","H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Senior)","Phase 2","17","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MCC-16992","August 3, 2012","July 26, 2012","March 2018","May 22, 2017","May 2017","No Study Results Posted","null","March 2018","Overall Response (OR)|Drop Out Rate|Number of Participants with Progression Free Survival (PFS)","https://ClinicalTrials.gov/show/NCT01659151"
2429,"NCT00002989","Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome","Unknown status","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: busulfan|Drug: cyclophosphamide|Drug: idarubicin|Drug: melphalan|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI)","All","16 Years to 60 Years   (Child, Adult)","Phase 3","207","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065526|EORTC-06962","November 1, 1999","March 1997","null","February 6, 2009","July 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002989"
2430,"NCT01526850","Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease","Unknown status","No Results Available","Chronic Graft Versus Host Disease","Biological: Biological: mesenchymal stem cell|Drug: Cyclosporine and Glucocorticoid","Chinese Academy of Medical Sciences|Zhejiang University|Chinese PLA General Hospital|307 Hospital of PLA|Peking Union Medical College","All","2 Years to 60 Years   (Child, Adult)","Phase 2|Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","D07050701350701","February 1, 2012","February 2012","June 2014","August 1, 2012","February 2012","No Study Results Posted","MSCsTcGVHD","December 2013","The total Response rate defined as patients with complete and partial response|one-year survival rate|disease relapse|quality of life","https://ClinicalTrials.gov/show/NCT01526850"
2431,"NCT02495454","GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma","Recruiting","No Results Available","CD20 Positive Diffuse Large B-cell Lymphoma|Elderly Unfit Patients","Drug: Ga101","Fondazione Italiana Linfomi ONLUS","All","65 Years and older   (Adult, Senior)","Phase 2","78","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","FIL_GAEL|2014-005697-10","June 8, 2015","May 2015","June 2020","August 24, 2016","August 2016","No Study Results Posted","FIL_GAEL","June 2018","Complete Response Rate (CRR)|Adverse Events (AEs)|Partial (PRR) and Overall Response Rate (ORR)|Overall Survival (OS)|Progression Free Survival (PFS)|Activities of daily living (ADL)|Instrumental Activities of Daily Living (IADL)|Cumulative Illness Rating Scale (CIRS)|Questionnaire for quality of life (EORTC QLQ C30)","https://ClinicalTrials.gov/show/NCT02495454"
2432,"NCT02169791","Nonmyeloablative Haploidentical Transplant Followed by MLN9708","Recruiting","No Results Available","Acute Leukemia|Chronic Leukemia|Myelodysplastic Syndrome|Lymphomas|Multiple Myeloma","Drug: MLN9708","Northside Hospital, Inc.|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","NSH 1074|X16035","June 19, 2014","September 2014","June 2020","December 12, 2016","December 2016","No Study Results Posted","null","December 2017","Incidence of Relapse and progression|Overall Survival|Event Free|Non-relapsed mortality|Graft-versus-host disease","https://ClinicalTrials.gov/show/NCT02169791"
2433,"NCT00113932","UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Procedure: High-Dose Density Therapy","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 2","140","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UARK 2003-41","June 10, 2005","December 2003","July 2010","September 1, 2011","September 2011","No Study Results Posted","null","February 2009","To evaluate whether high-dose density treatment during the initial seven months, including tandem transplants within six months after starting therapy, results in superior event-free and overall survival rates as compared to historical controls.|To evaluate the ability of pegfilgrastim to mobilize stem cells when administered following DTPACE in MM patients with active disease, compared to historical controls mobilized with DTPACE and either GM-CSF or G-CSF.","https://ClinicalTrials.gov/show/NCT00113932"
2434,"NCT00113828","Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies","Terminated","No Results Available","Lymphoma|Leukemia|Multiple Myeloma|Myelodysplastic Syndrome","Procedure: Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|Procedure: T-cell depleted peripheral blood stem cell transplant","Massachusetts General Hospital|Dana-Farber Cancer Institute","All","18 Years to 65 Years   (Adult)","Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","04-222","June 10, 2005","December 2004","March 2007","March 28, 2017","December 2007","No Study Results Posted","null","March 2007","To evaluate the risks of severe (grade III/IV) GVHD or transplant related mortality at < 100 days following HLA-matched non-myeloablative stem cell transplantation (or following ""prophylactic"" DLI given for chimerism conversion).|To evaluate the incidence of acute and chronic GVHD.|To evaluate the incidence of graft loss.|To evaluate progression free and overall survival.","https://ClinicalTrials.gov/show/NCT00113828"
2435,"NCT02991898","Treg Cell With IL-2 to Suppress aGVHD Umbilical Cord Blood Transplantation","Recruiting","No Results Available","Hematological Malignancy","Biological: Infusion of Treg","Masonic Cancer Center, University of Minnesota","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2016LS107|MT2016-17","December 7, 2016","February 16, 2017","January 2025","February 23, 2017","February 2017","No Study Results Posted","null","January 2025","Efficacy of Intervention|Feasibility of this protocol in preparation for future larger scale studies|Grade II-IV aGVHD|Treatment related mortality (TRM)|Relapse|Incidence of viral and fungal infections|Detectable Treg cells|Immune reconstitution|Toxicity|Treg Survival","https://ClinicalTrials.gov/show/NCT02991898"
2436,"NCT02996617","PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia","Recruiting","No Results Available","Lymphoma,Non-Hodgkin","Drug: rhG-CSF regimen|Drug: Pegylated rhG-CSF regimen","Shandong Provincial Hospital","All","18 Years to 80 Years   (Adult, Senior)","Phase 4","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","ShandongPH02","November 19, 2016","November 2016","December 2018","December 15, 2016","December 2016","No Study Results Posted","null","November 2018","Rate of grade 3/4 neutropenia（neutrophils≤1×10^ 9/L） in every cycle|Rate of the chemotherapy delay|Rate of the febrile neutropenia in every cycle","https://ClinicalTrials.gov/show/NCT02996617"
2437,"NCT00005977","Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia","Completed","No Results Available","Leukemia|Lymphoma","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: leucovorin calcium|Drug: methotrexate|Drug: vincristine sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 22 Years   (Child, Adult)","Phase 3","83","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9917|COG-9917|CDR0000067965","July 5, 2000","September 2000","September 2006","August 19, 2013","August 2013","No Study Results Posted","null","March 2004","Event-free survival","https://ClinicalTrials.gov/show/NCT00005977"
2438,"NCT00004114","Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer","Withdrawn","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067340|P30CA016042|UCLA-9902026|NCI-G99-1603","December 10, 1999","null","null","September 30, 2015","July 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004114"
2439,"NCT02672501","A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia","Recruiting","No Results Available","Leukemia, B-Cell","Drug: anti-CD19-CAR-T cells","Shanghai GeneChem Co., Ltd.","All","1 Year to 70 Years   (Child, Adult, Senior)","Phase 1|Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Genechem","January 25, 2016","January 2016","December 2019","February 1, 2016","February 2016","No Study Results Posted","null","June 2018","Number of patients with adverse event|Number of patients with tumor response|Detection of transferred T cells in the circulation using quantitative -PCR","https://ClinicalTrials.gov/show/NCT02672501"
2440,"NCT02926833","A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","Recruiting","No Results Available","Refractory Diffuse Large B Cell Lymphoma","Biological: KTE-C19|Drug: atezolizumab (anti-PD-L1)","Kite Pharma, Inc.|Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","31","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","KTE-C19-106","October 5, 2016","September 2016","June 2023","February 1, 2017","November 2016","No Study Results Posted","ZUMA-6","June 2018","Phase 1: Safety (Incidence of adverse events defined as dose-limiting toxicities (DLT))|Phase 2: Complete Response Rate|Objective response rate (complete response [CR] + partial response [PR])|Duration of Response|Progression Free Survival|Overall Survival|Safety (Incidence of adverse events and clinically significant changes in safety lab values.)","https://ClinicalTrials.gov/show/NCT02926833"
2441,"NCT00807196","Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma","Unknown status","No Results Available","Non-Hodgkins Lymphoma","Drug: Rituximab|Drug: 90Y ibritumomab tiuxetan (Zevalin)|Drug: Cyclophosphamide|Drug: Fludarabine|Other: Non myeloablative allogeneic stem cell transplantation","Maisonneuve-Rosemont Hospital|Bayer","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZEV0701","December 10, 2008","September 2008","December 2012","December 10, 2008","December 2008","No Study Results Posted","null","December 2011","Engraftment, chimerism, transplant related toxicity, acute and chronic GVHD|Overall response rate, overall and disease free survival","https://ClinicalTrials.gov/show/NCT00807196"
2442,"NCT02846584","a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies","Active, not recruiting","No Results Available","Lymphoma, Large B-Cell, Diffuse|Leukemia, Lymphocytic, Chronic, B-Cell|Lymphoma，Malignant","Biological: CD19 or CD20 CAR T cells briging HSCT","Southwest Hospital, China","All","14 Years to 75 Years   (Child, Adult, Senior)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Southwest Hospital，China","July 25, 2016","July 2016","December 2019","September 6, 2016","July 2016","No Study Results Posted","null","December 2019","Overall survival rate of patients treated with anti-CD19 or anti-CD20 CAR T cells|Treatment response rate of anti-CD19 CAR T cell infusion|Number of patients with adverse events","https://ClinicalTrials.gov/show/NCT02846584"
2443,"NCT02625480","A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia","Recruiting","No Results Available","Acute Lymphoblastic Leukemia","Biological: KTE-C19","Kite Pharma, Inc.","All","2 Years to 21 Years   (Child, Adult)","Phase 1|Phase 2","75","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","KTE-C19-104","December 5, 2015","December 2015","null","March 21, 2017","January 2017","No Study Results Posted","ZUMA-4","June 2017","Phase 1: Safety (Incidence of adverse events defined as dose-limiting toxicities (DLT)|Phase 2: Overall complete remission rate|Duration of Remission|Minimum Residual Disease Negative Remission Rate|Allogeneic Stem Cell Transplant Rate|Overall Survival","https://ClinicalTrials.gov/show/NCT02625480"
2444,"NCT02614066","A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)","Recruiting","No Results Available","Acute Lymphoblastic Leukemia","Biological: KTE-C19","Kite Pharma, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","75","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","KTE-C19-103","November 23, 2015","November 2015","null","March 21, 2017","September 2016","No Study Results Posted","ZUMA-3","March 2017","Phase 1: Safety (Incidence of adverse events defined as dose-limiting toxicities (DLT)|Phase 2: Overall complete remission rate|Duration of Remission|Minimum Residual Disease Negative Remission Rate|Allogeneic Stem Cell Transplant Rate|Overall Survival","https://ClinicalTrials.gov/show/NCT02614066"
2445,"NCT02348216","A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)","Recruiting","No Results Available","Refractory Diffuse Large B Cell Lymphoma|Refractory Primary Mediastinal B Cell Lymphoma|Refractory Transformed Follicular Lymphoma|Relapsed/Refractory Transplant Ineligible Diffuse Large B Cell Lymphoma|Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma|Relapsed/Refractory Transplant Ineligible Transformed Follicular Lymphoma","Biological: KTE-C19","Kite Pharma, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","142","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","KTE-C19-101","January 22, 2015","January 2015","null","May 1, 2017","May 2017","No Study Results Posted","ZUMA-1","March 2017","Phase 1: Safety (Incidence of adverse events defined as dose-limiting toxicities (DLT)|Phase 2: Overall Response Rate|Duration of Response|Progression Free Survival|Overall Survival|Safety","https://ClinicalTrials.gov/show/NCT02348216"
2446,"NCT02728271","Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome","Not yet recruiting","No Results Available","Churg-Strauss Syndrome","Biological: HPC cell infusion","Seah H Lim, MD, PhD|University of Pittsburgh","All","18 Years to 60 Years   (Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","15-146","March 14, 2016","August 2016","August 2025","March 30, 2016","March 2016","No Study Results Posted","null","August 2021","number of patients with adverse events during treatment|hematologic recovery|graft failure rate|resolution of eosinophilia","https://ClinicalTrials.gov/show/NCT02728271"
2447,"NCT02619630","Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)","Recruiting","No Results Available","T-cell Adult Acute Lymphoblastic Leukemia","Drug: nelarabine","Assistance Publique - Hôpitaux de Paris","All","18 Years to 59 Years   (Adult)","Phase 2","275","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AOM12629_2","November 25, 2015","December 2015","December 2025","June 23, 2016","June 2016","No Study Results Posted","GRAALL-2014/T","December 2020","Disease free survival (DFS)|Overall survival|Cumulative incidence of relapse|Non relapse mortality (NRM)|Disease free survival censored at allograft in first complete remission (CR)|Cumulative incidence of relapse censored at allograft in first complete remission (CR)|Overall survival censored at allograft in first complete remission (CR)|Non relapse mortality (NRM) censored at allograft in first complete remission (CR)|Minimal residual disease (MRD)|Proportion of patients having received the 5 cycles of nelarabine","https://ClinicalTrials.gov/show/NCT02619630"
2448,"NCT00689845","Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: bleomycin sulfate|Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide phosphate|Drug: ifosfamide|Drug: methotrexate|Drug: prednisolone|Drug: prednisone|Drug: vincristine sulfate|Drug: vindesine","University Hospital Southampton NHS Foundation Trust|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","120","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000588011|USCTU-IELSG-26-RHM-CAN0546|EU-20818|EudraCT 2006-005794-22|USCTU-07/Q1704/68","June 3, 2008","June 2007","null","July 7, 2009","July 2009","No Study Results Posted","null","null","Complete response rate on PET scanning at the completion of chemoimmunotherapy|Progression-free survival|Death|Survival time","https://ClinicalTrials.gov/show/NCT00689845"
2449,"NCT02601313","A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma","Recruiting","No Results Available","Relapsed/Refractory Mantle Cell Lymphoma","Biological: KTE-C19","Kite Pharma, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","70","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","KTE-C19-102","November 6, 2015","November 2015","null","March 22, 2017","September 2016","No Study Results Posted","ZUMA-2","September 2017","Phase 2: Overall Response Rate|Duration of Response|Best Objective Response|Progression Free Survival","https://ClinicalTrials.gov/show/NCT02601313"
2450,"NCT00274846","Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia","Completed","Has Results","Leukemia","Biological: aldesleukin|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: in vitro treated peripheral blood stem cell transplantation","Masonic Cancer Center, University of Minnesota","All","2 Years and older   (Child, Adult, Senior)","Phase 2","21","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000450852|UMN-2004LS073|UMN-MT2004-25","January 10, 2006","March 2005","June 2008","November 6, 2012","November 2012","July 24, 2009","null","June 2008","Number of Patients With Natural Killer (NK) Cell Expansion|Number of Patients With Complete Remission|Median Time to Disease Relapse (Months)|Overall Survival Time of Patients With Complete Remission|Number of Patients With Complete Remission and Natural Killer Cell Expansion","https://ClinicalTrials.gov/show/NCT00274846"
2451,"NCT01405924","Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)","Terminated","Has Results","Nausea|Vomiting","Drug: Fosaprepitant dimeglumine|Drug: 5-HT3 RA|Drug: Dexamethasone|Drug: Rescue medication","Merck Sharp & Dohme Corp.","Female","18 Years and older   (Adult, Senior)","Phase 2","111","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Prevention","0517-030","July 28, 2011","October 2011","December 2013","February 14, 2017","February 2017","October 24, 2014","EVADE","December 2013","Percentage of Participants With No Vomiting and No Retching During Cycle 2 of Chemotherapy|Percentage of Participants With No Vomiting and No Retching During Cycle 2 of Chemotherapy Per Type of Chemotherapy|Percentage of Participants With a Complete Response During Cycle 2 of Chemotherapy|Functional Living Index - Emesis (FLIE) Total Score During Cycle 2 of Chemotherapy|Percentage of Participants With No Significant Nausea During Cycle 2 of Chemotherapy|Percentage of Participants Who Used No Rescue Medication During Cycle 2 of Chemotherapy","https://ClinicalTrials.gov/show/NCT01405924"
2452,"NCT02622074","Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE 173)","Recruiting","No Results Available","Triple Negative Breast Neoplasms","Biological: Pembrolizumab|Drug: Nab-paclitaxel|Drug: Anthracycline (doxorubicin)|Drug: Cyclophosphamide|Drug: Carboplatin|Drug: Paclitaxel","Merck Sharp & Dohme Corp.","Female","18 Years and older   (Adult, Senior)","Phase 1","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","3475-173|2015-002405-11","December 2, 2015","January 27, 2016","June 16, 2018","May 8, 2017","May 2017","No Study Results Posted","null","June 16, 2018","Number of Participants with Dose Limiting Toxicities (DLTs)|Number of Participants with a Pathological Complete Response (pCR)|Objective Response Rate (ORR)","https://ClinicalTrials.gov/show/NCT02622074"
2453,"NCT00001830","Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants","Completed","No Results Available","Chronic Lymphocytic Leukemia|Graft vs Host Disease|Hodgkin's Disease|Multiple Myeloma|Non Hodgkin's Lymphoma","Drug: Th2 cells in allo HSCTT|Drug: Th2 Cells","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","12 Years to 75 Years   (Child, Adult, Senior)","Phase 1","110","NIH","Interventional","Primary Purpose: Treatment","990143|99-C-0143","November 3, 1999","July 20, 1999","May 19, 2015","April 19, 2017","May 19, 2015","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001830"
2454,"NCT00517894","Dose-Dense Therapy in Aggressive Lymphoma","No longer available","No Results Available","Lymphoma","Drug: CEOP/IMVP-Dexa chemotherapy","Arbeitsgemeinschaft medikamentoese Tumortherapie","All","18 Years to 70 Years   (Adult, Senior)","","null","Other","Expanded Access","","NHL-5","August 15, 2007","null","null","August 15, 2007","August 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00517894"
2455,"NCT01220297","Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT","Terminated","No Results Available","Hematologic Diseases","Drug: Sirolimus|Drug: Mycophenolate Mofetil|Drug: Carmustine|Drug: VP-16|Drug: cyclophosphamide","Stanford University","All","2 Years to 60 Years   (Child, Adult)","Phase 2","3","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT209|SU-09092009-3841","November 24, 2009","September 2009","May 2011","October 7, 2011","October 2011","No Study Results Posted","null","May 2011","Incidence of grade II-IV acute GVHD at D+100 post-transplant|Grade III-IV acute GVHD|Pharmacokinetics of MMF|Veno-occlusive Disease Incidence of Infection CMV reactivation|Chronic GVHD Disease-free and Overall Survival|Time to neutrophil and platelet engraftment Thrombotic microangiopathy Severity of Mucositis","https://ClinicalTrials.gov/show/NCT01220297"
2456,"NCT02042391","Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy","Recruiting","No Results Available","Posttransplant Lymphoproliferative Disorder","Drug: Rituximab sc|Drug: Rituximab sc consolidation|Drug: Rituximab sc combined with CHOP chemotherapy|Drug: Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx","Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH","All","18 Years and older   (Adult, Senior)","Phase 2","90","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","DPTLDSG-IIT-PTLD-2","January 20, 2014","February 3, 2015","September 2019","February 26, 2017","February 2017","No Study Results Posted","PTLD-2","September 2019","Event free survival (EFS) of low-risk patients in the intention to treat population with following definitions for low-risk and event:|Overall survival|Time to progression|Progression-free survival|Response at interim staging|Response after full treatment|Duration of response|Treatment-related mortality","https://ClinicalTrials.gov/show/NCT02042391"
2457,"NCT02930993","Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors","Recruiting","No Results Available","Mesothelin Positive Tumors","Biological: anti-mesothelin CAR T cells","China Meitan General Hospital|Marino Biotechnology Co., Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","K16-4","October 10, 2016","August 2016","August 2019","October 11, 2016","October 2016","No Study Results Posted","null","August 2018","safety of infusion of autologous anti-mesothelin CAR T cells as assessed by the incidents of treatment related adverse events per NCI CTCAE V4.0|treatment response rate of anti-mesothelin CAR T cells|progression free survival|overall survival|proliferation of anti-mesothelin CAR T cells in patients|activation of anti-mesothelin CAR T cells in patients|persistence of anti-mesothelin CAR T cells in patients","https://ClinicalTrials.gov/show/NCT02930993"
2458,"NCT01191060","Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years","Active, not recruiting","No Results Available","Myeloma","Drug: Lenalidomide, Bortezomib|Drug: Lenalidomide, Bortezomib","University Hospital, Toulouse|Dana-Farber Cancer Institute|Celgene Corporation|Janssen-Cilag Ltd.","All","18 Years to 65 Years   (Adult)","Phase 3","700","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","09 110 01","April 16, 2010","October 2010","September 2020","August 31, 2016","August 2016","No Study Results Posted","IFM/DFCI2009","September 2018","Progression Free Survival|Response Rates|Time To Progression|Toxicity comparison|Genetic prognostic groups definition|Best treatment examination in each GEP-defined prognostic group.","https://ClinicalTrials.gov/show/NCT01191060"
2459,"NCT02867566","A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients","Recruiting","No Results Available","Diffuse, Large B-Cell, Lymphoma","Drug: IBI301 plus CHOP|Drug: Rituximab plus CHOP","Innovent Biologics (Suzhou) Co. Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","CIBI301A301","August 11, 2016","August 2016","December 2018","April 14, 2017","August 2016","No Study Results Posted","null","December 2018","Overall response rate(ORR)|Complete remission(CR)|Progression-free survival(PFS)|Event-free survival(EFS)|Overall survival(OS)","https://ClinicalTrials.gov/show/NCT02867566"
2460,"NCT02930967","Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors","Recruiting","No Results Available","Recurrent PD-L1+ Malignant Tumors|Metastatic PD-L1+ Malignant Tumors","Biological: autologous CSR T","China Meitan General Hospital|Marino Biotechnology Co., Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","K16-3","October 10, 2016","August 2016","August 2019","October 11, 2016","October 2016","No Study Results Posted","null","August 2018","Safety as assessed by incidents of treatment related adverse events as assessed by CTCAE V4.0.|treatment response rate of CSR T cell infusion|overall survival rate|progression-free survival|proliferation of CSR T cells in patients|Persistence of CSR T cells in patients","https://ClinicalTrials.gov/show/NCT02930967"
2461,"NCT02624258","Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma","Recruiting","No Results Available","Hodgkin Lymphoma","Biological: CD19 RNA redirected autologous T-cells (RNA CART19 cells)","University of Pennsylvania|Children's Hospital of Philadelphia","All","18 Years to 24 Years   (Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","14BT055","December 1, 2015","November 2015","December 2017","July 15, 2016","July 2016","No Study Results Posted","null","July 2017","Incidence of Treatment-Emergent Adverse Events, defined as NCI CTCAE V4 > Grade 3","https://ClinicalTrials.gov/show/NCT02624258"
2462,"NCT01341899","Efficacy and Safety Study of Autologous Hematopoietic Stem Cell Transplantation to Treat New Onset Type 1 Diabetes","Completed","No Results Available","Type 1 Diabetes","Procedure: immunosuppression and stem cell transplantation","The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","All","8 Years to 35 Years   (Child, Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ZKX07012","April 21, 2011","June 2006","December 2015","October 31, 2016","October 2016","No Study Results Posted","null","December 2012","Changes in C-peptide levels during standard-meal tolerance test from baseline to different time points after transplantation|Changes in serum levels of HbA1c from baseline to different time points after transplantation|Temporal changes of exogenous insulin requirement from baseline to different time points after transplantation|Dynamic changes in islet antibody status from baseline to different time points after transplantation|Dynamic changes in lymphocyte immunophenotyping and cytokine profiles from baseline to different time points after transplantation|mortality and dysfunction of other endocrine glands","https://ClinicalTrials.gov/show/NCT01341899"
2463,"NCT00590941","Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma","Completed","No Results Available","Lymphoma|Diffuse Large Cell","Procedure: Blood draw","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","","52","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label","05-0122","December 28, 2007","February 2005","April 2011","May 14, 2013","May 2013","No Study Results Posted","null","July 2008","Negative [F-18]fluorodeoxyglucose-positron emission tomography (FDG-PET) scan after 2 cycles of R-CHOP|Response after six cycles of R-CHOP|Progression free survival|Grade 3-4 toxicity","https://ClinicalTrials.gov/show/NCT00590941"
2464,"NCT00003846","Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors|Neuroblastoma","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: thiotepa|Drug: vincristine sulfate|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 2","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","99702|COG-99702|CCG-99702|CDR0000067006","November 1, 1999","July 1999","March 2007","July 25, 2014","July 2014","No Study Results Posted","null","October 2004","Event Free Survival","https://ClinicalTrials.gov/show/NCT00003846"
2465,"NCT01433562","Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients","Completed","No Results Available","Breast Cancer","Drug: DLBS1425|Drug: Placebo DLBS1425","Dexa Medica Group","Female","18 Years to 65 Years   (Adult)","Phase 2|Phase 3","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","DLBS1425-0310","September 9, 2011","August 2011","November 2012","May 10, 2013","May 2013","No Study Results Posted","null","November 2012","Clinical response as measured by RECIST|Rate of clinical response|Rate of pathological complete response (after surgery)|Rate of potential breast-conserving procedure|The change level of relevant biomarkers|Haematology|Liver Function|Renal Function|Cardiac function|Adverse Events|The improvement of quality of life","https://ClinicalTrials.gov/show/NCT01433562"
2466,"NCT02858310","E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers","Recruiting","No Results Available","Cervical Cancer|Vaginal Cancer|Anal Cancer|Penile Cancer|Oropharyngeal Cancer","Biological: E7 TCR Transduced PBL cells|Drug: pembrolizumab|Drug: aldesleukin|Drug: fludarabine|Drug: cyclophosphamide","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 66 Years   (Adult, Senior)","Phase 1","180","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","160154|16-C-0154","August 4, 2016","July 21, 2016","January 1, 2026","May 20, 2017","May 17, 2017","No Study Results Posted","null","December 31, 2020","Determine a safe dose for E7 TCR cells plus aldesleukin with or without pembrolizumab","https://ClinicalTrials.gov/show/NCT02858310"
2467,"NCT02354313","STUDY WITH LENALIDOMIDE (Revlimid®) MAINTENANCE VS OBSERVATION AFTER INTENSIFIED INDUCTION REGIMEN CONTAINING RITUXIMAB FOLLOWED BY HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION AS FIRST LINE TREATMENT IN ADULT PATIENTS WITH ADVANCED MANTLE CELL LYMPHOMA","Active, not recruiting","No Results Available","MANTLE CELL LYMPHOMA","Drug: Lenalidomide","Fondazione Italiana Linfomi ONLUS","All","18 Years to 60 Years   (Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IIL-MCL0208|2009-012807-25","June 23, 2011","May 2010","January 2019","August 17, 2016","August 2016","No Study Results Posted","MCL-0208","December 2017","Progression Free Survival (PFS)|Overall Survival (OS)|Disease-free survival (DFS)|Event-free survival (EFS)|Complete Response (CR) Rate|Overall Response Rate (ORR)|Incidence of grade 3 or higher Toxicity measured by CTCAE v.4 at any time during therapy and follow-up.|Quality of life","https://ClinicalTrials.gov/show/NCT02354313"
2468,"NCT00578942","Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath","Completed","Has Results","Lymphoma|Myeloma|Leukemia|Myelodysplasia|Solid Tumors","Drug: Campath Purged Non-myeloablative ASCT","David Rizzieri, MD|Miltenyi Biotec GmbH|Duke University","All","17 Years and older   (Child, Adult, Senior)","Phase 2","48","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00008380","December 19, 2007","May 2005","April 2013","May 23, 2016","May 2016","April 25, 2014","null","April 2013","Toxicity|Overall Survival (OS)|Response","https://ClinicalTrials.gov/show/NCT00578942"
2469,"NCT00795613","Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)","Active, not recruiting","No Results Available","HODGKIN LYMPHOMA","Drug: ESCALATED BEACOPP|Drug: CONVENTIONAL ABVD","Ospedale Santa Croce-Carle Cuneo|GITIL (GRUPPO ITALIANO TERAPIE INNOVATIVE NEI LINFOMI)|Consorzio Mario Negri Sud","All","18 Years to 60 Years   (Adult)","Phase 2","450","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GITIL - HD0607","November 19, 2008","June 2008","October 2015","October 16, 2015","October 2015","No Study Results Posted","HD0607","November 2014","progression-free survival (PFS)|event-free survival (EFS)","https://ClinicalTrials.gov/show/NCT00795613"
2470,"NCT01336712","Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases","Completed","Has Results","Chronic Leukemia|Acute Leukemia|Hodgkin's Disease|Non-Hodgkin's Lymphoma|Myelodysplastic Syndrome","Procedure: Peripheral Blood Stem Cell Transplant","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","18 Years to 60 Years   (Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NSH 922","April 14, 2011","April 2011","July 2015","December 10, 2015","December 2015","October 16, 2015","null","December 2014","Percentage of Patients Experiencing Hemorrhagic Cystitis Post Transplant|Survival|Percentage of Participatns With Donor Chimerism Post-transplant|Disease Free Survival (DFS) Percentage|Non-relapsed Mortality (NRM) Percentage|Relapse Rate|Cumulative Incidence of Chronic Graft-versus-host Disease","https://ClinicalTrials.gov/show/NCT01336712"
2471,"NCT01583426","Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)","Active, not recruiting","No Results Available","Tubular Breast Cancer Stage II|Mucinous Breast Cancer Stage II|Breast Cancer Female NOS|Invasive Ductal Breast Cancer|Tubular Breast Cancer Stage III|HER-2 Positive Breast Cancer|Inflammatory Breast Cancer Stage IV|Inflammatory Breast Cancer","Drug: nab-Paclitaxel|Drug: Paclitaxel","German Breast Group|Celgene Corporation|Roche Pharma AG","Female","18 Years and older   (Adult, Senior)","Phase 3","1200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GBG 69|2011-004714-41","April 18, 2012","July 2012","December 2018","October 11, 2016","October 2016","No Study Results Posted","GeparSepto","December 2018","Pathological complete response (pCR=ypT0 ypN0) rates of neoadjuvant treatment of nab-paclitaxel with solvent-based paclitaxel as part of neoadjuvant treatment of operable or locally advanced primary breast cancer.|Rates of ypT0/is ypN0; ypT0 ypN0/+; ypT0/is ypN0/+; ypT(any) ypN0, and regression grade|Clinical and imaging response|Tolerability and safety|pCR rates per arm|Breast conservation rate|Onset of grade 3 neuropathy|Resolution of grade 3/4 neuropathy|Regional recurrence free survival (RRFS) in patients with initial node-positive axilla|pCR rate and local recurrence free survival (LRFS) in patients with a clinical complete response (cCR) and a negative core biopsy|Examination and comparison of molecular markers|CTC Substudy|Pharmacogenetic substudy|Ovarian substudy|Loco-regional invasive recurrence free survival (LRRFS) in both arms and according to stratified subpopulations.|Distant-disease-free survival (DDFS) in both arms and according to stratified subpopulations.|Invasive disease-free survival (IDFS) in both arms and according to stratified subpopulations.|Overall survival (OS) in both arms and according to stratified subpopulations.|Surgical substudy in patients with high probability for pCR","https://ClinicalTrials.gov/show/NCT01583426"
2472,"NCT00698191","Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE)","Unknown status","No Results Available","Refractory Systemic Lupus Erythematosus","Biological: Allogeneic MSC (AlloMSC)","Nanjing Medical University|National Natural Science Foundation of China","All","15 Years to 70 Years   (Child, Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NSFC30772014","June 13, 2008","March 2007","December 2012","June 16, 2008","June 2008","No Study Results Posted","null","December 2011","Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)|Lupus serology (ANA, dsDNA, C3, C4)|Renal function (GFR, BUN, urinalysis)|Percentage of systemic T regulatory population","https://ClinicalTrials.gov/show/NCT00698191"
2473,"NCT01130194","Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma","Completed","No Results Available","Follicular Lymphoma","Other: Combination of treatment modalities","St. Louis University","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","29","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IRB #14228","May 24, 2010","July 2006","June 2012","May 9, 2014","May 2014","No Study Results Posted","MasterPlan","June 2012","Disease-free survival percentage(intention to treat)|Incidence of second malignancies","https://ClinicalTrials.gov/show/NCT01130194"
2474,"NCT00974324","Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma","Unknown status","No Results Available","T Cell Lymphoma","Drug: endostar and CHOP","Fudan University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PTCL0908","September 9, 2009","August 2009","September 2011","September 14, 2010","September 2010","No Study Results Posted","PTCL","September 2010","efficacy include overall response rate, disease free survival and overall survival|safety of endostar combined with CHOP","https://ClinicalTrials.gov/show/NCT00974324"
2475,"NCT02441933","Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)","Recruiting","No Results Available","Breast Cancer","Drug: taxane plus carboplatin|Drug: Taxane","Yonsei University","Female","19 Years and older   (Adult, Senior)","Phase 3","840","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","4-2015-0074","May 4, 2015","December 2015","June 2023","February 2, 2017","February 2017","No Study Results Posted","null","December 2018","5-year event free survival|overall survival|Distant recurrence free survival|(loco-regional recurrence free survival|pathologic complete response rate","https://ClinicalTrials.gov/show/NCT02441933"
2476,"NCT00104299","Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis","Completed","Has Results","Vasculitis|Wegener's Granulomatosis|Microscopic Polyangiitis","Drug: Rituximab plus cyclophosphamide placebo (rituximab group)|Drug: Cyclophosphamide plus rituximab placebo (control group)|Drug: Azathioprine|Drug: Methylprednisolone (or other glucocorticoid)|Drug: Prednisone","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|Genentech, Inc.","All","15 Years and older   (Child, Adult, Senior)","Phase 2|Phase 3","197","NIH|Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","DAIT ITN021AI","February 24, 2005","January 2005","January 2010","March 23, 2017","March 2017","February 2, 2011","RAVE","December 2008","Disease Remission|Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy|Percentage of Participants Who Have a BVAS/WG Score of 0 and Have Successfully Completed the Glucocorticoid Taper by 6 Months Post-randomization|The Duration of Complete Remission (BVAS=0, Off Glucocorticoids), the Time to Limited and/or Severe Flare After Remission in the Two Treatment Groups|The Duration of Remission (BVAS=0), the Time to Limited and/or Severe Flare After Remission in the Two Treatment Groups|Time to Remission (BVAS=0) From the Visit 1 Baseline Visit in the Two Treatment Groups|Time to Complete Remission (BVAS=0, Off Glucocorticoids) From the Visit 1 Baseline Visit in the Two Treatment Groups","https://ClinicalTrials.gov/show/NCT00104299"
2477,"NCT00002836","Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: Filgrastim (G-CSF)|Drug: Carmustine|Drug: Cisplatin|Drug: Cyclophosphamide (CTX)|Drug: Etoposide|Drug: Thiotepa|Procedure: Peripheral Blood Stem Cell Transplantation","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 3","184","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM95-047|P30CA016672|MDA-DM-95047|NCI-G96-1014|CDR0000065048","November 1, 1999","May 1995","March 2006","July 27, 2012","July 2012","No Study Results Posted","null","March 2006","Compare Effectiveness of Chemotherapy + Filgrastim to Filgrastim Alone","https://ClinicalTrials.gov/show/NCT00002836"
2478,"NCT00842114","Rituximab and CVP Plus Interferon for Follicular Non Hodgkins Lymphoma (NHL)","Completed","No Results Available","Non-Hodgkin's Lymphoma","Biological: R+CVP+IFN","Fundación Leucemia y Linfoma, Spain|Roche Pharma AG","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LNH-Pro-05|EudraCT Number:2005-004761-42","February 10, 2009","February 2006","March 2016","March 31, 2016","March 2016","No Study Results Posted","LNH-Pro-05","March 2016","Progression-free survival (PFS) with the CVP + IFNalfa + Rituximab treatment|Overall response (ORR) and complete response (CR) rates. Overall Survival MRD by RT-PCR assay Toxicity","https://ClinicalTrials.gov/show/NCT00842114"
2479,"NCT00113919","UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients","Terminated","Has Results","Multiple Myeloma","Drug: Busulfan","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2003-25","June 10, 2005","June 2004","October 2009","April 10, 2015","April 2015","April 14, 2011","null","October 2009","Maximal Dose of Busulfex® Given in a 2, 3, or 4 Day Period With Acceptable Toxicity to Myeloma Patients|Response Rate (CR, NCR) and Overall Survival of Patients on Busulfex Treatment","https://ClinicalTrials.gov/show/NCT00113919"
2480,"NCT01639573","Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis","Recruiting","No Results Available","Scleroderma","Drug: Campath","Children's Hospital Los Angeles","All","8 Years to 18 Years   (Child, Adult)","","3","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CAMPATH-1H SSc","June 18, 2012","April 2011","April 2018","August 5, 2016","August 2016","No Study Results Posted","CAMPATH-1H","January 2018","Primary outcome|Campath","https://ClinicalTrials.gov/show/NCT01639573"
2481,"NCT02128061","Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+","Recruiting","No Results Available","Diffuse Large B Cell Lymphoma","Drug: Lenalidomide|Drug: Rituximab","The Lymphoma Academic Research Organisation","All","80 Years and older   (Senior)","Phase 3","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SENIOR","April 23, 2014","August 2014","February 2019","April 11, 2017","April 2017","No Study Results Posted","null","February 2019","The overall survival (OS)|Progression-Free Survival (PFS)|Event-Free Survival (EFS)|Duration of Response (DoR)|Disease-Free Survival (DFS)|OS according to GCB/non-GCB phenotype|Response Rate at the end of treatment|Simplified Geriatric Scales|Health related Quality of Life (HRQOL)","https://ClinicalTrials.gov/show/NCT02128061"
2482,"NCT00004224","Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: cyclophosphamide|Drug: etoposide|Drug: vincristine sulfate|Procedure: adjuvant therapy|Procedure: conventional surgery|Radiation: radiation therapy","Societe Internationale d'Oncologie Pediatrique|Children's Cancer and Leukaemia Group|Italian Association for Pediatric Hematology Oncology|National Cancer Institute (NCI)","All","3 Years to 20 Years   (Child, Adult)","Phase 2","65","Other","Interventional","Primary Purpose: Treatment","CDR0000067465|SIOP-EPENDYMOMA-99|AIEOP-EPENDYMOMA-99|CCLG-EPENDYMOMA-99|EU-99001","January 28, 2000","January 1999","March 2008","August 23, 2013","April 2008","No Study Results Posted","null","null","Event-free survival|Overall survival|Surgical operability|Response rate","https://ClinicalTrials.gov/show/NCT00004224"
2483,"NCT00003396","Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Biological: graft-versus-tumor induction therapy|Drug: cyclophosphamide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","University of Maryland|University of Maryland Greenebaum Cancer Center","All","Child, Adult, Senior","Phase 2","42","Other","Interventional","Primary Purpose: Treatment","CDR0000066397|MSGCC-9805|NCI-V98-1430","November 1, 1999","September 1998","December 2002","September 23, 2009","September 2009","No Study Results Posted","null","December 2002","","https://ClinicalTrials.gov/show/NCT00003396"
2484,"NCT01896102","A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)","Recruiting","No Results Available","Cerebral Adrenoleukodystrophy (CALD)","Genetic: Lenti-D Drug Product","bluebird bio","Male","up to 17 Years   (Child)","Phase 2|Phase 3","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ALD-102","March 22, 2013","August 2013","August 2019","March 20, 2017","March 2017","No Study Results Posted","null","August 2019","The proportion of subjects who are alive and have no Major Functional Disabilities (MFDs) as determined by key measures in the Neurological Function Score (NFS).|The proportion of subjects who experience either acute (≥Grade II) or chronic GVHD at Month 24.|Incidence of resolution of gadolinium positivity on MRI (i.e., GdE-).|Time to resolution of gadolinium positivity on MRI (i.e., GdE-).|Change in total NFS from Baseline.|MFD-free survival over time|Overall survival","https://ClinicalTrials.gov/show/NCT01896102"
2485,"NCT00536601","High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","Active, not recruiting","No Results Available","Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET)|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Plasma Cell Neoplasm|Primary Systemic Amyloidosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Neuroblastoma|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Regional Neuroblastoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia","Drug: etoposide|Drug: cyclophosphamide|Drug: carmustine|Drug: melphalan|Drug: busulfan|Drug: carboplatin|Drug: thiotepa|Radiation: total-body irradiation|Procedure: autologous hematopoietic stem cell transplantation|Procedure: autologous-autologous tandem hematopoietic stem cell transplantation","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","4 Years and older   (Child, Adult, Senior)","","174","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","I 72806|NCI-2011-00131|P30CA016056","September 27, 2007","June 29, 2006","April 18, 2018","March 30, 2017","March 2017","No Study Results Posted","null","April 18, 2018","Progression-free survival distribution of patients with HL, NHL, and MM for each disease-specific high-dose therapy regimen|Progression-free survival distribution of patients with amyloidosis, acute leukemia, and selected solid tumors for each disease-specific high-dose therapy regimen|Regimen-related toxicity|Response rate|Overall survival","https://ClinicalTrials.gov/show/NCT00536601"
2486,"NCT01208896","Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma","Active, not recruiting","No Results Available","Lymphoma, Follicular|Stem Cell Transplantation","Drug: Reduced_intensity conditioning","University Hospital, Bordeaux|Roche Pharma AG","All","18 Years to 65 Years   (Adult)","Phase 2","32","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CHUBX 2009/09","September 23, 2010","February 2011","October 2017","August 19, 2016","August 2016","No Study Results Posted","RITALLO","October 2017","Overall survival|Toxic mortality|Progression free survival|Incidence of relapse|Grade II-IV acute GVHD incidence|Chronic GVHD incidence|Morbidity and adverse event|Hematologic reconstitution, Immunologic reconstitution, Chimerism","https://ClinicalTrials.gov/show/NCT01208896"
2487,"NCT00186966","Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia","Completed","No Results Available","Acute Myeloid Leukemia","Drug: Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome)|Drug: Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan|Procedure: Hematopoietic stem cell transplant|Radiation: Total body irradiation","Dutch Childhood Oncology Group|International BFM Study Group|St. Jude Children's Research Hospital","All","up to 18 Years   (Child, Adult)","Phase 3","394","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TRIAL|TRIAL Relapsed AML 2001/01","September 12, 2005","March 2002","September 2010","April 5, 2011","April 2011","No Study Results Posted","null","April 2009","Response Rate|Toxicity between two arms","https://ClinicalTrials.gov/show/NCT00186966"
2488,"NCT02842138","Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma","Recruiting","No Results Available","B-cell Lymphoma","Biological: autologous anti-CD19 CAR T cells","Peking University|Marino Biotechnology Co., Ltd.","All","18 Years and older   (Adult, Senior)","Phase 1","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2016YJZ12","July 13, 2016","June 2016","June 2019","February 23, 2017","February 2017","No Study Results Posted","null","June 2018","Number of patients with adverse events|Treatment response rate of anti-CD19 CAR T cell infusion|overall survival rate of patients treated with anti-CD19 CAR T cells|progression-free survival of patients treated with anti-CD19 CAR T cells","https://ClinicalTrials.gov/show/NCT02842138"
2489,"NCT02845882","LBL-2016 for Children or Adolescents in China","Recruiting","No Results Available","Lymphoblastic Lymphoma","Drug: Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine|Drug: 6-mercaptopurine,Methotrexate|Drug: Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine|Drug: Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate|Drug: Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase|Drug: Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase|Drug: Methotrexate, 6-mercaptopurine","Children's Cancer Group, China|Shanghai Children's Medical Center|Tongji Hospital|West China Second University Hospital|Qilu Hospital of Shandong University|Tianjin Medical University Cancer Institute and Hospital|Children’s Hospital of Sochow University, China|Nanjing Children's Hospital|Xiangya Hospital of Central South University","All","12 Months to 18 Years   (Child, Adult)","Phase 2|Phase 3","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCCG-LBL-2016","July 24, 2016","January 2016","December 2025","July 27, 2016","June 2016","No Study Results Posted","null","December 2020","Event free survival for the whole cohort|Event free survival for patients in High risk group|Overall survival for all patients","https://ClinicalTrials.gov/show/NCT02845882"
2490,"NCT00002995","Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma","Completed","No Results Available","Sarcoma","Biological: dactinomycin|Biological: filgrastim|Biological: sargramostim|Drug: cyclophosphamide|Drug: vincristine sulfate|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 49 Years   (Child, Adult)","Phase 3","483","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","D9602|COG-D9602|CCG-D9602|POG-D9602|IRS-D9602|CDR0000065542","November 1, 1999","August 1997","January 2011","February 12, 2014","February 2014","No Study Results Posted","null","September 2006","Failure-free survival","https://ClinicalTrials.gov/show/NCT00002995"
2491,"NCT01190345","Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: bevacizumab|Drug: no bevacizumab","Institut Paoli-Calmettes","Female","18 Years and older   (Adult, Senior)","Phase 2","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AVASTEM/IPC 2009-001","August 24, 2010","May 2010","May 2017","March 19, 2013","March 2013","No Study Results Posted","AVASTEM","May 2017","Measure of the anti-cancer stem cell activity|Evaluation of the safety of the treatment|Evaluation of the disease-free survival, recurrence-free survival and overall survival|Evaluation of the pathological complete response rate","https://ClinicalTrials.gov/show/NCT01190345"
2492,"NCT02277639","Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases","Completed","No Results Available","Bone Marrow Failure Syndromes|Immunodeficiencies|Immune Dysregulation Syndromes","Device: CD3+/CD19+ delpletion using CliniMACs device follwing reduced intensity conditioning","Children's Hospital of Philadelphia","All","up to 22 Years   (Child, Adult)","Phase 2","2","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11-008330|CHP 980","October 22, 2014","November 2011","March 2016","April 20, 2016","April 2016","No Study Results Posted","MiniClini","March 2016","Engraftment","https://ClinicalTrials.gov/show/NCT02277639"
2493,"NCT03019666","Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL","Not yet recruiting","No Results Available","Multiple Myeloma|Non-Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Mantle-Cell Lymphoma|Follicular Lymphoma|Indolent B Cell Lymphoma|Primary Mediastinal Lymphoma|Lymphoplasmacytic Lymphoma","Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells","Masonic Cancer Center, University of Minnesota","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2015LS057|MT2015-46","January 11, 2017","March 2017","March 2019","January 13, 2017","January 2017","No Study Results Posted","null","April 2018","Occurrence of any grade 4 or greater suspected adverse reaction|Occurrence of Grade III or IV acute graft-versus-host disease (aGVHD)|Occurrence of treatment related mortality (TRM)|Occurrence of disease response|Number of patients alive without progression","https://ClinicalTrials.gov/show/NCT03019666"
2494,"NCT02339532","Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status","Recruiting","No Results Available","Breast Cancer","Drug: FEC100|Drug: Docetaxel|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Carboplatin","UNICANCER","Female","18 Years and older   (Adult, Senior)","Phase 2","90","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GEP13","December 14, 2014","January 2015","June 2023","August 31, 2015","August 2015","No Study Results Posted","NeoTOP","June 2018","Pathological complete response according to Chevallier classification|Predictive factors of response to both treatment regimens (anthracycline-based and non anthracycline-based regimens)|Pathological complete response (pCR), according to Sataloff's classification|Clinical and radiological response according to the WHO criteria|Toxicity according to NCI CTC-AE v4.0 criteria|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT02339532"
2495,"NCT01854372","Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.","Withdrawn","No Results Available","Newly Diagnosed Diffuse Large B-Cell Lymphoma|Intermediate (Burkitt-Like) Lymphoma","Drug: R-HCVAD and R-MC","The University of Texas Health Science Center at San Antonio","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CTRC 11-53","May 10, 2013","June 2013","November 2013","December 9, 2013","December 2013","No Study Results Posted","null","November 2013","Progression free survival verified by PET scan.","https://ClinicalTrials.gov/show/NCT01854372"
2496,"NCT00828009","BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery","Unknown status","No Results Available","Lung Cancer","Biological: bevacizumab|Biological: emepepimut-S|Drug: carboplatin|Drug: cyclophosphamide|Drug: paclitaxel|Radiation: radiation therapy","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","55","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000632611|E6508","January 22, 2009","December 2010","null","September 16, 2014","September 2014","No Study Results Posted","null","January 2016","Safety|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00828009"
2497,"NCT02633137","Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma","Recruiting","No Results Available","Mantle Cell Lymphoma|Untreated","Drug: Lenalidomide|Drug: R-CHOP|Drug: high-dose cytarabine (HIDAC)","Memorial Sloan Kettering Cancer Center|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","15-196","December 15, 2015","December 14, 2015","December 2018","April 6, 2017","April 2017","No Study Results Posted","null","December 2018","3-year progression-free survival (PFS)","https://ClinicalTrials.gov/show/NCT02633137"
2498,"NCT00504491","R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia","Withdrawn","No Results Available","Chronic Lymphocytic Leukaemia|Patients Resistant to a Purine Analogous|Patients Relapsed With Purines Therapy","Drug: Rituximab-CHOP-Alemtuzumab","CABYC|Francesc Bosch, MD|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea|Fundacion Clinic per a la Recerca Biomédica|Bayer|Genzyme, a Sanofi Company","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","0","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GELLC-2|2007-003097-26","July 19, 2007","July 2007","June 2012","December 28, 2011","December 2011","No Study Results Posted","R-CHOP","January 2012","Response rate obtained after R-CHOP regimen followed by consolidation therapy with Alemtuzumab, as second line therapy. Haematological and non haematological toxicity will be graded in accordance with the WHO system","https://ClinicalTrials.gov/show/NCT00504491"
2499,"NCT00103285","Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","Active, not recruiting","No Results Available","B-cell Childhood Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia","Drug: doxorubicin hydrochloride|Radiation: 3-dimensional conformal radiation therapy|Drug: cytarabine|Drug: dexamethasone|Drug: pegaspargase|Drug: methotrexate|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: cyclophosphamide|Drug: thioguanine|Drug: vincristine sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 9 Years   (Child)","Phase 3","5377","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AALL0331|NCI-2009-00302|COG-AALL0331|CDR0000409589|U10CA098543","February 7, 2005","April 2005","null","May 26, 2016","May 2016","No Study Results Posted","null","December 2013","Event-free survival (EFS) for SR-average patients|Health-related quality of life|Correlation of minimal residual disease (MRD) with EFS|Correlation of minimal residual disease (MRD) and overall survival|Correlation of early marrow response status with MRD","https://ClinicalTrials.gov/show/NCT00103285"
2500,"NCT01356680","HD17 for Intermediate Stage Hodgkin Lymphoma","Active, not recruiting","No Results Available","Hodgkin Lymphoma","Drug: BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)|Drug: ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)|Radiation: 30Gy IF-RT (Involved-Field Radiotherapy)|Radiation: 30Gy IN-RT (Involved-Node Radiotherapy)","University of Cologne","All","18 Years to 60 Years   (Adult)","Phase 3","1100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","HD17","May 13, 2011","December 2011","December 2019","May 2, 2017","May 2017","No Study Results Posted","null","December 2019","Progression Free Survival|Overall Survival|CR rate","https://ClinicalTrials.gov/show/NCT01356680"
2501,"NCT00342316","Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia","Active, not recruiting","No Results Available","Acute Myeloid Leukemia","Procedure: Reduced Intensity Conditioning Stem Cell Transplantation","Vastra Gotaland Region|The Canadian Blood and Marrow Transplant Group|Australasian Leukaemia and Lymphoma Group","All","51 Years to 70 Years   (Adult, Senior)","Phase 3","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TRALG1/02","June 20, 2006","December 2003","December 2017","September 22, 2016","September 2016","No Study Results Posted","null","July 2017","Overall survival at 3 years after inclusion|Time to relapse from inclusion up to 3 years|Quality of life at baseline, 12 and 24 months post inclusion|In RICT patients only: Safety and feasibility of the procedure from inclusion to 3 years|In RICT patients: Incidence & severity of acute and chronic GvHD from transplantation to three years after inclusion|In RICT patients: Rate of complete or partial chimerism from transplant to 3 months","https://ClinicalTrials.gov/show/NCT00342316"
2502,"NCT00408005","Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","Active, not recruiting","No Results Available","Adult T Acute Lymphoblastic Leukemia|Childhood T Acute Lymphoblastic Leukemia|Stage II Adult T-Cell Leukemia/Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage II Contiguous Adult Lymphoblastic Lymphoma|Stage II Non-Contiguous Adult Lymphoblastic Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-Cell Leukemia/Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-Cell Leukemia/Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia","Drug: Asparaginase|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Daunorubicin Hydrochloride|Drug: Dexamethasone|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Mercaptopurine|Drug: Methotrexate|Drug: Nelarabine|Drug: Pegaspargase|Drug: Prednisone|Radiation: Radiation Therapy|Drug: Thioguanine|Drug: Vincristine Sulfate","National Cancer Institute (NCI)","All","1 Year to 30 Years   (Child, Adult)","Phase 3","1900","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2009-00307|CDR0000514500|COG-AALL0434|AALL0434|U10CA098543","December 4, 2006","January 22, 2007","null","May 23, 2017","May 2017","No Study Results Posted","null","September 15, 2017","Efficacy of combination chemotherapy with vs without nelarabine|Efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine vs escalating-dose methotrexate (without leucovorin calcium rescue) and pegaspargase|Event-free survival (EFS) after initial remission|Incidence of toxicities of combination chemotherapy with vs without nelarabine as assessed by NCI CTCAE version 4.0|Incidence of toxicities of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine vs escalating-dose methotrexate (without leucovorin calcium rescue) and pegaspargase|Nelarabine toxicity assessment by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Incidence of CNS relapse|Overall survival","https://ClinicalTrials.gov/show/NCT00408005"
2503,"NCT02883049","Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","Recruiting","No Results Available","B Acute Lymphoblastic Leukemia|Bone Necrosis|Central Nervous System Leukemia|Cognitive Side Effects of Cancer Therapy|Neurotoxicity Syndrome|Pain|Testicular Leukemia|Therapy-Related Toxicity|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia","Drug: Clofarabine|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dasatinib|Drug: Dexamethasone|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Drug: Hydrocortisone Sodium Succinate|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Mercaptopurine|Drug: Methotrexate|Drug: Pegaspargase|Drug: Prednisone|Radiation: Radiation Therapy|Drug: Thioguanine|Drug: Vincristine Sulfate","National Cancer Institute (NCI)","All","1 Year to 30 Years   (Child, Adult)","Phase 3","5437","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2011-03797|CDR0000706370|COG-AALL1131|AALL1131|U10CA180886|U10CA098543","August 22, 2016","February 27, 2012","null","May 24, 2017","May 2017","No Study Results Posted","null","August 30, 2021","Comparison of DFS of children with HR B-ALL receiving post-Induction age adjusted ITT on an MBFM-IMHDM backbone compared to age adjusted IT MTX|DFS of children, adolescents, and young adults with VHR B-ALL between arms|Children and young adults with Ph-like B-ALL and a predicted TKI-sensitive mutation treated with dasatinib plus MBFM-IMHDM|Increase of greater than or equal to 65% of 5-year DFS and less than 10% induction mortality in patients with DS and HR B-ALL treated with modified Induction and post-Induction therapy regimen with MBFM-IMIDM|OS rate for HR B-ALL patients|OS rate for VHR B-ALL patients|Percentage of VHR-ALL patients randomized to control versus experimental arms that attain MRD less than or equal to 0.01% upon recovery from consolidation|Toxicity and tolerability of Experimental arm and Control arm in patients with VHR B-ALL|Toxicity and tolerability of MBFM-IMIDM in children with Down syndrome|Toxicity and tolerability of post-induction age-adjusted ITT compared to age-adjusted IT MTX in children with HR B-ALL","https://ClinicalTrials.gov/show/NCT02883049"
2504,"NCT00003113","Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas","Terminated","No Results Available","Lymphoma","Biological: filgrastim|Drug: cyclophosphamide|Drug: etoposide|Drug: lomustine|Drug: procarbazine hydrochloride|Radiation: radiation therapy","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","60 Years and older   (Adult, Senior)","Phase 2","6","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU4496|P30CA043703|CWRU-4496|AMC-1C-93|NCI-G97-1350","November 1, 1999","July 1997","December 2002","January 13, 2011","January 2011","No Study Results Posted","null","December 2002","study the effectiveness of oral combination chemotherapy and G-CSF in elderly patients with intermediate- or high-grade non-Hodgkin's lymphomas.","https://ClinicalTrials.gov/show/NCT00003113"
2505,"NCT00630032","Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: Docetaxel|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: ixabepilone","UNICANCER","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","762","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","PACS08 - UC-0140/0610|PACS-08/0610|2006-006494-24|PACS08-Tavlx|BMS-UNICANCER-PACS-08/0610|AMGEN-UNICANCER-PACS-08/0610","March 5, 2008","September 2007","September 2019","May 3, 2017","May 2017","No Study Results Posted","TavIx","June 2017","Disease-free survival (DFS) defined as a local, regional, or metastatic relapse, a contralateral breast cancer, or a death of any cause|DFS for triple-negative and ER+/PR-/HER2- subgroups|Distant metastasis-free survival for whole population and subgroups|Event-free survival defined as local, regional, or metastatic relapse, a contralateral breast cancer, a second cancer, or death of any cause|Overall survival|Toxicity as measured by CTC-AE scale version|Biotheque transcriptome and proteome analysis|Quality of life as measured by QlQ C30/Br23","https://ClinicalTrials.gov/show/NCT00630032"
2506,"NCT00610311","Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma","Terminated","Has Results","Metastatic Melanoma|Skin Cancer","Drug: cyclophosphamide|Drug: fludarabine phosphate|Biological: Aldesleukin|Biological: ALVAC gp100 Vaccine|Biological: anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","3","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","080055|08-C-0055","February 6, 2008","January 2008","February 2011","October 6, 2015","September 2015","March 14, 2012","null","February 2011","Number of Participants With Metastatic Melanoma Who Develop Clinical Tumor Regression (CR or PR)|Number of Participants With in Vivo Survival of T-cell Receptor (TCR) Gene-engineered Cells.|Number of Participants With Adverse Events|Number of Participants Who Develop Anti-mouse T Cell Receptor (TCR) Antibodies","https://ClinicalTrials.gov/show/NCT00610311"
2507,"NCT00791947","A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT","Completed","No Results Available","Peripheral T-Cell Lymphoma","Drug: CHOEP + G-CSF followed by BEAM","University of Aarhus|Nordic Lymphoma Group","All","18 Years to 67 Years   (Adult, Senior)","Phase 2","166","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NLG-T-01|2006-000389-35","November 14, 2008","October 2001","August 2010","September 7, 2011","September 2011","No Study Results Posted","null","August 2008","Time to treatment failure|Overall survival","https://ClinicalTrials.gov/show/NCT00791947"
2508,"NCT00966810","Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion","Unknown status","No Results Available","Philadelphia Chromosome-positive Chronic Myelocytic Leukemia","Procedure: Stem cell transplantation","Rambam Health Care Campus|Miltenyi Biotec GmbH","All","18 Years to 65 Years   (Adult)","Phase 2|Phase 3","40","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CML ASCTCTIL","August 26, 2009","December 1999","January 2011","August 26, 2009","January 2009","No Study Results Posted","null","January 2010","Disease free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00966810"
2509,"NCT02677714","99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer|Doxorubicin Induced Cardiomyopathy","Radiation: 99mTc-rhAnnexin V-128","Advanced Accelerator Applications","Female","18 Years and older   (Adult, Senior)","Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Diagnostic","AAA-Annexin-05","January 26, 2016","April 2016","April 2018","January 23, 2017","January 2017","No Study Results Posted","null","September 2017","Imaging feasibility (Proof of Concept step)|Detection of doxorubicin-induced cardiotoxicity (Phase II step)|Timing and extent of 99mTc-rhAnnexin V-128 myocardial uptake|CMRI LVEF|99mTc-rhAnnexin V-128 myocardial uptake correlations|Adverse events|Laboratory assessment","https://ClinicalTrials.gov/show/NCT02677714"
2510,"NCT00002547","Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes","Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: cytarabine|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation|Procedure: syngeneic bone marrow transplantation","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","up to 60 Years   (Child, Adult)","Phase 2","280","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000063305|P30CA022453|WSU-D-696-87|NCI-V93-0345","November 1, 1999","August 1987","October 2003","August 6, 2012","August 2012","No Study Results Posted","null","October 2003","","https://ClinicalTrials.gov/show/NCT00002547"
2511,"NCT02643589","Dose Study of Antithymocyteglobulin in Haploidentical Allogeneic Stem Cell Transplantation","Recruiting","No Results Available","Hematopoietic Stem Cell Transplantation","Drug: ATG","Nanfang Hospital of Southern Medical University|Peking University People's Hospital|Central South University Xiangya Hospital|Fujian Medical University","All","14 Years to 65 Years   (Child, Adult)","","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","NFEC-201304-K1(02)","December 29, 2015","June 2013","December 2016","December 30, 2015","December 2015","No Study Results Posted","null","June 2016","Incidence of acute GVHD|Immune reconstitution|Survival","https://ClinicalTrials.gov/show/NCT02643589"
2512,"NCT01883180","ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis","Recruiting","No Results Available","Hematopoietic Stem Cell Transplantation|Antithymocyte Globulin|Viral Infection","Drug: ATG","Nanfang Hospital of Southern Medical University|Peking University People's Hospital|First Affiliated Hospital of Guangxi Medical University|Southern Medical University, China|Guangzhou General Hospital of Guangzhou Military Command","All","14 Years to 65 Years   (Child, Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NFEC-201304-K1","June 14, 2013","June 2013","June 2018","May 14, 2017","September 2015","No Study Results Posted","null","December 2017","Incidence of Epstein-Barr virus(EBV)and cytomegalovirus(CMV) infections|Incidence of acute GVHD|Drug-related adverse events of ATG|Immune reconstitution|Survival|Incidence of chronic GVHD","https://ClinicalTrials.gov/show/NCT01883180"
2513,"NCT01597778","Double Cord Versus Haploidentical (BMT CTN 1101)","Recruiting","No Results Available","Acute Lymphocytic Leukemia|Acute Myelogenous Leukemia|Burkitt's Lymphoma|Follicular Lymphoma|Hodgkin Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin Lymphoma","Biological: Haploidentical Bone Marrow Transplant|Biological: Double Umbilical Cord Blood Transplant","Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","410","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","BMTCTN1101|2U10HL069294-11|5U24CA076518","May 10, 2012","June 2012","June 2019","February 7, 2017","February 2017","No Study Results Posted","null","June 2018","Progression Free Survival (PFS)|Neutrophil Recovery|Primary Graft Failure|Secondary Graft Failure|Platelet Recovery|Donor Cell Engraftment|Acute Graft-versus-Host Disease (aGVHD)|Chronic Graft-versus-Host Disease (cGHVD)|Overall Survival|Treatment-related Mortality (TRM)|Infections","https://ClinicalTrials.gov/show/NCT01597778"
2514,"NCT02789657","BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.","Recruiting","No Results Available","Breast Cancer","Drug: paclitaxel|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Carboplatin|Procedure: Breast surgery|Drug: AC","William Sikov|Women and Infants Hospital of Rhode Island|Rhode Island Hospital|Brown University","Female","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","BrUOG 308","May 30, 2016","November 2016","December 2018","May 23, 2017","May 2017","No Study Results Posted","null","July 2018","Percent of patients who achieve a pCR|Percentage of patients who develop major toxicities as defined in protocol.","https://ClinicalTrials.gov/show/NCT02789657"
2515,"NCT00577512","UARK 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE","Completed","Has Results","Multiple Myeloma","Drug: DTPACE","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 2","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2006-32","December 18, 2007","April 2007","April 2009","April 19, 2011","April 2011","April 19, 2011","null","April 2009","Number of Subjects Treated With (HD DTPACE Obtain a Complete Response or Near Complete Response That Lasts for 6 Months or Longer.|In Subjects Achieving a Response, to Find Out How Long the Response Will Last.","https://ClinicalTrials.gov/show/NCT00577512"
2516,"NCT00820547","Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients","Active, not recruiting","No Results Available","Breast Cancer","Biological: bevacizumab|Drug: cyclophosphamide|Drug: docetaxel|Drug: epirubicin hydrochloride|Drug: fluorouracil","UNICANCER","All","18 Years and older   (Adult, Senior)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PACS09 UC-0140/0802|UNICANCER-PACS-09-0802|EudraCT-2008-001807-53|EU-20889","January 9, 2009","January 2009","September 2017","June 22, 2016","June 2016","No Study Results Posted","Beverly1","April 2015","Complete histologic response rate|Progression-free survival|Overall survival|Toxicity as assessed by CTCAE v3.0|Predictive factors of response to bevacizumab|Circulating peripheral cells (circulating endothelial and tumor cells): correlation of initial rate and association with histological response after surgery|Genomic and proteomic analyses and correlation with histologic response","https://ClinicalTrials.gov/show/NCT00820547"
2517,"NCT00049634","Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Procedure: in vitro-treated peripheral blood stem cell transplantation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","30","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","1628.00|FHCRC-1628.00|NCI-H02-0099|CDR0000258137","November 12, 2002","January 2002","null","September 14, 2010","September 2010","No Study Results Posted","null","February 2007","Incidence of grade II, III, and IV graft-versus-host disease","https://ClinicalTrials.gov/show/NCT00049634"
2518,"NCT00055640","Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Genetic: microarray analysis","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","9","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU1402|P30CA043703|CWRU-060244|CWRU-1402","March 6, 2003","October 2002","March 2006","June 9, 2010","June 2010","No Study Results Posted","null","April 2005","Molecular risk assessment to see how well it works in predicting response to therapy in patients who are receiving treatment for non-Hodgkin's lymphoma.","https://ClinicalTrials.gov/show/NCT00055640"
2519,"NCT01099930","Autologous Stem Cell Transplant for Multiple Sclerosis","Completed","No Results Available","Multiple Sclerosis","Other: immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT),|Other: Standard Therapy","Ottawa Hospital Research Institute|Multiple Sclerosis Scientific Research Foundation","All","18 Years to 50 Years   (Adult)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","200037401H","March 1, 2010","August 2001","June 2016","September 27, 2016","September 2016","No Study Results Posted","MS/BMT","November 2012","3 year MS activity free survival|Transplant related morbidity|Transplant related mortality|Time to MS treatment failure|rate of immune reconstitution following treatment","https://ClinicalTrials.gov/show/NCT01099930"
2520,"NCT00025259","Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease","Completed","Has Results","Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma|Childhood Mixed Cellularity Classical Hodgkin Lymphoma|Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Childhood Nodular Sclerosis Classical Hodgkin Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage II Childhood Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma","Biological: Bleomycin Sulfate|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Biological: Filgrastim|Radiation: Involved-Field Radiation Therapy|Drug: Prednisone|Drug: Vincristine Sulfate Liposome","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","1734","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","AHOD0031|NCI-2011-02069|CDR0000068943|COG-AHOD0031|U10CA098543","October 11, 2001","September 2002","null","March 15, 2017","May 2016","October 19, 2016","null","August 2012","Event-free Survival|Disease Response Assessed by Modified RECIST Criteria|Grade 3 or 4 Non-hematologic Toxicity|Overall Survival","https://ClinicalTrials.gov/show/NCT00025259"
2521,"NCT00697671","Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies","Completed","No Results Available","Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma","Other: NK Cell Infusion|Biological: Immunotherapy|Device: Miltenyi Biotec CliniMACS device|Drug: Interleukin-2 (IL-2)|Drug: Clofarabine|Drug: Cyclophosphamide|Drug: Etoposide","St. Jude Children's Research Hospital|Assisi Foundation","All","up to 18 Years   (Child, Adult)","Phase 1","48","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NKHEM","April 14, 2008","March 2007","May 2013","July 15, 2013","July 2013","No Study Results Posted","null","February 2013","To assess the safety of chemotherapy and IL-2 administration to facilitate transient NK-cell engraftment in research participants with chemotherapy refractory non-acute myelogenous leukemia (non-AML) hematologic malignancies|To study the persistence, phenotype and function of donor natural killer (NK) cells after infusion in research participants with chemotherapy refractory hematologic malignancies.|To explore the efficacy of NK cell infusion in research participants with chemotherapy refractory hematologic malignancies","https://ClinicalTrials.gov/show/NCT00697671"
2522,"NCT01665001","Personalized Therapy of Precursor Lymphoid Neoplasms","Not yet recruiting","No Results Available","Precursor Lymphoid Neoplasms","Other: Treatment strategy: induction, consolidation, HSCT, maintenance","Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice|Polish Adult Leukemia Group","All","18 Years and older   (Adult, Senior)","Phase 2","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PALG ALL6","August 11, 2012","August 2012","August 2018","August 16, 2012","August 2012","No Study Results Posted","null","August 2016","Overall survival|Leukemia-free survival","https://ClinicalTrials.gov/show/NCT01665001"
2523,"NCT00366275","Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma","Completed","Has Results","Follicular Lymphoma","Procedure: Immunochemotherapy, in vivo purging and autrotransplant","IRCCS Policlinico S. Matteo","All","18 Years to 60 Years   (Adult)","Phase 2","64","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML17165|LNH 1-02","August 17, 2006","January 2002","September 2007","October 26, 2012","October 2012","February 18, 2009","null","January 2007","Progression-free Survival","https://ClinicalTrials.gov/show/NCT00366275"
2524,"NCT00670631","Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment","Completed","No Results Available","Multiple Myeloma","Combination Product: tandem autologous transplantation","Guido Tricot|National Cancer Institute (NCI)|University of Iowa","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","46","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","25009|7R01CA115399","April 3, 2008","February 2008","April 2014","April 4, 2017","April 2017","No Study Results Posted","null","May 2012","To determine whether, in comparison to TT II, the median EFS can be increased from 4.8 years to 6.2 years, which represents an increase in median EFS of approximately 30%|In assessing patient safety, we will examine treatment toxicity related mortality and SAEs. Historical study results indicate that a mortality rate of greater than 10% is not acceptable in this population, nor is an SAE rate of greater than 15%.|Overall survival will be compared to a historical control (UARK 98-026, TT2)as a secondary outcome.","https://ClinicalTrials.gov/show/NCT00670631"
2525,"NCT00148681","Preoperative Herceptin and Navelbine for Breast Cancer","Unknown status","No Results Available","Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer","Drug: Herceptin|Drug: Navelbine|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Paclitaxel","Dana-Farber Cancer Institute|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","49","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","00-273","September 7, 2005","May 2001","April 2010","October 30, 2009","October 2009","No Study Results Posted","null","May 2003","To assess the complete response rate after preoperative herceptin and navelbine in HER-2 positive breast cancer.|To determine the safety of herceptin and navelbine in this patient population (either high risk or low risk).","https://ClinicalTrials.gov/show/NCT00148681"
2526,"NCT03081780","Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML","Recruiting","No Results Available","Refractory Acute Myelogenous Leukemia|Relapsed Acute Myelogenous Leukemia","Biological: FATE-NK100","Masonic Cancer Center, University of Minnesota","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","29","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2016LS153","March 6, 2017","April 27, 2017","January 1, 2021","April 27, 2017","April 2017","No Study Results Posted","null","January 1, 2021","Maximum tolerated dose (MTD)|Clinical activity by CR/CRp leukemia clearance|Clinical activity by CR/CRp neutrophil recovery|In vivo expansion of NK cells|Treatment Related Mortality (TRM)|Minimal residual disease (MRD) by bone marrow morphology|Minimal residual disease (MRD) by flow cytometry|Leukemia free survival (LFS)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT03081780"
2527,"NCT00000703","Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members","Completed","No Results Available","Lymphoma, Non-Hodgkin|HIV Infections","Drug: Bleomycin sulfate|Drug: Vincristine sulfate|Drug: Doxorubicin hydrochloride|Drug: Cyclophosphamide|Drug: Allopurinol|Drug: Methotrexate|Drug: Cytarabine|Drug: Leucovorin calcium|Drug: Zidovudine|Drug: Dexamethasone","National Institute of Allergy and Infectious Diseases (NIAID)","All","19 Years to 69 Years   (Adult, Senior)","","45","NIH","Interventional","Primary Purpose: Treatment","ACTG 008|10984","November 2, 1999","null","March 1990","March 28, 2012","March 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00000703"
2528,"NCT01783535","Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma","Recruiting","No Results Available","Retinoblastoma","Drug: vincristine|Drug: topotecan|Drug: filgrastim|Drug: PEG-filgrastim|Drug: carboplatin|Other: focal therapy|Drug: etoposide|Drug: cyclophosphamide|Drug: MESNA|Drug: doxorubicin|Procedure: enucleation|Radiation: external beam radiation or proton beam radiation","St. Jude Children's Research Hospital","All","Child, Adult, Senior","Phase 2","155","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","SJRET6|NCI-2013-00409","January 31, 2013","June 19, 2013","June 30, 2022","March 30, 2017","October 2016","No Study Results Posted","null","June 30, 2020","Response rate (complete or partial response)|ocular survival|Event-free survival|The mechanism (or frequencies) for each RB1 biallelic inactivation","https://ClinicalTrials.gov/show/NCT01783535"
2529,"NCT02265770","An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma","Recruiting","No Results Available","Childhood Ependymoma","Drug: 16 weeks of VEC + CDDP|Drug: VEC + HD-MTX|Drug: Chemotherapy + Valproate|Radiation: Conformal radiotherapy|Drug: VEC|Drug: Chemotherapy|Radiation: conformal radiotherapy +/- boost","Centre Leon Berard","All","up to 22 Years   (Child, Adult)","Phase 2|Phase 3","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","SIOP Ependymoma II (ET-13-002)|2013-002766-39|VHP358","September 29, 2014","April 2015","August 2026","August 18, 2016","August 2016","No Study Results Posted","SIOP-EP-II","June 2023","Gross Total Resection rate|Progression-Free Survival|Number of treatment responders|Number of participants undergoing a second-look surgery|Overall Survival|Quality of Survival|Evaluation of neuropsychological morbidity|Comparison of neuroendocrine morbidity|Number of participants with adverse events as a measure of safety and tolerability|Radiotherapy-free survival rate","https://ClinicalTrials.gov/show/NCT02265770"
2530,"NCT00003715","Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma","Terminated","No Results Available","Melanoma (Skin)","Biological: BCG vaccine|Biological: autologous tumor cell vaccine|Biological: recombinant interferon alfa|Drug: chemotherapy|Drug: cyclophosphamide","AVAX Technologies","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","425","Industry","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066824|AVAX-A/100/0101","November 1, 1999","December 1998","null","December 2, 2015","December 2015","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003715"
2531,"NCT00911911","Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy","Completed","No Results Available","Breast Cancer","Procedure: Blood sampling|Procedure: BIOPSY|Procedure: SURGERY","Centre Oscar Lambret","Female","18 Years and older   (Adult, Senior)","","66","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label","SPAM 2006-10","May 22, 2009","January 2007","July 2009","July 30, 2012","July 2012","No Study Results Posted","SPAM","January 2009","Proteomic analysis by SELDI-TOF on the tumor biopsy and blood samples Histological response according To Chevallier and Sataloff|Correlation with node invasion|Correlation with basal, luminal phenotypes, HER2 status or hormonal status|Correlation with the response measured by ultrasound after chemotherapy","https://ClinicalTrials.gov/show/NCT00911911"
2532,"NCT00089479","A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer","Completed","Has Results","Breast Cancer","Drug: capecitabine [Xeloda]|Drug: Taxotere|Drug: Taxotere","Hoffmann-La Roche","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","2611","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NO17629","August 5, 2004","August 2002","May 2012","December 19, 2012","December 2012","March 31, 2011","null","June 2010","Disease Free Survival [Number of Events]|Disease Free Survival [Time to Event]|Overall Survival [Number of Events]|Overall Survival [Time to Event]|Breast Cancer Free Survival [Number of Events]|Breast Cancer Free Survival [Time to Event]|Disease Free Survival Including New Primary Breast Cancer as Event [Number of Events]|Disease Free Survival Including New Primary Breast Cancer as Event [Time to Event|Disease Free Survival Including Any New Cancer as Event [Number of Events]|Disease Free Survival Including Any New Cancer as Event [Time to Event]","https://ClinicalTrials.gov/show/NCT00089479"
2533,"NCT02409576","Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas","Recruiting","No Results Available","Ewing Sarcoma|Osteosarcoma|Rhabdomyosarcoma","Biological: Expanded , Activated NK cells","National University Hospital, Singapore|KK Women's and Children's Hospital","All","6 Months to 80 Years   (Child, Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DSRB 2014/00452|CTC1400413 (NUH)|CTC1400412 (KKWCH)","April 1, 2015","February 2015","September 2018","June 21, 2016","June 2016","No Study Results Posted","NKEXPSARC","September 2017","Disease response after expanded activated NK cell infusion|Persistence and phenotype of expanded NK cells in research participants with EWS, RMS and OS.|Toxicity of NK cells infusion (NCI toxicity criteria CTC version 4.0)|Performance status will be assessed by age-dependent Performances Scores ( Lansky scale or Karnofsky performance scale)|Acute and Chronic GVHD","https://ClinicalTrials.gov/show/NCT02409576"
2534,"NCT02706405","JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma","Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Drug: Cyclophosphamide|Biological: Durvalumab|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study","Fred Hutchinson Cancer Research Center|AstraZeneca|Juno Therapeutics, Inc.|MedImmune LLC|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","42","Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","9457|NCI-2015-02286|P30CA015704|R01CA136551","February 24, 2016","November 2016","null","January 5, 2017","January 2017","No Study Results Posted","null","December 2019","Area under the curve (AUC) of JCAR014 cells by flow cytometry|Area under the curve (AUC) of JCAR014 cells by qPCR analysis|Dose limiting toxicity (DLT) rates|Incidence of toxicity graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03|Maximum JCAR014 concentration (Cmax) by flow cytometry|Maximum JCAR014 concentration (Cmax) in blood by quantitative polymerase chain reaction (qPCR) analysis|Time to loss of JCAR014 detection in blood by qPCR analysis|Area under the concentration-time curve (AUC) of durvalumab in serum|Clearance of durvalumab in serum|Duration of response|Maximum durvalumab concentration (Cmax) in serum|Objective response rate (ORR, defined as the proportion of patients with a best response of either CR or PR) by investigator assessment using Lugano criteria|Overall survival|PFS|Rate of complete response (CR) by investigator assessment using Lugano criteria|Rate of partial response (PR) by investigator assessment using Lugano criteria|Terminal half-life of durvalumab in serum","https://ClinicalTrials.gov/show/NCT02706405"
2535,"NCT00054236","Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: umbilical cord blood transplantation|Drug: methylprednisolone","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 1","55","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU6Y01|P30CA043703|12-01-32J","February 5, 2003","May 2002","March 2011","September 11, 2012","September 2012","No Study Results Posted","null","March 2011","Event-free survival by disease assessment|Umbilical cord blood donor engraftment by chimerism and complete blood count (CBC)","https://ClinicalTrials.gov/show/NCT00054236"
2536,"NCT00554164","Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas","Completed","No Results Available","Lymphoma, High-grade","Drug: (R-)CHOP protocol|Drug: B-ALL protocol|Drug: (R-)CHOP protocol|Drug: (R-)CHOP protocol","University Hospital, Essen|Deutsche Krebshilfe e.V., Bonn (Germany)","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","1073","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","PETAL trial|EudraCT-Number 2006-001641-33|Krebshilfe Grant 107592","November 5, 2007","November 2007","March 2017","May 4, 2017","May 2017","No Study Results Posted","PETAL","March 2017","Time to treatment failure|Response rate, overall survival, disease-free survival, toxicity, quality of life","https://ClinicalTrials.gov/show/NCT00554164"
2537,"NCT03146234","CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma","Recruiting","No Results Available","Hepatocellular Carcinoma","Genetic: CAR-GPC3 T cells","RenJi Hospital|Carsgen Therapeutics, Ltd.","All","18 Years to 70 Years   (Adult, Senior)","","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CG1006","April 24, 2017","March 17, 2017","June 15, 2020","May 5, 2017","May 2017","No Study Results Posted","null","December 16, 2019","Safety and tolerance|Engraftment","https://ClinicalTrials.gov/show/NCT03146234"
2538,"NCT01920737","A Novel ""Pediatric-Inspired"" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia","Recruiting","No Results Available","Leukemia","Drug: Daunorubicin|Drug: Vincristine|Drug: Prednisone|Drug: PEG-Asparaginase|Drug: Methotrexate|Drug: 6-MP (6-Mercaptopurine)|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Leucovorin|Drug: Dexamethasone|Other: Blood draw|Device: CT/PET scans","Memorial Sloan Kettering Cancer Center|Baxalta US Inc.|Duke University|Weill Medical College of Cornell University|Lehigh Valley Health Network","All","18 Years to 60 Years   (Adult)","Phase 2","39","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","12-266","August 7, 2013","August 2013","August 2017","April 26, 2017","April 2017","No Study Results Posted","null","August 2017","rate of molecular remission|complete remission (CR)|overall survival (OS)|event-free survival (EFS)|disease free survival (DFS) rates|minimal residual disease (MRD) status|safety","https://ClinicalTrials.gov/show/NCT01920737"
2539,"NCT01091168","Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer|Metastases","Drug: vinflunine|Drug: alkylating agent of physician choice registered in cancer","Pierre Fabre Medicament","Female","18 Years to 75 Years   (Adult, Senior)","Phase 3","594","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","L00070 IN 308 B0","February 3, 2010","September 2009","January 2013","October 12, 2016","October 2016","No Study Results Posted","null","January 2013","Overall survival|Quality of life questionnaire|Adverse event profile|Tumour response rate|Progression free survival","https://ClinicalTrials.gov/show/NCT01091168"
2540,"NCT00544115","Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","Active, not recruiting","No Results Available","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Precancerous/Nonmalignant Condition","Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Drug: methotrexate|Drug: mycophenolate mofetil|Drug: sirolimus|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation","City of Hope Medical Center|National Cancer Institute (NCI)","All","up to 120 Years   (Child, Adult, Senior)","Phase 2","260","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","01089|P30CA033572|CHNMC-01089|CDR0000566376","October 13, 2007","September 2001","null","September 16, 2016","September 2016","No Study Results Posted","null","September 2017","Neutrophil and platelet engraftment|Incidence of acute and chronic graft-versus-host disease (GVHD)|Impact of HLA class I and class II allele-matching on the incidence of GVHD and on the survival outcome|Overall survival|Disease-free survival|Relapse","https://ClinicalTrials.gov/show/NCT00544115"
2541,"NCT00027885","Phase II Bevacizumab + Tax In Advanced Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: bevacizumab|Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","49","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU3100|U01CA062502|P30CA043703|CWRU-3100|NCI-2722","December 7, 2001","November 2001","August 2010","June 14, 2013","June 2013","No Study Results Posted","null","December 2005","To evaluate the ability of bevacizumab and docetaxel to reduce microvessel density and induce apoptosis of endothelial and tumor cells.|Number of patients with objective response","https://ClinicalTrials.gov/show/NCT00027885"
2542,"NCT01037764","Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)","Terminated","No Results Available","Acute Lymphoid Leukemia","Procedure: alloHCT","Asan Medical Center","All","15 Years to 75 Years   (Child, Adult, Senior)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-ALLO-036","December 22, 2009","January 2010","December 2016","May 22, 2016","May 2016","No Study Results Posted","AHCTALL","December 2014","Cumulative incidence of relapse|leukemia free survival|engraftment rate|donor chimerism|secondary graft failure rate|Incidence & severity of acute GVHD|incidence and severity of chronic GVHD|degree of immune recovery|cumulative incidence and severity of infection|transplantation-related mortality rate|overall survival rate & median survival time|duration of remission","https://ClinicalTrials.gov/show/NCT01037764"
2543,"NCT01484470","Umbilical Cord Transplantation for the Elderly Population","Active, not recruiting","No Results Available","Hematologic Malignancies","Biological: StemEx","Loyola University|Gamida Cell ltd","All","55 Years to 73 Years   (Adult, Senior)","Phase 2","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","202041","November 30, 2011","January 2010","December 2017","February 23, 2017","February 2017","No Study Results Posted","null","February 2017","Efficacy of StemEx|Time to engraftment","https://ClinicalTrials.gov/show/NCT01484470"
2544,"NCT02706392","Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies","Recruiting","No Results Available","Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Breast Carcinoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Mantle Cell Lymphoma|Recurrent Non-Small Cell Lung Carcinoma|Refractory Chronic Lymphocytic Leukemia|Stage IV Breast Cancer|Stage IV Non-Small Cell Lung Cancer|Triple-Negative Breast Carcinoma","Other: Laboratory Biomarker Analysis|Biological: ROR1 CAR-specific Autologous T-Lymphocytes","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","60","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","9330|NCI-2015-01753|P30CA015704|P50CA138293","March 1, 2016","March 16, 2016","null","March 15, 2017","February 2017","No Study Results Posted","null","December 2021","Maximum tolerated dose of ROR1 CAR-specific autologous T lymphocytes defined as a true dose limiting toxicity rate of 25% probably or definitely attributed to T cell infusion|Duration of persistence of adoptively transferred ROR1 CAR-T cells|Identification of sites where ROR1 CAR-T cells migrate|Objective response rate of complete remission and partial remission|Overall survival|Progression free survival","https://ClinicalTrials.gov/show/NCT02706392"
2545,"NCT00429416","Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation","Completed","Has Results","Hematologic Malignancies","Drug: L-leucyl-L-leucine Methyl Ester (LLME)|Drug: Fludarabine|Drug: Cytarabine|Drug: Cyclophosphamide|Drug: Tacrolimus|Drug: Mesna|Biological: Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|Procedure: Hematopoietic stem cell transplantation (HSCT)","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","04U.115|2003-68","January 29, 2007","March 2004","May 2009","October 19, 2016","October 2016","July 19, 2013","null","December 2008","Safety of CD34+ Stem Cell Infusions Followed by LLME as Measured by 100-Day Mortality|Rate of Engraftment of Non-Myeloablative Transplants|Incidence of Grade II-IV Acute Graft-Versus-Host-Disease (GVHD)|Rate of Serious Infectious Complications|Number of Patients Who Achieve a CD4 Count > 200/Micro-liters","https://ClinicalTrials.gov/show/NCT00429416"
2546,"NCT01275287","Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab","Withdrawn","No Results Available","Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","Drug: Standard of care treatment|Drug: eculizumab","University of North Carolina, Chapel Hill|Alexion Pharmaceuticals|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","0","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","10-2218|P01DK058335","December 13, 2010","May 2011","December 2012","February 17, 2017","September 2016","No Study Results Posted","null","December 2012","Birmingham Vasculitis Activity Score (BVAS)|Complement levels elevation|Birmingham Vasculitis Activity Score(BVAS)|Normalisation of complement activation|Change in complement levels|change in complement levels 2|Birmingham Vasculitis Activity Score (BVAS) 2","https://ClinicalTrials.gov/show/NCT01275287"
2547,"NCT02323867","Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies","Recruiting","No Results Available","Leukemia|Lymphoma|Myelodysplasia","Device: Alpha Beta T cell depletion","Children's Hospital of Philadelphia","All","up to 23 Years   (Child, Adult)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","13-010495|BT13BTθ51","October 22, 2014","October 2014","June 2020","November 14, 2016","November 2016","No Study Results Posted","AB-CliniMACs","October 2019","Engraftment: rates of engraftment, defined as the first day of Absolute Neutrophil Count (ANC) greater than 500 for the first of three consecutive days|Severe acute and chronic graft versus host disease (GVHD)","https://ClinicalTrials.gov/show/NCT02323867"
2548,"NCT00604136","Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy","Recruiting","No Results Available","Metastatic Melanoma","Biological: tumor infiltrating lymphocytes","Hadassah Medical Organization","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MS269- HMO-CTIL","January 17, 2008","July 2008","January 2018","August 19, 2015","August 2015","No Study Results Posted","null","January 2017","To determine the response rate of this approach when administered in our hospital","https://ClinicalTrials.gov/show/NCT00604136"
2549,"NCT00001239","Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer|Breast Neoplasms","Drug: FLAC with GM-CSF","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","100","NIH","Interventional","Primary Purpose: Treatment","890119|89-C-0119","November 3, 1999","July 1989","January 2001","March 3, 2008","April 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001239"
2550,"NCT00003899","Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Biological: filgrastim|Drug: cyclophosphamide|Drug: melphalan|Drug: paclitaxel|Drug: thiotepa|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","1343.00|FHCRC-1343.00|NCI-H99-0032|CDR000006707","November 1, 1999","January 1999","November 2001","October 3, 2016","September 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003899"
2551,"NCT00002961","Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia","Terminated","No Results Available","Leukemia","Drug: cyclophosphamide|Drug: cyclosporine|Drug: etoposide|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation|Radiation: Total Body Irradiation|Drug: Busulfan|Drug: Mesna|Radiation: Radiation","Children's Hospital of Philadelphia","All","up to 21 Years   (Child, Adult)","Phase 3","43","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","1995-9-1013|CHP-BMT-583|BMS-CHP-BMT-583|NCI-V97-1183","November 1, 1999","October 1995","February 2001","October 14, 2013","October 2013","No Study Results Posted","null","February 2001","","https://ClinicalTrials.gov/show/NCT00002961"
2552,"NCT02568839","Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer","Recruiting","No Results Available","Early-Stage Breast Carcinoma|HER-2 Positive Breast Cancer","Drug: docetaxel + trastuzumab sc + pertuzumab|Drug: trastuzumab emtansin","Thomas Hatschek|Karolinska University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PREDIX HER2","September 21, 2015","November 2014","December 2022","September 6, 2016","September 2016","No Study Results Posted","PREDIX HER2","December 2017","Pathological objective response to primary medical treatment|Clinical/radiological objective response during neoadjuvant treatment|Disease-free survival|Breast cancer specific survival|Overall survival|Incidence of treatment-emergent adverse events [Safety and Tolerability]|Quality of life|Frequency of breast-conserving surgery","https://ClinicalTrials.gov/show/NCT02568839"
2553,"NCT01110291","Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events","Completed","No Results Available","CYP3A Phenotyping|CYP3A5 and MDR1 Genotyping|Docetaxel Toxicity|Associations Between Genetic Data and Docetaxel Toxicity","Drug: docetaxel + CEF","University of Turku|Sanofi|Turku University Hospital|Vaasa Central Hospital, Vaasa, Finland|medbase Oy Ltd","Female","18 Years to 60 Years   (Adult)","","20","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","XRP 6976A/6022","April 22, 2010","April 2003","March 2009","April 26, 2010","April 2010","No Study Results Posted","Docetaxel","January 2004","docetaxel toxicity|survival","https://ClinicalTrials.gov/show/NCT01110291"
2554,"NCT00912223","Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)","Completed","Has Results","Lymphoma, Non-Hodgkin","Biological: Hematopoietic Stem Cell Transplant","Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program","All","1 Year to 75 Years   (Child, Adult, Senior)","Phase 2","65","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","BMTCTN0701|U01HL069294|U01HL06929406|5U24CA076518","June 1, 2009","April 2009","August 2016","February 7, 2017","February 2017","August 5, 2016","null","November 2014","Progression-Free Survival (PFS)|Graft Failure|Donor Cell Engraftment|Time to Neutrophil Recovery|Acute Graft-versus-Host Disease (GVHD)|Chronic GVHD|Overall Survival|Treatment-related Mortality (TRM)|Infections|Quality of Life|Immunologic Reconstitution|Incidence of Toxicities|Serum Rituximab (RTX) Levels","https://ClinicalTrials.gov/show/NCT00912223"
2555,"NCT00042367","Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors","Completed","No Results Available","Brain Tumors","Drug: Induction therapy (Regimen 1, Course 1, Cycle A1|Drug: Regimen 1, Course 1, Cycle A2 (Days 22 - 42)|Drug: Cycle B|Drug: Regimen 1, Course 2|Drug: Intrathecal Mafosfamide|Drug: Regimen 1 Course 2, IT mafosfamide|Drug: Regimen 2, Course 1|Drug: Regimen 2, Course, 1, Cycle C1|Drug: Regimen 2, Course 2|Radiation: radiation therapy","Baylor College of Medicine|Texas Children's Hospital|Duke University|St. Jude Children's Research Hospital|Children's Research Institute|Seattle Children's Hospital|Children's Hospital of Philadelphia|Children's Hospital of Pittsburgh|Dana-Farber Cancer Institute|University of California, San Francisco","All","up to 36 Months   (Child)","","119","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H8619|BB'98","July 26, 2002","April 2000","June 2006","February 10, 2012","February 2012","No Study Results Posted","BB'98","December 2005","To evaluate the feasibility, including expected disease progression, of delivering 20 weeks of systemic chemotherapy plus (IT) mafosfamide.|To evaluate the safety and feasibility of a limited dose escalation schedule of IT mafosfamide in children < 3 years of age.","https://ClinicalTrials.gov/show/NCT00042367"
2556,"NCT00004228","Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma","Active, not recruiting","Has Results","Lymphoma","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: thioguanine|Drug: vincristine sulfate|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 30 Years   (Child, Adult)","Phase 3","393","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","A5971|CCG-59701|CCG-59701C|CCG-A5971|POG-A5971|CDR0000067470","January 28, 2000","June 2000","null","December 1, 2016","November 2016","October 8, 2013","null","August 2008","Event-free Survival|Percentage of Patients With Overall Survival as Assessed by Time to Death","https://ClinicalTrials.gov/show/NCT00004228"
2557,"NCT00025077","Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: thiotepa|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","up to 20 Years   (Child, Adult)","Phase 2","50","Other","Interventional","Primary Purpose: Treatment","CCLG-CNS-2000-01|CDR0000068910|EU-20105","October 11, 2001","January 2000","April 2011","August 1, 2013","June 2007","No Study Results Posted","null","null","Event-free survival|Toxic death rate","https://ClinicalTrials.gov/show/NCT00025077"
2558,"NCT00004921","High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery","Completed","No Results Available","Ovarian Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: melphalan|Drug: paclitaxel|Procedure: adjuvant therapy|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","EBMT Solid Tumors Working Party|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult)","Phase 3","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000067604|EBMT-HIDOC-EIS|EBMT-OVCAT|EU-99040","March 7, 2000","September 1998","September 2007","September 16, 2013","July 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004921"
2559,"NCT00003877","Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: paclitaxel|Drug: thiotepa|Procedure: in vitro-treated bone marrow transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Female","18 Years to 64 Years   (Adult)","Phase 1|Phase 2","30","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000067043|P30CA016056|RPCI-DS-9828|CWRU-OSIR-1198|OSIRIS-101|NCI-G99-1516","November 1, 1999","September 1998","December 2000","March 3, 2011","March 2011","No Study Results Posted","null","February 2000","","https://ClinicalTrials.gov/show/NCT00003877"
2560,"NCT00003398","Bone Marrow Transplantation in Treating Patients With Hematologic Cancer","Completed","No Results Available","Anemia|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: cyclophosphamide|Drug: thiotepa|Procedure: allogeneic bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Radiation: radiation therapy","University of Maryland|University of Maryland Greenebaum Cancer Center","All","up to 50 Years   (Child, Adult)","Phase 4","45","Other","Interventional","Primary Purpose: Treatment","CDR0000066400|MSGCC-9739|NCI-V98-1433","November 1, 1999","September 1998","May 2000","September 23, 2009","September 2009","No Study Results Posted","null","May 2000","","https://ClinicalTrials.gov/show/NCT00003398"
2561,"NCT02014506","Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents","Recruiting","No Results Available","Haploidentical Hematopoietic Stem Cell Transplantation|Malignant Disease|Non-malignant Disease","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: anti-thymocyte globulin|Biological: filgrastim|Radiation: Total body irradiation|Procedure: TCRαβ-depleted hematopoietic cell transplantation|Device: CliniMACS","Asan Medical Center","All","up to 21 Years   (Child, Adult)","Phase 1|Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","AMCPHO-SCT1303","December 4, 2013","January 2017","December 2018","March 24, 2017","March 2017","No Study Results Posted","null","December 2018","To evaluate tralsplant-related mortality after haploidentical hematopoietic stem cell transplantation using TCRαβ-depleted graft|To assess engraftment and graft failure|To estimate the risk of acute GVHD|To estimate the incidence of relapse|To estimate the incidence and severity of chronic GVHD|To estimate the overall survival|To estimate the incidence of bacterial, fungal and viral infection|To estimate the reactivation rate of CMV, EBV|To evaluate the immune reconstitution of T, B, and NK cells|To evaluate the lineage-specific chimerism using flow cytomery of CD3+, CD19, CD56, TCR αβ, and TCRγδ at pre-transplant|To assess event free survival","https://ClinicalTrials.gov/show/NCT02014506"
2562,"NCT00004907","Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: busulfan|Drug: cyclophosphamide|Drug: etoposide|Procedure: allogeneic bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Northwestern University|National Cancer Institute (NCI)","All","15 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","NU 95H4T|NU-95H4T|NCI-G00-1692","March 7, 2000","October 1999","August 2004","June 8, 2012","June 2012","No Study Results Posted","null","August 2004","","https://ClinicalTrials.gov/show/NCT00004907"
2563,"NCT00881920","Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL","Recruiting","No Results Available","Lymphoma|Myeloma|Leukemia","Biological: Kappa CD28 T cells","Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine","All","18 Years and older   (Adult, Senior)","Phase 1","54","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","H-23574-CHARKALL|CHARKALL","April 14, 2009","July 2009","July 2034","April 17, 2017","April 2017","No Study Results Posted","CHARKALL","July 2019","Number of Patients with Dose-Limiting Toxicities (DLT)|Survival and Function of CAR-K+ T cells|To measure the anti-tumor effects of CAR-K+ T lymphocytes.","https://ClinicalTrials.gov/show/NCT00881920"
2564,"NCT00179803","Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors","Unknown status","No Results Available","Glioblastoma|Astrocytoma|Pineoblastoma|Rhabdoid Tumor|Supratentorial Neoplasms","Procedure: Stem Cell Transplant","Ann & Robert H Lurie Children's Hospital of Chicago","All","18 Months to 25 Years   (Child, Adult)","Phase 2|Phase 3","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT 0398","September 10, 2005","March 1998","null","March 10, 2011","March 2011","No Study Results Posted","null","January 2008","To determine if the use of sequential myeloablative chemotherapy with peripheral blood stem cell rescue will increase the overall survival rate in patients with newly diagnosed high risk CNS tumors|The overall survival and progression free survival in children with recurrent CNS malignancies after obtaining a state of minimum residual disease with submyeloablative chemotherapy, surgery, and/or radiation.|To determine the progression free survival and overall survival using sequential myeloablative chemotherapy as compared to historical controls with single autologous stem cell rescue following myeloablative chemotherapy.|Determine the long term neurocognitive, endocrinologic, cardiopulmonary, and hematologic sequelae of sequential myeloablative chemotherapy and stem cell rescues in patients treated for high risk CNS and recurrent CNS tumors.|Determine the feasibility and utility of the myeloablative preparatory regimen of Carboplatinum, VP-16 and Thiotepa administered in an outpatient setting, and to determine the cost savings obtained via this strategy.","https://ClinicalTrials.gov/show/NCT00179803"
2565,"NCT02549586","Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance","Enrolling by invitation","No Results Available","Complication of Transplanted Organ, Nos","Other: Autologous Hematopoietic Stem Cell Transplant","Gary A Levy, O. Ont. MD. FRCP AGAF|Ottawa Hospital Research Institute|University of Toronto","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Tol 001","September 1, 2015","December 2015","January 2020","October 27, 2016","October 2016","No Study Results Posted","ASCOTT","January 2018","Number of patients who develop tolerance post autologous HSCT|HSCT mortality|HSCT related morbidity|Rate of immune reconstitution","https://ClinicalTrials.gov/show/NCT02549586"
2566,"NCT01458548","Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)","Terminated","No Results Available","Post-transplantation Lymphoproliferative Disorder","Drug: Rituximab|Drug: CHOP","Charite University, Berlin, Germany","All","16 Years and older   (Child, Adult, Senior)","Phase 2","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PTLD-1","October 18, 2011","December 2002","October 2011","October 24, 2011","October 2011","No Study Results Posted","null","May 2008","number of patients with complete and partial remission|response duration|number of patients with treatment-related death|overall survival","https://ClinicalTrials.gov/show/NCT01458548"
2567,"NCT00113646","Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies","Terminated","No Results Available","Lymphoma|Leukemia|Multiple Myeloma|Myelodysplastic Syndrome","Drug: MEDI-507|Procedure: Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant","Massachusetts General Hospital|Dana-Farber Cancer Institute","All","up to 65 Years   (Child, Adult)","Phase 2","14","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","02-163","June 9, 2005","November 2002","December 2007","March 4, 2016","March 2016","No Study Results Posted","null","December 2007","To evaluate the risk of graft loss and severe GVHD or transplant related mortality at < 100 days following HLA-mismatched non-myeloablative stem cell transplantation.|To evaluate progression free and overall survival following HLA mismatched non-myeloablative stem cell transplantation for hematologic malignancy.","https://ClinicalTrials.gov/show/NCT00113646"
2568,"NCT00004061","Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer","Completed","No Results Available","Leukemia|Lymphoma|Oral Complications","Biological: filgrastim|Biological: palifermin|Drug: cyclophosphamide|Drug: etoposide|Drug: ifosfamide|Procedure: peripheral blood stem cell transplantation|Procedure: quality-of-life assessment|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 2","111","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Supportive Care","AMGEN-KGF-980231-04|MSKCC-99029|CDR0000067261|NCI-G99-1574","December 10, 1999","May 1999","December 2009","June 25, 2013","December 2009","No Study Results Posted","null","May 2003","","https://ClinicalTrials.gov/show/NCT00004061"
2569,"NCT02119715","A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy","Completed","No Results Available","Breast Cancer|Neutropenia|Febrile Neutropenia","Drug: Pegylated rhG-CSF 100μg/kg|Drug: Pegylated rhG-CSF:150 μg/kg|Drug: rhG-CSF 5 μg/kg/day","Jiangsu HengRui Medicine Co., Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","182","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HHPG-19K-II-01","April 17, 2014","February 2011","December 2012","April 17, 2014","April 2014","No Study Results Posted","null","August 2012","Incidence and the duration of grade 3/4 neutropenia in cycle 2 and the time frame of ANC recovery to 2.0×109/L|Incidence of the febrile neutropenia in cycle 1 and cycle 2|ANC alteration in cycle 1 and cycle 2","https://ClinicalTrials.gov/show/NCT02119715"
2570,"NCT00003416","S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: recombinant interferon alfa|Drug: dexamethasone|Drug: melphalan|Procedure: peripheral blood stem cell transplantation","Southwest Oncology Group|National Cancer Institute (NCI)","All","up to 69 Years   (Child, Adult, Senior)","Phase 2","9","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","S9805|U10CA032102","November 1, 1999","September 1998","January 2004","March 5, 2015","March 2015","No Study Results Posted","null","August 2000","confirmed remission rate|overall survival (OS)|progression free survival (PFS)|toxicity","https://ClinicalTrials.gov/show/NCT00003416"
2571,"NCT00003309","Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: vincristine sulfate|Procedure: adjuvant therapy|Radiation: radiation therapy","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group","All","18 Years and older   (Adult, Senior)","Phase 2","33","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066256|E4397|SWOG-E4397","November 1, 1999","July 1998","null","January 26, 2010","January 2010","No Study Results Posted","null","March 2004","","https://ClinicalTrials.gov/show/NCT00003309"
2572,"NCT02862704","A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)","Recruiting","No Results Available","Liver Metastases","Biological: MG7-CART","Xijing Hospital|Shanghai GeneChem Co., Ltd.","All","18 Years to 69 Years   (Adult, Senior)","Phase 1|Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MG7-CART","August 7, 2016","June 2016","December 2017","August 8, 2016","August 2016","No Study Results Posted","null","May 2017","Number of patients with adverse event|Number of patients with tumor response|Detection of transferred T cells in the circulation using quantitative -PCR","https://ClinicalTrials.gov/show/NCT02862704"
2573,"NCT01167192","Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer","Terminated","Has Results","Breast Neoplasms","Drug: Cisplatin|Drug: Carboplatin|Radiation: Radiation therapy|Procedure: Mastectomy (recommended but not mandatory)","Washington University School of Medicine","Female","18 Years and older   (Adult, Senior)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","201310089","July 14, 2010","February 2011","September 2016","November 9, 2016","November 2016","September 8, 2016","null","August 2012","Response Rate as Measured by Number of Participants Who Achieved Complete Response (CR) or Partial Response (PR)|Relationship Between Tumor Response and Deficiencies in DNA Repair Mechanisms|Time to Disease Progression|Number of Participants With Surgical Complications|Determine the Effect of Neoadjuvant Chemoradiation Therapy in Disseminated Cancer Cells in the Bone Marrow|Overall Survival Rate|Medical Toxicities as Measured by Number of Grade 3 or Higher Adverse Events|Successful Development of Animal Models of Triple Negative Breast Cancers as Measured by the Ability to Grow the Tumors in Mice.|Successful Development of Animal Models for Triple Negative Breast Cancers as Measured by the Ability to Passage the Tumors in Mice|Successful Development of Animal Models in Triple Negative Breast Cancers as Measured by the Ability of the Tumors to Metastasize to Other Organs|Successful Development of Animal Models of Triple Negative Breast Cancer as Measured by the Genetic Similarity Between the Primary Tumor and the Tumor in Animals|Determine the Effect of Neoadjuvant Chemoradiation Therapy in Disseminated Cancer Cells in the Bone Marrow and the Correlation to Tumor Response","https://ClinicalTrials.gov/show/NCT01167192"
2574,"NCT00025610","Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma","Completed","No Results Available","Neuroblastoma","Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: vincristine sulfate","European Infant Neuroblastoma Study Group - 1999|National Cancer Institute (NCI)","All","up to 1 Year   (Child)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068979|EURO-INF-NB-STUDY-1999-99.2|EU-20125B","October 11, 2001","July 1999","March 2009","September 16, 2013","November 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00025610"
2575,"NCT00003816","Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer","Active, not recruiting","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Nonmalignant Neoplasm|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Drug: thiotepa|Radiation: total-body irradiation","Roswell Park Cancer Institute","All","4 Years to 70 Years   (Child, Adult, Senior)","Phase 2|Phase 3","362","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","CDR0000066968|RP 98-15","November 1, 1999","October 19, 1998","May 1, 2018","May 8, 2017","May 2017","No Study Results Posted","null","July 1, 2017","Activity of allogeneic stem cell transplant|Influence of donor histocompatibility on outcome","https://ClinicalTrials.gov/show/NCT00003816"
2576,"NCT00006256","Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: paclitaxel|Procedure: adjuvant therapy|Radiation: radiation therapy","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","18 Years to 120 Years   (Adult, Senior)","Phase 2","44","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU2199|P30CA043703|CWRU-2199|NCI-G00-1851|NCI-2010-01058","September 11, 2000","June 2000","August 2017","September 15, 2016","September 2016","No Study Results Posted","null","November 2005","Determine the feasibility of concurrent paclitaxel and breast radiotherapy|Cosmetic outcome based upon established descriptive parameters: excellent, good, fair, and poor.|Pulmonary function|Survival","https://ClinicalTrials.gov/show/NCT00006256"
2577,"NCT02715362","A Study of GPC3 Redirected Autologous T Cells for Advanced HCC","Recruiting","No Results Available","Carcinoma, Hepatocellular","Drug: TAI-GPC3-CART cells","Shanghai GeneChem Co., Ltd.","All","18 Years to 69 Years   (Adult, Senior)","Phase 1|Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GeneChem GPC3-CART","March 11, 2016","March 2016","March 2019","March 16, 2016","March 2016","No Study Results Posted","GPC3-CART","July 2018","Safety of CAR-T cell infusion mediated by TAI as measured by number of participants with adverse Events|Number of participants with tumor response as measured by RECIST|Detection of CART cells in the circulation using quantitative -PCR|Serum cytokine levels","https://ClinicalTrials.gov/show/NCT02715362"
2578,"NCT01158118","Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors","Completed","Has Results","Leukemia, Myeloid, Acute|Myelodysplastic Syndromes|Lymphoma, Non-Hodgkin|Hodgkin Disease|Leukemia, Lymphocytic, Chronic, B-Cell|Multiple Myeloma","Drug: Sargramostim|Drug: Plerixafor","Washington University School of Medicine","All","18 Years to 65 Years   (Adult)","Phase 2","48","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","10-1154 / 201108083","July 6, 2010","April 1, 2011","December 31, 2016","March 22, 2017","March 2017","March 22, 2017","null","January 15, 2014","Number of Donors Requiring a Second Collection to Obtain a Minimum CD34/Kg (2 x 10^6) Necessary for Allogeneic Stem Cell Transplantation|Proportion of Donors Who Experience Grade 3-4 Infusion Toxicity|Number of Donors Who Mobilize ≥ 2x10^6 CD34+ Cells/Kg Recipient Weight Safely Following One or Two Aphereses|Percentage of Donors Who Reach 5x10^6 CD34+ Cells/Kg Recipient Weight in 1 or 2 Aphereses|Determine if Peripheral Blood Stem Cell Products Collected After Mobilization With IV Plerixafor Can be Used Safely for Hematopoietic Cell Transplantation in HLA-matched Recipients as Measured by Time to Neutrophil Engraftment (Recipient Only)|Kinetics of Immune Reconstitution as Measured by Time to Neutrophil Engraftment (Recipient Only)|Kinetics of Immune Reconstitution as Measured by Time to Platelet Engraftment (Recipient Only)|Rate of Acute Graft vs. Host Disease (GvHD) (Recipient Only)|Rate of Chronic Graft vs. Host Disease (GvHD) (Recipient Only)|Transplant Related Mortality (Recipient Only)|Relapse and Disease Progression Rate|Death of Any Cause (Recipients Only)","https://ClinicalTrials.gov/show/NCT01158118"
2579,"NCT02706782","A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma","Recruiting","No Results Available","Pancreatic Cancer","Drug: TAI-meso-CART","Shanghai GeneChem Co., Ltd.","All","18 Years to 69 Years   (Adult, Senior)","Phase 1","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Genechem meso-CART","March 8, 2016","March 2016","September 2018","March 8, 2016","March 2016","No Study Results Posted","meso-CART","February 2018","Number of patients with adverse event|Number of patients with tumor response|Detection of transferred T cells in the circulation using quantitative -PCR","https://ClinicalTrials.gov/show/NCT02706782"
2580,"NCT02396043","Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma","Recruiting","No Results Available","Lymphoma, Lymphoblastic","Drug: induction|Drug: induction|Drug: protocol M|Drug: maintenance therapy|Drug: reinduction|Drug: reinduction|Drug: Intrathecal (IT)","Sun Yat-sen University","All","18 Years to 65 Years   (Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LBL-308","March 18, 2015","March 2015","March 2019","October 18, 2016","January 2016","No Study Results Posted","null","March 2017","progression free survival|complete remission rate|overall survival|safety, including hematological safety and non-hematological safety.All the adverse events will be classified according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","https://ClinicalTrials.gov/show/NCT02396043"
2581,"NCT00632827","Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)","Unknown status","No Results Available","Peripheral T-Cell Lymphoma","Drug: REGIMEN|Drug: REGIMEN B","University of California, San Francisco|Eisai Inc.|Washington University Early Recognition Center|Wake Forest University Health Sciences|University of Chicago|University of North Carolina|Roswell Park Cancer Institute|Weill Medical College of Cornell University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","21","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","UC-PTCL-ONTAK","February 28, 2008","June 2008","December 2014","October 3, 2014","October 2014","No Study Results Posted","null","December 2014","The primary endpoint of this trial is improvement in 3-year progression-free survival from 30% to 50% under the study regimen.","https://ClinicalTrials.gov/show/NCT00632827"
2582,"NCT00612222","Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma","Terminated","Has Results","Metastatic Melanoma|Skin Cancer","Biological: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|Biological: ALVAC MART-1 Vaccine|Biological: aldesleukin|Drug: cyclophosphamide|Drug: fludarabine phosphate","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","4","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","080056|08-C-0056","February 8, 2008","January 2008","March 2011","October 6, 2015","October 2015","March 13, 2012","null","March 2011","Number of Participants With Metastatic Melanoma Who Develop Clinical Tumor Regression (CR or PR)|Number of Participants With in Vivo Survival of T-cell Receptor (TCR) Gene-engineered Cells|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00612222"
2583,"NCT00567554","Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: epirubicin - cyclophosphamide / docetaxel|Drug: epirubicin - cyclophosphamide / docetaxel + bevacizumab|Drug: paclitaxel|Drug: paclitaxel + everolimus (RAD001)|Drug: epirubicin - cyclophosphamide / docetaxel + trastuzumab|Drug: epirubicin - cyclophosphamide / docetaxel + lapatinib","German Breast Group|AGO Study Group","Female","18 Years and older   (Adult, Senior)","Phase 3","2600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GBG 44|2006-005834-19","December 4, 2007","October 2007","October 2015","February 9, 2016","February 2016","No Study Results Posted","GeparQuinto","August 2011","To compare the pCR rates of neoadjuvant treatment in all 3 Settings|To assess the toxicity of and compliance to all six treatments.|To determine the breast conservation rate after each treatment.|To determine the (loco-regional and distant) disease-free and overall survival after each treatment. In Her-2 positive disease the cerebral disease-free survival will be determined separately.|To assess treatment efficacies in subgroups defined according to tumor stage (T2-3 vs T4) receptor status (ER and/or PR pos. vs ER and PR neg.) and response by best appropriate imaging method to the first 4 cycles of treatment (complete vs partial vs no)|To examine and compare prespecified molecular markers on core biopsy before and after end of chemotherapy","https://ClinicalTrials.gov/show/NCT00567554"
2584,"NCT00594308","In-Vivo Activated T-Cell Depletion to Prevent GVHD","Terminated","Has Results","Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Myelodysplasia|Lymphoma, Non-Hodgkin's|Mantle-Cell Lymphoma|Hodgkin's Disease|Multiple Myeloma|Myelofibrosis","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Cyclosporine|Drug: Mycophenolate mofetil|Drug: Basiliximab","Indiana University","All","18 Years to 75 Years   (Adult, Senior)","","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0705-20 IUCRO-0196","January 4, 2008","October 2007","null","September 26, 2014","September 2014","August 5, 2011","null","October 2008","Number of Patients With Acute Grade II-IV GVHD|Number of Patients Engrafting at Day +30 by Short Tandem Repeat (STR) on Peripheral Blood Mononuclear Cells (PBMC's).|Number of Days for Absolute Neutrophil Count to Recover|Time to Resolution of Cytopenias: Platelet Transfusion Independence|Patients Who Experience Serious Transplant Related Toxicities as Evaluated by Bone Marrow Transplant-adjusted NCI Common Toxicity Criteria.","https://ClinicalTrials.gov/show/NCT00594308"
2585,"NCT00335556","Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors","Completed","No Results Available","Childhood Renal Cell Carcinoma|Clear Cell Renal Cell Carcinoma|Clear Cell Sarcoma of the Kidney|Papillary Renal Cell Carcinoma|Rhabdoid Tumor of the Kidney|Stage I Renal Cell Cancer|Stage I Renal Wilms Tumor|Stage II Renal Cell Cancer|Stage II Renal Wilms Tumor|Stage III Renal Cell Cancer|Stage III Renal Wilms Tumor|Stage IV Renal Cell Cancer|Stage IV Renal Wilms Tumor","Drug: Doxorubicin Hydrochloride|Drug: Irinotecan Hydrochloride|Procedure: Conventional Surgery|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Carboplatin|Biological: Dactinomycin|Drug: Vincristine Sulfate|Radiation: Radiation Therapy|Other: Laboratory Biomarker Analysis","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 29 Years   (Child, Adult)","Phase 2","294","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AREN0321|NCI-2009-00414|COG-AREN0321|CDR0000472893|U10CA098543","June 8, 2006","June 2006","null","April 14, 2016","April 2016","No Study Results Posted","null","December 2015","Event-free survival of patients with diffuse anaplastic Wilms' tumor (DAWT) treated with HU-1|Long-term survival of patients with Stage I-IV malignant rhabdoid tumors|Efficacy of vincristine/irinotecan when delivered in an 6-week window|Event-free survival|Toxicity as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Frequency of INI1 mutations in renal and extrarenal malignant rhabdoid tumor by fluorescent in situ hybridization|Frequency of TP53 mutations in patients with anaplastic Wilms' tumor by immunohistochemistry","https://ClinicalTrials.gov/show/NCT00335556"
2586,"NCT01385423","Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)","Completed","No Results Available","Acute Myelogenous Leukemia|Myelodysplastic Syndrome","Drug: Preparative Regimen|Biological: Intravenous Recombinant Human IL-15 (rhIL-15)","Masonic Cancer Center, University of Minnesota","All","18 Years and older   (Adult, Senior)","Phase 1","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2010LS063|MT2010-10|1009M89012","June 28, 2011","September 2011","March 2015","January 21, 2016","January 2016","No Study Results Posted","null","March 2015","Maximum Tolerated/Minimum Efficacious Dose|Incidence of Expansion of Natural Killer Cells|Treatment Related Mortality (TRM)|Rate of CRp","https://ClinicalTrials.gov/show/NCT01385423"
2587,"NCT01431196","Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer","Completed","No Results Available","Stage II Breast Cancer|Stage III Breast Cancer","Biological: Autologous dendritic cell vaccination","Clinica Universidad de Navarra, Universidad de Navarra|Spanish Clinical Research Network - CAIBER|National Institutes of Health (NIH)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","29","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DEND/CM","April 1, 2011","February 2011","December 2013","May 18, 2016","May 2016","No Study Results Posted","null","June 2012","pathologic complete response (pCR) in the breast and the axilla|Number of participants with adverse events|Impact of the vaccine on patients DFS and OS|EORTC quality of life|Correlation among the specific immune response induced in patients and the pathologic response of the tumor","https://ClinicalTrials.gov/show/NCT01431196"
2588,"NCT01646385","Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry","Completed","Has Results","Rheumatoid Arthritis","Drug: etanercept|Drug: non-biologic anti-rheumatic drugs","Pfizer","All","18 Years and older   (Adult, Senior)","","6393","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","B1801348","April 12, 2012","February 2012","August 2012","July 7, 2014","July 2014","April 3, 2014","null","August 2012","Crude Incidence Rate of Malignancy|Crude Incidence Rate of Lymphoproliferative Malignancy (LM)|Crude Incidence Rate of Serious Infections|Crude Incidence Rate of Other Serious Adverse Events|Crude Incidence Rate of All-Cause Mortality|Percentage of Participants Who Switched to Other Therapy Following Etanercept Discontinuation|Time on Etanercept Therapy|Disease Activity Score Based on 28-Joints Count (DAS28) at Baseline|Change From Baseline in Disease Activity Score Based on 28-Joints Count (DAS28) at Year 1, 2, 3, 4, and 5|Percentage of Participants With Remission and Low Disease Activity as Assessed by Disease Activity Score Based on 28-Joints Count (DAS28)|Time to Remission|Health Assessment Questionnaire (HAQ) Score at Baseline|Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Year 1, 2, and 3|Percentage of Participants With Remission Based on Health Assessment Questionnaire (HAQ) Score|Health Assessment Questionnaire (HAQ) Score 6 Months Prior to And 6 Months Post-Switching Etanercept","https://ClinicalTrials.gov/show/NCT01646385"
2589,"NCT01220128","Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer","Terminated","Has Results","Neoplasms, Breast","Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A|Drug: Placebo|Drug: Aromatase inhibitor|Drug: 5-Fluorouracil|Drug: Carboplatin AUC|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Doxorubicin|Drug: Epirubicin|Drug: Paclitaxel|Drug: Trastuzumab","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator, Outcomes Assessor|Primary Purpose: Treatment","113172|2010-019909-42","October 7, 2010","April 1, 2011","November 14, 2014","April 24, 2017","April 2017","November 28, 2016","INDUCT","November 1, 2014","Number of Subjects With Severe Toxicities|Number of Patients With an Anti-Wilm's Tumor Gene (Anti-WT1) Humoral Response|Number of Patients With Adverse Events (AEs)|Number of Subjects With Serious Adverse Events SAE(s)|Number of Subjects With Alanine Aminotransferase Increased Abnormality, by Common Terminology Criteria for Adverse Events (CTCAE) Maximum Grade|Number of Subjects With Alkaline Phosphatase Increased Abnormality, by CTCAE Maximum Grade|Number of Subjects With Anemia, by CTCAE Maximum Grade|Number of Subjects With Aspartate Aminotransferase Increased Abnormality, by CTCAE Maximum Grade|Number of Subjects With Blood Bilirubin Increased Abnormality, by CTCAE Maximum Grade|Number of Subjects With Creatine Increased Abnormality, by CTCAE Maximum Grade|Number of Subjects With Hemoglobin Increased Abnormality, by CTCAE Maximum Grade|Number of Subjects With Hypercalcemia Abnormality, by CTCAE Maximum Grade|Number of Subjects With Hyperkalemia Abnormality, by CTCAE Maximum Grade|Number of Subjects With Hypernatremia Abnormality, by CTCAE Maximum Grade|Number of Subjects With Hypoalbuminemia Abnormality, by CTCAE Maximum Grade|Number of Subjects With Hypocalcemia Abnormality, by CTCAE Maximum Grade|Number of Subjects With Hypokalemia Abnormality, by CTCAE Maximum Grade|Number of Subjects With Hyponatremia Abnormality, by CTCAE Maximum Grade|Number of Subjects With Lymphocyte Count Decreased Abnormality, by CTCAE Maximum Grade|Number of Subjects With Lymphocyte Count Increased Abnormality, by CTCAE Maximum Grade|Number of Patients With Adverse Events (AEs), by CTCAE Maximum Grade Reported|Number of Subjects With Platelet Count Decreased Abnormality, by CTCAE Maximum Grade|Number of Subjects With White Blood Cell Decreased Abnormality, by CTCAE Maximum Grade|Number of Subjects With Neutrophil Count Decreased Abnormality, by CTCAE Maximum Grade|Number of Subjects With Serious Adverse Events (SAEs), by CTCAE Maximum Grade Reported|Number of Subjects With Adverse Events (AEs) Assessed by the Investigators as Causally Related to GSK2302024A Treatment, by CTCAE Maximum Grade Reported|Number of Subjects With Serious Adverse Events (SAEs), Assessed by the Investigators as Causally Related to GSK2302024A Treatment, by CTCAE Maximum Grade Reported|Number of Subjects With Breast Cancer Pathological Response","https://ClinicalTrials.gov/show/NCT01220128"
2590,"NCT00002581","Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: fluorouracil|Drug: methotrexate|Drug: tamoxifen citrate|Procedure: conventional surgery|Radiation: radiation therapy","Scottish Cancer Therapy Network|National Cancer Institute (NCI)","Female","up to 70 Years   (Child, Adult, Senior)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000063696|SCTN-BR9402|EU-94003|UKCCCR-ABC/BR9402","November 1, 1999","June 1993","null","November 5, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002581"
2591,"NCT01597414","Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1","Active, not recruiting","No Results Available","Elderly Metastatic Breast Cancer Population","Drug: Pertuzumab + trastuzumab|Drug: Pertuzumab + trastuzumab + metronomic chemotherapy","European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche","All","60 Years and older   (Adult, Senior)","Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-75111-10114|2011-006342-32","May 7, 2012","June 2013","September 2018","October 25, 2016","October 2016","No Study Results Posted","null","December 2016","Progression free survival rate|Overall survival|Breast cancer specific survival|Tumor response rate as measured by RECIST v1.1|Evolution of HRQoL as assessed by EORTC QLQ-C30 and ELD 14|Evolution of geriatric assessment|if T-DM1: progression free survival rate","https://ClinicalTrials.gov/show/NCT01597414"
2592,"NCT00017654","Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia","Unknown status","No Results Available","Graft Versus Host Disease|Aplastic Anemia","Drug: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methylprednisolone|Procedure: Allogeneic Bone Marrow Transplantation","Northwestern Memorial Hospital|Office of Rare Diseases (ORD)","All","15 Years to 55 Years   (Child, Adult)","","3","Other","Interventional","Primary Purpose: Treatment","199/14983|NU-96AA1T|NU-96H","June 6, 2001","April 2001","null","June 23, 2005","October 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00017654"
2593,"NCT00003960","Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer","Completed","No Results Available","Leukemia|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: busulfan|Drug: cyclophosphamide|Drug: methylprednisolone|Procedure: allogeneic bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","19 Years to 55 Years   (Adult)","Phase 2","36","Other|NIH","Interventional","Primary Purpose: Treatment","J9828 CDR0000067159|P30CA006973|JHOC-98032006|JHOC-J9828|NCI-G99-1543","November 1, 1999","April 1998","September 2001","May 1, 2014","May 2014","No Study Results Posted","null","September 2001","","https://ClinicalTrials.gov/show/NCT00003960"
2594,"NCT03139370","A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers","Recruiting","No Results Available","Solid Tumor","Genetic: Autologous genetically modified MAGE-A3/A6 TCR transduced T cells (KITE-718)|Diagnostic Test: MAGE-A3/A6 test","Kite Pharma, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","KITE-718-301","April 26, 2017","May 8, 2017","February 2024","May 5, 2017","May 2017","No Study Results Posted","null","February 2019","Phase 1A - Safety: Maximum Tolerated Dose|Phase 1B - Efficacy: Objective Response Rate","https://ClinicalTrials.gov/show/NCT03139370"
2595,"NCT00433433","Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: ABVD q4 weeks|Drug: BEACOPP escalated q3 weeks|Radiation: IN-RT 30 Gy (+ boost 6 Gy residual)|Procedure: FDG-PET scan","European Organisation for Research and Treatment of Cancer - EORTC|Lymphoma Study Association|Fondazione Italiana Linfomi ONLUS","All","15 Years to 70 Years   (Child, Adult, Senior)","Phase 3","1952","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-20051|GELA-H10|IIL-EORTC-20051|EUDRACT-2005-002765-37|EU-20657","February 8, 2007","October 2006","null","June 13, 2014","June 2014","No Study Results Posted","H10","December 2011","Progression-free survival|Event-free survival|Overall survival|Long-term toxicity, in terms of secondary malignancies, cardiovascular events, and pulmonary events","https://ClinicalTrials.gov/show/NCT00433433"
2596,"NCT00233987","S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma","Active, not recruiting","Has Results","Lymphoma","Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Drug: melphalan|Procedure: autologous-autologous tandem hematopoietic stem cell transplantation|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)","All","15 Years to 70 Years   (Child, Adult, Senior)","Phase 2","98","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CDR0000442392|U10CA032102|S0410","October 5, 2005","October 2005","July 2017","March 16, 2017","March 2017","January 2, 2013","null","November 2014","2-year Progression-free Survival|Response Rate|Overall Survival|Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug","https://ClinicalTrials.gov/show/NCT00233987"
2597,"NCT00002870","High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation","UNICANCER","Female","18 Years to 59 Years   (Adult)","Phase 3","180","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","PEGASE03|FRE-FNCLCC-PEGASE03|EU-96032","November 1, 1999","December 1994","January 2002","December 14, 2014","December 2014","No Study Results Posted","null","January 2002","Disease free survival","https://ClinicalTrials.gov/show/NCT00002870"
2598,"NCT00005854","Bone Marrow Transplantation in Treating Patients With Hematologic Cancer","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation|Radiation: radiation therapy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 50 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","1457.00|FHCRC-1457.00|NCI-H00-0059|CDR0000067879","June 2, 2000","December 1999","October 2000","November 28, 2011","November 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005854"
2599,"NCT00705120","Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation","Completed","No Results Available","Osteogenesis Imperfecta","Other: Bone Marrow Cell Transplantation|Radiation: Irradiation, Total Body|Drug: Cyclophosphamide|Drug: Cyclosporin|Procedure: Mesenchymal Stem Cell Transplantation|Drug: Busulfan","St. Jude Children's Research Hospital","All","3 Years and older   (Child, Adult, Senior)","Phase 1","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TOIT","June 23, 2008","November 1995","October 2007","June 23, 2008","June 2008","No Study Results Posted","null","July 2000","To investigate the safety and toxicity of allogeneic bone marrow transplantation (BMT) in children with severe Osteogenesis Imperfecta (OI)","https://ClinicalTrials.gov/show/NCT00705120"
2600,"NCT00024128","Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma","Withdrawn","No Results Available","Lymphoma","Biological: anti-thymocyte globulin|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: cyclosporine|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","AIDS Malignancy Consortium|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-028|CDR0000068894","September 13, 2001","August 2001","March 2003","February 1, 2016","February 2016","No Study Results Posted","null","March 2003","","https://ClinicalTrials.gov/show/NCT00024128"
2601,"NCT00600353","Multi-day Doses in Prevention of Nausea and Emesis","Completed","Has Results","Myeloma, Plasma-Cell|Lymphoma, Malignant","Drug: Palonosetron|Drug: Aprepitant|Drug: Dexamethasone","University of Kansas Medical Center|Eisai Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Supportive Care","10862","January 7, 2008","October 2007","January 2010","January 18, 2017","January 2017","March 27, 2013","null","January 2010","Overall Emetic Response: Acute|Overall Emetic Response: Delayed|Overall Emetic Response: Extended|Overall Emetic Response|Impact of Nausea and Vomiting on the Quality of Life of Patients Undergoing Autologous HSCT","https://ClinicalTrials.gov/show/NCT00600353"
2602,"NCT01338987","Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation","Active, not recruiting","No Results Available","Myelodysplastic Syndrome RAEB 2|Acute Lymphocytic Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndrome RAEB 1","Procedure: Allogeneic HSC Transplantation|Drug: Lupron|Drug: 18F FLT|Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Tacrolimus|Radiation: Total Body Irradiation","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","9 Years to 40 Years   (Child, Adult)","Phase 2","70","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","110136|11-C-0136","April 19, 2011","March 30, 2011","December 1, 2018","May 12, 2017","January 24, 2017","No Study Results Posted","null","December 1, 2017","To determine if Lupron improves B lymphocyte reconstitution after HSCT.|To assess whether 18F FLT PET/CT could predict early engraftment/immune reconstitution in marrow and thymus after allogeneic HSCT.|To assess safety of Lupron after 2nd HSCT and evaluate whetherFLT can predict relapse|To investigate whether Lupron will decrease the incidence of acute or chronic GVHD without altering GVT after allogeneic HSCT.|To evaluate if Lupron decreases the incidence of infections after HSCT.","https://ClinicalTrials.gov/show/NCT01338987"
2603,"NCT00309881","Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)","Completed","No Results Available","Chronic Lymphocytic Leukemia","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","German CLL Study Group","All","18 Years and older   (Adult, Senior)","Phase 2","75","Other","Interventional","Primary Purpose: Treatment","CLL2G|EU-20549|GCLLSG-423|MEDAC-GCLLSG-CLL2G","March 29, 2006","April 2003","March 2011","September 30, 2016","September 2016","No Study Results Posted","null","March 2006","Rate of remission|Quality of remission|Toxicity|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00309881"
2604,"NCT01173887","Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15","Completed","No Results Available","Adult T-cell Leukemia-Lymphoma","Drug: VCAP/AMP/VECP(mLSG15)|Biological: KW-0761","Kyowa Hakko Kirin Co., Ltd","All","20 Years and older   (Adult, Senior)","Phase 2","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","0761-003","July 30, 2010","July 2010","April 2012","March 29, 2017","March 2017","No Study Results Posted","null","April 2012","Complete response rate in the best overall response assessment for antitumor effect|Response rate in the best overall response assessment for antitumor effect, complete or response rates by lesion site in the best overall response assessment for antitumor effect|Progression-free survival and Overall survival|Adverse events|anti-KW-0761 antibody|Plasma KW-0761 concentrations and pharmacokinetic parameters","https://ClinicalTrials.gov/show/NCT01173887"
2605,"NCT00281905","Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors","Unknown status","No Results Available","Brain and Central Nervous System Tumors|Neuroblastoma","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: methotrexate|Drug: vincristine sulfate|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","up to 3 Years   (Child)","Phase 2","50","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000454575|CCLG-CNS-9204|EU-20574|CCLG-CNS-1992-04","January 24, 2006","June 1992","null","September 19, 2013","June 2007","No Study Results Posted","null","null","Response rate|Event-free survival|Local recurrence or occurrence of CNS metastases|Quality of survival|Tolerance|Long-term toxicity|Proportion of patients requiring radiotherapy|Prognosis of children who receive both chemotherapy and radiotherapy|Nature and behavior of brain tumors","https://ClinicalTrials.gov/show/NCT00281905"
2606,"NCT00002616","Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: aldesleukin|Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation","University of Illinois at Chicago|National Cancer Institute (NCI)","All","up to 64 Years   (Child, Adult)","Phase 1","36","Other","Interventional","Primary Purpose: Treatment","CDR0000063925|UIC-95-1011|LUMC-6728|NCI-V94-0573","November 1, 1999","February 1995","null","September 19, 2013","September 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002616"
2607,"NCT00003093","Combination Chemotherapy in Treating Children With Neuroblastoma","Completed","No Results Available","Neuroblastoma","Biological: filgrastim|Biological: sargramostim|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 20 Years   (Child, Adult)","Phase 3","573","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","A3961|COG-A3961|CCG-A3961|POG-A3961|CDR0000065804","November 1, 1999","March 1988","January 2011","July 31, 2014","July 2014","No Study Results Posted","null","September 2006","Event Free Survival","https://ClinicalTrials.gov/show/NCT00003093"
2608,"NCT00910650","Study of Gene Modified Immune Cells in Patients With Advanced Melanoma","Recruiting","No Results Available","Metastatic Melanoma","Biological: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells|Drug: non-myeloablative conditioning chemotherapy","Jonsson Comprehensive Cancer Center|California Institute of Technology|University of Southern California|University of Connecticut|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","22","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","10-001212|08-02-020","May 1, 2009","October 2009","December 2018","January 18, 2017","September 2016","No Study Results Posted","F5","December 2017","Response rate: The two-stage phase II study design includes response rate by RECIST criteria as the primary endpoint.|Other key measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study.","https://ClinicalTrials.gov/show/NCT00910650"
2609,"NCT02539017","The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer","Withdrawn","No Results Available","Triple Negative Breast Neoplasms","Drug: Chemo|Biological: Immunotherapy","First Affiliated Hospital Xi'an Jiaotong University","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Renyu-012","August 5, 2015","November 2015","null","August 9, 2016","August 2016","No Study Results Posted","null","September 2017","disease free survival|overall survival|percentage of participants with fever, skin rash, bone marrow suppression, allergy, gastrointestinal response, myalgia and arthralgia","https://ClinicalTrials.gov/show/NCT02539017"
2610,"NCT00002757","TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma","Completed","No Results Available","Leukemia|Lymphoma","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: methotrexate|Drug: prednisolone|Drug: prednisone|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate","Children's Oncology Group|National Cancer Institute (NCI)|Societe Francaise Oncologie Pediatrique|Children's Cancer and Leukaemia Group","All","up to 20 Years   (Child, Adult)","Phase 3","1148","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","5961|COG-C5961|CCG-5961|SFOP-LMB-96|CCLG-NHL-9600|EU-96048|CDR0000064702","November 1, 1999","June 2001","October 2009","July 23, 2014","July 2014","No Study Results Posted","null","October 2003","Event Free Survival|Conditional Survival|Failure Free Survival","https://ClinicalTrials.gov/show/NCT00002757"
2611,"NCT03128996","Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders","Recruiting","No Results Available","Severe Sickle Cell Disease|Bone Marrow Failure Syndromes|Metabolic Disorders|Immunologic Disorders|Hemoglobinopathies|Non-malignant Disorders","Drug: RIC regimen|Drug: GVHD prophylaxis regimen","Washington University School of Medicine","All","up to 21 Years   (Child, Adult)","Phase 1|Phase 2","29","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","FAM BMT","April 3, 2017","March 20, 2017","April 2024","May 1, 2017","May 2017","No Study Results Posted","null","April 2022","Donor engraftment|Time to neutrophil engraftment|Time to platelet engraftment|Effect of BMT on pulmonary function|Effect of BMT on hepatic function|Effect of BMT on neurologic function|Effect of BMT on cardiac function|Effect of BMT on renal function|Pharmacokinetics of alemtuzumab|Pharmacokinetics of abatacept|Incidence of acute graft-versus-host disease (GVHD)|Incidence of chronic graft-versus-host disease (GVHD)|Immune reconstitution","https://ClinicalTrials.gov/show/NCT03128996"
2612,"NCT00664599","Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease","Completed","No Results Available","Behcet's Syndrome","Drug: Rituximab|Drug: Cytotoxic Combination","Tehran University of Medical Sciences|Hoffmann-La Roche","All","16 Years and older   (Child, Adult, Senior)","Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment","132/12487","April 20, 2008","April 2006","January 2008","April 27, 2008","April 2008","No Study Results Posted","null","January 2008","Visual acuity|Inflammatory index for posterior uveitis|Inflammatory index for retinal vasculitis, especially for edema|Total Adjusted Disease Activity Index (TADAI)","https://ClinicalTrials.gov/show/NCT00664599"
2613,"NCT01219816","Multi-centric Study","Recruiting","No Results Available","B ALL|CD22+ Expression|Refractory B-ALL","Drug: Epratuzumab|Drug: Epratuzumab","Nantes University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","55","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","BRD 10/05-O","October 12, 2010","November 2010","May 2017","December 23, 2015","December 2015","No Study Results Posted","CHEPRALL","December 2016","complete response rate (CR and CRp)|Overall response rate (ORR)(CR, CRp and PR)|Overall survival|Disease free survival|CD22 expression after Epratuzumab|Safety and tolerance of Epratuzumab in combination with chemotherapy","https://ClinicalTrials.gov/show/NCT01219816"
2614,"NCT00003214","Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer","Completed","No Results Available","Ovarian Cancer","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: in vitro sensitivity-directed chemotherapy|Drug: paclitaxel","Swiss Group for Clinical Cancer Research","Female","up to 80 Years   (Child, Adult, Senior)","Phase 3","300","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","SAKK 45/94|SWS-SAKK-45/94|EU-97036","November 1, 1999","July 1996","April 2000","May 14, 2012","May 2012","No Study Results Posted","null","April 2000","","https://ClinicalTrials.gov/show/NCT00003214"
2615,"NCT01889069","A Study to Evaluate Safety, Efficacy and Pharmacokinetics of MabThera/Rituxan (Rituximab) in Patients With Diffuse Large B Cell Lymphoma or Follicular Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Drug: MabThera/Rituxan|Drug: Standard chemotherapy","Hoffmann-La Roche","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","161","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ML28881|2013-000647-12","June 26, 2013","July 2013","June 2019","November 1, 2016","November 2016","No Study Results Posted","null","June 2019","Safety: Incidence of Administration-associated reactions|Safety: Incidence of adverse events|Event-free survival (EFS)|Progression-free survival (PFS)|Overall survival (OS)|Disease-free survival (DFS)|Complete response rate (CRR)|Follicular lymphoma patients: plasma concentration of rituximab|Diffuse large B-cell lymphoma patients: plasma concentration of rituximab|Patient-assessed satisfaction using Rituximab Administration Satisfaction Questionnaire (RASQ)","https://ClinicalTrials.gov/show/NCT01889069"
2616,"NCT00057005","Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation","Completed","No Results Available","Leukemia","Drug: CAMPATH-1H|Drug: Anti-CD45|Drug: Ara-C|Drug: Cyclophosphamide|Drug: Mesna|Radiation: Total Body Irradiation","Baylor College of Medicine|The Methodist Hospital System|Texas Children's Hospital|Center for Cell and Gene Therapy, Baylor College of Medicine","All","up to 45 Years   (Child, Adult)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H12870|ADVL","March 26, 2003","February 2003","October 2009","January 19, 2010","November 2009","No Study Results Posted","ADVL","October 2009","To evaluate the toxicity and the anti-tumor activity of anti-human CD45 antibodies (anti-CD45) administered to patients with relapsed/resistant leukemia prior to bone marrow transplantation.|To describe the effects of anti-CD45 on normal hematopoiesis and on complement levels and to describe the effects of anti-CD45 on leukemic blast cells.","https://ClinicalTrials.gov/show/NCT00057005"
2617,"NCT00923195","Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma","Completed","Has Results","Melanoma|Skin Cancer","Drug: MART-1: 26-35(27L) Peptide|Drug: Montanide ISA 51 VG|Drug: gp100:154-162 Peptide|Procedure: Radiation|Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide|Genetic: Anti-gp 100:154 TCR PBL|Genetic: Anti-MART-1 F5 TCR PBL","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","4","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","090051|09-C-0051","June 17, 2009","December 2008","August 2011","October 6, 2015","October 2015","October 4, 2012","null","August 2011","Complete Response Rates for Patients With Metastatic Melanoma|Toxicity Profile","https://ClinicalTrials.gov/show/NCT00923195"
2618,"NCT00849758","Gene Polymorphisms and Gene Products as Biological Markers of Aging and Correlation With Clinical Geriatric Assessment, Tolerance of Chemotherapy and Outcome in Elderly Breast Cancer Patients","Completed","No Results Available","Breast Cancer|Elderly","","Universitaire Ziekenhuizen Leuven","Female","70 Years and older   (Senior)","","110","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","S51518","February 20, 2009","May 2009","September 2014","December 8, 2014","December 2014","No Study Results Posted","EBS","September 2012","the primary question is whether Chemotherapy affects biological aging markers, such as telomere length and immune status","https://ClinicalTrials.gov/show/NCT00849758"
2619,"NCT02881086","Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma","Drug: Rituximab|Drug: Nelarabine|Drug: PEG-Asparaginase|Procedure: Cranial irradiation|Drug: Imatinib|Drug: Idarubicin|Drug: Dexamethasone|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Vincristine|Drug: Mercaptopurine|Drug: VP16|Drug: Daunorubicin (DNR)|Drug: Methotrexate|Procedure: Stem cell transplantation|Drug: Cytarabine|Drug: Vindesine|Drug: Adriamycin|Drug: Prednisolone","Johann Wolfgang Goethe University Hospital","All","18 Years to 55 Years   (Adult)","Phase 3","900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GMALL08_2013","August 4, 2016","August 2016","June 2025","August 23, 2016","August 2016","No Study Results Posted","null","July 2021","Event free survival|Time until consolidation treatment I|Disease free survival","https://ClinicalTrials.gov/show/NCT02881086"
2620,"NCT01611051","A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy","Completed","No Results Available","Breast Cancer|Neutropenia|Febrile Neutropenia","Drug: Drug: Pegylated rhG-CSF: 100µg/kg|Drug: Pegylated rhG-CSF: 6mg|Drug: rhG-CSF 5ug/kg/day","Jiangsu HengRui Medicine Co., Ltd.","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","HHPG-19K -III-01","May 31, 2012","March 2012","null","January 5, 2013","January 2013","No Study Results Posted","null","January 2013","Rate and the duration of grade 3/4 neutropenia in cycle 1|Rate and the duration of grade 3/4 neutropenia in cycle 2-4|Rate of the febrile neutropenia in cycle 1","https://ClinicalTrials.gov/show/NCT01611051"
2621,"NCT02963831","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies","Not yet recruiting","No Results Available","ColoRectal Cancer|Platinum-resistant Ovarian Cancer","Biological: ONCOS-102|Drug: Durvalumab","Ludwig Institute for Cancer Research|Cancer Research Institute, New York City|MedImmune LLC|Targovax ASA","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","78","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","LUD2015-008","November 10, 2016","January 2017","October 2022","January 19, 2017","January 2017","No Study Results Posted","null","July 2020","Number of Adverse Events|Clinical Benefit (Complete Response, Partial Response and Stable Disease)|Objective Response Rate|Progression-free survival|Overall Survival","https://ClinicalTrials.gov/show/NCT02963831"
2622,"NCT00914628","TK008: Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia","Recruiting","No Results Available","Acute Leukemia (Category)","Genetic: HSV-Tk|Other: T-cell depleted or T-cell replete strategies","MolMed S.p.A.","All","18 Years and older   (Adult, Senior)","Phase 3","170","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TK008|2009-012973-37","June 3, 2009","February 2010","December 2018","April 13, 2016","April 2016","No Study Results Posted","null","December 2018","Disease-free survival (DFS)|Overall Survival (OS)|Immuno reconstitution (IR)|Engraftment rate|Cumulative incidence of grade 2, 3, or 4 acute GVHD (aGvHD)|Cumulative incidence of extensive chronic GvHD (cGvHD)|Cumulative incidence of relapse (CIR)|Incidence and duration of infectious episodes and infectious disease mortality|Evaluate the acute and long-term toxicity related to the HSV-Tk infusions|Quality of life (QoL) and Medical Care Utilization (MCU) in both arms|Non-relapse mortality (NRM)","https://ClinicalTrials.gov/show/NCT00914628"
2623,"NCT02546167","CART-BCMA Cells for Multiple Myeloma","Recruiting","No Results Available","Multiple Myeloma","Biological: CART-BCMA","University of Pennsylvania","All","18 Years and older   (Adult, Senior)","Phase 1","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","UPCC 14415","September 9, 2015","September 2015","September 2017","March 3, 2017","March 2017","No Study Results Posted","null","September 2017","Number of Adverse Events","https://ClinicalTrials.gov/show/NCT02546167"
2624,"NCT00324467","Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment","Active, not recruiting","No Results Available","Lymphoma, Non-Hodgkin|Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma","Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Ondansetron|Drug: Dexamethasone|Drug: Diphenhydramine|Drug: Acetaminophen|Drug: Ifosfamide|Drug: Mesna (IV)|Drug: Mesna (oral)|Drug: Carboplatin|Drug: Etoposide|Drug: Rituximab|Drug: Ondansetron|Drug: Dexamethasone|Drug: Diphenhydramine|Drug: Acetaminophen|Other: PET Scan","British Columbia Cancer Agency|Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","150","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","H06-00017","May 9, 2006","August 2006","July 2017","April 26, 2017","April 2017","No Study Results Posted","LYTPET","July 2017","Progression-free survival (PFS) in participants with advanced stage DLBCL|Overall survival (OS) in participants with advanced stage DLBCL|The safety of R-ICE therapy in first-line therapy of DLBCL following four cycles of R-CHOP as assessed using the NCI Common Terminology Criteria for Adverse Events Version 3.0|Investigate clinical and biologic markers that characterize participant heterogeneity and may serve as predictors of response to therapy and overall outcome.|Efficacy of tailoring first-line therapy bases on a mid-treatment PET scan result for patients with advanced stage DLBCL","https://ClinicalTrials.gov/show/NCT00324467"
2625,"NCT00050167","Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Paclitaxel|Drug: Docetaxel|Drug: Capecitabine","M.D. Anderson Cancer Center|Roche Pharma AG","Female","Child, Adult, Senior","Phase 1","603","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ID01-580","November 25, 2002","November 2002","August 2011","August 25, 2011","August 2011","July 7, 2011","null","July 2008","Percentage of Participants With Reoccurrence|Proportion of Participants With Pathological Complete Response|Treatment Effectiveness at Eradicating Tumor in the Breast and Lymph Nodes","https://ClinicalTrials.gov/show/NCT00050167"
2626,"NCT03020030","Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","Not yet recruiting","No Results Available","Acute Lymphoblastic Leukemia, Pediatric","Drug: Pegaspargase|Drug: Erwinia asparaginase|Drug: Cyclophosphamide|Drug: CYTARABINE|Drug: DASATINIB|Drug: DEXAMETHASONE|Drug: Dexrazoxane|Drug: Doxorubicin|Drug: ETOPOSIDE|Drug: HYDROCORTISONE|Drug: LEUCOVORIN CALCIUM|Drug: MERCAPTOPURINE|Drug: METHOTREXATE|Drug: NELARABINE|Drug: Vincristine","Dana-Farber Cancer Institute|Baxalta US Inc.","All","1 Year to 21 Years   (Child, Adult)","Phase 3","400","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","16-001","January 6, 2017","January 2017","January 2026","January 11, 2017","January 2017","No Study Results Posted","null","May 2021","Complete Remission Rate|Event-Free Survival|Overall Survival|Disease Free Survival|Nadir Serum Asparaginase Activity (NSAA)|Non-allergic Asparaginase Toxicity","https://ClinicalTrials.gov/show/NCT03020030"
2627,"NCT00075725","Dexamethasone Compared With Prednisone During Induction Therapy and MTX With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","Completed","Has Results","Leukemia","Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: pegaspargase|Drug: prednisone|Drug: thioguanine|Drug: vincristine sulfate|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 30 Years   (Child, Adult)","Phase 3","3154","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","AALL0232|COG-AALL0232|NCI-2009-00301","January 9, 2004","December 2003","null","February 14, 2017","February 2017","July 10, 2015","null","December 2010","Comparison of the Increase in Cure Rate of High Risk ALL Without Causing More Serious Side Effects Between Interventions|Correlation of Minimal Residual Disease (MRD) Positive With Overall Survival (OS)|Correlation of Minimal Residual Disease (MRD) Negative With Overall Survival (OS).|Correlation of Early Marrow Response Status With MRD Positive.|Correlation of Early Marrow Response Status With MRD Negative.|Correlation of Minimal Residual Disease (MRD) Positive With Event Free Survival (EFS)|Correlation of Minimal Residual Disease (MRD) Negative With Event Free Survival (EFS).","https://ClinicalTrials.gov/show/NCT00075725"
2628,"NCT02229266","Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML","Recruiting","No Results Available","Acute Myeloid Leukemia","Biological: NK cells|Drug: Cytarabine","Technische Universität Dresden|German Research Foundation","All","60 Years to 99 Years   (Adult, Senior)","Phase 2","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","TUD-HINKL1-059","August 28, 2014","September 2015","September 2020","January 15, 2016","January 2016","No Study Results Posted","HINKL","September 2019","2-year overall survival|Time to relapse|Relapse-free survival|Yield and purity of NK cells (CD3-CD56+) after CD3 depletion and CD56 enrichment|NK cell analysis|Clinical performance (ECOG score)|Incidence and severity of GVHD|Incidence of (S)AEs","https://ClinicalTrials.gov/show/NCT02229266"
2629,"NCT00516685","Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV","Terminated","No Results Available","Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV","Biological: Recombinant Human rEGF-P64K/Montanide Vaccine","Bioven Sdn. Bhd.","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","230","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CT 07-03","August 14, 2007","July 2007","null","September 29, 2011","September 2011","No Study Results Posted","NSCLC","null","Survival|Assessment of immunogenecity, safety as well as preliminary assessment of objective response, time of progression and quality of life","https://ClinicalTrials.gov/show/NCT00516685"
2630,"NCT00946374","Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma","Unknown status","No Results Available","Mantle-Cell Lymphoma","Drug: Immunochemotherapy|Drug: High-dose BEAM plus autologous SCT|Other: HLA-identical allogenic SCT","Heidelberg University","All","18 Years to 55 Years   (Adult)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","L-149/2003|BfArM: A-7140-00-37/4021157","July 24, 2009","July 2004","June 2011","July 24, 2009","July 2009","No Study Results Posted","HD-MCL2003","December 2010","Efficacy: ORR, OS, EFS|Toxicity according to WHO-Grading|GvL-effect after allogenic SCT|Comparison of OS between patients completing the protocol and patients not receiving allogenic SCT","https://ClinicalTrials.gov/show/NCT00946374"
2631,"NCT01563211","Predictive Model of Therapy Outcomes in Breast Cancer Patients","Completed","No Results Available","Toxicity From Medication (Endocrine Treatment and Chemotherapy) Given for Breast Cancer Treatment.","","Imperial College London","Female","18 Years and older   (Adult, Senior)","","70","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","72393/271478/14/611|11-LO-1644","January 25, 2012","February 2012","August 2014","March 25, 2015","March 2012","No Study Results Posted","null","August 2014","The primary outcome measure for the study is to determine the relationship between metabonomics spectrum and side effects from chemotherapy and endocrine therapy for patients receiving treatment for breast cancer.|Conduct pharmokinetic analysis of drugs administered and determine relationship between pharmacokinetics and severity of side effects experienced.|Conduct cytokine analysis pre and post treatment, to determine relationship with severity of side effects experienced.|Conduct targeted genetic analysis to determine relationship with severity of side effects experienced.|To find underlying mechanism to explain the interpatient variability in severity of side effects experienced using above techniques (i.e. metabolic profile, pharmacokinetic analysis, cytokine analysis and targeted genetic analysis).|To identify a biomarker based on metabnomic profiling for response to treatment for those receiving neoadjuvant treatment.","https://ClinicalTrials.gov/show/NCT01563211"
2632,"NCT00004221","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer","Terminated","No Results Available","Malignant Ovarian Mixed Epithelial Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Primary Peritoneal Carcinoma|Stage III Ovarian Cancer|Undifferentiated Ovarian Carcinoma","Drug: Carboplatin|Drug: Cyclophosphamide|Biological: Filgrastim|Drug: Paclitaxel|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Topotecan Hydrochloride","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GOG-9903|NCI-2012-02312|CDR0000067462|U10CA027469","January 28, 2000","November 1999","null","March 17, 2016","March 2016","No Study Results Posted","null","March 2010","Complete response defined as complete disappearance of all measurable and evaluable tumor documented at second-look surgery|Indication of excessive toxicity defined as hospitalization > 14 days per course, delay of day 1 therapy > 14 days, or grade 3 (irreversible) or grade 4 vital organ toxicity (non-hematologic)|Overall survival|PFS","https://ClinicalTrials.gov/show/NCT00004221"
2633,"NCT00185523","Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)","Terminated","No Results Available","Leukemia, Lymphocytic, Acute|Leukemia|Leukemia Acute Promyelocytic Leukemia (APL)|Leukemia Acute Lymphoid Leukemia (ALL)|Leukemia Chronic Myelogenous Leukemia (CML)|Leukemia Acute Myeloid Leukemia (AML)|Leukemia Chronic Lymphocytic Leukemia (CLL)","Procedure: Allogeneic hematopoietic cell transplantation","Stanford University","All","up to 55 Years   (Child, Adult)","Phase 2","88","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BMT142|78149|12570","September 12, 2005","May 2002","April 2009","June 14, 2016","June 2016","No Study Results Posted","null","April 2009","To evaluate the overall and disease free survival of recipients who have received G-CSF mobilized stemcells from their donors.","https://ClinicalTrials.gov/show/NCT00185523"
2634,"NCT01247688","Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies","Withdrawn","No Results Available","Lymphoid Hematological Malignancies|Umbilical Cord Blood Transplant","Drug: Cytoxan|Drug: Fludarabine|Radiation: Total Body Irradiation (TBI)|Procedure: Cord Blood Stem Cell Infusion","Baylor College of Medicine|Texas Children's Hospital|Center for Cell and Gene Therapy, Baylor College of Medicine","All","Child, Adult, Senior","","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","26336-UCALL","November 17, 2010","November 2010","December 2013","December 11, 2013","December 2013","No Study Results Posted","UCALL","December 2013","Overall Survival at 1 year after UCB transplant in pediatric patients|Assessment of Platelet Count Recovery|Number of participants with severe acute GVHD grade III-IV as an assessment of safety|Number of participants with chronic GvHD as an assessment of safety|Assess relapse rate after transplant|Assessment of neutrophil count recovery|To evaluate cell recovery and function|Assess leukemia free survival","https://ClinicalTrials.gov/show/NCT01247688"
2635,"NCT02800447","Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol","Not yet recruiting","No Results Available","Advanced Hodgkin's Lymphoma","Drug: Natulan|Drug: ABVD","Lee's Pharmaceutical Limited","All","18 Years to 65 Years   (Adult)","","184","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Zhaoke-NTL-2015-01","May 24, 2016","June 2016","null","June 10, 2016","May 2016","No Study Results Posted","null","February 2020","overall response rate (ORR)|safety as measured by changes of vital signs, ECG and AE number","https://ClinicalTrials.gov/show/NCT02800447"
2636,"NCT00002611","Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer","Completed","No Results Available","Kidney Cancer","Biological: dactinomycin|Biological: filgrastim|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: vincristine sulfate|Procedure: conventional surgery|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 15 Years   (Child)","Phase 3","3031","Other|NIH","Interventional","Primary Purpose: Treatment","9440|COG-Q9401|NWTS-Q9401|CCG-4941|POG-9440|INT-0150|NWTS-5|CDR0000063901","November 1, 1999","July 1995","August 2003","July 23, 2014","July 2014","No Study Results Posted","null","June 2002","Progression free survival","https://ClinicalTrials.gov/show/NCT00002611"
2637,"NCT01422603","Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)","Active, not recruiting","No Results Available","Acute Myeloid Leukaemia|Myelodysplasia","Drug: Clofarabine|Drug: Clofarabine","University Hospital Southampton NHS Foundation Trust|Genzyme, a Sanofi Company","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RHM CAN0638|2008-007043-14","August 22, 2011","February 2011","May 2017","October 12, 2016","October 2016","No Study Results Posted","null","May 2014","Treatment related mortality (TRM)|Overall survival (OS)|Event free survival (EFS)|Efficacy of Clofarabine as a leukaemia bulk-reducing agent prior to transplant conditioning|Time to engraftment|Donor/recipient chimerism|Immune reconstitution parameters (T, B and NK cell subsets)|Duration of hospital stay|Incidence of acute and chronic graft versus host disease|Grade of acute and chronic graft versus host disease","https://ClinicalTrials.gov/show/NCT01422603"
2638,"NCT02813135","European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","Recruiting","No Results Available","Children, Adolescents and Young Adults With Refractory or Recurrent Malignancies","Drug: Ribociclib|Drug: Topotecan|Drug: Temozolomide|Drug: Everolimus|Drug: AZD1775|Drug: Carboplatin|Drug: Olaparib|Drug: Irinotecan|Drug: AZD2014|Drug: Nivolumab|Drug: Cyclophosphamide|Radiation: Radiotherapy","Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute, France","All","up to 18 Years   (Child, Adult)","Phase 1|Phase 2","285","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2016-000133-40|2016/2396","June 16, 2016","June 2016","December 2020","August 22, 2016","August 2016","No Study Results Posted","ESMART","December 2020","Objective tumor response|Time to progression","https://ClinicalTrials.gov/show/NCT02813135"
2639,"NCT02457039","Acupuncture Prevents Chemobrain in Breast Cancer Patients","Recruiting","No Results Available","Chemo-brain|Drug-Related Side Effects and Adverse Reactions|Mild Cognitive Impairment|Breast Cancer","Procedure: Dense cranial electroacupuncture stimulation|Procedure: Body acupuncture|Procedure: Least acupuncture stimulation|Drug: Cytoxan-containing chemotherapy regimens","The University of Hong Kong|Chinese University of Hong Kong","Female","18 Years to 65 Years   (Adult)","","168","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","UW-14206","May 15, 2015","August 2015","August 2018","September 27, 2016","September 2016","No Study Results Posted","null","July 2017","Changes in cognitive function (objective measurement)|Changes in cognitive function (subjective measurement)|Changes in quality of Life - composite measure|Changes in illness related fatigue measured by FACIT-Fatigue|Changes in chemo adverse effects - composite measure|Changes in subject perception of chemotherapy treatment measured by FACIT-TS-G","https://ClinicalTrials.gov/show/NCT02457039"
2640,"NCT00308178","Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Abraxane","Harold J. Burstein, MD, PhD|Celgene Corporation|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Senior)","","66","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","05-249","March 28, 2006","March 2006","June 2008","February 15, 2013","February 2013","No Study Results Posted","null","September 2006","To evaluate the feasibility and toxicity of Abraxane after chemotherapy as part of dose-dense adjuvant chemotherapy for breast cancer.|To evaluate the feasibility of administering Abraxane on a dose dense schedule without G-CSF support|to estimate the percentage of patients with various grades of hematologic toxicity, neurotoxicity, and other non-hematologic toxicity associated with dose-dense Abraxane|to evaluate quality of life.","https://ClinicalTrials.gov/show/NCT00308178"
2641,"NCT02115984","Study of the Safety and Leukostimulatory Activity of the Preparation ""Panagen"" in Patients With Breast Cancer","Completed","Has Results","Breast Cancer","Drug: Panagen|Drug: Placebo|Procedure: Chemotherapy","Panagen, Limited Liability Company","Female","18 Years and older   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","P-bc-2","April 7, 2014","May 2010","May 2012","June 11, 2014","April 2014","May 12, 2014","null","May 2012","The Quantity of Leukocytes and Neutrophils in the Blood of Patients","https://ClinicalTrials.gov/show/NCT02115984"
2642,"NCT00152139","Stem Cell Transplantation for Patients With Hematologic Malignancies","Completed","No Results Available","Acute Lymphoblastic Leukemias|Acute Myelocytic Leukemia|Chronic Myeloid Leukemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic Syndrome|Hemoglobinuria, Paroxysmal|Non-Hodgkin Lymphoma","Procedure: Allogeneic Stem Cell Transplantation|Drug: Chemotherapy and antibodies","St. Jude Children's Research Hospital","All","2 Years to 21 Years   (Child, Adult)","Phase 3","33","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MUDSCT","September 8, 2005","May 2002","January 2009","January 28, 2009","January 2009","No Study Results Posted","null","June 2005","To estimate the occurrence of acute graft versus host disease in patients who have received an unmanipulated hematopoietic stem cell transplant from a matched unrelated donor","https://ClinicalTrials.gov/show/NCT00152139"
2643,"NCT00072007","Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL","Completed","No Results Available","Leukemia","Biological: filgrastim|Biological: rituximab|Drug: CHOP regimen|Drug: cladribine|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","Swiss Group for Clinical Cancer Research","All","18 Years to 65 Years   (Adult)","Phase 2","43","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SAKK 34/02|EU-20321","November 4, 2003","June 2002","October 2010","May 14, 2012","May 2012","No Study Results Posted","null","March 2003","Complete-remission rate after induction|Very good partial remission and nodular partial remission after induction|Toxicity (hematotoxicity and infection rate) at 30 days following study treatment","https://ClinicalTrials.gov/show/NCT00072007"
2644,"NCT01033552","Stem Cell Transplant for Epidermolysis Bullosa","Recruiting","No Results Available","Epidermolysis Bullosa","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Anti-thymocyte globulin|Drug: Cyclosporine A|Drug: Mycophenolate mofetil|Procedure: Mesenchymal stem cell transplantation|Radiation: Total body irradiation|Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation","Masonic Cancer Center, University of Minnesota","All","up to 25 Years   (Child, Adult)","Phase 2","75","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MT2009-09|0911M74035","December 14, 2009","January 2010","October 2019","February 17, 2017","February 2017","No Study Results Posted","null","October 2019","Event-free survival|Incidence of transplant-related mortality (TRM)|Pattern of biochemical improvement measured by increase in protein expression (collagen, laminin, integrin or plakin)|Quality of Life","https://ClinicalTrials.gov/show/NCT01033552"
2645,"NCT00691015","Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant","Unknown status","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Biological: rituximab|Drug: busulfan|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Radiation: total-body irradiation","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","48","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","CDR0000597130|P30CA022453|WSU-2007-127|GENZ-WSU-2007-127","June 4, 2008","May 2008","January 2014","August 6, 2012","August 2012","No Study Results Posted","null","January 2014","Incidence and severity of acute graft-versus-host disease (GVHD)|Safety, as defined by serious adverse events and adverse events related to study treatment.|Incidence of chronic GVHD.|Time to engraftment (i.e., absolute neutrophil recovery [ANC > 1,500/mm³] and platelet recovery [platelet count > 25,000/mm³])|Overall and disease-free survival.|Length of hospital stay.|Incidence of infections, including bacterial, fungal, and viral infections (i.e., CMV and EBV reactivation, including post-transplant lymphoproliferative disorders)|Incidence of thrombotic microangiopathy|Karnofsky performance status|Biomarkers and immunocorrelative studies (i.e., T-cell, B-cell, NK-cell, regulatory T-cell, and allo-reactive T-cell quantitation studies by flow cytometry)","https://ClinicalTrials.gov/show/NCT00691015"
2646,"NCT00187122","Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma","Completed","No Results Available","Lymphoblastic Lymphoma","Drug: Vincristine|Procedure: Radiation Therapy|Drug: Daunomycin|Drug: L-Asparaginase|Drug: Cytarabine|Drug: Methotrexate|Drug: Mercaptopurine|Drug: Etoposide|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Dexamethasone","St. Jude Children's Research Hospital","All","Child, Adult, Senior","","42","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NHL13","September 13, 2005","March 1993","June 2004","April 21, 2008","April 2008","No Study Results Posted","null","June 2004","To determine toxicity and feasibility of intensified multiagent chemotherapy and high dose methotrexate.","https://ClinicalTrials.gov/show/NCT00187122"
2647,"NCT00940524","Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia|Acute Lymphoblastic Leukemia","Drug: Dasatinib, Mitoxantrone, Cytarabine","Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 1","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","09-046","July 14, 2009","July 2009","April 2014","April 9, 2014","April 2014","No Study Results Posted","null","April 2014","To determine the dose of dasatinib that can be safely administered with cytarabine, and high-dose mitoxantrone in patients with Ph+ ALL / lymphoid blast crisis of known chronic myelogenous leukemia.|To determine the toxicity of this combination in these patients.|To determine Abl-mutational status at baseline and at the time of disease progression as a possible mechanism of resistance.","https://ClinicalTrials.gov/show/NCT00940524"
2648,"NCT00005945","Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia","Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: mercaptopurine|Drug: methotrexate|Drug: pegaspargase|Drug: thioguanine|Drug: vincristine sulfate|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 9 Years   (Child)","Phase 3","3054","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","1991|CCG-1991|CDR0000067855|NCI-2012-02333|U10CA098543","July 5, 2000","June 2000","June 2008","February 19, 2016","February 2016","No Study Results Posted","null","November 2007","Event Free Survival","https://ClinicalTrials.gov/show/NCT00005945"
2649,"NCT00068523","Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: methylprednisolone|Procedure: UV light therapy|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ICC7Y02|P30CA043703|CWRU-ICC-7Y02","September 10, 2003","June 2003","null","June 10, 2010","June 2010","No Study Results Posted","null","March 2004","Study the effectiveness of combining ultraviolet-B light therapy with allogeneic stem cell transplantation in treating patients who have hematologic malignancies.","https://ClinicalTrials.gov/show/NCT00068523"
2650,"NCT00580034","Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath","Completed","Has Results","Lymphoma|Myeloma|Leukemia|Myelodysplasia|Solid Tumors","Drug: Campath Purged Non-myeloablative ASCT|Procedure: Donor Apheresis","David Rizzieri, MD|Miltenyi Biotec GmbH|Duke University","All","17 Years and older   (Child, Adult, Senior)","Phase 2","176","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","Pro00009528","December 20, 2007","February 2003","April 2013","May 2, 2014","May 2014","February 5, 2014","null","April 2013","Toxicity|Overall Survival (OS)|Response","https://ClinicalTrials.gov/show/NCT00580034"
2651,"NCT00513474","Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant","Completed","Has Results","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporin-A|Drug: etoposide|Drug: methotrexate|Drug: rasburicase|Drug: sirolimus|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation|Drug: fludarabine|Drug: allopurinol","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult)","Phase 1","46","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Supportive Care","CDR0000558480|MGH-07-071|DFCI-07-071","August 6, 2007","January 2008","February 12, 2013","April 20, 2017","April 2017","February 27, 2017","null","February 12, 2013","Percentage of Participants With Grades II to IV Acute Graft-Versus-Host Disease (aGVHD)|Uric Acid Levels|Number of Participant With Adverse Events (AE)|Graft-versus-host and Host-versus-graft Immune Responses","https://ClinicalTrials.gov/show/NCT00513474"
2652,"NCT00002744","Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: mercaptopurine|Drug: methotrexate|Drug: pegaspargase|Drug: prednisone|Drug: therapeutic hydrocortisone|Drug: thioguanine|Drug: vincristine sulfate|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET photon therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 9 Years   (Child)","Phase 3","1970","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single Blind (masked role unspecified)|Primary Purpose: Treatment","1952|CCG-1952|CDR0000064665","November 1, 1999","May 1996","March 2007","February 7, 2017","July 2014","No Study Results Posted","null","March 2007","Event Free Survival|Comparisons of CNS relapse incidence rates","https://ClinicalTrials.gov/show/NCT00002744"
2653,"NCT01793844","A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients","Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","","Sun Yat-sen University","All","18 Years to 70 Years   (Adult, Senior)","","732","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","CSWOG0001","December 24, 2008","January 2008","December 2017","December 10, 2015","December 2015","No Study Results Posted","null","June 2017","disease free survival|5-year overall survival|response rate|Number of participants with SAE|quality of life","https://ClinicalTrials.gov/show/NCT01793844"
2654,"NCT02179359","Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies","Recruiting","No Results Available","Sickle Cell Disease|Transfusion Dependent Alpha- or Beta- Thalassemia|Diamond Blackfan Anemia|Paroxysmal Nocturnal Hemoglobinuria|Glanzmann Thrombasthenia|Severe Congenital Neutropenia|Shwachman-Diamond Syndrome|Non-Malignant Hematologic Disorders","Drug: Reduced Toxicity Ablative Regimen|Drug: Reduced Intensity Preparative Regimen|Drug: Myeloablative Preparative Regimen","Masonic Cancer Center, University of Minnesota","All","up to 55 Years   (Child, Adult)","","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2014OC034|MT2014-10C","June 27, 2014","September 2, 2014","August 2021","February 17, 2017","February 2017","No Study Results Posted","null","August 2019","incidence of graft failure|overall survival|disease free survival","https://ClinicalTrials.gov/show/NCT02179359"
2655,"NCT01358253","Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia","Completed","No Results Available","Acute Lymphoblastic Leukemia","Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Dexamethasone|Drug: Cytarabine|Drug: Methotrexate|Drug: Rituximab|Drug: 6-Mercaptopurine|Drug: Prednisone|Drug: L-asparaginase","Ruijin Hospital","All","18 Years to 60 Years   (Adult)","Phase 4","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RJ-2010-56","May 18, 2011","December 2010","December 2012","May 19, 2014","May 2011","No Study Results Posted","null","December 2012","CR duration|disease free survival","https://ClinicalTrials.gov/show/NCT01358253"
2656,"NCT00753103","Anti-Cytokine Therapy for Vasculitis","Completed","No Results Available","Wegener's Granulomatosis|Renal Limited Vasculitis|Microscopic Polyangiitis","Biological: Infliximab|Drug: Cyclophosphamide|Drug: Prednisolone|Drug: Azathioprine|Procedure: Plasma exchange|Drug: Mycophenolate mofetil|Drug: Methylprednisolone","University Hospital Birmingham NHS Foundation Trust","All","18 Years and older   (Adult, Senior)","Phase 2","37","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RRK2031","September 15, 2008","January 2003","July 2006","September 15, 2008","September 2008","No Study Results Posted","ACTIVE","July 2006","Time to clinical remission (Birmingham Vasculitis Activity Score 0 or 1)|Adverse events|Vasculitis Damage Index Score|Renal function","https://ClinicalTrials.gov/show/NCT00753103"
2657,"NCT00110006","Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma","Withdrawn","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Procedure: positron emission tomography|Radiation: fludeoxyglucose F 18","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic","CASE2404|P30CA043703|CASE-CWRU-2404|CWRU-100401","May 3, 2005","December 2004","null","June 10, 2010","June 2010","No Study Results Posted","null","null","Complete remission as measured by positron emission tomography (PET) at 7-10 days after R-CHOP, and after completion of study treatment|Overall survival at 7-10 days after R-CHOP, and after completion of study treatment|Disease-free survival at 7-10 days after R-CHOP, and after completion of study treatment","https://ClinicalTrials.gov/show/NCT00110006"
2658,"NCT00002524","Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma","Completed","No Results Available","Lymphoma","Biological: Bleomycin Sulfate|Biological: Filgrastim|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Doxorubicin Hydrochloride (DOX)|Drug: Etoposide|Drug: Fluorouracil|Drug: Ifosfamide|Drug: Leucovorin calcium|Drug: Methotrexate|Drug: Methylprednisolone|Drug: Pentamidine|Drug: Prednisone|Drug: Trimethoprim-Sulfamethoxazole|Drug: Vincristine Sulfate|Drug: Zidovudine (AZT)|Radiation: Radiation Therapy","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","15 Years and older   (Child, Adult, Senior)","Phase 2","46","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DM93-058|P30CA016672|MDA-DM-93058|NCI-T93-0088D|CDR0000078316","November 1, 1999","June 1993","October 2005","July 27, 2012","July 2012","No Study Results Posted","null","October 2005","Number of Patients with Clinical Response","https://ClinicalTrials.gov/show/NCT00002524"
2659,"NCT01302392","A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma","Completed","Has Results","Multiple Myeloma","Drug: Carfilzomib|Drug: Best Supportive Care","Amgen","All","18 Years and older   (Adult, Senior)","Phase 3","315","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","PX-171-011","February 10, 2011","September 2010","September 2015","April 28, 2017","April 2017","July 6, 2015","FOCUS","July 2014","Overall Survival|Progression-free Survival|Overall Response|Duration of Response|Clinical Benefit Response|Duration of Clinical Benefit|Disease Control|Duration of Disease Control","https://ClinicalTrials.gov/show/NCT01302392"
2660,"NCT01619761","Natural Killer (NK) Cells in Cord Blood Transplantation","Recruiting","No Results Available","Leukemia|Chronic Lymphocytic Leukemia","Drug: Lenalidomide|Drug: Fludarabine monophosphate|Drug: Melphalan|Procedure: NK Infusion|Procedure: CB Infusion|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Drug: Rituximab|Drug: Cyclophosphamide","M.D. Anderson Cancer Center|Celgene|American Cancer Society, Inc.|CLL Global Research Foundation","All","up to 75 Years   (Child, Adult, Senior)","Phase 1","13","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2011-0493|NCI-2012-02071|13369","June 12, 2012","May 3, 2013","May 2019","April 17, 2017","April 2017","No Study Results Posted","null","May 2019","Success Rate|Treatment-Related Mortality (TRM)","https://ClinicalTrials.gov/show/NCT01619761"
2661,"NCT01914770","Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76","Completed","No Results Available","Systemic Lupus Erythematosus","Drug: Belimumab 1 mg/kg|Drug: Belimumab 10 mg/kg|Drug: Placebo","GlaxoSmithKline|Human Genome Sciences Inc.","All","18 Years and older   (Adult, Senior)","","1016","Industry","Observational","Time Perspective: Retrospective","114246","April 3, 2012","July 2009","November 2010","September 12, 2013","September 2013","No Study Results Posted","null","November 2010","Responder Rate|SELENA SLEDAI|SF-36|Time to first flare by SLE Flare Index","https://ClinicalTrials.gov/show/NCT01914770"
2662,"NCT00002835","Combination Chemotherapy in Treating Patients With Lymphoma","Completed","No Results Available","Lymphoma","Biological: Bleomycin Sulfate (BLM)|Biological: Filgrastim (G-CSF)|Biological: Recombinant Interferon Alfa|Drug: Carmustine|Drug: Cisplatin (CDDP)|Drug: Cyclophosphamide|Drug: Cytarabine (ARA-C)|Drug: Etoposide (VP-16)|Drug: Idarubicin|Drug: Ifosfamide|Drug: Leucovorin Calcium|Drug: Melphalan|Drug: Methotrexate|Drug: Methylprednisolone|Drug: mitoxantrone hydrochloride (DHAD)|Drug: Vincristine Sulfate|Procedure: Peripheral Blood Stem Cell Transplantation|Radiation: Radiation Therapy","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","15 Years to 59 Years   (Child, Adult)","Phase 3","116","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MDA DM95-121|P30CA016672|MDA-DM-95121|NCI-V96-1010|CDR0000065044","November 1, 1999","July 1995","February 2004","July 27, 2012","July 2012","No Study Results Posted","null","February 2004","Efficacy of Early Intensification vs. Alternating Triple Chemotherapy","https://ClinicalTrials.gov/show/NCT00002835"
2663,"NCT02665065","Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML","Recruiting","No Results Available","Acute Myeloid Leukemia|Leukemia, Acute Myeloid|Myeloid Leukemia, Acute|Leukemia, Myeloid, Acute|Acute Myelogenous Leukemia|Leukemia, Acute Myelogenous|Myelogenous Leukemia, Acute","Drug: Iomab-B|Drug: Conventional Care|Drug: Fludarabine|Radiation: Total Body Irradiation|Procedure: HCT|Drug: Mycofenolate mofetil (MMF)|Drug: Cyclosporine or Tacrolimus","Actinium Pharmaceuticals","All","55 Years and older   (Adult, Senior)","Phase 3","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","Iomab-01","January 22, 2016","June 2016","null","April 24, 2017","April 2017","No Study Results Posted","SIERRA","April 2018","Durable Complete Remission (dCR) defined as CR or CRp lasting 180 days or more from time of initial CR or CRp is documented with evidence of subsequent relapse|Overall Survival (OS) at 1 year from randomization","https://ClinicalTrials.gov/show/NCT02665065"
2664,"NCT00017095","Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: cyclophosphamide|Drug: docetaxel|Drug: epirubicin hydrochloride|Drug: fluorouracil|Genetic: microarray analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: biopsy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC|Swedish Breast Cancer Group|Swiss Group for Clinical Cancer Research|Anglo Celtic Cooperative Oncology Group","Female","up to 70 Years   (Child, Adult, Senior)","Phase 3","1856","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-10994-p53|EORTC-10994|ACCOG-EORTC-10994|SAKK-EORTC-10994|SBGC-EORTC-10994|BIG-1-00","June 6, 2001","March 2001","null","October 23, 2013","October 2013","No Study Results Posted","null","November 2006","Progression-free survival|Distant metastasis-free survival|Overall survival|Clinical and pathological responses|Clinical response according to RECIST criteria without pathologic response|Toxicity according to CTC v2.0|Agreement between p53 assessment by IHC method and functional test in yeast by analyzing the correlation between p52 and tumor status after 3 and 6 cycles of chemotherapy|Tumor assessment using cDNA microarray technology","https://ClinicalTrials.gov/show/NCT00017095"
2665,"NCT00003392","High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: melphalan|Drug: paclitaxel|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 2","61","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LCCC 9727|UNC-LCCC-970135|NCI-G98-1446","November 1, 1999","September 1997","January 2003","February 19, 2012","February 2012","No Study Results Posted","null","August 2002","","https://ClinicalTrials.gov/show/NCT00003392"
2666,"NCT00005962","Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia","Completed","No Results Available","Leukemia","Biological: sargramostim|Drug: cyclophosphamide|Drug: cytarabine|Drug: gemtuzumab ozogamicin|Drug: liposomal daunorubicin citrate|Drug: topotecan hydrochloride","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000067944|E-4999","July 5, 2000","July 2000","June 2007","August 16, 2013","August 2013","No Study Results Posted","null","October 2005","","https://ClinicalTrials.gov/show/NCT00005962"
2667,"NCT00276705","Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer","Unknown status","No Results Available","Liver Cancer","Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: thalidomide|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","up to 29 Years   (Child, Adult)","Phase 2","47","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000454579|CCLG-LT-2005-05|CCLG-SIOPEL-HCC|CCLG-SIOPEL-5|EU-20590|EUDRACT-2005-000427-42","January 12, 2006","June 2005","null","September 16, 2013","June 2009","No Study Results Posted","null","April 2009","Event-free and overall survival following tumor resection|Efficacy and tolerability following course 2 and 4 of pre-operative chemotherapy","https://ClinicalTrials.gov/show/NCT00276705"
2668,"NCT00003577","Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: CMF regimen|Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: methotrexate|Procedure: adjuvant therapy|Radiation: radiation therapy","University Hospital Birmingham|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","2000","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066644|CRC-TU-NEAT|EU-98041","November 1, 1999","March 1996","September 2008","December 18, 2013","February 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003577"
2669,"NCT00002579","Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: CMF regimen|Drug: cyclophosphamide|Drug: fluorouracil|Drug: methotrexate|Drug: tamoxifen citrate|Procedure: conventional surgery|Radiation: radiation therapy","Scottish Cancer Therapy Network|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","2000","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000063694|SCTN-BR9403|EU-94004","November 1, 1999","March 1993","null","November 5, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002579"
2670,"NCT00112827","Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma","Active, not recruiting","No Results Available","Refractory Multiple Myeloma|Smoldering Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma","Radiation: total marrow irradiation|Drug: melphalan|Procedure: peripheral blood stem cell transplantation|Biological: filgrastim|Genetic: fluorescence in situ hybridization|Genetic: cytogenetic analysis|Drug: cyclophosphamide|Procedure: autologous-autologous tandem hematopoietic stem cell transplantation|Drug: lenalidomide","City of Hope Medical Center","All","up to 70 Years   (Child, Adult, Senior)","Phase 1|Phase 2","86","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","COH 04064|NCI-2009-01601|CDR0000428410","June 2, 2005","November 2004","November 2017","May 17, 2017","May 2017","No Study Results Posted","null","November 2017","Feasibility|Response rate|Progression-free survival|Overall survival|Assessment of cell biology","https://ClinicalTrials.gov/show/NCT00112827"
2671,"NCT00683319","Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy","Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors|Cognitive/Functional Effects|Long-term Effects Secondary to Cancer Therapy in Children|Ototoxicity","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: methotrexate|Drug: vincristine sulfate|Procedure: adjuvant therapy|Procedure: cognitive assessment|Procedure: magnetic resonance imaging|Procedure: magnetic resonance spectroscopic imaging|Procedure: quality-of-life assessment","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","up to 2 Years   (Child)","Phase 3","50","Other","Observational","","CDR0000590666|CCLG-CNS-2007-09|EU-20835","May 21, 2008","April 2008","null","September 19, 2013","June 2009","No Study Results Posted","null","March 2034","Overall survival|Event-free survival|Response to chemotherapy, if there is residual disease|Requirement for radiotherapy (i.e., residual disease at the completion of chemotherapy, progressive disease during chemotherapy, or recurrent disease during or after completion chemotherapy)|Late effects of treatment (i.e., ototoxicity and nephrotoxicity at the completion of chemotherapy and neurocognitive outcomes at 5, 7, 11, and 16 years of age)","https://ClinicalTrials.gov/show/NCT00683319"
2672,"NCT00544570","High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Drug: melphalan|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy|Radiation: total-body irradiation","City of Hope Medical Center|National Cancer Institute (NCI)","All","up to 64 Years   (Child, Adult)","","30","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000567466|P30CA033572|P01CA030206|CHNMC-97160","October 13, 2007","April 1998","December 2007","February 5, 2010","February 2010","No Study Results Posted","null","December 2007","Feasibility|Toxicity as assessed by NCI CTC v2.0|Response rate|Progression-free survival|Overall survival|Percentage of patients who achieve minimal disease status after 2 courses","https://ClinicalTrials.gov/show/NCT00544570"
2673,"NCT00265889","Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma","Completed","Has Results","Lymphoma","Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: etoposide|Drug: melphalan|Procedure: autologous-autologous tandem hematopoietic stem cell transplantation|Radiation: radiation therapy","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","42","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CCF5386|P30CA043703|CCF-5386","December 14, 2005","February 2002","April 2010","October 28, 2013","October 2013","June 10, 2013","null","April 2010","Progression-free Survival|Response Rate|Number of Patients That Experience Pulmonary Toxicity","https://ClinicalTrials.gov/show/NCT00265889"
2674,"NCT00025324","Chemotherapy, Surgery, Radiation Therapy and Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Primary CNS Germ Cell Tumors","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: thiotepa|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Children's Hospital Los Angeles|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000068950|CHLA-NYU-0007H|NCI-G01-2019","October 11, 2001","December 2000","null","December 17, 2013","December 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00025324"
2675,"NCT00004132","Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer","Completed","No Results Available","Drug/Agent Toxicity by Tissue/Organ|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Oral Complications|Radiation Toxicity","Biological: filgrastim|Biological: palifermin|Drug: cyclophosphamide|Drug: etoposide|Drug: ifosfamide|Procedure: quality-of-life assessment|Radiation: radiation therapy","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","12 Years to 65 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Supportive Care","AMGEN-KGF-980231-03|UCLA-9812041|CDR0000067362|NCI-G99-1609","December 10, 1999","January 2000","May 2004","June 25, 2013","June 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004132"
2676,"NCT01865110","R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL","Recruiting","No Results Available","Mantle Cell Lymphoma","Drug: R-CHOP|Drug: R-CHOP / R-HAD|Drug: Rituximab|Drug: Lenalidomide","The Lymphoma Academic Research Organisation","All","60 Years and older   (Adult, Senior)","Phase 3","633","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MCL R2 Elderly","May 24, 2013","November 2013","March 2024","September 8, 2016","September 2016","No Study Results Posted","null","June 2021","Progression free survival","https://ClinicalTrials.gov/show/NCT01865110"
2677,"NCT00056095","Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer","Unknown status","No Results Available","Kidney Cancer","Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","UNICANCER|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 2","170","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000271936|FRE-FNCLCC-GETUG-11/0105|EU-20234","March 6, 2003","December 2002","null","February 6, 2009","December 2006","No Study Results Posted","null","null","Survival rate at 18 months|Objective rate of response|Post-transplant immunological reactions and recuperation|Antitumoral activity","https://ClinicalTrials.gov/show/NCT00056095"
2678,"NCT00092222","Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","Recruiting","No Results Available","Lymphoproliferative Disorder|HHV-8|Malignancy|HIV","Drug: Etoposide|Drug: Interferon-alpha|Drug: Rituximab|Drug: Zidovudine|Drug: Liposomal Doxorubicin|Drug: Bortezomib|Drug: Valganciclovir|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Filgrastim (G-CSF)|Drug: Prednisone|Drug: Sirolimus","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","12 Years to 65 Years   (Child, Adult)","Phase 2","55","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","040275|04-C-0275","September 21, 2004","September 17, 2004","October 1, 2020","May 12, 2017","October 6, 2016","No Study Results Posted","null","October 1, 2018","Describe natural history|Therapeutic efficacy and toxicity of several rationally designed therapeutic approaches to KSHV-MCD","https://ClinicalTrials.gov/show/NCT00092222"
2679,"NCT00024050","Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes","Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","1536.00|FHCRC-1536.00|NCI-G01-2009|CDR0000068887","September 13, 2001","February 2001","August 2007","May 12, 2010","May 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00024050"
2680,"NCT00006126","Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery","Withdrawn","No Results Available","Breast Cancer|Kidney Cancer|Lung Cancer|Melanoma (Skin)|Testicular Germ Cell Tumor","Drug: busulfan|Drug: cyclophosphamide|Drug: etoposide|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Northwestern University|National Cancer Institute (NCI)","All","up to 59 Years   (Child, Adult)","Phase 1","0","Other|NIH","Interventional","Primary Purpose: Treatment","NU 99H2|NU-99H2|NCI-G00-1838","August 3, 2000","September 1999","April 2001","November 10, 2015","November 2015","No Study Results Posted","null","April 2001","","https://ClinicalTrials.gov/show/NCT00006126"
2681,"NCT00002789","Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia","Completed","No Results Available","Leukemia","Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","15 Years to 65 Years   (Child, Adult)","Phase 3","100","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","1092.00|FHCRC-1092.00|NCI-H96-0926|CDR0000064853","November 1, 1999","May 1996","September 2001","March 29, 2010","March 2010","No Study Results Posted","null","September 2001","","https://ClinicalTrials.gov/show/NCT00002789"
2682,"NCT00002780","Biological Therapy in Treating Women With Metastatic Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: aldesleukin|Biological: cytokine therapy|Biological: sargramostim|Drug: carboplatin|Drug: cyclophosphamide|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation","St. Luke's Medical Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","60","Other","Interventional","Primary Purpose: Treatment","CDR0000064792|STLMC-BRM-9503|NCI-V96-0902","November 1, 1999","May 1996","null","December 18, 2013","February 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002780"
2683,"NCT00477035","Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies","Completed","No Results Available","Leukemia|Multiple Myeloma","Drug: CIK cells|Drug: etoposide|Drug: bcnu|Drug: cyclophosphamide|Drug: gemcitabine|Drug: vinorelbine|Drug: melphalan","Sally Arai|Stanford University","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","IRB-00245|95889|BMT173","May 18, 2007","May 2006","March 2011","January 9, 2017","January 2017","No Study Results Posted","null","March 2011","To document the toxicities of infusion of autologous CIK cells|Measure freedom from progression (FFP)|Measure event free survival|Measure overall survival|Measure disease response","https://ClinicalTrials.gov/show/NCT00477035"
2684,"NCT00574730","CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma","Completed","No Results Available","Non-Hodgkins Lymphoma","Drug: CHOP/Rituximab|Drug: PEG INTRON","University of Nebraska|Schering-Plough","All","19 Years to 75 Years   (Adult, Senior)","","27","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","013-01","December 12, 2007","May 2001","June 2012","January 8, 2013","January 2013","No Study Results Posted","null","August 2005","Time to Treatment Failure/Duration of Response/Time to Treatment Failure/Survival|Biologic/Immunologic Evaluation on Study","https://ClinicalTrials.gov/show/NCT00574730"
2685,"NCT00287950","Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Infants With Neuroblastoma","Unknown status","No Results Available","Neuroblastoma","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: vincristine sulfate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","up to 1 Year   (Child)","","120","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000454726|CCLG-1992-05|EU-20593|CCLG-9205","February 6, 2006","September 1992","null","September 16, 2013","December 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00287950"
2686,"NCT00276731","Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma","Unknown status","No Results Available","Neuroblastoma","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: vincristine sulfate|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","1 Year and older   (Child, Adult, Senior)","Phase 3","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000454725|CCLG-NB-1995-02|EU-20595|UKCCSG-ENSG-9","January 12, 2006","March 1995","null","September 16, 2013","January 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00276731"
2687,"NCT00052923","Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","427","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000258802|ECOG-E2499|CALGB-50205|CALGB-E2499","January 24, 2003","March 2003","null","February 6, 2009","June 2006","No Study Results Posted","null","June 2006","Progression-free survival|Procedure-related mortality|Overall survival|Potential infectious complications of the addition of rituximab to autologous stem cell transplantation","https://ClinicalTrials.gov/show/NCT00052923"
2688,"NCT00007982","Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer","Completed","No Results Available","Brain and Central Nervous System Tumors|Head and Neck Cancer|Lymphoma","Biological: filgrastim|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: thiotepa|Procedure: adjuvant therapy|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068360|CPMC-IRB-8445|CPMC-CAMP-004A|NCI-G00-1881","January 6, 2001","April 1999","May 2008","February 1, 2013","July 2007","No Study Results Posted","null","February 2005","Response rate|Disease-free suvival|Overall survival|Toxicity|Quality of life","https://ClinicalTrials.gov/show/NCT00007982"
2689,"NCT00003364","Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: vincristine sulfate|Radiation: radiation therapy","London Lung Cancer Group|National Cancer Institute (NCI)","All","up to 74 Years   (Child, Adult, Senior)","Phase 3","398","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066349|LLCG-TR8SCLC|EU-98011","November 1, 1999","January 1993","August 2006","December 18, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003364"
2690,"NCT00451178","An Study of Patients With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Patients Who Take R-CHOP Only","Completed","No Results Available","Lymphoma","Drug: enzastaurin|Drug: rituximab|Drug: cyclophosphamide|Drug: doxorubicin|Drug: vincristine|Drug: prednisone","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","9824|H6Q-MC-S028","March 21, 2007","May 2007","January 2013","March 26, 2013","March 2013","No Study Results Posted","null","February 2012","Progression Free Survival time|Compare R-CHOP plus enzastaurin versus R-CHOP in terms of CR and/or CRu rate and ORR|Compare R-CHOP plus enzastaurin versus R-CHOP in terms of 2-year Progression Free Survival rate|To evaluate PET-negative rate for each treatment arm|To investigate concordance between CT scan/MRI and PET scan|Event Free Survival|Overall Survival|Duration of complete response|Assess biomarkers and their correlation to clinical outcomes|Evaluate toxicity and tolerability of R-CHOP plus enzastaurin","https://ClinicalTrials.gov/show/NCT00451178"
2691,"NCT00020176","Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation","National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","null","NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000067899|NCI-00-C-0119|NCI-1027","July 11, 2001","June 2000","August 2007","June 18, 2013","November 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00020176"
2692,"NCT00003944","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","Completed","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: paclitaxel|Drug: topotecan hydrochloride|Procedure: peripheral blood stem cell transplantation","Fox Chase Cancer Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","3","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067137|FCCC-98030|NCI-G99-1536","November 1, 1999","August 1998","February 2003","April 16, 2013","April 2013","No Study Results Posted","null","December 1999","","https://ClinicalTrials.gov/show/NCT00003944"
2693,"NCT00003943","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.","Completed","No Results Available","Carcinoma of Unknown Primary|Lung Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: paclitaxel|Drug: topotecan hydrochloride|Procedure: peripheral blood stem cell transplantation","Fox Chase Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","3","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000067136|FCCC-98039|NCI-G99-1535","November 1, 1999","September 1998","February 2003","April 16, 2013","April 2013","No Study Results Posted","null","November 2000","Determine the one year progression-free survival|Overall survival; safety of regimen; CR rate; lab correlates; pharmacokinetics","https://ClinicalTrials.gov/show/NCT00003943"
2694,"NCT00003007","Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: recombinant interferon alfa|Biological: sargramostim|Drug: cyclophosphamide|Drug: dexamethasone|Drug: melphalan|Procedure: peripheral blood stem cell transplantation","University of Tennessee|National Cancer Institute (NCI)","All","19 Years to 64 Years   (Adult)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","UTENNM-BCG-5889|CDR0000065577|BCG-5889|INTTHERA-UTENNM-BCG-5889|NCI-V97-1263","November 1, 1999","July 1996","January 2004","June 25, 2013","September 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003007"
2695,"NCT00006258","Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: methotrexate|Drug: vincristine sulfate|Procedure: adjuvant therapy|Radiation: radiation therapy","Children's Hospital Los Angeles|National Cancer Institute (NCI)","All","10 Years to 65 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CHLA-NYU-0002H|CDR0000068192|NYU-0027H|NCI-G00-1852","September 11, 2000","November 1997","January 2005","July 17, 2013","December 2004","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006258"
2696,"NCT00003386","Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer","Terminated","No Results Available","Ovarian Cancer","Biological: BCG vaccine|Biological: autologous tumor cell vaccine|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: paclitaxel|Other: dinitrophenyl|Procedure: surgical procedure","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066382|GOG-9802","November 1, 1999","July 1999","null","April 10, 2013","December 2008","No Study Results Posted","null","April 2001","","https://ClinicalTrials.gov/show/NCT00003386"
2697,"NCT00002596","Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors","Completed","No Results Available","Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Testicular Germ Cell Tumor","Biological: bleomycin sulfate|Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Southwest Oncology Group|Cancer and Leukemia Group B","Male","12 Years and older   (Child, Adult, Senior)","Phase 3","270","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","SWOG-9442|MSKCC-94076|CLB-99812|E-3894|CDR0000063820|NCI-T94-0086D","November 1, 1999","September 1994","July 2006","June 25, 2013","October 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002596"
2698,"NCT00266136","Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)","Completed","No Results Available","Acute Myeloid Leukemia","Drug: Cytarabine|Drug: Thioguanine|Drug: Daunorubicin|Drug: Cyclophosphamide|Drug: G-CSF|Procedure: Autologous stem cell transplantation|Procedure: Allogeneic stem cell transplantation","University Hospital Muenster|Deutsche Krebshilfe e.V., Bonn (Germany)|German Federal Ministry of Education and Research","All","16 Years and older   (Child, Adult, Senior)","Phase 3","3500","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","AMLCG 99|BMBF 01 GI 02070","December 14, 2005","June 1999","October 2012","October 25, 2012","October 2012","No Study Results Posted","null","January 2007","Remission rate, Remission duration,Relapse-free survival, Overall survival, Event-free survival|Time and dose compliance, Realisation of SCT, Toxicity according to WHO","https://ClinicalTrials.gov/show/NCT00266136"
2699,"NCT00002675","Chemotherapy in Treating Patients With Retinoblastoma","Completed","No Results Available","Retinoblastoma","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: mesna|Drug: vincristine sulfate","Memorial Sloan Kettering Cancer Center","All","up to 17 Years   (Child)","Phase 2","50","Other","Interventional","Primary Purpose: Treatment","95-040|CDR0000064317|NCI-V95-0710","November 1, 1999","May 1995","January 2001","June 26, 2013","June 2013","No Study Results Posted","null","January 2001","","https://ClinicalTrials.gov/show/NCT00002675"
2700,"NCT00002638","Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Biological: filgrastim|Biological: sargramostim|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: etoposide|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","University of Nebraska|National Cancer Institute (NCI)","All","1 Year to 19 Years   (Child, Adult)","Phase 2","30","Other","Interventional","Primary Purpose: Treatment","UNMC-06695|CDR0000064114|NCI-V95-0639","November 1, 1999","March 1995","March 2005","July 9, 2013","September 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002638"
2701,"NCT00003060","Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma","Unknown status","No Results Available","Melanoma (Skin)","Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation","Feist-Weiller Cancer Center at Louisiana State University Health Sciences|National Cancer Institute (NCI)","All","16 Years to 44 Years   (Child, Adult)","Phase 1","6","Other","Interventional","Primary Purpose: Treatment","CDR0000065722|LSU-95456|NCI-V97-1318","November 1, 1999","March 1995","null","February 6, 2009","June 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003060"
2702,"NCT00003955","Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma","Completed","No Results Available","Sarcoma","Biological: dactinomycin|Biological: filgrastim|Biological: pegfilgrastim|Biological: sargramostim|Drug: cyclophosphamide|Drug: irinotecan hydrochloride|Drug: vincristine sulfate|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 49 Years   (Child, Adult)","Phase 2","77","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","D9802|COG-D9802|IRS-D9802|CCG-D9802|POG-D9802|CDR0000067154","November 1, 1999","September 1999","October 2009","February 12, 2014","February 2014","No Study Results Posted","null","January 2005","Event Free Survival","https://ClinicalTrials.gov/show/NCT00003955"
2703,"NCT00846157","Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients","Unknown status","No Results Available","Diffuse Large B-cell Lymphoma","Biological: NKM injection","NKBio Co.Ltd.","All","20 Years to 70 Years   (Adult, Senior)","Phase 3","276","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NKMGI 4-06","February 15, 2009","September 2007","September 2014","June 26, 2011","February 2009","No Study Results Posted","NKCell","September 2011","Event Free survival|Progression free survival","https://ClinicalTrials.gov/show/NCT00846157"
2704,"NCT00818961","Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer","Terminated","Has Results","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: alemtuzumab|Biological: graft-versus-tumor induction therapy|Biological: rituximab|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methotrexate|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","40 Years to 72 Years   (Adult, Senior)","Phase 2","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000630617|BMTGG-NSH-756","January 7, 2009","May 2005","March 2012","October 28, 2013","October 2013","March 22, 2013","null","March 2011","Survival at Day 100|Overall Survival at 1 Year|Non-relapse Mortality at Day 100|Non-relapse Mortality at 1 Year Post-transplant|Complete Donor Chimerism|Neutrophil Recovery|Platelet Engraftment|Number of Patients Requiring the Use of Donor Leukocyte Infusion (DLI) for Early Mixed T-cell Chimerism|Number of Patients Experiencing Grade 2-4 Acute Graft-versus-host Disease Post-transplant|Number of Patients Experiencing Chronic Graft Versus Host Disease|Number of Patients Experiencing Veno-occlusive Disease (VOD) Post-transplant","https://ClinicalTrials.gov/show/NCT00818961"
2705,"NCT01859819","Treatment for Advanced B-Cell Lymphoma","Recruiting","No Results Available","Diffuse Large Cell Lymphoma|Burkitt's Lymphoma|High Grade B-cell Lymphoma","Drug: Rituximab|Drug: IT Cytarabine","New York Medical College","All","3 Years to 31 Years   (Child, Adult)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NYMC-157|L 10,753","April 16, 2013","January 2013","December 2018","July 29, 2016","July 2016","No Study Results Posted","REBOOT","December 2017","To determine if disease response rate will improve with this combination of therapy.|To determine if the combination of IT Depocyte®, Rituximab and FAB Chemotherapy is safe.","https://ClinicalTrials.gov/show/NCT01859819"
2706,"NCT00003243","Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer","Completed","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: aldesleukin|Biological: filgrastim|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: etoposide|Drug: pegylated liposomal doxorubicin hydrochloride","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066119, J9743|P30CA006973|JHOC-97112101|NCI-V98-1387","November 1, 1999","January 1998","null","March 9, 2010","March 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003243"
2707,"NCT00914849","Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies","Completed","Has Results","Hematologic Neoplasms","Drug: AMD3100|Procedure: Leukopheresis|Procedure: Stem cell transplant","Washington University School of Medicine","All","18 Years to 65 Years   (Adult)","Phase 2","68","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","09-0713 / 201103429","June 1, 2009","August 2009","February 2012","April 6, 2017","April 2017","July 14, 2016","null","January 2011","Number of Donors Treated With IV AMD3100 Who Required a Second Collection to Obtain the Minimum CD34/kg (2 X 106) Necessary for Allogeneic Stem Cell Transplant|Number of Donors Who Experience Grade 3-4 Infusional Toxicity|Number of Recipients Who Have Neutrophil Engraftment|Pharmacokinetics of IV AMD3100 as Measured by the Mean Maximum Plasma Concentration (Cmax)|Pharmacokinetics of IV AMD3100 as Measured by Half Life|Pharmacokinetics of IV AMD3100 as Measured by Mean Area Under Curve (AUC)|Rate of Acute GVHD (Grade II-IV) in Recipients|Rate of Acute GVHD (Grade III-IV) in Recipients|Time to Neutrophil Engraftment for Recipients|Time to Platelet Engraftment for Recipients|Transplant Related Mortality Rate for Recipients|Grade 3-4 Toxicity for Recipients|Rate of Chronic GVHD in Recipients|Number of Donors Who Experience Grade 3-4 Mobilization Toxicity Due to Pheresis Procedure","https://ClinicalTrials.gov/show/NCT00914849"
2708,"NCT00590447","Risk Stratified Sequential Treatment for CD20-positive PTLD","Completed","No Results Available","PTLD|Posttransplant Lymphoproliferative Disorder","Drug: rituximab monotherapy|Drug: sequential R-CHOP","Charite University, Berlin, Germany","All","16 Years and older   (Child, Adult, Senior)","Phase 2","152","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","PTLD-1, 3rd. amendment|EudraCT 2005-000743-29","December 28, 2007","December 2006","July 2015","March 6, 2017","March 2017","No Study Results Posted","PTLD-1/3","December 2014","The primary objective is the evaluation of the efficacy.For this aim the overall objective response rates after therapy = complete and partial response and the duration of the response will be measured.|The secondary objective is to determine the adverse events and tolerability of rituximab and/or chemotherapy. Furthermore, the long-term safety will be determined, especially the frequency of complicating infections and the overall survival.","https://ClinicalTrials.gov/show/NCT00590447"
2709,"NCT00187057","Study for Treatment of Cancer in Children With Ataxia-telangiectasia","Completed","No Results Available","Ataxia-Telangiectasia","Drug: vinblastine, vincristine, prednisone, daunorubicin|Drug: doxorubicin, methotrexate, cyclophosphamide, L-asparaginase|Drug: etoposide, cytarabine, mercaptopurine|Drug: dexamethasone, procarbazine|Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy","St. Jude Children's Research Hospital|Children's Hospital of Philadelphia|National Cancer Institute (NCI)","All","up to 10 Years   (Child)","","6","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AT-1","September 12, 2005","September 2002","June 2013","August 26, 2015","August 2013","No Study Results Posted","null","August 2006","To determine the feasibility of delivering modified intensive chemotherapy to children with A-T who present with cancer.","https://ClinicalTrials.gov/show/NCT00187057"
2710,"NCT00429299","Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer","Completed","Has Results","Neoplasms, Breast","Drug: lapatinib|Biological: trastuzumab|Drug: paclitaxel|Drug: fluorouracil|Drug: epidoxorubicin|Drug: cyclophosphamide","GlaxoSmithKline","Female","18 Years to 65 Years   (Adult)","Phase 2","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EGF106988","January 29, 2007","August 2006","June 2012","February 22, 2016","January 2016","July 21, 2014","CHERLOB","June 2012","Percentage of Participants With Pathological Complete Response (pCR) in the Breast and in the Lymph Nodes|Percentage of Participants With the Indicated Clinical Objective Response (Complete Response and Partial Response), Stable Disease, and Progressive Disease, as Assessed by Ultrasonography|Percentage of Participants Who Had Breast-conserving Surgery (BCS), Mastectomy, and Conversion From Mastectomy to BCS|Time to Treatment Failure From the Start of Primary Therapy|Number of Participants With Treatment Failure|Percentage of Inhibition of Biomarkers Ki67, pAKT, pMAPK, Tunel Test, PTEN, and pEGFR After Treatment|Number of Participants With Any Adverse Event (AE), Including Serious Adverse Events (SAEs), Occurring in >=5% of Participants|Number of Variations/Somatic Mutation in PI3KCA at Baseline","https://ClinicalTrials.gov/show/NCT00429299"
2711,"NCT01309789","A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms","Active, not recruiting","No Results Available","Lymphoma, Large-Cell, Anaplastic|Lymphoma, NK-cell|Lymphoma, T-cell","Drug: brentuximab vedotin|Drug: cyclophosphamide|Drug: brentuximab vedotin|Drug: prednisone|Drug: cyclophosphamide|Drug: doxorubicin|Drug: doxorubicin|Drug: prednisone|Drug: vincristine","Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","39","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SGN35-011|2010-022839-11","February 25, 2011","February 2011","June 2017","February 2, 2017","February 2017","No Study Results Posted","null","April 2013","Incidence of adverse events and laboratory abnormalities|Brentuximab vedotin concentration in blood|Antitherapeutic antibodies in blood|Best clinical response|Progression-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT01309789"
2712,"NCT02386332","A Randomized Multicenter Study to Compare Two Types of Transplant in Adult Patients With Hematologic Malignancies","Not yet recruiting","No Results Available","Hematologic Malignancies","Procedure: transplantation","Instituto de Investigacion Sanitaria La Fe","All","18 Years to 55 Years   (Adult)","Phase 3","206","Other","Observational","Time Perspective: Prospective","TPH","February 26, 2015","March 2015","March 2020","March 5, 2015","March 2015","No Study Results Posted","null","February 2020","Disease-Free Survival (DFS)","https://ClinicalTrials.gov/show/NCT02386332"
2713,"NCT00864227","Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)","Completed","Has Results","Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Myeloid, Acute|Burkitt Lymphoma|Lymphoma, B-Cell|Lymphoma, Follicular|Lymphoma, Large B-Cell, Diffuse","Biological: Hematopoietic Umbilical Cord Blood Stem Cell Transplantation|Biological: GVHD prophylaxis","Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program","All","1 Year to 70 Years   (Child, Adult, Senior)","Phase 2","54","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMTCTN0604|U01HL069294|5U24CA076518","March 17, 2009","December 2008","November 2013","August 1, 2016","August 2016","May 20, 2015","null","April 2011","Overall Survival at 180 Days From the Time of Transplant|Neutrophil Recovery|Primary Graft Failure|Secondary Graft Failure|Platelet Recovery to 20K|Donor Cell Engraftment|Acute Graft-versus-host Disease (GVHD)|Chronic GVHD|Progression-free Survival|Treatment-related Mortality (TRM)|Incidence of Infections|Platelet Recovery to 50K","https://ClinicalTrials.gov/show/NCT00864227"
2714,"NCT02317471","Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96","Recruiting","No Results Available","Gastric Carcinoma","Biological: autologous gp96 vaccination|Drug: Oxaliplatin+S-1","Chinese PLA General Hospital|Cure&Sure Biotech Co., LTD","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","45","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PLAG-CS-Ga-01","December 10, 2014","November 2014","December 2017","June 2, 2016","June 2016","No Study Results Posted","null","December 2017","Disease free survival|Number of participants with adverse events related to gp96 immunotherapy|Changes in antigen specific T cells|Overall survival","https://ClinicalTrials.gov/show/NCT02317471"
2715,"NCT00554502","Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy","Completed","No Results Available","IgA Nephropathy","Drug: supportive therapy with: ACE-inhibitor / ARB / Statin|Drug: supportive and immunosuppressive therapy","RWTH Aachen University","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","148","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","STOP-IgAN","October 29, 2007","February 2008","February 2015","September 21, 2015","September 2015","No Study Results Posted","STOP-IgAN","February 2015","Patients reaching full clinical remission of their disease|GFR loss of 15 ml/min or higher from baseline GFR|-Absolute GFR-change.|GFR loss >=30 ml/min from baseline GFR|-Onset of end stage renal disease.|Mean annual change in one over serum creatinine concentration|Proteinuria at 12 and 36 months|Disappearance of microhematuria","https://ClinicalTrials.gov/show/NCT00554502"
2716,"NCT02465801","Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein","Recruiting","No Results Available","Chemotherapy-induced Neutropenia","Drug: HSA-GCSF 1.2 mg|Drug: HSA-GCSF 1.5 mg|Drug: GCSF","Tianjin SinoBiotech Ltd.","Female","18 Years to 65 Years   (Adult)","Phase 2","216","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention","RG01N-0778","November 17, 2014","December 2014","April 2016","November 2, 2015","November 2015","No Study Results Posted","null","December 2015","The mean of duration for class IV neutrophilic granulocytopenia|The mean of duration for ANC up to 2.0×109/L|ANC|The usage of antibiotics|febrile neutropenia","https://ClinicalTrials.gov/show/NCT02465801"
2717,"NCT00849147","Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)","Completed","Has Results","Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Myeloid, Acute|Burkitt Lymphoma|Lymphoma, B-Cell|Lymphoma, Follicular|Lymphoma, Large B-Cell, Diffuse","Biological: Haploidentical Bone Marrow Transplantation|Biological: GVHD prophylaxis","Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program","All","1 Year to 70 Years   (Child, Adult, Senior)","Phase 2","55","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMTCTN0603|U01HL069294|5U24CA076518","February 20, 2009","October 2008","November 2013","August 1, 2016","August 2016","May 20, 2015","null","June 2011","Overall Survival at 180 Days From the Time of Transplant|Neutrophil Recovery|Primary Graft Failure|Secondary Graft Failure|Platelet Recovery|Donor Cell Engraftment|Acute Graft-versus-host Disease (GVHD)|Chronic GVHD|Progression-free Survival|Treatment-related Mortality (TRM)|Infections","https://ClinicalTrials.gov/show/NCT00849147"
2718,"NCT00152113","Haploidentical Stem Cell Transplant for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Ultrasound","Completed","No Results Available","Sickle Cell Disease","Procedure: Hematopoietic Stem Cell Transplantation|Device: CliniMACS|Drug: See intervention description","St. Jude Children's Research Hospital","All","2 Years to 16 Years   (Child)","Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","SCDHAP","September 7, 2005","April 2005","January 2009","April 24, 2017","February 2009","No Study Results Posted","null","December 2008","To assess the safety of haploidentical stem cell transplantation for children and adolescents with severe sickle cell disease and stroke or abnormal transcranial Doppler ultrasound requiring chronic transfusion therapy.","https://ClinicalTrials.gov/show/NCT00152113"
2719,"NCT01861106","Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","Recruiting","No Results Available","GATA2|Immunodeficiency|MDS","Procedure: Allogeneic HSC|Drug: Busulfan Test dose|Drug: Fludarabine(Fludara, Berlex Laboratories)|Drug: Busulfan (Busulfex)|Drug: Cyclophosphamide(CTX, Cytoxan)|Procedure: Total Body Irradiation (TBI)|Drug: Equine Anti-Thymocyte Globulin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","6 Years to 70 Years   (Child, Adult, Senior)","Phase 2","144","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","130132|13-C-0132","May 21, 2013","April 26, 2013","December 31, 2020","May 12, 2017","January 31, 2017","No Study Results Posted","null","December 31, 2019","To determine whether allogeneic HSCT approach results in engraftment and restores normal hematopoiesis by day + 100 in patients with mutations GATA2.|To determine the safety|Immune reconstitution|To determine the incidence of acute and chronic graft-versus-host disease|Overall survival, and disease-free survival.","https://ClinicalTrials.gov/show/NCT01861106"
2720,"NCT00736450","Oblimersen Sodium and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma","Terminated","No Results Available","Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma","Biological: oblimersen sodium|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Procedure: biopsy|Genetic: microarray analysis|Other: immunohistochemistry staining method|Genetic: gene expression analysis|Genetic: cytogenetic analysis","University of Nebraska|National Cancer Institute (NCI)|Genta Incorporated","All","19 Years and older   (Adult, Senior)","","37","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","462-07|NCI-2009-01692|P30CA036727","August 14, 2008","July 2008","October 2022","October 11, 2012","October 2012","No Study Results Posted","null","October 2022","Feasibility of performing an AFFYmetrix microarray study|Rate of rapid turn around of the microarray testing results, as assessed by the proportion of patients whose microarray and IHC tests are completed|Efficacy of treatment, in terms of complete response rate (anyone achieving a CR or Cru)|Toxicity as assessed by NCI CTCAE v3.0","https://ClinicalTrials.gov/show/NCT00736450"
2721,"NCT02624973","PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial","Recruiting","No Results Available","Breast Cancer","Drug: Neoadjuvant tamoxifen + goserelin (premenopausal women)|Drug: Neoadjuvant letrozole (postmenopausal women)|Drug: Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)|Drug: Neoadjuvant docetaxel + cyclophosphamide|Drug: Neoadjuvant docetaxel|Drug: Neoadjuvant docetaxel + trastuzumab + pertuzumab|Drug: Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab|Drug: Neoadjuvant olaparib|Drug: Neoadjuvant olaparib + carboplatin (if lack of response to olaparib alone)|Procedure: Breast conserving surgery or mastectomy + SNB/axillary dissection|Radiation: Postoperative radiotherapy breast/chest wall + regional lymph nodes|Drug: Adjuvant trastuzumab|Drug: Adjuvant letrozole (postmenopausal women)|Drug: Adjuvant tamoxifen + goserelin (premenopausal women)|Drug: Adjuvant palbociclib (if palbociclib given neoadjuvant)|Drug: Adjuvant Epirubicin+ Cyclophosphamide","Haukeland University Hospital|Helse Vest|Pfizer|AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","200","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science","2015/8463","November 30, 2015","April 2016","June 2030","December 6, 2016","December 2016","No Study Results Posted","PETREMAC","June 2020","Predictive and prognostic value of mutations in 300 cancer-related genes assessed in breast cancer tissue by next generation sequencing before starting neoadjuvant therapy.|To assess genetic/epigenetic changes within the tumor tissue during therapy|The objective response rate (ORR) of personalized medicine, compared to ORR for best standard-of-care using historical data for comparison|Tumor Ki67 reduction after 2 and 5 weeks of treatment in Arm A|To estimate recurrence-free and overall survival when patients are treated with the optimal personalized treatment available as of 2015, using historical data for comparison|To evaluate the percentage of patients completing neoadjuvant treatment and completing surgery|Breast conserving surgery rate (potential to avoid mastectomy)|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02624973"
2722,"NCT02911142","Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma","Recruiting","No Results Available","Primary Effusion Lymphoma|B-Cell Lymphoma","Drug: Lenalidomide|Drug: Rituximab|Drug: Prednisone|Drug: Etopside|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide on day 10 (for 6 cycles), each patient will get a 750 mg/m2 dose.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 1|Phase 2","36","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","160171|16-C-0171","September 21, 2016","September 15, 2016","October 1, 2025","May 20, 2017","May 12, 2017","No Study Results Posted","null","October 1, 2022","(Phase I) Maximum tolerated dose of DA-EPOCH_R2|(Phase II) Overall survival in treatment-naive patients with primary effusion lymphoma treated with DA-EPOCH-R2","https://ClinicalTrials.gov/show/NCT02911142"
2723,"NCT00029380","Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia","Completed","No Results Available","Hematologic Diseases|Anemia, Sickle Cell|Beta-Thalassemia|Hematopoietic Stem Cell Transplantation","Drug: Sangstat|Drug: Cyclophosphamide|Drug: Busulfan|Drug: Mycophenolate Mofetil|Drug: Cyclosporine|Procedure: Cord Blood Transplantation","National Heart, Lung, and Blood Institute (NHLBI)","All","3 Years to 14 Years   (Child)","Phase 2","30","NIH","Interventional","Primary Purpose: Treatment","141|U01HL061877","January 10, 2002","January 1999","August 2006","July 28, 2016","September 2008","No Study Results Posted","null","August 2006","Hematologic parameters|GVHD","https://ClinicalTrials.gov/show/NCT00029380"
2724,"NCT00003050","Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel|Drug: tamoxifen citrate|Procedure: surgical procedure|Radiation: radiation therapy","University of Southern California|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","46","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000065692 (1B-97-2)|LAC-USC-1B972|NCI-G97-1304","November 1, 1999","April 1997","March 2000","May 20, 2014","May 2014","No Study Results Posted","null","March 2000","","https://ClinicalTrials.gov/show/NCT00003050"
2725,"NCT02063685","Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma","Recruiting","No Results Available","Follicular Non-Hodgkin's Lymphoma","Drug: R-CHOP or R-bendamustine|Drug: Observation|Drug: Maintenance weekly x4|Drug: Ibritumomab Tiuxetan + Maintenance|Drug: Standard Maintenance","Fondazione Italiana Linfomi ONLUS","All","18 Years and older   (Adult, Senior)","Phase 3","810","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","FIL_FOLL12","November 21, 2013","July 2012","December 2020","March 24, 2017","March 2017","No Study Results Posted","null","December 2017","PFS|CRR|ORR|DR|EFS|OS|Molecular response analysis","https://ClinicalTrials.gov/show/NCT02063685"
2726,"NCT00309920","Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: darbepoetin alfa|Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: fluorouracil","Heinrich-Heine University, Duesseldorf|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult)","","1234","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000458037|WGSG-ARA-PLUS|AVENTIS-WGSG-ARA-PLUS|SANOFI-WGSF-ARA-PLUS|EU-205108","March 29, 2006","January 2004","null","February 6, 2009","April 2006","No Study Results Posted","null","null","Disease-free survival at 6 months to 5 years after treatment|Overall survival at 6 months to 5 years after treatment|Toxicity by NCI toxicity criteria at every course and periodically thereafter|Anemia and cognitive function by Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog) at every course|Local relapses at 6 months to 5 years after treatment","https://ClinicalTrials.gov/show/NCT00309920"
2727,"NCT01751997","Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors","Recruiting","No Results Available","Acute Myeloid Leukemia","Drug: Transplants from 8/8-matched Unrelated donors|Drug: Transplants from family-mismatched/haploidentical donors","Byung-Sik Cho|Seoul St. Mary's Hospital","All","17 Years to 65 Years   (Child, Adult)","Phase 3","116","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CBMTC-AML-1","December 14, 2012","January 2013","December 2019","October 18, 2016","October 2016","No Study Results Posted","null","December 2017","Overall survival|Neutrophil recovery|Primary Graft failure|Secondary Graft failure|Platelet recovery|Donor cell engraftment|Acute graft-versus-host disease (aGVHD)|Chronic graft-versus-host disease (cGVHD)|Disease free survival|Non-relapse mortality|Infection","https://ClinicalTrials.gov/show/NCT01751997"
2728,"NCT01004991","Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma","Completed","Has Results","Diffuse Large B Cell Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: vincristine|Drug: doxorubicin|Drug: prednisone|Drug: azacytidine","Weill Medical College of Cornell University|Celgene","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","14","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","0907010513","October 29, 2009","January 2010","February 2016","February 23, 2017","February 2017","February 23, 2017","null","September 2013","Complete Response","https://ClinicalTrials.gov/show/NCT01004991"
2729,"NCT00014508","Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: sargramostim|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: melphalan|Procedure: peripheral blood stem cell transplantation","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000068551|ECOG-E4A98","April 10, 2001","April 2001","null","February 25, 2009","November 2005","No Study Results Posted","null","February 2007","","https://ClinicalTrials.gov/show/NCT00014508"
2730,"NCT00379340","Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor","Active, not recruiting","No Results Available","Stage III Wilms Tumor With Loss of Heterozygosity (LOH) for 1p and 16q|Stage IV Wilms Tumor","Drug: doxorubicin hydrochloride|Drug: liposomal vincristine sulfate|Procedure: conventional surgery|Radiation: 3-dimensional conformal radiation therapy|Biological: dactinomycin|Drug: cyclophosphamide|Drug: etoposide","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 29 Years   (Child, Adult)","Phase 3","395","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AREN0533|NCI-2009-00419|CDR0000496508|U10CA098543|COG-AREN0533","September 19, 2006","February 2007","null","October 31, 2016","October 2016","No Study Results Posted","null","October 2015","EFS of patients with stage IV and rapid complete response (RCR) of lung metastases|EFS of patients with stage IV and slow incomplete response (SIR) of lung metastases|EFS of patients with stage IV, non lung disease only, and stage III with LOH 1p and 16q|Correlate between the burden of pulmonary metastatic disease with outcome in patients with stage IV FH Wilms' tumor","https://ClinicalTrials.gov/show/NCT00379340"
2731,"NCT00025623","Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma","Completed","No Results Available","Neuroblastoma","Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: vincristine sulfate|Procedure: conventional surgery","European Infant Neuroblastoma Study Group - 1999|National Cancer Institute (NCI)","All","up to 1 Year   (Child)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068980|EURO-INF-NB-STUDY-1999-99.3|EU-20125C","October 11, 2001","July 1999","March 2009","September 16, 2013","December 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00025623"
2732,"NCT00025597","Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma.","Completed","No Results Available","Neuroblastoma","Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: vincristine sulfate|Procedure: conventional surgery","European Infant Neuroblastoma Study Group - 1999|National Cancer Institute (NCI)","All","up to 1 Year   (Child)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068977|EURO-INF-NB-STUDY-1999-99.1|EU-20125A","October 11, 2001","July 1999","February 2011","September 16, 2013","November 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00025597"
2733,"NCT00006110","Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: trastuzumab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel|Procedure: conventional surgery|Radiation: Radiation Therapy","UNC Lineberger Comprehensive Cancer Center","Female","up to 120 Years   (Child, Adult, Senior)","Phase 2","85","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","LCCC 9818|UNC-9818|NCI-G00-1836","August 3, 2000","December 1998","April 2013","January 20, 2016","January 2016","No Study Results Posted","NRR","March 2012","To determine the cardiac and other toxicity of weekly Taxol given with weekly Herceptin when delivered immediately following four cycles of standard dose AC|To identify whether the addition of Taxol® with or without Herceptin® further decreases tumor size and the number of positive axillary lymph nodes beyond that achieved by conventional breast cancer adjuvant therapy (4AC).|To determine the 10 year DFS and OS in patients receiving and not receiving Herceptin®, and determine whether the initial pathologic response in Neoadjuvant patients correlates with the eventual 5-year DFS or OS","https://ClinicalTrials.gov/show/NCT00006110"
2734,"NCT01175356","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","Completed","No Results Available","Disseminated Neuroblastoma|Ganglioneuroblastoma|Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Regional Neuroblastoma|Stage 4S Neuroblastoma","Drug: cyclophosphamide|Drug: topotecan hydrochloride|Drug: cisplatin|Drug: etoposide phosphate|Drug: vincristine sulfate|Drug: doxorubicin hydrochloride|Radiation: iobenguane I 131|Procedure: therapeutic conventional surgery|Drug: busulfan|Drug: melphalan|Procedure: autologous hematopoietic stem cell transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation|Radiation: 3-dimensional conformal radiation therapy|Radiation: external beam radiation therapy|Radiation: intensity-modulated radiation therapy|Drug: isotretinoin|Other: pharmacological study|Other: questionnaire administration|Other: laboratory biomarker analysis","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 30 Years   (Child, Adult)","","99","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ANBL09P1|NCI-2011-01745|CDR0000682629|U10CA180886|U10CA098543","August 3, 2010","October 2010","September 28, 2016","February 7, 2017","February 2017","No Study Results Posted","null","September 28, 2016","Proportion of MIBG avid patients who are able to be treated with iobenguane I 131|Proportion of MIBG avid patients who are able to be treated with iobenguane I 131 and then Bu/Mel|Percentage of average per capita income encompassed by the total of travel + housing + lost wages|Proportion of eligible high-risk patients accrued to the study|Event-free survival rate|Response rate, defined as the proportion of evaluable patients who attain a response of partial response or better at the end of iobenguane I 131 + Bu/Mel therapy and local radiotherapy|Incidence of adverse events and SOS, assessed by Common Terminology Criteria version 4.0 for toxicity assessment and grading","https://ClinicalTrials.gov/show/NCT01175356"
2735,"NCT00806182","Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome","Completed","No Results Available","Opsoclonus-myoclonus Syndrome","","National Pediatric Neuroinflammation Organization, Inc.","All","1 Year to 18 Years   (Child, Adult)","","400","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","Thrasher Award 02826-2","December 8, 2008","January 2008","December 2016","May 19, 2017","May 2017","No Study Results Posted","OMS","December 2016","Reduction in inflammatory cytokines|Correlation of cytokine concentration and clinical severity score.","https://ClinicalTrials.gov/show/NCT00806182"
2736,"NCT03007147","Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","Not yet recruiting","No Results Available","B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Daunorubicin Hydrochloride|Drug: Dexamethasone|Drug: Dexrazoxane Hydrochloride|Drug: Doxorubicin|Drug: Etoposide|Biological: Filgrastim|Drug: Ifosfamide|Drug: Imatinib Mesylate|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Mercaptopurine|Drug: Mercaptopurine|Drug: Mesna|Drug: Methotrexate|Drug: Methylprednisolone|Drug: Pegaspargase|Drug: Prednisolone|Other: Questionnaire Administration|Drug: Therapeutic Hydrocortisone|Drug: Thioguanine|Drug: Vincristine Sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","2 Years to 21 Years   (Child, Adult)","Phase 3","700","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator|Primary Purpose: Treatment","AALL1631|NCI-2016-01588|U10CA180886","December 28, 2016","July 2017","July 2027","April 24, 2017","April 2017","No Study Results Posted","null","December 2025","DFS|DFS of high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate|Imatinib mesylate administration after allogeneic HSCT in high risk Ph+ ALL patients|Incidence of grade 3 or higher infections in standard risk Ph+ ALL patients in the two randomized arms evaluated according to NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0","https://ClinicalTrials.gov/show/NCT03007147"
2737,"NCT02112916","Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","Recruiting","No Results Available","Adult T Acute Lymphoblastic Leukemia|Childhood T Acute Lymphoblastic Leukemia|Stage II Childhood Lymphoblastic Lymphoma|Stage II Contiguous Adult Lymphoblastic Lymphoma|Stage II Non-Contiguous Adult Lymphoblastic Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia","Drug: Bortezomib|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Daunorubicin Hydrochloride|Drug: Dexamethasone|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Drug: Hydrocortisone Sodium Succinate|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Mercaptopurine|Drug: Methotrexate|Drug: Pegaspargase|Radiation: Radiation Therapy|Drug: Thioguanine|Drug: Vincristine Sulfate","National Cancer Institute (NCI)","All","2 Years to 30 Years   (Child, Adult)","Phase 3","1400","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2014-00712|AALL1231|U10CA180886|U10CA098543","April 9, 2014","September 30, 2014","null","May 24, 2017","May 2017","No Study Results Posted","null","February 15, 2022","EFS between modified ABFM backbone with or without bortezomib in all randomized patients|Cumulative incidence rates|EFS|EFS between very high risk (VHR) T-ALL patients treated with HR BFM intensification blocks who become MRD negative and those who remain MRD positive at the end of HR Block 3|EFS between VHR T-LLy patients treated with HR BFM intensification blocks who have partial remission or complete remission with those who do not respond|Incidence of toxicity associated with modified standard therapy, including dexamethasone and additional pegaspargase as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0","https://ClinicalTrials.gov/show/NCT02112916"
2738,"NCT00720109","Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","Completed","Has Results","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1|Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia","Drug: Asparaginase|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dasatinib|Drug: Daunorubicin Hydrochloride|Drug: Dexamethasone|Drug: Etoposide|Biological: Filgrastim|Drug: Hydrocortisone Sodium Succinate|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Mercaptopurine|Drug: Methotrexate|Drug: Methylprednisolone|Drug: Pegaspargase|Drug: Prednisone|Radiation: Radiation Therapy|Drug: Vincristine Sulfate","National Cancer Institute (NCI)","All","2 Years to 30 Years   (Child, Adult)","Phase 2|Phase 3","63","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00312|CDR0000600217|COG-AALL0622|AALL0622|U10CA098543","July 19, 2008","July 2008","September 2015","September 8, 2016","September 2016","September 8, 2016","null","December 2014","Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy|Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events|Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy|Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation|Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)","https://ClinicalTrials.gov/show/NCT00720109"
2739,"NCT01622439","Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma","Active, not recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Valproate|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Lund University Hospital|Valcuria","All","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","Version1.1","June 12, 2012","June 2012","March 2018","March 6, 2017","September 2016","No Study Results Posted","VALFRID","March 2018","Establishment of maximum tolerable dose of valproate.","https://ClinicalTrials.gov/show/NCT01622439"
2740,"NCT00458250","Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H","Completed","No Results Available","Leukemia, Myeloid, Acute|Leukemia, Lymphoblastic, Acute","Procedure: Haploidentical hematopoietic stem cell transplantation|Drug: Busulfan|Drug: Cyclophosphamide|Drug: CAMPATH-1H|Drug: Cyclosporin A|Drug: Methotrexate","Tehran University of Medical Sciences","All","2 Years to 50 Years   (Child, Adult)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","418-A-1954","April 7, 2007","September 2006","February 2008","November 15, 2008","November 2008","No Study Results Posted","null","null","Engraftment one month after transplantation|six months survival","https://ClinicalTrials.gov/show/NCT00458250"
2741,"NCT00005959","Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","Amgen|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Industry","Interventional","Primary Purpose: Treatment","CDR0000067940|AMGEN-GCSF-990756|NCI-V00-1593","July 5, 2000","December 1999","null","December 3, 2013","June 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00005959"
2742,"NCT00004179","Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Biological: rituximab|Drug: CHOP regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","European Organisation for Research and Treatment of Cancer - EORTC|Lymphoma Trials Office|Stichting Hemato-Oncologie voor Volwassenen Nederland|Australasian Leukaemia and Lymphoma Group|NCIC Clinical Trials Group|Nordic Lymphoma Group","All","18 Years to 120 Years   (Adult, Senior)","Phase 3","475","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-20981|ALLG-NHLLOW4|BNLI-EORTC-20981|HOVON-H039|CAN-NCIC-LY7|NORDIC-EORTC-20981","January 21, 2000","May 1999","null","February 3, 2016","February 2016","No Study Results Posted","null","April 2004","Response to treatment|Overall survival|Progression Free survival","https://ClinicalTrials.gov/show/NCT00004179"
2743,"NCT00004112","Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: CHOP regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","University of Nebraska|National Cancer Institute (NCI)","All","19 Years and older   (Adult, Senior)","Phase 3","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","447-97|P30CA036727|UNMC-447-97|UCLA-HSPC-9812071|NCI-G99-1601","December 10, 1999","September 1999","March 2003","April 13, 2010","April 2010","No Study Results Posted","null","December 2000","","https://ClinicalTrials.gov/show/NCT00004112"
2744,"NCT00049036","Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma","Completed","Has Results","AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma","Biological: rituximab|Drug: etoposide|Drug: doxorubicin hydrochloride|Drug: vincristine sulfate|Drug: prednisone|Drug: cyclophosphamide|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","106","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02926|ECOG-AMC34|CDR0000257660|AMC-034|U01CA070019","November 12, 2002","March 2003","May 2009","April 28, 2014","December 2012","May 23, 2011","null","May 2009","Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment","https://ClinicalTrials.gov/show/NCT00049036"
2745,"NCT00481832","Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma","Active, not recruiting","No Results Available","Lymphoma, Non-Hodgkin","Drug: Cyclophosphamide|Drug: Carmustine|Drug: Etoposide|Drug: Filgrastim|Drug: Antithymocyte globulin|Drug: Cyclosporine|Drug: Mycophenolate mofetil|Drug: rituximab","Stanford University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT185|97623","May 31, 2007","January 2007","June 2019","August 4, 2015","August 2015","No Study Results Posted","null","June 2016","Event-free survival|Toxicity|Incidence of chemotherapy-associated pneumonitis|Overall and non-relapse mortality rate|Kinetics of donor hematopoietic cell engraftment and chimerism.|Incidence and extent of acute and chronic Graft versus host disease","https://ClinicalTrials.gov/show/NCT00481832"
2746,"NCT00057811","Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","Completed","Has Results","Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Untreated Childhood Acute Lymphoblastic Leukemia","Drug: doxorubicin hydrochloride|Drug: cyclophosphamide|Drug: methotrexate|Drug: rasburicase|Drug: leucovorin calcium|Drug: prednisone|Drug: methylprednisolone|Biological: filgrastim|Biological: rituximab|Drug: cytarabine|Drug: etoposide|Drug: vincristine sulfate|Drug: hydrocortisone sodium succinate|Other: laboratory biomarker analysis","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 29 Years   (Child, Adult)","Phase 2","97","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ANHL01P1|NCI-2009-00405|COG-ANHL01P1|CDR0000271941|U10CA098543","April 7, 2003","June 2004","July 2014","September 10, 2014","September 2014","January 21, 2014","null","October 2009","Grade ≥ 3 Stomatitis|Response Rate|Minimal Residual Disease|Toxic Death","https://ClinicalTrials.gov/show/NCT00057811"
2747,"NCT02297126","A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","Recruiting","No Results Available","Adverse Drug Reaction","Device: Pharmacogenetic Intervention Arm (pharmacogenetic testing)","Indiana University|National Human Genome Research Institute (NHGRI)","All","18 Years and older   (Adult, Senior)","","6000","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Other","1401206188|U01HG007762-01","November 5, 2014","January 2015","June 2018","February 28, 2017","February 2017","No Study Results Posted","INGenious","December 2017","Financial impact on the total cost of patient care resulting from implementation of a Pharmacogenetics testing program within a safety-net and Academic healthcare system|Impact of implementing a Pharmacogenetics program on Clinical Outcomes (incidence and severity of adverse events, frequency of healthcare visits, length of hospital stay, and readmissions) within a safety-net and Academic healthcare system|Impact of implementing a Pharmacogenetics program on prescribing patterns within a safety-net healthcare system","https://ClinicalTrials.gov/show/NCT02297126"
2748,"NCT00704938","Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer","Terminated","Has Results","Kidney Cancer|Melanoma (Skin)|Unspecified Adult Solid Tumor, Protocol Specific","Biological: aldesleukin|Biological: anti-p53 T-cell receptor-transduced peripheral blood lymphocytes|Biological: autologous dendritic cell-adenovirus p53 vaccine|Biological: filgrastim|Drug: cyclophosphamide|Drug: fludarabine phosphate","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","3","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","080155|NCI-08-C-0155|NCI-P07215","June 24, 2008","June 2008","August 2009","October 6, 2015","September 2015","July 10, 2012","null","August 2009","Clinical Response (Complete Response + Partial Response)|Number of Participants With Adverse Events","https://ClinicalTrials.gov/show/NCT00704938"
2749,"NCT00899847","Ph II of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG","Unknown status","No Results Available","Transplantation, Homologous|Transplantation, Autologous|Multiple Myeloma|Blood and Marrow Transplant (BMT)","Procedure: Autologous/Allogeneic HCT|Drug: cyclophosphamide|Biological: filgrastim|Drug: melphalan|Procedure: peripheral blood stem cell transplantation|Radiation: total nodal irradiation|Biological: anti-thymocyte globulin|Drug: cyclosporine|Drug: mycophenolate mofetil|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Other: laboratory biomarker analysis","Stanford University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","43","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BMT201|SU-04142009-2259","May 8, 2009","May 2009","November 2016","October 29, 2013","October 2013","No Study Results Posted","null","November 2015","Incidence of Graft-versus-host disease|Relapse, Event free survival, Overall survival","https://ClinicalTrials.gov/show/NCT00899847"
2750,"NCT01190930","Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma","Recruiting","No Results Available","Adult B Lymphoblastic Lymphoma|Childhood B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1|Childhood B Lymphoblastic Lymphoma|Down Syndrome|Stage I B Lymphoblastic Lymphoma|Stage II B Lymphoblastic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia","Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone|Drug: Doxorubicin Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Mercaptopurine|Drug: Methotrexate|Drug: Pegaspargase|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Drug: Thioguanine|Drug: Vincristine Sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 30 Years   (Child, Adult)","Phase 3","9022","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AALL0932|NCI-2011-02599|CDR0000683227|U10CA180886|U10CA098543","August 27, 2010","August 2010","null","September 23, 2016","September 2016","No Study Results Posted","null","March 2020","Determination of whether less intensive therapy will maintain DFS >= 95% for LR patients randomized to 1 of 2 low-intensity regimens|Determination of whether the 5-year DFS in AR patients is adversely affected by the reduced pulses in maintenance|DFS for B-LLy patients|DFS for Down syndrome patients|Improvement in DFS from 93% to 96% in AR patients based on the methotrexate randomization|Burden of therapy in AR patients overall at different time points during and at the end of therapy|Burden of therapy in AR patients randomized to every 4-week vs every 12-week pulses during maintenance therapy","https://ClinicalTrials.gov/show/NCT01190930"
2751,"NCT00022737","Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia","Completed","No Results Available","Childhood Acute Lymphoblastic Leukemia in Remission|Recurrent Childhood Acute Lymphoblastic Leukemia","Biological: filgrastim|Drug: asparaginase|Drug: cyclophosphamide|Drug: cyclosporine|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: etoposide|Drug: ifosfamide|Drug: imatinib mesylate|Drug: leucovorin calcium|Drug: mercaptopurine tablet|Drug: methotrexate|Drug: pegaspargase|Drug: vincristine sulfate|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 3","220","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01862|CDR0000068859|COG-AALL0031|AALL0031|U10CA098543","August 10, 2001","October 2002","null","February 26, 2014","November 2012","No Study Results Posted","null","October 2006","Feasibility, in terms of patient accrual|Feasibility, in terms of incidence of adverse events graded according to NCI CTC v 2.0|Event-free survival","https://ClinicalTrials.gov/show/NCT00022737"
2752,"NCT00557193","Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","Active, not recruiting","No Results Available","Acute Undifferentiated Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia","Drug: vincristine sulfate|Drug: daunorubicin hydrochloride|Drug: cyclophosphamide|Drug: pegaspargase|Drug: asparaginase|Drug: prednisone|Drug: methylprednisolone|Drug: dexamethasone|Drug: cytarabine|Drug: methotrexate|Drug: therapeutic hydrocortisone|Biological: filgrastim|Drug: leucovorin calcium|Drug: etoposide|Drug: mercaptopurine|Drug: lestaurtinib|Other: laboratory biomarker analysis|Other: pharmacological study","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 1 Year   (Child)","Phase 3","242","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AALL0631|NCI-2009-00313|COG-AALL0631|CDR0000573996|U10CA098543|U10CA180886","November 9, 2007","January 2008","null","September 23, 2016","September 2016","No Study Results Posted","null","September 2018","Lestaurtinib-related dose limiting toxicity as graded by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Event-free survival (EFS) of MLL-R infants randomized to combination chemotherapy with or without lestaurtinib|EFS of patients treated on Arm C|EFS|Incidence of grade 3/4 non-hematologic adverse events as assessed by the NCI CTCAE version 4.0|Incidence of toxic death|Proportion of infants who received prophylactic treatment for prevention of fungal infections|Minimal residual disease (MRD) assessed by multiparameter flow cytometry and by quantitative reverse transcriptase-polymerase chain reaction","https://ClinicalTrials.gov/show/NCT00557193"
2753,"NCT02370550","Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome","Unknown status","No Results Available","Sjogren's Syndrome","Drug: Cyclosporin A|Drug: Prednisone|Drug: Placebo|Drug: Calcium carbonate D","Peking University People's Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 4","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2014-M03|U1111-1167-1974|ChiCTR-IPR-15005990","February 18, 2015","March 2015","March 2017","February 18, 2015","February 2015","No Study Results Posted","CTRIPS","March 2016","The forced vital capacity (FVC)|The diffusing capacity of carbon monoxide (DLco)","https://ClinicalTrials.gov/show/NCT02370550"
2754,"NCT00284271","Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma","Completed","No Results Available","Hodgkin´s Lymphoma","Drug: Cyclophosphamide|Drug: Adramycin|Drug: Procarbacine|Drug: Prednisone|Drug: Vincristine|Drug: Bleomycin|Drug: Erythropoietin beta","University of Cologne","All","61 Years to 75 Years   (Adult, Senior)","Phase 2","65","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","BACOPP-21","January 27, 2006","January 2004","null","July 28, 2011","July 2011","No Study Results Posted","null","December 2005","","https://ClinicalTrials.gov/show/NCT00284271"
2755,"NCT00047099","Combination Chemotherapy in Treating Women With Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: docetaxel|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: goserelin acetate|Drug: tamoxifen citrate|Procedure: adjuvant therapy|Radiation: radiation therapy","Ludwig-Maximilians - University of Munich|National Cancer Institute (NCI)","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","446","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","LMU-ADEBAR|EU-20221","October 3, 2002","August 2001","March 2012","May 29, 2013","December 2002","No Study Results Posted","null","February 2012","Comparison of time to progression|Overall survival time|Toxicity|Changes in quality of life over time as measured by the EORTC QLQ-C30 and BR23 questionnaires","https://ClinicalTrials.gov/show/NCT00047099"
2756,"NCT00792948","Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","Active, not recruiting","Has Results","Adult Acute Lymphoblastic Leukemia in Remission|Adult B Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1|Adult L1 Acute Lymphoblastic Leukemia|Adult L2 Acute Lymphoblastic Leukemia|Adult T Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dasatinib|Drug: Dexamethasone|Drug: Doxorubicin Hydrochloride|Drug: Etoposide|Biological: Filgrastim|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Methotrexate|Drug: Methylprednisolone|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Prednisone|Drug: Sirolimus|Drug: Tacrolimus|Radiation: Total-Body Irradiation|Drug: Vincristine Sulfate","National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 2","97","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2009-00800|CDR0000624250|S0805|U10CA180888|U10CA032102","November 16, 2008","September 2009","September 2019","March 16, 2017","March 2017","November 21, 2016","null","June 2016","Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation|Continuous Complete Remission (CCR) Rate","https://ClinicalTrials.gov/show/NCT00792948"
2757,"NCT02549534","Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer","Completed","No Results Available","Peripheral Neuropathy","Procedure: Axon Reflexes|Procedure: Axon Flares|Procedure: Self-Reported Signs & Symptoms of CIPN","Indiana University|National Institute of Nursing Research (NINR)|Midwest Nursing Research Society (MNRS)|Council for the Advancement of Nursing Science (CANS)|Indiana Center for Vascular Biology & Medicine (ICVBM)|Indiana University School of Medicine","Female","18 Years to 85 Years   (Adult, Senior)","","29","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","1502603664|F31NR01521201A1","September 9, 2015","September 2015","July 2016","August 24, 2016","July 2016","No Study Results Posted","null","July 2016","Differences in the mean size of axon reflexes between healthy women and women with breast cancer BEFORE starting Taxol.|Differences in the mean size of axon reflexes between healthy women and women with breast cancer DURING Taxol therapy.|Differences in the mean size of axon reflexes OVER TIME for women with breast during the initial six weeks of Taxol therapy.|Differences in the mean size of axon reflexes between healthy female controls OVER TIME the six-week study period.|Differences in the mean size of heat-evoked axon flares between healthy women and women with breast cancer BEFORE starting Taxol therapy.|Differences in the mean size of heat-evoked axon flares between healthy women and women with breast cancer DURING six weeks of study visits.|Differences in the mean size of heat-evoked axon flares between women with breast cancer DURING their initial six weeks of Taxol therapy.|Differences in the size of heat-evoked axon flares for healthy women during the six-week study period.","https://ClinicalTrials.gov/show/NCT02549534"
2758,"NCT00077116","Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes","Drug: busulfan|Drug: cyclophosphamide|Drug: cytarabine|Drug: gemtuzumab ozogamicin|Drug: idarubicin|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","16 Years to 70 Years   (Child, Adult, Senior)","Phase 2","31","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","EORTC-06013","February 10, 2004","November 2003","null","July 13, 2012","July 2012","No Study Results Posted","null","November 2006","Rate of complete remission (CR) or complete remission with incomplete recovery of platelets (CRp) as measured by Cheson response criteria after the start of treatment|Severe toxicity after the start of treatment|Disease-free survival from CR/CRp|Duration of overall survival|Severity of pancytopenia and duration of recovery in patients who reached CR/CRp after the start of treatment","https://ClinicalTrials.gov/show/NCT00077116"
2759,"NCT00026208","Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma, Hodgkin Disease|Lymphoma|Hodgkin Disease|Lymphoma: Hodgkin","Drug: bleomycin|Drug: cyclophosphamide|Drug: prednisone|Drug: vincristine|Drug: Adriamycin|Drug: Velban|Drug: VP-16","Stanford University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","76","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","LYMHD0002|IRB-13081","November 9, 2001","June 2001","February 13, 2017","March 2, 2017","March 2017","No Study Results Posted","null","February 13, 2017","Progression-free survival by Kaplan-Meier|Early and late treatment-related toxicity|Freedom from second disease progression by Kaplan-Meier|Overall survival by Kaplan-Meier|Frequency of complete response by positron-emission tomography scan","https://ClinicalTrials.gov/show/NCT00026208"
2760,"NCT00003603","Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma","Unknown status","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Drug: cyclophosphamide|Drug: dexamethasone|Drug: idarubicin|Drug: lomustine|Drug: melphalan|Drug: prednisolone","Riverside Haematology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","660","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066676|RHG-MM97|EU-98030","November 1, 1999","March 1998","null","September 19, 2013","February 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003603"
2761,"NCT02251821","JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis","Recruiting","No Results Available","Primary Myelofibrosis|Secondary Myelofibrosis","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Busulfan|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Drug: Methotrexate|Drug: Momelotinib|Drug: Mycophenolate Mofetil|Drug: Pacritinib|Drug: Ruxolitinib|Drug: Tacrolimus|Radiation: Total-Body Irradiation|Procedure: Umbilical Cord Blood Transplantation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Senior)","Phase 2","33","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","9033|NCI-2014-01882|P30CA015704|R44HL106868","September 12, 2014","October 2014","null","May 22, 2017","May 2017","No Study Results Posted","null","March 2018","Probability of 2-year survival in patients with MF who receive treatment with a JAK inhibitor followed by an allogeneic transplant|Biology of post transplant disease progression|Incidence and severity of acute GVHD|Incidence and severity of chronic GVHD|Incidence of relapse|Kinetics of donor chimerism|Mechanism of responses to JAK inhibitors|Neutrophil engraftment, defined as the first of 3 days absolute neutrophil count (ANC) >= 500|Non-relapse mortality (NRM)|NRM|Overall incidence of primary graft failure/rejection|Overall incidence of secondary graft failure/rejection|Overall survival|Platelet engraftment defined as first day of 20,000 and 50,000 with no transfusions x 7 days","https://ClinicalTrials.gov/show/NCT02251821"
2762,"NCT01343043","A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma","Recruiting","No Results Available","Synovial Sarcoma","Biological: NY-ESO-1(c259)T Cells","Adaptimmune","All","4 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","65","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ADP 04511","April 26, 2011","March 2011","March 2028","May 12, 2017","May 2017","No Study Results Posted","NY-ESO-1","October 2017","Proportion of subjects with a confirmed Complete Response (CR) or Partial Response (PR) in each cohort|Number of subjects with dose-limiting toxicity (DLT) and adverse events (AE), including serious adverse events (SAE)|Evaluation of the persistence of genetically modified T cells|Percentage of total gene modified T cells with memory subtype|After progressing and after receiving a 2nd dose of NY-ESO-1ᶜ²⁵⁹T, proportion of subjects with a confirmed Complete Response (CR)","https://ClinicalTrials.gov/show/NCT01343043"
2763,"NCT02885610","Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","Recruiting","No Results Available","Systemic Lupus Erythematosus","Biological: Placebo plus standard therapy|Biological: RC18 80 mg plus standard therapy|Biological: RC18 160 mg plus standard therapy|Biological: RC18 240 mg plus standard therapy","RemeGen","All","18 Years to 65 Years   (Adult)","Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","C005 SLECLLI","August 26, 2016","December 2015","December 2017","February 15, 2017","February 2017","No Study Results Posted","null","September 2017","SLE Responder Index (SRI) Response Rate|Percent of subjects with ≥ 4 point reduction from baseline in SELENA SLEDAI score","https://ClinicalTrials.gov/show/NCT02885610"
2764,"NCT00093587","Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","Unknown status","No Results Available","Graft Versus Host Disease|Leukemia","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 55 Years   (Adult)","","null","Other|NIH","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Supportive Care","CDR0000389241|UCLA-0402009-01|GENZ-SMC-101-1026","October 6, 2004","August 2004","null","November 5, 2013","January 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00093587"
2765,"NCT00004172","Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: ifosfamide|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Northwestern University|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU 92B3T|NU-92B3T|NCI-G99-1640","December 10, 1999","October 1999","October 2003","June 8, 2012","June 2012","No Study Results Posted","null","October 2003","","https://ClinicalTrials.gov/show/NCT00004172"
2766,"NCT00653068","Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System","Active, not recruiting","Has Results","Childhood Atypical Teratoid/Rhabdoid Tumor","Procedure: autologous hematopoietic stem cell transplantation|Radiation: 3-dimensional conformal radiation therapy|Drug: methotrexate|Drug: leucovorin calcium|Drug: etoposide|Drug: cyclophosphamide|Drug: cisplatin|Biological: filgrastim|Drug: carboplatin|Drug: thiotepa|Drug: vincristine sulfate|Other: laboratory biomarker analysis","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","70","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","ACNS0333|NCI-2009-00337|COG-ACNS0333|U10CA098543","April 3, 2008","December 2008","null","February 13, 2017","February 2017","December 20, 2016","null","April 2015","Event-free Survival|Overall Survival (OS)|Toxic Death|Non-hematological Toxicity Associated With Chemotherapy: Grade 3 or Higher During Protocol Therapy","https://ClinicalTrials.gov/show/NCT00653068"
2767,"NCT00003680","Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: CMF regimen|Drug: cyclophosphamide|Drug: fluorouracil|Drug: methotrexate|Drug: tamoxifen citrate|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Scottish Cancer Therapy Network|National Cancer Institute (NCI)","Female","18 Years to 60 Years   (Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066782|SCTN-BR9810|EU-98054","November 1, 1999","November 1998","null","November 5, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003680"
2768,"NCT00637832","Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisolone|Drug: vincristine sulfate|Radiation: yttrium Y 90 ibritumomab tiuxetan","University Hospital Southampton NHS Foundation Trust|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000588042|USCTU-SCHRIFT-06-DOG05-44|USCTU-SCHRIFT|USCTU-RHM-CAN0542|EUDRACT 2007-000222-51|EU-20819","March 14, 2008","April 2008","null","October 6, 2009","July 2009","No Study Results Posted","null","March 2010","Overall response rate, including combined complete response and partial response|Time to disease progression|Time to next treatment|Response duration in patients with responding disease|Safety","https://ClinicalTrials.gov/show/NCT00637832"
2769,"NCT00025038","Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia","Completed","No Results Available","Juvenile Myelomonocytic Leukemia","Drug: tipifarnib|Drug: isotretinoin|Drug: fludarabine phosphate|Drug: cytarabine|Radiation: radiation therapy|Drug: cyclophosphamide|Biological: anti-thymocyte globulin|Procedure: allogeneic bone marrow transplantation|Procedure: double-unit umbilical cord blood transplantation|Procedure: umbilical cord blood transplantation|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","Phase 2","100","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01861|AAML0122|U10CA098543|CDR0000068788","October 11, 2001","June 2001","null","April 10, 2013","January 2013","No Study Results Posted","null","October 2007","Response rate (CR or PR)|Duration of response|Progression-free survival|Evaluation of prognostic importance of genetic marker|Grade 3 or greater toxicities assessed using CTC version 2.0|Survival of patients receiving the window vs. not|Response status on end of course reports (pre vs.post)","https://ClinicalTrials.gov/show/NCT00025038"
2770,"NCT00039377","Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","Completed","Has Results","Adult Acute Lymphoblastic Leukemia in Remission","Drug: imatinib mesylate|Drug: methotrexate|Drug: vincristine sulfate|Drug: leucovorin calcium|Procedure: peripheral blood stem cell transplantation|Procedure: autologous hematopoietic stem cell transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Radiation: total-body irradiation|Drug: tacrolimus|Biological: filgrastim|Drug: etoposide|Drug: cyclophosphamide|Drug: cytarabine|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","15 Years to 59 Years   (Child, Adult)","Phase 2","58","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2009-00436|CDR0000069378|CALGB 10001/SWOG C10001|CALGB-10001|U10CA031946","June 6, 2002","April 2002","February 2014","November 13, 2014","June 2014","November 27, 2013","null","April 2012","Disease Free Survival|Overall Survival|Number of Participants Who Achieved a BCR-ABL Response at 12 Months|5 Year Disease-free Survival for Autologous & Allogeneic Transplant Groups|5 Year Overall Survival for Autologous & Allogeneic Transplant Groups","https://ClinicalTrials.gov/show/NCT00039377"
2771,"NCT02003222","Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","Recruiting","No Results Available","B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|Untreated Adult Acute Lymphoblastic Leukemia","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Biological: Blinatumomab|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Daunorubicin Hydrochloride|Drug: Dexamethasone|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Drug: Mercaptopurine|Drug: Methotrexate|Drug: Pegaspargase|Drug: Prednisone|Biological: Rituximab|Drug: Vincristine Sulfate","National Cancer Institute (NCI)","All","30 Years to 70 Years   (Adult, Senior)","Phase 3","360","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2013-02229|E1910|ECOG-E1910|PE1910_A08PAMDREVW01|U10CA180820|U10CA021115","December 2, 2013","December 23, 2013","null","May 24, 2017","May 2017","No Study Results Posted","null","June 30, 2018","Overall survival|Incidence of adverse events, per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Minimal residual disease status|Relapse-free survival","https://ClinicalTrials.gov/show/NCT02003222"
2772,"NCT00016302","Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","Completed","No Results Available","T-cell Childhood Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia","Drug: prednisone|Drug: vincristine sulfate|Drug: daunorubicin hydrochloride|Drug: asparaginase|Drug: methotrexate|Drug: cyclophosphamide|Drug: cytarabine|Drug: mercaptopurine|Drug: leucovorin calcium|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: thioguanine|Radiation: radiation therapy|Drug: nelarabine|Drug: pegaspargase|Radiation: radiation therapy|Other: pharmacological study|Other: laboratory biomarker analysis","National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","","100","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01857|COG-AALL00P2|U10CA098543|CDR0000068620","May 6, 2001","April 2001","null","January 15, 2013","January 2013","No Study Results Posted","null","July 2007","Grade 3+ unusual CNS toxicities assessed using NCI CTCAE v. 3.0","https://ClinicalTrials.gov/show/NCT00016302"
2773,"NCT00003194","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors","Unknown status","No Results Available","Unspecified Childhood Solid Tumor, Protocol Specific","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: thiotepa|Drug: topotecan hydrochloride|Procedure: peripheral blood stem cell transplantation","Seattle Children's Hospital|National Cancer Institute (NCI)","All","1 Year to 30 Years   (Child, Adult)","Phase 1","24","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066029|CHMC-6006|FHCRC-1244.00|NCI-G98-1373","April 6, 2000","July 1997","null","February 6, 2009","March 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003194"
2774,"NCT00003784","S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: CHOP regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: tositumomab and iodine I 131 tositumomab","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","102","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000066917|S9911|U10CA032102","November 1, 1999","May 1999","null","January 23, 2013","January 2013","No Study Results Posted","null","January 2003","","https://ClinicalTrials.gov/show/NCT00003784"
2775,"NCT00671034","Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","Active, not recruiting","No Results Available","B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia","Drug: calaspargase pegol|Drug: calaspargase pegol|Drug: DAUNOrubicin Hydrochloride|Drug: DOXOrubicin Hydrochloride|Drug: Cytarabine|Drug: Prednisone|Drug: methotrexate|Drug: cyclophosphamide|Drug: mercaptopurine tablet|Drug: Dexamethasone|Drug: thioguanine|Drug: pegaspargase|Drug: vincristine sulfate|Radiation: radiation therapy|Other: laboratory biomarker analysis|Other: pharmacological study","Children's Oncology Group|National Cancer Institute (NCI)","All","2 Years to 30 Years   (Child, Adult)","","166","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AALL07P4|NCI-2009-00317|COG-AALL07P4|CDR0000594340|U10CA098543","May 1, 2008","July 2008","null","December 14, 2016","December 2016","No Study Results Posted","null","February 2011","Pharmacokinetics (PK) of SC-PEG E. coli L-asparaginase (EZN-2285) compared to pegaspargase during induction and consolidation therapy|Pharmacodynamics (PD) of EZN-2285 compared to pegaspargase during induction and consolidation therapy|Minimal residual disease (MRD)|Complete remission (CR) rates|Event-free survival (EFS)|Asparaginase level|Plasma and CSF concentrations of asparagine in ug/ml|Asparaginase immunogenicity toxicities (AEs)|Incidence of adverse events (AEs) as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Level of anti- EZN-2285 antibodies and anti- EZN-2285 neutralizing antibodies","https://ClinicalTrials.gov/show/NCT00671034"
2776,"NCT00381680","Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","Completed","Has Results","B-cell Childhood Acute Lymphoblastic Leukemia|L1 Childhood Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia","Drug: vincristine sulfate|Drug: prednisone|Drug: doxorubicin hydrochloride|Drug: pegaspargase|Drug: cytarabine|Drug: methotrexate|Drug: dexamethasone|Drug: etoposide|Drug: cyclophosphamide|Drug: leucovorin calcium|Biological: filgrastim|Drug: asparaginase|Drug: mercaptopurine","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 29 Years   (Child, Adult)","Phase 3","275","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","AALL0433|NCI-2009-00306|COG-AALL0433|CDR0000495359|U10CA098543","September 26, 2006","March 2007","null","April 5, 2017","December 2016","December 16, 2016","null","March 2016","Event Free Survival. EFS|Frequency and Severity of Adverse Effects|Gene Expression Profile|Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 1|Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3|Event Free Survival (EFS)|Adjusted Event Free Survival","https://ClinicalTrials.gov/show/NCT00381680"
2777,"NCT00002798","Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome","Completed","No Results Available","Childhood Acute Erythroleukemia (M6)|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Monoblastic Leukemia (M5a)|Childhood Acute Monocytic Leukemia (M5b)|Childhood Acute Myeloblastic Leukemia With Maturation (M2)|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)|Childhood Acute Myelomonocytic Leukemia (M4)|Childhood Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Refractory Anemia With Ringed Sideroblasts|Secondary Myelodysplastic Syndromes|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies","Drug: asparaginase|Drug: daunorubicin hydrochloride|Drug: fludarabine phosphate|Drug: therapeutic hydrocortisone|Procedure: allogeneic bone marrow transplantation|Radiation: 3-dimensional conformal radiation therapy|Biological: filgrastim|Drug: cytarabine|Drug: idarubicin|Drug: dexamethasone|Drug: thioguanine|Drug: etoposide|Drug: methotrexate|Drug: cyclophosphamide|Biological: aldesleukin|Drug: busulfan","National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","880","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01834|2961|U10CA098543|CDR0000064883","November 24, 2000","August 1996","null","January 15, 2013","January 2013","No Study Results Posted","null","September 2006","Proportions of patients achieving remission rate during induction therapy|Proportion of patients dying or with residual disease during induction therapy|Time to marrow recovery (induction phase)|Frequency of toxicities, including infectious complications (induction phase)|Marrow status|Percent of blasts|Complete remission at the end of consolidation therapy|Survival following consolidation|Event-free survival following consolidation|Overall survival (intensification)|EFS (intensification)","https://ClinicalTrials.gov/show/NCT00002798"
2778,"NCT00009997","Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: trastuzumab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel|Drug: tamoxifen citrate|Procedure: conventional surgery","New York University School of Medicine|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068430|P30CA016087|NYU-9901|GENENTECH-NYU-9901|NCI-G00-1905","February 2, 2001","March 1999","null","March 25, 2011","March 2011","No Study Results Posted","null","January 2004","","https://ClinicalTrials.gov/show/NCT00009997"
2779,"NCT00533936","Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: trastuzumab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: fluorouracil|Drug: paclitaxel|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Instituto Nacional de Cancerologia, Columbia|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000557417|MEX-INC-INCAN-CC-09506","September 20, 2007","September 2006","null","August 23, 2013","March 2008","No Study Results Posted","null","December 2009","Percentage of pathological responses|Disease-free survival|Overall survival at 3 years|Cardiac toxicity|Percentage of patients that become negative on the fluorescence in situ hybridization (FISH) test at the end of neoadjuvant therapy","https://ClinicalTrials.gov/show/NCT00533936"
2780,"NCT00003150","Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: rituximab|Drug: CHOP regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B|Southwest Oncology Group","All","60 Years and older   (Adult, Senior)","Phase 3","630","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065935|ECOG-E4494|CLB-9793|SWOG-E4494","November 1, 1999","December 1997","September 2006","June 20, 2013","August 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003150"
2781,"NCT00365755","Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma","Completed","No Results Available","Neuroblastoma","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: melphalan|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","1 Year to 18 Years   (Child, Adult)","Phase 3","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CCLG-ENSG-5|CDR0000454576|EU-20592|CCLG-NB-1990-11","August 16, 2006","null","March 2008","August 1, 2013","March 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00365755"
2782,"NCT00005612","Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer","Terminated","No Results Available","Ovarian Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: paclitaxel|Drug: topotecan hydrochloride|Procedure: peripheral blood stem cell transplantation","H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","3","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MCC-12085|MCC-IRB-5418|NCI-G00-1745","May 2, 2000","August 1999","February 2004","September 24, 2012","September 2012","No Study Results Posted","ETC","February 2004","Progression free survival","https://ClinicalTrials.gov/show/NCT00005612"
2783,"NCT00003152","Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma","Terminated","No Results Available","Lymphoma","Biological: filgrastim|Biological: recombinant interferon alfa|Drug: cyclophosphamide|Drug: prednisone|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC|Lymphoma Trials Office|Stichting Hemato-Oncologie voor Volwassenen Nederland","All","18 Years to 65 Years   (Adult)","Phase 3","469","Other","Interventional","Primary Purpose: Treatment","EORTC-20963|BNLI-EORTC-20963|HOVON-35","November 1, 1999","March 1997","null","June 29, 2012","June 2012","No Study Results Posted","null","November 1999","","https://ClinicalTrials.gov/show/NCT00003152"
2784,"NCT00003042","Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Biological: filgrastim|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: melphalan|Drug: mesna|Drug: paclitaxel|Drug: tamoxifen citrate|Procedure: bone marrow ablation with stem cell support|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation","City of Hope Medical Center|National Cancer Institute (NCI)","All","up to 60 Years   (Child, Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","96139|P30CA033572|CHNMC-96139|NCI-G97-1288|CDR0000065672","November 1, 1999","May 1997","null","September 16, 2016","September 2016","No Study Results Posted","null","September 2017","Time to progression at year 5|Feasibility at year 5|Overall survival at year 5","https://ClinicalTrials.gov/show/NCT00003042"
2785,"NCT00002566","Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors","Unknown status","No Results Available","Extragonadal Germ Cell Tumor|Testicular Germ Cell Tumor","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: ifosfamide|Drug: vinblastine sulfate|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation","UNICANCER|National Cancer Institute (NCI)","Male","16 Years and older   (Child, Adult, Senior)","Phase 3","280","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000063579|FRE-IT94|FRE-FNCLCC-IT94|NCI-F94-0019","November 1, 1999","February 1994","null","November 2, 2010","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002566"
2786,"NCT00005803","Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma","Active, not recruiting","No Results Available","Prolymphocytic Leukemia|Recurrent Adult Hodgkin Lymphoma|Recurrent Childhood Hodgkin Lymphoma|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma|T-Cell Chronic Lymphocytic Leukemia|T-Cell Prolymphocytic Leukemia","Procedure: Autologous Hematopoietic Stem Cell Transplantation|Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Drug: Cyclophosphamide|Drug: Cyclosporine|Drug: Cytarabine|Drug: Etoposide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Drug: Mycophenolate Mofetil|Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Peripheral Blood Stem Cell Transplantation|Biological: Therapeutic Autologous Lymphocytes|Radiation: Total-Body Irradiation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 75 Years   (Child, Adult, Senior)","Phase 1|Phase 2","80","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","1409.00|NCI-2010-00130|P30CA015704","June 2, 2000","September 1999","null","February 23, 2016","February 2016","No Study Results Posted","null","January 2016","Engraftment of HLA identical PBSC allografts|Non-relapse mortality|Overall survival (OS)|Progression free-survival (PFS)","https://ClinicalTrials.gov/show/NCT00005803"
2787,"NCT00052351","Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine|Biological: recombinant vaccinia-CEA(6D)-TRICOM vaccine|Biological: sargramostim|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel|Radiation: radiation therapy","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","null","NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000258196|NCI-03-C-0005|NCI-5191","January 24, 2003","September 2002","October 2007","June 17, 2013","May 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00052351"
2788,"NCT00027937","Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma","Completed","No Results Available","Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific","Biological: aldesleukin|Biological: filgrastim|Biological: sargramostim|Drug: busulfan|Drug: cyclophosphamide|Drug: melphalan|Drug: paclitaxel|Drug: thiotepa|Procedure: bone marrow ablation with stem cell support|Procedure: in vitro-treated peripheral blood stem cell transplantation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 56 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","1595.00|FHCRC-1595.00|IMMUNEX-FHCRC-1595.00|NCI-G01-2037|CDR0000069095","December 7, 2001","August 2001","November 2007","May 12, 2010","May 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00027937"
2789,"NCT02101853","Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","Recruiting","No Results Available","B Acute Lymphoblastic Leukemia","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Asparaginase|Biological: Blinatumomab|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone|Drug: Etoposide|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Mercaptopurine|Drug: Methotrexate|Drug: Mitoxantrone Hydrochloride|Drug: Pegaspargase|Other: Pharmacological Study|Drug: Therapeutic Hydrocortisone|Drug: Thioguanine|Drug: Vincristine Sulfate","National Cancer Institute (NCI)","All","1 Year to 30 Years   (Child, Adult)","Phase 3","598","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2014-00631|COG-AALL1331|AALL1331|U10CA180886|U10CA098543","March 28, 2014","December 8, 2014","null","May 23, 2017","May 2017","No Study Results Posted","null","April 3, 2018","DFS of HR and IR relapse patients|DFS of LR relapse patients|OS of HR and IR relapse patients|OS of LR relapse patients","https://ClinicalTrials.gov/show/NCT02101853"
2790,"NCT01256398","Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","Active, not recruiting","No Results Available","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Untreated Adult Acute Lymphoblastic Leukemia","Biological: Alemtuzumab|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dasatinib|Drug: Daunorubicin Hydrochloride|Drug: Dexamethasone|Drug: Etoposide Phosphate|Biological: Filgrastim|Drug: Fludarabine Phosphate|Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Melphalan|Drug: Mercaptopurine|Drug: Methotrexate|Biological: Pegfilgrastim|Other: Pharmacological Study|Drug: Tacrolimus|Drug: Vincristine Sulfate","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","66","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2011-02621|CDR0000690286|CALGB 10701/CTSU C10701|CALGB-10701|U10CA180821|U10CA031946","December 7, 2010","December 14, 2010","null","May 23, 2017","May 2017","No Study Results Posted","null","February 28, 2018","DFS defined from the date of first induction complete response (CR) to relapse or death due to any cause|DFS|Feasibility of maintenance therapy in this patient population (restricted to those patients achieving a CR)|OS|Probability of being BCR-ABL negative in the bone marrow and peripheral blood at the completion of the CNS prophylaxis course (restricted to those patients achieving a CR)|Response","https://ClinicalTrials.gov/show/NCT01256398"
2791,"NCT00301925","Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery","Active, not recruiting","No Results Available","Breast Cancer","Biological: pegfilgrastim|Drug: capecitabine|Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: methotrexate|Procedure: adjuvant therapy","Institute of Cancer Research, United Kingdom|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","4400","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000463447|ICR-TACT2|EU-205114|EUDRACT-2004-000066-13|MREC-04/MRE00/88|ISRCTN68068041","March 9, 2006","December 2005","null","November 25, 2010","July 2009","No Study Results Posted","null","September 2024","Disease-free survival (DFS) at 5 years|Overall survival at 5 years|Distant DFS at 5 years|Tolerability (including serious adverse events, dose-intensity, and toxicity)|Detailed toxicity|Quality of life","https://ClinicalTrials.gov/show/NCT00301925"
2792,"NCT00081055","OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies","Withdrawn","No Results Available","Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes","Biological: autologous expanded mesenchymal stem cells OTI-010|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Mesoblast International Sàrl|National Cancer Institute (NCI)|Mesoblast, Ltd.","All","18 Years to 55 Years   (Adult)","Phase 2","0","Industry|NIH","Interventional","Allocation: Randomized|Masking: Double-Blind|Primary Purpose: Supportive Care","Mesoblast|UCLA-0303036|CDR0000358809","April 7, 2004","null","null","December 3, 2014","December 2014","No Study Results Posted","null","null","Incidence of acute GVHD grade II-IV of skin, liver and gut (stomach to rectum) through Day 84 post-PBSC transplantation|Safety as measured by infusional toxicity, relapse nd survival, formation of potential ectopic tissue foci","https://ClinicalTrials.gov/show/NCT00081055"
2793,"NCT00003957","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: recombinant human stem cell factor|Drug: cyclophosphamide|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Drug: mitoxantrone hydrochloride|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation","Fox Chase Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","3","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067156|FCCC-98052|NCI-G99-1541","November 1, 1999","December 1998","August 2001","April 16, 2013","April 2013","No Study Results Posted","null","September 2000","","https://ClinicalTrials.gov/show/NCT00003957"
2794,"NCT00408408","Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery","Active, not recruiting","No Results Available","Breast Cancer","Biological: bevacizumab|Drug: capecitabine|Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride (Adriamycin)|Drug: gemcitabine hydrochloride","NSABP Foundation Inc|National Cancer Institute (NCI)","Female","18 Years to 120 Years   (Adult, Senior)","Phase 3","1206","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NSABP B-40","December 6, 2006","November 2006","March 2017","June 3, 2016","May 2016","No Study Results Posted","null","March 2011","Pathologic complete response (pCR) of the primary tumor in the breast|pCR in the breast and nodes|Clinical overall response (cOR) following docetaxel alone, docetaxel/capecitabine, and docetaxel/gemcitabine hydrochloride, with or without bevacizumab, as assessed by physical exam at the completion of the docetaxel-based portion of chemotherapy|cOR as assessed by physical exam at the completion of the sequential chemotherapy regimens|Clinical complete response (cCR) following docetaxel alone, docetaxel/capecitabine, and docetaxel/gemcitabine hydrochloride, with or without bevacizumab, as assessed by physical exam at completion of therapy|cCR as assessed by physical exam at the completion of the sequential chemotherapy regimens physical exam at the completion of the sequential chemotherapy regimens|Percentage of cardiac events|Percentage of surgical complications|Toxicities including events other than congestive heart failure, of chemotherapy alone, bevacizumab with chemotherapy, and bevacizumab alone|Disease-free survival (DFS)","https://ClinicalTrials.gov/show/NCT00408408"
2795,"NCT00028717","Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","Commissie Voor Klinisch Toegepast Onderzoek|National Cancer Institute (NCI)","All","65 Years and older   (Adult, Senior)","Phase 3","400","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000069122|CKTO-2000-10|HOVON-46NHL|EU-20130|HOVON-CKVO-2000-10","January 4, 2002","February 2001","null","September 16, 2013","November 2007","No Study Results Posted","null","null","Event-free survival|Complete response|Overall survival|Disease-free interval|Toxicity","https://ClinicalTrials.gov/show/NCT00028717"
2796,"NCT00376961","S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","Active, not recruiting","Has Results","Lymphoma","Biological: rituximab|Drug: bortezomib|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","68","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000494646|U10CA032102|S0601","September 13, 2006","August 2006","June 2017","December 21, 2016","December 2016","January 2, 2013","null","December 2012","2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM)|Response Rate in Patients Treated With Rituximab-CHOPbortezomib Induction Therapy (R-CHOP-V) Followed by Bortezomib Maintenance Therapy(VM).|2-year Overall Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM)|Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug","https://ClinicalTrials.gov/show/NCT00376961"
2797,"NCT00004039","Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma","Withdrawn","No Results Available","Lymphoma","Biological: recombinant interferon alfa|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate","Hoag Memorial Hospital Presbyterian|Cancer Biotherapy Research Group","All","Child, Adult, Senior","Phase 2","0","Other","Interventional","Primary Purpose: Treatment","CDR0000066762|CBRG-9807|NCI-V98-1494","December 10, 1999","June 1998","January 2000","August 17, 2015","August 2015","No Study Results Posted","null","January 2000","","https://ClinicalTrials.gov/show/NCT00004039"
2798,"NCT00008190","Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia","Completed","No Results Available","Leukemia","Biological: aldesleukin|Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: etoposide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation","Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068386|CPMC-IRB-8872|CPMC-CAMP-27|NCI-G00-1889","January 6, 2001","March 1999","May 2008","February 1, 2013","April 2004","No Study Results Posted","null","November 2005","","https://ClinicalTrials.gov/show/NCT00008190"
2799,"NCT01008462","Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia","Recruiting","No Results Available","B-Cell Prolymphocytic Leukemia|Hypodiploidy|Loss of Chromosome 17p|Plasma Cell Leukemia|Progression of Multiple Myeloma or Plasma Cell Leukemia|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Non-Hodgkin Lymphoma|Recurrent Childhood Hodgkin Lymphoma|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Small Lymphocytic Lymphoma|t(14;16)|t(4;14)|T-Cell Prolymphocytic Leukemia|Waldenstrom Macroglobulinemia","Procedure: Allogeneic Bone Marrow Transplantation|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Autologous Hematopoietic Stem Cell Transplantation|Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Drug: Carmustine|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Etoposide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Drug: Mycophenolate Mofetil|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Tacrolimus|Radiation: Total-Body Irradiation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2241.00|NCI-2009-01334|P30CA015704","November 4, 2009","March 2010","null","January 6, 2017","January 2017","No Study Results Posted","null","January 2020","Progression-free survival (PFS)|Early non-relapse mortality (NRM)|Early NRM|Immune reconstitution after allografting|Incidence of acute and chronic GVHD|Incidence of engraftment failure or rejection|Incidence of infections|Overall survival|Rates of relapse, defined by presence of malignant cells in marrow, peripheral blood or extramedullary sites detectable by morphologic, flow cytometric, cytogenetic or molecular assays not evident at the time of transplant|Reconstitution of lymphocyte subsets in peripheral blood|Severity of acute and chronic GVHD","https://ClinicalTrials.gov/show/NCT01008462"
2800,"NCT00007995","Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Biological: recombinant interferon alfa|Biological: sargramostim|Drug: busulfan|Drug: cyclophosphamide|Drug: melphalan|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","75","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000068361|CPMC-IRB-7328|CPMC-CAMP-009|NCI-G00-1882","January 6, 2001","July 1999","May 2008","February 1, 2013","July 2007","No Study Results Posted","null","November 2007","Disease-free survival at 2 years (patients with responsive disease)|Duration of hematologic toxicity|Time to an absolute neutrophil count|Platelet independence","https://ClinicalTrials.gov/show/NCT00007995"
2801,"NCT00006123","Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: trastuzumab|Drug: carboplatin|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation","Beth Israel Deaconess Medical Center|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068138|BIH-99-12|BIH-W-99-0053-FB|NCI-V00-1610","August 3, 2000","July 2000","null","February 6, 2009","December 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006123"
2802,"NCT00017290","Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine|Biological: keyhole limpet hemocyanin|Biological: sargramostim|Drug: cyclophosphamide|Drug: prednisone|Drug: vincristine sulfate","Genitope Corporation|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","null","Industry","Interventional","Allocation: Randomized|Masking: Double-Blind|Primary Purpose: Treatment","CDR0000068673|GENITOPE-G2000-03|CUMC-0101-142|UCLA-0010061","June 6, 2001","November 2000","null","December 3, 2013","August 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00017290"
2803,"NCT00003119","Surgery in Treating Children With Neuroblastoma","Completed","No Results Available","Neuroblastoma","Biological: filgrastim|Biological: sargramostim|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Procedure: adjuvant therapy|Procedure: conventional surgery|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","968","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","P9641|COG-P9641|POG-P9641|CCG-P9641|CDR0000065874","November 1, 1999","March 1998","March 2006","March 9, 2017","March 2017","No Study Results Posted","null","March 2006","Estimate the 3 year survival rate for low risk asymptomatic stage 2A/2B patients who are treated with surgery alone","https://ClinicalTrials.gov/show/NCT00003119"
2804,"NCT00085462","Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma","Completed","No Results Available","Melanoma (Skin)","Biological: aldesleukin|Biological: filgrastim|Biological: gp100-fowlpox vaccine|Biological: therapeutic autologous lymphocytes|Biological: therapeutic tumor infiltrating lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","61","NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","040181|04-C-0181|NCI-6470|CDR0000370798","June 10, 2004","May 2004","September 2008","June 21, 2012","June 2012","No Study Results Posted","null","May 2007","","https://ClinicalTrials.gov/show/NCT00085462"
2805,"NCT00046852","Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma","Completed","No Results Available","Infection|Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Biological: pneumococcal polyvalent vaccine|Biological: therapeutic autologous lymphocytes|Biological: therapeutic tumor infiltrating lymphocytes|Drug: carmustine|Drug: cyclophosphamide|Drug: melphalan|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","University of Maryland|University of Maryland Greenebaum Cancer Center","All","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000256870|MSGCC-0065|UPCC-6401|NCI-V02-1709","October 3, 2002","December 2001","February 2008","September 23, 2009","September 2009","No Study Results Posted","null","November 2004","","https://ClinicalTrials.gov/show/NCT00046852"
2806,"NCT00004900","Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: anastrozole|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Hackensack University Medical Center|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU-HAC98B2|CDR0000067579|NCI-G00-1689","March 7, 2000","October 1999","August 2004","May 29, 2013","October 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004900"
2807,"NCT03126916","Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma","Not yet recruiting","No Results Available","Childhood Ganglioneuroblastoma|Childhood Neuroblastoma|NMYC Gene Amplification|Recurrent Neuroblastoma","Biological: Aldesleukin|Procedure: Autologous Hematopoietic Stem Cell Transplantation|Drug: Busulfan|Drug: Carboplatin|Drug: Cisplatin|Drug: Crizotinib|Drug: Cyclophosphamide|Drug: Dexrazoxane Hydrochloride|Biological: Dinutuximab|Drug: Doxorubicin Hydrochloride|Drug: Etoposide Phosphate|Radiation: External Beam Radiation Therapy|Radiation: Iobenguane I-131|Drug: Isotretinoin|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Other: Pharmacological Study|Biological: Sargramostim|Procedure: Therapeutic Conventional Surgery|Drug: Thiotepa|Drug: Topotecan Hydrochloride|Drug: Vincristine Sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","365 Days to 30 Years   (Child, Adult)","Phase 3","774","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","ANBL1531|NCI-2016-01734|U10CA180886","April 17, 2017","August 2017","March 2022","April 24, 2017","April 2017","No Study Results Posted","null","March 2022","EFS rate|Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria version 4.0|Non-inferiority of 131I-MIBG plus BuMel and 131I-MIBG plus tandem transplant","https://ClinicalTrials.gov/show/NCT03126916"
2808,"NCT01649856","A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma","Completed","Has Results","Lymphoma, Large B-Cell, Diffuse","Drug: CHOP|Drug: rituximab [MabThera/Rituxan]|Drug: rituximab [MabThera/Rituxan]","Hoffmann-La Roche","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","572","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","MO28107|2012-000669-19","July 23, 2012","August 24, 2012","January 5, 2017","April 19, 2017","April 2017","January 15, 2016","null","October 21, 2014","Percentage of Participants With CR or CRu at the Time of Primary Analysis|Cancer Treatment Satisfaction Questionnaire (CTSQ) Domain Scores|Rituximab Administration Satisfaction Questionnaire (RASQ) Domain Scores|Median Duration of Rituximab Administration for Each Treatment Cycle|Percentage of Participants by Time Spent in the Infusion Chair/Bed for Each Treatment Cycle|Percentage of Participants by Time Spent in the Hospital for Each Treatment Cycle|Number of Participants With an Event-Free Survival (EFS) Event at the Time of Primary Analysis|Duration of EFS at the Time of Primary Analysis|Number of Participants With Relapse or Death at the Time of Primary Analysis|Duration of Disease-Free Survival (DFS) at the Time of Primary Analysis|Number of Participants With Progression, Relapse, or Death at the Time of Primary Analysis|Duration of Progression-Free Survival (PFS) at the Time of Primary Analysis|Number of Deaths at the Time of Primary Analysis|Duration of Overall Survival (OS) at the Time of Primary Analysis","https://ClinicalTrials.gov/show/NCT01649856"
2809,"NCT00446030","Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer","Completed","Has Results","Breast Neoplasms","Drug: Docetaxel|Drug: Doxorubicin|Drug: Carboplatin|Drug: Cyclophosphamide|Drug: Trastuzumab|Drug: Bevacizumab","Sanofi","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","127","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","DOCET_L_00713","March 8, 2007","March 2007","August 2010","June 21, 2012","June 2012","August 18, 2011","null","August 2010","Percent of Participants With Grade 3/4 Clinical Congestive Heart Failure (CHF)|Disease-free Survival (DFS) & Overall Survival (OS) of Participants","https://ClinicalTrials.gov/show/NCT00446030"
2810,"NCT02844530","Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL","Withdrawn","No Results Available","CD22+ Relapsed/Refractory B-ALL","Drug: 90Y-epratuzumab tetraxetan|Drug: chemotherapy/ immunotherapy","Nantes University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","RC15_0088","November 13, 2015","null","January 2017","January 17, 2017","January 2017","No Study Results Posted","RITEPRALL","January 2017","Compare the complete response rate (CR + CRp) in the two arms|Overall survival: overall and comparison between both groups|Disease free survival|time to disease progression|duration of response|CD22 expression|Safety and tolerance of fractionated RIT with 90Y-epratuzumab tetraxetan assessed by NCI Criteria|Immunization test to search for antibodies by ELISA test|Realization of a blood pharmacokinetics profile of 111In /90Y-epratuzumab tetraxetan|Tumour and organ dosimetry of 90Y-epratuzumab tetraxetan assessed using 111In-epratuzumab tetraxetan biodistribution|Correlation between FLT3-ligand serum value and efficacy and toxicity after treatment|Relapse incidence: overall and comparison between both groups|Minimal Residual Disease (MRD) (by FACS analysis)","https://ClinicalTrials.gov/show/NCT02844530"
2811,"NCT00083538","Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally","Completed","No Results Available","Multiple Myeloma","Drug: Dexamethasone|Drug: Thalidomide|Drug: Cisplatinum|Drug: Adriamycin|Drug: Cyclophosphamide|Drug: Etoposide","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UARK 2000-46","May 25, 2004","February 2001","December 2007","July 6, 2010","July 2010","No Study Results Posted","null","December 2007","To determine if vaccination with autologous idiotype- or tumor lysate-pulsed dendritic cells induces the generation of anti-idiotypic and anti-tumor immunologic responses.","https://ClinicalTrials.gov/show/NCT00083538"
2812,"NCT01850108","Non-Myeloablative Conditioning and Bone Marrow Transplantation","Recruiting","No Results Available","Sickle Cell Disease|Hemoglobinopathies","Drug: Thymoglobulin|Drug: Fludarabine|Drug: Cyclophosphamide (CTX)|Drug: Mesna|Drug: Sirolimus|Drug: Mycophenolate mofetil (MMF)|Procedure: Bone marrow transplantation|Radiation: Total body irradiation","Vanderbilt-Ingram Cancer Center","All","2 Years to 70 Years   (Child, Adult, Senior)","","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","VICCNC BMT 12108","May 1, 2013","May 2013","November 2017","January 9, 2017","January 2017","No Study Results Posted","null","May 2017","Transplant-related mortality (TRM)|Progression-free survival|Characterize donor hematopoietic chimerism in peripheral blood after mini-haploBMT|Characterize hematologic and non-hematologic toxicities of minihaploBMT","https://ClinicalTrials.gov/show/NCT01850108"
2813,"NCT00262067","A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)","Unknown status","Has Results","Metastatic Breast Cancer","Drug: Bevacizumab|Drug: Placebo|Drug: Chemotherapy","Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 3","1237","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","AVF3694g|BO20094","December 2, 2005","December 2005","December 2013","November 18, 2013","November 2013","August 20, 2013","null","July 2008","Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)|Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)|Duration of Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)|Overall Survival|1-year Survival|Progression-free Survival (PFS) as Determined by the Independent Review Committee Using Response Evaluation Criteria in Solid Tumors (RECIST)","https://ClinicalTrials.gov/show/NCT00262067"
2814,"NCT00222612","Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003","Unknown status","No Results Available","Acute Lymphoblastic Leukemia","Other: Reduced intensification|Drug: Standard childhood UK ALL protocol|Drug: Intensified treatment including Capizzi maintenance","University of Oxford|Medical Research Council","All","1 Year to 18 Years   (Child, Adult)","Phase 4","2100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","UKALL2003","September 13, 2005","October 2003","August 2013","February 2, 2010","February 2010","No Study Results Posted","null","August 2013","Event free survival|Survival|Quality of life","https://ClinicalTrials.gov/show/NCT00222612"
2815,"NCT01239368","Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma","Recruiting","No Results Available","Myeloma, Plasma-Cell|Myeloma-Multiple|Myelomatosis","Procedure: Adoptive Immunotherapy|Biological: Rapamycin-Generated Autologous Th1/Tc1 Cells|Biological: Th1/TC1 Rapa Cell Therapy","National Cancer Institute (NCI)|Hackensack University Medical Center|Georgetown University|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","86","NIH|Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","110016|11-C-0016","November 10, 2010","October 26, 2010","August 30, 2019","May 12, 2017","March 2, 2017","No Study Results Posted","null","November 30, 2018","Evaluate the safety|Progression free survival in cohort A|PR+CR rate in cohort B","https://ClinicalTrials.gov/show/NCT01239368"
2816,"NCT00339118","EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children","Unknown status","No Results Available","Rhabdomyosarcoma","Drug: doxorubicin, cytoxan","Sheba Medical Center","All","6 Months to 21 Years   (Child, Adult)","Phase 4","null","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","SHEBA-06-4013-IK-CTIL","June 19, 2006","null","null","June 19, 2006","June 2006","No Study Results Posted","null","null","event free survival|overall survival","https://ClinicalTrials.gov/show/NCT00339118"
2817,"NCT00062881","Intrathecal Mafosfamide","Completed","No Results Available","Malignant Meningeal Neoplasms","Drug: Intrathecal Mafosfamide","Baylor College of Medicine|Texas Children's Hospital","All","3 Years and older   (Child, Adult, Senior)","Phase 1","65","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","H3241|I.T. Mafosfamide","June 17, 2003","June 1990","September 2005","August 21, 2006","April 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00062881"
2818,"NCT00031928","Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: mafosfamide","National Cancer Institute (NCI)","All","3 Years and older   (Child, Adult, Senior)","Phase 1","3000","NIH","Interventional","Primary Purpose: Treatment","CDR0000069240|NCI-90-C-0095K|BCM-H-3241","March 8, 2002","January 2002","null","April 29, 2015","November 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00031928"
2819,"NCT00774826","Multicentric Study, Three Randomized Arms (R−CVP vs R−CHOP vs R−FM),for Patients With Stage II−IV Follicular Lymphoma","Unknown status","No Results Available","Follicular Lymphoma","Drug: R-CVP|Drug: R-CHOP|Drug: R-FM","Fondazione Italiana Linfomi ONLUS","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","534","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IIL−FOLL05|Eudract Number 2005−005406−24","October 14, 2008","December 2005","March 2014","February 14, 2011","February 2011","No Study Results Posted","null","September 2010","Assessment of the Time to Treatment Failure (TTF)in patients treated with R-CVP, R-CHOP and R-FM.|Assessment of Overall Survival (OS)in patients treated with R−CVP, R−CHOP and R−FM. −|Assessment of Progression Free Survival (PFS)in patients treated with R-CVP, R-CHOP|Assessment of Duration of Response (DR)in patients treated with R-CVP, R-CHOP and R-FM.|Assessment of Response Rate(RR) in patients treated with R-CVP, R-CHOP and R-FM.|Assessment of molecular Response Rate in patients treated with R-CVP, R-CHOP and R-FM.|Assessment of toxicity of R-CVP, R-CHOP, R-FM treatments.","https://ClinicalTrials.gov/show/NCT00774826"
2820,"NCT00128895","Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis","Unknown status","No Results Available","Vasculitis","Drug: azathioprine","University Medical Center Groningen|ZonMw: The Netherlands Organisation for Health Research and Development|Dutch Arthritis Association|Dutch Kidney Foundation","All","18 Years and older   (Adult, Senior)","Phase 4","180","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AZA-ANCA-1","August 9, 2005","June 2003","December 2014","December 31, 2014","December 2014","No Study Results Posted","null","June 2014","disease free survival|cumulative organ damage|side-effects|cumulative dosages of cyclophosphamide, prednisolone and azathioprine|quality of life","https://ClinicalTrials.gov/show/NCT00128895"
2821,"NCT00499018","Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma","Unknown status","No Results Available","Diffuse Large B-Cell Lymphoma|IPI≥2","Drug: Rituximab|Drug: Ciclofosfamide|Drug: Doxorubicina|Drug: Vincristina|Drug: Prednisone|Drug: Pegfilgrastim|Drug: Mitoxantrone|Drug: ARA-C|Drug: Lenograstim|Drug: BCNU|Drug: ARA-C|Drug: VP-16|Procedure: ASCT|Drug: Ciclofosfamide|Drug: Doxorubicina|Drug: Vincristina","Fondazione Italiana Linfomi ONLUS|Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte","All","18 Years to 60 Years   (Adult)","Phase 3","399","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","IIL-DLCL04|EudraCT number 2007-000275-42","July 10, 2007","January 2006","September 2013","February 14, 2011","February 2011","No Study Results Posted","DLCL04","June 2011","To evaluate the activity of arms ""R-MegaCHOP14/R-CHOP14 + R-MAD+BEAM and ASCT"" and ""R-MegaCHOP14/R-CHOP14"" in terms of 2-years Failure Free Survival (FFS).|To evaluate the activity of arms ""R-MegaCHOP14/R-CHOP14 + R-MAD+BEAM and ASCT"" and ""R-MegaCHOP14/R-CHOP14"" in terms of 3-years Overall Survival (OS).|To evaluate the efficacy of two different dose-dense + Rituximab chemotherapy regimens in term of 2-years Failure Free Survival (FFS).|To evaluate the activity of the first four courses of two different dose dense + Rituximab chemotherapy regimens (standard dose R-CHOP14 or intensified dose R-MegaCHOP14) in terms of Overall Response Rate (ORR) and Complete Remission (RC).|To evaluate the efficacy of the four different induction arms in terms of 2-years FFS (exploratory analysis).","https://ClinicalTrials.gov/show/NCT00499018"
2822,"NCT00681993","Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens","Active, not recruiting","No Results Available","Breast Cancer","Other: Standard Dose Dense Doxorubucin and Cyclophosphomide|Other: Standard Doxorubucin and Cyclophosphomide|Other: Standard Docetaxel, Carboplatin, and Herceptin|Other: Standard Docetaxel, Doxorubucin and Cyclophosphomide|Other: Standard Docetaxel and Cyclophosphomide","Sidney Kimmel Comprehensive Cancer Center","Female","18 Years and older   (Adult, Senior)","","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J-0805|NA_00015271","May 19, 2008","April 2008","July 2017","November 15, 2012","November 2012","No Study Results Posted","PBIC","June 2014","To assess the potential acute and late skin and subcutaneous toxicities of partial breast irradiation concurrent with chemotherapy.|To assess cosmetic effect of PBIC.|To assess local control rate of patients treated with PBIC.","https://ClinicalTrials.gov/show/NCT00681993"
2823,"NCT00433459","Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: cyclophosphamide|Drug: dacarbazine|Drug: prednisolone|Drug: prednisone|Drug: procarbazine hydrochloride|Drug: vincristine sulfate|Radiation: fludeoxyglucose F 18|Radiation: radiation therapy","Christine Mauz-Körholz|Deutsche Krebshilfe e.V., Bonn (Germany)|Euronet Worldwide|Martin-Luther-Universität Halle-Wittenberg","All","up to 17 Years   (Child)","Phase 3","2134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000531687|EURONET-PHL-C1|EU-20703|EUDRACT-2006-000995-33|CCLG-HD-2007-10","February 8, 2007","January 2007","January 2013","November 17, 2015","November 2015","No Study Results Posted","null","January 2013","Event-free survival|Overall survival|Progression-free survival|Toxicity|Evidence of male infertility score|Evidence of female infertility score|Long-term consequences (e.g., premature menopause, secondary cancer)","https://ClinicalTrials.gov/show/NCT00433459"
2824,"NCT00002580","Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: fluorouracil|Drug: goserelin acetate|Drug: leuprolide acetate|Drug: methotrexate|Drug: tamoxifen citrate|Procedure: conventional surgery|Procedure: laparoscopic surgery|Procedure: oophorectomy|Radiation: radiation therapy","Scottish Cancer Therapy Network|National Cancer Institute (NCI)","Female","up to 70 Years   (Child, Adult, Senior)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000063695|SCTN-BR9401|EU-94002|UKCCCR-ABC/BR9401","November 1, 1999","June 1993","null","November 5, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002580"
2825,"NCT02098512","Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients","Recruiting","No Results Available","Hodgkin Lymphoma","Drug: Brentuximab Vedotin|Procedure: Allogeneic Stem Cell Transplantation|Drug: Reduced Intensity Conditioning","New York Medical College|St. Baldrick's Foundation","All","up to 45 Years   (Child, Adult)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NYMC 564","March 17, 2014","March 2014","December 2018","July 29, 2016","July 2016","No Study Results Posted","null","December 2017","Safety|Overall Survival|To assess feasibility of developing a bank of LMP-specific CTLs from healthy donors","https://ClinicalTrials.gov/show/NCT02098512"
2826,"NCT00002680","Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: cyclophosphamide|Drug: megestrol acetate|Drug: melphalan|Drug: tamoxifen citrate|Drug: thiotepa|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Yale University","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other","Interventional","Primary Purpose: Treatment","CDR0000064338|YALE-HIC-7372|NCI-V95-0721","November 1, 1999","February 1994","December 2000","July 23, 2013","August 2009","No Study Results Posted","null","December 2000","","https://ClinicalTrials.gov/show/NCT00002680"
2827,"NCT00662233","Combination Chemotherapy in Treating Patients With Sarcoma","Completed","No Results Available","Ovarian Cancer|Sarcoma","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: vincristine sulfate|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery|Radiation: brachytherapy|Radiation: intraoperative radiation therapy|Radiation: radiation therapy","Mayo Clinic|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","","28","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Treatment","CDR0000582271|P30CA015083|919110|542-91|0791","April 18, 2008","October 1991","October 21, 2013","May 23, 2017","April 2016","No Study Results Posted","null","October 21, 2013","Efficacy in terms of long-term disease-free survival|Clinical response of the tumors|Pathologic response of the tumors|Long term disease-free survival","https://ClinicalTrials.gov/show/NCT00662233"
2828,"NCT02573935","Clarithromycin in Multiple Myeloma Induction Therapy","Terminated","No Results Available","Multiple Myeloma","Drug: Clarithromycin|Drug: Placebo|Drug: VCD induction therapy","Henrik Gregersen|Danish Myeloma Study Group|Aalborg Universitetshospital","All","18 Years and older   (Adult, Senior)","Phase 2","58","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DMSG 03/14|2014-002187-32","October 8, 2015","January 2015","September 2016","September 19, 2016","September 2016","No Study Results Posted","CLAIM","September 2016","Comparison of number of participants with very good partial response or better response after three courses of VCD combined with clarithromycin or placebo|Comparison of number of participants with very good partial response or better response after HDT in patients treated with three courses of VCD combined with clarithromycin or placebo|Comparison of number of participants with sCR, CR, PR, PD or SD in the treatment groups after induction therapy and HDT, respectively|Comparison of frequency of infections in patients treated VCD combined with clarithromycin or placebo|Comparison of number of stem cells harvested in patients treated with clarithromycin and placebo in combination with VCD|Neurotoxicity assessed by FACT/GOG-Ntx, Version 4.0|Quality of life assessed by EORTC QLQ-MY20|Quality of life assessed by EORTC QLQ-C30|Comparison of adverse events in patients treated VCD combined with clarithromycin or placebo assessed by CTCAE v4.0","https://ClinicalTrials.gov/show/NCT02573935"
2829,"NCT00002792","Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Myelodysplastic/Myeloproliferative Diseases","Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","20","Other|NIH","Interventional","Primary Purpose: Treatment","1032.01|FHCRC-1032.01|NCI-H96-0929|CDR0000064859","November 1, 1999","June 1996","April 2003","March 31, 2010","March 2010","No Study Results Posted","null","April 2003","","https://ClinicalTrials.gov/show/NCT00002792"
2830,"NCT00562068","Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma","Unknown status","No Results Available","Lymphoma|Small Intestine Cancer","Biological: alemtuzumab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisolone|Drug: vincristine sulfate|Genetic: polymerase chain reaction|Other: flow cytometry|Other: laboratory biomarker analysis|Other: pharmacological study","Cancer Research UK|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000576439|UCL-BRD/05/170|EU-20785|EUDRACT-2006-000365-11|CTA 21786/0201/001-0001|CRUK-UCL-BRD/05/170-CHOP-CAMPA|UCL-CHOP-CAMPATH","November 20, 2007","May 2007","null","August 23, 2013","November 2008","No Study Results Posted","null","May 2009","Immediate toxicity (incidence of infusion-related reactions)|Hematopoietic toxicity (number of cycles of therapy associated with neutrophils < 0.5e9/L or platelets < 50e9/L)|Incidence of infection (number of days with fever ≥ 38 degrees C, days of intravenous antibiotics, number of inpatient days, number of episodes of cytomegalovirus reactivation)|Disease response (remission rate [complete response and partial response])|Disease outcome (time to progression and overall survival at 2 years from completion of therapy)|Immune reconstitution (time to recover peripheral blood CD4 count to 0.2 e9/L)|Relative dose intensity|Pharmacokinetics assessment of alemtuzumab trough levels before each cycle of treatment|Epstein-Barr virus copy number (measured retrospectively)","https://ClinicalTrials.gov/show/NCT00562068"
2831,"NCT00005998","Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease","Withdrawn","No Results Available","Lymphoma","Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: etoposide|Drug: filgrastim|Drug: mitoxantrone hydrochloride|Drug: retrovirus vector LN|Procedure: in vitro-treated peripheral blood stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: radiation therapy","Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Primary Purpose: Treatment","1999LS080|MT1999-19|NCI-G00-1807","July 5, 2000","January 2000","March 2003","October 9, 2012","October 2012","No Study Results Posted","null","March 2003","","https://ClinicalTrials.gov/show/NCT00005998"
2832,"NCT01917578","Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction","Unknown status","No Results Available","Breast Cancer","Device: Ultrasound|Procedure: CNB|Procedure: BCS, Modified Radical Mastectomy|Device: Pathologic Large Tissue Selected Table|Device: Leica TP1020|Device: Pathologic Large Tissue Embedded Table|Device: Leica SM2000 R|Procedure: HE Stain|Device: CX22|Device: Epson V600|Device: MRI|Procedure: Three-Dimensional Reconstruction|Device: Mammography|Drug: TAC,TC,TA,CAF,CEF|Drug: AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF","Shandong Cancer Hospital and Institute","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic","BCSMANC001","August 4, 2013","August 2008","July 2014","August 4, 2013","August 2013","No Study Results Posted","BCSMANC","March 2014","The shrinkage modes of breast tumor after NAC.|The WMSS and 3D pathological reconstruction of the residual tumors after NAC.","https://ClinicalTrials.gov/show/NCT01917578"
2833,"NCT00025428","Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma","Completed","No Results Available","Neuroblastoma","Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: vincristine sulfate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy","Societe Internationale d'Oncologie Pediatrique|Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","1 Year to 18 Years   (Child, Adult)","Phase 3","100","Other","Interventional","Primary Purpose: Treatment","CDR0000068960|SIOP-NB-2009|CCLG-NB-2000-09|EU-20107","October 11, 2001","December 2000","November 2013","December 3, 2013","November 2006","No Study Results Posted","null","null","Event-free survival at 3 years","https://ClinicalTrials.gov/show/NCT00025428"
2834,"NCT01632241","Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)","Recruiting","No Results Available","Systemic Lupus Erythematosus","Biological: Placebo plus standard therapy|Biological: Belimumab 10 mg/kg plus standard therapy|Drug: Standard therapy","Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 4","816","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","115471|HGS1006-C1112|2011-005672-42|U1111-1139-9723","June 28, 2012","February 19, 2013","March 12, 2019","April 6, 2017","April 2017","No Study Results Posted","EMBRACE","August 28, 2018","SYSTEMIC LUPUS ERYTHEMATOSUS RESPONDER INDEX (SRI) RESPONSE RATE WITH THE MODIFIED SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX (SLEDAI)-2000 SCORING FOR PROTEINURIA AT WEEK 52|SRI RESPONSE RATE WITH THE SELENA SLEDAI FOR SCORING OF PROTEINURIA AT WEEK 52|TIME TO FIRST SEVERE FLARE (SLE FLARE INDEX)|REDUCTION IN PREDNISONE DOSE|NUMBER OF PARTICIPANTS WITH ADVERSE EVENTS (AES), SERIOUS AES, SEVERE AES AND AES LEADING TO DICSONTINUATION|NUMBER OF PARTICIPANTS WITH LABORATORY ABNORMALITIES","https://ClinicalTrials.gov/show/NCT01632241"
2835,"NCT01484496","A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)","Completed","No Results Available","Systemic Lupus Erythematosus","Biological: Placebo|Biological: Belimumab 200 mg SC|Drug: Standard therapy","Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 3","839","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","112341|2011-003814-18|HGS1006-C1115","November 28, 2011","November 2011","October 2015","November 7, 2016","November 2016","No Study Results Posted","BLISS-SC","February 2015","SLE Responder Index (SRI) response rate|Time to first severe flare (SLE Flare Index)|Reduction in prednisone dose","https://ClinicalTrials.gov/show/NCT01484496"
2836,"NCT00028600","Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma","Completed","No Results Available","Multiple Myeloma|Plasma Cell Neoplasm","Biological: filgrastim|Biological: CD34+ cells|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: melphalan|Drug: methotrexate|Drug: tacrolimus","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","up to 64 Years   (Child, Adult)","Phase 2","60","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-100001|U10CA031946|CDR0000069109","January 4, 2002","November 2001","February 2010","July 1, 2016","July 2016","No Study Results Posted","null","June 2006","Treatment-related mortality|Treatment Completion Rate|Respone Rate|Chimerism Rate|GVHD Incidence|Survival|Correlation of cytogenetics and response","https://ClinicalTrials.gov/show/NCT00028600"
2837,"NCT00003852","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors","Terminated","No Results Available","Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Ovarian Cancer|Testicular Germ Cell Tumor","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: paclitaxel|Drug: thiotepa|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","UNICANCER","All","15 Years to 120 Years   (Child, Adult, Senior)","Phase 2","45","Other","Interventional","Primary Purpose: Treatment","CDR0000067015|FRE-FNCLCC-GETUG-04|EU-99004","November 1, 1999","March 1998","March 2000","June 22, 2016","June 2016","No Study Results Posted","null","March 2000","","https://ClinicalTrials.gov/show/NCT00003852"
2838,"NCT00298506","Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V)","Completed","No Results Available","Lupus Nephritis","Drug: Multitherapy","Nanjing University School of Medicine","Female","12 Years to 50 Years   (Child, Adult)","","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NJCT-0601","March 1, 2006","September 2005","June 2009","September 28, 2011","September 2011","No Study Results Posted","null","December 2008","To assess the efficacy of FK506 combined with MMF versus intravenous CTX pulses in treatment of LN|To investigate the safety and tolerability of FK506 combined with MMF versus intravenous CTX pulses","https://ClinicalTrials.gov/show/NCT00298506"
2839,"NCT00361621","Ph II CHOP+Velcade in Mediastinal LBCL","Terminated","No Results Available","Non-Hodgkin's Lymphoma","Drug: bortezomib|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Radiation: Radiation therapy","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","3","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","06-012|X05194","August 7, 2006","July 2006","May 2008","November 30, 2012","October 2009","No Study Results Posted","null","November 2007","To evaluate the rate of complete response to therapy defined as resolution of PET avidity in all previously documented sites at the completion of chemotherapy.|Assess toxicity|evaluate event-free survival at 2 years|evaluate overall survival at 2 years|assess early PET restaging after 3 cycles of chemotherapy.","https://ClinicalTrials.gov/show/NCT00361621"
2840,"NCT00004006","Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma","Completed","No Results Available","Retinoblastoma","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: topotecan hydrochloride|Procedure: autologous bone marrow transplantation|Radiation: radiation therapy","St. Jude Children's Research Hospital|National Cancer Institute (NCI)","All","up to 15 Years   (Child)","Phase 2","4","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067217|P30CA021765|SJCRH: RET4|NCI-G99-1555","November 1, 1999","November 1997","September 2005","October 3, 2011","October 2011","No Study Results Posted","null","September 2005","","https://ClinicalTrials.gov/show/NCT00004006"
2841,"NCT00003402","Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia","Completed","No Results Available","Leukemia|Lymphoma","Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: dexamethasone|Drug: etoposide|Drug: melphalan|Drug: paclitaxel|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","University of Maryland|University of Maryland Greenebaum Cancer Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","35","Other","Interventional","Primary Purpose: Treatment","CDR0000066407|MSGCC-9734|NCI-V98-1439","November 1, 1999","January 1999","December 2002","September 23, 2009","September 2009","No Study Results Posted","null","December 2002","","https://ClinicalTrials.gov/show/NCT00003402"
2842,"NCT00003399","Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: dexamethasone|Drug: etoposide|Drug: melphalan|Drug: paclitaxel|Procedure: in vitro-treated peripheral blood stem cell transplantation","University of Maryland","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","MSGCC-9732|CDR0000066402|NCI-V98-1435","November 1, 1999","September 1998","September 2002","March 28, 2017","March 2017","No Study Results Posted","null","September 2002","","https://ClinicalTrials.gov/show/NCT00003399"
2843,"NCT01464359","T-Cell Depleted Double UCB for Refractory AML","Terminated","Has Results","Acute Myelogenous Leukemia|Refractory Acute Myelogenous Leukemia","Drug: Allopurinol|Drug: Fludarabine|Radiation: Total body irradiation|Drug: Cyclophosphamide|Drug: Levetiracetam|Drug: Busulfan|Biological: Umbilical Cord Blood Transplantation|Biological: Interleukin-2","Masonic Cancer Center, University of Minnesota","All","2 Years to 45 Years   (Child, Adult)","Phase 2","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","MT2011-15","November 1, 2011","October 2011","October 2013","April 6, 2017","April 2015","April 29, 2015","null","October 2013","Disease Free Survival|Incidence of Graft Failure|Incidence of Acute Graft-Versus-Host Disease|Transplant-Related Mortality|Clinical Disease Response|Duration of Survival","https://ClinicalTrials.gov/show/NCT01464359"
2844,"NCT00004905","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia","Completed","No Results Available","Leukemia","Biological: filgrastim|Biological: recombinant interferon alfa|Drug: cyclophosphamide|Drug: cytarabine|Drug: etoposide|Drug: idarubicin|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Loyola University|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","LUMC-5892|NU-L94H2|CDR0000067584|NCI-G00-1702","March 7, 2000","October 1999","September 2004","May 29, 2013","February 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004905"
2845,"NCT00005589","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","EBMT Solid Tumors Working Party|Lymphoma Trials Office|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","460","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000067665|EBMT-EBMTLYM1|BNLI-EBMT-EBMTLYM1|EU-99050","May 2, 2000","October 1999","April 2013","September 16, 2013","March 2007","No Study Results Posted","null","null","Time to disease progression|Response rate and survival|Molecular remission rates|Safety","https://ClinicalTrials.gov/show/NCT00005589"
2846,"NCT00285389","Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years","Completed","No Results Available","Mantle Cell Lymphoma","Drug: Adriblastin|Drug: dexamethasone|Drug: Chlorambucil|Drug: rituximab|Drug: cyclophosphamide|Drug: alkeran|Procedure: Total body irradiation (8Gy/4fr)|Drug: vincristine","French Innovative Leukemia Organisation|Hoffmann-La Roche","All","18 Years to 65 Years   (Adult)","Phase 2","39","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","MANTEAU 2001","January 31, 2006","February 2002","December 2008","February 11, 2009","February 2009","No Study Results Posted","null","December 2005","failure event free survival at 3 years|Response rate after 4 R-(VAD+C) cycles|Incident of Molecular residual disease on blood, marrow and stem cell collection|Safety of the R-( VAD+C) regimen|Overall survival|Efficacy of the stem cell collection after HD Cyclosphosphamide mobilization and rituximab purging","https://ClinicalTrials.gov/show/NCT00285389"
2847,"NCT00004903","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma","Unknown status","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Biological: recombinant interferon alfa|Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation","Robert H. Lurie Cancer Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067582|NU-C94H1|NU-94H1|UCCRC-7071|NCI-G00-1690","March 7, 2000","October 1999","null","January 3, 2014","June 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004903"
2848,"NCT02842931","R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: R-DA-EPOCH-21|Drug: R-DA-EPOCH-21 + auto-SCT|Drug: R-mNHL-BFM-90|Drug: R-mNHL-BFM-90 + auto-SCT","National Research Center for Hematology, Russia|National Research Center for Hematology","All","18 Years to 60 Years   (Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","DLBCL-2015","March 11, 2016","February 2015","February 2023","July 20, 2016","July 2016","No Study Results Posted","null","February 2020","complete response|overall survival|disease-free survival|event-free survival","https://ClinicalTrials.gov/show/NCT02842931"
2849,"NCT00004128","Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia","Unknown status","No Results Available","Leukemia","Biological: aldesleukin|Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: etoposide|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC|Gruppo Italiano Malattie EMatologiche dell'Adulto|National Cancer Institute (NCI)","All","15 Years to 60 Years   (Child, Adult)","Phase 3","2000","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000067356|EORTC-06991|GIMEMA-EORTC-06991","December 10, 1999","September 1999","null","December 22, 2009","April 2008","No Study Results Posted","null","January 2008","Duration of overall survival and disease-free survival after first randomization|Duration of overall survival and disease-free survival after second randomization|Response after induction and consolidation|Toxicity measured by Cancer and Leukemia Group B (CALGB) CTCAE v3.0 after induction and consolidation|Disease-free survival after complete remission (CR)|Disease-free interval from CR|Time to death in CR|Peripheral stem cell harvest after consolidation|Rate of completion of autologous peripheral blood stem cell transplantation (auto-PBSCT) and allogeneic stem cell transplantation (allo-SCT)","https://ClinicalTrials.gov/show/NCT00004128"
2850,"NCT00248547","Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant","Completed","Has Results","Cancer","Drug: aprepitant|Drug: dexamethasone|Drug: ondansetron|Drug: placebo","OHSU Knight Cancer Institute","All","18 Years and older   (Adult, Senior)","","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Supportive Care","CDR0000445452|OHSU-HEM-03074-L|OHSU-1057|MERCK-OHSU-HEM-03074-L","November 3, 2005","May 2004","January 2009","May 7, 2017","May 2017","November 21, 2011","null","January 2009","Number of Emesis Free Participants During the Study Period.|Safety in Transplant Population|Effects on Nausea, Appetite and Taste Changes|Pharmacokinetic Interaction","https://ClinicalTrials.gov/show/NCT00248547"
2851,"NCT01415765","MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma","Withdrawn","No Results Available","Lymphoma, Diffuse Large-Cell B-cell|Diffuse, Large B-cell Lymphoma|Lymphoma, Diffuse Large-Cell|Large-Cell Lymphoma, Diffuse","Drug: MLN4924|Drug: Etoposide|Drug: Prednisone|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Rituximab|Drug: Filgrastim","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 1|Phase 2","0","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","110216|11-C-0216","August 11, 2011","July 15, 2011","January 7, 2014","May 12, 2017","January 7, 2014","No Study Results Posted","null","January 7, 2014","Assess response of MLN4924 in relapsed/refractory DLBCL|Assess toxicity and safe tolerated dose of MLN4924 and DA-EPOCH-R|Assess ORR (CR/PR) and PFS of MLN4924 and DA-EPOCH-R in relapsed/refractory DLBCL|Analyze molecular subtype (ABC and GCB)|Assess difference in response between ABC and GCB subtypes of relapsed/refractory DLBCL/MLN 4924 alone and w/MLN4924 and DA-EPOCH-R|Analyze mutations of the ITAM motifs, CARD11 and A20 in DLBCL","https://ClinicalTrials.gov/show/NCT01415765"
2852,"NCT00830544","Study of Neoadjuvant Chemotherapy of Breast Cancer","Unknown status","No Results Available","Breast Cancer","Drug: Neoadjuvant chemotherapy|Drug: Chemotherapy|Drug: Neoadjuvant chemotherapy","Auxilio Mutuo Cancer Center|Sanofi","Female","19 Years and older   (Adult, Senior)","Phase 2","54","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CCAM 07-03","January 27, 2009","July 2008","December 2012","July 12, 2012","July 2012","No Study Results Posted","Neoadjuvant","December 2011","To evaluate the pathological CR rate in breast and lymph nodes of a novel neoadjuvant regimen for invasive breast carcinoma|To evaluate the clinical anti-tumor activity of the TEC combination chemotherapy regimen as judged by MRI when feasible or if not, with ultrasound.","https://ClinicalTrials.gov/show/NCT00830544"
2853,"NCT00137111","Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","Active, not recruiting","Has Results","Lymphoblastic Leukemia, Acute","Drug: Prednisone, Dexamethasone, Vincristine, Daunorubicin|Drug: Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase|Drug: Methotrexate, Cyclophosphamide, Cytarabine, Etoposide|Drug: Mercaptopurine, Imatinib|Procedure: chemotherapy, intrathecal chemotherapy|Procedure: steroid therapy, hematopoietic stem cell transplantation","St. Jude Children's Research Hospital|National Cancer Institute (NCI)","All","12 Months to 18 Years   (Child, Adult)","Phase 3","501","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","TOTXV|R37CA036401|P30CA021765|F32CA141762","August 25, 2005","June 2000","November 2020","March 31, 2017","April 2016","February 28, 2011","null","November 2010","Overall Event-free Survival (EFS)|Continuous Complete Remission Since Week 56 Therapy.|Minimal Residual Disease (MRD)|Mean Difference of Active Methotrexate Polyglutamates (MTXPG) in Leukemia Cells Between Two Arms (4 Hours vs. 24 Hours).|Circulating Leukemia Cells in Peripheral Blood Change From Prior to the Methotrexate Infusion to Three Days After Between Two Arms (4 Hours vs. 24 Hours)","https://ClinicalTrials.gov/show/NCT00137111"
2854,"NCT02393833","Serum Protein Research Substudy","Active, not recruiting","No Results Available","Breast Cancer","Drug: Cyclophosphamide|Drug: Doxorubicin hydrochloride|Drug: Epirubicin hydrochloride|Drug: Fluorouracil|Drug: Methotrexate|Procedure: Adjuvant therapy|Drug: Docetaxel|Drug: Paclitaxel","International Breast Cancer Study Group","Female","18 Years and older   (Adult, Senior)","Phase 3","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","IBCSG 22-00 Serum Substudy|2005-005666-36|IBCSG 22-00","March 12, 2014","June 2002","null","April 12, 2016","April 2016","No Study Results Posted","null","December 2019","Change from baseline to 18 months in serum VEGF values|Change from baseline to 18 months in serum VCAM-1 values|Change from baseline to 18 months in serum NRP values|Change from baseline to 12 and 36 months in serum VEGF values|Change from baseline to 12 and 36 months in serum VCAM-1 values|Change from baseline to 12 and 36 months in serum NRP values|Change in serum VEGF values from last measurement before progression to measurement at time of confirmatory evidence of progression|Change in serum VCAM-1 values from last measurement before progression to measurement at time of confirmatory evidence of progression|Change in serum NRP values from last measurement before progression to measurement at time of confirmatory evidence of progression","https://ClinicalTrials.gov/show/NCT02393833"
2855,"NCT00311636","Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery","Completed","No Results Available","Breast Cancer","Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: methotrexate|Drug: paclitaxel|Drug: triptorelin|Procedure: adjuvant therapy","Gruppo Italiano Mammella (GIM)|National Cancer Institute (NCI)","Female","18 Years to 45 Years   (Adult)","Phase 3","280","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Supportive Care","GIM-6|CDR0000468839|GIM-PROMISE|EU-20606|GIM-5104","April 5, 2006","September 2003","April 2008","June 25, 2013","April 2008","No Study Results Posted","null","January 2008","Chemotherapy-induced early menopause as measured by follicle-stimulating hormone, 17 beta estradiol levels, and menstrual activity resumption at 1 year following the completion of chemotherapy|Toxicity as measured by Common Toxicity Criteria at each chemotherapy course","https://ClinicalTrials.gov/show/NCT00311636"
2856,"NCT00066417","Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia","Terminated","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Myelodysplastic/Myeloproliferative Diseases","Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: methylprednisolone|Drug: therapeutic allogeneic lymphocytes|Drug: thiotepa|Procedure: allogeneic bone marrow transplantation|Procedure: biological therapy|Procedure: bone marrow ablation with stem cell support|Procedure: bone marrow transplantation|Procedure: chemotherapy|Procedure: leukocyte therapy|Procedure: non-specific immune-modulator therapy|Procedure: peripheral blood lymphocyte therapy|Procedure: peripheral blood stem cell transplantation|Procedure: radiation therapy","National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)","All","10 Years to 50 Years   (Child, Adult)","Phase 2","51","NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000315900|NHLBI-03-H-0209","August 6, 2003","null","January 2007","April 30, 2013","November 2006","No Study Results Posted","null","null","Incidence of graft failure 100 days post-transplant|Incidence of acute and chronic graft-vs-host disease100 days post-transplant|Transplant-related mortality 100 days post-transplant|Disease-free survival 100 days post-transplant|Overall survival 100 days post-transplant","https://ClinicalTrials.gov/show/NCT00066417"
2857,"NCT00265031","HD12 for Advanced Stages","Completed","No Results Available","Hodgkin´s Lymphoma","Drug: Cyclophosphamide|Drug: Adriamycin|Drug: Etoposide|Drug: Procarbazine|Drug: Prednisone|Drug: Vincristine|Drug: Bleomycin|Procedure: radiation therapy","University of Cologne","All","16 Years to 65 Years   (Child, Adult)","Phase 3","null","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","HD12","December 12, 2005","January 1999","null","June 22, 2012","August 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00265031"
2858,"NCT00199004","Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab","Completed","No Results Available","Adult Acute Lymphocytic Leukemia","Drug: Cyclophosphamide|Drug: Dexamethasone / Prednisolone|Drug: Vincristine|Drug: Daunorubicin|Drug: Asparaginase|Drug: Methotrexate|Drug: Cytarabine|Drug: Mercaptopurine|Drug: G-CSF|Drug: Vindesine|Drug: VP16|Drug: Adriamycin|Drug: Thioguanine|Drug: VM26|Drug: Rituximab|Procedure: CNS irradiation|Procedure: Mediastinal irradiation (if residual TU)|Procedure: Stem cell transplantation","Johann Wolfgang Goethe University Hospital","All","15 Years to 65 Years   (Child, Adult)","Phase 4","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GMALL03","September 12, 2005","April 2004","March 2009","August 20, 2010","May 2008","No Study Results Posted","null","March 2009","Remission rate (cytologic, Remission rate (molecular), Remission duration, Disease free survival, Overall survival|Dose and time compliance, Toxicity according to WHO, Death in induction and CR, Course of MRD","https://ClinicalTrials.gov/show/NCT00199004"
2859,"NCT00198978","German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","Unknown status","No Results Available","Adult Acute Lymphocytic Leukemia","Drug: Cyclophosphamide|Drug: Dexamethasone / Prednisolone|Drug: Cytarabine|Drug: Idarubicin|Drug: Granulocyte-Colony-Stimulating Factor|Drug: Mercaptopurine|Drug: Methotrexate|Drug: Rituximab|Drug: HDARAC|Drug: Vincristine|Drug: Depocyte|Drug: Asparaginase","Johann Wolfgang Goethe University Hospital","All","55 Years and older   (Adult, Senior)","Phase 4","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GMALL02","September 12, 2005","January 2003","null","June 4, 2008","June 2008","No Study Results Posted","null","June 2008","Remission rate (cytologic, Remission rate (molecular), Survival time, Duration of Remission, Toxicity (CTC, Treatment realization","https://ClinicalTrials.gov/show/NCT00198978"
2860,"NCT00002905","Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Drug: cyclophosphamide|Drug: didanosine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: mitoxantrone hydrochloride|Drug: prednimustine|Drug: zidovudine","Centro di Riferimento Oncologico - Aviano|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Primary Purpose: Treatment","CDR0000065256|ITA-GICAT-C-941202-3|EU-96059","November 1, 1999","June 1995","null","September 19, 2013","September 2011","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002905"
2861,"NCT00416832","Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: cyclophosphamide|Drug: dacarbazine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: procarbazine hydrochloride|Drug: vincristine sulfate|Radiation: radiation therapy","Christine Mauz-Körholz|Martin-Luther-Universität Halle-Wittenberg","All","up to 17 Years   (Child)","Phase 2","648","Other","Interventional","Primary Purpose: Treatment","CDR0000514355|GPOH-HD-2002|EU-20651","December 27, 2006","November 2002","December 2005","November 17, 2015","November 2015","No Study Results Posted","null","December 2005","Safety and efficacy|Reduction of gonadotoxicity|Quality assurance","https://ClinicalTrials.gov/show/NCT00416832"
2862,"NCT00198991","German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)","Unknown status","No Results Available","Adult Acute Lymphocytic Leukemia","Drug: Cyclophosphamide|Drug: Dexamethasone|Drug: Vincristine|Drug: daunorubicin|Drug: Asparaginase|Drug: Methotrexate|Drug: Cytarabine|Drug: Mercaptopurine|Drug: G-CSF|Drug: Vindesine|Drug: VP16|Drug: Prednisolone|Drug: Adriamycin|Drug: Thioguanine|Drug: VM26|Procedure: CNS irradiation|Procedure: Mediastinal Irradiation|Procedure: Stem cell transplantation|Drug: Idarubicin|Drug: Fludarabine|Drug: Cladribine","Johann Wolfgang Goethe University Hospital|Deutsche Krebshilfe e.V., Bonn (Germany)|German Federal Ministry of Education and Research","All","15 Years to 65 Years   (Child, Adult)","Phase 4","1250","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GMALL01","September 12, 2005","April 2003","null","May 29, 2008","May 2008","No Study Results Posted","null","December 2008","Remission rate, Remission duration, Disease free survival,Overall survival|Time and dose compliance, Realisation of SCT, Toxicity according to WHO, Course of MRD","https://ClinicalTrials.gov/show/NCT00198991"
2863,"NCT00053911","Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer","Terminated","No Results Available","Breast Cancer","Drug: anastrozole|Drug: cyclophosphamide|Drug: docetaxel|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: goserelin acetate|Drug: tamoxifen citrate|Procedure: adjuvant therapy","UNICANCER","Female","18 Years to 65 Years   (Adult)","Phase 3","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","PACS03|FRE-FNCLCC-PACS-03/003|EU-20237","February 5, 2003","November 2002","null","December 14, 2014","December 2014","No Study Results Posted","null","April 2004","Evaluation of the disease free survival|Evaluation of the overall survival","https://ClinicalTrials.gov/show/NCT00053911"
2864,"NCT00002534","Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission","Completed","No Results Available","Leukemia","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cytarabine|Drug: methylprednisolone|Drug: thiotepa|Procedure: allogeneic bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","null","Other|NIH","Interventional","Primary Purpose: Treatment","93-045|CDR0000078464|NCI-H93-0293","November 1, 1999","May 1993","April 2003","June 24, 2013","June 2013","No Study Results Posted","null","April 2003","","https://ClinicalTrials.gov/show/NCT00002534"
2865,"NCT01005758","Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","Unknown status","No Results Available","Leukemia","Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide phosphate|Drug: hydrocortisone sodium succinate|Drug: imatinib mesylate|Drug: mercaptopurine|Drug: methotrexate|Drug: methylprednisolone|Drug: pegaspargase|Drug: prednisolone|Drug: prednisone|Drug: vincristine sulfate|Other: laboratory biomarker analysis|Radiation: radiation therapy","Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 50 Years   (Adult)","Phase 2","180","Other|NIH","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000632144|OSU-08066|2008C0112|DFCI-06254","October 30, 2009","January 2009","null","January 9, 2014","October 2009","No Study Results Posted","null","January 2013","Feasibility of intensification therapy, measured as the percentage of patients who, having achieved a complete remission after induction therapy, receive > 25 weeks of pegaspargase IV as part of intensification therapy|Toxicity|Complete remission rate|Disease-free and overall survival|Prognostic significance of prednisone prophase response, minimal residual disease at various time points, tyrosine kinase mutations, and gene expression profiles at diagnosis","https://ClinicalTrials.gov/show/NCT01005758"
2866,"NCT00574496","Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: gemcitabine hydrochloride|Drug: ifosfamide|Drug: mechlorethamine hydrochloride|Drug: melphalan|Drug: methotrexate|Drug: mycophenolate mofetil|Drug: prednisone|Drug: procarbazine hydrochloride|Drug: vincristine sulfate|Drug: vinorelbine tartrate|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: total-body irradiation","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","13 Years to 65 Years   (Child, Adult)","Phase 2","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","07-147|MSKCC-07147","December 14, 2007","November 2007","November 2018","May 2, 2017","May 2017","No Study Results Posted","null","November 2018","Progression-free survival at 1 year|Survival after 1 year|Failure of neutrophil recovery and/or donor engraftment|Graft versus-host disease measured weekly during the first 100 days of treatment|Transplant-related mortality measured 180 days after transplantation|Disease relapse or progression as measured by CT scan or PET|Immunologic recovery","https://ClinicalTrials.gov/show/NCT00574496"
2867,"NCT00558519","Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","Active, not recruiting","No Results Available","Leukemia","Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: mercaptopurine|Drug: methotrexate|Drug: pegaspargase|Drug: thioguanine|Drug: vincristine sulfate|Radiation: radiation therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","16 Years to 39 Years   (Child, Adult)","Phase 2","300","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CALGB-10403|ECOG C10403|CDR0000574230","November 14, 2007","November 2007","null","January 20, 2017","January 2017","No Study Results Posted","null","June 2017","Complete response rate|Event-free survival|Disease-free survival|Overall survival|Toxicity|Outcomes of adolescent and young adult patients treated on this study compared with those of patients treated per COG-AALL0232|Adherence of adult hematologists/oncologists and their patients to a ""pediatric"" acute lymphoblastic leukemia treatment regimen and identification of reasons for variances|Outcomes of patients treated on this study according to pretreatment characteristics such as age, gender, white blood cell count, other hematologic parameters, blood chemistry, immunophenotype, cytogenetics and molecular genetic characteristics|Analysis and description of the outcomes of patients treated on this study according to baseline psychosocial characteristics, demographics, and family support","https://ClinicalTrials.gov/show/NCT00558519"
2868,"NCT00398554","Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vinblastine sulfate|Drug: vincristine sulfate|Radiation: radiation therapy","Christine Mauz-Körholz|Martin-Luther-Universität Halle-Wittenberg","Male","up to 18 Years   (Child, Adult)","Phase 2","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000514344|GPOH-HD-2002-PILOT-VECOPA|EU-20652|EUDRACT-2004-005244-28","November 9, 2006","June 2005","March 2013","November 17, 2015","November 2015","No Study Results Posted","null","October 2012","Toxicity at days 21 and 42 (+/- 2 days) of treatment|Event-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00398554"
2869,"NCT00131027","High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)","Unknown status","No Results Available","Lymphoblastic Leukemia, Acute","Drug: Cyclophosphamide|Drug: Daunorubicin|Drug: Vincristine|Drug: Prednisolone|Drug: L-asparaginase|Drug: Cytarabine|Drug: Etoposide|Drug: Dexamethasone|Drug: Methotrexate|Drug: Mercaptopurine|Drug: Doxorubicin|Drug: Methotrexate","Japan Adult Leukemia Study Group","All","25 Years to 64 Years   (Adult)","Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","JALSG ALL202-O","August 15, 2005","September 2002","September 2011","November 13, 2008","November 2008","No Study Results Posted","null","March 2011","Disease-free survival|Toxicity|The rate of complete remission","https://ClinicalTrials.gov/show/NCT00131027"
2870,"NCT00006455","Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma","Unknown status","No Results Available","Lymphoma","Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: leucovorin calcium|Drug: methotrexate|Drug: therapeutic hydrocortisone|Drug: vinblastine sulfate","Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","400","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000068133|FRE-IGR-ALCL99|EU-20031|NHL2000/06","November 6, 2000","December 1999","null","August 25, 2011","August 2011","No Study Results Posted","null","null","Event-free survival|Overall survival|Complete remission achieved after treatment course B3 and lasting ≥ 4 weeks|Short- and long-term toxicity|Nonlymphoma related death and early deaths (excluding deaths occurring after second-line treatment for failure or relapse)|CNS relapses","https://ClinicalTrials.gov/show/NCT00006455"
2871,"NCT00002494","Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia","Completed","No Results Available","Leukemia|Lymphoma","Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: leucovorin calcium|Drug: mesna|Drug: methotrexate|Drug: prednisone|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET photon therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","15 Years and older   (Child, Adult, Senior)","Phase 2","134","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-9251|U10CA031946|CLB-9251|CDR0000077643","November 1, 1999","May 1992","January 2006","June 30, 2016","June 2016","No Study Results Posted","null","March 2004","complete response","https://ClinicalTrials.gov/show/NCT00002494"
2872,"NCT02582775","MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs","Recruiting","No Results Available","Epidermolysis Bullosa","Drug: Thymoglobulin|Drug: Cyclophosphamide|Drug: Fludarabine|Radiation: Total Body Irradiation|Procedure: Bone marrow infusion|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Biological: Donor mesenchymal stem cell infusions","Masonic Cancer Center, University of Minnesota","All","up to 25 Years   (Child, Adult)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2015LS076","October 16, 2015","March 2016","September 2022","February 17, 2017","February 2017","No Study Results Posted","null","September 2021","Event-free survival|Percentage change of a patient's iscorEB|Transplant-related mortality|Quality of life|Donor Chimerism in the Skin","https://ClinicalTrials.gov/show/NCT02582775"
2873,"NCT00513188","Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma","Withdrawn","No Results Available","Lymphoma","Biological: denileukin diftitox|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: leucovorin calcium|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate|Genetic: protein expression analysis|Other: flow cytometry|Other: laboratory biomarker analysis","University of Miami","All","18 Years to 65 Years   (Adult)","","0","Other","Interventional","Primary Purpose: Treatment","20060912|SCCC-2006068","August 6, 2007","February 2007","null","December 14, 2016","December 2016","No Study Results Posted","null","June 2008","Failure-free survival|Response rate (CR, CRu, and PR)|Overall survival|Toxicity profile|Correlation of response with CD25 expression","https://ClinicalTrials.gov/show/NCT00513188"
2874,"NCT00365287","Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer","Completed","No Results Available","Breast Cancer|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: radiation therapy|Procedure: umbilical cord blood transplantation","Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI)","All","up to 69 Years   (Child, Adult, Senior)","Phase 1|Phase 2","148","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","2000LS039|MT2000-15","August 16, 2006","June 2000","December 2005","October 9, 2012","October 2012","No Study Results Posted","null","December 2005","Safety as assessed by a non-relapse mortality < 30% within day 100|Hematopoietic recovery and the degree of chimerism at days 21, 60, 100, 180, and 360 after study completion","https://ClinicalTrials.gov/show/NCT00365287"
2875,"NCT00003893","Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: CMF regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: methotrexate|Drug: mitomycin C|Drug: mitoxantrone hydrochloride|Procedure: adjuvant therapy|Radiation: radiation therapy","University Hospital Birmingham|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","2250","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000067062|CRC-TU-BR3015|EU-99005","November 1, 1999","July 1998","April 2006","December 18, 2013","November 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003893"
2876,"NCT00003187","Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma","Completed","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes","Biological: filgrastim|Drug: cyclophosphamide|Drug: cyclosporine|Drug: cytarabine|Drug: methotrexate|Drug: methylprednisolone|Procedure: allogeneic bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation|Radiation: radiation therapy","Virginia Commonwealth University|National Cancer Institute (NCI)","All","up to 55 Years   (Child, Adult)","Phase 2|Phase 3","19","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066016|P30CA016059|MCV-CCHR-9504-2X|DUMC-75951|NCI-G98-1388","May 2, 2000","May 1995","February 2005","February 23, 2010","February 2010","No Study Results Posted","null","February 2005","","https://ClinicalTrials.gov/show/NCT00003187"
2877,"NCT00002582","Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: CMF regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: fluorouracil|Drug: goserelin acetate|Drug: leuprolide acetate|Drug: methotrexate|Drug: tamoxifen citrate|Procedure: oophorectomy|Radiation: radiation therapy","Institute of Cancer Research, United Kingdom|Cancer Research Campaign Clinical Trials Centre|Scottish Cancer Therapy Network|Yorkshire Regional Clinical Trials Research Unit|National Cancer Institute (NCI)","Female","Child, Adult, Senior","Phase 3","6000","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","NCRI-ABC|CDR0000063697|CRC-TU-BR3010|SCTN-BR9401/BR9402|YRCO-ABC|EU-94029|UKCCCR-ABC","November 1, 1999","June 1993","April 2007","August 1, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002582"
2878,"NCT00002542","Tamoxifen in Treating Women With High-Risk Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: CMF regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: methotrexate|Drug: tamoxifen citrate|Radiation: radiation therapy","NCIC Clinical Trials Group|Canadian Cancer Trials Group","Female","up to 120 Years   (Child, Adult, Senior)","Phase 3","800","Other","Interventional","Allocation: Randomized|Masking: Double-Blind|Primary Purpose: Treatment","MA12|CAN-NCIC-MA12|NCI-V93-0323|CDR0000063224","November 1, 1999","July 1993","January 2011","March 21, 2016","January 2011","No Study Results Posted","null","January 2011","","https://ClinicalTrials.gov/show/NCT00002542"
2879,"NCT00589563","Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer","Completed","Has Results","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Precancerous Condition|Secondary Myelofibrosis|Small Intestine Cancer","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Drug: methotrexate|Drug: sirolimus|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: hematopoietic stem cell transplantation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation","City of Hope Medical Center|National Cancer Institute (NCI)","All","2 Years and older   (Child, Adult, Senior)","Phase 2","32","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","06141|P30CA033572|CHNMC-06141|CDR0000579340","December 21, 2007","May 2007","February 2012","September 3, 2014","September 2014","July 21, 2014","null","February 2012","Cumulative Incidence of Grade II-IV Acute Graft-Versus-Host Disease (GVHD) at Day 100|Severity of Acute GVHD|Cumulative Incidence of Chronic GVHD|Severity of Chronic GVHD|Time to Absolute Neutrophil Count Recovery (Engraftment)|Time to Platelet Count Recovery (Engraftment)|Occurence of Infections Including Cytomegalovirus and Epstein-Barr Virus Reactivation|Occurrence of Thrombotic Microangiopathy|Occurence of Sinusoidal Obstructive Syndrome (SOS)|Non-relapse Mortality at 100 Days Post HSCT|Non-relapse Mortality at Two Years Post HSCT|Overall Survival at Two Years Post HSCT|Event Free Survival at Two Years Post HSCT|Incidence of Disease Relapse/Progression at 2 Years Post HSCT","https://ClinicalTrials.gov/show/NCT00589563"
2880,"NCT00494897","PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia","Completed","No Results Available","Acute Lymphoblastic Leukemia","Drug: Asparaginase|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Daunorubicin|Drug: Mercaptopurine|Drug: Prednisone|Drug: Vincristine|Drug: Methotrexate|Procedure: Intrathecally treatment","PETHEMA Foundation","All","15 Years and older   (Child, Adult, Senior)","Phase 4","374","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LAL-RI/96","June 29, 2007","June 1996","December 2007","May 15, 2009","May 2009","No Study Results Posted","null","May 2007","Efficacy of treatment in adults with standard risk acute lymphoblastic leukemia|Demonstrate that in this group of patients, the CNS relapse is not frequently and is not necessary cranial radiotherapy|To evaluate the treatment tolerance","https://ClinicalTrials.gov/show/NCT00494897"
2881,"NCT00199095","Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia","Completed","No Results Available","Adult Acute Lymphocytic Leukemia","Drug: Adriamycin|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone|Drug: Idarubicin|Drug: Ifosfamide|Drug: Methotrexate|Drug: Mercaptopurine|Drug: VM26|Drug: Vincristine","Johann Wolfgang Goethe University Hospital","All","65 Years and older   (Adult, Senior)","Phase 4","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GMALL11","September 12, 2005","February 1997","null","May 16, 2008","May 2008","No Study Results Posted","null","null","Results of induction therapy,Distribution of entry criteria,Treatment feasibility,Relapse rate and localisation,Death in CR,Remission duration, survival and leukemia free survival,Prognostic factors,Quality of life","https://ClinicalTrials.gov/show/NCT00199095"
2882,"NCT00165139","Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas","Completed","No Results Available","Neuroblastoma|Ewings Sarcoma|Non-rhabdomyosarcoma Soft Tissue Sarcoma","Drug: Vincristine|Drug: Cyclophosphamide|Drug: Adriamycin|Drug: Etoposide (VP-16)|Drug: Cisplatin|Drug: Carboplatin|Drug: Melphalan|Drug: Ifosfamide|Drug: G-CSF (granulocyte-colony stimulating factor)|Drug: Mesna","Dana-Farber Cancer Institute|Boston Children’s Hospital|Children's Hospital of Philadelphia","All","up to 19 Years   (Child, Adult)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","94-131","September 9, 2005","January 1996","February 2009","October 30, 2009","October 2009","No Study Results Posted","null","November 2000","To determine the toxicity and feasibility of double dose chemo-radiotherapy with blood progenitor cell rescue in this patient population.","https://ClinicalTrials.gov/show/NCT00165139"
2883,"NCT00041288","Comparison of Fludarabine Plus Total-Body Irradiation With Combination Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia","Unknown status","No Results Available","Leukemia|Lymphoma","Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: methotrexate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Simmons Cancer Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000069462|UTSMC-0501228|AMGEN-UTSMC-0501228|IBMTR-SC-00-02.1|ROCHE-UTSMC-0501228|SPRI-UTSMC-0501228|NCI-V02-1706","July 8, 2002","October 2001","null","February 6, 2009","March 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00041288"
2884,"NCT00019409","Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia","Withdrawn","No Results Available","Leukemia","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate|Radiation: radiation therapy","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","1 Year to 20 Years   (Child, Adult)","Phase 3","0","NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","999998007|98-C-N007|MCP943|NCI-0H98-C-N007|CDR0000066120","July 11, 2001","October 1999","July 2001","March 21, 2012","March 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00019409"
2885,"NCT00006451","Bone Marrow Transplantation in Treating Patients With Leukemia","Withdrawn","No Results Available","Graft Versus Host Disease|Leukemia|Lymphoma","Drug: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Drug: methylprednisolone|Procedure: allogeneic bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation|Procedure: radiation therapy","Masonic Cancer Center, University of Minnesota","All","up to 45 Years   (Child, Adult)","Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1996LS142|UMN-MT-9506","November 6, 2000","April 1996","November 2000","November 6, 2012","November 2012","No Study Results Posted","null","November 2000","","https://ClinicalTrials.gov/show/NCT00006451"
2886,"NCT00005987","Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma","Terminated","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Drug: carmustine|Drug: cyclophosphamide|Drug: dexamethasone|Drug: etoposide|Drug: filgrastim|Drug: mitoxantrone hydrochloride|Drug: recombinant interferon alfa|Drug: sargramostim|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Procedure: radiation therapy","Masonic Cancer Center, University of Minnesota","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","87","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","1996LS137|UMN-MT-9216|UMN-MT-1992-16","July 5, 2000","August 2000","July 2003","October 9, 2012","October 2012","No Study Results Posted","null","July 2003","","https://ClinicalTrials.gov/show/NCT00005987"
2887,"NCT00003671","Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: thioguanine|Drug: vincristine sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","Phase 2","59","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9705|POG-9705|CDR0000066768","November 1, 1999","December 1998","February 2009","July 24, 2014","July 2014","No Study Results Posted","null","November 2002","Event-free survival","https://ClinicalTrials.gov/show/NCT00003671"
2888,"NCT00290628","Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer","Terminated","No Results Available","Chronic Myeloproliferative Disorders|Diamond-blackfan Anemia|Fanconi Anemia|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Drug: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: filgrastim|Drug: melphalan|Drug: methylprednisolone|Drug: mycophenolate mofetil|Procedure: radiation therapy|Procedure: umbilical cord blood transplantation","Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI)","All","up to 45 Years   (Child, Adult)","","43","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","2000LS017|UMN-MT1999-28","February 9, 2006","October 1999","April 2007","October 9, 2012","October 2012","No Study Results Posted","null","April 2007","","https://ClinicalTrials.gov/show/NCT00290628"
2889,"NCT00003662","Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases","Completed","No Results Available","Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes|Thymic Carcinoma","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: melphalan|Drug: methylprednisolone|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","90","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066755|P30CA016056|RPCI-RP-9803|NCI-G98-1486","November 1, 1999","August 1998","January 2001","March 3, 2011","March 2011","No Study Results Posted","null","January 2001","","https://ClinicalTrials.gov/show/NCT00003662"
2890,"NCT00003336","Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: melphalan|Drug: methylprednisolone|Procedure: bone marrow ablation with stem cell support|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","up to 55 Years   (Child, Adult)","Phase 2","6","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CWRU5Y97|P30CA043703|CASE-CWRU-5Y97|NCI-G98-1431|CASE-5Y97","November 1, 1999","January 1998","February 2006","June 10, 2010","June 2010","No Study Results Posted","null","December 2005","Event-free survival by disease assessment|Umbilical cord blood donor engraftment by chimerism and complete blood count (CBC) at time of myeloid recovery.","https://ClinicalTrials.gov/show/NCT00003336"
2891,"NCT00199082","Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults","Completed","No Results Available","Burkitt's Lymphoma|Burkitt's Leukemia|Mediastinal Neoplasms|Lymphoblastic Lymphoma|Large Cell Anaplastic Lymphoma","Drug: Adriamycin|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone/Prednisolone|Drug: VP16|Drug: Ifosfamide|Drug: Methotrexate|Drug: G-CSF|Drug: Rituximab|Drug: Vincristine/Vindesine|Procedure: Irradiation (in specific conditions)","Nicola Goekbuget|Johann Wolfgang Goethe University Hospital","All","15 Years to 65 Years   (Child, Adult)","Phase 4","650","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GMALL05","September 12, 2005","July 2002","June 2010","August 4, 2016","August 2016","No Study Results Posted","null","June 2010","Remission rate|Remission duration|Disease free survival|Overall survival|Dose and time compliance|Toxicity according to National Cancer Institute (NCI)-Common Toxicity Criteria (CTC)|Death under therapy and in complete remission (CR)|Localisations of relapse","https://ClinicalTrials.gov/show/NCT00199082"
2892,"NCT00199017","German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults","Completed","No Results Available","Lymphoma, Lymphoblastic","Drug: Dexamethasone/Prednisolone|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Daunorubicin|Drug: Asparaginase|Drug: G-CSF|Drug: Mercaptopurine|Drug: Cytarabine|Drug: Methotrexate|Drug: VP16|Drug: Vindesine|Drug: Adriamycin|Drug: Thioguanine|Drug: HDARAC|Procedure: CNS irradiation|Procedure: Mediastinal irradiation|Drug: Cladribine","Johann Wolfgang Goethe University Hospital","All","15 Years to 65 Years   (Child, Adult)","Phase 4","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GMALL04","September 12, 2005","April 2004","null","August 20, 2010","May 2008","No Study Results Posted","null","March 2009","remission rate, remission duration, disease free survival, overall survival|time and dose compliance, toxicity according to World Health Organization (WHO)","https://ClinicalTrials.gov/show/NCT00199017"
2893,"NCT00130195","Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)","Completed","No Results Available","Acute Lymphoblastic Leukemia","Drug: imatinib|Drug: cyclophosphamide|Drug: daunorubicin|Drug: vincristine|Drug: prednisolone|Drug: methotrexate|Drug: cytarabine|Drug: dexamethasone","Japan Adult Leukemia Study Group","All","15 Years to 64 Years   (Child, Adult)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JALSG Ph+ALL202","August 12, 2005","September 2002","May 2008","November 13, 2008","November 2008","No Study Results Posted","null","February 2008","The rate of complete remission|The duration of remission|Overall survival|Toxicity caused by combination of imatinib and chemotherapy","https://ClinicalTrials.gov/show/NCT00130195"
2894,"NCT00061945","Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia","Completed","Has Results","Acute Undifferentiated Leukemia|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|L1 Adult Acute Lymphoblastic Leukemia|L1 Childhood Acute Lymphoblastic Leukemia|L2 Adult Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia","Drug: allopurinol|Drug: cyclophosphamide|Drug: daunorubicin hydrochloride|Drug: vincristine sulfate|Drug: dexamethasone|Drug: asparaginase|Biological: filgrastim|Drug: imatinib mesylate|Drug: methotrexate|Drug: cytarabine|Drug: trimethoprim-sulfamethoxazole|Drug: mercaptopurine|Drug: leucovorin calcium|Biological: alemtuzumab|Drug: acyclovir|Other: laboratory biomarker analysis|Other: pharmacological study","National Cancer Institute (NCI)","All","15 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","302","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-02807|CDR302482|CALGB 10102|CALGB-10102|U10CA031946","June 5, 2003","June 2003","October 2012","March 20, 2014","December 2013","December 5, 2013","null","December 2007","Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)|Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)|Modulation of Minimal Residual Disease During Treatment With Alemtuzumab (Phase II)|Disease-free Survival (Phase II)|Overall Survival (Phase II)","https://ClinicalTrials.gov/show/NCT00061945"
2895,"NCT00002987","Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease","Unknown status","No Results Available","Lymphoma","Biological: bleomycin sulfate|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisolone|Drug: vincristine sulfate|Radiation: radiation therapy","Medical Research Council|National Cancer Institute (NCI)","All","16 Years to 75 Years   (Child, Adult, Senior)","Phase 3","400","Other","Interventional","Primary Purpose: Treatment","CDR0000065522|MRC-UKLG-LY07|EU-97004","November 1, 1999","January 1997","null","December 3, 2013","March 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002987"
2896,"NCT00002516","Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma","Unknown status","No Results Available","Sarcoma","Biological: dactinomycin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: mesna|Drug: vincristine sulfate|Procedure: conventional surgery|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET photon therapy","University Hospital Muenster|Medical Research Council|National Cancer Institute (NCI)","All","up to 35 Years   (Child, Adult)","Phase 3","null","Other","Interventional","Primary Purpose: Treatment","CDR0000078196|GER-GPOH-EICESS-92|MRC-EICESS-92|EU-92030|EU-205116|UKCCSG-ET1993-02","November 1, 1999","July 1992","null","September 16, 2013","January 2010","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002516"
2897,"NCT00199056","German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)","Completed","No Results Available","Adult Acute Lymphocytic Leukemia","Drug: Dexamethasone / Prednisolone|Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Vincristine / Vindesine|Drug: Daunorubicin|Drug: Asparaginase|Drug: G-CSF|Drug: Cytarabine|Drug: 6-Mercaptopurine|Drug: VP16|Drug: Adriamycin|Drug: Thioguanine|Drug: VM26|Drug: Idarubicin|Drug: Fludarabine|Drug: Ifosfamide|Procedure: CNS irradiation|Procedure: Mediastinal irradiation (if residual tumor)|Procedure: stem cell transplantation","Johann Wolfgang Goethe University Hospital","All","15 Years to 65 Years   (Child, Adult)","Phase 4","225","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GMALL10","September 12, 2005","October 1999","null","May 16, 2008","May 2008","No Study Results Posted","null","null","Remission rate,Remission duration,Disease free survival,Overall survival|Time and dose compliance,Realisation of SCT,Toxicity according to WHO,Course of MRD","https://ClinicalTrials.gov/show/NCT00199056"
2898,"NCT00003423","Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: etoposide|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisolone|Drug: thioguanine|Drug: vincristine sulfate","United Kingdom Children's Cancer Study Group|National Cancer Institute (NCI)","All","up to 14 Years   (Child)","Phase 3","100","Other","Interventional","Primary Purpose: Treatment","CDR0000066443|UKCCSG-NHL-9503|EU-98012","November 1, 1999","May 1995","null","December 18, 2013","April 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003423"
2899,"NCT00002701","Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia","Unknown status","No Results Available","Leukemia","Drug: busulfan|Drug: cyclophosphamide|Drug: cytarabine|Drug: etoposide|Drug: idarubicin|Drug: mercaptopurine|Drug: methotrexate|Drug: mitoxantrone hydrochloride|Drug: thioguanine|Drug: tretinoin|Procedure: allogeneic bone marrow transplantation|Procedure: autologous bone marrow transplantation|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC|Gruppo Italiano Malattie EMatologiche dell'Adulto|National Cancer Institute (NCI)","All","16 Years to 74 Years   (Child, Adult, Senior)","Phase 3","750","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000064499|EORTC-06952|ITA-GIMEMA-AIEOP-1","November 1, 1999","October 1995","null","September 19, 2013","November 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002701"
2900,"NCT00002676","Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: methotrexate|Drug: vincristine sulfate|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET photon therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","36","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCCTG-937351|E-N9371|CDR0000064319","November 1, 1999","July 1995","October 2006","July 12, 2016","July 2016","No Study Results Posted","null","October 2006","Response rate|Overall survival","https://ClinicalTrials.gov/show/NCT00002676"
2901,"NCT00004255","Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation","Completed","No Results Available","Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methylprednisolone|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation|Radiation: radiation therapy","Chimeric Therapies|National Cancer Institute (NCI)","All","12 Years to 50 Years   (Child, Adult)","Phase 2|Phase 3","null","Industry","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CHIMERIC-HM01|CDR0000067502|WSU-10-02-99-M01-FB","January 28, 2000","March 2000","May 2003","July 9, 2013","February 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004255"
2902,"NCT01569204","Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma","Active, not recruiting","No Results Available","Hodgkin Lymphoma","Drug: Etoposide|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Prednisone|Drug: Procarbazine|Drug: Dexamethasone|Drug: Dacarbazine|Drug: Brentuximab Vedotin","University of Cologne","All","18 Years to 60 Years   (Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","Targeted BEACOPP","April 2, 2012","October 2012","December 2017","May 10, 2017","May 2017","No Study Results Posted","null","March 2014","Response rate (RR) after six cycles of chemotherapy|Complete remission rate (CR/CRr) as final treatment outcome after completion of treatment|Progression Free Survival (PFS)|Overall survival (OS)|Adverse event rate|Dose reduction rate|Relative dose intensity","https://ClinicalTrials.gov/show/NCT01569204"
2903,"NCT01156883","Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia","Active, not recruiting","No Results Available","Leukemia","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: ifosfamide|Drug: mercaptopurine|Drug: methotrexate|Drug: methylprednisolone|Drug: prednisone|Drug: thioguanine|Drug: vincristine sulfate|Drug: vindesine","Gruppo Italiano Malattie EMatologiche dell'Adulto","All","18 Years to 34 Years   (Adult)","","30","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","LAL1308|GIMEMA-LAL1308|EU-21042","July 2, 2010","April 2010","February 2017","February 16, 2017","February 2017","No Study Results Posted","LAL1308","November 2014","Treatment feasibility|Disease free survival|Event free survival|Overal survival|Toxicity|Compliance","https://ClinicalTrials.gov/show/NCT01156883"
2904,"NCT01117441","International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia","Active, not recruiting","No Results Available","Leukemia","Drug: PEG-L-asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: thioguanine|Drug: vincristine sulfate|Drug: vindesine|Drug: daunoxome|Drug: fludarabine|Radiation: Radiation Therapy","University of Schleswig-Holstein|Deutsche Krebshilfe e.V., Bonn (Germany)","All","1 Year to 18 Years   (Child, Adult)","Phase 3","4750","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: No masking|Primary Purpose: Treatment","AIEOP-BFM ALL 2009","May 3, 2010","June 2010","December 2021","January 19, 2017","January 2017","No Study Results Posted","null","December 2021","Event-free survival|Disease-free survival|minimal residual disease (MRD)|survival|treatment-related mortality|adverse events|event-free survival|minimal residual disease","https://ClinicalTrials.gov/show/NCT01117441"
2905,"NCT00764907","Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia","Unknown status","No Results Available","Leukemia","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: thioguanine|Drug: vincristine sulfate|Drug: vindesine","University Hospital, Motol|National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","Phase 3","4000","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000613220|MOTOL-ALL-IC-BFM-2002|EU-20871","October 1, 2008","November 2002","null","July 7, 2009","July 2009","No Study Results Posted","null","October 2007","Disease-free survival|Event-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00764907"
2906,"NCT00669812","High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma","Unknown status","No Results Available","Lymphoma|Small Intestine Cancer","Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: melphalan|Drug: methotrexate|Drug: prednisolone|Drug: vincristine sulfate|Procedure: autologous hematopoietic stem cell transplantation|Procedure: biopsy|Procedure: peripheral blood stem cell transplantation","Cancer Research UK|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000593564|CRUK-2005-003906-27|CRUK-BRD/05/93","April 30, 2008","February 2008","null","August 23, 2013","November 2008","No Study Results Posted","null","null","Survival at 1 year|Toxicity","https://ClinicalTrials.gov/show/NCT00669812"
2907,"NCT00430118","Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: thioguanine|Drug: vincristine sulfate|Drug: vindesine|Radiation: radiation therapy","University of Schleswig-Holstein","All","1 Year to 18 Years   (Child, Adult)","Phase 3","4559","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000528029|ALL-BFM-2000|EU-20682","January 30, 2007","July 2000","January 2012","May 28, 2013","May 2013","No Study Results Posted","null","January 2012","Efficacy of dexamethasone vs prednisone during the induction phase|Event-free survival (EFS) and overall survival after initial remission in intermediate-risk and high-risk patients|Safety and efficacy of treatment reduction during reintensification in standard-risk patients|EFS after second delayed reintensification in intermediate-risk patients|Outcome after extended reintensification therapy in high-risk patients","https://ClinicalTrials.gov/show/NCT00430118"
2908,"NCT00400946","Treatment of Acute Lymphoblastic Leukemia in Children","Unknown status","No Results Available","Drug/Agent Toxicity by Tissue/Organ|Leukemia","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: methylprednisolone|Drug: pegaspargase|Drug: prednisolone|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate|Radiation: radiation therapy","Dana-Farber Cancer Institute|National Cancer Institute (NCI)","All","1 Year to 17 Years   (Child)","Phase 3","800","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","05-001 / CDR0000513019|P01CA068484|P30CA006516|DFCI-05001","November 16, 2006","April 2005","June 2015","March 17, 2015","March 2015","No Study Results Posted","null","June 2015","Toxicity of pegasparaginase vs E. coli asparaginase|Efficacy of pegasparaginase vs E. coli asparaginase|Prognostic significance of asparaginase antibody formation|Correlation of trough enzyme levels with outcome (toxicity and relapse)|Quality of life|Comparison of trough serum asparaginase enzyme levels, asparagine levels, and anti-asparaginase antibody levels|Rate of infections (episodes of bacteremia and disseminated fungal infections) during the remission induction phase of combination chemotherapy|Prognostic significance of response to remission induction chemotherapy as measured by morphology and minimal residual disease (MRD)|Outcome based on MRD status after 28 days of multiagent chemotherapy that intensifies treatment for B-lineage patients with MRD levels > 0.001 at the end of remission induction therapy|Outcome based on MRD status after 14 days of multiagent chemotherapy, every 18 weeks after achieving complete remission, and at the completion of all chemotherapy|Comparison of the outcome of patients (based on bone marrow morphology after 14 days of multiagent chemotherapy) with M2/M3 status vs M1 status or hypoplastic marrows|Efficacy of CNS-directed treatment|CNS-related toxicity of CNS-directed treatment|Relationship between dietary intake and rate of infections and risk of development of fractures during treatment","https://ClinicalTrials.gov/show/NCT00400946"
2909,"NCT00343369","Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia","Unknown status","No Results Available","Leukemia","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: mercaptopurine|Drug: methotrexate|Drug: pegaspargase|Drug: prednisolone|Drug: teniposide|Drug: thioguanine|Drug: vincristine sulfate|Radiation: radiation therapy","Universitätsklinikum Hamburg-Eppendorf|National Cancer Institute (NCI)","All","1 Year to 18 Years   (Child, Adult)","","550","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000455738|GER-COALL-07-03|EU-205104","June 22, 2006","January 2003","null","August 23, 2013","June 2006","No Study Results Posted","null","null","Dose of daunorubicin hydrochloride that is equivalent to 30 mg/m² of doxorubicin hydrochloride|Reduce therapy in low-risk patients without loss of efficacy|Reduce neurological complications|Reduce allergic reactions against asparaginase","https://ClinicalTrials.gov/show/NCT00343369"
2910,"NCT00275106","Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma","Terminated","No Results Available","Lymphoma","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisolone|Drug: thioguanine|Drug: vincristine sulfate|Procedure: radiation therapy","Children's Cancer and Leukaemia Group|European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","600","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CCLG-NHL-2004-08|CDR0000454508|EU-20598|CCLG-EURO-LIB-02|EICNHL-ERURO-LB02|EUDRACT-2004-0011861-17","January 10, 2006","September 2004","August 2012","July 9, 2013","April 2008","No Study Results Posted","null","December 2009","Conditional event-free survival|Overall survival|Acute and long-term toxicity|Non-lymphoma-related deaths and early deaths (excluding deaths occurring after second line treatment for failure or relapse)","https://ClinicalTrials.gov/show/NCT00275106"
2911,"NCT00040690","Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia","Completed","No Results Available","Leukemia|Lymphoma","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: leucovorin calcium|Drug: methotrexate|Drug: vincristine sulfate|Radiation: radiation therapy","Medical Research Council|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 2","120","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000069374|MRC-LY10|EU-20117","July 8, 2002","November 2008","December 2008","December 18, 2013","May 2007","No Study Results Posted","null","null","Progression-free survival|Survival time","https://ClinicalTrials.gov/show/NCT00040690"
2912,"NCT00022126","Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia","Drug: asparaginase|Drug: cyclophosphamide|Drug: cyclosporine|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: mercaptopurine|Drug: methotrexate|Drug: methylprednisolone|Drug: pegaspargase|Drug: thioguanine|Drug: vincristine sulfate|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 1 Year   (Child)","Phase 2","6","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AALL01P1|COG-AALL01P1|CDR0000068787","August 10, 2001","November 2002","April 2006","February 18, 2014","February 2014","No Study Results Posted","null","January 2005","Establish whether the CCG Augmented Regimen (AR) can be successfully administered in the infant age group|Grade 3 or 4 non-hematologic toxicity rates|Event-free survival","https://ClinicalTrials.gov/show/NCT00022126"
2913,"NCT00018954","Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma","Completed","No Results Available","Leukemia|Lymphoma","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate|Procedure: conventional surgery|Radiation: radiation therapy","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","null","NIH","Interventional","Primary Purpose: Treatment","CDR0000077227|NCI-92-C-0030|NCI-T91-0259N|OH92-C-0030","July 11, 2001","October 1992","October 2002","February 16, 2012","February 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00018954"
2914,"NCT00005603","Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: thioguanine|Drug: vincristine sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 3","276","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","9906|COG-P9906|POG-9906|CDR0000067722","May 2, 2000","March 2000","null","February 18, 2014","February 2014","No Study Results Posted","null","September 2005","Augmented Berlin Frankfurt Muenster (BFM) therapy is superior to ALinC 14/15 therapy","https://ClinicalTrials.gov/show/NCT00005603"
2915,"NCT00003728","Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Leukemia|Lymphoma","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: methylprednisolone|Drug: mitoxantrone hydrochloride|Drug: prednisolone|Drug: therapeutic hydrocortisone|Drug: thioguanine|Drug: vincristine sulfate|Drug: vindesine|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI)","All","up to 17 Years   (Child)","Phase 3","1500","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066840|EORTC-58951","November 1, 1999","December 1998","null","January 20, 2011","June 2009","No Study Results Posted","null","May 2008","Event-free survival after first randomization|Disease-free survival after second and third randomization|Overall survival|Response to prephase as assessed by number of blasts/mm³ in peripheral blood (< 1,000 vs ≥ 1,000) after randomization|Response as assessed by bone marrow (BM) blasts after first randomization, at evaluation of prephase, and on day 15 of induction|Toxicity and long-term toxicity as assessed by CTC v2","https://ClinicalTrials.gov/show/NCT00003728"
2916,"NCT00003650","Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: etoposide|Drug: mercaptopurine|Drug: methotrexate|Drug: methylprednisolone|Drug: mitoxantrone hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","UNICANCER|National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","Phase 3","200","Other","Interventional","Primary Purpose: Treatment","CDR0000066742|FNCLCC-SFOP-96006-LMT-96|EU-98049","November 1, 1999","June 1998","null","January 20, 2011","March 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003650"
2917,"NCT00003437","Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia","Unknown status","No Results Available","Leukemia","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: mercaptopurine|Drug: methotrexate|Drug: pegaspargase|Drug: prednisolone|Drug: thioguanine|Drug: vincristine sulfate|Radiation: radiation therapy","Medical Research Council|National Cancer Institute (NCI)","All","1 Year to 18 Years   (Child, Adult)","Phase 3","1800","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066464|MRC-LEUK-ALL97|EU-97032","November 1, 1999","January 1997","null","December 3, 2013","February 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003437"
2918,"NCT00003013","Chemotherapy Plus Surgery in Treating Women With Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: CMF regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: fluorouracil|Drug: methotrexate|Drug: paclitaxel|Drug: tamoxifen citrate|Procedure: conventional surgery|Radiation: radiation therapy","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|National Cancer Institute (NCI)","Female","18 Years to 70 Years   (Adult, Senior)","Phase 3","450","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065593|INT-23/96|EU-97001","November 1, 1999","October 1996","March 2009","September 16, 2013","June 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003013"
2919,"NCT00002865","High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: leucovorin calcium|Drug: mesna|Drug: methotrexate|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET photon therapy","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","25","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000065137|CCCWFU-21195|NCI-V96-1062","November 1, 1999","April 1995","August 2001","January 12, 2017","September 2015","No Study Results Posted","null","June 2000","response rate for patients with relapsed or refractory acute lymphoblastic leukemia after brief, high intensity chemotherapy|evaluate adverse events after brief, high intensity chemotherapy","https://ClinicalTrials.gov/show/NCT00002865"
2920,"NCT00002700","Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia|Lymphoma","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: mitoxantrone hydrochloride|Drug: prednisolone|Drug: prednisone|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate|Procedure: allogeneic bone marrow transplantation|Procedure: autologous bone marrow transplantation|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC|Acute Leukemia French Association","All","15 Years to 60 Years   (Child, Adult)","Phase 3","392","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-06951|FRE-LALA-94","November 1, 1999","August 1995","null","June 11, 2013","June 2013","No Study Results Posted","null","March 2004","","https://ClinicalTrials.gov/show/NCT00002700"
2921,"NCT00002665","SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia","Completed","No Results Available","Leukemia|Neutropenia|Thrombocytopenia","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: thioguanine|Drug: vincristine sulfate|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","Southwest Oncology Group|National Cancer Institute (NCI)","All","15 Years to 65 Years   (Child, Adult)","Phase 2","50","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","SWOG-9400|U10CA032102","November 1, 1999","July 1995","December 2003","March 5, 2015","March 2015","No Study Results Posted","null","December 2001","response","https://ClinicalTrials.gov/show/NCT00002665"
2922,"NCT00002590","Combination Chemotherapy in Treating Children With Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: pegaspargase|Drug: prednisone|Drug: thioguanine|Drug: vincristine sulfate|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 20 Years   (Child, Adult)","Phase 2","221","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","5941|CCG-5941|CDR0000063751","November 1, 1999","July 1994","March 2007","July 23, 2014","July 2014","No Study Results Posted","null","March 2001","Estimate toxicity and feasibility of 11 month multiagent chemotx|Provide preliminary data for a future phase III study|Investigate the biology of lymphoblastic lymphoma|Obtain preliminary data on treatment of anaplastic large cell","https://ClinicalTrials.gov/show/NCT00002590"
2923,"NCT00002531","Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia","Unknown status","No Results Available","Leukemia","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: mitoxantrone hydrochloride|Drug: prednisolone|Drug: teniposide|Drug: thioguanine|Drug: vincristine sulfate|Drug: vindesine|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Johann Wolfgang Goethe University Hospital|National Cancer Institute (NCI)","All","15 Years to 65 Years   (Child, Adult)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000078421|GER-GMALL-ALL-05/93|EU-93002","November 1, 1999","January 1993","null","September 16, 2013","December 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002531"
2924,"NCT00002471","Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma","Completed","No Results Available","Leukemia|Lymphoma","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: methylprednisolone|Drug: therapeutic hydrocortisone|Drug: thiotepa|Drug: vincristine sulfate","Memorial Sloan Kettering Cancer Center","All","Child, Adult, Senior","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","90-013|CDR0000076672|NYU-97-9|NCI-V90-0104","November 1, 1999","February 1990","January 2003","June 19, 2013","June 2013","No Study Results Posted","null","January 2003","","https://ClinicalTrials.gov/show/NCT00002471"
2925,"NCT01027000","Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","Active, not recruiting","Has Results","Leukemia|Lymphoma","Biological: rituximab|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methotrexate|Drug: sirolimus|Drug: tacrolimus|Procedure: allogeneic stem cell transplant","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Genentech, Inc.|Biologics, Inc.","All","18 Years to 69 Years   (Adult, Senior)","Phase 2","68","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CALGB 100701|CDR0000660555|U10CA031946|NCI-2011-01995","December 4, 2009","February 2010","null","March 23, 2017","March 2017","March 23, 2017","null","January 2016","2-year Progression-free Survival in Early Disease Participants|Response|Acute Graft-vs-host Disease (GVHD)|Chronic GVHD|Treatment-related Mortality|Overall Survival|Chimerism for CD3","https://ClinicalTrials.gov/show/NCT01027000"
2926,"NCT00253552","G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders","Terminated","No Results Available","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Sarcoma","Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: etoposide|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","up to 24 Years   (Child, Adult)","","4","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000445188|OHSU-HEM-04007-L|OHSU-1381","November 11, 2005","May 2004","May 2006","May 24, 2012","June 2010","No Study Results Posted","null","May 2006","","https://ClinicalTrials.gov/show/NCT00253552"
2927,"NCT00006056","Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders","Unknown status","No Results Available","Chediak-Higashi Syndrome|Graft Versus Host Disease|X-Linked Lymphoproliferative Syndrome|Familial Erythrophagocytic Lymphohistiocytosis|Hemophagocytic Lymphohistiocytosis|Virus-Associated Hemophagocytic Syndrome","Drug: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: etoposide|Drug: filgrastim|Drug: methotrexate|Procedure: allogeneic hematopoietic stem cell transplantation","Fairview University Medical Center|Office of Rare Diseases (ORD)","All","up to 55 Years   (Child, Adult)","","40","Other","Interventional","Primary Purpose: Treatment","199/15106|UMN-MT-1997-08|UMN-MT-9708","July 5, 2000","March 2000","null","June 23, 2005","October 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006056"
2928,"NCT00005852","Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant","Terminated","No Results Available","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Biological: filgrastim|Biological: muromonab-CD3|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methylprednisolone|Procedure: allogeneic bone marrow transplantation","H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)","All","15 Years to 55 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","MCC-11309|MCC-IRB-4251|NCI-G00-1791","June 2, 2000","June 1996","July 2007","December 10, 2012","December 2012","No Study Results Posted","null","July 2007","","https://ClinicalTrials.gov/show/NCT00005852"
2929,"NCT00003913","Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease","Completed","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: methylprednisolone|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)","All","up to 18 Years   (Child, Adult)","Phase 2","390","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","1330.00|FHCRC-1330.00|UMN-MT-9817|NCI-G99-1523|CDR0000067092","November 1, 1999","December 1998","August 2005","March 31, 2010","March 2010","No Study Results Posted","null","August 2005","","https://ClinicalTrials.gov/show/NCT00003913"
2930,"NCT01020734","Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission","Completed","No Results Available","Leukemia","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: methotrexate|Procedure: allogeneic hematopoietic stem cell transplantation","Asan Medical Center","All","15 Years to 75 Years   (Child, Adult, Senior)","Phase 2","263","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000659891|AMC-UUCM-2009-0579","November 24, 2009","May 2011","July 2015","December 29, 2015","December 2015","No Study Results Posted","null","July 2015","Efficacy of the treatment measured in terms of frequency of relapse and duration of remission|Engraftment|Acute and chronic graft-versus-host disease|Treatment-related mortality|Leukemia-free survival and overall survival","https://ClinicalTrials.gov/show/NCT01020734"
2931,"NCT00032149","Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: bleomycin sulfate|Biological: filgrastim|Drug: cyclophosphamide|Drug: etoposide|Drug: mitoxantrone hydrochloride|Drug: prednisolone|Drug: vincristine sulfate","Lymphoma Trials Office|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Other","Interventional","Primary Purpose: Treatment","CDR0000069261|BNLI-GOODRISKHIV|EU-20144","March 8, 2002","October 2001","null","September 19, 2013","March 2007","No Study Results Posted","null","null","Toxicity|Effects of treatment on response rate, time to disease progression, and survival","https://ClinicalTrials.gov/show/NCT00032149"
2932,"NCT00006054","Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies","Terminated","No Results Available","Immunologic Deficiency Syndromes|Chediak-Higashi Syndrome|Common Variable Immunodeficiency|Graft Versus Host Disease|X-Linked Lymphoproliferative Syndrome|Familial Erythrophagocytic Lymphohistiocytosis|Hemophagocytic Lymphohistiocytosis|X-linked Agammaglobulinemia|Wiskott-Aldrich Syndrome|Chronic Granulomatous Disease|X-linked Hyper IgM Syndrome|Severe Combined Immunodeficiency|Leukocyte Adhesion Deficiency Syndrome|Virus-Associated Hemophagocytic Syndrome","Drug: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: etoposide|Drug: methotrexate|Drug: methylprednisolone|Drug: prednisone|Procedure: Allogeneic Bone Marrow Transplantation","Fairview University Medical Center|Office of Rare Diseases (ORD)","All","up to 35 Years   (Child, Adult)","","null","Other","Interventional","Primary Purpose: Treatment","199/15104|UMN-MT-1995-26|UMN-MT-9526","July 5, 2000","March 2000","December 2002","October 14, 2009","October 2003","No Study Results Posted","null","December 2002","","https://ClinicalTrials.gov/show/NCT00006054"
2933,"NCT00005985","Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: etoposide|Drug: mitoxantrone hydrochloride|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Masonic Cancer Center, University of Minnesota","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","213","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","1996LS155|UMN-MT-9527|UMN-MT-1995-27","July 5, 2000","August 2000","February 2007","October 16, 2012","October 2012","No Study Results Posted","null","February 2007","Disease-free survival at 2 years|Relapse or progression transplant related mortality at 1½ years","https://ClinicalTrials.gov/show/NCT00005985"
2934,"NCT00005641","Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation","Terminated","No Results Available","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: leucovorin calcium|Drug: methotrexate|Drug: methylprednisolone|Procedure: allogeneic bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation|Radiation: radiation therapy","H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)","All","15 Years to 60 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","11587|MCC-11587|MCC-IRB-4599|NCI-G00-1781|BB-IDE-7181","May 2, 2000","September 1997","September 2000","December 10, 2012","December 2012","No Study Results Posted","null","September 2000","","https://ClinicalTrials.gov/show/NCT00005641"
2935,"NCT00003700","Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia","Biological: G-CSF|Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate|Drug: Allopurinol","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","15 Years and older   (Child, Adult, Senior)","Phase 2","163","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-19802|U10CA031946|CDR0000066807","November 1, 1999","January 1999","January 2010","July 1, 2016","July 2016","No Study Results Posted","null","February 2004","Complete Response|Toxicity|CNS relapse rate","https://ClinicalTrials.gov/show/NCT00003700"
2936,"NCT00002898","Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma","Completed","No Results Available","Childhood Malignant Fibrous Histiocytoma of Bone|Sarcoma","Biological: dactinomycin|Drug: carboplatin|Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: vincristine sulfate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: brachytherapy|Radiation: radiation therapy","Societe Internationale d'Oncologie Pediatrique|National Cancer Institute (NCI)","All","up to 17 Years   (Child)","Phase 3","400","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000065228|SIOP-MMT-95|EU-96035","November 1, 1999","January 1995","December 2009","December 3, 2013","May 1999","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002898"
2937,"NCT00801632","Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection","Completed","Has Results","Kidney Transplantation|Kidney Failure, Chronic","Procedure: Kidney Transplantation|Procedure: Bone marrow transplantation|Biological: MEDI-507|Drug: cyclophosphamide|Biological: rituximab|Drug: Tacrolimus|Drug: corticosteroids|Radiation: thymic irradiation","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)","All","18 Years to 60 Years   (Adult)","Phase 2","5","NIH|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","DAIT ITN036ST","December 2, 2008","December 2008","November 2014","November 6, 2015","November 2015","April 21, 2015","null","April 2014","Number of Participants Successfully Withdrawn Off of Immunosuppressant Medication for 104 Weeks|Percentage of Participants Experiencing Acute Rejection|Change in Renal Function|Percentage of Participants With Graft Survival Through 156 Weeks|Percentage of Participants Surviving Through 156 Weeks|Time to Neutrophil Recovery Following Transplant|Time to Platelet Recovery Following Transplant|Percentage of Participants Experiencing a Clinically Significant Invasive or Resistant Opportunistic Infection","https://ClinicalTrials.gov/show/NCT00801632"
2938,"NCT00262886","Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer","Completed","No Results Available","Kidney Cancer","Biological: anti-thymocyte globulin|Biological: graft-versus-tumor induction therapy|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","University of Rochester","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","35","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000449939|URCC-U1801|URCC-RSRB-09084","December 6, 2005","August 2001","null","June 5, 2013","June 2013","No Study Results Posted","null","July 2007","Response rate based on tumor measurements at 1 year|Toxicity as measured by NCI CTC at days 0, 7, 14, 21 and 28 after transplantation and monthly for 11 months|Overall and disease-free survival at day 100 and 1 year after transplantation","https://ClinicalTrials.gov/show/NCT00262886"
2939,"NCT00060255","High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors","Completed","No Results Available","Breast Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Testicular Germ Cell Tumor|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific","Drug: busulfan|Drug: carboplatin|Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Drug: melphalan|Drug: thiotepa|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Roswell Park Cancer Institute","All","4 Years and older   (Child, Adult, Senior)","Phase 2","451","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000301587|RPCI-DS-9115","May 6, 2003","December 1991","February 2013","May 7, 2013","May 2013","No Study Results Posted","null","August 2006","Morbidity|Mortality|Overall outcome|Response rate|Toxicity|Disease-free survival|Overall survival","https://ClinicalTrials.gov/show/NCT00060255"
2940,"NCT00004904","Stem Cell Transplantation in Treating Patients With Hematologic Cancer","Completed","No Results Available","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Small Intestine Cancer","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: cladribine|Drug: cyclophosphamide|Drug: etoposide|Drug: methylprednisolone|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation","Northwestern University|National Cancer Institute (NCI)","All","up to 45 Years   (Child, Adult)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU FDA97H1|NU-97H1|NCI-G00-1691","March 7, 2000","October 1999","July 2000","May 31, 2012","May 2012","No Study Results Posted","null","July 2000","","https://ClinicalTrials.gov/show/NCT00004904"
2941,"NCT00004197","Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: keyhole limpet hemocyanin|Biological: sargramostim|Biological: tumor cell-based vaccine therapy|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: mitoxantrone hydrochloride|Drug: prednisone|Drug: vincristine sulfate","University of Nebraska|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","197-99|P30CA036727|UNMC-197-99|GENITOPE-9902|SUMC-9902","January 21, 2000","June 1999","November 2003","June 23, 2010","June 2010","No Study Results Posted","null","January 2002","","https://ClinicalTrials.gov/show/NCT00004197"
2942,"NCT00629278","Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: trastuzumab|Drug: aromatase inhibition therapy|Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: paclitaxel|Drug: releasing hormone agonist therapy|Drug: tamoxifen citrate|Procedure: adjuvant therapy|Radiation: radiation therapy","Azienda Ospedaliera - Universitaria di Modena|National Cancer Institute (NCI)","Female","18 Years to 75 Years   (Adult, Senior)","Phase 3","2500","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","AOUMODENA-SHORT-HER|CDR0000584446|EUDRACT-2007-004326-25|EU-20825","March 4, 2008","December 2007","null","August 6, 2013","July 2009","No Study Results Posted","null","December 2010","Disease-free survival|Overall survival|Failure rate at 2 years due to relapse, death, or toxicity|Incidence of cardiac events as assessed by NCI CTCAE V3.0","https://ClinicalTrials.gov/show/NCT00629278"
2943,"NCT00556127","Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma","Completed","No Results Available","Diffuse Large B-Cell Lymphoma|POOR PROGNOSIS","Drug: Rituximab|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisone|Drug: Granulocyte-colony-stimulating factor|Drug: Mitoxantrone|Drug: Cytarabine ARA-C|Drug: Dexamethasone|Drug: Carmustine BCNU|Drug: Etoposide|Drug: Melphalan|Radiation: Radiotherapy|Procedure: PBSC reinfusion","Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie","All","18 Years to 60 Years   (Adult)","Phase 2","94","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","GIMURELL-DLBCL|Eudract Number 2004-000543-19","November 8, 2007","June 2002","September 2006","November 8, 2007","November 2007","No Study Results Posted","DLBCL","null","Failure-free survival","https://ClinicalTrials.gov/show/NCT00556127"
2944,"NCT00303810","Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide phosphate|Drug: high-dose chemotherapy|Drug: lomustine|Drug: methotrexate|Drug: thiotepa|Drug: vincristine sulfate|Radiation: radiation therapy","Universitätsklinikum Hamburg-Eppendorf","All","up to 21 Years   (Child, Adult)","","567","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000455572|GPOH-HIT-2000|EU-205105","March 15, 2006","January 2001","null","January 27, 2014","July 2009","No Study Results Posted","null","December 2013","","https://ClinicalTrials.gov/show/NCT00303810"
2945,"NCT00199186","Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)","Unknown status","No Results Available","Philadelphia Positive Acute Lymphoblastic Leukemia|Lymphoid Blastic Phase of Chronic Myeloid Leukemia","Drug: imatinib|Drug: vincristine|Drug: cyclophosphamide|Drug: cytosine arabinoside|Drug: dexamethasone|Drug: idarubicin|Drug: methotrexate (intrathecal)|Drug: AraC (intrathecal)|Drug: dexamethasone (intrathecal)","Johann Wolfgang Goethe University Hospital","All","56 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CSTI571ADE10|GMALL-STI571-ELDERLY-01/02","September 16, 2005","March 2002","null","October 18, 2007","September 2005","No Study Results Posted","null","null","Remission rate after induction therapy|Mortality rate during induction|Severe adverse events during induction|Efficacy of salvage therapy after crossover|Levels of minimal residual disease|Incidence of relapse|Remission duration|Disease free survival|Overall survival|Frequency of point mutations in the BCR-ABL gene","https://ClinicalTrials.gov/show/NCT00199186"
2946,"NCT00047138","Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor","Unknown status","No Results Available","Kidney Cancer","Biological: dactinomycin|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: vincristine sulfate|Procedure: adjuvant therapy|Procedure: conventional surgery|Procedure: neoadjuvant therapy|Radiation: radiation therapy","University of Leicester|Societe Francaise Oncologie Pediatrique|Children's Cancer and Leukaemia Group|Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","Phase 3","350","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000257531|SIOP-WT-2001|SFOP-SIOP-WT-2001|CCLG-SIOP-WT-2001|GPOH-GERMANY-SIOP-WT-2001|EU-20208","October 3, 2002","January 2001","null","June 23, 2014","June 2009","No Study Results Posted","null","null","Event-free survival|Treatment failure, in terms of disease recurrence or death","https://ClinicalTrials.gov/show/NCT00047138"
2947,"NCT00025103","Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney","Unknown status","No Results Available","Kidney Cancer","Biological: dactinomycin|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: melphalan|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","up to 17 Years   (Child)","Phase 2","75","Other","Interventional","Primary Purpose: Treatment","CCLG-UKWR|CDR0000068913|EU-20127","October 11, 2001","May 2001","null","August 1, 2013","June 2009","No Study Results Posted","null","November 2008","Unified treatment strategy|Improvement of current survival rates|Efficacy and toxicity|Prognostic variables","https://ClinicalTrials.gov/show/NCT00025103"
2948,"NCT00003401","Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: dexamethasone|Drug: etoposide|Drug: gemcitabine hydrochloride|Drug: melphalan|Drug: paclitaxel|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","University of Maryland","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","MSGCC-9731|CDR0000066405|NCI-V98-1437","November 1, 1999","January 1999","September 2002","March 28, 2017","March 2017","No Study Results Posted","null","September 2002","","https://ClinicalTrials.gov/show/NCT00003401"
2949,"NCT00002740","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma","Completed","No Results Available","Neuroblastoma","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: mesna|Drug: vincristine sulfate|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET photon therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","Phase 1","30","Other|NIH","Interventional","Primary Purpose: Treatment","3951|CCG-3951|CDR0000064656","November 1, 1999","May 1996","September 2005","July 23, 2014","July 2014","No Study Results Posted","null","March 2004","Event Free Survival","https://ClinicalTrials.gov/show/NCT00002740"
2950,"NCT00002691","Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: etoposide|Drug: leucovorin calcium|Drug: mesna|Drug: methotrexate|Drug: vincristine sulfate","Memorial Sloan Kettering Cancer Center","All","up to 21 Years   (Child, Adult)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","95-065|CDR0000064426|NCI-V95-0763","November 1, 1999","August 1995","June 2000","June 24, 2013","June 2013","No Study Results Posted","null","June 2000","","https://ClinicalTrials.gov/show/NCT00002691"
2951,"NCT00002643","Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor","Completed","No Results Available","Neutropenia|Sarcoma","Biological: filgrastim|Drug: amifostine trihydrate|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: topotecan hydrochloride|Drug: vincristine sulfate|Procedure: conventional surgery|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy","National Cancer Institute (NCI)|Children's Cancer Group","All","up to 30 Years   (Child, Adult)","Phase 2","130","NIH|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01832|POG-9457|CCG-P9457|CDR0000064137","November 1, 1999","April 1995","null","January 31, 2013","March 2007","No Study Results Posted","null","June 2003","","https://ClinicalTrials.gov/show/NCT00002643"
2952,"NCT02523976","Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia","Enrolling by invitation","No Results Available","Acute,Leukemia, Lymphoid","Drug: Dasatinib|Drug: prednisone|Drug: cyclophosphamide|Drug: daunorubicin|Drug: vincristine|Drug: cytarabine|Drug: mercaptopurine|Drug: methotrexate|Drug: dexamethasone|Drug: mitoxantrone|Drug: etoposide|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: autologous hematopoietic stem cell transplantation","Institute of Hematology & Blood Diseases Hospital","All","18 Years to 55 Years   (Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","IHBDH-IIT2015001","August 5, 2015","August 2015","August 2019","May 3, 2016","May 2016","No Study Results Posted","null","August 2018","Overall survival (OS)|Disease-free survival (DFS)|The complete remission (CR) rate|The molecular CR rate|The plasma level of dasatinib in the regimen|The Cerebrospinal fluid level of dasatinib in the regimen|Number of adverse event of combined treatment|Grade of adverse event of combined treatment","https://ClinicalTrials.gov/show/NCT02523976"
2953,"NCT00379457","Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma","Unknown status","No Results Available","Sarcoma","Biological: dactinomycin|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: topotecan hydrochloride|Drug: vincristine sulfate|Drug: vinorelbine tartrate|Procedure: conventional surgery|Radiation: radiation therapy","European Paediatric Soft Tissue Sarcoma Study Group|Italian Association for Pediatric Hematology Oncology|Children's Cancer and Leukaemia Group|Dutch Childhood Oncology Group|National Cancer Institute (NCI)","All","up to 20 Years   (Child, Adult)","Phase 3","600","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CCLG-EPSSG-RMS-2005|CDR0000508635|EU-20639|EUDRACT-2005-000217-35|UKCCSG-RMS-2005","September 19, 2006","June 2006","null","August 9, 2013","July 2009","No Study Results Posted","null","May 2011","Event-free survival|Disease-free survival (in patients treated with maintenance chemotherapy)|Overall survival|Progression-free survival|Response rate|Toxicity as measured by NCI-CTC version 3","https://ClinicalTrials.gov/show/NCT00379457"
2954,"NCT00032019","Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","78","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-50103|U10CA031946|CDR0000069249","March 8, 2002","February 2002","April 2009","July 15, 2016","July 2016","No Study Results Posted","null","December 2004","Response|Progression free Survival|Overall survival|Toxicity","https://ClinicalTrials.gov/show/NCT00032019"
2955,"NCT00003815","Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: bleomycin sulfate|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: melphalan|Drug: prednisolone|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Radiation: radiation therapy","Scotland and Newcastle Lymphoma Group|National Cancer Institute (NCI)","All","15 Years to 65 Years   (Child, Adult)","Phase 3","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066967|SNLG-NHL-Va|EU-98032","November 1, 1999","June 1994","null","September 16, 2013","July 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003815"
2956,"NCT00003783","Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia","Completed","No Results Available","Leukemia","Biological: filgrastim|Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: etoposide|Drug: idarubicin|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 17 Years   (Child)","Phase 2","36","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9806|POG-9806|CDR0000066915","November 1, 1999","March 1999","March 2007","July 24, 2014","July 2014","No Study Results Posted","null","November 2002","Assess the feasibility of delivering a new combination of agents during a 20 week post-induction consolidation phase","https://ClinicalTrials.gov/show/NCT00003783"
2957,"NCT00002802","Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma","Completed","No Results Available","Neuroblastoma","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: dacarbazine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: melphalan|Drug: mesna|Drug: vincristine sulfate|Drug: vindesine|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy|Radiation: radioisotope therapy","Children's Hospital Medical Center, Cincinnati|National Cancer Institute (NCI)","All","up to 20 Years   (Child, Adult)","Phase 3","500","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000064902|GER-NB90|EU-96004","November 1, 1999","July 1990","September 2003","December 18, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002802"
2958,"NCT00002658","Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia","Unknown status","No Results Available","Leukemia|Neutropenia","Biological: filgrastim|Drug: amsacrine|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: etoposide|Drug: idarubicin|Drug: mitoxantrone hydrochloride|Drug: thioguanine|Drug: tretinoin|Procedure: allogeneic bone marrow transplantation|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Medical Research Council|National Cancer Institute (NCI)","All","15 Years and older   (Child, Adult, Senior)","Phase 3","2000","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000064208|MRC-LEUK-AML12|EU-95001","November 1, 1999","January 1994","null","December 18, 2013","October 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002658"
2959,"NCT00002549","Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia","Unknown status","No Results Available","Leukemia","Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: etoposide|Drug: idarubicin|Drug: mesna|Drug: mitoxantrone hydrochloride|Procedure: allogeneic bone marrow transplantation|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI)","All","15 Years to 60 Years   (Child, Adult)","Phase 3","1520","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000063311|EORTC-06931","November 1, 1999","November 1993","null","December 22, 2009","December 2009","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002549"
2960,"NCT00002514","Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission","Completed","No Results Available","Leukemia","Biological: sargramostim|Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: etoposide|Drug: imatinib mesylate|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: thioguanine|Drug: vincristine sulfate|Procedure: allogeneic bone marrow transplantation|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Medical Research Council","All","15 Years to 65 Years   (Child, Adult)","Phase 3","1929","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000078099|E2993|MRC-LEUK-UKALL-XII|EST-4491","November 1, 1999","April 1993","null","November 21, 2012","August 2007","No Study Results Posted","null","December 2006","Overall Survival","https://ClinicalTrials.gov/show/NCT00002514"
2961,"NCT02723994","A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","Recruiting","No Results Available","B-cell Acute Lymphoblastic Leukemia","Drug: Ruxolitinib|Drug: Asparaginase Erwinia Chrysanthemi|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: Dexamethasone|Drug: Doxorubicin|Drug: Leucovorin Calcium|Drug: Mercaptopurine|Drug: Methotrexate|Drug: Pegaspargase|Drug: Prednisone|Drug: Thioguanine|Drug: Vincristine Sulfate","Incyte Corporation|Children's Oncology Group","All","1 Year to 21 Years   (Child, Adult)","Phase 2","170","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","INCB 18424-269|AALL1521","March 9, 2016","August 2016","May 2024","May 12, 2017","May 2017","No Study Results Posted","null","February 2024","Part 1: Safety/tolerability of ruxolitinib in combination with chemotherapy as measured by adverse events (AEs), vital signs, clinical laboratory tests, and echocardiograms|Part 2: Efficacy of ruxolitinib in combination with chemotherapy as measured by Event-free survival, defined as the percentage of patients alive without relapse, progression, or death at 3 years from study Day 1|Safety and tolerability of the combination treatment for subjects beginning treatment at the recommended dose for Part 2, as assessed by AEs, vital signs, clinical laboratory tests, and echocardiograms","https://ClinicalTrials.gov/show/NCT02723994"
2962,"NCT01085617","Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","Unknown status","No Results Available","Leukemia|Mucositis|Oral Complications","Biological: palifermin|Biological: rituximab|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: etoposide|Drug: fludarabine phosphate|Drug: imatinib mesylate|Drug: melphalan|Drug: mercaptopurine|Drug: methotrexate|Drug: nelarabine|Drug: pegaspargase|Drug: vincristine sulfate|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: assessment of therapy complications|Radiation: total-body irradiation","University College London Hospitals|National Cancer Institute (NCI)","All","25 Years to 65 Years   (Adult)","Phase 3","720","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","CDR0000667211|UCL-08-0167|EU-21009|EUDRACT-2009-012717-22|UCL-UKALL14|MREC-09-H0711-90|NCRI-UCL-08-0167|CRUK-C27995-A9609","March 11, 2010","January 2010","null","August 23, 2013","June 2011","No Study Results Posted","null","January 2016","Event-free survival|Toxicity related to pegaspargase|Mucositis score in patients treated with palifermin|Anti-asparaginase antibodies in patients treated with monoclonal antibody therapy|Overall survival|Complete remission (CR) rate|Minimal-residual disease quantification after first phase of induction and post-transplantation|Relapse rate (including bone marrow and CNS relapse)|Death in CR","https://ClinicalTrials.gov/show/NCT01085617"
2963,"NCT00974792","Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: pegfilgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide phosphate|Drug: ifosfamide|Drug: leucovorin calcium|Drug: methotrexate|Drug: vincristine sulfate","Cancer Research UK|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 2","150","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000644893|CRUK-UCL-R-CODOX-M/IVAC|EUDRACT-2005-003479-19|EU-20956","September 9, 2009","January 2006","null","August 23, 2013","September 2009","No Study Results Posted","null","May 2011","Complete response rate|Toxicity|Progression-free survival","https://ClinicalTrials.gov/show/NCT00974792"
2964,"NCT00334672","Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis","Unknown status","No Results Available","Nonneoplastic Condition","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: dexamethasone|Drug: etoposide|Drug: methotrexate|Drug: mycophenolate mofetil|Drug: therapeutic hydrocortisone|Other: laboratory biomarker analysis|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: biopsy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","up to 17 Years   (Child)","Phase 3","288","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000481605|CCLG-LCH-2006-02|EU-20619|UKCCSG-HLH-2004|EUDRACT-2005-002187-28","June 7, 2006","March 2006","null","September 16, 2013","June 2009","No Study Results Posted","null","November 2010","Survival","https://ClinicalTrials.gov/show/NCT00334672"
2965,"NCT00077285","Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma","Active, not recruiting","No Results Available","Sarcoma","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: dexrazoxane hydrochloride|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: irinotecan hydrochloride|Drug: vincristine sulfate|Procedure: conventional surgery|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","up to 50 Years   (Child, Adult)","Phase 2","65","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","03-099|MSKCC-03099","February 10, 2004","October 2003","October 2017","November 1, 2016","November 2016","No Study Results Posted","null","October 2017","Response rate|Toxicity|Safety and feasibility|Rate of local control|Correlation of in vitro measurements of angiogenesis with clinical features (extent of disease), response to therapy, and outcome|Efficacy in terms of improved outcomes","https://ClinicalTrials.gov/show/NCT00077285"
2966,"NCT00070174","Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy","Completed","No Results Available","Leukemia","Drug: asparaginase|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: etoposide|Drug: gemtuzumab ozogamicin|Drug: methotrexate|Drug: mitoxantrone hydrochloride|Procedure: allogeneic bone marrow transplantation","Children's Oncology Group|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","350","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","AAML03P1|CDR0000330133|COG-AAML03P1","October 3, 2003","December 2003","December 2013","February 19, 2014","February 2014","No Study Results Posted","null","September 2006","Safety|Complete remission rate|Feasibility|Effect of karyotypic abnormalities","https://ClinicalTrials.gov/show/NCT00070174"
2967,"NCT00060385","Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma","Terminated","No Results Available","Lymphoma","Drug: CHOP regimen|Drug: EPOCH regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","European Organisation for Research and Treatment of Cancer - EORTC","All","70 Years and older   (Senior)","Phase 2|Phase 3","3","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","EORTC-20991","May 6, 2003","March 2003","null","September 20, 2012","September 2012","No Study Results Posted","null","August 2004","","https://ClinicalTrials.gov/show/NCT00060385"
2968,"NCT00028886","Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma","Unknown status","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Biological: recombinant interferon alfa|Drug: cyclophosphamide|Drug: dexamethasone|Drug: doxorubicin hydrochloride|Drug: melphalan|Drug: thalidomide|Drug: vincristine sulfate|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","Commissie Voor Klinisch Toegepast Onderzoek|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 3","450","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000069144|CKTO-2001-02|HOVON-50MM|EU-20133|HOVON-CKVO-2001-02","January 4, 2002","March 2001","null","September 16, 2013","October 2012","No Study Results Posted","null","null","Event-free survival|Partial response and complete response|Overall survival|Progression-free survival|Toxicity","https://ClinicalTrials.gov/show/NCT00028886"
2969,"NCT00003578","High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Drug: CHOP regimen|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: melphalan|Drug: prednisone|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Lymphoma Trials Office|National Cancer Institute (NCI)","All","16 Years to 65 Years   (Child, Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066645|BNLI-LY02|EU-98039","November 1, 1999","January 1993","null","September 19, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003578"
2970,"NCT00003215","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Drug: CHOP regimen|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: melphalan|Drug: methotrexate|Drug: methylprednisolone|Drug: mitoxantrone hydrochloride|Drug: prednisone|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Swiss Group for Clinical Cancer Research","All","18 Years to 60 Years   (Adult)","Phase 3","400","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","SAKK 38/97|SWS-SAKK-38/97|EU-97037","November 1, 1999","April 1997","March 2004","May 14, 2012","May 2012","No Study Results Posted","null","March 2004","","https://ClinicalTrials.gov/show/NCT00003215"
2971,"NCT00002822","Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer","Completed","No Results Available","Lung Cancer","Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: mesna|Drug: vincristine sulfate|Radiation: radiation therapy","Medical Research Council|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","400","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000064998|MRC-LU21|EU-96019","November 1, 1999","March 1996","November 2005","December 18, 2013","December 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002822"
2972,"NCT00002785","Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia","Biological: filgrastim|Drug: asparaginase|Drug: cyclophosphamide|Drug: cyclosporine|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: etoposide|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: mesna|Drug: methotrexate|Drug: methylprednisolone|Drug: pegaspargase|Drug: prednisone|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate|Procedure: allogeneic bone marrow transplantation|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET photon therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 1 Year   (Child)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","1953|CCG-1953|CDR0000064841","November 1, 1999","July 1996","March 2007","July 23, 2014","July 2014","No Study Results Posted","null","August 2000","Event Free Survival","https://ClinicalTrials.gov/show/NCT00002785"
2973,"NCT00002756","Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia","Biological: filgrastim|Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 1 Year   (Child)","Phase 2","221","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","P9407|COG-P9407|POG-9407|CDR0000064693","November 1, 1999","June 1996","March 2012","February 12, 2014","February 2014","No Study Results Posted","null","September 2007","Feasibility of intensification|Event-free survival|Comparison of event-free survival rates in infants with and without leukemic blasts translocations|Correlation of minimal residual disease at completion of induction, beginning of continuation, and at completion of therapy with patient outcome|Clinical prognostic features associated with outcome|Correlation of biologic characteristics of leukemia cells at diagnosis with outcome|Patterns of gene expression","https://ClinicalTrials.gov/show/NCT00002756"
2974,"NCT00002704","Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia","Biological: filgrastim|Drug: asparaginase|Drug: cyclophosphamide|Drug: daunorubicin hydrochloride|Drug: dexamethasone|Drug: etoposide|Drug: leucovorin calcium|Drug: liposomal cytarabine|Drug: mercaptopurine|Drug: mesna|Drug: methotrexate|Drug: therapeutic hydrocortisone|Drug: thiotepa|Drug: vincristine sulfate|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy","National Cancer Institute (NCI)","All","up to 20 Years   (Child, Adult)","Phase 2","156","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01528|POG-9412|CDR0000064509","November 1, 1999","January 1996","null","January 31, 2013","November 2007","No Study Results Posted","null","June 2004","","https://ClinicalTrials.gov/show/NCT00002704"
2975,"NCT00055653","Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders","Completed","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic-Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: melphalan|Drug: methylprednisolone|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","Roswell Park Cancer Institute|National Heart, Lung, and Blood Institute (NHLBI)","All","up to 17 Years   (Child)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000270487|RPCI-DS-00-22","March 6, 2003","January 2003","September 2005","March 3, 2011","March 2011","No Study Results Posted","null","September 2003","","https://ClinicalTrials.gov/show/NCT00055653"
2976,"NCT00012311","Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: filgrastim|Drug: CMF regimen|Drug: carboplatin|Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: fluorouracil|Drug: ifosfamide|Drug: methotrexate|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation","Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","18 Years to 59 Years   (Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068504|CPMC-IRB-9244|NCI-G01-1922","March 3, 2001","January 2000","null","January 3, 2014","September 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00012311"
2977,"NCT00008203","Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: aldesleukin|Biological: recombinant interferon gamma|Drug: carboplatin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: thiotepa|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult)","Phase 3","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000068387|CPMC-IRB-7608|CPMC-CAMP-014|NCI-G00-1890","January 6, 2001","May 1996","May 2008","February 1, 2013","May 2003","No Study Results Posted","null","December 2005","","https://ClinicalTrials.gov/show/NCT00008203"
2978,"NCT00003414","Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease","Completed","No Results Available","Graft Versus Host Disease|Lymphoma","Biological: aldesleukin|Biological: recombinant interferon gamma|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","50","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","J9726 CDR0000066427|P30CA006973|P01CA015396|JHOC-97080106|JHOC-9726|NCI-V98-1453","November 1, 1999","October 1997","May 2004","July 16, 2015","July 2015","No Study Results Posted","null","May 2004","Relapse rate for lymphoma after autologous transplant","https://ClinicalTrials.gov/show/NCT00003414"
2979,"NCT01279616","A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease","Terminated","No Results Available","Sickle Cell Disease","Drug: Fludarabine monophosphate|Drug: Rituximab|Drug: Busulfan|Drug: ATG|Drug: Cyclophosphamide|Drug: Mycophenolate mofetil|Drug: Tacrolimus","Nationwide Children's Hospital","All","up to 21 Years   (Child, Adult)","Phase 2","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","09-00383","January 18, 2011","September 2010","January 2015","February 2, 2017","February 2017","No Study Results Posted","null","January 2015","Event free survival|feasibility and toxicity of preparative regimen","https://ClinicalTrials.gov/show/NCT01279616"
2980,"NCT00053989","Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic Anemia","Active, not recruiting","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Biological: graft-versus-tumor induction therapy|Biological: sargramostim|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methylprednisolone|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: umbilical cord blood transplantation","Roswell Park Cancer Institute","All","5 Years to 75 Years   (Child, Adult, Senior)","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","CDR0000269673|RP01-05","February 5, 2003","January 29, 2002","May 1, 2018","May 16, 2017","May 2017","No Study Results Posted","null","May 1, 2018","Safety|Toxicity|Clinical response|Overall outcome|Incidence of graft-vs-tumor effect, graft-vs-host disease, and chimerism","https://ClinicalTrials.gov/show/NCT00053989"
2981,"NCT00003086","Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer","Unknown status","No Results Available","Breast Cancer","Biological: filgrastim|Drug: CAF regimen|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: fluorouracil|Drug: ifosfamide|Drug: melphalan|Drug: paclitaxel|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation|Radiation: samarium Sm 153 lexidronam pentasodium","Feist-Weiller Cancer Center at Louisiana State University Health Sciences|National Cancer Institute (NCI)","Female","21 Years to 65 Years   (Adult)","Phase 1|Phase 2","12","Other","Interventional","Primary Purpose: Treatment","CDR0000065786|LSU-97447|NCI-V97-1341","November 1, 1999","March 1997","null","February 6, 2009","December 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003086"
2982,"NCT00755313","Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer|Chemotherapeutic Agent Toxicity|Cognitive/Functional Effects|Fatigue|Long-term Effects Secondary to Cancer Therapy in Adults|Neurotoxicity|Psychosocial Effects of Cancer and Its Treatment","Biological: trastuzumab|Drug: aromatase inhibition therapy|Drug: carboplatin|Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Other: metabolic assessment|Other: questionnaire administration|Other: study of socioeconomic and demographic variables|Procedure: cognitive assessment|Procedure: positron emission tomography|Radiation: fludeoxyglucose F 18","University of California, San Francisco|National Cancer Institute (NCI)","Female","35 Years to 80 Years   (Adult, Senior)","","81","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","CDR0000613050|UCSF-06803|UCSF-H6961-29940-02B","September 17, 2008","May 2007","December 2016","May 12, 2016","May 2016","No Study Results Posted","null","September 2012","Change in glucose metabolism|MRI measures of the brain (hippocampal volume, cortical gray matter volume, white matter signal hyperintensities, ventricular volume, whole brain volume)|Measures of cognitive function over time by Wechsler memory scale, word list memory, Stroop Color Word Test, Boston Naming Test, verbal fluency, FACIT-B functional assessment, Mini Mental State Exam, Hamilton Depression Rating Scale (Ham-D), Beck De ...|Cognitive assessments over time by FACIT-B, Ham-D, BDI-II, STAI, FSI, and MASQ, demographic and medical data","https://ClinicalTrials.gov/show/NCT00755313"
2983,"NCT00002761","Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia","Withdrawn","No Results Available","Leukemia","Biological: filgrastim|Biological: recombinant interferon gamma|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: cytarabine|Drug: idarubicin|Procedure: peripheral blood stem cell transplantation","Columbia University","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","0","Other","Interventional","Primary Purpose: Treatment","AAAA7158|CU-CAMP-10|NCI-V96-0873","November 1, 1999","February 1996","October 2007","November 16, 2012","November 2012","No Study Results Posted","null","February 2007","","https://ClinicalTrials.gov/show/NCT00002761"
2984,"NCT00002552","Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma","Completed","No Results Available","Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Biological: sargramostim|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: perfosfamide|Drug: therapeutic hydrocortisone|Procedure: allogeneic bone marrow transplantation|Procedure: autologous bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: syngeneic bone marrow transplantation|Radiation: radiation therapy","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","40","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000063370|P30CA022453|WSU-D-701-87|NCI-V94-0364","November 1, 1999","October 1993","October 2003","April 5, 2013","April 2013","No Study Results Posted","null","September 2001","","https://ClinicalTrials.gov/show/NCT00002552"
2985,"NCT01659099","GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma","Active, not recruiting","No Results Available","Diffuse Large B Cell Lymphoma CD20 Positive","Drug: GA101|Drug: Rituximab|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Prednisone|Drug: Bleomycin|Drug: Vindesin|Drug: Vincristine","The Lymphoma Academic Research Organisation|Hoffmann-La Roche","All","18 Years to 60 Years   (Adult)","Phase 3","670","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","GAINED","July 4, 2012","September 2012","February 2019","March 8, 2017","March 2017","No Study Results Posted","GAINED","February 2019","2-year Event Free Survival|• Overall Response rate and Best overall response after 4 cycles and end of treatment according to Cheson 2007 criteria|• Overall Response Rate and Best overall response after 4 cycles and end of treatment according to Cheson 1999 criteria|• Duration of response (DoR)|• Progression-Free Survival (PFS)|• Overall survival (OS)|• Blood samples and on tumor tissue biopsy|• Focus on subpopulation|Number of stem cell collected after GA101 treatment|• Early metabolic response according to PET after 2 and 4 cycles","https://ClinicalTrials.gov/show/NCT01659099"
2986,"NCT00199069","German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)","Completed","No Results Available","Adult Acute Lymphocytic Leukemia","Drug: Asparaginase|Drug: Vincristine|Drug: Daunorubicin, Adriamycin|Drug: Cyclophosphamide|Drug: Ifosfamide|Drug: Cytarabine|Drug: Mitoxantrone|Drug: Methotrexate|Drug: 6-Mercaptopurine|Drug: 6-Thioguanine|Drug: VM26|Drug: Dexamethasone / Prednisolone|Procedure: CNS Irradiation|Procedure: Mediastinal Irradiation|Procedure: Stem Cell Transplantation","Johann Wolfgang Goethe University Hospital|Deutsche Krebshilfe e.V., Bonn (Germany)","All","15 Years to 65 Years   (Child, Adult)","Phase 4","720","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","GMALL09","September 12, 2005","April 1993","null","May 16, 2008","May 2008","No Study Results Posted","null","null","remission rate, disease free survival, overall survival|death in induction, toxicity, time and dose compliance","https://ClinicalTrials.gov/show/NCT00199069"
2987,"NCT00025649","Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma","Completed","No Results Available","Neuroblastoma","Biological: filgrastim|Drug: busulfan|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: melphalan|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation","European Infant Neuroblastoma Study Group - 1999|National Cancer Institute (NCI)","All","up to 1 Year   (Child)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068982|EURO-INF-NB-STUDY-1999-99.4|EU-20125D","October 11, 2001","July 1999","March 2009","September 16, 2013","December 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00025649"
2988,"NCT00025636","Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: filgrastim|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: etoposide|Drug: melphalan|Drug: methotrexate|Drug: vincristine sulfate|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","German Hodgkin's Lymphoma Study Group|European Organisation for Research and Treatment of Cancer - EORTC|EBMT Solid Tumors Working Party|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 3","220","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000068981|GHSG-HD-R2|EBMT-GHSG-HD-R2|EORTC-20011","October 11, 2001","July 2001","null","September 16, 2013","June 2007","No Study Results Posted","null","null","Efficacy at 3 months|Toxicity at 3 months|Complete remission at 3 months|Relapse-free survival at 3 months|Overall survival at 3 months","https://ClinicalTrials.gov/show/NCT00025636"
2989,"NCT00025402","Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia","Unknown status","No Results Available","Leukemia","Biological: filgrastim|Biological: recombinant interferon alfa|Drug: busulfan|Drug: cyclophosphamide|Drug: cytarabine|Drug: etoposide|Drug: hydroxyurea|Drug: idarubicin|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","III. Medizinische Klinik Mannheim|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","1000","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000068957|III-MK-CML-3A|EU-20118","October 11, 2001","July 1997","null","December 17, 2013","July 2002","No Study Results Posted","null","null","Survival|Frequency, time-point, and duration of hematologic and cytogenetic remissions and of Philadelphia chromosome-negative and/or BCL-ABL-positive cells|Correlation of quality of hematological and cytogenetic remission with survival time|Course of the terminal phase|Toxicity|Effect of prognostic criteria and normal or subnormal WBC on chronic phase duration and survival time|Effect of early vs late high-dose therapy and autografting on feasibility, toxicity and survival times","https://ClinicalTrials.gov/show/NCT00025402"
2990,"NCT00024193","Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Neuroblastoma","Unknown status","No Results Available","Neuroblastoma","Biological: filgrastim|Drug: busulfan|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: melphalan|Drug: vincristine sulfate|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation","Children's Cancer and Leukaemia Group|Societe Francaise Oncologie Pediatrique|National Cancer Institute (NCI)","All","1 Year and older   (Child, Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CCLG-NB-1999-02|CDR0000068899|SFOP-NB97|EU-20106","September 13, 2001","April 1999","null","August 6, 2013","November 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00024193"
2991,"NCT00016887","Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: filgrastim|Biological: recombinant interferon alfa|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: dexamethasone|Drug: etoposide|Drug: melphalan|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","German Low Grade Lymphoma Study Group|European Organisation for Research and Treatment of Cancer - EORTC|Gruppo Italiano Studio Linfomi|Lymphoma Study Association|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 3","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000068609|GER-LGLSG-INTERGROUP-20995|EORTC-20995|GELA-INTERGROUP-20995|GISL-INTERGROUP-20995","June 6, 2001","December 2000","null","September 16, 2013","August 2003","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00016887"
2992,"NCT00002634","Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma","Completed","No Results Available","Neuroblastoma","Biological: filgrastim|Biological: monoclonal antibody 3F8|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: mesna|Drug: perfosfamide|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET photon therapy|Radiation: radioisotope therapy","Memorial Sloan Kettering Cancer Center","All","1 Year and older   (Child, Adult, Senior)","Phase 2","45","Other","Interventional","Primary Purpose: Treatment","94-011|CDR0000064084|MSKCC-FDR001041|NCI-V95-0622","November 1, 1999","February 1995","September 2004","July 1, 2013","July 2013","No Study Results Posted","null","September 2004","","https://ClinicalTrials.gov/show/NCT00002634"
2993,"NCT00002610","Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors","Completed","No Results Available","Kidney Cancer","Biological: dactinomycin|Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: vincristine sulfate|Procedure: conventional surgery|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","203","Other|NIH","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","9444|COG-Q9402|NWTS-Q9402|CCG-4942|POG-9444|INT-0152|NWTS-5/R|CDR0000063900","November 1, 1999","January 1996","February 2006","July 23, 2014","July 2014","No Study Results Posted","null","June 2002","Event free survival|Event Free Survival|Post-relapse survival|Response rate","https://ClinicalTrials.gov/show/NCT00002610"
2994,"NCT01383759","Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis","Active, not recruiting","No Results Available","Light Chain Deposition Disease (LCDD or MIDD)|Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD)|Monoclonal Immunoglobulin Deposition Disease (MIDD)|Amyloidosis","Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone","Memorial Sloan Kettering Cancer Center|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","11-061","June 27, 2011","June 24, 2011","June 2018","May 10, 2017","May 2017","No Study Results Posted","null","June 2018","To examine the tolerability|To examine the toxicity|To estimate the hematologic response rate|To estimate the organ response rate|To estimate the time to hematologic progression","https://ClinicalTrials.gov/show/NCT01383759"
2995,"NCT00425802","Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia","Completed","No Results Available","Leukemia|Lymphoma","Biological: anti-thymocyte globulin|Biological: filgrastim|Biological: graft-versus-tumor induction therapy|Biological: rituximab|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Radiation: total-body irradiation","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","61","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","06-150|MSKCC-06150","January 19, 2007","November 28, 2006","October 28, 2016","February 8, 2017","February 2017","No Study Results Posted","null","October 28, 2016","Overall and event-free survival at 1 year|Speed of neutrophil and platelet recovery|Incidence and speed of donor-derived engraftment|Incidence and severity of acute graft versus host disease (GVHD) at 100 days|Incidence and severity of chronic GVHD at 1 year|Correlation of incidence of serious infectious complications with immune recovery|Response to treatment|Incidence of transplant-related mortality at 100 and 180 days|Incidence of malignant relapse or disease progression at 1 and 2 years|Probabilities of overall and event-free survival at 2 years","https://ClinicalTrials.gov/show/NCT00425802"
2996,"NCT00030719","Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma","Unknown status","No Results Available","Neuroblastoma","Biological: filgrastim|Biological: monoclonal antibody Ch14.18|Drug: busulfan|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: isotretinoin|Drug: melphalan|Drug: vincristine sulfate|Procedure: bone marrow ablation with stem cell support|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","University of Leicester|National Cancer Institute (NCI)","All","1 Year to 20 Years   (Child, Adult)","Phase 3","175","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000069191|SIOP-EUROPE-HR-NBL-1|ESIOP|EU-20148","February 14, 2002","December 2001","null","June 23, 2014","August 2010","No Study Results Posted","null","null","Event-free survival at 3 years|Mean number of febrile events during induction|Response rate assessed by the International Neuroblastoma Response Criteria after 4 and 8 induction chemotherapy courses|Event-free survival at 5 years|Overall survival|Toxicity|Biological factors (i.e., MycNM amplification, 1p deletion, ploidy, 17 q+, CD44, and Trk-A)|Serum concentrations of lactic dehydrogenase, ferritin, neurone specific enolase|Urinary catecholamines at diagnosis","https://ClinicalTrials.gov/show/NCT00030719"
2997,"NCT00417053","Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant","Unknown status","No Results Available","Neuroblastoma","Biological: filgrastim|Drug: busulfan|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide phosphate|Drug: melphalan|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","up to 1 Year   (Child)","Phase 3","null","Other","Interventional","Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment","CCLG-NB-1999-03|CDR0000454507|EU-20597","December 27, 2006","null","null","August 1, 2013","December 2006","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00417053"
2998,"NCT00025441","Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors","Completed","No Results Available","Ovarian Cancer|Sarcoma|Small Intestine Cancer","Biological: dactinomycin|Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Societe Internationale d'Oncologie Pediatrique|Children's Cancer and Leukaemia Group|Societe Francaise Oncologie Pediatrique|National Cancer Institute (NCI)","All","6 Years to 17 Years   (Child)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068961|SIOP-MMT-98|SFOP-SIOP-MMT-98|CCLG-SIOP-MMT-98|EU-20126|STS-1998","October 11, 2001","November 1998","March 2010","December 3, 2013","November 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00025441"
2999,"NCT00017225","Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma","Completed","No Results Available","Neuroblastoma","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: dacarbazine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: melphalan|Drug: tretinoin|Drug: vincristine sulfate|Drug: vindesine|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI)","All","up to 20 Years   (Child, Adult)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","GPOH-GERMANY-NB97|CDR0000068664|EU-20102|GER-GPOH-NB97","June 6, 2001","May 1997","February 2002","August 1, 2013","August 2002","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00017225"
3000,"NCT00006669","Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma","Unknown status","No Results Available","Lymphoma","Biological: rituximab|Biological: sargramostim|Drug: EPOCH regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: vincristine sulfate","Washington Hospital Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068283|WHC-99365|NCI-V00-1630","December 6, 2000","September 1999","null","February 6, 2009","May 2001","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00006669"
3001,"NCT00003541","Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Drug: CHOP regimen|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: prednisone|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","24","Other|NIH","Interventional","Primary Purpose: Treatment","98-045|CDR0000066595|NCI-H98-0021","November 1, 1999","June 1998","July 2006","June 20, 2013","June 2013","No Study Results Posted","null","July 2006","","https://ClinicalTrials.gov/show/NCT00003541"
3002,"NCT00003273","Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor","Withdrawn","No Results Available","Brain and Central Nervous System Tumors|Neuroblastoma|Retinoblastoma|Sarcoma","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: temozolomide|Drug: thiotepa|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","New York University School of Medicine","All","up to 10 Years   (Child)","Phase 2","0","Other","Interventional","Primary Purpose: Treatment","CDR0000066174|NYU-P9712|NCI-V98-1400","November 1, 1999","November 1997","null","November 30, 2015","November 2015","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00003273"
3003,"NCT00002489","Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors","Completed","No Results Available","Extragonadal Germ Cell Tumor|Ovarian Cancer","Biological: dactinomycin|Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: vincristine sulfate|Procedure: conventional surgery","Memorial Sloan Kettering Cancer Center","All","up to 20 Years   (Child, Adult)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","91-119|CDR0000077384|NCI-V92-0021","November 1, 1999","October 1991","June 2002","June 24, 2013","June 2013","No Study Results Posted","null","June 2002","","https://ClinicalTrials.gov/show/NCT00002489"
3004,"NCT00613457","Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia","Completed","No Results Available","Leukemia","Drug: dexamethasone|Drug: asparaginase|Drug: Asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin|Drug: doxorubicin|Drug: Etoposide|Drug: Ifosfamide|Drug: mercaptopurine|Drug: Methotrexate|Drug: prednisone|Drug: thioguanine|Drug: Vincristine|Drug: Vindesine","Associazione Italiana Ematologia Oncologia Pediatrica","All","1 Year to 17 Years   (Child)","Phase 3","2039","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AIEOP LLA 2000","January 21, 2008","September 2000","July 2006","January 13, 2015","January 2015","No Study Results Posted","AIEOP LLA 2000","July 2006","Efficacy of dexamethasone vs prednisone during the induction phase|Event-free survival (EFS) and overall survival after initial remission in intermediate-risk and high-risk patients|Safety and efficacy of treatment reduction during reintensification in standard-risk patients|EFS after second delayed reintensification in intermediate-risk patients|Outcome after extended reintensification therapy in high-risk patients","https://ClinicalTrials.gov/show/NCT00613457"
3005,"NCT00550992","Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia","Unknown status","No Results Available","Leukemia","Biological: anti-thymocyte globulin|Drug: asparaginase|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: melphalan|Drug: mercaptopurine|Drug: methotrexate|Drug: mitoxantrone hydrochloride|Drug: pegaspargase|Drug: prednisolone|Drug: prednisone|Drug: therapeutic hydrocortisone|Drug: thioguanine|Drug: vincristine sulfate|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation","Dutch Childhood Oncology Group|BFM Germany|CORS Monza Italy|Associazione Italiana Ematologia Oncologia Pediatrica|Australian and New Zealand Children's Oncology Group|BFM Austria|CLCG France Belgium Portugal|COALL Germany|CPH, Czech republic|DFCI consortium USA|FRALLE France|Hong Kong|MD Anderson USA|NOPHO Scandinavian countries|PINDA, Chile|PPLLSG Poland|Seattle USA|SJCRH USA|UKCCSG United Kingdom","All","up to 1 Year   (Child)","","445","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000570260|DCOG-INTERFANT-06|EUDRACT-2005-004599-19|CCLG-LK-2006-10","October 22, 2007","June 2007","null","February 14, 2014","February 2014","No Study Results Posted","Interfant06","June 2014","Disease-free survival|Survival|Event-free survival|Event-free survival within each risk group (i.e., low-risk, medium-risk, or high-risk)","https://ClinicalTrials.gov/show/NCT00550992"
3006,"NCT00526318","Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma","Recruiting","No Results Available","Neuroblastoma","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: dacarbazine|Drug: doxorubicin hydrochloride|Drug: etoposide phosphate|Drug: ifosfamide|Drug: isotretinoin|Drug: melphalan|Drug: topotecan hydrochloride|Drug: vincristine sulfate|Drug: vindesine|Procedure: autologous hematopoietic stem cell transplantation|Radiation: iobenguane I 131|Radiation: radiation therapy","Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","","360","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","GPOH-NB2004-HR|CDR0000564820|UNI-KOELN-161|EU-20661","September 5, 2007","January 2007","null","July 15, 2015","July 2015","No Study Results Posted","null","December 2016","Event-free survival (EFS)|Overall survival (OS)|Impact of well established clinical and molecular risk factors on EFS and OS|Early response, measured after 2 courses of induction chemotherapy|Response to induction therapy, measured before autologous stem cell transplantation|Toxicity during the first 2 courses and the last 6 courses of induction chemotherapy|Impact of the extent of initial and best surgery on outcome and frequency of complications|Acute and late toxicity of radiotherapy|Correlation of MIBG activity with whole-body radiation dose|Molecular markers (MYCN and status of chromosome 1p and 11q)","https://ClinicalTrials.gov/show/NCT00526318"
3007,"NCT00410631","Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma","Unknown status","No Results Available","Neuroblastoma","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: dacarbazine|Drug: doxorubicin hydrochloride|Drug: etoposide phosphate|Drug: ifosfamide|Drug: isotretinoin|Drug: melphalan|Drug: topotecan hydrochloride|Drug: vincristine sulfate|Drug: vindesine|Procedure: autologous hematopoietic stem cell transplantation|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: iobenguane I 131|Radiation: radiation therapy","Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","642","Other","Interventional","Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment","GPOH-NB2004|CDR0000517312|EU-20661","December 11, 2006","October 2004","null","August 6, 2013","January 2008","No Study Results Posted","null","December 2010","Event-free survival (EFS)|Locoregional EFS|Time from diagnosis to transition to stage 4 disease, to death from disease, or to the last follow-up (if no transition to stage 4 disease is observed)|Overall survival|Time to the beginning of primary tumor regression (in patients in the low-risk group [LRG])|Time to the normalization of tumor markers HVA and VMA in urine|Time to no evidence of disease (in patients in the LRG with stage 4S disease)|Status of the primary tumor 12 months after diagnosis (LRG)|Best status of the primary tumor within the first 12 months (LRG)|Status of chromosome 1p (unblinded) and status of chromosome 11q (blinded)|Comparison of the extent of initial surgery (incomplete resection vs macroscopic complete resection) (LRG)|Comparison of the extent of best surgery during protocol treatment (incomplete resection vs macroscopic complete resection)|Surgery-related complications (i.e., bleeding, infection, intestinal obstruction, or other)|Disease progression and symptoms controlled after the first, second, third, and fourth N4 course (LRG)|Disease progression and symptoms not controlled after four N4 courses (LRG)|Transition to stage 4 disease at any time (LRG)|Acute and late side effects of external-beam radiotherapy (medium-risk group [MRG] and high-risk group [HRG])|Early response after 2 courses of induction therapy (N5 and N6 or two courses of N8) (HRG)|Response to induction therapy prior to conditioning therapy or after 280 days (HRG)|Grade of toxicity observed during induction therapy course 1 (N5 or N8) (HRG)|Grade of toxicity observed during induction therapy course 2 (N6 or N8) (HRG)|Frequency of grade 3 or 4 toxicity observed during the last 6 courses of induction therapy (3 courses of N5 and N6) (HRG)|Activity and whole body dose of radiotherapy","https://ClinicalTrials.gov/show/NCT00410631"
3008,"NCT00041327","Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: recombinant interferon alfa|Drug: Etoposide|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: lamivudine|Drug: prednisone|Drug: vincristine sulfate|Drug: zidovudine","AIDS Malignancy Consortium|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","19","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AMC-033|U01CA070019|CDR0000069469","July 8, 2002","October 2002","December 2006","February 1, 2016","February 2016","No Study Results Posted","null","December 2006","Efficacy|Duration of response|Effects on markers of virus replication and expression and immune function|Toxicity","https://ClinicalTrials.gov/show/NCT00041327"
3009,"NCT00020943","Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years to 69 Years   (Adult, Senior)","Phase 2","79","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-59909|U10CA031946|CDR0000068732","July 11, 2001","June 2001","September 2009","July 15, 2016","July 2016","No Study Results Posted","null","December 2006","Progression Free Survival|Response|Survival","https://ClinicalTrials.gov/show/NCT00020943"
3010,"NCT00002766","Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma","Completed","Has Results","Leukemia|Lymphoma","Biological: dactinomycin|Biological: sargramostim|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: mercaptopurine|Drug: methotrexate|Drug: mitoxantrone hydrochloride|Drug: pegaspargase|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 3","170","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","96-015|P30CA008748|MSKCC-96015A1|NCI-V96-0881","November 1, 1999","March 1996","September 2011","January 25, 2016","January 2016","December 17, 2015","null","September 2011","Complete Remission (CR)","https://ClinicalTrials.gov/show/NCT00002766"
3011,"NCT00526409","LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia","Completed","No Results Available","Acute Lymphoblastic Leukemia","Drug: Prednisolone|Drug: Daunorubicin|Drug: Vincristine|Drug: L-Asparaginase|Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Cytosine Arabinoside","PETHEMA Foundation","All","up to 16 Years   (Child)","Phase 4","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LAL-AR-N-2005","September 6, 2007","June 2005","October 2014","October 27, 2014","October 2014","No Study Results Posted","LAL-AR-N-2005","October 2014","To improve the global results obtained in PETHEMA LAL-AR-93 study in terms of events free time","https://ClinicalTrials.gov/show/NCT00526409"
3012,"NCT00998270","Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma","Recruiting","No Results Available","Multiple Myeloma","Procedure: Autologous bone marrow transplantation|Procedure: Allogeneic bone marrow transplantation","Tehran University of Medical Sciences","All","18 Years to 55 Years   (Adult)","Phase 2|Phase 3","185","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","HORCSCT-0901","October 17, 2009","October 2009","October 2017","May 31, 2012","May 2012","No Study Results Posted","null","October 2014","Overall Survival and Progressive Free Survival in both two arms|Treatment Related Mortality (TRM) in both two arms|Acute and Chronic GVHD in Allogeneic arm","https://ClinicalTrials.gov/show/NCT00998270"
3013,"NCT00295997","Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia","Unknown status","No Results Available","Chronic Myeloproliferative Disorders|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Biological: anti-thymocyte globulin|Biological: filgrastim|Biological: graft-versus-tumor induction therapy|Biological: therapeutic allogeneic lymphocytes|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methotrexate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","University of California, San Francisco|National Cancer Institute (NCI)","All","up to 74 Years   (Child, Adult, Senior)","","35","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000463522|UCSF-01251|UCSF-H5010-19585-05|UCSF-2101","February 23, 2006","May 2005","null","January 3, 2014","April 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00295997"
3014,"NCT00003397","Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Biological: sargramostim|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: dexamethasone|Drug: etoposide|Drug: gemcitabine hydrochloride|Drug: melphalan|Drug: paclitaxel|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","University of Maryland|University of Maryland Greenebaum Cancer Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","25","Other","Interventional","Primary Purpose: Treatment","CDR0000066399|MSGCC-9740|NCI-V98-1432","November 1, 1999","September 1998","December 2002","September 23, 2009","September 2009","No Study Results Posted","null","December 2002","","https://ClinicalTrials.gov/show/NCT00003397"
3015,"NCT00526175","LAL-BR/2001: Study Treatment to Low Risk ALL","Completed","No Results Available","Acute Lymphoblastic Leukemia","Drug: Prednisone|Drug: Vincristine|Drug: Daunorubicin|Drug: L-Asparaginase|Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Cytosine Arabinoside|Drug: Mercaptopurine|Drug: VP-16","PETHEMA Foundation","All","up to 15 Years   (Child)","Phase 4","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LAL-BR/2001","September 6, 2007","June 2001","December 2015","January 16, 2016","January 2016","No Study Results Posted","null","May 2015","To evaluate the efficacy of treatment in order to response rate, relapse free survival and global survival","https://ClinicalTrials.gov/show/NCT00526175"
3016,"NCT00002599","Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma","Unknown status","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Biological: recombinant interferon alfa|Biological: sargramostim|Drug: carmustine|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: melphalan|Drug: methylprednisolone|Drug: prednisone|Drug: vincristine sulfate|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET photon therapy","Medical Research Council|National Cancer Institute (NCI)","All","up to 64 Years   (Child, Adult)","Phase 3","750","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000063834|MRC-LEUK-MYEL-VII|EU-94030","November 1, 1999","September 1994","null","December 18, 2013","May 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00002599"
3017,"NCT00916045","Pilot Study of Unrelated Cord Blood Transplantation","Terminated","No Results Available","Leukemia, Myeloid, Acute|Myelodysplastic Syndromes|Leukemia, Lymphoblastic, Acute|Lymphoma, Non-Hodgkin|Hodgkin Disease|Chronic Lymphocytic Leukemia","Drug: Thiotepa|Drug: Fludarabine|Drug: Intravenous busulphan|Drug: Thymoglobulin|Drug: Ciclosporin|Drug: Mycophenolate mofetil (MMF)|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Radiotherapy|Drug: Thymoglobulin|Drug: Ciclosporin|Drug: Mycophenolate mofetil (MMF)|Drug: Fludarabine|Drug: Melphalan|Drug: Thymoglobulin|Drug: Ciclosporin|Drug: Mycophenolate mofetil (MMF)","King's College Hospital NHS Trust","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","07CC12|REC - 07/H0808/193|EudraCT - 2007-001657-26","June 5, 2009","September 2009","March 2012","February 10, 2015","March 2012","No Study Results Posted","null","March 2012","Treatment related mortality at day 100|Disease free survival at one year post-transplant for each cohort|Chimerism|Incidence of neutrophil engraftment by day 42|Incidence of platelet engraftment by 6 months|Incidence of grade II-IV and III-IV acute GVHD|Incidence of chronic GVHD during the first year|One year overall survival for each treatment cohort|Incidence of systemic infections|Incidence of CMV, adenovirus and EBV activation|Immune reconstitution|Dynamics of EBV infection and immunity following cord blood transplantation|The development (if any) of transplant associated post transplant lymphoproliferative disease (PTLD)|Identify any possible predictive markers for patients most at risk of PTLD development|Quality of life|Incidence of one year relapse or disease progression for each treatment cohort","https://ClinicalTrials.gov/show/NCT00916045"
3018,"NCT00945009","Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor","Active, not recruiting","No Results Available","Adult Renal Wilms Tumor|Beckwith-Wiedemann Syndrome|Childhood Renal Wilms Tumor|Diffuse Hyperplastic Perilobar Nephroblastomatosis|Hemihypertrophy|Stage I Renal Wilms Tumor|Stage II Renal Wilms Tumor|Stage III Renal Wilms Tumor|Stage IV Renal Wilms Tumor|Stage V Renal Wilms Tumor","Biological: Dactinomycin|Drug: Doxorubicin Hydrochloride|Drug: Vincristine Sulfate|Drug: Carboplatin|Drug: Cyclophosphamide|Drug: Etoposide Phosphate|Radiation: Radiation Therapy|Procedure: Therapeutic Conventional Surgery|Procedure: Adjuvant Therapy|Procedure: Neoadjuvant Therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 29 Years   (Child, Adult)","Phase 3","249","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","AREN0534|NCI-2011-01953|CDR0000649716|U10CA180886|U10CA098543","July 22, 2009","July 2009","null","November 28, 2016","November 2016","No Study Results Posted","null","October 2018","Event-free survival|Prevention of complete removal of at least one kidney in 50% of patients with bilateral Wilms tumor (BWT)|Efficacy of chemotherapy in preserving renal units and preventing Wilms tumor development in patients with diffuse hyperplastic perilobular nephrogenic rests|Facilitation of partial nephrectomy in lieu of total nephrectomy in 25% of patients with unilateral Wilms tumor|Percentage of patients with bilateral Wilms tumor (BWT) undergoing definitive surgical treatment by week 12","https://ClinicalTrials.gov/show/NCT00945009"
3019,"NCT00017368","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma","Completed","No Results Available","Neuroblastoma","Biological: filgrastim|Biological: sargramostim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: etoposide phosphate|Drug: ifosfamide|Drug: isotretinoin|Drug: melphalan|Drug: thiotepa|Drug: vincristine sulfate|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","Phase 2","42","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","ANBL00P1|COG-ANBL00P1|CDR0000068681","June 6, 2001","April 2001","January 2012","February 12, 2014","February 2014","No Study Results Posted","null","September 2005","Transplant-related mortality|Incidence of symptomatic CMV, disseminated adenovirus infection, or EBV-LPD|Event-free Survival","https://ClinicalTrials.gov/show/NCT00017368"
3020,"NCT00004906","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: anastrozole|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: docetaxel|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: pamidronate disodium|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation","Hackensack University Medical Center|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU-H97B1|CDR0000067586|NCI-G00-1682","March 7, 2000","October 1999","June 2001","May 29, 2013","November 2007","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00004906"
3021,"NCT00004231","Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma","Completed","No Results Available","Lymphoma","Biological: aldesleukin|Biological: filgrastim|Biological: recombinant interferon alfa|Drug: busulfan|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: leucovorin calcium|Drug: methotrexate|Drug: prednisone|Drug: teniposide|Drug: vincristine sulfate|Procedure: allogeneic bone marrow transplantation|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Northwestern University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU 96H3|NU-96H3|NCI-G99-1659","January 28, 2000","October 1999","August 2006","May 31, 2012","May 2012","No Study Results Posted","null","August 2006","","https://ClinicalTrials.gov/show/NCT00004231"
3022,"NCT00822120","S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma","Active, not recruiting","No Results Available","Lymphoma|Nonneoplastic Condition","Biological: bleomycin sulfate|Biological: filgrastim|Drug: ABVD regimen|Drug: BEACOPP regimen|Drug: cyclophosphamide|Drug: dacarbazine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: procarbazine hydrochloride|Drug: vinblastine sulfate|Drug: vincristine sulfate","Southwest Oncology Group|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 2","230","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CDR0000630501|S0816|U10CA032102","January 13, 2009","July 2009","April 2020","April 21, 2016","April 2016","No Study Results Posted","null","April 2016","2-year progression-free survival (PFS) of HIV-negative patients after treatment with 2 courses of ABVD|2-year PFS of patients who are PET-positive after treatment with ABVD and escalated-dose BEACOPP|2-year overall survival (OS) for HIV-negative patients treated with response- adapted therapy|Complete and partial response rates for HIV-negative patients treated with response- adapted therapy|Toxicity as assessed by NCI CTCAE v3.0","https://ClinicalTrials.gov/show/NCT00822120"
3023,"NCT00476190","ALL Adult Consortium Trial: Adult ALL Trial","Active, not recruiting","No Results Available","Acute Lymphoblastic Leukemia","Drug: Doxorubicin|Drug: Cytarabine|Drug: Methotrexate|Drug: Vincristine|Drug: Cyclophosphamide|Drug: Methylprednisone|Drug: Hydrocortisone Sodium Succinate|Drug: Dexamethasone|Drug: 6-MP|Drug: PEG-Asparaginase|Drug: Imatinib|Drug: Etoposide|Procedure: Radiation Therapy|Drug: E. coli Asparaginase","Dana-Farber Cancer Institute|Massachusetts General Hospital|Boston Children’s Hospital|NCIC Clinical Trials Group","All","18 Years to 50 Years   (Adult)","Phase 2","112","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","06-254","May 18, 2007","April 2007","December 2016","February 11, 2016","February 2016","No Study Results Posted","null","June 2016","To determine the feasibility, toxicity and efficacy of the high-risk pediatric treatment in adult patient 18 year of age or older.|To determine the complete response rate at the end of induction therapy.|Disease-free survival, defined as the time from achieving a complete remission to the first of disease recurrence or death, will be estimated using Kaplan-Meier methods.|Overall survival, defined as time from study entry to death from any cause, will be estimated using Kaplan-Meier methods.","https://ClinicalTrials.gov/show/NCT00476190"
3024,"NCT00238368","Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: busulfan|Drug: cisplatin|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: methylprednisolone|Drug: prednisone|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: positron emission tomography|Radiation: fludeoxyglucose F 18|Radiation: radiation therapy","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","59","Other|NIH","Interventional","Primary Purpose: Diagnostic","J0348 CDR0000445618|P30CA006973|JHOC-J0348|JHOC-03082605","October 12, 2005","February 2004","February 2009","April 16, 2014","April 2014","No Study Results Posted","null","February 2009","2-year event free survival|Overall survival|Predictive value of early negative fludeoxyglucose F 18 positron emission tomography (FDG-PET)|Correlation of International Prognostic Index risk category with FDG-PET results and overall outcome","https://ClinicalTrials.gov/show/NCT00238368"
3025,"NCT00080925","T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Biological: filgrastim|Biological: graft-versus-tumor induction therapy|Biological: rituximab|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: cyclosporine|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: fludarabine phosphate|Drug: prednisone|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","18 Years to 55 Years   (Adult)","Phase 1","20","NIH","Interventional","Primary Purpose: Treatment","040116|04-C-0116|CDR0000357432","April 7, 2004","February 2004","December 2010","March 7, 2012","March 2012","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00080925"
3026,"NCT00040872","Multiple Therapies in Treating Patients With Advanced Neuroblastoma","Completed","No Results Available","Neuroblastoma","Biological: filgrastim|Biological: monoclonal antibody 3F8|Biological: sargramostim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: isotretinoin|Drug: thiotepa|Drug: topotecan hydrochloride|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: conventional surgery|Procedure: drug resistance inhibition treatment|Procedure: peripheral blood stem cell transplantation|Procedure: syngeneic bone marrow transplantation|Radiation: radiation therapy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","up to 50 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","00-065|P30CA008748|MSKCC-00065|NCI-G02-2083","July 8, 2002","June 2000","January 2007","March 6, 2013","March 2013","No Study Results Posted","null","January 2007","","https://ClinicalTrials.gov/show/NCT00040872"
3027,"NCT00003727","Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia","Completed","No Results Available","Leukemia","Biological: filgrastim|Biological: recombinant interferon alfa|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Drug: gemcitabine hydrochloride|Drug: melphalan|Procedure: bone marrow ablation with stem cell support|Procedure: in vitro-treated peripheral blood stem cell transplantation","University of Maryland|University of Maryland Greenebaum Cancer Center","All","Child, Adult, Senior","Phase 2","22","Other","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000066839|MSGCC-9851|MSGCC-1198006|NCI-V98-1513","November 1, 1999","March 1999","February 2008","September 23, 2009","September 2009","No Study Results Posted","null","March 2005","Response (i.e., major cytogenetic or molecular response) within 12 months after completion of study therapy|Mortality rate","https://ClinicalTrials.gov/show/NCT00003727"
3028,"NCT03150693","Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","Not yet recruiting","No Results Available","B Acute Lymphoblastic Leukemia","Drug: Allopurinol|Drug: Cytarabine|Drug: Daunorubicin Hydrochloride|Drug: Vincristine Sulfate|Drug: Dexamethasone|Drug: Pegylated Recombinant L-Asparaginase Erwinia Chrysanthemi|Drug: Methotrexate|Procedure: Bone Marrow Aspiration and Biopsy|Drug: Cyclophosphamide|Drug: Mercaptopurine|Biological: Rituximab|Drug: Doxorubicin|Drug: Thioguanine|Biological: Inotuzumab Ozogamicin|Other: Laboratory Biomarker Analysis","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years to 39 Years   (Adult)","Phase 3","310","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","A041501|NCI-2016-01981|U10CA180821","May 9, 2017","June 2017","August 2024","May 10, 2017","May 2017","No Study Results Posted","null","March 2023","EFS|DFS|OS|Proportion of patients who achieve CR or any response to induction therapy|Overall induction response rates|Incidence of adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0|Proportion of patients who go off treatment due to adverse reactions|Proportion of patients who refuse further treatment for lesser toxicities that inhibit their willingness to continue participation on the trial","https://ClinicalTrials.gov/show/NCT03150693"
3029,"NCT01132807","Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Biological: Bleomycin Sulfate|Drug: Doxorubicin Hydrochloride|Drug: Procarbazine Hydrochloride|Drug: Vinblastine Sulfate|Drug: Dacarbazine|Drug: Cyclophosphamide|Drug: Etoposide phosphate|Drug: prednisone|Drug: Radiation Therapy|Radiation: Fludeoxyglucose F-18|Procedure: computed tomography|Procedure: Positron Emission Tomography","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 2","149","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CALGB-50604|NCI-2011-02042|U10CA180821|CDR0000672913","May 27, 2010","May 2010","null","September 23, 2016","September 2016","No Study Results Posted","null","June 2017","Progression-free survival (PFS) at 36 months|complete response rate","https://ClinicalTrials.gov/show/NCT01132807"
3030,"NCT00131053","Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)","Unknown status","No Results Available","Lymphoblastic Leukemia, Acute","Drug: Methotrexate|Drug: Prednisolone|Drug: Dexamethasone|Drug: Vincristine|Drug: Pirarubicin|Drug: Cyclophosphamide|Drug: L-asparaginase|Drug: Cytarabine|Drug: Hydrocortisone|Drug: Mercaptopurine","Japan Adult Leukemia Study Group","All","15 Years to 24 Years   (Child, Adult)","Phase 2","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","JALSG ALL202-U","August 15, 2005","September 2002","September 2011","November 13, 2008","November 2008","No Study Results Posted","null","May 2011","Disease-free survival|The rate of complete remission","https://ClinicalTrials.gov/show/NCT00131053"
3031,"NCT00049595","Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma","Active, not recruiting","No Results Available","Lymphoma","Biological: bleomycin sulfate|Biological: filgrastim|Biological: pegfilgrastim|Drug: ABVD regimen|Drug: BEACOPP regimen|Drug: cyclophosphamide|Drug: dacarbazine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: prednisone|Drug: procarbazine hydrochloride|Drug: vinblastine sulfate|Drug: vincristine sulfate","European Organisation for Research and Treatment of Cancer - EORTC|Lymphoma Trials Office|Lymphoma Study Association|Grup per l'Estudi dels Limfomes de Catalunya i Balears|NCIC Clinical Trials Group|Australasian Leukaemia and Lymphoma Group|Nordic Lymphoma Group","All","16 Years to 60 Years   (Child, Adult)","Phase 3","552","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EORTC-20012|GELA-EORTC-20012|BNLI-EORTC-20012|GELCAB-EORTC-20012|NORDICLG-EORTC-20012|CAN-NCIC-EORTC-20012|ALLG-HD04|2004-001558-10","November 12, 2002","August 2002","null","February 5, 2016","February 2016","No Study Results Posted","null","January 2010","Event-free survival|Complete response as assessed by Cheson criteria adapted to Hodgkin's lymphoma|Disease-free survival in patients with complete response|Overall survival|Quality of life as assessed by European Organization for Research of the Treatment of Cancer (EORTC) Quality of Life Questionnaire (QoLQ) C30 version 3.0","https://ClinicalTrials.gov/show/NCT00049595"
3032,"NCT02894645","Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study","Recruiting","No Results Available","Acute Lymphoblastic Leukemia (ALL)","Drug: Prednisolone|Drug: Dexamethasone|Drug: L-Asparaginase|Drug: Vincristine|Drug: Methotrexate|Drug: Daunorubicin|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Cytarabine|Drug: 6-Mercaptopurine|Drug: Thioguanine|Drug: Fludarabine|Drug: Imatinib","National University Hospital, Singapore","All","1 Year to 17 Years   (Child)","Phase 4","500","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","Ma-Spore ALL 2010","August 25, 2016","October 2008","null","September 29, 2016","September 2016","No Study Results Posted","null","October 2018","Event-free survival (EFS)|Overall survival (OS)|Minimal residual disease (MRD) measurement|Number of participants with chemotherapy-related adverse events as assessed by CTCAE version 4.0|Dose intensity of chemotherapy during various phases of therapy","https://ClinicalTrials.gov/show/NCT02894645"
3033,"NCT00526305","LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive","Completed","No Results Available","Acute Lymphoblastic Leukemia","Drug: Vincristine|Drug: Daunorubicin|Drug: Prednisone|Drug: L-Asparaginase|Drug: Mitoxantrone|Drug: Cytosine Arabinoside|Drug: Hydrocortisone|Drug: Mercaptopurine|Drug: Cyclophosphamide|Drug: Dexamethasone","PETHEMA Foundation","All","up to 65 Years   (Child, Adult)","Phase 4","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LAL-Ph-2000","September 5, 2007","January 2000","April 2005","January 3, 2010","January 2010","No Study Results Posted","null","April 2005","To evaluate the efficacy of treatment in order to response rate, relapse free survival and overall survival","https://ClinicalTrials.gov/show/NCT00526305"
3034,"NCT00439296","ABT-751 With Chemotherapy for Relapsed Pediatric ALL","Terminated","No Results Available","Recurrent Pediatric ALL|Relapsed Pediatric ALL|Acute Lymphoblastic Leukemia|Refractory Pediatric ALL","Drug: ABT-751|Drug: dexamethasone|Drug: PEG-asparaginase|Drug: doxorubicin|Drug: cytarabine|Drug: methotrexate|Drug: cyclophosphamide|Drug: 6-thioguanine","Therapeutic Advances in Childhood Leukemia Consortium","All","up to 21 Years   (Child, Adult)","Phase 1","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","T2005-001","February 21, 2007","May 2006","September 2009","November 28, 2012","November 2012","No Study Results Posted","null","June 2009","Dose Limiting Toxicity|Maximum Tolerated Dose|Rate of Remission|Pharmacokinetic profile on blood and CSF","https://ClinicalTrials.gov/show/NCT00439296"
3035,"NCT00049569","Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia","Completed","No Results Available","L1 Childhood Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Non-T, Non-B Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia","Drug: cytarabine|Drug: methotrexate|Drug: vincristine sulfate|Drug: prednisone|Drug: pegaspargase|Drug: doxorubicin hydrochloride|Drug: imatinib mesylate|Drug: cyclophosphamide|Drug: etoposide|Biological: filgrastim|Drug: leucovorin calcium|Drug: asparaginase|Drug: therapeutic hydrocortisone","National Cancer Institute (NCI)","All","1 Year to 21 Years   (Child, Adult)","","126","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NCI-2012-01798|COG-AALL01P2|CDR0000258120|AALL01P2|U10CA098543","November 12, 2002","January 2003","null","October 7, 2013","October 2013","No Study Results Posted","null","March 2006","Feasibility assessed by excessive early deaths, induction failures, and early relapses|Toxicity assessed using CTC version 2.0|Overall remission reinduction (CR2) rate|EFS|MRD|Feasibility of combining intensive re-induction therapy with imatinib mesylate|Percentage of patients who were able to complete the triple re-induction therapy with imatinib mesylate","https://ClinicalTrials.gov/show/NCT00049569"
3036,"NCT00186823","Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies","Completed","No Results Available","Leukemia, Acute Lymphocytic (ALL)|Leukemia, Myeloid, Acute(AML)|Leukemia, Myeloid, Chronic(CML)|Juvenile Myelomonocytic Leukemia(JMML)|Hemoglobinuria, Paroxysmal Nocturnal (PNH)|Lymphoma, Non-Hodgkin (NHL)|Myelodysplastic Syndrome (MDS)","Device: Miltenyi Biotec CliniMACS|Procedure: Stem Cell Transplantation|Drug: TBI, systemic chemotherapy and antibodies as follows:","St. Jude Children's Research Hospital","All","2 Years to 21 Years   (Child, Adult)","Phase 3","57","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","HAPSCT","September 9, 2005","March 2002","January 2009","January 28, 2009","January 2009","No Study Results Posted","null","September 2005","To describe rate of hematopoietic and immune reconstitution in first 100 days posttransplant for pediatric patients with high-risk hematologic malignancies receiving haploidentical transplant processed with investigational CliniMACS cell sorting device.","https://ClinicalTrials.gov/show/NCT00186823"
3037,"NCT01639339","Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis","Recruiting","No Results Available","Lupus Nephritis","Biological: Placebo plus standard therapy|Biological: Belimumab 10 mg/kg plus standard therapy|Drug: Standard therapy","Human Genome Sciences Inc., a GSK Company|GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 3","464","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Care Provider, Investigator, Outcomes Assessor|Primary Purpose: Treatment","114054","July 10, 2012","July 2012","February 2020","March 21, 2017","March 2017","No Study Results Posted","BLISS-LN","July 2019","Number of participants with a renal response at Week 104|Number of participants with a complete renal response at Week 104|Number of participants with a renal response at Week 52|Number of participants who experienced adverse events","https://ClinicalTrials.gov/show/NCT01639339"
3038,"NCT00734877","UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","Recruiting","No Results Available","Multiple Myeloma","Drug: M-VTD-PACE|Drug: TT3-LITE Regimen (L-TT3)","University of Arkansas|Millennium Pharmaceuticals, Inc.","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","400","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","103668","August 12, 2008","July 2008","September 2017","October 6, 2016","October 2016","No Study Results Posted","TT4B","September 2017","Progression-free survival rate","https://ClinicalTrials.gov/show/NCT00734877"
3039,"NCT01941680","High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant","Recruiting","No Results Available","T-cell Lymphoma|Leukaemia","","University Hospital Center of Martinique","All","18 Years to 75 Years   (Adult, Senior)","","20","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","13/B/04|2013-A00327-38","September 3, 2013","October 31, 2013","October 2018","April 25, 2017","April 2017","No Study Results Posted","ATLL-HR-01","September 2018","Number of patients with relapse|Evidence of presence of gene expression of Tax and HBZ confirmed by Rt-PCR","https://ClinicalTrials.gov/show/NCT01941680"
3040,"NCT02135380","Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis","Unknown status","No Results Available","Idiopathic Pulmonary Fibrosis","Biological: Autologous Stromal Vascular Fraction (SVF)|Biological: Autologous Adipose Derived MSCs (ADMSCs)|Other: Control","Kasiak Research Pvt. Ltd.","All","30 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","KRPL/IPF/11-12/002","May 8, 2014","August 2014","null","May 12, 2014","May 2014","No Study Results Posted","null","August 2015","Safety|Efficacy","https://ClinicalTrials.gov/show/NCT02135380"
3041,"NCT02579967","Pilot Trial of Allogeneic Blood or Marrow Transplanation for Primary Immunodeficiencies","Recruiting","No Results Available","Primary T-cell Immunodeficiency Disorders|Common Variable Immunodeficiency|Immune System Diseases|Autoimmune Lymphoproliferative|Lymphoproliferative Disorders","Drug: Immunosuppression Only Conditioning|Drug: Reduced Intensity Conditioning|Drug: Myeloablative Conditioning|Drug: GVHD Prophylaxis|Procedure: Allo BMT","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","4 Years to 75 Years   (Child, Adult, Senior)","Phase 2","124","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","160003|16-C-0003","October 16, 2015","October 9, 2015","October 1, 2022","May 12, 2017","April 6, 2017","No Study Results Posted","null","October 1, 2021","To estimate the aGVHD-free, graft failure-free survival","https://ClinicalTrials.gov/show/NCT02579967"
3042,"NCT00145587","Stem Cell Transplantation for Children Affected With Osteopetrosis","Terminated","Has Results","Osteopetrosis","Procedure: Stem Cell Transplantation|Device: Miltenyi Biotec CliniMACS|Drug: Systemic chemotherapy and antibodies","St. Jude Children's Research Hospital","All","Child, Adult, Senior","","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","OPBMT2","September 1, 2005","July 2004","February 2009","July 26, 2012","January 2011","June 22, 2011","null","February 2009","Engraftment","https://ClinicalTrials.gov/show/NCT00145587"
3043,"NCT00117598","Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)","Completed","Has Results","Lymphoma","Drug: Temsirolimus (CCI-779)|Drug: Temsirolimus (CCI-779)|Drug: Investigator's choice","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 3","169","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","3066K1-305","June 30, 2005","May 2005","January 2011","March 10, 2015","March 2015","February 2, 2012","OPTIMAL","August 2007","Progression-Free Survival (PFS)|Percentage of Participants With Objective Response","https://ClinicalTrials.gov/show/NCT00117598"
3044,"NCT02188368","Pomalidomide for Lenalidomide for Failures","Recruiting","No Results Available","Multiple Myeloma","Drug: POM|Drug: Steroids|Drug: PLD|Drug: CFZ|Drug: BTZ|Drug: CLA|Drug: Other drugs","Oncotherapeutics|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PO-CL-MM-PI-003854","July 7, 2014","August 2014","August 2017","March 8, 2016","March 2016","No Study Results Posted","null","February 2017","Maximum Tolerated Dose (MTD)|Number of subjects with adverse events|Overall Response Rate|Clinical Benefit Rate (CBR)|Time to Progression|Progression-free survival (PFS)|Time to first response (TTP)|Duration of response (DOR)|Overall survival (OS)","https://ClinicalTrials.gov/show/NCT02188368"
3045,"NCT00317096","FCM Versus R-FCM Followed by R-Maintenance or Observation Only","Active, not recruiting","No Results Available","Lymphoma, Follicular|Lymphoma, Low-Grade|Lymphoma, Intermediate-Grade","Procedure: FCM|Procedure: R-FCM|Drug: rituximab maintenance|Other: observation only","Ludwig-Maximilians - University of Munich","All","18 Years and older   (Adult, Senior)","Phase 3","319","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","NHL-1998-1","April 20, 2006","November 1998","June 2021","September 6, 2016","September 2016","No Study Results Posted","null","June 2001","Remission rate|Event free interval|Time to Progression|Overall survival|adverse events|serious infectious complications","https://ClinicalTrials.gov/show/NCT00317096"
3046,"NCT00592111","A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)","Completed","No Results Available","Pediatric|Hodgkin's Disease","Drug: COPP/ABV|Drug: COPP/ABV|Drug: intensive chemo with concurrent growth factor","Memorial Sloan Kettering Cancer Center|Children's Cancer Group","All","up to 21 Years   (Child, Adult)","Phase 2","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","96-016|CCG 5942|CA42764","December 26, 2007","March 1996","January 2008","December 21, 2015","December 2015","No Study Results Posted","null","February 1999","Determine the role of adjuvant low dose involved field radiotherapy in pediatric patients with Hodgkin's disease who attain a complete response following initial chemotherapy","https://ClinicalTrials.gov/show/NCT00592111"
3047,"NCT00246649","Stem Cell Transplant With Specially Treated Cells in Treating Patients With Acute Leukemia","Completed","No Results Available","AML|ALL (High Risk)","Procedure: Ex vivo expansion of mafosfamide purged marrow or mobilized stem cells with growth factors (rhSCF and rhTPO)","Sidney Kimmel Comprehensive Cancer Center|National Institutes of Health (NIH)","All","1 Year to 70 Years   (Child, Adult, Senior)","","25","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","J0563","October 27, 2005","September 2005","null","December 16, 2008","December 2008","No Study Results Posted","null","null","To assess the feasibility of ex vivo expanding a CD34 selected, mafosfamide purged autograft.|To assess the duration of aplasia associated with mafosfamide purging and ex vivo cytokine expanded autografting for high risk acute leukemia.|To estimate the event-free survival following mafosfamide purging and ex vivo cytokine expanded autografting for high risk acute leukemia|To obtain blood samples for future laboratory studies that may include immune reconstitution.","https://ClinicalTrials.gov/show/NCT00246649"
3048,"NCT01362452","Infusion of Allogeneic Umbilical Cord Blood-Derived CD19-Specific T Cells","Active, not recruiting","No Results Available","Leukemia|Lymphoma","Genetic: T-Cell Infusion|Procedure: Cord Blood Infusion","M.D. Anderson Cancer Center","All","1 Year to 75 Years   (Child, Adult, Senior)","Phase 1","54","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","2010-0835|FD-R-04369-01|NCI-2011-01046|RP130516","May 26, 2011","December 2012","null","July 13, 2016","July 2016","No Study Results Posted","null","December 2018","Maximum Tolerated Dose (MTD) of T-Cell Infusions","https://ClinicalTrials.gov/show/NCT01362452"
3049,"NCT01044069","Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19","Active, not recruiting","No Results Available","Leukemia|Acute Lymphoblastic Leukemia","Biological: gene-modified T cells targeted","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1","93","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","09-114","January 6, 2010","January 5, 2010","January 2018","May 12, 2017","May 2017","No Study Results Posted","null","January 2018","To evaluate the safety of adoptive transfer of gene-modified autologous CD19-specific T cells in adult patients with B-ALL.|To assess the anti-leukemic effect of adoptively transferred anti-CD19 T cells.","https://ClinicalTrials.gov/show/NCT01044069"
3050,"NCT02858258","ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma","Recruiting","No Results Available","Mantle Cell Lymphoma","Drug: R-CHOP/R-DHAP|Drug: Ibrutinib (Induction)|Drug: ASCT conditioning|Drug: Ibrutinib (Maintenance)","Prof. Dr. M. Dreyling (co-chairman)|Klinikum der Universitaet Muenchen|European Mantle Cell Lymphoma Network","All","18 Years to 65 Years   (Adult)","Phase 3","870","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","TRIANGLE","July 14, 2016","July 2016","May 2026","March 6, 2017","March 2017","No Study Results Posted","null","May 2021","Failure Free Survival|Overall Survival|Number of participants with treatment-related adverse events as assessed by CTC Version 4.03|Progression-free survival (PFS)|Number of Secondary Primary Malignancies|Number of Adverse Events by CTC grade (Version 4.03)","https://ClinicalTrials.gov/show/NCT02858258"
3051,"NCT02428517","Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia (2015)","Terminated","No Results Available","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Procedure: AlloHCT for Young/MSD|Procedure: AlloHCT for Young/MUD&FMD|Procedure: AlloHCT for Old/MSD|Procedure: AlloHCT for Old/MUD&FMD","Asan Medical Center","All","15 Years and older   (Child, Adult, Senior)","Phase 2","20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AMC-ALLO-044","April 21, 2015","April 2015","December 2024","July 13, 2016","July 2016","No Study Results Posted","ATLAS2015","December 2019","relapse-free survival (RFS) rate|overall survival (OS) rate|cumulative incidence of relapse|treatment-related mortality rate|cumulative incidence of acute graft-versus-host disease|cumulative incidence of chronic graft-versus-host disease|molecular relapse-free survival","https://ClinicalTrials.gov/show/NCT02428517"
3052,"NCT00366834","Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting","Completed","No Results Available","Vomiting|Nausea|Nausea and Vomiting, Chemotherapy-Induced","Drug: Casopitant (GW679769) oral tablets|Drug: Casopitant (GW679769) intravenous|Drug: Dexamethasone intravenous|Drug: Ondansetron oral tablets|Drug: placebo","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 3","1840","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NKV102549","August 17, 2006","July 2006","October 2009","September 6, 2012","June 2012","No Study Results Posted","null","October 2007","Complete response as assessed by a visual analogue scale and a subject diary over the 120 hours following the first cycle of chemotherapy.|Complete response over 120 hours following subsequent chemotherapy cycles Use of rescue medication over 120 hours following all chemotherapy cycles Impact on daily life activities over 120 hours, assessed using a subject diary questionnaire|The proportion of subjects who achieve a complete response during the acute (0-24 hours) and the delayed (24-120 hours) phase following the first cycle of MEC.|The proportion of subjects who achieve a complete response over the first 120 hours, during the acute (0-24 hours), the delayed (24-120 hours), and the overall (0-120 hours) phase following subsequent cycles of MEC.|Maximum nausea score (to assess the severity of nausea), as assessed by a Visual Analogue Scale (VAS) over the first 120 hours and in the acute and delayed phases following each cycle of MEC.|Time to first antiemetic rescue medication, defined as the time elapsed from the start of administration of the MEC regimen to the first use of antiemetic rescue medication.|If a subject withdraws prematurely during the first 120 hours, then the time of withdrawal will be considered to be their time to first use of antiemetic rescue medication, and will be censored.|Time to first emetic event, defined as the time elapsed from the start of administration of the MEC regimen to the first emetic episode. If a subject withdraws prematurely during the first 120 hours,|then the time of withdrawal will be considered to be their time to first emetic episode, and will be censored.|The proportion of subjects who receive rescue medication.|The proportion of subjects reporting significant nausea defined as a maximum nausea score greater than or equal to 25 mm on the VAS.|The proportion of subjects reporting nausea defined as a maximum nausea score greater than or equal to 5 mm on the VAS.|The proportion of subjects achieving complete protection, defined as complete responders who had no significant nausea.|The impact on subjects' daily life activities for the first 120 hours following the first cycle of chemotherapy as assessed by the FLIE questionnaire.|Subject satisfaction with the prophylactic antiemetic regimens, and the willingness of subjects to use the same treatment during future chemotherapy, as assessed by the Subject Satisfaction\Willingness Assessment in the Subject Diary.|Nausea as assessed by a categorical scale, over the first 120 hours following MEC administration.|Assessment of the safety and tolerability of casopitant through: routine physical exam, routine clinical laboratory tests, clinical monitoring and adverse events reporting.|The proportion of subjects who vomit/retch.|The proportion of subjects achieving total control, defined as complete responders who had no nausea.","https://ClinicalTrials.gov/show/NCT00366834"
3053,"NCT01731886","Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma","Active, not recruiting","No Results Available","Multiple Myeloma","Procedure: Autologous peripheral blood stem cell transplant|Drug: Lenalidomide|Drug: Dexamethasone|Procedure: Stem Cell Mobilization","Columbia University","All","18 Years and older   (Adult, Senior)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AAAJ2355","November 19, 2012","September 2012","February 2020","January 14, 2017","January 2017","No Study Results Posted","null","February 2017","Difference in complete response rate|Difference in overall survival rate","https://ClinicalTrials.gov/show/NCT01731886"
3054,"NCT00083551","UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy","Completed","Has Results","Multiple Myeloma","Drug: Thalidomide|Drug: Ara-C|Drug: BCNU|Drug: Cisplatin|Drug: Cytoxan|Drug: Dexamethasone|Drug: Doxorubicin|Drug: Etoposide|Drug: Filgrastim|Drug: Recombinant GM-CSF|Drug: Interferon-alpha-2b|Drug: Melphalan|Drug: Vincristine","University of Arkansas|Celgene Corporation","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","668","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","5226","May 25, 2004","August 1998","August 2014","October 21, 2015","October 2015","August 24, 2015","null","August 2014","Overall Survival","https://ClinicalTrials.gov/show/NCT00083551"
3055,"NCT02995330","Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer","Recruiting","No Results Available","Prostate Cancer","Procedure: Bone marrow transplantation|Drug: Bone marrow cell|Drug: Cytoxan and testosterone","Sidney Kimmel Comprehensive Cancer Center","Male","18 Years to 75 Years   (Adult, Senior)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","J1608|IRB00086105","December 14, 2016","January 2017","January 2022","March 20, 2017","March 2017","No Study Results Posted","null","January 2020","PSA response|Transplant-related mortality|PSA response rate|Objective response rate|Time to PSA progression|Clinical/radiographic progression|Incidence of acute graft versus host disease|Incidence of chronic GVHD|Incidence of donor chimerism and graft failure|Effects of post-transplantation cyclophosphamide on the immune reconstitution of T cells, B cells, and NK cells|Incidence of HLA specific antibodies","https://ClinicalTrials.gov/show/NCT02995330"
3056,"NCT03114865","A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance","Not yet recruiting","No Results Available","Acute Lymphoblastic Leukemia|B-cell Non Hodgkin Lymphoma|Pre B-Cell Acute Lymphoblastic Leukaemia","Drug: Blinatumomab|Drug: Blinatumomab|Drug: Blinatumomab|Drug: Dexamethasone","Sidney Kimmel Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","J1713|IRB00125679","April 11, 2017","May 2017","May 2020","April 13, 2017","April 2017","No Study Results Posted","null","May 2020","Overall survival at two years post first treatment cycle|Non-Relapse Mortality|Progression-free survival|Disease-free Survival|Overall Survival|Minimal Residual Disease","https://ClinicalTrials.gov/show/NCT03114865"
3057,"NCT02765243","Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma","Recruiting","No Results Available","Neuroblastoma|Effects of Immunotherapy","Biological: Anti-GD2 CART","Zhujiang Hospital","All","1 Year to 14 Years   (Child)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","2016-EKZX-001","May 3, 2016","May 2016","May 2017","March 9, 2017","March 2017","No Study Results Posted","4SCAR-GD2","May 2017","Number of patients with adverse events.|Anti-tumor effects|To evaluate the expansion and persistence of anti-GD2 CAR T cells|Survival time of the patients","https://ClinicalTrials.gov/show/NCT02765243"
3058,"NCT01238562","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients","Completed","No Results Available","Chemotherapy Patients","Drug: YPEG-Filgrastim|Drug: YPEG-Filgrastim|Drug: YPEG-Filgrastim|Drug: YPEG-Filgrastim|Drug: YPEG-Filgrastim","Xiamen Amoytop Biotech Co., Ltd.|Cancer Institute and Hospital, Chinese Academy of Medical Sciences","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","30","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label","TB1004CSF","November 5, 2010","April 2010","November 2011","January 31, 2013","March 2010","No Study Results Posted","Filgrastim","November 2011","Measurement of absolute neutrophil counts in the 3 cycles for pharmacodynamic study.|Measurement of serum concentration of drugs for Pharmacokinetic study.","https://ClinicalTrials.gov/show/NCT01238562"
3059,"NCT02043587","Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma","Recruiting","No Results Available","Acute Lymphocytic Leukemia|Adult Lymphoblastic Lymphoma","Drug: DNR|Drug: VCR|Drug: PEG-asp|Drug: CTX|Drug: Prednisone|Drug: Liposomal AraC|Drug: MTX|Drug: LCV|Drug: AraC|Drug: Etoposide|Drug: Dasatinib|Drug: Rituximab|Drug: Hydrocortisone","University of California, San Diego|Leadiant Biosciences, Inc.","All","18 Years to 60 Years   (Adult)","Phase 2","100","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","130934","January 21, 2014","January 2014","January 2020","October 26, 2016","October 2016","No Study Results Posted","null","January 2020","Event-free survival|Liposomal cytarabine toxicity|CNS relapse rate|Overall survival|Leukemia-free survival|Efficacy of hydrocortisone premedication for reduced PEG-asparaginase allergic reactions|PEG-asparaginase toxicities|Complete and overall response rates|Non-relapse mortality","https://ClinicalTrials.gov/show/NCT02043587"
3060,"NCT00328237","Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation","Unknown status","No Results Available","Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia|Non-Hodgkin Lymphoma|Myelodysplastic Syndromes","Procedure: Cord Blood Transplant","Colorado Blood Cancer Institute","All","18 Years to 49 Years   (Adult)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","RMBMT-149","May 17, 2006","November 2005","null","June 23, 2006","November 2005","No Study Results Posted","null","null","Evaluate the incidence of neutrophil engraftment after transplantation of one or two cord blood units|Evaluate safety as measured by day 100 treatment related mortality|Evaluate incidence of platelet engraftment|Evaluate incidences of acute and chronic graft-versus-host disease (GVHD)|Evaluate efficacy as measured by survival at 1 and 2 years after transplant|Evaluate chimerism from double cord transplants to determine source of long term engraftment","https://ClinicalTrials.gov/show/NCT00328237"
3061,"NCT03079089","Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Disorders","Not yet recruiting","No Results Available","Refractory or Relapsed Lymphoid Haemopathy","Drug: Sequential Packaging (SET)|Drug: Transfusion graft|Drug: Prevention of GVHD|Drug: Care supports|Drug: Lymphocyte injection of prophylactic donor (PDLI)","Association for Training, Education, and Research in Hematology, Immunology, and Transplantation","All","18 Years to 60 Years   (Adult)","","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Other","2016-A00861-50","February 16, 2017","April 15, 2017","April 15, 2022","March 23, 2017","March 2017","No Study Results Posted","LY-SET-HAPLO","April 15, 2020","Overall survival (OS)|Partial or complete remission rate by standard criteria relapse incidence and death related to the disease and free survival|Cumulative incidence of death not related to relapse|Cumulative incidence of acute and chronic graft against host disease (GVHD)|Number of patients for whom PDLI was possible and number PDLI / patient ; incidence, severity and treatment of possible secondary GVHD in these patients|Immune reconstitution post-transplantation in the peripheral blood|Tolerance of this therapeutic strategy","https://ClinicalTrials.gov/show/NCT03079089"
3062,"NCT00577096","Effects of Exercise in Combination With Epoetin Alfa","Completed","Has Results","Multiple Myeloma","Drug: Epoetin Alfa|Behavioral: Exercise|Biological: Autologous Peripheral Blood Stem Cell Transplantation|Biological: Red Blood Cell Transfusion|Drug: Thalidomide|Drug: Heparin, Low-Molecular-Weight|Biological: Platelet Transfusion|Drug: Melphalan|Drug: Epoetin Alfa|Drug: Total Therapy II|Biological: Red Blood Cell Transfusion|Drug: Thalidomide|Drug: Heparin, Low-Molecular-Weight|Biological: Platelet Transfusion|Drug: Melphalan","University of Arkansas|National Institutes of Health (NIH)|Ortho Biotech Clinical Affairs, L.L.C.","All","Child, Adult, Senior","","120","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","IRB # 29287|R01NR008937|Ortho Biotech Clinical Affairs","December 17, 2007","October 2001","June 2004","April 2, 2015","April 2015","March 17, 2011","null","June 2004","Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Short Term)|Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Long Term)|Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets.(Short Term)|Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets. (Long Term)|Number of Stem Cell Collection Attempts (Short Term)|Number of Stem Cell Collection Attempts (Long Term)|Total Number of Days of Stem Cell Collection (Short Term)|Total Number of Days of Stem Cell Collection (Long Term)|Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Short Term)|Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Long Term)","https://ClinicalTrials.gov/show/NCT00577096"
3063,"NCT02315196","Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer","Recruiting","No Results Available","Estrogen Receptor-negative Breast Cancer|HER2-negative Breast Cancer|Progesterone Receptor-negative Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-negative Breast Cancer","Drug: pegylated liposomal doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: carboplatin|Procedure: therapeutic conventional surgery|Drug: paclitaxel|Other: laboratory biomarker analysis|Other: quality-of-life assessment","Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey","Female","18 Years and older   (Adult, Senior)","Phase 2","60","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","041401|NCI-2014-02029|P30CA072720","October 28, 2014","December 2014","July 2018","January 19, 2017","January 2017","No Study Results Posted","null","July 2018","Rate of pathologic complete response (pCR) based on Response Evaluation Criteria in Solid Tumors criteria|RFS, defined as time to local recurrence following surgery, regional recurrence, distant recurrence, or death from any cause prior to recurrence or second primary cancer following initiation of chemotherapeutic treatment|OS|Mutational spectrum of tumors|Sensitivity to paclitaxel or cyclophosphamide, targeted agents selected based on genomic profile, standard cytotoxins, or the combination of targeted agents with standard cytotoxins evaluated by patient derived xenograft and ex vivo models|Quality of life, assessed using a quality of life survey instrument","https://ClinicalTrials.gov/show/NCT02315196"
3064,"NCT00132691","Multicenter Uveitis Steroid Treatment (MUST) Trial","Completed","Has Results","Uveitis","Drug: fluocinolone acetonide intraocular implant|Drug: oral corticosteroid with immunosuppressive agents as needed","JHSPH Center for Clinical Trials|National Eye Institute (NEI)","All","13 Years and older   (Child, Adult, Senior)","Phase 4","255","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","NEI-106|U10EY014660|1U10EY014660-2|ISRCTN15396562","August 19, 2005","September 2005","December 2010","October 13, 2016","October 2016","May 14, 2012","MUST","December 2010","Change in Best-corrected Visual Acuity (Change in the Numbers of Letters Read From a Standard ETDRS Eye Chart) From Baseline to 24 Months in Eyes With Uveitis|Macular Edema|Uveitis Activity|Intraocular Pressure - Incident IOP Greater Than or Equal to 30 mm Hg|Intraocular Pressure - Incident IOP Greater Than or Equal to 24 mm Hg|Intraocular Pressure - Incident IOP Elevation >= 10 mmHg Above Baseline|Glaucoma - Incident|Intraocular Pressure (IOP) - Incident Use of IOP-lowering Medical Therapy (Percentage of Eyes With Uveitis That Were Not Being Treated With IOP-lowering Medical Therapy at Baseline and Underwent IOP Lowering Therapy During the 24 Month Follow-up.|Intraocular Pressure - IOP-lowering Surgery|Cataract - Incident Cataract|Change in Self-reported Vision-related Function as Measured by the National Eye Institute 25-Item Visual Function Questionnaire (NEI-VFQ 25) Vision Targeted Composite Score From Baseline to 24 Months|Change in SF-36 Mental Component Score From Baseline to 24 Months|Change in SF-36 Physical Component Score From Baseline to 24 Months|Hyperlipidemia - Incident|Hypertension Diagnosis Requiring Treatment|Diabetes Mellitus|Mortality","https://ClinicalTrials.gov/show/NCT00132691"
3065,"NCT03035422","Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia","Not yet recruiting","No Results Available","Refractory Acute Myeloid Leukemia","Drug: Sequential Packaging (SET)|Drug: Transfusion graft|Drug: Prevention of GVHD|Drug: Care supports|Drug: Lymphocyte injection of prophylactic donor (PDLI)","Association for Training, Education, and Research in Hematology, Immunology, and Transplantation","All","18 Years to 60 Years   (Adult)","","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Other","2016-A00862-49","November 24, 2016","January 2017","January 2020","January 27, 2017","January 2017","No Study Results Posted","SET-HAPLO","January 2020","Overall survival (OS)|Partial or complete remission rate by standard criteria Relapse incidence and death related to the disease|Cumulative incidence of death not related to relapse|Cumulative incidence of acute and chronic graft against host disease (GVHD)|Number of patients for whom pDLI was possible.|Study of immune reconstitution post-transplant in the peripheral blood will be used:CD4 lymphocyte levels, CD8, T regulators, Natural Killer cells and B cells|Leukemia free survival|Number of pDLI / patient; incidence, severity and treatment of possible secondary GVHD in these patients","https://ClinicalTrials.gov/show/NCT03035422"
3066,"NCT01042379","I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","Recruiting","No Results Available","Breast Neoplasms|Breast Cancer|Breast Tumors","Drug: Standard Therapy|Drug: AMG 386 with or without Trastuzumab|Drug: AMG 479 (Ganitumab) plus Metformin|Drug: MK-2206 with or without Trastuzumab|Drug: AMG 386 and Trastuzumab|Drug: T-DM1 and Pertuzumab|Drug: Pertuzumab and Trastuzumab|Drug: Ganetespib|Drug: ABT-888|Drug: Neratinib|Drug: PLX3397|Drug: Pembrolizumab|Drug: Talazoparib plus Irinotecan|Drug: Patritumab and Trastuzumab","QuantumLeap Healthcare Collaborative","Female","18 Years and older   (Adult, Senior)","Phase 2","1920","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","097517","December 31, 2009","March 2010","null","December 5, 2016","December 2016","No Study Results Posted","I-SPY 2","December 2018","Determine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry.|Establishing predictive and prognostic indices based on qualification and exploratory markers to predict pCR and residual cancer burden (RCB).|To determine three- and five-year relapse-free survival (RFS) and OS among the treatment arms.|To determine incidence of adverse events (AEs), serious adverse events (SAEs), and laboratory abnormalities of each investigational agent tested.|MRI Volume","https://ClinicalTrials.gov/show/NCT01042379"
3067,"NCT00617890","A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)","Terminated","Has Results","Osteosarcoma|Sarcoma, Ewing's|Peripheral Neuroectodermal Tumor","Biological: robatumumab","Merck Sharp & Dohme Corp.","All","4 Years and older   (Child, Adult, Senior)","Phase 2","219","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","P04720","January 17, 2008","February 2008","August 2013","August 26, 2016","August 2016","November 9, 2015","null","August 2011","Number of Participants Achieving a Complete Response or Partial Response (Group 3 Only)|Number of Participants With >= 25% Change in Tumor Proliferation After Exposure to Robatumumab (Group 1 Only)|Number of Participants Achieving a Complete Response, a Partial Response, or Stable Disease (Group 2 Only)|Overall Survival|Time Until Tumor Relapse (Group 1 Only)|Area Under the Concentration-time Curve (AUC) of Serum Levels of Robatumumab (Group 1 Only)|Incidence of Anti-robatumumab Antibodies|Number of Participants Experiencing Treatment-Emergent Adverse Events|Time to Disease Progression (Groups 2 and 3 Only)|Overall Survival (Groups 2 and 3 Only)|Duration of Response (Groups 2 and 3 Only)","https://ClinicalTrials.gov/show/NCT00617890"
3068,"NCT03144947","Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in Patients With HER2-positive Breast Cancer","Recruiting","No Results Available","Cancer, Breast","Biological: Trastuzumab IV|Biological: Trastuzumab SC|Biological: Pertuzumab|Drug: Docetaxel","Gruppo Oncologico Italiano di Ricerca Clinica|University Hospital of Parma: Department of Biomedical, Biotechnological and Translational Sciences, Pathological Anatomy and Histology Unit|University Hospital of Parma:Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology|University Hospital of Parma:Statistica medica ed epidemiologia clinica-UO Ricerca e Innovazione|Clirest s.r.l.|Mipharm SpA|Arithmos srl|Temas srl","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Other","GOIRC-01-2016","April 7, 2017","November 29, 2016","January 2019","May 4, 2017","May 2017","No Study Results Posted","IMMUN-HER","December 2018","Tumor Infiltrating lymphocites (TIL) rate on residual disease after either IV trastuzumab or SC trastuzumab (see related paragraph)|Associations between biomarkers (TIL, Tumor specific lymphocyte cell activity (TLA), and Fc-gamma-R polymorphisms) and between each biomarker with clinical outcome variables.|Frequency of toxicity Events: frequency of moderate and severe toxicity events and drop-out rate due to theraphy related toxicity (NCICommon Toxicity Criteria v 4.0)|HRQOL during study treatment based on FACT-B|Complete pathological response rate by treatment arm|5-year disease-free survival by treatment arm between treatment arms","https://ClinicalTrials.gov/show/NCT03144947"
3069,"NCT01996410","The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients","Terminated","Has Results","Breast Cancer Stages I Through III","Device: Acupuncture","OhioHealth","Female","18 Years and older   (Adult, Senior)","","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","OH1-13-00465","November 11, 2013","November 2013","May 2015","September 29, 2016","September 2016","July 15, 2016","null","January 2015","MDASI Score of Chemotherapy-associated Symptoms With Acupuncture Treatment","https://ClinicalTrials.gov/show/NCT01996410"
3070,"NCT00189488","Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation","Completed","Has Results","Graft Versus Host Disease|Hematologic Malignancies","Drug: Palifermin|Drug: Placebo|Other: Conditioning Regimen|Procedure: Allogeneic stem cell transplant|Drug: Methotrexate","Swedish Orphan Biovitrum|Amgen","All","18 Years and older   (Adult, Senior)","Phase 2","155","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","20040213","September 15, 2005","December 2005","August 2013","September 12, 2014","September 2014","November 25, 2009","null","November 2008","Number of Participants With Severe (Grade 3 and 4) Acute Graft Versus Host Disease (GVHD)|Number of Participants With Grade 2 to 4 Acute Graft Versus Host Disease (GVHD)|Number of Participants With Day 11 Methotrexate Graft Versus Host Disease Prophylaxis Administration|Number of Participants With Severe (Grade 3 or 4) Oral Mucositis|Duration of Severe Oral Mucositis (WHO Grade 3 and 4)|Number of Participants With Parenteral or Transdermal Opioid Analgesic Use|Duration of Hospitalization|Area Under the Curve (AUC) of Mouth and Throat Soreness Score","https://ClinicalTrials.gov/show/NCT00189488"
3071,"NCT01928589","Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer","Recruiting","No Results Available","Breast Cancer|Adenocarcinoma of the Breast","Radiation: PBI|Other: PBI with chemotherapy","Richard Zellars|Indiana University","Female","18 Years to 100 Years   (Adult, Senior)","Phase 1|Phase 2","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J13104","August 21, 2013","September 2013","null","August 15, 2016","August 2016","No Study Results Posted","PBI 3","September 2018","Grade 3 or 4 short-term toxicity|1st tumor recurrence|Long-term grade 3-4 toxicities|Time to tumor recurrence|Quality of Life assessment|Quantify risks and benefits comparison for each arm","https://ClinicalTrials.gov/show/NCT01928589"
3072,"NCT00001748","HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies","Completed","No Results Available","Graft vs Host Disease|Hematologic Neoplasms|Lymphoma|Myelodysplastic Syndromes|Myeloid Leukemia","Procedure: Peripheral blood progenitor cell transplant","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 1","35","NIH","Interventional","Primary Purpose: Treatment","980122|98-H-0122","November 3, 1999","June 1998","May 2000","March 3, 2008","August 1999","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001748"
3073,"NCT00122005","GVAX in Advanced Prostate Cancer Patients Made Lymphopenic","Unknown status","No Results Available","Prostate Cancer","Biological: GM-CSF gene transduced allogeneic vaccine GVAX","Providence Health & Services|Providence Cancer Center, Earle A. Chiles Research Institute|Cell Genesys","Male","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","18","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PPMC-EACRI-IRB-02-119|DOD Grant #DAMD17-03-1-0097","July 18, 2005","July 2005","July 2005","February 23, 2009","February 2009","No Study Results Posted","null","null","To evaluate the safety of combined CG1940 & CG8711, chemotherapy with cyclophosphamide +/- fludarabine and hematopoietic reconstitution in patients with advanced hormone-refractory prostate cancer (HRPC)|To explore the effects of different chemotherapy regimens on the immune response of CG1940 & CG8711 vaccinated and reconstituted lymphopenic patients with HRPC|To compare the frequency of tumor vaccine-specific, PSMA-specific T cells, and the titer of vaccine-specific antibodies in Cohorts A-C, compare in Cohorts A-C|To evaluate in vitro sensitization (IVS) methods for their capacity to expand tumor vaccine-specific CD4+ and CD8+ T cells from the peripheral blood|To determine whether the degree of lymphopenia inversely correlates with the expansion of tumor-specific CD4 and CD8 T cells|To evaluate the effects of these procedures on serum PSA levels and tumor response","https://ClinicalTrials.gov/show/NCT00122005"
3074,"NCT01370408","Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients","Completed","Has Results","Chemotherapy-induced Nausea and Vomiting","Drug: Palonosetron|Drug: ondansetron|Drug: Dexamethasone","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","18 Years to 85 Years   (Adult, Senior)","Phase 2","85","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Prevention","NSH 940","June 8, 2011","February 2012","March 2016","March 16, 2017","March 2017","October 6, 2016","null","March 2016","Complete Response Rate for Delayed Chemotherapy Induced Nausea & Vomiting|Complete Remission During Acute Phase Post-chemotherapy|Complete Remission During Overall Chemotherapy Time Period|Complete Control Rate for Nausea & Vomiting|Emetic Episodes|Patients Who Experience First Emetic Episode Within 24 Hours|Number of Patients That Required First Administration of Rescue Medication Within 24 Hours|Number of Patients That Experience Treatment Failure Within the First 24 Hours","https://ClinicalTrials.gov/show/NCT01370408"
3075,"NCT00003838","Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow","Recruiting","No Results Available","Hematologic Disease|Lymphoma|Multiple Myeloma|Myelodysplastic Syndrome|Myeloproliferative Disorder","Procedure: Stem cell transplantation","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","2 Years to 80 Years   (Child, Adult, Senior)","Phase 2","214","NIH","Interventional","Allocation: Non-Randomized|Masking: No masking|Primary Purpose: Treatment","990050|99-H-0050","November 1, 1999","February 22, 1999","December 31, 2017","May 12, 2017","August 10, 2016","No Study Results Posted","null","December 31, 2017","To evaluate engraftment by bone marrow chimerism analysis.|To determine the incidence and severity of acute and chronic graft-versus-host disease (GVHD).","https://ClinicalTrials.gov/show/NCT00003838"
3076,"NCT03114670","Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT","Recruiting","No Results Available","Adult Acute Myeloid Leukemia","Biological: CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells","Affiliated Hospital to Academy of Military Medical Sciences","All","18 Years and older   (Adult, Senior)","Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","307-RV-CAR-123","March 21, 2017","January 10, 2017","January 10, 2021","April 10, 2017","April 2017","No Study Results Posted","null","January 10, 2019","Incidence of adverse events related to treatment as assessed by NCI CTCAE version 4.03|CART cells persistence in vivo|CAR123-specific antibody level|Overall survival|Disease response(CR, CRi)","https://ClinicalTrials.gov/show/NCT03114670"
3077,"NCT00001880","Stem Cell Transplantation for Metastatic Solid Tumors","Completed","No Results Available","Cholangiocarcinoma|Colon/Rectal Ca|Bladder Ca|Breast Ca|Esophageal/Gastric Ca|Hepatocellular Ca|Ovarian Ca|Prostate Ca|Pancreatic Ca|Bony/Soft Tissue Sarcoma","","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","10 Years to 80 Years   (Child, Adult, Senior)","","84","NIH","Observational","","990064|99-H-0064","July 3, 2006","March 11, 1999","null","April 20, 2017","August 30, 2016","No Study Results Posted","null","null","To identify an anti-tumor effect of allogeneic PBSC transplantation by induction of a graft-versus-tumor (GVT) effect in patients with a diversity of metastatic solid tumors, which are refractory to standard therapy.|To evaluate engraftment by bone marrow and blood chimerism analysis.","https://ClinicalTrials.gov/show/NCT00001880"
3078,"NCT00001623","Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia","Completed","No Results Available","Graft vs Host Disease|Hematologic Neoplasm|Leukemia|Multiple Myeloma|Myelodysplastic Syndrome","Procedure: Allogeneic Bone Marrow Transplant","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","10 Years to 55 Years   (Child, Adult)","","41","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","970099|97-H-0099","November 3, 1999","March 27, 1997","January 31, 2008","May 12, 2017","August 18, 2016","No Study Results Posted","null","January 31, 2008","To evaluate the feasibility of using G-CSF mobilized donor blood to transplant a predetermined dose of stem cells and T lymphocytes to recipients with hematologic malignacies.","https://ClinicalTrials.gov/show/NCT00001623"
3079,"NCT00083876","D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma","Completed","No Results Available","Multiple Myeloma","Drug: Thalidomide","University of Arkansas|Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 3","500","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","UARK 98-035","June 2, 2004","September 1998","November 2007","July 1, 2010","July 2010","No Study Results Posted","null","null","1.1 To evaluate, in a randomized phase III clinical trial in previously treated multiple myeloma patients whether angio-chemotherapy with D.T. PACE may be equivalent or superior to tandem transplant.","https://ClinicalTrials.gov/show/NCT00083876"
3080,"NCT00001637","Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults","Completed","No Results Available","Chronic Lymphocytic Leukemia|Graft vs Host Disease|Leukemia|Myelodysplastic Syndrome|Myeloid Leukemia","Procedure: Blood cell transplantation","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","55 Years to 71 Years   (Adult, Senior)","Phase 2","28","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","970202|97-H-0202","November 3, 1999","September 29, 1997","December 28, 2016","May 12, 2017","December 28, 2016","No Study Results Posted","null","July 28, 2008","The proportion of patients with clinically significant acute GHVD (Grade II or higher) following the T depleted PBPC transplant.","https://ClinicalTrials.gov/show/NCT00001637"
3081,"NCT01361438","De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients","Active, not recruiting","No Results Available","ALL Ph Positive","Other: Total therapy approach","Gruppo Italiano Malattie EMatologiche dell'Adulto","All","18 Years to 60 Years   (Adult)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LAL1509","May 13, 2011","June 2011","October 2017","June 21, 2016","June 2016","No Study Results Posted","LAL1509","October 2014","The primary objective of the trial is to estimate the feasibility of a total therapy strategy in de novo adult Ph positive ALL.|The median value of the minimum of PCR levels achieved in each patient during the Dasatinib treatment within day +85, whenever achieved from the start of the Dasatinib.|The rate of patients who become PCR negative after Dasatinib induction.|Out of patients who become PCR negative after induction, the rate of patients who remain persistently negative during maintenance treatment with Dasatinib (without chemotherapy or allogeneic transplant).|The median value of the minimum of PCR levels achieved in each patient after an allogeneic transplant or Clofarabine-Cyclophosphamide treatment as consolidation therapy.|The rate of patients alive in CHR who have completed the maintenance program with Dasatinib after an allogeneic transplant or two cycles of Clofarabine-Cyclophosphamide as consolidation therapy.|Disease free survival estimation starting from the date of evaluation of CHR.|Cumulative incidence of relapse estimation starting from the date of evaluation of CHR.|Overall survival estimation starting from date of inclusion.","https://ClinicalTrials.gov/show/NCT01361438"
3082,"NCT01484093","Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma","Active, not recruiting","No Results Available","Mantle Cell Lymphoma","Other: R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.","Memorial Sloan Kettering Cancer Center|GlaxoSmithKline","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","96","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","11-095","November 29, 2011","November 2011","November 2017","September 7, 2016","September 2016","No Study Results Posted","null","November 2017","maximum tolerated dose (MTD)|3 year Event Free Survival (EFS)|3-year Event Free Survival (EFS)|rates of complete remission (CR)|Determine 3 year overall survival (OS).","https://ClinicalTrials.gov/show/NCT01484093"
3083,"NCT00189644","6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N+ Breast Cancer","Unknown status","No Results Available","Breast Cancer","Procedure: 6 FEC 100|Procedure: 4 FEC 100 followed by 4 Taxol","Association Européenne de Recherche en Oncologie|Bristol-Myers Squibb","Female","18 Years and older   (Adult, Senior)","Phase 3","null","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","AERO-B2000","September 12, 2005","null","null","September 12, 2005","September 2005","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00189644"
3084,"NCT01478542","OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine","Recruiting","No Results Available","CD20+ Aggressive B-Cell Lymphoma","Drug: Conventional Vincristine|Drug: Liposomal Vincristine|Drug: Ricover-scheme rituximab|Drug: optimised rituximab-schedule","University Hospital, Saarland|German High-Grade Non-Hodgkin's Lymphoma Study Group","All","61 Years to 80 Years   (Adult, Senior)","Phase 3","1152","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment","DSHNHL 2009-1","November 18, 2011","November 2011","October 2019","December 20, 2016","October 2015","No Study Results Posted","OPTIMAL>60","October 2019","Progression-free survival|for efficacy: CR-rate, PR-rate, rate of primary progressions, relapse rate, EFS and OS; rate and CTC grades of PNP. Prognostic value of the FDG-PET derived imaging biomarkers for lymphoma load: SUV, MTV, TLG.","https://ClinicalTrials.gov/show/NCT01478542"
3085,"NCT00827424","The Impact of the PACE Program Implementation on Health Services Utilization by Obese Arab Women","Completed","No Results Available","Obesity","Behavioral: Lifestyle counseling by applying a modified PACE protocol","Clalit Health Services","Female","35 Years to 64 Years   (Adult)","","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","CMC-07-0054CTIL","January 21, 2009","December 2008","July 2010","August 23, 2010","August 2010","No Study Results Posted","AWESOME","May 2010","A significant change in BMI|Patient's lifestyle habits: physical activity, eating habits|Patient's clinical measures: BP, Waist Circumference|Patient's metabolic measure: HbA1c, lipid profile, fasting plasma glucose (FPG)|Patient's readiness for change: Determined by the PACE score","https://ClinicalTrials.gov/show/NCT00827424"
3086,"NCT00001338","A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer","Completed","No Results Available","Breast Neoplasms|Fever|Hematologic Diseases|Neutropenia|Sepsis","Drug: FLAC chemotherapy with GM-CSF","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 3","65","NIH","Interventional","Primary Purpose: Treatment","930153|93-C-0153","November 3, 1999","June 1993","January 2001","March 3, 2008","April 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001338"
3087,"NCT00001269","Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer","Completed","No Results Available","Breast Neoplasms|Neoplasm Metastasis","Drug: IL-3","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 1","100","NIH","Interventional","Primary Purpose: Treatment","910121|91-C-0121","November 3, 1999","May 1991","February 2001","March 3, 2008","April 2000","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00001269"
3088,"NCT01175772","Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy","Terminated","No Results Available","Ovarian Carcinoma","Drug: Cytophosphan, Celecoxib, Methotrexate","HaEmek Medical Center, Israel","Female","20 Years to 80 Years   (Adult, Senior)","Phase 2","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","0082-09-EMC","August 1, 2010","August 2010","April 2013","June 21, 2015","June 2015","No Study Results Posted","null","April 2013","Time to Progression","https://ClinicalTrials.gov/show/NCT01175772"
3089,"NCT00992992","Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma","Completed","Has Results","Lymphoma, Mantle-Cell","Biological: Tositumomab and Iodine I 131 Tositumomab followed by CHOP","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","393229/005","October 8, 2009","June 2001","June 2013","February 27, 2014","November 2013","February 27, 2014","null","June 2013","Number of Participants With the Indicated Unconfirmed Response (Complete Response, Complete Response Unconfirmed, and Partial Response)|Number of Participants With the Indicated Confirmed Response (Confirmed Complete Response, Complete Response Unconfirmed, and Partial Response)|Duration of Response for All Confirmed Responders (CR + CRu + PR)|Duration of Response for All Unconfirmed Responders (CR + CRu + PR)|Duration of Response for Unconfirmed Complete Responders|Duration of Response for Confirmed Complete Responders|Progression-free Survival|Time to Treatment Failure|Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)|Mean Nadir Value for Absolute Neutrophil Count (ANC)|Mean Nadir Value for Hemoglobin|Mean Nadir Values for Platelets and White Blood Cell (WBC) Count|Time to Nadir for the Indicated Hematology Parameters|Time to Recovery From the Indicated Hematology Parameters|Number of Participants Negative for Human Anti-Murine (Mouse) Antibody (HAMA) at Screening Who Converted to HAMA Positivity or Remained Negative During the Course of the Study|Number of Participants With an Adverse Event of Cytopenia|Overall Survival","https://ClinicalTrials.gov/show/NCT00992992"
3090,"NCT00684970","Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)","Unknown status","No Results Available","Metastatic Castration Resistant Prostate Cancer (CRPC)","Drug: Hamsa-1™ TL-118","Tiltan Pharma Ltd.","Male","18 Years and older   (Adult, Senior)","Phase 2","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TLH-202","May 22, 2008","March 2009","null","December 4, 2013","December 2013","No Study Results Posted","TLH-202","February 2014","Progression free survival (PFS) measured 24 weeks after treatment initiation|Overall Survival, Time to PSA Progression, PSA Response, Pain Response measured in evaluable patients.|Safety and tolerability","https://ClinicalTrials.gov/show/NCT00684970"
3091,"NCT00204568","Trofosfamide Versus Adriamycin in Elderly Patients With Soft Tissue Sarcoma (STS)","Unknown status","No Results Available","Sarcoma, Soft Tissue","Drug: Adriamycin|Drug: Trofosfamide","University of Schleswig-Holstein|Arbeitsgemeinschaft fur Internistische Onkologie|German Sarcoma Group|French Sarcoma Group","All","60 Years and older   (Adult, Senior)","Phase 2","117","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","jth_001","September 13, 2005","August 2004","October 2013","January 7, 2013","January 2013","No Study Results Posted","null","October 2013","Progression-free survival after 6 months|Grade III/IV toxicity Objective remission rate according to RECIST criteria Overall survival • Quality of life according to EORTC QLQ-30","https://ClinicalTrials.gov/show/NCT00204568"
3092,"NCT00647218","Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Post-operative adjuvant therapy|Drug: neoadjuvant therapy|Procedure: therapeutic surgical procedure|Radiation: Radiation therapy with concurrent Paclitaxel|Drug: Hormonal Therapy","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","38","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","VCC BRE 9936|P30CA068485|VU-VICC-BRE-9936","March 28, 2008","February 2000","November 2004","February 21, 2017","February 2017","No Study Results Posted","null","November 2004","Pathologic Complete Response Rate|Toxicity paclitaxel and radiation|Correlation of tumor response with local recurrence-free survival, distant disease-free survival, and overall survival|Protein expression profiles as measured by mass spectrometry before and after treatment with paclitaxel","https://ClinicalTrials.gov/show/NCT00647218"
3093,"NCT01501487","MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","Active, not recruiting","No Results Available","Breast Cancer","Drug: TAC chemotherapy|Drug: TC chemotherapy|Drug: Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy|Drug: TCH chemotherapy|Drug: T + trastuzumab followed by CEF + trastuzumab|Drug: Dose dense AC followed by T + trastuzumab|Drug: Dose dense AC followed by T + trastuzumab + pertuzumab|Drug: PTH followed by dose dense AC of FEC","Agendia|University of South Florida|University of Miami|Morton Plant Mease Health Care|Florida Hospital|Plano Cancer Center|Ohio State University Comprehensive Cancer Center|University of Oklahoma|University of South Alabama","Female","18 Years and older   (Adult, Senior)","Phase 4","226","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Diagnostic","P0334","December 22, 2011","October 2011","June 2017","January 23, 2017","January 2017","No Study Results Posted","MINT","February 2016","Determine the predictive power of chemosensitivity of MammaPrint as measured by pCR.|Determine the predictive power of chemosensitivity of the combination of MammaPrint and BluePrint as measured by pCR.|Compare TargetPrint single gene read out of ER, PR and HER2 with local and centralized IHC and/or CISH/FISH assessment of ER, PR and HER2.|Identify possible correlations between the TheraPrint Research Gene Panel outcomes and chemoresponsiveness.|Identify and/or validate predictive gene expression profiles of clinical response/resistance to chemotherapy.|Compare the three BluePrint molecular subtype categories with IHC-based subtype classification.","https://ClinicalTrials.gov/show/NCT01501487"
3094,"NCT01645059","Multicenter Descriptive Study of the Patient Clinical Profile That Begins With Disseminated Her 2 + Breast Cancer or Develops a Metastasis After or During the Adjuvant Therapy","Completed","Has Results","Disseminated HER2+ Breast Cancer","","Asociación Cacereña para la Investigación y el Desarrollo en Oncología Médica","Female","18 Years and older   (Adult, Senior)","","129","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","ACI-CMM-2010-01","July 13, 2012","July 2011","March 2013","November 20, 2013","November 2013","July 9, 2013","PRIMHER","March 2013","The Patient Clinical Profile (General Clinical Data and Breast Cancer Characteristics)|Adjuvant Treatment in Primary Breast Cancer: Chemotherapy (Treatment With TAC-Docetaxel, Adriamicine and Cyclophosphamide), Hormonal Therapy Anti-HER Biological Therapy|The Pattern of Treatment in Metastatic Breast Cancer: Chemotherapy, Hormonal Therapy Anti-HER Biological Therapy|Adjuvant Treatment and Age|Adjuvant Treatment-Physical Activity|Adjuvant Treatment-Node Affectation|Disseminated Breast Cancer Treatment-Age|Disseminated Breast Cancer Treatment-physical Activity|Disseminated Breast Cancer Treatment-Smoking","https://ClinicalTrials.gov/show/NCT01645059"
3095,"NCT01818323","Phase I Trial: T4 Immunotherapy of Head and Neck Cancer","Recruiting","No Results Available","Head and Neck Cancer","Other: Intra-tumoral T4 immunotherapy","King's College London|Guy's and St Thomas' NHS Foundation Trust","All","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label","2012-001654-25","March 19, 2013","June 2015","December 2017","August 29, 2016","August 2016","No Study Results Posted","null","June 2017","Dose limiting toxicities for T4 immunotherapy in SCCHN and determine a safe and feasible recommended dose for phase II testing of intra-tumoral T4 immunotherapy.|To investigate serum cytokine levels after administration of T4 immunotherapy|To investigate persistence of T4+ T-cells at the site of administration and in the peripheral circulation|To achieve preliminary assessment of anti-tumour activity, using cross-sectional imaging to quantify objective responses|To investigate tumour ErbB receptor phenotype, before and after administration of T4 immunotherapy|To investigate immunomodulatory effects of metronomic cyclophosphamide on T4 immunotherapy|To investigate effect of T4 immunotherapy upon immune reactivity against endogenous tumour antigens","https://ClinicalTrials.gov/show/NCT01818323"
3096,"NCT02620280","Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1","Recruiting","No Results Available","Invasive Ductal Breast Carcinoma","Drug: Carboplatin|Drug: Abraxane|Drug: MPDL3280A|Procedure: Surgery|Drug: Anthra","Fondazione Michelangelo","Female","18 Years and older   (Adult, Senior)","Phase 3","272","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","FM-14-B02|2014-005017-23","November 3, 2015","April 2016","October 2022","July 12, 2016","July 2016","No Study Results Posted","NeoTRIPaPDL1","May 2022","Event Free Survival (EFS)|Pathological complete response (pCR)|Clinical objective response|Distant Event Free Survival (DEFS)|Number of participants with adverse events as a Measure of Safety and Tolerability","https://ClinicalTrials.gov/show/NCT02620280"
3097,"NCT01134484","VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)","Unknown status","No Results Available","Multiple Myeloma","Drug: Velcade|Drug: Thalidomide|Drug: Dexamethasone|Procedure: Peripheral Blood Stem Cell (PBSC) collection|Procedure: First Autologous Transplantation|Procedure: Second Autologous Transplantation","Michele Cavo|Janssen-Cilag S.p.A.|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi","All","18 Years to 65 Years   (Adult)","Phase 3","480","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MM-BO2005|2005-003723-39|26866138-MMY-3006","May 28, 2010","May 2006","December 2015","July 19, 2012","July 2012","No Study Results Posted","null","August 2008","Rate of CR+nCR to induction treatment|Rate of CR+nCR to autotransplantation(s) and subsequent consolidation therapy|Time To Progression (TTP)|Progression-Free Survival (PFS)|Overall Survival (OS)|Safety","https://ClinicalTrials.gov/show/NCT01134484"
3098,"NCT01370213","NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases","Active, not recruiting","No Results Available","Acute Myeloid Leukemia|Myelodysplastic Syndrome","Drug: Preparative Regimen|Biological: NK Cells|Drug: Interleukin-2|Biological: Anti-thymocyte globulin|Biological: Donor TCR α/β-depleted Cells","Masonic Cancer Center, University of Minnesota","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2011LS027|MT2011-05","June 8, 2011","September 2011","January 2019","March 24, 2016","March 2016","No Study Results Posted","null","January 2017","Rate of Donor Neutrophil Engraftment|Disease Free Survival|Treatment Related Mortality (TRM)|Incidence of Relapse|Rate of Early In Vivo Expansion of Natural Killer (NK) Cells","https://ClinicalTrials.gov/show/NCT01370213"
3099,"NCT02084563","Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms","Completed","No Results Available","Acute Myeloid Leukemia|Myeloproliferative Neoplasms|Myelodysplastic Syndromes|Myeloproliferative/Myelodysplastic Neoplasm","Drug: Induction Chemotherapy|Drug: Consolidation Chemotherapy|Drug: Autologous Stem Cell Transplantation|Drug: Allogeneic Stem Cell Transplantation|Drug: Low Dose Cytarabine|Drug: Decitabine","Hospital Israelita Albert Einstein","All","18 Years and older   (Adult, Senior)","Phase 2","455","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science","LMA Brasil|11/1714","January 2, 2013","October 2012","November 2016","November 7, 2016","November 2016","No Study Results Posted","null","December 2014","Prevalence of molecular and cytogenetic abnormalities|Overall survival|Response rate|Disease Free Survival|Cumulative incidence of relapse and non-relapse mortality|Number of participants with adverse events as a measure of safety and tolerability|Cumulative Incidence of Transformation to Acute Myeloid Leukemia","https://ClinicalTrials.gov/show/NCT02084563"
3100,"NCT00560053","Pethema Multiple Myeloma 2000","Completed","No Results Available","Multiple Myeloma","Drug: Alternating chemotherapy|Procedure: Autologous Transplantation|Drug: Maintenance|Procedure: Second transplantation|Procedure: ALOGENIC MINI TRASPLANTATION","PETHEMA Foundation","All","up to 69 Years   (Child, Adult, Senior)","Phase 3","500","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","PETHEMA MM-2000","November 15, 2007","January 2000","February 2005","November 26, 2008","November 2008","No Study Results Posted","null","null","","https://ClinicalTrials.gov/show/NCT00560053"
3101,"NCT01576692","Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma","Active, not recruiting","No Results Available","Neuroblastoma","Biological: Humanized anti-GD2 antibody|Drug: Chemotherapy|Other: Cytokines|Biological: Natural killer cells|Device: CliniMACS","St. Jude Children's Research Hospital|CURE Childhood Cancer, Inc.","All","up to 21 Years   (Child, Adult)","Phase 1","34","Other","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","GD2NK|NCI-2012-00495","April 10, 2012","April 2012","February 2019","March 30, 2017","February 2017","No Study Results Posted","null","October 2014","Number of patients experiencing unacceptable toxicity associated with humanized anti-GD2 antibody/chemotherapy (course 1) and anti-GD2 antibody/chemotherapy/NK cells (course 2).|Response to treatment|Time to progression.|Event free survival.|Overall survival","https://ClinicalTrials.gov/show/NCT01576692"
3102,"NCT01516593","Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma","Unknown status","No Results Available","HIV|Burkitt's Lymphoma","Drug: Induction Phase|Drug: Consolidation Phase (on day +50)|Drug: Intensification phase|Drug: BEAM conditioning|Radiation: Consolidation radiotherapy","Andres J. M. Ferreri|IRCCS San Raffaele","All","18 Years to 60 Years   (Adult)","Phase 2","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CARMEN","January 6, 2012","November 2011","August 2015","January 24, 2012","January 2012","No Study Results Posted","CARMEN","April 2013","evaluation of activity of the induction phase in terms of complete remission rate|Feasibility and tolerability of the investigational intensive chemotherapy in terms of grade ≥4 adverse events|Feasibility and tolerability of the consolidation phase followed by BEAM conditioning and autologous stem cell transplantation in terms of prevalence of grade ≥4 adverse events|Feasibility and tolerability of intensification phase in terms of prevalence of grade ≥4 adverse events|Activity of the whole investigational program in terms of complete remission rate","https://ClinicalTrials.gov/show/NCT01516593"
3103,"NCT02903381","A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma","Recruiting","No Results Available","Smoldering Multiple Myeloma","Drug: Nivolumab|Drug: Lenalidomide|Drug: Dexamethasone","Dana-Farber Cancer Institute|Bristol-Myers Squibb|Multiple Myeloma Research Consortium","All","18 Years and older   (Adult, Senior)","Phase 2","41","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","16-242|CA209-607","August 30, 2016","October 2016","February 2024","March 6, 2017","March 2017","No Study Results Posted","null","June 2020","2 Year Progression Free Rate|Objective Response Rate|Time to Progression Rate|Duration of Response Rate|Progression Free Survival (PFS) Rate|Overall Survival Rate|Progression Free Survival Rate-Without cyclophosphamide|Number of Participants with Adverse Events","https://ClinicalTrials.gov/show/NCT02903381"
3104,"NCT00482066","Abatacept in ANCA Associated Vasculitis","Terminated","No Results Available","ANCA-associated Vasculitis","Drug: Abatacept (Orencia)","Imperial College London|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 2","7","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","cro632|2006-001859-35|BMS protocol No: IST110","June 1, 2007","November 2007","November 2008","May 28, 2015","March 2015","No Study Results Posted","ABAVAS","November 2008","Relapse rate over 24 months.|Proportion of patients in sustained remission (i.e. remission at 3 months sustained for 6 months and remission at 6 months sustained for a further 12 months);|Time to remission;|The average steroid dosage at 6 months, 1 year, 18 months and 2 years in abatacept and placebo groups respectively;|Time to ANCA negativity by immunofluorescence or negative anti-PR3 or anti-MPO Ab test by ELISA.|Proportion of patients defaulting to cyclophosphamide (MMF, azathioprine or other rescue) therapy.|Proportion of patients unable to stick with trial protocol.|Degree of chronic disease activity|Health related quality of life","https://ClinicalTrials.gov/show/NCT00482066"
3105,"NCT02356159","Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","Recruiting","No Results Available","Myelodysplastic Syndrome|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Acute Leukemia|Multiple Myeloma","Biological: Rituximab|Drug: Conditioning Chemotherapy|Drug: TMS|Drug: FLAG|Drug: EPOCH-F|Procedure: Hematopoietic Stem Cell Transplant|Drug: Palifermin","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","50","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","150067|15-C-0067","February 4, 2015","January 9, 2015","January 1, 2019","May 12, 2017","December 9, 2016","No Study Results Posted","null","January 1, 2019","For Phase I:To assess the safety and tolerability|For Phase II portion: to determine the incidence of chronic GVHD","https://ClinicalTrials.gov/show/NCT02356159"
3106,"NCT01946880","Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)","Recruiting","No Results Available","Systemic Lupus Erythematosus|SLE","Drug: Mycophenolate Mofetil|Drug: Hydroxychloroquine or Chloroquine|Drug: Prednisone","National Institute of Allergy and Infectious Diseases (NIAID)|Autoimmunity Centers of Excellence","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","120","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","DAIT ALE06","September 13, 2013","November 2013","May 2018","February 3, 2017","February 2017","No Study Results Posted","ALE06","May 2018","The probability of experiencing clinically significant disease reactivation in each arm|Time to clinically significant disease reactivation|probability of experiencing any SELENA-SLEDAI flare and the probability of experiencing any severe SELENA-SLEDAI flare|Time from initiation of withdrawal to first SELENA-SLEDAI flare and time to first severe SELENA-SLEDAI flare|The probability of experiencing any BILAG A flare|Proportion of subjects in the renal subgroup with BILAG Renal A flare|Change in SLICC/DI|The probability of adding aggressive adjunctive therapy added to MMF (including IV immunoglobulin or rituximab) or change in MMF therapy to cytotoxic drug (e.g., cyclophosphamide) due to flare|Cumulative systemic steroid dose|Change in FACIT fatigue score|Change in Lupus QoL-US|Time to improvement in BILAG from maximum level during flare|Time to recovery of baseline BILAG scores|Cumulative excess systemic steroid dose|Time to return to pre-flare steroid dose|Amount of SLE Related Grade 3-5 adverse events|Amount of MMF related Grade 3-5 adverse events|Amount of all NCI-CTCAE Grade 3-5 adverse events.|Amount of serious adverse events.|Frequency of malignancies|Amount of NCI-CTCAE Grade 3-5 hematological events.|Total incidence of mortality possibly, probably, or definitely related to SLE.|Total incidence of all-cause mortality","https://ClinicalTrials.gov/show/NCT01946880"
3107,"NCT00136539","Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: Herceptin|Drug: Taxol|Drug: Adriamycin|Drug: Cytoxan","Harold J. Burstein, MD, PhD|Dana-Farber Cancer Institute|Genentech, Inc.|Bristol-Myers Squibb|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Harvard Vanguard Medical Associates|Brigham and Women's Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","41","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","98-222","August 26, 2005","March 1999","March 2012","February 15, 2013","February 2013","No Study Results Posted","null","November 2006","To determine the response of HER2-positive breast cancer to treatment with Herceptin and Taxol prior to surgery|To examine the safety of Herceptin and Taxol therapy followed by surgery and chemotherapy","https://ClinicalTrials.gov/show/NCT00136539"
3108,"NCT00558220","R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas","Completed","No Results Available","Diffuse Large B-Cell Lymphoma.|Primary Mediastinal B-Cell Lymphoma|Follicular Lymphoma Grade III","Procedure: immunotherapy|Procedure: Induction treatment part 1|Procedure: Induction treatment part 2 with PBPC collection|Procedure: Induction treatment part 3|Procedure: Consolidation treatment part 1: HD-chemotherapy with ASCT|Radiation: Consolidation treatment part 2: Radiotherapy","Czech Lymphoma Study Group|Ministry of Health, Czech Republic|Hoffmann-La Roche","All","18 Years to 65 Years   (Adult)","Phase 2","106","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CLSG 5_02|NR-8231/3","February 12, 2007","May 2002","October 2006","November 10, 2007","November 2007","No Study Results Posted","R-MCEB","null","Progression-free survival|Complete remission and overall response rate|Overall survival","https://ClinicalTrials.gov/show/NCT00558220"
3109,"NCT02586025","A Randomized, Double-Blind, Placebo-Controlled Study in Patients With Early-Stage or Locally Advanced HER2-positive Breast Cancer to Evaluate Treatment With Trastuzumab + Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel","Active, not recruiting","No Results Available","Breast Cancer","Drug: FEC chemotherapy|Procedure: Surgery|Drug: docetaxel|Drug: pertuzumab|Drug: placebo|Drug: trastuzumab","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 3","328","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Participant, Investigator|Primary Purpose: Treatment","YO28762","October 23, 2015","March 14, 2016","April 30, 2022","May 2, 2017","May 2017","No Study Results Posted","null","April 30, 2022","Total pathologic complete response (tpCR) rate, defined as ypT0/is, ypN0 as assessed by an Independent Review Committee (IRC)|tpCR rate as assessed by the local pathologist|Breast pathologic complete response (bpCR) rate, defined as ypT0/is according to the American Joint Committee on Cancer [AJCC] staging system as assessed by the IRC|bpCR rate as assessed by the local pathologist|Clinical response rates during cycles 1 to 4, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1|Event-free survival|Disease-free survival|Overall survival|Safety (composite outcome measure): Incidence, type, and severity of adverse events, incidence of symptomatic left ventricular systolic dysfunction, incidence of asymptomatic decline in left ventricular ejection fraction, laboratory test abnormalities","https://ClinicalTrials.gov/show/NCT02586025"
3110,"NCT01834157","Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis","Recruiting","No Results Available","Systemic Sclerosis|Arthritis","","Prof. Laszlo Czirjak|European Union|University of Giessen|University of Zurich|University of Paris 5 - Rene Descartes|University of Florence|Second University of Naples|University of Basel|University College, London|Charite University, Berlin, Germany|University of Leeds|Schoen Klinik Hamburg Eilbek|University of Pecs","All","Child, Adult, Senior","","160","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HEALTH-F5-2012-305495-OT2","April 9, 2013","April 2013","November 2017","December 21, 2015","December 2015","No Study Results Posted","null","November 2017","Improvement of HAQ-DI (CHAQ-DI in jSSc) by at least -0.21 in one year|Improvement of the CHFS in one year|Improvement of the CDAI in one year|Improvement of the SDAI in one year|Improvement of the DAS28(We) in one year|Improvement of the DAS28(CRP) in one year","https://ClinicalTrials.gov/show/NCT01834157"
3111,"NCT02520895","Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia","Completed","No Results Available","LYMPHOMA","Biological: blood samplings","Hospices Civils de Lyon","All","18 Years and older   (Adult, Senior)","","98","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2009.548|2010-A00591-38","September 15, 2014","September 2010","October 2013","August 7, 2015","July 2015","No Study Results Posted","RIPAL","October 2013","change in variations of the T and B cell repertoire in patients with lymphoid blood disease under treatment|performance of the mapping of the immune repertoire to predict treatment response|performance of the mapping of the immune repertoire to predict progression free survival|performance of the mapping of the immune repertoire to predict the risk of infection|sensitivity of detection of the circulating clones","https://ClinicalTrials.gov/show/NCT02520895"
3112,"NCT00169143","Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma","Completed","No Results Available","Untreated CD20-Positive Large B-Cell Lymphoma","Drug: Rituximab + ACVBP regimen plus Pegfilgrastim|Procedure: Autologous stem cell transplant","Lymphoma Study Association|Amgen","All","18 Years to 61 Years   (Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","LNH 03-39B","September 12, 2005","May 2004","January 2007","September 6, 2006","September 2006","No Study Results Posted","null","null","To evaluate the optimal combined dose intensity of the drug regimen|Specific dose intensities, incidence of neutropenia and neutropenic fever, duration of severe neutropenia, complete response rate, event-free and overall survival","https://ClinicalTrials.gov/show/NCT00169143"
3113,"NCT01362530","A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)","Completed","Has Results","Chemotherapy Induced Nausea and Vomiting","Drug: Aprepitant 125 mg|Drug: Aprepitant 80 mg|Drug: Aprepitant powder for suspension (PFS)|Drug: Ondansetron|Drug: Placebo for Aprepitant 125 mg|Drug: Placebo for Aprepitant 80 mg|Drug: Placebo for Aprepitant PFS|Drug: Emetogenic chemotherapy","Merck Sharp & Dohme Corp.","All","6 Months to 17 Years   (Child)","Phase 3","307","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","0869-208","May 26, 2011","September 2011","August 2013","April 17, 2015","April 2015","February 24, 2014","null","March 2013","Percentage of Participants With a Complete Response in the Delayed Phase of Cycle 1|Percentage of Participants With a Complete Response in the Acute Phase of Cycle 1|Percentage of Participants With a Complete Response in the Overall Phase of Cycle 1|Percentage of Participants With No Vomiting in the Overall Phase of Cycle 1","https://ClinicalTrials.gov/show/NCT01362530"
3114,"NCT01614301","Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma","Unknown status","No Results Available","Advanced Melanoma","Drug: dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus","University of Regensburg|ClinAssess GmbH","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","136","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MEL001","June 5, 2012","May 2012","May 2016","June 5, 2012","June 2012","No Study Results Posted","null","May 2014","response rate|Time to progession","https://ClinicalTrials.gov/show/NCT01614301"
3115,"NCT01203722","Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies","Recruiting","No Results Available","Hematologic Malignancies","Other: Fludarabine, Cytoxan, TBI, Sirolimus + MMF|Other: Fludarabine, Cytoxan, TBI, Tacrolimus + MMF","Sidney Kimmel Comprehensive Cancer Center","All","6 Months to 75 Years   (Child, Adult, Senior)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","J1055|NA_00039823","September 15, 2010","September 2010","December 2017","May 17, 2016","May 2016","No Study Results Posted","null","September 2017","Phase 1: Identify a transplant regimen with acceptable rates of severe acute GVHD (< 25%) and transplant-related NRM (< 20%) Phase 2: Estimate the 6-month probability of survival without having grade III-IV GVHD or evidence of graft failure.|Estimate the progression-free survival, event-free survival, overall survival, cumulative incidence of progression or relapse, and cumulative incidence of NRM.|Estimate the cumulative incidence of acute grade II-IV GVHD, acute grade III-IV GVHD, and chronic GVHD.","https://ClinicalTrials.gov/show/NCT01203722"
3116,"NCT00083681","DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse","Completed","No Results Available","Multiple Myeloma","Drug: Thalidomide|Drug: Dexamethasone|Drug: Cytoxan|Drug: Etoposide|Drug: Cisplatin|Drug: G-CSF","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","UARK 98-018","May 27, 2004","June 1998","May 2005","July 1, 2010","July 2010","No Study Results Posted","null","null","To evaluate the effectiveness of the DCEP chemoregimen with G-CSF support as compared to the DCEP regimen with G-CSF support in combination with thalidomide in high risk patients relapsing after autologous transplantation.|To evaluate the quantitative and qualitative toxicities associated with the regimens.","https://ClinicalTrials.gov/show/NCT00083681"
3117,"NCT02969083","Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma","Not yet recruiting","No Results Available","Upper Tract Urothelial Carcinoma","Procedure: RNU|Drug: Gemcitabine/Cisplatin|Drug: M-VAC Protocol","The European Uro-Oncology Group|Centre for Human Drug Research, Netherlands","All","18 Years and older   (Adult, Senior)","Phase 2","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label","EudraCT 2016-004017-27","November 11, 2016","January 2017","December 2018","November 24, 2016","November 2016","No Study Results Posted","URANUS","June 2018","Proportion of UTUC patients randomized to neo- or adjuvant chemotherapy that is actually able to start and finalize three courses of planned chemotherapy|Disease Free Survival (DFS)|Overall Survival (OS)|Cancer-Specific Survival (CSS)","https://ClinicalTrials.gov/show/NCT02969083"
3118,"NCT00184041","Intensified Post Remission Therapy Containing PEG-Asparaginase","Completed","No Results Available","Acute Lymphoblastic Leukemia","Drug: Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine","University of Southern California","All","18 Years to 55 Years   (Adult)","Phase 2","47","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9L-03-1","September 12, 2005","July 2004","December 2012","May 20, 2014","May 2014","No Study Results Posted","null","December 2011","Assessment of pt developing anti-asparaginase antibody|Response","https://ClinicalTrials.gov/show/NCT00184041"
3119,"NCT02180867","Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery","Recruiting","No Results Available","Adult Fibrosarcoma|Alveolar Soft Part Sarcoma|Angiomatoid Fibrous Histiocytoma|Atypical Fibroxanthoma|Clear Cell Sarcoma of Soft Tissue|Epithelioid Malignant Peripheral Nerve Sheath Tumor|Epithelioid Sarcoma|Extraskeletal Myxoid Chondrosarcoma|Extraskeletal Osteosarcoma|Fibrohistiocytic Neoplasm|Glomus Tumor of the Skin|Inflammatory Myofibroblastic Tumor|Intimal Sarcoma|Leiomyosarcoma|Liposarcoma|Low Grade Fibromyxoid Sarcoma|Low Grade Myofibroblastic Sarcoma|Malignant Cutaneous Granular Cell Tumor|Malignant Peripheral Nerve Sheath Tumor|Malignant Triton Tumor|Mesenchymal Chondrosarcoma|Myxofibrosarcoma|Myxoid Chondrosarcoma|Myxoinflammatory Fibroblastic Sarcoma|Nerve Sheath Neoplasm|PEComa|Pericytic Neoplasm|Plexiform Fibrohistiocytic Tumor|Sclerosing Epithelioid Fibrosarcoma|Stage IB Soft Tissue Sarcoma|Stage IIB Soft Tissue Sarcoma|Stage III Soft Tissue Sarcoma|Stage IV Soft Tissue Sarcoma|Synovial Sarcoma|Undifferentiated (Embryonal) Sarcoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone","Drug: Doxorubicin Hydrochloride|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Drug: Pazopanib Hydrochloride|Other: Pharmacological Study|Radiation: Radiation Therapy|Procedure: Therapeutic Conventional Surgery","National Cancer Institute (NCI)","All","2 Years and older   (Child, Adult, Senior)","Phase 2|Phase 3","340","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2014-01340|ARST1321|U10CA180886|U10CA098543","July 1, 2014","July 11, 2014","null","May 24, 2017","May 2017","No Study Results Posted","null","June 13, 2018","EFS (Phase III)|Potential benefit for chemoradiotherapy plus pazopanib hydrochloride defined as protocol week 13 pathologic response (Phase II)|Potential benefit for radiotherapy plus pazopanib hydrochloride defined as protocol week 10 pathologic response (Phase II/III)|Adverse event profile of the treatments delivered (chemo-radiotherapy; radiotherapy) characterized using the current Common Terminology Criteria for Adverse Events version|Distant failure defined as disease recurrence at sites other than the primary site and diagnosis and nodes regional to that site (metastatic disease, whether or not present at diagnosis), with or without loco-regional failure|Local failure defined as disease recurrence only at the primary site of disease at diagnosis|Regional failure defined as disease recurrence at lymph nodes regional to the primary disease site, with or without local failure but without distant failure","https://ClinicalTrials.gov/show/NCT02180867"
3120,"NCT03077828","Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","Recruiting","No Results Available","Lymphocyte-Rich Classical Hodgkin Lymphoma|Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma|Recurrent Mixed Cellularity Classical Hodgkin Lymphoma|Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma|Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma|Refractory Mixed Cellularity Classical Hodgkin Lymphoma|Refractory Nodular Sclerosis Classical Hodgkin Lymphoma","Drug: Carboplatin|Drug: Etoposide|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab","Northwestern University|Merck Sharp & Dohme Corp.|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NU 16H07|P30CA060553|NCI-2016-01439|STU00203658","March 8, 2017","April 21, 2017","February 2020","April 22, 2017","April 2017","No Study Results Posted","null","November 2019","Complete Response Rate|Incidence of Adverse Events|Event Free Survival (EFS)|Overall Survival (OS)","https://ClinicalTrials.gov/show/NCT03077828"
3121,"NCT03016871","Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma","Recruiting","No Results Available","CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma","Drug: Carboplatin|Drug: Etoposide|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Biological: Nivolumab","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","43","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","16403|NCI-2016-02038","January 6, 2017","April 24, 2017","April 24, 2019","May 4, 2017","May 2017","No Study Results Posted","null","April 24, 2019","CR rate autologous stem cell transplantation assessed by Lugano criteria|Incidence of adverse events assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.03|Non-relapse mortality (NRM)|ORR|OS (overall survival) of hematopoietic cell transplant (HCT)|Overall survival|PFS|PFS of HCT|Relapse/progression event","https://ClinicalTrials.gov/show/NCT03016871"
3122,"NCT02050919","Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma","Recruiting","No Results Available","Stage IIB Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma","Drug: Epirubicin Hydrochloride|Radiation: External Beam Radiation Therapy|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Drug: Sorafenib Tosylate|Procedure: Therapeutic Conventional Surgery","OHSU Knight Cancer Institute|Bayer|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","IRB00009464|NCI-2013-02414|P30CA069533","January 29, 2014","December 2013","October 2017","May 1, 2017","May 2017","No Study Results Posted","null","October 2017","Pathologic response rate, classified as either greater than or equal to 95% necrosis or less than 95% necrosis|Distant disease-free survival (stage IIB-III patients)|Levels of toxicity, graded according to NCI CTCAE version 4.0|Local disease-free survival|Overall disease-free survival (stage IIB-III patients)|Overall survival|Wound complication rate","https://ClinicalTrials.gov/show/NCT02050919"
3123,"NCT02227199","Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","Recruiting","No Results Available","Recurrent Adult Hodgkin Lymphoma|Refractory Hodgkin Lymphoma","Drug: Brentuximab Vedotin|Drug: Carboplatin|Drug: Etoposide|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","9111|NCI-2014-01782|P30CA015704","August 25, 2014","October 10, 2014","null","January 18, 2017","January 2017","No Study Results Posted","BV-ICE","September 15, 2018","Maximum tolerated dose of brentuximab vedotin that can be combined with ifosfamide, carboplatin, and etoposide chemotherapy, defined as the dose at which =< 1 of 6 patients experience a dose-limiting toxicity|Percentage of patients that achieve a complete remission following study treatment|Overall survival|Progression-free survival","https://ClinicalTrials.gov/show/NCT02227199"
3124,"NCT02628405","R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma","Recruiting","No Results Available","CD20 Positive|Diffuse Large B-Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma","Drug: Carboplatin|Drug: Etoposide|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Biological: Rituximab","Academic and Community Cancer Research United|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","63","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","RU051417I|NCI-2015-01990|P30CA015083","December 9, 2015","May 2016","January 2023","May 23, 2017","May 2017","No Study Results Posted","null","May 2018","Maximum tolerated dose defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients of the addition of lenalidomide to rituximab-ifosfamide-carboplatin-etoposide (Phase I)|Overall response rate defined as a complete metabolic response or partial metabolic response (Phase II)|Toxicity profile defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment as measured by Common Terminology Criteria for Adverse Events version 4.0 (Phase I)|Complete metabolic response rate|Incidence of adverse events|Overall survival|Percentage of patients proceeding to stem cell transplant","https://ClinicalTrials.gov/show/NCT02628405"
3125,"NCT01446809","Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma","Active, not recruiting","No Results Available","Stage IIA Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma","Drug: Doxorubicin Hydrochloride|Radiation: External Beam Radiation Therapy|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Drug: Pazopanib Hydrochloride|Other: Pharmacological Study|Other: Placebo|Procedure: Therapeutic Conventional Surgery","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","21","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment","7487|NCI-2011-02488|P30CA015704","September 12, 2011","April 2012","null","November 14, 2016","November 2016","No Study Results Posted","null","July 2016","Change in maximum SUV of tumors measured by FDG-PET pre- and post receipt of pazopanib versus placebo|Change in maximum SUV of tumors measured by FDG-PET post receipt of 2 courses of preoperative chemotherapy|Tumor response by RECIST criteria|Correlation of pazopanib hydrochloride trough concentration with the change in SUV from FDG PET and change in RECIST measurements on MRIs|Change in plasma and tumor angiogenic biomarker levels pre- and post neoadjuvant therapy|Overall survival|Pathologic response at the time of surgery as measured by % tumor viability|Progression free survival|Safety profile of sequential treatment with pazopanib and pre-operative chemotherapy with doxorubicin and ifosfamide","https://ClinicalTrials.gov/show/NCT01446809"
3126,"NCT02219737","Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","Recruiting","No Results Available","CD20 Positive|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma","Drug: Carboplatin|Drug: Etoposide|Drug: Ibrutinib|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Biological: Rituximab","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","24","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","NCI-2014-00571|14-145|9588|P30CA008748","July 16, 2014","September 12, 2014","null","May 23, 2017","May 2017","No Study Results Posted","null","March 21, 2018","Maximum tolerated dose of the combination of ibrutinib with standard dosing R-ICE, graded using the Common Terminology Criteria for Adverse Events 4.0|Toxicity of the combination of ibrutinib with standard dosing R-ICE, graded using the CTCAE 4.0|Overall response rate, defined as the sum of partial and complete responses as determined by revised International Working Group Criteria for Malignant Lymphoma|PK parameters of ibrutinib in the presence of R-ICE as a measure of potential drug-drug interaction","https://ClinicalTrials.gov/show/NCT02219737"
3127,"NCT01959698","Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma","Recruiting","No Results Available","CD20 Positive|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Stage I Diffuse Large B-Cell Lymphoma|Stage II Diffuse Large B-Cell Lymphoma|Stage III Diffuse Large B-Cell Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma","Drug: Carboplatin|Drug: Carfilzomib|Drug: Etoposide|Drug: Ifosfamide|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Biological: Rituximab","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","73","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment","I 240813|NCI-2013-01784|P30CA016056|R01CA136907","October 8, 2013","April 17, 2014","July 15, 2018","February 15, 2017","February 2017","No Study Results Posted","null","July 15, 2017","Best overall response rate (PR + CR) (Phase II)|MTD defined as the dose of carfilzomib added to standard R-ICE chemotherapy which, if exceeded, would put the patient at an undesirable risk of medically unacceptable dose-limiting toxicities (Phase I)|Complete response rate according to the International Working Group Response criteria as reported by the revised Cheson criteria|Overall survival|Pharmacokinetics (PK)/pharmacodynamics (PD) of carfilzomib and standard R-ICE combination therapy in adult patients with relapsed/refractory diffuse large B-cell lymphoma|Progression-free survival|Toxicity of the addition of carfilzomib to R-ICE at the MTD, assessed by the CTEP version 4.0 of the NCI CTCAE","https://ClinicalTrials.gov/show/NCT01959698"
3128,"NCT01097057","Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells","Active, not recruiting","No Results Available","Non-Hodgkin Lymphoma","Drug: Carboplatin|Drug: Etoposide|Biological: Filgrastim|Drug: Ifosfamide|Procedure: Leukapheresis|Drug: Plerixafor|Biological: Rituximab","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","37","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","2310.00|NCI-2009-01562|P30CA015704","March 30, 2010","July 2010","null","February 17, 2016","February 2016","No Study Results Posted","null","September 2013","Ability to mobilize an adequate number of autologous PBSC|Delayed platelet engraftment after transplant|Engraftment after transplant as assessed by initial neutrophil recovery|Secondary graft failure|Toxicity assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0|Tumor status","https://ClinicalTrials.gov/show/NCT01097057"
